nct_id,title,official_title,primary_drug,all_drug_names,drug_count,study_type,phases,primary_phase,primary_purpose,primary_condition,all_conditions,keywords,overall_status,why_stopped,start_date,completion_date,primary_outcomes,secondary_outcomes,outcome_count,min_age,max_age,sex,healthy_volunteers,lead_sponsor,sponsor_class,collaborator_count,enrollment_count,enrollment_type,collected_date,api_version,is_interventional,has_drug_interventions,is_completed,is_failed,has_safety_outcomes,failure_reason
NCT01198509,Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA),Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA),doxycycline,"['Vibramycin', 'vancomycin', 'Vancocin', 'doxycycline']",4,INTERVENTIONAL,['NA'],,,Rheumatoid Arthritis,"['Rheumatoid Arthritis', 'Psoriatic Arthritis', 'Periodontal Disease']","['rheumatoid arthritis', 'psoriatic arthritis', 'periodontitis', 'microbiota', 'microbiome', 'vancomycin', 'doxycycline', 'T cell', 'Th17']",COMPLETED,,2010-01,2013-01,"[{'measure': 'Alteration of Microbiota, Alteration of T Cell Function/Activation', 'description': 'Oral and intestinal microbiota, and T cell function and activation, will be assessed at baseline, and at 1, 2, 3, 4 and 5 months after baseline, to determine whether changes are associated with vancomycin treatment versus doxycycline treatment versus no treatment.\n\nResults are reported as number of participants who experienced changes in oral/intestinal microbiota, T cell function/activation.\n\nMethods/criteria to assess change in microbiota: change in relative abundance of microorganisms at genus and species level (as assessed high-throughput 16S rDNA sequencing).\n\nMethods/criteria to assess change in T cell function/activation: change in percentage of inhibition of regulatory T cells as measured by interferon gamma levels in in-vitro assays.', 'timeFrame': '6 months'}]","[{'measure': 'Mean Units Change in DAS28 From Baseline to 6 Months', 'description': 'DAS28 (disease activity score with 28 joint count). Possible score range: 0 to 10. This is a composite index calculated from 4 measures: two from a physician (28 tender joint count, 28 swollen joint count), one from the patient (patient global estimate of disease activity), and one laboratory biomarker (erythrocyte sedimentation rate or ESR). A score of 0 represents best possible health status (no apparent disease activity) and 10 represents worst possible.\n\nThe outcome is reported as mean change in DAS28 score from baseline to 6 months. The mean changes reported are negative values for downward change in score (i.e., improvement in health status).', 'timeFrame': '6 months'}]",2,18 Years,70 Years,ALL,True,NYU Langone Health,OTHER,2,178.0,ACTUAL,2025-09-01T16:18:10.927174,v2_robust,True,True,True,False,False,
NCT03508999,Effectiveness of Metronidazole Gel and Mobile SMS Reminders on Gingivitis in Orthodontic Patients,Effectiveness of Metronidazole Gel and Mobile Telephone Short- Message Service Reminders on Gingivitis in Orthodontic Patients: A Randomized Controlled Trial,Metronidazole gel,"['Metronidazole gel', 'Anaerobic gel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Gingivitis,['Gingivitis'],[],COMPLETED,,2018-05-23,2018-11-30,"[{'measure': 'Improvement of Bleeding Index', 'description': 'Improvement in Bleeding Index Scores In Orthodontic Patients, Change from Baseline in Index at 4 weeks. All the measurements at the baseline (To) and follow ups (T1) will be recorded by the investigator on separate To and T1 sheets. Six standard sites on incisors, canines and premolars have been used in this study as study sites. The study sites will be six proximal-buccal line angles on the following teeth: right maxillary second premolar, mesiobuccal line angle; right maxillary canine, distobuccal line angle; left maxillary central incisor, distolabial line angle; right mandibular central incisor, distolabial line angle; left mandibular canine, distobuccal line angle; and left mandibular second premolar, mesiobuccal line angle. If a study tooth was missing, the corresponding tooth on the contralateral side will be examined.\n\n0\\. Absence of bleeding after 30 seconds\n\n1. Bleeding observed after 30 seconds\n2. Immediate bleeding', 'timeFrame': 'Improvement in Bleeding Index Scores at 4 Weeks'}, {'measure': 'Improvement in Gingival index', 'description': 'Improvement in Gingival Index Scores In Orthodontic Patients, Change from Baseline in Index at 4 weeks. All the measurements at the baseline (To) and follow ups (T1) will be recorded by the investigator on separate To and T1 sheets. Six standard sites on incisors, canines and premolars have been used in this study as study sites (same as above).\n\n0\\. No inflammation.\n\n1. Mild inflammation, slight change in color, slight edema, no bleeding on probing.\n2. Moderate inflammation, moderate glazing, redness, bleeding on probing.\n3. Severe inflammation, marked redness and hypertrophy, ulceration, tendency to spontaneous bleeding', 'timeFrame': 'Improvement in Gingival Index Scores at 4 Weeks'}, {'measure': 'Improvement of Orthodontic Plaque Index', 'description': 'Improvement in Orthodontic Plaque Index Scores In Orthodontic Patients, Change from Baseline in Index at 4 weeks. All the measurements at the baseline (To) and follow ups (T1) will be recorded by the investigator on separate To and T1 sheets. Six standard sites on incisors, canines and premolars have been used in this study as study sites (same as above) and the condition of adjacent marginal gingiva by staining the teeth with plaque disclosing solution will be assessed.\n\n0\\. No plaque deposits on the tooth surfaces surrounding the bracket base\n\n1. Plaque deposits on one tooth surface at the bracket base\n2. Plaque deposits on two tooth surface at the bracket base\n3. Plaque deposits on three tooth surface at the bracket base\n4. Plaque deposits on four tooth surface at the bracket base and/or gingival inflammation indicators (plaque deposits near the gingiva do not necessarily have to be present)', 'timeFrame': 'Improvement in Orthodontic Plaque Index Scores at 4 Weeks'}]",[],3,18 Years,40 Years,ALL,True,Aga Khan University,OTHER,0,63.0,ACTUAL,2025-09-01T16:18:10.927283,v2_robust,True,True,True,False,False,
NCT06081699,"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food Effect of TNP-2198 Capsules After Single Oral Dose in Healthy Participants","A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase 1 Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of TNP-2198 Capsules in Healthy Participants and the Effect of Food on the Pharmacokinetics of TNP-2198 Capsules in Healthy Participants",TNP-2198,"['Rifasutenizol', 'TNP-2198', 'TNP-2198 Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],[],COMPLETED,,2019-05-09,2019-09-18,"[{'measure': 'Percentage of Participants With Adverse Events (AEs)', 'description': 'An Adverse Event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An Adverse Event can therefore be any unfavorable and unintended sign (including abnormal laboratory values or abnormal clinical test results), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as Adverse Events.', 'timeFrame': 'Day 1 to Day 4'}]","[{'measure': 'Area Under the Plasma Concentration Versus Time Curve Extrapolated to Infinity (AUC0-inf)', 'description': 'Plasma concentrations of TNP-2198 were measured by a specific and validated assay. Plasma Pharmacokinetics (PK) parameters of TNP-2198 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'timeFrame': 'Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration.'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve from 0 to the Last Measurable Concentration (AUC0-t)', 'description': 'Plasma concentrations of TNP-2198 were measured by a specific and validated assay. Plasma PK parameters of TNP-2198 were read directly from the plasma concentration versus time profiles or calculated by using standard non-compartmental methods.', 'timeFrame': 'Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration.'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of TNP-2198', 'description': 'Plasma concentrations of TNP-2198 were measured by a specific and validated assay at specified time points', 'timeFrame': 'Hour 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24, 36, 48 and 72 after administration.'}]",4,18 Years,55 Years,ALL,True,TenNor Therapeutics (Suzhou) Limited,INDUSTRY,0,78.0,ACTUAL,2025-09-01T16:18:10.927403,v2_robust,True,True,True,False,True,
NCT05306899,Multi-center RCT of IV Ketamine Efficacy and Safety in Chronic Daily Headaches,A Multi-center Randomized Controlled Trial of Efficacy and Safety of Intravenous Ketamine for Chronic Daily Headaches: The KetHead Study,Ketamine,"['Ketamine hydrochloride', 'Ketamine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Daily Headache,['Chronic Daily Headache'],"['ketamine', 'migraine', 'daily headache', 'chronic pain']",RECRUITING,,2022-06-01,2026-02-01,"[{'measure': 'Difference in headache days between the 2 groups', 'description': 'Between-group difference in the number of headache days in the first 4 weeks after the infusion.\n\n(Defined as a day in which the headache lasts 4 or more hours, or a headache of any duration for which abortive treatment (anti-inflammatories, triptans, ergot derivatives, opioids) are taken. Patients will be asked to keep track of their headache days in a diary)', 'timeFrame': 'At 4 weeks'}]","[{'measure': 'Impact of ketamine on headache intensity after infusion', 'description': 'Impact of ketamine on headache intensity at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using Numerical Rating Scale (0-10)', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of ketamine on headache frequency after infusion', 'description': 'Impact of ketamine on headache frequency at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, as number of headache episodes per day', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of ketamine on headache duration after infusion', 'description': 'Impact of ketamine on duration of headache at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, from the headache diary maintained by patient', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact on sleep efficiency after ketamine infusion', 'description': 'Impact of ketamine on efficiency of sleep at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, measured with an actigraphy device', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact on quality of sleep after ketamine infusion', 'description': 'Impact of ketamine on quality of sleepat one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, assessed with the PSQI (Pittsburgh Sleep Quality Index) questionnaire', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact on physical activity after ketamine infusion', 'description': 'Impact of ketamine on physical activity at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, measured with actigraphy device', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact after ketamine infusion on daily activity', 'description': 'Impact of ketamine on seven daily activities (e.g. general activity, walking, mood etc.) at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, measured with Brief Pain Inventory (BPI) scale', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of on emotional well being (for catastrophizing) after ketamine infusion', 'description': 'Impact of ketamine on emotional well being at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using the PCS (pain catastrophizing scale) scale', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of on emotional well being for anxiety after ketamine infusion', 'description': 'Impact of ketamine on emotional well being at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using anxiety (GAD7- Generalized Anxiety Disorder-7) scale', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of on emotional well being for depression after ketamine infusion', 'description': 'Impact of ketamine on emotional well being at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using depression (PHQ9-Patient Health Questionnaire9) questionnaire', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of ketamine infusion on patient satisfaction', 'description': 'Impact of ketamine on patient satisfaction at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using global improvement (PGIC) scales', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact on quality of life after ketamine infusion', 'description': 'Impact of ketamine on quality of life at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using EQ-5D (European Quality of life) questionnaire', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Impact of ketamine infusion on analgesic consumption', 'description': 'Impact of ketamine on analgesic consumption at one month (4 weeks), two month (week 5-8) and three month (week 9-12) month after infusion, using name and dose of the analgesic use', 'timeFrame': 'At 1 month, 2 months and 3 months'}, {'measure': 'Side effects after ketamine infusion', 'description': 'Side effects after the ketamine infusion as assessed using Bowdle questionnaire', 'timeFrame': 'Immediately after infusion and after 1 week'}, {'measure': 'Side effects after ketamine infusion', 'description': 'Dissociative side effects assessed after the ketamine infusion, using the CADSS (Clinician Administered Dissociative States Scale) checklist', 'timeFrame': 'Immediately after the infusion'}]",16,18 Years,75 Years,ALL,False,"University Health Network, Toronto",OTHER,2,56.0,ESTIMATED,2025-09-01T16:18:10.927423,v2_robust,True,True,False,False,False,
NCT04634799,Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Study to AntagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19 (STOP Severe COVID-19),TM5614,"['TM5614', 'Plasminogen activator inhibitor-1 (PAI-1)']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Covid19,['Covid19'],"['PAI-1', 'TM5614', 'Plasminogen Activator Inhibitor']",SUSPENDED,Enrollment challenges; new batch of drug is being manufactured and there may be additional impetus to reactivate after the analogous Phase 2 study in Japan is completed and those results are made available,2021-01-08,2025-05-30,"[{'measure': 'Clinical improvement', 'description': 'Change of at least 2 points in the NIAID-defined ordinal scale (higher scores indicate improved outcome),:\n\n1. Death\n2. Hospitalized, receiving invasive mechanical ventilation or ECMO\n3. Hospitalized, receiving noninvasive ventilation or high-flow oxygen devices\n4. Hospitalized, requiring low-flow supplemental oxygen\n5. Hospitalized, not requiring supplemental oxygen but receiving ongoing medical care (related or not related to Covid-19)\n6. Hospitalized, requiring neither supplemental oxygen nor ongoing medical care (other than that specified in the protocol)\n7. Not hospitalized', 'timeFrame': '7 Days'}]","[{'measure': 'Sequential organ failure assessment (SOFA) score change', 'description': 'Change in degree of organ dysfunction as defined by the Sequential Organ Failure Assessment (SOFA) Score.\n\nThe SOFA score ranges from 0 to 24 (higher scores indicate more severe organ failure), with 0 to 4 points assigned for each of 6 organ dysfunctions (ie, central nervous system, cardiovascular, respiratory, renal, coagulation, and liver).', 'timeFrame': '7 Days'}, {'measure': 'PAI-1 Levels', 'description': 'Change in circulating levels', 'timeFrame': '48 hours'}, {'measure': 'Ventilator free days', 'description': 'For subjects who received mechanical ventilation, total number of days the subject was not on mechanical or non invasive mechanical ventilation while in the hospital', 'timeFrame': '14 days'}]",4,18 Years,,ALL,False,Northwestern University,OTHER,0,9.0,ACTUAL,2025-09-01T16:18:10.927469,v2_robust,True,True,False,True,False,Enrollment challenges; new batch of drug is being manufactured and there may be additional impetus to reactivate after the analogous Phase 2 study in Japan is completed and those results are made available
NCT05608499,Duobrii Treatment of Acne Keloidalis Nuchae (AKN),Efficacy and Safety of Duobrii in the Management of Acne Keloidalis Nuchae (AKN),Duobrii,"['halobetasol propionate and tazarotene', 'halobetasol propionate', 'Placebo', 'Duobrii', 'Bryhali']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Acne Keloidalis Nuchae,"['Acne Keloidalis Nuchae', 'AKN']",[],ACTIVE_NOT_RECRUITING,,2022-10-26,2025-07,"[{'measure': 'Changes in lesion count classification', 'description': 'Changes in lesion count classification as captured by photography.\n\nAKN Classification: Lesion Distribution Class I: sagittal width ≤ 3cm Class II: sagittal width \\< 3cm ≤ 6.5cm', 'timeFrame': 'Baseline and Week 12'}]","[{'measure': 'Changes in Pain Rating Scale', 'description': 'Changes in Pain Rating Scale as compared to baseline. Full scale is 0-10, where higher scores indicate greater severity of AKN pain symptoms.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Changes in Itch Rating Scale', 'description': 'Changes in Itch Rating Scale as compared to baseline. Full scale is 0-10, where higher scores indicate greater severity of AKN itch symptoms.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Changes in degree of dyspigmentation', 'description': 'Changes in percent of treatment area affected with dyspigmentation as compared to baseline.', 'timeFrame': 'Baseline and Week 12'}]",4,18 Years,,ALL,False,Icahn School of Medicine at Mount Sinai,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:10.927515,v2_robust,True,True,False,False,False,
NCT00045799,Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill,Safety & Efficacy of Omeprazole Sodium Bicarbonate for the Prevention of Upper GI Bleeding in the Critically Ill,Omeprazole sodium bicarbonate immediate release PWD/FS,"['Cimetidine IV', 'Omeprazole sodium bicarbonate immediate release PWD/FS']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Upper Gastrointestinal Bleeding,['Upper Gastrointestinal Bleeding'],[],COMPLETED,,2002-05,2003-05,[],[],0,16 Years,,ALL,False,"Bausch Health Americas, Inc.",INDUSTRY,0,354.0,ACTUAL,2025-09-01T16:18:10.927534,v2_robust,True,True,True,False,False,
NCT00234299,Effects of ASA on Prostate Tissue,In Vivo Molecular Effects of Aspirin on Prostate Tissue,Aspirin,"['Aspirin', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Prostate Cancer,['Prostate Cancer'],"['Cancer', 'Prostate', 'Preventive Therapy']",COMPLETED,,2005-12,2015-12,"[{'measure': 'Assess the effect of oral aspirin on in vivo prostate epithelial cells.', 'timeFrame': '6 months'}]","[{'measure': 'Changes in COX-2 and COX-2 related gene expression in prostate biopsy tissue before and after the intervention; effects of the intervention on measures of apoptosis and cell cycle; effects of the intervention on global prostate gene expression.', 'timeFrame': '6 months'}, {'measure': 'To measure changes in COX-2 and COX-2 related gene expression in prostate biopsy tissue before and after a 6 month intervention with enteric coated aspirin (325mg/day).', 'timeFrame': '6 months'}]",3,45 Years,74 Years,MALE,True,University of Washington,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:10.927540,v2_robust,True,True,True,False,False,
NCT01210599,A Pilot Trial of IV Pamidronate for Low Back Pain,A Pilot Trial of Intravenous Pamidronate for Low Back Pain,Pamidronate,['Pamidronate'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Chronic Low Back Pain,['Chronic Low Back Pain'],"['Back Pain', 'Bisphosphonate', 'Pamidronate', 'Bone Pain']",COMPLETED,,2004-04,2009-10,[],[],0,21 Years,,ALL,True,"Pappagallo, Marco, M.D.",INDIV,0,44.0,ACTUAL,2025-09-01T16:18:10.927782,v2_robust,True,True,True,False,False,
NCT02149199,A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma.,A Clinical Study Comparing Symbicort® 'as Needed' With Terbutaline 'as Needed' and With Pulmicort® Twice Daily Plus Terbutaline 'as Needed' in Adult and Adolescent Patients With Asthma.,budesonide/formoterol 'as needed' + budesonide placebo bid,"[""budesonide/formoterol 'as needed' + budesonide placebo bid"", ""budesonide bid + terbutaline 'as needed'"", ""terbutaline 'as needed' + placebo budesonide bid""]",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],[],COMPLETED,,2014-07-07,2017-08-02,"[{'measure': ""'Well-controlled Asthma Week' - a Derived Binary Variable (Yes/No)"", 'description': ""A well-controlled asthma week is defined as the fulfilment of both conditions A) and B) below: A) Two or more of the following criteria are fulfilled: - No more than 2 days with a daily asthma symptom score \\>1 - No more than 2 days of 'as needed' medication use, up to a maximum of 4 occasions per week (multiple occasions per day should be regarded as separate occasions) - Morning PEF ≥80% of Predicted Normal every day B) Both of the following criteria are fulfilled: - No nighttime awakenings due to asthma - No additional inhaled and/or systemic glucocorticosteroid treatment due to asthma. The binary variable well-controlled asthma week was derived for each patient and study week. In addition, for each week, the percent of patients with well-controlled asthma week was derived. It is required that the eDiary had to be completed on at least 5 days in a week to be a well-controlled asthma week."", 'timeFrame': 'Weekly, up to 52 weeks'}]","[{'measure': 'Number of Participants Experiencing at Least One Severe Asthma Exacerbation', 'description': 'A severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids', 'timeFrame': 'Day 1 up to 52 weeks'}, {'measure': 'Number of Participants Experiencing at Least One Moderate or Severe Asthma Exacerbation', 'description': 'A moderate exacerbation is defined as a deterioration of asthma requiring a change in treatment, i.e. initiation of prescribed additional ICS treatment to avoid progression of the worsening of asthma to a severe exacerbation.\n\nA severe exacerbation is defined as a deterioration of asthma requiring any of the following: use of systemic glucocorticosteroids (GCS) for at least 3 days, inpatient hospitalization, or emergency room visit due to asthma that required systemic steroids', 'timeFrame': 'Day 1 up to 52 weeks'}, {'measure': 'Average Change From Baseline in Pre-dose Forced Expiratory Volume in 1 Second (FEV1)', 'description': 'Overall estimate of FEV1 (mL) pre-bronchodilator change from baseline. Baseline is the measurement at Visit 3 (prior to first dose of Investigational Product) from MMRM (mixed model repeated measures analysis).', 'timeFrame': 'Study weeks 0,4,16,28,40,52'}, {'measure': 'Average Change From Baseline in Morning Peak Expiratory Flow (PEF)', 'description': 'Morning peak expiratory flow (eDiary) change from baseline over the randomised treatment period. Baseline is defined as the mean of all non-missing morning measurements during the last 10 days of the run-in period.', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Average Change From Baseline in Evening PEF', 'description': 'Evening peak expiratory flow (eDiary) change from baseline during the randomised treatment period. Baseline is defined as the mean of all non-missing evening measurements during the last 10 days of the run-in period.', 'timeFrame': 'up to 52 weeks'}, {'measure': ""Average Change From Baseline in Number of Inhalations of 'as Needed' Medication."", 'description': ""'As needed' inhalations change from baseline over the randomised treatment period. Baseline is defined as the last 10 days of the run-in period. 'As needed' use was calculated as the cumulative doses of 'as needed' medication over the randomised treatment period divided by the follow-up time (number of days - 1). ie, average number of inhalations per day."", 'timeFrame': 'up to 52 weeks'}, {'measure': 'Average Change From Baseline in Asthma Symptom Score', 'description': 'Asthma symptom score (eDiary) change from baseline during the randomised treatment period. Symptom score is entered morning and evening by the patient on a 4-point scale from 0 to 3 with higher values indicating more severe symptoms. Asthma symptom score is then the sum of the day and night scores, which implies a range of scores from 0 - 6, with higher values indicating more severe symptoms. Baseline is defined as the mean of all non-missing measurements during the last 10 days of the run-in period.', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Change From Baseline in the Percentage of Nighttime Awakenings Due to Asthma', 'description': 'Night-time awakenings (%) due to asthma change from baseline. Variable analysed is the proportion (%) of nights during the relevant period with night-time awakenings. Baseline refers to the last 10 nights of the run-in period.', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Change From Baseline in Percentage of Symptom-free Days', 'description': 'Symptom-free days (%) change from baseline during the randomised treatment period.Variable analysed is the proportion (%) of symptom-free days during the relevant period. Baseline refers to the last 10 days of the run-in period.', 'timeFrame': 'up to 52 weeks'}, {'measure': ""Change From Baseline in Percentage of 'As Needed' Free Days"", 'description': ""'As needed' free days (%) change from baseline during the randomised treatment period. An 'as needed' free day is defined as a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of 'as needed' free days during the relevant period. Baseline refers to the last 10 days of the run-in period."", 'timeFrame': 'up to 52 weeks'}, {'measure': 'Change From Baseline in Percentage of Asthma Control Days', 'description': ""Asthma control days (%) change from baseline. An asthma control day is defined as the fulfilment of all of the following criteria; a day and night with no asthma symptoms, a night with no awakenings due to asthma symptoms and a day and night with no use of 'as needed' medication. Variable analysed is the proportion (%) of asthma control days during the randomised treatment period. Baseline refers to the last 10 days of the run-in period."", 'timeFrame': 'up to 52 weeks'}, {'measure': 'Number of Patients With Study Specific Asthma Related Discontinuation', 'description': 'Study specific asthma related discontinuation', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Poorly Controlled Asthma Weeks', 'description': ""A poorly-controlled asthma week is defined as a week meeting any one of the following conditions: Two or more consecutive days with awakenings due to asthma on both nights; A recorded use of 'as needed' medication for symptom relief of at least 3 occasions per day, for at least 2 consecutive days; Additional systemic GCS treatment required for severe exacerbation. If there were sufficient data within a week available to confirm the week was not poorly-controlled, the week is labelled as 'does not meet criteria for poorly-controlled'."", 'timeFrame': 'Weekly for up to 52 weeks'}, {'measure': 'Number of Participants Experiencing at Least One Occasion With Additional Steroids for Asthma', 'description': 'Additional steroids for asthma includes any additional inhaled and/or systemic glucocorticosteroids treatment due to asthma while in the randomised treatment period.', 'timeFrame': 'Day 1 up to 52 weeks'}, {'measure': 'Average Change From Baseline in Asthma Control Questionnaire (ACQ-5)', 'description': ""Asthma Control Questionnaire 5-item version score change from baseline. ACQ questionnaire contains five questions on patients' symptoms, which are assessed on a 7-point scale from 0 (representing good control) to 6 (representing poor control). The score is the mean score of all questions for which responses are provided."", 'timeFrame': 'Study weeks 0,4,16,28,40,52'}, {'measure': 'Average Change From Baseline in Asthma Quality of Life Questionnaire; Standard Version (AQLQ(S))', 'description': 'Asthma Quality of Life Questionnaire Standardised Version (AQLQ (S) overall score change from baseline. AQLQ(S) consists of 32 questions in 4 domains. Each question is assessed on a 7-point scale from 1 to 7, with higher values indicating better health-related quality of life. The overall score is calculated as the mean score of all 32 items.', 'timeFrame': 'Study weeks 0,16,28,40,52'}, {'measure': 'Percentage of Controller Use Days', 'description': ""ICS controller use days (%) during the randomised treatment period is calculated as the cumulative number of days when any controller medication (containing ICS) was taken including maintenance (Pulmicort bid group) and 'as needed' medication (Symbicort 'as needed' group) and additional prescribed ICS for asthma exacerbations and/or long term poor asthma control (all treatment groups), divided by the number of days in the randomised treatment period."", 'timeFrame': 'up to 52 weeks'}, {'measure': 'Annual Severe Asthma Exacerbation Rate', 'description': 'Severe asthma exacerbations over the randomised treatment period.', 'timeFrame': 'up to 52 weeks'}, {'measure': 'Annual Moderate or Severe Asthma Exacerbation Rate', 'description': 'Moderate or severe asthma exacerbations during the randomised treatment period.', 'timeFrame': 'up to 52 weeks'}]",20,12 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,3850.0,ACTUAL,2025-09-01T16:18:10.927787,v2_robust,True,True,True,False,False,
NCT05488132,Administration of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML),Application of Anti-siglec-6 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML),anti-siglec-6 CAR-T cell therapy,['anti-siglec-6 CAR-T cell therapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Acute Myeloid Leukemia Refractory,"['Acute Myeloid Leukemia Refractory', 'Acute Myeloid Leukemia, in Relapse']",[],UNKNOWN,,2022-04-01,2025-03-31,"[{'measure': 'Dose-limiting toxicity（DLT）', 'description': 'Adverse events assessed according to NCI-CTCAE v5.0 criteria', 'timeFrame': 'Baseline up to 28 days after T cell infusion'}]","[{'measure': 'MRD negative overall response rate (MRD- ORR)', 'description': 'Assessment of MRD negative overall response rate (MRD- ORR) at 3 months of treatment', 'timeFrame': '3 months'}, {'measure': 'Overall response rate (ORR)', 'description': 'Assessment of ORR (ORR = CR + CRi ) at Month 6, 12, 18 and 24', 'timeFrame': 'Month 6, 12, 18 and 24'}, {'measure': 'Event-free survival (EFS)', 'description': 'Assessment of EFS at Month 6, 12, 18 and 24', 'timeFrame': 'Month 6, 12, 18 and 24'}, {'measure': 'Overall survival (OS)', 'description': 'Assessment of OS at Month 6, 12, 18 and 24', 'timeFrame': 'Time Frame: Month 6, 12, 18 and 24'}]",5,18 Years,70 Years,ALL,False,Xuzhou Medical University,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:10.927898,v2_robust,True,True,False,False,True,
NCT02985632,A Study to Evaluate the Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants,Single-dose Pharmacokinetics of BMS-986141 in Participants With Hepatic Impairment Compared to Healthy Participants,BMS-986141,['BMS-986141'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatic Impairment,['Hepatic Impairment'],[],WITHDRAWN,Business objectives have changed.,2017-01-11,2017-07-07,"[{'measure': 'Maximum observed plasma concentration (Cmax) of BMS-986141', 'timeFrame': 'Days 1-7 (healthy) Days 1-10 (heaptic Impairment)'}, {'measure': 'Area under the plasma concentration-time curve from time zero extrapolated to infinite time (AUC(INF)) of BMS-986141', 'timeFrame': 'Days 1-7 (healthy) Days 1-10 (heaptic Impairment)'}, {'measure': 'Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC(0-T)) of BMS-986141', 'timeFrame': 'Days 1-7 (healthy) Days 1-10 (heaptic Impairment)'}, {'measure': 'Area under the plasma concentration-time curve from time zero to 144 hours postdose (AUC(0-144h)) of BMS-986141', 'timeFrame': 'Days 1-7 (healthy) Days 1-10 (heaptic Impairment)'}]","[{'measure': 'Safety endpoints include the incidence of adverse events (AEs), serious adverse events (SAEs), leading to discontinuation.', 'timeFrame': 'Days 1-7 (healthy) Days 1-10 (heaptic Impairment)'}]",5,18 Years,70 Years,ALL,True,Bristol-Myers Squibb,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:10.927918,v2_robust,True,True,False,True,True,Business objectives have changed.
NCT00997932,A Pilot Study of Early Postpartum Intrauterine Contraception,A Pilot Study of Early Postpartum Intrauterine Contraception,"Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration","['LNG-IUS', 'Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Unplanned Pregnancy,['Unplanned Pregnancy'],"['levonorgestrel releasing intrauterine device', 'levonorgestrel releasing intrauterine contraception', 'unintended pregnancy prevention', 'postpartum contraception']",COMPLETED,,2009-06,2012-11,"[{'measure': 'IUD Expulsion', 'description': 'Expulsion of the LNG-IUS', 'timeFrame': 'From time of insertion to final study date which is 6 months after IUD insertion.'}]",[],1,21 Years,45 Years,FEMALE,False,"University of North Carolina, Chapel Hill",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:10.927932,v2_robust,True,True,True,False,False,
NCT04665232,Immunomodulatory Effects of Subcutaneous Progesterone in Patients Affected by Autoimmune Diseases,Immunomodulatory Effects of Subcutaneous Progesterone in Patients Undergoing IVF Affected by Autoimmune Diseases,aqueous subcutaneous progesterone,['aqueous subcutaneous progesterone'],1,OBSERVATIONAL,[],,,Autoimmune Diseases,"['Autoimmune Diseases', 'Infertility']","['autoimmune diseases and infertility', 'luteal supplementation with subcutaneous progesterone', 'Systemic effect of progesterone']",COMPLETED,,2014-04,2017-04,"[{'measure': 'Pregnancy Rate percentage, Implantation Rate percentage, Live Birth Rate percentage', 'description': 'number of pregnancies / 100 embryotransfer, number of implanted embryos/ number of embryos trafsferred, number of live birth', 'timeFrame': '12 mounths'}]",[],1,18 Years,42 Years,FEMALE,False,"San Carlo Public Hospital, Potenza, Italy",OTHER,0,18.0,ACTUAL,2025-09-01T16:18:10.928044,v2_robust,False,True,True,False,False,
NCT00695032,Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors,Biologic Evaluation of Renal Toxicity of Cisplatin and Ifosfamide (TOXIPLAT),cisplatin,"['cisplatin', 'ifosfamide']",2,INTERVENTIONAL,['NA'],,,Chemotherapeutic Agent Toxicity,"['Chemotherapeutic Agent Toxicity', 'Renal Toxicity', 'Unspecified Adult Solid Tumor, Protocol Specific']","['renal toxicity', 'chemotherapeutic agent toxicity', 'unspecified adult solid tumor, protocol specific']",SUSPENDED,,2007-10,,"[{'measure': 'Evolution of different biomarkers'}, {'measure': 'Sensitivity, specificity, and predictive value (positive and negative) of different markers'}]",[],2,18 Years,,ALL,False,Institut Claudius Regaud,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:10.928157,v2_robust,True,True,False,True,False,
NCT06316232,DBS and Levodopa for Treating Freezing of Gait in Parkinson's Disease,Efficacy of Deep Brain Stimulation and Levodopa on Freezing of Gait in Advanced Parkinson's Disease: a Comparative Study,MED ON plus,['MED ON plus'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Freezing of Gait,"['Freezing of Gait', 'Parkinson Disease']","['freezing of gait', 'gait disturbances', 'parkinson disease']",RECRUITING,,2023-10-10,2026-12-31,"[{'measure': 'Time spent with FOG during protocol', 'description': 'Video-assessed reduction in the total time of FoG during the standardize walking protocol in MED ON plus or STIM ON plus condition compared to baseline.', 'timeFrame': 'immediate post monitoring'}]","[{'measure': 'Gait performance', 'description': 'Changes in gait parameters measured by a system of 3 wearable inertial sensors, including: gait speed, stride lenght, number of step, cadence, gait variability, left-right asymmetry during MED ON plus or STIM ON plus protocol compared to baseline.', 'timeFrame': 'immediate post monitoring'}, {'measure': ""MDS-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III"", 'description': 'Change in items 3.10 and 3.11 MDS UPDRS part III and total score between MED ON plus or STIM ON plus condition and baseline.', 'timeFrame': 'immediate post monitoring'}, {'measure': 'Patient global impression of change (PGI-C)', 'description': 'Change in PGI-C scores on MED ON plus or STIM ON plus condition compared to baseline.', 'timeFrame': 'immediate post monitoring'}, {'measure': 'Trail Making test A and B', 'description': 'Change in Trail Making test A and B scores during MED ON plus or STIM ON plus protocol compared to baseline.', 'timeFrame': 'immediate post monitoring'}, {'measure': 'Phonemic/Semantic alternate Fluency test', 'description': 'Change in during Phonemic/Semantic alternate Fluency test scores between MED ON plus or STIM ON plus condition and baseline.', 'timeFrame': 'immediate post monitoring'}]",6,18 Years,80 Years,ALL,False,IRCCS Istituto delle Scienze Neurologiche di Bologna,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:10.928165,v2_robust,True,True,False,False,False,
NCT01536132,Intermittent Intravenous Levosimendan in Ambulatory Advanced Chronic Heart Failure Patients,"Multicenter, Double-blind, Placebo-controlled Randomized Trial to Evaluate the Efficacy and Safety of Intravenous Administration of Intermittent Doses of Levosimendan in Ambulatory Patients With Advanced CHF: the LION-HEART Study",Levosimendan,"['Placebo', 'Levosimendan', 'SIMDAX (trade mark)']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure,['Heart Failure'],"['Levosimendan', 'chronic heart failure', 'inotropic drug']",COMPLETED,,2010-04,2015-11,"[{'measure': 'Changes of natriuretic peptide levels between baseline and end of treatment.', 'timeFrame': '3 months.'}]","[{'measure': 'Mortality .', 'timeFrame': 'from baseline to end of follow-up (12 months).'}, {'measure': 'Hospitalisation.', 'timeFrame': 'from baseline to end of follow-up (12 months).'}]",3,18 Years,,ALL,False,Parc de Salut Mar,OTHER,0,70.0,ACTUAL,2025-09-01T16:18:10.928409,v2_robust,True,True,True,False,False,
NCT00928798,Topical Rapamycin for Fibrofolliculomas,Topical Rapamycin to Treat Fibrofolliculomas in Birt-Hogg-Dubé Syndrome,Rapamycin,"['Rapamycin', 'Sirolimus', 'Rapamune', 'placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Birt-Hogg-Dubé Syndrome,['Birt-Hogg-Dubé Syndrome'],[],COMPLETED,,2010-01,2011-08,"[{'measure': 'Significant regression of lesions (reduction of fibrofolliculoma size and count) in the treated area.', 'timeFrame': '3 and 6 months'}]","[{'measure': 'Side effects', 'timeFrame': '3 and 6 months'}]",2,18 Years,,ALL,False,Maastricht University Medical Center,OTHER,1,19.0,ACTUAL,2025-09-01T16:18:10.928489,v2_robust,True,True,True,False,False,
NCT05273398,Effects of Diazepam on RNS Detections,Exploratory Open-Label Study of Effects on Responsive Neurostimulator Activity After Intranasal Administration of Single Dose of Valtoco® to People With Epilepsy,nasal diazepam,"['nasal diazepam', 'Nasal diazepam (Valtoco)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Epilepsies, Partial","['Epilepsies, Partial']","['epilepsy', 'responsive neurostimulator', 'diazepam', 'rescue medication']",COMPLETED,,2022-03-01,2022-11-10,"[{'measure': 'Change in Detections', 'description': 'The investigators will assess the percent change in Detections calculated separately for each hour during the first 8 hours of the post-dose observation period. The number of Detections during each hour of the 8-hour period post dose will be compared to the same hour during the seven comparable 8-hour sessions of the 7-day pre-dose observation period.', 'timeFrame': '8 days'}]","[{'measure': 'Change in hourly histograms', 'description': 'Hourly histograms generated by the RNS system and stored in the PDMS will be collected. In addition, using ""detailed diagnostics"" visual analysis of minute-by-minute Detections will be reviewed for obvious patterns of interest for the 8 hours post dosing.', 'timeFrame': '8 hours'}, {'measure': 'Detection reduction of >50%', 'description': 'Total number of hours during the 48-hour post-dose observation period where the number of Detections is \\<50% of the mean hourly Detection rate over the 7-day pre-dose observation period will be calculated.', 'timeFrame': '9 days'}, {'measure': 'Change in diary recorded seizures', 'description': 'The number of diary-recorded seizures during the post-dose observation period will be recorded.', 'timeFrame': '14 days'}]",4,18 Years,,ALL,False,University of Cincinnati,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:10.928522,v2_robust,True,True,True,False,False,
NCT05859698,Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia,"A Phase 4, Single-Arm, Open-Label Study to Evaluate the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Subjects With Tardive Dyskinesia",Valbenazine,"['NBI-98854', 'Valbenazine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder', 'Bipolar Disorder', 'Major Depressive Disorder', 'Tardive Dyskinesia']",[],COMPLETED,,2023-05-25,2024-12-27,"[{'measure': 'Change from baseline in the Tardive Dyskinesia Impact Scale (TDIS) total score at Week 24', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change from baseline in the Sheehan Disability Scale (SDS) Items 1, 2, and 3 at Week 24', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change from baseline in the EQ-visual analogue scale (EQ-VAS) score at Week 24', 'timeFrame': 'Baseline, Week 24'}]","[{'measure': 'Patient Global Impression of Change (PGI-C) score at Week 24', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change from baseline in the Clinical Global Impression of Severity - TD (CGI-TD-S) score at Week 24', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change from baseline in the Abnormal Involuntary Movement Scale (AIMS) dyskinesia total score at Week 24', 'timeFrame': 'Baseline, Week 24'}]",6,18 Years,,ALL,False,Neurocrine Biosciences,INDUSTRY,0,59.0,ACTUAL,2025-09-01T16:18:10.928636,v2_robust,True,True,True,False,False,
NCT01075698,A Trial of Telmisartan Prevention of Cardiovascular Disease,A Trial of Telmisartan Prevention of Cardiovascular Disease,Non-ARB (standard therapy),"['Non-ARB (standard therapy)', 'ARB (Telmisartan)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],"['Type 2 Diabetes', 'Cerebrovascular disease', 'Coronary Artery Disease', 'Chronic Kidney Disease', 'Peripheral Artery Disease']",COMPLETED,,2009-07,2016-03,"[{'measure': 'The effects of ARB therapy and that of standard therapy except ARB on the biomarker levels (UACR and BNP)', 'timeFrame': 'for three years'}]","[{'measure': 'The effect of the two treatments on the incidence of events, and the relationship between the incidence of events and the biomarker levels (UACR, BNP, urine 8-hydroxy-2-deoxyguanosine, serum adiponectin, serum high-molecule adiponectin, eGFR)', 'timeFrame': 'for three years'}]",2,40 Years,79 Years,ALL,False,Kumamoto University,OTHER,1,1228.0,ACTUAL,2025-09-01T16:18:10.928683,v2_robust,True,True,True,False,False,
NCT06934798,Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery,Inotropic Effects of Vasopressin Versus Noradrenaline In Patients With Vasoplegic Syndrome After Cardiac Surgery,Vasopressin intravenous infusion,"['Noradrenaline', 'Arginine Vasopressin', 'Norepinephrine intravenous infusion', 'Vasopressin intravenous infusion', 'Pitressin', 'Levophed', 'ADH']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Vasoplegic Syndrome of Cardiac Surgery,['Vasoplegic Syndrome of Cardiac Surgery'],"['Shock Cardiogenic', 'Postoperative Complications', 'Cardiac Surgical Procedures']",RECRUITING,,2024-04-01,2025-07-30,"[{'measure': 'Change in inotropic function assessed by cardiac output between T0 and T1', 'description': 'The primary outcome is the variation in cardiac output (CO), measured by transthoracic echocardiography, from the beginning of the vasopressor infusion (T0) until the achievement of target mean arterial pressure ≥65 mmHg (T1), in patients with vasoplegic syndrome after cardiac surgery. This measurement reflects the inotropic effect of vasopressin versus norepinephrine', 'timeFrame': 'Up to 1 hour after initiation of vasopressor therapy'}]","[{'measure': 'Change in left ventricular ejection fraction (LVEF) between T0 and T1', 'description': 'LVEF will be measured using transthoracic echocardiography at T0 (baseline) and T1 (after achieving MAP ≥65 mmHg), to assess changes in left ventricular systolic function.', 'timeFrame': 'Up to 1 hour after vasopressor initiation'}, {'measure': 'Time to achieve target mean arterial pressure (MAP ≥65 mmHg)', 'description': 'Time (in minutes) between the start of vasopressor infusion (T0) and the point at which MAP ≥65 mmHg is reached (T1), indicating hemodynamic stabilization.', 'timeFrame': 'Up to 1 hour'}, {'measure': 'Change in heart rate (HR) between T0 and T1', 'description': 'Heart rate will be measured at baseline (T0) and after stabilization (T1) to assess the chronotropic effect of each drug.', 'timeFrame': 'Up to 1 hour'}, {'measure': 'Change in arterial lactate levels between T0 and T1', 'description': 'Arterial lactate will be used as a marker of tissue perfusion, measured at T0 and T1, to evaluate response to vasopressor therapy.', 'timeFrame': 'Up to 1 hour'}, {'measure': 'Change in central venous oxygen saturation (SvO₂)', 'description': 'SvO₂ will be measured at T0 and T1 as an indirect marker of oxygen delivery and cardiac output adequacy.', 'timeFrame': 'Up to 1 hour'}, {'measure': 'Change in CO₂ gap (central venous-to-arterial CO₂ difference)', 'description': 'The CO₂ gap will be evaluated at T0 and T1 to assess tissue hypoperfusion and response to vasopressor use.', 'timeFrame': 'Up to 1 hour'}, {'measure': 'Need for additional open-label norepinephrine', 'description': 'Number of participants in each arm requiring additional norepinephrine outside the study drug to reach MAP ≥65 mmHg.', 'timeFrame': 'During initial vasopressor titration (up to 1 hour)'}]",8,18 Years,,ALL,True,University of Sao Paulo,OTHER,2,350.0,ESTIMATED,2025-09-01T16:18:10.928695,v2_robust,True,True,False,False,False,
NCT01062698,Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke,The Contribution of Intra-arterial Thrombectomy in Acute Ischemic Stroke in Patients Treated With Intravenous Thrombolysis,Alteplase (rt-PA)/Actilyse,['Alteplase (rt-PA)/Actilyse'],1,INTERVENTIONAL,['NA'],,,Cerebral Stroke,"['Cerebral Stroke', 'Cerebrovascular Accident']","['mechanical Thrombectomy', 'CVA (Cerebrovascular Accident)', 'Cerebrovascular Accident, Acute']",TERMINATED,Efficacy,2010-06,2016-03,"[{'measure': 'Modified Rankin Score (mRs )', 'timeFrame': '3 months after treatment'}]","[{'measure': 'Quality of Life (Euroqol EQ-5D)', 'timeFrame': '3 months after treatment'}, {'measure': 'Barthel Score', 'timeFrame': '3 months after treatment'}]",3,18 Years,80 Years,ALL,False,"Central Hospital, Nancy, France",OTHER,0,412.0,ACTUAL,2025-09-01T16:18:10.928766,v2_robust,True,True,False,True,False,Efficacy
NCT02422498,Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy,A Phase II Trial of Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy,cisplatin,['cisplatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Recurrent/Metastatic Triple Negative Breast Cancer,['Locally Recurrent/Metastatic Triple Negative Breast Cancer'],"['Treated with Concurrent Cisplatin', 'Treated with Radiation Therapy', 'Homologous Recombination Repair Status', 'Biomarker of Response', '15-032', 'Patients']",COMPLETED,,2015-04-14,2022-12-19,"[{'measure': 'Response (RECIST 1.1 vs. PET Response Criteria (PRC) as Measurement Tools for Treatment Response)', 'description': 'RECIST 1.1 as measurement tools for treatment response.', 'timeFrame': '2 years'}]",[],1,18 Years,,FEMALE,False,Memorial Sloan Kettering Cancer Center,OTHER,1,49.0,ACTUAL,2025-09-01T16:18:10.928776,v2_robust,True,True,True,False,False,
NCT00971763,"Gemcitabine Hydrochloride, Cyclophosphamide, Vincristine Sulfate, Prednisolone, and Rituximab in Treating Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma","A Phase II Multicentre Trial of Gemcitabine, CVP, and Rituximab (R-GCVP) for the Treatment of Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma, Considered Unsuitable for R-CHOP Chemotherapy",cyclophosphamide,"['vincristine sulfate', 'cyclophosphamide', 'prednisolone', 'gemcitabine hydrochloride']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,['Lymphoma'],"['stage I adult diffuse large cell lymphoma', 'contiguous stage II adult diffuse large cell lymphoma', 'noncontiguous stage II adult diffuse large cell lymphoma', 'stage III adult diffuse large cell lymphoma', 'stage IV adult diffuse large cell lymphoma']",COMPLETED,,2006-03,2011-07,"[{'measure': 'Overall response rate', 'timeFrame': 'End of treatment'}]","[{'measure': 'Toxicity', 'timeFrame': 'End of treatment'}, {'measure': 'Progression-free survival', 'timeFrame': 'Not specified in protocol'}, {'measure': 'Overall survival', 'timeFrame': 'Not specified in protocol'}]",4,18 Years,,ALL,False,"University College, London",OTHER,0,62.0,ACTUAL,2025-09-01T16:18:10.928877,v2_robust,True,True,True,False,False,
NCT00215163,Paroxetine-CR to Treat Post-Traumatic Stress Disorder (PTSD) Symptomatic After Initial Exposure Therapy,Randomized Trial of Paroxetine-CR for the Treatment of Patients With Post-Traumatic Stress Disorder (PTSD) Remaining Symptomatic After Initial Exposure Therapy,Cognitive-behavioral therapy and paroxetine-CR,['Cognitive-behavioral therapy and paroxetine-CR'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Stress Disorders, Post-Traumatic","['Stress Disorders, Post-Traumatic']","['PTSD', 'Anxiety', 'CBT', 'Exposure', 'Paroxetine', 'Paroxetine-CR']",COMPLETED,,2002-12,2006-06,"[{'measure': 'Short PTSD Rating Interview (SPRINT)'}, {'measure': 'Davidson Trauma Scale (DTS)'}]","[{'measure': 'Clinical Global Impressions Severity Scale (CGI-S)'}, {'measure': 'Clinical Global Impressions Improvement Scale (CGI-I)'}, {'measure': 'Posttraumatic Diagnostic Scale (PDS)'}, {'measure': 'Beck Depression Inventory (BDI)'}, {'measure': 'Quality of Life Enjoyment and Satisfaction Questionnaire/General Activities Subscale (Q-LES-Q/GA)'}, {'measure': 'Sheehan Disability Scale (SDS)'}, {'measure': 'Connor-Davidson Resilience Scale (CD-RISC)'}, {'measure': 'Post-Traumatic Cognitions Inventory (PTCI)'}, {'measure': 'Severity of Symptoms Scale (SOSS)'}, {'measure': 'Pittsburgh Sleep Quality Index (PSQI)'}, {'measure': 'World Assumptions Scale (WAS)'}, {'measure': 'Mood-SR Lifetime'}]",14,18 Years,65 Years,ALL,False,Duke University,OTHER,2,17.0,ACTUAL,2025-09-01T16:18:10.928887,v2_robust,True,True,True,False,False,
NCT00013663,Immune Therapies and Anti-HIV Therapy Withdrawal in Controlling Viral Load,A Randomized Controlled Study Testing the Efficacy of Immunotherapies to Control Plasma HIV RNA Concentrations Upon Interruption of Highly Active Antiretroviral Therapy,Aldesleukin,['Aldesleukin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infections,['HIV Infections'],"['Virus Replication', 'HIV-1', 'AIDS Vaccines', 'RNA, Viral', 'Avipoxvirus', 'Genetic Vectors', 'Viral Load', 'aldesleukin', 'Antiretroviral Therapy, Highly Active', 'HIV Therapeutic Vaccine', 'Treatment Interruption']",COMPLETED,,,2006-06,[{'measure': 'Mean log10 viral load for each experimental group from the average of 5 values obtained during Weeks 21 to 25 (8 to 12 weeks following HAART interruption'}],"[{'measure': 'Proportion of participants who relapse during the first 12 weeks following stopping of HAART'}, {'measure': 'length of time to the termination of Step II among participants'}, {'measure': 'changes in frequency, activation state, and HIV-specific functional capacity of T and NK cells in blood, as monitored by expression of intracellular cytokines during the first 12 weeks after stopping HAART, with respect to termination of Step II'}]",4,19 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,92.0,,2025-09-01T16:18:10.928968,v2_robust,True,True,True,False,False,
NCT06771063,A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients,"A Multicenter, Randomized, Double-blind, Positive-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of WXSH0102 Tablets in the Treatment of Vulvovaginal Candidiasis (VVC)",WXSH0102/placebo,"['fluconazole capsules/placebo', 'WXSH0102/placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Vaginitis,['Vaginitis'],[],RECRUITING,,2025-01-13,2025-07-31,"[{'measure': 'Proportion of subjects achieving cure at the D11±2 visit.', 'description': 'Proportion of subjects achieving cure (defined as the disappearance of VVC symptoms and signs along with a negative Candida culture) at the D11±2 visit.', 'timeFrame': 'day 11±2'}]","[{'measure': 'Proportion of subjects achieving clinical cure at the D11±2 visit', 'description': 'Proportion of subjects achieving clinical cure (complete disappearance of VVC symptoms and signs) at the D11±2 visit;', 'timeFrame': 'day 11±2'}, {'measure': 'Proportion of subjects achieving mycological clearance at the D11±2 visit', 'description': 'Proportion of subjects achieving mycological clearance (negative growth of Candida species in fungal culture) at the D11±2 visit;', 'timeFrame': 'day 11±2'}, {'measure': 'Proportion of subjects achieving clinical improvement at the D11±2 visit', 'description': 'Proportion of subjects achieving clinical improvement (partial or complete resolution of symptoms and signs, with a total VVC scale score ≤1) at the D11±2 visit', 'timeFrame': 'day 11±2'}, {'measure': 'Difference in VVC scale scores between the D11±2 visit and baseline visit', 'description': 'Difference in VVC scale scores between the D11±2 visit and baseline visit', 'timeFrame': 'day 11±2'}, {'measure': 'Proportion of subjects achieving cure at the D25±3 visit.', 'description': 'Proportion of subjects achieving cure (defined as the disappearance of VVC symptoms and signs along with a negative Candida culture) at the D25±3 visit..', 'timeFrame': 'Day 25±3'}, {'measure': 'Proportion of subjects achieving mycological clearance at the D25±3 visit', 'description': 'Description: Proportion of subjects achieving mycological clearance (negative growth of Candida species in fungal culture) at the D25±3 visit;', 'timeFrame': 'Day 25±3'}, {'measure': 'Proportion of subjects achieving clinical improvement at the D25±3 visit', 'description': 'Description: Proportion of subjects achieving clinical improvement (partial or complete resolution of symptoms and signs, with a total VVC scale score ≤1) at the D25±3visit', 'timeFrame': 'Day 25±3'}, {'measure': 'Proportion of subjects requiring rescue therapy during the trial;', 'description': 'Proportion of subjects requiring rescue therapy during the trial;', 'timeFrame': 'Day 25±3'}, {'measure': 'Proportion of subjects with normal vaginal microecology assessments', 'description': 'Proportion of subjects with normal vaginal microecology assessments at the D11±2 and D25±3 visits', 'timeFrame': 'Day11±2 and day 25±3'}, {'measure': 'adverse events', 'description': 'Incidence and severity of adverse events and serious adverse events', 'timeFrame': 'Day 25±3'}, {'measure': 'AUC0-tau', 'description': 'the AUC0-tau estimated using non-compartmental and/or population pharmacokinetic models', 'timeFrame': 'day 4'}, {'measure': 'Cmax', 'description': 'the Cmax estimated using non-compartmental and/or population pharmacokinetic models', 'timeFrame': 'day 4'}]",13,18 Years,64 Years,FEMALE,True,"Cisen Pharmaceutical CO., LTD.",INDUSTRY,0,108.0,ESTIMATED,2025-09-01T16:18:10.928989,v2_robust,True,True,False,False,True,
NCT03106363,Combined Alcohol and Cannabis Effects on Skills of Young Drivers,Effects of Combined Alcohol and Cannabis on Young Drivers' Simulated Driving,delta 9 tetrahydrocannabinol,"['Tonic water', 'delta 9 tetrahydrocannabinol', 'cannabis sativa', 'Alcohol', 'marijuana', 'Placebo alcohol', 'placebo delta 9 tetrahydrocannabinol', 'ethanol']",8,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Psychomotor Impairment,['Psychomotor Impairment'],[],COMPLETED,,2017-07-04,2020-01-17,"[{'measure': 'Psychomotor impairment: Standard deviation of lateral position', 'description': 'The driving simulator will objectively measure changes in driving behavior after alcohol and/or cannabis exposure.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Driving simulation tests occur within 2 hours before and approximately 45 minutes after Time 0.'}]","[{'measure': 'Psychomotor impairment: Mean speed, standard deviation of speed, and maximum speed', 'description': 'The driving simulator will objectively measure changes in driving behavior after alcohol and/or cannabis exposure.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Driving simulation tests occur within 2 hours before and approximately 45 minutes after Time 0.'}, {'measure': 'Psychomotor impairment: Minimum time to collision and brake latency', 'description': 'The driving simulator will objectively measure changes in driving behavior after alcohol and/or cannabis exposure.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Driving simulation tests occur within 2 hours before and approximately 45 minutes after Time 0.'}, {'measure': 'Psychomotor impairment: Number of collisions', 'description': 'The driving simulator will objectively measure changes in driving behavior after alcohol and/or cannabis exposure.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Driving simulation tests occur within 2 hours before and approximately 45 minutes after Time 0.'}, {'measure': 'Subjective alcohol and cannabis effects', 'description': 'Visual analogue scale measures how participants feel before and after alcohol and/or cannabis exposure.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Visual analogue scales are administered within 2 hours before as well as approximately 15, 30, 45, and 75 minutes and 2, 3, 4, and 5 hours after Time 0.'}, {'measure': 'Cognitive testing', 'description': 'Measures changes in performance related to attention, memory, field of view, and dexterity before and after alcohol and/or cannabis exposure.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Cognitive testing is administered within 2 hours before Time 0 as well as approximately 75 minutes after Time 0.'}, {'measure': 'Breath alcohol content', 'description': 'Changes in BAC after drinking alcohol.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Breath alcohol content is measured within 2 hours before Time 0 as well as approximately 15, 30, 45, and 75 minutes and 2, 3, 4, and 5 hours after Time 0.'}, {'measure': 'Blood concentration for delta 9 tetrahydrocannabinol, carboxy-tetrahydrocannabinol, and 11 hydroxy tetrahydrocannabinol.', 'description': 'Changes in concentration of delta 9 tetrahydrocannabinol (THC) , carboxy-tetrahydrocannabinol (THC-COOH), and 11 hydroxy tetrahydrocannabinol (11-OH-THC) in blood.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Blood concentration for THC, THC-COOH, and 11-OH-THC is assessed within 2 hours before Time 0 as well approximately 45 minutes after Time 0.'}, {'measure': 'Urine cannabinoids corrected for creatinine', 'description': 'Determination of the ratio of excreted THC metabolite carboxy-THC to creatinine will determine whether participants have used cannabis between testing days, and hence will be excluded from further participation.', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Ratio of excreted THC metabolite carboxy-THC to creatinine is assessed within 2 hours before Time 0 as well as approximately 5 hours after Time 0.'}, {'measure': 'Vital signs: blood pressure', 'description': 'Changes in blood pressure (systolic/diastolic)', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Vital signs are assessed within 2 hours before as well as approximately 15, 30, 45, and 75 minutes and 2, 3, 4, and 5 hours after Time 0.'}, {'measure': 'Vital signs: pulse', 'description': 'Changes in pulse', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Vital signs are assessed within 2 hours before as well as approximately 15, 30, 45, and 75 minutes and 2, 3, 4, and 5 hours after Time 0.'}, {'measure': 'Vital signs: temperature', 'description': 'Changes in temperature', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Vital signs are assessed within 2 hours before as well as approximately 15, 30, 45, and 75 minutes and 2, 3, 4, and 5 hours after Time 0.'}, {'measure': 'Vital signs: respiration', 'description': 'Changes in respiration', 'timeFrame': 'Alcohol exposure is Time 0. Cannabis exposure follows 15 minutes after Time 0. Vital signs are assessed within 2 hours before as well as approximately 15, 30, 45, and 75 minutes and 2, 3, 4, and 5 hours after Time 0.'}]",13,19 Years,29 Years,ALL,True,Centre for Addiction and Mental Health,OTHER,2,85.0,ACTUAL,2025-09-01T16:18:10.929073,v2_robust,True,True,True,False,False,
NCT00645463,"Effect of Diltiazem Administration on CP-945,598 Pharmacokinetics","A Phase 1, Randomized, Fixed Sequence Study To Evaluate The Effect Of Multiple Dose Administration Of Modified Release Diltiazem On The Multiple Dose Pharmacokinetics Of CP-945,598 In Healthy Overweight And Obese Subjects","CP-945,598","['CP-945,598']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Obesity,['Obesity'],[],COMPLETED,,2007-03,2007-06,"[{'measure': 'Pharmacokinetic parameters of CP-945,598 and its metabolite, CE-156,706, (AUCtau, Cmax and Tmax)', 'timeFrame': 'Days 7 and 28'}, {'measure': 'Safety endpoints including adverse event monitoring, physical examinations, vital signs, ECGs, and clinical laboratory tests.', 'timeFrame': '28 days'}]",[],2,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:10.929132,v2_robust,True,True,True,False,True,
NCT00771563,Enoxaparin Low Molecular Weight Heparin (LMWH) in Advanced Non Small Cell Lung Cancer: Effect on Survival and Symptom Control in Patients Undergoing First Line Chemotherapy (SYRINGES),Low Molecular Weight Heparin in Advanced Non Small Cell Lung Cancer (NSCLC): a Randomized Open Label Phase III Study Evaluating the Effect of Enoxaparin (Clexane) on Survival and Symptom Control in Patients With Stage IIIB and IV NSCLC Undergoing a Cisplatin Based First Line Chemotherapy: the SYRINGES Trial,cisplatin + docetaxel,"['Clexane', 'cisplatin + docetaxel + enoxaparin', 'cisplatin + docetaxel', 'Taxotere', 'Platinol', 'LMWH']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],"['Non-Small Cell Lung Cancer', 'chemotherapy', 'Low Molecular Weight Heparin']",COMPLETED,,2008-06,2012-10,"[{'measure': 'Progression Free Survival', 'timeFrame': 'during chemotherapy and follow-up'}]","[{'measure': 'Symptom control evaluated with the Lung Cancer Symptoms Scale (LCSS)', 'timeFrame': 'during chemotherapy and follow-up'}, {'measure': 'Overall Survival', 'timeFrame': 'during chemotherapy and follow-up'}, {'measure': 'Best Overall Response', 'timeFrame': 'during chemotherapy and follow-up'}, {'measure': 'Incidence of total documented thromboembolic and hemorrhagic events', 'timeFrame': 'during chemotherapy and follow-up'}, {'measure': 'Overall safety and tolerability', 'timeFrame': 'during chemotherapy and follow-up'}]",6,18 Years,,ALL,False,"University Hospital, Antwerp",OTHER,1,104.0,ACTUAL,2025-09-01T16:18:10.929143,v2_robust,True,True,True,False,True,
NCT06917963,Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1,"Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1: a Randomized, Non-blinded, Controlled Trial","Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM)","['Standard intravenous omeprazole therapy (40 mg IV once daily at 6:00 AM).', 'Intensified intravenous omeprazole therapy (loading dose 80 mg IV, then 40 mg IV twice daily at 6:00 AM and 6:00 PM)']",2,INTERVENTIONAL,['NA'],,,Stoma - Ileostomy,"['Stoma - Ileostomy', 'High Output Stoma', 'Colon Cancer', 'IBD (Inflammatory Bowel Disease)', 'Ileus', 'Omeprazole']","['stoma', 'ileostomy', 'high output stoma', 'omeprazole', 'ipp', 'colon cancer', 'ibd']",RECRUITING,,2025-04-10,2027-07,"[{'measure': 'difference in mean ileostomy output (ml/24h) between postoperative days (POD) 1-3 between the experimental and control groups', 'description': 'The primary endpoint is the difference in mean ileostomy output (ml/24h) between postoperative days (POD) 1-3 between the experimental and control groups, after excluding patients with minimal output (\\<200 ml in any POD 1-3). A clinically significant reduction in output is defined as ≥250 ml/day.', 'timeFrame': 'from stoma creation to postoperative day 3'}]","[{'measure': 'Proportion of patients meeting the criteria for high-output stoma', 'description': 'Proportion of patients meeting the criteria for high-output stoma (HOS ≥1400 ml/day) on consecutive postoperative days.', 'timeFrame': '1 month from stoma creation'}, {'measure': 'Time to stabilization of ileostomy output', 'description': 'Time to stabilization of ileostomy output (defined as output consistently \\<1400 ml/day for three consecutive days).', 'timeFrame': '1 month from stoma creation'}, {'measure': 'Incidence of dehydration-related complications', 'description': 'Incidence of dehydration-related complications (hyponatremia, hypokalemia). Hyponatremia will be evaluated by the number of hyponatremia incidents during the hospitalization and 30 days after discharge. Hypokalemia will be evaluated by the total sum of supplementation (g) needed and the number of hypokalemia incidents during the hspitalization.', 'timeFrame': '30 days post discharge after stoma creation'}, {'measure': 'Total length of hospitalization', 'description': 'Length of initial hospital stay (LOS - length of stay), rehospitalization rate within 30 days post-discharge, and total length of hospitalization (TLOS - total length of stay).', 'timeFrame': '30 days post discharge after stoma creation'}]",5,18 Years,,ALL,False,Medical University of Gdansk,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:10.929156,v2_robust,True,True,False,False,False,
NCT01611363,A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin,An Exploratory Study to Investigate the Effects of Ipragliflozin (ASP1941) on Glucose Homeostasis and Urinary Glucose Excretion in Healthy Subjects and Subjects With Type 2 Diabetes Mellitus (T2DM),ASP1941,"['ASP1941', 'Ipragliflozin', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['Ipragliflozin', 'Phase 1', 'Healthy', 'Diabetes Mellitus', 'Pharmacokinetics', 'Pharmacodynamics']",COMPLETED,,2011-10-27,2012-02-03,"[{'measure': 'Part A: Assessment of glucose homeostasis in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin in healthy subjects and subjects with T2DM', 'timeFrame': '4 days'}, {'measure': 'Part A: Assessment of peripheral glucose utilization after an oral glucose load, following multiple doses of ipragliflozin', 'timeFrame': '4 days'}, {'measure': 'Part A: Assessment of splanchnic uptake after an oral glucose load, following multiple doses of ipragliflozin', 'timeFrame': '4 days'}, {'measure': 'Part A: Assessment of mean glucose levels in fasted condition and after an oral glucose load, following multiple doses of ipragliflozin', 'timeFrame': '4 days'}, {'measure': 'Part B: Assessment of the relationship between the exposure to ipragliflozin in plasma, urinary glucose excretion and plasma glucose levels in subjects with T2DM', 'timeFrame': '6 days (PK), 12 days (urine) and 8 days (PD)'}]","[{'measure': 'Part A: Assessment of steady state urinary sodium excretion and urinary glucose excretion following multiple doses of ipragliflozin', 'timeFrame': '4 days (sodium) and 14 days (glucose) days'}, {'measure': 'Part A: Assessment of energy production and utilization of energy sources following multiple doses of ipragliflozin', 'timeFrame': '4 days'}, {'measure': 'Part A: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia', 'timeFrame': 'Up to 21 days'}, {'measure': 'Part B: Safety and tolerability following multiple doses of ipragliflozin assessed by recording adverse events, laboratory assessments, vital signs, electrocardiograms (ECGs) and signs and symptoms of hypoglycemia', 'timeFrame': 'Up to 21 days'}]",9,35 Years,65 Years,ALL,True,Astellas Pharma Europe B.V.,INDUSTRY,0,44.0,ACTUAL,2025-09-01T16:18:10.929187,v2_robust,True,True,True,False,True,
NCT00499863,Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD,"A Phase IIIb, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Dose Optimization Study, Designed to Evaluate the Efficacy and Safety of MTS in Adolescents Aged 13-17 Years With ADHD",methylphenidate transdermal system,"['Sham treatment', 'methylphenidate transdermal system', 'Placebo', 'DAYTRANA']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,ADHD,['ADHD'],[],COMPLETED,,2007-07,2008-05,"[{'measure': 'Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint', 'description': 'The Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54.', 'timeFrame': 'baseline and endpoint (up to 7 weeks)'}]","[{'measure': ""Change From Baseline in the Conner's Parent Rating Scale-Revised (CPRS-R) Total Score at Endpoint"", 'description': ""The Conner's Parent rating Scale-revised short version (CPRS-R) consists of 27 questions graded on a scale from 0 (not true at all) to 3 (very much true)."", 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}, {'measure': 'Improvement in Clinical Global Impressions-Improvement (CGI-I) Score', 'description': 'Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.', 'timeFrame': 'up to 7 weeks'}, {'measure': 'Improvement in Parent Global Assessment (PGA) Score', 'description': 'Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement includes a score of 1 (very much improved) or 2 (much improved) on the scale.', 'timeFrame': 'up to 7 weeks'}, {'measure': 'Change From Baseline in Youth Quality of Life-research Version (YQOL-R) Total Score at Endpoint', 'description': 'The Youth Quality of Life Instrument-research version (YQOL-R) is a validated 56-item generic instrument for comparing quality of life of adolescents across condition groups that scores each question on a scale from 0 (never) to 4 (very often).', 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}, {'measure': 'Dermal Response Scale (DRS) Scores', 'description': 'Mean dermal reaction scores were graded on a scale ranging from 0 (no irritation) to 7 (strong reaction) for observed findings of erythema, edema, papules, and vesicles.', 'timeFrame': 'up to 7 weeks'}, {'measure': 'Change From Baseline in Electrocardiogram Results(QTcF Interval) at Endpoint', 'description': ""QTcF is the QT interval using Fridericia's correction formula. QT interval is a measure of time between the start of the Q wave and the end of the T wave and is dependent on the heart rate(e.g., the faster the heart rate, the shorter the QT interval). The QT interval has to be corrected in order to aid interpretation."", 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}, {'measure': 'Change From Baseline in Pulse Rate at Endpoint', 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}, {'measure': 'Change From Baseline in Systolic Blood Pressure at Endpoint', 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}, {'measure': 'Change From Baseline in Diastolic Blood Pressure at Endpoint', 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}, {'measure': 'Change From Baseline in Weight at Endpoint', 'timeFrame': 'Baseline and endpoint (up to 7 weeks)'}]",11,13 Years,17 Years,ALL,False,Noven Therapeutics,INDUSTRY,0,217.0,ACTUAL,2025-09-01T16:18:10.929219,v2_robust,True,True,True,False,False,
NCT00063687,Oxypurinol Compared With Placebo for Class III-IV NYHA Congestive Heart Failure,"A Phase II-III Prospective, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Oxypurinol Added to Standard Therapy in Patients With NYHA Class III-IV Congestive Heart Failure",Oxypurinol,['Oxypurinol'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Congestive Heart Failure,['Congestive Heart Failure'],[],COMPLETED,,2003-03,2005-06,[],[],0,18 Years,85 Years,ALL,False,Advanz Pharma,INDUSTRY,0,400.0,,2025-09-01T16:18:10.929251,v2_robust,True,True,True,False,False,
NCT01631487,"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Participants","A Double-Blind, Randomized, Placebo-Controlled, Sequential Group, Single Ascending and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-39439335 in Healthy Japanese and Caucasian Adult Male Subjects",JNJ-39439335 10 mg,"['JNJ-39439335 50 mg', 'JNJ-39439335 25 mg', 'JNJ-39439335 10 mg', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Healthy', 'JNJ-39439335', 'Japanese', 'Caucasian', 'Male']",COMPLETED,,2012-07,2013-03,"[{'measure': 'Plasma concentrations of JNJ-39439335 (Part 1)', 'timeFrame': 'up to 14 days'}, {'measure': 'Urine concentrations of JNJ-39439335 (Part 1)', 'timeFrame': 'up to 5 days'}, {'measure': 'Plasma concentrations of JNJ-39439335 (Part 2)', 'timeFrame': 'up to 21 days'}, {'measure': 'Urine concentrations of JNJ-39439335 (Part 2)', 'timeFrame': 'up to 21 days'}]","[{'measure': 'Incidence of Adverse Events (Part 1)', 'timeFrame': 'Approximately 8 weeks'}, {'measure': 'Incidence of Adverse Events (Part 2)', 'timeFrame': 'Approximately 11 weeks'}]",6,20 Years,55 Years,MALE,True,"Janssen Research & Development, LLC",INDUSTRY,0,86.0,ACTUAL,2025-09-01T16:18:10.929299,v2_robust,True,True,True,False,True,
NCT00002387,The Safety and Effectiveness of Indinavir Sulfate Plus Efavirenz,"A Multicenter, Open, Randomized, Forty-Eight-Week, Pilot Study to Evaluate the Activity, Safety, and Pharmacokinetics of Indinavir Sulfate, 1200 Mg q 12h and DMP 266, 300 Mg q 12h Versus Indinavir Sulfate, 1000 Mg q 8h and DMP 266, 600 Mg q.h.s.",Indinavir sulfate,"['Indinavir sulfate', 'Efavirenz']",2,INTERVENTIONAL,['NA'],,,HIV Infections,['HIV Infections'],"['Acquired Immunodeficiency Syndrome', 'Drug Administration Schedule', 'HIV Protease Inhibitors', 'Indinavir', 'Reverse Transcriptase Inhibitors', 'Anti-HIV Agents', 'efavirenz']",COMPLETED,,,,[],[],0,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,80.0,,2025-09-01T16:18:10.929324,v2_robust,True,True,True,False,False,
NCT02489487,"Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500","Phase I, Drug-drug Interaction Study in Healthy Volunteers to Investigate the Safety, Tolerability and Pharmacokinetics of VM-1500 When Administered Orally, in Combination With Raltegravir or Darunavir",VM-1500,"['Darunavir', 'Ritonavir', 'VM-1500', 'Raltegravir']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV-infection,['HIV-infection'],[],COMPLETED,,2014-09,2014-10,"[{'measure': 'Number of participants with treatment-related adverse events as assessed by Division of AIDS table for grading the severity of ADULT Adverse Events', 'description': 'Safety and tolerability of VM-1500 alone or in combination with raltegravir or darunavir in adult healthy subjects', 'timeFrame': '36 days'}]","[{'measure': 'Plasma concentrations of VM-1500 from Day 1 to Day 36', 'description': 'Plasma concentrations of VM-1500 given alone or in combination with raltegravir or darunavir', 'timeFrame': '36 days'}, {'measure': 'Plasma concentrations of VM1500A (active metabolite of VM1500) from Day 1 to Day 36', 'description': 'Plasma concentrations of VM-1500A alone or in combination with raltegravir or darunavir', 'timeFrame': '36 days'}]",3,18 Years,45 Years,MALE,True,Viriom,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:10.929352,v2_robust,True,True,True,False,True,
NCT05093387,"SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer",A Pilot Study of SGT-53 With Carboplatin and Pembrolizumab in Metastatic Triple Negative Inflammatory Breast Cancer,Carboplatin,"['Blastocarb', 'Carboplatinum', 'Paraplatin', 'Carboplatino', 'Paraplatine', 'Ribocarbo', 'Ercar', 'Novoplatinum', 'Carbotec', 'Carboplat', 'Carboplatin', 'Carbosol', 'Carbosin', 'Platinwas', 'Nealorin', 'Displata', 'CBDCA', 'JM-8', 'Paraplatin AQ', 'Carboplatin Hexal']",20,INTERVENTIONAL,['PHASE1'],PHASE1,,Anatomic Stage IV Breast Cancer AJCC v8,"['Anatomic Stage IV Breast Cancer AJCC v8', 'Breast Inflammatory Carcinoma', 'Metastatic Triple-Negative Breast Carcinoma', 'Prognostic Stage IV Breast Cancer AJCC v8']",[],WITHDRAWN,funding issues and pharmacy preparation for the drug,2022-11-10,2022-11-10,"[{'measure': 'Rate of Successful Administration', 'description': 'Assess feasibility of SGT-53 with carboplatin and pembrolizumab in metastatic triple negative IBC with a Combined Positive Score of ≥10 in PD-L1 expression.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Clinical Benefit Rate', 'description': 'Evaluate preliminary activity of SGT-53 with carboplatin and pembrolizumab in metastatic triple negative IBC with a Combined Positive Score of ≥10 in PD-L1 expression, as measured by (complete response + particle response + stable disease \\>= 6 months using Response Evaluation Criteria in Solid Tumors criteria version 1.1).', 'timeFrame': 'Up to 3 cycles (each cycle = 21 days)'}]","[{'measure': 'Incidence of adverse events', 'description': 'Measured by Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 28 (+/- 3 days) after last study treatment'}]",3,18 Years,,FEMALE,False,Northwestern University,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:10.929395,v2_robust,True,True,False,True,True,funding issues and pharmacy preparation for the drug
NCT02222987,Influence of Clopidogrel on the Pharmacodynamics and Safety of Terbogrel in Healthy Male Subjects,"Influence of Oral Doses of 75 mg Clopidogrel on the Pharmacodynamics and Safety of Oral Doses of 100 mg Terbogrel Bid Over 8 Days in Healthy Male Subjects. An Intra-individual, Open Trial.",Terbogrel,"['Terbogrel', 'Clopidogrel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,1999-02,,"[{'measure': 'Change in inhibition of platelet aggregation in platelet rich plasma (PRP)', 'timeFrame': 'baseline, up to day 17'}, {'measure': 'Change in thromboxane receptor occupancy (TRO)', 'timeFrame': 'baseline, up to day 17'}, {'measure': 'Change in 6-keto-prostaglandinF-1-alpha', 'timeFrame': 'baseline, up to day 17'}, {'measure': 'Change in thromboxan synthesis inhibition (TSI)', 'timeFrame': 'baseline, up to day 17'}]","[{'measure': 'Plasma levels of terbogrel', 'timeFrame': 'up to day 17'}, {'measure': 'Number of patients with adverse events', 'timeFrame': 'up to day 17'}, {'measure': 'Change in bleeding time', 'timeFrame': 'baseline, up to day 17'}, {'measure': 'Change in systolic and diastolic blood pressure', 'timeFrame': 'baseline, up to day 17'}, {'measure': 'Change in pulse rate', 'timeFrame': 'baseline, up to day 17'}, {'measure': 'Number of patients with haematuria', 'description': 'dipstick test', 'timeFrame': 'up to day 17'}, {'measure': 'Number of patients with positive Haemoccult test', 'timeFrame': 'up to day 17'}, {'measure': 'Number of patients with clinically significant laboratory findings', 'timeFrame': 'up to day 17'}]",12,18 Years,45 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:10.929417,v2_robust,True,True,True,False,True,
NCT03899987,Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery,Randomized Phase 2 Study: Neoadjuvant Conditioning of Prostate Cancer Tumor Microenvironment Using a Novel Chemokine-Modulating Regimen,EC Aspirin,"['aspirin', 'Enteric-coated aspirin', 'ASA', 'Extren', 'Rintatolimod', 'Ampligen', 'Empirin', 'Acetylsalicylic Acid', 'Entericin', 'Measurin', 'Atvogen', 'EC Aspirin', 'Aspergum', 'Ecotrin']",14,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Adenocarcinoma,"['Prostate Adenocarcinoma', 'Stage I Prostate Cancer AJCC v8', 'Stage II Prostate Cancer AJCC v8', 'Stage IIA Prostate Cancer AJCC v8', 'Stage IIB Prostate Cancer AJCC v8', 'Stage IIC Prostate Cancer AJCC v8', 'Stage III Prostate Cancer AJCC v8', 'Stage IIIA Prostate Cancer AJCC v8', 'Stage IIIB Prostate Cancer AJCC v8', 'Stage IIIC Prostate Cancer AJCC v8']",[],ACTIVE_NOT_RECRUITING,,2019-11-29,2026-11-29,"[{'measure': 'Count of tumor infiltrating CD8+ lymphocytes', 'description': 'This will be assessed by the increase in the total number of tumor infiltrating CD8+ T cells in the radical prostatectomy specimen (measured as cell density of CD8+ cell by immunohistochemistry), comparing Arm A versus Arm B versus Arm C. Will be natural log transformed prior to analysis. The primary analysis will consist of testing the single degree of freedom planned contrast at alpha = .10 that the 3 treatment means are in the ratio of 3:2:1 (contrast coefficients 3, -2, -1) for groups A, B and C, respectively groups. If this test rejects the null hypothesis of no group differences, will proceed to estimate group means and pairwise differences between groups with 90% confidence intervals. Non-overlapping confidence intervals will serve as evidence of differential treatment effects.', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Pathologic response', 'description': 'Spearman rank correlation coefficients will be used to estimate the correlation between CD8+ tumor infiltrate, pathologic response rate and prostate specific antigen (PSA) response.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Number of patients with Surgical margin positivity', 'timeFrame': 'Up to 3 years'}, {'measure': 'PSA response', 'description': 'Spearman rank correlation coefficients will be used to estimate the correlation between CD8+ tumor infiltrate, pathologic response rate and PSA response.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Incidence of treatment-related adverse events', 'description': 'Will be evaluated with National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 30 days post treatment'}]",5,18 Years,,MALE,False,Roswell Park Cancer Institute,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:10.929440,v2_robust,True,True,False,False,True,
NCT06393387,Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States,Retrospective Review of DTG/3TC Versus BIC/F/TAF Across a Multi Clinic Infectious Disease Organization in Southeast United States (REVIVE Study),DTG/3TC versus BIC/F/TAF,['DTG/3TC versus BIC/F/TAF'],1,OBSERVATIONAL,[],,,Hiv,"['Hiv', 'HIV-1-infection', 'HIV Infections']","['HIV', 'Social Determinants of Health', 'Adherence', 'Viral Suppression', 'Percent of Days Covered']",COMPLETED,,2024-06-01,2025-04-01,"[{'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of switching treatment to DTG/3TC vs. BIC/F/TAF through 48 weeks in virally suppressed ART experienced individuals with no interruptions in prior therapy.', 'timeFrame': '48 Weeks'}]","[{'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of switching treatment to DTG/3TC vs. BIC/F/TAF through 24 weeks in virally suppressed ART experienced individuals with no interruptions in prior therapy.', 'timeFrame': '24 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 48 weeks in ART naïve individuals (i.e., no prior ART regimen received).', 'timeFrame': '48 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 24 weeks in ART naïve individuals.', 'timeFrame': '24 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 48 weeks in ART experienced individuals who are returning to care (i.e., previous ART therapy received but not in the last month).', 'timeFrame': '48 Weeks'}, {'measure': 'Viral Suppression', 'description': 'To evaluate the effectiveness of DTG/3TC vs. BIC/F/TAF through 24 weeks in ART experienced individuals who are returning to care.', 'timeFrame': '24 Weeks'}, {'measure': 'Clinical Characteristics of Persons with HIV', 'description': 'To describe the baseline demographics and clinical characteristics of individuals on DTG/3TC and BIC/F/TAF by the following sub-groups: (1) Virally suppressed, (2) ART experienced individuals, \\& (3) ART naïve individuals ART experienced individuals who are returning to care', 'timeFrame': 'Baseline'}, {'measure': 'Tolerability', 'description': 'To assess the tolerability (i.e., all drug-related adverse reactions (ARs) as per label) of DTG/3TC vs. BIC/F/TAF through 24 weeks and 48 weeks by the following sub-groups: (1) Virally suppressed ART experienced individuals, (2) ART naïve individuals \\& (3) ART experienced individuals who are returning to care.', 'timeFrame': '24, 48 Weeks'}, {'measure': 'Treatment Discontinuation', 'description': 'To assess treatment discontinuations (i.e., withdrawals due to drug-related ARs) of DTG/3TC vs. BIC/F/TAF through 24 weeks and 48 weeks by the following sub-groups: (1) Virally suppressed ART experienced individuals, (2) ART naïve individuals, (3) ART experienced individuals who are returning to care.', 'timeFrame': '24, 48 Weeks'}]",9,18 Years,,ALL,False,Midway Specialty Care Center,OTHER,0,800.0,ACTUAL,2025-09-01T16:18:10.929461,v2_robust,False,True,True,False,True,
NCT02750293,The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors,The Effect of Vitamin D Supplementation on Cardiovascular Risk Factors in Subjects With Low Serum 25-hydroxyvitamin D Levels,Cholecalciferol,"['Dekristol', 'Cholecalciferol', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Vitamin D Deficiency,['Vitamin D Deficiency'],"['vitamin D', 'blood pressure', 'serum lipids', 'glucose metabolism', 'muscle function', 'arterial stiffness', 'depression', 'psoriasis', 'sleep', 'bone density']",COMPLETED,,2015-06,2017-09,"[{'measure': 'Change from baseline in systolic and diastolic blood pressure', 'timeFrame': '4 months'}]","[{'measure': 'Change from baseline in hand-grip, quadriceps and biceps muscle strength measured by hand held dynamometry .', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in score on Becks Depression Inventory', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in cognitive function evaluated with The Twelve Word Memory Test', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in cognitive function evaluated with The Digit Symbol Coding Test', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in cognitive function evaluated with The Tapping Test', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in arterial stiffness and endothelial function evaluated with pulse wave velocity', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in arterial stiffness and endothelial function evaluated with augmentation index (AIX)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in arterial stiffness and endothelial function evaluated with the subendocardial viability ratio (SEVR)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in number of subjects with nasal staphylococcus aureus colonization', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in bone mass density measured with dual energy x-ray absorptiometry (DEXA) at the lumbar spine and hip', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the bone turnover marker serum type 1 procollagen (P1NP)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the bone turnover marker serum collagen type 1 cross-linked C-telopeptide (CTX-1)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in serum marker of interferon-γ mediated macrophage activation', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in serum vitamin B6 status.', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the glycosylation marker HbA1c', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the glycosylation marker the receptor for advanced glycosylation end products (s-RAGE)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the glycosylation marker carboxy-methyllysine', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in psoriasis Activity in subjects with psoriasis evaluated with the Self-Administered Psoriasis Area Severity Index (SAPASI)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Dermatological Life Quality Index (DLQI)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in psoriasis Activity in subjects with psoriasis, evaluated with the Psoriasis Area Severity Index (PASI)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in transcriptomic profile (mRNA) in adipose tissue biopsies', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in number of subjects with nocturnal legg cramps', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in sleep pattern evaluated with the Tromsø Study 7th Survey sleep pattern questionnaire', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the serum total cholesterol', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the serum HDL-cholesterol', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the serum LDL-cholesterol', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the serum triglycerides', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the serum Apolipoprotein A1', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in the serum Apolipoprotein B,', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in insulin resistance evaluated with the homeostasis model assessment (HOMA) index based on fasting serum glucose and serum insulin', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in proteomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)', 'timeFrame': '4 months'}, {'measure': 'Change from baseline in metabolomic profile with relative quantification in adipose tissue biopsies with the use of Liquid chromatography mass spectrometry Technology (LC-MS/MS)', 'timeFrame': '4 months'}]",33,20 Years,80 Years,ALL,True,University of Tromso,OTHER,0,411.0,ACTUAL,2025-09-01T16:18:10.929734,v2_robust,True,True,True,False,False,
NCT00416793,Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer,A Phase II Study of Bortezomib in Combination With Carboplatin in Patients With Metastatic Pancreatic Cancer,bortezomib,"['bortezomib', 'carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acinar Cell Adenocarcinoma of the Pancreas,"['Acinar Cell Adenocarcinoma of the Pancreas', 'Duct Cell Adenocarcinoma of the Pancreas', 'Stage IV Pancreatic Cancer']",[],TERMINATED,Study was terminated due to poor accrual,2006-12,2009-12,"[{'measure': 'Overall Survival Rate at 6 Months', 'description': 'Overall survival (OS) at 6 months with the combination of bortezomib and carboplatin in participants who previously received 1 prior regimen for metastatic pancreatic cancer from date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 6 months. Rate equals number of participants living at 6 months following treatment divided by the total number of participants.', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Overall Response Rate', 'description': 'Overall Response Rate measured by number of patients per the total treatment population who partially or completely responded to treatment. Participants reevaluated for response every 6 weeks. In addition to a baseline scan, confirmatory scans at 4 weeks following initial documentation of objective response.', 'timeFrame': 'from assignment of treatment until the date of first documented progression, assessed up to 17 months'}]",2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,9.0,ACTUAL,2025-09-01T16:18:10.929782,v2_robust,True,True,False,True,False,Study was terminated due to poor accrual
NCT03669393,A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1),"A Phase 2, Open-label, Multi-centre Study to Assess the Efficacy and Safety of Intravitreal THR-317 for the Treatment of Macular Telangiectasia Type 1 (MacTel 1)",THR-317 8mg,['THR-317 8mg'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Retinal Telangiectasis,"['Retinal Telangiectasis', 'Idiopathic Juxtafoveal Retinal Telangiectasia']",[],COMPLETED,,2018-09-18,2019-11-22,"[{'measure': 'Change from baseline in central subfield thickness (CST), based on spectral domain optical coherence tomography (SD-OCT)', 'timeFrame': 'At Day 84 (Month 3)'}]","[{'measure': 'Change from baseline in CST, based on SD-OCT, by study visit', 'timeFrame': 'From baseline to Day 140'}, {'measure': 'Change from baseline in area of cystoid spaces, based on SD-OCT, by study visit', 'timeFrame': 'From baseline to Day 140'}, {'measure': 'Change from baseline in best-corrected visual acuity (BCVA), by study visit', 'timeFrame': 'From Day 0 to Day 140'}, {'measure': 'Incidence of systemic and ocular adverse events including serious adverse events', 'timeFrame': 'From Day 0 to Day 140'}]",5,18 Years,,ALL,False,ThromboGenics,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:10.929796,v2_robust,True,True,True,False,True,
NCT06099093,Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan,A Pilot Study of 18F-DCFPyL-PSMA PET in Patients Receiving 177Lu-Vipivotide Tetraxetan Therapy for Metastatic Castrate-resistant Prostate Cancer,18F-DCFPyl,"['[F18]-Piflufolastat, Pylarify, 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]- pentyl}ureido)-pentanedioic acid', '18F-DCFPyl']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Prostate Cancer,"['Prostate Cancer', 'Metastatic Castration-resistant Prostate Cancer', 'Metastatic Castration-resistant Prostate Carcinoma']","['Prostate Cancer', 'Metastatic Castration-resistant Prostate Cancer', 'Metastatic Castration-resistant Prostate Carcinoma']",RECRUITING,,2024-04-01,2025-12-01,"[{'measure': 'Proportion of Participants with PSMA-Positive Lesion', 'description': 'Defined as the number of participants with at least 1 PSMA-positive lesion on 18F-DCFPyL PSMA-PET.', 'timeFrame': '1 Day'}]",[],1,18 Years,,MALE,False,Brigham and Women's Hospital,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:10.929966,v2_robust,True,True,False,False,False,
NCT05543993,COVID Booster in Pregnancy and Lactation,Serological and Functional Impact of COVID-19 Vaccination on the Maternal Fetal Unit and Infant Immunity,Bivalent COVID-19 Booster,['Bivalent COVID-19 Booster'],1,OBSERVATIONAL,[],,,COVID-19,['COVID-19'],"['vaccine', 'COVID-19 vaccine', 'booster', 'pregnancy', 'breastfeeding', 'immunity']",RECRUITING,,2022-09-29,2025-03-01,"[{'measure': 'Maternal Serological Profile', 'description': 'Quantitative Maternal IgG to SARS CoV2 spike and other domains', 'timeFrame': '3 months'}, {'measure': 'Maternal Functional Immunity', 'description': 'Quantitative Antibody neutralization capacity', 'timeFrame': '3 months'}]","[{'measure': 'Infant serological profile', 'description': 'Quantitative IgG to SARS CoV2', 'timeFrame': '3 months old'}, {'measure': 'Infant functional immunity', 'description': 'Quantitative Antibody neutralization capacity', 'timeFrame': '3 months old'}, {'measure': 'Breastmilk serological profile', 'description': 'Quantitative IgA to SARS CoV2', 'timeFrame': '3 months'}, {'measure': 'Infant oral immunity', 'description': 'Quantitative Salivary SARS CoV2 IgG', 'timeFrame': '3 months'}]",6,13 Years,55 Years,FEMALE,True,Thomas Jefferson University,OTHER,2,200.0,ESTIMATED,2025-09-01T16:18:10.929974,v2_robust,False,True,False,False,False,
NCT01737593,Can Acetaminophen Given 1-2 Hours to Children Before Ear Tube Surgery Reduce Agitation After Anesthesia?,Can Acetaminophen PO Given 1-2 Hours Before Bilateral Myringotomy Tube (BMT) Placement Reduce Emergence Agitation (EA) in Children After General Sevoflurane Anesthesia?,Acetaminophen,"['Tylenol', 'Acetaminophen']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Emergence Agitation,"['Emergence Agitation', 'Pain']","['acetaminophen', 'emergence agitation', 'children', 'sevoflurane']",TERMINATED,Interim analysis revealed a negative effect.,2012-11,2014-04,"[{'measure': 'Postanesthesia Emergence Agitation (EA) Score', 'description': ""EA was evaluated using the Pediatric Anesthesia Emergence Delirium (PAED) scale. This scale measures if the: 1. Child makes eye contact with the caregiver, 2. Child's actions are purposeful, 3. Child is aware of his/her surroundings, 4. Child is restless, 5. Child is inconsolable.\n\nItems 1, 2, and 3 are reversed scored as follows: 4 \\_ not at all, 3 \\_ just a little, 2 \\_ quite a bit, 1 \\_ very much, 0 \\_ extremely. Items 4 and 5 are scored as follows: 0 \\_ not at all, 1 \\_ just a little, 2 \\_ quite a bit, 3 \\_ very much, 4\\_extremely. Scores of each item are summed to obtain a total PAED scale score, range 0-20, with higher PAED scores indicating a greater degree of emergence delirium.\n\nThe average PAED score of all the time points is use"", 'timeFrame': 'Induction,Emergence(spontaneous extremity movement),and every 5 min after emergence until the patient is discharged. This is an average of 3 hours till discharge.'}]","[{'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': 'Induction'}, {'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': 'Emergence (spontaneous extremity movement)'}, {'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': '5 minutes post-emergence'}, {'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': '15 minutes post-emergence'}, {'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': '30 minutes post-emergence'}, {'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': '45 minutes post-emergence'}, {'measure': 'Postanesthesia Pain Score', 'description': ""Children's Hospital of Eastern Ontario pain scale (CHEOPS) is an observational scale for measuring postoperative pain in young children. The scale includes six categories of pain behavior: (Cry, facial, verbal, torso, touch, and legs). A score ranging from 0 to 2 or 1 to 3 is assigned to each activity and the summed score ranges between 4 and 13, with a higher score meaning more pain."", 'timeFrame': 'Prior to discharge, up to 3 hours after induction.'}]",8,6 Months,6 Years,ALL,True,"University of California, Los Angeles",OTHER,0,108.0,ACTUAL,2025-09-01T16:18:10.929999,v2_robust,True,True,False,True,False,Interim analysis revealed a negative effect.
NCT01919593,Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compare 10% Povidone Iodine in Blood Culture in Children,The Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compared With 10% Povidone Iodine in Reducing Blood Culture Contamination in Pediatric Patients,2% chlorhexidine gluconate in 70% alcohol,"['Chloraprep', 'Betadine', '10%povidone iodine', '2% chlorhexidine gluconate in 70% alcohol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Bacteremia,['Bacteremia'],"['Blood culture', 'Contamination', 'Chlorhexidine gluconate', 'Povidone iodine']",COMPLETED,,2012-01,2013-04,"[{'measure': 'efficacy of 2% chlorhexidine gluconate in 70% alcohol compared with 10% povidone iodine', 'description': 'Pediatric patients who needed percutaneous blood cultures were recruited and were assigned 10% povidone iodine in odd months and 2% chlorhexidine gluconate in 70% alcohol in even months as an antiseptic for blood cultures. Blood culture isolates were categorized into two groups including a true pathogen and a contaminant by clinical criteria combined with laboratory data.', 'timeFrame': '5 days'}]","[{'measure': 'safety of 2% chlorhexidine gluconate in 70% alcohol compared with 10% povidone iodine', 'description': 'direct observe skin reaction after use both antiseptics', 'timeFrame': '48 hours'}]",2,1 Day,15 Years,ALL,False,Thammasat University,OTHER,0,1269.0,ACTUAL,2025-09-01T16:18:10.930070,v2_robust,True,True,True,False,True,
NCT03575793,"A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer","A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127",Nivolumab,"['Plinabulin', 'Ipilimumab', 'Nivolumab', 'Opdivo', 'Yervoy']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Lung Cancer,"['Lung Cancer', 'SCLC']",[],COMPLETED,,2018-09-06,2024-07-01,"[{'measure': 'Phase I: Maximum Tolerated Dose (MTD)', 'description': 'Establish MTD of plinabulin in combination with nivolumab and ipilimumab for patients with recurrent SCLC. MTD reflects the highest dose of plinabulin that did not cause a Dose-Limiting Toxicity (DLT) in \\> 33% of participants. DLTs were defined in accordance to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.', 'timeFrame': 'Up to 42 days of first Plinabulin dose'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease(PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD.\n\nProgression Free Survival (PFS) is defined as time from registration until disease progression met by RECIST 1.1 or death from any cause.', 'timeFrame': 'Up to maximum of 9 months'}]","[{'measure': 'Number of Participants With Adverse Events', 'description': ""Assess adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4"", 'timeFrame': 'Up to a maximum of 43 months'}, {'measure': 'Number of Participants With Immune-related Adverse Events (irAEs)', 'description': ""Assess Immune-related adverse events according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.\n\nirAE's are defined as any treatment-related AE that is inflammatory in nature, consistent with the mechanism of action of immunotherapy and generally medically manageable with topical and/or systemic immunosuppressants."", 'timeFrame': 'Up to a maximum of 43 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST1.1): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. Objective Response (OR) = CR + PR', 'timeFrame': 'Up to maximum of 9 months'}, {'measure': 'Clinical Benefit Rate', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. Clinical Benefit Rate (CBR) = CR+PR+SD per RECIST v1.1.', 'timeFrame': 'Up to maximum of 9 months'}, {'measure': 'Progression Free Survival at 6 Months', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \\>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as time from registration until disease progression met by RECIST 1.1 or death from any cause. PFS at 6 months is defined as the percentage of patient who was progression free at 6 months from the initiation of treatment.', 'timeFrame': '6 Months'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time from treatment start until death or date of last contact.', 'timeFrame': 'Up to a maximum of 45 months'}]",8,18 Years,,ALL,False,Salma Sabbour,OTHER,3,39.0,ACTUAL,2025-09-01T16:18:10.930082,v2_robust,True,True,True,False,True,
NCT06660693,Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis,Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis: an Open-label Randomized Controlled Trial (RESCUE-UC).,Upadacitinib Oral Product,['Upadacitinib Oral Product'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Colitis, Ulcerative","['Colitis, Ulcerative']",[],RECRUITING,,2025-04-16,2027-09,"[{'measure': 'Measure treatment success of upadacitinib vs standard care.', 'description': 'The primary objective of this study is to evaluate whether treatment success in ASUC patients in patients treated with strategy U is non-inferior to strategy C after 16 weeks of initiating therapeutic management.', 'timeFrame': '16 weeks'}]",[],1,18 Years,64 Years,ALL,False,McMaster University,OTHER,1,134.0,ESTIMATED,2025-09-01T16:18:10.930118,v2_robust,True,True,False,False,False,
NCT00329693,Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide,"A Randomised, Double-blind, Parallel Groups, Dose-finding, Placebo-controlled, Multi-centre, Proof of Concept Study Assessing the Effect of 3-wk Treatment With 1 of 3 Oral Doses of Quinagolide & Placebo in Preventing Ovarian Hyperstimulation Syndrome in Women Undergoing Controlled Ovarian Hyperstimulation.",Norprolac,['Norprolac'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Hyperstimulation Syndrome,['Ovarian Hyperstimulation Syndrome'],[],COMPLETED,,2006-06,2008-05,"[{'measure': 'OHSS', 'timeFrame': '41 days after hCG injection'}]",[],1,21 Years,37 Years,FEMALE,False,Ferring Pharmaceuticals,INDUSTRY,0,182.0,ACTUAL,2025-09-01T16:18:10.930129,v2_robust,True,True,True,False,False,
NCT05126121,Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection,Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori: A Pilot Study,"three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol","['antibiotics', 'three kinds of antibiotics including amoxicillin，tetracycline, furazolidone, levofloxacin,clarithromycin,levofloxacin,tinidazole,metronidazol']",2,INTERVENTIONAL,['NA'],,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],['Concomitant Therapy'],UNKNOWN,,2021-11-20,2022-12-30,"[{'measure': 'Eradication rates', 'description': 'Six weeks after completion of treatment,number of patients get H.pylori eradicated will be investigated.Then eradication rate will be calculated by using intention-to-treat analysis and per-protocol analysis.\n\nresults will be investigated by an independent researcher.Then eradication rate in each group will be calculated by using intention-to-treat analysis and per-protocol analysis. of Helicobacter pylori infection. The ITT analysis includes all the patients who take at least one dose of the study medications. The PP analysis is limited to patients who take over 90% of the study medications and complete follow up.', 'timeFrame': '6 month'}]","[{'measure': 'The rate of adverse events happening', 'description': 'At the follow-up, adverse events complained by patients will be recorded by an independent researcher.Adverse events were graded as mild, moderate, or severe.', 'timeFrame': '6 month'}, {'measure': 'Compliance of patients', 'description': 'Compliance was evaluated by assessing the total pills patients have taken.Compliance was defined as good when more than 80% or less than 120% of the total pills were taken.', 'timeFrame': '6 month'}]",3,18 Years,70 Years,ALL,False,Xiuli Zuo,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:10.930233,v2_robust,True,True,False,False,True,
NCT01846221,Comparison of Epidural Fentanyl and Clonidine for Breakthrough Pain,Comparison of Fentanyl-bupivacaine and Clonidine-bupivacaine for Breakthrough Pain in Advanced Labor in Patients With Continuous Epidural Analgesia,Clonidine,"['Sublimaze', 'Fentanyl', 'DuraClon', 'Clonidine']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Labor Pain,['Labor Pain'],"['Analgesia', 'Epidural', 'Pregnancy', 'Labor', 'Clonidine', 'Fentanyl', 'Bupivacaine', 'Childbirth']",COMPLETED,,2014-07-15,2017-01-20,"[{'measure': 'Number of Subjects With Success Rate at 15 Minutes Post-epidural Bolus Injection', 'description': ""Pain Visual Analogue Scale (VAS) was evaluated every 5 min for 15 min. 'Success' is defined as at least a 4-point reduction in VAS at 15 min. (0=no pain, 10= worst pain)"", 'timeFrame': 'Baseline, 15 Minutes post epidural administration'}]","[{'measure': 'Maternal Systolic Blood Pressure', 'description': 'Blood pressure will be measured at different timepoints.', 'timeFrame': 'Baseline, 30 Minutes post epidural administration'}, {'measure': 'Maternal Heart Rate', 'description': 'Heart rate will be measured at different timepoints.', 'timeFrame': 'Baseline, 30 Minutes post epidural administration'}, {'measure': 'Neonatal Apgar Score', 'description': 'The Apgar score is based on a total score of 1 to 10. The higher the score, the better the baby is doing after birth. A score of 7, 8, or 9 is normal and is a sign that the newborn is in good health.', 'timeFrame': '1 minute and 5 minutes post delivery'}, {'measure': 'Number of Spontaneous Vaginal Deliveries', 'description': 'Mode of delivery: spontaneous vaginal or instrumental vaginal versus cesarean.', 'timeFrame': 'Upon delivery (approximately up to 8 hours from baseline)'}]",5,18 Years,,FEMALE,False,Columbia University,OTHER,0,101.0,ACTUAL,2025-09-01T16:18:12.167557,v2_robust,True,True,True,False,False,
NCT01415921,Safety Study of Pyridostigmine in Heart Failure,Augmentation of Parasympathetic Signaling With Pyridostigmine in Heart Failure,Pyridostigmine Bromide,"['Pyridostigmine Bromide', 'Mestinon']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Heart Failure,['Heart Failure'],"['heart failure', 'autonomic function', 'sympathovagal balance', 'cholinesterase inhibitors', 'pharmacology']",COMPLETED,,2011-10,2015-07,"[{'measure': 'Baseline Heart Rate Recovery', 'description': 'Change in peak HR at end of exercise to 1 minute post-exercise (beats per minute)', 'timeFrame': 'Baseline'}, {'measure': 'Post Exercise Heart Rate Recovery', 'description': 'Change in heart rate from peak exercise to 1 minute post-exercise (beats per minute)', 'timeFrame': '12 weeks'}]",[],2,21 Years,75 Years,ALL,False,NYU Langone Health,OTHER,3,33.0,ACTUAL,2025-09-01T16:18:12.167579,v2_robust,True,True,True,False,False,
NCT00075621,Tandem Autologous Stem Cell Transplantation in Treating Patients With Primary Systemic (AL) Amyloidosis,A Phase II Trial of Tandem Transplantation in AL Amyloidosis,filgrastim,"['filgrastim', 'melphalan', 'alkeran']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],['primary systemic amyloidosis'],COMPLETED,,2000-08,2020-09-04,"[{'measure': 'safety', 'timeFrame': '100 days, 6 months, and annual'}]","[{'measure': 'Efficacy', 'timeFrame': 'one year'}]",2,18 Years,65 Years,ALL,False,Boston Medical Center,OTHER,0,62.0,ACTUAL,2025-09-01T16:18:12.167608,v2_robust,True,True,True,False,True,
NCT00057421,Tuberculosis in HIV Infected Patients in Uganda,Impact of Tuberculosis on HIV Infection in Uganda,prednisolone,['prednisolone'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Tuberculosis,"['Tuberculosis', 'HIV Infections']","['Tuberculosis', 'HIV infection', 'Prednisolone', 'Safety', 'Immune activation']",COMPLETED,,1998-11,2002-09,[],[],0,18 Years,60 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,190.0,,2025-09-01T16:18:12.167629,v2_robust,True,True,True,False,False,
NCT02163421,Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration,"A Phase 1, Open Label, Randomized, Parallel Group Study to Assess the Absolute Bioavailability and Pharmacokinetics of Vedolizumab in Healthy Participants Following Single Subcutaneous Administration",Vedolizumab SC,"['Vedolizumab IV', 'MLN0002SC', 'Vedolizumab SC']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Drug therapy'],COMPLETED,,2014-06,2015-01,"[{'measure': 'Population Mean Estimate for Bioavailability Following Subcutaneous (SC) Administration', 'description': 'Bioavailability is defined as the rate and extent to which the active moiety of the e.g. subcutaneous administered drug reaches the systemic circulation. Population mean estimate for bioavailability was based on population pharmacokinetic (PK) analysis to find one measure. The exposure data were pooled across visits and subjects to identify population PK parameter estimates and covariate effects. The outcome measure data was planned to be analyzed using a model collating all arms measures to report pooled data across arms, as per planned analysis. Bioavailability was estimated using population pharmacokinetic (popPK) analysis.', 'timeFrame': 'Day 1: predose and on multiple time points (up to Day 127)'}]",[],1,18 Years,60 Years,ALL,True,Takeda,INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:12.167684,v2_robust,True,True,True,False,False,
NCT06748521,Dynamic CtDNA-guided Targeted Therapy in DLBCL,Efficacy and Safety of Dynamic CtDNA-guided Targeted Therapy in Patients with Previously Untreated Diffuse Large B-cell Lymphoma,R-CHOP + X,['R-CHOP + X'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B Cell Lymphoma (DLBCL),['Diffuse Large B Cell Lymphoma (DLBCL)'],[],NOT_YET_RECRUITING,,2024-12-31,2028-06-01,"[{'measure': 'Complete response (CR) rate', 'description': 'CR rate at the end of treatment. Defined as the proportion of participants who achieved CR at the end of treatment.', 'timeFrame': 'End of Cycle 6 (each cycle is 21 days)'}]","[{'measure': '2-year progression-free survival (PFS) rate', 'description': 'PFS, defined as the time from enrollment to the first occurrence of disease progression or relapse using the 2014 Lugano Response Criteria or death due to any cause, whichever occurs first; as determined by the investigator. The 2-year PFS rate was the percentage of patients who did not experience disease progression or death within two years of enrollment.', 'timeFrame': '2 years'}, {'measure': '2-year Overall survival (OS) rate', 'description': 'OS defined as the time from enrollment to death from any cause. The 2-year OS rate was the percentage of patients who did not die within two years of enrollment.', 'timeFrame': '2 years'}, {'measure': 'The incidence and severity of adverse events were determined according to the NCI CTCAE v5.0 rating scale', 'description': 'An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.', 'timeFrame': 'From enrollment to study completion, a maximum of 4 years'}]",4,18 Years,75 Years,ALL,False,Ruijin Hospital,OTHER,0,108.0,ESTIMATED,2025-09-01T16:18:12.167903,v2_robust,True,True,False,False,True,
NCT03308721,Research Study Investigating Study Medicine (NNC9204-1177) for Weight Management in People With Overweight or Obesity,"A Multiple Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Multiple Doses of NNC9204-1177 in Subjects Being Overweight or With Obesity",NNC9204-1177 A 1.0 mg/mL,"['PLACEBO', 'NNC9204-1177 A 1.0 mg/mL']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Metabolism and Nutrition Disorder,"['Metabolism and Nutrition Disorder', 'Obesity']",[],COMPLETED,,2017-10-16,2020-01-03,"[{'measure': 'Number of treatment emergent adverse events (TEAEs)', 'description': 'Count of events', 'timeFrame': 'Day 1-110'}]","[{'measure': 'The area under the NNC9204-1177 serum concentration-time curve at steady state', 'description': 'Calculated based on NNC9204-1177 measured in blood.', 'timeFrame': '0-168 hours'}, {'measure': 'The maximum serum concentration of NNC9204-1177 at steady state', 'description': 'Calculated based on NNC9204-1177 measured in blood.', 'timeFrame': 'Day 78-110'}, {'measure': 'The time to maximum serum concentration of NNC9204-1177', 'description': 'Calculated based on NNC9204-1177 measured in blood.', 'timeFrame': 'Day 78-110'}, {'measure': 'The terminal half-life of NNC9204-1177 from steady state', 'description': 'Calculated based on NNC9204-1177 measured in blood.', 'timeFrame': 'Day 78-110'}]",5,18 Years,55 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,99.0,ACTUAL,2025-09-01T16:18:12.167967,v2_robust,True,True,True,False,True,
NCT03423121,A Trial of Bile Acid Supplementation in Patients With Multiple Sclerosis,A Phase 1/2 Trial of Tauroursodeoxycholic Acid Supplementation in Progressive MS Patients,Tauroursodeoxycholic Acid,"['Taurolite', 'Tauroursodeoxycholic Acid', 'Placebo oral capsule']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Progressive Multiple Sclerosis,['Progressive Multiple Sclerosis'],[],COMPLETED,,2018-06-19,2022-07-05,"[{'measure': 'Number of Participants With at Least One Treatment-related Adverse Event', 'description': 'Safety and tolerability will be assessed based on treatment-related adverse events in the two arms.', 'timeFrame': '16 weeks'}, {'measure': 'Number of Total Treatment-related Adverse Events', 'description': 'Safety and tolerability will be assessed based on treatment-related adverse events in the two arms.', 'timeFrame': '16 weeks'}, {'measure': 'Incidence of Treatment-related Adverse Events (AE)', 'description': 'Safety and tolerability will be assessed based on treatment-related adverse events in the two arms. AE incidence will be measured as total number of events per 1000 exposure years.', 'timeFrame': '16 weeks'}]","[{'measure': 'Change in Fasting Bile Acid Levels in Plasma', 'description': 'The change of targeted bile acid levels over the course of 16 weeks (duration of the study) is reported.\n\nBile acid levels (ng/mL) were log transformed before analysis to approximate normal distribution. Units are log(levels) per 16 weeks. Values are derived from linear mixed-effects models.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Change in Microbiome Alpha-diversity Measured by Shannon Index at the End of the Study', 'description': 'Change in Shannon index of the gut microbiota between baseline and end of study (16 weeks). Shot-gun metagenomic sequencing in first morning stool specimen was utilized to derive the microbiome composition. Higher values of the index indicate more diversity in the microbial community. The minimum value the Shannon index can take is 0 (no diversity). There is no upper limit to the index.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Change in Flow Cytometric Assessments of Peripheral Blood Mononuclear Cells (PBMCs)', 'description': 'Change in flow cytometric assessments over the course of 16 weeks (duration of the study).\n\nCells are expressed as ratios of their parent types. Units reported as change in the ratio per 16 weeks. Values are derived from linear mixed-effects models.', 'timeFrame': 'Baseline to 16 weeks'}, {'measure': 'Change in Quality of Life Based on Multiple Sclerosis Quality of Life (MSQOL)-54 Instrument', 'description': 'Change in physical and mental health scores as assessed using the Multiple Sclerosis Quality of Life-54 (MSQOL-54) instrument over the course of 16 weeks (duration of the study). This 54-item instrument generates 12 subscales along with two summary scores, and two additional single-item measures. Two summary scores - physical health and mental health - are derived from a weighted combination of scale scores. Higher scores suggest a better quality of life. Scores can range from 0 to 100.', 'timeFrame': 'Baseline to 16 weeks'}]",7,18 Years,,ALL,False,Johns Hopkins University,OTHER,0,59.0,ACTUAL,2025-09-01T16:18:12.167975,v2_robust,True,True,True,False,True,
NCT06957821,Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques,Study to Image Inflammatory Activity of a Fluorescence Imaging Agent in Excised Human Artery Plaques,Pegulicianine,"['LUMISIGHT', 'Pegulicianine']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Carotid Artery Diseases,"['Carotid Artery Diseases', 'Peripheral Arterial Disease']",[],NOT_YET_RECRUITING,,2025-07-30,2027-12-31,"[{'measure': 'Demonstrate lumisight fluorescence activity in lumisight cohort vs controls', 'description': 'Mean difference in plaque for fluorescence ratio to show that fluorescence in the Lumisight cohort is 2 fold greater than that of the control', 'timeFrame': '2-6 hours'}]",[],1,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,2,25.0,ESTIMATED,2025-09-01T16:18:12.168083,v2_robust,True,True,False,False,False,
NCT01839214,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With Ulcerative Colitis,"A Randomized, Double-Blind, 12-Week, Placebo-Controlled Study Followed by a 12-Week Extension Phase Without Placebo to Evaluate the Efficacy and Safety of Oral VB-201 in Subjects With Mild to Moderate Ulcerative Colitis",VB-201 160mg,"['VB-201 160mg', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ulcerative Colitis,['Ulcerative Colitis'],[],COMPLETED,,2013-01,2014-11,"[{'measure': 'Modified Mayo Score indicating remission', 'description': 'The proportion of subjects in remission at Weeks 12 and 24 in the VB-201 160mg (80 mg BID) treatment group compared to placebo group.', 'timeFrame': 'Week 12 and Week 24'}]","[{'measure': 'Modified Mayo Score indicating response', 'description': 'The proportion of subjects responding at Weeks 12 and 24 in the VB-201 160mg (80 mg BID) treatment group compared to placebo group.', 'timeFrame': 'Week 12 and Week 24'}]",2,18 Years,,ALL,False,Vascular Biogenics Ltd. operating as VBL Therapeutics,INDUSTRY,0,112.0,ACTUAL,2025-09-01T16:18:12.168218,v2_robust,True,True,True,False,False,
NCT01736514,A Study to Evaluate Safety and Efficacy of Oral Febuxostat in Patients With Gout,"A Randomized, Open Label, Multicenter, Allopurinol- Controlled Study to Assess the Safety and Efficacy of Oral Febuxostat in Patients With Gout",febuxostat,"['febuxostat', 'Adenuric, Uloric, Feburic', 'Allopurinol']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Gout,['Gout'],"['xanthine oxidase inhibitor', 'Uric acid lowering drug']",COMPLETED,,2011-03,2012-02,"[{'measure': 'Proportion of subjects whose serum urate level decreases to < 6.0 mg/dL', 'timeFrame': 'week 12'}]","[{'measure': 'Percent reduction in serum urate levels', 'timeFrame': 'Baseline and at week 12'}, {'measure': 'Safety assessed by the incidence of adverse events, physical exam. and vital signs, tabo-tests and 12-lead ECG', 'timeFrame': 'Baseline and at week 12'}]",3,20 Years,65 Years,ALL,False,"Astellas Pharma Taiwan, Inc.",INDUSTRY,0,109.0,ACTUAL,2025-09-01T16:18:12.168228,v2_robust,True,True,True,False,True,
NCT01737814,Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC),"Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trial of MST-188 (Purified Poloxamer 188) Injection in Subjects With Sickle Cell Disease Experiencing Vaso Occlusive Crisis",Saline,"['Saline', 'MST-188', 'vepoloxamer']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Vaso-occlusive Crisis,"['Vaso-occlusive Crisis', 'Sickle Cell Disease']","['sickle cell disease', 'vaso-occlusive crisis']",COMPLETED,,2013-05,,"[{'measure': 'Reduction of the duration of vaso occlusive crisis (VOC) in subjects with sickle cell disease.', 'timeFrame': 'Study participants will be followed for the duration of hospital stay, an expected average of 4 days'}]","[{'measure': 'Re-hospitalization rate for VOC', 'timeFrame': 'Hospital discharge to 14 days post-discharge'}, {'measure': 'Occurence of acute chest syndrome', 'timeFrame': 'Randomization to 120 hours after randomization'}]",3,4 Years,65 Years,ALL,False,"Mast Therapeutics, Inc.",INDUSTRY,0,388.0,ACTUAL,2025-09-01T16:18:12.168246,v2_robust,True,True,True,False,False,
NCT01208714,Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study),Endovascular Treatment Versus Optimal Medical Treatment of Atherosclerotic Renal Artery for Preserving Renal Function of the Ischemic Kidney.,Optimal medical therapy,['Optimal medical therapy'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Renal Artery Stenosis,['Renal Artery Stenosis'],"['Renal artery stenosis', 'Atherosclerosis', 'Arterial hypertension', 'Percutaneous renal angioplasty', 'Stenting']",UNKNOWN,,2010-12,2016-03,"[{'measure': 'Glomerular filtration rate in the ischemic kidney after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'The Primary Objective of the study is to determine if revascularization by means of PTRAS is superior or equivalent to optimal medical treatment for preserving glomerular filtration rate in the ischemic kidney as assessed by 99TcDTPA sequential renal scintiscan', 'timeFrame': '24 months'}]","[{'measure': 'Lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in lowering blood pressure after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'timeFrame': '1, 3, 6, 12, 24, 36, 48 and 60 months'}, {'measure': 'Preserving overall renal function after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in preserving overall renal function, as assessed by total estimated GFR, the reciprocal of serum creatinine, and indexes of Ca2+ and PO43- metabolism.', 'timeFrame': '1, 3, 6, 12, 24, 36, 48 and 60 months'}, {'measure': 'Regression of damage in the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness after revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment.', 'description': 'One secondary objective of the study is to determine if the two treatments (revascularization by means of percutaneous renal angioplasty (PTRAS) or optimal medical treatment) are equivalent in tregressing damage of the target organs of hypertension, including cardiac hypertrophy, microalbuminuria and aortic stiffness.', 'timeFrame': '1, 3, 6, 12, 24, 36, 48 and 60 months'}]",4,18 Years,,ALL,False,University Hospital Padova,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:12.168258,v2_robust,True,True,False,False,False,
NCT00800514,Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury (TBI),Amantadine and Temporal Discrimination in Patients With Traumatic Brain Injury,amantadine,['amantadine'],1,INTERVENTIONAL,['NA'],,,Traumatic Brain Injury,['Traumatic Brain Injury'],"['perception of time, traumatic brain injury, amantadine']",WITHDRAWN,Principal investigator took a position at another institution. No subjects enrolled.,2009-01,2010-11,"[{'measure': 'The primary outcome measure is the Interval Bisection Timing Task.', 'timeFrame': '12 -16 months'}]","[{'measure': 'The secondary efficacy measure is the Barrett Impulsiveness Scale (BIS-11).', 'timeFrame': '12-16 moths'}]",2,18 Years,55 Years,ALL,False,Wake Forest University Health Sciences,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.168318,v2_robust,True,True,False,True,False,Principal investigator took a position at another institution. No subjects enrolled.
NCT01122914,A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis,A Pilot Study Using Anakinra/Kineret for the Treatment of Patients With Severe Atopic Dermatitis,Anakinra,['Anakinra'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Anakinra,"['Anakinra', 'Kineret', 'Atopic Dermatitis', 'Eczema', 'Allergic Disease']","['Kineret', 'Anakinra', 'Atopic Dermatitis', 'Eczema', 'Allergic Disease']",TERMINATED,,2010-04-14,2015-04-07,"[{'measure': 'Improvement of Atopic Dermatitis symptoms without increase in serious infections; Response to treatment with a 30 percent decrease in SCORAD score.', 'timeFrame': '2 years'}]","[{'measure': 'Determine immunological phenotype and cytokine profile of peripheral blood before and after treatment with Anakinra; Determine impact of IL-1 r neutralization on total and antigen specific allergen sensitivity.', 'timeFrame': '2 years'}]",2,10 Years,30 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,1.0,ACTUAL,2025-09-01T16:18:12.168369,v2_robust,True,True,False,True,False,
NCT00189514,A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects,Extension Study of Protocol 137OB-201 to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects,pramlintide acetate,"['pramlintide acetate', 'Symlin', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Obesity,['Obesity'],"['obesity', 'weight loss', 'Amylin', 'pramlintide']",COMPLETED,,2005-09,2007-06,"[{'measure': 'Examine the long-term effect of subcutaneously (SC) injected pramlintide on body weight in obese subjects.', 'timeFrame': 'open ended'}, {'measure': 'Examine the long-term safety and tolerability of SC injected pramlintide in obese subjects.', 'timeFrame': 'open ended'}]","[{'measure': 'Investigate the long-term effect of SC injected pramlintide in obese subjects on various anthropometric and pharmacodynamic parameters.', 'timeFrame': 'open ended'}]",3,18 Years,70 Years,ALL,False,AstraZeneca,INDUSTRY,0,210.0,ACTUAL,2025-09-01T16:18:12.168449,v2_robust,True,True,True,False,True,
NCT05862714,Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor,Comparison of Efficacy of Single Oral Dose Fluconazole and Itraconazole in Patients With Pityriasis Versicolor,Fluconazole,"['Fluderm', 'Itraconazole', 'Fluconazole', 'Icon']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Tinea Versicolor,['Tinea Versicolor'],[],COMPLETED,,2022-03-01,2022-09-30,"[{'measure': 'Clinical Improvement Resolution of symptoms', 'description': 'Efficacy of treatment was assessed by mycological test by making KOH mount at start of treatment and than at follow up at 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'Efficacy of treatment through KOH mount', 'description': 'Efficacy of treatment was assessed by mycological test by making KOH mount at start of treatment and than at follow up at 4 weeks', 'timeFrame': '4 weeks'}]",[],2,18 Years,100 Years,ALL,True,Combined Military Hospital Abbottabad,OTHER,0,164.0,ACTUAL,2025-09-01T16:18:12.168478,v2_robust,True,True,True,False,False,
NCT00495014,Study To Investigate The Safety And Metabolism Of GSK376501 In Overweight Subjects,"A Single-Blind, Randomized, Placebo-Controlled, Ascending Single Dose and Repeat Dose Study With Once Daily Dosing To Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK376501 in Healthy Overweight and Obese Subjects",GSK376501,"['GSK376501', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['GSK376501,', 'Single Dose,', 'Dose Escalation,', 'Healthy Overweight/Obese Volunteer']",COMPLETED,,2007-06,2007-12,"[{'measure': 'Adverse reactions and changes in laboratory values, vital signs, and/or ECGs following each dose', 'timeFrame': 'following each dose'}]","[{'measure': 'Blood levels of GSK376501 following 1 day (Part A) or 14 days (Part B) of dosing', 'timeFrame': 'following 1 day (Part A) or 14 days (Part B) of dosing'}, {'measure': 'GSK376501 plasma levels to derive pharmacokinetic parameters following single and repeat doses for 14 days'}, {'measure': 'Standard markers that may serve as possible surrogates of volume expansions with GSK376501.'}, {'measure': 'Body weight following 14 days of repeat dosing with GSK376501.'}]",5,18 Years,65 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,70.0,ACTUAL,2025-09-01T16:18:12.168643,v2_robust,True,True,True,False,True,
NCT03814616,Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections,"A Randomized, Open-Label Exploratory Study To Determine The Efficacy Of Different Treatment Regimens Of Pyramax® (Pyronaridine-Artesunate) In Asymptomatic Carriers Of Plasmodium Falciparum Monoinfections",Pyronaridine tetraphosphate 180mg:artesunate 60mg,"['Pyronaridine tetraphosphate 180mg:artesunate 60mg', 'Pyramax']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Malaria,Falciparum","['Malaria,Falciparum']",['Asymptomatic malaria'],UNKNOWN,,2018-10-03,2019-10,"[{'measure': 'PCR-adjusted APR at Day 28 (based on slide assessment by microscopy)', 'description': 'To assess the efficacy of each dosing regimen PCR-adjusted Adequate parasitological response (APR) at Day 28', 'timeFrame': 'Day 28'}]","[{'measure': 'PCR-adjusted APR', 'description': 'To assess the efficacy of each dosing regimen PCR-adjusted APR at Day 63', 'timeFrame': '63 days'}, {'measure': 'PCR-unadjusted APR', 'description': 'To assess the efficacy of each dosing regimen PCR-unadjusted APR at Day 63', 'timeFrame': '63 days'}, {'measure': 'Rate of recurrent infections, recrudescence and new infections', 'description': 'To assess the efficacy of each dosing regimen on rate of recurrent infections, recrudescence and new infections', 'timeFrame': '63 days'}, {'measure': 'Proportion of parasite free participants', 'description': 'Proportion of participants who are parasite free by 4-8 hours, Day 1, Day 2 and Day 3 post first dosing', 'timeFrame': '4 days'}, {'measure': 'Gametocyte incidence', 'description': 'The area under the curve (AUC) up to Day 14 (post first dose) of gametocytes in participants with gametocytes at baseline, and separately in participants without gametocytes at baseline', 'timeFrame': '14 days'}, {'measure': 'Adverse Events', 'description': '* Number (%) of patients and number of events with:\n\n  * TEAEs,\n  * serious TEAEs,\n  * study drug related TEAEs,\n  * study drug related serious TEAEs,\n  * malaria-related TEAEs,\n  * malaria-related serious TEAEs\n* Number (%) of patients with TEAEs and drug-related TEAEs by maximum severity, based on Grade 1 to Grade 5 (CTCAE V4.03) severity grading Adverse events will be coded by MedDRA primary system organ class and preferred term.\n* Hepatotoxicity related TEAEs o The number and percentage of patients with hepatotoxicity related TEAEs, based on the Standard MedDRA Query (SMQ) narrow search ""Drug-related hepatic disorders"" will be summarised and clinical biochemistry parameters', 'timeFrame': '63 days'}, {'measure': 'Clinical laboratory data - Haematology', 'description': 'Haemoglobin, haematocrit, erythrocytes, platelets, white blood cells, neutrophils, lymphocytes, monocytes, eosinophils, basophils will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. SI units will be used to summarise the data.', 'timeFrame': '63 days'}, {'measure': 'Clinical laboratory data - Biochemistry', 'description': 'Total and conjugated bilirubin will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. SI units will be used to summarise the data.', 'timeFrame': '63 days'}, {'measure': 'Clinical laboratory data - Liver Enzymes', 'description': 'Alanine aminotransaminase (ALT), Aspartate aminotransaminase (AST), Alkaline Phosphatase will be summarised over time, as absolute values and changes from baseline with the number of observations, mean, standard deviation, median, quartiles, minimum and maximum. IU/L units will be used to summarise the data', 'timeFrame': '63 days'}, {'measure': 'Clinical laboratory data - Liver Enzyme Elevations', 'description': ""The number (%) of participants with liver enzyme elevations after first drug administration as defined below will be summarised.\n\n* ALT or AST \\> 3 x Upper Limit of Normal (ULN)\n* ALT or AST \\> 5 x ULN\n* ALT or AST \\> 8 x ULN\n* ALT or AST \\> 3 x ULN and bilirubin \\> 2 x ULN at the same time point (when conjugated bilirubin fraction is missing)\n* ALT or AST \\> 3 x ULN and bilirubin \\> 2 x ULN, together with a conjugated bilirubin fraction \\>35% (Potential Hy's law cases), at the same time point"", 'timeFrame': '63 days'}, {'measure': 'Vital signs - Blood pressure', 'description': 'Supine systolic and diastolic blood pressure (mm Hg) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles', 'timeFrame': '63 days'}, {'measure': 'Vital signs - Pulse rate', 'description': 'Pulse rate (bpm) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles', 'timeFrame': '63 days'}, {'measure': 'Vital signs - Temperature', 'description': 'Temperature (degrees Celsius) absolute values and changes from baseline will be summarised by time point with the number of observations, mean, standard deviation, median, minimum and maximum, and quartiles', 'timeFrame': '63 days'}]",14,5 Years,,ALL,False,Shin Poong Pharmaceutical Co. Ltd.,INDUSTRY,1,300.0,ACTUAL,2025-09-01T16:18:12.168711,v2_robust,True,True,False,False,True,
NCT02835716,Pre-Clinical (Alzheimers) Diagnosis PCD = Optimum Outcomes OO,Pre-Clinical Alzheimer's (ALZ) Diagnosis (PCD) = Optimum Outcomes (OO),roflumilast,"['roflumilast', 'Daliresp']",2,OBSERVATIONAL,[],,,Alzheimer Disease,['Alzheimer Disease'],"['Phosphodiesterase type 4 inhibitor', 'ustekinumab', 'secukinumab', 'P40 subunit', 'Interleukin IL-12', 'Interleukin IL-23', 'Apoprotein e4', 'Interleukin IL-17A']",UNKNOWN,,2016-09,2020-09,"[{'measure': 'Number of Participants who Develop Cognitive Decline', 'description': 'Cognitive decline is defined as a reduction from baseline performance within each individual of at least one standard deviation (SD) on at least one of the three principal outcome indices (DRS-2, RAVLT Sum of Trials 1-5 \\[T1- 5\\], RAVLT Delayed Recall \\[DR\\]).', 'timeFrame': '18-24 month'}]",[],1,50 Years,75 Years,ALL,True,"Millennium Magnetic Technologies, LLC",INDUSTRY,0,150.0,ESTIMATED,2025-09-01T16:18:12.168765,v2_robust,False,True,False,False,False,
NCT03619616,"Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults","A Phase 1 Randomized,Double-Blind,Parallel-Group, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ZSP1603 in Chinese Healthy Subjects",ZSP1603 7.5 mg,"['ZSP1603 50 mg', 'ZSP1603 25 mg', 'ZSP1603 12.5 mg', 'Placebo 25mg', 'Placebo 50mg', 'Placebo 12.5mg', 'ZSP1603 7.5 mg']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Idiopathic Pulmonary Fibrosis(IPF),"['Idiopathic Pulmonary Fibrosis(IPF)', 'Solid Tumor']",[],COMPLETED,,2018-07-16,2019-10-22,"[{'measure': 'Number of participants with treatment-emergent adverse events (TEAEs) following oral doses of ZSP1603 and placebo,separately.', 'description': 'Number of participants with TEAEs as assessed by CTCAE v5.0.', 'timeFrame': 'At Day 6 post-dose.'}]","[{'measure': 'AUClast（AUC0-t）of ZSP1603', 'description': 'AUClast is defined as the concentration of drug from time zero to the last quantifiable concentration.', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'AUC0-24 of ZSP1603', 'description': 'AUC0-24 is defined as the concentration of drug from zero(0) hrs to 24h (area under the plasma concentration versus time curve from zero(0) hrs to 24h).', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'Cmax of ZSP1603', 'description': 'Cmax is defined as the maximum observed concentration of drug in plasma.', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'Tmax of ZSP1603', 'description': 'Tmax is defined as the time to maximum concentration.', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 't1/2 of ZSP1603', 'description': 't1/2 is defined as the time to half of the drug concentration in plasma.', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'CL/F of ZSP1603', 'description': 'CL/F is defined as the ratio of total clearance(CL) to bioavailability(F).', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'λz of ZSP1603', 'description': 'λz is defined as the ratio between the elimination of compound per unit time and the total amount of compound.', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'VD/F of ZSP1603', 'description': 'VD/F is defined as apparent volume of distribution', 'timeFrame': 'Up to 6 days post-dose'}, {'measure': 'MRT of ZSP1603', 'description': 'MRT is defined as mean residence time', 'timeFrame': 'Up to 6 days post-dose'}]",10,18 Years,50 Years,ALL,True,"Guangdong Zhongsheng Pharmaceutical Co., Ltd.",INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:12.168794,v2_robust,True,True,True,False,True,
NCT04679506,the Efficacy and Safety of CLAE in R/R T-ALL/LBL,Clinical Observation on the Efficacy and Safety of CLAE Regimen (Cladribine + Cytarabine + Etoposide) in the Treatment of Relapsed/Refractory T- Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma,Cladribine,"['Cladribine', 'etoposide', 'cytarabine']",3,OBSERVATIONAL,[],,,Precursor T-Cell Lymphoblastic Leukemia-Lymphoma,['Precursor T-Cell Lymphoblastic Leukemia-Lymphoma'],"['R/R T-ALL/LBL', 'CLAE']",UNKNOWN,,2020-12,2023-12,"[{'measure': 'ORR', 'description': 'Objective response rate，sum of complete response rate and partial response rate', 'timeFrame': 'From the date of first study drug administration until the end of Cycle 2 (each cycle is 28 days)'}]","[{'measure': 'PFS', 'description': 'progression-free survival', 'timeFrame': 'From the date of first study drug administration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months.'}, {'measure': 'OS', 'description': 'overall survival', 'timeFrame': 'From the date of first study drug administration until the date of death due to any cause, assessed up to 24 months.'}]",3,18 Years,,ALL,False,Peking University Third Hospital,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:12.169026,v2_robust,False,True,False,False,False,
NCT03020706,Effect of Magnesium Sulphate on Neostigmine,Effect of Magnesium Sulphate on Neostigmine-induced Reversal of Neuromuscular Block by Rocuronium,"Magnesium Sulfate, Injectable","['Magnesium Sulfate, Injectable', 'magnesium sulphate']",2,INTERVENTIONAL,['NA'],,,Neuromuscular Blockade,['Neuromuscular Blockade'],"['magnesium sulphate', 'neostigmine']",UNKNOWN,,2016-12,2017-12,"[{'measure': 'reversal time', 'description': 'reversal time: from neostigmine injection to TOF ratio 0.9', 'timeFrame': 'through study completion, an average of 90 minutes'}]",[],1,20 Years,65 Years,ALL,True,Gachon University Gil Medical Center,OTHER,1,166.0,ESTIMATED,2025-09-01T16:18:12.169090,v2_robust,True,True,False,False,False,
NCT04392206,AMSC for Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses,"A Phase I, Open Label Study of Allogeneic Adipose Derived Mesenchymal Stem Cells in Reducing Anastomotic Stenosis in Primary Arteriovenous Anastomoses",Adipose Derived Mesenchymal Stem Cells,"['AMSC', 'Adipose Derived Mesenchymal Stem Cells']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,End Stage Renal Disease,['End Stage Renal Disease'],[],RECRUITING,,2020-05-15,2027-06,"[{'measure': 'Number of participants with treatment-related adverse events', 'description': 'Evaluate the safety of AMSC administration by assessing the number of participants to experience an adverse event as defined by inflammation, infection (local or systemic), aneurysm formation, clinically significant increase or decrease in blood flow or thrombosis formation as evaluated through physical exam and ultrasound.', 'timeFrame': '12 months'}]",[],1,18 Years,85 Years,ALL,False,"Houssam Farres, M.D.",OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:12.169204,v2_robust,True,True,False,False,True,
NCT00916006,"A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","A Multi-center, Randomized, Parallel Group, Double-blind, Vehicle-controlled Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, 0.015% In Patients With Actinic Keratoses ON the Head (Face or Scalp) (REGION-IIa)",PEP005 Gel,"['PEP005', 'Vehicle gel', 'Placebo', 'PEP005 Gel']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Actinic Keratosis,['Actinic Keratosis'],"['Peplin', 'Actinic keratosis', 'PEP005']",COMPLETED,,2009-06,2009-09,"[{'measure': 'Patients With Complete Clearance of Actinic Keratosis (AK) Lesions.', 'description': 'Complete clearance rate of actinic keratosis (AK) lesions, defined as the proportion of patients with no clinically visible AK lesions in the selected treatment area.', 'timeFrame': '57 days'}]","[{'measure': 'Patients With Partial Clearance of Actinic Keratosis (AK)', 'description': 'Patients with partial clearance defined as ≥ 75% reduction in the number of actinic keratosis (AK) lesions identified at baseline in the treatment area', 'timeFrame': 'baseline and 57 days'}]",2,18 Years,,ALL,False,Peplin,INDUSTRY,0,269.0,ACTUAL,2025-09-01T16:18:12.169212,v2_robust,True,True,True,False,False,
NCT01508806,Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function,"A Single-centre, Open-label, Trial Investigating the Pharmacokinetics and the Tolerability of Liraglutide in Subjects With Normal Renal Function and in Subjects With Impaired Renal Function",liraglutide,['liraglutide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2005-08,2006-03,[{'measure': 'Area under the Curve (AUC)'}],"[{'measure': 'AUC (0-t)'}, {'measure': 'Cmax, maximum concentration'}, {'measure': 'tmax, time to reach Cmax'}, {'measure': 't½, terminal half-life'}, {'measure': 'CLR (renal clearance)'}, {'measure': 'Adverse events'}]",7,18 Years,75 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:12.169284,v2_robust,True,True,True,False,True,
NCT00043706,"Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis","A Phase 1/2 Double Blind, Placebo Controlled, Randomized, Dose Ranging, Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of CAT-192 Human Anti-TGF-Beta1 Monoclonal Antibody in Patients With Early Stage Diffuse Systemic Sclerosis",Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody,['Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Systemic Sclerosis,"['Systemic Sclerosis', 'Scleroderma']",[],COMPLETED,,,2003-09,[],[],0,18 Years,75 Years,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,1,,,2025-09-01T16:18:12.169297,v2_robust,True,True,True,False,False,
NCT02823106,Superselective Citicoline and Verapamil for Ischemic Neuroprotection and Greater Effective Response,Superselective Citicoline And Verapamil for Ischemic Neuroprotection and Greater Effective Response (SCAVINGER) in the Kentucky Regional Population: A Clinical and Translational Study,Verapamil and Citicoline,"['CDP-choline', 'Verapamil and Citicoline']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Ischemic Stroke,['Ischemic Stroke'],[],WITHDRAWN,Study put on clinical hold by FDA. Sponsor decided to no pursue the study.,2016-08,2016-09,"[{'measure': 'Number of participants having no symptomatic intracranial hemorrhage', 'description': 'Defined as a hemorrhage occurring within 48 hours after study inclusion, temporally related to the intervention, and occurring with worsening neurological status as documented in the clinical exam.', 'timeFrame': 'within 48 hours after treatment'}]","[{'measure': 'Number of participants who had no systemic side effects from verapamil and citicoline administration.', 'description': 'At any point during study treatment', 'timeFrame': 'within 90 days'}]",2,18 Years,101 Years,ALL,False,Justin Fraser,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.169303,v2_robust,True,True,False,True,False,Study put on clinical hold by FDA. Sponsor decided to no pursue the study.
NCT00012506,The Safety and Efficacy of a Tumor Necrosis Factor Receptor Fusion Protein on Uveitis Associated With Juvenile Rheumatoid Arthritis,,TNFR:Fc,['TNFR:Fc'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Uveitis,"['Uveitis', 'Arthritis, Juvenile Rheumatoid']",[],UNKNOWN,,,,[],[],0,2 Years,18 Years,ALL,False,National Eye Institute (NEI),NIH,0,,,2025-09-01T16:18:12.169326,v2_robust,True,True,False,False,False,
NCT02058706,LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer,Randomized Phase II Screening Trial of Enzalutamide/MDV-3100 and LHRH Analogue vs Combined Androgen Deprivation (LHRH Analogue + Bicalutamide) in Metastatic Hormone Sensitive Prostate Cancer,enzalutamide,"['Casodex', 'Enantone', 'bicalutamide', 'ICI-118630', 'ZDX', 'Zoladex', 'Lupron Depot', 'CDX', 'Lupron', 'MDV3100', 'leuprolide acetate', 'goserelin acetate', 'LEUP', 'enzalutamide', 'XTANDI', 'selective androgen receptor modulator MDV3100']",16,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of the Prostate,"['Adenocarcinoma of the Prostate', 'Recurrent Prostate Cancer', 'Stage IV Prostate Cancer']",[],COMPLETED,,2014-05,2021-03-01,"[{'measure': 'Number of Participants With PSA Remission Assessed Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria', 'description': 'Number of Participants with PSA Remission Assessed Using the Prostate Cancer Clinical Trials Working Group (PCWG2) Criteria specifically at the 7 month time point. The binary endpoint (yes/no) will be summarized with its point estimate (an occurrence rate), and 2-sided Wilson type 95% confidence interval (CI). PSA response rates will be compared by treatment arm in a stratified logistic regression model.', 'timeFrame': 'Month 7'}]","[{'measure': 'Achievement of Measurable Disease Response', 'description': 'The number of participants with Measurable disease response per RECIST v1.1.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Achievement of PSA Response Assessed Using PCWG2 Criteria', 'description': 'Will be summarized with point estimates (occurrence rates), and 2-sided Wilson type 95% CIs.', 'timeFrame': 'Up to 2 years'}, {'measure': 'The Percentage of Patients Responding', 'description': 'Point estimates will be calculated and CI estimates will be derived from the Wilcoxon method using STATA software.', 'timeFrame': '6 months'}, {'measure': 'Time to Treatment Failure', 'description': 'Time to Treatment Failure from date of first treatment to date off treatment or date patient is taken off study for any reason. TTF will be estimated with standard K-M methodology. Point and CI estimates of the median and various time point-specific rates will be derived from the K-M life table.', 'timeFrame': 'Assessed up to 6 years.'}, {'measure': 'Percentage of Patients Progression Free at One Year', 'description': 'Percentage of patients progression free at one year using the Kaplan-Meier method.', 'timeFrame': 'assessed at 1 year'}, {'measure': 'Percentage of Patients With Bone Metastases Progression Free at Six Months', 'description': 'Percentage of patients with bone metastases Progression free at six months using the Kaplan-Meier method.', 'timeFrame': 'assessed at six months'}, {'measure': 'Percentage of Patients Progression-free at 6 Months', 'description': 'Will be estimated with standard K-M methodology. Point and CI estimates of the six-month rate will be derived from the K-M life table.', 'timeFrame': 'From registration to PSA progression defined by PCWG II criteria or measurable disease by RECIST 1.1, assessed at 6 months'}, {'measure': 'Overall Survival at 2 Years', 'description': 'Overall Survival will be measured from date of registration to death or last follow up. OS will be estimated with standard K-M methodology. Point and CI estimates of the 2-year rate will derived from the K-M life table.', 'timeFrame': 'Assessed at 2 years'}, {'measure': 'The Number of Participants With a CTC Response', 'description': 'Will be summarized with point estimates (occurrence rates). A CTC response is defined as any level of CTC \\< 5 that is maintained or any level of CTC that is reduced from baseline.', 'timeFrame': 'Up to month 1'}]",10,18 Years,,MALE,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,71.0,ACTUAL,2025-09-01T16:18:12.169391,v2_robust,True,True,True,False,False,
NCT00461006,A Comparison of the Effects of Aleglitazar and Actos on Renal Function on Patients With Type 2 Diabetes.,"A Randomized, Double Blind Study to Compare the Effects of Aleglitazar and Actos on Glomerular Filtration Rate and Other Parameters of Renal Function in Patients With Type 2 Diabetes.",Actos,"['aleglitazar', 'Actos']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetes Mellitus Type 2,['Diabetes Mellitus Type 2'],[],COMPLETED,,2007-06,2008-09,"[{'measure': 'Relative change from baseline in glomerular filtration rate', 'timeFrame': '26 weeks'}]","[{'measure': 'Relative change from baseline in estimated renal plasma flow (ERPF) and urine albumin-creatinine ratio (UACR)', 'timeFrame': '26 weeks'}, {'measure': 'Absolute change in Hemoglobin A1c (HbA1c), fasting plasma glucose (FPG) and fasting plasma insulin (FPI).', 'timeFrame': 'End of treatment'}, {'measure': 'Adverse events (AEs), laboratory parameters.', 'timeFrame': 'Throughout study'}]",4,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,176.0,ACTUAL,2025-09-01T16:18:12.169442,v2_robust,True,True,True,False,True,
NCT04723004,Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC,"A Randomized, Open-label, Multi-center Phase III Clinical Study to Evaluate the Safety and Efficacy of Toripalimab (JS001) Combined With Bevacizumab Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma",Sorafenib,['Sorafenib'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Advanced Hepatocellular Carcinoma (HCC),['Advanced Hepatocellular Carcinoma (HCC)'],[],ACTIVE_NOT_RECRUITING,,2020-10-15,2024-12-31,"[{'measure': 'Progression-free survival (PFS)', 'description': 'A duration from the date of initial treatment with Toripalimab Plus Bevacizumab or Sorafenib to disease progression (defined by RECIST 1.1) or death of any cause, whichever comes first.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'Duration from the date of initial treatment with Toripalimab Plus Bevacizumab or Sorafenib monotherapy to the date of death due to any cause.', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'ORR', 'description': 'The rate of participants that achieve either a complete response (CR) or a partial response (PR).', 'timeFrame': 'Up to 2 years'}, {'measure': 'DoR', 'description': 'Duration from the first time reported partial response or complete response to the first time of disease progression or death.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'Proportion of patients with reduction and non-change in tumor burden of a predefined amount, including complete remission, partial remission and stable disease', 'timeFrame': 'Up to 2 years'}, {'measure': 'TTP', 'description': 'Define as the time from randomization to the first documented disease progression', 'timeFrame': 'Up to 2 years'}, {'measure': 'Incidence of AEs/SAEs as Assessed by CTCAE v5.0', 'description': 'Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0', 'timeFrame': 'From date of consent informed until 60 days after the last investigational product administration. Up to 2 approximately years.'}, {'measure': 'TMB', 'description': 'Correlation between tumor mutation burden (TMB) and the efficacy of Toripalimab combined with Bevacizumab', 'timeFrame': 'Up to 12 years'}, {'measure': 'ADA', 'description': 'Serum levels and incidence of Anti-drug antibody of Toripalimab combined with Bevacizumab treatment group', 'timeFrame': 'Up to 12 years'}]",9,18 Years,75 Years,ALL,False,"Shanghai Junshi Bioscience Co., Ltd.",OTHER,0,326.0,ACTUAL,2025-09-01T16:18:12.169488,v2_robust,True,True,False,False,True,
NCT01387204,"Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212","An Open-label Mass Balance Study to Investigate the Absorption, Distribution, Metabolism and Elimination of a Single Oral Dose of MEK Inhibitor [14C]GSK1120212 in Male Subjects With Solid Tumors",GSK1120212,['GSK1120212'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],"['MEK inhibitor', 'elimination', 'Phase 1', 'GSK1120212', 'cancer', 'Pharmacokinetics', 'oncology', 'radiolabeled ADME']",COMPLETED,,2011-02-15,2011-07-18,"[{'measure': 'Total excretion of radioactivity', 'description': '• Total and relative excretion of radioactivity in urine and feces following a single, 2 mg oral solution dose of \\[14C\\]GSK1120212', 'timeFrame': '11 days'}]","[{'measure': 'Total radioactivity concentration in blood and plasma', 'description': 'AUC(0- t), AUC(0-∞), Cmax, tmax and t1/2', 'timeFrame': '11 days'}, {'measure': 'Characterize and quantify metabolites in urine plasma and feces', 'description': 'Characterize and quantify metabolites of GSK1120212 in plasma, urine and feces (studied separately under a DMPK protocol).', 'timeFrame': '11 days'}, {'measure': 'Assess covalent binding of drug related material to plasma proteins', 'description': 'Assess percentage of drug-related material that covalently bonds to plasma proteins (studied separately under a DMPK protocol)', 'timeFrame': '11 days'}, {'measure': 'Blood:plasma ratio', 'description': 'Blood:plasma ratio of total drug-related material (radioactivity)', 'timeFrame': '11 days'}, {'measure': 'Pharmacokentic concentrations in plasma', 'description': 'Plasma GSK1120212 concentrations AUC(0-t), AUC(0-∞), Cmax, tmax, and t1/2', 'timeFrame': '11 days'}, {'measure': 'AEs', 'description': 'Number of adverse events (AEs)', 'timeFrame': 'From dosing on Day 1 to Follow-up'}, {'measure': 'Vital signs', 'description': 'Changes from baseline', 'timeFrame': 'Screening, Day -1, Day 1, Day 5, and Follow-up'}, {'measure': 'ECGs', 'description': 'Changes from baseline', 'timeFrame': 'Screening, Day 1 pre-dose, 24 hours, Day 11 and Follow-up'}, {'measure': 'Clinical Laboratory assessments', 'description': 'Changes from baslines', 'timeFrame': 'Screening, Day -1, and Day 11'}]",10,18 Years,,MALE,False,GlaxoSmithKline,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:12.169511,v2_robust,True,True,True,False,True,
NCT06795204,Effects of HSK3486 on Cardiac Repolarization in Health Subjects (TQT),"A Randomized, Positive and Placebo-Controlled Study to Evaluate the Effects of HSK3486 Administration on Cardiac Repolarization in Healthy Subjects",HSK3486,"['Cipepofol', 'HSK3486', 'Moxifloxacin Hydrochloride', 'Placebo']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Anesthesia; Adverse Effect,"['Anesthesia; Adverse Effect', 'Cardiac Arrhythmia']",[],COMPLETED,,2024-04-09,2024-05-19,"[{'measure': 'change-from-baseline in QTc interval', 'description': 'corrected for HR using the individual QT correction method (QTcI) - ΔQTcI', 'timeFrame': 'From screen period to safety follow up ( up to 40 days)'}]",[],1,18 Years,45 Years,ALL,True,"Haisco-USA Pharmaceuticals, Inc.",INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:12.169539,v2_robust,True,True,True,False,True,
NCT04048304,"Short Post-surgical Antibiotic Therapy in Spine Infections - a Prospective, Randomized, Unblinded, Non-inferiority Trial","Short Post-surgical Antibiotic Therapy in Spine Infections - a Pro-spective, Randomized, Unblinded, Non-inferiority Trial",duration of standard antibiotic therapy,"['Co-amoxiclav, vancomycin', 'duration of standard antibiotic therapy']",2,INTERVENTIONAL,['NA'],,,Infection,['Infection'],[],RECRUITING,,2019-07-31,2025-12-31,"[{'measure': 'Remission of infection at 12 months after treatment', 'description': 'no clinical and microbiological recurrences', 'timeFrame': '12 months after treatment'}]","[{'measure': 'costs', 'description': 'total costs for treatment of infection', 'timeFrame': 'up to 12 months'}, {'measure': 'duration of sick leave', 'description': 'duration of sick leave for treatment of infection', 'timeFrame': 'up to 12 months'}, {'measure': 'length of hospital stay', 'description': 'number of days of hospital stay', 'timeFrame': 'up to 12 months'}]",4,18 Years,,ALL,False,Balgrist University Hospital,OTHER,0,236.0,ESTIMATED,2025-09-01T16:18:12.169548,v2_robust,True,True,False,False,False,
NCT06548204,Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial,Effect and Safety of Fexofenadine Hydrochloride vs Placebo in Patients With Acute Myocardial Infaction: A Randomized Clinical Trial,Fexofenadine Hydrochloride 60mg bid,"['Fexofenadine Hydrochloride 120mg bid', 'Fexofenadine Hydrochloride 60mg bid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,ST-segment Elevation Myocardial Infarction (STEMI),['ST-segment Elevation Myocardial Infarction (STEMI)'],[],NOT_YET_RECRUITING,,2024-09,2026-09,"[{'measure': 'Late gadolinium enhancement/Left ventricular mass (LGE/LV%)', 'description': 'LGE/LV% will be assessed by CMR', 'timeFrame': '6 months after myocardial infarction'}]","[{'measure': 'Left ventricular ejection fraction (LVEF)', 'description': 'LVEF will be assessed by CMR', 'timeFrame': '6 months after myocardial infarction'}, {'measure': 'Left ventricular internal dimension in systole/body surface area (LVIDs/BSA%)', 'description': 'LVIDs will be assessed by CMR and BSA will be calculated by height and weight', 'timeFrame': '6 months after myocardial infarction'}, {'measure': 'Left ventricular internal dimension in diastole/body surface area (LVIDd/BSA%)', 'description': 'LVIDd will be assessed by CMR and BSA will be calculated by height and weight', 'timeFrame': '6 months after myocardial infarction'}, {'measure': 'BNP', 'description': 'Analysis of differences of BNP', 'timeFrame': '6 months after myocardial infarction'}, {'measure': 'VO2 max', 'description': 'Analysis of VO2 max', 'timeFrame': '6 months after myocardial infarction'}, {'measure': 'SAQ scale score', 'description': 'Analysis of SAQ scale score', 'timeFrame': '6 months after myocardial infarction'}, {'measure': 'Drug-associated adverse reaction', 'description': 'Heart, nerve system, mental system, digestive system and immune system reactions', 'timeFrame': '1 month, 3 months and 6 months after myocardial infarction'}, {'measure': 'Incidence of MACE', 'description': 'Incidence of death, acute myocardial infarction and shock.', 'timeFrame': '1 month, 3 months and 6 months after myocardial infarction'}]",9,18 Years,,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,165.0,ESTIMATED,2025-09-01T16:18:12.169561,v2_robust,True,True,False,False,True,
NCT01210404,Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance,Open Label Single Sequence Study To Estimate The Effect Of Filibuvir (PF-00868554) On S-And R-Methadone In Subjects Receiving Chronic Methadone Treatment And To Evaluate The Pharmacokinetics Of Filibuvir,filibuvir,['filibuvir'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Hepatitis C,['Chronic Hepatitis C'],['Drug interaction with methadone.'],COMPLETED,,2011-02,2011-06,"[{'measure': 'Methadone plasma pharmacokinetic parameters, AUC24, Cmax', 'timeFrame': 'day 1'}, {'measure': 'Methadone plasma pharmacokinetic parameters, AUC24, Cmax', 'timeFrame': 'day 11'}]","[{'measure': 'Methadone plasma pharmacokinetic parameters Tmax and C24h', 'timeFrame': 'day 1'}, {'measure': 'Methadone plasma pharmacokinetic parameters Tmax and C24h', 'timeFrame': 'day 11'}, {'measure': 'Filibuvir plasma pharmacokinetic parameters: Auc 12, Cmax, and Tmax.', 'timeFrame': 'day 2'}, {'measure': 'Filibuvir plasma pharmacokinetic parameters: Auc 12, Cmax, and Tmax.', 'timeFrame': 'day 11'}, {'measure': 'Safety and tolerability, including adverse events, vital signs, 12 lead ECG and lab safety assessments.', 'timeFrame': 'days 0-12'}, {'measure': 'Symptoms of methadone withdrawal as assessed by short Opiate Withdrawal Scale, Desires for Drug questionnaire and pupillary diameter measurement .', 'timeFrame': 'days 0-12'}]",8,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:12.169714,v2_robust,True,True,True,False,True,
NCT01892384,Safety and Tolerability of BI 409306 in Patients With Schizophrenia,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 409306 Film-coated Tablets Given Orally q.d. for 14 Days in Patients With Schizophrenia (Randomized, Parallel-group, Double-blind, Placebo-controlled Study)",Placebo,"['BI 409306', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Schizophrenia,['Schizophrenia'],[],COMPLETED,,2013-06-28,2013-12-05,"[{'measure': 'Number of Participants With Drug-related Adverse Events', 'description': 'Number of participants with drug-related adverse events.', 'timeFrame': 'From first drug administration until 30 days after last drug administration, up to 44 days.'}]","[{'measure': 'Maximum Measured Concentration of BI 409306 in Plasma After Single Dose (Cmax)', 'description': 'Maximum measured concentration of BI 409306 in plasma after single dose (Cmax) is presented.', 'timeFrame': '2 hours (h) before first drug administration and 10minutes (min), 20min, 30min, 45min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h and 14h after first drug administration'}, {'measure': 'Maximum Measured Concentration of BI 409306 in Plasma at Steady-state (Cmax,ss)', 'description': 'Maximum measured concentration of BI 409306 in plasma at steady-state (Cmax,ss) is presented.', 'timeFrame': '2 hours (h) before drug administration and 10minutes (min), 20min, 30min, 45min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 48h and 72h after drug administration on day 14.'}, {'measure': 'Time From Dosing to Maximum Measured Concentration of BI 409306 in Plasma After Single Dose (Tmax)', 'description': 'Time from dosing to maximum measured concentration of BI 409306 in plasma after single dose (tmax) is presented.', 'timeFrame': '2 hours (h) before first drug administration and 10minutes (min), 20min, 30min, 45min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h and 14h after first drug administration.'}, {'measure': 'Time From Dosing to Maximum Measured Concentration of BI 409306 in Plasma at Steady-state (Tmax,ss)', 'description': 'Time from dosing to maximum measured concentration of BI 409306 in plasma at steady-state (tmax,ss) is presented.', 'timeFrame': '2 hours (h) before drug administration and 10minutes (min), 20min, 30min, 45min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 48h and 72h after drug administration on day 14.'}, {'measure': 'Area Under the Concentration-time Curve of BI 409306 in Plasma Over the Time Interval From 0 Extrapolated to Infinity After a Single Dose (AUC0-infinity)', 'description': 'Area under the concentration-time curve of BI 409306 in plasma over the time interval from 0 extrapolated to infinity after a single dose (AUC0-infinity) is presented.', 'timeFrame': '2 hours (h) before first drug administration and 10minutes (min), 20min, 30min, 45min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h and 14h after first drug administration.'}, {'measure': 'Area Under the Concentration-time Curve of BI 409306 in Plasma at Steady State Over a Uniform Dosing Interval Tau (AUCtau,ss)', 'description': 'Area under the concentration-time curve of BI 409306 in plasma at steady state over a uniform dosing interval tau (AUCtau,ss) is presented.', 'timeFrame': '2 hours (h) before drug administration and 10minutes (min), 20min, 30min, 45min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 14h, 24h, 48h and 72h after drug administration on day 14.'}]",7,18 Years,55 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:12.169740,v2_robust,True,True,True,False,True,
NCT05965284,Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis (TTCAZAREM),"A Prospective, Open-label, Controlled, Single Center Clinical Study of the Efficacy and Safety for Telitacicept in the Remission Maintenance Treatment of ANCA-associated Vasculitis",Azathioprine,"['Azathioprine', 'Taiai for commercial name', 'Telitacicept']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,ANCA-associated Vasculitis,"['ANCA-associated Vasculitis', 'Maintenance Therapy']","['ANCA-associated Vasculitis', 'Telitacicept', 'Azathioprine', 'Relapse rate']",RECRUITING,,2023-03-09,2026-12-31,"[{'measure': 'The time of first relapse during 12 months follow-up of two groups', 'description': 'The time from baseline to first relapse(re-appearance of disease with a BVAS \\>0) of patients during 12 months follow-up of two groups', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}]","[{'measure': 'The percentage of patients with severe relapse at months 12', 'description': 'The percentage of patients with severe relapse (re-appearance or worsening of disease with a BVAS ≥6 and involvement of at least one major organ, a life-threatening manifestation, or both) at months 12', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}, {'measure': 'The percentage of patients with moderate relapse at months 12', 'description': 'The percentage of patients with moderate relapse (re-appearance or worsening of disease with a BVAS ≥3 without involvement of major organ or life-threatening manifestation) at months 12', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}, {'measure': 'The percentage of patients with mild relapse at months 12', 'description': 'The percentage of patients with mild relapse (re-appearance or worsening of disease with a 0 \\< BVAS \\< 3 without involvement of major organ or life-threatening manifestation) at months 12', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}, {'measure': 'The percentage of patients with sustained remission at months 12', 'description': 'The percentage of patients with sustained remission (BVAS =0 without dosage increase of glucocorticoid) at months 12', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}, {'measure': 'The rate of adverse events', 'description': 'The rate of adverse events and their severity (Severe events were defined as the adverse events of grade 3 or 4, deaths caused by any cause, cancers, side effects that necessitate hospitalization) in both two groups during the study period.', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}, {'measure': 'The percentage of patients who progress to ESRD', 'description': 'The percentage of patients who progress to ESRD at the end of the study', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}, {'measure': 'The rate of complication of AAV', 'description': 'The rate of complication of AAV in both treatment groups during 12 months of the study period.', 'timeFrame': 'from inclusion to the end of the study, 12 months in total'}]",8,18 Years,65 Years,ALL,False,Chinese SLE Treatment And Research Group,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:12.169750,v2_robust,True,True,False,False,True,
NCT04771884,Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance,Population Pharmacokinetics of Commonly Used Antimicrobial Agents in Children of Bacterial Meningitis With Augmented Renal Clearance,meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid,['meropenem vancomycin ceftazidime ceftriaxone ceftizoxime linezolid'],1,OBSERVATIONAL,[],,,Bacterial Meningitis,"['Bacterial Meningitis', 'Augmented Renal Clearance']",[],RECRUITING,,2020-10-01,2026-03-20,"[{'measure': 'The peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.', 'description': 'To detect the peak plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.', 'timeFrame': 'at (5-10) minutes after intravenous administration'}, {'measure': 'The random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.', 'description': 'To detect the random plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.', 'timeFrame': 'at (0.5-10) hours after intravenous administration'}, {'measure': 'The trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid.', 'description': 'To detect the trough plasma and cerebrospinal fluid drug concentration of meropenem，vancomycin，ceftazidime，ceftriaxone，ceftizoxime，linezolid after intravenous administration.', 'timeFrame': 'at 1-2 hours before the next administration'}]","[{'measure': 'clinical response', 'description': 'Blood routine examination, cerebrospinal fluid routine examination and infection indicators (C-reaction protein, procalcitonin)', 'timeFrame': 'Through study completion, an average of 14 days'}]",4,2 Months,18 Years,ALL,False,Shandong University,OTHER,1,300.0,ESTIMATED,2025-09-01T16:18:12.169811,v2_robust,False,True,False,False,False,
NCT05225584,"Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors","A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients With Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors",KT-333,['KT-333'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Non Hodgkin Lymphoma (NHL),"['Non Hodgkin Lymphoma (NHL)', 'Peripheral T-cell Lymphoma (PTCL)', 'Cutaneous T-Cell Lymphoma (CTCL)', 'Large Granular Lymphocytic Leukemia (LGL-L)', 'T-cell Prolymphocytic Leukemia (T-PLL)', 'Solid Tumors']",[],COMPLETED,,2022-05-19,2025-03-03,"[{'measure': 'Safety', 'description': 'Incidence and severity of adverse events as assessed by CTCAE v5.0 Phase 1a/1b', 'timeFrame': 'Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy'}, {'measure': 'Safety', 'description': 'Incidence and severity of clinical laboratory abnormalities in Serum Chemistry, Hematology, Coagulation Parameters and urinalysis tests as assessed by CTCAE v5.0 Phase 1a/1b', 'timeFrame': 'Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy'}, {'measure': 'Safety', 'description': 'Changes in the ECG parameters, including heart rate and measures PR, QRS, QT, and QTc intervals as assessed by CTCAE v5.0 Phase 1a/1b', 'timeFrame': 'Safety will be assessed from the time ICF signature through 30 days post dose or prior to start of a new anticancer therapy'}, {'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'To establish the Maximum Tolerated Dose (MTD) Phase 1a', 'timeFrame': 'Within the first 28 days of treatment'}, {'measure': 'Dose Limiting Toxicities (DLTs)', 'description': 'Number of Participants with protocol specified Dose Limiting Toxicities (DLTs) Phase 1a', 'timeFrame': 'Within the first 28days of treatment'}]","[{'measure': 'Area under the plasma concentration versus time curve for KT-333', 'description': 'Area under the plasma concentration versus time curve for KT-333 from time to zero to last quantifiable time point (AUC 0-t ) Phase 1a/1b', 'timeFrame': 'Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)'}, {'measure': 'Maximum Plasma Concentration of KT-333 (Cmax)', 'description': 'Maximum Plasma Concentration of KT-333 (Cmax)', 'timeFrame': 'Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)'}, {'measure': 'Time of maximum plasma concentration of KT-333 (Tmax)', 'description': 'Time of maximum plasma concentration of KT-333 (Tmax) Phase 1a/1b', 'timeFrame': 'Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)'}, {'measure': 'Half-life of KT-333 if data permits (T1/2)', 'description': 'Half-life of KT-333 if data permits (T1/2) Phase 1a/1b', 'timeFrame': 'Blood samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)'}, {'measure': 'Amount of KT-333 dose excreted in urine from time zero to last collected time point (Ae0-t)', 'description': 'Amount of KT-333 dose excreted in urine from time zero to last collected time point (Ae0-t) Phase 1a', 'timeFrame': 'Urine samples for PK analysis collected at multiple visits during cycle 1 and cycle 2 (each cycle is 28days)'}, {'measure': 'Evidence of clinical activity of KT-333', 'description': 'Evidence of clinical activity of KT-333 as determined by Objective Response Rate (ORR) as per Lugano criteria 2014 for Lymphomas Phase 1a/1b.', 'timeFrame': 'From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months'}, {'measure': 'Evidence of clinical activity of KT-333', 'description': 'Evidence of clinical activity of KT-333 as determined by RECIST 1.1 to determine ORR , complete response (CR), partial response (PR) for solid tumors Phase 1a/1b.', 'timeFrame': 'From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months'}, {'measure': 'Evidence of clinical activity of KT-333', 'description': 'Evidence of clinical activity of KT-333 as determined by ORR by Modified Severity-Weighted Assessment Tool (mSWAT) for Cutaneous T-Cell Lymphoma (CTCL) Phase 1a/1b', 'timeFrame': 'Composite assessment from date of baseline assessment until the date of first documented progression or date of death from any cause, whichever came first, about 18 months'}, {'measure': 'Evidence of clinical activity of KT-333', 'description': 'Evidence of clinical activity of KT-333 as determined by ORR by investigator assessment for Large Granular Lymphocytic Leukemia (LGL-L) Phase 1a/1b', 'timeFrame': 'From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months'}, {'measure': 'Evidence of clinical activity of KT-333', 'description': 'Evidence of clinical activity of KT-333 as determined by ORR based on T-PLL International Study Group criteria, Phase 1a', 'timeFrame': 'From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, about 18 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Duration of Response (DOR) Phase 1a/1b', 'timeFrame': 'From date of first of response to the date of documented first progression or death whichever comes first, about 18 months'}]",16,18 Years,,ALL,False,"Kymera Therapeutics, Inc.",INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:12.169863,v2_robust,True,True,True,False,True,
NCT07106684,ASCT Combined With BCMA CAR-T and GPRC5D/CD3 BiTEs Maintenance for Transplant-Eligible Primary Plasma Cell Leukemia,"A Prospective, Single-Arm, Phase II Study of Autologous Stem Cell Transplantation Combined With BCMA CAR-T Therapy Followed by GPRC5D/CD3 Bispecific Antibody Maintenance in Transplant-Eligible Patients With Primary Plasma Cell Leukemia",GPRC5D/CD3 BiTEs,['GPRC5D/CD3 BiTEs'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Multiple Myeloma, Plasma Cell Leukemia","['Multiple Myeloma, Plasma Cell Leukemia']","['Plasma cell leukemia', 'CAR-T', 'ASCT', 'BiTEs']",RECRUITING,,2025-08-10,2029-08-01,"[{'measure': 'Sustained MRD-negative rate', 'description': 'Rate of patients achieving sustained MRD negativity for more than 12 months', 'timeFrame': 'Up to 2 year'}, {'measure': 'MRD negativity rate', 'description': 'Rate of patients achieving MRD negativity', 'timeFrame': 'Up to 2 years'}]","[{'measure': 'Safety and Tolerability', 'description': 'The incidence of treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 2 year'}, {'measure': 'Complete response rate (CRR)', 'description': 'CR or better is defined as percentage of participants who achieve a CR response or Stringent Complete Response (sCR) response accoording to the IMWG criteria', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression free survival (PFS)', 'description': 'Progression free survival is defined as the time from the date of diagnosis to the date of first documented PD, as defined in the IMWG criteria, or death due to any cause, whichever occurs first', 'timeFrame': 'Up to 3 year'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival is defined as the time from the date of diagnosis to the date of death due to any cause', 'timeFrame': 'Up to 5 year'}]",6,18 Years,70 Years,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:12.170045,v2_robust,True,True,False,False,True,
NCT04610684,"Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases","Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases",Carboplatin,"['Imfinzi', 'Etoposide', 'Carboplatin', 'paraplatin', 'Atezolizumab', 'VP-16']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Small-cell Lung Cancer,"['Small-cell Lung Cancer', 'Brain Metastases']",[],TERMINATED,Lack of Enrollment,2021-01-05,2022-09-20,"[{'measure': 'Intracranial Progression Free Survival (iPFS)', 'description': 'Intracranial PFS is defined as the time from Day 1 of treatment until the criteria for intracranial disease progression is met as defined by RANO-BM or death as a result of any cause, whichever comes first. Progression disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).', 'timeFrame': 'From C1D1 until death or up to a maximum of 6 months'}]","[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR will include complete response (CR) + partial response (PR) as determined by RECIST 1.1. Complete response is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.Partial response is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.', 'timeFrame': 'From C1D1 until death or up to a maximum of 6 months'}, {'measure': 'Extracranial Progression Free Survival (PFS)', 'description': 'Extracranial PFS is defined as the time from Day 1 of treatment until the criteria for extracranial disease progression is met as defined by RECIST 1.1 or death as a result of any cause, whichever comes first.Progression disease is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).', 'timeFrame': 'From C1D1 until death or up to a maximum of 6 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from Day 1 of treatment until death as a result of any cause.', 'timeFrame': 'From C1D1 until death or up to a maximum of 9 months'}, {'measure': 'Toxicity of Atezolizumab Plus Carboplatin and Etoposide', 'description': 'Toxicity of atezolizumab has been evaluated when administered with carboplatin and etoposide in subjects with untreated SCLC brain metastases.Toxicity will be graded by Common Toxicity Criteria for Adverse Events (CTCAE V5).', 'timeFrame': 'From C1D1 until death or up to a maximum of 9 months'}]",5,18 Years,,ALL,False,Jeffrey Clarke,OTHER,2,3.0,ACTUAL,2025-09-01T16:18:12.170077,v2_robust,True,True,False,True,True,Lack of Enrollment
NCT06218784,"A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.","A Randomized, Double-blind, Placebo-controlled, Multiple-Ascending Dose Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Properties of iN1011-N17 After Oral Administration in Healthy Volunteers and Post-Herpetic Neuralgia Patients and to Assess the Relative Bioavailability of Mesylate vs Hydrochloride Salt Capsules in Healthy Volunteers",iN1011-N17 HCl Suspension (Part 1),"['iN1011-N17 Mesylate Capsule (Part 3)', 'Placebo Capsule (Part 3)', 'iN1011-N17 HCl Suspension (Part 1)', 'iN1011-N17 HCl Capsule (Part 3)', 'iN1011-N17 Mesylate Capsule (Part 2)', 'Placebo Capsule (Part 1)', 'iN1011-N17 HCl Capsule (Part 2)', 'iN1011-N17 HCl Capsule (Part 1)']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Post Herpetic Neuralgia,"['Post Herpetic Neuralgia', 'Pain', 'Osteoarthritis', 'Neuropathic Pain', 'Chronic Pain', 'Dorsal Root Ganglion', 'Nav 1.7']","['Nav 1.7', 'Nav 1.7 inhibitor', 'Postoperative pain', 'Chemotherapy-induced neuropathic pain', 'Pain', 'Neurological Pain', 'Sodium Channel', 'Action Potential', 'Voltage Gated Sodium Channel', 'DRG Voltage Gated Sodium Channel 1.7', 'Sodium Channel 1.7', 'Volatage Gated Sodium Channel 1.7']",RECRUITING,,2022-11-11,2024-07-29,"[{'measure': 'Incidence, severity, and causality of AEs and serious AEs (SAEs)', 'timeFrame': 'Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days'}, {'measure': 'Incidence of Physical examination abnormalities', 'timeFrame': 'Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days'}, {'measure': 'Incidence of Vital signs abnormalities', 'timeFrame': 'Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days'}, {'measure': 'Incidence of 12-lead ECG abnormalities', 'timeFrame': 'Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days'}, {'measure': 'Incidence of Continous cardiac telemetry abnormalities', 'timeFrame': 'Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days'}, {'measure': 'Incidence of Laboratory tests abnormalities', 'timeFrame': 'Part 1: From baseline until follow-up, an average of 14 days Part 2: From baseline until follow-up, an average of 22 days Part 3: From baseline until follow-up, up to 21 days'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'timeFrame': 'Part 1: Day 1 Part 2: 0-72 hours post dose Part 3: Day 1'}, {'measure': 'Time to maximum plasma concentration (Tmax)', 'timeFrame': 'Part 1: Day 1 Part 2: 0-72 hours post dose Part 3: Day 1'}, {'measure': 'Terminal half-life (t1/2)', 'timeFrame': 'Part 1: Day 1 Part 2: 0-72 hours post dose Part 3: Day 1'}, {'measure': 'Area under the plasma concentration curve (AUC0-12, AUC0-t, AUCinf)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 2: 0-72 hours post dose Part 3: Day 1 and Day 14'}, {'measure': 'Percentage of AUCinf based on extrapolation (AUC%extrap)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 2: 0-72 hours post dose Part 3: Day 1 and Day 14'}, {'measure': 'Apparent volume of distribution (Vz/F)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14'}, {'measure': 'Apparent plasma elimination rate constant (λz)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 3: Day 1'}, {'measure': 'Apparent clearance (CL/F)', 'timeFrame': 'Part 1: Day 1 Part 3: Day 1'}, {'measure': 'Fraction excreted unchanged in urine (fe)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14'}, {'measure': 'Amount of drug excreted unchanged in the urine (Ae)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14'}, {'measure': 'Renal clearance (CLR)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14'}, {'measure': 'Mean residence time (MRT)', 'timeFrame': 'Part 1: Day 1 and Day 7 Part 3: Day 1 and Day 14'}, {'measure': 'Maximum (peak) steady-state plasma drug concentration during a dosage interval (Cmax,ss)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Minimum steady-state plasma drug concentration during a dosage interval (Cmin,ss)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Average steady-state plasma drug concentration during multiple-dose administration (Cav,ss)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Time to reach maximum (peak) plasma concentration following drug administration at steady-state (Tmax,ss)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Area under the plasma concentration-time curve during a dosage interval (τ) (AUCτ)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Apparent clearance at steady state (CLss/F)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Apparent volume of distribution at steady state (Vz,ss/F)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}, {'measure': 'Accumulation ratio of Cmax and AUC (RAcmax or RAAUC)', 'timeFrame': 'Part 1: Day 7 Part 3: Day 14'}]",26,18 Years,75 Years,ALL,True,"iN Therapeutics Co., Ltd.",INDUSTRY,0,64.0,ESTIMATED,2025-09-01T16:18:12.170129,v2_robust,True,True,False,False,False,
NCT01656733,Nicotine Replacement for Smoking Cessation During Pregnancy,Nicotine Replacement for Smoking Cessation During Pregnancy,Nicotrol Inhaler,"['Nicotrol Inhaler', 'Nicotine Inhaler', 'Placebo Inhaler']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Nicotine Dependence,"['Nicotine Dependence', 'Smoking Cessation']","['Smoking Cessation', 'Pregnancy', 'Nicotrol Inhaler', 'Placebo Inhaler', 'Nicotine Inhaler']",COMPLETED,,2012-08,2017-10-25,"[{'measure': 'Number of Participants Who Self Report an Average of Zero Cigarettes Smoked Per Day in Preceding 7 Days', 'description': 'Number of participants who self report an average of zero cigarettes smoked per day in preceding 7 days', 'timeFrame': '32-34 weeks gestation (Visit 6)'}]","[{'measure': 'Exhaled Carbon Monoxide', 'description': 'As measured by parts per million (ppm) on CO breathalyzer', 'timeFrame': '32-34 weeks gestation'}, {'measure': 'Birth Weight', 'description': 'Birth weight in grams', 'timeFrame': 'At delivery'}, {'measure': 'Gestational Age', 'description': 'Measure of age of pregnancy at delivery', 'timeFrame': 'At delivery'}]",4,16 Years,,FEMALE,True,UConn Health,OTHER,1,154.0,ACTUAL,2025-09-01T16:18:12.170206,v2_robust,True,True,True,False,False,
NCT03428633,Thoracic Paravertebral Blocks in Open Nephrectomy,"Thoracic Paravertebral Blocks in Open Nephrectomy. A Prospective, Randomized Study of Block Efficacy and Influence on Oxidative Stress and Patient Outcome.",Ropivacaine,"['Morphine', 'Ropivacaine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Nephrectomy,"['Nephrectomy', 'Analgesia']",[],COMPLETED,,2018-03-09,2023-02-01,"[{'measure': 'Postoperative pain', 'description': 'Numerical Rating Scale (NRS) scores (Range 0-10, 0=no pain, 10=the worse pain ever)', 'timeFrame': '48 hours'}, {'measure': 'Oxidative stress - lactic acid (mmol/L)', 'timeFrame': '24 hours'}, {'measure': 'Oxidative stress - superoxide dismutase (units/ml)', 'timeFrame': '24 hours'}, {'measure': 'Oxidative stress - malondialdehyde (nmol/mg protein)', 'timeFrame': '24 hours'}, {'measure': 'Oxidative stress - neutrophil gelatinase-associated lipocalin (NGAL) (ng/ml)', 'timeFrame': '24 hours'}]","[{'measure': 'Complications', 'timeFrame': '48 hours'}, {'measure': 'Patient satisfaction', 'description': 'Patients asked whether they would choose the same anaesthetic management in a future operation: Yes/No', 'timeFrame': '48 hours'}, {'measure': 'Patient mobilization', 'description': 'Patient reporting time of first standing to the side of the bed', 'timeFrame': '7 days'}, {'measure': 'Intestinal function', 'description': 'Time of first passing of rectal gas, reported by the patient', 'timeFrame': '7 days'}, {'measure': 'Chronic pain', 'description': 'Using of Graded Chronic Pain Scale (GCPS) Grade 0: No pain in prior 6 months Grade 1: Low Intensity - Low Disability Grade II: High Intensity Characteristic Pain Intensity - Low Disability Grade III: High Disability - Moderately Limiting Grade IV: High Disability - Severely Limiting', 'timeFrame': '6 months'}]",10,14 Years,80 Years,ALL,False,Asklepieion Voulas General Hospital,OTHER_GOV,3,60.0,ACTUAL,2025-09-01T16:18:12.170283,v2_robust,True,True,True,False,False,
NCT03632733,Effects of Antimicrobials on the Altered Skin Flora in Arsenical Keratosis,Effects of Antimicrobials on the Altered Skin Flora in Patients With Palmar Arsenical Keratosis,Tetracycline,"['Clotrim', 'Tetracycline and Clotrimazole', 'No other name', 'Clotrimazole', 'Tetracycline', 'Tetrax']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Keratotic Nodular Size,['Keratotic Nodular Size'],[],UNKNOWN,,2018-01-21,2018-12-31,"[{'measure': 'Changes in keratotic nodular size', 'description': 'palmar arsenical keratosis will be measured before and after applying interventions', 'timeFrame': 'three months'}]",[],1,18 Years,60 Years,ALL,False,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:12.170332,v2_robust,True,True,False,False,False,
NCT00996333,"Study of Gemzar®, Taxotere®, and Xeloda® (GTX) in Patients With Metastatic Pancreatic Cancer (Stage IVB)","Phase II Study of a Biochemically Synergistic Regimen for Metastatic Pancreatic Cancer (Stage IVB) With Gemzar, Taxotere and Xeloda (GTX)","Gemcitabine, Docetaxel, Capecitabine","['Gemzar', 'Xeloda', 'Gemcitabine, Docetaxel, Capecitabine', 'Taxotere']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Pancreatic Cancer,['Metastatic Pancreatic Cancer'],['Stage IVB'],COMPLETED,,2003-06,2014-10,"[{'measure': 'To Determine Response Rate to the GTX Regimen in Patients With Pancreatic Cancer', 'description': 'Data was not analyzed because original PI left institution before data analysis was completed.', 'timeFrame': '10 weeks'}]","[{'measure': 'Determine Overall and One Year Survival Rates', 'description': 'Data was not analyzed because original PI left institution before data analysis was completed.', 'timeFrame': 'One year'}, {'measure': 'Toxicity Assessment', 'description': 'Data was not analyzed because original PI left institution before data analysis was completed.', 'timeFrame': 'Every month'}]",3,18 Years,70 Years,ALL,False,Columbia University,OTHER,1,46.0,ACTUAL,2025-09-01T16:18:12.170341,v2_robust,True,True,True,False,False,
NCT04532333,Efficacy and Safety of Bivalirudin Versus Heparin During Coil Embolization in Patients With Ruptured Intracranial Aneurysms,"Anticoagulant Efficacy and Safety of BivalirUdin Versus heparIn During coiL Embolization in Patients With ruptureD Intracranial Aneurysms: an Open-label, Multicenter, Randomized Pilot Study（BUILD）",Bivalirudin 250 MG Injection,"['Bivalirudin 250 MG Injection', 'Heparin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Subarachnoid Hemorrhage, Aneurysmal","['Subarachnoid Hemorrhage, Aneurysmal']","['Anticoagulant Agents', 'Aneurysm, Intracranial Berry', 'Therapeutic Embolization', 'Anticoagulation Agents', 'Heparin Sodium', 'Bivalirudin']",UNKNOWN,,2020-08,2021-06,"[{'measure': 'Procedure-related complication', 'description': 'A composite of of death from any cause, thromboembolic events, or bleeding defined by BARC definition 3 or 5 BARC=Bleeding Academic Research Consortium', 'timeFrame': '30 days'}]","[{'measure': 'Modified Rankin Scale (mRS)', 'description': 'The mRS score, and proportion of subjects achieving mRS score of 0-2', 'timeFrame': '30 days'}, {'measure': 'Activated Clotting Time (ACT)', 'description': 'ACT values of 0 min and 5 min after bolus injection will be recorded in all patients Extra ACT values of 15 min, 30 min, 55min, 65 min,and 115 min after bolus injection will be recorded in 8 patients of both arm, and the curve will be simulated', 'timeFrame': 'During procedure'}, {'measure': 'Procedure-related complication', 'description': 'A composite of of death from any cause, thromboembolic events, or bleeding defined by BARC definition 3 or 5 BARC=Bleeding Academic Research Consortium', 'timeFrame': 'During procedure, at 24hs, 7days'}, {'measure': 'Thromboembolic events', 'description': 'Definition:\n\n1. Intraoperative: stent thrombosis/stenosis, distal vascular occlusion on imaging\n2. Postoperative： 1) new deficits or change in level of consciousness, intracranial hemorrhage cause is excluded by CT, 2) no clinical symptom but CT showed new infarction', 'timeFrame': 'During procedure, at 24hs, 7days, 30days'}, {'measure': 'Bleeding events', 'description': 'Any bleeding as defined by the BARC definition (except grade 4) Any bleeding as defined by the GUSTO definition', 'timeFrame': 'During procedure, at 24hs, 7days, 30days'}, {'measure': 'Intracranial hemorrhage', 'description': 'Intracranial hemorrhage and Symptomatic intracranial hemorrhage', 'timeFrame': 'During procedure, at 24hs, 7days, 30days'}, {'measure': 'Heparin-induced thrombocytopenia(HIT)', 'description': 'defined as a platelet count decrease ofmore than50%or more than 150 × 109/L frombaseline', 'timeFrame': '7days'}]",8,18 Years,80 Years,ALL,False,Changhai Hospital,OTHER,5,236.0,ESTIMATED,2025-09-01T16:18:12.170421,v2_robust,True,True,False,False,False,
NCT00884533,QTc Study of Rosi XR in Healthy Volunteers,A Study to Evaluate the Effect of Extended Release Rosiglitazone (RSG XR) on Cardiac Conduction as Compared to Placebo and a Single Oral Dose of Moxifloxacin,Rosi XR,"['Rosi XR', 'Moxifloxacin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Alzheimer's Disease,"[""Alzheimer's Disease""]","['QTc', 'pharmacokinetics', 'rosiglitazone XR', 'cardiac conduction', 'healthy volunteers']",WITHDRAWN,The whole project was terminated,2009-06,2009-08,"[{'measure': 'Day 20 time-matched change from baseline in QTcI for RSG- XR 8mg and placebo', 'timeFrame': 'Day 20'}, {'measure': 'Day 21 time-matched change from baseline in QTcI for RSG- XR 20mg, placebo and moxifloxacin 400mg', 'timeFrame': 'Day 21'}]","[{'measure': 'Day 20 time-matched change from baseline in QTcF and QTcB for RSG XR 8mg and placebo.', 'timeFrame': 'Day 20'}, {'measure': 'Day 21 time-matched change from baseline in QTcF and QTcB for RSG XR 20mg, placebo and moxifloxacin 400mg', 'timeFrame': 'Day 21'}, {'measure': 'Tolerability of repeat doses of RSG- XR at 8 mg and a single oral dose of RSG- XR at 20 mg as assessed by 12-lead ECGs, vital signs, adverse events, and clinical laboratory tests.', 'timeFrame': '21 days'}]",5,18 Years,45 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:12.170464,v2_robust,True,True,False,True,True,The whole project was terminated
NCT02846233,Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?,Is the Stepping-down Approach a Better Option Than Multiple Daily Injections in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?,GLP1 receptor agonist,"['Lantus, Toujeo, NPH, levemir', 'Albiglutide (Tanzeum) or , Dulaglutide (Trulicity)', 'GLP1 receptor agonist', 'Empagliflozin (Jardiance)', 'basal insulin', 'SGLT2 inhibitor', 'Metformin']",7,INTERVENTIONAL,['NA'],,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],COMPLETED,,2016-08,2018-12,"[{'measure': 'Change in A1c at the End of Study Period', 'description': 'change in A1c (%) from baseline to end of study at 16 weeks', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}]","[{'measure': 'Changes in Weight', 'description': 'change (in pounds) from baseline to the end of study at 16 weeks', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}, {'measure': 'Changes in Blood Pressure', 'description': 'change (mmHg) of systolic BP from baseline to the end of study at 16 weeks', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}, {'measure': 'Changes in Heart Rate', 'description': 'change (beats/min) from baseline to the end of study at 16 weeks', 'timeFrame': '16 weeks'}, {'measure': 'Changes in LDL', 'description': 'change (mg/dL) from baseline to the end of study at 16 weeks', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}, {'measure': 'Changes in Total Cholesterol', 'description': 'change (mg/dL) from baseline to the end of study at 16 weeks', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}, {'measure': 'Changes in Serum Creatinine', 'description': 'change (mg/dL) from baseline to the end of study at 16 weeks', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}, {'measure': 'Changes in Treatment Satisfaction Scores (DM-SAT Total Score)', 'description': 'Patient satisfaction with treatment in both groups will be measured by the validated the Diabetes Medications Satisfaction Tool (DM-SAT). Response options range from 0=""not at all satisfied"" to 10=""extremely satisfied"" and a total score is calculated ranging from 0 to 100, with higher scores indicating more diabetes medication satisfaction.', 'timeFrame': '16 weeks (from baseline to end of study at 16 weeks)'}]",8,21 Years,,ALL,False,"University of California, San Francisco",OTHER,0,22.0,ACTUAL,2025-09-01T16:18:12.170504,v2_robust,True,True,True,False,False,
NCT02389933,Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF),Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF),LCZ696,['LCZ696'],1,EXPANDED_ACCESS,[],,,Heart Failure With Reduced Ejection Fraction (HF-rEF),['Heart Failure With Reduced Ejection Fraction (HF-rEF)'],"['Multiple Patient Program, LCZ696, heart failure, heart failure with reduced ejection fraction, HF-rEF']",NO_LONGER_AVAILABLE,,,,[],[],0,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,,,2025-09-01T16:18:12.170526,v2_robust,False,True,False,False,False,
NCT04438733,Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted Condition,"Bioequivalence of Oral Formulations of Anastrozole in Healthy Chinese Volunteers Under Fasted Condition: A Open-label, Randomized,Single-dose,Two-period, Two-group, Crossover Study",test-anastrozole tablet (Salutas Pharma GmbH),"['Arimidex', 'reference-anastrozole tablet (Arimidex)', 'test-anastrozole tablet (Salutas Pharma GmbH)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],UNKNOWN,,2020-06-18,2020-09-30,"[{'measure': 'the ratios of geometrical mean', 'description': 'The two preparations were considered bioequivalent if the 90% CIs of the ratios of the primary pharmacokinetics parameters were within the predefined acceptance range of 80%-125%.', 'timeFrame': '31 days'}]",[],1,18 Years,65 Years,FEMALE,True,The Affiliated Hospital of Qingdao University,OTHER,0,26.0,ESTIMATED,2025-09-01T16:18:12.170582,v2_robust,True,True,False,False,False,
NCT03866733,Continuous Erector Spinea Block Versus Intravenous Analgesia in Coronary Bypass Surgery,"Lecturer of Anesthesia, Intensive Care and Pain Management in Ain Shams University",intravenous narcotics,"['iv narcotics and NSAID', 'intravenous narcotics']",2,INTERVENTIONAL,['NA'],,,Erector Spinea Block in Open Heart Surgery,['Erector Spinea Block in Open Heart Surgery'],"['erector spinea block, open heart surgeries,analgesia']",COMPLETED,,2019-03-18,2020-12-10,"[{'measure': 'effectiveness of perioperative analgesia', 'description': 'total dose of perioperative narcotics', 'timeFrame': '48 hours after surgery'}]","[{'measure': 'extubation time', 'description': 'time passed between end of surgery and removal of endotracheal tube', 'timeFrame': '12 hours after end of surgery'}]",2,18 Years,65 Years,ALL,False,Ain Shams University,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:12.170603,v2_robust,True,True,True,False,False,
NCT06367452,Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate,Exploratory Pilot Study to Evaluate the Pharmacokinetic Profile of Magaldrate,Sodium alginate + sodium bicarbonate + magaldrate + simeticone,"['Gastrofast Advance', 'Sodium alginate + sodium bicarbonate + magaldrate + simeticone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Healthy,['Healthy'],[],COMPLETED,,2023-10-31,2024-03-30,"[{'measure': 'Cmax for Aluminum', 'description': 'To evaluate the Cmax of Aluminum to check if there is any absorption of aluminum and/or magnesium ions after oral administration of the drug in fed conditions', 'timeFrame': '-12:00 / -06:00 / -00:10 (baseline) y 00:10 / 00:20 / 00:30 / 00:40 / 00:50 / 01:00 / 01:15 / 01:30 / 01:45 / 02:00 / 02:15 / 02:30 / 02:45 / 03:00 / 03:30 / 04:00 / 04:30 / 05:00 / 05:30 / 06:00 / 08:00 / 10:00 / 12:00 after drug administration'}, {'measure': 'AUC for Aluminum', 'description': 'To evaluate the AUC for Aluminum to check if there is any absorption of aluminum and/or magnesium ions after oral administration of the drug in fed conditions', 'timeFrame': '-12:00 / -06:00 / -00:10 (baseline) y 00:10 / 00:20 / 00:30 / 00:40 / 00:50 / 01:00 / 01:15 / 01:30 / 01:45 / 02:00 / 02:15 / 02:30 / 02:45 / 03:00 / 03:30 / 04:00 / 04:30 / 05:00 / 05:30 / 06:00 / 08:00 / 10:00 / 12:00 after drug administration'}, {'measure': 'Cmax for Magnesium', 'description': 'To evaluate the Cmax for Magnesium to check if there is any absorption of aluminum and/or magnesium ions after oral administration of the drug in fed conditions', 'timeFrame': '-12:00 / -06:00 / -00:10 (baseline) y 00:10 / 00:20 / 00:30 / 00:40 / 00:50 / 01:00 / 01:15 / 01:30 / 01:45 / 02:00 / 02:15 / 02:30 / 02:45 / 03:00 / 03:30 / 04:00 / 04:30 / 05:00 / 05:30 / 06:00 / 08:00 / 10:00 / 12:00 after drug administration'}, {'measure': 'AUC for Magnesium', 'description': 'To evaluate the AUC for Magnesium to check if there is any absorption of aluminum and/or magnesium ions after oral administration of the drug in fed conditions', 'timeFrame': '-12:00 / -06:00 / -00:10 (baseline) y 00:10 / 00:20 / 00:30 / 00:40 / 00:50 / 01:00 / 01:15 / 01:30 / 01:45 / 02:00 / 02:15 / 02:30 / 02:45 / 03:00 / 03:30 / 04:00 / 04:30 / 05:00 / 05:30 / 06:00 / 08:00 / 10:00 / 12:00 after drug administration'}]","[{'measure': 'Amount of aluminum ions absorbed after drug administration vs amount provided by food', 'description': 'To evaluate the amount of aluminum ions absorbed after drug administration compared to the amount provided by food', 'timeFrame': '-12:00 / -06:00 / -00:10 (baseline) y 00:10 / 00:20 / 00:30 / 00:40 / 00:50 / 01:00 / 01:15 / 01:30 / 01:45 / 02:00 / 02:15 / 02:30 / 02:45 / 03:00 / 03:30 / 04:00 / 04:30 / 05:00 / 05:30 / 06:00 / 08:00 / 10:00 / 12:00 after drug administration'}]",5,18 Years,55 Years,FEMALE,True,Tecnoquimicas,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:12.170670,v2_robust,True,True,True,False,False,
NCT04284852,Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting,"Niraparib Maintenance in Patients With Advanced Ovarian Cancer at Neoadjuvant Setting - a Phase 2, Single-arm Trial (NEOPRIMA Trial)",Niraparib,"['Niraparib', 'Zejula']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,['Ovarian Cancer'],"['advanced', 'ovarian', 'cancer', 'neoadjuvant', 'niraparib']",COMPLETED,,2020-05-01,2023-10-01,"[{'measure': 'PFS rate at 18 months', 'description': 'Proportion of patients who are progression-free at 18 months according to the RECIST 1.1', 'timeFrame': 'up to 18 months'}]","[{'measure': 'PFS by the RECIST 1.1', 'description': 'The time from first dose of trial medication to first documentation of objective tumor progression (PD) or to death due to any cause, whichever occurs first.', 'timeFrame': 'up to 5 years'}, {'measure': 'Overall survival', 'description': 'Overall survival is defined as the time from first dose of trial medication to date of death due to any cause.', 'timeFrame': 'up to 5 years'}, {'measure': 'OS rate at 18 months', 'description': 'Proportion of patients who are alive at 18 months', 'timeFrame': 'up to 18 months'}, {'measure': 'Change of biomarkers', 'description': 'Expression levels of markers like Ki-67 before and after chemotherapy', 'timeFrame': 'up to 18 months'}, {'measure': 'Treatment-related adverse events', 'description': 'Incidence of treatment-related adverse events classified by CTCAE version 5.0', 'timeFrame': 'up to 18 months'}]",6,18 Years,,FEMALE,False,The University of Hong Kong,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:12.170709,v2_robust,True,True,True,False,True,
NCT02398552,A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma.,A Randomized Phase II Trila of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.,Sunitinib,"['Sutent', 'Sunitinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Renal Cell Carcinoma,['Metastatic Renal Cell Carcinoma'],"['metastatic renal cell carcinoma', 'sunitinib', 'schedule 2weeks on/1 week off']",UNKNOWN,,2015-03,2017-03,"[{'measure': 'progress-free survival (PFS)', 'description': 'Time from enrollment to the dates of disease progression,death from any cause or last tumor assessment reported between date of first patient enrollment until March 2017 cut off date', 'timeFrame': '2 years'}]","[{'measure': 'The percentage of patients who can get complete response, partial response.', 'timeFrame': '2 years'}]",2,18 Years,75 Years,ALL,False,Peking University Cancer Hospital & Institute,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:12.170775,v2_robust,True,True,False,False,False,
NCT01168752,Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma,"Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma",Debio 0932,['Debio 0932'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,"['Cancer', 'Neoplasms', 'Solid Tumors', 'Lymphoma']","['Cancer', 'solid tumour', 'lymphoma', 'dose-escalation', 'Hsp90 inhibitor']",COMPLETED,,2010-04,2013-04,"[{'measure': 'Occurence of DLTs for both schedules', 'description': 'Occurrence of dose-limiting toxicities (DLTs) for both schedule A and schedule B', 'timeFrame': '30 days'}]","[{'measure': 'Incidence of AEs, change in safety and efficacy parameters', 'description': 'Incidence of Adverse Events (AEs), Serious Adverse Events (SAEs), laboratory abnormalities, treatment discontinuations due to AEs for both schedules and expansion phase, change in 12-lead ECG (RR, PR, QRS, QT and QTcF intervals), rate of confirmed response, duration of response and disease control, pharmacodynamic biomarkers and drug pharmacokinetic parameters.', 'timeFrame': 'Duration of study'}]",2,18 Years,,ALL,False,Debiopharm International SA,INDUSTRY,0,81.0,ACTUAL,2025-09-01T16:18:12.170858,v2_robust,True,True,True,False,True,
NCT04824352,Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma,"Apatinib in Combination With Ifosfamide and Etoposide (IE) for Relapsed or Refractory Osteosarcoma Progressed Upon First-line Chemotherapy (AIEO): a Prospective, Multiple-centre, Single-arm, Phase 2 Trial",apatinib,"['IE chemotherapy', 'apatinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Effect of Drug,"['Effect of Drug', 'Toxicity, Drug']","['osteosarcoma', 'apatinib', 'ifosfamide', 'etoposide', 'advanced']",SUSPENDED,Because we then tried another trial with radomised design.,2021-04-01,2026-04-01,"[{'measure': 'Progression free survival', 'description': 'from the start of target treatment until disease progression or death, whichever came first.', 'timeFrame': '2 years'}]","[{'measure': 'Overall survival', 'description': 'from the date of treatment initiation to death from any cause.', 'timeFrame': '3 years'}]",2,12 Years,70 Years,ALL,False,Peking University People's Hospital,OTHER,1,44.0,ESTIMATED,2025-09-01T16:18:12.170867,v2_robust,True,True,False,True,False,Because we then tried another trial with radomised design.
NCT00002152,A Study of WF 10 IV Solution in Patients With Advanced HIV Disease,"Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of WF 10 IV Solution ( TCDO ) in the Management of Patients With Advanced HIV Disease",WF10,['WF10'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infections,['HIV Infections'],"['Acquired Immunodeficiency Syndrome', 'Antiviral Agents']",COMPLETED,,,,[],[],0,18 Years,,ALL,False,Oxo Chemie GmbH,INDUSTRY,0,60.0,,2025-09-01T16:18:12.170877,v2_robust,True,True,True,False,False,
NCT01155947,Bioavailability Study of Anastrozole Tablets 1 mg of Dr.Reddy's Under Fasting Conditions,"An Open Label, Balanced, Randomized,Two-Treatment, Two-Sequence, Two Period, Crossover, Single Dose Comparative Oral Bioavailability Study Of Anastrozole Tablets 1 mg (Test) Of Dr. Reddy's Laboratories Ltd., India And ARIMIDEX® Tablets 1 mg (Reference) Of Astrazeneca Pharmaceuticals LP, USA In Post Menopausal Healthy Women Subjects Under Fasting Conditions.",Anastrozole,"['Arimidex® Tablets 1 mg', 'Anastrozole']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bioavailability', 'Anastrozole', 'Crossover']",COMPLETED,,2008-05,2008-07,"[{'measure': 'Bioavailability based on Cmax and AUC parameters', 'timeFrame': '3 Months'}]",[],1,37 Years,67 Years,FEMALE,True,Dr. Reddy's Laboratories Limited,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:12.170952,v2_robust,True,True,True,False,False,
NCT04233047,Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1),Fostemsavir Compassionate Use Named Patient Program for the Treatment of Human Immunodeficiency Virus 1 (HIV-1),Fostemsavir,['Fostemsavir'],1,EXPANDED_ACCESS,[],,,HIV Infections,['HIV Infections'],['Human Immunodeficiency Virus 1 (HIV-1)'],AVAILABLE,,,,[],[],0,18 Years,,ALL,,ViiV Healthcare,INDUSTRY,0,,,2025-09-01T16:18:12.170959,v2_robust,False,True,False,False,False,
NCT03732547,Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma,A Phase II Study on the Safety and Therapeutic Effect of Combination of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma,PD-1 mAb,"['Programmed cell death-1 monoclonal antibody', 'PolyIC', 'PD-1 mAb', 'Polyinosinic-polycytidylic acid']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Hepatocellular","['Carcinoma, Hepatocellular']","['Hepatocellular carcinoma', 'Polyinosinic-polycytidylic acid', 'PD-1 mAb']",UNKNOWN,,2018-10-22,2023-10-22,"[{'measure': 'Objective response rate (ORR)', 'description': 'Percentage of patients whose cancer shrinks or disappears after treatment', 'timeFrame': 'Up to approximately 5 years'}]","[{'measure': 'Disease control rate (DCR)', 'description': ""Percentage of patients whose cancer doesn't progress after treatment"", 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Progression free survival (PFS)', 'description': 'The percentage of people does not get worse for a period of time after diagnosis', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Overall survival (OS)', 'description': 'The percentage of people still alive for a given period of time after diagnosis', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Number of participants with treatment-related adverse events', 'description': 'Number of participants with treatment-related adverse events after drug initiation, as assessed by CTCAE v4.0', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Percentage of participants with a better life quality', 'description': 'The percentage of participants with a better life quality after treatment, assessed by the questionnaires of European Organization for Research and Treatment of Cancer Quality of Life', 'timeFrame': 'Up to approximately 5 years'}, {'measure': 'Level of alpha-fetoprotein (AFP)', 'description': 'The percentage of participants with a decreased serum level of alpha-fetoprotein (AFP) after treatment', 'timeFrame': 'Up to approximately 5 years'}]",7,18 Years,,ALL,False,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:12.171068,v2_robust,True,True,False,False,True,
NCT07047547,A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure,"A Prospective, Observational, Single-arm Study to Evaluate the Efficacy and Safety of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure.",Vericiguat,['Vericiguat'],1,INTERVENTIONAL,['NA'],,,Hemodialysis Complication,"['Hemodialysis Complication', 'Heart Failure']","['Vericiguat', 'Heart failure', 'Hemodialysis Complication']",RECRUITING,,2025-06-01,2026-06-01,"[{'measure': 'Left ventricular ejection fraction(LVEF)', 'description': 'Change from baseline in left ventricular ejection fraction(LVEF)between baseline and end of study', 'timeFrame': '12weeks'}, {'measure': 'Left ventricular ejection fraction (LVEF)', 'description': 'Change from baseline in left ventricular ejection fraction (LVEF) between baseline and end of study', 'timeFrame': '12weeks'}]","[{'measure': 'N terminal proB type natriuretic peptide (NT-prpBNP)', 'description': 'Blood samples will be collected for analysis of concentration of N terminal pro B type natriuretic pel proBNP) every 2 weeks', 'timeFrame': '12 weeks'}, {'measure': 'Left ventricular end diastolic volume (LVEDV)', 'description': 'LVEDV is measured as baseline and after 12 weeks follow-up.', 'timeFrame': '12 weeks'}, {'measure': 'Left atrial volume (LAV)', 'description': 'LAVis measured as baseline and after 12 weeks follow-up.', 'timeFrame': '12 weeks'}, {'measure': ""The ratio of mitral early diastolic blood flow peak and mitral annulus velocity (E/E')"", 'description': ""E/E' is measured as baseline and after 12 weeks follow-up."", 'timeFrame': '12 weeks'}, {'measure': 'Pulmonary Artery Pressure', 'description': 'Pulmonary Artery Pressure is measured as baseline and after 12 weeks follow-up.', 'timeFrame': '12 weeks'}, {'measure': 'Concentration of high-sensitivity serum troponin T', 'description': 'Blood samples will be collected for analysis of concentration of serum troponin every 4 weeks.', 'timeFrame': '12 weeks'}, {'measure': 'Minnesota Heart Failure Quality of Life Questionnaire (LiHFe)', 'description': 'Change in health status is assessed using the disease-specific Minnesota Heart Failure Quality of L Questionnaire.', 'timeFrame': '12 weeks'}, {'measure': 'Systolic and diastolic blood pressure', 'description': 'Systolic and diastolic blood pressure will be measured every 2 weeks.', 'timeFrame': '12 weeks'}, {'measure': 'Electrocardiogram(ECG)', 'description': 'ECG QT Interval analysis was performed at baseline and 12 weeks follow-up.', 'timeFrame': '12 weeks'}, {'measure': 'Estimated glomerular filtration rate(eGFR)', 'description': 'changes in estimated glomerular filtration rate(eGFR)', 'timeFrame': '12 weeks'}]",12,18 Years,80 Years,ALL,False,Guangdong Provincial People's Hospital,OTHER,0,118.0,ESTIMATED,2025-09-01T16:18:12.171111,v2_robust,True,True,False,False,False,
NCT02955147,Ustekinumab for the Treatment of Giant Cell Arteritis,Open Label Study to Test the Safety and Efficacy of Ustekinumab in Patients With Giant Cell Arteritis,Ustekinumab,"['Prednisone', 'Stelara', 'Ustekinumab']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Giant Cell Arteritis,"['Giant Cell Arteritis', 'Temporal Arteritis', ""Horton's Disease""]",[],TERMINATED,Inefficacy,2016-12-01,2019-09-19,"[{'measure': 'Percentage of Patients in Glucocorticoid-free Remission', 'description': 'The primary study endpoint, prednisone-free remission, was defined as: 1) absence of relapse from the time that remission was achieved through week 52; 2) normalization of ESR (\\<40 mm/hour) and CRP (\\<10 mg/L); and, 3) adherence to the protocol prednisone taper.', 'timeFrame': '52 weeks'}]","[{'measure': 'Number of Participants With Disease Flare', 'description': 'Disease relapse was defined as the recurrence of signs or symptoms of GCA (e.g., cranial or PMR) that required treatment intensification, regardless of the ESR and CRP levels.', 'timeFrame': '52 weeks'}, {'measure': 'Cumulative Prednisone Dose', 'timeFrame': '52 weeks'}]",3,50 Years,,ALL,False,Massachusetts General Hospital,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:12.171169,v2_robust,True,True,False,True,False,Inefficacy
NCT03746847,PET Imaging in Patients With Suspected Cardiac Sarcoidosis,Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis,Gallium-68 DOTATATE,['Gallium-68 DOTATATE'],1,OBSERVATIONAL,[],,,Cardiac Sarcoidosis,['Cardiac Sarcoidosis'],[],COMPLETED,,2018-12-01,2022-12-01,"[{'measure': 'Dotatate SUVmax activity in the heart', 'description': 'The standardized uptake value (SUV) is a nuclear medicine unit commonly used to distinguish between ""normal"" and ""abnormal"" levels of tissue uptake.', 'timeFrame': '3 years'}]","[{'measure': 'Change in Dotatate SUVmax activity in the heart on follow-up PET/CT scan compared to baseline', 'description': 'Dotatate activity (in SUVmax units) in the heart will be measured at baseline and then again at least 3 months after immunotherapy initiation in subjects with suspected cardiac sarcoidosis', 'timeFrame': '3 years'}]",2,18 Years,,ALL,False,University of Pennsylvania,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:12.171183,v2_robust,False,True,True,False,False,
NCT05596747,A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus,"Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3209590 Following Multiple Weekly Doses in Chinese Patients With Type 2 Diabetes Mellitus",LY3209590,"['LY3209590', 'Insulin Glargine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2022-11-30,2023-10-10,"[{'measure': 'Number of Participants with One or More Adverse Events (AEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration', 'description': 'Number of Participants with One or More AEs and SAEs Considered by the Investigator to be Related to Study Drug Administration', 'timeFrame': 'Baseline up to Week 12'}, {'measure': 'Incidence and Severity of Hypoglycemia', 'description': 'Incidence and Severity of Hypoglycemia', 'timeFrame': 'Baseline up to Week 12'}]","[{'measure': 'Pharmacodynamics (PD): Change from Baseline in Fasting Plasma Glucose', 'description': 'PD: Change from Baseline in Fasting Plasma Glucose', 'timeFrame': 'Baseline through Week 6'}, {'measure': 'PD: Change from Baseline in 7-Point Glucose', 'description': 'PD: Change from Baseline in 7-Point Glucose', 'timeFrame': 'Baseline through Week 6'}]",4,18 Years,70 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,31.0,ACTUAL,2025-09-01T16:18:12.171203,v2_robust,True,True,True,False,True,
NCT00161447,Male Hormonal Contraceptive Development-ACY-5,Male Hormonal Contraceptive Development: Suppression of Spermatogenesis With the Addition of a Potent Antagonist (Acyline) to Testosterone and DMPA (ACY-5),Acyline,"['Acyline', 'Testosterone Gel', 'Depo-Medroxyprogesterone', 'DMPA', 'Testim']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Contraception,['Contraception'],"['Male contraception', 'testosterone', 'acyline']",COMPLETED,,2004-05,2006-04,"[{'measure': 'The primary biological end points in this trial will be suppression of spermatogenesis and gonadotropins while monitoring for any adverse changes in lipid metabolism, sexual side effects or in general health', 'timeFrame': 'One year'}]","[{'measure': 'Regimen acceptability, sexual function, glucose tolerance, intratesticular hormone levels', 'timeFrame': 'One year'}]",2,18 Years,55 Years,MALE,True,University of Washington,OTHER,2,43.0,ACTUAL,2025-09-01T16:18:12.171213,v2_robust,True,True,True,False,True,
NCT05392647,"Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.","Hetrombopag for Lower-risk MDS With Thrombocytopenia: a Prospective，Open-label, Single-arm Study.",Hetrombopag,"['Hetrombopag', 'Hetrombopag Olamine Tablets']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Myelodysplastic Syndromes,['Myelodysplastic Syndromes'],"['hetrombopag', 'thrombocytopenia', 'Myelodysplastic Syndromes']",UNKNOWN,,2022-07-01,2024-12-31,"[{'measure': 'Platelet response', 'description': 'proportion of patients achieving platelet responses at week 24', 'timeFrame': '24 weeks'}]","[{'measure': 'Overall response rate', 'description': 'Patients will be assessed for response according to the IWG criteria.', 'timeFrame': '24 weeks'}, {'measure': 'Proportion of patients with platelet response during treatment', 'description': 'Improvement in platelet counts by 24 weeks of therapy', 'timeFrame': '24 weeks'}, {'measure': 'Incidence and severity of bleeding events according to the WHO Bleeding Scale', 'description': 'The severity of bleeding symptoms was graded according to the World Health Organization (WHO) bleeding scale (grade 0: no bleeding; grade 1: petechiae; grade 2: mild blood loss; grade 3, gross blood loss; grade 4: debilitating blood loss).', 'timeFrame': '28 weeks'}, {'measure': 'Adverse events', 'description': 'Adverse events were recorded and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0', 'timeFrame': '28 weeks'}]",5,18 Years,,ALL,False,Tongji Hospital,OTHER,0,28.0,ESTIMATED,2025-09-01T16:18:12.171249,v2_robust,True,True,False,False,True,
NCT03661047,OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer,OMICC: OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer,"AMR101 (VASCEPA, icosapent ethyl)","['AMR101 (VASCEPA, icosapent ethyl)', 'Omega-3 fatty acid']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Colon Cancer,['Colon Cancer'],"['Nutrition', 'Omega-3 fatty acid', 'Fish oil', 'Tumor microenvironment', 'Immune response', 'Gut microbiota', 'Polyp', 'Colorectal cancer']",WITHDRAWN,Study will be closed due to zero enrollment in over 2 years.,2019-11-30,2021-11-30,"[{'measure': 'The change in the marine omega-3 polyunsaturated fatty acid (MO3PUFA) composition in colorectal tissues as a result of the AMR101 treatment for up to 30 days.', 'description': 'The effect of daily 4-gram AMR101 treatment on MO3PUFA composition in colorectal tissue will be measured through the extraction of fatty acid with gas chromatography-mass spectrometry from the biopsy tissue.', 'timeFrame': 'An average of 2 years after study completion'}]","[{'measure': 'The change in Tumor CD8+ T cells in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The influence of MO3PUFA treatment on the balance of Teff and Treg cells will be measured by the ratio of CD8+/Treg in the tumor microenvironment.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in gene expression profile of colorectal tissue between pre- and post- AMR101 treatment period.', 'description': 'RNA-seq analysis to profile gene expression in the mucosal tissue collected before and after AMR101 treatment will be performed to examine whether the AMR101 treatment reduces the gene expression of inflammatory cytokines, chemokines (e.g., TNFα, IL6 and CCL2), and immunosuppressive factors.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of FOXP3 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of IL10 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of LAG-3 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of CD49b in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell inhibitory markers will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of CTLA-4 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of TIGIT in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of TIM-3 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of PD-1 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in protein levels of PD-L1 in the tumor tissue between pre- and post- AMR101 treatment period.', 'description': 'The changes in protein levels of T cell immune checkpoints will be measured before and after intervention.', 'timeFrame': 'An average of 2 years after study completion'}, {'measure': 'The change in the gut microbiome composition and function between pre- and post- AMR101 treatment period', 'description': 'Metagenomic and metatranscriptomic sequencing of microbial DNA and RNA on pre- and post-treatment stool samples will be performed to examine the biomolecular mechanisms by which gut microbial activity may be altered or respond to AMR101 treatment', 'timeFrame': 'An average of 2 years after study completion'}]",13,18 Years,,ALL,False,Massachusetts General Hospital,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:12.171267,v2_robust,True,True,False,True,False,Study will be closed due to zero enrollment in over 2 years.
NCT01809847,Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation,Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation(CLL-X4 Trial),Ofatumumab,"['Ofatumumab', 'Anti-CD20 antibody', 'Arzerra']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Lymphatic Leukemia,['Chronic Lymphatic Leukemia'],"['CLL', 'Chronic Lymphatic Leukemia', 'Leukemia', 'HLA', 'Histocompatibility', 'HCT', 'hematopoietic stem cell transplantation', 'Ofatumumab', 'CD20']",COMPLETED,,2013-03,2015-01,"[{'measure': 'Response rate after induction therapy', 'description': 'efficacy analysis of anti-CD20 blockade with ofatumumab', 'timeFrame': 'week 9'}, {'measure': 'rate of MRD-negative patients', 'description': 'rate of MRD-negative patients who did not experience relapse, progression or death within the first 14 months after study enrollment', 'timeFrame': 'baseline, week 9, month 14'}]","[{'measure': 'Rate of allogeneic HCT', 'description': 'Rate of patients who reach allogeneic HCT if HLA-matched donor is available', 'timeFrame': 'month 9'}, {'measure': 'adverse drug reactions grade III/IV', 'timeFrame': 'week 1 till week 9; month 4 till month 9; month 12; month 14; until 30 days after last administration of the study medication'}, {'measure': 'Overall, event-, and progression free survival', 'timeFrame': 'week 1 till week 9; month 4 till month 9; month 12; month 14; up to 5 years follow-up'}, {'measure': 'relapse incidence', 'timeFrame': 'month 4 till month 9; month 12; month 14; up to 5 years follow-up'}, {'measure': 'non-relapse mortality', 'timeFrame': 'week 1 till week 9; month 4 till month 9; month 12; month 14; up to 5 years follow-up'}, {'measure': 'Incidences of acute and chronic GVHD', 'description': 'provided that allogeneic HCT was conducted', 'timeFrame': 'during maintenance therapy; month 12, month 14; up to 5 years follow-up'}]",8,56 Years,,ALL,False,Technische Universität Dresden,OTHER,4,20.0,ACTUAL,2025-09-01T16:18:12.171319,v2_robust,True,True,True,False,True,
NCT01452347,Dabigatran Etexilate in Patients With Mechanical Heart Valves,"A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt",warfarin 1mg,"['warfarin 1mg', 'dabigatran etexilate intermediate dose', 'warfarin 5mg', 'warfarin 3mg', 'dabigatran etexilate low dose', 'dabigatran etexilate high dose']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Heart Valve Diseases,['Heart Valve Diseases'],[],TERMINATED,,2011-10,2013-06,"[{'measure': 'Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations at Steady State (C Trough,ss) at Week 1', 'description': 'Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE) .\n\nDespite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.', 'timeFrame': 'Week 1'}, {'measure': 'Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 2', 'description': 'Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).\n\nDespite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.', 'timeFrame': 'Week 2'}, {'measure': 'Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at Week 4', 'description': 'Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).\n\nDespite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.', 'timeFrame': 'Week 4'}, {'measure': 'Comparison of Observed and Predicted Trough Dabigatran Plasma Concentrations (C Trough,ss) at End of Trial (EoT) at Week 12', 'description': 'Comparisons between dabigatran trough plasma levels as predicted by simulations to those observed in the study are performed to validate the dosing algorithm for Dabigatran Etexilate (DE).\n\n(As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients)\n\nDespite the primary endpoint only being assessed in patients who received dabigatran etexilate, Warfarin was included as a comparator treatment in this study in order to facilitate informal comparisons of outcome events, and to look for efficacy signals in this previously unexplored population.', 'timeFrame': 'Week 12'}]","[{'measure': 'Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 1', 'description': 'Percentage of patients with observed Ctrough,ss value \\< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.', 'timeFrame': 'Week 1'}, {'measure': 'Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 2', 'description': 'Percentage of patients with observed Ctrough,ss value \\< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.', 'timeFrame': 'Week 2'}, {'measure': 'Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at Week 4', 'description': 'Percentage of patients with observed Ctrough,ss value \\< 50 ng/mL are presented. This outcome measure was only analysed for all patients together and not by dose group.', 'timeFrame': 'Week 4'}, {'measure': 'Percentage of Patients With Observed Trough Dabigatran Plasma Concentrations < 50 ng/mL at End of Trial (EoT) Week 12', 'description': 'Percentage of patients with observed Ctrough,ss value \\< 50 ng/mL (As the trial was stopped prematurely, EOT may not be 12 weeks after randomisation for most of the patients) This outcome measure was only analysed for all patients together and not by dose group.', 'timeFrame': 'Week 12'}]",8,18 Years,75 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,328.0,ACTUAL,2025-09-01T16:18:12.171335,v2_robust,True,True,False,True,False,
NCT06788249,Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine,Establishing Glutamatergic Changes as the Mechanism of Action in the Rapid Antidepressant Effects of Ketamine,Ketamine only,['Ketamine only'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Major Depressive Disorder (MDD),['Major Depressive Disorder (MDD)'],[],NOT_YET_RECRUITING,,2025-07-15,2026-04-15,"[{'measure': 'GluCEST imaging metrics', 'description': 'relative change in glutamate concentration (% baseline)', 'timeFrame': 'From pre to post-ketamine infusion (2 imaging sessions over a 9-hour span)'}]","[{'measure': 'Hamilton Depression Rating Scale', 'description': 'Assessment of severity and change in depressive symptoms, from 0-52, with 52 indicating most severe', 'timeFrame': 'From pre to post-ketamine infusion (2 evaluations over a 9-hour span)'}]",2,25 Years,65 Years,ALL,False,University of Pennsylvania,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:12.171413,v2_robust,True,True,False,False,False,
NCT03339349,Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma,Weight-Based Enoxaparin Dosing and Real-Time Dose Adjustment in Orthopaedic Trauma,Enoxaparin,['Enoxaparin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Venous Thromboembolism,"['Venous Thromboembolism', 'Deep Vein Thrombosis', 'Pulmonary Embolus']",[],COMPLETED,,2017-11-15,2019-10-29,"[{'measure': 'Number of Participants With Venous Thromboembolism Events', 'description': 'Any symptomatic venous thromboembolism events, including deep venous thrombosis or pulmonary embolus occurring within 90 days of surgery', 'timeFrame': '90 days'}, {'measure': 'Number of Participants With Bleeding Events', 'description': 'Bleeding events requiring alteration in the course of care within 90 days of surgery', 'timeFrame': '90 days'}]",[],2,18 Years,,ALL,False,University of Utah,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:12.171423,v2_robust,True,True,True,False,False,
NCT02038049,A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple Sclerosis,"A Randomized, Partially Blind, Placebo-controlled, Proof-of-concept Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity as Measured by Brain MRI Scans in Patients With Relapsing-remitting Multiple Sclerosis",VAY736,"['Placebo', 'VAY736', 'Lanalumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapse Remitting Multiple Sclerosis,['Relapse Remitting Multiple Sclerosis'],"['Multiple Sclerosis', 'Relapsing-Remitting Multiple Sclerosis', 'Magnetic Resonance Imaging', 'VAY736', 'Lanalumab', 'monoclonal antibody', 'gadolinium [Gd]-enhancing lesions', 'B-Cell']",TERMINATED,The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.,2013-12-20,2018-09-13,"[{'measure': 'Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 8, 12 and 16', 'description': 'The effect of VAY736, compared to placebo on the cumulative number of new gadolinium \\[Gd\\]-enhancing lesions on T1-weighted brain MRI scans in relapsing-remitting multiple sclerosis (RRMS) patient population at weeks 8, 12 and 16. Only descriptive statistics performed.', 'timeFrame': 'Week 8, Week 12, Week 16'}]","[{'measure': 'Number of All T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16', 'description': 'Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.', 'timeFrame': 'Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Number of New T1-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16', 'description': 'Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess all new T1-weighted Gadolinium (Gd) enhancing lesions. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.', 'timeFrame': 'Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Number of New or Enlarging T2-weighted Gadolinium (Gd)-Enhancing Lesions at Weeks 4, 8, 12 and 16', 'description': 'Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 hyperintense lesions (new or enlarging T2-weighted lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.', 'timeFrame': 'Week 4, Week 8, Week 12, Week 16'}, {'measure': 'T2 Burden of Disease (Total Volume of T2-weighted Lesions) at Weeks 4, 8, 12 and 16.', 'description': 'Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess T2 burden of disease. Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.', 'timeFrame': 'Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Number of Subjects Without Any New MRI Disease Activity at Weeks 4, 8, 12 and 16.', 'description': 'Magnetic resonance imaging (MRI) scanning of the brain was performed at screening/baseline, week 4, week 8, week 12 and week 16 to assess patients without any new MRI disease activity (no new Gd-enhancing lesions nor new or enlarging T2 lesions). Each MRI scan was reviewed by a local neuro-radiologist. Only descriptive statistics performed.', 'timeFrame': 'Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Proportion of Relapse-free Patients Over the 16 Weeks of the Treatment Period.', 'description': 'A relapse is defined as the appearance of a new neurological abnormality, or worsening of previously stable, or improving pre-existing neurological abnormality, separated by at least 30 days from the onset of a preceding clinical demyelinating event. The abnormality must be present for at least 24 hours and occur in the absence of fever (\\<37.5 C) or infection. A relapse was considered confirmed when confirmed by an Extended disability status scale (EDSS)-certified physician who was not involved in the treatment of the patient, was blinded to treatment allocation, and had no access to patient medical records. It was recommended that this occurs within 5 days of the onset of symptoms. A relapse was confirmed when it was accompanied by an increase of at least half a point (0.5) on the EDSS or an increase of 1 point on two different Functional Systems (FS) of the EDSS or 2 points on one of the FS (excluding Bowel/Bladder or Cerebral FS). Only descriptive statistics performed.', 'timeFrame': 'Week 0 (Day 1), Week 4, Week 8, Week 12, Week 16'}, {'measure': 'Number of Participants With On-Treatment Adverse Events, Serious Adverse Event, and Death', 'description': 'Analysis of absolute and relative frequencies for treatment emergent Adverse Event (AE), Serious Adverse Event (SAE) and Deaths by primary System Organ Class (SOC) to demonstrate that VAY736 is safe for the treatment of patients with relapsing-remitting multiple sclerosis through the monitoring of relevant clinical and laboratory safety parameters. Only descriptive statistics performed.', 'timeFrame': 'From first dosing (single administration, Day 1) up to End of Study Visit (EOS) depending on B cell recovery (ranging from week 48 to 216)'}]",8,18 Years,55 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:12.171434,v2_robust,True,True,False,True,True,The study recruitment was terminated based on strategic considerations after 8 patients were enrolled.
NCT01645449,"Bioequivalence Study of Atorvastatin Calcium Tablets, 80 mg of Dr. Reddy's Under Fasting Conditions","An Open Label, Balanced, Randomized, Two-treatment, Two-period, Two-way Crossover Oral BE Study of Atorvastatin Ca 80 mg Tablets of Dr. Reddy's and Lipitor 80 mg Tablets of Pfizer in Healthy Adult, Human Subjects Under Fasting Conditions","Atorvastatin Calcium Tablets, 80 mg","['Atorvastatin Calcium Tablets, 80 mg', 'Lipitor 80 mg Tablets']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bioequivalence', 'Atorvastatin calcium', 'crossover']",COMPLETED,,2010-06,2010-08,"[{'measure': 'Area under curve (AUC)', 'timeFrame': 'Pre-dose at 0.00 hour and post-dose at 0.167, 0.333, 0.50, 0.667, 0.833, 1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00,6.00, 8.00, 10.00, 12.00, 16.00, 24.00, 36.00, 48.00 and 72.00 hours'}]",[],1,18 Years,55 Years,ALL,True,Dr. Reddy's Laboratories Limited,INDUSTRY,0,77.0,ACTUAL,2025-09-01T16:18:12.171483,v2_robust,True,True,True,False,False,
NCT03655249,Effects of AD on VI in Patients With CF,Effects of Autogenic Drainage on Ventilation Inhomogeneity in Patients With Cystic Fibrosis,Aerosoltherapy,['Aerosoltherapy'],1,INTERVENTIONAL,['NA'],,,Cystic Fibrosis,['Cystic Fibrosis'],"['Multiple breath washout', 'Electrical impedance tomography', 'Lung clearance index', 'Chest physiotherapy', 'Autogenic drainage', 'Cystic fibrosis']",RECRUITING,,2018-08-01,2025-12,"[{'measure': 'Change in Lung Clearance Index', 'description': 'LCI will be measured before, immediately after and 2h after the experimental or control conditions as well as before and after an hospitalization.', 'timeFrame': 'Up to 2 weeks'}]","[{'measure': 'Impedance variation', 'description': 'Impedance change in different lung zones', 'timeFrame': 'Up to 1 hour'}]",2,6 Years,,ALL,False,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:12.171526,v2_robust,True,True,False,False,False,
NCT00916149,Cognitive Effects of Treatment of Interictal Discharges,Cognitive Effects of Treatment of Interictal Discharges,levetiracetam,"['Lamictal', 'Keppra', 'levetiracetam', 'Lamotrigine']",4,INTERVENTIONAL,['NA'],,,Epilepsy,['Epilepsy'],"['Epilepsy', 'Cognition', 'Lamictal', 'Lamotrigine', 'Keppra', 'Levetiracetam']",COMPLETED,,2007-01,2012-10,"[{'measure': 'Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment', 'description': 'This descriptive analysis examined the change in interictal discharge rates pre to post-treatment with levetiracetam in subjects with epilepsy and with no treatment in healthy controls.', 'timeFrame': '1 and 11 weeks'}]","[{'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Trial 1 Learning Score', 'description': 'Change in California Verbal Learning Test (CVLT) Trial 1 learning score (range 0-16; higher score indicates better memory)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Total Learning', 'description': 'Change in California Verbal Learning Test (CVLT) Total Learning Score (the total learning score is summed across 5 learning trials, range 0-80). Higher scores indicate better memory. Scores on the CVLT reflect the number of words recalled.', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Short Delay', 'description': 'Change in California Verbal Learning Test (CVLT) Short Delay Recall Score (the score ranges from 0-16, reflecting the number of words recalled)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CVLT Long Delay', 'description': 'Change in California Verbal Learning Test (CVLT) Long Delay Recall score (the score ranges from 0-16, reflecting the number of words recalled)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Learning', 'description': 'Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Learning score (the score ranges from 0-6, reflecting the number of shapes recalled on the initial learning trial)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Total Learning', 'description': 'Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Total Learning score (the score is summed across 3 learning trials, score range 0-18, reflecting the total number of shapes recalled)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: BVMT-R Delayed Recall', 'description': 'Change in Brief Visuospatial Memory Test-Revised (BVMT-R) Delayed Recall score (the score ranges from 0-6, reflecting the number of shapes recalled after a 25 minute delay)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: QOLIE', 'description': 'Change in Quality of Life Inventory in Epilepsy-89 score (QOLIE; score ranges from 0-100; higher scores reflect better quality of life)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: LNS', 'description': 'Change in Letter-Number Sequencing score (LNS; score ranges from 0-21; higher scores indicate better performance). The score reflects the number of items that the subject can correctly recall and place in proper alphabetical and numerical sequence.', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Spatial Span', 'description': 'Change in Spatial Span score (score ranges from 0-32; higher scores indicate better performance). Scores indicate the number of spatial sequences correctly recalled, forwards and backwards.', 'timeFrame': '1 and 11 Weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Span', 'description': 'Change in Digit Span score (score ranges from 0-30; higher scores indicate better performance). Scores indicate the number of digit sequences correctly recalled, forwards and backwards.', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Fluency', 'description': 'Change in Verbal Fluency score (Score range: lowest score = 0, with no upper limit, reflecting total number of words generated. Higher scores indicate better performance.)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Stroop', 'description': 'Change in Stroop score (The score is the time for completion in seconds; less time reflects better performance.)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Design Fluency', 'description': 'Change in Design Fluency score (Score range: lowest score = 0; there is no upper limit. A higher score reflects more designs generated, hence better performance.)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Trails Test', 'description': 'Change in Trails Test score (The score is the time for completion in seconds. A lower score reflects better performance.)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Grooved Pegboard', 'description': 'Change in Grooved Pegboard Score (The score is the time for completion. A lower score reflects better performance.)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Digit Symbol', 'description': 'Change in Digit Symbol Score (The score is the number of items completed. A higher score reflects better performance.)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Accuracy', 'description': 'Change in Continuous Performance Test Score - Accuracy (CPT; score ranges from 0-100% correct)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: CPT Reaction Time (CPT RT)', 'description': 'Change in Continuous Performance Test Score - Reaction Time, measured in seconds (CPT RT; less time reflects better performance)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Accuracy', 'description': 'Change in Choice Accuracy Score (indicate if red or blue stimulus; accuracy 0-100%)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Choice Reaction Time', 'description': 'Change in Choice Reaction Time Score, with reaction time measured in seconds (indicate if red or blue stimulus; lower reaction time suggests better performance)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Accuracy', 'description': 'Change in Verbal Working Memory Accuracy Score (range 0-100%)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Working Memory Reaction Time', 'description': 'Change in Verbal Working Memory Reaction Time Score, with reaction time measured in seconds (indicates processing speed)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Accuracy', 'description': 'Change in Non-verbal Working Memory Accuracy Score (accuracy ranges from 0-100%)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Non-verbal Working Memory Reaction Time', 'description': 'Change in Non-verbal Working Memory Reaction Time Score (indicates processing speed, with reaction time measured in seconds)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Accuracy', 'description': 'Change in Verbal Recognition Accuracy Score (accuracy ranges from 0-100%)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Verbal Recognition Reaction Time', 'description': 'Change in Verbal Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Accuracy', 'description': 'Change in Facial Recognition Accuracy Score (accuracy ranges from 0-100%)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Facial Recognition Reaction Time', 'description': 'Change in Facial Recognition Reaction Time Score (indicates processing speed, with reaction time measured in seconds)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: NDDIE', 'description': 'Change in Neurological Disorders Depression Inventory for Epilepsy (NDDIE) score (scores range from 0-24; higher scores indicate greater depressive symptoms)', 'timeFrame': '1 and 11 weeks'}, {'measure': 'Performance on Neuropsychological Batteries and Computerized Cognitive Testing: Adverse Events Profile (AEP)', 'description': 'Change in Adverse Events Profile score (scores range from 19-76; higher scores indicate greater side effects)', 'timeFrame': '1 and 11 weeks'}]",32,18 Years,55 Years,ALL,True,Massachusetts General Hospital,OTHER,4,31.0,ACTUAL,2025-09-01T16:18:12.171562,v2_robust,True,True,True,False,True,
NCT06651749,Hemodynamic Effects of a High Dose Versus Low Dose Propofol During Induction of Anesthesia.,Hemodynamic Effects of a High Dose Versus Low Dose Propofol During Induction of Anesthesia. a Randomized Comparative Trial.,Propofol injection,['Propofol injection'],1,INTERVENTIONAL,['NA'],,,Hemodynamic Effects of Propofol,['Hemodynamic Effects of Propofol'],[],RECRUITING,,2024-11-01,2025-03-31,"[{'measure': 'Percentage difference of lowest mean arterial blood pressure from baseline value.', 'description': 'will', 'timeFrame': 'from injection till 7 minutes post-injection'}]",[],1,21 Years,40 Years,ALL,True,Ain Shams University,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:12.171824,v2_robust,True,True,False,False,False,
NCT01163149,Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP),"A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, Pharmacokinetic of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults With Hypophosphatasia (HPP)",asfotase alfa,['asfotase alfa'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Hypophosphatasia,['Hypophosphatasia'],"['Hypophosphatasia', 'HPP', 'Bone Disease', 'Soft Bones', 'Low Alkaline Phosphatase', 'genetic metabolic disorder', 'alkaline phosphatase', 'tissue-specific alkaline phosphatase (TNSALP)', 'rickets', 'osteomalacia']",COMPLETED,,2010-06,2016-06,"[{'measure': ""Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP)"", 'description': ""Blood samples were collected to evaluate the effect of asfotase alfa on reduction in plasma pyridoxal-5' phosphate (PLP)"", 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline to Week 24 for Plasma Inorganic Pyrophosphate (PPi)', 'description': 'Blood samples were collected to evaluate the effect of asfotase alfa on reduction in plasma inorganic pyrophosphate (PPi)', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Safety and Tolerability of Asfotase Alfa', 'description': 'The safety and tolerability of daily subcutaneous (SC) injections of asfotase alfa was assessed by routine monitoring of patients for treatment-emergent adverse events (TEAEs) and injection-associated reactions (IARs).', 'timeFrame': 'Up to 288 weeks exposure to asfotase alfa'}]","[{'measure': 'Change From Baseline in Bone Mineral Content (BMC) as Measured by Dual-energy X-ray Absorptiometry (DXA)', 'description': 'A DXA scan was performed to evaluate bone mineral content (BMC) of the spine, hip, and whole body during the primary (first 24 weeks) and extension treatment periods (up to 288 weeks).', 'timeFrame': 'Baseline, every 24 weeks through Week 96, then every 48 weeks until Week 288.'}, {'measure': 'Change From Baseline in Bone Mineral Density (BMD) as Measured by Dual-energy X-ray Absorptiometry (DXA)', 'description': 'A DXA scan was performed to evaluate bone bone mineral density (BMD) of the spine, hip, and whole body during the primary (first 24 weeks) and extension treatment periods (up to 288 weeks).', 'timeFrame': 'Baseline, every 24 weeks through Week 96, then every 48 weeks until Week 288.'}, {'measure': 'Change in Walking Ability as Measured by the Six-Minute Walk Test (6MWT)', 'description': 'The patient was instructed to walk the length of a pre-measured hallway for 6 minutes. The primary measurement was distance walked (in meters).', 'timeFrame': 'Baseline, Week 24 (primary treatment period) and up to 288 weeks of asfotase alfa exposure'}, {'measure': 'Change From Baseline in HPP-related Osteomalacia as Measured by Trans-iliac Crest Bone Biopsy: Osteoid Volume/Bone Volume', 'description': 'A trans-iliac crest bone biopsy was performed to quantify changes from Baseline in histomorphometric parameters relevant for evaluation of osteomalacia severity, including Osteoid Volume/Bone Volume (%). The difference in time under observation between asfotase alfa groups (Week 48) and control group (Week 24) resulted from study design, ie, control subjects transitioned to active treatment after the Week 24 visit.', 'timeFrame': 'Baseline, Week 24 (Control group), and Week 48 (Asfotase alfa groups).'}, {'measure': 'Change From Baseline in HPP-related Osteomalacia as Measured by Trans-iliac Crest Bone Biopsy: Osteoid Thickness', 'description': 'A trans-iliac crest bone biopsy was performed to quantify changes from Baseline in histomorphometric parameters relevant for evaluation of osteomalacia severity, including Osteoid Thickness (um). The difference in time under observation between asfotase alfa groups (Week 48) and control group (Week 24) resulted from study design, ie, control subjects transitioned to active treatment after the Week 24 visit.', 'timeFrame': 'Baseline, Week 24 (Control group), and Week 48 (Asfotase alfa groups).'}, {'measure': 'Change From Baseline in HPP-related Osteomalacia as Measured by Trans-iliac Crest Bone Biopsy: Mineralization Lag Time', 'description': 'A trans-iliac crest bone biopsy was performed to quantify changes from Baseline in histomorphometric parameters relevant for evaluation of osteomalacia severity, including Mineralization Lag Time (days). The difference in time under observation between asfotase alfa groups (Week 48) and control group (Week 24) resulted from study design, ie, control subjects transitioned to active treatment after the Week 24 visit.', 'timeFrame': 'Baseline, Week 24 (Control group), and Week 48 (Asfotase alfa groups).'}]",9,13 Years,65 Years,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:12.171833,v2_robust,True,True,True,False,True,
NCT04157738,A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus,Fixed Dose for Fixed Carbohydrates vs. Variable Dosing for Variable Carbohydrates: A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus.,Rapid-Acting Insulin,"['Glargine', 'Lispro, Aspart, glulisine', 'Rapid-Acting Insulin', 'Long acting insulin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus,"['Diabetes Mellitus', 'Type 1 Diabetes']","['Diabetes', 'Glycemic variability', 'Insulin', 'Parental Stress', 'Advanced carbohydrates counting', 'Insulin for meals']",COMPLETED,,2019-11-27,2020-12-17,"[{'measure': 'Number of All Consented Participants', 'description': 'The capacity for recruitment was assessed, including all subjects that signed the Informed Consent Form (ICF).', 'timeFrame': '4 months post-intervention'}, {'measure': 'Number of Participants That Completed All Visits', 'description': 'Number of participants that were able to complete all study visits, including the visits in-person at 1 month and 4 months post-randomization.', 'timeFrame': '4 months post-intervention'}, {'measure': 'Caregiver Treatment Adherence at 1 Month and 4 Months Post-intervention', 'description': 'Caregiver treatment adherence was assessed using a blood glucose log. Subjects and caregivers recorded blood glucose levels and the amount/type of insulin given. This data was used to calculate adherence as a percentage ranging from 0% (no adherence) to 100% (full adherence).', 'timeFrame': '1 month post-intervention and 4 months post-intervention'}]","[{'measure': 'Caregiver Anxiety', 'description': 'Caregiver anxiety was measured with the ""parental stress scale"". Caregivers completed the ""parental stress scale"" at initial enrollment and at each clinic follow up visit. The Parental Stress Scale includes 18 questions that are rated from 1 (strongly disagree) to 5 (strongly agree). Scoring ranges from 18 - 90. The higher the score, the higher the stress and anxiety level.', 'timeFrame': 'Baseline, 1 month post-intervention, 4 months post-intervention'}, {'measure': 'Glycemic Variability (GV) at 1 Month and 4 Months Post-intervention', 'description': ""The GV was calculated in all subjects using the average blood glucose levels collected from the daily blood glucose paper log. A subjective qualification system was used to label each subject's GV based on their blood glucose levels and an established glucose monitoring (GM) data system. Subjects are considered to have appropriate GV if their blood glucose levels are in the range of 80 mg/dL - 180 mg/dL. Percentage of participants within each specific average BG range is shown."", 'timeFrame': '1 month post-intervention, 4 months post-intervention'}]",5,7 Years,15 Years,ALL,False,Emory University,OTHER,0,24.0,ACTUAL,2025-09-01T16:18:12.171847,v2_robust,True,True,True,False,False,
NCT03243838,Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer,"Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer (LANCET): A Multicenter, Single-arm, Phase II Trial",Apatinib,['Apatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Triple-Negative Breast Cancer,['Triple-Negative Breast Cancer'],"['Triple-Negative Breast Cancer', 'apatinib', 'pCR', 'OS', 'Neoadjuvant chemotherapy']",COMPLETED,,2018-08-01,2021-12-31,"[{'measure': 'The pathological complete response (pCR) rate in the breast and lymph nodes (ypTis/0ypN0)', 'description': 'Absence of invasive tumor cells in the breast and lymph nodes and was determined by a local pathologist', 'timeFrame': 'up to 24 weeks (at the end of cycle 8, each cycle is 21 days)'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'ORR was assessed according to RECIST version 1.1, which included patients with measurable disease who achieved a complete or partial response of target lesions.', 'timeFrame': 'up to 24 weeks (at the end of cycle 8, each cycle is 21 days)'}, {'measure': 'Event-free survival (EFS)', 'description': 'The interval from the start of treatment to progression prior to surgery, post-surgery recurrence, or death due to any cause', 'timeFrame': 'up to 24 months'}, {'measure': 'Overall survival (OS)', 'description': 'The time from registration to death from any cause', 'timeFrame': 'up to 24 months'}, {'measure': 'Adverse events', 'description': 'The treatment-related adverse events were assessed by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (NCI-CTCAE 4.0).', 'timeFrame': 'up to 24 weeks'}]",5,18 Years,70 Years,FEMALE,False,Guangdong Provincial People's Hospital,OTHER,0,31.0,ACTUAL,2025-09-01T16:18:12.171886,v2_robust,True,True,True,False,True,
NCT05121038,CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab,"A Phase 1B/2A Trial of CEND-1 in Combination with Neoadjuvant FOLFIRINOX Based Therapies in Pancreatic, Colon and Appendiceal Cancers (CENDIFOX)",CEND-1,"['CEND-1', 'LSTA1', 'Folfirinox', 'Panitumumab', 'Oxaliplatin,Leucovorin,Irinotecan,Fluorouracil', 'Certepetide']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Colon Cancer,"['Colon Cancer', 'Pancreas Cancer', 'Digestive Cancer']",[],ACTIVE_NOT_RECRUITING,,2021-10-20,2026-09,"[{'measure': 'Drug Safety: Number of participants with treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'Adverse Events : Counts and proportions of grade 3 -5 Adverse Events', 'timeFrame': '24 months'}]","[{'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) will be reported using median survival time along with a 90% confidence interval', 'timeFrame': '48 months'}, {'measure': 'Disease-free survival (DFS)', 'description': 'Disease-free survival (DFS) will be reported using median survival time along with a 90% confidence interval', 'timeFrame': '48 months'}, {'measure': 'Overall response rate (ORR)', 'description': 'Overall response rate (ORR) will be reported as a proportion with 90% confidence interval.', 'timeFrame': '24 months'}, {'measure': 'RO resection rate (RORR)', 'description': 'RO resection rate (RORR) will be reported as a proportion with 90% confidence interval.', 'timeFrame': '24 months'}, {'measure': 'Pathological response rate (PCR) .', 'description': 'Pathological response rate (PCR) will be reported as a proportion with 90% confidence interval.', 'timeFrame': '24 months'}]",6,18 Years,,ALL,False,Anup Kasi,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:12.171905,v2_robust,True,True,False,False,True,
NCT00502138,A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes,"A Pilot Study to Assess the Pharmacokinetics, Pharmacodynamics and Safety/Tolerability of Pramlintide Acetate When Administered by Subcutaneous Infusion in a Basal-Bolus Manner as an Adjunct to Continuous Subcutaneous Insulin Infusion Therapy in Patients With Type 1 Diabetes",Continuous Pramlintide infusion,"['Continuous Pramlintide infusion', 'pramlintide']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,IDDM,['IDDM'],"['diabetes', 'insulin', 'pramlintide', 'IDDM']",COMPLETED,,2007-07,2008-01,"[{'measure': 'Fasting and postprandial pramlintide pharmacokinetics', 'timeFrame': 'Four months'}]","[{'measure': 'Hemoglobin A1c, body weight, blood glucose variability, patient satisfaction', 'timeFrame': 'four months'}, {'measure': 'Hemoglobin A1c', 'timeFrame': '16 weeks'}]",3,18 Years,70 Years,ALL,False,University Diabetes & Endocrine Consultants,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:12.171913,v2_robust,True,True,True,False,False,
NCT03954938,Behavioral Effects of Drugs (Inpatient): 38,Influence of Craving Manipulation on Cocaine Self-Administration,Cocaine,"['Cocaine', 'Placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Cocaine Use, Unspecified","['Cocaine Use, Unspecified']",[],TERMINATED,COVID-19,2019-05-15,2021-12-03,"[{'measure': 'Number of Times Cocaine Was Selected', 'description': 'The reinforcing effects of cocaine were determined using a modified progressive ratio procedure (Stoops et al., 2010) in which subjects can make 5 choices for each available cocaine dose. Reinforcing effects were measured for each cocaine dose during across the craving manipulation conditions.', 'timeFrame': 'One test for each of the craving manipulations for placebo and each cocaine dose level over approximately two weeks of participation.'}]","[{'measure': 'Cocaine Craving', 'description': 'Cocaine craving was assessed using a 10 point craving questionnaire that asks subjects to rate how much they are craving cocaine at that moment. The minimum craving score is 0 (i.e., no craving), the maximum craving score is 10 (i.e., highest craving).', 'timeFrame': 'Measured for each of the craving manipulations for placebo and each cocaine dose level over approximately two weeks of participation.'}]",2,18 Years,55 Years,ALL,True,William Stoops,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:12.172014,v2_robust,True,True,False,True,False,COVID-19
NCT02926638,Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches,A Phase II/III Randomized Study of Rilotumumab Plus Erlotinib Versus Erlotinib as Second Line Therapy for C-Met Positive Patients With Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study),Erlotinib Hydrochloride,"['OSI-774', 'Tarceva', 'Erlotinib Hydrochloride', 'Cp-358,774']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,MET Positive,"['MET Positive', 'Recurrent Squamous Cell Lung Carcinoma', 'Stage IV Squamous Cell Lung Carcinoma AJCC v7']",[],TERMINATED,Drug company decided to terminate all sponsored clinical studies involving rilotumumab.,2014-06-16,2016-10-12,"[{'measure': 'Investigator-assessed Progression-free Survival Between Arms', 'description': 'A stratified (using randomization stratification factors) log-rank test will be used to test the primary hypotheses related to investigator-assessed progression-free survival, comparing the two treatment arms.', 'timeFrame': 'From date of sub-study registration to date of first documentation of progression assessed by local review or symptomatic deterioration, or death due to any cause, assessed up to 18 months since completion of accrual'}, {'measure': 'Objective Response Rate (Confirmed and Unconfirmed, Complete and Partial) Between Arms', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'Frequency and Severity of Toxicities Associated With Investigational Therapy Versus Standard of Care', 'timeFrame': 'Up to 3 years'}]",3,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,9.0,ACTUAL,2025-09-01T16:18:12.172159,v2_robust,True,True,False,True,False,Drug company decided to terminate all sponsored clinical studies involving rilotumumab.
NCT03770858,Wearable Skin Sensors to Assess Nocturnal Scratch Behavior,"A Single Arm, Prospective Clinical Study Using Novel Wearable Sensors to Assess the Improvement of Nocturnal Scratch Behavior and Sleep Quality in Children With Mild-to-moderate Atopic Dermatitis Treated With Topical Crisaborole",Crisaborole,['Crisaborole'],1,OBSERVATIONAL,[],,,Atopic Dermatitis,['Atopic Dermatitis'],"['Wearables', 'Atopic Dermatitis', 'Scratch sensor']",COMPLETED,,2019-04-18,2022-08-24,"[{'measure': 'Percent agreement of scratching between the experimental sensor and the infrared camera', 'timeFrame': '3 weeks'}]","[{'measure': 'Improvement of sleep parameters (time asleep) measured by the experimental sensor during treatment', 'description': 'Baseline compared to treatment time points will be compared in units of time (minutes/hours)', 'timeFrame': '3 weeks'}, {'measure': 'Improvement of sleep parameters (time until onset of sleep) measured by the experimental sensor', 'description': 'Baseline compared to treatment time points will be compared in units of time (minutes/hours)', 'timeFrame': '3 weeks'}, {'measure': 'Improvement of sleep parameters (heart rate) measured by the experimental sensor', 'description': 'Baseline compared to treatment time points will be compared in units of beats/min', 'timeFrame': '3 weeks'}, {'measure': 'Improvement of sleep parameters (respiratory rate) measured by the experimental sensor', 'description': 'Baseline compared to treatment time points will be compared in units of breaths/min.', 'timeFrame': '3 weeks'}]",5,2 Years,,ALL,True,Northwestern University,OTHER,1,23.0,ACTUAL,2025-09-01T16:18:12.172233,v2_robust,False,True,True,False,False,
NCT02596958,Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants,"Available - Avastin in Addition to Platinum-based Chemotherapy is Indicated for First-lime Treatment of Patients With Locally Advanced, Metastatic or Recurrent Non-small Lung Cancer Other Than Predominantly Squamous Cell Histology",Bevacizumab,"['Avastin', 'Bevacizumab']",2,OBSERVATIONAL,[],,,Non-Squamous Non-Small Cell Lung Cancer,['Non-Squamous Non-Small Cell Lung Cancer'],[],COMPLETED,,2007-09,2013-10,"[{'measure': 'Percentage of Participants With Adverse Drug Reactions (ADRs), Toxicities, Avastin-Related ADRs, and Serious ADRs', 'description': 'ADRs were defined as any response to a drug which was noxious and unintended, and which occurred at dose normally used related to the pharmacological properties. Serious ADRs were defined as any untoward medical occurrence or effect that at any dose resulted in death or life-threatening conditions or required hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, congenital anomaly or birth defect or medically important condition. Toxicity was defined as an adverse event that had an attribution (the relationship to investigational agent) of possible, probable or definite. Avastin-related ADRs (an adverse event with a possible relationship or a relationship to the treatment with AVASTIN) were due to Avastin. ADRs includes serious as well as non-serious ADRs.', 'timeFrame': 'Up to 74 months'}]","[{'measure': 'Percentage of Participants Who Withdrew or Modified Treatment', 'description': 'Percentage of participants who withdrew treatment or experienced at least 1 dose deviation in relation to the planned Avastin therapy were reported.', 'timeFrame': 'Up to 74 months'}, {'measure': 'Number of Cycles of Systemic Therapy', 'description': 'Number of cycles of systemic therapy was the mean number of cycles received by participants in combination therapy with Avastin and chemotherapy and with Avastin monotherapy (maintenance).', 'timeFrame': 'Up to 74 months'}, {'measure': 'Percentage of Participants With Best Tumor Response Over Time', 'description': 'Best tumor response (assessed as per clinical routine of the individual center) was categorized according to the following criteria at the investigator discretion: complete response (CR: commonly defined as disappearance of all target lesions, all non-target lesions, and no new lesion), partial response (PR: commonly defined as at least a 30 percent \\[%\\] decrease in the sum of the longest diameter \\[LD\\] of target lesions, no progression in non-target lesion, and no new lesion), stable disease (SD: commonly defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease \\[PD\\], in addition to no new target lesions). PD: commonly defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started and not evaluable (NE).', 'timeFrame': 'Up to 74 months'}, {'measure': 'Percentage of Participants With Eastern Cooperative Group(ECOG) Performance Status Grades', 'description': ""ECOG Performance Status measured on-therapy (time between first dose and last dose date with a 30-day lag) assessed participant's performance status on 5 point scale: 0 is equal to (=) fully active/able to carry on all pre-disease activities without restriction; 1=restricted in physically strenuous activity, ambulatory/able to carry out light or sedentary work; 2=ambulatory (greater than \\[\\>\\] 50% of waking hours \\[hrs\\]), capable of all self care, unable to carry out any work activities; 3=capable of only limited self care, confined to bed/chair \\>50% of waking hrs; 4=completely disabled, cannot carry on any self care, totally confined to bed/chair; 5=dead."", 'timeFrame': 'Up to 74 months'}, {'measure': 'Percentage of Participants With Disease Control', 'description': 'Disease control was defined as having achieved CR (commonly defined as disappearance of all target lesions, all non-target lesions, and no new lesion), PR (commonly defined as at least a 30% decrease in the sum of the LD of target lesions, no progression in non-target lesion, and no new lesion), or SD (commonly defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, in addition to no new target lesions) during the course of observation which were assessed as per investigator discretion. PD: commonly defined as at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started and NE.', 'timeFrame': 'Up to 74 months'}, {'measure': 'Progression Free Survival (PFS)', 'description': 'PFS was defined as the time (months) between the start of therapy and progression (unequivocal progression of existing non-target lesions) or death. Progression: at least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started. PFS was estimated using Kaplan-Meier method.', 'timeFrame': 'Up to 74 months'}, {'measure': 'Percentage of Participants Who Died', 'timeFrame': 'Up to 74 months'}, {'measure': 'Overall Survival', 'description': 'Overall survival was defined as the time (months) between the start of therapy and the date of death.', 'timeFrame': 'Up to 74 months'}]",9,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,996.0,ACTUAL,2025-09-01T16:18:12.172261,v2_robust,False,True,True,False,True,
NCT07081958,A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Center, Phase II Study to Evaluate the Efficacy, Safety, and Tolerability of Once-Daily RO7795081 Administered for 38 Weeks to Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity",RO7795081,"['RG6652', 'Placebo', 'RO7795081', 'CT-996']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Obesity or Overweight,['Obesity or Overweight'],[],RECRUITING,,2025-07-29,2026-09-18,"[{'measure': 'Percent Change in Body Weight From Baseline to Week 30', 'timeFrame': 'Baseline to Week 30'}]","[{'measure': 'Absolute Change in Body Weight (kg) from Baseline to Week 30', 'timeFrame': 'Baseline to Week 30'}, {'measure': 'Absolute Change in Body Weight (kg) from Baseline to Week 38', 'timeFrame': 'Baseline to Week 38'}, {'measure': 'Percent Change in Body Weight From Baseline to Week 38', 'timeFrame': 'Baseline to Week 38'}, {'measure': 'Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, or ≥20% Body Weight Reduction from Baseline at Week 30', 'timeFrame': 'Baseline and Week 30'}, {'measure': 'Percentage of Participants Who Achieve ≥5%, ≥10%, ≥15%, or ≥20% Body Weight Reduction from Baseline at Week 38', 'timeFrame': 'Baseline and Week 38'}, {'measure': 'Absolute Change in BMI (kg/m^2) from Baseline to Week 30', 'timeFrame': 'Baseline to Week 30'}, {'measure': 'Absolute Change in BMI (kg/m^2) from Baseline to Week 38', 'timeFrame': 'Baseline to Week 38'}, {'measure': 'Incidence of Adverse Events (AEs), Adverse Events of Special Interest (AESIs), and Serious AEs (SAEs)', 'timeFrame': 'From first dose until 28 days after the final dose of study treatment (42 weeks)'}, {'measure': 'Change in Columbia-Suicide Severity Rating Scale (C-SSRS) Scores from Baseline to Week 42', 'description': 'The C-SSRS is an assessment tool to evaluate suicidal ideation and behavior during the assessment period via a participant-reported questionnaire comprising 2 to 6 questions (yes or no). Affirmative responses count as 1 point, which are then summed to indicate the level of suicide risk on a scale of 0 (no risk) to 6 (high risk).', 'timeFrame': 'Baseline to Week 42'}, {'measure': 'Change in Patient Health Questionnaire-9 (PHQ-9) Scores from Baseline to Week 42', 'description': 'PHQ-9 is a 9-item patient reported outcome (PRO) used to assess severity of depression. Responses are rated based on the frequency of symptoms on a 4-point Likert scale, ranging from 0 (not at all) to 3 (nearly every day). A PHQ-9 total score ranging from 0 to 27 can be calculated by summing the nine items; a higher score corresponds with more severe depression.', 'timeFrame': 'Baseline to Week 42'}, {'measure': 'Plasma Concentrations of RO7795081 at Prespecified Timepoints', 'timeFrame': 'Predose on Day 1 and at prespecified timepoints until Week 38'}]",12,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,340.0,ESTIMATED,2025-09-01T16:18:12.172276,v2_robust,True,True,False,False,True,
NCT03856658,Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases,A Phase II Trial of Hepatic Artery Infusional Floxuridine With Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases,Floxuridine (FUDR),"['Heparinized Saline', 'Floxuridine (FUDR)', 'FUDR']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Adenocarcinoma,"['Pancreatic Adenocarcinoma', 'Liver Metastases']","['pancreatic cancer, pancreatic ductal carcinoma, liver metastases, HAI, hepatic artery infusion pump, FUDR, Floxuridine']",ACTIVE_NOT_RECRUITING,,2019-02-05,2025-12,"[{'measure': 'Hepatic progression-free survival', 'description': 'The length of time from the start of trial therapy to the time when target liver lesions show progression or new lesions appear. (Determined by RECIST criteria: ≥20% growth in target lesions and/or appearance of new lesions).', 'timeFrame': '1 year'}]","[{'measure': 'Overall survival', 'description': 'The length of time from diagnosis to death, measured as the proportion of patients surviving at specific time points (6, 12 and 18 months from diagnosis).', 'timeFrame': '2 years'}, {'measure': 'Progression-free survival at any site', 'description': 'The length of time from diagnosis to disease progression at any anatomical site (as determined by RECIST criteria) or death.', 'timeFrame': '2 years'}, {'measure': 'Rate of tumor response in the liver', 'description': 'Determined by RECIST criteria on imaging studies done every 3 months', 'timeFrame': '2 years'}, {'measure': 'EORTC Quality of Life Questionnaire', 'description': 'As measured by the EORTC Quality of Life Questionnaire Core 30 instrument', 'timeFrame': '2 years'}]",5,18 Years,75 Years,ALL,False,Spectrum Health Hospitals,OTHER,0,14.0,ACTUAL,2025-09-01T16:18:12.172361,v2_robust,True,True,False,False,False,
NCT04793958,Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10),A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy,MRTX849,"['FOLFIRI Regimen', 'MRTX849', 'mFOLFOX6 Regimen']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Advanced Colorectal Cancer,"['Advanced Colorectal Cancer', 'Metastatic Colorectal Cancer']","['Colorectal Cancer', 'Colorectal Cancer Trial', 'Colorectal Carcinoma', 'Rectal Cancer', 'Colon Cancer', 'KRAS', 'KRAS G12C', 'RAS', 'Colorectal Adenocarcinoma']",ACTIVE_NOT_RECRUITING,,2021-06-24,2026-01-30,"[{'measure': 'Overall Survival (OS)', 'description': 'Defined as time from date of randomization to date of death due to any cause.', 'timeFrame': '30 months'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'Defined as time from randomization until disease progression or death from any cause, whichever occurs first.', 'timeFrame': '30 months'}]","[{'measure': 'Adverse Events', 'description': 'Defined as number of patients with treatment emergent AEs.', 'timeFrame': '30 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Defined as the percent of patients documented to have a confirmed CR or PR.', 'timeFrame': '30 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'Defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of either Progression of Disease (PD) or death due to any cause, whichever occurs first.', 'timeFrame': '30 months'}, {'measure': 'Patient Reported Outcomes (PROs)', 'description': 'To be assessed by European Quality of Life Questionnaire for Cancer Patients (QLQ-C30).', 'timeFrame': '30 months'}, {'measure': 'Quality of Life Assessment', 'description': 'To be assessed by European Quality of Life Five Dimensions Questionnaire (EQ-5D-5L).', 'timeFrame': '30 months'}]",7,18 Years,,ALL,False,Mirati Therapeutics Inc.,INDUSTRY,0,461.0,ACTUAL,2025-09-01T16:18:12.172419,v2_robust,True,True,False,False,True,
NCT04480658,Effectiveness of Bryophyllum in Nocturia-Therapy,Effectiveness of Bryophyllum Pinnatum by Patients With Nocturia and Its Effect on Sleep Quality,"Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)","['Bryophyllum pinnatum 50 %, tablets into capsules (verum: 2x2capsules/day)']",1,INTERVENTIONAL,['NA'],,,Nocturia,"['Nocturia', 'Sleep Disorder']",[],COMPLETED,,2018-01-01,2022-01-14,"[{'measure': 'Reduction of nocturia frequency', 'description': 'micturition protocol will be handed over during the baseline visit, it will be filled three days before the second visit in 1 week( therapy-start), follow-up control 3 weeks after medication intake and after the completed medication period \\]', 'timeFrame': '4 Weeks'}, {'measure': 'Sleep-Quality.', 'description': 'Pittsburgh Sleep Quality Index (PSQI; score 0-21) will be handed over during the baseline visit and will be filled three days before the second visit in 1 Week and three days after the therapy-end (after 3 Weeks). The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.', 'timeFrame': '4 Weeks'}]","[{'measure': 'Changes of overactive bladder symptoms', 'description': 'quality of life is measured by the ICIQ-OAB (score 0-16), a specific questionnaire for OAB', 'timeFrame': 'before the second visit in 1 week, at follow-up control 3 weeks after begin of medication intake and 4 weeks after end of medication intake.'}, {'measure': 'Safety of Bryophyllum: adverse events', 'description': 'during medication intake at 1 week and 3 weeks after start of medication intake, measured by a personal adverse event protocol', 'timeFrame': '4 weeks'}, {'measure': 'Daytime sleepiness', 'description': 'quality of life is measured by Epworth Sleepiness Scale Questionnaire (score 0-24)', 'timeFrame': 'before the second visit in 1 week, at follow-up control 3 weeks after begin of medication intake and 4 weeks after end of medication intake.'}]",5,18 Years,,FEMALE,False,University of Zurich,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:12.172444,v2_robust,True,True,True,False,True,
NCT05186558,Penpulimab Plus R2-GemOx Regimen in Relapsed or Refractory DLBCL,"A Multi-center, Single-arm, Open Label Study to Assess the Efficacy and Safety of Anti-PD-1 Antibody (Penpulimab) Plus Lenalidomide, Rituximab, Gemcitabine and Oxaliplatin (R2-GemOx) in Patients With Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)","penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin","['Oxaliplatin', 'Rituximab', 'penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin', 'Gemcitabine', 'lenalidomide']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lymphoma, Large B-Cell, Diffuse","['Lymphoma, Large B-Cell, Diffuse', 'Neoplasms by Histologic Type']",[],NOT_YET_RECRUITING,,2022-05-15,2026-02-15,"[{'measure': 'Complete response rate', 'description': 'Complete response rate after treated by penpulimab and R2-GemOx', 'timeFrame': '6 weeks after the last dose of the combination therapy (each cycle is 14 days)'}]","[{'measure': 'Overall Survival (OS)', 'description': 'from date of inclusion to date of death from any cause', 'timeFrame': '2 years'}, {'measure': 'Progression-free survival（PFS）', 'description': 'from date of inclusion to date of progression, relapse, or death from any cause', 'timeFrame': '2 years'}, {'measure': 'Rate of grade 3 or 4 treatment related adverse effect', 'description': 'All the adverse events of the patients related will be assessed and graded by NCI CTCAE v 5.0', 'timeFrame': 'Up to 30 days after the last cycle of per-protocol treatment and 90 days after last dose of anti-PD-1 antibody'}]",4,18 Years,80 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,54.0,ESTIMATED,2025-09-01T16:18:12.172517,v2_robust,True,True,False,False,True,
NCT03696758,Improving Right Ventricular Function in Young Adults Born Preterm,Improving Right Ventricular Function in Young Adults Born Preterm: A Pilot Study,Metoprolol,"['Lopressor', 'Sildenafil', 'Metoprolol', 'Metolar XR', 'Revatio']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,"Infant,Premature","['Infant,Premature']","['premature adults', 'premature', 'premature cardiac function', 'MRI', 'sildenafil', 'metoprolol', 'CMR']",COMPLETED,,2018-10-30,2020-02-24,"[{'measure': 'Right Ventricular Energetic Efficiency Pre and Post Metoprolol', 'description': 'To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Metoprolol intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Energetic Efficiency Pre and Post Sildenafil', 'description': 'To characterize energy efficiency, the total Kinetic Energy across the cardiac cycle is normalized to right ventricular end-diastolic volume and left ventricular end-diastolic volume, respectively. Analysis will be completed in blinded fashion. Two imaging scans will be done - one pre and one post Sildenafil intervention. Total time from Pre-intervention scan till post intervention scan may take up to 2 hours.', 'timeFrame': 'up to 2 hours'}]","[{'measure': 'Left Ventricular Energetic Efficiency Pre and Post Metoprolol', 'description': 'Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Ejection Fraction Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Stroke Volume Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Systolic Volume Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Diastolic Volume Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Ejection Fraction Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Stroke Volume Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Systolic Volume Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Diastolic Volume Pre and Post Metoprolol', 'description': 'Participants will receive intravenous metoprolol in between scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Energetic Efficiency Pre and Post Sildenafil', 'description': 'Kinetic energy (from 4D flow) normalized to ventricular volume (from MRI). Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Ejection Fraction Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans. The term ""ejection fraction"" refers to the percentage of blood that\'s pumped out of a filled ventricle with each heartbeat.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Stroke Volume Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Systolic Volume Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Right Ventricular Diastolic Volume Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Ejection Fraction Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Stroke Volume Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Systolic Volume Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}, {'measure': 'Left Ventricular Diastolic Volume Pre and Post Sildenafil', 'description': 'Participants will be given sildenafil in between imaging scans.', 'timeFrame': 'up to 2 hours'}]",20,18 Years,35 Years,ALL,False,"University of Wisconsin, Madison",OTHER,1,10.0,ACTUAL,2025-09-01T16:18:12.172620,v2_robust,True,True,True,False,False,
NCT03906058,Anlotinib in Recurrent or Metastatic Nasopharyngeal Carcinoma Patients After Failure of no Less Than Second-line Therapy,"Open-Label, Phase Ⅱ Study of Anlotinib Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of no Less Than Second-line Chemotherapy or Targeted Therapy",Anlotinib,['Anlotinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Nasopharyngeal Carcinoma,['Nasopharyngeal Carcinoma'],[],COMPLETED,,2019-04-29,2022-04-30,"[{'measure': 'disease control rate', 'description': 'disease control rate', 'timeFrame': '30 months'}]","[{'measure': 'overall response rate', 'description': 'overall response rate', 'timeFrame': '30 months'}, {'measure': 'progression-free survival', 'description': 'progression-free survival', 'timeFrame': '30 months'}, {'measure': 'overall survival', 'description': 'overall survival', 'timeFrame': '30 months'}, {'measure': 'duration of response', 'description': 'duration of response', 'timeFrame': '30 months'}]",5,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,39.0,ACTUAL,2025-09-01T16:18:12.172660,v2_robust,True,True,True,False,False,
NCT00408148,High Density Lipoprotein Turnover,"A Randomized, Double-blind, Two Arm, Parallel, Placebo Controlled Study of Rimonabant 20 mg Effect on High Density Lipoprotein Kinetics in Patients With Abdominal Obesity and Additional Cardiometabolic Risk Factors",Placebo,"['Rimonabant', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,['Obesity'],[],TERMINATED,Company decision has been taken in light of recent demands by certain national health authorities,2006-10,2008-12,"[{'measure': 'The fractional catabolic rate (FCR) of HDL ApoA-I', 'timeFrame': 'After 12 months of treatment.'}]","[{'measure': 'Production Rate (PR) of HDL ApoA-I and A-II, (FCR) of HDL ApoA-II', 'timeFrame': 'All across the study'}, {'measure': 'PR and FCR of VLDL1 and VLDL2 Apo B, VLDL1 and VLDL2 TG, IDL Apo B and LDL Apo B', 'timeFrame': 'All across the study'}, {'measure': 'Variation in ApoA-I, ApoA-II, Lp-AI, Lp-AII, pre-beta-HDL HDL2a, HDL2b, HDL3a, HDL3b, HDL3c, Apo B, Apo C III, TG, LDL-C, HDL-C levels', 'timeFrame': 'All across the study'}, {'measure': 'Variation in Glucose, insulin, HbA1c, leptin, adiponectin', 'timeFrame': 'All across the study'}, {'measure': 'Variation in hs-CRP, TNF-alpha, CETP, PLTP and LCAT activities, lipoprotein and hepatic lipase activities in post-heparin plasma', 'timeFrame': 'All across the study'}, {'measure': 'Variation in whole body fat', 'timeFrame': 'All across the study'}, {'measure': 'Variation in abdominal sub-cutaneous and visceral fat', 'timeFrame': 'All across the study'}, {'measure': 'Variation in liver fat', 'timeFrame': 'All across the study'}, {'measure': 'Variation in blood pressure', 'timeFrame': 'All across the study'}, {'measure': 'Variation in body weight, waist circumference, waist/hip ratio', 'timeFrame': 'From the beginning to the end of the study'}, {'measure': 'CE/TG ratio in HDL', 'timeFrame': 'All across the study'}, {'measure': 'Adverse events', 'timeFrame': 'From the beginning to the end of the study'}]",13,35 Years,65 Years,ALL,False,Sanofi,INDUSTRY,0,64.0,ACTUAL,2025-09-01T16:18:12.172742,v2_robust,True,True,False,True,True,Company decision has been taken in light of recent demands by certain national health authorities
NCT04893148,Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes,Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes Insufficiently Controlled by Insulin Glargine and Metformin Combination Therapy,IGlarLixi,"['Dulaglutide', 'IGlarLixi', 'Insulin Glargine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,"['Type 2 Diabetes Mellitus', 'Glucose, High Blood']","['IGlarLixi', 'Dulaglutide', 'Continuous glucose monitoring system', 'Type 2 diabetes mellitus']",UNKNOWN,,2020-05-26,2022-12-30,"[{'measure': 'Changes in glycated hemoglobin (HbA1c)', 'description': 'HbA1c will be measured at baseline and week 12', 'timeFrame': 'Baseline, week 12'}]","[{'measure': 'Changes in fasting plasma glucose (FPG)', 'description': 'Comparison of FPG changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in glucose time in range (TIR)', 'description': 'Comparison of %TIR changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in glucose time above range (TAR)', 'description': 'Comparison of %TAR changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in glucose time below range (TBR)', 'description': 'Comparison of %TBR changes in week 12 from baseline between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Incidence of hypoglycemia', 'description': 'Comparison of the incidence of hypoglycemia between the two groups', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Changes in weight', 'description': 'Comparison of weight changes in week 12 from baseline between the two', 'timeFrame': 'Baseline, week 12'}]",7,18 Years,,ALL,False,Chungbuk National University Hospital,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:12.172916,v2_robust,True,True,False,False,False,
NCT05084248,Vitamin D Deficiency in Adults Following a Major Burn Injury,Vitamin D Deficiency in Adults Following a Major Burn Injury,Ergocalciferol Capsules,"['Ergocalciferol Capsules', 'Vitamin D']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Vitamin D Deficiency,"['Vitamin D Deficiency', 'Burns']",[],RECRUITING,,2022-09-29,2025-12,"[{'measure': 'Patient-Reported Outcomes Measurement Information System-29', 'description': 'Measures change in physical health, mental health and social health between time points.\n\nWhen the scores are transformed into t-score metric, all PROMIS measures range from 0-100. For each domain, the higher scores indicate more of what is being measured. Therefore, higher scores on anxiety indicate more anxiety, while higher scores on physical function indicate higher physical function. Please see more information here: https://www.healthmeasures.net/explore-measurement-systems/promis/intro-to-promis.', 'timeFrame': '6 months and 12 months'}]","[{'measure': 'Demographics', 'description': 'include subject demographics, injury demographics and characteristics', 'timeFrame': '6 months'}, {'measure': 'Patient-Reported Outcomes Measurement Information System-Global', 'description': 'Measures change in emotional, physical, and social health between timepoints.\n\nWhen the scores are transformed into t-score metric, all PROMIS measures range from 0-100. For each domain, the higher scores indicate more of what is being measured. Therefore, higher scores indicates a higher global health.', 'timeFrame': '6 months and 12 months'}, {'measure': 'Patient-Reported Outcomes Measurement Information System-Itch', 'description': 'Measures change in itch between timepoints. When the scores are transformed into t-score metric, all PROMIS measures range from 0-100. For each domain, the higher scores indicate more of what is being measured. Therefore, higher scores indicate more itch.', 'timeFrame': '6 months and 12 months'}]",4,18 Years,,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:12.172933,v2_robust,True,True,False,False,False,
NCT05153148,"A Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Participants With Active Psoriatic Arthritis","A Phase 2b, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy, Safety, and Tolerability of NDI-034858 in Subjects With Active Psoriatic Arthritis",NDI-034858,"['NDI-034858', 'TAK-279']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Psoriatic Arthritis,['Psoriatic Arthritis'],"['Placebo-Controlled', 'Double-blind', 'Multiple-dose study']",COMPLETED,,2022-01-06,2023-06-02,"[{'measure': 'Percentage of Participants Who Achieved at Least an American College of Rheumatology 20 (ACR20) Response at Week 12', 'description': 'ACR20 is composite measure defined as improvement of 20 percent(%) from baseline in both number of tender (68) \\& number of swollen (66) joints \\& a 20% improvement in at least 3 of following 5 criteria: patient global assessment of psoriatic arthritis (PGA-PsA) \\[visual analog scale (VAS) where, 0=very good, no symptoms \\& 100=very poor, severe symptoms\\], physician global assessment of psoriatic arthritis (PhGA-PsA) \\[(VAS) where 0=no disease activity \\& 100=maximum disease activity\\], patient global assessment of psoriatic arthritis pain (PGAAP) \\[(VAS) where 0=no pain \\& 100=most severe pain\\], disability history questionnaire i.e., Health Assessment Questionnaire-Disability Index \\[HAQ-DI\\] (20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip \\& activities, 0=without difficulty to 3=unable to do) \\& acute phase reactant like high sensitivity C-reactive protein \\[hsCRP\\]). Percentages are rounded off to the nearest decimal.', 'timeFrame': 'Week 12'}]","[{'measure': 'Percentage of Participants Who Achieved at Least an ACR-50 Response at Week 12', 'description': ""The ACR-50 is a composite measure defined as improvement of 50% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 50% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \\[(VAS) where 0=no disease activity and 100=maximum disease activity\\], PGAAP \\[(VAS) where 0=no pain \\& 100=most severe pain\\], disability history questionnaire (i.e., HAQ-DI) \\[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\\] and an acute phase reactant \\[i.e., erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP)\\]. Percentages are rounded off to the nearest decimal."", 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Who Achieved at Least an ACR-70 Response at Week 12', 'description': ""The ACR-70 is a composite measure defined as improvement of 70% from baseline in both the number of tender (68) and number of swollen (66) joints, and a 70% improvement in at least three of the following five criteria: PGA-PsA (VAS where, 0 is 'very good, no symptoms' and 100 is 'very poor, severe symptoms'), PhGA-PsA \\[(VAS) where 0=no disease activity and 100=maximum disease activity\\], PGAAP \\[(VAS) where 0=no pain \\& 100=most severe pain\\], disability history questionnaire (i.e., HAQ-DI) \\[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do\\] and an acute phase reactant (i.e., ESR or CRP). Percentages are rounded off to the nearest decimal."", 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Tender Joint Count (TJC) at Week 12', 'description': ""The TJC 68 is a total score of points assigned for the presence of tenderness in the 68 joints in the upper body and upper/lower extremity. The response to tenderness for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all tender joints was derived. The overall tender joint count ranged from 0 to 68, with a higher score indicating a greater degree of tenderness. A negative change from baseline indicates improvement."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Swollen Joint Count (SJC) at Week 12', 'description': ""The SJC 66 (TJC 68 joint assessment minus hip joints, which cannot be assessed for swelling) is a total score of points assigned for presence of swelling in the 66 joints in the upper body and upper/lower extremity. The response to swelling for each joint was evaluated using the following scale: 'Present' was assigned a score of 1 whereas, 'Absent', 'Not Done', 'Not Applicable', or joints with missing response were assigned a score of 0. The sum of all swollen joints was derived. The overall swollen joint count ranged from 0 to 66, with a higher score indicating a greater degree of swelling. A negative change from baseline indicates improvement."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in PGA-PsA at Week 12', 'description': 'Participants assessed their overall disease status based on symptoms of psoriasis and psoriatic arthritis at the time of the visit using the PGA-PsA VAS of 100 millimeters (mm) which ranges from 0 (very good, no symptoms) to 100 (very poor, severe symptoms). A negative change from Baseline indicates improvement in symptoms.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in PGAAP at Week 12', 'description': 'Participants assessed their overall psoriatic arthritis-related pain at the time of the visit using the PGAAP VAS of 100 mm which ranges from 0 (no pain) to 100 (most severe pain). A negative change from Baseline indicates improvement in pain.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in PhGA-PsA at Week 12', 'description': ""The participants' overall disease status was assessed, taking into account signs, symptoms, and function, of all components of joint and skin affected at the time of the visit and this overall status was rated by the investigator using the PhGA-PsA VAS of 100 mm where 0 is 'very good, asymptomatic, and no limitation of normal activities' and 100 is 'very poor, very severe symptoms which are intolerable, and inability to carry out all normal activities'. A negative change from Baseline indicates improvement in symptoms."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in HAQ-DI Total Score at Week 12', 'description': ""The HAQ-DI consists of 20 questions referring to eight domains consisting of dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 (without any difficulty) to 3 (unable to do). The worst score within each domain will be used as the domain score (i.e., if the score for one question is 1 and 2 for the other, then the worst score for the domain is 2). The HAQ-DI total score is calculated by dividing the sum of the domain scores by the number of non-missing domains. The total score indicates the patient's self-assessed level of functional ability and higher scores indicate worse functional ability. The HAQ-DI total score ranges from 0 to 3. A higher score indicates worse function and greater disability. A negative change from Baseline indicates improved function."", 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Dactylitis Count (DC) at Week 12', 'description': 'Tender score (0 = no tenderness, 1 = tender, 2 = tender and wince, 3 = tender and withdraw) is collected for Dactylitis Assessments on the Dactylitis Score Sheet that is used for calculation of total score. DC equals the number of tender fingers and toes (tender score \\>0). For participants with dactylitis status absent for all the fingers and toes, the DC is set as 0. The total score range of DC is from 0 to 60, higher scores indicate greater presence of dactylitis. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in Leeds Enthesitis Index (LEI) at Week 12', 'description': 'Enthesitis is assessed using LEI. The enthesitis examination by LEI evaluates the presence or absence of pain by applying local pressure on 6 anatomical sites: medial femoral condyle (left and right), lateral epicondyle (left and right), and the achilles tendon insertion (left and right). Enthesitis at each site is scored as 0 (enthesitis absent) and 1 (enthesitis present). LEI is derived as the sum of the enthesitis score over the 6 sites, divided by the number of sites with non-missing score. The total score ranges from 0 to 6, higher scores indicate greater degree of enthesitis. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percentage of Participants With Minimal Disease Activity (MDA) Response at Week 12', 'description': 'MDA is a measure to indicate a state of minimal disease activity, and is a composite score of 7 domains. A participant is considered as having achieved the MDA if the participant fulfills at least 5 of the following 7 criteria: TJC 68 ≤1; SJC 66 ≤1; Psoriasis area and severity index (PASI) score ≤1 \\[The total score ranges from 0 (no disease) to 72 (maximal disease)\\] or body surface area (BSA) ≤3%; PGAAP ≤15 \\[using VAS on a scale of 0 (no pain) to 100 (serious pain)\\]; PGA-PsA ≤20 \\[using VAS on a scale of 0 (very well) to 100 (very poor)\\]; HAQ-DI score ≤0.5; LEI score ≤1. Percentages are rounded off to the nearest decimal.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Disease Activity Index for Psoriatic Arthritis (DAPSA) at Week 12', 'description': 'The DAPSA score is a composite score and was calculated using: TJC68, SJC66, PGA-PsA, PGAAP, and hsCRP level (milligram per deciliter \\[mg/dL\\]). DAPSA scores 0-4 = remission, 5-14 = low disease activity, 15-28 = moderate disease activity, and \\>28 = high disease activity. The DAPSA score has a lower bound of 0 and has no upper bound. A higher DAPSA score indicated more active disease activity. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Percentage of Participants Who Achieved PASI-75 Response at Week 12', 'description': 'PASI-75 is assessed in participants with psoriasis involvement for ≥ 3% of the BSA at Baseline and assesses the extent of involvement and severity of psoriasis. To calculate the PASI, the body is divided into 4 regions: the head and neck, trunk, upper limbs, and lower limbs. Each of these areas are assessed separately for the percentage of the area involved and for erythema, induration, and scaling, which are each rated on a scale of 0 to 4, which translates to a numeric score that ranges from 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 (no disease) to 72 (maximal disease). For PASI-75, the improvement threshold from baseline in PASI score is 75%. A higher score indicates more severe disease. Percentages are rounded off to the nearest decimal.', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants Who Achieved a Physician Global Assessment of Psoriasis (PhGA-PsO) of 0 or 1 and at Least a 2-point Improvement at Week 12', 'description': 'PhGA-PsO responder is defined as participants 1) who had PhGA-PsO score of 0 or 1 at any given post-baseline visit; and 2) who had at least 2-point improvement from baseline. The PhGA-PsO is measured using a 0 to 4 scale with a 0 meaning clear or a 4 meaning severe. The proportion of participants achieving PhGA-PsO response at Week 12 was calculated and analyzed for participants with a score of at least 2 at baseline. Percentages are rounded off to the nearest decimal.', 'timeFrame': 'Week 12'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)', 'description': 'Adverse Event(AE)=medical occurrence that does not necessarily have a causal relationship with this drug also including clinically meaningful findings in laboratory safety tests,vital signs,weight,and electrocardiogram(ECG).TEAEs=AEs occurring at time of or post study drug dosing until study end.SAE=any medical occurrence at any dose that resulted in death,was life-threatening,required inpatient hospitalization/prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was a congenital abnormality/birth defect,an important medical event.AESIs included Common Terminology Criteria for Adverse Events(CTCAE)Grade≥2 cytopenia,CTCAE Grade≥3 elevation of creatine phosphokinase(CPK)\\[clinically significant or not\\]defined as CPK\\>5xupper limit of normal(ULN),infections,adverse events of abnormal liver function tests,adverse events of renal dysfunction,major adverse cardiovascular events,thromboembolic events,gastrointestinal perforation,and malignancies.', 'timeFrame': 'From first dose of study drug up to end of study (up to Week 16)'}, {'measure': 'Plasma Concentration of NDI-034858', 'description': 'Plasma concentration of NDI-034858 was measured in participants who received low, medium, or high doses of NDI-034858.', 'timeFrame': 'Pre-dose, 1 hour post-dose on Day 1 and Week 4, 4 hours post-dose at Week 4, Pre-dose at Week 8, and anytime at Week 12'}]",17,18 Years,70 Years,ALL,False,Takeda,INDUSTRY,1,305.0,ACTUAL,2025-09-01T16:18:12.172955,v2_robust,True,True,True,False,True,
NCT01876355,The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients,The Effect of Clonidine-enhanced Sedation on Delirium in Ventilated Critically Ill Patients CATAPRES (Confusion and Alpha-Two Agonist Prescription Randomised Efficacy Study),Clonidine,"['SodiumChloride', 'Clonidine', 'Placebo', 'Catapressan']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Delirium,['Delirium'],"['Delirium, clonidine, ICU, sedation']",UNKNOWN,,2024-01,2025-06,"[{'measure': 'CAM-ICU (Confusion Assessment Method for the Intesive Care Unit)', 'description': 'The total amount of delirium-free periods during 7 days after randomisation and start of the study medication. An observation period is a period of 8 hours, coinciding with one nursing shift. A delirium-free period is a shift in which the delirium score is negative.', 'timeFrame': '7 days'}]","[{'measure': 'Signs of agitation', 'description': 'Signs of agitation (for example self removed catheter).', 'timeFrame': '7 days'}, {'measure': 'Opiate use', 'timeFrame': '7 days'}, {'measure': 'Sedative use', 'timeFrame': '7 days'}, {'measure': 'Anti-psychotic use', 'timeFrame': '7 days'}, {'measure': 'Ventilation free days', 'timeFrame': '7 days'}, {'measure': 'Sedation free days', 'timeFrame': '7 days'}]",7,18 Years,,ALL,False,Deventer Ziekenhuis,OTHER,0,115.0,ESTIMATED,2025-09-01T16:18:12.173207,v2_robust,True,True,False,False,False,
NCT02244255,FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia,"An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia",FLOMAX® capsules,"['FLOMAX® capsules', 'Tamsulosin hydrochloride', 'Ascending doses of HYTRIN® capsules']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Prostatic Hyperplasia,['Prostatic Hyperplasia'],[],COMPLETED,,1998-08,,"[{'measure': 'Changes in American Urological Association (AUA) symptom score index', 'timeFrame': 'Pre-dose, up to day 57 after start of treatment'}]","[{'measure': 'Changes in AUA bother score index', 'description': 'Validated quality of life questionnaire for urinary problems containing:\n\n* AUA obstructive symptom score\n* AUA irritative symptom score\n* AUA nocturia symptom score', 'timeFrame': 'Pre-dose, up to 57days after start of treatment'}, {'measure': 'Changes in BPH impact index score', 'timeFrame': 'Pre-dose, up to 57 days after start of treatment'}, {'measure': 'Global assessment by investigator on a 5-point scale', 'timeFrame': 'Day 5, up to day 57 after start of treatment'}, {'measure': 'Number of patients with clinically relevant changes from baselinein laboratory values', 'timeFrame': 'Pre-dose, day 57 after start of treatment'}, {'measure': 'Number of patients with clinically significant changes in vital signs', 'timeFrame': 'Pre-dose, up to 57 days after start of treatment'}, {'measure': 'Number of patients with clinically relevant changes from baseline in ECG', 'timeFrame': 'Pre-dose, up to 57 days after start of treatment'}, {'measure': 'Number of patients with adverse events', 'timeFrame': 'Up to day 57'}]",8,45 Years,,MALE,False,Boehringer Ingelheim,INDUSTRY,0,1993.0,ACTUAL,2025-09-01T16:18:12.173242,v2_robust,True,True,True,False,True,
NCT00282555,Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis,"Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na (STU-Na) 15 mg, 30 mg, 60 mg, 90 mg and Esomeprazole 40 mg. A Multicenter, Randomized, Double-Blind, Parallel Group Study.",S-Tenatoprazole-Na (STU-Na),['S-Tenatoprazole-Na (STU-Na)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Esophagitis, Reflux","['Esophagitis, Reflux']","['Esophagitis, Reflux', 'S-Tenatoprazole-Na', 'Heartburn', 'Esophageal endoscopy']",SUSPENDED,,2006-02,,"[{'measure': 'Esophageal endoscopy: assessment of achievement of grade ""not present"" in the Los Angeles scale of esophagitis after two weeks of treatment'}]","[{'measure': 'Esophageal endoscopy: assessment of achievement of grade ""not present"" in the Los Angeles scale of esophagitis after four weeks of treatment.'}, {'measure': 'Assessment of complete relief of heartburn'}]",3,18 Years,75 Years,ALL,False,STEBA France,INDUSTRY,0,450.0,,2025-09-01T16:18:12.173313,v2_robust,True,True,False,True,False,
NCT02561455,Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,A Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial,Gilteritinib,"['Gilteritinib', 'ASP2215']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Solid Tumors,"['Advanced Solid Tumors', 'Acute Myeloid Leukemia']","['Advanced solid tumors', 'Acute myeloid leukemia', 'gilteritinib', 'ASP2215']",COMPLETED,,2016-05-03,2020-07-28,"[{'measure': 'Number of Participants With Adverse Events', 'description': 'AE was defined as any untoward medical occurrence in a participant administered a study drug or has undergone study procedures and which did not necessarily have a causal relationship with this treatment. An abnormality identified during a medical test (e.g., laboratory parameter, vital sign, Electrocardiography (ECG) data, and physical exam) was defined as an AE only if the abnormality induces clinical signs or symptoms or requires active intervention or requires interruption or discontinuation of study medication or the abnormality or investigational value is clinically significant in the opinion of the investigator.', 'timeFrame': 'From first dose of study drug up to 30 days after last dose of study drug (median treatment duration was 811.0 days, minimum of 43 days and maximum of 1067 days)'}, {'measure': 'Eastern Cooperative Oncology Group (ECOG) Performance Status at End Of Treattment Visit (EOT)', 'description': 'ECOG performance status was used to assess participants disease progression, and ability to carry out the daily living activities. The participants were graded on a scale of 0 to 5 where 0 = fully active, able to carry on all predisease performance without restriction; 1 = restricted in physically strenuous activity, but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care, but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = capable of only limited self-care,confined to bed or chair more than 50% of waking hours; 4 = completely disabled. Cannot carry on any self-care. Totally confined to bed or chair; 5 = Dead. Number of participants with ECOG performance status was reported.', 'timeFrame': 'EOT Visit (30 days post-last dose, maximum treatement duration of 1067 days)'}]",[],2,18 Years,,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:12.173332,v2_robust,True,True,True,False,True,
NCT04151355,Effect of Atorvastatin on 5-Fluorouracil Induced Mucositis,The Effect of Atorvastatin on The Prevention of 5-fluorouracil-induced Mucositis in Colorectal Cancer Patients,Atorvastatin 20mg,['Atorvastatin 20mg'],1,INTERVENTIONAL,['NA'],,,Colorectal Cancer,['Colorectal Cancer'],[],UNKNOWN,,2019-10-01,2020-09-30,"[{'measure': 'incidence of mucositis', 'description': 'screening the patients seeking mucositis \\& grading mucositis using Common Terminology Criteria for Adverse Events, CTCAE version 5 ( ranging from grade 1 of better outcome to 5 of worst outcome ) and evaluating the effect of atorvastatin on mucositis', 'timeFrame': '6 months'}]","[{'measure': 'grade of mucositis', 'description': 'the grade of mucositis will be assessed using common terminology criteria of adverse effects version 5', 'timeFrame': '6 month'}, {'measure': 'Pain score', 'description': 'the pain due to mucositis will be assessed using visual analogue scale', 'timeFrame': '6 month'}, {'measure': ""Effect of mucositis on patient's daily life"", 'description': ""The Oral Health Impact Proﬁle-14 (OHIP-14) will be used to assess the effect of mucositis on the patients' liferanging from 0 of better outcome to 56 of worst outcome"", 'timeFrame': '6-months'}, {'measure': 'liver function test', 'description': 'serum ALT and AST will be assessed before each cycle', 'timeFrame': '6 months'}, {'measure': 'serum levels of tumor necrosis factor α (TNF-α)', 'description': 'serum tumor necrosis factor α (TNF-α) will be assessed at baseline and after 6 months', 'timeFrame': '6 months'}]",6,18 Years,,ALL,False,Ain Shams University,OTHER,1,100.0,ESTIMATED,2025-09-01T16:18:12.173367,v2_robust,True,True,False,False,True,
NCT00095355,Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease,Stimulation of Tyrosine Kinase and ERK Signaling Pathways in Huntington's Disease,Lithium,"['Lithium', 'Divalproex']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Huntington's Disease,"[""Huntington's Disease""]","['BDNF', 'Lithium', 'Divalproex', 'Huntington Disease', 'HD']",COMPLETED,,2004-10,2005-03,[],[],0,,,ALL,False,National Institute of Neurological Disorders and Stroke (NINDS),NIH,0,35.0,,2025-09-01T16:18:12.173451,v2_robust,True,True,True,False,False,
NCT06581055,A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes,A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes Who Discontinued Treatment With Luspatercept or Epoetin Alfa and the COMMANDS Trial,Luspatercept,"['Epoetin Alfa', 'Luspatercept']",2,OBSERVATIONAL,[],,,Myelodysplastic Syndromes (MDS),['Myelodysplastic Syndromes (MDS)'],['Myelodysplastic syndromes (MDS)'],WITHDRAWN,Sponsor decision,2024-11-30,2025-03-30,"[{'measure': 'Participant treatment patterns: Type of treatment received', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Duration of treatment received', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Dosage of treatment received', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Dosing route of treatment administration', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Reason for treatment administration', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Time to next line of therapy (LoT)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Reason for treatment discontinuation', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Type of concomitant medications received', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant treatment patterns: Start and end dates of concomitant medications received', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Participant clinical outcomes: Number of units of red blood cell transfusions received', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical outcomes: Red blood cell transfusion burden (RBC-TB) category', 'description': 'Category 1: Transfusion dependent (at least 4 units of red blood cell (RBC) with 8 weeks for hemoglobin (Hb) \\<9g/dL) Category 2: Transfusion independence (\\<4 units of RBC with 8 weeks for Hb \\<9 g/dL)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical outcomes: Red blood cell transfusion burden (RBC-TB) category per International Working Group (IWG) 2018', 'description': 'IWG 2028 criteria:\n\n1. Non-transfused (0 Red Blood Cells \\[RBC\\] in 16 weeks)\n2. Low-transfusion burden (3-7 RBCs in 16 weeks in at least 2 transfusion episodes, maximum 3 in 8 weeks)\n3. High-transfusion burden (≥8 RBCs in 16 week, ≥4 in 8 weeks)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical outcomes: Blood test results', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical outcomes: Number of participants that progressed to acute myeloid leukemia (AML) status', 'timeFrame': 'Up to 24 months'}, {'measure': 'Number of participants that progressed to high-risk myelodysplastic syndromes (MDS)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical outcomes: Participant survival status', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical outcomes: Date and primary cause of death', 'timeFrame': 'Up to 24 months'}, {'measure': 'Participant clinical characteristics', 'timeFrame': 'Up to 24 months'}]",18,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:12.173558,v2_robust,False,True,False,True,False,Sponsor decision
NCT02337426,"Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Phase I Trial of Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Glioblastoma Multiforme",Dimethyl Fumarate,"['TMZ', 'Fumaric Acid, Dimethyl Ester', 'Dimethyl Fumarate', 'Temozolomide']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Adult Brain Glioblastoma,"['Adult Brain Glioblastoma', 'Adult Giant Cell Glioblastoma', 'Adult Gliosarcoma']",[],COMPLETED,,2015-02-13,2017-11-09,"[{'measure': 'RP2D for DMF when combined with concurrent temozolomide and radiotherapy determined by the incidence of dose limiting toxicities (DLTs) graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.0', 'description': ""Subjects' treatment dosing level, dose modification, DLTs, and evaluability for DLTs and response will be listed and summarized by basic descriptive statistics (such as frequency and proportion)."", 'timeFrame': 'Up to 6 weeks'}]","[{'measure': 'Incidence of adverse events graded according to NCI CTCAE version 4.0', 'description': ""Subjects' demographics, adverse events, serious adverse events, and treatment status will be listed and summarized by descriptive statistics (such as frequency, proportion, mean, standard deviation, median, and range)."", 'timeFrame': 'Up to 30 days after completion of treatment'}, {'measure': 'Progression free survival (PFS)', 'description': 'The Kaplan-Meier method will be conducted to describe PFS, and median PFS will be estimated, along with 95% confidence intervals. A Cox regression model may be used to model the PFS and adjusting for any effects of potential clinical characteristics.', 'timeFrame': 'Time from registration to time of symptomatic and/or radiographic progression or death, whichever occurs first, assessed up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'The Kaplan-Meier method will be conducted to describe OS, and median OS will be estimated, along with 95% confidence intervals. A Cox regression model may be used to model the OS and adjusting for any effects of potential clinical characteristics.', 'timeFrame': 'Time from registration until death from any cause, assessed up to 2 years'}, {'measure': 'Response rate assessed as per the Response Assessment in Neuro-oncology for magnetic resonance imaging scans or Macdonald criteria for computed tomography scans', 'description': 'The clinical response rate will be calculated for each cohort, along with their corresponding 95% confidence intervals. Logistic regression may be used to model the rate by adjusting potential clinical characteristics (such as age, gender, and tumor grade). Mean and standard deviation of duration of response (overall response, complete response, and stable disease, respectively), along with its 95% confidence interval, will be estimated based on the method proposed by Ellis et al. via the exponential distribution.', 'timeFrame': 'Up to 2 years'}]",5,18 Years,,ALL,False,Virginia Commonwealth University,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:12.173641,v2_robust,True,True,True,False,True,
NCT05552326,A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia,"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia",Olezarsen,"['ISIS 678354', 'AKCEA-APOCIII-LRx', 'Olezarsen', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Severe Hypertriglyceridemia,['Severe Hypertriglyceridemia'],"['Hypertriglyceridemia', 'Hyperlipidemias', 'Metabolic Diseases']",ACTIVE_NOT_RECRUITING,,2022-08-31,2025-09,"[{'measure': 'Percent Change from Baseline in Fasting TG Compared to Placebo', 'timeFrame': 'Baseline and Month 6'}]","[{'measure': 'Percent Change from Baseline in Fasting TG Compared to Placebo', 'timeFrame': 'Baseline and Month 12'}, {'measure': 'Percent Change from Baseline in Fasting Apolipoprotein C-III (ApoC-III), Remnant Cholesterol and Fasting Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C) Compared to Placebo', 'timeFrame': 'Baseline, Month 6 and 12'}, {'measure': 'Proportion of Patients Who Achieve Fasting TG <500 mg/dL (5.65 mmol/L) Compared to Placebo', 'timeFrame': 'Month 12'}, {'measure': 'Proportion of Participants Who Achieve Fasting TG < 880 mg/dL (10 mmol/L) Compared to Placebo in the Subgroup of Participants with Baseline TG ≥ 880 mg/dL', 'timeFrame': 'Month 12'}, {'measure': 'Adjudicated Acute Pancreatitis Event Rate During the Treatment Period Compared to Placebo', 'timeFrame': 'Week 1 through Week 53'}, {'measure': 'Absolute Change in Hepatic Fat Fraction (HFF) Between Olezarsen Treatment Group and Pooled Placebo', 'timeFrame': 'Baseline through Month 12'}]",7,18 Years,,ALL,False,"Ionis Pharmaceuticals, Inc.",INDUSTRY,0,446.0,ACTUAL,2025-09-01T16:18:12.173679,v2_robust,True,True,False,False,False,
NCT06841926,Study to Evaluate the Pharmacokinetics and Relative Bioavailability of Metabolites in Healthy Chinese Adult Males,A Study to Evaluate the Pharmacokinetics of ZX-7101A for Suspension Versus Tablets in a Single Oral Administration Under Fasting Conditions in Healthy Chinese Adult Male Subjects,ZX-7101A dry suspension,['ZX-7101A dry suspension'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Respiratory Viral Infection,['Respiratory Viral Infection'],[],COMPLETED,,2025-02-20,2025-04-18,"[{'measure': 'The pharmacokinetic parameters Cmax of the active metabolite ZX-7101 (parent drug)', 'description': 'Pharmacokinetic parameters Cmax of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets', 'timeFrame': 'From Day1 up to Day 36'}, {'measure': 'The pharmacokinetic parameters AUC0-t of the active metabolite ZX-7101 (parent drug)', 'description': 'Pharmacokinetic parameters AUC0-t of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets', 'timeFrame': 'From Day1 up to Day 36'}, {'measure': 'The pharmacokinetic parameters AUC0-inf of the active metabolite ZX-7101 (parent drug)', 'description': 'Pharmacokinetic parameters AUC0-inf of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets', 'timeFrame': 'From Day1 up to Day 36'}, {'measure': 'Relative bioavailability of the active metabolite ZX-7101 (parent drug)', 'description': 'Relative bioavailability of the active metabolite ZX-7101 (parent drug) in plasma after administration of ZX-7101A dry suspension /ZX-7101A tablets.', 'timeFrame': 'From Day1 up to Day 36'}]","[{'measure': 'Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v5.0', 'description': 'To evaluate the safety and tolerability of a single oral administration of ZX-7101A dry suspension (40 mg/tablet) in healthy Chinese adult male subjects', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'Cmax', 'description': 'To evaluate the pharmacokinetic: Cmax of ZX-7101A (prodrug) after a single oral administration of ZX-7101A dry suspension 40 mg and ZX-7101A tablets 40 mg in healthy Chinese adult male subjects', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'AUC0-t', 'description': 'To evaluate the pharmacokinetic: AUC0-t of ZX-7101A (prodrug) after a single oral administration of ZX-7101A dry suspension 40 mg and ZX-7101A tablets 40 mg in healthy Chinese adult male subjects', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'AUC0-inf', 'description': 'To evaluate the pharmacokinetic:AUC0-inf of ZX-7101A (prodrug) after a single oral administration of ZX-7101A dry suspension 40 mg and ZX-7101A tablets 40 mg in healthy Chinese adult male subjects', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'Evaluation of palatability', 'description': 'The proportion of all subjects who received ZX-7101A dry suspension with a score ≥50 (including not good not bad, good, very good)', 'timeFrame': 'On Day 1'}, {'measure': 'Tmax', 'description': 'PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : Tmax', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'Vz/F', 'description': 'PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : Vz/F', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'CL/F', 'description': 'PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : CL/F', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 't1/2', 'description': 'PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : t1/2', 'timeFrame': 'From Day 1 up to Day 36'}, {'measure': 'λz', 'description': 'PK parameters of prodrug ZX-7101A and its active metabolite ZX-7101 (parent drug) : λz', 'timeFrame': 'From Day 1 up to Day 36'}]",14,18 Years,45 Years,MALE,True,Nanjing Zenshine Pharmaceuticals,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:12.173722,v2_robust,True,True,True,False,True,
NCT00921726,Pharmacokinetic Study of Oseltamivir and Intravenous Zanamivir in Healthy Adults,"Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interactions Between Orally-Administered Oseltamivir and Intravenous Zanamivir in Healthy Thai Adult Subjects",Zanamivir,"['Oseltamivir', 'Zanamivir', 'Tamiflu', 'Relenza']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Influenza,"['Influenza', 'Virus Diseases']",['Drug Interaction'],COMPLETED,,2009-07,2009-10,"[{'measure': 'Oseltamivir carboxylate Cmax and AUC (0-12)', 'timeFrame': 'Throughout study'}]","[{'measure': 'Zanamivir Cmax and AUC (0-12) for continuous infusion and Zanamivir Cmax, AUC (-12), and C12 for intermittent infusions', 'timeFrame': 'Throughout study'}, {'measure': 'Oseltamivir Cmax, AUC (0-12), and C12', 'timeFrame': 'Throughout study'}, {'measure': 'Oseltamivir carboxylate AUC (0-24), C12, delta-z, and t(1/2)', 'timeFrame': 'Throughout study'}]",4,18 Years,60 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,17.0,ACTUAL,2025-09-01T16:18:12.173812,v2_robust,True,True,True,False,False,
NCT05088226,Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen,Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen for Patients With Acute B Cell Lymphoblast Leukemia Underwenting Haploidenticl Peripheral Blood Stem Cell Transplantation,Ruxolitinib combined with Chidamide.,"['Modified By/Cy conditioning regimen intensified by Ruxolitinib and Chidamide', 'Ruxolitinib combined with Chidamide.']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Peripheral Blood Stem Cell Transplantation,['Peripheral Blood Stem Cell Transplantation'],[],UNKNOWN,,2021-12-01,2023-06-01,"[{'measure': 'Proportion of participants relapse as assessed by NCCN (National Comprehensive Cancer Network ) criteria', 'description': 'Defined as the proportion of participants whose underlying malignancy relapsed.', 'timeFrame': '365 days after transplantation'}]","[{'measure': 'DFS(disease-free survival )', 'description': 'DFS was defined as survival with no evidence of relapse or progression.', 'timeFrame': '365 days after transplantation'}, {'measure': 'TRM(treatment-related mortality )', 'description': 'Defined as the proportion of subjects who died due to causes other than malignancy relapse.', 'timeFrame': '365 days after transplantation'}, {'measure': 'Proportion of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria)', 'description': 'Defined as the proportion of participants who developed acute GVHD.', 'timeFrame': '365 days after transplantation'}, {'measure': 'Proportion of participants with cGVHD as assessed by chronic graft versus host disease grading criteria (refer to NIH criteria)', 'description': 'Defined as the proportion of participants who developed chronic GVHD.', 'timeFrame': '365 days after transplantation'}, {'measure': 'OS(overall survival )', 'description': 'OS was defined as the time from transplantation to death due to any cause.', 'timeFrame': '365 days after transplantation'}, {'measure': 'Failure-free survival (FFS)', 'description': 'Defined as the time from tranplantation to the earliest date that a participant died, had a relapse/progression of the underlying malignancy, required additional therapy for aGVHD, or demonstrated signs or symptoms of chronic graft-versus-host disease (cGVHD).', 'timeFrame': '365 days after transplantation'}, {'measure': 'infection rate', 'description': 'Defined as the proportion of participants who developed all kinds of infection.', 'timeFrame': '365 days after transplantation'}]",8,12 Years,65 Years,ALL,False,Chinese PLA General Hospital,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:12.173823,v2_robust,True,True,False,False,False,
NCT01965626,A Multicenter Randomized Open-label Study of Oseltamivir Combined With HD-DEX Versus HD-DEX in the Management of ITP,A Multicenter Randomized Open-label Study of Oseltamivir Combined With High-dose Dexamethasone Versus High-dose Dexamethasone in the Management of Immune Thrombocytopenia,Oseltamivir,"['Oseltamivir', 'Dexamethasone']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Thrombocytopenia,['Thrombocytopenia'],"['Oseltamivir', 'Dexamethasone', 'ITP']",COMPLETED,,2016-02-01,2019-05,"[{'measure': 'initial response and sustained response (SR)', 'description': 'CR: platelet count ≥ 100 × 109/L and absence of bleeding; R: platelet count ≥ 30 × 109/L but \\< 100 × 109/L and a doubling from baseline and absence of bleeding.', 'timeFrame': 'Initial responses were assessed by day 14. Response lasting for at least 6 consecutive months without additional ITP-specific intervention was regarded as SR.'}]",[],1,18 Years,70 Years,ALL,False,Shandong University,OTHER,0,96.0,ACTUAL,2025-09-01T16:18:12.173872,v2_robust,True,True,True,False,False,
NCT02927626,Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma,Clinical Research of Yang Yin Fu Zheng Therapy in HBV Associated Hepatocellular Carcinoma Basing on Immune Microenviroment,Yang Yin Fu Zheng therapy,"['Yang Yin Fu Zheng therapy', 'Routine medical care']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],COMPLETED,,2016-08,2018-12,"[{'measure': 'Survival rate', 'timeFrame': '2 years'}]","[{'measure': 'Objective response rate', 'timeFrame': '2 years'}, {'measure': 'quality of life(QOL)', 'timeFrame': '2 years'}]",3,18 Years,75 Years,ALL,False,Beijing Ditan Hospital,OTHER,0,132.0,ACTUAL,2025-09-01T16:18:12.173906,v2_robust,True,True,True,False,False,
NCT01352026,Evaluation of Metformin Activity in Addition to Conventional Treatment of Grade II or III Pulmonary Arterial Hypertension (PAH),,Metformin,['Metformin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Pulmonary Arterial Hypertension,['Pulmonary Arterial Hypertension'],[],WITHDRAWN,Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials,2011-05,,[{'measure': 'The primary objective of this study will be to demonstrate the improvement of walk test distance in patients with pulmonary arterial hypertension (PAH) treated by metformin.'}],[],1,18 Years,80 Years,ALL,False,Nantes University Hospital,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.173928,v2_robust,True,True,False,True,False,Several therapeutic have been developed making more difficult the eligibility of patients - Recruitment of new centers wasn't possible due to competing trials
NCT02160626,Dose-Response Profile of A-101 in Subjects With Seborrheic Keratosis,"A Randomized, Double-Blind, Vehicle Controlled, Parallel Group Study of the Dose-Response Profile of A-101 Topical Solution in Subjects With Seborrheic Keratosis.",A-101 Vehicle,"['A-101 Vehicle', 'A-101 (32.5) Topical Solution', 'A-101 (40) Topical Solution']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Seborrheic Keratosis,['Seborrheic Keratosis'],"['Seborrheic keratosis', 'A101']",COMPLETED,,2014-06,2014-12,"[{'measure': ""Mean Per Subject Percentage Target Lesions Judged Clear by the Physician's Lesion Assessment (PLA)"", 'description': 'Mean of per-subject percentages of target lesions judged to be clear on the PLA (PLA = 0) at end of study (Visit 8). The PLA is a four point scale from 0 being clear to 3 being most severe lesion.', 'timeFrame': 'Baseline, visit 8'}]","[{'measure': ""Mean Change From Baseline to Visit 8 in the Physician's Lesion Assessment"", 'description': 'Change from baseline PLA will be calculated for each lesion first, then per-subject mean changes from baseline will be calculated.\n\nThe PLA is a score on a four scale from 0 to 3 with 0 being clear and 3 being the most severe, a lower score indicating a better result. For the mean change in this score, a larger mean change is a better result.', 'timeFrame': 'Baseline, visit 8'}, {'measure': 'Proportion of Subjects Who Had at Least 3 of 4 Target Lesions Judged to be Clear on the Physician Lesion Assessment (PLA =0) at Visit 8.', 'description': 'Proportion of Subjects who had at least 3 of 4 target lesions judged to be clear on the Physician Lesion Assessment (PLA =0) at visit 8. The PLA is a 4 point scale evaluating the severity of a lesion with 0 being clear and 3 being the most severe.', 'timeFrame': 'Baseline, visit 8'}]",3,18 Years,,ALL,False,"Aclaris Therapeutics, Inc.",INDUSTRY,0,172.0,ACTUAL,2025-09-01T16:18:12.173952,v2_robust,True,True,True,False,False,
NCT01366326,Evaluate the Pharmacokinetics (PK) of Methylnaltrexone (MNTX) in Healthy Adult Subjects,"A Multiple-Dose, Open-Label Study to Evaluate the Pharmacokinetics of MNTX in Healthy Adult Subjects",Methylnaltrexone bromide,['Methylnaltrexone bromide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Subjects,['Healthy Adult Subjects'],[],COMPLETED,,2010-07,2010-08,"[{'measure': 'Peak Plasma Concentration (Cmax) of MNTX and its Metabolites', 'description': 'To evaluate the PK profile of MNTX and its metabolites when administered as a SC injection once daily for seven days in healthy adult subjects.', 'timeFrame': '7 days'}]","[{'measure': 'Peak Time of Maximum Concentration (Tmax) of MNTX and its Metabolites', 'description': 'To evaluate the PK profile of MNTX and its metabolites when administered as a SC injection once daily for seven days in healthy adult subjects.', 'timeFrame': '7 Days'}, {'measure': 'Area Under the Plasma Concentration versus Time Curve (AUC) of MNTX and its Metabolites.', 'description': 'To evaluate the PK profile of MNTX and its metabolites when administered as a SC injection once daily for seven days in healthy adult subjects.', 'timeFrame': '7 Days'}]",3,18 Years,50 Years,ALL,True,"Bausch Health Americas, Inc.",INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:12.174044,v2_robust,True,True,True,False,False,
NCT00533026,Duloxetine - Warfarin Pharmacodynamic Study,Evaluation of the Effect of Duloxetine on the Pharmacodynamics of Warfarin at Steady-State in Healthy Subjects,Duloxetine,"['Warfarin', 'LY248686', 'Cymbalta', 'Duloxetine']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Anticoagulant Effect of Warfarin When Taken With Duloxetine.,['Anticoagulant Effect of Warfarin When Taken With Duloxetine.'],[],COMPLETED,,2007-07,2007-10,"[{'measure': 'International Normalized Ratio (INR)', 'timeFrame': '58 days'}]","[{'measure': 'Effect of duloxetine on pharmacokinetics of warfarin.', 'timeFrame': '58 days'}, {'measure': 'Safety/ tolerability of duloxetine and warfarin given in combination.', 'timeFrame': '58 days'}, {'measure': 'Bleeding times when duloxetine and warfarin are given in combination.', 'timeFrame': '58 days'}]",4,18 Years,64 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:12.174056,v2_robust,True,True,True,False,True,
NCT03044626,Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC,Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC,Radiotherapy,"['Nivolumab', 'Radiotherapy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Carcinoma，Non-Small-Cell Lung,"['Carcinoma，Non-Small-Cell Lung', 'Metastatic Lung Cancer', 'Nonsmall Cell Lung Cancer', 'Lung Adenocarcinoma Metastatic', 'Large Cell Lung Carcinoma Metastatic']","['Nivolumab', 'Radiotherapy']",COMPLETED,,2017-02-10,2020-12-31,"[{'measure': 'objective response rate (ORR) according to RECIST 1.1 criteria', 'timeFrame': 'through study completion, an average of 18 months'}]","[{'measure': 'progression free survival (PFS)', 'timeFrame': 'approx. 6 months'}, {'measure': 'PFS using assessment according to irRECIST', 'description': 'Immune-related Response Evaluation Criteria In Solid Tumors (irRECIST)', 'timeFrame': 'approx. 6 months'}, {'measure': 'ORR using assessment according to irRECIST', 'description': 'Immune-related Response Evaluation Criteria In Solid Tumors (irRECIST)', 'timeFrame': 'approx. 6 months'}, {'measure': 'Overall Survival (OS)', 'timeFrame': 'approx. 57 months'}, {'measure': 'Adverse Events', 'description': 'Adverse Events: Type, incidence, and severity according to NCI CTCAE version 4.03', 'timeFrame': 'approx. 36 months'}, {'measure': 'Assesment of Quality of life', 'description': 'as determined with FACT-L (Functional Assessment of Cancer Therapy - Lung)', 'timeFrame': 'approx. 57 months'}]",7,18 Years,,ALL,False,AIO-Studien-gGmbH,OTHER,1,101.0,ACTUAL,2025-09-01T16:18:12.174070,v2_robust,True,True,True,False,True,
NCT05886478,A Study in Adults With Cutaneous T-cell Lymphoma (CTCL) Retreated With Brentuximab Vedotin,Real-World Evidence Study on Brentuximab Vedotin Retreatment Outcomes of Cutaneous T-cell Lymphoma Patients,No intervention,['No intervention'],1,OBSERVATIONAL,[],,,T-Cell Lymphoma,['T-Cell Lymphoma'],['Drug Therapy'],COMPLETED,,2024-02-08,2024-10-31,"[{'measure': 'Objective Response Rate (ORR) After First BV Administration', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'ORR After Re-Treatment', 'timeFrame': 'Up to approximately 12 months after BV retreatment'}, {'measure': 'Progression Free Survival (PFS) After First BV Administration', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'PFS After BV Re-Treatment', 'timeFrame': 'Up to approximately 24 months after BV retreatment'}, {'measure': 'Time to Next Treatment (TTNT) After First BV Administration (Regardless of Type of Next Treatment, i.e., BV or non-BV)', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'TTNT After BV Re-Treatment', 'timeFrame': 'Up to approximately 24 months after BV retreatment'}, {'measure': 'Number of Participant With Grading of Motor Neuropathy During First BV Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Time to Improvement of Motor Neuropathy During/ Post First BV Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to Resolution of Motor Neuropathy During/ Post First BV Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of Participants With Grading of Motor Neuropathy During BV Re-Treatment', 'timeFrame': 'Up to approximately 12 months after BV retreatment'}, {'measure': 'Time to Improvement of Motor Neuropathy During/ Post BV Re-Treatment', 'timeFrame': 'Up to approximately 16 months'}, {'measure': 'Time to Resolution of Motor Neuropathy During/ Post BV Re-Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of Participants With Grading of Sensory Neuropathy During First BV Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Time to Improvement of Sensory Neuropathy During/ Post First BV Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to Resolution of Sensory Neuropathy During/ Post First BV Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of Participants With Grading of Sensory Neuropathy During BV Re-Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Time to Improvement of Sensory Neuropathy During/ Post BV Re-Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to Resolution of Sensory Neuropathy During/ Post BV Re-Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of Participants With Grading of Neutropenia During First BV Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Number of Participants With Grading of Neutropenia During BV Re-Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Number of Participants With Grading of Febrile Neutropenia During First BV Treatment', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Number of Participants With Grading of Febrile Neutropenia During BV Re-Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Number of Participants With Grading of Serious Infections During First BV Treatment', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Number of Participants With Grading of Serious Infections During BV Re-Treatment', 'timeFrame': 'Up to approximately 12 months'}]","[{'measure': 'Number of Participants With Cutaneous Lymphoma Co-Medications or Strategies Used to Treat CTCL Disease', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Amount of BV Dose', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Number of Cycles of BV Administered', 'timeFrame': 'Up to approximately 12 months'}, {'measure': 'Time Interval Between BV Administration', 'timeFrame': 'Up to approximately 24 months'}]",28,18 Years,,ALL,False,Takeda,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:12.174110,v2_robust,False,True,True,False,False,
NCT05439278,Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma,Randomized Phase III Study of Conventional Versus Hypofractionated Radiotherapy Combined With Temozolomide in Elderly Glioblastoma Patients,Temozolomide,['Temozolomide'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Glioblastoma,['Glioblastoma'],[],RECRUITING,,2025-02-01,2030-12-31,"[{'measure': 'Overall survival', 'description': 'from randomization', 'timeFrame': 'follow-up until 2 years'}]","[{'measure': 'progression-free survival', 'description': 'from randomization', 'timeFrame': 'follow-up until 2 years'}, {'measure': 'treatment-related toxicity', 'description': 'any treatment-related toxicity', 'timeFrame': 'follow-up until 2 years'}, {'measure': 'patient-reported quality of life', 'description': 'European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 version 3.0): range, 0-100 (a high score for a functional scale represents a high / healthy level of functioning; a high score for the global health status / QoL represents a high QoL; a high score for a symptom scale / item represents a high level of symptomatology / problems) Quality of Life Questionnaire-Brain Neoplasm (EORTC QLQ-BN20): range, 20-80; lower score means better outcome', 'timeFrame': 'follow-up until 2 years'}]",4,70 Years,,ALL,False,Severance Hospital,OTHER,0,178.0,ESTIMATED,2025-09-01T16:18:12.174314,v2_robust,True,True,False,False,False,
NCT01361178,Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement,Immunoglobulin Levels and Occurrence of Infections After Lung Transplantation and Impact of IgG Replacement - Observational Arm,SQ IVIG,['SQ IVIG'],1,INTERVENTIONAL,['NA'],,,Infections After Lung Transplant,['Infections After Lung Transplant'],[],COMPLETED,,2011-01,2016-01,"[{'measure': 'The Primary Outcome Will be the Total Number of Days With Pneumonia.', 'description': 'The primary outcome for this study will be the total number of days with pneumonia. Pneumonia will be defined by the presence of both clinical and radiographic criteria: fever (temperature ≥ 38oC), cough, dyspnea, purulent expectoration and/or changes in the previous characteristics of respiratory secretions; and chest X-ray or CT scan revealing a new or progressive alveolar or interstitial infiltrate or cavitation that could not be explained by any other noninfectious cause.', 'timeFrame': 'Up to two years post-transplant'}]",[],1,18 Years,,ALL,False,University of Pittsburgh,OTHER,1,133.0,ACTUAL,2025-09-01T16:18:12.174353,v2_robust,True,True,True,False,False,
NCT01844778,Ease of Use and Microbial Contamination of Tobramycin Inhalation Powder (TIP) Versus Nebulised Tobramycin Inhalation Solution (TIS) and Nebulised Colistimethate (COLI),"An Open-label, Crossover, Interventional Phase IV Study to Compare the Ease of Use of TIP With Nebulized TIS and Nebulized COLI for the Treatment of Pulmonary Pseudomonas Aeruginosa (P.a) in Patients With Cystic Fibrosis",Tobramycin Inhalation Powder,"['Tobramycin inhalation solution', 'TIP', 'COLI', 'TIS', 'Colistimethate', 'Tobramycin Inhalation Powder']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Cystic Fibrosis,['Cystic Fibrosis'],"['Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI,', 'colistimethate', 'Cystic Fibrosis, Pseudomonas aeruginosa, FEV1, tobramycin inhalation powder, TOBI, colistimethate']",COMPLETED,,2013-08,2015-10,"[{'measure': 'Mean Total Administration Time', 'description': 'The mean total time for administration of TIP via T-326 inhaler versus the total time for administration of COLI or TIS was assessed from information entered by participants into an ediary during the last 7 days prior to the last dose of a cycle. The total time included the setup, preparation, administration and cleaning/disinfection time.', 'timeFrame': 'days 22 through 28 (cycle 1), days 78 through 84 (cycle 2)'}]","[{'measure': 'Change in P. Aeruginosa Sputum Density', 'description': 'Sputum samples were sent to a central laboratory at the start and end of 2 treatment periods. The absolute change in the number of colony forming units (CFU) of Pseudomonas aeruginosa in sputum = the value of end of on/off treatment period of the cycle minus the pre-dose value at the start of that cycle. A negative change from baseline indicates improvement.', 'timeFrame': 'days 1, 28 (cycle 1); 57, 84, 112 (cycle 2)'}, {'measure': 'Number of Participants With Any Contaminated Delivery Device', 'description': 'Devices used to administer the drugs (the T-326 inhaler and nebulisers) were swabbed for contamination testing at the start and end of each treatment cycle (or discontinuation visit if the participant withdrew). No assessments were required from the T-326 inhaler when participants started the treatment period (days 1 and 57). Microbial contamination was measured according to device type and the frequency of organism growth (light/ moderate/ heavy). All nebulisers (neb) used by the participants were analyzed, including those for inhaling other medications, like mucolytics.', 'timeFrame': 'days (d) 1, 28, 57, 84'}, {'measure': 'Minimum Inhibitory Concentration (MIC) - MIC50 and MIC90 Tobramycin Values', 'description': 'MIC50/90 is the lowest concentration required to inhibit 50%/90% of the isolates tested. The MIC50/90 of a range of antibiotics for P.aeruginosa was determined at the start and end of each treatment cycle, and at the end of the off-treatment period of the second cycle.', 'timeFrame': 'days 1, 28, 57, 84, 112'}, {'measure': 'Number of Participants With Post-inhalation Bronchospasm', 'description': 'Bronchospasm was defined as the relative decrease of 20% or more in forced expiratory volume in 1 second (FEV1) percent predicted from pre-dose to 15 to 45 minutes post-dose.', 'timeFrame': 'days 1, 28, 57, 84'}]",5,6 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:12.174452,v2_robust,True,True,True,False,False,
NCT04976478,Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma,"A Perspective, Multi-center, Single Arm Study of Nimotuzumab Combined With IMRT in Elder Patients With Cervical Squamous Cell Carcinoma",Nimotuzumab,['Nimotuzumab'],1,OBSERVATIONAL,[],,,Cervical Squamous Cell Carcinoma,['Cervical Squamous Cell Carcinoma'],[],NOT_YET_RECRUITING,,2021-07,2026-12,"[{'measure': '3-year disease-free survival(DFS)', 'description': 'The rate of patient without disease in 3 years after treatment', 'timeFrame': 'up to 3 years'}]","[{'measure': 'Complete response rate(CRR)', 'description': 'The percentage of subjects who achieve complete response by imaging assessment from the end of the treatment to disease progression', 'timeFrame': '3 months later after treatment'}, {'measure': 'Objective response rate(ORR)', 'description': 'The percentage of patients who experienced complete or partial cancer shrinkage or disappearance after treatment', 'timeFrame': '3 months later treatment'}, {'measure': '3-year overall survival(OS)', 'description': 'The rate of patient alive in 3 years after treatment', 'timeFrame': 'up to 3 years'}, {'measure': 'The change of tumor related markers', 'description': 'the correlation of the value of SCC，Cyfra 21-1 and therapeutic effect \\[The changes of serum tumor markers (such as SCC-Ag and CYFRA21-1) were observed before and after treatment\\]', 'timeFrame': 'up to 3 years'}, {'measure': 'The change of cervical tumor', 'description': 'the change of the volume of the cervical tumor at diagnosis and before brachytherapy', 'timeFrame': 'At diagnosis and before brachytherapy'}, {'measure': 'QUALITY OF LIFE(QoL)', 'description': 'Quality of life assessed by EORTC QLQ-CX 24 \\[EORTC QLQ-CX 24 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 24 items\\]', 'timeFrame': 'up to 3 years'}, {'measure': 'SAFETY', 'description': 'Including severity of adverse events, the incidence of adverse events and serious adverse events. Adverse events should be reported and graded according to CTCAE version 5.0', 'timeFrame': 'up to 3 years'}]",8,65 Years,,FEMALE,False,Peking University Third Hospital,OTHER,0,125.0,ESTIMATED,2025-09-01T16:18:12.174478,v2_robust,False,True,False,False,True,
NCT02786485,Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT,A Phase I Study of Matched Unrelated Donor BPX-501 T Cell Infusion for Adults With Recurrent or Minimal Residual Disease Hematologic Malignancies Post-Allogeneic Transplant,Rimiducid,"['AP1903', 'Rimiducid']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Leukemia,"['Leukemia', 'Myelodysplastic Syndromes', 'Lymphomas', 'Multiple Myeloma', 'Other High-risk Hematological Malignancies']","['BPX-501', 'Rimiducid', 'AP1903', 'Hematological malignancies', 'Hematologic diseases', 'Leukemias and Myelodysplastic Syndromes', 'Lymphomas', 'Multiple myeloma']",WITHDRAWN,,2016-05,2018-12,"[{'measure': 'Adverse events', 'description': 'Number of adverse events after study drug (BPX-501 and/or rimiducid) administration as a measure of safety', 'timeFrame': '30 days after last dose of study drug (BPX-501 and/or rimiducid)'}]",[],1,18 Years,65 Years,ALL,False,Bellicum Pharmaceuticals,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:12.174578,v2_robust,True,True,False,True,True,
NCT05088785,Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer,Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer,FES,['FES'],1,INTERVENTIONAL,['NA'],,,Breast Cancer,['Breast Cancer'],[],RECRUITING,,2021-10-11,2025-04,"[{'measure': 'FES uptake in lesions: Ki (net influx rate) or VT (volume of distribution) values', 'description': 'FES uptake in lesions will be expressed as Ki or VT values', 'timeFrame': '1 year'}]","[{'measure': 'SUV and TBR values', 'description': 'Quantification of FES uptake in lesions will be assessed by determining standardized uptake values and tumor-to-blood ratios.', 'timeFrame': '1 year.'}]",2,18 Years,,FEMALE,False,"Amsterdam UMC, location VUmc",OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:12.174675,v2_robust,True,True,False,False,False,
NCT01001585,Anesthetic Effects in Mitochondrial Disease,Anesthetic Effects in Mitochondrial Disease,sevoflurane,['sevoflurane'],1,INTERVENTIONAL,['NA'],,,Mitochondrial Disease,['Mitochondrial Disease'],"['mitochondrial disease', 'sevoflurane', 'mitochondrial disease and sevoflurane sensitivity']",TERMINATED,"However, no intervention reduced the risk of major morbidity or 1 yr mortality",2006-09,2011-10,"[{'measure': 'Measure cardiovascular stability and electrical brain activity during slow induction with sevoflurane.', 'description': 'The investigators plan to monitor patients with mitochondrial disease using expanded measures of cardiovascular stability and measurements of brain electrical activity while slowly inducing general anesthesia. The investigators will use those measurements to limit the amount of anesthetic these patients receive in an attempt to minimize their risk.', 'timeFrame': 'during induction'}]","[{'measure': 'Use cardiovascular and electrical brain measurements to limit amount of sevoflurane and predict individual sensitivity.', 'description': 'In addition, the investigators will correlate their sensitivity to the type of mitochondrial defect so that it may be possible to predict which patients are likely to have an increased sensitivity.', 'timeFrame': 'during induction'}]",2,12 Months,16 Years,ALL,False,d sessler,OTHER,0,55.0,ACTUAL,2025-09-01T16:18:12.174741,v2_robust,True,True,False,True,False,"However, no intervention reduced the risk of major morbidity or 1 yr mortality"
NCT00523185,A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal,A Comparison of Lorazepam and Diazepam in the Treatment of Alcohol Withdrawal,Lorazepam,"['Diazepam', 'Ativan', 'Valium', 'Lorazepam']",4,INTERVENTIONAL,['NA'],,,Alcohol Withdrawal,['Alcohol Withdrawal'],"['alcohol withdrawal', 'lorazepam', 'diazepam']",COMPLETED,,2003-05,2004-11,"[{'measure': 'The primary outcome measures include serial measures of vital signs and scores on the Clinical Institute Withdrawal Assessment for Alcohol-Revised scale (CIWA-Ar), a widely used scale that monitors alcohol withdrawal symptoms.', 'timeFrame': 'one to two weeks'}]","[{'measure': 'Secondary outcome measures include total benzodiazepine use.', 'timeFrame': 'one to two weeks'}]",2,19 Years,,ALL,False,Stanford University,OTHER,0,55.0,ACTUAL,2025-09-01T16:18:12.174792,v2_robust,True,True,True,False,False,
NCT03753685,X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases,"Efficacy and Safety of X-396(Ensartinib) in ALK-Positive NSCLC Patients With Brain Metastases: A Phase Ⅱ, Open-Label, Single Arm, Multicenter Study",X-396(Ensartinib) Capsule,['X-396(Ensartinib) Capsule'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Nonsmall Cell Lung Cancer,"['Nonsmall Cell Lung Cancer', 'Brain Metastases']","['NSCLC', 'Brain metastases', 'ALK mutations', 'X-396 (Ensartinib)']",ACTIVE_NOT_RECRUITING,,2019-04-12,2026-06-30,"[{'measure': 'Intracranial objective response rate (iORR) based on investigator assessment according to RNAO-BM.', 'description': 'iORR per RANO-BM calculated as the proportion of patients with a best intracranial overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.', 'timeFrame': '12 weeks'}]","[{'measure': 'Disease control rate based on intracranial response (iDCR) according to RANO-BM.', 'description': 'Defined as the percentage of patients who have achieved intracranial overall response of CR, PR and stable disease (SD), assessed by investigator.', 'timeFrame': '12 weeks'}, {'measure': 'Progression-free survival based on intracranial response (iPFS) according to RANO-BM', 'description': 'Defined as time from first dose of X-396 capsule to intracranial disease progression or death due to any causes, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Time to progression based on intracranial response (iTTP) according to RANO-BM.', 'description': 'Defined as time from first dose of X-396 capsule to intracranial disease progression, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Duration of response based on intracranial response (iDOR) according to RANO-BM.', 'description': 'Defined as time from documentation of intracranial response (CR or PR) to intracranial disease progression or death, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Intracranial objective response rate (iORR) based on intracranial response according to RECIST 1.1', 'description': 'iORR per RECIST 1.1 calculated as the proportion of patients with a best intracranial overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.', 'timeFrame': '12 weeks'}, {'measure': 'Disease control rate based on intracranial response (iDCR) according to RECIST 1.1', 'description': 'Defined as the percentage of patients who have achieved intracranial overall response of CR, PR and stable disease (SD), assessed by investigator.', 'timeFrame': '12 weeks'}, {'measure': 'Progression-free survival based on intracranial response (iPFS) according to RECIST 1.1', 'description': 'Defined as time from first dose of X-396 capsule to intracranial disease progression or death due to any causes, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Time to progression based on intracranial response (iTTP) according to RECIST 1.1', 'description': 'Defined as time from first dose of X-396 capsule to intracranial disease progression, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Duration of response based on intracranial response (iDOR) according to RECIST 1.1', 'description': 'Defined as time from documentation of intracranial response (CR or PR) to intracranial disease progression or death, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Objective response rate (ORR) based on overall response according to RECIST 1.1.', 'description': 'ORR per RECIST 1.1 calculated as the proportion of patients with a best overall response defined as complete response (CR) or partial response (PR), based on investigator assessment.', 'timeFrame': '12 weeks'}, {'measure': 'Disease control rate based on overall response (DCR) according to RECIST 1.1', 'description': 'Defined as the percentage of patients who have achieved overall response of CR, PR and stable disease (SD), assessed by investigator.', 'timeFrame': '12 weeks'}, {'measure': 'Progression-free survival based on overall response (PFS) according to RECIST 1.1', 'description': 'Defined as time from first dose of X-396 capsule to overall disease progression or death due to any causes, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Time to progression based on overall response (TTP) according to RECIST 1.1', 'description': 'Defined as time from first dose of X-396 capsule to overall disease progression, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Duration of response based on overall response (DOR) according to RECIST 1.1', 'description': 'Defined as time from documentation of overall response (CR or PR) to overall disease progression or death, assessed by investigator.', 'timeFrame': '36 months'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as time from first dose of X-396 to death due to any causes.', 'timeFrame': '36 months'}, {'measure': 'Incidence of patients experiencing adverse events.', 'description': 'Incidence of adverse events occurred during the study (from the timeoint of signing a informed consent form to 30days after the end of trial).', 'timeFrame': '36 months'}]",17,18 Years,,ALL,False,Fudan University,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:12.174801,v2_robust,True,True,False,False,True,
NCT06223685,The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin,"Randomized, Double-blind, Placebo-Controlled Study on Efficacy of a Dietary Intervention With Probiotic Bacterial Strains as an Adjunct to Treatment of Small Intestinal Bacterial Overgrowth With Rifaximin",Rifaximin 200 MG,"['Rifaximin 200 MG', 'Xifaxan']",2,INTERVENTIONAL,['NA'],,,Irritable Bowel Syndrome,"['Irritable Bowel Syndrome', 'Small Intestinal Bacterial Overgrowth', 'SIBO']","['SIBO', 'rifaximin', 'probiotics', 'intestinal permeability']",UNKNOWN,,2023-04-01,2025-04-30,"[{'measure': 'Change in bloating on Visual Analog Score', 'description': 'Visual Analog Score (range 0-10, the lower the better) reduction in bloating by 50% in patients with a baseline positive hydrogen test', 'timeFrame': '12 weeks'}, {'measure': 'Change in bowel movements in a bowel-movement diary', 'description': 'increase in bowel frequency by 1/week in patients with a baseline positive methane test', 'timeFrame': '12 weeks'}]","[{'measure': 'The number of patients with a negative hydrogen test', 'description': '\\< 20 ppm in 90 minutes in hydrogen test', 'timeFrame': '12 weeks'}, {'measure': 'The number of patients with a negative methane test', 'description': 'no increase ≥ 10 ppm in 90 minutes in methane test)', 'timeFrame': '12 weeks'}, {'measure': 'Change in subjective symptoms on Visual Analog Score', 'description': 'assessed by VAS - bloating and abdominal pain or discomfort (range 0-10, the lower the better)', 'timeFrame': '12 weeks'}, {'measure': 'Change in subjective symptoms on Gastrointestinal Symptom Rating', 'description': 'change in symptoms expressed as a decrease in total score on the GSRS (range 1-7, the lower score the better)', 'timeFrame': '12 weeks'}, {'measure': 'Change in patient-reported stool quality by Bristol Stool Chart', 'description': 'Range 1-7 Types 1 and 2 indicate severe or mild constipation, 3 and 4 - normal stool 5 indicating lack of dietary fiber, 6 and 7 indicate mild or severe diarrhoea.', 'timeFrame': '12 weeks'}, {'measure': 'Depression risk in Patient Health Questionnaire-9 (PHQ-9)', 'description': 'Range 0-27 points Interpretation: Total scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively.', 'timeFrame': '12 weeks'}, {'measure': 'Change in mesenteric root lymph node ultrasound', 'description': 'reduction of peri-nodal inflammation and reduction/atrophy of mesenteric root lymph nodes is a favorable outcome', 'timeFrame': '12 weeks'}, {'measure': 'Improved indices of liver function and metabolism', 'description': 'as well as inflammatory markers (blood biochemical tests)', 'timeFrame': '12 weeks'}, {'measure': 'Changes in liver tests - alanine transaminase (ALT)', 'description': 'normal range 7 to 56 U/L (units per liter)', 'timeFrame': '12 weeks'}, {'measure': 'Changes in liver tests - aspartate transaminase (AST)', 'description': 'normal range 8 to 33 U/L (units per liter)', 'timeFrame': '12 weeks'}, {'measure': 'Changes in liver tests - Gamma-glutamyl transpeptidase (GGTP or GGT)', 'description': '7 to 47 U/L for males. 5 to 25 U/L for females. (units per liter)', 'timeFrame': '12 weeks'}, {'measure': 'Changes in liver tests - triglycerides', 'description': 'Normal - Less than 150 milligrams per deciliter (mg/dL), or less than 1.7 millimoles per liter (mmol/L) Borderline high - 150 to 199 mg/dL (1.8 to 2.2 mmol/L) High - 200 to 499 mg/dL (2.3 to 5.6 mmol/L)', 'timeFrame': '12 weeks'}, {'measure': 'Changes in cholesterol', 'description': 'A total cholesterol level of less than 200 mg/dL (5.17 mmol/L) is normal.', 'timeFrame': '12 weeks'}, {'measure': 'Changes in liver function - Fatty Liver Index', 'description': ""Fatty Liver Index (FLI) is calculated using a formula which requires patient's triglycerides, BMI, GGT and waist circumference\n\nFLI = (e0.953×loge(triglycerides)+0.139×BMI+0.718×loge(GGT)+0.053×waistcircumference-15.745)/ (1 + e0.953×loge(triglycerides)+0.139×BMI+0.718×loge(GGT)+0.053×waistcircumference-15.745) × 100.\n\nFLI \\<30 most likely excludes fatty liver disease. FLI ≥60 confirms the presence of disease"", 'timeFrame': '12 weeks'}, {'measure': 'Changes in the microbiome and metabolome', 'description': 'qualitative microbiota assessment based on stool and blood samples', 'timeFrame': '12 weeks'}, {'measure': 'Change in intestinal permeability parameters - intestinal fatty acid binding protein', 'description': 'Normal range values have not been well validated. Generally lower value at the end of treatment is considered a favorable outcome', 'timeFrame': '12 weeks'}, {'measure': 'Change in intestinal permeability parameters - calprotectin', 'description': 'Normal range values have not been well validated. Generally lower value at the end of treatment is considered a favorable outcome', 'timeFrame': '12 weeks'}, {'measure': 'Change in intestinal permeability parameters - fecal zonulin content', 'description': 'Normal range values have not been well validated.', 'timeFrame': '12 weeks'}, {'measure': 'Change of hepatic steatosis - Controlled Attenuation Parameter', 'description': 'assessed with Fibroscan. Lower values of CAP at the end of treatment indicate steatosis reduction.', 'timeFrame': '12 weeks'}, {'measure': 'Change of hepatic steatosis - Ultrasound-Guided Attenuation Parameter', 'description': 'assessed with ultrasound. Lower values of UGAP at the end of treatment indicate steatosis reduction.', 'timeFrame': '12 weeks'}, {'measure': 'Change of hepatic fibrosis - Shear Wave Elastography', 'description': 'assessed with ultrasound. Lower values of SWE at the end of treatment indicate fibrosis reduction.', 'timeFrame': '12 weeks'}, {'measure': 'Change of hepatic fibrosis - Transient Elastography', 'description': 'assessed with Fibroscan. Lower values of TE at the end of treatment indicate fibrosis reduction.', 'timeFrame': '12 weeks'}]",24,18 Years,70 Years,ALL,False,Pomeranian Medical University Szczecin,OTHER,0,125.0,ESTIMATED,2025-09-01T16:18:12.174885,v2_robust,True,True,False,False,False,
NCT00607685,5FU vs 5FU With Viscoelastic Formulation for the Prevention of Scarring Post-trabeculectomy,Prospective Case-controlled Study Comparing 5-Fluorouracil vs 5-Fluorouracil With Viscoelastic (Hyaluronic Acid) Formulation for the Prevention of Subconjunctival Scarring Post-trabeculectomy,5 Fluorouracil with hyaluronic acid,"['5 Fluorouracil with hyaluronic acid', '5 Fluorouracil', 'Healon 5 - hyaluronic acid 23mg/ml']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Glaucoma,"['Glaucoma', 'Trabeculectomy', 'Wound Healing']","['Trabeculectomy', 'Wound healing', '5 Fluorouracil', 'Hyaluronic acid', 'post-operative scarring']",COMPLETED,,2008-02,2010-01,"[{'measure': 'intraocular pressure', 'timeFrame': '12 weeks'}]","[{'measure': 'bleb morphology', 'timeFrame': '12 weeks'}]",2,21 Years,90 Years,ALL,False,Singapore National Eye Centre,OTHER_GOV,2,50.0,ESTIMATED,2025-09-01T16:18:12.175005,v2_robust,True,True,True,False,False,
NCT00866385,AZD8566 Food Effect/Microtracer Study,"An Open, Randomised, Phase I, 2-Period Crossover Trial to Investigate the Absolute Bioavailability and the Effect of Food on the Oral Bioavailability of AZD8566 in Healthy Volunteers",AZD8566,"['AZD8566', 'AZD8566 IV carbon labelled']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteer Study,['Healthy Volunteer Study'],"['Healthy Volunteer', 'AZD8566', 'Food Effect', 'Microtracer']",COMPLETED,,2009-03,2009-04,"[{'measure': 'Pharmacokinetic profile: concentration of AZD8566 in blood in the presence or absence of food', 'timeFrame': 'Samples taken during visit 2 and visit 3, at up to 16 defined timepoints pre and post dose'}]","[{'measure': 'Safety and tolerability of AZD8566 in healthy volunteers in the fed and fasted state by assessment of vital signs, laboratory variables, ECGs and adverse events', 'timeFrame': 'Assessments taken during visit 1 and at defined timepoints pre and post dose during visits 2 and 3. Volunteers will be monitored throughout the study for adverse events.'}, {'measure': 'Bioavailability of an oral solution formulation of AZD8566 in the fasted state compared with an intravenous carbon-14 microtracer dose', 'timeFrame': 'Samples taken during visit 2, at up to 40 defined timepoints pre and post dose'}, {'measure': 'Intravenous pharmacokinetics', 'timeFrame': 'Samples taken during visit 2, at up to 40 defined timepoints pre and post dose'}]",4,18 Years,55 Years,ALL,True,AstraZeneca,INDUSTRY,0,21.0,ACTUAL,2025-09-01T16:18:12.175021,v2_robust,True,True,True,False,True,
NCT04468685,Ondansetron Effect on Pain Relief After Laparoscopic Cholecystectomy,Efficacy of Intraperitoneal Ondansetron Administration on Pain Relief After Laparoscopic Cholecystectomy,Ondansetron,"['Ondansetron', 'Normal saline']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cholecystitis,['Cholecystitis'],[],COMPLETED,,2020-07-15,2020-12-18,"[{'measure': 'change in postoperative pain between the two groups using visual analogue score (VAS)', 'timeFrame': '24 hours'}]",[],1,18 Years,70 Years,ALL,False,National Hepatology & Tropical Medicine Research Institute,OTHER_GOV,0,50.0,ACTUAL,2025-09-01T16:18:12.175057,v2_robust,True,True,True,False,False,
NCT06784843,Dexmedetomidine Versus Midazolam for Peribulbar Block,"Dexmedetomidine Versus Midazolam as an Adjuvant to Local Anesthetic Mixture (Bupivacaine, Lidocaine, and Hyaluronidase) for Peribulbar Block During Cataract Surgery: A Randomized Controlled Trial",Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block,"['Midazolam as an adjuvant to local anesthesia for peribulbar block', 'Dexmedetomidine as an adjuvant to local anesthesia for peribulbar block', 'MID', 'DEX']",4,INTERVENTIONAL,['NA'],,,Cataract,['Cataract'],"['dexmedetomidine', 'midazolam', 'peribulbar block', 'cataract']",COMPLETED,,2023-12-01,2024-09-30,"[{'measure': 'onset of motor block', 'description': 'The period of time that passed after the local anesthetic mixture was injected before the eye globe was completely immobile', 'timeFrame': 'Intraoperative from the moment of local anesthesia injection until the moment of complete and full globe akinesia up to 1 hour'}]","[{'measure': 'onset of sensory block', 'description': 'the period of time following the local anesthetic mixture injection that resulted in total insensitivity and absent eye reflexes', 'timeFrame': 'Intraoperative from the moment of local anesthesia injection until the moment of complete insensitivity and absent reflexes of the eye up to 1 hour'}, {'measure': 'length of the motor block', 'description': 'The time it takes for the entire eye globe to return to free motion after experiencing akinesia', 'timeFrame': 'Periperative from the moment of complete and full globe akinesia until the moment of return back of eye movement up to 1 hour'}, {'measure': 'length of the sensory block', 'description': 'The amount of time before the entire eye globe regains sensation after experiencing insensitivity and areflexia andreflexes', 'timeFrame': 'Periperative from the moment of complete areflexia until the moment of return back of sensation and reflexes up to 1 hour'}]",4,18 Years,75 Years,ALL,False,Suez Canal University,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:12.175103,v2_robust,True,True,True,False,False,
NCT00655343,Acute Graft-Versus-Host Disease (aGvHD) Prophylaxis With ATG-Fresenius in Matched Unrelated Donor-Stem Cell Transplantation (MUD-SCT),GvHD Prophylaxis With ATG-Fresenius S in Allogeneic Stem Cell Transplantation From Matched Unrelated Donors: A Randomized Phase III Multicenter Trial Comparing a Standard GvHD Prophylaxis With Cyclosporine A and Methotrexate With Additional Pretransplant ATG-Fresenius S,ATG-Fresenius S,"['Anti-T-Lymphocyte globulin', 'ATG-Fresenius', 'ATG-Fresenius S']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Graft vs Host Disease,['Graft vs Host Disease'],"['GvHD', 'aGvHD prophylaxis', 'Matched unrelated donor', 'ATG', 'SCT', 'BMT', 'polyclonal antibody', 'GvHD prophylaxis for patients with ALL, AML, CML, MDS, OMF', 'Patients with allogeneic BM or PBSC transplantation', 'Patients with a matched unrelated donor']",COMPLETED,,2003-02,2009-03,"[{'measure': 'Primary: Early treatment failure defined by the occurrence of severe acute GvHD (°III-°IV) or early mortality within 100 days post transplantation.', 'timeFrame': '100 days'}]","[{'measure': 'Time to onset of acute GvHD, incidence and severity of infections until day +100, time to engraftment, incidence of cGvHD, disease free survival, relapse, death without relapse, overall survival, safety, tolerability.', 'timeFrame': '24 months'}]",2,18 Years,60 Years,ALL,False,Neovii Biotech,INDUSTRY,1,202.0,ACTUAL,2025-09-01T16:18:12.175121,v2_robust,True,True,True,False,True,
NCT04494243,"A Study to Compare PK, PD and Safety of the AD-214 10/600mg and Rabeprazole","A Randomized, Open-label, Multiple-dose, Crossover Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of AD-214 10/600mg to Rabeprazole 10mg in Healthy Volunteers",AD-214 10/600mg,"['AD-214 10/600mg', 'Reference Drug', 'Test drug', 'Rabeprazole 10mg']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Gastroesophageal Reflux Disease,['Gastroesophageal Reflux Disease'],[],COMPLETED,,2020-08-28,2021-01-15,"[{'measure': 'AUCtau,ss(Area under the plasma drug concentration-time curve)', 'description': 'Evaluateion PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'Gastric acidity(After 7days of repeated administration, The change of integrated gastric acidity)', 'description': 'Evaluation PD Rabeprazole after multiple dose', 'timeFrame': 'Day1 24hours pH monitoring, Day7 24hours pH monitoring, Day22 24hours monitoring, Day28 24hours pH monitoring'}]","[{'measure': 'AUCtau(Area under the plasma drug concentration-time curve)', 'description': 'Evaluation PK Rabeprazole after single dose', 'timeFrame': 'Day1'}, {'measure': 'Cmax(Maximum concentration of drug in plasma)', 'description': 'Evaluation PK Rabeprazole after single dose', 'timeFrame': 'Day1'}, {'measure': 'Tmax(Time to maximum plasma concentration)', 'description': 'Evaluation PK Rabeprazole after single dose', 'timeFrame': 'Day1'}, {'measure': 't1/2(Terminal elimination half-life)', 'description': 'Evaluation PK Rabeprazole after single dose', 'timeFrame': 'Day1'}, {'measure': 'CL/F(Apparent clearance)', 'description': 'Evaluation PK Rabeprazole after single dose', 'timeFrame': 'Day1'}, {'measure': 'Vd/F(Apparent volume of distribution)', 'description': 'Evaluation PK Rabeprazole after single dose', 'timeFrame': 'Day1'}, {'measure': 'Cmax,ss(Maximum concentration of drug in plasma at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'Cmin,ss(Minimum concentration of drug in plasma at steady state) Cmin,SS(Minimum concentration of drug in plasma)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'Cav,ss(Average concentration of drug in plasma at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'Tmax,ss(Time to maximum plasma concentration at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 't1/2,ss(Terminal elimination half-life at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'CLss/F(Apparent Clearance at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'Vss/F(Apparent Volume of distribution at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'PTF(Peak trough fluctuation over one dosing interal at steady state)', 'description': 'Evaluation PK Rabeprazole after multiple dose', 'timeFrame': 'From Day 1 up to Day 29'}, {'measure': 'After the first administration of esomeprazole, The change of integrated gastric acidity compared to baseline for 24 hours', 'description': 'Evaluation PD Rabeoprazoke', 'timeFrame': 'Day1 24hours monitoring'}, {'measure': 'After the first dose and 7 days of repeated dosing, Percentage of time to maintain gastric pH 4.0 or higher for 24 hours', 'description': 'Evaluation PD Rabeoprazoke', 'timeFrame': 'Day1 24hours pH monitoring, Day7 24hours pH monitoring, Day22 24hours monitoring, Day28 24hours pH monitoring'}, {'measure': 'After the first administration and 7 days of repeated administration, The median pH measured for 24 hours', 'description': 'Evaluation PD Rabeoprazoke', 'timeFrame': 'Day1 24hours pH monitoring, Day7 24hours pH monitoring, Day22 24hours monitoring, Day28 24hours pH monitoring'}]",19,19 Years,50 Years,ALL,True,Addpharma Inc.,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:12.175150,v2_robust,True,True,True,False,False,
NCT01395043,Transversus Abdominis Plane Catheter: a Study of Method,"TAP-catheter With Intermittent Bolus Injections of Bupivacain, an Alternative to Epidural Catheter Infusion After Colon Surgery?",Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters,['Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters'],1,INTERVENTIONAL,['NA'],,,Postoperative Pain,['Postoperative Pain'],"['Transversus Abdominis Plane catheter', 'TAP catheter']",COMPLETED,,2010-09,2011-06,"[{'measure': 'Postoperative Pain Using Numerical Rating Scale (NRS) 0-10', 'description': 'NRS is a pain score and the score can vary between 0 and 10 by which 0 means no pain and 10 equals the worst possible pain.\n\nNRS was evaluated at the time 0, 1, 2, 4, 8 , 12, 18 , 24 and 36 hours after arriving in the post anesthesia care unit at rest and during coughing.', 'timeFrame': '0-36 hours postoperative'}]","[{'measure': 'Opioid Requirements Postoperative', 'description': 'Supplementary opioid requirements for the first 48 hours from arriving in the post anesthesia care unit. Results are total opioid-requirements for the first 48 hours. Way of administration was intravenous in all but 6 administrations. If given orally, a 1:3 ratio was used for conversion from oral to intravenous morphine.', 'timeFrame': '48 hours from arriving in the post anesthesia care unit.'}]",2,18 Years,,ALL,False,Aalborg University Hospital,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:12.175188,v2_robust,True,True,True,False,False,
NCT00989443,Safety and Tolerability of Cidofovir Gel Applied on Cervix Squamous Lesions,"A Phase I Clinical Study to Evaluate the Tolerance and Safety of an Aqueous Gel Containing 2% (w/w) of Cidofovir, Directly Applied on the Cervix Exhibiting High Grade Squamous Intraepithelial Lesion(s) (CIN 2 and 3)",Cidofovir gel,['Cidofovir gel'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Uterine Cervical Neoplasms,"['Uterine Cervical Neoplasms', 'Cervix Intraepithelial Neoplasia']",['Cervix Intraepithelial Neoplasia grades 2 and 3'],COMPLETED,,2010-05,,"[{'measure': 'adverse events', 'timeFrame': 'weeks 1, 2, 3 and 4'}]",[],1,18 Years,50 Years,FEMALE,False,Mithra Pharmaceuticals,INDUSTRY,0,6.0,ESTIMATED,2025-09-01T16:18:12.175333,v2_robust,True,True,True,False,True,
NCT01908543,Iron Deficiency and Hereditary Haemorrhagic Telangiectasia,Iron Deficiency and Hereditary Haemorrhagic Telangiectasia,Ferrous sulphate 200mg oral tablet,"['Ferrous sulphate 200mg oral tablet', 'Iron tablet']",2,INTERVENTIONAL,['NA'],,,Hereditary Haemorrhagic Telangiectasia,['Hereditary Haemorrhagic Telangiectasia'],"['Iron deficiency', 'Nosebleeds']",TERMINATED,Technical issues with availability of relevant personnel,2013-07,2015-07,"[{'measure': 'Blood iron indices', 'timeFrame': '4-5 hours after iron tablet ingestion'}]",[],1,18 Years,80 Years,ALL,False,Imperial College London,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:12.175347,v2_robust,True,True,False,True,False,Technical issues with availability of relevant personnel
NCT01938443,A Dose Escalation Study to Assess Safety of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors,"A Phase 1b, Multi-center, Open-label, Dose Escalation Study of GSK2256098 (FAK Inhibitor) in Combination With Trametinib (MEK Inhibitor) in Subjects With Advanced Solid Tumors",GSK2256098,"['GSK2256098', 'Trametinib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,"['Cancer', 'Neoplasms']","['pharmacodynamics', 'MEK inhibitor', 'Focal adhesion kinase inhibitor', 'cancer', 'pharmacokinetic', 'mesothelioma', 'Phase 1']",COMPLETED,,2013-11-18,2016-06-23,"[{'measure': 'Part 1: Safety assessment as assessed by adverse events (AEs) and serious adverse events (SAEs)', 'description': 'AEs and SAEs will be assessed to determine the MTD and RP2D combination of GSK2256098 and trametinib.', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 1: Safety assessment as assessed by 12-lead electrocardiogram (ECG)', 'description': 'Twelve lead ECGs will be obtained to determine the MTD and RP2D combination of GSK2256098 and trametinib.', 'timeFrame': 'Screening, Day 1, Day 15, Day 22, and every 8 weeks from first dose till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 1: Safety assessment as assessed by vital signs', 'description': 'Vital sign measurements will include systolic and diastolic blood pressure, pulse rate, and temperature', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 1: Safety assessment as assessed by change from baseline in laboratory values', 'description': 'Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 1: Safety assessment as assessed by echocardiogram', 'description': 'Echocardiograms will be performed to assess cardiac ejection fraction.', 'timeFrame': 'Screening, Day 28 and Day 1 of Weeks 13, 21, 33, then every 12 weeks.'}, {'measure': 'Part 1: Safety assessment as assessed by eye examination', 'description': 'A standard ophthalmic exam will be performed by an ophthalmologist.', 'timeFrame': 'Screening and as clinically warranted'}, {'measure': 'Part 1: Safety assessment as assessed by urine protein to creatinine (UPC) ratio', 'description': 'Urine samples will be collected for the analyses of UPC ratio.', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 2: Long term safety assessment as assessed by AEs and SAEs', 'description': 'AEs and SAEs will be recorded to assess longer term safety of the GSK2256098/trametinib combination at the RP2D in a larger cohort of subjects with MPM.', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 2: Long term safety assessment as assessed by 12-lead ECG', 'description': 'Twelve lead ECGs will be obtained to assess longer term safety of the GSK2256098/trametinib combination at the RP2D in a larger cohort of subjects with MPM', 'timeFrame': 'Screening, Day 1, Day 15, Day 22, and every 8 weeks from first dose till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 2: Long term safety assessment as assessed by vital signs', 'description': 'Vital sign measurements will include systolic and diastolic blood pressure, pulse rate, and temperature', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 2: Long term safety assessed as change from baseline in laboratory values', 'description': 'Clinical laboratory assessments will include hematology, clinical chemistry, routine urinalysis and additional parameters', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}, {'measure': 'Part 2: Long term safety assessment as assessed by echocardiogram', 'description': 'Echocardiograms will be performed to assess cardiac ejection fraction.', 'timeFrame': 'Screening, Day 28 and Day 1 of Weeks 13, 21, 33, then every 12 weeks.'}, {'measure': 'Part 2: Long term safety assessment as assessed by eye examination', 'description': 'A standard ophthalmic exam will be performed by an ophthalmologist.', 'timeFrame': 'Screening and as clinically warranted'}, {'measure': 'Part 2: Long term safety assessment as assessed by UPC ratio', 'description': 'Urine samples will be collected for the analyses of UPC ratio.', 'timeFrame': 'From Day 1 till post study visit (approximately 21 days from last dose)'}]","[{'measure': 'Part 1: GSK2256098 and trametinib PK assessment following repeat-dose (Day 15) administration of GSK2256098 and trametinib', 'description': 'Blood sample will be collected for measurements of GSK2256098 and trametinib PK parameters including AUC(0-tau), Ctau, Cmax, and tmax.', 'timeFrame': 'Day 15 (pre-dose, 1, 1.5, 2, 4, 6, 8 hours)'}, {'measure': 'Part 1: Tumor response and analysis of change from baseline levels of PD markers including pFAK/FAK, and pERK/ERK measured in tumor biopsies', 'description': 'PD markers pFAK/FAK, and pERK/ERK levels will be analyzed in fresh tumor tissue to assess the level of target inhibition by GSK2256098 and trametinib, respectively. Tumor tissue will be collected at screening (before the first dose on Day 1) and between 1 and 6 hours after GSK2256098 dosing on a day between Day 15 and Day 22, inclusive.', 'timeFrame': 'Screening (before the first dose on Day 1), Day 15 and 22'}, {'measure': 'Part 2: Tumor response as measured by modified Response Evaluation Criteria In Solid Tumors (RECIST) for mesothelioma', 'description': 'CT and MRI scans.', 'timeFrame': 'Screening, Every 8 weeks from first dose and at progression and post study (approximately 21 days from last dose)'}, {'measure': 'Part 2: Change from baseline in observer assessed components of the Lung cancer symptom scale (LCSS)-mesothelioma', 'description': 'The LCSS- mesothelioma is a disease- and site-specific quality of life instrument to measure physical and functional dimensions in patients with lung cancer. The LCSS- mesothelioma will be completed by the investigator at each scheduled disease assessment and at progression.', 'timeFrame': 'Screening, Every 8 weeks from first dose and at progression and post study (approximately 21 days from last dose)'}, {'measure': 'Part 2: Change from baseline in forced vital capacity', 'description': 'Forced vital capacity will be measured at each scheduled disease assessment using standard methods.', 'timeFrame': 'Screening, Every 8 weeks from first dose and at progression and post study (approximately 21 days from last dose)'}, {'measure': 'Part 2: Progression-free survival (PFS)', 'description': 'PFS is defined as the interval between first dose and the earliest date of disease progression or death due to any cause by investigator assessment.', 'timeFrame': 'Day 1 up to disease progression or death due to any cause'}, {'measure': 'Part 2: Change from baseline in patient reported components of the LCSS-mesothelioma', 'description': 'The LCSS- mesothelioma is a disease- and site-specific quality of life instrument to measure physical and functional dimensions in patients with lung cancer. The LCSS- mesothelioma will be completed by the by the subjects with mesothelioma at each scheduled disease assessment and at progression.', 'timeFrame': 'Baseline and every 8 weeks from first dose till disease progression and post study (21 days from last dose)'}, {'measure': 'Part 2: GSK2256098 and trametinib PK parameters following repeat-dose (Day 22) administration of GSK2256098 and trametinib', 'description': 'Blood samples will be collected to analyze the PK parameters including AUC (0 tau), Ctau, Cmax, and tmax . If data permitting, population PK parameters, such as oral clearance (CL/F) and oral volume of distribution (Vz/F) of GSK2256098 and trametinib may be determined.', 'timeFrame': 'Day 8 (pre-dose), 15 (pre-dose),22 (pre-dose, 1, 1.5,2,4,6 and 8 hrs), 29 and 57'}, {'measure': 'Part 2: Exploratory analysis between PK parameters, change from baseline levels of PD markers including pFAK/FAK, pERK/ERK measured in tumor biopsies, and tumor response', 'description': 'The relationship between GSK2256098 and trametinib PK, PD and clinical endpoints in subjects with MPM will be assessed.', 'timeFrame': 'Day 8, 15, 22, 29, and 57'}, {'measure': 'Part 1 and 2: GSK2256098 dried blood spot (DBS) and whole blood PK parameter following repeat-dose (Day15 and 22) administration of GSK2256098 and trametinib', 'description': 'Blood samples will be collected to analyses PK parameters includes area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration within a subject across all treatments \\[AUC(0-tau)\\], maximum observed plasma concentration (Cmax), time to Cmax (tmax), and trough concentration (Ctau) of GSK2256098 DBS and whole blood following repeat-dose (Day15 and 22) administration of GSK2256098 and trametinib.', 'timeFrame': 'Day 15 and 22'}]",24,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:12.175355,v2_robust,True,True,True,False,True,
NCT00076843,Hu Mik-Beta-1 to Treat HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis,Phase I Study of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) Using the Humanized MiK-Beta-1 Monoclonal Antibody Directed Toward the IL-2L-15R-Beta; Subunit (CD122) That Blocks IL-15 Action,Hu MiK-Beta-1,['Hu MiK-Beta-1'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HTLV-1,['HTLV-1'],"['Interleukin-15', 'CD8+ T-cells', 'HAM/TSP', 'HTLV-1', 'HTLV-1 Associated Myelopathy', 'Tropical Spastic Paraparesis']",COMPLETED,,2004-02-03,2019-06-25,[],[],0,18 Years,,ALL,False,National Institute of Neurological Disorders and Stroke (NINDS),NIH,0,9.0,ACTUAL,2025-09-01T16:18:12.175393,v2_robust,True,True,True,False,False,
NCT03198143,Effect of Ghrelin on Decision-Making,Effect of Ghrelin on Nutritional and Financial Decision-Making,Ghrelin,"['Ghrelin', 'Saline', 'Octanoyl Ghrelin', 'Acylated Ghrelin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,"['Healthy Volunteers', 'Obesity']","['Decision-making', 'Ghrelin', 'Healthy Volunteers', 'Obese']",WITHDRAWN,PI leaving institution,2019-10,2022-02,"[{'measure': 'Effect of Ghrelin on food choices in Task 1.', 'description': 'The difference in the proportion of healthy and unhealthy choices in the Saline and Ghrelin conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Effect of Ghrelin on temporal choices in Task 2', 'description': 'The difference in the proportion of smaller sooner and larger later choices in the Saline and Ghrelin conditions', 'timeFrame': 'Approximately 25 minutes'}]","[{'measure': 'Dwell time on each choice during Task 1', 'description': 'For eye-tracking, total dwell time (in ms) on each item in a food choice will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Number of fixations on foods during Task 1', 'description': 'The total number of fixations on each food option will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Dwell time on each choice during Task 2', 'description': 'For eye-tracking, total dwell time (in ms) on each item in the monetary choice will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}, {'measure': 'Number of fixations on foods during Task 2', 'description': 'The total number of fixations on each monetary option will be compared in both experimental conditions.', 'timeFrame': 'Approximately 25 minutes'}]",6,18 Years,40 Years,ALL,True,"Jenny Tong, MD, MPH",OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.175405,v2_robust,True,True,False,True,False,PI leaving institution
NCT00794443,ONO-5920/YM529 Confirmatory Study in Involutional Osteoporosis Patients,A Multi-center Double-blind Parallel-group Comparison Study in Involutional Osteoporosis Patients to Examine the Efficacy and Safety of ONO-5920/YM529 Monthly Intermittent Formulation With Its Daily Formulation.,YM529 / ONO-5920,"['YM529 / ONO-5920', 'ONO-5920', 'Minodronic acid', 'YM529']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Osteoporosis,"['Osteoporosis', 'Bone Loss, Age-Related']","['ONO-5920', 'YM529', 'Bone mineral density', 'Minodronic acid']",COMPLETED,,2008-11,2010-04,"[{'measure': 'Percent changes in the lumbar vertebral bone mineral density (L2-4BMD) by the DXA method', 'timeFrame': 'At the final evaluation point'}]","[{'measure': 'Time-course changes in the percent change of bone metabolism markers', 'timeFrame': 'Through the treatment period'}, {'measure': 'Time-course changes in the total femoral bone mineral density by the DXA method', 'timeFrame': 'Through the treatment period'}, {'measure': 'Assessment of adverse events, lab test values', 'timeFrame': 'Through the treatment period'}, {'measure': 'Frequency of fracture', 'timeFrame': 'At the final evaluation point'}]",5,45 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,1,692.0,ACTUAL,2025-09-01T16:18:12.175473,v2_robust,True,True,True,False,True,
NCT00613743,Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis,Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis,mouth wash with morphine,"['mouth wash with morphine', 'placebo']",2,INTERVENTIONAL,['NA'],,,Cancer,"['Cancer', 'Mucositis']",[],COMPLETED,,2007-12,2008-12,"[{'measure': 'difference of pain alleviation in the two branches one hour after mouthwash and as well as the duration of pain relief.', 'timeFrame': '1 year'}]","[{'measure': 'the requirement of supplementary systemic analgesics', 'timeFrame': '1 year'}]",2,18 Years,,ALL,False,"University Hospital, Geneva",OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:12.175485,v2_robust,True,True,True,False,False,
NCT00468715,Bicalutamide in Treating Patients With Metastatic Breast Cancer,"Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+)), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-)) Metastatic Breast Cancer Patients: A Phase II Feasibility Study",bicalutamide,['bicalutamide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['stage IV breast cancer', 'recurrent breast cancer', 'male breast cancer']",COMPLETED,,2007-03-23,2021-06-24,"[{'measure': '6-month Response Rate (Complete Response, Partial Response, and Stable Disease)', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': '6 months'}]","[{'measure': 'Count of Participants With Progression-free Survival', 'description': 'Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': '1 year'}, {'measure': 'Number of Participants Evaluated for Toxicity', 'description': 'Toxicity measured by CTCAE v3.0', 'timeFrame': '1 year'}]",3,18 Years,120 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,2,28.0,ACTUAL,2025-09-01T16:18:12.175584,v2_robust,True,True,True,False,False,
NCT00004815,Descriptive Study of Recombinant Human Insulin-Like Growth Factor for Osteoporosis in Werner's Syndrome,,growth hormone,['growth hormone'],1,INTERVENTIONAL,['NA'],,,Werner's Syndrome,"[""Werner's Syndrome""]","[""Werner's syndrome"", 'genetic diseases and dysmorphic syndromes', 'rare disease']",COMPLETED,,1992-05,,[],[],0,0 Years,,ALL,False,National Center for Research Resources (NCRR),NIH,2,1.0,,2025-09-01T16:18:12.175618,v2_robust,True,True,True,False,False,
NCT00576615,Propofol's Hypnotic and Memory Effects,CNS Targets of Propofol's Hypnotic and Memory Effects,Placebo solution,"['Placebo solution', 'propofol']",2,OBSERVATIONAL,[],,,Healthy,['Healthy'],"['healthy volunteers', 'amnesic effects']",COMPLETED,,2002-05,2016-05,"[{'measure': 'Demonstrate the persistence of defined stimulation-related changes in brain activity during various levels of propofol and thiopental sedation.', 'timeFrame': 'fifteen hours over several different days'}]","[{'measure': 'Identify the neuroanatomical regions mediating propofol-induced amnesia and sedation.', 'timeFrame': 'fifteen hours over several different days'}]",2,18 Years,45 Years,ALL,True,Memorial Sloan Kettering Cancer Center,OTHER,2,102.0,ACTUAL,2025-09-01T16:18:12.175657,v2_robust,False,True,True,False,False,
NCT05740215,Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors,"A Multicenter, Open-label, Phase Ib/II Study on the Efficacy and Safety of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors",F520,"['F520', 'Lenvatinib']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Tumors,['Solid Tumors'],"['F520', 'PD-1']",UNKNOWN,,2022-05-23,2024-05-22,"[{'measure': 'Serious adverse events', 'description': 'Phase Ib: The incidence of adverse events/serious adverse events, their correlation with the trial drug and their severity.', 'timeFrame': '21 days after first dose'}, {'measure': 'Adverse events', 'description': 'Phase Ib: The incidence of adverse events/serious adverse events, their correlation with the trial drug and their severity.', 'timeFrame': '21 days after first dose'}, {'measure': 'Dose-limiting toxicity (DLT)', 'description': 'Phase Ib: Assess the incidence of dose-limiting toxicity (DLT), and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D).', 'timeFrame': '21 days after first dose'}, {'measure': 'Maximum tolerated dose (MTD)', 'description': 'Phase Ib: Assess the incidence of dose-limiting toxicity (DLT), and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D).', 'timeFrame': '21 days after first dose'}, {'measure': 'Phase II recommended dose (RP2D).', 'description': 'Phase Ib: Assess the incidence of dose-limiting toxicity (DLT), and determine the maximum tolerated dose (MTD) and/or phase II recommended dose (RP2D).', 'timeFrame': '21 days after first dose'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Phase II: Objective Response Rate (ORRW24) evaluated by the Independent Review Committee (IRC) based on RECIST 1.1.', 'timeFrame': '24 weeks'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'Phase Ib: To determine the preliminary efficacy by evaluating the objective response rate (ORR) of F520 combined with lenvatinib in patients with advanced solid tumors (The last subject completed the 8th cycle of administration and completed the corresponding visits).', 'timeFrame': 'through study completion, an average of 2 year'}, {'measure': 'Maximum Plasma Concentration (Cmax）', 'description': 'Phase Ib: To evaluate the pharmacokinetic characteristics of F520 and lenvatinib in patients with advanced solid tumors.', 'timeFrame': '30 days (±7 days) after the last dose, early withdrawal or occurrence of SAE or grade ≥ 3 TRAE related to the study drug'}, {'measure': 'Objective response rate (ORR)', 'description': 'Phase II: The objective response rate evaluated by the investigator based on RECIST 1.1 (ORRW24).', 'timeFrame': '24 weeks'}, {'measure': 'PFS', 'description': 'Phase II: PFS evaluated by IRC and investigator based on RECIST.', 'timeFrame': 'through study completion, an average of 2 year'}, {'measure': 'PFS', 'description': 'Phase II: PFS evaluated by IRC and investigator based on iRECIST.', 'timeFrame': 'through study completion, an average of 2 year'}, {'measure': 'Adverse events', 'description': 'Phase II: Evaluate the number and percent of patients with adverse events/adverse reactions and serious adverse events/severe adverse reactions in selected patients with advanced solid tumors treated with F520 combined with lenvatinib.', 'timeFrame': '30 days after the last dose'}, {'measure': 'Adverse reactions', 'description': 'Phase II: Evaluate the number and percent of patients with adverse events/adverse reactions and serious adverse events/severe adverse reactions in selected patients with advanced solid tumors treated with F520 combined with lenvatinib.', 'timeFrame': '30 days after the last dose'}, {'measure': 'Serious adverse events', 'description': 'Phase II: Evaluate the number and percent of patients with adverse events/adverse reactions and serious adverse events/severe adverse reactions in selected patients with advanced solid tumors treated with F520 combined with lenvatinib.', 'timeFrame': '30 days after the last dose'}, {'measure': 'Severe adverse reactions', 'description': 'Phase II: Evaluate the number and percent of patients with adverse events/adverse reactions and serious adverse events/severe adverse reactions in selected patients with advanced solid tumors treated with F520 combined with lenvatinib.', 'timeFrame': '30 days after the last dose'}]",15,18 Years,75 Years,ALL,False,"Shandong New Time Pharmaceutical Co., LTD",INDUSTRY,0,158.0,ESTIMATED,2025-09-01T16:18:12.175747,v2_robust,True,True,False,False,True,
NCT03170115,Induction Chemotherapy Plus Chemoradiotherapy With or Without Aspirin in High Risk Rectal Cancer,Phase II Randomized Study of Induction Chemotherapy Followed by Chemoradiotherapy With or Without Aspirin in High Risk Locally Advanced Rectal Cancer,Aspirin,"['Aspirin', 'Placebo Oral Tablet', 'aas', 'placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Rectal Cancer, Adenocarcinoma","['Rectal Cancer, Adenocarcinoma', 'Locally Advanced Malignant Neoplasm', 'Chemoradiation']","['Rectal Cancer', 'Total neoadjuvant therapy', 'Induction chemotherapy', 'Aspirin colorectal cancer']",TERMINATED,Aspirin added to chemoradiotherapy was safe but did not improve response to total neoadjuvant treatment. The study was closed due absence of benefit.,2017-11-30,2020-01-17,"[{'measure': 'Tumor downstaging after induction chemotherapy followed by chemoradiotherapy with or without aspirin', 'description': 'This will be assessed by MR imaging 8-10 weeks after chemoradiotherapy and it will be considered tumor downstaging if mrTRG 1 to 3', 'timeFrame': '8-10 weeks after chemoradiotherapy'}]","[{'measure': 'Radiological Tumor response rate after induction chemotherapy', 'description': 'This will be assessed by MR imaging after induction chemotherapy', 'timeFrame': '3-4 weeks after last induction chemotherapy'}, {'measure': 'Pathological Tumor response rate', 'description': 'Amount of tumor regression after surgery according to the guideline including Mandard', 'timeFrame': '10-12 weeks after chemoradiotherapy'}, {'measure': 'Pathologic complete response', 'description': 'it will be defined as the absence of residual invasive cancer on pathological evaluation of the complete resected rectal specimen', 'timeFrame': '8-10 weeks after chemoradiotherapy'}, {'measure': 'Disease-free survival', 'description': 'defined as the time from surgery to relapse or death, whichever occurred first', 'timeFrame': '3 years'}, {'measure': 'Overall survival', 'description': 'defined as the time from surgery to death, whichever occurred first', 'timeFrame': '5 years'}]",6,18 Years,75 Years,ALL,False,"Instituto Nacional de Cancer, Brazil",OTHER_GOV,0,25.0,ACTUAL,2025-09-01T16:18:12.175789,v2_robust,True,True,False,True,False,Aspirin added to chemoradiotherapy was safe but did not improve response to total neoadjuvant treatment. The study was closed due absence of benefit.
NCT06681415,Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass,A Randomized Controlled Trial on the Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass,Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution,['Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Pleural Effusions Post Coronary Artery Bypass Graft,"['Pleural Effusions Post Coronary Artery Bypass Graft', 'Hypoxia', 'Hypoalbuminemia']",['Pleural effusion following cardiopulmonary bypass'],COMPLETED,,2022-09-01,2024-01-01,"[{'measure': 'Pleural effusion (centimetres) in thoracic CT images and calculated in millilitres.', 'description': 'Thorax CT scans were performed on all patients on the first postoperative day, with subsequent image analysis conducted by a single radiologist. The radiologist measured pleural effusion size (cm).', 'timeFrame': 'Thorax CT scans were performed on all patients on the first postoperative day.'}, {'measure': 'Pleural effusion in thoracic CT images and calculated in millilitres.', 'description': 'Thorax CT scans were performed on all patients on the first postoperative day, with subsequent image analysis conducted by a single radiologist. The investigators calculated effusion volume (ml).', 'timeFrame': 'Thorax CT scans were performed on all patients on the first postoperative day.'}]",[],2,18 Years,,ALL,False,Pauls Stradins Clinical University Hospital,OTHER,1,70.0,ACTUAL,2025-09-01T16:18:12.175832,v2_robust,True,True,True,False,False,
NCT02261415,The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial,The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial: Tranexamic Acid (TXA) Versus Placebo to Reduce Perioperative Blood Transfusion in Patients Undergoing Liver Resection: A Randomized Controlled Trial,Tranexamic acid (TXA),"['Cyklokapron', 'Tranexamic acid (TXA)', '0.9% sodium chloride', 'Normal saline']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Cancer,"['Cancer', 'Tumour', 'Surgery']","['blood transfusion', 'blood loss', 'feasibility', 'outcome', 'liver resection']",ACTIVE_NOT_RECRUITING,,2014-11,2027-08,"[{'measure': 'Receipt of blood transfusion (% transfused): 7 days', 'description': 'Receipt of one or more RBC transfusions between Day 0 and Day 7', 'timeFrame': '7 days'}]","[{'measure': 'Intraoperative blood loss', 'description': 'Intraoperative blood loss will be assessed by adding the net weight of sponges and fluid suction (minus irrigation and intraoperative bile or other fluids in suction/sponge)', 'timeFrame': '7 days'}, {'measure': 'Total blood loss', 'description': ""Total blood loss (postoperative day (POD)0 - POD7) will be assessed by Gross' formula, which uses the maximum postoperative decrease in the level of hemoglobin adjusted for the weight and height of the patient"", 'timeFrame': '7 days'}, {'measure': 'Number of packed red blood cells (PRBC) units transfused', 'description': 'Number of packed red blood cells (PRBC) units transfused (POD0 - POD7)', 'timeFrame': '7 days'}, {'measure': 'Postoperative incidence of symptomatic venous thromboembolic event', 'description': 'Postoperative incidence of symptomatic venous thromboembolic event confirmed with either computed tomography (CT) angiogram (for pulmonary embolism) or venous Doppler ultrasound (for deep venous thrombosis) (within 90 days of surgery)', 'timeFrame': '90 days'}, {'measure': 'Postoperative complications assessed using Clavien-Dindo Grading System', 'description': 'Postoperative complications (within 90 days of surgery) will be determined using the Clavien-Dindo classification', 'timeFrame': '90 days'}, {'measure': 'Recurrence Free Survival (within 5 years of surgery)', 'description': ""Disease recurrence is defined as the clinical presence of cancer that has either been confirmed by biopsy, has had treatment initiated, or is documented in the treating physician's notes. Five year disease recurrence from day of surgery will be evaluated approximately every 6 months until 5 years via medical record review."", 'timeFrame': '60 months'}, {'measure': 'Overall Survival (within 5 years of surgery)', 'description': 'Overall survival is defined as the time from date of surgery to death from any cause. It will be determined by review of patient medical record every 6 months until 5 years post-surgery.', 'timeFrame': '60 months'}, {'measure': 'Quality of Life (QOL) Assessment using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30', 'description': 'QOL will be determined by administering the EORTC QLQ-C30 at baseline, 30 and 90 days following surgery.', 'timeFrame': 'Baseline, 30 days, 90 days'}, {'measure': 'Quality of Life (QOL) Assessment using European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-Liver Module (LM)C21 Questionnaire', 'description': 'QOL will be determined by administering QLQ-LMC21 at baseline, 30 and 90 days following surgery.', 'timeFrame': 'Baseline, 30 days, 90 days'}, {'measure': 'Perioperative mortality', 'description': 'Perioperative mortality will be recorded between POD0 and POD7', 'timeFrame': '7 days'}, {'measure': 'Compare the cost of tranexamic acid (TXA) versus placebo on perioperative blood transfusion in patients undergoing liver resection', 'description': 'Economic analysis will assess impact of TXA incorporation on health care resources and strategies for systematic utilization of TXA. The analysis will be using data collected in the randomized controlled trial from a societal perspective.The output of the economic analysis is the incremental cost of TXA compared to placebo (control group).', 'timeFrame': '90 days'}]",12,18 Years,,ALL,False,Sunnybrook Health Sciences Centre,OTHER,1,1386.0,ACTUAL,2025-09-01T16:18:12.175845,v2_robust,True,True,False,False,False,
NCT03986515,Apatinib Plus SHR1210 in Advanced Mucosal Melanoma,Clinical Study of SHR-1210 Plus Apatinib in Patients With Advanced Mucosal Melanoma Whose Diseases Progress After Chemotherapy,apatinib plus SHR-1210,['apatinib plus SHR-1210'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Mucosal Melanoma,"['Mucosal Melanoma', 'Advanced Cancer', 'Apatinib', 'SHR-1210']",[],UNKNOWN,,2019-06-04,2022-05-31,"[{'measure': 'objective response rate', 'description': 'the proportion of patients with CR, PR, and SD in the group', 'timeFrame': 'three months'}]","[{'measure': 'progression-free survival', 'description': 'the time frame from the first day of apatinib to the date of confirmed progressive disease or death which one occurrs first.', 'timeFrame': 'six months'}, {'measure': 'overall survival', 'description': 'the time frame from the first day of apatinib to the date of death', 'timeFrame': 'eighteen months'}]",3,18 Years,75 Years,ALL,False,Henan Cancer Hospital,OTHER_GOV,0,40.0,ESTIMATED,2025-09-01T16:18:12.175884,v2_robust,True,True,False,False,False,
NCT00763815,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","A Randomized, Double-blind, Placebo-controlled, 2-arm Parallel-group, Multicenter Study With a 24-week Main Treatment Period and an Extension Assessing the Efficacy and Safety of AVE0010 on Top of Pioglitazone in Patients With Type 2 Diabetes Not Adequately Controlled With Pioglitazone",Lixisenatide (AVE0010),"['Lixisenatide (AVE0010)', 'Metformin', 'Pioglitazone', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes Mellitus Type 2,['Diabetes Mellitus Type 2'],['hyperglycemia GLP-1 pioglitazone'],COMPLETED,,2008-09,2011-06,"[{'measure': 'Absolute Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24', 'description': 'Absolute change = HbA1c value at Week 24 minus HbA1c value at baseline. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Baseline, Week 24'}]","[{'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24', 'description': 'Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Body Weight at Week 24', 'description': 'Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 3 days after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Fasting Plasma Insulin (FPI) at Week 24', 'description': 'Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Percentage of Patients With Glycosylated Hemoglobin (HbA1c) Level Less Than 7% at Week 24', 'description': 'The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Patients With HbA1c Level Less Than or Equal to 6.5% at Week 24', 'description': 'The on-treatment period for this efficacy variable is the time from the first dose of study drug up to 3 days after the last dose of study drug or up to the introduction of rescue therapy, whichever is the earliest. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Week 24'}, {'measure': 'Change From Baseline in Beta-cell Function Assessed by Homeostasis Model Assessment for Beta-cell Function (HOMA-beta) at Week 24', 'description': 'Beta cell function was assessed by HOMA-beta. HOMA-beta (% of normal beta cells function) = (20 multiplied by fasting plasma insulin \\[micro unit per milliliter\\]) divided by (fasting plasma glucose \\[mmol/L\\] minus 3.5). Change was calculated by subtracting baseline value from Week 24 value. The on-treatment period for this efficacy variable is time from the first dose of study drug and up to 1 day after the last dose of study drug, on or before Visit 12 (Week 24) or Day 169 if Visit 12 is not available, and before the introduction of rescue therapy. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Percentage of Patients Requiring Rescue Therapy During Main 24-Week Period', 'description': 'Routine fasting self-monitored plasma glucose (SMPG) and central laboratory FPG (and HbA1c after week 12) values were used to determine the requirement of rescue medication. If fasting SMPG value exceeded the specified limit for 3 consecutive days, the central laboratory FPG (and HbA1c after week 12) were performed. Threshold values - from baseline to Week 8: fasting SMPG/FPG \\>270 milligram/deciliter (mg/dL) (15.0 mmol/L), from Week 8 to Week 12: fasting SMPG/FPG \\>240 mg/dL (13.3 mmol/L), and from Week 12 to Week 24: fasting SMPG/FPG \\>200 mg/dL (11.1 mmol/L) or HbA1c \\>8.5%. For a patient to be included in mITT population, both baseline and at least 1 post baseline assessment for at least 1 efficacy variable, were required.', 'timeFrame': 'Baseline up to Week 24'}]",8,18 Years,,ALL,False,Sanofi,INDUSTRY,0,484.0,ACTUAL,2025-09-01T16:18:12.175922,v2_robust,True,True,True,False,False,
NCT01151735,C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation,"Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Determine the Efficacy of 1000u, and 1500u of C1-INH Compared to Placebo at the Time of Prodromal Symptoms in Preventing an Acute HAE Exacerbation.",C-1-esterase,"['C-1-esterase', 'placebo arm', 'placebo', 'high dose intervention', 'low dose intervention']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Hereditary Angioedema,['Hereditary Angioedema'],"['Angioedema', 'Hereditary Diseases', 'Orphan Disease', 'HAE']",WITHDRAWN,PennState would not allow the study to move forward,2010-07,2012-07,"[{'measure': 'percentage of full blown HAE attacks occurring within 24 hours following treatment at the prodromal', 'description': 'To compare the percentage of full blown HAE attacks occurring within 24 hours following treatment at the prodromal stage of an attack using placebo or one of two doses of C1-INH.', 'timeFrame': '24 hours'}]",[],1,18 Years,65 Years,ALL,False,Penn State University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.176005,v2_robust,True,True,False,True,False,PennState would not allow the study to move forward
NCT06601335,A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC),"A Randomized, Controlled, Multicenter Phase 3 Study of AK112 in Combination With AK117 Versus Pembrolizumab as First Line Treatment for a Programmed Cell Death-ligand 1 (PD-L1) Positive Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)",AK117 in combination with AK112,"['Placebo in combination with Pembrolizumab', 'AK117 in combination with AK112']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Head and Neck Squamous Cell Carcinoma,['Head and Neck Squamous Cell Carcinoma'],[],RECRUITING,,2024-10-30,2027-10,"[{'measure': 'Overall Survival (OS)', 'description': 'OS is the time from randomization to death due to any cause.', 'timeFrame': 'Up to approximately 2 years'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from randomization to the first documented disease progression (per RECIST v1.1 criteria) assessed by investigators or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is the proportion of subjects with complete response(CR) or partial response(PR) , assessed by investigators based on RECIST v1.1.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Cmax', 'description': 'Maximum plasma concentration of AK112 and AK117 after administration.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Cmin', 'description': 'Minimum plasma concentration of AK112 and AK117 after administration.', 'timeFrame': 'Up to approximately 2 years'}, {'measure': 'Anti-drug antibodies (ADA)', 'description': 'Number of subjects with detectable ADA.', 'timeFrame': 'Up to approximately 2 years'}]",7,18 Years,75 Years,ALL,False,Akeso,INDUSTRY,0,510.0,ESTIMATED,2025-09-01T16:18:12.176023,v2_robust,True,True,False,False,True,
NCT03526835,A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors,Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors,MCLA-158,"['petosemtamab', 'MCLA-158']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced/Metastatic Solid Tumors,"['Advanced/Metastatic Solid Tumors', 'Colorectal Cancer', 'Gastric Cancer', 'Gastroesophageal-junction Cancer', 'NSCLC', 'HNSCC', 'Head and Neck Squamous Cell Carcinoma', 'Esophageal Cancer']","['Bispecific antibody', 'First-in-human', 'MCLA-158', 'Antibodies', 'Bispecific', 'immunologic factors', 'Cytokines', 'EGFR', 'LGR5']",RECRUITING,,2018-05-02,2027-11,"[{'measure': 'Escalation: Number of patients with Dose Limiting Toxicities (DLTs) during Cycle 1', 'description': 'Evaluation of the number and severity of participants with treatment related toxicities observed during the dose escalation.', 'timeFrame': '4 weeks'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer, and combination cohorts): Safety and tolerability: AEs and SAEs', 'description': 'Incidence, severity, and relationship of AEs and SAEs', 'timeFrame': '6-12 months'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Treatment discontinuations and dose modifications due to AEs', 'description': 'Treatment discontinuations due to AEs and dose modifications due to AEs', 'timeFrame': '6-12 months'}, {'measure': 'Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): Best overall response (BOR)', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining Best overall response (BOR)', 'timeFrame': '36 months'}, {'measure': 'Expansion (Single agent - non-randomized, and combination cohorts): Objective response rate (ORR)', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)', 'timeFrame': '36 months'}, {'measure': 'Expansion (single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: TEAEs', 'description': 'Incidence of TEAEs at Week 8', 'timeFrame': '8 weeks'}]","[{'measure': 'Escalation & Expansion: Duration of response (DOR)', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining duration of response (DOR)', 'timeFrame': '36 months'}, {'measure': 'Expansion: Progression Free Survival (PFS)', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining progression free survival (PFS)', 'timeFrame': '36 months'}, {'measure': 'Expansion (mCRC combination cohorts): Progression Free Survival (PFS) rate at 4 months', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining progression free survival (PFS) rate at 4 months', 'timeFrame': '4 months'}, {'measure': 'Expansion (Single agent - non-randomized cohorts): Overall survival (OS)', 'description': 'Evaluation of clinical benefit determining overall survival (OS)', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion (single agent - non-randomized cohorts): Safety and tolerability: AEs and SAEs', 'description': 'Incidence, severity, and relationship of AEs and SAEs', 'timeFrame': 'up to 30 days post-last dose'}, {'measure': 'Escalation & Expansion (Single agent - non-randomized and Combination cohorts): Treatment discontinuations and dose modifications due to AEs', 'description': 'Treatment discontinuations due to AEs and dose modifications due to AEs', 'timeFrame': 'up to 30 days post-last dose'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-efficacy relationship of petosemtamab administered at 1100 mg and 1500 mg: Target Lesions', 'description': 'Percentage change from baseline in sum of the diameters of target lesions at Week 8', 'timeFrame': '8 weeks'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: Grade 3-4 TEAEs', 'description': 'Incidence of Grade 3-4 TEAEs at Week 8', 'timeFrame': '8 weeks'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg: IRR TEAEs', 'description': 'Incidence of IRR TEAEs at Week 8', 'timeFrame': '8 weeks'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): exposure-safety relationship of petosemtamab administered at 1100 mg and 1500 mg : non-IRR TEAEs', 'description': 'Incidence of non-IRR TEAEs at Week 8', 'timeFrame': '8 weeks'}, {'measure': 'Escalation and Expansion: Safety and tolerability: laboratory values', 'description': 'Number of participants with abnormal laboratory tests results', 'timeFrame': '6-12 months'}, {'measure': 'Escalation and Expansion: Safety and tolerability: (ECG)', 'description': 'Number of participants with abnormal ECG readings', 'timeFrame': '6-12 months'}, {'measure': 'Escalation and Expansion: Safety and tolerability: vital signs', 'description': 'Number of participants with abnormal vital signs', 'timeFrame': '6-12 months'}, {'measure': 'Expansion (Single agent - randomized expansion in 2/3L Head and Neck cancer): Objective response rate (ORR)', 'description': 'Evaluation of clinical benefit assessed by RECIST v1.1 determining objective response rate (ORR)', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Incidence of anti-drug antibodies against MCLA-158', 'description': 'Number of participants with anti-drug antibodies against MCLA-158', 'timeFrame': '36 months'}, {'measure': 'Escalation: Cytokine Panel Expression Profile', 'description': 'Evaluation of the cytokine expression profile', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: End of infusion (EOI) plasma concentration [Ceoi]', 'description': 'End of infusion (EOI) plasma concentration \\[Ceoi\\] as measured from all individual plasma concentrations', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Maximum plasma concentration [Cmax]', 'description': 'Maximum plasma concentration as measured from all individual plasma concentrations', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Plasma concentration at 0 hours [C0h]', 'description': 'Plasma concentration at 0 hours \\[C0h\\] as measured from all individual plasma concentrations', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Area under the concentration versus time curve from time zero to time t [AUC0-t]', 'description': 'Area under the concentration versus time curve from time zero to time t \\[AUC0-t\\]', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Area under the concentration versus time curve [AUC0-∞]', 'description': 'Area under the concentration versus time curve \\[AUC0-∞\\]', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Clearance of plasma [CL]', 'description': 'Clearance of plasma \\[CL\\]', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Volume of distribution at steady state [Vss]', 'description': 'Volume of distribution at steady state \\[Vss\\]', 'timeFrame': '36 months'}, {'measure': 'Escalation & Expansion: Half-life [t1/2]', 'description': 'Half-life \\[t1/2\\]', 'timeFrame': '36 months'}]",30,18 Years,,ALL,False,Merus N.V.,INDUSTRY,0,523.0,ESTIMATED,2025-09-01T16:18:12.176061,v2_robust,True,True,False,False,True,
NCT01862835,Impact of Estradiol Addback,Impact of Estradiol Addback on Somatostatin Rebound in Older Men,Degarelix,"['Estrogen patch', 'Degarelix', 'Testosterone', 'Anastrozole']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Normal Healthy Volunteers,['Normal Healthy Volunteers'],[],COMPLETED,,2013-05,2018-12-30,"[{'measure': 'BioStatistical Analysis', 'description': 'The primary analytical outcome is the summed mass of GH secreted in pulses over the 15 h of overnight blood sampling. The outcome measure is relevant, since sex-steroid hormones and regulatory peptides uniquely control GH secretory-burst mass.', 'timeFrame': 'Subjects will undergo 15-h overnight (2200 - 1300 h) fasting, 10-min blood sampling'}]",[],1,60 Years,80 Years,MALE,True,Mayo Clinic,OTHER,0,43.0,ACTUAL,2025-09-01T16:18:12.176116,v2_robust,True,True,True,False,False,
NCT02943135,Lidocaine In-situ Gel Before Intrauterine Device Insertion,Effect of Self-administered Lidocaine In-situ Gel on Intrauterine Device Insertion Pain: A Randomized Controlled Trial,lidocaine in-situ gel,"['placebo in-situ gel', 'lidocaine in-situ gel']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Pain Relief,['Pain Relief'],[],COMPLETED,,2017-10-01,2020-03-30,"[{'measure': 'Mean pain score during intrauterine device insertion', 'timeFrame': '30 min'}]",[],1,20 Years,50 Years,FEMALE,False,Assiut University,OTHER,0,120.0,ACTUAL,2025-09-01T16:18:12.176422,v2_robust,True,True,True,False,False,
NCT06733935,"NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Participants With Immune-Mediated Diseases (Ntrust-2)","A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With Immune-Mediated Diseases",NKX019,"['NKX019', 'Cyclophosphamide', 'Fludarabine']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Systemic Sclerosis,"['Systemic Sclerosis', 'Idiopathic Inflammatory Myopathies', 'Antineutrophil Cytoplasmic Antibody-Associated Vasculitis']","['CD19', 'CAR', 'Allogeneic', 'NKX019', 'Natural Killer Cells', 'Interleukin-15', 'IL-15', 'Cell Therapy', 'Immunotherapy', 'Adoptive cell therapy', 'Scleroderma', 'Myositis', 'AAV', 'Systemic Sclerosis', 'Idiopathic Inflammatory Myopathies', 'Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis', 'Ntrust-2']",RECRUITING,,2024-11-04,2028-10,"[{'measure': 'Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability]', 'description': 'Incidence of DLTs will be evaluated', 'timeFrame': 'The first 28 days after the first NKX019 dose'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Incidence and severity of treatment-emergent adverse events will be evaluated', 'timeFrame': 'From the first administration of NKX019 until the last administration of any study treatment + 30 days'}]","[{'measure': 'For participants with SSc, change from baseline in % predicted forced vital capacity (FVC)', 'timeFrame': 'Up to 2 years after NKX019 infusion including at 6 and 12 months'}, {'measure': 'For participants with SSc, change from baseline in modified Rodnan skin score (mRSS)', 'description': 'mRSS measures skin involvement at 17 sites on the body and each body site is scored 0 to 3 with 0 indicating normal skin thickness and 3 indicating severe skin thickening or fibrosis, and the scores are summed with a range of 0 to 51 with the higher the score indicating a worse disease state', 'timeFrame': 'Up to 2 years after NKX019 infusion including at 3, 6, and 12 months'}, {'measure': 'For participants with IIM, change from baseline in manual muscle testing (MMT) measured by bilateral MMT-8 scores (potential score range 0-140 with a higher score indicating greater muscle strength)', 'timeFrame': 'Up to 2 years after NKX019 infusion including at 3, 6, and 12 months'}, {'measure': 'For participants with IIM, change from baseline in normalization of muscle enzymes measured by creatine kinase (CK) in normal range', 'timeFrame': 'Up to 2 years after NKX019 infusion including at 3, 6, and 12 months'}, {'measure': 'For participants with IIM, change from baseline in achievement of major clinical response per 2016 ACR-EULAR myositis response criteria', 'timeFrame': 'Up to 2 years after NKX019 infusion including at 3, 6, and 12 months'}, {'measure': 'For participants with AAV, achievement of Birmingham Vasculitis Activity Score (BVAS) remission', 'description': 'BVAS of 0 and with prednisone ≤ 5 mg/day within past 4 weeks. The BVAS consists of 9 organ systems domains and within each organ system specific clinical features indicative of disease activity are evaluated and scored 0 to 3, based on severity or extent of involvement, with 0 indicating no activity and 3 indicating severe activity. The total BVAS score is calculated by summing the scores for each individual clinical feature across all organ system domains', 'timeFrame': 'Up to 2 years after NKX019 infusion including 3, 6, and 12 months'}, {'measure': 'Pharmacokinetics parameter: maximum concentration (Cmax)', 'timeFrame': 'Up to 2 years after NKX019 infusion'}, {'measure': 'Pharmacokinetics parameter: Time-to-maximum concentration (Tmax)', 'timeFrame': 'Up to 2 years after NKX019 infusion'}, {'measure': 'Pharmacokinetics parameter: Area under the curve (AUC)', 'timeFrame': 'Up to 2 years after NKX019 infusion'}, {'measure': 'Pharmacokinetics parameter: Half-life (t1/2)', 'timeFrame': 'Up to 2 years after NKX019 infusion'}, {'measure': 'Duration of persistence of NKX019 in peripheral blood', 'timeFrame': 'Up to 2 years after NKX019 infusion'}, {'measure': 'Assess humoral immunogenicity over time with validated methods that include: a cell-based flow cytometry assay for anti-NKX019 antibodies and an antigen bead-assay using flow cytometry for detection of anti-HLA antibodies', 'timeFrame': 'Up to 2 years after NKX019 infusion'}]",14,18 Years,65 Years,ALL,False,"Nkarta, Inc.",INDUSTRY,0,72.0,ESTIMATED,2025-09-01T16:18:12.176443,v2_robust,True,True,False,False,True,
NCT02057835,"Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers","Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.",Placebo to BI 691751,"['BI 691751 high dose', 'BI 691751 low dose 2', 'BI 691751 low dose 1', 'BI 691751 middle dose', 'Placebo to BI 691751']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2014-03,2014-05,"[{'measure': 'Percentage of Participants With Drug Related Adverse Events', 'description': 'Percentage of participants with drug related adverse events (AEs)', 'timeFrame': 'From drug administration until 31 days after drug administration, 31 days'}]","[{'measure': 'Maximum Measured Concentration of the Analyte (Cmax)', 'description': 'Maximum measured concentration of the analyte in plasma/whole blood', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Maximum Measured Concentration of the Analyte (Cmax) - Overall', 'description': 'Maximum measured concentration of the analyte in plasma/whole blood for all participants (Chinese and Japanese)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Time From Dosing to the Maximum Measured Concentration of the Analyte (Tmax)', 'description': 'Time from (last) dosing to the maximum measured concentration of the analyte in plasma/whole blood', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Time From Dosing to the Maximum Measured Concentration of the Analyte (Tmax) - Overall', 'description': 'Time from (last) dosing to the maximum measured concentration of the analyte in plasma/whole blood for all participants (Chinese and Japanese)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Area Under the Concentration-time Curve of the Analyte Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)', 'description': 'Area under the concentration-time curve of the analyte in plasma/whole blood over the time interval from 0 extrapolated to infinity (AUC0-infinity)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Area Under the Concentration-time Curve of the Analyte Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity) - Overall', 'description': 'Area under the concentration-time curve of the analyte in plasma/whole blood over the time interval from 0 extrapolated to infinity for all participants (Chinese and Japanese)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Area Under the Concentration-time Curve of the Analyte Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz)', 'description': 'Area under the concentration-time curve of the analyte in plasma/whole blood over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Area Under the Concentration-time Curve of the Analyte Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC0-tz) - Overall', 'description': 'Area under the concentration-time curve of the analyte in plasma/whole blood over the time interval from 0 to the time of the last quantifiable data point (AUC0-tz) for all participants (Chinese and Japanese)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Terminal Half-life of the Analyte (T1/2)', 'description': 'Terminal half-life (T1/2) of the analyte in plasma/whole blood', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}, {'measure': 'Terminal Half-life of the Analyte (T1/2) - Overall', 'description': 'Terminal half-life (T1/2) of the analyte in plasma/whole blood for all participants (Chinese and Japanese)', 'timeFrame': '1 hour (h) before drug administration and 20minutes (min), 40min, 1h, 1h 30min, 2h, 2h 30min, 3h, 4h, 6h, 8h, 10h, 12h, 24h, 36h, 48h, 60h, 72h, 96h, 120h, 144h, 192h, 240h, 288h and 336h after drug administration'}]",11,18 Years,45 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,64.0,ACTUAL,2025-09-01T16:18:12.176512,v2_robust,True,True,True,False,True,
NCT05405608,The Effect of iv Ondansetron on Reducing Hypotension Due to BCIS in Total Knee Prosthesis Surgery,The Effect of Intravenous Ondansetron on Reducing Hypotension Due to Bone Cement Syndrome in Total Knee Prosthesis Surgery,Ondansetron,['Ondansetron'],1,OBSERVATIONAL,[],,,Bone Cement Syndrome,['Bone Cement Syndrome'],"['Bone cement syndrome', 'Hypotension', 'Ondansetron']",UNKNOWN,,2022-06,2022-09,"[{'measure': 'Hypotension (mmHg)', 'description': 'The primary outcome was hypotension.Hypotension was defined as systolic blood pressure(mmHg) decrease exceeded 20% of baseline', 'timeFrame': 'Intraoperative'}]","[{'measure': 'Systolic blood pressure (mmHg)', 'description': 'Change in systolic blood pressure (mmHg)', 'timeFrame': 'Intraoperative'}, {'measure': 'Diastolic blood pressure (mmHg)', 'description': 'Change in diastolic blood pressure (mmHg)', 'timeFrame': 'Intraoperative'}, {'measure': 'Heart rate (beats/min)', 'description': 'Change in heart rate (beats/min)', 'timeFrame': 'Intraoperative'}]",4,18 Years,,ALL,,Ataturk University,OTHER,0,1.0,ESTIMATED,2025-09-01T16:18:12.176521,v2_robust,False,True,False,False,False,
NCT04135508,A Phase III Study Evaluate the Efficacy and Safety of BAT1406 and Humira,"A Multicenter, Randomized, Double-Blind, Phase III Clinical Trial Parallel Controlled With Humira to Evaluate the Efficacy and Safety of BAT1406 Injection in the Treatment of Ankylosing Spondylitis",BAT1406,"['No Other Intervention Names', 'Adalimumab', 'BAT1406', 'Humira']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Ankylosing Spondylitis,['Ankylosing Spondylitis'],[],COMPLETED,,2016-12-13,2018-05-31,"[{'measure': 'Assessment in SpondyloArthritis international Society (ASAS) 20', 'description': 'the percentage of subjects achieving the Assessment in SpondyloArthritis international Society (ASAS) 20 treatment response', 'timeFrame': 'week 12'}]","[{'measure': 'Percentage of subjects achieving ASAS20 treatment response', 'description': 'the percentage of subjects achieving the Assessment in SpondyloArthritis international Society (ASAS) 20 treatment response', 'timeFrame': 'week 24'}, {'measure': 'Percentage of subjects achieving ASAS40 treatment response', 'description': 'the percentage of subjects achieving the Assessment in SpondyloArthritis international Society (ASAS) 40 treatment response', 'timeFrame': 'week 12; week 24'}, {'measure': 'Percentage of subjects achieving ASAS5/6 treatment response', 'description': 'the percentage of subjects achieving ASAS5/6 treatment response', 'timeFrame': 'week 12; week 24'}, {'measure': 'Percentage of subjects achieving BASDAI50 treatment response', 'description': 'the percentage of subjects achieving BASDAI50 treatment response', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of the performance status score compared with baseline', 'description': 'The performance status is used for measuring and evaluating disease activity in Ankylosing Spondylitis', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of the spinal pain score compared with baseline', 'description': 'the spinal pain is used for measuring and evaluating disease pain in Ankylosing Spondylitis', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of morning stiffness duration compared with baseline', 'description': 'The morning stiffness duration is used for measuring and evaluating disease activity in Ankylosing Spondylitis', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of ASDAS compared with baseline', 'description': 'The ASDAS is used for measuring and evaluating disease activity in Ankylosing Spondylitis', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of BASDAI compared with baseline', 'description': 'The BASDAI is used for measuring and evaluating disease activity in Ankylosing Spondylitis', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of BASFI compared with baseline', 'description': ""The BASFI consist of a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The BASFI score was derived based on the average of questions 1 through 10. The first 8 questions considered activities related to functional anatomy and the final 2 questions assessed the subject's ability to cope with everyday life over the last week. A 10 cm visual analog scale (VAS) was used to answer the questions and the mean of the ten scales gave the BASFI score a value between 0 (easy) and 10 (impossible)."", 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of BASMI compared with baseline', 'description': ""The BASMI measures the range of motion based on five clinical measurements: 1) cervical rotation, 2) tragus to wall distance, 3) lumbar side flexion, 4) lumbar flexion (modified Schober's) and 5) intermalleolar distance. The total BASMI score ranges from 0 to 10 reflecting mild to moderate disease activity and functional ability in the spinal column. The higher the BASMI score the more severe the patient's limitation of movement due to their ankylosing spondylitis"", 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of SF-36 compared with baseline', 'description': 'SF-36 survey will be used to calculate overall, mental (MCS) and physical (PCS) component scores at week 12; week 24 compared to baseline', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of EQ-5D compared with baseline', 'description': 'EQ-5D is a standard instrument to measure of health status', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of chest expansion compared with baseline', 'description': 'Chest expansion, measured in cm, is defined as the difference in thoracic circumference during full expiration versus full inspiration, measured at the fourth intercostal space (nipple line). The better of 2 tries was recorded. Higher scores indicate better health. Change from baseline greater than (\\>) 0 represented improvement.', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of MASES compared with baseline', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis Score quantitates inflammation of the entheses (enthesitis) by assessing pain at the following entheses (sites where tendons or ligaments insert into the bone): 1st costochondral joints left/right; 7th costochondral joints left/right; posterior superior iliac spine left/right; anterior superior iliac spine left/right; iliac crest left/right; 5th lumbar spinous process; and the proximal insertion of the Archilles tendon left/right.', 'timeFrame': 'week 12; week 24'}, {'measure': 'Change of swollen and tender joint counts at week 12 and week 24 compared with baseline.', 'timeFrame': 'week 12; week 24'}]",17,16 Years,65 Years,ALL,False,Bio-Thera Solutions,INDUSTRY,0,554.0,ACTUAL,2025-09-01T16:18:12.176646,v2_robust,True,True,True,False,False,
NCT04587908,A Phase 3 Study of TAS-205 in Patients With Duchenne Muscular Dystrophy（REACH-DMD）,"A Phase 3, Randomized, Placebo-controlled, Double-blind and Open-label, Extension Study of TAS-205 in Patients With Duchenne Muscular Dystrophy",TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort],"['Placebo [Ambulatory Cohort] only', 'TAS-205 [Ambulatory Cohort] [Non-ambulatory Cohort]']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Duchenne Muscular Dystrophy,['Duchenne Muscular Dystrophy'],[],ACTIVE_NOT_RECRUITING,,2020-11-01,2027-05,"[{'measure': 'Mean change from baseline to Week 52 in the time to rise from the floor', 'description': 'Ambulatory Cohort', 'timeFrame': 'Baseline to Week 52 of treatment'}, {'measure': 'Incidence of Adverse Events and Adverse Reactions', 'description': 'Non-ambulatory Cohort', 'timeFrame': 'Week 52'}]","[{'measure': 'Time measured in the time to rise from the floor test, as well as the change from baseline in each measured value', 'description': 'Ambulatory Cohort', 'timeFrame': 'Baseline to 52 weeks of treatment'}, {'measure': 'Change from baseline in the Timed Up and Go Test (TUG)', 'description': 'Ambulatory Cohort Timed Up and Go Test (TUG) The time required for the subject to stand up from a sitting position on a table (chair), walk to a cone placed 3 m ahead as quickly as possible, and then return to the table will be evaluated.\n\nThe time required for the subject to stand up from a sitting position on a table (chair), walk to a cone placed 3 m ahead as quickly as possible, and then return to the table will be evaluated.', 'timeFrame': 'Baseline to 52 weeks of treatment'}, {'measure': 'Change from baseline in North Star Ambulatory Assessment (NSAA)', 'description': 'Ambulatory Cohort', 'timeFrame': 'Baseline to 52 weeks of treatment'}, {'measure': 'Change from baseline in Six-minutes Walk Test (6MWT)', 'description': 'Ambulatory Cohort', 'timeFrame': 'Baseline to 52 weeks of treatment'}, {'measure': 'Measured values of Muscle volume index (MVI), Percent Muscle volume index (%MVI) and skeletal muscle mass in skeletal muscle computed tomography (CT), as well as the change from baseline in each measured value', 'description': 'Ambulatory Cohort', 'timeFrame': 'Baseline to 52 weeks of treatment'}, {'measure': 'Assessment of upper limb function: The Brooke upper extremity scale, measured values of performance of the upper limb (PUL) and change from baseline in measured values', 'description': 'Non-ambulatory Cohort', 'timeFrame': 'week 52'}, {'measure': 'Change from baseline in grip strength', 'description': 'Non-ambulatory Cohort', 'timeFrame': 'week 52'}, {'measure': 'Pulmonary function tests: measured effort lung capacity (FVC, %FVC), volume in 1 second (Forced Expiratory Volume :FEV1.0), fraction in 1 second (FEV1.0%), and change from baseline (at enrollment) of measured values.', 'description': 'Non-ambulatory Cohort', 'timeFrame': 'week 52'}, {'measure': 'Echocardiography: Measured EF and FS and change from baseline in measured values', 'description': 'Non-ambulatory Cohort', 'timeFrame': 'week 52'}]",11,5 Years,,MALE,False,"Taiho Pharmaceutical Co., Ltd.",INDUSTRY,0,104.0,ACTUAL,2025-09-01T16:18:12.176695,v2_robust,True,True,False,False,True,
NCT03173508,Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With Respiratory Disease at Altitude,"Effect of Acetazolamide on Right Ventricular Function at Rest in Patients With Chronic Obstructive Pulmonary Disease at Altitude. A Randomized, Placebo-controlled, Double-blind Parallel Trial",ACETAZOLAMIDE oral capsule,"['ACETAZOLAMIDE oral capsule', 'Placebo oral capsule']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],"['right ventricular function', 'echocardiography', 'obstructive airway disease', 'emphysema', 'acetazolamide', 'altitude']",COMPLETED,,2017-05-24,2018-08-02,"[{'measure': 'pulmonary artery pressure', 'description': 'Difference in altitude-induced change of pulmonary artery pressure (PAP) between acetazolamide and placebo group, measured by transthoracic echocardiography (tricuspid pressure gradient and pulmonary valve acceleration time)', 'timeFrame': 'Day 2 at 760m and 3200m'}]","[{'measure': 'pulmonary artery pressure', 'description': 'Difference at altitude of pulmonary artery pressure (PAP) between acetazolamide and placebo group, measured by transthoracic echocardiography (tricuspid pressure gradient and pulmonary valve acceleration time)', 'timeFrame': 'Day 2 at 3200m'}, {'measure': 'cardiac output', 'description': 'Difference in altitude-induced change of cardiac output between acetazolamide and placebo group, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 760m and 3200m'}, {'measure': 'cardiac output', 'description': 'Difference at altitude between acetazolamide and placebo group in cardiac output, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 3200m'}, {'measure': 'right heart dimensions', 'description': 'Difference in altitude-induced change of right heart dimensions between acetazolamide and placebo group, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 760m and 3200m'}, {'measure': 'right heart dimensions', 'description': 'Difference at altitude of right heart dimensions between acetazolamide and placebo group, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 3200m'}, {'measure': 'right heart function', 'description': 'Difference in altitude-induced change of right heart function between acetazolamide and placebo group, measured by transthoracic echocardiography (TAPSE)', 'timeFrame': 'Day 2 at 760m and 3200m'}, {'measure': 'right heart function', 'description': 'Difference at altitude of right heart function between acetazolamide and placebo group, measured by transthoracic echocardiography (TAPSE)', 'timeFrame': 'Day 2 at 3200m'}, {'measure': 'stroke volume', 'description': 'Difference in altitude-induced change of stroke volume between acetazolamide and placebo group, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 760m and 3200m'}, {'measure': 'stroke volume', 'description': 'Difference at altitude between acetazolamide and placebo group in stroke volume, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 3200m'}, {'measure': 'volumes', 'description': 'Difference in altitude-induced change of volumes between acetazolamide and placebo group, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 760m and 3200m'}, {'measure': 'volumes', 'description': 'Difference at altitude of volumes between acetazolamide and placebo group, measured by transthoracic echocardiography', 'timeFrame': 'Day 2 at 3200m'}]",12,18 Years,75 Years,ALL,False,University of Zurich,OTHER,1,110.0,ACTUAL,2025-09-01T16:18:12.176714,v2_robust,True,True,True,False,False,
NCT03337308,"A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy","A Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of Bempedoic Acid 180 Mg + Ezetimibe 10 Mg Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo Alone in Patients Treated With Maximally Tolerated Statin Therapy",Bempedoic Acid,"['Zetia', 'Placebo', 'Placebos', 'Bempedoic Acid', 'ETC-1002', 'Ezetimibe']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyperlipidemias,['Hyperlipidemias'],"['hyperlipidemia', 'heterozygous familial hypercholesterolemia', 'atherosclerotic cardiovascular disease', 'high cholesterol', 'ASCVD', 'HeFH', 'LDL']",COMPLETED,,2017-10-23,2018-07-18,"[{'measure': 'Percent Change From Baseline to Week 12 in Low-density Lipoprotein Cholesterol (LDL-C)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for LDL-C. Baseline was defined as the mean of the LDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in LDL-C was analyzed using analysis of covariance (ANCOVA) with treatment group and randomization stratification as a factors and baseline LDL-C as a covariate. Percent change from baseline was calculated as: (\\[LDL-C value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100. For LDL-C, if measured LDL-C value was available, measured LDL-C was used.', 'timeFrame': 'Baseline; Week 12'}]","[{'measure': 'Percent Change From Baseline to Week 12 in High-sensitivity C-reactive Protein (hsCRP)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for hsCRP. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in hsCRP was analyzed using a non-parametric analysis. Percent change from baseline was calculated as: (\\[hsCRP value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.', 'timeFrame': 'Baseline; Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for non-HDL-C. Baseline was defined as the mean of the non-HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline in non-HDL-C was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline non-HDL-C as a covariate. Percent change from baseline was calculated as: (\\[non-HDL-C value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.', 'timeFrame': 'Baseline; Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Total Cholesterol (TC)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TC. Baseline was defined as the mean of the TC values from Week -2 and predose Day 1/Week 0. Percent change from baseline in TC was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline TC as a covariate. Percent change from baseline was calculated as: (\\[TC value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.', 'timeFrame': 'Baseline; Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Apolipoprotein B (Apo B)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for apo B. Baseline was defined as the predose Day 1/Week 0 value. Percent change from baseline in apo B was analyzed using ANCOVA with treatment group and randomization stratification as a factors and baseline apo B as a covariate. Percent change from baseline was calculated as: (\\[apo B value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.', 'timeFrame': 'Baseline; Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in High-density Lipoprotein Cholesterol (HDL-C)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for HDL-C. Baseline was defined as the mean of the HDL-C values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\\[HDL-C value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.', 'timeFrame': 'Baseline; Week 12'}, {'measure': 'Percent Change From Baseline to Week 12 in Triglycerides (TGs)', 'description': 'Blood samples were drawn after a minimum 10-hour fast (water was allowed) at pre-specified intervals. Samples were collected and analyzed for TGs. Baseline was defined as the mean of the TGs values from Week -2 and predose Day 1/Week 0. Percent change from baseline was calculated as: (\\[TGs value at Week 12 minus Baseline value\\] divided by \\[Baseline Value\\]) multiplied by 100.', 'timeFrame': 'Baseline; Week 12'}]",7,18 Years,,ALL,False,"Esperion Therapeutics, Inc.",INDUSTRY,0,382.0,ACTUAL,2025-09-01T16:18:12.176772,v2_robust,True,True,True,False,False,
NCT03737708,A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA),"Compare Efficacy and Safety Between Biologics + Methotrexate (MTX) vs Biologics + Tacrolimus (TAC) (Switched From Biologics + Methotrexate (MTX)) in the Patients With Rheumatoid Arthritis (RA): Randomized, Interventional, Open, Active Controlled, Parallel Group, Multicenter-designed, Phase 4 Clinical Trial",tacrolimus,"['methotrexate', 'FK506', 'tacrolimus', 'Prograf']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Rheumatoid Arthritis (RA),['Rheumatoid Arthritis (RA)'],"['tacrolimus', 'abatacept', 'Prograf', 'adalimumab', 'methotrexate', 'tocilizumab', 'FK506']",COMPLETED,,2019-02-13,2020-06-16,"[{'measure': 'Change in disease activity score 28 (DAS28) erythrocyte sedimentation rate score (ESR) score at 12 weeks', 'description': ""DAS28-ESR will be calculated using data from tender joint count (TJC) (28 joints), swollen joint count (SJC) (28 joints), ESR and Subject's Global Assessment of Arthritis (SGA) with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA.\n\nHigh disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission."", 'timeFrame': 'From baseline (week 1) to week 12'}]","[{'measure': 'Disease activity score 28 (DAS28) erythrocyte sedimentation rate (ESR) rate score at 4 weeks', 'description': 'DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA.\n\nHigh disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission.', 'timeFrame': 'At 4 weeks'}, {'measure': 'DAS28 (ESR) score at 8 weeks', 'description': 'DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA.\n\nHigh disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission.', 'timeFrame': 'At 8 weeks'}, {'measure': 'DAS28 (ESR) score at 12 weeks', 'description': 'DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA.\n\nHigh disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission.', 'timeFrame': 'At 12 weeks'}, {'measure': 'Change in DAS28 (ESR) score at 4 weeks', 'description': 'DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA.\n\nHigh disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission.', 'timeFrame': 'From baseline (week 1) to week 4'}, {'measure': 'Change in DAS28 (ESR) score at 8 weeks', 'description': 'DAS28-ESR will be calculated using data from TJC (28 joints), SJC (28 joints), ESR and SGA with the formula; DAS28- ESR = 0.56√(TJC) + 0.28√(SJC) + 0.70 ln ESR + 0.014 x SGA.\n\nHigh disease activity: DAS28 score exceeding 5.1 Moderate disease activity: DAS28 score of exceeding 3.2 to 5.1 Low disease activity: DAS28 score of less than or equal to 3.2 If the DAS28 score is less than 2.6, the participant will be considered to be in DAS28 remission.', 'timeFrame': 'From baseline (week 1) to week 8'}, {'measure': 'ACR 20 response rate', 'description': ""Percent of participants with American College of Rheumatology (ACR) 20 response rate The ACR20 response requires that all criteria from (1) to (3) be met compared with Week 0 (baseline); (1), Tender Joint Count (TJC) \\>= 20% reduction; (2), Swollen Joint Count (SJC) \\>= 20% reduction;(3) \\>= 20% improvement in three or more of the following five parameters - \\[1\\] subject's assessment of pain, \\[2\\] Subject's Global Assessment of Arthritis (SGA), \\[3\\] Physician's Global Assessment of Arthritis (PGA), \\[4\\] health assessment questionnaire-disability index (HAQ-DI), \\[5\\] acute phase reactant (erythrocyte sedimentation rate (ESR))."", 'timeFrame': 'At 12 weeks'}, {'measure': 'ACR50 response rate', 'description': 'Percent of participants with ACR50 response rate The ACR50 response indicates a 50% improvement in all criteria used in the ACR20 assessment.', 'timeFrame': 'At 12 weeks'}, {'measure': 'ACR70 response rate', 'description': 'Percent of participants with ACR70 response rate The ACR70 response indicates a 70% improvement in all criteria used in the ACR70 assessment.', 'timeFrame': 'At 12 weeks'}, {'measure': 'Safety assessed by Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Safety assessed by incidence of serious adverse events (SAE)', 'description': 'Adverse Event (AE) is considered ""serious"" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Safety assessed by incidence of treatment emergent adverse events (TEAE)', 'description': 'Treatment Emergent Adverse Event (TEAE) is defined as any AE which starts, or worsens, after the first dose of study drug through 30 days after the last dose of study drug.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Number of participants with laboratory value abnormalities and/or adverse events (AEs)', 'description': 'Number of participants with potentially clinically significant laboratory values.', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Number of participants with vital sign abnormalities and /or adverse events (AEs)', 'description': 'Number of participants with potentially clinically significant vital sign values.', 'timeFrame': 'Up to 16 weeks'}, {'measure': 'Number of participants with physical exam abnormalities and/or adverse events (AEs)', 'description': 'Number of participants with potentially clinically significant physical exam values.', 'timeFrame': 'Up to 16 weeks'}]",15,19 Years,75 Years,ALL,False,"Astellas Pharma Korea, Inc.",INDUSTRY,0,21.0,ACTUAL,2025-09-01T16:18:12.176896,v2_robust,True,True,True,False,True,
NCT00295308,Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients,Clonidine for Relapse Prevention in Buprenorphine-Maintenance Patients,Clonidine,"['Clonidine', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Opioid-Related Disorders,['Opioid-Related Disorders'],"['Opioid Dependence', 'Clonidine', 'Buprenorphine', 'Opioid Abstinence', 'Relapse']",COMPLETED,,2005-11-08,2014-07-30,"[{'measure': 'Opiate-negative urine screens', 'timeFrame': '38 weeks'}]","[{'measure': 'HIV risk behaviors', 'timeFrame': '38 weeks'}, {'measure': 'Craving', 'timeFrame': '18 weeks'}]",3,18 Years,50 Years,ALL,True,National Institute on Drug Abuse (NIDA),NIH,0,208.0,ACTUAL,2025-09-01T16:18:12.176982,v2_robust,True,True,True,False,False,
NCT02662608,Compassionate Use of Brontictuzumab for Adenoid Cystic Carcinoma (ACC),NOTCH 1 Inhibitor Brontictuzumab for Adenoid Cystic Carcinoma Bearing Two Activating NOTCH1 Mutations,Brontictuzumab,"['Brontictuzumab', 'OMP-52M51']",2,INTERVENTIONAL,['NA'],,,Adenoid Cystic Carcinoma,['Adenoid Cystic Carcinoma'],['Brontictuzumab'],COMPLETED,,2015-12-29,2016-03-06,"[{'measure': 'Number of Participants With Disease Progression', 'description': 'Tumor response for measurable disease based on Response Evaluation Criteria In Solid Tumors (RECIST) to establish disease progression. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': '6 weeks'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:12.177107,v2_robust,True,True,True,False,False,
NCT01396408,A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours,Sunitinib,"['Temsirolimus', 'Sunitinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Rare Tumours,['Advanced Rare Tumours'],[],ACTIVE_NOT_RECRUITING,,2012-02-09,2025-12-31,"[{'measure': 'Objective Response', 'description': 'Objective response as assessed by RECIST version 1.1 criteria as a 30% decrease in the sum of the longest diameters of the target lesions (partial response) maintained for at least 4 weeks, or complete disappearance of disease and cancer related symptoms (complete response), also maintained for at least 4 weeks. Early progression is defined as progressive disease at or prior to the first assessment. The 95% confidence interval for response rate will be calculated. The median and range of the duration of response will be assessed', 'timeFrame': 'Every 4 weeks'}]","[{'measure': 'Efficacy Outcomes', 'description': '* Response duration: median and range\n* Time to progression: median, 95% confidence interval\n* Progression free survival: median, 95% confidence interval\n* Overall survival: median, 95% confidence interval\n* Comparison of the time to first and second progression for patients who receive sunitinib and temsirolimus in sequence.', 'timeFrame': '48 months'}, {'measure': 'Translational Research', 'description': 'Primary tumour tissue specimens and baseline blood samples, will be obtained from all subjects prior to first dose for genetic analysis and other evaluation. In addition, optional for responding patients will be a fresh tumour biopsy at time of progression and also optional for patients entered in the second stage of accrual for any disease cohort will be fresh tumour biopsy at baseline.', 'timeFrame': '48 months'}, {'measure': 'Safety Monitoring', 'description': ""Adverse events will be monitored on an ongoing basis by the central office and their frequencies reported annually at investigators' meetings."", 'timeFrame': 'Daily up to an expected average of 4 weeks after treatment'}]",4,16 Years,,ALL,False,Canadian Cancer Trials Group,NETWORK,1,137.0,ACTUAL,2025-09-01T16:18:12.177117,v2_robust,True,True,False,False,True,
NCT05083208,PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma,"A Single Arm, Multi-center, Phase Ib/II Clinical Trial of PI3Kδ Inhibitor Parsaclisib Combined With Chidamide for the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma",Parsaclisib,"['PI3K inhibitor', 'Parsaclisib', 'IBI376', 'Chidamide']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Peripheral T-Cell Lymphoma,['Peripheral T-Cell Lymphoma'],"['Relapsed/Refractory Peripheral T-cell Lymphoma', 'PI3Kδ inhibitor', 'Chidamide']",TERMINATED,The clinical development of parsaclisib was stopped by it's manufacturer.,2022-02-20,2025-02-08,"[{'measure': 'objective response rate', 'description': 'the total proportion of patients with complete response (CR) and partial response (PR)', 'timeFrame': ""every 8 or 12 weeks from the day of the first cycle to 2 years after the last patient's enrollment (each cycle is 28 days).""}]","[{'measure': '2-year progression-free survival', 'description': 'the total proportion of patients with no progression from date of the first day of treatment to the date of confirmed progressive disease or death which one occurs first', 'timeFrame': ""from the day of the first cycle of treatment to the date of confirmed progressive disease or death, whichever occurs first, up to 2 years after last patient's enrollment (each cycle is 28 days).""}, {'measure': '2-year overall survival', 'description': 'from date of first day of treatment to the date of death by any cause', 'timeFrame': ""from date of the first cycle of treatment to the date of death from any cause, assessed up to 2 years after last patient's enrollment (each cycle is 28 days).""}, {'measure': 'incidence and relationship with study drugs of grade 3-4 adverse events', 'description': 'the incidence and relationship with study drugs of grade 3 or 4 adverse events (based on NCI CTC-AE v4.03', 'timeFrame': ""from the date of the first cycle of treatment to 2 years after last patient's enrollment (each cycle is 28 days).""}]",4,18 Years,75 Years,ALL,False,Henan Cancer Hospital,OTHER_GOV,0,12.0,ACTUAL,2025-09-01T16:18:12.177140,v2_robust,True,True,False,True,True,The clinical development of parsaclisib was stopped by it's manufacturer.
NCT06556108,ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors,"A Single-Arm, Single-Center, Open-Label Pilot Study of Anti-ALPP CAR-T Cells for Alkaline Phosphatase, Placental (ALPP)-Positive Advanced Solid Tumors",Fludarabine,"['Cyclophosphamide', 'Fludarabine']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],[],RECRUITING,,2018-01-01,2026-01-30,"[{'measure': 'Dose Limiting Toxicity or Maximum Tolerated Dose (MTD)', 'description': 'Dose Limiting Toxicity (DLT) is defined as patients with the adverse event (AE) or laboratory abnormality assessed by the principal investigator (PI). These should be possibly related to ALPP CAR-T cell therapy, and should be unrelated to the disease itself, disease progression, concomitant diseases or concomitant medication. The MTD is the highest dose at which no more than one out of six patients experiences DLT, or the highest dose level tested if no DLTs are observed across all dose levels.', 'timeFrame': 'Day 28 post-initial ALPP CAR-T infusion'}, {'measure': 'Overall response rate', 'description': 'The efficacy of ALPP CAR-T is assessed by the objective response rate (ORR) according to RECIST 1.1 and iRECIST. ORR is defined as patients who have achieved either a partial response (PR) or a complete response (CR).', 'timeFrame': 'Day 0 - Day 730'}, {'measure': 'Treatment-related adverse events as assessed by CTCAE v5.0', 'description': 'The type, incidence and severity of adverse events include clinically significant post-treatment abnormal laboratory examination results, abnormal physical examination and blood examination results, bone marrow examination results, etc. Clinical and laboratory AEs will be classified according to the National Cancer Institute general terminology standard for adverse events (NCI CTCAE) version 5.0.', 'timeFrame': 'Day 0 - Day 730'}]","[{'measure': 'Duration of response', 'description': 'The efficacy of ALPP CAR-T will be assessed by duration of response (DOR). The DOR refers to the length of time from the first appearance of a treatment response to the first occurrence of progressive disease or recurrence.', 'timeFrame': 'Day 0 - Day 730'}, {'measure': 'Progression free survival', 'description': 'The efficacy of ALPP CAR-T will be assessed by progression free survival (PFS). The PFS refers to the time from treatment to progressive disease or death for any reason.', 'timeFrame': 'Day 0 - Day 730'}, {'measure': 'Overall survival', 'description': 'The efficacy of ALPP CAR-T will be assessed by overall survival (OS). The OS refers to the time from treatment to death.', 'timeFrame': 'Day 0 - Day 730'}, {'measure': 'Expansion and persistence of ALPP CAR-T cells in peripheral blood or serous effusion (if present)', 'description': 'Blood and serous effusion (if present) samples were collected to measure persistence of infused ALPP CAR-T using polymerase chain reaction of a vector specific sequence in deoxyribonucleic acid (DNA) extracted from peripheral blood mononuclear cell (PBMC).', 'timeFrame': 'Day 0 - Day 730'}, {'measure': 'Cell cytokine levels and tumor biomarkers in peripheral blood and serous effusion (if present)', 'description': 'Blood samples and serous effusion (if present) were collected to measure cytokines IL-6, TNF-α, IL-8, IFN-γ, C-reactive protein (CRP), as well as ALPP concentration, Alpha-fetoprotein (AFP), Human chorionic gonadotropin (hCG), etc.', 'timeFrame': 'Day 0 - Day 730'}]",8,18 Years,70 Years,ALL,False,Xinqiao Hospital of Chongqing,OTHER,0,9.0,ESTIMATED,2025-09-01T16:18:12.177177,v2_robust,True,True,False,False,True,
NCT04689425,Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer,The Efficacy and Safety of Umbilical Cord Blood Mononuclear Cell Gel in the Treatment of Refractory Diabetic Foot Ulcer.,Umbilical cord blood mononuclear cell gel（MNC）,"['PRP', 'The platelet rich plasma（PRP）', 'MNC+PRP', 'Umbilical cord blood mononuclear cell gel（MNC）']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetic Foot Ulcer,['Diabetic Foot Ulcer'],"['Diabetic Foot Ulcer', 'Umbilical cord blood mononuclear cells']",UNKNOWN,,2021-03-30,2024-12-31,"[{'measure': 'Wound area reduction rate', 'description': 'The ratio of the reduced area after one week of treatment to the original area', 'timeFrame': 'one week'}]","[{'measure': 'Wound healing rate at 4 weeks', 'description': 'Percentage of patients with healed wound at 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'Amputation rate at 8 weeks', 'description': 'Percentage of patients with major amputation at 8 weeks', 'timeFrame': '8 weeks'}]",3,18 Years,80 Years,ALL,False,Peking University Third Hospital,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:12.177225,v2_robust,True,True,False,False,False,
NCT06067425,"Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia","A Phase 2, Open-label, Multi-center, 2-stage Sequential Cohort, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Subcutaneous SAR442501 in Pediatric Participants With Achondroplasia",SAR442501,['SAR442501'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteochondrodysplasia,['Osteochondrodysplasia'],[],TERMINATED,Sponsor decision. Not related to safety concern.,2023-10-10,2025-02-12,"[{'measure': 'Number of participants with adverse events (AE), serious adverse events (SAE), and adverse events of special interest (AESI) during the treatment-emergent period', 'timeFrame': 'Baseline to Week 52'}]","[{'measure': 'Change in annualized growth velocity (AGV) Zscore', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in AGV (cm/year)', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in height Z score', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper-to-lower body segment ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper to lower extremity ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in sitting to standing height ratio (crown-to-rump length to total length for infants)', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in arm span to height ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper arm to forearm length ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in upper leg to lower leg ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in head circumference to height ratio', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in brainstem parameter', 'description': 'Change in surface area of the bony foramen magnum (cm2) as measured by head and neck Magnetic Resonance Imaging (MRI).', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in skull parameter', 'description': 'Change in dimensions of skull base parameters, and degree of synchondroses fusion as measured by head and neck MRI.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in spine morphometric parameter', 'description': 'Change in grading of cord compression and cord constriction as assessed by head and neck MRI.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in volumetric parameter', 'description': 'Change in brainstem and spinal cord volume as measured by head and neck MRI.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Change in overall health-related quality of life score in the PedsQL Inventory Generic Core Scale', 'description': 'PedsQL Generic Core Scales, global score ranging from 0-100, with higher scores representing better outcomes', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in fatigue score in the PedsQL Multidimensional Fatigue Scale', 'description': 'PedsQL Multidimensional Fatigue Scale, global score ranging from 0-100, with higher scores representing better outcomes', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in present pain and worst pain rating (PPQ) score', 'description': 'Pediatric Pain Questionnaire (PPQ) score value between 0-4. The lower the better.', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in mobility and symptom rating (STEMS) score', 'description': 'Screening Tool for Everyday Mobility and Symptoms (STEMS) score value between 1-5. The lower the better.', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Change in developmental score in the Achondroplasia Developmental Recording Form', 'description': 'Achondroplasia Developmental Recording Form to record the age at which participants achieve developmental milestones. The earlier the better.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Assessment of pharmacokinetic (PK) parameter: plasma concentration of SAR442501', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: maximum plasma concentration observed (Cmax)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: time to reach Cmax (Tmax)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: Area under the plasma concentration versus time curve calculated using the trapezoidal method during a dose interval (AUC0-t)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of PK parameter: concentration observed before treatment administration during repeated dosing (Ctrough)', 'timeFrame': 'Baseline to Week 26 and 52'}, {'measure': 'Assessment of pharmacodynamics (PD) parameter: change in collagen X biomarker (CXM) levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in osteocalcin levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in bone-specific alkaline phosphatase', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in procollagen type 1 N-terminal propeptide (P1NP) levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Assessment of PD parameter: change in collagen-type 1 C-Telopeptide (CTX) levels', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Number of participants with treatment-emergent anti-drug antibodies (ADA)', 'timeFrame': 'Baseline to Week 26 and Week 52'}, {'measure': 'Changes in neurological examination', 'description': 'Percentage of participants with changes (i.e. abnormal to normal or normal to abnormal) in neurological examination findings', 'timeFrame': 'Baseline through Week 26 and Week 52'}]",32,0 Days,12 Years,ALL,False,Sanofi,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:12.177235,v2_robust,True,True,False,True,True,Sponsor decision. Not related to safety concern.
NCT01429025,"Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma","A Pilot/Feasibility Phase I Study of Bendamustine, Rituximab and Lenalidomide in Patients With Refractory/Relapsed Indolent NHL",bendamustine,"['lenalidomide', 'bendamustine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Refractory/Relapsed Indolent Non-Hodgkin Lymphoma,['Refractory/Relapsed Indolent Non-Hodgkin Lymphoma'],"['recurrent grade 1 follicular lymphoma', 'recurrent grade 2 follicular lymphoma', 'recurrent marginal zone lymphoma', 'recurrent small lymphocytic lymphoma', 'extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue', 'Waldenström macroglobulinemia', 'nodal marginal zone B-cell lymphoma', 'splenic marginal zone lymphoma']",COMPLETED,,2012-05,2019-07-01,"[{'measure': 'Maximum-tolerated dose of lenalidomide in combination with bendamustine hydrochloride and rituximab', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Toxicity profile', 'timeFrame': 'Up to 5 years'}, {'measure': 'Progression-free survival', 'timeFrame': 'Time from registration to the earliest date of documented disease progression or death due to any cause, assessed up to 5 years'}, {'measure': 'Overall response rate', 'timeFrame': 'Up to 5 years'}, {'measure': 'Complete response rate', 'timeFrame': 'Up to 5 years'}]",5,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,2,26.0,ACTUAL,2025-09-01T16:18:12.177243,v2_robust,True,True,True,False,False,
NCT06066125,A Study to Evaluate the Efficacy and Safety of AK111 in Subjects With Moderate to Severe Plaque Psoriasis,"A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Clinical Study to Evaluate the Efficacy and Safety of AK111 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis",AK111,"['AK111', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriasis,"['Psoriasis', 'Skin Diseases']",[],COMPLETED,,2023-03-31,2024-08-19,"[{'measure': 'The percentage of subjects who achieved at least 75% reduction in psoriasis area and severity index(PASI) score from baseline (PASI 75) and the percentage of subjects who achieved static physician global assessment(sPGA) 0/1 at week 12.', 'description': 'PASI is a combined assessment of a lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). The body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for a final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%),and severity is estimated by clinical signs, erythema, induration and desquamation: scale 0 (none) to 4 (maximum).Final PASI = sum of severity parameters for each area \\* area score weight of section (head: 0.1, arms: 0.2, body: 0.3,legs: 0.4).PASI 50, PASI75 and PASI 90 were defined as participants achieving \\>= 50%, \\>= 75% or \\>= 90% improvement from baseline, respectively.The sPGA is an instrument providing a subjective evaluation of the overall severity of psoriasis, based on severity of induration, scaling, and erythema. The scores are: 0 = clear; 1 = minimal; 2 = mild; 3 = moderate; 4 = marked; 5 =severe.', 'timeFrame': 'at week 12'}]","[{'measure': 'The percentage of subjects who achieved at least 90% reduction in PASI score from baseline (PASI 90) at week 12.', 'timeFrame': 'at week 12'}, {'measure': 'The percentage of subjects who achieved PASI 75 and the percentage of subjects who achieved sPGA 0/1 at week 52.', 'timeFrame': 'at week 52'}]",3,18 Years,,ALL,False,Akeso,INDUSTRY,0,351.0,ACTUAL,2025-09-01T16:18:12.177256,v2_robust,True,True,True,False,False,
NCT00216125,Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer,A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With or Without Consolidation Docetaxel in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN01-24,Cisplatin,"['Etoposide', 'Docetaxel', 'Cisplatin', 'Platinol', 'Taxol', 'VP-16']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],['Non-Small Cell Lung Cancer'],COMPLETED,,2002-02,2008-03,"[{'measure': 'Overall Survival', 'description': 'A comparison of overall survival following cisplatin/etoposide/radiotherapy between the consolidation docetaxel and observation arms was analyzed using Kaplan-Meier analysis. Median survival time and a log rank test were used to analyze the hypothesized improvement in overall survival.', 'timeFrame': 'Participants were measured from treatment initiation to death'}]","[{'measure': 'Progression Free Survival', 'description': 'A comparison of progression free survival following cisplatin/etoposide/radiotherapy between the consolidation docetaxel and observation arms was analyzed using Kaplan-Meier analysis. Median PFS time and a log rank test were used to analyze the hypothesized improvement in progression free survival.\n\nProgression is defined by RECIST as a 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed (over baseline if no decrease during therapy) or by the appearance of a new lesion.', 'timeFrame': 'Participants were monitored from treatment initiation until disease progression per RECIST or death'}]",2,18 Years,,ALL,False,"Nasser Hanna, M.D.",OTHER,2,243.0,ACTUAL,2025-09-01T16:18:12.177278,v2_robust,True,True,True,False,False,
NCT00473525,12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin,"A Phase 2a, Randomized, Placebo-Controlled, Parallel Group, Multiple-Dose Study To Evaluate The Efficacy, Safety, And Tolerability Of 12-Week Oral Administration Of PF-00734200 Tablets To Subjects With Type 2 Diabetes Mellitus On Stable Treatment With Metformin",Placebo,"['PF-00734200 2 mg QD', 'PF-00734200 10 mg QD', 'Placebo', 'PF-00734200 5 mg QD', 'PF-00734200 20 mg QD']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2007-07,2008-06,"[{'measure': 'HbA1C levels (%)', 'timeFrame': '12 weeks'}, {'measure': 'Evaluation of Dose Response in HbA1c (%)', 'timeFrame': '12 weeks'}]","[{'measure': 'Insulin and Glucose AUC following a mixed meal tolerance test', 'timeFrame': '12 weeks'}, {'measure': 'Proportion of subjects achieving ADA glycemic goal of Hb A1c <7%', 'timeFrame': '12 weeks'}, {'measure': 'Incidence of Adverse Events', 'timeFrame': '12 weeks'}]",5,18 Years,70 Years,ALL,False,Pfizer,INDUSTRY,0,303.0,ACTUAL,2025-09-01T16:18:12.177296,v2_robust,True,True,True,False,True,
NCT03467425,INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design,The Clinical Effectiveness of Fluticasone Furoate/Umeclidinium Bromide/Vilanterol in a Single Inhaler (TRELEGY™ ELLIPTA™) When Compared With Non-ELLIPTA Multiple Inhaler Triple Therapies in COPD Patients Within a Usual Care Setting,FF/UMEC/VI,"['LAMA', 'FF/UMEC/VI', 'COPD rescue medications', 'LABA', 'Inhaled Corticosteroid']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']","['FF/VI/UMEC', 'TRELEGY ELLIPTA', 'COPD', 'Effectiveness']",COMPLETED,,2018-04-11,2019-10-10,"[{'measure': 'Number of Responders and Non-responders Based on the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) at Week 24 and Number of Participants With Imputed CAT Score at Week 24', 'description': 'The CAT is a 8-item questionnaire, used to measure the health status of par. with COPD. Par. rated their experience on a 6-point scale: 0 (no impact) to 5 (maximum impact). CAT score was calculated by summing the non-missing scores of the 8 items with a range of 0-40. Higher scores indicate greater disease impact. Responders were par. who had a change from Baseline score \\>=2 at Week 24. Non-responders were the par. who had change from Baseline score \\<2 at Week 24. Change from Baseline was calculated as Week 24 value minus the Baseline value (Day 1). A composite strategy was applied when intercurrent events of randomized treatment modification, change in pulmonary rehabilitation or start of oxygen therapy occurred, otherwise a treatment policy strategy was applied. Missing Week 24 CAT data were imputed assuming missing at random and are presented in a separate category. Number of responders, non-responders based on CAT and par. with imputed CAT score at Week 24 are presented.', 'timeFrame': 'At Week 24'}]","[{'measure': 'Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Week 24', 'description': 'FEV1 is a measure of lung function and is defined as the maximal amount of air that can be forcefully exhaled in one second. FEV1 measurements were collected using a spirometer. Baseline was defined as the value recorded at Day 1. Change from Baseline was calculated as FEV1 value at Week 24 minus the Baseline value. A treatment policy strategy was used for the intercurrent events of randomized treatment discontinuation, randomized treatment modification, change of pulmonary rehabilitation status and start of oxygen therapy. Only those participants with non-missing covariates were included in the analysis.', 'timeFrame': 'Baseline (Day 1) and at Week 24'}, {'measure': 'Percentage of Participants Making at Least 1 Critical Error in Inhalation Technique at Week 24', 'description': 'Participants were trained on the correct use of their inhaler devices. All participants who had spirometry measured were to have an assessment of inhaler errors. During the assessment, participants were asked to demonstrate inhaler use when taking their regular dose of medication. A critical error is defined as an error that is most likely to result in no or significantly reduced medication being inhaled. These errors were recorded in an error checklist, during the assessment. A hypothetical strategy was used for the intercurrent event of randomized treatment modification. Percentage of participants making at least 1 critical error in inhalation technique at the Week 24 is presented.', 'timeFrame': 'At Week 24'}]",3,40 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,3109.0,ACTUAL,2025-09-01T16:18:12.177388,v2_robust,True,True,True,False,False,
NCT06923176,Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment,Effect of Biejia-Ruangan Compound on Survival Rate and Recurrence Rate of Hepatocellular Carcinoma After Radical Treatment,Biejia-Ruangan compound,['Biejia-Ruangan compound'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hepatocellular Carcinoma (HCC),['Hepatocellular Carcinoma (HCC)'],[],NOT_YET_RECRUITING,,2025-04-19,2031-04-30,"[{'measure': 'Recurrence-free survival', 'timeFrame': '96 weeks'}]","[{'measure': 'Overall survival rate', 'timeFrame': '96 weeks'}, {'measure': 'quality of life (QOL) questionnaire', 'description': 'The questionnaire includes appetite, sleep, fatigue, pain, etc.', 'timeFrame': '96 weeks'}]",3,18 Years,75 Years,ALL,False,Zhiyun Yang,OTHER,0,704.0,ESTIMATED,2025-09-01T16:18:12.177421,v2_robust,True,True,False,False,False,
NCT04007276,"The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients","The Effect of Lumify™ (Brimonidine Tartrate Ophthalmic Solution 0.025%) on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients Using Brimonidine 0.2%, 0.15%, or 0.1%",brimonidine tartrate ophthalmic solution 0.025%,"['brimonidine tartrate ophthalmic solution 0.025%', 'Lumify™']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Glaucoma,"['Glaucoma', 'Glaucoma, Open-Angle', 'Glaucoma; Drugs', 'Droopy Eyelid', 'Ptosis', 'Glaucoma, Primary Open Angle']",[],NOT_YET_RECRUITING,,2025-11-10,2035-06-01,"[{'measure': 'Ocular redness', 'description': 'Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)', 'timeFrame': '5 minutes after application of eye drop'}, {'measure': 'Ocular redness', 'description': 'Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)', 'timeFrame': '15 minutes after application of eye drop'}, {'measure': 'Ocular redness', 'description': 'Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)', 'timeFrame': '30 minutes after application of eye drop'}, {'measure': 'Ocular redness', 'description': 'Scoring of ocular redness on clinical photographs using the the Investigator Ocular Redness Scale (0-4; 0 = no ocular redness, 4 = extremely severe ocular redness)', 'timeFrame': '60 minutes after application of eye drop'}, {'measure': 'Intraocular pressure', 'description': 'Measurement of intraocular pressure using handheld tonometer (TonoPen)', 'timeFrame': '60 minutes after application of eye drop'}]","[{'measure': 'Palpebral fissure height', 'description': 'Measurement of distance between inner margin of upper and lower eyelids from clinical photographs', 'timeFrame': '60 minutes after application of eye drop'}, {'measure': 'Eye discomfort', 'description': 'Subjective scoring of ocular discomfort by patient on a 0-10 unit scale (0 = very comfortable, 10 = very uncomfortable)', 'timeFrame': '60 minutes after application of eye drop'}]",7,18 Years,,ALL,False,Tulane University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:12.177430,v2_robust,True,True,False,False,False,
NCT02980276,RCT Metformin for Reduction of Gestational Diabetes Mellitus Effects,A Randomised Placebo Controlled Trial of the Effectiveness of Early MEtformin in Addition to Usual Care in the Reduction of Gestational Diabetes Mellitus Effects (EMERGE),Metformin Hydrochloride,['Metformin Hydrochloride'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Gestational Diabetes,['Gestational Diabetes'],"['Gestational Diabetes', 'Diabetes', 'Pregnancy']",COMPLETED,,2017-06-06,2023-04-13,"[{'measure': 'Primary Composite Outcome', 'description': 'The primary efficacy outcome was achieved if any participant experienced:\n\n* Insulin initiation\n* Fasting glucose value \\>5.1 mmol/l at 32weeks or 38 weeks gestation.', 'timeFrame': 'Enrolment through delivery, an average of 16 weeks.'}, {'measure': 'Insulation of Insulin', 'description': 'Initiation of insulin treatment at any time up to delivery.', 'timeFrame': 'Enrolment through delivery, an average of 16 weeks.'}]","[{'measure': 'Time to Insulin Initiation', 'description': 'Time to Insulin Initiation, from date of randomization until the date of delivery.', 'timeFrame': 'Time to Insulin Initiation, from date of randomization until the date of delivery, an average of 16 weeks..'}, {'measure': 'Insulin Initiated', 'description': 'Whether or not insulin was initiated at any time during the study.', 'timeFrame': 'Enrolment through delivery, an average of 16 weeks.'}, {'measure': 'Fasting Hyperglycemia', 'description': 'Number of women with fasting hyperglycemia at 32wks or at 38wks gestation.', 'timeFrame': ""Measured at 32 and 38 weeks' gestation.""}, {'measure': 'Insulin Dose Required', 'description': 'Insulin dose required in any participant requiring insulin.', 'timeFrame': 'Enrolment through delivery, an average of 16 weeks.'}, {'measure': 'Gestational Weight Gain', 'description': 'Change in weight (kg) from randomization until last visit before delivery', 'timeFrame': 'Enrolment through delivery, an average of 16 weeks.'}, {'measure': 'Postpartum Impaired Fasting Glucose', 'description': 'Impaired fasting glucose at 12 weeks postpartum', 'timeFrame': '12 weeks post-partum'}, {'measure': 'Postpartum Impaired Glucose Tolerance', 'timeFrame': '12 weeks postpartum'}, {'measure': 'Postpartum Metabolic Syndrome', 'timeFrame': '12 weeks postpartum'}, {'measure': 'Gestational Age at Delivery', 'timeFrame': 'At delivery, an average of 16 weeks after enrolment'}, {'measure': 'Mode of Delivery - Cesarian Delivery', 'description': 'Delivered by Cesarian section.', 'timeFrame': 'At delivery, an average of 16 weeks after enrolment'}, {'measure': 'Mode of Delivery - Emergency Cesarian Section', 'description': 'Among those having cesarian section, count of emergency procedures.', 'timeFrame': 'At delivery, an average of 16 weeks after randomization.'}, {'measure': 'Mode of Delivery - Induced', 'description': 'Labor induced.', 'timeFrame': 'At time of labor, an average of 16 weeks after enrolment.'}, {'measure': 'Maternal Morbidity - Pregnancy-induced Hypertension', 'timeFrame': 'From enrolment through 6 weeks postpartum, an average of 22 weeks.'}, {'measure': 'Maternal Morbidity - Pre-eclampsia', 'description': 'Pre-eclampsia diagnosed during study participation', 'timeFrame': 'Enrolment through 6 weeks postpartum, an average of 22 weeks.'}, {'measure': 'Maternal Morbidity - Antepartum Hemorrhage', 'description': 'Any vaginal bleeding prior to delivery', 'timeFrame': 'From enrolment through delivery, an average of 16 weeks.'}, {'measure': 'Maternal Morbidity - Postpartum Hemorrhage', 'timeFrame': 'From delivery through 6 weeks postpartum.'}, {'measure': 'Birthweight', 'timeFrame': 'At birth'}, {'measure': 'Neonatal Head Circumference', 'timeFrame': 'At birth'}, {'measure': 'Neonatal Height', 'description': 'Height in cm (crown-heel length)', 'timeFrame': 'At birth'}, {'measure': 'Neonatal Abdominal Circumference', 'timeFrame': 'At birth'}, {'measure': 'Neonatal Ponderal Index', 'description': 'Ponderal index is calculated as 100 x weight(grams)/(crown-heel length).', 'timeFrame': 'At birth'}, {'measure': 'Birth Weight >4000g', 'timeFrame': 'At birth'}, {'measure': 'Birth Weight >90th Percentile', 'timeFrame': 'At birth'}, {'measure': 'Birth Weight <2500g', 'timeFrame': 'At birth'}, {'measure': 'Birth Weight <10th Percentile', 'timeFrame': 'At birth'}, {'measure': 'Neonatal Morbidity - Need for NICU Care', 'timeFrame': 'From birth until 6 weeks of life.'}, {'measure': 'Neonatal Morbidity - Preterm Birth', 'description': 'Delivery at gestational age \\<37 weeks.', 'timeFrame': 'At birth'}, {'measure': 'Neonatal Morbidity - Respiratory Distress Syndrome Requiring Respiratory Support', 'timeFrame': 'From birth until 6 weeks of life.'}, {'measure': 'Neonatal Morbidity - Jaundice Requiring Phototherapy', 'timeFrame': 'From birth until 6 weeks of life.'}, {'measure': 'Neonatal Morbidity - Major Congenital Anomalies', 'timeFrame': 'From birth until 6 weeks of life.'}, {'measure': 'Neonatal Morbidity - Apgar Score <7 at 5 Minutes', 'description': 'The Apgar score comprises five components: 1) color, 2) heart rate, 3) reflexes, 4) muscle tone, and 5) respiration, each of which is given a score of 0, 1, or 2.\n\n(for example see: https://www.acog.org/clinical/clinical-guidance/committee-opinion/articles/2015/10/the-apgar-score#:\\~:text=The%20Apgar%20score%20comprises%20five,0%2C%201%2C%20or%202)', 'timeFrame': 'At 5 minutes after birth'}, {'measure': 'Neonatal Morbidity - Neonatal Hypoglycemia', 'description': 'serum glucose \\<2.6mmol/l on at least one occasion \\<60 minutes after delivery', 'timeFrame': 'First hour of life.'}]",34,18 Years,50 Years,FEMALE,False,"National University of Ireland, Galway, Ireland",OTHER,7,535.0,ACTUAL,2025-09-01T16:18:12.177450,v2_robust,True,True,True,False,False,
NCT00003076,Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus,Phase IIb Chemoprevention Trial of Difluoromethylornithine (DFMO) in Human Subjects With Intestinal-type Barrett's Esophagus,eflornithine,['eflornithine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Cancer,['Esophageal Cancer'],['esophageal cancer'],COMPLETED,,1995-10,2005-10,[],[],0,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,152.0,ESTIMATED,2025-09-01T16:18:12.177508,v2_robust,True,True,True,False,False,
NCT02380976,Phase 1 Clinical Trial of DW340 and DW330SR + DW1030 Co-administration in Healthy Male Volunteers,,"combination drug: DW330SR, DW1030","['DW340', 'combination drug: DW330SR, DW1030']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2015-10,,"[{'measure': 'Cmax of DW330SR', 'timeFrame': '9 days'}, {'measure': 'Cmax of DW340', 'timeFrame': '9 days'}, {'measure': 'Cmax of DW1030', 'timeFrame': '9 days'}, {'measure': 'AUClast of DW330SR', 'timeFrame': '9 days'}, {'measure': 'AUClast of DW340', 'timeFrame': '9 days'}, {'measure': 'AUClast of DW1030', 'timeFrame': '9 days'}]",[],6,20 Years,40 Years,MALE,True,"Daewon Pharmaceutical Co., Ltd.",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:12.177549,v2_robust,True,True,True,False,False,
NCT01269476,Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers,Phase 1 Safety and Pharmacokinetics of Methane Sulfonylfluoride (MSF or SNX-001) After Single and Multiple Oral Dose Administration in Healthy Adult Aged Volunteers,SNX-001,"['MSF', 'SNX-001', 'Placebo', 'methanesulfonyl fluoride', 'Oil vehicle']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Safety,['Safety'],[],COMPLETED,,2009-12,2010-08,"[{'measure': 'Relationship of clinical safety measurements to dose', 'description': 'Adverse events (AEs), vital signs, electrocardiogram (ECG), Acetylcholinesterase (AChE) inhibition, laboratory parameters after single and multiple dose administration', 'timeFrame': 'Throughout 14-day study period (Days 1, 2, 3, 10, 12, 13, 14) and 7 days after last dose (Day 21)'}]","[{'measure': 'Effect of dose on pharmacokinetic (PK) parameters', 'description': 'Pharmacokinetic parameters after single and multiple dose administration of SNX-001 (3.6, 7.2 and 10.8 mg)', 'timeFrame': 'After single (Day 1) and multiple (Day 12) doses'}]",2,50 Years,,ALL,True,SeneXta Therapeutics SA,INDUSTRY,0,27.0,ACTUAL,2025-09-01T16:18:12.177560,v2_robust,True,True,True,False,True,
NCT06500676,A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations,"An Open-Label, Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of GFH375 in Patients With KRAS G12D Mutant Advanced Solid Tumors",GFH375,['GFH375'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,KRAS G12D Mutations,"['KRAS G12D Mutations', 'Advanced Solid Tumors']",[],RECRUITING,,2024-07-09,2028-12-31,"[{'measure': 'Phase Ia:The incidence and severity of AEs and SAEs', 'description': 'The incidence and severity of AEs and SAEs', 'timeFrame': '24 months'}, {'measure': 'Phase Ia:The incidence of DLT events', 'description': 'The incidence of DLT events', 'timeFrame': '21 days'}, {'measure': 'Phase Ib:The incidence and severity of AEs and SAEs', 'description': 'The incidence and severity of AEs and SAEs', 'timeFrame': '24 months'}, {'measure': 'Phase II:Overall response rate (ORR)', 'description': 'Aassessed by investigators according to RECIST 1.1', 'timeFrame': '24 months'}]","[{'measure': 'Plasma concentrations', 'description': 'Plasma concentrations and PK parameters of GFH375', 'timeFrame': 'up to 21 days'}, {'measure': 'Efficacy endpoints', 'description': 'Duration of response (DoR)', 'timeFrame': '24 months'}, {'measure': 'Efficacy endpoints', 'description': 'Disease control rate (DCR)', 'timeFrame': '24 months'}, {'measure': 'Efficacy endpoints', 'description': 'Progression free survival (PFS)', 'timeFrame': '24 months'}, {'measure': 'Efficacy endpoints', 'description': 'Overall survival (OS)', 'timeFrame': '24 months'}]",9,18 Years,75 Years,ALL,False,Genfleet Therapeutics (Shanghai) Inc.,INDUSTRY,0,390.0,ESTIMATED,2025-09-01T16:18:12.177567,v2_robust,True,True,False,False,False,
NCT00954876,Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer,"Phase II, Multi-Center, Open-Label, Prospective Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type KRAS Colorectal Cancer Who Are Considered Nonoptimal Candidates or Are Intolerant to a First-Line Oxaliplatin/Irinotecan Regimen",capecitabine and cetuximab,['capecitabine and cetuximab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],[],WITHDRAWN,"Study halted prematurely, prior to enrollment of first participant",2009-08,2010-01,"[{'measure': 'Primary objective is to assess PFS in patients with WT KRAS CRC treated with the combination regimen of capecitabine and cetuximab', 'timeFrame': '18 months'}]","[{'measure': 'To assess the response rate in patients with metastatic WT KRAS CRC treated with capecitabine and cetuximab', 'timeFrame': '18 months'}, {'measure': 'To assess the overall survival rate among patients with metastatic WT KRAS CRC treated with capecitabine and cetuximab', 'timeFrame': '18 months'}, {'measure': 'To characterize the toxic effects and AEs of the combination regimen of capecitabine and cetuximab in this patient population', 'timeFrame': 'every three months'}, {'measure': 'To perform exploratory analyses of serum and tumor biomarkers (EGFR mutations and genotyping) on toxicity and efficacy.', 'timeFrame': '1 year after study closure'}]",5,18 Years,,ALL,False,Translational Genomics Research Institute,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:12.177586,v2_robust,True,True,False,True,False,"Study halted prematurely, prior to enrollment of first participant"
NCT04372017,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Randomized, Double-Blind, Controlled Trial of Hydroxychloroquine vs Placebo as Post-Exposure Prophylaxis Against COVID-19 Infection",Hydroxychloroquine,['Hydroxychloroquine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,COVID-19,"['COVID-19', 'SARS-CoV 2']",[],TERMINATED,Unlikelihood of benefit based on other studies.,2020-05-14,2021-06-04,"[{'measure': 'Cohort A: Percentage of COVID-19 Exposed Healthcare Workers Treated With Hydroxychloroquine With a Positive COVID-19 Test.', 'description': 'Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in healthcare workers who have been exposed to a known case of COVID-19.', 'timeFrame': 'At enrollment completion outcome 1 will be analyzed.'}, {'measure': 'Cohort B: Percentage of COVID-19 Exposed High-risk Individuals Treated With Hydroxychloroquine With a Positive COVID-19 Test.', 'description': 'Determine whether post-exposure prophylaxis with hydroxychloroquine can prevent COVID-19 in high-risk individuals who have been exposed to a known case of COVID-19.', 'timeFrame': 'At enrollment completion outcome 2 will be analyzed.'}]",[],2,18 Years,,ALL,True,Sanford Health,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:12.177599,v2_robust,True,True,False,True,False,Unlikelihood of benefit based on other studies.
NCT03369717,Use of Perioperative Antibiotics in Endoscopic Sinus Surgery,Use of Perioperative Antibiotics in Endoscopic Sinus Surgery,Amoxi Clavulanate,['Amoxi Clavulanate'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Sinus Infection,['Chronic Sinus Infection'],"['endoscopic sinus surgery', 'antibiotics']",TERMINATED,Study terminated early,2018-08-01,2020-05-07,"[{'measure': 'Postoperative Infection', 'description': 'The number/percentage of participants with postoperative infection rate, as assessed by rigid nasal endoscopy in the office and culture of suspected infectious material noted within the paranasal sinuses will be reported. A postoperative infection as defined by having an infection at ANY of the postoperative visits AND detected initially by evidence of purulence on nasal endoscopy will be considered an infection if the culture swab from the site of purulence during that office visit confirms that there is an actual bacterial source of the infection.', 'timeFrame': 'During all three scheduled postoperative visits: 7-10 days postoperatively; 2-4 weeks postoperatively; 6-8 weeks postoperatively'}]","[{'measure': 'Postoperative Sino-nasal Outcome Test (SNOT-22) Scores', 'description': 'Postoperative SNOT-22 scores will be summarized for each visit based on patient-reported symptoms. The SNOT-22 is a 22-item questionnaire used to assess the impact of chronic rhinosinusitis (CRS) on a patient\'s health-related quality of life. Participants are presented with a list of symptoms and social/emotional consequences of rhinosinusitis and asked to rate each problem over the prior 2-week period on a 6-point Likert scale ranging from 0 (""No Problem"") to 5 (""Problem as bad as it can be)"" yielding an overall possible scoring range of 0-110. Higher scores are indicative of a greater burden CRS-related symptoms. Scores are summarized by study arm using basic descriptive statistics.', 'timeFrame': 'During all three scheduled postoperative visits: 7-10 days postoperatively; 2-4 weeks postoperatively; 6-8 weeks postoperatively'}, {'measure': 'Perioperative Sinus Endoscopy (POSE) Scores', 'description': 'Sinonasal crusting and inflammation was determined using the perioperative sinus endoscopy (POSE) scoring system based on patient-reported symptoms obtained during all three study visits. POSE assigns points to various areas within the nasal passages, based on the presence of certain conditions like crusting, edema, polyps, secretions, etc. For purposes of this study each parameter was scored from 0-2 yielding an overall possible score of 0-10, with higher scores being indicative of more extensive disease severity or surgical extent in the sinuses. Scores are summarized by study arm using basic descriptive statistics.', 'timeFrame': 'During all three scheduled postoperative visits: 7-10 days postoperatively; 2-4 weeks postoperatively; 6-8 weeks postoperatively'}]",3,18 Years,,ALL,True,Montefiore Medical Center,OTHER,4,24.0,ACTUAL,2025-09-01T16:18:12.177665,v2_robust,True,True,False,True,False,Study terminated early
NCT03241017,Durvalumab in DLBCL After Autologous Transplant,A Phase II Trial Investigating the Benefit of Immunotherapy With Durvalumab After Autologous Transplant in High-risk Diffuse-large B-cell Lymphomas (the IDA-D Trial),Durvalumab,['Durvalumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lymphoma, Large B-Cell, Diffuse","['Lymphoma, Large B-Cell, Diffuse']","['Diffuse Large B-Cell Lymphoma', 'Double-hit Lymphomas', 'Grey Zone Lymphomas', 'Double or Triple Expressor Lymphomas', 'Unclassifiable Aggressive Lymphoma types', 'Aggressive Lymphomas']",WITHDRAWN,Celgene withdrew the support for this study (Durvalumab cannot be provided),2017-10,2021-12,"[{'measure': 'Progression-free survival', 'description': 'Number of Patients with Progression-free survival (PFS) two years after autologous stem cell transplantation (ASCT) in high-risk DLBCL patients receiving PD-L1 inhibition with durvalumab.', 'timeFrame': '24 months'}]","[{'measure': 'Response Rate', 'description': 'The Response (Tumor measurement) to durvalumab treatment will be assessed by PET-CT 24 months after ASCT', 'timeFrame': '24 months'}, {'measure': 'Adverse Events', 'description': 'Number of Patients experiencing Toxicity (Adverse Events)', 'timeFrame': '24 months'}, {'measure': 'Hematologic engraftment', 'description': 'Number of days until hematological engraftment. Hematologic engraftment after high-dose chemotherapy induced myelosuppression is defined as the first day of neutrophils rising again above 0.5 G/l, and of platelets rising again above 20 G/L in the absence of platelet transfusions in the previous 3 days. Hematological values will be performed every 4 weeks', 'timeFrame': '24 months'}, {'measure': 'The quality of life', 'description': 'The EORTC Q30 questionnaire will be given to patients before the first durvalumab administration, and after 3, 12 and 24 months after ASCT to assess quality of life.', 'timeFrame': '24 months'}, {'measure': 'Overall Survival', 'description': 'Number of Patient alive at 24 months', 'timeFrame': '24 months'}]",6,18 Years,75 Years,ALL,False,"Insel Gruppe AG, University Hospital Bern",OTHER,1,0.0,ACTUAL,2025-09-01T16:18:12.177692,v2_robust,True,True,False,True,True,Celgene withdrew the support for this study (Durvalumab cannot be provided)
NCT05821517,METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation (HYPNOLUX),METHOXYFLURANE or Virtual Reality Headset vs Standard Analgesic Management for the Reduction of Anterior Shoulder Dislocation,Administration of METHOXYFLURANE,"['Administration of METHOXYFLURANE', 'Standard of care']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Anterior Shoulder Dislocation,['Anterior Shoulder Dislocation'],[],RECRUITING,,2023-05-01,2025-02-01,"[{'measure': 'Decrease in the rate of procedural sedation of anterior shoulder dislocation', 'description': 'Rate of use of procedural sedation for anterior shoulder dislocation reduction in the interventional groups compared to the control group', 'timeFrame': 'Day 1 (day of reduction of anterior shoulder dislocation)'}]","[{'measure': 'The amount of co-antalgesics administered', 'description': 'Posology of co-analgesic medications administered', 'timeFrame': '3 months'}, {'measure': 'The duration of the procedure', 'description': 'Time lenght of the reduction procedure', 'timeFrame': 'Day 1 (day of change of anterior shoulder dislocation)'}, {'measure': 'The dosage of drugs used in procedural sedation', 'description': 'Posology of sedative drugs administered for a procedural sedation', 'timeFrame': 'Day 1 (day of reduction of anterior shoulder dislocation)'}, {'measure': 'The average length of stay in the emergency department', 'description': 'Average length of stay in the emergency department', 'timeFrame': '3 months'}, {'measure': 'Patient satisfaction', 'description': 'Patient satisfaction at the end of care evaluated with a questionnaire EVA', 'timeFrame': '3 months'}, {'measure': 'The rate of reduction-related complications', 'description': 'Complications related to the reduction', 'timeFrame': '3 months'}]",7,18 Years,,ALL,False,Centre Hospitalier Universitaire de Nice,OTHER,0,150.0,ESTIMATED,2025-09-01T16:18:12.177704,v2_robust,True,True,False,False,False,
NCT00446017,The Effects of Adrenaline and Milrinone in Patients With Myocardial Dysfunction After CABG,Phase 3 Study of Adrenaline and Milrinone in Patients With Myocardial Dysfunction,adrenaline,"['milrinone', 'adrenaline']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Cardiac Output, Low","['Cardiac Output, Low']","['coronary artery bypass grafting', 'inotropes', 'metabolism', 'renal failure']",COMPLETED,,2003-06,2007-04,[{'measure': 'Plasma lactate concentration in the immediate postoperative period'}],"[{'measure': 'Hemodynamics'}, {'measure': 'Plasma pyruvate'}, {'measure': 'Plasma glucose'}, {'measure': 'Plasma creatinine'}, {'measure': 'Urinary excretion of alpha-1-microglobulin'}, {'measure': 'Plasma cystatin C'}]",7,18 Years,85 Years,ALL,False,University of Luebeck,OTHER,1,60.0,,2025-09-01T16:18:12.177812,v2_robust,True,True,True,False,False,
NCT00578617,Ablation vs Drug Therapy for Atrial Fibrillation - Pilot Trial,Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation - Pilot Trial,Rate Control,"['Lanoxin', 'Inderal', 'Cardizem', 'Calan', 'Tykosin', 'Toprol', 'Tenormin', 'Sectral', 'Cordarone', 'Betapace', 'Rate control', 'Quini-glute/dex', 'Rhythm Control', 'Rhythmol', 'Rhythm control', 'Tambacor', 'Coreg', 'Rate Control']",18,INTERVENTIONAL,['NA'],,,Atrial Fibrillation,"['Atrial Fibrillation', 'Arrhythmia']","['Atrial fibrillation', 'Left Atrial Ablation', 'Pulmonary Vein Isolation', 'Catheter Ablation', 'Antiarrhythmic Drug Therapy']",COMPLETED,,2006-09,2010-06,"[{'measure': 'Number of Participants Experiencing Recurrence of Atrial Fibrillation by One Year Follow-up', 'description': 'Documentation of atrial fibrillation using a cardiac event recorder', 'timeFrame': '12 months after intervention'}]",[],1,18 Years,90 Years,ALL,False,Mayo Clinic,OTHER,2,60.0,ACTUAL,2025-09-01T16:18:12.177918,v2_robust,True,True,True,False,False,
NCT06233240,Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator,A Bioequivalence Study of Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg Relative to Originator Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000 mg in Healthy Thai Volunteers Under Fed Condition,Sitagliptin and Metformin Hydrochloride Tablets Test product,"['Sitagliptin and Metformin Hydrochloride Tablets Reference product', 'Sitagliptin and Metformin Hydrochloride Tablets Test product']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],['Sitagliptin and Metformin Hydrochloride Tablets 50 mg/1000mg'],NOT_YET_RECRUITING,,2024-04-30,2024-06-12,"[{'measure': 'Area under the plasma concentration-time curve from time zero to the last measurable concentration (AUC 0-t)', 'description': 'pre-dose (0.00 hour) and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.000, 5.500, 6.000, 7.000, 8.000, 10.000, 12.000, 24.000, 36.000 and 48.000 hours post-dose', 'timeFrame': 'Blood samples will be collected for PK analyses in pre-dose and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.000, 5.500, 6.000, 7.000, 8.000, 10.000, 12.000, 24.000, 36.000 and 48.000 hours post-dose'}, {'measure': 'Maximal measured plasma concentration (Cmax)', 'description': 'pre-dose (0.00 hour) and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.000, 5.500, 6.000, 7.000, 8.000, 10.000, 12.000, 24.000, 36.000 and 48.000 hours post-dose', 'timeFrame': 'Blood samples will be collected for PK analyses in pre-dose and at 0.333, 0.667, 1.000, 1.500, 2.000, 2.500, 3.000, 3.333, 3.667, 4.000, 4.333, 4.667, 5.000, 5.500, 6.000, 7.000, 8.000, 10.000, 12.000, 24.000, 36.000 and 48.000 hours post-dose'}]","[{'measure': 'Number of subjects with adverse events', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'timeFrame': 'Approximately the day 14 after the last visit'}]",3,18 Years,55 Years,ALL,True,"Bio-innova Co., Ltd",INDUSTRY,0,34.0,ESTIMATED,2025-09-01T16:18:12.177975,v2_robust,True,True,False,False,True,
NCT02429440,Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides,Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides,Granulocyte Macrophage Colony Stimulating Factor,"['Montanide ISA-51', 'Granulocyte Macrophage Colony Stimulating Factor', 'GM-CSF']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Renal Cell Cancer,"['Renal Cell Cancer', 'Advanced Renal Cell Cancer']",[],UNKNOWN,,2005-05,2018-06,"[{'measure': 'Tolerability', 'description': 'Tolerability, as measured by number of Participants with Adverse Events', 'timeFrame': 'Day 0-365'}]","[{'measure': 'All Cause Mortality', 'description': 'All cause Mortality, as measured as length of Overall Survival', 'timeFrame': '60 Months'}, {'measure': 'Progression-free Survival', 'description': 'Progression-free Survival, as measured as time to radiographic progression', 'timeFrame': '36 Months'}, {'measure': 'Immune Response', 'description': 'Immune Response, as as measured by in vitro and in vivo T cell response on day 0 and day 70. In selected cases additional immune response evaluation might be applicable.', 'timeFrame': 'Day 0-365'}]",4,18 Years,,ALL,False,University Hospital Tuebingen,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:12.178117,v2_robust,True,True,False,False,True,
NCT04623840,Combined Effect of Continuous and Interval in Addition to Tadalafil Drug on Erectile Dysfunction,Obesity-induced ED Response to Combined Effect of Tadalafil Drug in Addition to Interval and Continuous Training,Tadalafil 5Mg Tab,"['group 2', 'Tadalafil 5Mg Tab']",2,INTERVENTIONAL,['NA'],,,Erectile Dysfunction,['Erectile Dysfunction'],[],UNKNOWN,,2020-10-12,2021-03-30,"[{'measure': 'Five-Item Version of International Index of Erectile Function (IIEF-5)', 'description': 'It is a questionnaire of five questions to diagnose ED in male patients', 'timeFrame': 'It will be measured after eight weeks of training'}]","[{'measure': 'Triglycerides', 'description': 'It will be measured via a venous blood sample', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'High density lipoprotein', 'description': 'It will be measured via a venous blood sample', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'Insulin', 'description': 'It will be measured via a venous blood sample', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'Fasting blood glucose', 'description': 'it will be measured via a blood glucose meter', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'The HOMA-IR (Homeostatic Model Assessment for Insulin Resistance', 'description': 'HOMA-IR = \\[fasting insulin (μU/mL)\n\n× fasting glucose (mmol)\\]/22.5', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'body mass index', 'description': 'It will be obtained by dividing the weight in Kilograms on the squared height in meter', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'systolic blood pressure', 'description': 'it will be measured by a manual sphygmomanometer', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'diastolic blood pressure', 'description': 'it will be measured by a manual sphygmomanometer', 'timeFrame': 'It will be measured after eight weeks of training'}, {'measure': 'Waist circumference', 'description': 'it will be measured by inelastic tape at the umbilicus level', 'timeFrame': 'It will be measured after eight weeks of training'}]",10,40 Years,50 Years,MALE,False,Cairo University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:12.178139,v2_robust,True,True,False,False,False,
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide (TAC) Versus 5-fluorouracil in Combination With Doxorubicin and Cyclophosphamide (FAC) as Adjuvant Treatment of Operable Breast Cancer Patients With Positive Axillary Lymph Nodes.,Docetaxel,"['Taxotere®', 'Doxorubicin', 'Cyclophosphamide', 'Docetaxel', '5-fluorouracil', '5-FU']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],['adjuvant treatment'],COMPLETED,,1997-06,2010-01,"[{'measure': 'Number of Participants With Disease-Free Survival Events', 'description': 'Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first.', 'timeFrame': 'up to 10 year follow-up'}]","[{'measure': 'Number of Participants With Overall Survival Events', 'description': 'Overall Survival - time from the date of randomization up to the date of death of any cause.', 'timeFrame': 'up to 10 year follow-up'}, {'measure': 'Number of Participants With Second Primary Malignancies (Toxicity)', 'description': 'Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast.', 'timeFrame': 'up to 10 year follow-up'}]",3,18 Years,70 Years,FEMALE,False,Sanofi,INDUSTRY,1,1491.0,ACTUAL,2025-09-01T16:18:12.178200,v2_robust,True,True,True,False,False,
NCT00968240,Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab),Phase I Trial of Super-Selective Intraarterial Intracranial Infusion of Avastin (Bevacizumab) For Treatment of Relapsed/Refractory Glioblastoma Multiforme and Anaplastic Astrocytoma,Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB,"['Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB', 'Avastin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Glioblastoma Multiforme,"['Glioblastoma Multiforme', 'Anaplastic Astrocytoma']","['GBM', 'AA', 'AO', 'Brain', 'Tumors', 'Malignant', 'Glioblastoma', 'Multiforme', 'Anaplastic', 'Astrocytoma']",COMPLETED,,2009-07,2014-01,"[{'measure': 'To determine the safety of superselective intracranial intraarterial infusion of Avastin up to a dose of 10mg/kg IA.', 'timeFrame': '3 years'}]","[{'measure': 'Composite overall response rate: The composite overall response rate (CORR) will be examined. The overall response proportion along with a 95% confidence interval will be estimated via binomial proportions.', 'timeFrame': '3 years'}, {'measure': 'Six-month progression-free survival (PFS) and overall survival (OS) will be assessed by Kaplan-Meier survival analysis, assuming adequate follow-up time.', 'timeFrame': '3 years'}]",3,18 Years,,ALL,False,Northwell Health,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:12.178302,v2_robust,True,True,True,False,True,
NCT00649740,Fasting Study of Topiramate Sprinkle Capsules 25 mg and Topamax® Sprinkle Capsules 25 mg,Single-Dose Fasting Bioequivalence Study of Topiramate Sprinkle Capsules (25 mg; Mylan) and Topamax® Sprinkle Capsules (25 mg; Ortho-McNeil Neurologics) in Healthy Volunteers,Topiramate Sprinkle Capsules 25 mg,"['Topamax® Sprinkle Capsule 25 mg', 'Topiramate Sprinkle Capsules 25 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2005-11,2005-12,"[{'measure': 'The 90% confidence interval for the LSMeans ratio of CPEAK, AUCL, and AUCI for the test and reference product should be between 80.00% and 125.00% for the natural log-transformed data.', 'timeFrame': 'blood collections through 144 hours'}]",[],1,18 Years,,ALL,True,Mylan Pharmaceuticals Inc,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:12.178421,v2_robust,True,True,True,False,False,
NCT01718340,Effectiveness of Metformin in Recurrent Miscarriage in a Woman With Hyperinsulinaemia,Phase 4 Study of Effectiveness of Metformin in Patients With Unexplained Recurrent Miscarriages,Metformin,"['glucophage', 'cidophage', 'amophage', 'Metformin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Abortion, Habitual","['Abortion, Habitual']","['PCOS', 'Hyper insulinaemia', 'metformin', 'recurrent abortion']",WITHDRAWN,,2012-06,2014-06,"[{'measure': 'The primary outcome is to evaluate the clinical pregnancy rate and the effectiveness of Metformin in the reduction of EPL in women with PCOS', 'description': 'The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy,', 'timeFrame': '2 ys'}]","[{'measure': 'Secondary outcomes like gestational diabetes, pregnancy-induced hypertension and intrauterine growth restriction were also analyzed at the end of the study and any fetal malformation', 'description': 'The patients with PCO and hyper insulinemia will be subdivided into two groups, one group will continue metformin 500 mg three times per day from the start of induction of ovulation till the end of pregnancy, the other group will stop the drug once pregnancy test become positive. Pregnancy follow up including the early and second trimester pregnancy loss, Secondary outcomes like gestational diabetes, pregnancy-induced hypertension and intrauterine growth restriction were also analyzed at the end of the study.', 'timeFrame': '2 ys'}]",2,18 Years,40 Years,FEMALE,True,"Woman's Health University Hospital, Egypt",OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.178430,v2_robust,True,True,False,True,False,
NCT02460640,The Effects of TAP Block on Postsurgical Pain After Minimally Invasive Partial Nephrectomy:,"The Effects of Ultrasound-guided Transversus Abdominis Plane Block on Acute and Chronic Postsurgical Pain After Robotic Partial Nephrectomy. A Prospective, Randomized, Clinical Trial",Morphine,"['Ropivacaine', 'Morphine']",2,INTERVENTIONAL,['NA'],,,Acute Pain,"['Acute Pain', 'Chronic Pain']","['Minimally invasive surgery', 'Partial nephrectomy']",COMPLETED,,2015-05,2017-08,"[{'measure': 'Morphine consuption 24 hr after surgery', 'description': 'Cumulative morphine consuption (mg) 24 hr starting from the time of extubation.', 'timeFrame': '24 hours'}, {'measure': 'Acute pain after surgery measured with Numerical Rating Scale', 'description': 'patients were assessed for pain, according to Numerical Rating Scale (NRS; 0: no pain to 10: worst pain imaginable)', 'timeFrame': '24 hours'}]",[],2,18 Years,,ALL,False,Regina Elena Cancer Institute,OTHER,0,96.0,ACTUAL,2025-09-01T16:18:12.178445,v2_robust,True,True,True,False,False,
NCT00107289,"Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma",Open Access Protocol of Targeted Radiotherapy With I-metaiodobenzylguanidine (I-MIBG) in Patients With Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors,iobenguane I 131,['iobenguane I 131'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuroblastoma,"['Neuroblastoma', 'Pheochromocytoma']","['metastatic pheochromocytoma', 'recurrent pheochromocytoma', 'regional pheochromocytoma', 'recurrent neuroblastoma', '04-148']",RECRUITING,,2006-05,2026-05,"[{'measure': 'Response (complete or partial)', 'timeFrame': '2 years'}]","[{'measure': 'Correlation between tumor self-absorbed dose and response and tumor volume decrease', 'timeFrame': '2 years'}]",2,1 Year,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,200.0,ESTIMATED,2025-09-01T16:18:12.178506,v2_robust,True,True,False,False,False,
NCT05426889,The Role of Meningeal Lymphatic Vessels in the Absorption of Chronic Subdural Hematoma and Its Injury Mechanism,Establishment of a Clinical Efficacy Prediction System Based on the Role of Meningeal Lymphatic Vessels in the Absorption of Chronic Subdural Hematoma and Its Injury Mechanism,drug conservative treatment,['drug conservative treatment'],1,INTERVENTIONAL,['NA'],,,"Hematoma, Subdural, Chronic","['Hematoma, Subdural, Chronic']",[],UNKNOWN,,2022-05-02,2023-12-20,"[{'measure': 'Magnetic resonance signal intensity of meningeal lymphatic vessels', 'description': 'The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital', 'timeFrame': 'The first day after admission'}, {'measure': 'Magnetic resonance signal intensity of meningeal lymphatic vessels', 'description': 'The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital', 'timeFrame': '3 days after surgery'}, {'measure': 'Magnetic resonance signal intensity of meningeal lymphatic vessels', 'description': 'The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital', 'timeFrame': '1 months after surgery'}, {'measure': 'Magnetic resonance signal intensity of meningeal lymphatic vessels', 'description': 'The signal intensity of meningeal lymphatic vessels was measured by PACS system in hospital', 'timeFrame': '6 months after surgery'}]",[],4,18 Years,90 Years,ALL,True,"Second Affiliated Hospital, School of Medicine, Zhejiang University",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:12.178514,v2_robust,True,True,False,False,False,
NCT00225589,A Study Measuring Effects on Intima Media Thickness: An Evaluation of Rosuvastatin 40 mg (METEOR),"A Randomized, Double-blind, Placebo-controlled, Multicenter Parallel Group Phase III Study Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR)",Rosuvastatin calcium,"['Rosuvastatin calcium', 'Crestor']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesteremia,['Hypercholesteremia'],['Hypercholesteremia'],COMPLETED,,2002-08,2006-05,"[{'measure': 'Assess the effects of rosuvastatin treatment on the change in the mean maximum intima media thickness (IMT) of the 12 vessel segments: the near & far walls of the CCA, the carotid bulb & the ICA'}]","[{'measure': 'Assess the effects of rosuvastatin treatment on the following variables, with the same analyses being applied to the IMT variables:'}, {'measure': 'Change in the mean maximum IMT of the near & far walls of the right & left CCA, carotid bulb, ICA'}, {'measure': 'Change in the mean IMT of the near & far walls of the right & left CCA'}, {'measure': 'Change in LDL-C, TC, HDL-C, TG, nonHDL-C, ApoB, ApoA-I, nonHDL-C/HDL-C, & ApoB/ApoA-I'}, {'measure': 'Change in inflammatory marker: C-reactive protein (CRP)'}, {'measure': 'Safety & tolerability, by evaluating the incidence & severity of adverse events & abnormal laboratory values'}]",7,45 Years,70 Years,ALL,False,AstraZeneca,INDUSTRY,0,840.0,,2025-09-01T16:18:12.178573,v2_robust,True,True,True,False,True,
NCT01799889,"Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies","A Phase 2, Open-Label Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacodynamics of GS-9973 in Subjects With Relapsed or Refractory Hematologic Malignancies",Entospletinib MM,"['GS-9973 SDD', 'GS-9973', 'Entospletinib SDD', 'Entospletinib MM']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Lymphocytic Leukemia,"['Chronic Lymphocytic Leukemia', 'Mantle Cell Lymphoma', 'Diffuse Large B-cell Lymphoma', ""Non-FL Indolent Non-Hodgkin's Lymphoma"", 'Follicular Lymphoma']",['SYK inhibitor'],TERMINATED,Sponsor's decision to discontinue development of entospletinib.,2013-03-14,2020-01-30,"[{'measure': 'Progression-Free Survival (PFS) Rate of Participants With CLL After BCR Targeted Therapy, MCL, and DLBCL at Week 16', 'description': 'PFS rate was assessed by Independent Review Committee (IRC) and defined per standardized criteria (2007 Cheson criteria) (for NHL) and International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria (for CLL), as the percentage of participants not experiencing definitive progression or death. Disease progression was defined per standardized criteria as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal immunoglobulin M (IgM) concentration or total serum IgM quantitation. Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL. PFS rate was analyzed using Kaplan-Meier (KM) estimates.', 'timeFrame': 'Week 16'}, {'measure': 'PFS Rate of Participants With CLL (Including CLL, Prior BCR Inhibitor Naive Participants), FL, and Non-FL iNHL at Week 24', 'description': 'PFS rate was assessed by IRC and defined per standardized criteria (2007 Cheson criteria) (for NHL) and IWCLL criteria (for CLL), as the percentage of participants not experiencing definitive progression or death. Disease progression was defined per standardized criteria (2007 Cheson criteria) as: evidence of any new disease; worsening of nodal or extra-nodal index lesions; unequivocal increase in the size of non-index lesions or non-measurable disease, size of the liver, spleen, or other organ; and a ≥ 25% increase from nadir in either monoclonal IgM concentration or total serum IgM quantitation. Disease progression was defined per standardized IWCLL criteria as: evidence of any new disease; worsening of index lesions, spleen or liver, or non-index disease; and decrease in platelet count or hemoglobin that is attributable to CLL. PFS rate was analyzed using KM estimates.', 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage of Participants Experiencing Treatment-Emergent Adverse Events', 'description': 'A treatment-emergent Adverse Event (AE) was defined as an AE that occurs in the period from the first dose of study treatment to 30 days after the last dose of study treatment or leads to discontinuation of study treatment. Participants were assessed for AEs according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), version 4.03.', 'timeFrame': 'First dose date up to the last dose date plus 30 days (maximum: 78.4 months)'}, {'measure': 'Percentage of Participants With Hematology Postbaseline Toxicity Grade 3 or Higher', 'description': 'Hematology toxicity at any time postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test.\n\nANC = absolute neutrophil count; Hb = hemoglobin; WBC = white blood cells', 'timeFrame': 'First dose date up to the last dose date plus 30 days (maximum: 78.4 months)'}, {'measure': 'Percentage of Participants With Serum Chemistry Toxicity Postbaseline Grade 3 or Higher', 'description': 'Serum chemistry toxicity at anytime postbaseline was summarized according to the NCI CTCAE, version 4.03. The most severe graded abnormality was counted for each participant per test. ALT = alanine aminotransferase; ALP = alkaline phosphatase; AST = aspartate aminotransferase', 'timeFrame': 'First dose date up to the last dose date plus 30 days (maximum: 78.4 months)'}, {'measure': 'Objective Response Rate (ORR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)', 'description': 'ORR: percentage of participants with complete response (CR) or partial response (PR) (or very good PR \\[VGPR\\] or minor response \\[MR\\] for participants with LPL/WM). Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in sum of products (SPD) of the longest diameters of all index lesions, no new lesions; VGPR: \\>90% decrease from baseline (DFB) in IgM, and other criteria for CR met; MR: ≥25% but \\<50% DFB in IgM, no increase from baseline (IFB) in SPD of lesions, no new lesions. Per IWCLL, CR: lymphocytes (Ly) \\<4\\*10\\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, absolute neutrophil count (ANC) \\>1.5\\*10\\^9/L, platelets ≥100\\*10\\^9/L, hemoglobin (Hb) \\>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \\>1500/μL, platelets ≥100,000/µL, Hb \\>11 g/dL.', 'timeFrame': 'From first dose date until first occurrence of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)'}, {'measure': 'Duration of Response (DOR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)', 'description': 'DOR was defined as the interval from first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to earlier of first documentation of definitive disease progression or death from any cause. Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥50% reduction in SPD of longest diameters of all index lesions, no new lesions; VGPR: \\>90% DFB in IgM, and other criteria for CR met; MR: ≥25% but \\<50% DFB in IgM, no IFB in SPD of lesions, no new lesions. Per IWCLL criteria, CR: Ly \\<4\\*10\\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \\>1.5\\*10\\^9/L, platelets ≥100\\*10\\^9/L, Hb \\>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC\\>1500/μL, platelets ≥100,000/µL, Hb \\>11 g/dL. Disease progression: as defined in Outcome measure 1. DOR was analyzed using KM estimates.', 'timeFrame': 'From the date of first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) to disease progression or death from any cause (up to approximately 7 years)'}, {'measure': 'Time to Response (TTR), as Assessed by IRC Per Standardized Criteria (2007 Cheson Criteria) (for NHL) and IWCLL Criteria (for CLL)', 'description': 'TTR was defined as the interval from the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM). Per 2007 Cheson criteria, CR: complete resolution of all disease-related radiological abnormalities; PR: ≥ 50% reduction in SPD of the longest diameters of all index lesions, no new lesions; VGPR: \\>90% DFB in IgM, and other criteria for CR met; MR: ≥25% but \\<50% DFB in IgM, no IFB in SPD of lesions, no new lesions. Per IWCLL criteria, CR: Ly \\<4\\*10\\^9/L, no lymphadenopathy, normal spleen and liver size, absence of disease, ANC \\>1.5\\*10\\^9/L, platelets ≥100\\*10\\^9/L, Hb \\>110 g/L, bone marrow at least normocellular for age; PR: ≥2 of these: ≥50% decrease in Ly, lymphadenopathy, size of liver and spleen, bone marrow infiltrates; and ≥1 of these: ANC \\>1500/μL, platelets ≥100,000/µL, Hb \\>11 g/dL.', 'timeFrame': 'From the first dose of study drug to the first documentation of CR or PR (or VGPR or MR for participants with LPL/WM) (up to approximately 7 years)'}]",8,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,0,326.0,ACTUAL,2025-09-01T16:18:12.178623,v2_robust,True,True,False,True,True,Sponsor's decision to discontinue development of entospletinib.
NCT00004068,Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor,Treatment of Newly Diagnosed High-Grade Gliomas in Patients Ages Greater Than or Equal to 3 and Less Than or Equal to 21 Years With a Phase II Irinotecan Window Followed by Radiation Therapy and Temozolomide,irinotecan hydrochloride,"['irinotecan hydrochloride', 'temozolomide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Brain and Central Nervous System Tumors,['Brain and Central Nervous System Tumors'],"['childhood high-grade cerebral astrocytoma', 'childhood high-grade cerebellar astrocytoma', 'childhood oligodendroglioma', 'untreated childhood brain stem glioma', 'untreated childhood cerebellar astrocytoma']",COMPLETED,,1999-03,2003-04,[],[],0,3 Years,21 Years,ALL,False,St. Jude Children's Research Hospital,OTHER,1,53.0,ACTUAL,2025-09-01T16:18:12.178685,v2_robust,True,True,True,False,False,
NCT00399568,Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery,"Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel, Multiple-Dose Study of the Analgesic Efficacy and Safety of IV Acetaminophen (APAP) Versus Placebo Over 48 Hours(Hrs) for the Treatment of Postoperative Pain After Gynecologic Surgery",IV Acetaminophen,"['IV Acetaminophen (IV APAP)', 'IV Acetaminophen', 'IV Placebo (non-active product)', 'IV Placebo 100 mL solution']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Postoperative Pain,"['Postoperative Pain', 'Hysterectomy']","['Pain', 'Gynecologic', 'IV Acetaminophen', 'Postoperative', 'Analgesic']",COMPLETED,,2006-11,2007-09,"[{'measure': 'Sum of Pain Intensity at Rest-Baseline to 24 Hours (SPI24rest), 1 Gram IV Acetaminophen vs. Placebo.', 'description': 'The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 24 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 24 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100mm VAS scale was used with the left terminus (0 mm) of the scale ""No Pain"" and the right terminus (100 mm) with ""Worst Pain Imaginable"". The range of measurement is 0-2400 mm for 24 hours.', 'timeFrame': 'Baseline (just prior to the first dose) through 24 hours'}, {'measure': 'Sum Pain Intensity at Rest-Baseline to 48 Hours (SPI48rest), 1 Gram IV Acetaminophen vs. Placebo', 'description': 'The Sum of Pain Intensity (SPI) score incorporates the analgesic effects on pain intensity (PI) from Baseline to 48 hours. SPI was measured by the 100 millimeter (mm) long Visual Analog Scale (VAS) over 48 hours after treatment. Subjects were asked to mark the level of pain they were experiencing at a certain timepoint on the scale The 100 mm VAS scale was used with the left terminus (0 mm) of the scale ""No Pain"" and the right terminus (100 mm) with ""Worst Pain Imaginable"". The range of measurement is 0-4800 mm for 48 hours.', 'timeFrame': 'Baseline (just prior to the first dose) through 48 hours'}]","[{'measure': 'Subjects Who Experienced at Least One Treatment-emergent Adverse Event (TEAE)', 'description': 'Number of subjects who experienced at least one treatment emergent adverse event (TEAE) A TEAE is an adverse event that occurs on or after administration of the first dose of study medication (T0)', 'timeFrame': 'First dose through 7 day follow up'}, {'measure': 'Subjects Who Experienced at Least One Treatment-emergent Serious Adverse Event.', 'description': 'Number of subjects who reported SAEs during the study.\n\nA serious Adverse event (SAE) is defined as any untoward medical occurence at any dose of study medication that:\n\nResults in Death, Is Life Threatening, Requires inpatient hospitalization or causes prolongation of existing hospitalization, Results in persistent or significant disability/incapacity, Is a congenital anomaly/birth defect, or Is an important medical event', 'timeFrame': '32 days following first dose of study medication.'}]",4,18 Years,75 Years,FEMALE,False,Mallinckrodt,INDUSTRY,0,331.0,ACTUAL,2025-09-01T16:18:12.178838,v2_robust,True,True,True,False,True,
NCT02636868,The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age,"A Multinational, Multicenter, Masked, Randomized, Controlled Study to Assess The Safety and Efficacy of Lucinactant for Inhalation in Preterm Neonates 26 to 32 Weeks Gestational Age With Respiratory Distress Syndrome",Lucinactant delivered via investigational delivery device,"['AEROSURF', 'nCPAP', 'Lucinactant delivered via investigational delivery device']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Respiratory Distress Syndrome,['Respiratory Distress Syndrome'],[],COMPLETED,,2015-12,2019-08-06,"[{'measure': 'Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS)', 'description': 'Number of participants who had respiratory failure due to RDS or death due to RDS; known as nasal continuous positive airway pressure (nCPAP) failure', 'timeFrame': '72 hours'}]","[{'measure': 'Incidence of Respiratory Failure or Death Due to RDS', 'description': 'Incidence of Respiratory Failure or Death Due to RDS by Intubation or Failure Criteria', 'timeFrame': '72 hours'}, {'measure': 'Time to nCPAP Failure', 'description': 'Time from birth to nCPAP Failure', 'timeFrame': '72 hours'}, {'measure': 'Incidence of Respiratory Failure or Death Due to RDS With Poisson Distribution Modeling', 'description': 'The measure tests the differences between treatments on respiratory failure or death due to RDS using Poisson distribution modeling, which accounts for the time over which the event could have occurred.', 'timeFrame': '72 hours'}, {'measure': 'Incidence of Respiratory Failure or Death Due to RDS', 'description': 'Incidence of Respiratory Failure or Death due to RDS by Intubation or Failure Criteria', 'timeFrame': '28 days'}, {'measure': 'Number of Participants With Bronchopulmonary Dysplasia (BPD)', 'description': 'Summarizes the number of participants with BPD or alive without BPD', 'timeFrame': '36 weeks post-menstrual age (PMA)'}]",6,26 Weeks,32 Weeks,ALL,False,Windtree Therapeutics,INDUSTRY,0,221.0,ACTUAL,2025-09-01T16:18:12.178858,v2_robust,True,True,True,False,False,
NCT05567068,Atorvastatin Efficacy and Safety in Patients With Ulcerative Colitis,Repurposing Atorvastatin in Patients With Ulcerative Colitis Treated With Mesalamine by Modulation of mTOR/NLRP3 Pathway.,Atorvastatin 80mg,"['Atorvastatin 80mg', 'Mesalamine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Inflammatory Bowel Diseases,['Inflammatory Bowel Diseases'],[],RECRUITING,,2023-02-01,2027-09-20,"[{'measure': 'Improvement in health related quality of life', 'description': 'HRQL questionnaire will be assessed according to bowel symptoms, emotional symptoms, systemic symptoms, and social symptoms', 'timeFrame': '6 months'}]","[{'measure': 'changes in serum and fecal inflammatory biomarkers', 'description': 'The secondary endpoint is estimated by changes in serum IL-18, and fecal calprotectin.', 'timeFrame': '6 months'}]",2,18 Years,75 Years,ALL,False,Tanta University,OTHER,0,44.0,ESTIMATED,2025-09-01T16:18:12.178906,v2_robust,True,True,False,False,False,
NCT04126668,A Study to Investigate the Food Effect on the Pharmacokinetics of CM082 Tablet in Chinese Healthy Volunteers,A Pharmacokinetic Study in Chinese Healthy Male and Female Volunteers to Investigate the Effect of Food on the Pharmacokinetics of CM082 Tablet.,CM082 with fed or fasting,['CM082 with fed or fasting'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Malignant Solid Tumors,['Advanced Malignant Solid Tumors'],[],COMPLETED,,2019-12-19,2020-01-16,"[{'measure': 'Peak plasma concentration (Cmax) of CM082', 'description': 'The effect of food on Cmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions', 'timeFrame': 'pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)'}, {'measure': 'Area under the plasma concentration versus time curve (AUC) of CM082', 'description': 'The effect of food on AUC after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions', 'timeFrame': 'pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)'}, {'measure': 'Time of maximum concentration（Tmax）of CM082', 'description': 'The effect of food on Tmax after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions', 'timeFrame': 'pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)'}, {'measure': 'Half life（T1/2）of CM082', 'description': 'The effect of food on T1/2 after high fat diet and fasting Blood sampling over a 72 hour period post dose in all dosing sessions', 'timeFrame': 'pre-dose(30minute),30min、1、1.5、2、2.5、3、3.5、4、4.5、5、6、8、10、12、24、36、48、72hour (after administration)'}]","[{'measure': 'Percentage of adverse events', 'description': 'Percentage of adverse events as assessed by CTCAE v4.03', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 2 months'}]",5,18 Years,45 Years,ALL,True,AnewPharma,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:12.178917,v2_robust,True,True,True,False,True,
NCT02885168,Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C,Modulation of Vasoreactivity in Septic Shock: Impact of Recombinant Protein C,Recombinant Activated Protein C,"['Xigris', 'Phenylephrine', 'Recombinant Activated Protein C']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Septic Shock,['Septic Shock'],"['vasoreactivity', 'recombinant activated protein C']",COMPLETED,,2008-02,2009-04,"[{'measure': 'Vascular reactivity measured with dose-response to phenylephrine', 'timeFrame': 'baseline'}, {'measure': 'Vascular reactivity measured with dose-response to phenylephrine', 'timeFrame': '4 hours'}, {'measure': 'Vascular reactivity measured with dose-response to phenylephrine', 'timeFrame': '24 hours'}]",[],3,18 Years,,ALL,False,"Central Hospital, Nancy, France",OTHER,0,30.0,ACTUAL,2025-09-01T16:18:12.178952,v2_robust,True,True,True,False,False,
NCT02982668,Optimizing Early Enteral Nutrition in Severe Stroke,A Multi-center Randomised Controlled Trial to Explore the Ideal Initial Enteral Feeding Strategies in Patients With Severe Stroke at Acute Stage,metoclopramide or mosapride,['metoclopramide or mosapride'],1,INTERVENTIONAL,['NA'],,,Severe Stroke,"['Severe Stroke', 'Acute Stroke', 'Dysphagia']","['severe stroke', 'Acute Stroke', 'Enteral Feeding', 'Mortality', 'Disability', 'Clinical trial']",TERMINATED,Significantly higher mortality,2017-01,2020-12,"[{'measure': 'Rate of patients with death or major disability (modified Rankin scale score ≥3)', 'description': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'timeFrame': '3 months after enrollment'}]","[{'measure': 'Mortality (rate of patients with death)', 'description': 'Rate of patients with death', 'timeFrame': '3 months after enrollment'}, {'measure': 'The scores of National Institute of Health stroke scale', 'description': 'National Institute of Health stroke scale, with scores ranging from 0 (normal function) to 42 (functional impairment)) was used to evaluate the impairment caused by a stroke.', 'timeFrame': '7 days after enrollment'}, {'measure': 'Glasgow Coma Scale', 'description': 'Glasgow Coma Scale, with scores ranging from 3 (no response) to 15 (normal response), was used to grade the conscious state.', 'timeFrame': '7 days after enrollment'}, {'measure': 'modified Rankin scale', 'description': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'timeFrame': '7 days after enrollment'}, {'measure': 'Barthel index', 'description': 'The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients', 'timeFrame': '7 days after enrollment'}, {'measure': 'modified Rankin scale', 'description': 'modified Rankin scale score, with score ranging from 0 (normal) to 6 (death), was used to evaluate the functional outcomes after stroke.', 'timeFrame': '3 months after enrollment'}, {'measure': 'Barthel index', 'description': 'The Barthel Index is a scale, with score ranging from 0 to 100 (normal), that measures disability or dependence in activities of daily living in stroke patients', 'timeFrame': '3 months after enrollment'}, {'measure': 'The incidence of treatment intolerance', 'description': 'The intolerance including gastric retention, diarrhea, constipation, gastrointestinal hemorrhage', 'timeFrame': '7 days after enrollment'}, {'measure': 'The incidence of serious adverse events', 'timeFrame': '3 months after enrollment'}, {'measure': 'The incidence of adverse events That are related to treatment', 'timeFrame': '3 months after enrollment'}]",11,18 Years,,ALL,False,Xijing Hospital,OTHER,14,306.0,ACTUAL,2025-09-01T16:18:12.178961,v2_robust,True,True,False,True,True,Significantly higher mortality
NCT02593968,Yallaferon in Chinese Population,"a Multi-sites, Randomized, Parallel, Placebo-Controlled Clinical, Pilot Study to Evaluated the Efficacy and Safety of Recombinant Human Interferon Alpha-2b Gel (Yallaferon®) in HPV Infection",Recombinant Human Interferon a-2b Gel,"['Recombinant Human Interferon a-2b Gel', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HPV Infection,['HPV Infection'],[],UNKNOWN,,2015-09,2016-11,"[{'measure': 'HPV-16 and/or HPV-18 negative conversion rate', 'description': 'hr-HPV DNA negative conversion rate will be evaluated at 3 months after treatment in treatment and placebo group; calculation method: proportion of patient with HPV negative expression', 'timeFrame': '3 months'}]","[{'measure': 'HPV-16 and/or HPV-18 negative conversion rate', 'description': 'hr-HPV DNA negative conversion rate will be evaluated at 6 months after treatment in treatment and placebo group; calculation method: proportion of patient with HPV negative expression', 'timeFrame': '6 months'}, {'measure': 'HPV-16 and/or HPV-18 negative conversion rate', 'description': 'hr-HPV DNA negative conversion rate will be evaluated at 9 months after treatment in treatment and placebo group; calculation method: proportion of patient with HPV negative expression', 'timeFrame': '9 months'}, {'measure': 'HPV-16 and/or HPV-18 negative conversion rate', 'description': 'hr-HPV DNA negative conversion rate will be evaluated at 12 months after treatment in treatment and placebo group; calculation method: proportion of patient with HPV negative expression', 'timeFrame': '12 months'}, {'measure': 'reinfection at 12 months', 'timeFrame': '12 months'}]",5,25 Years,65 Years,FEMALE,False,Lee's Pharmaceutical Limited,INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:12.179002,v2_robust,True,True,False,False,False,
NCT01066468,"Glivec/Gleevec Pediatric (Age 1 to Less Than 4) PK Study in CML, Ph+ ALL Patients and Other Glivec/Gleevec® Indicated Hematological Disorders.","A Non-randomized, Open-label Study to Characterize the Pharmacokinetics (PK) of Glivec/Gleevec® (Imatinib Mesylate) in Pediatric (Age Range 1 to Less Than 4 Years) Patients With Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) or Other Glivec/ Gleevec® Indicated Hematological Disorders (HES, CEL, MDS/ MPN)",Gleevec/Glivec,"['Gleevec/Glivec', 'STI571']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Myeloid Leukemia (CML),"['Chronic Myeloid Leukemia (CML)', 'Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)', 'Other Glivec/Gleevec Indicated Hematological Disorders (HES, CEL, MDS/ MPN)']","['Chronic myeloid leukemia', 'CML', 'Philadelphia chromosome positive', 'acute lymphoblastic leukemia', 'PhGlivec,', 'Gleevec,', 'hypereosinophilic syndrome,', 'HES,', 'chronic eosinophilic leukemia,', 'CEL,', 'myelodysplastic syndrome,', 'MDS,', 'myeloproliferative disease,', 'MPD+ ALL']",TERMINATED,,2010-10,,"[{'measure': 'Measure: Pharmacokinetic data o (CL/F (clearance) o V/F (Volume of distribution) o Tmax o Physiologically based pharmacokinetic (PBPK) parameters (plasma protein binding and α-1 acid glycoprotein concentration)', 'timeFrame': '2 PK sample collection within 21 days'}]","[{'measure': 'safety and tolerability of imatinib during the study period', 'timeFrame': 'study period of 21 days'}]",2,1 Year,3 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,3.0,ACTUAL,2025-09-01T16:18:12.179017,v2_robust,True,True,False,True,True,
NCT02145468,A Phase 3 Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (LATITUDE-TIMI 60),A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,Losmapimod 7.5 mg twice daily,"['Placebo twice daily', 'Standard therapy', 'GW856553', 'Losmapimod 7.5 mg twice daily']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Coronary Syndrome,['Acute Coronary Syndrome'],"['Myocardial infarction', 'Acute coronary syndrome', 'Cardiovascular disease', 'p38 mitogen-activated protein kinase (MAPK) inhibitor', 'NSTEMI', 'Losmapimod', 'STEMI']",COMPLETED,,2014-06-03,2015-12-14,"[{'measure': 'Number of Participants With First Occurrence of Major Adverse Cardiovascular Events (MACE) Through Week 12', 'description': 'The primary efficacy endpoint is the composite measure of adjudicated MACE that includes the time to first occurrence of CV death (death due to a cardiovascular cause), MI or SRI-UR (Severe Recurrent Ischemia requiring Urgent coronary artery Revascularization). Death for which the Clinical Events Committee (CEC) or investigator were unable to establish cause were analyzed as CV deaths.', 'timeFrame': 'Up to 12 weeks'}]","[{'measure': 'Number of Participants With First Occurrence of MACE Through Week 24', 'description': 'Number of participants with first occurrence of MACE through Week 24 including CV death, MI or SRI-UR are presented. Death for which the CEC or investigator were unable to establish cause were analyzed as CV deaths.', 'timeFrame': 'Up to Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CV Death or MI up to Week 12 and Week 24', 'description': 'Week 12 results are considered the principal secondary endpoint. Number of participants with first occurrence of the composite of CV death or MI up to Week 12 and Week 24 are summarized.', 'timeFrame': 'Week 12 and Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CV Death, MI or Hospitalization for Heart Failure (HF) up to Week 12 and Week 24.', 'description': 'Number of participants with first occurrence of the composite of CV death, MI or hospitalization for HF up to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12 and Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Expanded Composite of Arterial CV Events Defined as CV Death, MI, SRI-UR or Stroke Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the expanded composite of arterial CV events defined as CV death, MI, SRI-UR or stroke through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of Coronary Events Defined as CHD Death, MI, SRI-UR or Any Unplanned Coronary Artery Revascularization Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of coronary events defined as coronary heart disease (CHD) death, MI, SRI-UR or any unplanned coronary artery revascularization through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CV Death or Hospitalization for HF Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of CV death or hospitalization for HF through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CV Death, MI or Stroke Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of CV death, MI or stroke through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Expanded Composite of CV Death, MI, SRI-UR, Stroke or Hospitalization for HF Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the expanded composite of CV death, MI, SRI-UR, stroke or hospitalization for HF through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CHD Death, MI or SRI-UR Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of CHD death, MI or SRI-UR through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CHD Death or MI Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of CHD death or MI through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of All-cause Death, MI or SRI-UR Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of all-cause death, MI or SRI-UR through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of All-cause Death or MI Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of all-cause death or MI through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CV Death, Type I (Spontaneous) MI or SRI-UR Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of CV death, type I (spontaneous) MI or SRI-UR through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of the Composite of CV Death or Type I (Spontaneous) MI Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of the composite of CV death or type I (spontaneous) MI through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of Definite or Probable Stent Thrombosis Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of definite or probable stent thrombosis through to Week 12 and Week 24 are presented. Participants receiving stent prior to randomization or during the study prior to Week 12 were included.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants Re-hospitalized Within 30 Days of Discharge', 'description': 'Participants who had a death or re-hospitalization within 30 days of discharge, plus participants who were never discharged from the initial hospitalization were included.', 'timeFrame': 'Within up to 30 days of post discharge'}, {'measure': 'Number of Participants With All-cause Mortality Through to Week 12 and Week 24', 'description': 'Number of participants with all-cause mortality through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With CV Death Events Through to Week 12 and Week 24', 'description': 'Number of participants with CV death events through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With CHD Death Events Through to Week 12 and Week 24', 'description': 'Number of participants with CHD death events through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of Myocardial Infarction (Fatal and Non-fatal) Events Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of myocardial infarction (fatal and non-fatal) events through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of Type I (Spontaneous) MI Events Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of type I (spontaneous) MI events through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of SRI-UR Events Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of SRI-UR events through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of Stroke (Fatal and Non-fatal) Events Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of stroke (fatal and non-fatal) events through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of Hospitalization for HF Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of hospitalization for HF through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}, {'measure': 'Number of Participants With First Occurrence of Any Unplanned Coronary Revascularization Through to Week 12 and Week 24', 'description': 'Number of participants with first occurrence of any unplanned coronary revascularization through to Week 12 and Week 24 are presented.', 'timeFrame': 'Week 12, Week 24'}]",26,35 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,1,3503.0,ACTUAL,2025-09-01T16:18:12.179037,v2_robust,True,True,True,False,True,
NCT01017250,Radiosurgery and Avastin for Recurrent Malignant Gliomas,Radiosurgery and Avastin for Recurrent Malignant Gliomas,Bevacizumab,"['Avastin', 'Bevacizumab']",2,INTERVENTIONAL,['NA'],,,Malignant Glioma,['Malignant Glioma'],['Recurrent'],COMPLETED,,2009-12,2012-02,"[{'measure': 'Central Nervous System (CNS) Toxicity', 'description': 'Number of participants who experience Grade 3 or higher adverse events in the ""Nervous System Disorder"" domain of Common Toxicity Criteria for Adverse Events (CTCAE) v4.0.', 'timeFrame': '2 months after Stereotactic Radiosurgery'}]","[{'measure': 'Progression-free Survival (PFS)', 'description': 'Time in months from the start of stereotactic radiosurgery (SRS) to the date of first progression according to Revised Assessment in Neuro-Oncology (RANO)criteria, or to death due to any cause. Patients alive who had not progressed as of the last follow-up had PFS censored at the last follow-up date. Median PFS was estimated using a Kaplan-Meier curve. Per RANO, progression is defined as a 20% increase in the sum of the longest diameter of target lesions,or a measurable increase in a non-target lesion or the appearance of new lesions.', 'timeFrame': '1 year'}, {'measure': 'Radiographic Response at Month 2', 'description': 'Radiographic response at 2 months after stereotactic radiosurgery (SRS) assessed by MRI and based on modified Response Assessment in Neuro-Oncology (RANO) criteria.Per RANO, complete response (CR) is the disappearance of all target lesions;Partial Response(PR)is a \\>=30% decrease in the sum of the longest diameter of target lesions.', 'timeFrame': '2 months after SRS'}, {'measure': 'Overall Survival(OS)', 'description': 'Time in months from the start of stereotactic radiosurgery (SRS) to date of death due to any cause. Patients alive as of the last follow-up had OS censored at the last follow-up date. Median OS was estimated using a Kaplan-Meier curve.', 'timeFrame': '2 years'}, {'measure': 'Change in Quality of Life From Baseline to 2 Months After Stereotactic Radiosurgery (SRS)', 'description': 'Quality of life as measured by the change in Functional Assessment of Cancer Therapy-Brain (FACT-Br) scores from baseline to 2 months after SRS. The FACT-Br (version 4) is comprised of the Functional Assessment of Cancer Therapy-General (FACT-G), a 27-item core questionnaire evaluating the domains of physical, family/social, emotional and functional well-being, with the addition of 23 brain cancer specific questions. The FACT-G total score is the sum of the four FACT-G domain scores. The Brain Cancer Subscale (BrCS) is the sum of 19 brain cancer specific questions. The FACT-Br Trial Outcome Index (TOI) is the sum of the BrCS score and the physical and family/social domain scores. The FACT-Br total score is the sum of the FACT-G total score and the BrCS score. Higher scores for all scales indicate improved quality of life (QOL).Change score = score at 2 months after SRS - score at baseline. Positive change scores indicate improved quality of life.', 'timeFrame': '2 months after SRS'}, {'measure': 'Cognition at 2 Months After Stereotactic Radiosurgery (SRS)as Measured by the Mini-Mental State Exam ( MMSE)', 'description': 'Cognition as measured by the change in the Mini-Mental State Exam (MMSE) scores from baseline to 2 months after SRS. The MMSE is an 11-item measure that tests five areas of cognitive function: orientation, registration, attention and calculation, recall and language. The maximum score is 30. Change score = score at 2 months after SRS - score at baseline. Higher scores for this scale indicate improved quality of life(QOL). Positive change scores indicate improved cognition.', 'timeFrame': '2 months after SRS'}, {'measure': 'Cognition at 2 Months After Stereotactic Radiosurgery (SRS) as Measured by the Trail Making Test (TMT)', 'description': 'Cognition as measured by the change in scores on the Trail Making Test (TMT). The TMT consists of two parts. Part A (TMT-A) requires an individual to draw lines sequentially connecting 25 encircled numbers distributed on a sheet of paper. Task requirements are similar for Part B (TMT-B) except the person must alternate between numbers and letters (e.g., 1, A, 2, B, 3, C, etc.). The score on each part represents the amount of time required to complete the task. Shorter time scores indicates improved cognition. Change score = score at 2 months after SRS - score at baseline. Negative change scores indicate improved cognition.', 'timeFrame': '2 months after SRS'}, {'measure': 'Performance Status at 2 Months After Stereotactic Radiosurgery (SRS)', 'description': 'Number of patients with a 10% decline in Karnofsky Performance Status (KPS) from baseline to 2 months after SRS. KPS is rated on a 0 to 100 scale representing a patient\'s ability to perform normal activity, ability to do active work, and the need for assistance. A score of 100 is ""perfect"" health and 0 represents death.', 'timeFrame': '2 months after SRS'}, {'measure': 'Steroid Usage After Stereotactic Radiosurgery (SRS)', 'description': 'Number of patients using steroids at baseline and at 2 months after SRS.', 'timeFrame': '2 months after SRS 2 months after SRS 2 months after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): K-trans', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. K-trans is the widely accepted MR method for quantitating brain tumor microvascular permeability( a measure of blood transport.) K-trans will indicate a combination of both flow and permeability properties of tissue. K-trans will indicate the tissue perfusion per unit volume, with a reduction in K-trans suggesting an increased anti-tumor effect and potentially improved outcome. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '1 week after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): K-trans', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. K-trans is the widely accepted MR method for quantitating brain tumor microvascular permeability( a measure of blood transport.) K-trans will indicate a combination of both flow and permeability properties of tissue. K-trans will indicate the tissue perfusion per unit volume with a reduction in K-trans suggesting an increased anti-tumor effect and potentially improved outcome. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '2 months after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): AUC', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. Area under the curve (AUC) is utilized to measure the signal enhancement ratio washout volume and could be predictive of cancer treatment response. It is possible AUC could be used as a prognostic indicator of the eventual response. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '1 week after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): AUC', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. Area under the curve (AUC) is utilized to measure the signal enhancement ratio washout volume and could be predictive of cancer treatment response. It is possible AUC could be used as a prognostic indicator of the eventual response. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '2 months after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): EVF', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. By measuring extracellular extravascular volume fraction (EVF) it is possible to gain information on brain tissue perfusion. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '1 week after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): EVF', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '2 months after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 1 Week After Stereotactic Radiosurgery (SRS): ADC', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. Diffusion-weighted imaging, dependent on motion of water molecules, provides information regarding tissue integrity. Apparent diffusion coefficient (ADC) values in the normal brain parenchyma, and those in brain tumors were measured. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '1 week after SRS'}, {'measure': 'Dynamic Contrasted-enhanced MRI (DCE-MRI) Perfusion Indices at 2 Months After Stereotactic Radiosurgery (SRS): ADC', 'description': 'DCE-MRI is a quantitative method that allows for non-invasive analysis of tumor vascular characteristics. Diffusion-weighted imaging, dependent on motion of water molecules, provides information regarding tissue integrity. Apparent diffusion coefficient (ADC) values in the normal brain parenchyma, and those in brain tumors were measured. Patients had a DCE-MRI at baseline and at 1 week and 2 months after SRS.', 'timeFrame': '2 months after SRS'}]",17,18 Years,80 Years,ALL,False,Duke University,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:12.179048,v2_robust,True,True,True,False,True,
NCT05399550,Study to Evaluate The Safety and Efficacy of Balovaptan in Participants With Acute Ischemic Stroke at a High Risk of Developing Malignant Brain Edema,"A Phase II, Randomized, Double Blind, Placebo Controlled Multicenter Study to Evaluate The Safety and Efficacy of Balovaptan in Patients With Acute Ischemic Stroke at High Risk of Developing Malignant Cerebral Edema",Balovaptan,"['Balovaptan', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Ischemic Stroke,['Acute Ischemic Stroke'],[],WITHDRAWN,Sponsor's decision,2022-06-22,2022-11-17,"[{'measure': 'Amount of midline shift (MLS) at 72 hours from Last Known Well (LKW)', 'description': 'Midline shift will be measured in millimeter on non-contrast computer tomography (NCCT)', 'timeFrame': '72 Hours from Last Known Well'}]","[{'measure': 'Percentage of Participants with modified Rankin Scale-Structured Interview (mRS-SI) score </= 4 vs. >4', 'timeFrame': 'At Day 90'}, {'measure': 'Amount of MLS', 'description': 'MLS will be measured in millimeter on NCCT', 'timeFrame': 'At 48 hours and 96-120 hours from LKW'}, {'measure': 'Percentage of Participants with Surgical DHC Performed', 'timeFrame': 'From Baseline up to Day 90'}, {'measure': 'Percentage of Participants Who Received Hyperosmolar therapy following initiation of study treatment', 'timeFrame': 'From Baseline up to Day 90'}, {'measure': 'National Institute of Health Stroke Scale (NIHSS) score', 'timeFrame': 'At Day 4 and Day 90'}, {'measure': 'Mortality', 'description': 'Mortality in the first 30 days after the enrollment', 'timeFrame': 'At Day 30'}, {'measure': 'mRS-SI score', 'timeFrame': 'At Day 30'}, {'measure': 'Functional Independence Measure (FIM) score', 'timeFrame': 'At Discharge or Day 10 and Day 90'}, {'measure': 'Glasgow Outcome Scale Extended (GOSE) Score', 'timeFrame': 'at Discharge or Day 10, Day 30 and Day 90'}, {'measure': 'Stroke Impact Scale-16 (SIS-16) score', 'timeFrame': 'At Day 30 and Day 90'}, {'measure': 'Length (in days) of ICU and Hospital Stay', 'timeFrame': 'From Baseline to Day 90'}, {'measure': 'Number of participants with adverse events and severity of adverse events', 'description': 'Severity will be determined according to the NCI CTCAE v5.0', 'timeFrame': 'From Baseline to Day 90'}, {'measure': 'Plasma concentrations of balovaptan at specified timepoints', 'timeFrame': 'From Baseline to 120 Hours After the End of the Last Infusion (or at discharge)'}, {'measure': 'Area under the concentration-time curve from Time 0 to 24 hours after a given dose (AUC24hr)', 'description': 'As calculated by NCA from measured concentration', 'timeFrame': 'From Baseline to 120 Hours After the End of the Last Infusion (or at discharge)]'}, {'measure': 'Maximum observed concentration (Cmax)', 'description': 'As calculated by NCA or taken directly from measured concentration', 'timeFrame': 'From Baseline to 120 Hours After the End of the Last Infusion (or at discharge)]'}, {'measure': 'Plasma drug concentration 24hours after the administration of a given dose (C24hr)', 'description': 'As calculated by NCA or taken directly from measured concentration', 'timeFrame': 'From Baseline to 120 Hours After the End of the Last Infusion (or at discharge)]'}, {'measure': 'Number of participants with safety findings on brain imaging', 'timeFrame': 'From Baseline to Day 90'}]",18,18 Years,80 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:12.179056,v2_robust,True,True,False,True,True,Sponsor's decision
NCT03665350,Insulin Treatment in Diabetic Older People With Heart Failure.,Management of the Patient With Heart Failure and Diabetes: May Insulin be a Problem? A Pilot Randomized Clinical Study (Insulin-HF),Insulin,['Insulin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Heart Failure,"['Heart Failure', 'Diabetes Mellitus, Type 2']","['Heart Failure', 'Type 2 diabetes mellitus', 'Insulin', 'Older adults']",TERMINATED,Insulin-HF study was prematurely ended due principally to low recruitment rate.,2018-11-08,2019-09-18,"[{'measure': 'Change in blood glucose variability', 'description': 'Mean change from baseline to 12 months in glucose variability. Glucose variability is estimated as standard deviation (SD) of serial glycemic values, and is based on 3 daily glucose profiles (each with at least 5 self-measurements of blood glucose).', 'timeFrame': 'baseline to 12 months.'}]","[{'measure': 'Number of patients with episodes of hypoglycemia.', 'description': 'Hypoglycemic episodes: an event accompanied or not accompanied by typical symptoms but with a measured plasma glucose concentration ≤70 mg/dl (3.9 mmol/l).', 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': 'Change in body weight.', 'description': 'Weight will be measured in Kg. An increase in body weight ≥2 kg gain in one week will be considered a marker of fluid congestion.', 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': 'Change in plasma concentration of a natriuretic peptide', 'description': 'BNP or NT-proBNP concentrations will be measured as ng/L of plasma.', 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': 'Changes in urinary albumin excretion', 'description': 'Urinary albumin concentration will be expressed as the urinary albumin-to-creatinine ratio (UACR), measured in milligrams per grams of creatinine, with a limit of detection of 1.5 mg/g.', 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': 'Change in New York Heart Association (NYHA) class', 'description': 'Any change in NYHA class. The New York Heart Association (NYHA) Functional Classification places patients in one of four categories (I through IV) based on heart failure symptoms and functional limitations. Higher NYHA classes indicate a greater heart failure severity and poorer outcome.""', 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': 'All-cause hospitalizations', 'description': 'Number of patients admitted to hospital for any cause.', 'timeFrame': 'baseline to 12 months'}, {'measure': 'Hospitalizations for worsening of HF.', 'description': 'Number of patients admitted to hospital for worsening of HF.', 'timeFrame': 'baseline to 12 months'}, {'measure': 'All-cause mortality', 'description': 'Number of patients who died for cardiovascular and non-cardiovascular causes.', 'timeFrame': 'baseline to 12 months'}, {'measure': 'Number of patients with episodes of ketoacidosis as evaluation of safety.', 'description': 'Ketoacidosis is defined as the presence of at least two of the following factors: a) elevated plasma glucose (\\>250 mg/dL), b) ketones in serum or urine and c) acidosis (serum bicarbonate \\<18 mEq/L and/or pH \\<7.30).', 'timeFrame': 'baseline to 12 months'}, {'measure': 'Number of patients with episodes of lactic acidosis as evaluation of safety.', 'description': 'Lactic acidosis is characterized by persistently increased blood lactate levels (usually \\>5 mmol/L) in association with metabolic acidosis.', 'timeFrame': 'baseline to 12 months'}, {'measure': 'Changes in left ventricular ejection fraction (LVEF).', 'description': 'LVEF will be calculated from left ventricular volume in diastole and systole estimated by echocardiography. LVEF will be measured as percentage. A decrease in LVEF will be taken as a marker of worsening of cardiac function.', 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': ""Changes in E/e'."", 'description': ""E/e' ratio will be calculated from echo-Doppler recordings. As a ratio it will not have a unit of measure."", 'timeFrame': 'baseline, 1, 6, 12 months.'}, {'measure': 'Changes in Hemoglobin A1c (HbA1c).', 'description': 'HbA1c will be measured as percentage of total hemoglobin concentration.', 'timeFrame': 'baseline, 1, 6, 12 months.'}]",14,70 Years,100 Years,ALL,False,Mario Negri Institute for Pharmacological Research,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:12.179081,v2_robust,True,True,False,True,True,Insulin-HF study was prematurely ended due principally to low recruitment rate.
NCT02387450,Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication,Reduction de la Morbi-mortalité Cardiovasculaire Chez l'artériopathe Claudicant Par le Sildenafil,Sildenafil,"['Sildenafil', 'Viagra or revatio', 'Placebo']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Peripheral Arterial Disease,['Peripheral Arterial Disease'],"['Claudication', 'Maximal walking distance', 'Morbi-mortality']",UNKNOWN,,2015-09,2017-09,"[{'measure': 'Morbi-mortality : combined criterion (Cardiovascular fatal and non fatal event Improvement of 1 stage)', 'timeFrame': '6 months'}]","[{'measure': 'Quality of life Questionnaire', 'timeFrame': '3, 6 and 9 months'}, {'measure': 'Safety and secondary effects (Headache, Hypotension) (Proportion of Participants with Adverse Event)', 'description': 'Proportion of Participants with Adverse Events (sildenafil vs. placebo)', 'timeFrame': '3, 6 and 9 months'}, {'measure': 'Walking capacity (treadmill test)', 'description': 'treadmill test', 'timeFrame': '3, 6 and 9 months'}, {'measure': 'Proportion of revascularized patients', 'description': 'Revascularisation', 'timeFrame': '6 and 9 months'}]",5,30 Years,90 Years,ALL,False,"University Hospital, Angers",OTHER_GOV,0,400.0,ESTIMATED,2025-09-01T16:18:12.179119,v2_robust,True,True,False,False,True,
NCT03573050,"Rivastigmine BA Trial With Multiple Application of Transdermal Patches, Adaptation and Tapering Phase",Multiple Dose Crossover Comparative Bioavailability Study of a Transdermal Patch Formulation of Rivastigmine Compared With Exelon® Transdermal Patch With a Release Rate of 13.3 mg/24 Hours in Healthy Male Subjects With Preceding Adaptation Phase and Post-treatment Tapering Phase,RIV-TDS 13.3 mg/24 h,"['RIV-TDS 13.3 mg/24 h', 'Exelon® 13.3 mg/24 hours transdermal patch']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Bioequivalence,['Bioequivalence'],[],COMPLETED,,2018-05-16,2018-07-05,"[{'measure': 'AUC0-tau,ss', 'description': 'Area under the plasma concentration vs. time curve at steady state for rivastigmine', 'timeFrame': 'from 0 to 24 hours following the 5th patch application'}, {'measure': 'Ctau,ss', 'description': '(Trough) minimum plasma concentration at the end of the dosing interval at steady state for rivastigmine', 'timeFrame': 'from 0 to 24 hours following the 5th patch application'}, {'measure': 'Cmax,ss', 'description': 'Maximum plasma concentration within the dosing interval at steady state for rivastigmine', 'timeFrame': 'from 0 to 24 hours following the 5th patch application'}]","[{'measure': 'Patch adhesion', 'description': 'one-sided lower 90% confidence limit of mean adherence percentage at the end of the dosing interval of the 5th patch', 'timeFrame': 'from first investigational patch application until removal of the last investigational patch (approx. 10 days)'}, {'measure': 'Skin irritation', 'description': 'frequency of scores for quantification of skin irritation per treatment and time point', 'timeFrame': 'from first investigational patch removal until last investigational patch removal (approx. 10 days)'}, {'measure': 'Adverse events', 'description': 'descriptive evaluation of frequency and intensity, relationship to the IMP, action taken, outcome, seriousness, period and treatment', 'timeFrame': 'approximately 2 weeks, through study completion in case of follow-up'}]",6,18 Years,50 Years,MALE,True,SocraTec R&D GmbH,OTHER,1,36.0,ACTUAL,2025-09-01T16:18:12.179308,v2_robust,True,True,True,False,True,
NCT06440850,Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation,"A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy",Cobimetinib,"['RO 5185426', 'Vemurafenib', 'RG7204', 'RG 7204', 'BRAF (V600E) kinase inhibitor RO5185426', 'XL518', 'Zelboraf', 'Cobimetinib', 'PLX-4032', 'PLX4032', 'Cotellic', 'BRAF(V600E) Kinase Inhibitor RO5185426', 'GDC-0973', 'MEK Inhibitor GDC-0973']",14,INTERVENTIONAL,['PHASE2'],PHASE2,,Thyroid Gland Follicular Carcinoma,"['Thyroid Gland Follicular Carcinoma', 'Thyroid Gland Oncocytic Carcinoma', 'Thyroid Gland Papillary Carcinoma']",[],RECRUITING,,2024-07-15,2026-11-22,"[{'measure': 'Patients who achieve excellent or indeterminate response with vemurafenib and cobimetinib treatment prior to radioactive iodine therapy', 'description': 'Excellent and indeterminate responses are defined by 2015 American Thyroid Association Management Guildelines for Differentiated Thyroid Cancer:\n\n* Excellent: Negative imaging and either suppresed thyroglobulin \\< 0.2 ng/mL or TSH-stimulated thyroglobulin \\< 1 ng/mL\n* Indeterminate: Nonspecific findings on imaging studies, faint uptake in thyroid bed on RAI scans, nonstimulated thyroglobulin detectable, but \\<1 ng/mL, stimulated thyroglobulin detectable but \\<10 ng/mL or thyroglobulin antibodies stable or declining in the absence of structural or functional disease', 'timeFrame': 'Up to completion of 6 week vemurafenib and cobimetinib therapy'}]","[{'measure': 'Proportion of patients who achieve increased iodine incorporation to a predicted lesion absorbed dose of 2000 cGy with I-131 dose of ≤ 300 mCi', 'timeFrame': 'Up to completion of 6 week vemurafenib and cobimetinib therapy'}, {'measure': 'Incidence of treatment related adverse events', 'description': 'Will be summarized by type, severity (by Common Terminology Criteria for Adverse Events version 5.0 and nadir or maximum values for lab measures), date of onset, duration, reversibility, and attribution.', 'timeFrame': 'Up to completion of 6 week vemurafenib and cobimetinib therapy and 3 days of post-radioactive iodine therapy'}, {'measure': 'Progression free survival', 'description': 'From initiation of study therapy to the first observation of disease relapse/progression or death from any cause, whichever occurs first.', 'timeFrame': 'Up to one year after treatment'}, {'measure': 'Changes in thyroglobulin levels', 'timeFrame': 'Baseline, 3, 6, 9, months post-treatment up to one year'}]",5,18 Years,,ALL,False,City of Hope Medical Center,OTHER,1,21.0,ESTIMATED,2025-09-01T16:18:12.179330,v2_robust,True,True,False,False,True,
NCT00555750,Sleep Loss and Mechanisms of Impaired Glucose Metabolism,The Effects of Eszopiclone Treatment (3mg for Two Months) to Counteract the Adverse Metabolic Consequences of Primary Insomnia,eszopiclone,"['Lunesta', 'eszopiclone', 'placebo']",3,INTERVENTIONAL,['NA'],,,Primary Insomnia,['Primary Insomnia'],"['sleep', 'metabolism', 'insulin', 'glucose', 'actigraphy', 'diary', 'volumetry', 'GABA']",COMPLETED,,2006-03,2008-08,"[{'measure': 'Change in Glucose Tolerance (Kg) in Response to Insulin-modified Intravenous Glucose Tolerance Test', 'description': 'Difference in glucose tolerance (Kg) in response to insulin-modified intravenous glucose tolerance test. Glucose tolerance was calculated as the slope of the natural log of declining glucose values from minute 5 to minute 19 post-infusion. By convention, this negative slope is multiplied by -1, in other words, expressed as a rate of disposal.', 'timeFrame': 'baseline and 2 months post-treatment'}]","[{'measure': 'Acute Insulin Response to Glucose (AIRg)', 'description': 'Change over two months in 1st phase Insulin secretion', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Change in Insulin Sensitivity (SI)', 'description': 'Insulin sensitivity index (SI) ""was defined in quantitative terms as the effect of insulin to catalyse the disappearance of glucose from plasma."" \\[R. Bergman, Horm Res 2005;64(suppl 3):8-15\\].\n\nSI calculated using Bergman\'s Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Change in Glucose Effectiveness (SG)', 'description': 'Glucose effectiveness was defined as ""the ability of glucose itself to enhance its own disappearance independent of an increment in insulin."" \\[R. Bergman, Horm Res 2005;64(suppl 3):8-15\\].\n\nSG calculated using Bergman\'s Minimal model analyses (Minmod Millennium 2000; R. Bergman, University of South- ern California, Los Angeles, CA)', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Change in HbA1c Levels', 'description': 'Difference in HbA1c levels following two months treatment with eszopiclone versus placebo', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Pre-Treatment Leptin Levels', 'description': 'Leptin Levels prior to two months treatment with eszopiclone or placebo, measure after an overnight fast', 'timeFrame': 'baseline'}, {'measure': 'Post-treatment Leptin Levels', 'description': 'Leptin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast', 'timeFrame': 'two months post-treatment'}, {'measure': 'Pre-treatment Ghrelin Levels', 'description': 'Ghrelin levels prior to two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast', 'timeFrame': 'baseline'}, {'measure': 'Post-treatment Ghrelin Levels', 'description': 'Ghrelin levels following two months treatment with 3mg eszopiclone or placebo, measured after an overnight fast', 'timeFrame': '2 months post-treatment'}, {'measure': 'Change in Subjective Sleepiness as Measured on the Karolinska Sleepiness Scale (KSS)', 'description': 'At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery including the Karolinska Sleepiness Scale (KSS) every three hours during wake periods. KSS is a single-item scale of sleepiness on a scale from 1 (""very alert"") to 9 (""very sleepy, fighting sleep, an effort to keep awake""). Subjective sleepiness was defined as mean deviation from baseline KSS.', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Change in Mean Lapses of Attention', 'description': 'At visits before and after two months treatment with 3mg eszopiclone or placebo, subjects completed a short test battery every three hours during wake periods. The battery included the Psychomotor Vigilance Task (PVT). The PVT involved a 10-minute visual reaction time (RT) performance test in which the subject was instructed to maintain the fastest possible RT to a simple visual stimulus. Lapses of attention refer to the number of times the subject failed to respond to the signal within 500ms. Mean lapses per test across 6 tests given a 4 hour intervals during normal waking hours (and not during the IVGTT) during the 30-hr were compared for the post-treatment visit as the absolute deviation from the baseline mean lapses/test.', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Change in Total Sleep Time as Reported in Sleep Diaries', 'description': 'Total sleep time reported on sleep diaries prior to treatment with 3mg eszopiclone or placebo. Change defined as baseline minus post-treatment).', 'timeFrame': 'baseline and 2 months post-treatment'}, {'measure': 'Change in Total Sleep Time Measured by PSG', 'description': 'Change (baseline minus post-treatment) in total sleep time measured by polysomnography after two months treatment with 3mg eszopiclone or placebo', 'timeFrame': 'baseline and 2 months post-treatment'}]",13,25 Years,55 Years,ALL,False,Brigham and Women's Hospital,OTHER,3,20.0,ACTUAL,2025-09-01T16:18:12.179385,v2_robust,True,True,True,False,False,
NCT05169450,Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke,Efficacy of Diterpene Ginkgolides Meglumine Injection in Elderly Patients With Ischemic Stroke: A Post Hoc Analysis of a Randomized Controlled Trial,Diterpene ginkgolides meglumine injection,"['Ginkgolides Diterpene Lactone Meglumine Injection', 'Diterpene ginkgolides meglumine injection', 'Ginaton']",3,INTERVENTIONAL,['NA'],,,Stroke,"['Stroke', 'Ischemic Stroke', 'Nervous System Diseases', 'Cerebral Infarction', 'Brain Ischemia', 'Brain Infarction']","['Diterpene Ginkgolides Meglumine Injection', 'acute ischemic stroke', 'effectiveness']",COMPLETED,,2013-07-01,2014-04-01,"[{'measure': 'Excellent functional outcome', 'description': 'Excellent functional outcome defined as an Modified Rankin Scale (mRS) score ≤ 1 at 90 days(scores ranged from 0 to 6, with 0 to 1 indicating no disability, 2 to 5 indicating increasing disability, and 6 indicating death)', 'timeFrame': '90 days'}]","[{'measure': 'Neurological deficit amelioration', 'description': 'neurological deficit amelioration, which was defined as a change in the National Institutes of Health Stroke Scale (NIHSS) score (range = 0-42, with higher scores indicating more severe strokes) from baseline to D14', 'timeFrame': '14 post-randomization days, 90days'}, {'measure': 'Patient quality of life', 'description': 'Patient quality of life, as measured using the EuroQol questionnaire \\[consisting of two parts: EuroQol-5 Dimension(EQ-5D) and EQ visual analog scale (EQ-VAS)\\]. A value of 100 on this scale indicates a perfect score for health, whereas a score of 0 indicates death. The EQ-5D index score is measured on a scale of 0 (death) to 1 (full health).', 'timeFrame': '14 post-randomization days, 90days'}]",3,35 Years,,ALL,False,"Dongzhimen Hospital, Beijing",OTHER,0,998.0,ACTUAL,2025-09-01T16:18:12.179432,v2_robust,True,True,True,False,False,
NCT02912650,A Safety And Efficacy Study of Ibuprofen 250 mg / Acetaminophen 500 mg In The Treatment Of Post-Surgical Dental Pain,"A Phase 3, Double-Blind, Randomized, Safety And Efficacy Study Comparing A Single Oral Dose Of Ibuprofen (IBU) 250 Mg/Acetaminophen (APAP) 500 Mg (Administered As Two Tablets Of IBU/APAP 125 Mg/250 Mg) To Each Active Drug Monocomponent Alone And To Placebo In The Treatment Of Post-Surgical Dental Pain",Ibuprofen 250 mg / Acetaminophen 500 mg,"['IBU 250', 'Acetaminophen 650 mg', 'IBU 250 / APAP 500', 'APAP 650', 'Placebo', 'Ibuprofen 250 mg', 'Ibuprofen 250 mg / Acetaminophen 500 mg']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Post-surgical Pain Following Extraction of Molar Teeth,['Post-surgical Pain Following Extraction of Molar Teeth'],"['ibuprofen', 'acetaminophen', 'pain', 'molar extraction']",COMPLETED,,2015-09,2016-06,"[{'measure': 'Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 0 to 8 Hours Post-dose (SPID11 [0-8])', 'description': 'Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 (0-8): Time-weighted sum of pain intensity difference (PID) scores over 8 hours. SPID11 score range was -40 (worst score) to 80 (best score) for SPID 0-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).', 'timeFrame': '0 to 8 hours post-dose'}]","[{'measure': 'Time-weighted Sum of Pain Intensity Difference Scores on 11-Point Numerical Scale From 6 to 8 Hours Post-dose (SPID11 [6-8])', 'description': 'Pain intensity was assessed on an 11-point numerical pain severity rating scale. SPID11 (6-8): Time-weighted sum of PID scores over 6 to 8 hours. SPID11 score range was -15 (worst score) to 30 (best score) for SPID 6-8. PID was calculated by subtracting the pain intensity score at given post-dose time points (pain severity score range: 0 =no pain to 10 =worst possible pain) from the baseline pain intensity scores (score range: 5 =moderate pain to 10 =worst possible pain; as participants with baseline pain score of at least moderate were included in study). Total possible score range for PID: -5 (worst score) to 10 (best score).', 'timeFrame': '6 to 8 hours post-dose'}, {'measure': 'Time-weighted Sum of Pain Relief Rating (TOTPAR) From 0 to 8 Hours and 6 to 8 Hours Post-dose', 'description': 'TOTPAR: Time-weighted sum of Pain Relief Rating (PRR) scores over 0 to 8 and 6 to 8 hours. TOTPAR total score range: 0 (worst score) to 32 (best score) for TOTPAR 0-8 and 0 (worst score) to 12 (best score) for TOTPAR 6-8 hours. PRR was assessed on a 5-point categorical pain relief rating scale which ranges from 0 =no relief to 4 =complete relief.', 'timeFrame': '0 to 8 hours, 6 to 8 hours post-dose'}, {'measure': 'Time to Treatment Failure', 'description': 'Time to treatment failure was defined as the time interval from the study drug administration up to the first documentation of treatment failure. Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first.', 'timeFrame': '0 to 12 hours post-dose'}, {'measure': 'Cumulative Percentage of Participants With Treatment Failure at 6 and 8 Hours', 'description': 'Treatment failure was defined as taking the rescue medication or discontinuation of the participants from the study due to lack of efficacy, whichever came first. Participants were censored at 12 hours or at their final assessment time, whichever came first. Percentage of participants who had treatment failure were reported.', 'timeFrame': '6 hours, 8 hours post-dose'}, {'measure': 'Time to Onset of Meaningful Pain Relief', 'description': 'Participants evaluated time to meaningful relief by stopping a second stopwatch labelled as ""meaningful relief"" at the moment they first began to experience meaningful relief. Stopwatch was active up to 12 hours after dosing or until stopped by participant, or participant became treatment failure prior to depressing the second stopwatch. Treatment failure was defined as participant taking rescue medication, or discontinuing due to lack of efficacy.', 'timeFrame': '0 to 12 hours post-dose'}]",6,18 Years,40 Years,ALL,False,Pfizer,INDUSTRY,0,568.0,ACTUAL,2025-09-01T16:18:12.179453,v2_robust,True,True,True,False,False,
NCT02323191,A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors,"Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Phase to Evaluate the Safety, Pharmacokinetics, and Activity of RO5509554 (Emactuzumab) and MPDL3280A (Atezolizumab) Administered in Combination in Patients With Advanced Solid Tumors",Atezolizumab,"['Emactuzumab', 'Atezolizumab', 'MPDL3280A, TECENTRIQ', 'RO5509554']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Cancers,['Solid Cancers'],[],COMPLETED,,2015-01-19,2020-08-21,"[{'measure': 'Percentage of Participants With Dose Limiting Toxicities (DLTs)', 'timeFrame': '21 days'}, {'measure': 'Maximum Tolerated Dose (MTD) of Emactuzumab', 'timeFrame': '21 days'}, {'measure': 'Percentage of Participants With Adverse Events (AEs)', 'timeFrame': 'Baseline up to 3 years'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of Emactuzumab', 'description': 'predose (-4 hours \\[h\\]) and 0.5h post end of infusion (90 minutes infusion) on Days (D) 1 of Cycle (C) 1, 2, 3, 4, 5, 6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Atezolizumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, then every 8 cycles (Cycle Length=21 days); 0.5h post end of infusion (60 minutes infusion) on D1 of C1; 120 days post last infusion (up to approximately 3 years)'}, {'measure': 'Minimum Observed Plasma Trough Concentration (Cmin) of Emactuzumab', 'timeFrame': 'predose (-4 h) on D1 of C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years)'}, {'measure': 'Minimum Observed Plasma Trough Concentration (Cmin) of Atezolizumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, then every 8 cycles (Cycle Length=21 days)'}, {'measure': 'Area under the Concentration-Time Curve (AUC) of Emactuzumab', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Total Clearance (CL) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Volume of Distribution at Steady State (Vss) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Accumulation Ratio (Rac) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Terminal Elimination Half-life (t1/2) of Emactuzumab', 'timeFrame': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C4 (Cycle Length=21 days); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D12, D15, D19 of C1, C4'}, {'measure': 'Emactuzumab Concentration at the time of Tumor Progression (Cprog)', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Emactuzumab Concentration at the Time of Tumor Response (Complete Response/Partial Response)', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Emactuzumab Concentration at the Time of Infusion-related Reaction (IRR) or Hypersensitivity Reaction', 'description': 'predose (-4 h) and 0.5h post end of infusion (90 minutes infusion) on D1 of C1, C2, C3, C4, C5, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years); 5h postdose on D1 of C1; postdose on D2, D4 or D5, D8, D15 of C1, C2, C4; D12, D19 of C1, C4; 44 and 120 days post last infusion; 28 day follow-up visit (up to approximately 3 years)', 'timeFrame': 'predose (-4 h) on Day 1 of Cycle 1 up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Change From Baseline in Tumor-Associated Macrophages (TAMs) Levels in Paired-Tumor Biopsies at Specified Timepoints', 'timeFrame': 'Baseline (predose [-4 h] on D1 of C2; Cycle Length=21 days), at disease progression (up to approximately 3 years)'}, {'measure': 'Change From Baseline in Dermal Macrophages Levels in Paired Skin Biopsies at Specified Timepoints', 'timeFrame': 'Baseline, D15 of C1 (Cycle Length=21 days)'}, {'measure': 'Change From Baseline in Circulating Cluster of Differentiation (CD) 14DimCD16high Monocytes Levels in Peripheral Blood at Specified Timepoints', 'description': 'Baseline (predose \\[-4 h\\] on D1 of C1), predose \\[-4 h\\] on D1 of C2, C3, C5, then every other cycle (Cycle Length=21 days) until disease progression (up to approximately 3 years); postdose on D2, D8, D15 of C1, C2; D4 or D5 of C1; 44 days post last infusion (up to approximately 3 years)', 'timeFrame': 'Baseline up to approximately 3 years (detailed timeframe provided in measure description)'}, {'measure': 'Percentage of Participants With Anti-therapeutic Antibodies to Emactuzumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, all subsequent cycles (Cycle Length=21 days) until disease progression (up to approximately 3 years), 44 and 120 days post last infusion, 28 day follow-up visit (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Anti-therapeutic Antibodies to Atezolizumab', 'timeFrame': 'predose (-4 h) on D1 of C1, C2, C3, C4, C6, then every 8 cycles (Cycle Length=21 days; up to approximately 3 years), 120 days post last infusion (up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Best Overall Response as Determined Using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Best Overall Response as Determined Using Modified RECIST', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Objective Response as Determined Using RECIST v1.1', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}, {'measure': 'Percentage of Participants With Objective Response as Determined Using Modified RECIST', 'timeFrame': 'Baseline up to disease progression or death, whichever occurs first (assessed up to approximately 3 years)'}]",24,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,221.0,ACTUAL,2025-09-01T16:18:12.179495,v2_robust,True,True,True,False,True,
NCT00561691,Nimotuzumab in Children With Intrinsic Pontine Glioma,Phase III Study on the Effectiveness of OSAG 101 (Theraloc®)in Newly Diagnosed Intrinsic Pontine Gliomas of Children and Adolescents,nimotuzumab,"['Theraloc', 'nimotuzumab']",2,OBSERVATIONAL,[],,,Diffuse Instrinsic Ponitine Glioma,['Diffuse Instrinsic Ponitine Glioma'],"['diffuse instrinsic ponitine glioma, brainstem']",COMPLETED,,2006-04,2012-01,"[{'measure': 'To determine the progression-free survival (PFS) of the combination of monoclonal anti-EGFR antibody OSAG 101 and standard local radiotherapy', 'timeFrame': 'week 12, 24, 36'}]","[{'measure': 'To determine the objective response rate (R=CR+PR+SD/Nr) according to RECIST To determine the duration of response and the overall survival To assess adverse events and the toxicity profile according to CTCAE version 3.0', 'timeFrame': 'week 12, 24, 36'}]",2,3 Years,20 Years,ALL,False,Oncoscience AG,INDUSTRY,12,41.0,ACTUAL,2025-09-01T16:18:12.179601,v2_robust,False,True,True,False,True,
NCT03315091,Phase I Study to Assess the Effect of Food on AZD1775 Pharmacokinetics in Patients With Advanced Solid Tumours,"A Randomised, Open-label, Phase I Study to Determine the Effect of Food on the Pharmacokinetics of AZD1775 After Oral Dosing of a Capsule Formulation in Patients With Advanced Solid Tumours",Treatment A - AZD1775 administered under fasted conditions,"['Treatment B - AZD1775 administered under fed conditions.', 'Treatment A - AZD1775 administered under fasted conditions']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumours,['Solid Tumours'],"['Pharmacokinetics, WEE1 inhibitor, food effect, safety assessments']",COMPLETED,,2017-09-29,2018-04-05,"[{'measure': 'Area under the plasma concentration-time curve from zero to infinity for AZD1775', 'description': 'To investigate the effect of food on the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': 'Area under the plasma concentration-time curve from time zero to the time ""t"" (AUC0-t) of the last quantifiable concentration for AZD1775', 'description': 'To investigate the effect of food on the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': 'Cmax: maximum plasma drug concentration for AZD1775', 'description': 'To investigate the effect of food on the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}]","[{'measure': 'tmax,: time to reach maximum plasma concentration for AZD1775', 'description': 'To characterise the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': 'λz: Elimination rate constant for AZD1775', 'description': 'To characterise the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': 'Apparent clearance following oral administration for AZD1775', 'description': 'To characterise the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': 't½,: terminal half-life for AZD1775', 'description': 'To characterise the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': 'Apparent volume of distribution for AZD1775', 'description': 'To characterise the PK of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours', 'timeFrame': 'Blood samples are collected on Day 1 of each treatment period at pre-dose, 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 hours post AZD1775 dose'}, {'measure': ""Adverse Events, graded by the National Cancer Institute Common Terminology Criteria for Adverse Event's (CTCAE v4.3)"", 'description': 'To assess the safety and tolerability of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}, {'measure': 'Complete physical examination including performance status assessed using the Eastern Cooperative Oncology Group (ECOG) Performance Status criteria.', 'description': 'To assess the safety and tolerability of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours. If new or aggravated physical findings imply deterioration compared with baseline, the finding will be reported as an Adverse Event.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}, {'measure': 'Pulse Rate (beats/min)', 'description': 'To assess the safety and tolerability of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}, {'measure': 'Evaluation of Haematology Parameters (Haemoglobin, Leukocyte and Leukocyte counts, Red blood cell count, Haematocrit and Platelet Count)', 'description': 'Laboratory tests will be performed by an accredited laboratory. Deterioration of haematology laboratory values as compared to baseline will be reported as Adverse Events if they fulfill any of the Serious Adverse Events criteria or are the reason for discontinuation of the study treatment unless clearly due to the progression of disease under study. If deterioration in a laboratory value is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result will be considered as additional information.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}, {'measure': 'Electrocardiogram (ECG) - A 12-lead safety ECG (paper ECG printout of 10 seconds for Investigator review)', 'description': 'To assess the safety and tolerability of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours. The Investigator will judge the overall interpretation as normal or abnormal. If abnormal, it will be decided as to whether or not the abnormality is clinically significant or not clinically significant.', 'timeFrame': 'Until 7 days following the final dose of AZD1775'}, {'measure': 'Blood Pressure (mm Hg)', 'description': 'To assess the safety and tolerability of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}, {'measure': 'Body Temperature (°C)', 'description': 'To assess the safety and tolerability of a single dose of AZD1775 printed capsules following oral dosing in patients with advanced solid tumours.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}, {'measure': 'Evaluation of Clinical Chemistry Parameters (Albumin, Alanine Transaminase, Aspartate Transaminase, Alkaline Phosphatase, Bilirubin, Calcium, Creatinine, Glucose, Total protein, Chloride, Potassium, Sodium, Urea nitrogen)', 'description': 'Laboratory tests will be performed by an accredited laboratory. Deterioration of clinical chemistry values as compared to baseline will be reported as Adverse Events if they fulfil any of the Serious Adverse Events criteria or are the reason for discontinuation of the study treatment unless clearly due to the progression of disease under study.\n\nIf deterioration in a laboratory value is associated with clinical signs and symptoms, the sign or symptom will be reported as an AE and the associated laboratory result will be considered as additional information.', 'timeFrame': 'Until 30 days following the final dose of AZD1775'}]",16,18 Years,99 Years,ALL,False,AstraZeneca,INDUSTRY,1,31.0,ACTUAL,2025-09-01T16:18:12.179682,v2_robust,True,True,True,False,True,
NCT05995691,Study to Determine the Pharmacokinetic (PK) Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Participants,"A Randomized, Single-blind, Single-dose, 2-Arm, Parallel-group Study to Determine the Pharmacokinetic Bioequivalence of ABP 501 and Adalimumab (Humira®) in Healthy Adult Japanese Subjects",ABP 501,"['Adalimumab', 'ABP 501', 'Humira®']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['ABP 501', 'Adalimumab', 'Humira®']",COMPLETED,,2014-11-24,2015-12-04,"[{'measure': 'AUCinf of ABP 501', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Cmax of ABP 501', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'AUCinf of Adalimumab', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Cmax of Adalimumab', 'timeFrame': 'Day 1 to Day 63'}]","[{'measure': 'Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)', 'description': 'Any clinically significant changes in vital signs or clinical laboratory test results after the dose of treatment will be recorded as TEAEs.', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Number of Participants With Anti-drug Antibodies (ADA)', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Terminal Phase Elimination Half-life (t1/2) of ABP 501', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 't1/2 of Adalimumab', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Time at Which the Maximum Observed Serum Concentration is Observed (Tmax) of ABP 501', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Tmax of Adalimumab', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'Area Under the Serum Concentration-time Curve from Time 0 to the Last Quantifiable Concentration (AUClast) of ABP 501', 'timeFrame': 'Day 1 to Day 63'}, {'measure': 'AUClast of Adalimumab', 'timeFrame': 'Day 1 to Day 63'}]",12,18 Years,45 Years,ALL,True,Amgen,INDUSTRY,0,179.0,ACTUAL,2025-09-01T16:18:12.179724,v2_robust,True,True,True,False,True,
NCT03601091,EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY,"RANDOMİZED,DOUBLE-BLİND TRİAL OF EFFECT OF DEXMEDETOMİDİNE AND MİDAZOLAM SEDATİON ON HEART RATE VARİABİLİTY AFTER CORONARY ARTERY BYPASS GRAFT SURGERY",Precedex 200 MCG in 2 ML Injection,"['Precedex 200 MCG in 2 ML Injection', 'DORMICUM 5MG/5 ML']",2,INTERVENTIONAL,['NA'],,,Effect of Sedation on Heart Rate Variability,['Effect of Sedation on Heart Rate Variability'],"['dexmedetomidine', 'coronary artery bypass graft', 'heart rate variability']",UNKNOWN,,2018-03-22,2021-12-31,"[{'measure': 'Heart rate variability', 'description': 'Low and high frequency of heart rate regarding with aritmia incidence', 'timeFrame': '24 hours'}]",[],1,25 Years,65 Years,ALL,True,Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital,OTHER_GOV,0,80.0,ACTUAL,2025-09-01T16:18:12.179765,v2_robust,True,True,False,False,False,
NCT00517491,Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG),A Pilot Study to Evaluate the Correlation Between Plasma Lanreotide Levels and GH/IGF-1 Dynamics and Clinical Improvement in Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG),lanreotide (Autogel formulation),['lanreotide (Autogel formulation)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Acromegaly,['Acromegaly'],[],WITHDRAWN,Administrative reasons,2008-05,2008-12,"[{'measure': 'GH (basal and during Oral Glucose Tolerance Test (OGTT)) and IGF-1 levels, in acromegalic patients previously treated with octreotide long acting release (LAR) 20 mg.', 'timeFrame': 'Weeks 16, 18 & 20'}, {'measure': 'Acromegaly symptoms.', 'timeFrame': 'Weeks 16, 18 & 20'}, {'measure': 'Indices of insulin secretion & sensitivity', 'timeFrame': 'Weeks 16, 18 & 20'}, {'measure': 'Adverse events', 'timeFrame': 'Throughout study'}]","[{'measure': 'Number of patients with GH levels ≤ 2.5 ng/mL and the number of patients with IGF-1 level < upper limit of normal (ULN).', 'timeFrame': 'Weeks 16, 18 & 20.'}, {'measure': 'Serum lanreotide Autogel 120 mg concentrations.', 'timeFrame': 'Weeks 16, 18 & 20.'}, {'measure': 'ECG and gallbladder ultrasound', 'timeFrame': 'Week 20'}]",7,18 Years,70 Years,ALL,False,Ipsen,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:12.179854,v2_robust,True,True,False,True,True,Administrative reasons
NCT05112991,Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer,"An Open-label, Multi-center, Multi-corhort Phase II Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer",Envafolimab+Lenvatinib,"['Envafolimab', 'Envafolimab+Lenvatinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Endometrial Cancer,['Advanced Endometrial Cancer'],['endometrial cancer'],RECRUITING,,2022-03-04,2025-12,"[{'measure': 'ORR of Envafolimab alone or with Lenvatinib', 'description': 'The ORR (either confirmed complete response \\[CR\\] or partial response \\[PR\\]) based on RECIST 1.1 will be determined in participants who have measurable disease at study entry.', 'timeFrame': 'Up to approximately 24 months'}]","[{'measure': 'The duration of response (DoR）', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Time to response (TTR)', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'Up to approximately 24 months'}, {'measure': 'To evaluate the overall survival (OS) in in subjects with advance endometrial cancer', 'timeFrame': 'Up to approximately 24 months'}]",6,18 Years,,FEMALE,False,"3D Medicines (Sichuan) Co., Ltd.",INDUSTRY,0,108.0,ESTIMATED,2025-09-01T16:18:12.179887,v2_robust,True,True,False,False,False,
NCT01942291,Short-term Effect of Extended-release Niacin on Endothelial Function.,Short-term Effect of Extended-release Niacin With and Without the Addition of Laropiprant on Endothelial Function,Niacin,"['Niacin', 'Vitamin B3', 'Nicotinic acid']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypoalphalipoproteinemia,['Hypoalphalipoproteinemia'],"['Niacin', 'Endothelial function', 'Laropiprant', 'HDL']",COMPLETED,,2012-03,2013-06,"[{'measure': 'The short-term effect of niacin on endothelial function.', 'description': 'Endothelial-dependent vasodilation was assessed by ischemia-induced reactive hyperemia of the brachial artery by using an ultrasound equipment', 'timeFrame': '7 days'}]","[{'measure': 'Plasma C-reactive protein levels', 'description': 'Systemic inflammatory activity as estimated by the plasma concentration of C-reactive protein', 'timeFrame': '7 days'}, {'measure': 'HDL-C and HDL size', 'description': 'Plasma concentration of high-density lipoprotein (HDL) cholesterol and HDL size', 'timeFrame': '7 days'}]",3,20 Years,60 Years,ALL,False,"University of Campinas, Brazil",OTHER,0,18.0,ACTUAL,2025-09-01T16:18:12.179917,v2_robust,True,True,True,False,False,
NCT04230174,Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation,Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation,11C-PBR28,['11C-PBR28'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Multiple Sclerosis,['Multiple Sclerosis'],[],UNKNOWN,,2020-02,2022-07,"[{'measure': 'Neuroinflammation Changes under Ocrelizumab Therapy', 'description': 'To measure changes in 11C-PBR28 uptake in the brain of multiple sclerosis patients under Ocrelizumab therapy', 'timeFrame': '12 months'}, {'measure': 'To assess whether changes in neuroinflammation under Ocrelizumab treatment relate to changes in structural MR metrics of brain tissue damage', 'description': 'To measure changes in 11C-PBR28 uptake in the brain of multiple sclerosis patients under Ccrelizumab therapy correlate with changes in WM lesion load, cortical atrophy and demyelination in the cortex and in the NAWM as measured by magnetization transfer ratio (MTR)', 'timeFrame': '12 months'}]","[{'measure': 'To explore whether changes in functional and structural imaging metrics under Ocrelizumab are associated with changes in clinical outcomes measures', 'description': 'To measure whether changes in 11C-PBR28 uptake or in structural imaging metrics correlate with measures of neurological disability and cognition', 'timeFrame': '12 months'}]",3,18 Years,65 Years,ALL,False,Massachusetts General Hospital,OTHER,1,24.0,ESTIMATED,2025-09-01T16:18:12.179975,v2_robust,True,True,False,False,False,
NCT00479674,"Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer","A Phase II Study of Abraxane®, Carboplatin and Bevacizumab in ""Triple Negative"" (Demonstrating No Expression for Estrogen, Progesterone, or Her2 Receptors) Metastatic Breast Cancer",Abraxane,"['Carboplatin', 'nanoparticle albumin-bound paclitaxel', 'Abraxane', 'Bevacizumab', 'Avastin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['Metastatic Breast Cancer', 'Advanced Breast Cancer', 'Hormone Receptor AND Her2/neu Negative', 'Triple Negative', 'Triple Negative Breast Cancer', 'Stage IV or Inoperable Stage III Breast Cancer']",COMPLETED,,2007-05,2014-03,"[{'measure': 'Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane® and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III ""Triple Negative"" Metastatic Breast Cancer.', 'description': 'Best clinical response is based on RECIST criteria, the proportion in each response category along with the exact binomial confidence intervals are estimated. Toxicity summaries are also provided.', 'timeFrame': '5 years'}]","[{'measure': 'Median Proportion Progression-free as Estimated by Kaplan-Meier Methods', 'description': 'PFS was defined as time from trial enrollment to disease progression or death, whichever occurred first.', 'timeFrame': '5 years'}, {'measure': 'To Evaluate Sequential Plasma Samples for Presence of Selected Angiogenic Markers', 'timeFrame': '18 months'}, {'measure': 'to Determine if Apolipoprotein Alleles (Apo-E) Correlate With Treatment-related Neuropathy', 'timeFrame': '18 months'}, {'measure': 'to Determine if SPARC Expression in Breast Tumors Predicts Progression-free Survival (PFS)', 'timeFrame': '18 months'}]",5,18 Years,,FEMALE,False,Duke University,OTHER,2,41.0,ACTUAL,2025-09-01T16:18:12.179991,v2_robust,True,True,True,False,False,
NCT02733874,A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris.,,Compound Clobetasol Propionate Ointment,"['Calcipotriol Betamethasone Ointment', 'Compound Clobetasol Propionate Ointment']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Psoriasis,['Psoriasis'],[],COMPLETED,,2015-04,,"[{'measure': 'The improvement of psoriasis area and severity index scores(PASI scores)', 'description': 'The improvement of psoriasis area and severity index scores(PASI scores) are a system that assesses the damage of psoriasis severity and treatment response . The system is used to classify and evaluate according to the severity of lesions, areas of skin lesion and body surface area ratio of various body parts.', 'timeFrame': 'At baseline, 2 weeks and 4 weeks after baseline.'}, {'measure': 'The overall evaluation of the researchers (Physician Global Assessment,PGA)', 'description': 'On every visiting viewpoint , researchers give a mark of the infiltration / hypertrophy (I), erythema (E) and scales (s) according to the level.PGA scores are acquired by the average of above three kinds of scores.', 'timeFrame': 'At baseline, 2 weeks and 4 weeks after baseline.'}, {'measure': 'The Symptom score reduce index (SSRI)', 'description': '1)According to the improvement of psoriasis area and severity index scores(PASI scores) before and after treatments, the symptom score reduce index (SSRI) was calculated.\n\n2）The symptom score reduce index (SSRI) = (the PASI scores before treatment - the PASI scores after treatment) / the PASI scores before treatment x 100%', 'timeFrame': '4 weeks after baseline.'}, {'measure': 'Efficiency of treatment', 'description': '1）Healing patients : SSRI ≥ 90%, Marked effectiveness patients : 60% \\< SSRI \\< 90%, Improvement patients : 20% \\< SSRI \\< 60%, ineffectiveness patients :SSRI \\< 20%.\n\n2)Efficiency of treatment = (The number of healing patients + The number of markedly effective patients + The number of improved patients ) / total number of patients in this group x 100%', 'timeFrame': '4 weeks after baseline.'}]","[{'measure': 'Healing rate', 'description': '1）Healing patients : SSRI ≥ 90%, Marked effectiveness patients : 60% \\< SSRI \\< 90%, Improvement patients : 20% \\< SSRI \\< 60%, ineffectiveness patients :SSRI \\< 20%.\n\n2)Healing rate = The number of healing patients / total number of patients in this group x 100%', 'timeFrame': '4 weeks after treatment'}, {'measure': 'Markedly effective rate', 'description': '1）Healing patients : SSRI ≥ 90%, Marked effectiveness patients : 60% \\< SSRI \\< 90%, Improvement patients : 20% \\< SSRI \\< 60%, ineffectiveness patients :SSRI \\< 20%.\n\n2)Markedly effective rate = The number of markedly effective patients / total number of patients in this group x 100%', 'timeFrame': '4 weeks after treatment'}, {'measure': 'Response rate of PASI (PASI 75) after the treatment of 4 weeks', 'description': 'Response rate of PASI (PASI 75) after the treatment of 4 weeks = The number of patients whose SSRI are more than 75% / total number of patients x 100%', 'timeFrame': '4 weeks after treatment'}, {'measure': 'Response rate of PGA ( basic fading rate of PGA) after the treatment of 4 weeks', 'description': 'Response rate of PGA ( basic fading rate of PGA) after the treatment of 4 weeks：patients with 1 score of PGA for the last time/ total number of patients in this group x 100%', 'timeFrame': '4 weeks after treatment'}]",8,18 Years,65 Years,ALL,False,First Hospital of China Medical University,OTHER,0,240.0,ACTUAL,2025-09-01T16:18:12.180163,v2_robust,True,True,True,False,False,
NCT01229774,Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty,"Use of Etoricoxib Compared to Diclofenac in the Perioperative Treatment of Patients After Total Hip Arthroplasty, a Prospective, Double Blind, Phase III Study",Etoricoxib,"['Diclofenac', 'Etoricoxib']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Coxarthrosis,"['Coxarthrosis', 'Arthroplasties Hip Replacement', 'Perioperative Blood Loss']",[],COMPLETED,,2011-02,2014-08,"[{'measure': 'Perioperative blood loss after implantation of a hip joint endoprosthesis', 'description': 'The primary objective of the study is the designation of the perioperative blood loss after implantation of a hip joint endoprosthesis under the influence of Etoricoxib or of Diclofenac. The expectations hypothesis is that under Etoricoxib patients will loose a smaller quantity of blood than under Diclofenac.', 'timeFrame': 'Three days'}]","[{'measure': 'Heterotopic ossification', 'description': 'The secondary objectives are to investigate whether after hip joint endoprosthesis Etoricoxib can prevent heterotopic ossification in equal measure as Diclofenac', 'timeFrame': 'six months'}, {'measure': 'Postoperative pain', 'description': 'It will be investigated if Diclofenac and Etoricoxib effectively reduce postoperative pain after hip joint endoprosthesis at rest and during movement.', 'timeFrame': 'nine days'}, {'measure': 'Reduction of rescue medication', 'description': 'It will be investigated whether Etioricoxib can reduce the use of rescue-medication as compared to Diclofenac', 'timeFrame': 'nine days'}, {'measure': 'Gastroinstestinal tolerance', 'description': 'It will be investigated if the gastrointestinal tolerance of Etoricoxib is superior to the one of Diclofenac', 'timeFrame': 'nine days'}]",5,55 Years,85 Years,ALL,False,University of Regensburg,OTHER,1,100.0,ACTUAL,2025-09-01T16:18:12.180452,v2_robust,True,True,True,False,False,
NCT00018018,Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency,Treatment of SCID Due to ADA Deficiency With Autologous Cord Blood or Bone Marrow CD34+ Cells Transduced With a Human ADA Gene,CD34+ cells transduced with ADA retrovir,['CD34+ cells transduced with ADA retrovir'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Severe Combined Immunodeficiency Syndrome,['Severe Combined Immunodeficiency Syndrome'],"['Gene Therapy', 'ADA-SCID', 'Stem Cells', 'Retroviruses', 'Immune Deficiency Disease', 'Adenosine Deaminase Deficiency', 'ADA-Deficiency', 'Retroviral Vectors', 'Hematopoietic Progenitors', 'Severe Combined Immunodeficiency', 'SCID', 'Immune Deficiency']",COMPLETED,,2001-06-20,2014-09-17,[],[],0,1 Month,,ALL,False,National Human Genome Research Institute (NHGRI),NIH,0,8.0,ACTUAL,2025-09-01T16:18:12.180525,v2_robust,True,True,True,False,False,
NCT02217618,A Study of LY2409021 in Healthy Participants,A Single Dose Pharmacokinetic Study of LY2409021 Tablet Administered in Healthy Subjects,LY2409021,['LY2409021'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,['Healthy Participants'],[],COMPLETED,,2014-08,2014-09,"[{'measure': 'Pharmacokinetics: Area Under the Concentration Curve (AUC) of LY2409021', 'description': 'Area under the concentration versus time curve from zero to infinity (AUC\\[0-inf\\]) of LY2409021 is presented.', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 192, 264, and 336 hours post-dose'}, {'measure': 'Pharmacokinetics: Maximum Concentration (Cmax) of LY2409021', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 192, 264, and 336 hours post-dose'}, {'measure': 'Pharmacokinetics: Time to Maximum Observed Drug Concentration (Tmax) of LY2409021', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 4, 8, 12, 24, 48, 72, 96, 144, 192, 264, and 336 hours post-dose'}]",[],3,18 Years,85 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:12.180560,v2_robust,True,True,True,False,False,
NCT02937818,"A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer","A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer",Durvalumab and Tremelimumab,"['AZD6738 and olaparib', 'AZD1775 and carboplatin (CBPT)', 'Durvalumab and Tremelimumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma,['Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma'],"['Platinum Refractory Extensive-Stage Carcinoma, Small Cell Lung', 'Platinum Refractory Extensive-Stage Oat Cell Carcinoma of Lung', 'Platinum Refractory Extensive-Stage Oat Cell Lung Cancer', 'Platinum Refractory Extensive-Stage Small Cell Cancer Of The Lung', 'Platinum Refractory Extensive-Stage Small Cell Lung Cancer']",COMPLETED,,2016-11-28,2023-11-27,"[{'measure': 'Number of Participants With Overall Response', 'description': 'Overall Response Rate (ORR) using Investigator assessments according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. ORR was defined as the number (percentage) of participants with a confirmed Complete Response (CR) or confirmed Partial Response (PR) and was estimated for each treatment arm with corresponding 2-sided 95% exact confidence intervals (CIs). A confirmed response of CR/PR meant that a response of CR/PR was recorded at one visit and confirmed by repeat imaging, preferably at the next regularly scheduled imaging visit, and not less than 4 weeks after the visit when the response was first observed, with no evidence of progression between the initial and CR/PR confirmation visit.', 'timeFrame': 'Until disease progression [PD] (Up to 3.5 Years)'}]","[{'measure': 'Duration of Response (DoR)', 'description': 'The DoR was defined as the time from the date of first documented response (which was subsequently confirmed) CR/PR until the date of documented progression, or death in the absence of disease progression. The DoR in participants with confirmed objective response are reported.', 'timeFrame': 'Until disease progression or data cut-off or Death (Up to 3.5 Years)'}, {'measure': 'Percentage of Participants With Disease Control at 12 Weeks', 'description': 'The disease control rate (DCR) at 12 weeks was defined as the percentage of participants who had a best objective response of CR or PR in the first 13 weeks or who had demonstrated stable disease (SD) for a minimum interval of 11 weeks following the start of study treatment. The DCR was determined programmatically based on RECIST 1.1 using site Investigator data and all data up until the first progression event.', 'timeFrame': 'At 12 Weeks'}, {'measure': 'Time to Response (TTR)', 'description': 'The TTR (per RECIST 1.1 as assessed by the Investigator) was defined as the time from the date of first dose until the first date of documented response.', 'timeFrame': 'Until disease progression or data cut-off or Death (Up to 3.5 Years)'}, {'measure': 'Progression Free Survival (PFS)', 'description': ""The PFS (per RECIST 1.1 according to the Investigator's assessment) was defined as the time from the date of the first dose of study treatment until the date of objective disease progression or death (by any cause in the absence of progression) regardless of whether the participant withdrew from allocated therapy or received another anti-cancer therapy prior to progression."", 'timeFrame': 'Until disease progression or data cut-off or Death (Up to 3.5 Years)'}, {'measure': 'Overall Survival (OS)', 'description': 'The OS was defined as the time from the date of the first dose of study treatment until death due to any cause.', 'timeFrame': 'Until disease progression or data cut-off or Death (Up to 3.5 Years)'}, {'measure': 'Time to Maximum Concentration (Tmax)', 'description': 'Time to maximum concentration for ceralasertib and olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)'}, {'measure': 'Maximum Concentration (Cmax)', 'description': 'Maximum concentration for ceralasertib and olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose)'}, {'measure': 'Partial Area Under the Concentration-time Curve (AUC0-6)', 'description': 'Partial area under the concentration-time curve for ceralasertib and olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)'}, {'measure': 'Area Under the Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-t)', 'description': 'Area under the concentration-time curve from time zero to the last measurable concentration for Ceralasertib and Olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 1 (post-dose) and Cycle 1 Day 7 (pre-dose and post-dose)'}, {'measure': 'Time to Maximum Concentration at Steady State (Tmax,ss)', 'description': 'Time to maximum concentration at steady state for Ceralasertib and Olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)'}, {'measure': 'Maximum Concentration at Steady State (Cmax,ss)', 'description': 'Maximum concentration at steady state for Ceralasertib and Olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)'}, {'measure': 'Minimum Concentration at Steady State (Cmin,ss)', 'description': 'Minimum concentration at steady state for Ceralasertib and Olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)'}, {'measure': 'Area Under the Concentration-time Curve at Steady State (AUCss)', 'description': 'Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)'}, {'measure': 'Apparent Clearance of Drug at Steady State at Steady State (CLss/F)', 'description': 'Area under the concentration-time curve at steady state at steady state for Ceralasertib and Olaparib are reported.', 'timeFrame': 'Cycle 1 (each cycle was 28 days in length) Day 7 (pre-dose and post-dose)'}, {'measure': 'Serum Concentrations of Durvalumab and Tremelimumab', 'description': 'Serum concentrations of Durvalumab and Tremelimumab are reported.', 'timeFrame': 'Durvalumab: Cycle 1 (each cycle was 4 weeks) Day 1(post-dose); Cycle 2 Day 1(pre-dose); Cycle 5 Day 1 (pre-dose); Tremelimumab: Cycle 1 (each cycle was 4 weeks) Day 1 (post-dose); Cycle 2 Day 1 (pre-dose); Cycle 5 Day 1 (No dose); Cycle 7 Day 1 (No dose)'}, {'measure': 'Plasma Concentrations of Adavosertib and Carboplatin', 'description': 'Plasma concentrations of Adavosertib and Carboplatin are reported.', 'timeFrame': 'Adavosertib: Cycle 1 (each cycle was 21 days) Day 3 (pre-dose and post-dose); Cycle 3 Day 3 (pre-dose and post-dose); Carboplatin: Cycle 1 (each cycle was 21 days) Day 1 (post-dose)'}, {'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An AE is the development of an undesirable medical condition or the deterioration of a pre-existing medical condition following or during exposure to a pharmaceutical product, whether or not considered causally related to the product. SAE is an AE that results in any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability, or is a significant medical event.', 'timeFrame': 'Day 1 until disease progression, and follow-up visit (Up to 3.5 Years)'}]",18,18 Years,130 Years,ALL,False,AstraZeneca,INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:12.180590,v2_robust,True,True,True,False,True,
NCT00638118,"Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen","A Comparison of Fexofenadine HCl 180 mg, Montelukast Sodium 10 mg and Placebo in Suppression of Wheal and Flare Induced by Seasonal Allergen",Fexofenadine,['Fexofenadine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Allergic Rhinitis,['Allergic Rhinitis'],[],COMPLETED,,2003-02,2003-05,"[{'measure': 'Size of change in skin flares from baseline will be measured.', 'timeFrame': 'Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)'}]","[{'measure': 'Size of change in skin wheals from baseline will be measured.', 'timeFrame': 'Post-dose (20 min, 40 min, 60 min, and hourly through 12 hours with an additional 2 time points obtained at Hours 23 and 24)'}]",2,15 Years,55 Years,ALL,False,Sanofi,INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:12.180651,v2_robust,True,True,True,False,False,
NCT06722118,Corticosteroids Before Extubation in Pediatric Intensive Care Unit,"Corticoïdes Avant Extubation en réanimation pédiatrique : étude Multicentrique, Prospective, randomisée, Contre Placebo",Dexamethasone IV,['Dexamethasone IV'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Intensive Care Pediatric,['Intensive Care Pediatric'],"['Corticosteroids', 'Intensive Care Pediatrics']",NOT_YET_RECRUITING,,2025-06-15,2028-07,"[{'measure': 'Cumulative incidence of respiratory distress due to upper airway obstruction (RDUAO)', 'timeFrame': 'Within 48 hours post-extubation'}]","[{'measure': 'Cumulative incidence of reintubation due to RDUAO', 'timeFrame': 'Within 48 hours following a planned extubation'}, {'measure': 'Odds ratios associated with the occurrence of RDUAO', 'timeFrame': 'Within 48 hours post-extubation'}, {'measure': 'Number of days of hospitalization in pediatric intensive care unit (PICU)', 'timeFrame': 'Up to 28 days'}, {'measure': 'Number of ventilator-free days in PICU', 'timeFrame': 'Up to 28 days'}, {'measure': 'Number of days with non-invasive ventilation (NIV) post-extubation', 'timeFrame': 'Up to 28 days'}, {'measure': 'Incidence of IV-DXM side effects', 'timeFrame': 'Up to 48 hours post-extubation'}]",7,2 Days,6 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,348.0,ESTIMATED,2025-09-01T16:18:12.180661,v2_robust,True,True,False,False,False,
NCT01176318,Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Erdosteine for Treatment of Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD),"A Double Blind, Placebo Controlled Multicentre Study of the Effects of Standard Care Plus Erdosteine (Erdotin) Versus Standard Care Plus Placebo on Cough in Acute Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)",Erdosteine,"['Erdosteine', 'erdotin', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],"['cough', 'exacerbation', 'quality of life']",WITHDRAWN,grant was withdrawn no financial support to conduct the study.,2010-08-10,2012-01-13,"[{'measure': '24 hr cough recording', 'description': 'The primary objective is to evaluate the effectiveness of standard care plus erdosteine in reducing hourly cough (24 hour cough recording using automated cough recorder) measureing differerrence in hourly cough rate from baseline (Day 0) and Day 5 of treatment, compared with standard care plus placebo', 'timeFrame': '5 days'}]","[{'measure': 'Quality of life questionnaire', 'description': 'QOL questionnaire score,Compare differece in scores recorded at baseline (day 0) and day 10, compare the difference between erdosteine plus standard care with that of standard care plus placebo.', 'timeFrame': '10 days'}]",2,40 Years,80 Years,ALL,False,Hull University Teaching Hospitals NHS Trust,OTHER_GOV,1,0.0,ACTUAL,2025-09-01T16:18:12.180676,v2_robust,True,True,False,True,False,grant was withdrawn no financial support to conduct the study.
NCT06415318,TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer,"A Single-center, Single-arm Clinical Study of TIP(Paclitaxel + Ifosfamide + Cisplatin) Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer",Paclitaxel + Ifosfamide + Cisplatin & Toripalimab,['Paclitaxel + Ifosfamide + Cisplatin & Toripalimab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Penile Cancer,['Penile Cancer'],[],RECRUITING,,2024-05-31,2027-12-01,"[{'measure': 'ORR', 'description': 'Objective Response Rate (ORR) based on RECIST 1.1 criteria.', 'timeFrame': '6 weeks'}]","[{'measure': 'pCR', 'description': 'Percentage of Participants With Pathologically Complete Response', 'timeFrame': '12 weeks'}, {'measure': 'EFS', 'description': 'Event-free survival, EFS', 'timeFrame': '2 months'}, {'measure': 'OS', 'description': 'Overall Survival', 'timeFrame': '6 months'}, {'measure': 'Adverse events', 'description': 'Number of participants with treatment-related adverse events as assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)', 'timeFrame': '2 months'}]",5,18 Years,75 Years,MALE,False,Sun Yat-sen University,OTHER,0,25.0,ESTIMATED,2025-09-01T16:18:12.180688,v2_robust,True,True,False,False,True,
NCT02809118,Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment,Efficacy and Safety of AM-111 as Acute Sudden Sensorineural Hearing Loss Treatment,AM-111 0.4 mg/ml,"['Brimapitide', 'AM-111 0.8 mg/ml', 'AM-111 0.4 mg/ml']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Hearing Loss, Idiopathic Sudden Sensorineural","['Hearing Loss, Idiopathic Sudden Sensorineural']","['Deafness', 'Hearing Loss', 'Hearing Loss, Sensorineural', 'Ear Diseases', 'Hearing Disorders', 'Nervous System Diseases', 'Neurologic Manifestations', 'Otorhinolaryngologic Diseases', 'Sensation Disorders', 'Signs and Symptoms', 'Hearing and Speech Impairment', 'Hearing Loss, Unilateral']",TERMINATED,Availability of relevant new efficacy data from another study,2016-06,2018-02,"[{'measure': 'Pure Tone Average (PTA)', 'description': 'Measurement of the recovery of hearing between Day 0 (before treatment) and Day 91, i.e. change in pure tone audiometry between Day 0 and Day 91. The study was prematurely terminated. It was pre-specified not to complete analyses due to premature termination. Not all data planned were collected. No meaningful efficacy analysis could be performed on the data.', 'timeFrame': 'Day 0 and Day 91: The study was prematurely terminated.'}]","[{'measure': 'Word Recognition Score (WRS) - Main Secondary', 'description': 'Change in WRS from Day 0 to Day 91. The WRS was determined with country-/language-specific word lists. At least 20 mono- or disyllabic words were presented in random order. After each word was presented to the subject, the subject was asked to repeat it, and to guess it, if he/she was not sure of the word. The study was prematurely terminated. It was pre-specified not to complete analyses due to premature termination. Not all data planned were collected. No meaningful efficacy analysis could be performed on the data.', 'timeFrame': 'Day 0 and Day 91: The study was prematurely terminated.'}]",2,18 Years,,ALL,False,"Auris Medical, Inc.",INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:12.180702,v2_robust,True,True,False,True,False,Availability of relevant new efficacy data from another study
NCT02181218,"Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas","A Multicenter Phase I Dose-finding and Preliminary Efficacy Study of the Histone Deacetylase Inhibitor Romidepsin (Istodax) in Combination With Gemcitabine (Gemzar), Oxaliplatin (Eloxatin), and Dexamethasone for the Treatment of Adults With Relapsed/Refractory Aggressive Lymphomas",Romidepsin,"['Oxaliplatin', 'Dexpak® Taperpak®', 'Decadron®', 'Dexamethasone Intensol®', 'Istodax®', 'Gemcitabine', 'Pegfilgrastim', 'Eloxatin TM', 'Neulasta®', 'GEMZAR®', 'Romidepsin', 'Dexamethasone']",12,INTERVENTIONAL,['PHASE1'],PHASE1,,"Lymphoma, T-Cell, Cutaneous","['Lymphoma, T-Cell, Cutaneous', 'Lymphoma, T-Cell, Peripheral', 'Hodgkin Disease', 'Lymphoma, Large B-Cell, Diffuse']",[],COMPLETED,,2015-02-04,2020-06-26,"[{'measure': 'Maximum tolerated dose (recommended Phase II dose)', 'description': 'Three participants will be treated at each dose level. If 0/3 patients experience dose limiting toxicity (DLT), 3 patients will be treated at the next dose level. If a DLT attributable to the treatment is experienced in 1 of 3 patients, three more patients (for a total of six participants) will be treated at that dose level. If no additional DLTs are observed at the expanded dose level (i.e. 1 of 6 with DLT), the dose will be escalated. Escalation will terminate as soon as two or more participants experience any DLT attributable to study combination, at a given dose level. If 2 or more DLTs occur at the starting dose level, a decreased dose level will be explored at dose level -1.\n\nThere will be no more than 2 patients dosed for the first time within the same week, and patients in the next higher cohorts will not be enrolled until the last patient of the lower cohort has completed the DLT monitoring period, defined as 21 days after first dose of Cycle 1 therapy.', 'timeFrame': '37 months (completion of first cycle of all participants in study)'}]","[{'measure': 'Complete response rate', 'description': ""For study participants with relapsed/refractory peripheral T-cell lymphoma (PTCL), diffuse large b-cell lymphoma (DLBCL), and Hodgkin's lymphoma response will be assessed in accordance with the updated International Working Group (IWG) recommendations.\n\nFor study participants with cutaneous t-cell lymphoma (CTCL), the Global Response Score established by the ISCL/USCLC/EORTC consensus panel will be used to assess response to treatment."", 'timeFrame': 'Up to 1 year from time of maximal response'}, {'measure': 'Partial response rate', 'description': ""For study participants with relapsed/refractory peripheral T-cell lymphoma (PTCL), diffuse large b-cell lymphoma (DLBCL), and Hodgkin's lymphoma response will be assessed in accordance with the updated International Working Group (IWG) recommendations.\n\nFor study participants with cutaneous t-cell lymphoma (CTCL), the Global Response Score established by the ISCL/USCLC/EORTC consensus panel will be used to assess response to treatment."", 'timeFrame': 'Up to 1 year from time of maximal response'}, {'measure': 'Overall response rate', 'description': ""For study participants with relapsed/refractory peripheral T-cell lymphoma (PTCL), diffuse large b-cell lymphoma (DLBCL), and Hodgkin's lymphoma response will be assessed in accordance with the updated International Working Group (IWG) recommendations.\n\nFor study participants with cutaneous t-cell lymphoma (CTCL), the Global Response Score established by the ISCL/USCLC/EORTC consensus panel will be used to assess response to treatment.\n\nOverall response rate = complete response + partial response"", 'timeFrame': 'Up to 1 year from time of maximal response'}, {'measure': 'Progression free survival', 'description': 'Progression-free survival (PFS) will be defined as the time from registration until disease progression.', 'timeFrame': 'Up to 1 year from time of maximal response'}, {'measure': 'Duration of response', 'timeFrame': 'Up to 1 year from time of maximal response'}]",6,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:12.180838,v2_robust,True,True,True,False,False,
NCT02660190,Photodynamic Diagnosis (PDD) in Flexible Cystoscopy,Photodynamic Diagnosis (PDD) in Flexible Cystoscopy - DaBlaCa-11,hexaminoavolunate,"['hexvix', 'hexaminoavolunate']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Bladder Cancer,"['Bladder Cancer', 'Recurrence', 'PDD']",[],COMPLETED,,2016-02,2019-02,"[{'measure': 'Tumor recurrence', 'description': 'Tumor recurrence up to 8 months following first cystoscopy after TURB', 'timeFrame': '8 months'}]",[],1,18 Years,,ALL,False,Jørgen Bjerggaard Jensen,OTHER,2,696.0,ACTUAL,2025-09-01T16:18:12.180965,v2_robust,True,True,True,False,False,
NCT05286190,Caudal Block and Transversus Abdominis Plane Block in Pediatric Inguinal Hernia Repair,Effects Of Ultrasound Guided Caudal Epidural And Transversus Abdominis Plane Block On Postoperative Analgesia In Pediatric Inguinal Hernia Repair Surgeries,Bupivacaine 0.25% Injectable Solution,"['Marcaine', 'Bupivacaine 0.25% Injectable Solution']",2,INTERVENTIONAL,['NA'],,,Regional Anesthesia,"['Regional Anesthesia', 'Postoperative Pain, Acute']","['US guided Caudal Epidural Block', 'US guided Transversus Abdominis Plane Block']",COMPLETED,,2017-10-01,2018-10-31,"[{'measure': 'FLACC SCORES (FACE, LEG, ACTIVITY, CONSOLABILITY, CRY)', 'description': 'It includes five categories of behavior, each scored on 0-2 point scale so that total score ranges from 0 to 10. Total scores of 0-3 is defined as mild, 4-7 as moderate, and 8-10 as severe pain.', 'timeFrame': 'Up to 24 hours'}]","[{'measure': 'PONV (Postoperative nausea and vomiting)', 'description': 'Number of patients with nausea vomiting', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Additional analgesic requirement', 'description': 'Number of patients who require paracetamol (15 mg/kg) and tramadol (1 mg/kg)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Family satisfaction', 'description': 'A 3-point scale (satisfied:3; neutral:2, dissatisfied:1)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Surgeon satisfaction', 'description': 'A 3-point scale (satisfied:3; neutral:2, dissatisfied:1)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Complications', 'description': 'Possible complications related to caudal and transversus abdominis plane block (hematoma, infection and perforation)', 'timeFrame': 'Up to 24 hours'}, {'measure': 'Revised Bieri faces pain scale', 'description': ""Revised Bieri faces pain scale used for assessment of chronic pain. Score the chosen face 0,2,4,6,8,10 counting left to right so '0'=no pain and '10'=very much pain"", 'timeFrame': 'At postoperative 2nd month'}, {'measure': 'Length of hospital stay', 'description': 'Hospitalisation', 'timeFrame': 'Through study completion, an average of 1 week'}]",8,1 Year,7 Years,ALL,True,Istanbul University,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:12.181001,v2_robust,True,True,True,False,False,
NCT04950790,Study on the Effectiveness and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke,"A Randomized, Double-blind, Placebo-parallel-controlled, Multicenter Clinical Trial of the Efficacy and Safety of Shuxinin Injection in the Treatment of Acute Ischemic Stroke",Shuxinin injection,"['Shuxinin injection', 'Basic treatment', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Ischemic Stroke,['Acute Ischemic Stroke'],[],UNKNOWN,,2018-04-01,2021-12-01,"[{'measure': 'mRS score', 'description': 'Percentage of patients with mRS score ≤2 at 90 days post-onset.', 'timeFrame': 'baseline'}, {'measure': 'mRS score', 'description': 'Percentage of patients with mRS score ≤2 at 90 days post-onset.', 'timeFrame': '10 days after treatment'}, {'measure': 'mRS score', 'description': 'Percentage of patients with mRS score ≤2 at 90 days post-onset.', 'timeFrame': '30 days after onset'}, {'measure': 'mRS score', 'description': 'Percentage of patients with mRS score ≤2 at 90 days post-onset.', 'timeFrame': '90 days after onset'}]",[],4,40 Years,80 Years,ALL,False,Peking University Third Hospital,OTHER,1,480.0,ESTIMATED,2025-09-01T16:18:12.181107,v2_robust,True,True,False,False,False,
NCT01542190,"Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery","A Randomized, Masked Comparison of Topical Ketorolac 0,4% Versus Placebo in Cataract Surgery.",Ketorolac Tromethamine,"['Lacribell (Latinofarma)', 'Ketorolac Tromethamine', 'Acular LS (Allergan)']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Cystoid Macular Edema Following Cataract Surgery, Bilateral","['Cystoid Macular Edema Following Cataract Surgery, Bilateral']","['cataract surgery', 'cystoid macular edema', 'angiography']",COMPLETED,,2011-02,2013-08,"[{'measure': 'cystoid macular edema', 'description': ""Angiography (Miyake's criteria)"", 'timeFrame': '1 month'}]","[{'measure': 'Best corrected visual acuity', 'description': 'ETDRS.', 'timeFrame': '1 month'}]",2,50 Years,,ALL,False,"University of Campinas, Brazil",OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:12.181126,v2_robust,True,True,True,False,False,
NCT03571490,Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot Assisted Partiel Nephrectomy,"Improving Postoperative Pain Management With the Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot-assisted Partiel Nephrectomy: A Double Blind, Randomized, Placebo Controlled Trial",Ropivacaine,"['Saline', 'Ropivacaine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Pain,"['Postoperative Pain', 'Ultrasound Guided Transmuscular Quadratus Lumborum Block']",[],COMPLETED,,2018-06-26,2019-06-24,"[{'measure': 'opioid consumption', 'description': 'Opioid consumption postoperatively: data from Patient Controlled Analgesia(PCA) pump and patient medical record).', 'timeFrame': '12 hours postoperatively'}]","[{'measure': 'opioid consumption', 'description': 'Opioid consumption postoperatively (data from PCA pump and patient medical record).', 'timeFrame': '6 hours postoperatively'}, {'measure': 'opioid consumption', 'description': 'Opioid consumption postoperatively (data from PCA pump and patient medical record).', 'timeFrame': '18 hours postoperatively'}, {'measure': 'opioid consumption', 'description': 'Opioid consumption postoperatively (data from PCA pump and patient medical record).', 'timeFrame': '24 hours postoperatively'}, {'measure': 'NRS score', 'description': 'Numeric Rating Scale(NRS). Scores range from 0-10, 0=no pain-10=worst pain postoperatively at rest and activity', 'timeFrame': '12 hours postoperatively'}, {'measure': 'NRS score at rest and activity', 'description': 'Numeric Rating Scale(NRS). Scores range from 0-10, 0=no pain-10=worst pain', 'timeFrame': '6 hours postoperatively'}, {'measure': 'NRS score at rest and activity', 'description': 'Numeric Rating Scale(NRS). Scores range from 0-10, 0=no pain-10=worst pain', 'timeFrame': '18 hours postoperatively'}, {'measure': 'NRS score at rest and activity', 'description': 'Numeric Rating Scale(NRS). Scores range from 0-10, 0=no pain-10=worst pain', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Opioid-related side effects', 'description': 'The degree of morphine-related side effects (PONV, itching, fatigue, etc.)', 'timeFrame': '6 hours postoperatively'}, {'measure': 'Opioid-related side effects', 'description': 'The degree of morphine-related side effects (PONV, itching, fatigue, etc.)', 'timeFrame': '12 hours postoperatively'}, {'measure': 'Opioid-related side effects', 'description': 'The degree of morphine-related side effects (PONV, itching, fatigue, etc.)', 'timeFrame': '18 hours postoperatively'}, {'measure': 'Opioid-related side effects', 'description': 'The degree of morphine-related side effects (PONV, itching, fatigue, etc.)', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Patient satisfaction with application of the block. NRS', 'description': 'Numeric Rating Scale(NRS). Scores range from 0-10, 0=no pain-10=worst pain', 'timeFrame': 'Immediately after application of the block'}, {'measure': 'Ambulation', 'description': 'Time from operation to ambulation', 'timeFrame': 'within 24 hours postoperatively'}]",14,18 Years,,ALL,False,Zealand University Hospital,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:12.181135,v2_robust,True,True,True,False,False,
NCT06284590,"Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients","A Phase 2, Three-arm, Randomized Study of the Efficacy of Intratumorally Administered L19IL2 or L19TNF or L19IL2/L19TNF, All in Combination with Systemic Anti-PD1 Pembrolizumab, in Stage III and IV Unresectable Melanoma Patients with Resistance to or Progressing Upon Anti-PD1 Checkpoint Inhibitors and with Presence of Injectable Metastases",L19IL2,"['KEYTRUDA®', 'onfekafusp alfa', 'L19IL2', 'L19TNF', 'Daromun', 'L19IL2/L19TNF', 'bifikafusp alfa', 'pembrolizumab']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Melanoma Stage III,"['Melanoma Stage III', 'Melanoma Stage IV']",[],RECRUITING,,2024-07-12,2028-07,"[{'measure': 'Confirmed Objective Response Rate (ORR)', 'description': 'Objective Response Rate (ORR = CR + PR) in all three arms to demonstrate the efficacy of intralesional treatment with immunocytokines (L19IL2, or L19TNF, or L19IL2/L19TNF), in combination with the systemic anti-PD1 pembrolizumab, to induce objective responses in advanced melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors. The primary analysis will be performed in the Intention-to-Treat population (ITT).\n\nAssessed during Tumor Assessment (TA) visits.', 'timeFrame': 'Evaluated over a period of up to 2 years after first intralesional treatment. TA visits will be performed at week 12, 18, 24, 36, 48, 64, 80 and 96 after first intralesional treatment or until confirmed progression or death, whichever occurs first'}]","[{'measure': 'Best overall response (BOR)', 'description': 'Best response recorded from the start of the treatment until disease progression/recurrence after first treatment according to RECIST v1.1 criteria', 'timeFrame': 'From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 96 Weeks'}, {'measure': 'Duration of Response (DoR)', 'description': 'Time from first documented evidence of CR or PR until first documented disease progression or death due to any cause. DoR will be summarized descriptively using Kaplan-Meier medians and quartiles.', 'timeFrame': 'From the date of first treatment until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 36 Months'}, {'measure': 'Pathological response', 'description': 'Histopathological analysis will be performed on biopsies obtained at baseline and at Week 18 for one target injected lesions.\n\nThis is to determine:\n\n* Confirmation of melanoma metastasis( Biopsy at baseline)\n* Presence of residual tumor cells (%, biopsy at week 18),\n* Presence of Necrosis % (biopsy at week 18),\n* Presence of melanosis/fibrosis % (biopsy at weeks 18 after first treatment)', 'timeFrame': 'At 18 weeks after first treatment'}, {'measure': 'Confirmed ORR', 'description': 'Confirmed ORR over a period of up to 2 years after first intralesional treatment according to iRECIST and itRECIST criteria in each arm of the study', 'timeFrame': 'From date of first administration, after a period of up to 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Difference between date of randomization and the date of progression according to RECIST v. 1.1 criteria or death', 'timeFrame': 'From the date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 96 Weeks'}, {'measure': 'Overall survival (OS)', 'description': 'Difference between date of randomization and the date of death for any cause', 'timeFrame': 'From the date of randomization until the date of first documented progression or date of death from any cause, whichever comes first, assessed up to 96 Weeks'}, {'measure': 'Serious Adverse Event (SAEs)', 'description': 'Percentage of Patients in Each Treatment Group with Drug-Related Adverse Events, Serious Adverse Event (SAEs)', 'timeFrame': 'From date of ICF signature until first follow-up visit (Week 12). Subsequently only AEs and SAEs (and related medications or procedures) that were judged as drug or study related will be recorded, up to week 96'}, {'measure': 'Drug-Induced Liver Injury (DILI)', 'description': 'Number of patients with Drug-Induced Liver Injury (DILI)', 'timeFrame': 'From date of ICF signature until first follow-up visit (Week 12). Subsequently only DILI that were judged as drug or study related will be recorded, up to week 96'}, {'measure': 'Number of patients with Adverse Events of Special Interest (AESI)', 'timeFrame': 'From date of ICF signature until first follow-up visit (Week 12). Subsequently only AESI that were judged as drug or study related will be recorded, up to week 96'}, {'measure': 'Number of patients with Immune-Related Adverse Events (IRAEs)', 'timeFrame': 'From date of ICF signature until first follow-up visit (Week 12). Subsequently only IRAEs that were judged as drug or study related will be recorded, up to week 96'}, {'measure': 'Number of participants with abnormal hematology laboratory tests results', 'description': 'Red Blood cells; Millions/microliter (M/mcL)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal hematology laboratory tests results', 'description': 'Count of absolute neutrophil (ANC), White Blood cells (WBC), Platelet, Differential; thousands/microliter (K/mcL)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal hematology laboratory tests results', 'description': 'Hematocrit; percent (%)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal hematology laboratory tests results', 'description': 'Hemoglobin; grams/deciliter (g/dL)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal serum chemistry laboratory tests results', 'description': 'Creatinine, Blood Urea Nitrogen or Urea, Uric acid, Calcium, Glucose, Phosphorus, Magnesium; milligrams/deciliter (mg/dL)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal serum chemistry laboratory tests results', 'description': 'Potassium, Sodium, Chloride; milliequivalents/liter (mEq/L)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal serum chemistry laboratory tests results', 'description': 'Total proteins, Albumin; grams/deciliter (g/dL)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal serum chemistry laboratory tests results', 'description': 'Lactate dehydrogenase (LDH); units/liter (U/L)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal serum chemistry laboratory tests results', 'description': 'Adrenocorticotropic Hormone (ACTH); picograms/milliliter (pg/ml)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal coagulation laboratory tests results', 'description': 'Prothrombin Time PT or PT INR, PTT or aPTT; seconds (sec)', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal body temperature', 'description': 'Body temperature; degree centigrade', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal blood pressure', 'description': 'Systolic and diastolic blood pressure (after 3 minutes in sitting position); mmHg', 'timeFrame': 'From the screening to the last visit (Week 103)'}, {'measure': 'Number of participants with abnormal Electrocardiogram (ECG) readings', 'description': 'Heart rate, standard intervals (PR, QRS, QT, and QTc) and any observed abnormality; millisecond', 'timeFrame': 'At the screening visit, at Visit 6 (week 5) and at Visit 12 (week 18)'}, {'measure': 'Number of participants with abnormal Echocardiogram (ECHO) readings', 'description': 'Morphological and functional aspects of the heart. Left Ejection Fraction (LVEF) is determined; percentage %', 'timeFrame': 'At the screening visit, at Visit 6 (week 5) and at Visit 12 (week 18)'}, {'measure': 'Number of participants with abnormal physical examination results', 'timeFrame': 'From the screening to first follow up visit'}, {'measure': 'Concomitant medication usage', 'timeFrame': 'From the screening and throughout study'}, {'measure': 'Assessment of the formation of human anti-fusion protein antibodies (HAFA) against L19IL2 and L19TNF', 'timeFrame': 'At weeks 1, 2 and 12'}]",28,18 Years,,ALL,False,Philogen S.p.A.,INDUSTRY,1,162.0,ESTIMATED,2025-09-01T16:18:12.181163,v2_robust,True,True,False,False,True,
NCT04533490,A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma,"A Multi-center, Single-arm, Open Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma",SHR-1210,['SHR-1210'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Resectable Esophageal Squamous Cell Carcinoma,['Resectable Esophageal Squamous Cell Carcinoma'],"['ESCC,Adjuvant therapy,Camrelizumab']",UNKNOWN,,2021-10-01,2023-10-01,"[{'measure': 'RFS(relapse free survival)', 'description': 'Recurrence free survival of resectable esophageal squamous cell carcinoma treated with SHR-1210', 'timeFrame': 'up to 1 year'}, {'measure': 'DFS（disease-free survival）', 'description': 'Disease-free survival of resectable esophageal squamous cell carcinoma treated with SHR-1210', 'timeFrame': 'up to 1 year'}]","[{'measure': 'OS（overall survival rate）', 'description': 'From date of randomization until the date of death from any cause; Overall survival rate of resectable esophageal squamous cell carcinoma treated with SHR-1210', 'timeFrame': 'At time of surgery'}]",3,18 Years,75 Years,ALL,False,The First Affiliated Hospital of Zhengzhou University,OTHER,0,42.0,ESTIMATED,2025-09-01T16:18:12.181289,v2_robust,True,True,False,False,False,
NCT05269290,"Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections","A Multicenter, Double-blind, Randomized, Placebo-controlled Study of the Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children Aged 6 Months to 2 Years With Influenza and Other Acute Respiratory Viral Infections Against Standard Therapy","Ingavirin®, syrup, 30 mg/5 ml","['Ingavirin®, syrup, 30 mg/5 ml', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Influenza, Human","['Influenza, Human', 'Acute Respiratory Infection', 'Common Cold']",[],COMPLETED,,2021-09-23,2022-07-15,"[{'measure': 'Time of symptoms/events resolution', 'description': ""Time, in hours, from the first administration of the drug until all of the following symptoms/events have resolved (if each symptom/event has been achieved for at least 24 hours): Fever; Cough and/or runny nose/nasal congestion; Child's return to normal daytime activity and normal nighttime sleep (as assessed by the parent/adopter)."", 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4)'}]","[{'measure': 'Time to fever relief', 'description': 'Number of hours elapsed from the first administration of the medication to the time of persistent normalization of the temperature, i.e., the moment when the body temperature is \\< 37.5 °C during the day without the use of antipyretic medication', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4)'}, {'measure': 'Time to cough relief', 'description': ""Number of hours from the first dose to the time the coughing cough has gone away, i.e. the parent/adoptive parent rates the symptom as 0-1 during the day and records this in the patient's diary"", 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4)'}, {'measure': 'Time to cough/nasal congestion relief', 'description': 'Number of hours from first medication administration to cough/congestion cessation, i.e., when parent/adopter rates severity of this symptom during the day at 0-1 point and records this in patient diary', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4)'}, {'measure': 'Frequency of complications of acute viral infection and influenza', 'description': 'Acute otitis media, viral and bacterial pneumonia, exacerbation of chronic conditions such as bronchial asthma and urinary tract infections), toxemia \\[septic-like syndrome\\], acute stenotic laryngotracheitis', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4)'}, {'measure': 'Frequency of patients with PCR-confirmed viral infection', 'description': 'PCR-confirmed acute respiratory infections/flu by visits 1, 2, 3', 'timeFrame': 'Day 1, Day 3-4 (visit 2), Day 6-7 (visit 3)'}, {'measure': 'Need for paracetamol or ibuprofen', 'description': 'Daily dose on study days 1-7', 'timeFrame': 'Days 1-7'}, {'measure': 'Safety - Number of adverse events (AEs)', 'description': 'Total number of AEs stratified by severity and frequency', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Adverse reactions', 'description': 'Frequency of adverse reactions', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Serious adverse events (SAEs)', 'description': 'Frequency of serious adverse events (SAEs) associated with study drug/placebo use', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Percentage of patients with AEs', 'description': 'Percentage of patients with at least one AE', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Percentage of patients who interrupted treatment', 'description': 'Percentage of patients who interrupted treatment due to AE', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Frequency of complications', 'description': 'Frequency of complications', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Frequency of worsening', 'description': 'Frequency of worsening of the disease course', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}, {'measure': 'Safety - Frequency of hospitalization', 'description': 'Frequency of need for hospitalization', 'timeFrame': 'From Day 1 up to Day 13-14 (visit 4) or up to early termination visit within time frame of the study'}]",15,6 Months,2 Years,ALL,False,Valenta Pharm JSC,INDUSTRY,0,240.0,ACTUAL,2025-09-01T16:18:12.181463,v2_robust,True,True,True,False,True,
NCT06707090,Tissue Repair Gel in Venous Leg Ulcers (US),"A Phase 3 Randomized, Parallel Group, Double-Blind Study to Evaluate the Efficacy, Tolerability, and Safety of TR987® 0.1% Gel Versus Standard of Care in the Treatment of Chronic Venous Insufficiency Leg Ulcers (VLU)",TR987 0.1% gel + Standard of Care,['TR987 0.1% gel + Standard of Care'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Venous Leg Ulcer,"['Venous Leg Ulcer', 'Venous Ulcer', 'Venous Stasis Ulcer', 'Venous Stasis', 'Wound Heal', 'Wounds', 'Venous Insufficiency of Leg', 'Non-healing Wound']","['Tissue Repair', 'Glucoprime', 'TR Therapeutics', 'Debridement', 'VLU']",RECRUITING,,2025-01-28,2027-02,"[{'measure': 'Proportion of participants with Complete Closure of the target ulcer at or before the Week-16 end of treatment (EOT) visit.', 'description': 'Patient count', 'timeFrame': '16 weeks'}]","[{'measure': 'Proportion of participants with Complete Closure of the target ulcer at or before the Week 16 visit AND for whom the ulcer remains closed at the 3-Month Follow-Up visit after such closure (a composite endpoint)', 'description': 'Patient count', 'timeFrame': '16 weeks'}, {'measure': ""Change from baseline in participant's perception of pain level at 12 weeks."", 'description': 'Pain to be measured on a 10 point numeric rating scale', 'timeFrame': '12 weeks'}, {'measure': 'Percent change from baseline in the target ulcer area at 12 and 16 weeks. In the event of Complete Closure before these time points, the target ulcer area will be deemed to be zero at those time points for purposes of calculation of this endpoint.', 'description': 'Measure the are of the wound in cm2 at baseline and at 12 and 16 weeks and calculate the percentage change', 'timeFrame': '12 and 16 weeks'}, {'measure': 'Proportion of participants with Complete Closure of the target ulcer at or before the Week 12 treatment visit.', 'description': 'Count the number of patients with complete closure and divide by the total number of patients', 'timeFrame': '12 weeks'}, {'measure': 'Proportion of participants with any significant reduction in pain at or before 12 weeks.', 'description': 'Count the number of patients with any significant reduction in pain and divide by the total number of patients', 'timeFrame': '12 weeks'}, {'measure': 'Proportion of target ulcers which reach greater than 70% closure at 12 weeks and 16 weeks', 'description': 'Measured by MolecuLight® versus baseline area at TV1 after therapeutic debridement (Complete Closure at a time point before 12 or 16 weeks shall be deemed to be \\>70% closed at 12 or 16-weeks, respectively, for purposes of this analysis)', 'timeFrame': '12 and 16 weeks'}, {'measure': 'Proportion of target ulcers which reach greater than 90% closure at 12 weeks and 16 weeks', 'description': 'Measured by MolecuLight® versus baseline area at TV1 after therapeutic debridement (Complete Closure at a time point before 12 or 16 weeks shall be deemed to be \\>70% closed at 12 or 16-weeks, respectively, for purposes of this analysis)', 'timeFrame': '12 and 16 weeks'}, {'measure': 'Proportion of target ulcers which reach greater than 95% closure at 12 weeks and 16 weeks', 'description': 'Measured by MolecuLight® versus baseline area at TV1 after therapeutic debridement (Complete Closure at a time point before 12 or 16 weeks shall be deemed to be \\>70% closed at 12 or 16-weeks, respectively, for purposes of this analysis)', 'timeFrame': '12 and 16 weeks'}]",9,18 Years,,ALL,False,TR Therapeutics,INDUSTRY,0,312.0,ESTIMATED,2025-09-01T16:18:12.181549,v2_robust,True,True,False,False,False,
NCT06205797,To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III),"A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase III Clinical Trial to Evaluate the Efficacy and Safety of HU-045 Compared to Xeomin® in Adult Patients With Moderate or Severe Glabellar Lines",HU-045,"['Xeomin®', 'HU-045']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Glabellar Lines,['Glabellar Lines'],[],RECRUITING,,2024-06-20,2025-03-31,"[{'measure': 'Percentage of participants whose glabellar lines at maximal frown are improved', 'description': ""Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe.\n\nOnly the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved."", 'timeFrame': 'Week4'}]","[{'measure': 'Percentage of participants whose glabellar lines at maximal frown are improved', 'description': ""Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at maximal frown; 0=none, 1=mild, 2=moderate or 3=severe.\n\nOnly the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved."", 'timeFrame': 'Week8, Week12, Week16'}, {'measure': 'Percentage of participants whose glabellar lines at resting are improved', 'description': ""Investigators will assess participant's glabellar lines with Facial Wrinkle Scale(FWS) at resting; 0=none, 1=mild, 2=moderate or 3=severe.\n\nOnly the participants whose FWS score is 0 or 1 grade when it's assessed and ≥ 2 grade improvement from baseline will be defined as their glabellar lines are improved."", 'timeFrame': 'Week4, Week8, Week12, Week16'}, {'measure': ""Subject's satisfaction rate after injection"", 'description': 'Participants will rate their overall satisfaction by answering the question on a Questionnaire using 7 point scale. 6 and/or above grade will be defined as the participant is satisfied about their glabellar lines; (1 = very unsatisfied, 2 = un satisfied, 3 = slightly dissatisfied, 4 = average, 5 = slightly satisfied, 6 = Satisfaction, 7 = very satisfied', 'timeFrame': 'Week4, Week8, Week12, Week16'}, {'measure': 'Percentage of subjects who assessed their Glabellar Lines are improved ≥ +2 grade', 'description': 'Subjects will assess their glabellar Lines with a 9 point scale from -4 to +4;(+4 = 100% improvement, +3 = 75% improvement, +2 = 50% improvement, +1 = 25% improvement, 0 = no change, -1 = 25% worse, -2 = 50% worse, -3 = 75% worse, -4 = 100% worse', 'timeFrame': 'Week4, Week8, Week12, Week16'}]",5,19 Years,65 Years,ALL,True,Huons Biopharma,INDUSTRY,0,312.0,ESTIMATED,2025-09-01T16:18:12.181640,v2_robust,True,True,False,False,False,
NCT05735197,Effect of Dapagliflozin on Renal Outcomes and Bone Mineral Disease in Non-diabetic Chronic Kidney Disease Patients,Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Kidney Disease Progression and Bone Mineral Metabolism in Non-diabetic Patients With Chronic Kidney Disease,Dapagliflozin 10mg Tab,"['control', 'Placebo', 'Dapagliflozin 10mg Tab', 'Dapagliflozin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Kidney Diseases,"['Chronic Kidney Diseases', 'Bone Diseases, Metabolic']","['CKD', 'Bone mineral disease', 'SGLT2i']",COMPLETED,,2022-09-01,2023-11-01,"[{'measure': 'Effect of dapagliflozin on CKD progression', 'description': 'effect of Dapagliflozin on eGFR (ml/min)', 'timeFrame': '1 year'}, {'measure': 'Effect of dapagliflozin on Bone', 'description': 'effect on serum levels of bone turnover markers measured by ELISA', 'timeFrame': '1 year'}, {'measure': 'Effect of dapagliflozin on minerals', 'description': 'effect of Dapagliflozin on calcium, phosphorus and magnesium', 'timeFrame': '1 year'}, {'measure': 'Effect of dapagliflozin on BMD', 'description': 'assess Bone mineral disease (BMD) by using quantitative CT (QCT)', 'timeFrame': '1 year'}]","[{'measure': 'Effect of dapagliflozin on blood pressure', 'description': 'follow up systolic and diastolic blood pressure throughout the study', 'timeFrame': '1 year'}]",5,18 Years,,ALL,False,Mansoura University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:12.181852,v2_robust,True,True,True,False,False,
NCT01163097,Study to Characterize the Effect of Heparin on Palifermin Activity,"An Open-label, Randomized, Parallel-Design Study to Characterize the Effect of Heparin on Palifermin Activity in Healthy Adult Subjects",Palifermin,"['Heparin', 'Palifermin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Oral Mucositis,['Oral Mucositis'],[],COMPLETED,,2010-07,2011-01,"[{'measure': 'Ratio to Baseline of Epithelial Cell Proliferation as Assessed by Ki67 Staining of Buccal Mucosal Tissue.', 'description': 'This outcome is a measure of the palifermin effect on the buccal mucosal cells. Ki67 is a measure of proliferation of cells in the buccal mucosa. This measure assess the number of cells per millimeter (mm) before and after palifermin treatment.', 'timeFrame': 'Day 4'}, {'measure': 'Incidence of Grade 2 or Higher Specific Skin-related Adverse Events.', 'description': 'Incidence of grade 2 or higher specific skin-related treatment emergent adverse events following palifermin administration was calculated for subjects in treatment groups A and B. Incidence was calculated by treatment as number of subjects with grade 2 or higher specific skin-related AEs divided by the total number of subjects.\n\nThe Common Terminology Criteria for Adverse Events (CTCAE v3.0) for Dermatology/Skin was used to determine the toxicity grade for a skin-related adverse event. (http://ctep.cancer.gov/protocolDevelopment/electronic\\_applications/docs/ctcaev3.pdf)', 'timeFrame': 'Day 45'}, {'measure': 'Ratio to Baseline of Amylase', 'description': 'Ratio to baseline amylase at Day 5 was calculated as Day 5 amylase divided by baseline amylase.', 'timeFrame': 'Day 5'}, {'measure': 'Ratio to Baseline of Lipase.', 'description': 'Ratio to baseline lipase at Day 5 was calculated as Day 5 lipase divided by baseline lipase.', 'timeFrame': 'Day 5'}, {'measure': 'Ratio to Baseline of Protein/Creatinine', 'description': 'Protein/creatinine ratio is the urinary protein (mg) divided by the urinary creatinine (g) result.\n\nRatio to baseline protein/creatinine ratio was calculated as protein/creatinine ratio at specified day divided by baseline protein/creatinine ratio.', 'timeFrame': 'Day 4'}]","[{'measure': 'Palifermin Pharmacokinetic (PK) Parameters: Clearance (CL)', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin.\n\nDescriptive PK parameters for palifermin CL for subjects assigned to Treatment A and Treatment B was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was treated as zero.', 'timeFrame': 'Day 1'}, {'measure': 'Palifermin PK Parameters: CL', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin.\n\nDescriptive PK parameters for palifermin CL for subjects assigned to Treatment A and Treatment B was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was treated as zero.', 'timeFrame': 'Day 3'}, {'measure': 'Palifermin PK Parameters: Area Under the Serum Curve (AUC) (0-24)', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin.\n\nDescriptive pharmacokinetic parameters for palifermin AUC(0-24) was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was deleted from calculation.', 'timeFrame': 'Day 1'}, {'measure': 'Palifermin PK Parameters: AUC (0-24)', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin.\n\nDescriptive pharmacokinetic parameters for palifermin AUC(0-24) was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was deleted from calculation.', 'timeFrame': 'Day 3'}, {'measure': 'Palifermin PK Parameters: Estimated Concentration at Time 0 (C0)', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin.\n\nDescriptive pharmacokinetic parameters for palifermin C0 was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was treated as zero.', 'timeFrame': 'Day 1'}, {'measure': 'Palifermin PK Parameters: C0', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin.\n\nDescriptive pharmacokinetic parameters for palifermin C0 was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was treated as zero.', 'timeFrame': 'Day 3'}, {'measure': 'Palifermin PK Parameters: Apparent Volume of Distribution at Steady State (Vss)', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin (Treatment A and Treatment B only).\n\nDescriptive pharmacokinetic parameters for palifermin Vss was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was treated as zero.', 'timeFrame': 'Day 1'}, {'measure': 'Palifermin PK Parameters: Vss', 'description': 'Blood samples for palifermin PK was collected pre-dose on Days 1 and 3 of the treatment period; 2, 5, 15 and 30 minutes; and 1, 2, 4, 6, 12, 18 and 24 hours after the Day 1 and Day 3 dose of palifermin (Treatment A and Treatment B only).\n\nDescriptive pharmacokinetic parameters for palifermin Vss was determined by linear/log trapezoidal method. Parameters was calculated from individual subject serum concentration-time data using actual subject blood collection times. Serum concentrations reported below the lower limit of quantification (LLOQ) was treated as zero.', 'timeFrame': 'Day 3'}, {'measure': 'Subject Incidence of Treatment-emergent Adverse Event', 'description': 'Adverse events (AE) was considered treatment emergent if the AE started after the time of heparin titration (Treatment A), palifermin dosing on Day 1 (Treatment B), or set zero point (Treatment C).', 'timeFrame': 'Day 45'}, {'measure': 'Subject Incidence of Proteinuria', 'description': 'Protein/creatinine ratio is the urinary protein (mg) divided by the urinary creatinine (g) result at the specified time point.\n\nIncidence of proteinuria defined as urinary protein/creatinine ratio exceeding 200 mg/g was calculated at Day 4 and overall at any time point. Incidence was calculated by treatment as number of subjects with proteinuria divided by the total number of subjects.', 'timeFrame': 'Day 4'}, {'measure': 'Ratio to Baseline of Protein/Creatinine', 'description': 'Protein/creatinine ratio is the urinary protein (mg) divided by the urinary creatinine (g) result.\n\nRatio to baseline protein/creatinine ratio was calculated as protein/creatinine ratio at specified day divided by baseline protein/creatinine ratio.', 'timeFrame': 'Day 1'}, {'measure': 'Ratio to Baseline of Protein/Creatinine', 'description': 'Protein/creatinine ratio is the urinary protein (mg) divided by the urinary creatinine (g) result.\n\nRatio to baseline protein/creatinine ratio was calculated as protein/creatinine ratio at specified day divided by baseline protein/creatinine ratio.', 'timeFrame': 'Day 2'}, {'measure': 'Ratio to Baseline of Protein/Creatinine', 'description': 'Protein/creatinine ratio is the urinary protein (mg) divided by the urinary creatinine (g) result.\n\nRatio to baseline protein/creatinine ratio was calculated as protein/creatinine ratio at specified day divided by baseline protein/creatinine ratio.', 'timeFrame': 'Day 3'}, {'measure': 'Ratio to Baseline of Albumin/Creatinine', 'description': 'The albumin/creatinine ratio is the urinary albumin (mg) divided by the urinary creatinine (g) result at the specified time point.\n\nRatio to baseline was calculated as albumin/creatinine ratio at specified day divided by baseline albumin/creatinine ratio.', 'timeFrame': 'Day 1'}, {'measure': 'Ratio to Baseline of Albumin/Creatinine', 'description': 'The albumin/creatinine ratio is the urinary albumin (mg) divided by the urinary creatinine (g) result at the specified time point.\n\nRatio to baseline was calculated as albumin/creatinine ratio at specified day divided by baseline albumin/creatinine ratio.', 'timeFrame': 'Day 2'}, {'measure': 'Ratio to Baseline of Albumin/Creatinine', 'description': 'The albumin/creatinine ratio is the urinary albumin (mg) divided by the urinary creatinine (g) result at the specified time point.\n\nRatio to baseline was calculated as albumin/creatinine ratio at specified day divided by baseline albumin/creatinine ratio.', 'timeFrame': 'Day 3'}, {'measure': 'Ratio to Baseline of Albumin/Creatinine', 'description': 'The albumin/creatinine ratio is the urinary albumin (mg) divided by the urinary creatinine (g) result at the specified time point.\n\nRatio to baseline was calculated as albumin/creatinine ratio at specified day divided by baseline albumin/creatinine ratio.', 'timeFrame': 'Day 4'}]",22,18 Years,45 Years,ALL,True,Swedish Orphan Biovitrum,INDUSTRY,0,44.0,ACTUAL,2025-09-01T16:18:12.181991,v2_robust,True,True,True,False,True,
NCT01933997,"A Phase 1 Study to Assess Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered to Healthy Volunteers","A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of Metadoxine (MG01CI) 1400 mg, Administered as Repeated Doses to Healthy Volunteers",Metadoxine (MG01CI ),"['Metadoxine (MG01CI )', 'MG01CI ,metadoxine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adult Subjects,['Healthy Adult Subjects'],"['pharmacokinetics', 'metadoxine']",COMPLETED,,2013-08,2013-10,"[{'measure': 'Pharmacokinetic (PK) Endpoints', 'description': 'Pharmacokinetic calculations will be based on individual plasma concentrations of the blood sampling on Day 1 and Day 5.\n\nThe following pharmacokinetic parameter will be calculated based on the plasma concentrations measured:\n\nCmax Maximum concentration achieved', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetic (PK) Endpoints', 'description': 'The following pharmacokinetic parameter will be calculated based on the plasma concentrations measured:\n\nTmax Time to reach maximum concentration (hours).', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetic (PK) Endpoints', 'description': 'The following pharmacokinetic parameter will be calculated based on the plasma concentrations measured:\n\nAUC (area under the curve) 0-t The area under the concentration vs. time curve, calculated as T1/2 Apparent terminal elimination half-life time (hours), The individual concentrations per time point will be displayed in graphs and listed per treatment day. Mean concentration per day and time point will be displayed graphically as well.', 'timeFrame': '6 weeks'}]",[],3,18 Years,45 Years,ALL,True,Alcobra Ltd.,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:12.182009,v2_robust,True,True,True,False,False,
NCT03371797,Amlodipine VaLsartan Efficacy in Hypertensive Patients.A Real World Trial,Efficacy and Safety of Single Pill Combination (Amlodipine/Valsartan) in Hypertensive Patients Not Controlled on Previous Monotherapy: An Observational Real Life Study,"Valsartan, Amlodipine -","['Valsartan, Amlodipine -', 'AVSAR']",2,OBSERVATIONAL,[],,,Essential Hypertension,['Essential Hypertension'],"['ALERT, MSSBP, MSDBP']",COMPLETED,,2018-02-20,2018-11-05,"[{'measure': 'Efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure after 8 weeks of therapy.', 'description': 'To determine the efficacy of valsartan/amlodipine 80/5 mg once daily dose is reducing mean sitting systolic blood pressure (MSSBP) after 8 weeks of therapy.\n\n\\[Designated as safety issue: No\\]', 'timeFrame': '8 weeks'}]","[{'measure': 'Measure percentage of participant with blood pressure change of <139/89 mmHg at the end of 8 week', 'description': 'To measure percentage of participant with blood pressure change of \\<139/89 mmHg at the end of 8 week\n\n\\[Designated as safety issue: No\\]', 'timeFrame': '8 weeks'}, {'measure': 'Participants experiencing adverse effect after taking single pill combination', 'description': 'Proportion of participants experiencing adverse effect after taking single pill combination\n\n\\[Designated as safety issue: Yes\\]', 'timeFrame': '8 weeks'}]",3,18 Years,70 Years,ALL,False,PharmEvo Pvt Ltd,INDUSTRY,0,800.0,ACTUAL,2025-09-01T16:18:12.182026,v2_robust,False,True,True,False,True,
NCT03504410,Efficacy/Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. in Older Patients With R/R AML,Phase 3 Multicenter Randomized Trial to Evaluate Efficacy and Safety of CPI-613 in Combination With HD Cyt. and Mito. vs HD Cyt. and Mito. Therapy and Control Sub-groups in Older Patients With R/R AML,CPI-613 + High Dose Cytarabine and Mitoxantrone,"['Fludarabine, Cytarabine, Filgrastim', 'CPI-613, CHAM', 'High Dose Cytarabine and Mitoxantrone', 'FLAG', 'HAM', 'Mitoxantrone, Etoposide and Cytarabine', 'MEC', 'CPI-613 + High Dose Cytarabine and Mitoxantrone']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Relapsed/Refractory Acute Myeloid Leukemia,['Relapsed/Refractory Acute Myeloid Leukemia'],[],TERMINATED,Futile,2018-11-12,2022-01-19,"[{'measure': 'Complete Remission (CR)', 'description': 'Complete disappearance of all clinical evidence of disease', 'timeFrame': '12 months'}]",[],1,50 Years,,ALL,False,Cornerstone Pharmaceuticals,INDUSTRY,0,200.0,ACTUAL,2025-09-01T16:18:12.182071,v2_robust,True,True,False,True,False,Futile
NCT00552110,Study of Mometasone Furoate Nasal Spray and Oxymetazoline Nasal Spray Given Together Once A Day To Treat Seasonal Allergic Rhinitis (P04500),"Efficacy and Safety of Concurrent Administration of Mometasone Furoate Nasal Spray (MFNS) and Oxymetazoline Nasal Spray Administered Once Daily (QD) vs. Oxymetazoline Twice Daily (BID), Mometasone Furoate QD, and Placebo in the Treatment of Subjects With Seasonal Allergic Rhinitis",OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY),"['OXY BID', 'MFNS + OXY combination assessing a different dose (ie, number of sprays) from that used in Group 1', 'oxymetazoline nasal spray (OXY) twice daily', 'MFNS QD', 'MFNS + OXY combination', 'Placebo', 'OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)', 'mometasone furoate nasal spray (MFNS) once daily']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],[],COMPLETED,,2007-07,2008-02,"[{'measure': 'Change From Baseline in AM/PM Instantaneous Total Nasal Symptom Score (NOW TNSS) Averaged Over Days 1 to 15', 'description': 'Subjects scored severity of rhinorrhea, nasal congestion/stuffiness, nasal itching, and sneezing at the time of evaluation (NOW) using an ordinal scale from 0 = none to 3 = severe. Evaluations were performed daily in the morning (AM) and evening (PM). For each evaluation, individual symptom scores were summed to a TNSS, which was then averaged for a single score across the 15 day treatment period.', 'timeFrame': '15 days of treatment'}, {'measure': 'Standardized Area Under the Curve From 0 to 4 Hours [AUC(0-4 hr)] of the Change From Baseline to Hour 4 on Day 1 in Nasal Congestion Score', 'description': 'Subjects scored nasal congestion/stuffiness using an ordinal scale from 0 = none to 3 = severe. Baseline was the average of the scores assessed every 15 minutes for 1 hour prior to dosing on Day 1. After dosing on Day 1, congestion was scored every 15 minutes for the 1st hour and every 30 minutes for the next 3 hours. Area under the curve (AUC) was calculated using the trapezoid rule, then standardization achieved by dividing the calculation by 4 hours. Treatment comparisons were examined using the standardized AUC(0-4 hr) of the change from baseline to hour 4 on Day 1.', 'timeFrame': 'from baseline to hour 4 on Day 1'}]",[],2,12 Years,,ALL,False,Organon and Co,INDUSTRY,1,707.0,ACTUAL,2025-09-01T16:18:12.182242,v2_robust,True,True,True,False,False,
NCT02639910,Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi,"A Phase II, Two-Cohort, Open-Label, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of MOR00208 Combined With Idelalisib or Venetoclax in Patients With Relapsed or Refractory CLL/SLL Previously Treated With Bruton's Tyrosine Kinase (BTK) Inhibitor",Idelalisib,"['Venclexta, Venclyxto; ABT-199', 'Zydelig; GS-1101 or CAL-101', 'Venetoclax', 'Idelalisib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Leukemia, Lymphocytic, Chronic, B-Cell","['Leukemia, Lymphocytic, Chronic, B-Cell', 'Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma']","['CD19', 'MOR208', 'MOR00208', 'CLL', 'SLL', 'COSMOS', 'tafasitamab']",COMPLETED,,2016-11,2021-12,"[{'measure': 'Incidence and Severity of Adverse Events (AEs)', 'description': 'For details please see Section of Adverse Events Overview', 'timeFrame': '2 years'}]","[{'measure': 'Best Objective Response Rate (ORR)', 'description': 'ORR = complete response \\[CR\\] + partial response \\[PR\\]; Local Evaluation', 'timeFrame': '2 years'}, {'measure': 'Number of Participants With Treatment-emergent or Treatment-boosted Anti-MOR00208 Antibody Formation', 'description': 'Number of participants with treatment-emergent or treatment-boosted anti-MOR00208 (anti-tafasitamab) antibody formation', 'timeFrame': '2 years'}, {'measure': 'Maximum Plasma Concentration (Cmax) of MOR00208', 'description': 'Mean Cmax of tafasitamab (MOR00208) at Cycle 3 Day 15 (after the weekly dosing of tafasitamab in Cycles 1 to 3 including a loading dose at C1D4)', 'timeFrame': 'At Cycle 3 Day 15'}]",4,18 Years,,ALL,False,MorphoSys AG,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:12.182259,v2_robust,True,True,True,False,True,
NCT06395610,"Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers","Open-label, Non-randomised, One-sequence Crossover Study to Investigate the Effect of Inhibition of CYP3A4/5 by Erythromycin on the Pharmacokinetics of CHF6001 in Healthy Subjects",CHF6001 DPI,"['CHF6001 DPI', 'Erythromycin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],"['Drug-drug Interaction study', 'CYP3A4/5 inhibitor', 'CYP3A4/5 substrate']",COMPLETED,,2024-03-28,2024-06-18,"[{'measure': 'Pharmacokinetic parameter (AUC0-t)', 'description': 'Area under the curve from time 0 to the last quantifiable concentration (AUC0-t)', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (Cmax)', 'description': 'Maximum plasma concentration (Cmax) of CHF6001 without and with the concomitant administration of Erythromycin', 'timeFrame': 'Over 96 hours after administration in blood'}]","[{'measure': 'Pharmacokinetic parameter (AUC0-96)', 'description': 'Area under plasma concentration from 0 to 96 hours (AUC0-96) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (AUC0-∞)', 'description': 'Area under curve extrapolated to infinity (AUC0-∞) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (tmax)', 'description': 'Time to the maximum plasma concentration (tmax) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (CL/F)', 'description': 'Apparent systemic clearance for CHF6001', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (t1/2)', 'description': 'Terminal elimination half-life (t1/2) for CHF6001, CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (AUC0-t)', 'description': 'Area under the plasma concentration versus time curve (AUC0-t) for CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}, {'measure': 'Pharmacokinetic parameter (Cmax)', 'description': 'Peak Plasma Concentration (Cmax) for CHF5956 and CHF6095', 'timeFrame': 'Over 96 hours after administration in blood'}]",9,18 Years,55 Years,ALL,True,Chiesi Farmaceutici S.p.A.,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:12.182305,v2_robust,True,True,True,False,False,
NCT00335010,Intravenous NTG to Preserve Gastric Microcirculation During Gastric Tube Reconstruction,A Prospective Double Blinded Study on the Effect of Intravenously Administrated Nitroglycerine on Gastric Tissue Microvascular Bloodflow and Microvascular Hemoglobin Saturation During Gastric Tube Reconstruction,Nitroglycerin,['Nitroglycerin'],1,INTERVENTIONAL,['NA'],,,Esophageal Neoplasms,"['Esophageal Neoplasms', 'Microcirculation']","['Nitroglycerine', 'gastroesophageal anastomosis', 'microvascular bloodflow', 'microvascular hemoglobinsaturation']",COMPLETED,,2005-05,2005-12,"[{'measure': 'differences in Microvascular bloodflow'}, {'measure': 'differences in microvascular hemoglobinsaturation'}]","[{'measure': 'differences in anastomotic leakage'}, {'measure': 'differences in anastomotic stenosis'}]",4,18 Years,,ALL,False,Erasmus Medical Center,OTHER,0,32.0,,2025-09-01T16:18:12.182393,v2_robust,True,True,True,False,False,
NCT00621010,Safety Study of CTS21166 to Treat Alzheimer Disease,A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males,CTS21166 (ZPQ-21166),['CTS21166 (ZPQ-21166)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Alzheimer's Disease,"[""Alzheimer's Disease""]",[],COMPLETED,,2007-06,2008-02,[{'measure': 'To evaluate the safety and tolerability of single ascending doses of CTS21166 following intravenous administration'}],[{'measure': 'To evaluate the pharmacokinetics(PK) of CTS21166 and its major metabolites as assessed in plasma'}],2,22 Years,,MALE,True,CoMentis,INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:12.182402,v2_robust,True,True,True,False,True,
NCT00210210,Administration of Ketamine to Prevent the Post-operative Pain,"Effect of Ketamine, at the Induction and Its Maintenance to Prevent the Post-operative Pain: Clinical Trial in Cancerology",Ketamine,['Ketamine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Postoperative Pain,"['Postoperative Pain', 'Breast Cancer']","['Post-operative-pain', 'Breast cancer', 'Morphine', 'Analgesia']",COMPLETED,,2004-02,2005-12,[{'measure': 'Morphine consumption (first 48 post-operative hours)'}],"[{'measure': 'Visual analog rating scale during the first 48 post-operative hours: at 15mn,1H,2H,12H, 24H,36H,48H'}]",2,18 Years,,FEMALE,False,Institut Bergonié,OTHER,0,230.0,ACTUAL,2025-09-01T16:18:12.182430,v2_robust,True,True,True,False,False,
NCT00936910,Antifungal Locks to Treat Fungal-related Central Line Infections,The Use of Antifungal Lock Therapy in Intestinal Failure and Other Patients,amphotericin B liposomal (Ambisome),"['Ambisome', 'amphotericin B liposomal (Ambisome)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Central Line Fungal Infections,['Central Line Fungal Infections'],"['central line fungal infections', 'antifungal lock therapy', 'Ambisome lock therapy']",COMPLETED,,2006-09,2010-09,"[{'measure': 'Number of Patients With 2 Negative Fungal Cultures After 5 Days of Combined Systemic Antifungal and Antifungal Lock Therapy and the CVC Was Not Removed', 'description': 'Records the number of patients with 2 negative fungal cultures after 5 days of combined systemic antifungal and antifungal lock therapy and the CVC was not removed', 'timeFrame': '5 days of antifungal lock treatment'}]","[{'measure': 'The Number of Days Before the Infected Central Line Culture Becomes Negative', 'description': 'Records the mean number of days required for the cultures to become negative', 'timeFrame': '5 days of antifungal lock treatment'}, {'measure': 'The Development of Fungal-related Complications', 'description': 'Records the number of fungal related adverse complications that occurred', 'timeFrame': 'Usually 1-28 days'}, {'measure': 'Number of Participants With Negative Cultures on Day 5 and Day 30 During the Test of Cure Period Post Antifungal Lock', 'description': 'Records the number of participants with 2 negative cultures who completed the trial and had (-) test of cure cultures on day 5 and 30', 'timeFrame': '30 days'}]",4,30 Days,21 Years,ALL,False,Bill McGhee,OTHER,1,13.0,ACTUAL,2025-09-01T16:18:12.182455,v2_robust,True,True,True,False,True,
NCT02217813,A Bioequivalence Study Comparing Two Different Tafamidis Formulations,"A Phase 1, Open-label, Randomized, Crossover, Single Dose Study To Determine The Bioequivalence Of Pf-06291826 (Tafamidis) 20 Mg Capsule Manufactured By Catalent Versus Capsule Manufactured By Pii In Healthy Subjects Under Fasted Conditions",Tafamidis,"['Tafamidis', 'Vyndaqel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2014-10,2014-11,"[{'measure': 'Area under the Concentration-Time Curve (AUC)', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.', 'timeFrame': '168 hours'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '168 hours'}]","[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)]', 'description': 'AUC (0-t)= Area under the plasma concentration versus time curve from time zero (pre-dose) to time of last quantifiable concentration (0-t)', 'timeFrame': '168 hours'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '168 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '168 hours'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '168 hours'}]",6,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:12.182538,v2_robust,True,True,True,False,False,
NCT07052513,Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery,Modified Autologous Leukocyte Cells for the Treatment of Acute Kidney Injury After Cardiac Surgery,Placebo,"['Autologous Leukocyte Cells', 'Saline Solution', 'M2RLAB 001', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Kidney Injury,['Acute Kidney Injury'],"['Cardiac Surgery', 'Thoracic Surgery', 'Acute Renal Insufficiency', 'Acute Renal Injury', 'Major Adverse Kidney Event', 'Autologous Leukocyte Cells', 'Leukocyte Cells', 'Autologous Mononuclear Cells', 'Mononuclear Cells', 'Acute Kidney Disease']",NOT_YET_RECRUITING,,2025-07-17,2027-09-02,"[{'measure': 'Recovery time of kidney function', 'description': 'Time (in days) to recovery of the creatinine to baseline values (in the range of more or less than 30 percent from baseline).', 'timeFrame': 'Baseline Phase (Day 0), Observation Phase: From Visit 1 (1 day after treatment) to Visit 7 (7 days after treatment)'}, {'measure': 'Proportion of participants with persistently altered creatinine values (more than 31 percent from baseline values) 7 days after AKI episode', 'description': 'Measured as the incidence of Acute Kidney Disease (AKD): persistence of altered creatinine values 7 days after the AKI episode.', 'timeFrame': 'Baseline Phase (Day 0), Observation Phase: From Visit 1 (1 day after treatment) to Visit 7 (7 days after treatment'}, {'measure': 'Occurrence of adverse events (AEs)', 'description': 'Number of AEs reported.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Occurrence of serious AEs (SAEs)', 'description': 'Number of SAEs reported', 'timeFrame': 'Up to Day 90'}, {'measure': 'Occurrence of AEs resulting in discontinuation of study treatment', 'description': 'Number of AEs resulting in discontinuation of study treatment reported', 'timeFrame': 'Up to Day 90'}, {'measure': 'Occurrence of AEs of special interest (AESIs)', 'description': 'Number of AESIs reported.', 'timeFrame': 'Up to Day 90'}]","[{'measure': 'Major Adverse Kidney Events (MAKE) incidence reduction', 'description': 'Proportion of patients with MAKE incidence reduction. MAKE is considered as the development of events related to disease progression, which is defined as death related to renal failure, need for dialysis or permanent reduction of estimated Glomerular Filtration Rate more than 30 percent since baseline', 'timeFrame': 'Baseline Phase: Day 0, Observation Phase: From Visit 1 (1 day after treatment) to Visit 7 (7 days after treatment) and Follow-up phase: Day 30 and 90'}, {'measure': 'Time to appear of Major Adverse Kidney Events (MAKE)', 'description': 'Time to appear of MAKE. MAKE is considered as the development of events related to disease progression, which is defined as death related to renal failure, need for dialysis or permanent reduction of estimated Glomerular Filtration Rate more than 30 percent since baseline', 'timeFrame': 'Up to Day 90'}, {'measure': 'Number of participants on renal replacement therapy', 'description': 'Number of participants requiring dialysis', 'timeFrame': 'Up to Day 90'}, {'measure': 'Renal replacement therapy duration.', 'description': 'Time (in days) of the required dialysis.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Duration of admission to Intensive Care Unit (ICU)', 'description': 'Time (in days) of ICU stay of participants.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Duration of hospital stay', 'description': 'Time (in days) of hospital stay of participants.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Patient survival after 30 days', 'description': 'Proportion of participants who survived after 30 days.', 'timeFrame': 'Up to Day 30'}, {'measure': 'Patient survival after 90 days', 'description': 'Proportion of participants who survived after 90 days.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Participants requiring dialysis versus participants who survived without requiring dialysis after 30 days', 'description': 'Proportion of participants who survived requiring dialysis versus participants who survived without requiring dialysis after 30 days post cardiac surgery.', 'timeFrame': 'Up to Day 30'}, {'measure': 'Participants requiring dialysis versus participants who survived without requiring dialysis after 90 days', 'description': 'Proportion of participants who survived requiring dialysis versus participants who survived without requiring dialysis after 90 days post cardiac surgery.', 'timeFrame': 'Up to Day 90'}, {'measure': ""Maximum creatinine values (peak creatinine) recorded during participants' hospitalization"", 'description': 'Maximum creatinine value (peak creatinine) recorded. Creatinine levels will be measured in serum.', 'timeFrame': 'Baseline Phase: Day 0 and Observation Phase: From Visit 1 (1 day after treatment) to Visit 7 (7 days after treatment)'}, {'measure': ""Time (day) of maximum creatinine values (peak creatinine) recorded during participants' hospitalization"", 'description': 'Day of maximum creatinine values (peak creatinine) recorded. Creatinine levels will be measured in serum.', 'timeFrame': 'Baseline Phase: Day 0 and Observation Phase: From Visit 1 (1 day after treatment) to Visit 7 (7 days after treatment)'}, {'measure': 'Improvement in levels of injury biomarkers in urine', 'description': 'Proportion of participants with variations of more than 30 percent in the values of injury biomarkers in urine \\[Albumin and Neutrophil gelatinase-associated lipocalin (NGAL)\\]', 'timeFrame': 'Baseline Phase: Day 0 and Observation Phase: Visit 7 (7 days after treatment)'}, {'measure': 'Participants presenting surgical wound infections', 'description': 'Proportion of participants with surgical wound infections.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Participants presenting respiratory infections during ICU stay', 'description': 'Proportion of participants with respiratory infections during ICU stay.', 'timeFrame': 'Up to Day 90'}, {'measure': 'Participants who present complications related to surgery', 'description': 'Proportion of participants with any complication related to surgery (Sternotomy, Reintervention, Circulatory support).', 'timeFrame': 'Up to Day 90'}, {'measure': 'Number of complications related to surgery', 'description': 'Absolute number of any complication related to surgery (Sternotomy, Reintervention, Circulatory support).', 'timeFrame': 'Up to Day 90'}, {'measure': 'Unexplained haemodynamic worsening', 'description': 'Unexplained haemodynamic worsening measured as: drop in cardiac index to less than 2.5 L/min/m\\^2 (if it was previously higher), drop in systemic systolic blood pressure more than 30 percent or to less than 90 mmgHg, and/or more than 30 increase in vasoactive drugs dose.', 'timeFrame': 'Observational Phase: Day 1 and Day 7'}]",24,18 Years,,ALL,False,M2RLAB SL,INDUSTRY,0,98.0,ESTIMATED,2025-09-01T16:18:12.182652,v2_robust,True,True,False,False,True,
NCT00802113,Autologous and Allogeneic Transplant for Relapsed Lymphoma,Sequential Myeloablative Stem Cell Transplantation and Reduced Intensity Allogeneic Stem Cell Transplantation in Patients With Refractory or Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease,Fludarabine,"['Fludara', 'ATG', 'Busulfex', 'Busulfan', 'Fludarabine', 'Anti-Thymocyte Globulin']",6,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Non-Hodgkin's Lymphoma,"[""Non-Hodgkin's Lymphoma"", 'Hodgkins Disease']","['Autologous Stem Cell Transplant', 'Cord Blood Transplant', 'Allogeneic Stem Cell Transplant', 'Relapsed Lymphoma']",COMPLETED,,2003-06,2014-10-22,"[{'measure': 'Total Number of Subjects With a Complete Response (CR) Following Myeloablative Conditioning (MAC) and Autologous Stem Cell Transplantation (AutoSCT)', 'description': 'Complete Response is defined as the complete resolution of B symptoms (i.e., weight loss, night sweats and fever) and normalization of all sites of disease on the basis of physical exam, bone marrow biopsy, and imaging studies.', 'timeFrame': 'Up to 1 year post-transplantation'}, {'measure': 'Total Number of Subjects With a Disease Relapse or Progression Following MAC AutoSCT', 'description': 'Includes subjects with any measurable growth of disease in a previously affected site or detection of disease in a new site confirmed by biopsy.', 'timeFrame': 'Up to 1 year post-transplantation'}, {'measure': 'Total Number of Subjects With Partial Response or Stable Disease Following MAC AutoSCT', 'description': 'Total includes subjects with partial response and patients with stable disease, defined as \\<50% reduction in measurable disease or the uninterrupted persistence of B symptoms.', 'timeFrame': 'Up to 1 year post-transplantation'}]","[{'measure': 'Time to Neutrophil Engraftment', 'description': 'Following MAC AutoSCT, the median time to neutrophil (PMN) recovery will be measured.', 'timeFrame': 'Up to 1 year post-transplantation'}, {'measure': 'Time to Platelet Engraftment', 'description': 'Following MAC AutoSCT, the median time to platelet recovery will be measured.', 'timeFrame': 'Up to 1 year post-transplantation'}, {'measure': 'Total Number of Subjects With Grade II-IV Acute Graft-versus-Host-Disease (GVHD)', 'description': 'The criteria for grading is based on extent of organ involvement (i.e., Skin, Liver and Gut - rash on \\>50% of skin, bilirubin 2-3 mg/dl, diarrhea \\> 500 ml/day) with Grade II being better outcome and Grade IV being worse outcome.', 'timeFrame': 'Up to 1 year post-transplantation'}, {'measure': 'Total Number of Subjects That Experienced Transplant-related Mortality (TRM)', 'description': 'Status as subjects died post-AlloHCT', 'timeFrame': 'Up to 1 year post-transplantation'}]",7,,55 Years,ALL,False,Columbia University,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:12.182667,v2_robust,True,True,True,False,False,
NCT06071013,Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients,A Phase I/Phase II Study of Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients,"Nintedanib, gefitinib, erlotinib, afatinib, osimertinib","['Nintedanib, gefitinib, erlotinib, afatinib, osimertinib']",1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Non-small Cell Lung Cancer,"['Non-small Cell Lung Cancer', 'EGFR Gene Mutation', 'EGFR-TKI Resistant Mutation']","['nPKC delta', 'Angiogenesis', 'EGFR TKI drug resistant']",RECRUITING,,2024-02-23,2026-08-27,"[{'measure': 'The toxicity of combinate nintedanib and EGFR TKI', 'timeFrame': 'Assessed every 6 weeks of chest CT scan until PD.'}, {'measure': 'Patient objective response rate', 'timeFrame': 'Assessed every 6 weeks of chest CT scan'}]","[{'measure': 'Overall survival', 'timeFrame': 'Assessed every 12 weeks thereafter up to end of study at approximately 2 years'}]",3,20 Years,70 Years,ALL,False,China Medical University Hospital,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:12.182691,v2_robust,True,True,False,False,False,
NCT00196313,A Study to Evaluate the Efficacy of Seasonique for the Treatment of Cyclic Pelvic Pain,"A Multicenter Study to Compare the Efficacy of an Extended-cycle Oral Contraceptive, Seasonique Which Utilizes Ethinyl Estradiol During the Usual Hormone-free Interval to Placebo for the Treatment of Cyclic Pelvic Pain in Adolescents",levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets,"['levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets', 'Placebo tablet', 'Seasonique']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Dysmenorrhea,['Dysmenorrhea'],"['cyclic pelvic pain', 'dysmenorrhea', 'oral contraceptives']",COMPLETED,,2005-05,2008-10,"[{'measure': 'Mean Change in Average Severity for Abdominal/Pelvic Pain', 'description': 'Defined as the sum of pain scores divided by the total number of days in which the subject experienced abdominal/pelvic pain, from baseline to Week 13 The severity of the pain was assessed using a 4-points scale (0 = ""None"", 1 = ""Mild"", 2 = ""Moderate"", 3 = ""Severe"")', 'timeFrame': 'Baseline to end of 13-week treatment period'}]","[{'measure': 'Change From Baseline in Maximum Severity of Abdominal/Pelvic Pain', 'description': 'Maximum pain severity score was calculated by identifying each subject\'s maximum recorded pain severity from baseline to end of Week 13.\n\nThe severity of the pain was assessed using a 4-points scale (0 = ""None"", 1 = ""Mild"", 2 = ""Moderate"", 3 = ""Severe"")', 'timeFrame': 'Baseline to end of Week 13'}, {'measure': 'Incidence of Menstrual Bleeding and /or Spotting', 'timeFrame': 'Baseline to end of Week 13'}, {'measure': 'Number of Days Missed From School/Work or Other Activities', 'timeFrame': '13-week treatment period'}, {'measure': 'Analgesic Use', 'description': 'number of days analgesic (pain) medication was used over the 13 week treatment period', 'timeFrame': '13-week treatment period'}]",5,,17 Years,FEMALE,False,Duramed Research,INDUSTRY,0,95.0,ACTUAL,2025-09-01T16:18:12.182702,v2_robust,True,True,True,False,False,
NCT03445013,"A Study Assessing the PK, PD, Safety, and Tolerability of SB414 in Psoriasis","A Phase 1b Multi-Center, Double-Blind, Randomized, Vehicle-Controlled Study Assessing the PK, Pharmacodynamics, Safety, and Tolerability of SB414 in Subjects With Psoriasis",SB414 6%,"['NVN1000', 'Placebo', 'Vehicle', 'SB414 6%']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Psoriasis,['Psoriasis'],[],COMPLETED,,2017-10-13,2018-02-06,"[{'measure': 'Plasma concentrations of hMAP3', 'description': 'Peak plasma concentrations of hMAP3 after topical application of SB414', 'timeFrame': 'Day 29'}]","[{'measure': 'Safety Profile (Reported Adverse Events)', 'description': 'Reported Adverse Events', 'timeFrame': 'Day 29'}, {'measure': 'Subject Assessment of Tolerability', 'description': 'Subject-reported from 5-point tolerability scale overall presence and degree of itching and burning/stinging', 'timeFrame': 'Baseline, Week 2 and Week 4'}, {'measure': 'Efficacy Assessed by Target Plaque Severity Score (TPSS)', 'description': 'Target Plaque Severity Score will be collected', 'timeFrame': 'Baseline, Week 2 and Week 4'}, {'measure': 'Pharmacodynamics of SB414', 'description': 'Change in relevant Pre and Post-dose tissue cytokine levels (mg/mg tissue)', 'timeFrame': 'Day 29'}, {'measure': ""Efficacy Assessed by Physician's Static Global Assessment"", 'description': ""Physician's Static Global Assessment based on overall evaluation of the disease severity"", 'timeFrame': 'Screening, Baseline, Week 2 and Week 4'}, {'measure': 'Efficacy as assessed by Itch Numeric Rating Scale (NRS)', 'description': 'Itching due to psoriasis as reported by subject on a 11-point rating scale', 'timeFrame': 'Screening, Baseline, Week 2 and Week 4'}]",7,18 Years,70 Years,ALL,True,"Novan, Inc.",INDUSTRY,1,36.0,ACTUAL,2025-09-01T16:18:12.182755,v2_robust,True,True,True,False,True,
NCT05036213,The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion During Exercise in Patients With PAD,The Effects of Oral Inorganic Nitrate Supplementation on Lower Limb Perfusion and Metabolism During Exercise in Patients With Peripheral Arterial Disease (PAD),BEET IT - Concentrate Beet root juice,"['Dietary Nitrate supplementation (nitrate depleted)', 'BEET IT - Concentrate Beet root juice (nitrate depleted)', 'BEET IT - Concentrate Beet root juice', 'Dietary Nitrate supplementation (nitrate rich)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Peripheral Arterial Disease,"['Peripheral Arterial Disease', 'Peripheral Vascular Diseases']","['PAD', 'nitrate', 'nitric oxide']",RECRUITING,,2020-02-01,2024-12,"[{'measure': 'Phosphocreatine kinetics after maximal exercise', 'description': 'The primary outcomes to be analyzed will be treatment differences (BR v PL) in phosphocreatine recovery time constant (PCr) measured by Creatine chemical Exchange Saturation Transfer (CrCREST).\n\nThe subjects will be positioned within the scanner feet first with the calf at the isocenter of the magnet and a flexible phased array coil will be positioned and wrapped around the calf of interest. Imaging of calf muscle energetics using creatine chemical exchange saturation transfer (CrCEST, no contrast agent used) will be performed after pedal ergometry until exhaustion or limiting symptoms', 'timeFrame': 'After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.'}]","[{'measure': 'Maximal hyperemia in different lower limb compartments', 'description': 'At the Prisma 3T scanner at Fontaine, subjects will be positioned within the scanner feet first with the calf at the isocenter of the magnet and a flexible phased array coil will be positioned and wrapped around the calf of interest. Subjects to complete plantar flexion ergometry to exhaustion or claudication. Imaging of calf muscle perfusion by arterial spin labeling (ASL, no contrast agent used) will be performed after pedal ergometry until exhaustion or limiting symptoms.', 'timeFrame': 'After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.'}, {'measure': 'Peak exercise', 'description': 'Subjects will be tested on two different occasions (PL vs Beet root juice) for how long they can walk (in seconds) on a treadmill. The treadmill walking test is designed specifically for a claudication-limited population (i.e. the Gardner protocol). During this walking test the speed is maintain at 2mph with a 2%-grade increase every 2 minutes.', 'timeFrame': 'After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.'}, {'measure': 'Claudication Onset Time', 'description': 'During the treadmill exercise protocol subjects will report when they start to feel pain in their lower limbs (or the affect leg).', 'timeFrame': 'After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.'}, {'measure': 'Vascular Function - Brachial Flow Mediated Dilation', 'description': 'A high-resolution ultrasound will be used to capture images of the brachial artery at baseline, during 5 minutes of forearm occlusion, and for two minutes (with r-wave trigger) following occlusion cuff release. These data points will be utilized to calculate the percentage of change in brachial artery diameter following reactive hyperemia (occlusion release).', 'timeFrame': 'After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.'}, {'measure': 'Vascular stiffness', 'description': ""Vascular stiffness will be assessed by measures of pulse wave velocity using applanation tonometry (SphygmoCor EXCEL system V1). The measures provided by PWA include: central systolic pressure (mmHg); central pulse pressure (PP) mmHg; augmentation pressure (AP) and augmentation index (AIx).\n\nPulse wave velocity is measured via a simultaneous comparison of the carotid and femoral arterial pulses. A thigh cuff will be placed around the patient's upper thigh which acts to measure the femoral pulse via pulsations, whilst simultaneously a tonometer will be used to assess the carotid pulse. Higher pulse wave velocities from the carotid to femoral arteries indicates higher aortic stiffness."", 'timeFrame': 'After a minimum of 3 days of supplementation with either Placebo or nitrate rich beverage.'}]",6,40 Years,80 Years,ALL,False,University of Virginia,OTHER,0,28.0,ESTIMATED,2025-09-01T16:18:12.182763,v2_robust,True,True,False,False,False,
NCT02879513,Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy,A Randomized Phase III Trial of Comparing Combination Administration of Paclitaxel and Cisplatin Versus CEF as Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy,Paclitaxel,"['Paclitaxel', '5-fluoruracil', 'Cisplatin', 'Cyclophosphamide', 'Epirubicin', 'Taxol', '5-FU']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Invasive Ductal Breast Cancer,"['Invasive Ductal Breast Cancer', 'Tubular Breast Cancer', 'Mucinous Breast Cancer', 'Inflammatory Breast Cancer']",[],UNKNOWN,,2014-01,2022-12,"[{'measure': 'Disease-free survival (DFS)', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'overall survival (OS)', 'timeFrame': 'Up to 5 years'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '4 months during adjuvant therapy'}, {'measure': 'regional recurrence free survival (RRFS)', 'timeFrame': '5 years'}, {'measure': 'local recurrence free survival (LRFS)', 'timeFrame': '5 years'}, {'measure': 'distant-disease- free survival (DDFS)', 'timeFrame': '5 years'}]",6,18 Years,70 Years,FEMALE,False,RenJi Hospital,OTHER,0,290.0,ESTIMATED,2025-09-01T16:18:12.182840,v2_robust,True,True,False,False,True,
NCT03589313,Pharmacokinetics of GLPG3067 in Male Subjects With Cystic Fibrosis.,"Evaluation of the Pharmacokinetics, Safety and Tolerability of a Single Dose of GLPG3067 Administered as Solid Formulation in Male Subjects With Cystic Fibrosis.",GLPG3067 single dose,['GLPG3067 single dose'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cystic Fibrosis,['Cystic Fibrosis'],[],COMPLETED,,2018-02-12,2018-03-26,"[{'measure': 'Maximum observed plasma concentration (cmax) of GLPG3067 single dose.', 'description': 'To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.', 'timeFrame': 'Between Day 1 pre-dose and Day 4.'}, {'measure': 'Area under the plasma concentration-time curve from time zero until 24 hours post-dose ( (AUC0-24h) of GLPG3067 single dose.', 'description': 'To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.', 'timeFrame': 'Between Day 1 pre-dose and Day 4.'}, {'measure': 'Area under the plasma concentration-time curve from time zero until 72 hours post-dose (AUC0-72h) of GLPG3067 single dose.', 'description': 'To evaluate the PK profile of GLPG3067 after a single oral dose of GLPG3067.', 'timeFrame': 'Between Day 1 pre-dose and Day 4.'}]","[{'measure': 'The number of subjects with adverse events.', 'description': 'To evaluate the safety and tolerability of a single oral dose of GLPG3067 in adult male subjects with CF.', 'timeFrame': 'From screening to 19 days after the last dose.'}]",4,18 Years,,MALE,False,Galapagos NV,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:12.182860,v2_robust,True,True,True,False,True,
NCT02137213,Feasibility Study of Oral Naloxone for Treatment of Methadone-induced Constipation,Oral Naloxone for Treatment of Opioid-induced Constipation in Patients Receiving Methadone Maintenance Treatment,Naloxone,"['Naloxone hydrochloride solution for injections 0.4 mg/ml', 'Bacteriostatic normal saline', 'Placebo', 'Naloxone']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Constipation,['Constipation'],"['Opioid-induced constipation', 'Methadone', 'Naloxone']",COMPLETED,,2014-08,2015-03,"[{'measure': 'Severity of constipation symptoms', 'description': 'Severity of constipation symptoms will be measured after one week of receiving methadone with naloxone and after one week of receiving methadone alone in both arms of the study.', 'timeFrame': 'One week'}]","[{'measure': 'Severity of opioid withdrawal symptoms', 'description': 'The severity of opioid withdrawal symptoms will be assessed using Subjective Opioid Withdrawal Scale (SOWS) over the course of the study (2 weeks for each participant)', 'timeFrame': 'Two weeks'}]",2,18 Years,,ALL,False,Centre for Addiction and Mental Health,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:12.182911,v2_robust,True,True,True,False,False,
NCT05834413,Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors,Clinical Study on the Prevention of Driver Gene Negative II-IIIa Lung Cancer Recurrence and Metastasis by Staged Chinese Herbal Medicine Combined With Chemotherapy and Immune Checkpoint Inhibitors,chemotherapy plus TCM 1&ICIs plusTCM2 placebo,"['chemotherapy plus TCM 1&ICIs plusTCM2 placebo', 'chemotherapy plus TCM 1placebo &ICIs plus TCM2 placebo']",2,INTERVENTIONAL,['NA'],,,Lung Cancer,['Lung Cancer'],"['non-small cell lung cancer', 'traditional Chinese medicine', 'postoperative adjuvant therapy', 'immune checkpoint inhibitors']",NOT_YET_RECRUITING,,2023-05-01,2026-06-30,"[{'measure': 'Disease-free Survival(DFS)', 'description': 'Time from patient enrollment to date of objective tumour recurrence from any cause.', 'timeFrame': '5 years'}]","[{'measure': 'Overall Survival(OS)', 'description': 'The time from patient enrollment to date of any documented death from any cause.', 'timeFrame': '5 years'}, {'measure': 'Quality of Life Measurement Scale (EORTC QLQ-C30)', 'description': 'EORTC QLQ-C30 is assessed using and developed by the European Organzation for Research and Treatment of Cancer（EORTC）.QOL is evaluated by comparing changes in the quality of life scales before enrollment and every 1 month after treatment.The maximum score of QLQ-C30 scale is 100 and the minimum score is 0.Higher scores in functional areas and overall health represent better quality of life.Higher scores in the symptom area mean poorer quality of life.', 'timeFrame': '5 years'}, {'measure': 'Quality of Life Measurement Specific Module Scale for Patients with Lung Cancer (EORTC QLQ-LC13)', 'description': 'QOL is evaluated by comparing changes in the quality of life scales before enrollment and every 1 month after treatment.The maximum score of QLQ-LC13 scale is 100 and the minimum score is 0.Higher scores mean poorer quality of life.', 'timeFrame': '5 years'}, {'measure': 'TCM Symptoms Changes', 'description': 'TCM symptoms changes are according to the lung cancer symptom classification quantization table in ""Guiding Principles for Clinical Research of Traditional Chinese Medicine in the Treatment of Lung Cancer (2002 Edition)"".\n\n1. Significant improvement: clinical syndrome scores decreased by≥ 70%.\n2. Partial improvement: clinical syndrome scores decreased b≥30%;\n3. No improvement: clinical syndrome scores no change, or change\\<30%;\n4. Exacerbation: clinical syndrome scores increases by≥30%.', 'timeFrame': '5 years'}, {'measure': 'Laboratory Indicator Evaluation Criteria', 'description': 'Refer to the ""Guidelines for Clinical Research of New Drugs in Traditional Chinese Medicine (Trial)"" (China Medical Science and Technology Press, 2002) to develop evaluation criteria:\n\nImprove: Any increase after treatment is ≥10% before treatment, or from abnormal to normal; Decrease: Anyone who falls ≥10% after treatment or changes from normal to abnormal after treatment; Stable: Anyone who rises or falls less than 10% after treatment compared with before treatment.', 'timeFrame': '5 years'}, {'measure': 'Circulating Exosome PD-L1', 'description': 'The circulating exosome PD-L1 evaluation will be measured before treatment, during chemotherapy, before immunotherapy, during immunotherapy, after treatment, and every 6 months during the follow-up period.', 'timeFrame': '5 years'}, {'measure': 'Molecular Residual Disease Circulating Tumor DNA(ctDNA-MRD)', 'description': 'The ctDNA-MRD evaluation will be measured before treatment, during chemotherapy, before immunotherapy, during immunotherapy, after treatment, and every 6 months during the follow-up period.', 'timeFrame': '5 years'}, {'measure': 'Safety Assessment Evaluated According to Common Toxicity Criteria', 'description': 'Percentage of Participants with Adverse Events. Safety assessment is evaluated according to common terminology criteria for adverse events(CTCAE) 5.0.', 'timeFrame': '5 years'}]",9,18 Years,74 Years,ALL,False,Shanghai University of Traditional Chinese Medicine,OTHER,5,367.0,ESTIMATED,2025-09-01T16:18:12.182921,v2_robust,True,True,False,False,True,
NCT04568213,Hypochlorous Acid Disinfection Prior to Cataract Surgery,Effect of Hypochlorous Acid Disinfection on Ocular Flora Prior to Cataract Surgery,Hypochlorous Acid Gel 0.02%,['Hypochlorous Acid Gel 0.02%'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cataract,"['Cataract', 'Endophthalmitis']",['Ocular/Eyelid Flora'],COMPLETED,,2020-10-29,2022-12-09,"[{'measure': 'Reduction in bacterial flora in eyelashes of treatment eye compared to fellow eye', 'description': 'Swab will be used to obtain samples from the eyelashes bilaterally and cultured', 'timeFrame': 'On day of surgery prior to surgical prep'}, {'measure': 'Reduction in bacterial flora in conjunctiva of treatment eye compared to fellow', 'description': 'Swab will be used to obtain samples from the conjunctiva bilaterally and cultured', 'timeFrame': 'On day of surgery prior to surgical prep'}]",[],2,18 Years,95 Years,ALL,False,Loma Linda University,OTHER,0,54.0,ACTUAL,2025-09-01T16:18:12.182982,v2_robust,True,True,True,False,False,
NCT02461160,"Phase 1, TAK-915-1001, Single-Rising Dose, Multiple-Rising Dose, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Participants Study","A Phase 1 Safety, Tolerability, Pharmacokinetic, Placebo-Controlled and Open-Label Study of Escalating Single and Multiple Oral Doses, Drug-Drug Interaction, Relative Bioavailability, Food Effect, and Effect on Elderly Subjects of TAK-915 in Healthy Subjects",TAK-915 suspension,"['TAK-915 tablet', 'Midazolam', 'Versed', 'Placebo', 'TAK-915 suspension']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],['Drug therapy'],COMPLETED,,2015-05-12,2016-08-01,"[{'measure': 'Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)', 'description': 'An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (eg, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. A TEAE is defined as an adverse event with an onset that occurs after receiving study drug.', 'timeFrame': 'Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)'}, {'measure': 'Percentage of Participants With Markedly Abnormal Safety Laboratory Tests', 'description': 'The percentage of participants with any markedly abnormal standard safety laboratory values, including haematology, serum chemistries, or urinalysis, during the treatment period.', 'timeFrame': 'Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)'}, {'measure': 'Percentage of Participants With Markedly Abnormal Vital Sign Measurements', 'description': 'The percentage of participants who meet markedly abnormal criteria for vital signs after dosing, including oral body temperature (temp.), respiration rate, pulse rate (PR) Systolic blood pressure (SBP) and Diastolic blood pressure (DBP) for assessment in positions of supine or standing. Vital signs were considered abnormal if they were beyond the values defined in categories.', 'timeFrame': 'Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)'}, {'measure': 'Percentage of Participants With Markedly Abnormal Values of 12-Lead Electrocardiogram (ECG) Parameters', 'description': 'The percentage of participants who meet markedly abnormal criteria for ECG parameters as specified by the protocol and statistical analysis plan during the treatment period. ECG parameters were considered abnormal if they were beyond the values defined in categories.', 'timeFrame': 'Day 1 up to follow-up (SRD Cohorts: up to Day 13, MRD Cohorts: up to Day 26, DDI Cohort: up to Day 28, BA/FE Cohorts: up to Day 13, ESSD Cohort: up to Day 28)'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1, 8 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours) post dose'}, {'measure': 'Rac(AUC): Accumulation Ratios Between Day 14 AUC(0-24) and Day 1 AUC(0-24) for TAK-915', 'timeFrame': 'Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose'}, {'measure': 'Rac(Cmax): Accumulation Ratios Between Day 14 Cmax and Day 1 Cmax for TAK-915', 'timeFrame': 'Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose'}, {'measure': 'Time Dependency Assessment From AUC(0-24) After Last Dose for TAK-915 on Day 14 in MRD Cohorts Compared to AUC(0-inf) After a Single Dose on Day 1', 'timeFrame': 'Days 1 and 14 pre-dose and at multiple time points (up to 96 hours) post dose'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort', 'timeFrame': 'Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose'}, {'measure': 'AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for Midazolam Alone (Day 1) and in the Presence of TAK-915 (Day 16) in DDI Cohort', 'timeFrame': 'Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose'}, {'measure': 'AUC(0-24) for Midazolam After Single Dose (Day 1)/AUC(0-24) for Midazolam After 7 Daily Doses of TAK-915 (Day 16) in DDI Cohort', 'timeFrame': 'Days 1 and 16 pre-dose and at multiple timepoints (up to 24 hours) post dose'}]","[{'measure': 'Terminal Elimination Half-life (t1/2) for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'CL/F: Apparent Clearance for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'Apparent Volume of Distribution (Vz/F) for TAK-915', 'timeFrame': 'SRD and ESSD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'Total Amount of Drug Excreted in Urine (Ae) for TAK-915', 'timeFrame': 'SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'Fraction of Drug Excreted in Urine (Fe) for TAK-915', 'timeFrame': 'SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'Renal Clearance (CLr) for TAK-915', 'timeFrame': 'SRD Cohorts: Day 1 pre-dose and at multiple timepoints (up to 96 hours) post dose; MRD cohorts: Days 1 and 14 pre-dose and at multiple timepoints (up to 96 hours) post dose'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for TAK-915 on Day 1 in DDI Cohort', 'timeFrame': 'Days 1 at multiple time points (up to 96 hours) post dose'}, {'measure': 'AUC(0-24): Area Under the Plasma Concentration-Time Curve From Time 0 to 24 Hours Postdose for TAK-915 on Day 1 in DDI Cohort', 'timeFrame': 'Days 1 at multiple time points (up to 96 hours) post dose'}, {'measure': 'AUC(0-tau): Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval Where Tau is the Length of the Dosing Interval for TAK-915 in DDI Cohort', 'timeFrame': 'Days 16 at multiple time points (up to 96 hours) post dose'}, {'measure': 'Ratio of TAK-915 Metabolite Cmax to TAK-915 Cmax in SRD and MRD Cohorts', 'timeFrame': 'Day 1 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'Ratio of TAK-915 Metabolite AUC(0-inf) to TAK-915 AUC(0-inf) in SRD Cohorts', 'timeFrame': 'Day 1 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'Ratio of TAK-915 Metabolite Area Under the Plasma Concentration-Time Curve From Time 0 to Time Tau Over a Dosing Interval [AUC(0-tau)] Where Tau is the Length of the Dosing Interval to TAK-915 AUC(0-tau) in MRD Cohorts', 'timeFrame': 'Day 14 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'Cmax: Maximum Observed Plasma Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort', 'timeFrame': 'Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'AUClast: Area Under the Plasma Concentration-Time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort', 'timeFrame': 'Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'AUC(0-inf): Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort', 'timeFrame': 'Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort', 'timeFrame': 'Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'Terminal Elimination Half-life (t1/2) for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort', 'timeFrame': 'Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose'}, {'measure': 'λz: Terminal Elimination Rate Constant for TAK-915 and TAK-915 Metabolite M-I in BA/FE Cohort', 'timeFrame': 'Day 1 of Periods 1, 2 and 3 predose and at multiple time points (up to 96 hours) post-dose'}]",33,18 Years,75 Years,ALL,True,Takeda,INDUSTRY,0,88.0,ACTUAL,2025-09-01T16:18:12.183205,v2_robust,True,True,True,False,True,
NCT05275660,"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Chinese Healthy Adults","A Phase I Randomized, Double-Blind, Placebo-Controlled Study Investigating the Safety, Tolerability, and Pharmacokinetics of Single Dose Intravenously Administered HFB30132A, a Monoclonal Antibody Against SARS-CoV-2, in Chinese Healthy Adult Subjects",HFB30132A,['HFB30132A'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2021-05-09,2022-02-22,"[{'measure': 'Number of participants with treatment emergent serious adverse events (TESAEs)', 'description': 'Number of participants experiencing TESAEs', 'timeFrame': 'From Day 1 to up to Day 30 after the single dose administration of HFB30132A'}, {'measure': 'Number of participants with treatment emergent adverse events of special interest (TEAESI)', 'description': 'Safety and tolerability will be evaluated in terms of number of participants with TEAESI (hypersensitivity / anaphylactic reaction / local tolerability)', 'timeFrame': 'From Day 1 to up to Day 30 after the single dose administration of HFB30132A'}, {'measure': 'Number of participants with treatment-emergent adverse events (TEAE)', 'description': 'Safety and tolerability will be evaluated in terms of number of participants with TEAE', 'timeFrame': 'From Day 1 to up to Day 30 after the single dose administration of HFB30132A'}, {'measure': 'Number of participants with changes in laboratory values, vital signs and ECG parameters', 'description': 'Safety and tolerability will be evaluated in terms of number of participants with changes in laboratory values, vital signs and ECG parameters', 'timeFrame': 'From Day 1 to up to Day 30 after the single dose administration of HFB30132A'}, {'measure': 'Maximum observed serum concentration (Cmax)', 'timeFrame': 'From Day 1 to up to Day 30 of the last enrolled subject'}, {'measure': 'Time of maximum serum concentration (Tmax)', 'timeFrame': 'From Day 1 to up to Day 30 of the last enrolled subject'}, {'measure': 'Area under the concentration vs. time curve (AUC0-last), AUC0-∞)', 'timeFrame': 'From Day 1 to up to Day 30 of the last enrolled subject'}, {'measure': 'Terminal half-life (T1/2)', 'timeFrame': 'From Day 1 to up to Day 30 of the last enrolled subject'}, {'measure': 'Systemic clearance (CL)', 'timeFrame': 'From Day 1 to up to Day 30 of the last enrolled subject'}, {'measure': 'Apparent volume of distribution (Vd)', 'timeFrame': 'From Day 1 to up to Day 30 of the last enrolled subject'}]",[],10,18 Years,60 Years,ALL,True,HiFiBiO Therapeutics,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:12.183252,v2_robust,True,True,True,False,True,
NCT05020860,Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer,A Phase II Trial to Correlate Early Clinical Response to Pathologic Outcome With Neoadjuvant Systemic Therapy in Patients With Early Stage Breast Cancer,Paclitaxel,"['Pembrolizumab', 'Paclitaxel', 'Adriamycin', 'Keytruda', 'Pertuzumab/Trastuzumab/Hyaluronidase-zzxf', 'Carboplatin', 'Perjeta', 'Doxorubicin', 'Cyclophosphamide', 'Taxol', 'Herceptin', 'Trastuzumab', 'Pertuzumab', 'Cytoxan', 'PHESGO']",15,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'Breast Neoplasm', 'Breast Cancer Female', 'Breast Cancer Invasive', 'Breast Cancer Stage II', 'Breast Cancer Stage III', 'Triple Negative Breast Cancer', 'Hormone Receptor-positive Breast Cancer', 'HER2-positive Breast Cancer', 'Triple Negative Breast Neoplasms', 'Estrogen Receptor-positive Breast Cancer']",[],RECRUITING,,2023-04-18,2029-11,"[{'measure': 'Change in Clinical Tumor Measurement vs. Pathologic Response', 'description': 'Clinical tumor measurements are tumor measurements obtain via imaging (mammogram or ultrasound) or by physical exam. Pathologic response is the amount of tumor remaining at the time of surgery, as determined by the pathologist.', 'timeFrame': 'Baseline and at surgery (after 20 weeks)'}]","[{'measure': 'Pathologic Complete Response Rate in each Breast Cancer Subtype', 'description': 'A pathologic complete response (pCR) means that there is no residual invasive cancer identified in the tissue removed at surgery. The frequency of pCR will be estimated for each breast cancer subtype (triple negative, hormone receptor positive, and HER2-positive)', 'timeFrame': '20 weeks'}, {'measure': 'Predictive value of clinical response following 1 cycle of chemotherapy to predict pathologic complete response', 'description': 'This aims to determine whether a 30 percent reduction in tumor size (as measured by physical exam or imaging) following one cycle of chemotherapy can predict whether a patient will have no residual invasive cancer at the time of surgery', 'timeFrame': '20 weeks'}]",3,18 Years,,ALL,False,Baylor Breast Care Center,OTHER,0,185.0,ESTIMATED,2025-09-01T16:18:12.183317,v2_robust,True,True,False,False,False,
NCT02406560,A Study Comparing The Amounts of Tafamidis In The Blood With Or Without Food,"A Phase 1, Open-label, Randomized, Crossover, Oral, Single Dose Study To Estimate The Relative Bioavailability Of Pf-06291826 (Tafamidis) Following Administration Of A Tafamidis Free Acid Tablet Formulation In Healthy Subjects Under Fasted And Fed Conditions",tafamidis,"['tafamidis', 'fasted']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2015-04,2015-06,"[{'measure': 'Area under the Concentration-Time Curve (AUC)', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.', 'timeFrame': '168 hours'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '168 hours'}]","[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '168 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': '168 hours'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '168 hours'}]",5,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:12.183373,v2_robust,True,True,True,False,False,
NCT01928160,Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib,"A Randomized Open-Label Phase II Trial of Pemetrexed and a Platinum (Carboplatin or Cisplatin) With or Without Erlotinib in Patients With Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations and Acquired Resistance to First-Line EGFR TKIs, Erlotinib or Gefitinib",pemetrexed disodium,"['DDP', 'Paraplatin', 'MTA', 'Paraplat', 'CACP', 'Carboplat', 'erlotinib', 'CBDCA', 'CDDP', 'ALIMTA', 'JM-8', 'pemetrexed disodium', 'CPDD', 'OSI-774', 'cisplatin', 'erlotinib hydrochloride', 'carboplatin', 'CP-358,774', 'LY231514']",19,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Non-small Cell Lung Cancer,"['Recurrent Non-small Cell Lung Cancer', 'Stage IV Non-small Cell Lung Cancer']","['Non-small cell lung cancer, EGFR mutation, erlotinib acquired resistance']",WITHDRAWN,study not accruing,2014-06,2015-03,"[{'measure': 'Progression free survival using the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1', 'description': 'The Kaplan-Meier approach will be used to estimate the time-to-PFS distribution (and median PFS times) for each treatment arm. The stratified log-rank test will be used to compare the PFS distributions between the two treatment arms. The stratified Cox-regression model will be used to estimate the hazard ratio (erlotinib plus chemotherapy vs chemotherapy alone) and corresponding 80% confidence interval (CI).', 'timeFrame': 'From randomization to the first occurrence of disease progression or death from any cause, whichever occurs earlier, assessed up to 1 year'}]","[{'measure': 'Overall survival', 'description': 'The Kaplan-Meier approach will be used. The stratified log-rank test will be used to compare the Overall Survival (OS) distributions between the two treatment arms. The stratified Cox-regression model will be used to estimate the hazard ratio (erlotinib plus chemotherapy vs chemotherapy alone) and corresponding 80% confidence interval (CI).', 'timeFrame': 'From the date of randomization to the date of death from any cause, assessed up to 1 year'}, {'measure': 'Objective response rate defined as partial response (PR) and complete response (CR) using RECIST version 1.1', 'description': ""An estimate of the objective response rate and its 95% CI (Blyth-Still-Casella) will be calculated for each treatment arm. The Mantel-Haenszel chi-squared test stratified according to the factors specified by EGFR activating mutation type (exon 19 deletion vs. exon 21 single point mutation), time to progression on first-line EGFR TKI (≤ 1 year vs. \\> 1 year), and ECOG performance status (0 vs. 1) will be used to compare the response rates between the two treatment arms. An unadjusted Fisher's exact test result will also be provided."", 'timeFrame': 'Up to 1 year'}, {'measure': 'Number of patients with each worst grade toxicity grades 3-5 based on the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4', 'description': 'Safety will be assessed through summaries of Adverse Events (AEs), Serious Adverse Events (SAEs), deaths, grade 3 or 4 AEs, AEs with incidence rates greater than 10% (all grades), AE of grade 3 or 4 with incidence rates greater 2%, and changes in laboratory test results. Verbatim descriptions of AEs will be mapped to Medical Dictionary for Regulatory Activities (MedDRA) thesaurus terms', 'timeFrame': 'Up to 45 days post-treatment'}]",4,18 Years,,ALL,False,Vanderbilt-Ingram Cancer Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:12.183459,v2_robust,True,True,False,True,True,study not accruing
NCT02818920,Neoadjuvant Pembrolizumab,"Pembrolizumab Prior to Surgery for Stage 1B, 2 or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study",Pembrolizumab,"['Pembrolizumab', 'Keytruda']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-small Cell Lung Carcinoma,['Non-small Cell Lung Carcinoma'],"['Pembrolizumab', 'Neoadjuvant', 'Tumor Infiltrating Lymphocytes (TILs)']",ACTIVE_NOT_RECRUITING,,2017-01,2026-03,"[{'measure': 'Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab', 'description': 'A patient who meets the eligibility criteria, has received at least 1 dose of pembrolizumab, and undergone surgery in the window of 29-56 days after initiation of pembrolizumab is considered surgically feasible. All other situations are considered infeasible.', 'timeFrame': '29-56 days after initiation of pembrolizumab'}]",[],1,18 Years,,ALL,False,Neal Ready MD PhD,OTHER,1,35.0,ACTUAL,2025-09-01T16:18:12.183588,v2_robust,True,True,False,False,False,
NCT01999920,Vilazodone for Separation Anxiety Disorder,Vilazodone for Separation Anxiety Disorder,Vilazodone,"['Vilazodone', 'Viibryd (brand name)', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Separation Anxiety Disorder,['Separation Anxiety Disorder'],"['Adult separation anxiety disorder', 'ASAD']",COMPLETED,,2013-12,2017-12-30,"[{'measure': 'Clinical Global Impression-Improvement Scale', 'description': 'Clinical Global Impression-Improvement Scale rating at week 12 A quickly administered and widely used observer rating, with ratings from 1 (very much improved) to 7 (very much worse). ""Responder"" is a score of 1 or 2.', 'timeFrame': 'Up to 12 weeks'}]","[{'measure': 'Change From Baseline Hamilton Rating Scale for Depression 17-item Total Score', 'description': 'This standard scale will be used to assess severity of depression, looking at change in total score from baseline to week 12, rating severity of depression on a scale from 0 (least depression) to 50 (greatest depression).', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Change From Baseline in Attachment Style Questionnaire Score', 'description': 'Measure Description: (15 min) Attachment Style Questionnaire (Feeney at al., 1994) 40 items relating to quality of adult relationships. Questionnaire includes questions concerning Confidence (8 items, minimum score=8, maximum score=48), Discomfort (10 items, minimum score=10, maximum score=60), Relationships as Secondary (7 items, minimum score=7, maximum score=42), Need for Approval (7 items, minimum score=7, maximum score =42), and Preoccupation with Relationships (8 items, minimum score = 8, maximum score=48), each self-rated on a six-point scale, each self-rated from 1 (totally disagree) to 6 (totally agree).', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Change From Baseline in Quality of Life Enjoyment & Satisfaction Questionnaire', 'description': 'Measure Description: (10 min) Quality of Life Enjoyment \\& Satisfaction Questionnaire (Q-LES-Q, Endicott et al, 1993): self-rated assessment of quality of life. 16 items related to life quality, each rated on a score of 1 (very poor) to 5 (very good), with a minimum total score of 16, and a maximum total score of 80.', 'timeFrame': 'Up to 12 weeks'}, {'measure': 'Change From Baseline on Structured Clinical Interview for Separation Anxiety Disorder', 'description': ""The Structured Clinical Interview for Separation Anxiety Disorder was modified for DSM-5. The eight separation anxiety disorder criteria are rated for both childhood (rated at baseline only) and past week time frames, scored as 0 (not at all), 1 (sometimes), 2 (often) or ? (don't recall). In keeping with the DSM-5 guidelines, endorsement of three or more of the eight criterion symptoms (symptoms rated as '2' or 'often') is used as a threshold to determine categorical (yes/no) diagnosis of separation anxiety disorder. Scores on each of the eight items are also summed to produce a continuous measure of separation anxiety symptoms experienced during childhood and adulthood (range for each scale=0-16)."", 'timeFrame': 'Baseline and week 12'}, {'measure': 'Change From Baseline on Adult Separation Anxiety - 27 Scale', 'description': 'Measure Description: (15 min) Adult Separation Anxiety - 27 Scale 27 items pertaining to adult separation anxiety, each self-rated on a four-point scale, 0=best, 3=worse. Minimum Total Score=0 (better); Maximum Total Score = 81 (worse)', 'timeFrame': 'Up to 12 weeks'}]",6,18 Years,60 Years,ALL,False,New York State Psychiatric Institute,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:12.183718,v2_robust,True,True,True,False,False,
NCT06033820,Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL,"A Prospective, Single Arm, Open Label Study to Evaluate the Safety and Efficacy of Zanubrutinib, Lenalidomide With R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-cell Lymphoma.",ZR2-ICE,['ZR2-ICE'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B-cell Lymphoma Recurrent,"['Diffuse Large B-cell Lymphoma Recurrent', 'Diffuse Large B Cell Lymphoma Refractory']","['diffuse large B-cell lymphoma', 'Zanubrutinib', 'Lenalidomide', 'Salvage therapy']",RECRUITING,,2023-10-12,2025-06-30,"[{'measure': 'Objective response rate (ORR)', 'description': 'To evaluate the efficacy in terms of objective response rate including CR and PR rate after three cycles of ZR2-ICE', 'timeFrame': '9 weeks'}]","[{'measure': 'Complete remission rate (CR)', 'description': 'To evaluate the efficacy in terms of Complete Response Rate after three cycles of ZR2-ICE', 'timeFrame': '9 weeks'}, {'measure': 'DOR', 'description': 'Among participants who experience an objective response, DOR is defined as the date of their first objective response (which is subsequently confirmed) to disease progression', 'timeFrame': 'Up to 2 years'}, {'measure': 'Progression-free survival', 'description': 'Progression-free survival is defined as the time from enrolment to progression or death due to any cause. The distribution of PFS will be estimated using the method of Kaplan-Meier.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Overall survival', 'description': 'Overall survival is defined as the time from enrolment to death due to any cause.', 'timeFrame': 'Up to 2 years'}, {'measure': 'Safety Management Study', 'description': 'Incidence of Treatment-Emergent Adverse Events', 'timeFrame': 'Up to 100 days'}]",6,18 Years,75 Years,ALL,False,RenJi Hospital,OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:12.183878,v2_robust,True,True,False,False,True,
NCT01547520,Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy,"Meperidine as the Single Sedative Agent During Esophagogastroduodenoscopy, a Double-blind, Randomized Controlled Study",Meperidine,"['Meperidine', 'normal saline']",2,INTERVENTIONAL,['NA'],,,Esophagogastroduodenoscopy,['Esophagogastroduodenoscopy'],"['meperidine', 'esophagogastroduodenoscopy', 'unsedated', 'minimal sedation']",COMPLETED,,2011-06,2012-02,"[{'measure': 'discomfort score during esophageal intubation', 'description': 'patient self-reported discomfort score during esophageal intubation, assessed with a 0 to 10 visual analog scale (VAS)', 'timeFrame': '9 months'}]","[{'measure': 'patient and endoscopist satisfaction score', 'description': 'patient and endoscopist satisfaction with the procedure, score 0(not satisfied at all)-10 (very satisfied', 'timeFrame': '9 months'}, {'measure': 'patient tolerance of the procedure', 'description': 'patolerace of the EGD, evaluate by the endoscopist, score 0 (best tolerance)-10 (very poor tolerance, the procedure could not be completed)', 'timeFrame': '9 months'}, {'measure': 'endoscopist perception of patient tolerance ,', 'description': 'endoscopist evaluation of patient tolerance during EGD, score 0 (best tolerance)- 10 (worst tolerance, the procedure can not be completed)', 'timeFrame': '9 months'}]",4,20 Years,65 Years,,False,Dalin Tzu Chi General Hospital,OTHER,0,140.0,ACTUAL,2025-09-01T16:18:12.183954,v2_robust,True,True,True,False,False,
NCT00904020,"A Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain","A Prospective, Open-Label, Multicenter Study of the Effectiveness And Safety Of Lidoderm® As Add-On Treatment in Patients With Postherpetic Neuralgia, Diabetic Neuropathy, or Low Back Pain",Lidoderm,"['Lidocaine patach 5%', 'Lidoderm']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postherpetic Neuralgia,"['Postherpetic Neuralgia', 'Diabetic Neuropathy', 'Low Back Pain']",[],COMPLETED,,2002-06,,"[{'measure': 'Average daily pain intensity (Brief Pain Inventory [BPI] Questions 3, 4, 5, and 6)', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}]","[{'measure': 'Pain quality using the Neuropathic Pain Scale (NPS)', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Investigator and Patient Global Impression of Change', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Extent of numbness at the site of pain using the Numbness Questionnaire', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Patient Global Assessment of Pain Relief', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'Safety assessments included Adverse Events (AE), discontinuation due to AEs, physical and neurological examination results, vital signs, clinical laboratory data, sensory testing, numbness testing, and dermal assessments', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'QoL: Pain interference (BPI Question 9)', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}, {'measure': 'QoL: Patient Global Assessment of Patch Satisfaction', 'timeFrame': 'Visits - V2 (Day 0), V3 (Day 7), V4/EOS (Day 14)'}]",8,18 Years,,ALL,False,Endo Pharmaceuticals,INDUSTRY,0,107.0,ACTUAL,2025-09-01T16:18:12.184041,v2_robust,True,True,True,False,True,
NCT04577820,Study to Assess the Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP),Evaluation of Efficacy and Safety of Garetosmab in Japanese Adult Patients With Fibrodysplasia Ossificans Progressiva,garetosmab,"['garetosmab', 'REGN2477']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Fibrodyplasia Ossificans Progressiva (FOP),"['Fibrodyplasia Ossificans Progressiva (FOP)', 'Heterotopic Ossification (HO)']",[],WITHDRAWN,Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned,2021-10-13,2022-10-08,"[{'measure': 'Incidence and severity of treatment-emergent adverse event (TEAEs)', 'timeFrame': 'Through week 28'}, {'measure': 'Number of new HO lesions as assessed by CT', 'timeFrame': 'At week 28'}]","[{'measure': 'Total volume of new HO lesions as assessed by CT', 'timeFrame': 'At week 28'}, {'measure': 'Number of new HO lesions as assessed by positron emission tomography (PET)', 'timeFrame': 'At week 28'}, {'measure': 'Total lesion activity in new HO lesions as assessed by PET', 'timeFrame': 'At week 28'}, {'measure': 'Percent of patients with new HO lesions as assessed by CT', 'timeFrame': 'At week 28'}, {'measure': 'Percent of patients with new HO lesions as assessed by PET', 'timeFrame': 'At week 28'}, {'measure': 'Percent of patients with investigator-assessed flare-ups', 'timeFrame': 'Baseline to week 28'}, {'measure': 'Percent of patients with investigator-assessed flare-ups', 'timeFrame': 'Baseline to week 56'}, {'measure': 'Percent of patients with flare-ups assessed by patient e-diary', 'timeFrame': 'Baseline to week 28'}, {'measure': 'Percent of patients with flare-ups assessed by patient e-diary', 'timeFrame': 'Baseline to week 56'}, {'measure': 'Number of new HO lesions as assessed by CT', 'timeFrame': 'At week 56'}, {'measure': 'Total volume of new HO lesions as assessed by CT', 'timeFrame': 'At week 56'}, {'measure': 'Percent of patients with new HO lesions as assessed by CT', 'timeFrame': 'At week 56'}, {'measure': 'Number of new HO lesions as assessed by PET', 'timeFrame': 'At week 56'}, {'measure': 'Total lesion activity in new HO lesions as assessed by PET', 'timeFrame': 'At week 56'}, {'measure': 'Percent of patients with new HO lesions as assessed by PET', 'timeFrame': 'At week 56'}, {'measure': 'Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Percent change in mean maximum standard uptake volume (SUVmax) of individual active HO site(s) by PET', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Change in total lesion activity by PET', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Change in total lesion activity by PET', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Percent change in total lesion activity by PET', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Percent change in total lesion activity by PET', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Change in the total volume of HO lesions as assessed by CT', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Change in the total volume of HO lesions as assessed by CT', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Percent change in the total volume of HO lesions as assessed by CT', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Percent change in the total volume of HO lesions as assessed by CT', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Change in number of HO lesions as assessed by PET', 'description': 'HO lesions defined as target and new lesions relative to baseline.', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Change in number of HO lesions as assessed by PET', 'description': 'Defined above', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Change in the number of HO lesions detectable by CT', 'description': 'Defined above', 'timeFrame': 'Baseline and week 28'}, {'measure': 'Change in the number of HO lesions detectable by CT', 'description': 'Defined above', 'timeFrame': 'Baseline and week 56'}, {'measure': 'Time-weighted average (standardized area under curve [AUC]) change in daily pain due to FOP, as measured using the daily numeric rating scale (NRS)', 'description': 'The NRS is a categorical rating scale used by patients to rate their pain associated with FOP. Patients will be asked to rate their pain on a scale that ranges from ""0"" (no pain) to ""10"" (worst possible pain).', 'timeFrame': 'Baseline through week 28'}, {'measure': 'Time-weighted average (standardized AUC) change in daily pain due to FOP, as measured using the daily NRS', 'timeFrame': 'Baseline through week 56'}, {'measure': 'Total dosage of glucocorticoids use', 'timeFrame': 'Through week 56'}, {'measure': 'Incidence and severity of TEAEs', 'timeFrame': 'Through week 56'}, {'measure': 'Concentration of total activin A in serum over time', 'timeFrame': 'Through week 56'}, {'measure': 'Pharmacokinetic (Pk) Profile - concentrations of garetosmab in serum over time', 'timeFrame': 'Through week 56'}, {'measure': 'Immunogenicity as measured by Anti-drug antibodies (ADA) to garetosmab over time', 'timeFrame': 'Through week 28'}, {'measure': 'Percent change from baseline in biomarkers of bone formation levels in serum', 'timeFrame': 'Through week 28'}]",41,18 Years,60 Years,ALL,False,Regeneron Pharmaceuticals,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:12.184055,v2_robust,True,True,False,True,True,Phase 2 Study R2477-FOP-1940 has been withdrawn and the next phase of the development program is being planned
NCT03171220,Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors,Single Center Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) Combined With Programmed Cell Death-1（PD-1） Inhibitor in the Treatment of Chinese Patients With Advanced Refractory Solid Tumors,Fludarabine,"['Cyclophosphamide', 'FLU', 'Fludarabine', 'CTX']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Malignant Solid Tumor,['Advanced Malignant Solid Tumor'],"['Neoantigen', 'Neoantigen Reactive T cells (NRTs)', 'PD-1 Inhibitor', 'Advanced Solid Tumor', 'Adoptive Cell Therapy(ACT)', 'PD-1 antibody', 'SHR1210']",UNKNOWN,,2017-06-01,2020-12-31,"[{'measure': 'Number of participants with Adverse Events', 'description': 'using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Response Rate', 'description': 'Response Rate（RR） will be evaluated according Response Evaluation Criteria in Solid Tumors', 'timeFrame': 'At 3, 6 and 12 months'}, {'measure': 'Progression free survival (PFS)', 'description': 'the duration of progression free survival is measured from the time of treatment to the first date that recurrent or progressive disease or for any reason of death is objectively documented.', 'timeFrame': 'At 6,9 and 12 months'}]",3,18 Years,75 Years,ALL,False,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:12.184064,v2_robust,True,True,False,False,True,
NCT03576820,Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department,Intranasal Lidocaine to Treat Pediatric Migraine in the Emergency Department,Lidocaine,"['2% Lidocaine Hydrochloride Solution (20 mg/mL)', '0.9% sodium chloride solution', 'Lidocaine', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Migraine,['Migraine'],"['pediatrics', 'intranasal lidocaine', 'migraine', 'headache', 'emergency department', 'pain']",UNKNOWN,,2018-10-15,2022-12,"[{'measure': 'Change in Pain Score', 'description': 'The numeric rating scale (NRS) will be used to assess subjects\' pain severity. This pain scale is numbered by increments of one, with a minimum score of zero and a maximum score of ten. With zero, as ""no pain"", and ten as ""worst possible pain"". We will compare the change of median pain score from baseline to three discrete time points after study medication administration for the patients who receive intranasal lidocaine compared to placebo. For this study, we will assume a decrease in pain score of 3 or more from baseline to any of the post study medication administration time points to be clinically significant.', 'timeFrame': 'The NRS will be administered prior to study medication administration at baseline. As well as at 5 minutes, 10 minutes, and 20 minutes after study drug administration.'}]","[{'measure': 'The Number of Subjects with Improvement of Associated Symptoms', 'description': 'The presence or absence of nausea, vomiting, photophobia, phonophobia, aura, and avoidance of daily activities will be asked to each subject at baseline. At 20 minutes each subject will be asked to respond ""yes"" or ""no"" if each associated symptom has subjectively improved.', 'timeFrame': 'Prior to study drug administration at baseline and 20 minutes after study drug administration.'}, {'measure': 'The Number of Subjects Who Receive IV Pain Medications', 'description': ""All subjects will be ordered to receive IV metoclopramide. If a subject's pain significantly improved after intranasal drug administration and before IV metoclopramide administration, then metoclopramide will be held, as per discretion of the treating physician. At the end of the study the treating physician will document on the data collection sheet if the subject received IV pain medications."", 'timeFrame': '1 hour'}, {'measure': 'The Number of Subjects with Rebound headache', 'description': 'Each subject will be asked to respond ""yes"" or ""no"" if their headache returned at 1 hour post study drug administration.', 'timeFrame': '1 hour.'}, {'measure': 'The Number of Subjects with Rebound headache after discharge', 'description': 'Each subject will be called within 1 week of discharge and asked to respond ""yes"" or ""no"" if they had rebound headache.', 'timeFrame': '1 week'}, {'measure': 'The Number of Patients that Would Use Their Intranasal Medication the Next Time They Have a Migraine', 'description': 'At the end of the study all subjects will be asked if they would use their intranasal medication the next time they have a migraine', 'timeFrame': '1 hour'}]",6,10 Years,20 Years,ALL,True,New York City Health and Hospitals Corporation,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:12.184142,v2_robust,True,True,False,False,False,
NCT00264082,Assessment of Tartrate-Resistant Acid Phosphatase (TRAP) as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis,"""Tartrate-Resistant Acid Phosphatase as a Bone Resorption Marker in Stage IV Breast Cancer Patients With Bone Metastasis During Zometa Treatment: A Pilot Study""",Zometa(drug),['Zometa(drug)'],1,OBSERVATIONAL,[],,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2004-09,,[],[],0,18 Years,,FEMALE,False,University of Louisville,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:12.184175,v2_robust,False,True,True,False,False,
NCT01216982,Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders,Effects of Omega-3 EPA/DHA for Soldiers at Risk for Mood Disorders: A Mood Resilience Trial,"Lovaza, omega-3 fatty acid ethyl ester","['Placebo, visually identical to Lovaza', 'Omega-3-Acid Ethyl Esters', 'Lovaza, omega-3 fatty acid ethyl ester', 'LOVAZA 1g Soft Gelatin Capsules NDC NO. 65726-425-15', 'Corn oil']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Mood Disorders,"['Mood Disorders', 'Depression', 'Combat Disorders', 'Stress Disorders']","['Mood Disorders', 'Depression', 'Combat Disorders', 'Stress Disorders', 'Fatty Acids, Omega-3', 'Military Personnel', 'Docosahexaenoic Acids/*therapeutic use', 'Eicosapentaenoic Acid/*therapeutic use']",UNKNOWN,,2010-11,2011-06,"[{'measure': 'primary psychometric assessment battery', 'description': 'Specific components include:\n\nZung Depression Scale (ZDS) Zung Anxiety Scale (ZAS) Pittsburgh Sleep Quality Index (PSQI) Epworth Sleepiness Scale (ESS)', 'timeFrame': '3 months'}, {'measure': 'omega-3 fatty acid status', 'description': 'finger-prick blood spot is collected for determination of fatty acid composition and profile.', 'timeFrame': '3 months'}]","[{'measure': 'secondary psychometric assessment battery', 'description': 'This battery will generate index scores in the area of:\n\nMemory, Psychomotor Speed, Reaction Time, Cognitive Flexibility, and Complex Attention. It will also include the Alcohol Use Identification Test (AUdIT). Military-specific components include Post-Deployment Health Assessment (PDHA), Neurobehavioral Symptom Inventory (NSI), Combat Exposure Scale (CES), and parts of the Deployment Risk and Resilience Inventory (edited).', 'timeFrame': '3 months'}]",3,18 Years,55 Years,ALL,True,United States Department of Defense,FED,1,256.0,ESTIMATED,2025-09-01T16:18:12.184189,v2_robust,True,True,False,False,False,
NCT00345982,Augmenting Clozapine With Sertindole - SERCLOZ,Augmenting Clozapine With Sertindole - a Double Blinded Randomized Placebo Study,Serdolect,"['sertindole', 'Serdolect', 'placebo']",3,INTERVENTIONAL,['NA'],,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'Treatment-resistant', 'sertindole', 'clozapine']",COMPLETED,,2006-09,2010-09,"[{'measure': 'PANSS total score', 'timeFrame': '12 weeks'}]","[{'measure': 'GAF', 'timeFrame': '12 weeks'}, {'measure': 'WHOQOL-BREF', 'timeFrame': '12 weeks'}, {'measure': 'CGI', 'timeFrame': '12 weeks'}, {'measure': 'DAI', 'timeFrame': '12 weeks'}, {'measure': 'Cognitive test', 'timeFrame': '12 weeks'}, {'measure': 'Fasting glucose', 'timeFrame': '12 weeks'}, {'measure': 'Lipids', 'timeFrame': '12 weeks'}, {'measure': 'Hb1Ac', 'timeFrame': '12 weeks'}]",9,18 Years,65 Years,ALL,False,University of Aarhus,OTHER,1,50.0,ACTUAL,2025-09-01T16:18:12.184268,v2_robust,True,True,True,False,False,
NCT03291782,"D-0120 Safety and PK/PD, Food Effect Study in Healthy Volunteers","A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, and Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics; Including an Open-label Cohort to Determine the Effect of Food on the Pharmacokinetics of D-0120-NA Tablet in Healthy Volunteers in the United States",D-0120,['D-0120'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Gout,['Gout'],[],COMPLETED,,2017-09-13,2018-08-06,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'Adverse Events and changes of Laboratory, Electrocardiogram, and Vital Signs', 'timeFrame': '2 weeks'}]","[{'measure': 'Pharmacokinetic: area under the plasma concentration versus time curve (AUC)', 'description': 'AUC: area under the plasma concentration versus time curve for D-0120', 'timeFrame': 'Day-1 through 3'}, {'measure': 'Pharmacokinetic: maximum plasma drug concentration (Cmax)', 'description': 'Cmax: maximum plasma drug concentration of D-0120', 'timeFrame': 'Day-1 through 3'}, {'measure': 'Pharmacokinetic: Time to reach the Cmax (Tmax)', 'description': 'Tmax: Time to reach the Cmax of D-0120', 'timeFrame': 'Day-1 through 3'}, {'measure': 'Pharmacokinetic: Apparent terminal half-life (t1/2)', 'description': 't1/2: apparent terminal half-life of D-0120', 'timeFrame': 'Day-1 through 3'}, {'measure': 'Pharmacokinetic: Apparent oral clearance (CL/F)', 'description': 'CL/F: Apparent oral clearance of D-0120', 'timeFrame': 'Day-1 through 3'}, {'measure': 'Pharmacokinetic: Apparent volume of distribution (Vz/F)', 'description': 'Vz/F: Apparent volume of distribution of D-0120', 'timeFrame': 'Day-1 through 3'}, {'measure': 'PD profile of D-0120 from plasma and urine', 'description': 'Profile in terms of Serum uric acid and creatinine; Urine uric acid and creatinine. These parameters will be combined to report fractional excretion of uric acid (FEUa %)', 'timeFrame': 'Day-1 through 3'}]",8,18 Years,60 Years,ALL,True,"InventisBio Co., Ltd",INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:12.184303,v2_robust,True,True,True,False,True,
NCT03238482,Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI),Pharmacokinetic Study Comparing Salmeterol/Fluticasone Easyhaler 50/250 µg/Dose Products and Seretide Diskus 50/250 µg/Dose in Healthy Subjects,salmeterol-fluticasone,['salmeterol-fluticasone'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Asthma,['Asthma'],[],COMPLETED,,2017-08-16,2017-12-19,"[{'measure': 'Peak plasma concentration (Cmax) of salmeterol', 'description': 'Cmax of salmeterol', 'timeFrame': 'between 0-34 hours after dosing'}, {'measure': 'Peak plasma concentration (Cmax) of fluticasone propionate', 'description': 'Cmax of fluticasone propionate', 'timeFrame': 'between 0-34 hours after dosing'}, {'measure': 'Area under the plasma concentration versus time curve (AUC) of salmeterol', 'description': 'AUC from time zero to the last sample with the quantifiable concentration', 'timeFrame': '0-34 hours after dosing'}, {'measure': 'Area under the plasma concentration versus time curve (AUC) of fluticasone propionate', 'description': 'AUC from time zero to the last sample with the quantifiable concentration', 'timeFrame': '0-34 hours after dosing'}, {'measure': 'Truncated area under the plasma concentration versus time curve (AUC) of salmeterol', 'description': 'AUC from time zero to 30 min after study treatment administration', 'timeFrame': '0-30 minutes after dosing'}]","[{'measure': 'Area under the plasma concentration versus time curve (AUC) of salmeterol', 'description': 'AUC from time zero to infinity', 'timeFrame': '0-34 hours after dosing and extrapolation'}, {'measure': 'Area under the plasma concentration versus time curve (AUC) of fluticasone propionate', 'description': 'AUC from time zero to infinity', 'timeFrame': '0-34 hours after dosing and extrapolation'}, {'measure': 'The time to reach the maximum concentration (tmax) of salmeterol', 'description': 'tmax of salmeterol', 'timeFrame': '0-34 hours after dosing'}, {'measure': 'The time to reach the maximum concentration (tmax) of fluticasone propionate', 'description': 'tmax of fluticasone propionate', 'timeFrame': '0-34 hours after dosing'}, {'measure': 'The terminal elimination half-life (t1/2) of salmeterol', 'description': 't1/2 of salmeterol', 'timeFrame': '0-34 hours after dosing'}, {'measure': 'The terminal elimination half-life (t1/2) of fluticasone propionate', 'description': 't1/2 of fluticasone propionate', 'timeFrame': '0-34 hours after dosing'}]",11,18 Years,60 Years,ALL,True,"Orion Corporation, Orion Pharma",INDUSTRY,0,64.0,ACTUAL,2025-09-01T16:18:12.184339,v2_robust,True,True,True,False,False,
NCT00501982,Efficacy of Combining Prophylactic Curosurf With Early Nasal CPAP in Delivery Room: the Curpap Study,"An International, Open, Randomized, Controlled Study to Evaluate the Efficacy of Combining Prophylactic Curosurf® With Early Nasal CPAP Versus Early Nasal CPAP Alone in Very Preterm Infants at Risk of Respiratory Distress Syndrome",Poractant alfa (Curosurf®),['Poractant alfa (Curosurf®)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Respiratory Distress Syndrome, Newborn","['Respiratory Distress Syndrome, Newborn']","['surfactant', 'RDS', 'nCPAP', 'Mechanical Ventilation', 'Premature Infants', 'Neonatal Respiratory Distress Syndrome (nRDS)']",COMPLETED,,2007-03,2008-05,"[{'measure': 'Need for MV', 'timeFrame': 'Within the first 5 days of life'}]","[{'measure': 'Incidence of BPD and other complications of prematurity. Lenght of hospitalization. Clinical status until discharge home', 'timeFrame': 'entire study'}]",2,25 Weeks,28 Weeks,ALL,False,Chiesi Farmaceutici S.p.A.,INDUSTRY,0,208.0,ACTUAL,2025-09-01T16:18:12.184363,v2_robust,True,True,True,False,False,
NCT04810182,Regorafenib in Patients With Relapsed Glioblastoma. IOV-GB-1-2020 REGOMA-OSS,"Regorafenib in Relapsed Glioblastoma. An Observational, Multicentric and Prospective Study. IOV-GB-1-2020 REGOMA-OSS",Regorafenib 40 MG Oral Tablet [STIVARGA],['Regorafenib 40 MG Oral Tablet [STIVARGA]'],1,OBSERVATIONAL,[],,,Glioblastoma Multiforme,['Glioblastoma Multiforme'],[],COMPLETED,,2020-09-10,2023-12-31,"[{'measure': 'Overall Survival (OS)', 'description': 'Overall Survival is defined as the time from date of enrolment to the date of death due to any cause', 'timeFrame': 'From the enrolment date to the date of death, for any cause, or to the last follow-up, assessed up to 18 months'}]","[{'measure': 'Progression free survival (PFS)', 'description': 'from the date of enrolment to the date of disease progression determined using RANO criteria or to the date of death, whichever occurs first.', 'timeFrame': 'From the date of enrolment to the date of disease progression or to the date of death, assessed up to 18 months'}, {'measure': 'Objective response rate (ORR)', 'description': 'As percentage of patients achieving a complete response plus partial response', 'timeFrame': 'Approximately 24 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'As percentage of patients achieving a complete response plus partial response plus stable disease.', 'timeFrame': 'Approximately 24 months'}, {'measure': 'Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events-CTCAE v5.0)', 'description': 'Toxicity during the treatment will be recorded and graded according to the NCICommon Terminology Criteria for Adverse Events (CTCAE) v.4.. , related to severity of the adverse event from Grade 1 to Grade 5', 'timeFrame': 'From the start of Regorafenib treatment up to 30 days after the end of treatment'}]",5,18 Years,70 Years,ALL,False,Istituto Oncologico Veneto IRCCS,OTHER,0,192.0,ACTUAL,2025-09-01T16:18:12.184398,v2_robust,False,True,True,False,True,
NCT00349882,Effects of Contact Lens Care Regimens on the Corneal Epithelium,Effects of Contact Lens Care Regimens on the Corneal Epithelium,Marketed multipurpose disinfection regimen,['Marketed multipurpose disinfection regimen'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Myopia,['Myopia'],[],COMPLETED,,2005-06,,"[{'measure': 'The primary outcome measure of this study is to investigate the effects of two'}, {'measure': 'different contact lens care solutions on the cornea.'}]","[{'measure': 'The secondary outcome measure of this study is to compare the subjective and'}, {'measure': 'objective responses between two different contact lens care solutions.'}]",4,18 Years,,ALL,,University of Waterloo,OTHER,1,30.0,,2025-09-01T16:18:12.184459,v2_robust,True,True,True,False,False,
NCT00387582,Efficacy Study of Lucentis in the Treatment of Diabetic Macular Edema,"Lucentis in the Treatment of Macular Edema - A Phase II, Single Center, Randomized Study to Evaluate the Efficacy of Ranibizumab Versus Focal Laser Treatment in Subjects With Diabetic Macular Edema",Ranibizumab (Lucentis),"['Ranibizumab (Lucentis)', 'NDC # 50242-0080-01, Brand Name is Lucentis']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetic Retinopathy,"['Diabetic Retinopathy', 'Diabetic Macular Edema']","['Diabetes', 'Macular Edema', 'Diabetic Retinopathy', 'Lucentis', 'Ranibizumab']",COMPLETED,,2006-07,2009-02,"[{'measure': 'Prevention of vision loss at one year as evidenced by ETDRS visual acuity.', 'timeFrame': '6 and 12 months'}]","[{'measure': 'Reduction in retinal thickening based on Optical Coherence Tomography.', 'timeFrame': '6 and 12 months'}]",2,18 Years,,ALL,False,Rocky Mountain Retina Consultants,OTHER,1,49.0,ACTUAL,2025-09-01T16:18:12.184471,v2_robust,True,True,True,False,False,
NCT03592082,Use of Bismuth Subsalicylate in Clostridium Difficile Colitis,Can Use of Bismuth Subsalicylate in Clostridium Difficile Patients Decrease the Length of Stay and Time to Resolution of Symptoms,Bismuth Subsalicylate,"['standard antibiotic therapy', 'Bismuth Subsalicylate']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Clostridium Difficile Infection,['Clostridium Difficile Infection'],[],WITHDRAWN,Investigator left institution,2018-03-01,2018-07-01,"[{'measure': 'Length of stay', 'description': 'number of days hospitalized after the initiation of treatment for CDiff', 'timeFrame': '70 days (study period = 14 days of antibiotic treatment plus 8 weeks/56 days post treament completion)'}]","[{'measure': 'Time to resolution of symptoms', 'description': 'Resolution of symptoms is defined as having \\< 3 diarrheal episodes in 24 hours', 'timeFrame': '70 days'}, {'measure': 'CDiff Recurrence', 'description': 'Recurrence is defined as the reappearance of symptoms within 8 weeks of the completion of antibiotic treatment and the resolution of initial symptoms', 'timeFrame': '70 days'}]",3,18 Years,,ALL,False,Bassett Healthcare,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:12.184479,v2_robust,True,True,False,True,False,Investigator left institution
NCT04161482,"An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability","An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability",Furosemide 80 mg (8 mg/mL),['Furosemide 80 mg (8 mg/mL)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2019-12-02,2020-06-26,"[{'measure': 'Infusion Site Pain (11 Point Pain Scale)', 'description': 'Assessment of pain will be conducted upon placement of the subcutaneous (SC) needle, upon activation of SC infusion and periodically during the infusion and post-infusion completion for up to 8 hours after the start of the infusion using a standardized 11 point pain scale. Score will range from 0 to 10, where zero is equivalent to no pain and 10 is equivalent to the worst possible pain.', 'timeFrame': '8 hours'}]","[{'measure': 'Safety (Adverse Events)', 'description': 'Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) will be assessed from the start of study drug administration through 24-48 hours after the start of the infusion.', 'timeFrame': 'Hours 1-8 and at the 24-48 hour follow up visit.'}]",2,45 Years,80 Years,ALL,True,"scPharmaceuticals, Inc.",INDUSTRY,2,39.0,ACTUAL,2025-09-01T16:18:12.184492,v2_robust,True,True,True,False,True,
NCT02581982,Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer,Single-Arm Phase II Combination Study of Low-Dose Paclitaxel With Pembrolizumab in Platinum-Refractory Urothelial Carcinoma,Paclitaxel,"['Anzatax', 'Paclitaxel', 'Asotax', 'Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Transitional Cell Carcinoma,['Transitional Cell Carcinoma'],"['Urothelial cancer', 'Bladder cancer', 'Immunotherapy', 'Paclitaxel']",COMPLETED,,2016-04-06,2022-12-19,"[{'measure': 'Overall Response Rate', 'description': 'The overall response rate will be performed in all patients that are evaluable for efficacy and will have one interim analysis. Overall response is complete response (CR) = Disappearance of all target lesions (PR) = at least a 30% decrease in sum of diameters, taking as reference the baseline sum diameters; stable disease (SD) = neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters while on study; and progressive disease (PD) = at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started.', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Number of Adverse Events Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0', 'description': 'All adverse events will be tabulated and presented by preferred term and/or system organ class and grade. All deaths and serious adverse events will be tabulated.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Progression Free Survival (Kaplan Meier Method)', 'description': 'The Kaplan Meier methods will be used to estimate progression free survival. The 6-month PFS will be compared to historical rates using a chi-square test. Progressive disease is at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study based on all target lesions recorded since the treatment started. The sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression)', 'timeFrame': 'At 6 months'}]",3,18 Years,,ALL,False,Wake Forest University Health Sciences,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:12.184652,v2_robust,True,True,True,False,True,
NCT02380924,Recovery and Survival of EryDex in Non-patient Volunteers,Determination of the in Vivo Recovery and Survival of EryDex (Dexamethasone Sodium Phosphate Encapsulated in Autologous Erythrocytes) in Non-patient Volunteers,DSP loaded RBC using EryDex System,"['EryDex System', 'DSP loaded RBC using EryDex System', 'Sham treated RBC using the EryDex System']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['subjects'],COMPLETED,,2015-01,2015-06,"[{'measure': '24-hour post transfusion recovery of infused autologous RBCs', 'description': 'The 24-hour recovery of autologous RBCs loaded with DSP or sham using the EDS will be greater than 75% with 95% confidence. For RBC kinetics and recovery will be reported as mean, 2-sided 95% CI on the mean, standard deviation, minimum and maximum.', 'timeFrame': '24 hours'}, {'measure': 'Long-term survival of infused autologous RBCs assessed with T50 (Time to disappearance of 50% of the labelled red blood cells from the circulation)', 'description': 'For RBC T50 will be reported as mean, 2-sided 95% CI on the mean, standard deviation, minimum and maximum.', 'timeFrame': 'up to 49 days'}]","[{'measure': 'Special laboratory tests', 'description': 'pH at 37°C, hemolysis, ATP, 2,3-DPG, extracellular potassium, extracellular glucose, extracellular lactate, packed cell volume, RBC morphology and RBC indices. In particular free haemoglobin and and hematuria will be assessed on all defined time points.The measure is a composite outcome', 'timeFrame': 'up to 49 days'}]",3,18 Years,55 Years,ALL,True,Quince Therapeutics S.p.A.,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:12.184746,v2_robust,True,True,True,False,False,
NCT05772624,Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma,Safety and Efficacy Evaluation of Low-dose Nivolumab in Combination With AVD as Frontline Therapy for Classic Hodgkin's Lymphoma,low dose nivolumab in combination with AVD,['low dose nivolumab in combination with AVD'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Safety Issues,"['Safety Issues', 'Efficacy, Self']","['Nivolumab', 'lowdose nivolumab', 'NAVD', ""hodgkin's lymphoma""]",UNKNOWN,,2023-02-13,2024-06-01,"[{'measure': 'To determine general response', 'description': 'To determine patients achieving either a complete response or a partial response as demonstrated with PET C/T evaluation.', 'timeFrame': 'Six weeks after completion of therapy.'}]","[{'measure': 'Response duration', 'description': 'To evaluate the duration of the response achieved with the therapy.', 'timeFrame': 'up to 2 years'}, {'measure': 'Adverse effects', 'description': 'To record the side effects associated with the treatment as stablished by the international guidelines for chemotherapy and immunotherapy.', 'timeFrame': 'through the study completion and up to 6 months'}]",3,16 Years,,ALL,False,Hospital Universitario Dr. Jose E. Gonzalez,OTHER,0,16.0,ESTIMATED,2025-09-01T16:18:12.184864,v2_robust,True,True,False,False,True,
NCT05806723,Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men,Effects of High Intensity Statin Therapy on Steroid Hormones and Vitamin D in Type 2 Diabetic Men,Atorvastatin 40 Mg Oral Tablet,['Atorvastatin 40 Mg Oral Tablet'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2', 'Dyslipidemia Associated With Type II Diabetes Mellitus', 'Statin Adverse Reaction', 'Hypogonadism, Male', 'Adrenal Insufficiency', 'Vitamin D Deficiency']","['type 2 diabetes', 'statin', 'testosterone', 'cortisol', 'vitamin D', 'DHEAS']",COMPLETED,,2021-03-01,2022-09-15,"[{'measure': 'change in testosterone level after atorvastatin treatment', 'description': 'decrease in testosterone level', 'timeFrame': 'six months'}]","[{'measure': 'change in cortisol level after atorvastatin treatment', 'description': 'decrease in cortisol', 'timeFrame': 'six months'}, {'measure': 'change in DHEAS levels after atorvastatin treatment', 'description': 'decrease in DHEAS', 'timeFrame': 'six months'}]",3,40 Years,65 Years,MALE,False,Hopital La Rabta,OTHER,0,104.0,ACTUAL,2025-09-01T16:18:12.184979,v2_robust,True,True,True,False,False,
NCT01905423,Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis,Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis,Albendazole (annual),"['Albendazole (annual)', 'Albenza (Albendazole, also known as ALB)', 'Albendazole (semiannual)', 'Diethylcarbamazine (semiannual)', 'Diethylcarbamazine, Also known as DEC, (N, N-diethyl-4-methyl-1-piperazine carboxamide dihydrogen citrate). ATC Code: P02CB02 QP52AH02', 'Diethylcarbamazine (annual)']",6,OBSERVATIONAL,[],,,Lymphatic Filariasis,"['Lymphatic Filariasis', 'Soil Transmitted Helminth Infections']","['Filariasis', 'Albendazole', 'Diethylcarbamazine', 'STH Soil Transmitted Helminths', 'MDA Mass Drug Administration']",COMPLETED,,2011-05,2015-12,"[{'measure': 'Prevalence of Microfilaria in Blood as Determined by Microscopy of Participant Blood', 'description': 'Microfilariae (filarial parasites) will be detected in blood smears by microscopy. Samples will be collected in annual and semiannual community surveys. Prevalence rates (a measure of the disease rates in the population sampled) are expressed as % positive for microfilaremia (having microfilaria in the blood).', 'timeFrame': '3 years'}]","[{'measure': 'Prevalence of Positive Brugia Rapid Antifilarial Antibody Tests', 'description': 'This outcome is reported as the frequency of participants with positive Brugia Rapid antifilarial antibody tests. Data was only collected at baseline and at year 3 for this outcome measure and no antibody data was collected for the Pekalongan study sites.', 'timeFrame': '3 years'}, {'measure': 'Prevalence of Circulating Filarial Antigen in Blood as Determined by ICT Card Test', 'description': 'Prevalence of filarial antigenemia (detected with the Binax Filariasis Now card test ""ICT"" card test) among the population surveyed. Prevalence data are expressed as %.', 'timeFrame': '3 years'}, {'measure': 'Prevalence of Ascaris Infection', 'description': 'Prevalence of Ascaris infection is defined by the number of participants with any Ascaris worm eggs present in their stool sample as analyzed with microscopy.', 'timeFrame': '2 Years'}, {'measure': 'Prevalence of Hookworm Infection', 'description': 'Prevalence of hookworm infection is defined by the number of participants with any hookworm eggs present in their stool sample as analyzed with microscopy.', 'timeFrame': '2 years'}, {'measure': 'Prevalence of Trichuris Infection', 'description': 'Prevalence of trichuris infection is defined by the number of participants with any trichuris worm eggs present in their stool sample as analyzed with microscopy.', 'timeFrame': '2 years'}]",6,5 Years,,ALL,True,Washington University School of Medicine,OTHER,0,17108.0,ACTUAL,2025-09-01T16:18:12.184991,v2_robust,False,True,True,False,False,
NCT04688723,Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI,RE-DUAL PCI Real Life Registry Dual Therapy With Dabigatran/Ticagrelor Versus Dual Therapy With Dabigatran/Clopidogrel in ACS Patients With Indication for NOAC Undergoing PCI,Dabigatran + Ticagrelor,"['Dabigatran + Ticagrelor', 'Dabigatran + clopidogrel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Artery Disease,"['Coronary Artery Disease', 'Myocardial Ischemia', 'Myocardial Infarction', 'Atrial Fibrillation']",[],UNKNOWN,,2020-12-23,2023-07-01,"[{'measure': 'Bleeding', 'description': 'Bleeding defined as BARC bleeding score ≥2', 'timeFrame': '12 months'}]","[{'measure': 'Myocardial Infarction', 'description': 'Myocardial Infarction', 'timeFrame': '12 months'}, {'measure': 'Cerebrovascular accident', 'description': 'Cerebrovascular accident, ischemic of haemorrhagic', 'timeFrame': '12 months'}, {'measure': 'Systemic Embolic Complications', 'description': 'Systemic Embolic Complications', 'timeFrame': '12 months'}, {'measure': 'Death', 'description': 'Death', 'timeFrame': '12 months'}, {'measure': 'Combined endpoint of ischemic events', 'description': 'All secondary outcomes combined into one endpoint', 'timeFrame': '12 months'}]",6,18 Years,99 Years,ALL,False,Zuyderland Medisch Centrum,OTHER,1,1000.0,ESTIMATED,2025-09-01T16:18:12.185181,v2_robust,True,True,False,False,False,
NCT05115123,Duloxetine for Postoperative Pain of Laparoscopic Cholecystectomy,Duloxetine Efficacy and Tolerability for Pain Management in Patients Undergoing Laparoscopic Cholecystectomy,Duloxetine,"['Placebo', 'Duloxetine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Pain, Postoperative","['Pain, Postoperative']",[],COMPLETED,,2022-03-02,2022-04-30,"[{'measure': 'Change in postoperative pain between the two groups using visual analogue score (VAS)', 'description': 'pain will be assessed using visual analogue score (VAS) 0-100 mm (0 indicated no pain, 100 denoted the most severe pain)', 'timeFrame': '24 Hours postoperative'}]","[{'measure': 'Postoperative nausea and vomiting (PONV)', 'description': 'will be assessed using PONV scale a 4-point scale: none (0): no nausea, vomiting, and retching; mild (1): happened once; moderate (2): happened 2-3 times; and severe (3): continuous or more than three times.', 'timeFrame': '24 Hours postoperative'}]",2,18 Years,75 Years,ALL,False,Mansoura University,OTHER,1,60.0,ACTUAL,2025-09-01T16:18:12.185321,v2_robust,True,True,True,False,False,
NCT01940523,Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical,Randomized Controlled Trial of Tranexamic Acid in Total Knee Arthroplasty: Intravenous vs. Topical,Topical Tranexamic Acid,"['Topical Tranexamic Acid', 'Intravenous Tranexamic Acid']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Osteoarthritis,['Osteoarthritis'],"['total knee arthroplasty', 'total knee replacement', 'tranexamic acid', 'osteoarthritis', 'degenerative joint disease']",COMPLETED,,2013-05,2017-05-16,"[{'measure': 'Total Blood Loss', 'description': ""The amount of blood lost during surgery is the primary outcome measure. Blood loss is determineusing an equation that calculates the patient's blood volume based on their height and weight, then multiplies the patient's blood volume by the change in their hematocrit after surgery compared to before surgery."", 'timeFrame': 'during surgery'}]","[{'measure': 'Drain Output', 'description': 'The amount of blood collected by a drain attached to the knee is measured 24 hours after surgery.', 'timeFrame': 'from end of surgery to 24 hours postoperatively'}, {'measure': 'The Number Patients Requiring a Transfusion', 'description': ""TThe number Patients requiring a transfusion over the course of the patient's hospital stay."", 'timeFrame': 'over course of hospital stay (averaging three days)'}]",3,18 Years,100 Years,ALL,False,"Hospital for Special Surgery, New York",OTHER,1,640.0,ACTUAL,2025-09-01T16:18:12.185333,v2_robust,True,True,True,False,False,
NCT00532623,Phase II Study of Gemcitabine/Vinorelbine vs Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer,A Phase II Study of Gemcitabine in Combination With Vinorelbine vs. Sequential Gemcitabine Followed by Vinorelbine in Metastatic Breast Cancer,Gemcitabine plus Vinorelbine,"['Gemcitabine plus Vinorelbine', 'Gemzar', 'Sequential', 'Navelbine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],[],COMPLETED,,2004-05,2006-10,"[{'measure': 'overall response rate', 'timeFrame': '3 years'}]",[],1,18 Years,,FEMALE,False,"National Cancer Center, Korea",OTHER_GOV,0,82.0,ACTUAL,2025-09-01T16:18:12.185349,v2_robust,True,True,True,False,False,
NCT05823623,Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of HER2-positive Metastatic Breast Cancer,A Phase II Single-arm Clinical Trial of Inetetamab Combined With Pyrotinib Plus Oral Vinorelbine for the Treatment of Patients With HER2-positive Metastatic Breast Cancer,Inetetamab,"['Oral Vinorelbine Tartrate', 'Pyrotinib', 'Inetetamab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],RECRUITING,,2022-02-13,2025-12,"[{'measure': 'Progression Free Survival，PFS', 'description': 'The time from the beginning of treatment to the progression or death of the patient', 'timeFrame': '2 years'}]","[{'measure': 'overall survival，OS', 'description': 'The time from the beginning of treatment to the death of the patient', 'timeFrame': '4 years'}, {'measure': 'Objective Response Rate，ORR', 'description': 'The percentage of participants whose best overall response, according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1, is either complete response (CR) or partial response (PR)', 'timeFrame': '2 year'}, {'measure': 'Clinical Benefit Rate，CBR', 'description': 'the percentage of participants whose best overall response, is either CR, PR or stable disease (SD) lasting for at least 24 weeks', 'timeFrame': '2 year'}, {'measure': 'adverse events', 'description': 'The probability and severity of adverse reactions related to the treatment were assessed by CTCAE (National Cancer Institute Common Terminology Criteria for Adverse Events) v5.0.', 'timeFrame': '2 years'}]",5,18 Years,85 Years,FEMALE,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:12.185356,v2_robust,True,True,False,False,True,
NCT04259359,Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure,Predominant Sensitizations to Single Bee Venom Allergens as a Risk Factor for Therapy Failure,Insect Venom,['Insect Venom'],1,OBSERVATIONAL,[],,,Bee Venom Allergy,['Bee Venom Allergy'],[],RECRUITING,,2019-05-02,2026-03,"[{'measure': 'The primary objective of the study is to evaluate whether predominant sensitization to Api m 10 is a risk factor for treatment failure.', 'description': 'A sensitization is considered predominant if the proportion of specific IgE to a single venom allergen is at least 65% of the specific IgE to the venom preparations.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}]","[{'measure': 'To evaluate if predominant sensitization to either Api m 1, Api m 2, Api m 3 or Api m 5 is a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}, {'measure': 'To evaluate if low immunoglobulin G4 (IgG4) levels to bee venom or to Api m 1, Api m 2, Api m 3, Api m 5, or Api m 10 after VIT is a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}, {'measure': 'To evaluate if systemic side effects are a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}, {'measure': 'To evaluate if antihypertensive medication is a risk factor for treatment failure.', 'timeFrame': 'depends on the protocol used for VIT and the date of the sting challenge, a maximum of about 6 months if sting challenge is performed right after reaching the maintenance dose'}]",5,18 Years,70 Years,ALL,False,Medical University of Graz,OTHER,0,266.0,ESTIMATED,2025-09-01T16:18:12.185391,v2_robust,False,True,False,False,False,
NCT01130259,"An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer","An Open-Label, Expanded Access Protocol of Iniparib in Combination With Gemcitabine/Carboplatin in Patients With ER-, PR-, and HER2-Negative Metastatic Breast Cancer",iniparib,"['iniparib', 'BSI-201']",2,EXPANDED_ACCESS,[],,,Breast Cancer,['Breast Cancer'],"['mTNBC', 'triple negative breast cancer', 'metastatic triple negative breast cancer', 'metastatic breast cancer that is ER-, PR-, and HER2-negative']",NO_LONGER_AVAILABLE,,,,[],[],0,18 Years,,FEMALE,,Sanofi,INDUSTRY,0,,,2025-09-01T16:18:12.185483,v2_robust,False,True,False,False,False,
NCT04926259,Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders,Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders,18F-T807,['18F-T807'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Neurodegenerative Disorders,['Neurodegenerative Disorders'],[],UNKNOWN,,2021-11-01,2024-12-01,"[{'measure': 'standardized uptake value ratio (SUVR)', 'description': 'the ratio of radioactivity in a cerebral region to that in the cerebellum as a reference', 'timeFrame': 'From right after tracer injection to 2-hours post-injection'}, {'measure': 'Aβ42 in CSF', 'description': 'Aβ42 (amyloid beta isoform 42) is significantly lower in the cerebrospinal fluid of patients with neurodegenerative diseases and is one of the biomarkers used clinically to diagnose neurodegenerative diseases', 'timeFrame': 'Within 2 hours prior to tracer injection'}, {'measure': 't-tau in CSF', 'description': 't-tau (total tau) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration', 'timeFrame': 'Within 2 hours prior to tracer injection'}, {'measure': 'p-tau in CSF', 'description': 'p-tau (tau phosphorylated at Thr-181) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration', 'timeFrame': 'Within 2 hours prior to tracer injection'}, {'measure': 'NfL in CSF', 'description': 'NfL (neurofilament light chain) is significantly increased in the cerebrospinal fluid of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration', 'timeFrame': 'Within 2 hours prior to tracer injection'}, {'measure': 'NfL in the blood', 'description': 'NfL is significantly increased in the blood of patients with neurodegeneration and is one of the biomarkers used clinically to diagnose neurodegeneration', 'timeFrame': 'Within 2 hours prior to tracer injection'}]",[],6,18 Years,90 Years,ALL,False,First Affiliated Hospital of Fujian Medical University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:12.185495,v2_robust,True,True,False,False,False,
NCT06657859,Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients,"A Phase 2, Open-Label Extension Study to Assess the Safety and Efficacy of GLM101 Administered Intravenously to Participants With PMM2-CDG",GLM101,['GLM101'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Pmm2-CDG,"['Pmm2-CDG', 'Phosphomannomutase 2 Deficiency']","['GLM101', 'Pmm2', 'CDG', 'CDG 1a']",ENROLLING_BY_INVITATION,,2024-09-30,2029-10,"[{'measure': 'Evaluate long-term safety', 'description': 'Number of participants with treatment related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0', 'timeFrame': 'From enrollment to end of treatment up to 4 years'}]","[{'measure': 'Evaluate changes in ataxia using International Cooperative Ataxia Rating Scale (ICARS)', 'description': 'The scale is scored out of 100 with 19 items and 4 subscales of postural and gait disturbances, limb ataxia, dysarthria, and oculomotor disorders. Higher scores indicate higher levels of impairment.', 'timeFrame': 'From enrollment, at 3 months, 6 months and annually to end of treatment up to 4 years'}, {'measure': 'Maximum observed plasma concentration (Cmax)', 'description': 'Assessment of the pharmacokinetics (PK) of GLM101', 'timeFrame': 'From enrollment to end of treatment up to 4 years'}, {'measure': 'Time to maximum observed plasma concentration (Tmax)', 'description': 'Assessment pharmacokinetics (PK) of GLM101', 'timeFrame': 'From enrollment to end of treatment up to 4 years'}, {'measure': 'Area under the plasma concentration vs. time curve (AUC)', 'description': 'Assessment of the pharmacokinetics (PK) of GLM101', 'timeFrame': 'From enrollment to end of treatment up to 4 years'}]",5,2 Years,65 Years,ALL,False,"Glycomine, Inc.",INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:12.185519,v2_robust,True,True,False,False,True,
NCT00103259,Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck,"Phase II Two Arm Trial of the Proteasome Inhibitor, PS-341 (Velcade TM) in Combination With Irinotecan or PS-341 Alone Followed by the Addition of Irinotecan at Time of Progression in Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",bortezomib,"['irinotecan hydrochloride', 'VELCADE', 'bortezomib', 'LDP 341', 'MLN341', 'CPT-11', 'irinotecan', 'U-101440E', 'Camptosar', 'Campto']",10,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Squamous Cell Carcinoma of the Hypopharynx,"['Recurrent Squamous Cell Carcinoma of the Hypopharynx', 'Recurrent Squamous Cell Carcinoma of the Larynx', 'Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Recurrent Squamous Cell Carcinoma of the Nasopharynx', 'Recurrent Squamous Cell Carcinoma of the Oropharynx', 'Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity', 'Recurrent Verrucous Carcinoma of the Larynx', 'Recurrent Verrucous Carcinoma of the Oral Cavity', 'Stage IV Squamous Cell Carcinoma of the Hypopharynx', 'Stage IV Squamous Cell Carcinoma of the Larynx', 'Stage IV Squamous Cell Carcinoma of the Nasopharynx', 'Stage IV Verrucous Carcinoma of the Larynx', 'Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage IVA Squamous Cell Carcinoma of the Oropharynx', 'Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity', 'Stage IVA Verrucous Carcinoma of the Oral Cavity', 'Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage IVB Squamous Cell Carcinoma of the Oropharynx', 'Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity', 'Stage IVB Verrucous Carcinoma of the Oral Cavity', 'Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage IVC Squamous Cell Carcinoma of the Oropharynx', 'Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity', 'Stage IVC Verrucous Carcinoma of the Oral Cavity', 'Tongue Cancer']",[],COMPLETED,,2005-07,2011-11,"[{'measure': 'Response Rate on Step 1', 'description': 'Tumor response was evaluated via Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and response rate was defined as the proportion of patients with a complete response or partial response among all eligible and treated patients. Complete response was defined as disappearance of all tumor lesions. Partial response was defined as at least a 30% decrease in the sum of the longest diameters of target lesions.', 'timeFrame': 'Tumor response was assessed every 2 cycles until progression or intolerable toxicity with maximum of 3 years'}]","[{'measure': 'Response Rate on Step 2', 'description': 'Tumor response was evaluated via Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and response rate was defined as the proportion of patients with a complete response or partial response among all eligible and treated patients. Complete response was defined as disappearance of all tumor lesions. Partial response was defined as at least a 30% decrease in the sum of the longest diameters of target lesions.', 'timeFrame': 'Tumor response was assessed after every 2 cycles until progression or intolerable toxicity with maximum of 3 years'}, {'measure': 'Progression-free Survival on Step 1', 'description': 'Progression-free survival was defined as time from registration to step 1 to disease recurrence or death from any cause, whichever occurred first. Disease progression was measured by Response Evaluation Criteria In Solid Tumors (RECIST) v1.0, and defined as at least a 20% increase in the sum of the longest diameters of target lesions.', 'timeFrame': 'Every 3 months for first 2 years from protocol entry, then every 6 months until 3 years from study entry'}, {'measure': 'Overall Survival on Step 1', 'description': 'Overall survival was defined as time from registration on step 1 to death from any cause. It was evaluated in all 61 eligible and treated patients.', 'timeFrame': 'Survival was assessed every 3 month within 2 years and every 6 months betwen 2 and 3 years'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,71.0,ACTUAL,2025-09-01T16:18:12.185542,v2_robust,True,True,True,False,False,
NCT04646759,Fulvestrant or Capecitabine Combined With Pyrotinib in HR+/HER2+ Metastatic Breast Cancer,"Fulvestrant or Capecitabine Combined With Pyrotinib in HR-positive and HER2-Positive Metastatic Breast Cancer: A Multicenter, Randomized, Phase III Study",Fulvestrant combined with Pyrotinib,"['Capecitabine combined with Pyrotinib', 'xeloda combined with Pyrotinib', 'FASLODEX combined with Pyrotinib', 'Fulvestrant combined with Pyrotinib']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],"['HR-postitive/HER2-positive metastatic breast cancer', 'fulvestrant', 'Pyrotinib', 'capecitabine']",RECRUITING,,2020-10-14,2030-12-14,"[{'measure': 'Progression free survival', 'description': 'The interval from the date of randomization to the first imaging confirmed progression of disease or death from any cause.', 'timeFrame': '24 months'}, {'measure': 'Incidence of grade 3 hand foot syndrome (rate)', 'description': 'From the date of enrollment to one year, the incidence of grade 3 hand-foot syndrome in the fulvestrant combined with pyrotinib group was compared with that of capecitabine combined with pyrotinib group. The incidence and severity of hand-foot syndrome were evaluated according to CTCAE 5.0 every 9 weeks (± 7 days).', 'timeFrame': 'From the date of enrollment to one year'}]","[{'measure': 'Overall survival (OS)', 'description': 'The time interval from the date of randomization to death due to any cause', 'timeFrame': '50 months'}, {'measure': 'Objective response rate (ORR)', 'description': 'According to recist1.1 standard, the proportion of patients whose best remission was CR or PR accounted for the total number of evaluable patients.', 'timeFrame': '12 months'}, {'measure': 'Clinical Benefit Rate (CBR)', 'description': 'According to recist1.1 standard, the proportion of patients whose best remission was CR or PR or SD ≥ 24 weeks accounted for the total number of evaluable patients.', 'timeFrame': '12 months'}, {'measure': 'Biomarkers and treatment sensitivity analysis', 'description': 'Cox univariate and multivariate analysis will be used to explore the correlation between endocrine and HER2 pathway related biomarkers and treatment sensitivity（The biomarkers to be analyzed included 324 tumor related genes included in the FoundationOne CDx, and ER/PR/HER2/ki67 in IHC）', 'timeFrame': '12 months'}, {'measure': 'Quality of life score', 'description': 'Quality of life data will be collected using the following questionnaires: FACT-B score', 'timeFrame': '12 months'}, {'measure': 'Incidence of adverse events', 'description': 'From the date of enrollment to one year, the incidence of adverse events in the fulvestrant combined with pyrotinib group was compared with that of capecitabine combined with pyrotinib group.', 'timeFrame': 'from the date of enrollment to one year'}]",8,18 Years,80 Years,FEMALE,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,0,516.0,ESTIMATED,2025-09-01T16:18:12.185565,v2_robust,True,True,False,False,True,
NCT02566759,"A TAK-831-1001, Single and Multiple Rising Dose Study in Healthy Participants","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Safety, Tolerability and Pharmacokinetic Study of Escalating Single and Multiple Doses of TAK-831 in Healthy Subjects",TAK-831 Oral Suspension,"['TAK-831 Oral Suspension', 'TAK-831 Placebo', 'TAK-831 Tablet']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,"Schizophrenia, Cerebellar Ataxia","['Schizophrenia, Cerebellar Ataxia']",['Drug therapy'],TERMINATED,The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.,2015-09-23,2016-07-12,"[{'measure': 'Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE)', 'timeFrame': 'Baseline up to 30 days after the last dose of study drug (Part 1 Day 31, Part 2 Day 46, Part 3 Day 44 and Part 4 Day 43)'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Laboratory Tests at Least Once Post Dose', 'description': 'Clinical laboratory tests included hematology, serum chemistry and urinalysis.', 'timeFrame': 'Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Vital Sign Measurements at Least Once Post Dose', 'description': 'Markedly abnormal criteria for vital signs measurement was assessed. The lower criteria and upper criteria for abnormality are as follow: systolic blood pressure at less than (\\<) 85 millimeter of mercury (mm Hg) to greater than (\\>) 180 mm Hg; diastolic blood pressure \\< 50 mm Hg to \\>110 mm Hg; pulse rate \\<50 bpm to \\>120 bpm; Temperature \\<35.6 degree Celsius to \\>37.7 degree Celsius.', 'timeFrame': 'Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4'}, {'measure': 'Percentage of Participants Who Meet the Markedly Abnormal Criteria for Safety Electrocardiogram (ECG) Parameters at Least Once Post Dose', 'description': ""Markedly abnormal criteria for ECG was assessed. The lower cut-off point criteria and upper cut-off point criteria are as follow: heart rate \\<50 beats per minute (bpm) to \\>120 bpm; PR interval less than or equal to (\\<=) 80 millisecond (msec) to greater than or equal to (\\>=) 200 msec; QRS interval \\<=80 msec to \\>=180 msec; QT interval \\<=300 msec to \\>=460 msec; QTcB interval \\<=300 msec to \\>=500 msec or \\>=30 msec change from baseline and \\>=450 msec; QT interval with Fridericia's correction method (QTcF) interval \\<=50 msec to \\>=500 msec or \\>=30 msec change from baseline and \\>=450 msec."", 'timeFrame': 'Baseline up to Day 15 in Part 1, Day 30 in Part 2, Day 28 in Part 3 and Day 25 in Part 4'}]","[{'measure': 'Part 1, 2 and 4: Cmax: Maximum Observed Plasma Concentration for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose'}, {'measure': 'Part 2 and 3: Cmax, ss: Maximum Observed Plasma Concentration at Steady State for TAK-831', 'timeFrame': 'Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose; Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose'}, {'measure': 'Part 1, 2 and 4: AUCt: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose'}, {'measure': 'Part 1, 2 and 4: AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for TAK-831', 'timeFrame': 'Day 1 pre-dose and at multiple time points (up to 96 hours in Part 1 and up to 72 hours in Part 2 and 4) post-dose'}, {'measure': 'Part 2 and 3: AUCτ: Area Under the Plasma Concentration-time Curve From Time 0 to Time Tau Over the Dosing Interval for TAK-831', 'timeFrame': 'Day 16 (Part 2) and Day 14 (Part 3) pre-dose and at multiple time points (up to 24 hours) post-dose'}]",10,18 Years,55 Years,ALL,True,Neurocrine Biosciences,INDUSTRY,1,110.0,ACTUAL,2025-09-01T16:18:12.185604,v2_robust,True,True,False,True,True,The study was terminated by Takeda due to the discomfort observed in the study participants from the CSF collection procedure in Part 3 of the study.
NCT03458559,Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy,Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study,Radium-223 chloride,"['Rhenium-188-HEDP', '188Rhenium-etidronate', 'Re-188-HEDP', 'Radium-223 chloride', 'Xofigo', 'Radium-223 dichloride']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Cancer Metastatic to Bone,['Prostate Cancer Metastatic to Bone'],"['Bone metastases', 'Rhenium-188-HEDP', 'Radium 223-chloride', 'Survival', 'Prostate cancer']",UNKNOWN,,2018-05-16,2024-05-16,"[{'measure': 'Overall survival', 'description': 'Time from randomization until death due to any cause,', 'timeFrame': 'Time from randomization until death due to any cause, an average of 18 months'}]","[{'measure': 'Time to PSA progression', 'description': 'Time from randomization to the date of a minimum of rising PSA levels with an interval of \\>1week between each determination', 'timeFrame': 'Time from randomization to the date of a minimum of rising PSA levels, an average of 8 months (PSA measured at baseline and every 4 weeks).'}, {'measure': 'Time to total-ALP progression', 'description': 'Time from randomization to the date of earliest objective evidence of ALP progression.', 'timeFrame': 'Time from randomization to the date of earliest objective evidence of ALP progression, an average of 8 months (ALP measure at baseline and every 4 weeks)'}, {'measure': 'Clinical progression', 'description': 'Time from randomization to the date of first clinical progression.', 'timeFrame': 'Time from randomization to the date of first clinical progression, an average of 12 months'}, {'measure': 'Time to first SRE', 'description': 'Time from randomization to the date of first skeletal related events', 'timeFrame': 'Time from randomization to the date of first skeletal related events, an average of 12 months'}, {'measure': 'Quality of life', 'description': 'Measured by the EORTC quality of Life Questionnaire C30', 'timeFrame': 'Assessed through study completion, an average of 1 year'}, {'measure': 'Effect on pain', 'description': 'Measured with a visual analogue scale', 'timeFrame': 'Assessed through study completion, an average of 1 year'}, {'measure': 'Incremental Cost Effectiveness Ratio (IVER)', 'description': 'Ratio between the difference in costs and the difference in benefits (quality of life of treatment with rhenium-188-HEDP of radium-223-chloride)', 'timeFrame': 'Assessed through study completion, an average of 1 year'}]",8,18 Years,,MALE,False,"Amsterdam UMC, location VUmc",OTHER,0,402.0,ESTIMATED,2025-09-01T16:18:12.185615,v2_robust,True,True,False,False,False,
NCT02855359,Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma,"An Open Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) in Combination With RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone) or RCHP (Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone) Compared With RCHOP Alone as Frontline Therapy in Patients With Diffuse Large B-cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Grade 3b",denintuzumab mafodotin,"['doxorubicin', 'rituximab', 'cyclophosphamide', 'prednisone', 'denintuzumab mafodotin', 'vincristine']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,"Diffuse, Large B-Cell, Lymphoma","['Diffuse, Large B-Cell, Lymphoma', 'Follicular Lymphoma, Grade 3b', 'Transformed Lymphoma / DLBCL']","['Antibodies, Monoclonal', 'SGN-19A', 'Denintuzumab Mafodotin', 'DLBCL', 'Antibody-Drug Conjugate', 'Antigens, CD19', 'Hematologic Diseases', 'Immune System Diseases', 'Immunoproliferative Disorders', 'Immunotherapy', 'Lymphatic Diseases', 'Lymphoma', 'Lymphoma, B-Cell', 'Lymphoma, Large B-Cell, Diffuse', 'Lymphoma, Non-Hodgkin', 'Monomethyl auristatin F', 'Neoplasms', 'Neoplasms by Histologic Type', 'Transformed Lymphoma / DLBCL', 'Cyclophosphamide', 'Doxorubicin', 'Liposomal doxorubicin', 'Prednisone', 'Rituximab', 'Vincristine', 'Alkylating Agents', 'Anti-Inflammatory Agents', 'Antibiotic, Antineoplastic', 'Antimitotic Agents', 'Antineoplastic Agents, Alkylating', 'Antineoplastic Agents', 'Phytogenic Antirheumatic Agents', 'Glucocorticoids', 'Drug Therapy', 'Follicular Lymphoma Grade 3b', 'immunosuppressive agents']",TERMINATED,Sponsor decision based on portfolio prioritization,2016-08,2018-05-15,"[{'measure': 'Part B Outcome Measure: Complete Response Rate (CR)', 'description': 'Study did not progress to Part B.', 'timeFrame': 'N/A - Endpoint not assessed'}, {'measure': 'Part A and Part B Outcome Measure: Incidence of Adverse Events', 'description': 'Part A data only; study did not progress to Part B.', 'timeFrame': '54.7 weeks'}, {'measure': 'Part A and Part B Outcome Measure: Incidence of Laboratory Abnormalities', 'description': 'Part A data reported; study did not progress to Part B. Laboratory abnormalities Grade 1+ are reported.', 'timeFrame': 'Up to 183 days'}]","[{'measure': 'Event-free Survival (EFS) Between Study Arms in Part B', 'description': 'Study did not progress to Part B', 'timeFrame': 'N/A - Endpoint not assessed'}, {'measure': 'Progression-free Survival (PFS) Between Study Arms in Part B', 'description': 'Study did not progress to Part B.', 'timeFrame': 'N/A - Endpoint not assessed'}, {'measure': 'Overall Survival (OS) Between Study Arms in Part B', 'description': 'Study did not progress to Part B.', 'timeFrame': 'N/A - Endpoint not assessed'}, {'measure': 'Objective Response Rate (ORR) at End Of Treatment (EOT) Between Study Arms in Part B', 'description': 'Study did not progress to Part B.', 'timeFrame': 'N/A - Endpoint not assessed'}, {'measure': 'Duration of Objective Response and of Complete Response (CR) Between Study Arms in Part B', 'description': 'Study did not progress to Part B.', 'timeFrame': 'N/A - Endpoint not assessed'}]",8,18 Years,,ALL,False,Seagen Inc.,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:12.185640,v2_robust,True,True,False,True,True,Sponsor decision based on portfolio prioritization
NCT06379659,Effectiveness of Intrauterine Growth Hormone Administration as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer,Effectiveness of Intrauterine Growth Hormone Infusion as an add-on Therapy to Conventional Hormone Therapy Compared to Placebo in Patients With Thin Endometrium Undergoing Frozen Thawed Embryo Transfer: A Double-blinded Parallel Exploratory Randomized Controlled Clinical Trial,Growh hormone,['Growh hormone'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Thin Endometrium,"['Thin Endometrium', 'Infertility Female', 'Infertility']","['Infertility', 'Infertility, Female', 'endometrial thickness', 'Thin Endoetrium', 'Growth Hormone', 'Human Growth Hormone', 'Somatropin', 'Intra-uterine infusion']",COMPLETED,,2024-05-01,2024-09-14,"[{'measure': 'Endometrial thickness', 'description': ""Measurement of endometrial thickness will be performed utilizing transvaginal sonography due to its closer proximity to the endometrium and with an empty bladder. To minimize the potential bias of measuring endometrial thickness during uterus contraction, occur during contractions, measurements will be taken only after the patient's contractions have ceased."", 'timeFrame': 'Baseline (On the 10th day of menstrual cycle), and On the day of response to treatment (in case of response) and in case of non-response to treatment on the 18th day of the mesntrual cycle'}]","[{'measure': 'Clinical Pregnancy Rate', 'description': 'The number of fetuses that have a heartbeat and are not ectopic evaluated by Transvaginal Ultrasonography', 'timeFrame': '6-8 of gestational week'}, {'measure': 'Response to treatment', 'description': 'The number of patients that reach at least 7 mm of endometrial thickness', 'timeFrame': '2 days following the last dose of placebo or growth hormone'}, {'measure': 'Implantation rate', 'description': 'The number of gestational sacs to the number of transferred embryos evaluated by Transvaginal ultrasonography', 'timeFrame': '6-8 of gestational week'}, {'measure': 'IVF cancellation rate', 'description': 'The number of patients who do not reach enough endometrial thickness for transferring despite maximum treatment', 'timeFrame': '2 days following the last dose of placebo or growth hormone'}, {'measure': 'Early pregnancy complications', 'description': 'Including early miscarriage (miscarriage in less than 12th gestational week) and Ectopic pregnancy', 'timeFrame': 'During the first 12 weeks of pregnancy'}]",6,18 Years,45 Years,FEMALE,False,Isfahan University of Medical Sciences,OTHER,0,54.0,ACTUAL,2025-09-01T16:18:12.185692,v2_robust,True,True,True,False,False,
NCT01786759,Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion,Hepatic Function and Bile Acid in Preterm Infants Receiving Parenteral Lipids Emulsion,ClinOleic,"['ClinOleic', 'Intralipid']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Preterm Infants,['Preterm Infants'],"['lipids', 'preterm infants', 'parenteral nutrition', 'liver function']",UNKNOWN,,2012-10,2013-07,"[{'measure': 'liver function', 'description': 'Total Bile Acid(TBA),alanine aminotransferase(ALT),aspartate aminotransferase(AST),alkaline phosphatase(AKP),γ-glutamyl transpeptidase(GGT),total bilirubin(Tbi),Direct bilirubin(Dbi)', 'timeFrame': 'Change from Baseline in fatty acid at 7 days and 14 days'}]","[{'measure': 'bile acid', 'description': 'cholic acid,deoxycholic acid,Chenodeoxycholic Acid,ursodeoxycholic acid,lithocholic acid,et al.', 'timeFrame': 'Change from Baseline in fatty acid at 7 days and 14 days'}]",2,1 Day,28 Days,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:12.185736,v2_robust,True,True,False,False,False,
NCT04906980,A Study of JNJ-64281802 in Participants With Confirmed Dengue Fever,"A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Tolerability, and Pharmacokinetics of JNJ-64281802 in Participants With Confirmed Dengue Fever",JNJ-64281802,"['JNJ-64281802', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Dengue,['Dengue'],[],TERMINATED,Feasibility of enrollment impacted by COVID,2022-01-24,2023-03-21,"[{'measure': 'Area Under the Log10-Transformed Dengue Virus (DENV) RiboNucleic Acid (RNA) Viral Load (VL) Curve From Baseline Until Day 5 (AUCD1-D5 [log10VL]).', 'description': 'The antiviral activity of JNJ-64281802 versus placebo in terms of reduction of DENV RNA in participants with a primary DENV infection was planned to be measured by the area under the log10-transformed DENV RNA viral load concentration-time curves from baseline (Day 1) until Day 5 (AUCD1-D5 \\[log10VL\\]).', 'timeFrame': 'Baseline (Day 1) upto Day 5'}]","[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs were those AE events that occurred at or after the initial administration of study intervention through the last onsite visit.', 'timeFrame': 'From Day 1 up to the last onsite visit (Day 30)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings', 'description': ""Number of participants with clinically significant abnormalities in ECGs parameters as assessed based on investigator's discretion were reported."", 'timeFrame': 'From Day 1 up to the last onsite visit (Day 30)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Physical Examination', 'description': ""Number of participants with clinically significant abnormalities in physical examination parameters (head/neck/thyroid, eyes/ears/nose/throat, respiratory, cardiovascular, lymph nodes, abdomen, skin, musculoskeletal, and neurological) as assessed based on investigator's discretion were reported."", 'timeFrame': 'From Day 1 up to the last onsite visit (Day 30)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Vital Signs', 'description': ""Number of participants with clinically significant abnormalities in vital signs (temperature, pulse/heart rate, respiratory rate, peripheral capillary oxygen saturation \\[spO2\\], input-output \\[I/O\\] ratio and blood pressure) as assessed based on investigator's discretion were reported."", 'timeFrame': 'From Day 1 up to the last onsite visit (Day 30)'}, {'measure': 'Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters', 'description': ""Number of participants with clinically significant abnormalities in laboratory parameters (serum chemistry, hematology, and coagulation) were reported. Clinical significance was defined as per investigator's judgement."", 'timeFrame': 'From Day 1 up to the last onsite visit (Day 30)'}, {'measure': 'Plasma Concentrations of JNJ-64281802', 'description': 'Plasma Concentrations of JNJ-64281802 was assessed. Due to small number of enrolled participants, no summary statistics analysis was performed. Participant wise data were reported for this outcome measure.', 'timeFrame': 'Predose: 0, 8, 16 hours on Day 1; 24, 32, 40 hours on Day 2; Day 4, Day 5; and Post dose: 4, 12 hours on Day 1; 28, 36 hours on Day 2; 48 hours on Day 3; Day 6, Day 14, Day 21, Day 28'}, {'measure': 'Number of Participants With Occurrence of Detectable Dengue Virus (DENV) RiboNucleic Acid (RNA) in Primary DENV Infection', 'description': 'Number of participants with occurrence of detectable DENV RNA in primary DENV infection was a planned analysis.', 'timeFrame': 'Predose: 24 hour on Day 2; Post dose: 12 hour on Day 1; 36 hour on Day 2; Days 3, 4, 5, 6, 7, 8, 9, 14, 21 and 28'}, {'measure': 'Time to Undetectable Dengue Virus (DENV) RiboNucleic Acid (RNA) in Primary DENV Infection', 'description': 'Time to undetectable DENV RNA in primary DENV infection was a planned analysis.', 'timeFrame': 'Predose: 24 hour on Day 2; Post dose: 12 hour on Day 1; 36 hour on Day 2; Days 3, 4, 5, 6, 7, 8, 9, 14, 21 and 28'}, {'measure': 'Area Under the Plasma Concentration Time Curve During One Dosing Interval (AUC[Tau]) of JNJ-64281802', 'description': 'AUC\\[tau\\] is defined as area under the plasma concentration time curve during one dosing interval of JNJ-64281802.', 'timeFrame': '0, 8, 16 hours pre-dose on Day 1; 4 and 12 hours post-dose on Day 1'}, {'measure': 'Trough (Pre-dose) Analyte Concentration (Ctrough) of JNJ-64281802', 'description': 'Ctrough is defined as plasma concentration just prior to the beginning or at the end of a dosing interval of JNJ-64281802.', 'timeFrame': 'Pre-dose on Day 1: 0 hour, 8 hour, 16 hour; pre-dose on Day 2: 24 hour, 32 hour, 40 hour; pre-dose on Day 4 and Day 5'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-64281802', 'description': 'Cmax is defined as the maximum observed plasma concentration of JNJ-64281802.', 'timeFrame': '0, 8, 16 hours pre-dose on Day 1; 4 and 12 hours post-dose on Day 1'}]",12,18 Years,60 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,5.0,ACTUAL,2025-09-01T16:18:12.185763,v2_robust,True,True,False,True,True,Feasibility of enrollment impacted by COVID
NCT00980980,Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs),Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal,Chlorhexidine bath and nasal mupirocin,['Chlorhexidine bath and nasal mupirocin'],1,INTERVENTIONAL,['NA'],,,Methicillin-resistant Staphylococcus Aureus,['Methicillin-resistant Staphylococcus Aureus'],['MRSA infection'],COMPLETED,,2009-09,2011-09,"[{'measure': 'Main Outcome: Patients With Nosocomial MRSA Clinical Cultures', 'description': 'Hazard ratio for ICU-attributable MRSA+ clinical cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.', 'timeFrame': 'The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.'}]","[{'measure': 'MRSA Bloodstream Infection', 'description': 'Hazard ratio for ICU-attributable MRSA+ blood cultures comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.', 'timeFrame': 'The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.'}, {'measure': 'ICU-attributable All-pathogen Bloodstream Infection', 'description': 'Hazard ratio for ICU-attributable positive blood culture from any pathogen, comparing Baseline to Intervention period, by Arm, accounting for clustering by hospital.', 'timeFrame': 'The 30-month time frame represents 12-month baseline and 18-month intervention periods. During these time periods, outcomes are defined as events occurring during attributed ICU time: from day 3 of the ICU stay until 2 days after ICU discharge.'}, {'measure': 'Intervention Impact on Healthcare Costs', 'description': 'Costs (in dollars) per 1000 ICU-admissions associated with 3 ICU strategies to reduce ICU Bloodstream infection (BSI), (Arms 1-3).', 'timeFrame': '12-month period'}, {'measure': 'Blood Culture Contamination Rates', 'description': 'Odds ratio for ICU-attributable blood culture contamination rates, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital.', 'timeFrame': '24-month time frame for this analysis represents a 6-month baseline and 18-month intervention period.'}, {'measure': 'Intervention Impact on Bacteriuria and Candiduria', 'description': 'Proportional hazard ratio for as-randomized, unadjusted, ICU-attributable bacteriuria, comparing Baseline to Intervention period across Arms, accounting for clustering by hospital. High-level bacteriuria is defined as ≥50,000 CFU/mL, high-level candiduria is defined as ≥50,000 CFU/mL.', 'timeFrame': '30-month time frame represents 12-month baseline and 18-month intervention periods.'}, {'measure': 'Intervention Impact on Mupirocin Susceptibility of MRSA Isolates', 'description': 'Odds ratio for MRSA+ isolates from ICU patients expressing low-level mupirocin resistance (LLMR) and high-level mupirocin resistance (HLMR), comparing baseline to intervention period across arms, accounting for clustering by hospital.', 'timeFrame': '25-month time frame represents 7-month baseline and 18-month intervention periods'}, {'measure': 'Intervention Impact on Chlorhexidine Susceptibility of MRSA Isolates', 'description': 'Frequency of MRSA+ isolates from ICU patients with reduced susceptibility to chlorhexidine (CHG) (MIC \\>4 μg/ml), comparing baseline to intervention period across arms, accounting for clustering by hospital.', 'timeFrame': '25-month time frame represents 7-month baseline and 18-month intervention periods'}]",8,13 Years,,ALL,False,Harvard Pilgrim Health Care,OTHER,5,74256.0,ACTUAL,2025-09-01T16:18:12.185818,v2_robust,True,True,True,False,False,
NCT05485480,Nociception Level During Opioid-sparing Anaesthesia Versus Conventional Opioid-based Anaesthesia,Nociception Level During Opioid-sparing Anaesthesia Versus Conventional Opioid-based Anaesthesia: a Randomised Controlled Non-inferiority Trial,conventional opioid-based group,"['conventional opioid-based group', 'opioid-sparing group']",2,INTERVENTIONAL,['NA'],,,Analgesia,['Analgesia'],"['analgesia nociception', 'opioid-sparing anaesthesia', 'conventional opioid-based anaesthesia', 'Pain Monitoring Device (PMD-200)', 'intraoperative nociceptive levels', 'Post operative nausea and vomiting (PONV)']",COMPLETED,,2022-11-17,2024-02-08,"[{'measure': 'Mean of the nociception level as measured by the PMD-200', 'description': 'The PMD-200 device consists of a finger probe which continuously assesses pulse rate, pulse rate variability, pulse wave amplitude, skin conductance level, skin conductance fluctuations, skin temperature, and finger motion. A value of 0 corresponds to no pain and a value of 100 to maximal pain. A value will be measured every minute from the timepoint of skin incision until skin closure.', 'timeFrame': 'From the timepoint of skin incision until skin closure (within 1 day)'}]","[{'measure': 'Change in Aldrete score', 'description': 'Fitness for discharge to ward is checked every 15 minutes with the Aldrete score. The Aldrete score assigned a number of 0, 1, or 2 to 5 variables: activity, respiration, circulation, consciousness, and color. A score of 9 out of 10 is considered adequate for discharge from the recovery.', 'timeFrame': 'Every 15 minutes in recovery until patient discharge to the ward (within 1 day)'}, {'measure': 'Amount of morphine needed', 'description': 'Amount of morphine needed', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}, {'measure': 'Amount of ketamine needed', 'description': 'Amount of ketamine needed', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}, {'measure': 'Change in pain score at rest by numeric rating scale', 'description': 'Change in pain score at rest by numeric rating scale (to assess pain severity using a 0-10 scale, with zero meaning ""no pain"" and 10 meaning ""the worst pain imaginable)', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}, {'measure': 'Change in pain score at movement by numeric rating scale', 'description': 'Change in pain score at movement by numeric rating scale (to assess pain severity using a 0-10 scale, with zero meaning ""no pain"" and 10 meaning ""the worst pain imaginable)', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}, {'measure': ""Quality of night's sleep"", 'description': ""Quality of night's sleep assessed with a verbal numerical scale from 0 (very poor quality of sleep) to 10 (excellent quality of sleep)"", 'timeFrame': 'From the first postoperative day until discharge from ward (average of 1 week)'}, {'measure': 'Occurrence of nausea and vomiting', 'description': 'Occurrence of postoperative nausea and vomiting (PONV)', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}, {'measure': 'Change in level of sedation', 'description': 'Change in level of sedation', 'timeFrame': 'At 4 hours and then twice daily until discharge from the ward (average of 1 week)'}, {'measure': 'Perceived quality of recovery by QoR40 questionnaire', 'description': '40-item questionnaire that provides a global score and subscores across five dimensions: patient support, comfort, emotions, physical independence, and pain', 'timeFrame': 'At the first postoperative day'}, {'measure': 'Time to return of gastrointestinal function', 'description': 'Time to return of gastrointestinal function as defined as the time from the end of surgery to the first passage of flatus and to the first bowel movement', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}, {'measure': 'Time to return of spontaneous micturition', 'description': 'Time to return of spontaneous micturition', 'timeFrame': 'From the stay in recovery before discharge from the ward (average of 1 week)'}]",12,18 Years,,ALL,False,"University Hospital, Basel, Switzerland",OTHER,0,70.0,ACTUAL,2025-09-01T16:18:12.185859,v2_robust,True,True,True,False,False,
NCT00605280,"A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.","A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, In Parallel Groups, To Compare The Safety And Efficacy Of Intravitreous Injections Of 0.3 Mg Pegaptanib Sodium (Macugen®), Given As Often As Every 6 Weeks For 2 Years, To Sham Injections In Subjects With Diabetic Macular Edema (DME) Involving The Center Of The Macula With An Open-Label Macugen Year 3 Extension.",Standard of Care,"['Macugen', 'Standard of Care']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Macular Edema Associated With Diabetes Mellitus,['Macular Edema Associated With Diabetes Mellitus'],['randomized sham-controlled multicenter macular edema'],COMPLETED,,2005-09,2011-07,"[{'measure': 'Number of Participants With Greater Than or Equal to ≥10 Letter (or 2 Line) Improvement in Vision at 1 Year', 'description': 'Refraction and best-corrected visual acuity (VA) measurements were performed using retro-illuminated, modified Ferris-Bailey Early Treatment Diabetic Retinopathy Study (ETDRS) charts', 'timeFrame': 'Baseline, Year 1'}]","[{'measure': 'Number of Participants With a ≥ 10 Letter (or 2 Line) Improvement in Vision at 2 Years', 'description': 'Refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts', 'timeFrame': 'Baseline, Year 2'}, {'measure': 'Number of Participants With a ≥ 15 Letter Improvement in Vision at 1 Year', 'description': 'Refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts', 'timeFrame': 'Baseline, Year 1'}, {'measure': 'Number of Participants With a ≥ 15 Letter Improvement in Vision at 2 Years', 'description': 'Refraction and best-corrected VA measurements were performed using retro-illuminated, modified Ferris-Bailey ETDRS charts', 'timeFrame': 'Baseline, Year 2'}, {'measure': 'Number of Eyes With a 2 or More Step Increase in Degree of Retinopathy at 1 Year', 'description': 'Retinopathy changes were monitored using fundus photography and fluorescein angiograph (FA) assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where an increase in the step or retinopathy level indicated a worsening of the condition.', 'timeFrame': 'Baseline, Year 1'}, {'measure': 'Number of Eyes With a 2 or More Step Decrease in Degree of Retinopathy at 1 Year', 'description': 'Retinopathy changes were monitored using fundus photography and FA assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where a decrease in the step or retinopathy level indicated an improvement.', 'timeFrame': 'Baseline, Year 1'}, {'measure': 'Number of Eyes With a 2 or More Step Increase in Degree of Retinopathy at 2 Years', 'description': 'Retinopathy changes were monitored using fundus photography and FA assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where an increase in the step or retinopathy level indicated a worsening of the condition.', 'timeFrame': 'Baseline, Year 2'}, {'measure': 'Number of Eyes With a 2 or More Step Decrease in Degree of Retinopathy at 2 Years', 'description': 'Retinopathy changes were monitored using fundus photography and FA assessments. An Independent Reading Center, using trained graders, evaluated the presence of retinopathy using a modified 12-step version of the ETDRS Final Retinopathy Severity Scale, that ranged from step 1 (retinopathy level of 10 or 12) to step 12 (retinopathy level of 85A or 85B) where a decrease in the step or retinopathy level indicated an improvement.', 'timeFrame': 'Baseline, Year 2'}, {'measure': 'Change From Baseline in Mean VA Score at 1 Year', 'description': 'Changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled the visual acuity obtained at the observation minus the visual acuity at baseline.', 'timeFrame': 'Baseline, Year 1'}, {'measure': 'Change From Baseline in Mean VA Score at 2 Years', 'description': 'Changes in VA monitored through refraction and best-corrected VA measurements using retro-illuminated, modified Ferris-Bailey ETDRS chart with participants at a 4-meter distance from chart. Distance VA expressed as an ETDRS score (number of letters correctly read) ranging from 0 to 60, where higher ETDRS scores represented better vision. Change from baseline for each patient equaled the visual acuity obtained at the observation minus the visual acuity at baseline.', 'timeFrame': 'Baseline, Year 2'}, {'measure': 'Number of Participants Requiring Focal or Grid Laser Treatment During Year 1', 'description': 'Included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation', 'timeFrame': '1 year'}, {'measure': 'Number of Participants Requiring Focal or Grid Laser Treatment During Year 2', 'description': 'Included focal laser coagulation, focal laser photocoagulation, panretinal laser photocoagulation, retinal laser coagulation, and retinal laser photocoagulation', 'timeFrame': '2 years'}]",12,18 Years,,ALL,False,Pfizer,INDUSTRY,0,317.0,ACTUAL,2025-09-01T16:18:12.185896,v2_robust,True,True,True,False,False,
NCT04667780,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Colchicine,"['Standard COVID-19 care', 'Colchicine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,COVID-19,['COVID-19'],[],COMPLETED,,2020-12-01,2021-07-09,"[{'measure': ""Changes in the patients' clinical status through the 7 points ordinal scale WHO R&D Blueprint expert group"", 'description': 'Improvement in the clinical evolution of patients', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in IL-6 concentrations', 'description': 'Improvement in cytokine level', 'timeFrame': 'up to 14 days'}]","[{'measure': 'Improvement in the clinical status', 'description': 'time needed to reduce at least 2 points in the 7-point Ordinal Scale for Clinical Improvement by WHO R\\&D Blueprint expert group (0-7)', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in the score for the Sequential Organ Failure Assessment (SOFA score)', 'description': 'Sequential Organ Failure Assessment (SOFA score) (0-14)', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in the punctuation in the National Early Warning Score', 'description': 'National Early Warning Score (NEWS scale)', 'timeFrame': 'up to 14 days'}, {'measure': 'Number of days with invasive mechanical ventilation', 'timeFrame': 'up to 14 days'}, {'measure': 'Number of days with high flow oxygen therapy', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in other inflammatory markers', 'description': 'C-reactive protein', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in severity markers', 'description': 'D-dimer', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in severity markers', 'description': 'Leukocytes', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in severity markers', 'description': 'Lymphocytes', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in severity markers', 'description': 'Platelets', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in severity markers', 'description': 'LDH', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in severity markers', 'description': 'Ferritin', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in myocardial damage', 'description': 'myocardial stress markers hsTnT', 'timeFrame': 'up to 14 days'}, {'measure': 'Changes in myocardial damage', 'description': 'myocardial stress markers NT-proBNP', 'timeFrame': 'up to 14 days'}, {'measure': 'Time until reaching a virus negative status', 'description': 'RT-PCR assay', 'timeFrame': 'up to 14 days'}, {'measure': 'Length of hospital stay', 'description': 'Length of hospital stay', 'timeFrame': 'up to 14 days'}, {'measure': 'Number of days in the intensive care unit.', 'description': 'Number of days in the intensive care unit.', 'timeFrame': 'up to 14 days'}, {'measure': 'Mortality', 'description': 'Mortality', 'timeFrame': 'up to 14 days'}]",20,18 Years,65 Years,ALL,False,Ayub Teaching Hospital,OTHER,1,102.0,ACTUAL,2025-09-01T16:18:12.185949,v2_robust,True,True,True,False,False,
NCT04272580,Preload Optimization Guided by Inferior Vena Cava Collapsibility Index,"Preload Optimization Guided by Inferior Vena Cava Collapsibility Index in Parturients With Prophylactic Norepinephrine Infusion Undergoing Cesarean Section: a Randomized, Dose-finding Trial",Control group,"['8 ml/kg group.', '12 ml/kg group.', 'Control group', 'Crystalloid', '4 ml/kg group.']",5,INTERVENTIONAL,['NA'],,,Adverse Effect,['Adverse Effect'],"['Preload', 'Inferior vena cava collapsibility index', 'Norepinephrine', 'Cesarean section', 'Dose-finding']",COMPLETED,,2020-07-01,2021-03-27,"[{'measure': 'The minimum (IVC-min), maximum diameter (IVC-max) and collapsibility index (IVC-CI) of the inferior vena cava (IVC)', 'description': 'IVC-CI = \\[(IVC-max-IVC-min) /IVC-max\\*100%\\]', 'timeFrame': 'Baseline (before preload)'}, {'measure': 'The minimum (IVC-min), maximum diameter (IVC-max) and collapsibility index (IVC-CI) of the inferior vena cava (IVC)', 'description': 'IVC-CI = \\[(IVC-max-IVC-min) /IVC-max\\*100%\\]', 'timeFrame': 'Before spinal anesthesia (after preload)'}, {'measure': 'The minimum (IVC-min), maximum diameter (IVC-max) and collapsibility index (IVC-CI) of the inferior vena cava (IVC)', 'description': 'IVC-CI = \\[(IVC-max-IVC-min) /IVC-max\\*100%\\]', 'timeFrame': '5 min after spinal anesthesia'}, {'measure': 'The minimum (IVC-min), maximum diameter (IVC-max) and collapsibility index (IVC-CI) of the inferior vena cava (IVC)', 'description': 'IVC-CI = \\[(IVC-max-IVC-min) /IVC-max\\*100%\\]', 'timeFrame': '5 min after fetal delivery'}, {'measure': 'The minimum (IVC-min), maximum diameter (IVC-max) and collapsibility index (IVC-CI) of the inferior vena cava (IVC)', 'description': 'IVC-CI = \\[(IVC-max-IVC-min) /IVC-max\\*100%\\]', 'timeFrame': 'Before leaving the operating room'}]","[{'measure': 'The incidence of post-spinal anesthesia hypotension.', 'description': 'Systolic blood pressure (SBP) \\< 80% of the baseline.', 'timeFrame': '1-15 minutes after spinal anesthesia'}, {'measure': 'The incidence of severe post-spinal anesthesia hypotension.', 'description': 'Systolic blood pressure (SBP) \\< 60% of the baseline', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'The incidence of nausea and vomiting.', 'description': 'Presence of nausea and vomiting in patients after spinal anesthesia', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'The incidence of bradycardia', 'description': 'Heart rate \\< 55 beats/min.', 'timeFrame': '1-15 minutes after spinal anesthesia'}, {'measure': 'The incidence of hypertension', 'description': 'Systolic blood pressure (SBP) \\>120% of the baseline', 'timeFrame': '1-15 minutes after spinal anesthesia'}, {'measure': 'pH', 'description': 'From umbilical arterial blood gases', 'timeFrame': 'Immediately after delivery'}, {'measure': 'Partial pressure of oxygen', 'description': 'From umbilical arterial blood gases', 'timeFrame': 'Immediately after delivery'}, {'measure': 'Base excess', 'description': 'From umbilical arterial blood gases', 'timeFrame': 'Immediately after delivery'}, {'measure': 'APGAR score', 'description': 'A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration', 'timeFrame': '1min after delivery'}, {'measure': 'APGAR score', 'description': 'A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration', 'timeFrame': '5min after delivery'}, {'measure': 'Overall stability of systolic blood pressure control versus baseline', 'description': 'Evaluated by performance error (PE).', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'Overall stability of heart rate control versus baseline', 'description': 'Evaluated by performance error (PE).', 'timeFrame': '1-15 minutes after spinal anesthesia.'}]",17,18 Years,40 Years,FEMALE,False,General Hospital of Ningxia Medical University,OTHER,0,193.0,ACTUAL,2025-09-01T16:18:12.186106,v2_robust,True,True,True,False,False,
NCT04230980,Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery,The Use of Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery,Gabapentin,"['Gabapentin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-obstructive Azoospermia,['Non-obstructive Azoospermia'],[],COMPLETED,,2020-07-28,2022-12-16,"[{'measure': 'Pain Score as Measured by the NRS-11 Scale', 'description': 'The Numerical pain Rating Scale (NRS-11) is an 11-point numerical pain rating scale used to measure levels of pain. The lowest possible score is 0 with 0 meaning no pain, and the highest possible score is 10 with 10 meaning severe pain.', 'timeFrame': 'Post-operative day 0 (the day of surgery, after surgery was completed) through post-operative day 7'}]","[{'measure': 'Opioid Consumption, as Measured by Number of Tablets Taken.', 'description': 'Participants were requested to self-report the number of opioid tablets (oxycodone, 5mg) that they had taken since the last survey.', 'timeFrame': 'Post-operative day 0 (the day of surgery, after surgery was completed) through post-operative day 7'}, {'measure': 'Change in Narcotic Consumption, as Measured by Frequency of Narcotic Tablets Taken', 'description': 'Frequency of narcotic tablets that were taken after surgery', 'timeFrame': 'Post-operative day 0 (the day of surgery, after surgery was completed) through post-operative day 7'}, {'measure': 'Change in Narcotic Consumption, as Measured by Duration of Narcotic Tablets Consumption', 'description': 'Duration (time period) over which narcotic tablets that were consumed', 'timeFrame': 'Post-operative day 0 (the day of surgery, after surgery was completed) through post-operative day 7'}]",4,18 Years,,MALE,False,Weill Medical College of Cornell University,OTHER,0,74.0,ACTUAL,2025-09-01T16:18:12.186155,v2_robust,True,True,True,False,False,
NCT06892379,A Study of HS-20110 in Participants With Advanced Solid Tumors,"A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20110 in Participants With Advanced Solid Tumors",HS-20110 (Phase Ia：Dose escalation ),"['HS-20110 (Phase Ib:Dose expansion )', 'HS-20110 (Phase Ia：Dose escalation )']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],[],RECRUITING,,2025-02-26,2027-09-30,"[{'measure': 'Maximum tolerated dose (MTD) or maximum applicable dose (MAD)', 'timeFrame': 'From day 1 to one months after the last dose in Phase 1a'}, {'measure': 'Objective response rate (ORR) as per RECIST v1.1', 'timeFrame': 'From screening to 2 months after the last dose'}]","[{'measure': 'Incidence of adverse events (AEs), serious adverse events (SAEs), AEs leading to dose modification or permanent discontinuation, and specific laboratory abnormalities', 'timeFrame': 'From the first dose until 90 days after the last dose'}, {'measure': 'Objective response rate (ORR), disease control rate (DCR), duration of response (DoR), and progression-free survival (PFS) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; overall survival (OS)', 'timeFrame': 'From screening to up to 3 years after last dose'}, {'measure': 'Incidence of anti-HS-20110 antibody (ADA)', 'timeFrame': 'From the first dose until 90 days after the last dose'}, {'measure': 'Drug concentrations of the three components of HS-20110 (including antibody-drug conjugates, total antibody, and payload)', 'timeFrame': 'From the first dose until 90 days after the last dose'}]",6,18 Years,,ALL,False,Hansoh BioMedical R&D Company,INDUSTRY,0,475.0,ESTIMATED,2025-09-01T16:18:12.186172,v2_robust,True,True,False,False,True,
NCT05081479,A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma,Phase I Study of N-Acetylcysteine to Optimize Metabolic Tumor Microenvironment in CD19 CAR T-cell Therapy in Lymphoma,N-Acetylcysteine,"['N-AC', 'N-Acetylcysteine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Lymphoma,['Lymphoma'],"['N-AC', 'N-Acetylcysteine', 'Lymphoma', 'CD19 CAR T-cell Therapy', '21-386', 'Memorial Sloan Kettering Cancer Center']",ACTIVE_NOT_RECRUITING,,2021-12-08,2025-10-21,"[{'measure': 'Maximum tolerated dose of N-AC', 'description': 'This is a phase 1 dose escalation and expansion study to determine the maximum tolerated dose and recommended phase 2 dose of NAC given in conjunction with axicabtagene ciloleucel.', 'timeFrame': 'Up to 1 year'}]",[],1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,9.0,ACTUAL,2025-09-01T16:18:12.186183,v2_robust,True,True,False,False,False,
NCT06644079,Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma,Window of Opportunity Pilot Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma,Tranexamic acid,['Tranexamic acid'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Cutaneous Squamous Cell Carcinoma,['Cutaneous Squamous Cell Carcinoma'],"['topical tranexamic acid', 'cutaneous squamous cell carcinoma']",WITHDRAWN,Study not moving forward due to upcoming PI departure,2025-05,2026-04,"[{'measure': 'Percentage of subjects who have a reduction in tumor size', 'description': 'Determine the percentage of subjects who have a reduction in tumor size at the time of definitive surgery, as compared to tumor size at baseline. This is measured by comparing the total tumor area before treatment with the total tumor area at the time of definitive surgery. Tumor area will be measured via images and will be calculated using length x width x height in mm.', 'timeFrame': '35 days'}]","[{'measure': 'Difference in surgical defect size and tumor area at the time of surgery', 'description': 'Determine the difference in surgical defect size and tumor area at the time of surgery', 'timeFrame': 'At the time of surgery'}, {'measure': 'Maximal tumor reduction', 'description': 'Determine the maximal tumor volume by calculation of difference in total tumor volume between pre-treatment baseline and time of surgery. Tumor volume is calculated by direct visualization and measurements (in mm) of largest dimension in width x length x height of elevation off of skin surface.', 'timeFrame': '35 days'}, {'measure': 'Treatment compliance', 'description': 'Determine patient treatment compliance as measured by the percentage of doses applied out of total possible applications', 'timeFrame': '21-28 days'}, {'measure': 'Treatment tolerance', 'description': 'Determine patient treatment tolerance, as measured by patient reported description of irritation, difficulty in application, or other commentary on intolerance and by indirect evaluation of patient compliance.', 'timeFrame': '21-28 days'}]",5,18 Years,,ALL,False,University of Florida,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:12.186221,v2_robust,True,True,False,True,False,Study not moving forward due to upcoming PI departure
NCT05633979,Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer,Trastuzumab deruxtecan,"['Trastuzumab deruxtecan', 'Valemetostat']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Breast Cancer,['Breast Cancer'],[],RECRUITING,,2023-02-09,2032-12-31,"[{'measure': 'The Overall Response Rate (ORR)', 'timeFrame': 'through study completion; an average of 2-3 years.'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,37.0,ESTIMATED,2025-09-01T16:18:12.186316,v2_robust,True,True,False,False,False,
NCT01077479,Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome,Metformin in Preventing Androgen Deprivation Therapy Induced Insulin Resistance and Metabolic Syndrome,Metformin,['Metformin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Metabolic Syndrome,"['Metabolic Syndrome', 'Hypercholesterolemia']","['body fat mass gain', 'Insulin resistance']",COMPLETED,,2010-02,2013-06,"[{'measure': 'The percentage change in insulin resistance measured by homeostasis model assessment (HOMAIR) from baseline to 12 and 24 weeks', 'timeFrame': '12 and 24 weeks'}]","[{'measure': 'To assess the efficacy of metformin in abrogating ADT-induced insulin resistance as measured by whole-body insulin sensitivity index(ISI) at 3 and 6 months', 'timeFrame': '12 and 24 weeks'}, {'measure': 'To assess the efficacy of metformin in reducing the incidence of ADT-induced metabolic syndrome at 3 and 6 months', 'timeFrame': '12 and 24 weeks'}, {'measure': 'To assess the efficacy of metformin in reducing ADT-induced percentage body fat mass gain 6 months', 'timeFrame': '24 weeks'}, {'measure': 'To assess the efficacy of metformin in reducing ADT-induced hypercholesterolemia at 3 and 6 months', 'timeFrame': '12 and 24 weeks'}, {'measure': 'To validate measurement of insulin resistance by HOMAIR with euglycemic hyperinsulinemic clamp in a subgroup group of participants', 'timeFrame': '24 weeks'}]",6,18 Years,,MALE,False,Western Sydney Local Health District,OTHER,0,28.0,ACTUAL,2025-09-01T16:18:12.186349,v2_robust,True,True,True,False,False,
NCT02190279,18F-DCFBC PET/CT in Prostate Cancer,A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer,18F DCFBC,"['Sodium (Na)18F positron emission tomography (PET)/computed tomography (CT)', '18F DCFBC', 'Na 18F PET/CT']",3,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Prostatic Neoplasms,"['Prostatic Neoplasms', 'Prostate Cancer']","['Prostate Specific Membrane Antigen', 'Radiolabeled PET Agent', 'Imaging', 'NaF']",COMPLETED,,2014-07-12,2018-01-11,"[{'measure': 'Number of Participants With Local Recurrence, Lymph Node Metastases or Distant Metastatic Sites Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC) Imaging', 'description': 'Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered positive for prostate cancer, and each was classified as local recurrence, lymph node metastases or distant metastatic sites.', 'timeFrame': '1 hour and 2 hour timepoints at baseline'}, {'measure': 'Number of Lesions Detected by N-[N-[(S)-1,3-dicarboxypropyl]Carbamoyl]-4-(18)F-fluorobenzyl-L-cysteine ((18)F-DCFBC)', 'description': 'Any abnormal focus of 18F-DCFBC uptake higher than the surrounding background and not associated with physiological uptake was considered a positive lesion for prostate cancer.The measure would be compared with other imaging or pathology.', 'timeFrame': '1 hour and 2 hour timepoints at baseline'}]","[{'measure': 'Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0)', 'description': 'Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.', 'timeFrame': 'Date treatment consent signed to date off study, approximately 42 months and 21 days'}, {'measure': 'Number of Detectable Lesions in Bone With Respect to 18F-DCFBC Imaging and/or Na18F Positron Emission Tomography (PET)/Computed Tomography (CT) in Patients With Known Metastatic Disease', 'description': '18F-DFBC and conventional imaging was used to identify positive lesions in bone.', 'timeFrame': '3 months'}, {'measure': 'Average Standardized Uptake Value (SUVmax) for Primary Prostate Cancer Patients Compared to Benign Prostatic Hyperplasia (BPH)', 'description': 'Primary prostate cancer was compared to BPH nodules and normal prostate tissue using a one-way analysis of variance (Anova). Negative uptake is defined as tumor uptake less than adjacent background soft tissue, or blood pool for lymph nodes.', 'timeFrame': '1 hour and 2 hour post injection (p.i.)'}, {'measure': 'Median Tumor Foci Size in Suspected Localized Prostate Cancer Patients Undergoing Prostatectomy', 'description': 'Tissue was obtained and stained with hematoxylin-eosin. The resulting whole mount specimens were correlated with MRI and PET/CT imaging. For each dominant/index tumor (largest tumor with highest Gleason score) was determined.', 'timeFrame': '1 month'}, {'measure': 'Detectability of Suspicious Prostate Cancer Lesions in Suspected Localized Prostate Cancer Patients With Prostate Gland', 'description': 'Visualizing positive lesions with DCFBC and mpMRI.', 'timeFrame': '3 months'}, {'measure': 'Detectability of Suspicious Tumors Based on Prostate Specific-Antigen (PSA) Levels in the Biochemical Recurrence Group', 'description': 'Visualizing positive lesions as a function of PSA value. Undetectable PSA is normal in this population.', 'timeFrame': '3 months'}]",8,18 Years,99 Years,MALE,False,National Cancer Institute (NCI),NIH,0,116.0,ACTUAL,2025-09-01T16:18:12.186364,v2_robust,True,True,True,False,True,
NCT00673179,"Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy","Outpatient Chemotherapy in Pediatric Osteosarcoma: Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy",Doxorubicin,"['Paraplatin®', 'GM-CSF', 'Gemcitabine', 'Leucovorin', 'Zinecard', 'Dexrazoxane', 'Gemzar', 'Ifex', 'Leukine™', 'Methotrexate', 'Gemcitabine Hydrochloride', 'Cisplatin', 'Hydroxydaunomycin hydrochloride', 'Ifosfamide', 'Mesna', 'Mesnex', 'AD', 'Sargramostim', 'Doxorubicin']",19,INTERVENTIONAL,['NA'],,,Osteosarcoma,['Osteosarcoma'],"['Doxorubicin', 'AD', 'Hydroxydaunomycin hydrochloride', 'Cisplatin', 'Paraplatin®', 'Methotrexate', 'Ifosfamide', 'Osteosarcoma', 'Sargramostim', 'Leukine™', 'Leucovorin', 'Gemcitabine', 'Gemzar', 'Gemcitabine Hydrochloride', 'GM-CSF', 'Questionnaire', 'Survey']",TERMINATED,Low accrual.,2008-05,2010-11,"[{'measure': 'Treatment Success (6 or Fewer Hospitalizations During Front-line Chemotherapy)', 'description': 'Treatment success defined as a patient having 6 or fewer hospitalizations during front-line chemotherapy.', 'timeFrame': 'Baseline to 5 Years'}]","[{'measure': 'Quality of Life (Ped QL) Assessment', 'timeFrame': 'Peds QL measures at week 0 (during first chemo cycle), week 6, week 20, at end of therapy, and at 3 years.'}]",2,5 Years,40 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,7.0,ACTUAL,2025-09-01T16:18:12.186390,v2_robust,True,True,False,True,False,Low accrual.
NCT02224079,"Safety, Tolerability and Pharmacokinetics of Single Rising Doses of BIIB 722 CL and HPβCD in Young Healthy Male Volunteers","Safety, Tolerability and Preliminary Pharmacokinetics of Single Rising Doses of 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 37.5 mg, 50 mg, 75 mg, 100 mg, 125 mg and 150 mg BIIB 722 CL (Calculated as 'Free Base') and HPβCD Given as Intravenous Infusion Over 30 Minutes to Young Healthy Male Subjects. A Single-centre, Single-blind, Placebo-controlled, Randomised Study.",BIIB 722 CL,"['BIIB 722 CL', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2002-04,,"[{'measure': 'Number of subjects with adverse events', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of subjects with clinically significant findings in vital signs', 'description': 'blood pressure, pulse rate, respiratory rate, oral body temperature', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of subjects with clinically significant findings in ECG', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of subjects with clinically significant findings in laboratory tests', 'timeFrame': 'up to 12 days after drug administration'}]","[{'measure': 'Plasma concentration time profiles', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Maximum measured concentration of the analyte in plasma (Cmax)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Time from dosing to the maximum concentration of the analyte in plasma (tmax)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Area under the concentration-time curve of the analyte in plasma from time zero to a specified point in time (AUC0-t)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Terminal half-life of the analyte in plasma (t1/2)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Mean residence time of the analyte in the body (MRT)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Total clearance of the analyte in plasma (CL)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Apparent volume of distribution at steady state (Vss)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Amount of drug excreted into urine (Ae)', 'timeFrame': 'up to 72 hours after drug administration'}]",13,21 Years,50 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:12.186400,v2_robust,True,True,True,False,True,
NCT00323479,Arthralgia During Anastrozole Therapy for Breast Cancer,"A Multicentre, Open Study Assessing Joint Disorders Under ARIMIDEX® (1mg/Day) as Adjuvant Treatment in Post Menopausal Women With Early Breast Cancer",Anastrozole,"['ZD1033', 'ARIMIDEX', 'Anastrozole']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Early Breast Cancer,['Early Breast Cancer'],"['breast cancer treatment', 'joint disorders']",COMPLETED,,2006-06,2009-01,"[{'measure': 'Number of Participants With New Events of Arthralgia', 'timeFrame': '12 months'}]","[{'measure': 'Functional Index of Cochin at 12 Months in Patients Under Anastrozole.', 'description': 'Functional index of cochin score (from 0 to 90) : sum up of 18 questions on activities involving hands (each question scored from 0 = yes without difficulties (best) to 5 = impossible (worst)) based on 99 patients due to missing values.', 'timeFrame': '12 months'}, {'measure': 'Serum Collagen Degradation Type I - CTX-I at 12 Months in Patients Under Anastrozole', 'description': 'Results are based on 97 patients due to missing values', 'timeFrame': '12 months'}, {'measure': 'Kellgren and Lawrence Score at 12 Months in Patients Under Anastrozole', 'description': 'X ray evaluation of arthritis in 30 articulations ; each articulation scored from (0 = no arthritis to 4 = severe arthritis) based on 92 patients due to missing values', 'timeFrame': '12 months'}, {'measure': 'Synovial Membrane Thickness at 12 Months in Patients Under Anastrozole', 'description': 'X ray assessment on hands and wrists based on 99 patients due to missing values', 'timeFrame': '12 months'}, {'measure': 'Percentage of Participant With Therapeutic Maintenance Under Anastrozole', 'description': 'Treatment compliance. results based on 109 patients due to missing values', 'timeFrame': '12 months'}]",6,18 Years,,FEMALE,False,AstraZeneca,INDUSTRY,0,114.0,ACTUAL,2025-09-01T16:18:12.186450,v2_robust,True,True,True,False,False,
NCT02322879,Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing,Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing,First Treatment Period,"['First Treatment Period', 'Second Treatment Period']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Acetaminophen Toxicity,['Acetaminophen Toxicity'],"['Acetaminophen', 'Propylene glycol']",COMPLETED,,2013-05,2016-12,"[{'measure': 'Rise in Plasma Transaminases: Proportion of Responders.', 'description': 'Blood tests to monitor Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) were obtained on every visit prior dosing. ALT and AST were analyzed on a Roche Cobas c501 chemistry module at BIDMC. Responders was defined as peak ALT increased 2x baseline (average of first 3 days)', 'timeFrame': 'Daily during the treatment periods (D1-D14 and D29 to 42)'}]",[],1,20 Years,40 Years,ALL,True,Beth Israel Deaconess Medical Center,OTHER,1,21.0,ACTUAL,2025-09-01T16:18:12.186469,v2_robust,True,True,True,False,False,
NCT00704496,The Effect of Pseudoephedrine on Rhinitis and Sleep,The Effect of Pseudoephedrine on Rhinitis and Sleep,Pseudoephedrine,"['Pseudoephedrine', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Rhinitis,"['Rhinitis', 'Sleep']","['Sleep, Pseudoephedrine']",COMPLETED,,2007-06,2009-09,"[{'measure': 'Improvement of Sleep Associated With the Use of Pseudoephedrine as Compared to the Placebo', 'description': 'sleep improvement by subjective questionnaires', 'timeFrame': '3 years'}]","[{'measure': 'Improvement of Daytime Somnolence With Pseudoephedrine as Compared to Placebo', 'description': 'daytime sleepiness by subjective questionnaires', 'timeFrame': '3 years'}]",2,18 Years,65 Years,ALL,False,Milton S. Hershey Medical Center,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:12.186540,v2_robust,True,True,True,False,False,
NCT04991896,Beta Blockers Plus Intravenous Flecainide for Paroxysmal Atrial Fibrillation: a Real-world Chios Registry (BETAFLEC-CHIOS),Acute Management of Paroxysmal Atrial Fibrillation With Beta Blockers Plus Intravenous Flecainide: a Real-world Chios Registry (BETAFLEC-CHIOS),Flecainide Injectable Product,"['Sotalol, Bisoprolol, Metoprolol, Betaxolol', 'Flecainide Injectable Product']",2,OBSERVATIONAL,[],,,Atrial Fibrillation,"['Atrial Fibrillation', 'Arrhythmias, Cardiac']",[],COMPLETED,,2020-01-01,2021-06-30,"[{'measure': 'Number of patients converted to sinus rhythm at 1 hour', 'description': 'Successful cardioversion from atrial fibrillation to sinus rhythm at 1 hour', 'timeFrame': '1 hour'}]","[{'measure': 'Number of patients converted to sinus rhythm at 2 hour', 'description': 'Successful cardioversion from atrial fibrillation to sinus rhythm at 2 hours', 'timeFrame': '2 hours'}, {'measure': 'Number of patients with any documented proarrhythmic event', 'description': 'Ventricular tachycardia, ventricular fibrillation, torsades de pointes, atrial flutter with 1:1 atrioventricular conduction', 'timeFrame': '2 hours'}, {'measure': 'Number of arrhythmic events managed with defibrillation', 'description': 'Any arrhythmic event managed with defibrillation', 'timeFrame': '2 hours'}, {'measure': 'Number of patients with documented severe hypotension', 'description': 'Systolic blood pressure \\<90 mmHg for \\>10 min or requiring inotropic support', 'timeFrame': '2 hours'}, {'measure': 'Number of patients that discontinued IV flecainide infusion', 'description': 'Discontinuation of the IV flecainide infusion for any reason', 'timeFrame': '2 hours'}, {'measure': 'Hospitalization duration', 'description': 'Total length of hospitalization duration in hours', 'timeFrame': '48 hours'}]",7,18 Years,,ALL,False,AHEPA University Hospital,OTHER,1,81.0,ACTUAL,2025-09-01T16:18:12.186585,v2_robust,False,True,True,False,False,
NCT04777396,A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE),A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE),Semagludtide,"['Semagludtide', 'Placebo (semaglutide)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Early Alzheimer's Disease,"[""Early Alzheimer's Disease""]",[],ACTIVE_NOT_RECRUITING,,2021-05-18,2026-10-23,"[{'measure': 'Change in the Clinical Dementia Rating - Sum of Boxes (CDR-SB) score', 'description': 'Score on scale (0 to 18)\n\nMeasures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer\'s disease:\n\n* Cognitive domains: memory, orientation, and judgement and problem solving\n* Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents ""none"" to ""severe"" impairment for each of the six domains.\n\nThe CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}]","[{'measure': ""Main Phase: Change in the 24-item Alzheimer's Disease Cooperative Study Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-ADL-MCI) score"", 'description': 'Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase:Change in the ADCS-ADL-MCI (Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory-Mild Cognitive Impairment ) score"", 'description': 'Score on scale (0 to 53) An interview-based assessment of information provided by the study partner (informant). The total scores based on 18 items on the scale range from 0 to 53 with lower scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥) 1.0 among patients with CDR global score equal to (=) 0.5 at baseline', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Time to progression to Clinical Dementia Rating (CDR) global score greater than or equal to (≥) 1.0 among patients with CDR global score equal to (=) 0.5 at baseline', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': ""Main Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score"", 'description': 'Score on scale (0 to 85) ADAS-Cog-13 measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The ADAS-Cog-13 is composed of tasks in the original 11-item ADAS-Cog as well as delayed word recall and number cancellation items. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase: Change in the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog-13) score"", 'description': 'Score on scale (0 to 85) ADAS-Cog-13 measures the severity of cognitive impairment in various domains including memory, language, orientation, praxis and executive function. The ADAS-Cog-13 is composed of tasks in the original 11-item ADAS-Cog as well as delayed word recall and number cancellation items. The total scores on the scale range from 0 to 85 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the Montreal Cognitive Assessment (MoCA) score', 'description': 'Score on scale (0 to 30) The MoCA is a brief assessment of cognitive abilities including orientation, short-term memory, clock-drawing test, executive function, language abilities, animal naming, attention and abstrac-tion. The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the Montreal Cognitive Assessment (MoCA) score', 'description': 'Score on scale (0 to 30) The MoCA is a brief assessment of cognitive abilities including orientation, short-term memory, clock-drawing test, executive function, language abilities, animal naming, attention and abstrac-tion. The assessment includes 8 domains of cognitive function with total scores ranging from 0 to 30 and lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': ""Main Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)"", 'description': 'Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': ""Extension Phase: Change in the Alzheimer's Disease Composite Score (ADCOMS)"", 'description': 'Score on scale (0 to 1.97) The ADCOMS is a composite clinical outcome comprising 4 items from the ADAS-Cog-13, 2 items from the MMSE and all 6 items from the CDR-SB.32 The total scores on the scale range from 0 to 1.97 with higher scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the Mini-Mental State Examination (MMSE) score', 'description': 'Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the Mini-Mental State Examination (MMSE) score', 'description': 'Score on scale (0 to 30) The MMSE measures orientation, attention, memory, language and visuo-spatial function. The total scores on the scale range from 0 to 30 with lower scores indicating greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to progression in disease stage based on global CDR score', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Time to progression in disease stage based on global CDR score', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Main Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13', 'description': 'Score', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the composite Z-score based on the three outcome measures CDR-SB, ADCS-ADL-MCI, and ADAS-Cog-13', 'description': 'Score', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score', 'description': 'Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the 10-item Neuropsychiatric Inventory (NPI) score', 'description': 'Score on scale (0 to 120) The 10-item scale assesses symptoms including delusions, hallucinations, agitation/aggression, dysphoria, anxiety, euphoria, apathy, disinhibition, irritability/lability and aberrant motor activity. For each domain the frequency (4-point scale) and severity (3-point scale) of symptoms is reported. The score for each domain is calculated by multiplying the frequency and severity score. The total 10-item NPI score is 0 to 120 with higher scores indicating a greater symptomatology.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in high sensitivity C-reactive protein level', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in high sensitivity C-reactive protein level', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Number of treatment emergent adverse events (TEAEs)', 'description': 'Number of events', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Extension Phase: Number of treatment emergent adverse events (TEAEs)', 'description': 'Number of events', 'timeFrame': 'From baseline (week 0) up to week 156'}, {'measure': 'Main Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Time to first occurrence of major adverse cardiovascular event (MACE) comprising non-fatal myocardial infarction, non-fatal stroke and all-cause death', 'description': 'Week(s)', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Time to first occurrence of stroke', 'description': 'Week(s', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Time to first occurrence of stroke', 'description': 'Week(s', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Main Phase: Change in the EQ-5D-5L (proxy version) index score', 'description': 'Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \\[the proxy\\] would rate the subject´s health) will be used in this trial.', 'timeFrame': 'From baseline (week 0) to week 104'}, {'measure': 'Extension Phase: Change in the EQ-5D-5L (proxy version) index score', 'description': 'Score The EQ-5D-5L descriptive system comprises mobility, self-care, usual activities, pain/discomfort and anxiety/depression with five response levels each (no problems, slight problems, moderate problems, severe problems, unable to /extreme problems). The EQ-5D-5L proxy version 1 (the study partner is asked to rate how he/she \\[the proxy\\] would rate the subject´s health) will be used in this trial.', 'timeFrame': 'From baseline (week 0) to week 156'}, {'measure': 'Extension phase: Change in the CDR-SB score', 'description': 'Score on scale (0 to 18)\n\nMeasures the impact of cognitive decline on daily function using the following six domains commonly affected in Alzheimer\'s disease:\n\n* Cognitive domains: memory, orientation, and judgement and problem solving\n* Function domains: community affairs, home and hobbies, and personal care Based on clinical information obtained from the subject and informant, an individual box score ranging from 0 to 3 is determined that represents ""none"" to ""severe"" impairment for each of the six domains.\n\nThe CDR-Sum of Boxes (CDR-SB) score will be derived by adding the individual scores of the six domains at a given time point. The total CDR-SB score ranges from 0 to 18 with higher scores representing greater impairment.', 'timeFrame': 'From baseline (week 0) to week 156'}]",30,55 Years,85 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,1840.0,ESTIMATED,2025-09-01T16:18:12.186602,v2_robust,True,True,False,False,True,
NCT06271096,Intramuscular Midazolam Versus Intravenous Diazepam for Acute Seizure in Children,Intramuscular Midazolam Versus Intravenous Diazepam for Acute Seizure in Children,Intra muscular Midazolam,"['Intravascular Diazepam', 'Intra muscular Midazolam']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Seizures,['Seizures'],[],COMPLETED,,2019-11-01,2024-01-01,"[{'measure': 'Fits Controlled', 'description': 'Treatment was considered successful if seizures stopped within 300 seconds of administering the drug. If seizures were not controlled within 300 seconds, Treatment failures were marked. other anticonvulsants were tried.', 'timeFrame': '300 seconds'}]",[],1,3 Months,5 Years,ALL,False,Arooj Khan,OTHER,0,150.0,ACTUAL,2025-09-01T16:18:12.186678,v2_robust,True,True,True,False,False,
NCT01908296,Study to Evaluate the Effect of Multiple-dose of Fluvoxamine on the Plasma Concentration of Quetiapine (FK949E) in Healthy Male Volunteers,Phase I Study of FK949E - A Study of Drug-drug Interactions Between FK949E and Fluvoxamine in Healthy Male Adults,FK949E,"['Luvox®', 'extended release formulation of quetiapine', 'FK949E', 'fluvoxamine']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,"['Healthy', 'Pharmacokinetics of Quetiapine']","['FK949E', 'fluvoxamine', 'Antipsychotic', 'Quetiapine']",COMPLETED,,2011-07,2011-08,"[{'measure': 'Maximum plasma concentration (Cmax) of unchanged quetiapine', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 'AUC (area under the curve) of unchanged quetiapine', 'timeFrame': 'For 48 hours after dosing.'}]","[{'measure': 'tmax of plasma concentration of unchanged quetiapine', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 't1/2 of plasma concentration of unchanged quetiapine', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 'Maximum plasma concentration (Cmax) of quetiapine metabolites', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 'AUC (area under the curve) of quetiapine metabolites', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 'tmax of plasma concentration of quetiapine metabolites', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 't1/2 of plasma concentration of quetiapine metabolites', 'timeFrame': 'For 48 hours after dosing.'}, {'measure': 'Maximum plasma concentration (Cmax) of unchanged fluvoxamine', 'timeFrame': 'For 12 hours after dosing.'}, {'measure': 'AUC (area under the curve) of unchanged fluvoxamine', 'timeFrame': 'For 12 hours after dosing.'}, {'measure': 'tmax of plasma concentration of unchanged fluvoxamine', 'timeFrame': 'For 12 hours after dosing.'}, {'measure': 't1/2 of plasma concentration of unchanged fluvoxamine', 'timeFrame': 'For 12 hours after dosing.'}, {'measure': 'Safety assessed by the incidence of adverse events, clinical tab tests, vital signs, 12-lead ECGs and physical exam', 'timeFrame': 'Up to 20 Days.'}]",13,20 Years,44 Years,MALE,True,Astellas Pharma Inc,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:12.186687,v2_robust,True,True,True,False,True,
NCT01902862,An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma,Pilot Study With Bortezomib in Combination With Rituximab Standard Therapy in Patients With Relapsed or Refractory Follicular Lymphoma and at Least 2 Previous Therapies,Bortezomib,"['Bortezomib', 'VELCADE', 'Rituximab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lymphoma, Follicular","['Lymphoma, Follicular']","['Lymphoma, follicular', 'Bortezomib', 'Rituximab']",TERMINATED,Recruitment too slow,2006-02,2007-08,"[{'measure': 'Time to Progression or Relapse', 'description': 'Time to disease progression is defined as the time from start of treatment to the time of first documentation of disease progression.', 'timeFrame': 'Start of treatment (Day 1 of Cycle 1) up to Month 15'}]","[{'measure': 'Maximum Tolerated Dose (MTD) of Bortezomib in Combination With Rituximab', 'description': 'MTD is defined as the dose level combination below the dose level that produces a dose-limiting toxicity. If MTD is not reached, the recommended MTD is the maximum dose that the participants received. Tolerability of bortezomib in combination with rituximab standard therapy will be monitored.', 'timeFrame': 'Start of treatment (Day 1 of Cycle 1) up to Month 15'}, {'measure': 'Number of Participants With Remission Status', 'description': 'Participants with complete response (CR), partial response (PR) and stable disease (SD) separately for each category as well as participants with CR or PR (cumulative, i.e., either CR or PR) or participants with CR, PR or SD (cumulative, i.e., either CR or PR or SD) as best remission status will be reported.', 'timeFrame': 'Start of treatment (Day 1 of Cycle 1) up to Month 15'}, {'measure': 'Disease-Free Survival', 'description': 'Disease-free survival is the time until the date of documentation of first progressive disease (PD) or death.', 'timeFrame': 'Start of treatment (Day 1 of Cycle 1) up to Month 15'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time from the start of treatment until death (whatever the cause). Participants still alive will be censored at the moment of last visit or contact.', 'timeFrame': 'Start of treatment (Day 1 of Cycle 1) up to Month 15'}]",5,18 Years,70 Years,ALL,False,Janssen-Cilag G.m.b.H,INDUSTRY,0,7.0,ACTUAL,2025-09-01T16:18:12.186871,v2_robust,True,True,False,True,False,Recruitment too slow
NCT03522662,Anti IL-18 (GSK1070806) in Behcet's Disease,An Experimental Medicine Study to Characterise the Importance of IL-18 Production and to Evaluate the Therapeutic Potential of IL-18 Blockade With GSK1070806 in Subjects With Behcet's Disease,GSK1070806,"['anti IL-18', 'GSK1070806']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Behcet's Disease,"[""Behcet's Disease""]",[],UNKNOWN,,2018-08-01,2020-04-01,"[{'measure': 'The occurrence of all moderate, severe and life threatening adverse events', 'description': 'Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)', 'timeFrame': '24 weeks'}]","[{'measure': 'All adverse events, including mild events', 'description': 'Events that that are possibly, probably or definitely attributable to a single IV dose of GSK1070806 (10mg/kg)', 'timeFrame': '24 weeks'}, {'measure': 'Measurement of disease activity', 'description': ""Using a clinical scoring tool, the Behcet's disease current activity form (BDCAF)"", 'timeFrame': '24 weeks'}, {'measure': 'Measurement of the accumulation of damage', 'description': 'Using a clinical scoring tool, the Vasculitis Damage Index (VDI)', 'timeFrame': '24 weeks'}]",4,18 Years,,ALL,False,Cambridge University Hospitals NHS Foundation Trust,OTHER,0,12.0,ESTIMATED,2025-09-01T16:18:12.187001,v2_robust,True,True,False,False,True,
NCT05986162,Safety and Preliminary Clinical Activity of Itolizumab in Dermatomyositis,"A Phase 1 Study to Evaluate the Safety, Tolerability and Preliminary Clinical Activity of Itolizumab in Subjects With Dermatomyositis",Itolizumab,"['Itolizumab', 'T1h']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Dermatomyositis, Adult Type","['Dermatomyositis, Adult Type']",[],NOT_YET_RECRUITING,,2023-12-30,2025-06-25,"[{'measure': 'Incidence of Treatment Emergent Adverse Events', 'description': 'Number of subjects with treatment-related adverse events as assessed by the Common Terminology Criteria for Adverse Events (CTCAE) V5.0', 'timeFrame': 'Study Week 20'}]","[{'measure': 'Maximum serum concentration of Itolizumab, Cmax', 'description': 'Maximum serum concentration of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'Minimum serum concentration of Itolizumab, Cmin', 'description': 'Minimum serum concentration of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'Time to maximum serum concentration of Itolizumab, Tmax', 'description': 'Time to maximum serum concentration of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'Total Itolizumab exposure across time, AUC0-t', 'description': 'Total Itolizumab exposure across time', 'timeFrame': 'Study Week 16'}, {'measure': 'Half life of Itolizumab, t1/2', 'description': 'Half life of Itolizumab', 'timeFrame': 'Study Week 16'}, {'measure': 'IL-2', 'description': 'Inflammatory Markers：IL-2', 'timeFrame': 'Study Week 16'}, {'measure': 'IL-6', 'description': 'Inflammatory Markers:IL-6', 'timeFrame': 'Study Week 16'}, {'measure': 'TNF-α', 'description': 'Inflammatory Markers: TNF-α', 'timeFrame': 'Study Week 16'}, {'measure': 'IFN-γ', 'description': 'Inflammatory Markers:IFN-γ', 'timeFrame': 'Study Week 16'}, {'measure': 'CRP', 'description': 'Inflammatory Markers:CRP', 'timeFrame': 'Study Week 16'}, {'measure': 'Serum ferritin', 'description': 'Inflammatory Markers:Serum ferritin', 'timeFrame': 'Study Week 16'}, {'measure': 'ESR', 'description': 'Inflammatory Markers:ESR', 'timeFrame': 'Study Week 16'}, {'measure': 'IgG', 'description': 'Inflammatory Markers：IgG', 'timeFrame': 'Study Week 16'}, {'measure': 'IgM', 'description': 'Inflammatory Markers：IgM', 'timeFrame': 'Study Week 16'}, {'measure': 'IgA', 'description': 'Inflammatory Markers： IgA', 'timeFrame': 'Study Week 16'}, {'measure': 'CD6 receptor expression levels', 'description': 'Mean change of CD6 receptor expression levels in relative to baseline', 'timeFrame': 'Study Week 16'}, {'measure': 'T cell subsets', 'description': 'Mean change of different proportion of T cell subsets in relative to baseline', 'timeFrame': 'Study Week 16'}, {'measure': 'Proportion of patients achieving a TIS of ≥20', 'description': 'Defined as patients with an increase of ≥20 points on the Total Improvement Score in relative to baseline.', 'timeFrame': 'Study Week 16'}, {'measure': 'Proportion of patients achieving DOI', 'description': 'DOI defined as ≥ 20% improvement in 3 of any 6 core set measures, with no more than 2 core set measures worsening by ≥ 25% (MMT-8 cannot worsen by ≥ 25%).', 'timeFrame': 'Study Week 16'}, {'measure': 'Mean Change of Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) activity score', 'description': 'Defined as the mean change of activity score of CDASI（Score Range：0\\~132，The hingher score indcates the worse outcome） relative to baseline.', 'timeFrame': 'Study Week 16'}, {'measure': 'Incidence of ADA', 'description': 'Defined as the precentage of subjects presenting anti-drug antibody', 'timeFrame': 'Study Week 16'}]",22,18 Years,75 Years,ALL,False,"Biotech Pharmaceutical Co., Ltd.",OTHER,0,44.0,ESTIMATED,2025-09-01T16:18:12.187015,v2_robust,True,True,False,False,True,
NCT02182362,"Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects","Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of 20 mg, 48 mg, 120 mg, and 240 mg Once a Day of BI 201335 NA (Oral Solution) in Healthy Male Subjects, in a Randomized Double Blind, Placebo Controlled Study",BI 201335 NA,"['BI 201335 NA', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2007-05,,"[{'measure': 'Number of patients with abnormal findings in physical examination', 'timeFrame': 'Baseline and up to 46 days'}, {'measure': 'Number of patients with clinically relevant changes in vital signs (blood pressure (BP), pulse rate (PR))', 'timeFrame': 'Baseline and up to 32 days'}, {'measure': 'Number of patients with clinically relevant changes in 12-lead ECG (electrocardiogram)', 'timeFrame': 'Baseline and up to 32 days'}, {'measure': 'Number of patients with clinically relevant changes in clinical laboratory tests (haematology, clinical chemistry, urinalysis)', 'timeFrame': 'Baseline and up to 32 days'}, {'measure': 'Incidence of adverse events', 'timeFrame': 'up to day 46'}, {'measure': 'Assessment of tolerability by investigator', 'timeFrame': 'Day 28 or 32'}]","[{'measure': 'Cmax (maximum measured concentration of the analyte in plasma)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'tmax (time from dosing to maximum measured concentration of the analyte in plasma)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'AUCτ,1 (area under the concentration-time curve of the analyte in plasma over a uniform dosing interval τ after administration of the first dose)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'AUC0-∞ (area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'λz (terminal rate constant in plasma)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 't1/2 (terminal half-life of the analyte in plasma)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'MRTpo (mean residence time of the analyte in the body after single oral administration)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'CL/F (apparent clearance of the analyte in plasma)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'Vz/F (apparent volume of distribution during the terminal phase λz)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60 hours after first treatment'}, {'measure': 'Cmax,ss (maximum measured concentration of the analyte in plasma at steady state over a uniform dosing interval τ)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'tmax,ss (time from last dosing to maximum concentration of the analyte in plasma at steady state)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'Cmin,ss (minimum concentration of the analyte in plasma at steady state over a uniform dosing interval τ)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'λz,ss (terminal rate constant in plasma at steady state)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 't1/2,ss (terminal half-life of the analyte in plasma at steady state)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'MRTpo,ss (mean residence time of the analyte in the body at steady state after oral administration)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'CL/F,ss (apparent clearance of the analyte in the plasma at steady state following multiple oral dose administration)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}, {'measure': 'Vz/F,ss (apparent volume of distribution during the terminal phase λz at steady state following oral administration)', 'timeFrame': 'Pre-dose and 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24, 30, 36, 48, 60, 72, 84, 96 hours after last dose'}]",24,18 Years,55 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:12.187024,v2_robust,True,True,True,False,True,
NCT05041062,A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma,"A Phase II Prospective, Open-label Trial of Perioperative Combination Nivolumab and Ipilimumab in Patients With Resectable Malignant Peritoneal Mesothelioma",Nivolumab,"['Ipilimumab', 'Nivolumab', 'Opdivo', 'Yervoy', 'BMS-936558', 'MDX1106', 'ONO-4538']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Mesothelioma,"['Mesothelioma', 'Peritoneal Mesothelioma']","['chest cancer', 'abdominal cancer', 'lung cancer', 'cancer in lining of lungs']",COMPLETED,,2021-12-01,2023-04-13,"[{'measure': 'Major Pathologic (Disease) Response of Tumor to Nivolumab Combined With Ipilimumab Before Surgery', 'description': ""The response of participant's tumor to treatment with nivolumab and ipilimumab before surgery by analyzing tissue samples collected from participant during surgery for the presence of cancerous tumour cells. Major pathologic response will be defined as tissue samples containing less than or equal to 10% of residual (leftover) tumor/cancer in the tissue after surgery."", 'timeFrame': '24 months'}]","[{'measure': 'Rate of Participants Who Report Serious Side Effects to Nivolumab Combined With Ipilimumab Before Surgery (Neoadjuvant Treatment)', 'description': 'The rate of participants who report Grade 3 or 4 serious adverse events (side effects) after taking nivolumab combined with ipilimumab before surgery. These side effects will be measured according to Common Terminology Criteria for Adverse Events v5.0 for up to 30 days after surgery.', 'timeFrame': '3 weeks (timeframe for surgery ) + 30 days (timeframe for assessing side effects after surgery)'}, {'measure': 'Number of Participants Who Proceed to Surgery Without Delays After Receiving Nivolumab Combined With Ipilimumab', 'description': 'Number of participants who complete treatment with nivolumab and ipilimumab before surgery and proceed to surgery without extended treatment-related delays or progression precluding surgery as assessed by clinical /study records.', 'timeFrame': '19 weeks'}, {'measure': 'Overall Survival of Participants Who Take Nivolumab Combined With Ipilimumab Before Surgery', 'description': 'Overall survival of participants who receive neoadjuvant nivolumab combined with ipilimumab, defined as time from enrollment on study to death from any cause.', 'timeFrame': '42 Months'}, {'measure': 'Progression-Free Survival of Participants Who Take Nivolumab Combined With Ipilimumab Before Surgery', 'description': 'Progression-free survival of participants who receive neoadjuvant nivolumab combined with ipilimumab, defined as time from enrollment on study to death from any cause.', 'timeFrame': '42 months'}, {'measure': 'Rate of Participants Who Report Serious Side Effects to Taking Nivolumab Combined With Ipilimumab After Surgery (Adjuvant Treatment)', 'description': 'The rate of participants who report Grade 3 or 4 serious adverse events (side effects) after taking nivolumab combined with ipilimumab after surgery. These side effects will be measured according to Common Terminology Criteria for Adverse Events v5.0.', 'timeFrame': '12 weeks'}, {'measure': 'Radiologic Response to Nivolumab and Ipilimumab Before Surgery', 'description': 'Radiologic response to nivolumab and ipilimumab before surgery using radiology images of tumor pre- and post-treatment.', 'timeFrame': '24 months'}, {'measure': 'Peritoneal Carcinomatosis Index (PCI) of Participants Who Taking Nivolumab Combined With Ipilimumab Before Surgery', 'description': ""The effect of nivolumab and ipilimumab on participant's tumor as assessed by a peritoneal carcinomatosis index (PCI) score, a score determined based on the size of participant's tumor after abdominal surgery.\n\nThe Peritoneal Cancer Index (PCI) scoring system is a diagnostic and prognostic tool. The PCI score is calculated by dividing the peritoneal (abdominal) cavity into 13 regions and assigning a score to each of the 13 regions. Each region receives a score of 0-3 based on the largest tumor size in each region. The total sum of all 13 regions is the PCI score. PCI scores can range from 0 to 39. Higher scores indicate more widespread and/or larger tumors in the peritoneal cavity."", 'timeFrame': '12 weeks'}]",8,18 Years,,ALL,False,University of Chicago,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:12.187047,v2_robust,True,True,True,False,True,
NCT00065962,Secretin for the Treatment of Autism,Multisite Controlled Secretin Trial in Autism,"secretin, synthetic porcine","['secretin, biologically derived porcine', 'secretin, synthetic porcine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Autism,['Autism'],"['Pervasive Developmental Disorders', 'Secretin, synthetic porcine', 'Secretin, biological porcine', 'Autism Diagnostic Observation Schedule - Generic (ADOS-G)', 'Rimland Questionnaire', 'Expressive Vocabulary Test', 'MacArthur Communication Inventory', 'Aberrant Behavior Checklist']",COMPLETED,,1999-06,2000-05,[],[],0,3 Years,12 Years,ALL,False,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,1,85.0,,2025-09-01T16:18:12.187062,v2_robust,True,True,True,False,False,
NCT00396162,Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis,Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis,probiotic containing L.rhamnosus R0011 strain,"['L rhamnosus R0011', 'probiotic containing L.rhamnosus R0011 strain']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Rhinosinusitis,['Chronic Rhinosinusitis'],[],COMPLETED,,2006-11,2008-02,"[{'measure': 'Mean Reduction in SNOT-20 Scores', 'description': 'Mean reduction (and Standard deviation) in SNOT-20 scores, from baseline to 8 week measurements. SinoNasal Outcome Test measures symptom severity. It is a summary score, ranging from 0 to 100 with 100 indicating worse symptoms. Since 100 represents more severe symptoms, the changes represented here are reductions in SNOT-scores, even though they are not expressed as negative numbers.', 'timeFrame': '8 weeks'}]","[{'measure': 'Side Effect Summary', 'description': 'Totals of all side effects for placebo group and treatment group over the course of the eight week trial (including patients who dropped from the study after baseline measurement). Individual categories of side-effects are listed in Adverse events section.', 'timeFrame': '8 weeks'}, {'measure': 'Mean Number of Days of Antibiotic Use During the Study Period (0-8 Weeks)', 'description': 'Mean number of days that antibiotics were used in the subgroup (placebo vs Probiotic arm)', 'timeFrame': 'At 8 weeks after baseline measures'}, {'measure': 'Mean Number of Days of Steroid Spray Use for Each Group', 'timeFrame': '8 weeks'}]",4,15 Years,70 Years,ALL,False,University of Michigan,OTHER,1,77.0,ACTUAL,2025-09-01T16:18:12.187097,v2_robust,True,True,True,False,True,
NCT00565162,"Insulin Glargine, INITIATE Metabolic and Economic Outcomes of Lantus","A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating Lantus(Insulin Glargine) Therapy to Determine Metabolic and Economic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes Mellitus",Insulin Glargine,"['Insulin Glargine', 'Lantus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes Mellitus,['Diabetes Mellitus'],[],COMPLETED,,2003-11,2005-06,"[{'measure': 'Superiority is based on observing clinically significant difference in glycaemic control (> than or = to 0,5 % HbA1c). Programs are defined as equally successful if the HbA1c differs less than 0,5 %.', 'timeFrame': 'HbA1c values at visits 1, 2, 5 and 10'}]",[],1,18 Years,,ALL,False,Sanofi,INDUSTRY,0,124.0,ACTUAL,2025-09-01T16:18:12.187111,v2_robust,True,True,True,False,False,
NCT00866762,A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia,A Phase II Study of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia.,HDAC inhibitor (MK-0683),['HDAC inhibitor (MK-0683)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Polycythemia Vera,"['Polycythemia Vera', 'Essential Thrombocythemia']","['Polycythaemia Vera', 'Polycythemia Vera', 'Essential Thrombocythaemia', 'Essential Thrombocythemia', 'HDAC-inhibitor', 'Haematology', 'Hematology', 'Haematological disorder', 'Haematological disease', 'Hematological disorder', 'Hematological disease']",UNKNOWN,,2009-02,2012-12,"[{'measure': 'To evaluate the efficacy of study drug (MK-0683) in the treatment of patients with PV and ET.', 'timeFrame': 'one year'}]","[{'measure': 'To study changes in bone marrow morphology before and after treatment with study drug.', 'timeFrame': 'one year'}]",2,18 Years,,ALL,False,Copenhagen University Hospital at Herlev,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:12.187150,v2_robust,True,True,False,False,False,
NCT06780462,Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome,Randomized Controlled Multicenter Study Comparing Steroid Therapy Plus Anticoagulants to Steroid Therapy Alone in Deep Venous Thrombosis of Behçet's Syndrome,Corticosteroids + Rivaroxaban,"['Corticosteroids + Rivaroxaban', 'Corticosteroids alone']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Behcet Syndrome,['Behcet Syndrome'],[],NOT_YET_RECRUITING,,2025-01-15,2028-01-15,"[{'measure': 'Rate of success', 'description': 'Defined as absence of deep venous thrombosis relapse and of major bleeding event, without introduction of additional immunosuppressive medication for BS activity other than thrombotic events at 6 months.', 'timeFrame': 'At 6 months'}]","[{'measure': 'Cumulative incidence of deep venous thrombosis and superficial venous thrombosis relapse', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of major venous thrombosis', 'description': 'pulmonary embolism, vena cava , Budd Chiari syndrome , intra-cardiac relapse', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of venous repermeabilization', 'description': 'assessed by vascular imaging', 'timeFrame': 'At 6 months'}, {'measure': 'Proportion of patients with a dose ≤ 5 mg/day of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 6 months'}, {'measure': 'Proportion of patients with a dose ≤ 5 mg/day of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 12 months'}, {'measure': 'Dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 3 months'}, {'measure': 'Dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 6 months'}, {'measure': 'Dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 3 months'}, {'measure': 'Cumulative dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 6 months'}, {'measure': 'Cumulative dose of prednisone', 'description': '(prednisone or equivalent prednisone dose only if prednisone is out of stock in the market)', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of major bleeding event', 'timeFrame': 'At 12 months'}, {'measure': 'Cumulative incidence of bleeding event', 'timeFrame': 'At 12 months'}, {'measure': 'Number of adverse events', 'timeFrame': 'At 3 months'}, {'measure': 'Number of adverse events', 'timeFrame': 'At 6 months'}, {'measure': 'Number of adverse events', 'timeFrame': 'At 12 months'}, {'measure': 'Change in SF-36 quality-of-life', 'description': 'The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.', 'timeFrame': 'At 3 months'}, {'measure': 'Change in SF-36 quality-of-life', 'description': 'The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.', 'timeFrame': 'At 6 months'}, {'measure': 'Change in SF-36 quality-of-life', 'description': 'The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.', 'timeFrame': 'At 12 months'}, {'measure': ""Change in Behçet's Disease Current Activity Form"", 'description': 'It is a 7 items score ranging from 0 to 12. The higher the sore the higher the severity of the disease.', 'timeFrame': 'At 3 months'}, {'measure': ""Change in Behçet's Disease Current Activity Form"", 'description': 'It is a 7 items score ranging from 0 to 12. The higher the sore the higher the severity of the disease.', 'timeFrame': 'At 6 months'}, {'measure': ""Change in Behçet's Disease Current Activity Form"", 'description': 'It is a 7 items score ranging from 0 to 12. The higher the sore the higher the severity of the disease.', 'timeFrame': 'At 12 months'}, {'measure': ""Change in Behçet's Syndrome Assessment Score"", 'description': ""It is based on various clinical manifestations of Behçet's disease. Score ranges from 0 to 12. The higher the score the higher the severity of the disease."", 'timeFrame': 'At 3 months'}, {'measure': ""Change in Behçet's Syndrome Assessment Score"", 'description': ""It is based on various clinical manifestations of Behçet's disease. Score ranges from 0 to 12. The higher the score the higher the severity of the disease."", 'timeFrame': 'At 6 months'}, {'measure': ""Change in Behçet's Syndrome Assessment Score"", 'description': ""It is based on various clinical manifestations of Behçet's disease. Score ranges from 0 to 12. The higher the score the higher the severity of the disease."", 'timeFrame': 'At 12 months'}, {'measure': 'Change in Physician Global Assessment', 'description': 'Evaluation of the disease activity. It ranges from 0 to 10. The higher the score the higher the activity of the disease.', 'timeFrame': 'At 3 months'}, {'measure': 'Change in Physician Global Assessment', 'description': 'Evaluation of the disease activity. It ranges from 0 to 10. The higher the score the higher the activity of the disease.', 'timeFrame': 'At 6 months'}, {'measure': 'Change in Physician Global Assessment', 'description': 'Evaluation of the disease activity. It ranges from 0 to 10. The higher the score the higher the activity of the disease.', 'timeFrame': 'At 12 months'}, {'measure': 'Overall survival', 'timeFrame': 'At 12 months'}, {'measure': 'Event free survival', 'timeFrame': 'At 12 months'}, {'measure': 'Proportion of post thrombotic syndrome', 'description': ""According to Villalta's post-thrombotic syndrome scale. It assesses the prensece and severity of post thrombotic syndrome. The score ranges from 0 to 30. The higher the score the more severe are the symptoms"", 'timeFrame': 'At 12 months'}, {'measure': ""Changes in Villalta's post-thrombotic syndrome scale"", 'description': ""According to Villalta's post-thrombotic syndrome scale. It assesses the prensece and severity of post thrombotic syndrome. The score ranges from 0 to 30. The higher the score the more severe are the symptoms"", 'timeFrame': 'At 6 months'}, {'measure': ""Changes in Villalta's post-thrombotic syndrome scale"", 'description': ""According to Villalta's post-thrombotic syndrome scale. It assesses the prensece and severity of post thrombotic syndrome. The score ranges from 0 to 30. The higher the score the more severe are the symptoms"", 'timeFrame': 'At 12 months'}, {'measure': 'Proportion of remission', 'description': 'According to other organs involved', 'timeFrame': 'At 3 months'}, {'measure': 'Proportion of remission', 'description': 'According to other organs involved', 'timeFrame': 'At 6 months'}, {'measure': 'Proportion of remission', 'description': 'According to other organs involved', 'timeFrame': 'At 12 months'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 1 month'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 3 months'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 6 months'}, {'measure': 'Changes in acute-phase reactants', 'timeFrame': 'At 12 months'}]",41,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,134.0,ESTIMATED,2025-09-01T16:18:12.187203,v2_robust,True,True,False,False,True,
NCT04937062,Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy,Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy,Glycerol Phenylbutyrate 1100 MG/ML [Ravicti],['Glycerol Phenylbutyrate 1100 MG/ML [Ravicti]'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder","['STXBP1 Encephalopathy With Epilepsy, SLC6A1 Neurodevelopmental Disorder', 'Developmental and Epileptic Encephalopathy']","['phenylbutyrate, developmental and epileptic encephalopathy']",ENROLLING_BY_INVITATION,,2021-03-01,2025-12-31,"[{'measure': 'Short Term Adverse events (i.e., safety)', 'description': 'The qualitative safety endpoint will describe any adverse events. It will include a description of the incidence, frequency, and severity of adverse events (including known side effects of the medication, changes in vital signs, EKG changes, EEG changes, increase in seizures, changes in clinical laboratory results, and/or changes in physical examination). We will monitor for these adverse events throughout the study, and measure them definitely at the time of the second admission.', 'timeFrame': '20 weeks'}, {'measure': 'Long Term Adverse events (i.e., safety)', 'description': 'The long term qualitative safety endpoint will describe any adverse events. It will include a description of the incidence, frequency, and severity of adverse events (including known side effects of the medication, changes in vital signs, EKG changes, EEG changes, increase in seizures, changes in clinical laboratory results, and/or changes in physical examination). We will monitor for these adverse events throughout the study, and measure them yearly until December 2025.', 'timeFrame': 'through December 2025 (1 - 5 years, depending on participant)'}, {'measure': 'Percentage of doses taken by participants (i.e., tolerability)', 'description': 'The tolerability endpoint is quantitative and will measure medication compliance (i.e. what percentage of the doses are taken).', 'timeFrame': '20 weeks'}]","[{'measure': 'Plasma concentration of phenylbutyrate', 'description': 'We will measure the plasma concentration of phenylbutyrate at the second inpatient admission.', 'timeFrame': '20 weeks'}]",4,0 Months,17 Years,ALL,False,Weill Medical College of Cornell University,OTHER,6,50.0,ESTIMATED,2025-09-01T16:18:12.187246,v2_robust,True,True,False,False,True,
NCT06797362,Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors,Expanded Access Treatment of Zidesamtinib (NVL-520) in Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors,NVL-520,"['NVL-520', 'Zidesamtinib']",2,EXPANDED_ACCESS,[],,,Non Small Cell Lung Cancer,"['Non Small Cell Lung Cancer', 'ROS1-positive Non-Small Cell Lung Cancer (NSCLC)']",[],AVAILABLE,,,,[],[],0,18 Years,,ALL,,Nuvalent Inc.,INDUSTRY,0,,,2025-09-01T16:18:13.410548,v2_robust,False,True,False,False,False,
NCT05194046,"Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers","A Randomized, Open-label, Multiple-dose, 3-way Crossover Phase 1 Clinical Trial to Evaluate Drug-drug Interactions and Safety Among JP-1366, Amoxicillin, and Clarithromycin in Healthy Volunteers",JP-1366 20mg 1capsule,"['Clarithromycin 500Mg Tab', 'Amoxicillin 500Mg Cap', 'JP-1366 20mg 1capsule']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Helicobacter Pylori Associated Gastrointestinal Disease,['Helicobacter Pylori Associated Gastrointestinal Disease'],[],COMPLETED,,2020-11-18,2021-01-19,"[{'measure': 'Cmax,ss of JP-1366, Amoxicillin, Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': 'AUCτ of JP-1366, Amoxicillin, Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}]","[{'measure': 'Tmax of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': 't1/2 of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': 'CLss/F of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': 'Vdss/F of JP-1366, Amoxicillin, Clarithromycin, 14-OH-Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': 'Cmax,ss of 14-OH-Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': 'AUCτ of 14-OH-Clarithromycin', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}, {'measure': '14-OH-Clarithromycin/Clarithromycin metabolic ratio', 'timeFrame': 'The time of steady state (after repetition administration for 5 days)'}]",9,19 Years,,ALL,True,Onconic Therapeutics Inc.,INDUSTRY,0,29.0,ACTUAL,2025-09-01T16:18:13.410617,v2_robust,True,True,True,False,False,
NCT02393846,Topical Ketoprofen Versus Placebo in Patients With Ankle Sprain,Comparison of Topical Dexketoprofen Versus Placebo in Patients Presented With Ankle Sprain to the Emergency Department: A Randomised Placebo Controlled Trial,Ketoprofen gel,"['Ketoprofen gel', 'Placebo gel', 'Fastjel', 'Placebo']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Ankle Sprain,['Ankle Sprain'],"['ankle sprain', 'topical ketoprofen', 'non-steroidal anti-inflammatory drug', 'emergency department']",COMPLETED,,2015-02,2015-06,"[{'measure': 'Visual analogue scale', 'description': 'Pain intensity is measured by visual analogue scale at baseline, 15 and 30 minutes after the administration.', 'timeFrame': '30 minutes'}]","[{'measure': 'Adverse effects', 'description': 'Adverse effects occurred during the study is recorded to the study form.', 'timeFrame': '30 minutes'}]",2,18 Years,65 Years,ALL,False,Akdeniz University,OTHER,1,100.0,ACTUAL,2025-09-01T16:18:13.410743,v2_robust,True,True,True,False,True,
NCT03814746,Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients,"A Phase III, Multicenter, Randomized, Double-blind Study to Assess Efficacy and Safety of Two Doses of Crizanlizumab Versus Placebo, With or Without Hydroxyurea/ Hydroxycarbamide Therapy, in Adolescent and Adult Sickle Cell Disease Patients With Vaso-Occlusive Crises (STAND)",Crizanlizumab (SEG101),"['SEG101', 'Crizanlizumab (SEG101)', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Sickle Cell Disease (SCD),['Sickle Cell Disease (SCD)'],"['Sickle Cell Disease', 'SCD', 'SEG101', 'Crizanlizumab', 'Hydroxyurea/ Hydroxycarbamide Therapy', 'Vaso-Occlusive Crises', 'SCA', 'blood disorders', 'hemoglobin', 'red blood cells', 'sickle-like shape', 'mutation in hemoglobin gene', 'sickle-cell trait', 'sickle-cell crisis']",ACTIVE_NOT_RECRUITING,,2019-07-26,2026-12-14,"[{'measure': 'Annualized Rate of Vaso-occlusive Crisis (VOC) Events Leading to a Healthcare Visit', 'description': 'VOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration.\n\nHealthcare visit is defined as any visit to a medical facility such as emergency room (ER), hospital and/or office visit, which includes pain management of VOC in situ.\n\nAnnualized rate of corresponding VOC events = (Number of corresponding VOC events \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).', 'timeFrame': '1 year'}]","[{'measure': 'Annualized Rate of All VOCs Leading to a Healthcare Visit and Treated at Home Over the First-year Post Randomization (Key Secondary)', 'description': 'VOCs are based on documentation by provider following contact with participant. VOC:pain crisis requiring therapy with oral/parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome, priapism and hepatic or splenic sequestration. Healthcare visit:a visit to a medical facility (ER, hospital \\&/or office visit resulting in pain management of VOC. Managed at home: no visit to any medical facility \\&/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice is allowed. Annualized rate of corresponding VOC events = (# of corresponding VOC events \\* 365)/(# of days in observation period). Observation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor \\& erythropoietin therapies to treat SCD \\&/or to prevent/reduce VOCs), date of randomization + 365 days)', 'timeFrame': '1 year'}, {'measure': 'Annualized Rate of All VOCs Leading to a Healthcare Visit and Treated at Home Over 5 Years Post Randomization (Key Secondary)', 'description': 'To compare the efficacy of 5.0 mg/kg vs placebo \\& 7.5 mg/kg vs placebo on the annualized rate of all VOCs based on documentation by provider following contact with participant. VOC is defined as pain crisis (an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) requiring therapy with oral/parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome, priapism and hepatic or splenic sequestration. Healthcare visit is defined as a visit to a medical facility (emergency room, hospital and/or office visit resulting in pain management of VOC. Managed at home is defined as no visit to any medical facility and/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice is allowed. The annualized rate of VOC leading to healthcare visit is the number of VOC leading to healthcare visit multiplied by 365 \\& divided by the number of days in observation period.', 'timeFrame': '5 years'}, {'measure': 'Mean Duration of VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the duration of VOCs leading to healthcare visit in each group. Mean duration of VOC per participant is defined as the average duration of all individual episodes of VOCs leading to healthcare visits of a given participant (a VOC duration is defined as end date of the VOC - start date of the VOC + 1). Participants with no VOC leading to healthcare visits have been excluded.', 'timeFrame': '1 year'}, {'measure': 'Number of Participants Free From VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the number of participants free from VOCs leading to healthcare visit.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. A participant is free from VOC if they do not have a VOC crisis.', 'timeFrame': '1 year'}, {'measure': 'Percentage of Participants Free From VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the percentage of participants free from VOCs leading to healthcare visit. VOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. A participant is free from VOC if they do not have a VOC crisis.', 'timeFrame': '1 year'}, {'measure': 'Time to First and Second VOCs Leading to a Healthcare Visit Over the First-year Post Randomization', 'description': 'To assess the time to first and second VOC leading to healthcare visit in each group.\n\nTime to first occurrence of VOC leading to a healthcare visit is defined as the time from the date of randomization to the date of the first occurrence of the VOC.\n\nTime to second occurrence of VOC leading to a healthcare visit is defined as the time from date of randomization to the date of the second occurrence of VOC.', 'timeFrame': '1 year'}, {'measure': 'Annualized Rate of Visits to Clinic, Emergency Room (ER) and Hospitalizations, Both Overall and VOC-related Over the First-year Post-randomization', 'description': 'To assess Healthcare resource utilization (visits to clinic, Emergency room (ER) and hospitalizations) both overall and VOC-related in each group.\n\nAnnualized rate of corresponding healthcare visits =(Number of corresponding healthcare visits \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days)', 'timeFrame': '1 year'}, {'measure': 'Annualized Days of Visits to Clinic, Emergency Room (ER) and Hospitalizations, Both Overall and VOC-related Over the First-year Post-randomization', 'description': 'To assess Healthcare resource utilization (visits to clinic, Emergency room (ER) and hospitalizations) both overall and VOC-related in each group.\n\nAnnualized days of corresponding healthcare visits =(Number of days =(Number of days of corresponding healthcare visits \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).', 'timeFrame': '1 year'}, {'measure': 'Evolution of Albumin Creatinine Ratio (ACR) Over the First-year Post-randomization (Change From Baseline)', 'description': 'Laboratory values for parameters related to renal function (creatinine, estimated glomerular filtration rate, urine microalbumin, and urine albumin/creatinine ratio) were measured at 6-month intervals over time from baseline.', 'timeFrame': 'Over first year post-randomization (Baseline, Week 27 Day 1, Week 51 Day 1)'}, {'measure': 'Evolution of Albuminuria (Urine Microalbumin) Over the First-year Post-randomization (Change From Baseline)', 'description': 'Laboratory values for parameters related to renal function (creatinine, estimated glomerular filtration rate, urine microalbumin, and urine albumin/creatinine ratio) were measured at 6-month intervals over time from baseline.', 'timeFrame': 'Over first year post-randomization (Baseline, Week 27 Day 1, Week 51 Day 1)'}, {'measure': 'Pharmacokinetic (PK) Profile of Crizanlizumab: AUCd15, AUCtau', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: Area under the (concentration-time profile) curve.', 'timeFrame': 'AUCd15 (first-dose) was assessed at W1D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose) to W3D1; AUCtau (steady-state) was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PK Profile of Crizanlizumab: Cmax', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: Maximum concentration.', 'timeFrame': 'first-dose was assessed at W1D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose) through to W3D1; steady-state was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PK Profile of Crizanlizumab: Tmax', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: Time to maximum concentration.', 'timeFrame': 'first-dose was assessed at W1D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose) through to W3D1; steady-state was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PK Profile of Crizanlizumab: Half-life', 'description': 'To characterize the pharmacokinetic (PK) profile of crizanlizumab at 5.0 and 7.5 mg/kg: half life.', 'timeFrame': 'steady-state was assessed at W15D1 (pre-dose, 0.5 hr, 2 hrs and 4 hrs post-dose), W15D2, W15D4, W16D1, W17D1, W18D1, W19D1'}, {'measure': 'PD Parameter (P-selectin Inhibition)', 'description': 'To characterize the pharmacodynamic (PD) of crizanlizumab at 5.0 and 7.5 mg/kg: P-selectin inhibition (% inhibition multipled by hr)', 'timeFrame': 'AUCd15 (first dose): W1D1, W1D2, W1D4, W2D1 and W3D1; steady state: W15D1, W15D2, W15D4, W16D1, W17D1 W18D1 and W19D1'}, {'measure': 'Annualized Rate of Various Subtypes of VOCs Leading to a Healthcare Visit at 1 Year', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOCs leading to healthcare visit. VOC is defined as pain crisis which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. Healthcare visit: any visit to a medical facility such as ER, hospital and/or office visit, which includes pain management of VOC in situ.\n\nAnnualized rate of corresponding VOC events = (Number of corresponding VOC events \\* 365)/(number of days in the observation period).\n\nObservation period = time from date of randomization to minimum of (last dose date until treatment discontinuation + 27 days, date of initiation or discontinuation of HU/HC or L-Glutamine (or other therapies such as Voxelotor and erythropoietin therapies to treat SCD and/or to prevent/reduce VOCs), date of randomization + 365 days).', 'timeFrame': '1 year'}, {'measure': 'Annualized Rate of Various Subtypes of VOCs Leading to a Healthcare Visit at 5 Years', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the annualized rate of VOCs leading to healthcare visit.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration.\n\nHealthcare visit is defined as any visit to a medical facility such as emergency room, hospital and/or office visit, which includes pain management of VOC in situ.\n\nThe annualized rate of VOC leading to healthcare visit is the number of VOC leading to healthcare visit multiplied by 365 and divided by the number of days in the observation period.', 'timeFrame': '5 years'}, {'measure': 'Annualized Rate of All VOCs Leading to a Healthcare Visit and Treated at Home at 5 Years', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the rates of all VOCs (managed at home + leading to healthcare visit).', 'timeFrame': '5 years'}, {'measure': 'Number of VOCs Managed at Home at Year 1', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the number of VOC events that were managed at home.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. Managed at home is defined as no visit to any medical facility and/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice was allowed.', 'timeFrame': '1 year'}, {'measure': 'Number of VOCs Managed at Home at 5 Years', 'description': 'To compare the efficacy of 5.0 mg/kg versus placebo and 7.5 mg/kg of crizanlizumab versus placebo on the number of VOC events that were managed at home.\n\nVOC is defined as pain crisis (defined as an acute onset of pain for which there is no other medically determined explanation other than vaso-occlusion) which requires therapy with oral or parenteral opioids or parenteral NSAID as well as other complicated crisis such as acute chest syndrome (ACS), priapism and hepatic or splenic sequestration. Managed at home is defined as no visit to any medical facility and/or healthcare professional to receive treatment for VOC. Healthcare contact for medical advice was allowed.', 'timeFrame': '5 years'}, {'measure': 'Absolute Change From Baseline in Hemoglobin', 'description': 'To assess safety of crizanlizumab over the study period.', 'timeFrame': '5 years'}, {'measure': 'Growth and Sexual Maturity Assessment in Adolescents (Tanner Stage)', 'description': 'To assess safety of crizanlizumab over the study period.', 'timeFrame': '5 years'}, {'measure': 'Immunogenicity: Measurement of Anti-drug Antibodies (ADA) to Crizanlizumab', 'description': 'To assess immunogenicity of crizanlizumab over the study period.', 'timeFrame': '5 years'}]",24,12 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,257.0,ACTUAL,2025-09-01T16:18:13.410755,v2_robust,True,True,False,False,True,
NCT02259946,Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers,"A Randomised, Double-blind, Placebo-controlled (Within Dose Groups) Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses (2.5 μg, 5 μg, 10 μg, 20 μg and 40 μg) of BI 1744 CL (Administered With the Respimat®) in Free Dose Combination With Tiotropium Bromide 5 μg ( for Doses up to and Including 20 μg BI 1744 CL), 10 μg (for Doses of 20 μg and 40 μg BI 1744 CL) (Administered With the Respimat®) in Healthy Male Volunteers",BI 1744 CL,"['BI 1744 CL', 'Tiotropium bromide', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2006-04,,"[{'measure': 'Number of participants with abnormal findings in physical examination', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of participants with abnormal changes in laboratory parameters', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of participants with clinically significant changes in vital signs', 'description': 'blood pressure (BP), pulse rate (PR), respiratory rate (RR)', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of participants with adverse events', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of participants with clinically significant changes in 12-lead ECG', 'description': 'cardiac axis, heart rate, PQ interval, QRS interval, uncorrected QT interval, HR-corrected QT-interval according to Bazett and Fridericia', 'timeFrame': 'up to 12 days after drug administration'}, {'measure': 'Number of abnormal findings on oropharyngeal inspection', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Number of abnormal findings on pulmonary auscultation', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Assessment of tolerability by investigator on a 4-point scale', 'timeFrame': '12 days after drug administration'}, {'measure': 'Change in Airway resistance (Raw)', 'description': 'measured by whole-body plethysmography', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Change in specific conductance (sGaw)', 'description': 'measured by whole-body plethysmography', 'timeFrame': 'up to 24 hours after drug administration'}, {'measure': 'Change in Cyclic aminomonophosphate (cAMP)', 'timeFrame': 'up to 6 hours after drug administration'}, {'measure': 'Change in potassium', 'timeFrame': 'up to 6 hours after drug administration'}]","[{'measure': 'Cmax (maximum measured concentration of BI 1744 BS and tiotropium in plasma)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'tmax (time from dosing to maximum measured concentration)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'AUC0-∞ (area under the concentration-time curve of BI 1744 BS and tiotropium in plasma over the time interval from 0 extrapolated to infinity)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'AUC0-tz (area under the concentration-time curve of the analyte salmeterol in plasma over the time interval from 0 to the time of the last quantifiable data point)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': '%AUCtz-∞ (percentage of the extrapolated part of the total AUC0-∞)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'λz (terminal rate constant in plasma)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 't1/2 (terminal half-life of BI 1744 BS and tiotropium in plasma)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'MRTih (mean residence time of BI 1744 BS and tiotropium in the body after inhalation)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'CL/F (apparent clearance of BI 1744 BS and tiotropium in plasma after extravascular administration)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'Aet1-t2 (amount of BI 1744 BS and tiotropium eliminated in urine from the time point t1 to time point t2)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'fet1-t2 (fraction of BI 1744 BS and tiotropium eliminated in urine from time point t1 to time point t2)', 'timeFrame': 'up to 96 hours after drug administration'}, {'measure': 'CLR,t1-t2 (renal clearance of BI 1744 BS and tiotropium from the time point t1 until the time point t2)', 'timeFrame': 'up to 96 hours after drug administration'}]",25,21 Years,50 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:13.410918,v2_robust,True,True,True,False,True,
NCT02194946,Chinese Medicine on Deferring Dialysis Initiation,Effectiveness of Chinese Medicine on Deferring Dialysis Initiation for Stage 5 Chronic Kidney Disease,CM therapies,"['modern medicine', 'CKD-related management', 'Western medicine', 'CM therapies', 'Traditional Chinese medicine (TCM) treatment', 'Complementary Therapies', 'TCM treatment']",7,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,End-Stage Renal Disease,['End-Stage Renal Disease'],"['Chronic Kidney Disease,', 'End-Stage Renal Disease,', 'Traditional Chinese Medicine,', 'dialysis initiation.']",UNKNOWN,,2014-07,2020-12,"[{'measure': 'Time to initiation of dialysis from enrollment.', 'description': 'Averaged time from enrollment to dialysis initiation or death from any cause, whichever comes first.\n\nPatients commence dialysis based on the following criteria:\n\n1. Clinical indications of dialysis include medically refractory serum potassium\\> 6.5mmol/L, total carbon dioxide (TCO2) \\<13mmol/L, eGFR≤5ml/min/1.73m2 (calculated by EPI formula), or the patient is symptomatic (see criteria #2). If these indications remain occur after receiving conservative CKD-related management for 1 week, or if relapse twice within one month, the patient definitely reaches the endpoint.\n2. Uremic symptoms include nausea, vomit, malnutrition, pericarditis or pleurisy, volume overload, encephalopathy, bleeding tendency, refractory hypertension, or other symptoms that are likely to be ameliorated by dialysis.', 'timeFrame': 'From enrollment to dialysis initiation or death.The duration of follow up will be for a maximum of 4 years.'}]","[{'measure': 'all-cause mortality', 'description': 'percentage of subjects who die from any cause during follow-up.', 'timeFrame': 'From enrollment to dialysis initiation or death.The duration of follow up will be for a maximum of 4 years.'}, {'measure': 'Cardio-cerebro vascular events', 'description': 'Cardio-cerebro vascular events, i.e. cerebral hemorrhage, cerebral infarction, myocardial infarction, acute coronary syndrome, severe arrhythmia, acute heart failure, acute exacerbation of congestive heart failure.', 'timeFrame': 'From enrollment to dialysis initiation or death.The duration of follow up will be for a maximum of 4 years.'}, {'measure': 'Hospitalization or death caused by severe infection.', 'description': 'percentage of subjects who suffer from severe infection events before dialysis initiation.The severe infection will lead to hospitalization or death.\n\nInfection events refer to death or hospitalization due to infection.', 'timeFrame': 'From enrollment to dialysis initiation or death.The duration of follow up will be for a maximum of 4 years.'}, {'measure': 'incidence of severe adverse event/reaction', 'description': 'number of cases of any recorded severe adverse event/reaction per year. Any adverse events/reactions complained of by patients or observed by researchers should be recorded, as well as any newly accompanied disease or aggravation of original symptoms.', 'timeFrame': 'From enrollment to dialysis initiation or death.The duration of follow up will be for a maximum of 4 years.'}, {'measure': 'Slope of reciprocal serum creatinine', 'description': 'Reciprocal serum creatinine (1/SCr) slope,the serum creatinine was assessed every 2 months.', 'timeFrame': 'From date of enrollment until the date of first dialysis or date of death from any cause,or the end of study, whichever come first.The duration of follow up will be for a maximum of 4 years.'}, {'measure': 'Nutrition and microinflammation status', 'description': 'Malnutrition Inflammation Score is used to assess nutrition and microinflammation status.', 'timeFrame': 'From date of enrollment until the date of death from any cause,or the end of study, whichever come first, performed every 6 months.The duration of follow up will be for a maximum of 4 years.'}]",7,18 Years,75 Years,ALL,False,Guangdong Provincial Hospital of Traditional Chinese Medicine,OTHER,1,875.0,ESTIMATED,2025-09-01T16:18:13.410983,v2_robust,True,True,False,False,True,
NCT01502046,Neuroprotection by Cannabinoids in Huntington's Disease,"A Double Blind, Randomized, Cross Over, Placebo Controlled Phase 2 Clinical Trial to Asses Neuroprotection by Cannabinoids in Huntington's Disease",delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD),"['delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Huntington's Disease,"[""Huntington's Disease""]","[""Huntington's disease, cannabinoids""]",COMPLETED,,2011-09,2012-06,"[{'measure': 'Serious Adverse Events reported', 'timeFrame': '8 months'}, {'measure': 'Changes in the UHDRs Score', 'description': 'UHDRS scale scores from the following perspectives: motor, cognitive, psychiatric and functional.', 'timeFrame': 'On week 4 and 12 of each period'}]","[{'measure': 'Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in plasma', 'timeFrame': 'Basal and on week 4 and 12 of each period'}, {'measure': 'Changes in the BDNF levels (Brain-derived Neurotrophic Factor), oxidative stress (due to mitochondrial dysfunction) and proinflammatory cytokines in cerebrospinal fluid.', 'timeFrame': 'On week 12 of each period'}]",4,18 Years,,ALL,False,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,OTHER,1,25.0,ACTUAL,2025-09-01T16:18:13.411025,v2_robust,True,True,True,False,True,
NCT00449046,Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-,Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study-,GW815SF Salmeterol/Fluticasone propionate(HFA MDI),['GW815SF Salmeterol/Fluticasone propionate(HFA MDI)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Bronchial Asthma,['Bronchial Asthma'],"['salmeterol/fluticasone propionate combination', 'pediatric bronchial asthma']",COMPLETED,,2007-03,2007-11,"[{'measure': 'Most Frequent Adverse Events - On Therapy', 'description': 'Adverse events, Clinical laboratory tests, Adrenocortical function test, Physical examinations, 12-lead electrocardiogram (ECG), Oropharyngeal examination were included.', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Serious Adverse Events (SAEs) - On Therapy', 'description': ""Number of participants considered by the investigator to be related to study medication.\n\nAdverse events, Clinical laboratory tests, Adrenocortical function test, Physical examinations, 12-lead ECG, Oropharyngeal examination were included. Frequency threshold of reported SAE's is 0%(100% reported)"", 'timeFrame': 'Baseline to Week 24'}]","[{'measure': 'Change From Baseline in Morning Peak Expiratory Flow (PEF) During Weeks 1-24', 'description': 'PEF taken daily and average used for week 1-24 value. The peak expiratory flow rate measures how fast a person can (exhale) air. Then, compares it to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43"" is 147 L/min, whose height is 66"" is 454 L/min.', 'timeFrame': 'Baseline and during Weeks 1-24'}, {'measure': 'Change From Baseline in Percent Predicted Morning Peak Expiratory Flow (PEF) During Weeks 1-24', 'description': 'Percent Predicted Morning Peak Expiratory flow were the percent of patients that were predicted to have their Peak expiratory flow in the morning.', 'timeFrame': 'Baseline and during Weeks 1-24'}, {'measure': 'Change From Baseline in Evening Peak Expiratory Flow (PEF) During Weeks 1-24', 'description': 'The peak expiratory flow rate measures how fast a person can (exhale) air. Then compares it to normal flow rates to predict obstruction and disease. The average PEF for a child or adolescent whose height is 43"" is 147 L/min, whose height is 66"" is 454 L/min.', 'timeFrame': 'Baseline and during Weeks 1-24'}, {'measure': 'Change From Baseline in Circadian Variation in Peak Expiratory Flow (PEF) During Weeks 1-24', 'description': 'Circadian Variation means the various changes in a day. The peak expiratory flow rate measures how fast a person can (exhale) air using a mini-Wright peak flow meter. The average PEF for a child or adolescent whose height is 43"" is 147 L/min, whose height is 66"" is 454 L/min.', 'timeFrame': 'Baseline and during Weeks 1-24'}, {'measure': 'Number of Participants With Symptom-Free Nights and Days', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants With Rescue Medication-Free Nights and Days', 'description': 'Rescue free means without the use of other medication.', 'timeFrame': 'Baseline and Week 24'}]",8,5 Years,14 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:13.411056,v2_robust,True,True,True,False,True,
NCT04653246,"Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM","Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combination Regimen Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma",Isatuximab,"['Bortezomib Injection', 'Isatuximab', 'Sarclisa', 'Lenalidomide', 'Revlimid', 'Dexamethasone']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,"['Multiple Myeloma', 'Newly Diagnosed Multiple Myeloma (NDMM)', 'Autologous Stem Cell Transplant']","['Multiple Myeloma', 'Newly diagnosed multiple myeloma (NDMM)', 'Autologous stem cell transplant (ASCT).', 'High dose therapy (HDT)']",RECRUITING,,2021-07-13,2029-01-13,"[{'measure': 'stringent Complete Response (sCR)', 'description': 'proportion of patients who have achieved sCR, according to IMWG criteria, by the end of two cycles of induction treatment. Response will be evaluated using a Simon optimal two-stage design.', 'timeFrame': '84 days'}]","[{'measure': 'Time to Progression', 'description': 'Progression-free probabilities over time will be estimated using the Kaplan-Meier method (Kaplan, 1958), presenting an estimate of median time to progression (TTP) with 95% confidence intervals (CIs). Time to progression is defined as time from registration to progression, censored at date last known to be progression-free for those who have not progressed and censored at time of death for those who died.', 'timeFrame': 'time from registration to progression, censored at date last known to be progression-free for those who have not progressed and censored at time of death up to 42 months'}, {'measure': 'Progression Free Survival', 'description': '\\- Progression-free survival (PFS) will be analyzed similarly to time to progression: Progression-free probabilities over time will be estimated using the Kaplan-Meier method (Kaplan, 1958), presenting an estimate of median Time to progression (TTP) with 95% confidence intervals (CIs Time from registration to disease progression or death from any cause, censored at date last known to be progression-free for those who have not progressed or died', 'timeFrame': 'time from registration to disease progression or death from any cause, censored at date last known to be progression-free for those who have not progressed or died up to 42 months'}, {'measure': 'Duration of Response', 'description': 'Duration of Response will be analyzed similarly to time to progression: Progression-free probabilities over time will be estimated using the Kaplan-Meier method (Kaplan, 1958), presenting an estimate of median time to progression (TTP) with 95% confidence intervals (CIs Time from first response after treatment to the date of disease progression or death from any cause, or date last known progression-free and alive for those who have not progressed or died.', 'timeFrame': 'Time from first response after treatment to the date of disease progression or death from any cause, or date last known progression-free and alive for those who have not progressed or died up to 42 months'}, {'measure': 'Overall Survival', 'description': 'Overall Survival will be analyzed similarly to time to progression: Progression-free probabilities over time will be estimated using the Kaplan-Meier method (Kaplan, 1958), presenting an estimate of median time to progression (TTP) with 95% confidence intervals (CIs\n\nOverall survival: time from registration to death from any cause or date last known alive for those who have not died', 'timeFrame': 'Overall survival: time from registration to death from any cause or date last known alive for those who have not died up to 42 months'}, {'measure': 'Number of Participants with Treatment Related Adverse Events as Assessed by CTCAE v 5.0', 'description': 'Common Terminology Criteria for Adverse Events (CTCAE) of the National Cancer Institute (NCI) v5.0', 'timeFrame': 'Induction to up to 3.5 years'}]",6,75 Years,,ALL,True,"Jacob Laubach, MD",OTHER,1,52.0,ESTIMATED,2025-09-01T16:18:13.411066,v2_robust,True,True,False,False,True,
NCT02568488,The Effect of Metformin on Different Hormones in PCOS Patients,"The Effect of Metformin on Serum Insulin, Androgens and AMH in PCOS Patients",Metformin,"['glucophage', 'Metformin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Polycystic Ovarian Syndrome,['Polycystic Ovarian Syndrome'],[],COMPLETED,,2014-03,2015-09,"[{'measure': 'hormonal changes', 'description': 'total and free testosterone', 'timeFrame': 'Change from Baseline at 3 and 6 months'}]","[{'measure': 'serum insulin levels', 'description': 'serum insulin (fasting and 2 hr postprandial)', 'timeFrame': 'Change from Baseline at 3 and 6 months'}, {'measure': 'ovarian morphology', 'description': 'ovarian volume and number of follicles', 'timeFrame': 'Change from Baseline at 3 and 6 months'}, {'measure': 'sex hormone binding globulin (SHBG)', 'timeFrame': 'Change from Baseline at 3 and 6 months'}, {'measure': 'Antimullerian Hormone (AMH)', 'timeFrame': 'Change from Baseline at 3 and 6 months'}, {'measure': 'Dihydroepiandrostenedione sulphate (DHEAS)', 'timeFrame': 'Change from Baseline at 3 and 6 months'}]",6,18 Years,33 Years,FEMALE,False,Ahmed Maged,OTHER,0,48.0,ACTUAL,2025-09-01T16:18:13.411107,v2_robust,True,True,True,False,False,
NCT03750188,Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs,The Safety and Efficacy of ProHance® at the Dose of 0.10 mmol/kg in Magnetic Resonance Imaging of the Central Nervous System in Pediatric Patients Who Are Younger Than 2 Years of Age,ProHance,"['ProHance', 'Gadoteridol']",2,OBSERVATIONAL,[],,,Central Nervous System Diseases,"['Central Nervous System Diseases', 'Central Nervous System Neoplasms']","['CNS', 'MRI', 'ProHance', 'Gadoteridol']",COMPLETED,,2018-11-01,2019-10-16,"[{'measure': 'Border delineation of lesions', 'description': 'Blinded reader will assess the border delineation of lesion based on a 5 point scale, none (0) - Excellent (4)', 'timeFrame': 'Immediately post dose - Day 1'}, {'measure': 'Visualization of internal morphology of lesions', 'description': 'Blinded reader will assess the visualization of internal morphology of the lesion(s) based on a 5 point scale, none (0) - Excellent (4)', 'timeFrame': 'Immediately post dose - Day 1'}, {'measure': 'Contrast enhancement of lesions', 'description': 'Blinded reader will assess the contrast enhancement of the lesion(s) based on a 5 point scale, none (0) - Excellent (4)', 'timeFrame': 'Immediately post dose- Day 1'}, {'measure': 'Number and percentage of subjects with ProHance Related Adverse Events', 'description': 'In terms of frequency, type and severity of adverse events Data collected, will consist of Screening Serum Creatinine value (mg/dL), If available, Vital signs (systolic blood pressure, diastolic blood pressure, heart rate, respiration rate) and ECG.', 'timeFrame': 'up to 2 hours post-dose'}]",[],4,1 Day,2 Years,ALL,False,"Bracco Diagnostics, Inc",INDUSTRY,0,125.0,ACTUAL,2025-09-01T16:18:13.411132,v2_robust,False,True,True,False,True,
NCT02005588,Treatment of Iron Deficiency Anemia With Pregnancy,Comparison Between Aminoacid Chelated Iron and Iron Salt in Treatment of Iron Deficiency Anemia With Pregnancy,amino acid chelated iron,"['hemoton capsules', 'iron salt (ferrous fumarate)', 'amino acid chelated iron', 'ferrotron capsules']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Iron Deficiency Anemia of Pregnancy,['Iron Deficiency Anemia of Pregnancy'],"['amino acid chelated iron', 'iron salt', 'iron deficiency anemia']",COMPLETED,,2013-12,2015-07,"[{'measure': 'change in hemoglobin level', 'timeFrame': '6 months'}]","[{'measure': 'the occurence of side effects (abdominal colics, constipation, or metallic taste)', 'timeFrame': '6 months'}, {'measure': 'change in serum ferritin level', 'timeFrame': '6 months'}]",3,20 Years,40 Years,FEMALE,False,Cairo University,OTHER,0,150.0,ACTUAL,2025-09-01T16:18:13.411149,v2_robust,True,True,True,False,False,
NCT04745988,"An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer","An Open Label Phase 2 Study to Evaluate the Safety and Efficacy of Lenvatinib with Pembrolizumab or Lenvatinib, Pembrolizumab and FLOT in the Neoadjuvant / Adjuvant Treatment for Patients with Gastric Cancer",Lenvatinib 20mg,"['Pembrolizumab', 'Oxaliplatin', 'Lenvatinib 8mg', 'Levofolinate', 'Lenvatinib 20mg', 'Fluorouracil', 'Docetaxel']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastric Cancer,['Gastric Cancer'],[],ACTIVE_NOT_RECRUITING,,2021-11-11,2027-08,"[{'measure': 'Major pathological response (MPR) rate', 'description': 'The MPR rate will be defined as the proportion of patients whose percentage of residual tumor in the stomach and lymph node decreased to \\< 10%, as determined by a pathologist.', 'timeFrame': '6 months'}]","[{'measure': 'Pathological complete response (pCR) rate', 'description': 'The pCR rate will be defined as the proportion of patients whose tumor in the stomach and lymph node completely disappeared, as determined by a pathologist.', 'timeFrame': '6 months'}, {'measure': 'Tumor response in the gastric primary lesion', 'description': 'The number of patients achieving endoscopic CR, PR, SD, or PD will be separately tabulated.', 'timeFrame': '6 months'}, {'measure': 'Radical resection rate', 'description': 'The radical resection rate will be defined as the proportion of patients who underwent a radical resection (R0 resection).', 'timeFrame': '6 months'}, {'measure': 'Treatment completion rate until surgery', 'description': 'The treatment completion rate will be defined as the proportion of patients who started the protocol treatment, completed a three-cycle treatment with the study drug, and then underwent a radical resection (R0 resection).', 'timeFrame': '6 months'}, {'measure': 'Treatment completion rate until adjuvant treatment', 'description': 'The treatment completion rate will be defined as the proportion of patients who started the protocol treatment, completed a three-cycle treatment with the study drug, and then underwent a radical resection (R0 resection) and adjuvant treatment was performed up to 14 cycles.', 'timeFrame': '1 year 8 months'}, {'measure': 'Event free survival (EFS)', 'description': 'The registration date is the starting date, and is defined as the period until the event that occurs any of the following.\n\n* Disease progression based on image evaluation using RECIST 1.1\n* Recurrence based on CT or biopsy among patients with no postoperative lesions\n* Death of any cause If it is determined to be exacerbated based on the image evaluation, the inspection date on which the image inspection was performed shall be the exacerbation date.\n\nSecondary primary malignancies are not an EFS event. Patients for whom no EFS event has been recorded will be censored on the final image evaluation date.', 'timeFrame': '3 years'}, {'measure': 'Overall survival (OS)', 'description': 'The period will be from the day of enrollment, as the starting date of the computation, to the day of death of any cause.\n\nSurviving patients should be censored on the last day of PFS confirmed (Confirmation of survival by telephone inquiry will be acceptable. However, the fact of confirming survival should be documented in medical records.).\n\nPatients who are lost to follow up should be censored on the last day when their survival is confirmed before being lost to follow up.', 'timeFrame': '3 years'}, {'measure': 'The incidence of adverse events', 'description': 'For adverse events due to protocol treatment, determine the frequency of worst grades in all courses according to CTCAE v5.0, the incidence of adverse events of Grade 3 or higher, and the incidence of adverse events of Grade 4 or higher.', 'timeFrame': 'Up to 30 days after the last dose'}]",9,20 Years,,ALL,False,National Cancer Center Hospital East,OTHER,1,43.0,ESTIMATED,2025-09-01T16:18:13.411195,v2_robust,True,True,False,False,True,
NCT00400088,Lithium Versus Paroxetine in Patients With Major Depression Who Have a Family History of Bipolar Disorder or Suicide,"A Randomized, Double-blind, Double-dummy, Controlled Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide - a Pilot Study",paroxetine,"['paroxetine', 'lithium', 'paxil', 'lithium carbonate', 'lithane']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Major Depressive Disorder,['Major Depressive Disorder'],"['Major Depressive Disorder', 'Depression', 'Bipolar Disorder', 'Manic Depressive Illness', 'Randomized Trial', 'Antidepressant Treatment', 'Lithium Treatment']",TERMINATED,Recruitment difficulties,2007-06,2013-01,"[{'measure': 'Response will be defined as 50% reduction in MADRS score.', 'timeFrame': 'weekly'}, {'measure': 'Remission will be defined as MADRS ≤ 12.', 'timeFrame': 'weekly'}, {'measure': 'The MADRS will be done at week 0,1,2,3,4,5,6.', 'timeFrame': 'weekly'}]","[{'measure': 'The Hamilton Depression Rating Scale (HAM -D)-17 item scale, at weeks 0 and 6.', 'timeFrame': 'weeks 0 and 6'}, {'measure': 'Hamilton Anxiety Rating Scale (HAM-A),at weeks 0 and 6.', 'timeFrame': 'weeks 0 and 6'}, {'measure': 'The Young Mania Rating Scale (YMRS), at weeks 0,1,2,3,4,5,6.', 'timeFrame': 'weekly'}, {'measure': 'The Bipolar Depression Rating Scale (BDRS) (42),at weeks 0,1,2,3,4,5,6.', 'timeFrame': 'weekly'}, {'measure': 'Checklist of DSM IV symptoms of mania/ hypomania, with additional questions assessing the presence of mood lability, abnormally high energy, abnormally high libido, and rage. Done at weeks 0,1,2,3,4,5,6.', 'timeFrame': 'weekly'}, {'measure': 'The Beck Suicide Scale (BSS), at weeks 0, 1, 2,3,4,5, 6.', 'timeFrame': 'weekly'}]",9,18 Years,,ALL,False,Nova Scotia Health Authority,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:13.411233,v2_robust,True,True,False,True,False,Recruitment difficulties
NCT05125588,Fasting Comparative Bioavailability Study of 2 Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition,"Randomized, Single-dose, Crossover, Two-period, Two-sequence, Laboratory-blinded, Comparative Bioavailability Study of Meloxicam 15 mg Tablets in Healthy Volunteers Under Fasting Condition.","Reumoxicam® 15 mg tablets (PJSC ""Farmak"", Ukraine)","['Meloxicam', 'Reumoxicam® 15 mg tablets (PJSC ""Farmak"", Ukraine)', 'Movalis 15 mg tablets (""Boehringer Ingelheim Ellas A.E."", Greece)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics,['Pharmacokinetics'],"['bioequivalence', 'pharmacokinetics', 'generic drugs', 'Meloxicam']",COMPLETED,,2014-01-29,2014-02-26,"[{'measure': 'AUC0-t', 'description': 'Area under the plasma concentration-time curve from time zero to time t of the last quantifiable concentration', 'timeFrame': 'up to 72 hours post-administration'}, {'measure': 'Cmax', 'description': 'Maximum drug concentration in plasma', 'timeFrame': 'up to 72 hours post-administration'}]","[{'measure': 'AUC0-inf', 'description': 'Area under the plasma concentration-time curve from time zero to infinity', 'timeFrame': 'up to 72 hours post-administration'}, {'measure': 'tmax', 'description': 'time after administration to reach maximum drug concentration in plasma', 'timeFrame': 'up to 72 hours post-administration'}, {'measure': 't1/2', 'description': 'elimination half-life', 'timeFrame': 'up to 72 hours post-administration'}]",5,18 Years,45 Years,ALL,True,"Joint Stock Company ""Farmak""",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:13.411254,v2_robust,True,True,True,False,False,
NCT00030888,UCN-01 in Treating Patients With Advanced or Metastatic Kidney Cancer,A Phase 2 Study Of UCN-01 In Advanced Renal Cell Carcinoma,7-hydroxystaurosporine,['7-hydroxystaurosporine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Kidney Cancer,['Kidney Cancer'],"['stage III renal cell cancer', 'stage IV renal cell cancer', 'recurrent renal cell cancer']",UNKNOWN,,2002-12,,[],[],0,18 Years,,ALL,False,"University of California, San Francisco",OTHER,1,,,2025-09-01T16:18:13.411269,v2_robust,True,True,False,False,False,
NCT06732388,Itraconazole in Combination With Ablation for the Prevention of Esophageal Cancer in Patients With High-risk Barrett's Esophagus,Repurposing Itraconazole for Secondary Prevention of Metaplasia and Primary Prevention of Cancer in Patients With High-Risk Barrett's Esophagus in Combination With Ablation,Itraconazole,"['Sporanox', 'Placebo Administration', 'Itraconazole', 'Lozanoc', 'R 51,211', 'Oriconazole']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Barrett Esophagus,"['Barrett Esophagus', 'Clinical Stage I Esophageal Adenocarcinoma AJCC v8', 'Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8', 'Esophageal Adenocarcinoma']",[],NOT_YET_RECRUITING,,2025-10-01,2028-01-02,"[{'measure': 'Time to complete resolution of intestinal metaplasia (CRIM) in days', 'description': ""CRIM will be defined based on the absence of visible Barrett's esophagus (BE) and invisible BE (i.e., no intestinal metaplasia \\[IM\\] in biopsies of the gastroesophageal junction and the cardia). Will be reported descriptively. Will compare the unadjusted hazard rates between the itraconazole and control groups using log rank test."", 'timeFrame': 'Between day 1, cycle 1 (1 cycle = 6 weeks) and the date of endoscopy at which the participant is deemed to reach CRIM'}]","[{'measure': 'Time to complete eradication of dysplasia', 'description': 'Will be assessed by surveillance biopsies at the time of the endoscopy that documents CRIM and the biopsies at the time of first surveillance endoscopy will be evaluated for dysplasia.', 'timeFrame': 'Between day 1, cycle 1 (1 cycle = 6 weeks) and the date of endoscopy at which surveillance biopsies do not show dysplasia'}, {'measure': 'Rate of BE recurrence over follow-up', 'description': 'Will be assessed between the study treatment group and the control group. BE recurrence will be defined as histologic presence of IM (with or without dysplasia) in biopsies from the tubular esophagus or in biopsies at the gastroesophageal junction. The results from the standrd of care endoscopy closest to the 12-month time point after CRIM will be used to collect information for this endpoint.', 'timeFrame': 'At 12 months after CRIM'}, {'measure': 'Incidence of adverse events', 'description': 'Will be assessed by National Cancer Institutes Common Terminology Criteria for Adverse Events version 5.0 criteria to document adverse events and measure specific laboratory parameters to monitor for the safety and tolerability of itraconazole and assessed by descriptive statistics.', 'timeFrame': 'Up to 30 days after the end of intervention'}, {'measure': 'Correlate levels of itraconazole and its primary metabolite hydroxyitraconazole', 'description': 'Will be assessed in plasma and esophageal tissues with treatment response. Will measure these metabolites after two weeks of itraconazole therapy by obtaining biopsies of the esophagus. These measurements will be correlated with biomarker and clinical response to understand how tissue levels of the drug change the molecular and primary endpoints. Will also measure the blood levels to test the feasibility of blood levels for prediction of clinical response in the future.', 'timeFrame': 'After two weeks of itraconazole'}, {'measure': 'Biosocial impact', 'description': 'Will be assessed by questionnaires to collect information about the biosocial endpoints. These will include cancer-specific distress questionnaire, Gastrointestinal Symptom Rating Scale, Health-Related Quality of life short form 12 version 2, and Patient-Reported Outcomes Measurement Information System anxiety and depression scores as previously used at the beginning and at the end of the study. The summary measures such as mean or median of these distress scores will be compared between arms using t-test (or Wilcoxon rank test in case of non normality). Linear regression models will be used for studying the differences in the average distress scores between arms adjusted for age, sex and prior history of anxiety or depression.', 'timeFrame': 'At baseline and at the end of the study'}]",6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,64.0,ESTIMATED,2025-09-01T16:18:13.411319,v2_robust,True,True,False,False,True,
NCT00739388,Azacitidine in Treating Patients With Newly Diagnosed Previously Untreated or Secondary Acute Myeloid Leukemia Who Are Unsuitable For Intensive Chemotherapy,5-Azacytidine to Treat Acute Myeloid Leukemia in Elderly or Frail Patients Not Suitable for Intensive Chemotherapy. A Multicenter Phase II Trial.,azacytidine,"['Vidaza', 'Azacitidine', 'azacytidine', '5-azacytidine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['adult acute myeloid leukemia with 11q23 (MLL) abnormalities', 'adult acute myeloid leukemia with inv(16)(p13;q22)', 'adult acute myeloid leukemia with t(16;16)(p13;q22)', 'adult acute myeloid leukemia with t(8;21)(q22;q22)', 'secondary acute myeloid leukemia', 'untreated adult acute myeloid leukemia', 'adult acute myeloblastic leukemia without maturation (M1)', 'adult acute myeloblastic leukemia with maturation (M2)', 'adult acute myelomonocytic leukemia (M4)', 'adult acute monoblastic leukemia (M5a)', 'adult acute monocytic leukemia (M5b)', 'adult erythroleukemia (M6a)', 'adult pure erythroid leukemia (M6b)', 'adult acute megakaryoblastic leukemia (M7)']",COMPLETED,,2008-07,2012-11,"[{'measure': 'Best response (complete or partial response)', 'timeFrame': 'within 6 months'}]","[{'measure': 'Time to response', 'timeFrame': 'is defined as the time from trial registration until the date the criteria for either CR or PR are first met'}, {'measure': 'Response duration', 'timeFrame': 'is defined as the time from the date when the criteria for either CR or PR were first met until the date of relapse or death from any cause.'}, {'measure': 'Best response status', 'timeFrame': 'within 6 months'}, {'measure': 'Time to hematological improvement (HI)', 'timeFrame': 'is calculated for patients with HI and is defined as the time from trial registration until the date the criteria for HI are first met.'}, {'measure': 'Duration of HI', 'timeFrame': 'is defined as the time from the date when the criteria for HI were first met until the date of relapse or death from any cause.'}, {'measure': 'Event-free survival', 'timeFrame': 'is defined as the time from trial registration until progression, relapse or death from any cause, whichever occurs first.'}, {'measure': 'Overall survival', 'timeFrame': 'is defined as the time from trial registration until death from any cause.'}, {'measure': 'Adverse events according to NCI CTCAE v3.0', 'timeFrame': 'according to NCI CTCAE v3.0'}, {'measure': 'Adjusted hospitalization time', 'timeFrame': 'is defined as the time (nights) spent in hospital as a proportion of treatment duration (days).'}]",10,18 Years,,ALL,False,Swiss Cancer Institute,OTHER,0,47.0,ACTUAL,2025-09-01T16:18:13.411342,v2_robust,True,True,True,False,True,
NCT06702488,Dexmedetomidine and Magnesium Sulfate in the Reduction Cognitive Dysfunction in Geriatrics,The Efficacy of Dexmedetomidine and Magnesium Sulfate in Cognitive Dysfunction,dexmedetomidine,"['magnesium sulfate', 'dexmedetomidine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Mental Disorder,['Mental Disorder'],['Post-operative cognitive dysfunction'],RECRUITING,,2024-11-21,2025-05-15,"[{'measure': 'the incidence of Post Operative Cognitive Dysfunction', 'description': 'Post Operative Cognitive Dysfunction', 'timeFrame': '24 hours postoperative'}]","[{'measure': 'CRP levels and their correlation with POCD', 'description': 'CRP levels and their correlation with POCD', 'timeFrame': '24 hours of postoperative'}]",2,60 Years,80 Years,ALL,False,Fayoum University,OTHER,0,58.0,ESTIMATED,2025-09-01T16:18:13.411445,v2_robust,True,True,False,False,False,
NCT05132088,Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity,Efficacy and Safety of Oral Semaglutide 50 mg Once Daily in East Asian Participants With Overweight or Obesity,semaglutide 50 mg,"['placebo (semaglutide)', 'semaglutide 50 mg']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Overweight and Obesity,['Overweight and Obesity'],[],COMPLETED,,2021-11-16,2023-09-01,"[{'measure': 'Relative change in body weight', 'description': 'Percentage-point', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Achievement of body weight reduction greater than or equal to 5% (Yes/No)', 'description': 'Count of participants', 'timeFrame': 'At end of treatment (week 68)'}]","[{'measure': 'Achievement of body weight reduction greater than or equal to 10% (Yes/No)', 'description': 'Count of participants', 'timeFrame': 'At end of treatment (week 68)'}, {'measure': 'Change in Physical function domain (5-items) score (IWQOL-Lite-CT)', 'description': 'Score points', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Achievement of body weight reduction greater than or equal to 15% (Yes/No)', 'description': 'Count of participants', 'timeFrame': 'At end of treatment (week 68)'}, {'measure': 'Achievement of body weight reduction greater than or equal to 20% (Yes/No)', 'description': 'Count of participants', 'timeFrame': 'At end of treatment (week 68)'}, {'measure': 'Change in body mass index (BMI)', 'description': 'Count of participants', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in waist circumference measured according to the JASSO guideline', 'description': 'Messured in CM', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in Visceral Fat Area (VFA) measured by CT scan in a subset of the Japanese study population', 'description': '%-point', 'timeFrame': 'From baseline to end of treatment (week 68)'}, {'measure': 'Change in Visceral Fat Area (VFA) measured by CT scan in a subset of the Japanese study population', 'description': 'Messured in cm\\^2', 'timeFrame': 'From baseline to end of treatment (week 68)'}, {'measure': 'Change in systolic blood pressure', 'description': 'Messured in mmHg', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in diastolic blood pressure', 'description': 'Messured in mmHg', 'timeFrame': 'From randomisation (week 0) to end of treatment (week 68)'}, {'measure': 'Change in glycated haemoglobin (HbA1c)', 'description': '%-point', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in lipids: Total cholesterol', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in lipids: high density lipoprotein (HDL) cholesterol', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in lipids: low-density lipoprotein (LDL) cholesterol', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in lipids: very-low density lipoprotein (VLDL) cholesterol', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in lipids: Triglycerides', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in lipids: Free fatty acids', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Change in high sensitivity C Reactive Protein', 'description': 'Ratio to baseline', 'timeFrame': 'From baseline (week 0) to end of treatment (week 68)'}, {'measure': 'Number of treatment emergent adverse events', 'description': 'Count of events', 'timeFrame': 'From baseline (week 0) to end of study (week 75)'}, {'measure': 'Number of serious adverse events', 'description': 'Count of events', 'timeFrame': 'From baseline (week 0) to end of study (week 75)'}]",22,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,201.0,ACTUAL,2025-09-01T16:18:13.411455,v2_robust,True,True,True,False,True,
NCT00488488,A Pharmacovigilance Evaluation And Assessment Of The Prescribing Practice For Tygacil In Usual Health Care Setting,A Non-Interventional Study To Evaluate The Safety And Effectiveness Of Tygacil In The Treatment Of Patients With Complicated Intra-Abdominal Infections Or Complicated Skin And Skin Structure Infections,tigecycline,"['tigecycline', 'Tygacil']",2,OBSERVATIONAL,[],,,Infection,['Infection'],[],COMPLETED,,2006-11,2010-03,"[{'measure': 'Percentage of Participants With Clinical and Microbiological Cure: All Participants', 'description': 'Cure = complete resolution of infection symptoms; no further antibiotic treatment required. A second microbiological examination was documented only for participants with treatment failure.', 'timeFrame': 'End of Treatment (duration based on severity, location, and clinical response; maximum duration 47 days)'}, {'measure': 'Percentage of Participants With Clinical and Microbiological Cure: Nosocomial Infections', 'description': 'Cure = complete resolution of infection symptoms; no further antibiotic treatment required. A second microbiological examination was documented only for participants with treatment failure.', 'timeFrame': 'End of Treatment (duration based on severity, location, and clinical response; maximum duration 47 days)'}, {'measure': 'Percentage of Participants With Clinical and Microbiological Cure: Community-acquired Infections', 'description': 'Cure = complete resolution of infection symptoms; no further antibiotic treatment required. A second microbiological examination was documented only for participants with treatment failure.', 'timeFrame': 'End of Treatment (duration based on severity, location, and clinical response: maximum duration 47 days)'}, {'measure': 'Percentage of Participants With Composite Cure: All Participants', 'description': 'Composite Cure = complete resolution or improvement of infection symptoms; no further antibiotic treatment required.', 'timeFrame': 'End of Treatment (duration based on severity, location, and clinical response; maximum duration 47 days)'}, {'measure': 'Percentage of Participants With Composite Cure: Nosocomial Infections', 'description': 'Composite Cure = complete resolution or improvement of infection symptoms; no further antibiotic treatment required.', 'timeFrame': 'End of Treatment (duration based on severity, location, and clinical response; maximum duration 47 days)'}, {'measure': 'Percentage of Participants With Composite Cure: Community-acquired Infections', 'description': 'Composite Cure = complete resolution or improvement of infection symptoms; no further antibiotic treatment required.', 'timeFrame': 'End of Treatment (duration based on severity, location, and clinical response: maximum duration 47 days)'}]","[{'measure': 'Participants With Probable Failure at Follow-up', 'description': 'Participants with antibiogram follow-up due to treatment failure who had detectable pathogens. Treatment failure = no significant improvement of infection symptoms under Tygacil therapy.', 'timeFrame': 'Follow-up (up to Day 47)'}, {'measure': 'Percentage of Participants With Resistant Pathogens Identified at Follow-up Due to Treatment Failure', 'description': 'Percentage of participants with resistant pathogens for each pathogen identified at second (follow-up) microbial examination. A second microbiological examination was documented only for participants with treatment failure. Treatment failure = no significant improvement of infection symptoms under Tygacil therapy.', 'timeFrame': 'Follow-up (up to Day 47)'}, {'measure': 'Antibiotic Agents Chosen for Combination Therapy With Tigecycline', 'description': 'Percentage of participants who received each antibiotic administered as combination therapy with tigecycline.', 'timeFrame': 'Baseline to End of Treatment (up to Day 47)'}, {'measure': 'Change of Antibiotic Treatment From Tygacil to Alternative Antibiotic', 'description': 'Reasons for change in antibiotic treatment from Tygacil to another antibiotic.', 'timeFrame': 'Baseline to End of Treatment (up to Day 47)'}, {'measure': 'Reasons for Utilization of Tygacil', 'timeFrame': 'Baseline to End of Treatment (up to Day 47)'}, {'measure': 'Overall Mortality: All Participants', 'description': 'Deaths for any reasons occurring during the study observation period.', 'timeFrame': 'Baseline to End of Treatment (up to Day 47)'}]",12,18 Years,,ALL,False,Pfizer,INDUSTRY,0,1028.0,ACTUAL,2025-09-01T16:18:13.411524,v2_robust,False,True,True,False,False,
NCT00415103,AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors,"AMENO-2: Fase IV Study, National, Multiple Centers, Competitive, Randomized, Double Blind, Controlled With Parallel Groups to Determinate the Security, Tolerability and Efficacy of Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors",Aprepitant,"['Aprepitant', 'Palonosetron', 'Granisetron']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Leukemia,"['Leukemia', 'Lymphoma']","['Emesis', 'Nausea', 'leukemia', 'lymphoma']",COMPLETED,,2006-11,2009-09,"[{'measure': 'Determinate the security, tolerability and efficacy of aprepitant plus palonosetron versus granisetron in the prevention of nausea and emesis induced by chemotherapy in patients treated with haematopoietic progenitors transplant', 'timeFrame': '15 days'}]",[],1,18 Years,,ALL,False,PETHEMA Foundation,OTHER,1,196.0,ESTIMATED,2025-09-01T16:18:13.411601,v2_robust,True,True,True,False,False,
NCT02397603,Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine Induced Paravertebral Block in Patients Undergonig Thoracotomy,Peri-neural Dexmedetomidine as an Adjuvant to Bupivacaine-induced Paravertebral Block in Patients Undergoing Thoracotomy,dexmedetomidine bupivacaine,"['dexmedetomidine bupivacaine', 'Bupivacaine saline']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Post-thoracotomy Pain,['Acute Post-thoracotomy Pain'],[],COMPLETED,,2015-02,2015-12,"[{'measure': 'Duration of first loading preoperative dose of paravertebral injectate', 'description': 'Time interval between initiation of the paravertebral block and the time to first rescue analgesia', 'timeFrame': 'One day'}]","[{'measure': 'Duration of surgery and anesthesia', 'description': 'Times from start of anesthesia and surgery to the conclusion of surgical intervention', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'End tidal isoflurane', 'description': 'Average End-tidal isoflurane concentration required to maintain stable hemodynamics', 'timeFrame': 'Duration of anesthesia, up to 3-4 hours'}, {'measure': 'Total intraoperative fentanyl requirements', 'description': 'The total dose of fentanyl required during the surgical procedure to maintain hemodynamic stability', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'Total intraoperative ephedrine and atropine requirements', 'description': 'The total amounts of ephidrine and atropine required for the treatment of possible reduction of arterial blood pressure or heart rate', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'Total intraoperative crystalloid requirements', 'description': 'The total volume of intraoperative fluids in ml required to maintain hemodynamic stability', 'timeFrame': 'Intraoperative period, up to 3-4 hours'}, {'measure': 'Recovery time', 'description': 'the time interval between discontinuation of isoflurane and the patient first response to verbal commands', 'timeFrame': 'Immediate postoperative period, up to 2 hour'}, {'measure': 'Pain intensities at rest and during coughing as assessed by 0-10 VAS score', 'description': 'Pain scores will be assessed using the 11-points visual analogue pain score (VAS) where 0 indicates no pain and 10 indicates the worst pain.', 'timeFrame': 'Over 48 hours postoperatively'}, {'measure': 'Total doses of bupivacaine, dexmedetomidine, and morphine', 'description': 'The total doses of three medications will be recorded and compared in the intervention and control groups', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Number of paravertebral to-up injections', 'description': 'The number of to-up doses of bupivacaine required to maintain adequate postoperative analgesia over 48 hours postoperatively', 'timeFrame': '48 hours postoperatively'}, {'measure': 'Side effects', 'description': 'Patients will be monitored for the possible reductions in arterial blood pressure and heart rate', 'timeFrame': '48 hours postoperatively'}]",11,18 Years,60 Years,ALL,False,Cairo University,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:13.411610,v2_robust,True,True,True,False,False,
NCT00617903,Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea,"A 12-week Exploratory, Multicenter, Double-blind, Vehicle-controlled Study to Investigate the Efficacy and Safety of Topical Azelaic Acid 15% Foam Twice Daily in Patients With Papulopustular Rosacea",Azelaic acid,"['Azelaic acid', 'Vehicle foam']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Papulopustular Rosacea,['Papulopustular Rosacea'],"['rosacea', 'papulopustular', 'azelaic acid', 'foam']",COMPLETED,,2008-01,2008-06,"[{'measure': 'Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)', 'timeFrame': 'Baseline and End of Study (Week 12)'}, {'measure': ""Percentage of Participants With Investigator's Global Assessment (IGA) Based Therapeutic Success at End of Study (LOCF)"", 'description': 'IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success is defined as an IGA score of clear or minimal (0 to 1).', 'timeFrame': 'At End of Study (Week 12)'}, {'measure': 'Grouped Change From Baseline in Erythema Intensity Score at End of Study (LOCF)', 'description': 'Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'Baseline and End of Study (Week 12)'}]","[{'measure': 'Mean of Inflammatory Lesion Count Per Participant at Weeks 4, 8, 12 and End of Study (LOCF)', 'timeFrame': 'At Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Nominal Change From Baseline in Inflammatory Lesion Count Per Participant at Weeks 4, 8 and 12', 'timeFrame': 'Baseline and Weeks 4, 8 and 12'}, {'measure': 'Percent Change From Baseline in Inflammatory Lesion Count Per Participant at Weeks 4, 8, 12 and End of Study (LOCF)', 'timeFrame': 'Baseline and Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Percentage of Participants With Respective Disease Severity Measured by IGA Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success is defined as an IGA score of clear or minimal (0 to 1).', 'timeFrame': 'At Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Change From Baseline in IGA Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success is defined as an IGA score of clear or minimal (0 to 1).', 'timeFrame': 'Baseline and Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Percentage of Participants With Erythema Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'At Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Change From Baseline in Erythema Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'Baseline and Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Grouped Change From Baseline in Erythema Intensity Score at Weeks 4, 8 and 12', 'description': 'Erythema intensity score: 1 - Clear or almost clear; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'Baseline and Weeks 4, 8 and 12'}, {'measure': 'Percentage of Participants With Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'Telangiectasia intensity score: 1 - None; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'At Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Change From Baseline in Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'Telangiectasia intensity score: 1 - None; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'Baseline and Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': 'Grouped Change From Baseline in Telangiectasia Intensity Scores at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'Telangiectasia intensity score: 1 - None; 2 - Mild; 3 - Moderate; 4 - Severe', 'timeFrame': 'Baseline and Weeks 4, 8, 12 and End of Study (LOCF)'}, {'measure': ""Investigator's Rating of Overall Improvement at End of Study"", 'description': ""Investigator's rating of overall improvement: 1 - excellent improvement; 2 - marked improvement; 3 - moderate improvement; 4 - no change; 5 - deterioration"", 'timeFrame': 'At End of Study (Week 12)'}, {'measure': ""Patients' Rating of Overall Improvement at End of Study"", 'description': ""Patient's rating of overall improvement: 1 - excellent; 2 - good; 3 - fair; 4 - no improvement; 5 - worse"", 'timeFrame': 'At End of Study (Week 12)'}, {'measure': ""Patients' Opinion on Cosmetic Acceptability at End of Study"", 'description': ""Patient's opinion on cosmetic acceptability: 1 - very good; 2 - good; 3 - satisfactory; 4 - poor; 5 - no opinion"", 'timeFrame': 'At End of Study (Week 12)'}, {'measure': 'Percentage of Participants With IGA Based Therapeutic Success at Weeks 4, 8 and 12', 'description': 'IGA categories: 0 - Clear; 1 - Minimal; 2 - Mild; 3- Mild to Moderate; 4 - Moderate; 5 - Moderate to severe; 6 - Severe / Therapeutic success was defined as an IGA score of clear or minimal (0 to 1)."").', 'timeFrame': 'At Weeks 4, 8 and 12'}, {'measure': 'Percentage of Participants With IGA Based Patient Response at Weeks 4, 8, 12 and End of Study (LOCF)', 'description': 'IGA based Patient response was defined as an IGA score of clear, minimal or mild (0, 1, 2).', 'timeFrame': 'At Weeks 4, 8, 12 and End of Study (LOCF)'}]",19,18 Years,,ALL,False,LEO Pharma,INDUSTRY,1,83.0,ACTUAL,2025-09-01T16:18:13.411640,v2_robust,True,True,True,False,False,
NCT00052403,Monoclonal Antibody Therapy in Treating Patients With Advanced Solid Tumors,Phase I Study of Monoclonal Antibody Anti-Anb3 Integrin in Patients With Advanced Solid Tumors,monoclonal antibody anti-anb3 integrin,['monoclonal antibody anti-anb3 integrin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']",[],WITHDRAWN,Study was not successful at recruiting particpants,2002-02,,[],[],0,18 Years,,ALL,False,Barbara Ann Karmanos Cancer Institute,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:13.411687,v2_robust,True,True,False,True,False,Study was not successful at recruiting particpants
NCT02155803,ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study,ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study,ACTHAR Gel (adrenocorticotropic hormone),['ACTHAR Gel (adrenocorticotropic hormone)'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Sarcoidosis,"['Sarcoidosis', 'Hypercalcemia Due to Sarcoidosis']","['Sarcoidosis-Associated Calcium Dysregulation', 'Sarcoidosis-Associated hypercalciuria', 'hypercalcemia', 'hypercalciuria', 'nephrocalcinosis', 'nephrolithiasis', 'interstitial nephritis', 'glomerulonephritis', 'acute kidney disease', 'chronic kidney disease']",UNKNOWN,,2015-02,2015-11,"[{'measure': 'Reduction of 24 hour urine calcium', 'description': 'Reduction of 24 hour urine calcium in patients with sarcoidosis associated hypercalciuria (primary endpoint) between week 0 and week 12.', 'timeFrame': 'Between week 0 and week 12.'}]","[{'measure': 'Change in serum calcium during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline compared to 12 weeks.'}, {'measure': 'Change in 1,25 di-hydroxy Vitamin D during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline compared to 12 weeks.'}, {'measure': 'Change in patient global VAS during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline to 12 weeks'}, {'measure': 'Change in physician global VAS during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline to 12 Weeks'}, {'measure': 'Change in urinary symptoms during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline to 12 Weeks'}, {'measure': 'Change in Short Form-36 during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline to 12 Weeks'}, {'measure': 'Change in Sarcoidosis Health Questionnaire during 12 week ACTHAR GEL treatment', 'timeFrame': 'Baseline to 12 Weeks'}, {'measure': 'Change in eCOST during 12 week ACTHAR gel treatment', 'timeFrame': 'Baseline to 12 Weeks'}, {'measure': 'Change in adjusted eCOST (eCOSTadj) calculated as the eCOST/# organs with an eCOST score > 022 during 12 week ACTHAR gel treatment', 'timeFrame': 'Baseline to 12 Weeks'}]",10,18 Years,,ALL,False,Albany Medical College,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:13.411700,v2_robust,True,True,False,False,False,
NCT01631903,Extension of Study ZPV-200,"A Phase 2, Multi-Center, Five-Arm, Parallel Design, Randomized, Single-Blind Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Confirmed by Ultrasound",telepristone acetate 12 mg,"['telepristone acetate 3 mg', 'telepristone acetate 24 mg', 'Proellex', 'telepristone acetate 12 mg', 'telepristone acetate 6 mg']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Uterine Fibroids,['Uterine Fibroids'],[],COMPLETED,,2012-09,2014-04,"[{'measure': 'Bleeding Scores', 'description': 'The primary efficacy endpoint will be bleeding assessed using the change in PBAC scores from the 4 weeks prior to Visit 2 to the 4 weeks prior to Visit 10', 'timeFrame': '3 or 4 months depending on treatment arm'}]",[],1,18 Years,47 Years,FEMALE,False,Repros Therapeutics Inc.,INDUSTRY,0,48.0,ESTIMATED,2025-09-01T16:18:13.411740,v2_robust,True,True,True,False,False,
NCT02449603,Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes,Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes : a Randomised Open Parallel-controlled Study,Exenatide,"['Exenatide', 'Byetta', 'Biphasic insulin Aspart 30']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],['Chinese population'],COMPLETED,,2015-11,2018-04,"[{'measure': 'Change of mean amplitude of glycemic excursions', 'timeFrame': 'from baseline to Week 16'}]","[{'measure': 'HbA1c', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Hours of hypoglycemia as measured by continuous glucose monitoring system (CGMS)', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Blood pressure', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Lipids', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Body mass index', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Waist circumference', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Monocyte chemotactic protein-1 (MCP-1)', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'High-sensitivity C-reactive protein (hs-CRP)', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Urinary albumin', 'timeFrame': 'at baseline and Week 16'}, {'measure': 'Number of participants with adverse events/severe adverse events', 'timeFrame': 'from baseline to Week 16'}, {'measure': 'Number of participants with clinical hypoglycemia', 'timeFrame': 'from baseline to Week 16'}]",12,18 Years,70 Years,ALL,False,Xijing Hospital,OTHER,8,150.0,ACTUAL,2025-09-01T16:18:13.411749,v2_robust,True,True,True,False,True,
NCT00002803,Combination Chemotherapy or Observation Following Surgery in Treating Infants With Neuroblastoma,COOPERATIVE MULTICENTER TRIAL FOR THE TREATMENT OF INFANTS WITH NEUROBLASTOMA,cyclophosphamide,"['vincristine sulfate', 'doxorubicin hydrochloride', 'cyclophosphamide']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuroblastoma,['Neuroblastoma'],"['localized resectable neuroblastoma', 'regional neuroblastoma', 'stage 4S neuroblastoma', 'localized unresectable neuroblastoma']",COMPLETED,,1995-07,2002-02,[],[],0,,1 Year,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,0,44.0,ESTIMATED,2025-09-01T16:18:13.411782,v2_robust,True,True,True,False,False,
NCT02603003,"the""Fuzheng"" Therapy of TCM to Improve the Survival Quality of Early-stage NSCLC by Intervening the CTCs","A Study on the""Fuzheng""Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation",JinFuKang,"['Navelbine', 'Pemetrexeddisodium for Injection', 'JinFuKang', 'Cisplatin', 'Jin Fukang oral liquid', 'Pemetrexed']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-small Cell Lung Cancer(NSCLC),['Non-small Cell Lung Cancer(NSCLC)'],"['Circulating tumor cells(CTCs)', 'Traditional Chinese Medicine(TCM)', 'Myeloid-derived suppressor cells(MDSCs)']",COMPLETED,,2015-06,2019-09-01,"[{'measure': 'Progression-Free Survival', 'description': 'It is decided by a doctor via the clinical examinations', 'timeFrame': 'The progression disease is assessed based on CT or PET-CT every six months from date of randomization and the endpoints is the date of first documented progression or date of death due to lung cancer,assessed up to Two years.'}]","[{'measure': 'Circulating Tumor Cell', 'description': 'It is decided by a doctor via the clinical examinations', 'timeFrame': '24months'}, {'measure': 'Overall survival', 'description': 'It is decided by a doctor via the clinical examinations', 'timeFrame': 'Two years'}]",3,18 Years,80 Years,ALL,True,Shanghai University of Traditional Chinese Medicine,OTHER,0,218.0,ACTUAL,2025-09-01T16:18:13.411789,v2_robust,True,True,True,False,False,
NCT01002703,"Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma","Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma After Autologous Stem Cell Transplantation or Conventional Chemotherapy OSHO #077","Lenalidomide, Bendamustine, Prednisone","['Lenalidomide, Bendamustine, Prednisone']",1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Multiple Myeloma,['Multiple Myeloma'],"['Lenalidomide', 'Bendamustine', 'Multiple Myeloma', 'Myeloma', 'Revlimid', 'Phase I/II', 'refractory Myeloma', 'relapsed Myeloma']",UNKNOWN,,2009-09,2014-10,"[{'measure': 'To determine the maximum tolerable dose (MTD) of lenalidomide in combination with bendamustine and prednisone (RBP) in refractory and relapsed MM stage I/III', 'timeFrame': '2 month'}]","[{'measure': 'To determine the safety of lenalidomide, bendamustine and prednisone at MTD', 'timeFrame': '2 years'}]",2,18 Years,,ALL,False,University of Leipzig,OTHER,3,50.0,ESTIMATED,2025-09-01T16:18:13.411867,v2_robust,True,True,False,False,True,
NCT00118703,Once-Daily Investigational Nasal Spray In Adults And Adolescents With Vasomotor Rhinitis,"A 4 Week Randomized, Double Blind, Placebo Controlled Study of GW685698X Aq Nasal Spray 100mcg QD in Adults and Adolescents With Vasomotor Rhinitis",GW685698X,['GW685698X'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Vasomotor Rhinitis,"['Vasomotor Rhinitis', 'Rhinitis, Vasomotor']","['nonallergic rhinitis', 'GW685698X', 'VMR', 'vasomotor rhinitis']",COMPLETED,,2005-07-01,2006-02-09,"[{'measure': 'Mean Change From Baseline in Daily Reflective Total Nasal Symptom Scores (rTNSS)', 'description': 'The TNSS was the sum of the individual symptom scores for rhinorrhoea, nasal congestion and post-nasal drip which was scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The rTNSS was a rating of the severity of symptoms over the previous 12 hours and was performed in the morning (AM rTNSS) and evening (post meridian \\[PM\\] rTNSS). The daily rTNSS was the sum of two assessments. The Baseline daily rTNSS was defined as the average of the daily rTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline.', 'timeFrame': 'Baseline and up to Week 4'}]","[{'measure': 'Mean Change From Baseline in Morning (AM) Pre-dose Instantaneous Total Nasal Symptom Scores (iTNSS)', 'description': 'The morning pre-dose iTNSS was the sum of the individual symptom score for rhinorrhoea, nasal congestion and postnasal drip performed immediately prior to taking the daily dose which were scored on a scale of 0-3 (total score 0-9). The severity of symptoms was defined as 0: none-symptom was not present, 1: mild-sign/symptom was clearly present but minimal awareness; easily tolerated, 2: moderate-definite awareness of sign/symptom that was bothersome but tolerable, 3: severe (sign/symptom was hard to tolerate; causes interference with activities of daily living and/or sleeping. The Baseline daily iTNSS was defined as the average of the daily iTNSS over the 4 consecutive 24-hour periods prior to randomization, including the assessment on the morning of randomization. Change from Baseline was calculated as the on-treatment value minus the Baseline value.', 'timeFrame': 'Baseline and up to Week 4'}, {'measure': 'Number of Participants Based on Overall Evaluation of Response to Therapy', 'description': 'Participants were evaluated effectiveness of study medication for relieving non-allergic rhinitis symptoms over the entire treatment period. The overall evaluation of response to therapy was based on a 7-point categorical scale (1-7) where the participants rate their perception of the change or lack of change in their VMR symptoms at the end of the study. The 7 categories were: 1: significantly improved, 2: moderately improved, 3: mildly improved, 4: no change, 5: mildly worse, 6: moderately worse and 7: significantly worse. Effectiveness of study medication for relieving VMR symptoms over the entire treatment period.', 'timeFrame': 'Week 4 (Day 29) or Early Withdrawal'}]",3,12 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,350.0,ACTUAL,2025-09-01T16:18:13.411952,v2_robust,True,True,True,False,False,
NCT01214603,A Study in Participants With Acute Leukemia,A Phase 2 Study of LY2090314 in Participants With Acute Leukemia,LY2090314,['LY2090314'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Leukemia,['Leukemia'],"['Acute Myelogenous Leukemia, Acute Myeloid Leukemia, Acute', 'Leukemia, Leukemia']",COMPLETED,,2010-11,2012-12,"[{'measure': 'Number of Participants With 1 or More Study Drug-Related Adverse Events (AEs) or Any Serious AEs (SAEs)', 'description': 'Drug-related events were defined as treatment-emergent serious and other non-serious AEs that were considered by the investigator to be related to study drug. A summary of serious and other non-serious AEs regardless of causality is located in the Reported Adverse Events module.', 'timeFrame': 'Baseline through study completion [Cycle 9 plus 30 days post last dose (21-day or 28 day cycles)]'}]","[{'measure': 'Number of Participants With Best Response of Complete Response or Partial Response', 'description': 'The Revised International Working Group criteria were used to determine the response for participants with acute myelogenous leukemia (AML). Complete response, also known as complete remission (CR) included the following categories: Morphologic CR defined as \\<5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells, along with peripheral blood levels including platelets ≥100\\*10\\^9/Liter (L) and absolute neutrophil count (ANC) ≥1\\*10\\^9/L, Morphologic CR with incomplete blood count recovery (CRi), Cytogenetic CR, and Molecular CR. Partial response, also known as partial remission (PR) was defined as a decrease of at least 50% in blast count on the bone marrow aspirate. PR required all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate.', 'timeFrame': 'Baseline to progressive disease (up to Cycle 9, 21-day or 28 day cycles)'}, {'measure': 'Percentage of Participants With Best Response of Complete Response or Partial Response', 'description': 'The Revised International Working Group criteria were used to determine the response for participants with AML. Complete response, also known as complete remission (CR) included the following categories: Morphologic CR defined as \\<5% blasts in an aspirate sample with marrow spicules and with a count of at least 200 nucleated cells, along with peripheral blood levels including platelets ≥100\\*10\\^9/L and ANC ≥1\\*10\\^9/L, Morphologic CR with incomplete blood count recovery (CRi), Cytogenetic CR, and Molecular CR. Partial response, also known as partial remission (PR) was defined as a decrease of at least 50% in blast count on the bone marrow aspirate. PR required all of the hematologic values for a CR but with a decrease of at least 50% in the percentage of blasts to 5% to 25% in the bone marrow aspirate. Percentage of participants=\\[(number of participants with CR or PR)/(number of participants treated)\\]\\*100.', 'timeFrame': 'Baseline to progressive disease (up to Cycle 9, 21-day or 28 day cycles)'}, {'measure': 'Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time 0 to 8 Hours (h) Postdose [AUC(0-8)]', 'description': 'AUC(0-8) was estimated from the plasma drug concentration time profile.', 'timeFrame': 'Cycle 1: D1 and/or D9 and/or D15 [predose, 30 minutes (during infusion), up to 24 h after infusion started (1 h, 2 h, 4 h, 6 h, 8 h, and 24 h)]'}, {'measure': 'PK: AUC From Time 0 to Infinity [AUC(0-inf)]', 'description': 'AUC(0-inf) was estimated from the plasma drug concentration time profile.', 'timeFrame': 'Cycle 1: D1 and/or D9 and/or D15 [predose, 30 minutes (during infusion), up to 24 h after infusion started (1 h, 2 h, 4 h, 6 h, 8 h, and 24 h)]'}, {'measure': 'PK: Maximum Concentration (Cmax)', 'description': 'Cmax is the maximum observed concentration estimated from the plasma drug concentration time profile.', 'timeFrame': 'Cycle 1: D1 and/or D9 and/or D15 [predose, 30 minutes (during infusion), up to 24 h after infusion started (1 h, 2 h, 4 h, 6 h, 8 h, and 24 h)]'}, {'measure': 'Percent Change From Predose Beta (β)-Catenin Levels', 'description': 'Percent change=\\[(β-catenin level postdose-predose level)/(predose β-catenin levels)\\]\\*100. Participants in Cohort 1 had β-catenin samples collected on Cycle 1: D1, D8, and D15, and Cycles 2 through 9: D1. Participants in Cohort 2 had β-catenin samples collected on Cycle 1: D1, D5, and D9 and Cycles 2 through 9: D1. Participants in Cohort 3 had β-catenin samples collected on Cycle 1: D1, D5, D9, and D12 and Cycles 2 through 9: D1.', 'timeFrame': 'Cycle 1: D1 and D9 (predose, 1 h, 2 h, 4 h, 8 h, and 24 h after infusion started); Cycle 1: D5, D8, and D12 and C2 through C9: D1 (predose, 2 h after infusion started); Cycle 1: D15 (predose, 1 h, 2 h, 4 h, and 8 h after infusion started)'}, {'measure': 'Number of Participants Who Died', 'description': 'The number of participants who died while on study treatment and the number of participants who died during the 30-day follow-up (30 days post last dose) are reported.', 'timeFrame': 'Baseline through study completion [Cycle 9 plus 30 days post last dose (21-day or 28 day cycles)]'}]",8,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:13.411983,v2_robust,True,True,True,False,True,
NCT06269627,Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder,Temporally-Resolved Electrophysiology of Acamprosate Treatment of Alcohol Use Disorder,Acamprosate calcium,['Acamprosate calcium'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Alcohol Use Disorder,['Alcohol Use Disorder'],"['Multimodal', 'Neuroscience', 'Resting State', 'Event-Related Potentials', 'Artificial Intelligence', 'Machine Learning', 'ELECTROENCEPHALOGRAPHY', 'Acamprosate']",RECRUITING,,2025-05-07,2026-12-31,"[{'measure': 'Reduction of beta power', 'description': 'Spectral power of EEG signals will be calculated in the beta frequency band (beta power). We expect a reduction of beta power to be greater in participants receiving acamprosate for 21 days than participants receiving placebo.', 'timeFrame': '21 day period as inpatients'}]","[{'measure': 'Promotion of alpha power in active group compared to placebo group.', 'description': 'Spectral power of EEG signals will be calculated in the alpha frequency band (alpha power). We expect a promotion of alpha power to be greater in participants receiving acamprosate for 21 days than participants receiving placebo.', 'timeFrame': '21 day period as inpatients'}, {'measure': 'No change in slow band (delta and theta) power in active group compared to placebo group.', 'description': 'Spectral power of EEG signals will be calculated in the delta and theta frequency bands (slow band power). We do not expect a significant difference in change in slow band power between the active and placebo groups over the course of 21 days.', 'timeFrame': '21 day period as inpatients'}, {'measure': 'Reduction of theta event-related synchronization in active group compared to placebo group.', 'description': 'Immediate brain activity, recorded via EEG, in response to task-related stimuli is termed as event-related potentials (ERPs). Spectral power of such ERPs in theta frequency band is called theta event-related synchronization (ERS).We expect a reduction of theta ERS to be greater in participants receiving acamprosate for 21 days than participants receiving placebo.', 'timeFrame': '21 day period as inpatients'}, {'measure': 'Amplification and hastening of P300 in active group compared to placebo group.', 'description': 'Immediate brain activity, recorded via EEG, in response to task-related stimuli is termed as event-related potentials (ERPs). These ERPs have stereotypical peaks, e.g., P300. We expect amplification and hastening of P300 peaks in ERPs among participants receiving acamprosate for 21 days in comparison to participants receiving placebo.', 'timeFrame': '21 day period as inpatients'}, {'measure': 'Correlation of EEG markers of acamprosate treatment with clinical measures of anxiety and alcohol craving', 'description': 'The above EEG measures that are found to be associated with acamprosate treatment will be tested for correlation with clinical measures of anxiety and alcohol craving.', 'timeFrame': '21 day period as inpatients'}, {'measure': 'Correlation of EEG markers of acamprosate treatment with polysomnography markers', 'description': 'The above EEG measures that are found to be associated with acamprosate treatment will be tested for correlation with polysomnography markers such as total sleep time, slow wave sleep duration, sleep efficiency, and total wake duration after sleep onset.', 'timeFrame': '21 day period as inpatients'}, {'measure': 'Correlation of polysomnography markers of acamprosate treatment with clinical measures of anxiety and alcohol craving', 'description': 'The above polysomnography measures that are found to be associated with acamprosate treatment will be tested for correlation with clinical measures of anxiety and alcohol craving.', 'timeFrame': '21 day period as inpatients'}]",8,21 Years,65 Years,ALL,False,National Institute on Alcohol Abuse and Alcoholism (NIAAA),NIH,0,48.0,ESTIMATED,2025-09-01T16:18:13.411994,v2_robust,True,True,False,False,False,
NCT00597727,A Study of Sublingual Immunotherapy in Peanut-allergic Children,"A Double-blinded, Placebo-controlled Study of Peanut Sublingual Immunotherapy in Children - DBPC Peanut SLIT",Peanut SLIT,"['Placebo SLIT', 'Sublingual glycerin saline drops', 'Sublingual peanut protein drops', 'Peanut SLIT']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Food Hypersensitivity,['Food Hypersensitivity'],"['Peanut Allergy', 'Sublingual immunotherapy']",COMPLETED,,2008-01,2016-03,"[{'measure': 'Percentage of Subjects Who Can Tolerate the Peanut Oral Food Challenge After 12 Months of Peanut SLIT Dosing', 'description': 'Upon completion of 12 months of peanut SLIT treatment, subjects underwent a double-blind placebo controlled food challenge (DBPCFC) to assess desensitization (an increase in reaction threshold while on therapy). A DBPCFC involves the ingestion of small increasing amounts of peanut up to a cumulative total amount. The primary clinical efficacy outcome of the study was the percentage of peanut allergic subjects who completed a 2500 mg peanut protein DBPCFC without developing symptoms after 12 months of peanut SLIT therapy.', 'timeFrame': '12 months'}]","[{'measure': 'Percentage of Subjects Tolerating a Peanut Oral Food Challenge 2-4 Weeks After Discontining Peanut SLIT Dosing', 'description': 'Upon completion of 36-60 months of peanut SLIT treatment, subjects underwent a double-blind placebo controlled food challenge (DBPCFC) to assess desensitization (an increase in reaction threshold while on therapy). A DBPCFC involves the ingestion of small increasing amounts of peanut up to a cumulative total amount. Peanut SLIT therapy was then discontinued for 2-4 weeks to assess for persistence of the desensitization response called sustained unresponsiveness (SU). The secondary clinical efficacy outcome of the study was the percentage of peanut allergic subjects who completed a 5000 mg peanut protein DBPCFC without developing symptoms 2-4 weeks after discontinuing peanut SLIT therapy.', 'timeFrame': '36-60 months'}]",2,1 Year,11 Years,ALL,False,"University of North Carolina, Chapel Hill",OTHER,1,60.0,ACTUAL,2025-09-01T16:18:13.412026,v2_robust,True,True,True,False,False,
NCT00491127,Cisplatin With Gemcitabine With Dexamethasone in Patients With Aggressive Non-Hodgkin's Lymphoma,Phase II Study of Cisplatin With Gemcitabine in Fixed Dose Rate Infusion and Dexamethasone in Second-Line in Patients With Aggressive Non-Hodgkin's Lymphoma,gemcitabine,"['dexamethasone', 'gemcitabine', 'cisplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-Hodgkin's Lymphoma,"[""Non-Hodgkin's Lymphoma""]",[],COMPLETED,,2003-04,2004-06,[{'measure': 'To evaluate response rate'}],"[{'measure': 'To assess toxicity'}, {'measure': 'Overall survival'}, {'measure': 'Event-free survival'}, {'measure': 'Progression - free survival'}, {'measure': 'Disease - free survival'}, {'measure': 'Duration of response'}]",7,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,10.0,ACTUAL,2025-09-01T16:18:13.412045,v2_robust,True,True,True,False,False,
NCT01096927,Non Operative Treatment for Acute Appendicitis,Non Operative Treatment for Acute Appendicitis: Study on Efficacy and Safety of Antibiotic Treatment (Amoxicillin and Clavulanic Acid) in Patients With Right Sided Lower Abdominal Pain,Amoxicillin and Clavulanic Acid,['Amoxicillin and Clavulanic Acid'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Lower Abdominal Pain,"['Lower Abdominal Pain', 'Right Iliac Fossa Pain', 'Acute Appendicitis']","['Lower Abdominal Pain', 'Right Iliac Fossa Pain', 'Acute Appendicitis', 'Antibiotic Therapy', 'Conservative Management', 'Appendectomy', 'Recurrence', 'Length of hospital stay', 'Sick leave time', 'Short and Long Term Abdominal pain evaluation']",COMPLETED,,2010-01,2011-02,"[{'measure': 'Short Term Efficacy of Antibiotic Treatment', 'description': 'Failure of the conservative treatment with antibiotic within the period of the Amoxicillin + Clavulanic Acid therapy (7 days), defined as readmission for abscence of clinical improvement and/or worsening abdominal pain and/or localized/diffuse peritonitis', 'timeFrame': 'within 7 days (Antibiotic treatment course)'}, {'measure': 'Long Term Efficacy of Antibiotic Treatment', 'description': 'Efficacy of antibiotic therapy for acute appendicitis defined as incidence of recurrences of clinical episodes of appendicitis up to 1 year follow up (at 15 days, 6 months, 1 year)', 'timeFrame': '1 year'}, {'measure': 'Long Term Efficacy of Antibiotic Treatment (NO need for surgery)', 'description': 'Efficacy of antibiotic therapy for acute appendicitis defined as definite improvement without need for surgery within 1 year follow up (at 15 days, 6 months, 1 year)', 'timeFrame': '1 year'}, {'measure': 'Safety of Antibiotic treatment', 'description': 'Major side effects/complications drug/treatment-related (i.e. Allergy or other complications treatment related such as abscess formation)', 'timeFrame': '7 days'}]","[{'measure': 'Minor Complications', 'description': 'Minor side effects/complications drug/treatment-related (i.e. bloating, diarrhea, gas, headache, heartburn, nausea, and vomiting) (at 7 days, 15 days)', 'timeFrame': '15 days'}, {'measure': 'Abdominal Pain after discharge', 'description': 'Assessment of abdminal pain / discomfort evaluated by mean of Numerical rating scale (NRS) (at 7 days, 15 days)', 'timeFrame': '15 days'}, {'measure': 'Length of Hospital stay', 'description': 'Length of clinical observation as inpatient', 'timeFrame': '7 days'}, {'measure': 'Outpatient clinic checkup', 'description': 'Number of follow up appointments scheduled in outpatient clinic', 'timeFrame': '15 days'}, {'measure': 'Sick Leave', 'description': 'Number of days of sick leave needed by the patient (assessed at 7 days, 15 days, 6 months, 1 year)', 'timeFrame': '1 year'}, {'measure': 'Cost analysis', 'description': 'Analysis of the costs, including Antibiotic course, Length of Hospital Stay, Outpatient Clinic follow up appointments, sick leave days', 'timeFrame': '1 year'}]",10,14 Years,,ALL,False,"Maggiore Bellaria Hospital, Bologna",OTHER,0,160.0,ACTUAL,2025-09-01T16:18:13.412056,v2_robust,True,True,True,False,True,
NCT04795427,"Study of Efficacy and Safety of CML-CP Patients Treated With Asciminib Versus Best Available Therapy, Previously Treated With 2 or More Tyrosine Kinase Inhibitors","A Randomized, Open-label, Multi-center, Phase II Study of Asciminib Versus Best Available Therapy in Chinese Patients With Chronic Myelogenous Leukemia in Chronic Phase (CML-CP), Previously Treated With 2 or More Tyrosine Kinase Inhibitors",asciminib,"['ABL001', 'asciminib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Leukemia, Chronic Myelogenous","['Leukemia, Chronic Myelogenous']","['Chronic Myelogenous Leukemia in chronic phase', 'Chronic Myelogenous Leukemia', 'CML-CP', 'Chronic', 'Chronic Phase', 'ABL001', 'asciminib', 'prior treatment with 2 or more tyrosine kinase inhibitors (TKIs)', 'major molecular response', 'MMR', 'Chinese patients', 'phase ll', 'open label', 'best available therapy', 'BAT']",COMPLETED,,2021-12-06,2024-11-18,"[{'measure': 'Major molecular response rate of asciminib', 'description': 'Evaluate the major molecular response rate at 24 weeks in asciminib arm', 'timeFrame': 'week 24'}]","[{'measure': 'Cytogenetic response (CyR) rate', 'description': 'Evaluate the cytogenetic response rate (Complete, Partial, Major, Minor, Minimal, no response) at and by all scheduled data collection time points including 24, 48 and 96 weeks for both asciminib arm and best available treatment arm.', 'timeFrame': '24, 48, 96 weeks'}, {'measure': 'Major molecular response rate of best available treatment arm', 'description': 'Evaluate the major molecular response rate at week 24 of best available treatment arm, and compare with asciminib arm', 'timeFrame': 'week 24'}, {'measure': 'Major molecular response rate of both asciminib arm and BAT armn time points', 'description': 'Evaluate the major molecular response rate, collected at all scheduled data collection time point (except week 24)', 'timeFrame': 'Up to all participants received at least 96 weeks of randomized study treatment, except week 24'}, {'measure': 'major molecular response rate by all scheduled data collection time points', 'description': 'Evaluate the major molecular rate by all scheduled data collection time points including 24, 48 and 96 weeks by treatment group', 'timeFrame': 'Up to all participants received at least 96 weeks of randomized study treatment'}, {'measure': 'Time to major molecular response rate', 'description': 'Evaluate the time from the date of the first dose of study drug to the date of the first documented MMR by treatment group', 'timeFrame': 'Up to all participants received at least 96 weeks of randomized study treatment'}, {'measure': 'Duration of major molecular response', 'description': 'First document major molecular response to loss of MMR up to 96 weeks after last participant receive the first dose', 'timeFrame': 'Up to all participants received at least 96 weeks of randomized study treatment'}, {'measure': 'Overall survival', 'description': 'To evaluate the time from the date of randomization to the date of death (including the survival follow-up period)', 'timeFrame': 'Up to all participants received at least 96 weeks of randomized study treatment, plus 30 days for safety follow up'}, {'measure': 'Progression free survival', 'description': 'Evaluate the time from the date of randomization to the earliest occurrence of documented disease progression to AP/BC or the date of death from any cause (including progressions and deaths observed during the survival follow-up period)', 'timeFrame': 'Up to all participants received at least 96 weeks of randomized study treatment, plus 30 days for safety follow up'}, {'measure': 'Pharmacokinetics (PK) parameter of asciminib: Cmax', 'description': 'Characterize PK of asciminib in the Chinese CML-CP population. Cmax is the maximum (peak) observed plasma drug concentration after dose administration (ng/mL).', 'timeFrame': 'Week 2 Day 1 (W2D1)'}, {'measure': 'PK parameter of asciminib: Tmax', 'description': 'Characterize PK of asciminib in the Chinese CML-CP population. Tmax is the time to reach maximum (peak) plasma drug concentration after dose administration (hr).', 'timeFrame': 'Week 2 Day 1 (W2D1)'}, {'measure': 'PK parameter of asciminib: Ctrough', 'description': 'Characterize PK of asciminib in the Chinese CML-CP population. Trough plasma concentrations (Ctrough)', 'timeFrame': 'Week 2 Day 1 (W2D1)'}, {'measure': 'PK parameter of asciminib: AUCtau', 'description': 'Characterize PK of asciminib in the Chinese CML-CP population. The partial area under the plasma concentration-time curve from dose time to tau (ng\\*hr/mL). For a bid regimen, Tau=12h.', 'timeFrame': 'Week 2 Day 1 (W2D1)'}, {'measure': 'PK parameter of asciminib: AUClast', 'description': 'Characterize PK of asciminib in the Chinese CML-CP population. AUClast is the The AUC from the time of dosing to the time of the last measurable plasma concentration (Tlast) (ng\\*hr/mL)', 'timeFrame': 'Week 2 Day 1 (W2D1)'}]",14,18 Years,100 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,84.0,ACTUAL,2025-09-01T16:18:13.412175,v2_robust,True,True,True,False,True,
NCT01758627,The Role of Peritoneal Dialysis in Patients With Refractory Heart Failure and Chronic Kidney Disease,,Peritoneal dialysis (PD),"['Peritoneal dialysis (PD)', 'PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.']",2,INTERVENTIONAL,['NA'],,,Refractory Heart Failure,"['Refractory Heart Failure', 'Chronic Kidney Disease']","['Peritoneal dialysis,', 'chronic kidney disease,', 'refractory heart failure']",COMPLETED,,2013-12,2015-10-08,"[{'measure': 'Changes of New York Heart Association (NYHA) functional class', 'timeFrame': 'at 0 (±1 week), 12 (±1 week), and 24 (±1 week) weeks)'}]",[],1,20 Years,,ALL,False,Yonsei University,OTHER,0,7.0,ACTUAL,2025-09-01T16:18:13.412200,v2_robust,True,True,True,False,False,
NCT03856827,A Study of IW-6463 in Healthy Volunteers,"A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of IW-6463 When Administered to Healthy Volunteers as Single Ascending Doses, as Multiple Ascending Doses, and Under Fed Versus Fasting Conditions",IW-6463,"['Matching Placebo', 'CY6463', 'zagociguat', 'IW-6463']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Other,['Other'],[],COMPLETED,,2019-02-06,2019-10-22,"[{'measure': 'After single ascending doses, number of subjects with treatment-emergent adverse events (TEAEs) in the IW-6463 dose-level cohorts vs the (pooled) placebo group.', 'timeFrame': 'Up to 9 days'}, {'measure': 'After multiple ascending doses, number of subjects with TEAEs in the IW-6463 dose-level cohorts vs the (pooled) placebo group.', 'timeFrame': 'Up to 32 days'}, {'measure': 'After a single dose, number of subjects with TEAEs in the fed vs fasted dosing period', 'timeFrame': 'Up to 28 days'}, {'measure': 'Plasma concentration of IW-6463 after single-dose administration under fed vs fasted conditions', 'timeFrame': 'Up to 21 days'}]",[],4,,,ALL,True,Tisento Therapeutics,INDUSTRY,0,110.0,ACTUAL,2025-09-01T16:18:13.412210,v2_robust,True,True,True,False,True,
NCT02071927,Study of the Glutaminase Inhibitor CB-839 in Leukemia,"A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Relapsed and/or Treatment-Refractory Leukemia",CB-839,"['combo CB-839 and azacitidine', 'CB-Aza', 'Glutaminase inhibitor', 'CB-839']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia (AML),"['Acute Myeloid Leukemia (AML)', 'Acute Lymphocytic Leukemia (ALL)']","['leukemia', 'glutaminase', 'glutamine']",COMPLETED,,2014-03,2016-12,"[{'measure': 'Safety and tolerability of CB-839: Incidence of adverse events', 'timeFrame': 'Every 21 days from study start until disease progression or unacceptable toxicity, assessed an expected average of 6 months'}]","[{'measure': 'Pharmacokinetics: Area under the Curve (AUC) of CB-839 concentration in blood', 'timeFrame': 'Study Days 1, 15, and 22'}, {'measure': 'Pharmacodynamics: % inhibition of glutaminase in blood', 'timeFrame': 'Study Days 1 and 15'}, {'measure': 'Clinical Activity: % of Tumor Cells in Bone Marrow', 'timeFrame': 'Every 21 days from study start, assessed for an expected average of 6 months'}]",4,18 Years,,ALL,False,"Calithera Biosciences, Inc",INDUSTRY,0,43.0,ACTUAL,2025-09-01T16:18:13.412316,v2_robust,True,True,True,False,True,
NCT04140227,Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study),"A Phase 3, Multi-Center, Open-Label, Single-Arm Extension Clinical Trial to Assess the Extended Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)",NOV03,['NOV03'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Dry Eye Disease (DED),['Dry Eye Disease (DED)'],[],COMPLETED,,2020-09-24,2022-01-05,"[{'measure': 'Number of Participants With Ocular and Non-ocular Adverse Events', 'timeFrame': '12 months'}]",[],1,18 Years,,ALL,False,Bausch & Lomb Incorporated,INDUSTRY,0,256.0,ACTUAL,2025-09-01T16:18:13.412323,v2_robust,True,True,True,False,True,
NCT05776927,A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.,"A Double-dummy, Double-blind, Randomized, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Compared to Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.",QVM149,"['Run-In Medication', 'Placebo to QVM149', 'Salmeterol Xinafoate / Fluticasone Propionate', 'QVM149', 'Rescue Medication', 'Placebo to Salmeterol Xinafoate / Fluticasone Propionate']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],"['Asthma', 'Adolescent', 'QVM149', 'Pediatric', 'LABA', 'LAMA', 'ICS', 'Triple Combination']",NOT_YET_RECRUITING,,2026-02-01,2029-02-01,"[{'measure': 'Change from Baseline in Trough FEV1 at Week 26.', 'description': 'FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.', 'timeFrame': 'Baseline, Week 26'}]","[{'measure': 'Change from Baseline in Trough FEV1 at Week 52', 'description': 'FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing.', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change from Baseline in Asthma Control Questionnaire (ACQ-5) score at Week 26 and Week 52', 'description': 'The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. The five questions (concerning nocturnal awakening, waking in the morning, activity limitation, shortness of breath and wheeze) enquire about the frequency and/or severity of symptoms over the previous week. The response options for all these questions range from zero (no impairment/limitation) to six (total impairment/ limitation) scale. ACQ-5 score range from 0 to 6. Higher scores indicates worsening of condition.', 'timeFrame': 'Baseline, Week 26, Week 52'}, {'measure': 'Change from Baseline in average Morning and Evening PEFR over 26 weeks and over 52 weeks treatment periods', 'description': 'Morning and Evening PEFR (Peak Expiratory Flow Rate) over 26 weeks and over 52 weeks', 'timeFrame': 'Baseline, Week 26, Week 52'}, {'measure': 'Change from Baseline in average Rescue medication use (daily, daytime, and nighttime) over 26 and 52 week treatment periods', 'description': 'Rescue medication use over 26 and 52 weeks treatment periods', 'timeFrame': 'Baseline, Week 26, Week 52'}, {'measure': 'Change from Baseline in Asthma Quality of Life Questionnaire (AQLQ(S)-12) total score at Week 26 and Week 52', 'description': 'Asthma Quality of Life Questionnaire is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains: symptoms, emotions, exposure to environmental stimuli and activity limitation. Mean score will be calculated for the four domains, as well as the overall quality-of-life score defined as the mean score of all 32 items.', 'timeFrame': 'Baseline, Week 26, Week 52'}, {'measure': 'Incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'Incidence of AEs and SAEs, including changes in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs.', 'timeFrame': 'From first dose up to 30 days after last dose (up to 56 weeks)'}]",7,12 Years,17 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,304.0,ESTIMATED,2025-09-01T16:18:13.412430,v2_robust,True,True,False,False,True,
NCT04027361,Amphetamine Extended Release Tablets and Driving Performance in Subjects With Attention Deficit/Hyperactivity Disorder (ADHD),"Driving Performance in Patients Aged 18 to 25 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) After a Single-Dose of Amphetamine Extended-Release Tablets: A Pilot, Double-Blind, Placebo-Controlled Study",Amphetamine Extended Release (ER) Tablet 20 mg,"['Amphetamine extended-release oral tablet 20 mg', 'Amphetamine Extended Release (ER) Tablet 20 mg']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,ADHD,['ADHD'],[],COMPLETED,,2019-10-01,2021-10-15,"[{'measure': 'Change in Composite Reaction Time Score', 'description': 'Measurement of reaction time across a series of driving simulations', 'timeFrame': 'Measured at pre-dose, 45 minutes and 3 hours post-dose'}]",[],1,18 Years,25 Years,ALL,False,"Tris Pharma, Inc.",INDUSTRY,2,41.0,ACTUAL,2025-09-01T16:18:13.412772,v2_robust,True,True,True,False,False,
NCT00824161,Phase II Study of TAS-109 to Treat Advanced Colorectal Cancer,A Phase II Study of TAS-109 Given by Continuous Intravenous 14-day Infusion in Patients With Chemotherapy-refractory Advanced Colorectal Cancer,TAS-109,['TAS-109'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Colorectal Cancer,['Advanced Colorectal Cancer'],[],TERMINATED,,2009-01,2010-12,"[{'measure': 'Percentage of Progression Free Survival', 'description': 'The primary endpoint was percentage of progression free survival as defined by the percentage of patients without progressive disease(PD)or death, whichever came first, at 3 months of therapy.', 'timeFrame': 'From date of randomization until date of the first documented progressive disease (PD) or death from any cause, whichever came first, assessed up to 3 months.'}]","[{'measure': 'Antitumor Activity', 'description': 'Per RECIST Criteria and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall response rate was defined as percentage of patients of CR plus PR in ITT population.', 'timeFrame': 'From the date of initial treatment until the date of the first objective documentation of PD or death from any cause.'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the period from the date of first dose of TAS-109 to death date.', 'timeFrame': 'From the initial treatment until 12 months after enrollment of the last patient.'}]",3,18 Years,,ALL,False,"Taiho Pharmaceutical Co., Ltd.",INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:13.412842,v2_robust,True,True,False,True,False,
NCT00700661,A Study of MK0476 in the Treatment of Asthma Patients Aged 2-5 Years (0476-907),"A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group, Study to Determine the Efficacy of Montelukast in the Treatment of Exacerbations in Asthmatic Patients Aged 2-to-5 Years",montelukast,"['montelukast', 'MK0476', 'SINGULAIR ®', 'placebo (unspecified)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],[],COMPLETED,,2001-01,2002-12,"[{'measure': 'asthma episodes in 2 - 5 year old children', 'timeFrame': 'at 12 months'}]","[{'measure': 'the number of treatments and duration of asthma episodes', 'timeFrame': 'at 12 months'}]",2,2 Years,5 Years,ALL,False,Organon and Co,INDUSTRY,0,500.0,ACTUAL,2025-09-01T16:18:13.412869,v2_robust,True,True,True,False,False,
NCT00648661,Food Study of Escitalopram Oxalate Tablets 20 mg to Lexapro® Tablets 20 mg,Single-Dose Food In Vivo Bioequivalence Study of Escitalopram Oxalate Tablets (20 mg; Mylan) to Lexapro® Tablets (20 mg; Forest) in Healthy Volunteers,Escitalopram Oxalate Tablets 20 mg,"['Escitalopram Oxalate Tablets 20 mg', 'Lexapro® Tablets 20 mg']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2004-09,2004-10,"[{'measure': 'Bioequivalence', 'timeFrame': 'within 30 days'}]",[],1,18 Years,,ALL,True,Mylan Pharmaceuticals Inc,INDUSTRY,0,35.0,ACTUAL,2025-09-01T16:18:13.412879,v2_robust,True,True,True,False,False,
NCT00479661,Dexmedetomidine Versus Propofol for Continuous Sedation in the Intensive Care Unit (ICU),"A Prospective, Multi-centre, Randomised, Double-blind Comparison of Intravenous Dexmedetomidine With Propofol for Continuous Sedation of Ventilated Patients in Intensive Care Unit",Dexmedetomidine,"['Propofol', 'Dexmedetomidine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Continuous Sedation in Initially Sedated Adults in ICU,['Continuous Sedation in Initially Sedated Adults in ICU'],"['initial sedation', 'mechanical ventilation']",COMPLETED,,2007-05,2010-03,"[{'measure': 'Depth of sedation using the RASS. The target RASS range (target depth of sedation) should be 0 to -3 for a patient to be included in the study. The target may be amended during the study treatment, if clinically required.', 'timeFrame': '2 hourly and before each rescue treatment dose during the treatment period and the 48-hour follow-up'}, {'measure': 'Duration of mechanical ventilation', 'timeFrame': 'Start and stop times of mechanical ventilation while the patient is treated in the ICU'}]","[{'measure': ""Nurse's assessment of subject communication with visual analogue scales (VAS)"", 'timeFrame': 'At the end of each nursing shift during study treatment and 48 h follow-up period in the ICU'}, {'measure': 'Length of ICU stay', 'timeFrame': 'Admission and discharge dates and times during the current ICU treatment period'}]",4,18 Years,,ALL,False,"Orion Corporation, Orion Pharma",INDUSTRY,0,500.0,ACTUAL,2025-09-01T16:18:13.412885,v2_robust,True,True,True,False,False,
NCT01682161,A Comparative Study to Evaluate the Evolution of Medication Satisfaction and Adherence in Patients Unsatisfied With Current Oral Atypical Antipsychotics by Switching Medication to Paliperidone Palmitate,"An Open-Label, Comparative Study of Immediate or Delayed Switch to Paliperidone Palmitate in Patients Unsatisfied With Current Oral Atypical Antipsychotics to Evaluate the Evolution of Medication Satisfaction and Adherence",Paliperidone palmitate,"['Paliperidone palmitate', 'INVEGA SUSTENNA']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'Paliperidone Palmitate', 'Invega Sustenna', 'Antipsychotics', 'Atypical antipsychotics', 'Medication Satisfaction and Adherence']",COMPLETED,,2012-01,2013-09,"[{'measure': 'Change from baseline to Week 21 in scores of Medication Satisfaction Questionnaire (MSQ)', 'description': 'MSQ is designed to assess treatment satisfaction among patients with schizophrenia. The responses will be assessed on a 7-point Likert-type scale rated as follows: 1=extremely dissatisfied, 2=very dissatisfied, 3=somewhat dissatisfied, 4=neither satisfied nor dissatisfied, 5=somewhat satisfied, 6=very satisfied, and 7=extremely satisfied.', 'timeFrame': 'Screening (Week -2), baseline (Week 0), Week 1, Week 5, Week 8, Week 9, Week 13, Week 17, and Week 21'}]","[{'measure': 'Change from baseline to Week 21 in scores of Treatment Satisfaction Questionnaire for Medication (TSQM)', 'description': 'The TSQM is a 14-item subject assessed evaluation of treatment medication using a 7-point Likert-type scale rated as follows: 1=Extremely Dissatisfied, 2=Very Dissatisfied, 3=Somewhat Dissatisfied, 4=Neither Satisfied Nor Dissatisfied, 5=Somewhat Satisfied, 6=Very Satisfied, 7= Extremely Satisfied.', 'timeFrame': 'Screening, baseline, Week 1, Week 5, Week 8, Week 9, Week 13, Week 17, and Week 21'}, {'measure': 'Change from baseline to Week 21 in scores of Positive and Negative Syndrome Scale (PANSS)', 'description': 'The PANSS is a medical scale used for measuring symptom severity of patients with schizophrenia. The neuropsychiatric symptoms of schizophrenia will be assessed using the 30-item PANSS scale. Each item is rated as follows: 1=absent, 2=Minimal, 3=Mild, 4=Moderate, 5=Moderate Severe, 6=Severe, and 7=Extreme.', 'timeFrame': 'Baseline, Week 8, and Week 21'}, {'measure': 'Change from baseline to Week 21 in scores of Clinical Global Impression - Severity (CGI-S) scale', 'description': ""The CGI-S rating scale is used to rate the severity of a patient's psychotic condition on a 7-point scale. It is rated as follows: 1=Normal, not at all ill, 2=Borderline mentally ill, 3=Mildly ill, 4=Moderately ill, 5=Markedly ill, 6=Severely ill, and 7=Among the most extremely ill."", 'timeFrame': 'Baseline, Week 1, Week 5, Week 8, Week 9, Week 13, Week 17, and Week 21'}, {'measure': 'Change from baseline to Week 21 in scores of Personal and Social Performance (PSP) scale', 'description': 'The PSP is a clinician rated instrument providing an overall rating of personal and social functioning in patients with schizophrenia on a scale of 1-100. The scale defines a continuum from grossly impaired functioning, in which total lack of autonomy in basic functioning and survival risk is evident, to excellent functioning. Four domains of functioning are considered in the rating: 1) socially useful activities, including work and study, 2) personal and social relationships, 3) self-care, and 4) disturbing and aggressive behavior.', 'timeFrame': 'Baseline, Week 8, and Week 21'}, {'measure': 'Score of Mediation Adherence Rating Scale (MARS)', 'description': 'The MARS is a 10-items self-rating scale to measure the adherence of the drug medication for psychosis. Each item is answered ""yes/no"" and the total score ranges from 0 points (Low medication adherence) to 10 points (High medication adherence).', 'timeFrame': 'Baseline'}]",6,20 Years,65 Years,ALL,False,"Janssen Korea, Ltd., Korea",INDUSTRY,0,154.0,ACTUAL,2025-09-01T16:18:13.412900,v2_robust,True,True,True,False,False,
NCT02381561,Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy,Phase I and Pharmacology Study of Oral 5-Iodo-2-Pyrimidinone-2'- Deoxyribose (IPdR) as a Prodrug for IUdR-Mediated Tumor Radiosensitization in Gastrointestinal Cancers,Ropidoxuridine,"[""5-Iodo-2-pyrimidinone 2' deoxyribonucleoside"", 'IPdR', 'Ropidoxuridine', ""5-Iodo-2-pyrimidinone-2'-deoxyribose""]",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Bile Duct Carcinoma,"['Advanced Bile Duct Carcinoma', 'Stage II Esophageal Cancer AJCC v7', 'Stage II Pancreatic Cancer AJCC v6 and v7', 'Stage IIA Esophageal Cancer AJCC v7', 'Stage IIA Pancreatic Cancer AJCC v6 and v7', 'Stage IIB Esophageal Cancer AJCC v7', 'Stage IIB Pancreatic Cancer AJCC v6 and v7', 'Stage III Colon Cancer AJCC v7', 'Stage III Esophageal Cancer AJCC v7', 'Stage III Gastric Cancer AJCC v7', 'Stage III Liver Cancer', 'Stage III Pancreatic Cancer AJCC v6 and v7', 'Stage III Rectal Cancer AJCC v7', 'Stage III Small Intestinal Cancer AJCC v7', 'Stage IIIA Colon Cancer AJCC v7', 'Stage IIIA Esophageal Cancer AJCC v7', 'Stage IIIA Gastric Cancer AJCC v7', 'Stage IIIA Rectal Cancer AJCC v7', 'Stage IIIA Small Intestinal Cancer AJCC v7', 'Stage IIIB Colon Cancer AJCC v7', 'Stage IIIB Esophageal Cancer AJCC v7', 'Stage IIIB Gastric Cancer AJCC v7', 'Stage IIIB Rectal Cancer AJCC v7', 'Stage IIIB Small Intestinal Cancer AJCC v7', 'Stage IIIC Colon Cancer AJCC v7', 'Stage IIIC Esophageal Cancer AJCC v7', 'Stage IIIC Gastric Cancer AJCC v7', 'Stage IIIC Rectal Cancer AJCC v7', 'Stage IV Colon Cancer AJCC v7', 'Stage IV Esophageal Cancer AJCC v7', 'Stage IV Gastric Cancer AJCC v7', 'Stage IV Liver Cancer', 'Stage IV Pancreatic Cancer AJCC v6 and v7', 'Stage IV Rectal Cancer AJCC v7', 'Stage IV Small Intestinal Cancer AJCC v7', 'Stage IVA Colon Cancer AJCC v7', 'Stage IVA Liver Cancer', 'Stage IVA Rectal Cancer AJCC v7', 'Stage IVB Colon Cancer AJCC v7', 'Stage IVB Liver Cancer', 'Stage IVB Rectal Cancer AJCC v7']",[],ACTIVE_NOT_RECRUITING,,2016-02-01,2026-03-14,"[{'measure': 'Maximum tolerated dose (MTD) defined as the dose below which 2 or more of 6 patients experience dose-limiting toxicity', 'timeFrame': 'Up to 28 days'}]","[{'measure': '%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in tumor biopsies', 'description': 'Correlate %IUdR-DNA incorporation in human gastrointestinal (GI) tumor biopsies in the proposed phase I and pharmacokinetic (PK) clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic radiation therapy (RT) by linear regression.', 'timeFrame': 'Up to 2 weeks'}, {'measure': 'Pharmacokinetic (PK) incorporation in tumor biopsies', 'description': 'Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression.', 'timeFrame': 'Days 1, 15 and 22 before drug administration, at 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration'}, {'measure': '%iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation in peripheral (circulating) granulocytes', 'description': 'Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression.', 'timeFrame': 'Up to 4 weeks after completion of study treatment'}, {'measure': 'Pharmacokinetic (PK) incorporation in peripheral (circulating) granulocytes', 'description': 'Correlate %IUdR-DNA incorporation in human GI tumor biopsies in the proposed phase I and PK clinical trial in GI cancer patients receiving palliative abdominal and/or pelvic RT by linear regression.', 'timeFrame': 'Days 1, 15 and 22 before drug administration, 30, 60, 120, and 240 minutes (and 24 hours on day 1 only) following drug administration'}, {'measure': 'Tumor response relationship to the %iododeoxyuridine (IUdR)-deoxyribonucleic acid (DNA) incorporation using Response Evaluation Criteria in Solid Tumors (RECIST) criteria based on high-pressure liquid chromatography (HPLC) and flow cytometry measurements', 'description': 'Tumor response is the dependent variable and can be binomial (i.e. response versus \\[vs.\\] no response) or multinomial (i.e. complete response, partial response, stable disease or progressive disease) and the %IUdR-DNA incorporation is the independent variable.', 'timeFrame': 'Day 8'}]",6,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,19.0,ACTUAL,2025-09-01T16:18:13.412971,v2_robust,True,True,False,False,False,
NCT01296542,A Comparison of Prophylactic Antibacterial Efficacy of Besivance vs. VIGAMOX Prior to Cataract Surgery,A Comparison of Prophylactic Antibacterial Efficacy of Besivance Versus VIGAMOX Administered for Three Days and One Hour Prior to Phacoemulsification,Moxifloxacin Ophthalmic,"['Besifloxacin Ophthalmic', 'Moxifloxacin Ophthalmic']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Cataracts,['Cataracts'],[],COMPLETED,,2011-05,2013-01,"[{'measure': 'Number of Subjects With a Change in Bacterial Colonization of Lid and Conjunctival Cultures After 3 Days', 'description': 'Lid and Conjunctival cultures will be taken to measure bacterial colonization.', 'timeFrame': 'Following 3 days of antibiotic drops topically instilled'}]",[],1,18 Years,,ALL,True,Bucci Laser Vision Institute,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:13.413144,v2_robust,True,True,True,False,False,
NCT00004642,Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease,Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease,SDZ MSL-109,['SDZ MSL-109'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cytomegalovirus Infections,['Cytomegalovirus Infections'],"['congenital cytomegalovirus infection', 'cytomegalovirus infection', 'herpesvirus infection', 'immunologic disorders and infectious disorders', 'neonatal disorders', 'rare disease', 'viral infection']",COMPLETED,,1995-02,,[],[],0,0 Years,29 Days,ALL,False,National Center for Research Resources (NCRR),NIH,1,,,2025-09-01T16:18:13.413154,v2_robust,True,True,True,False,False,
NCT00916942,Study of NGX-4010 With the Use of Open Label Lidocaine (2.5%)/Prilocaine (2.5%) Cream for the Treatment of Postherpetic Neuralgia (PHN),An Open-Label Study Of The Use Of Topical Lidocaine (2.5%)/Prilocaine (2.5%) Cream As Pre-Treatment For NGX-4010 In Subjects With Postherpetic Neuralgia (PHN),capsaicin 8%,"['Lidocaine (2.5%)/Prilocaine (2.5%) Cream', 'capsaicin 8%']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Postherpetic Neuralgia,['Postherpetic Neuralgia'],['Tolerability study'],COMPLETED,,2009-06,2009-07,"[{'measure': 'Duration of patch application', 'timeFrame': 'Day of treatment'}]","[{'measure': 'Mean change in NPRS scores from pre-treatment values to subsequent time points on the day of treatment', 'timeFrame': 'Day of treatment'}]",2,18 Years,90 Years,ALL,False,NeurogesX,INDUSTRY,0,20.0,ESTIMATED,2025-09-01T16:18:13.413183,v2_robust,True,True,True,False,False,
NCT05014542,Needling Techniques for Knee Osteoarthritis,Needling Techniques for Tonifying Kidneys and Dredging Meridians for Knee Osteoarthritis: A Randomized Clinical Trial,Conventional Medical Treatment,"['Conventional Medical Treatment', 'Analgesics']",2,INTERVENTIONAL,['NA'],,,Knee Osteoarthritis,"['Knee Osteoarthritis', 'Kidney Yin Deficiency', 'Kidney Yang Deficiency']","['Needling', 'Techniques', 'Randomized', 'Reinforcing', 'Reducing', 'Acupuncture']",COMPLETED,,2021-01-02,2022-06-12,"[{'measure': 'WOMAC Total in Week 15', 'description': 'The Western Ontario and McMaster University Osteoarthritis Index (WOMAC) total score is the sum of the three subscales: pain, stiffness, and functional disability.\n\nThe minimum value is 0, and the maximum value is 96, where the lower score/value represents a better outcome, and the higher score/value represents a worse outcome.', 'timeFrame': 'Week 15'}]","[{'measure': 'WOMAC Pain in Week 15', 'description': 'Western Ontario and McMaster University Osteoarthritis (WOMAC) pain subscale, separated from the WOMAC index, evaluates knee OA pain by participants. It comprises 5 questions for pain assessed by a 5-point Likert scale ranging from minimal 0 to maximal 20 points. A bigger score presents a worse outcome, and a lower score relates to a better outcome.', 'timeFrame': 'Week 15'}, {'measure': 'WOMAC Stiffness in Week 15', 'description': 'Western Ontario and McMaster University Osteoarthritis (WOMAC) stiffness subscale, separated from the WOMAC index, and evaluate knee OA stiffness by participants. It comprises 2 questions for stiffness assessed by a 5-point Likert scale between the range from minimal 0 to maximal 8 points. A bigger score presents a worse outcome, and a lower score relates to a better result. WOMAC stiffness measures the stiffness of the knees.', 'timeFrame': 'Week 15'}, {'measure': 'WOMAC Functional Disability in Week 15', 'description': ""Western Ontario and McMaster University Osteoarthritis (WOMAC) functional disability subscale, separated from the WOMAC index, evaluates knee OA functional disability by participants' estimation. It comprises 17 items for functional disability assessment by a 5-point Likert scale ranging from minimal 0 to maximal 68 points. A bigger score presents a worse outcome, and a lower score relates to a better result. WOMAC functional disability measures climbing, rising from a chair/bed, standing, bending, walking, getting in/out of a car/bath/toilet, shopping, putting on socks, sitting and difficulties in domestic duties."", 'timeFrame': 'Week 15'}, {'measure': 'VAS in Week 15', 'description': 'Visual Analogue Scale (VAS) assesses knee OA pain intensity, ranging from 0 to 100; the lower value represents a better outcome, and the higher a worse outcome.', 'timeFrame': 'Week 15'}, {'measure': 'KDSQ in Week 15', 'description': 'The Kidney Deficiency Syndrome Questionnaire (KDSQ) assesses the intensity of Kidney deficiency (KD) symptoms; the minimum value is 0, and the maximum is 69. A lower score/value represents a better outcome, and a higher score/value represents a worse outcome.\n\nThis measure represents the effect of acupuncture treatment on KD.', 'timeFrame': 'Week 15'}, {'measure': 'DRUG in Week 15', 'description': ""DRUG is a measure that represents analgesics taken by participants, including various non-steroid anti-inflammatory drugs (NSAIDS) and/or tramadol. Recorded analgesics' doses from the last three days before assessment were recalculated in the comparable dose of the selective representative (ibuprofen) and converted into equivalent dose of milligrams of ibuprofen-ibuprofen equivalent units (IBU). DRUG's units of measure are IBU (units) on the scale ranging from 0 IBU to 4.500 IBU. DRUG decreasement represents a better therapeutic outcome, and an increase in DRUG represents a worse therapeutic outcome. All participants could self-manage the dosage according to their pain."", 'timeFrame': 'Week 15'}, {'measure': 'Active Extension L and R Knees in Week 15', 'description': 'The active extension of the left (L) and right (R) knees in Week 15 is an objective measure taken by an independent physiatrist with a goniometer, expressed on a scale with degrees of a goniometer angle as units.\n\nKnee active extension ranges between 0 and 5 degrees: the higher scores represent knee laxity/instability, and the negative scores represent knee flexion contraction. The higher values represent worse outcomes, and the lower values represent better outcomes.', 'timeFrame': 'Week 15'}, {'measure': 'Active Flexion L and R Knees in Week 15', 'description': 'Active flexion of left (L) and right (R) knees in Week 15 is an objective measure provided by an independent physiatrist with a goniometer, expressed on a scale with degrees of a goniometer angle (units).\n\nKnee active flexion ranges from 0 to a maximum of 135 degrees; the lower score/value represents a worse outcome, and the higher score/value a better one.', 'timeFrame': 'Week 15'}, {'measure': 'Circumference of L and R Upper Leg in Week 15', 'description': 'Circumference of the left (L) and right (R) upper leg in Week 15 is an objective measure, assessed by an independent physiatrist, at the thigh 15 centimetres above the patellar superior margin, measured with a tape measure. The unit of measure is a centimetre (unit) on the measuring tape (scale) with a range from 0 to 100 centimetres. This measure represents a measure of muscular strength or atrophy. Higher values indicate better outcomes from higher muscular volume, and decreased values indicate worse outcomes from weaker muscular volume.', 'timeFrame': 'Week15'}, {'measure': 'Circumference of L and R Knees in Week 15', 'description': 'Circumference of left (L) and right (R) knees at Week 15 is an objective measurement taken by an independent physiatrist; the measure includes the difference in circumference of the knees measured with a tape measure at the middle of the patellae. The unit of measure is a centimetre (unit) on the measuring tape (scale) with a range from 0 to 100 centimetres. This measure represents knee inflammation and joint deformation (abnormal bone growth). Increased values indicate worse outcomes from a higher level of knee inflammation/deformation, and decreased values indicate better outcomes from a lower level of knee inflammation/deformation.', 'timeFrame': 'Week 15'}, {'measure': 'WOMAC Total in Week 24', 'description': ""Western Ontario and McMaster University Osteoarthritis (WOMAC) index's total score is a sum of all three subscales for pain, stiffness, and functional disability, the minimum value is 0, and the maximum value is 96; the lower score/value represents a better outcome, and a higher score/value represents a worse outcome"", 'timeFrame': 'Week 24'}, {'measure': 'WOMAC Pain in Week 24', 'description': 'Western Ontario and McMaster University Osteoarthritis (WOMAC) pain subscale, separated from the WOMAC index, evaluates OA pain by participants. It comprises 5 questions for pain assessed by a 5-point Likert scale, ranging from minimal 0 to maximal 20 points. A bigger score presents a worse outcome, and a lower score relates to a better one.', 'timeFrame': 'Week 24'}, {'measure': 'WOMAC Stiffness in Week 24', 'description': 'Western Ontario and McMaster University Osteoarthritis (WOMAC) stiffness subscale, separated from the WOMAC index, evaluates knee OA stiffness by participants. It comprises 2 questions for stiffness assessed by a 5-point Likert scale ranging from minimal 0 to maximal 8 points. A bigger score represents a worse outcome, and a lower score relates to a better result. WOMAC stiffness measures the stiffness of the knees.', 'timeFrame': 'Week 24'}, {'measure': 'WOMAC Functional Disability in Week 24', 'description': ""Western Ontario and McMaster University Osteoarthritis (WOMAC) functional disability subscale, separated from the WOMAC index, evaluates knee OA functional disability by participants' estimation. It comprises 17 items of functional disability assessment by a 5-point Likert scale ranging from minimal 0 to maximal 68 points. A bigger score presents a worse outcome, and a lower score relates to a better result. WOMAC functional disability measures climbing, rising from a chair/bed, standing, bending, walking, getting in/out of a car/bath/toilet, shopping, putting on socks, sitting, and difficulties in domestic duties."", 'timeFrame': 'Week 24'}, {'measure': 'VAS in Week 24', 'description': 'Visual Analogue Scale (VAS) assesses knee OA pain intensity, ranging from 0 to 100; the lower value represents a better outcome, and the higher a worse outcome.', 'timeFrame': 'Week 24'}, {'measure': 'KDSQ in Week 24', 'description': 'The Kidney Deficiency Syndrome Questionnaire (KDSQ) assesses the intensity of kidney deficiency symptoms; the minimum value is 0, and the maximum is 69. A lower score/value represents a better outcome, and a higher score/value represents a worse outcome.\n\nThis measure represents the effect of acupuncture treatment on Kidney deficiency (KD).', 'timeFrame': 'Week 24'}, {'measure': 'DRUG in Week 24', 'description': ""DRUG is a measure that represents analgesics taken by participants, including various non-steroid anti-inflammatory drugs (NSAIDS) and/or tramadol. Recorded analgesics' doses from the last three days before assessment were recalculated in the comparable dose of the selective representative (ibuprofen) and converted into equivalent dose of milligrams of ibuprofen-ibuprofen equivalent units (IBU). DRUG's units of measure are IBU (units) on the scale ranging from 0 IBU to 4.500 IBU. DRUG decreasement represents a better therapeutic outcome, and an increase in DRUG represents a worse therapeutic outcome. All participants could self-manage the dosage according to their pain."", 'timeFrame': 'Week 24'}, {'measure': 'Active Extension L and R Knee in Week 24', 'description': 'The active extension of the left (L) and right (R) knees in Week 15 is an objective measure taken by an independent physiatrist with a goniometer, expressed on a scale with degrees of a goniometer angle as units.\n\nKnee active extension ranges between 0 and 5 degrees: the higher scores represent knee laxity/instability, and the negative scores represent knee flexion contraction. The higher values represent worse outcomes, and the lower values represent better outcomes.', 'timeFrame': 'Week 24'}, {'measure': 'Active Flexion L and R Knees in Week 24', 'description': 'Active flexion of left (L) and right (R) knees in Week 15 is an objective measure provided by an independent physiatrist with a goniometer, expressed on a scale with degrees of a goniometer angle (units).\n\nKnee active flexion ranges from 0 to a maximum of 135 degrees; the lower score/value represents a worse outcome, and the higher score/value a better one.', 'timeFrame': 'Week 24'}, {'measure': 'Circumference of L and R Upper Leg in Week 24', 'description': 'Circumference of the left (L) and right (R) upper leg in Week 24 is an objective measure, assessed by an independent physiatrist, at the thigh 15 centimetres above the patellar superior margin, measured with a tape measure. The unit of measure is a centimetre (unit) on the measuring tape (scale) with a range from 0 to 100 centimetres. This measure represents a measure of muscular strength or atrophy. Higher values indicate better outcomes from higher muscular volume, and decreased values indicate worse outcomes from weaker muscular volume.', 'timeFrame': 'Week 24'}, {'measure': 'Circumference of L and R Knee in Week 24', 'description': 'Circumference of the left (L) and right (R) upper leg in Week 24 is an objective measure, assessed by an independent physiatrist, at the thigh 15 centimetres above the patellar superior margin, measured with a tape measure. The unit of measure is a centimetre (unit) on the measuring tape (scale) with a range from 0 to 100 centimetres. This measure represents a measure of muscular strength or atrophy. Higher values indicate better outcomes from higher muscular volume, and decreased values indicate worse outcomes from weaker muscular volume.', 'timeFrame': 'Week 24'}, {'measure': 'WOMAC Total in Week 39', 'description': 'Western Ontario and McMaster University Osteoarthritis (WOMAC) total at the Added assessment at Week 39 in the crossover part compared to pre-experimental baseline value. The total score is a sum of all three subscales: pain, stiffness, and functional limitation. The minimum value is 0, and the maximum value is 96, where the lower score/value represents a better outcome, and a higher score/value represents a worse outcome.', 'timeFrame': 'Week 39'}, {'measure': 'WOMAC Pain in Week 39', 'description': 'The Western Ontario and McMaster University Osteoarthritis (WOMAC) pain subscale, selected from the WOMAC index, evaluates knee OA pain by participants. It comprises 5 questions for pain assessed by a 5-point Likert scale, ranging from minimal 0 to maximal 20 points. A bigger score presents a worse outcome, and a lower score relates to a better one.', 'timeFrame': 'Week 39'}, {'measure': 'WOMAC Stiffness in Week 39', 'description': 'Western Ontario and McMaster University Osteoarthritis (WOMAC) stiffness subscale, separated from the WOMAC index, evaluates knee OA stiffness by participants. It comprises 2 questions for stiffness assessed by a 5-point Likert scale ranging from minimal 0 to maximal 8 points. A bigger score represents a worse outcome, and a lower score relates to a better result. WOMAC stiffness measures the stiffness of the knees.', 'timeFrame': 'Week 39'}, {'measure': 'WOMAC Functional Disability in Week 39', 'description': ""Western Ontario and McMaster University Osteoarthritis (WOMAC) functional disability subscale, separated from the WOMAC index, evaluates knee OA functional disability by participants' estimation. It comprises 17 items for functional disability assessment by a 5-point Likert scale ranging from minimal 0 to maximal 68 points. A bigger score presents a worse outcome, and a lower score relates to a better result. WOMAC functional disability measures climbing, rising from a chair/bed, standing, bending, walking, getting in/out of a car/bath/toilet, shopping, putting on socks, sitting and difficulties in domestic duties."", 'timeFrame': 'Week 39'}, {'measure': 'VAS in Week 39', 'description': 'Visual Analogue Scale (VAS) assesses knee OA pain intensity, ranging from 0 to 100; the lower value represents a better outcome, and the higher a worse outcome.\n\nThis measure estimates the treatment effect of acupuncture on knee pain in Week 39 separately for groups A and C.', 'timeFrame': 'Week 39'}, {'measure': 'KDSQ in Week 39', 'description': 'The Kidney Deficiency Syndrome Questionnaire (KDSQ) assesses the intensity of Kidney deficiency symptoms; the minimum value is 0, and the maximum is 69. A lower score/value represents a better outcome, and a higher score/value represents a worse outcome.\n\nThis outcome represents the treatment effect of acupuncture on Kidney deficiency symptoms for both groups separately.', 'timeFrame': 'Week 39'}, {'measure': 'DRUG by Added Assessment in Week 39, Crossover Part', 'description': ""DRUG is a measure that represents analgesics taken by participants, including various non-steroid anti-inflammatory drugs (NSAIDS) and/or tramadol. Recorded analgesics' doses from the last three days before assessment were recalculated in the comparable dose of the selective representative (ibuprofen) and converted into equivalent dose of milligrams of ibuprofen-ibuprofen equivalent units (IBU). DRUG's units of measure are IBU (units) on the scale ranging from 0 IBU to 4.500 IBU. DRUG decreasement represents a better therapeutic outcome, and an increase in DRUG represents a worse therapeutic outcome. All participants could self-manage the dosage according to their pain."", 'timeFrame': 'Week 39'}, {'measure': 'Lequesne Index in Week 24, Between-group Analysis', 'description': 'The Lequesne index is an algofunctional index of knee osteoarthritis that comprises three sections. Its score ranges from a minimal 0 (no pain and disability) to 24 (the greatest pain and disability). This index is added to the study in Week 24 as an additional objective measure. It measures pain severity with 5 questions, walking distance with 2 questions, and activities of daily living with 4 questions.', 'timeFrame': 'Week 24'}]",30,50 Years,,ALL,False,Svijetlana Perculija Durdevic,OTHER,3,64.0,ACTUAL,2025-09-01T16:18:13.413363,v2_robust,True,True,True,False,False,
NCT00001542,Fluconazole Prophylaxis of Thrush in AIDS,Fluconazole Prophylaxis of Thrush in AIDS,fluconazole,['fluconazole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Acquired Immunodeficiency Syndrome,"['Acquired Immunodeficiency Syndrome', 'Candidiasis', 'Oral Candidiasis']","['Candidiasis', 'Azole', 'Resistance', 'Candida Albicans', 'Oropharynx']",COMPLETED,,1996-07,2001-11,[],[],0,,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,80.0,,2025-09-01T16:18:13.413520,v2_robust,True,True,True,False,False,
NCT03887442,Paclitaxel vs Paclitaxel + Cetuximab in Recurrent - Metastatic Head & Neck Carcinoma After Failure of a 1º Chemotherapy,"Phase II, Randomized Clinical Trial to Assess the Efficacy of Paclitaxel vs Paclitaxel + Cetuximab in Subjects With Recurrent and/or Metastatic Squamous Head & Neck Carcinoma After Failure of a 1º Line Chemotherapy EXTREME Type Treatment",Paclitaxel,"['Cetuximab + Paclitaxel', 'Paclitaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,['Head and Neck Cancer'],"['Head and Neck Cancer', 'Cetuximab', 'Erbitux', 'Paclitaxel', 'Extreme', 'Metastatic', 'Recurrent']",TERMINATED,low recruitment rate,2011-02-16,2012-10-02,"[{'measure': 'Progression Free Survival (PFS)', 'description': 'The primary endpoint was to select the most effective treatment arm based on the progression-free survival (PFS) reached in each treatment arm. This was defined as the time elapsed from inclusion in the study until the date when disease progression or death (for any cause) was documented.', 'timeFrame': 'Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The primary endopoint was not analyzed.'}]","[{'measure': 'Overall Survival', 'description': 'Calculate overall survival (OS) in both arms', 'timeFrame': 'Through study completion. The study was prematurely closed at 19 months due to lack of accrual. The secondary endopoint was not analyzed.'}, {'measure': 'Percentage of Objective Response', 'description': 'Calculate the percentage of objective responses (OR), following the new RECIST criteria, obtained in both arms', 'timeFrame': 'Through study completion. The study was prematurely closed at 19 months due to lack of accrual. Neither the primary nor the secondary endopoints were analyzed.'}, {'measure': 'Participants With Adverse Events', 'description': 'To perform a descriptive analysis of the adverse events observed in the patients included in the study. Further analysis could not be performed due to early closure of this study due to lack of accrual. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.', 'timeFrame': 'The duration of the study (Nineteen months) and until the last patient included completed one year of follow up / died or was lost to FU. Adverse events were registered from study entry until 60 days after receiving the last dose of study drug.'}, {'measure': 'Treatment Compliance', 'description': 'Evaluate treatment compliance rate in both treatment arms, in order to analyze it, the dose intensity would be calculated as the quantity of each of the administered study drugs per unit of time (mg/m2/week) regardless of the treatment arm. To analyze the relative dose intensity, the dose of each administered drug will be divided per a unit of time and the planned quantity of each drug according to the doses described in the protocol.', 'timeFrame': '3 years'}]",5,18 Years,75 Years,ALL,False,Grupo Español de Tratamiento de Tumores de Cabeza y Cuello,OTHER,2,17.0,ACTUAL,2025-09-01T16:18:13.413534,v2_robust,True,True,False,True,True,low recruitment rate
NCT07033442,Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery,Effects Of Inhalation Anaesthesia and Total Intravenous Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery,Sevoflurane (Volatile Anesthetic),"['Propofol 1%', 'Remifentanil 2 MG', 'Neostigmine 0,5 mg/ml ampoule', 'Crystalloid solutions', 'Thiopental 500 mg vial for injection', 'Atropine Sulphate 0.5mg/ml ampoule', 'Lidocaine %2 ampoule', 'Sevoflurane (Volatile Anesthetic)', 'Ephedrine Hydrochloride 0,05 mg/ml ampoule', 'Rocuronium 50 mg/5 ml']",10,INTERVENTIONAL,['NA'],,,Anaesthesia,"['Anaesthesia', 'Intraocular Pressure', 'Trendelenburg Position', 'Robot Assisted Laparoscopic Radical Prostatectomy', 'Total Intravenous Anesthesia', 'Inhalation Anesthesia']","['Robot Assisted Laparoscopic Radical prostatectomy', 'Intraoculer Pressure', 'Total Intravenous Anesthesia', 'Inhalation Anaesthesia']",COMPLETED,,2015-07-23,2015-12-24,"[{'measure': 'Intraocular Pressure Measured Using Tono-Pen at Multiple Perioperative Time Points (mmHg)', 'description': 'Intraocular pressure (IOP) will be measured in both eyes using a handheld Tono-Pen tonometer at the following predefined perioperative time points:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after steep Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nThe unit of measurement is mmHg at each time point. Each time point will be reported separately. To ensure consistency, all measurements will be performed by the same ophthalmologist.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively'}]","[{'measure': 'Heart Rate at Defined Perioperative Time Points (bpm)', 'description': 'Heart rate (HR) will be measured non-invasively using standard ASA monitoring equipment at the following perioperative time points:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nHeart rate will be reported separately for each time point.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Bispectral Index Score (BIS) Values at Defined Perioperative Time Points', 'description': 'The Bispectral Index Score (BIS) will be monitored to assess the depth of anesthesia. The BIS scale ranges from 0 (deep coma) to 100 (fully awake). Lower scores indicate deeper anesthesia, while higher scores indicate lighter anesthesia or awareness. Bispectral Index Score (BIS) values will be continuously monitored using the BIS VISTA Monitor (Covidien REF 185-0151). BIS values will be recorded at the following predefined perioperative time points to assess anesthetic depth:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively) Each BIS value will be reported separately for each time point.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Intraabdominal Pressure (IAP) at Defined Perioperative Time Points (mmHg)', 'description': 'Intraabdominal pressure (IAP) will be monitored via the robotic insufflation system and recorded at the following predefined perioperative time points during carbon dioxide (CO₂) insufflation:\n\nT3 (2 minutes after CO₂ insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation)\n\nEach IAP measurement will be reported separately for each time point.', 'timeFrame': 'From CO₂ insufflation to desufflation during the intraoperative period.'}, {'measure': 'Peripheral Oxygen Saturation (SpO₂) at Defined Perioperative Time Points (%)', 'description': 'Description:\n\nPeripheral oxygen saturation (SpO₂) will be continuously monitored using pulse oximetry as part of standard ASA monitoring.\n\nSpO₂ values will be documented at the following predefined perioperative time points to assess oxygenation:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after returning to supine position) T9 (45 minutes postoperatively)\n\nEach SpO₂ measurement will be reported separately for each time point.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'End-Tidal Carbon Dioxide (ETCO₂) Levels at Defined Perioperative Time Points (mmHg)', 'description': 'End-tidal carbon dioxide (ETCO₂) will be continuously measured through the ventilator (Mindray WATO EX-65) and documented at the following predefined perioperative time points:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nEach ETCO₂ measurement will be reported separately for each time point.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Mean Arterial Pressure at Defined Perioperative Time Points (mmHg)', 'description': 'Mean arterial pressure (MAP) will be measured non-invasively using standard ASA monitoring equipment at the following perioperative time points:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nMean arterial pressure will be reported separately for each time point.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Arterial Partial Pressure of Oxygen (PaO₂) at Selected Perioperative Time Points (mmHg)', 'description': 'Arterial blood gas samples will be collected at the following perioperative time points to measure partial pressure of oxygen (PaO₂):\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nEach PaO₂ measurement will be reported separately.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Arterial Partial Pressure of Carbon Dioxide (PaCO₂) at Selected Perioperative Time Points (mmHg)', 'description': 'Arterial blood gas samples will be collected at the following perioperative time points to measure partial pressure of carbon dioxide (PaCO₂):\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nEach PaCO₂ measurement will be reported separately.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively'}, {'measure': 'Arterial Blood pH at Selected Perioperative Time Points', 'description': 'Arterial blood gas samples will be collected at the following perioperative time points to measure blood pH:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively) Each pH measurement will be reported separately.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Arterial Bicarbonate (HCO₃-) Level at Selected Perioperative Time Points (mEq/L)', 'description': 'Arterial blood gas samples will be collected at the following perioperative time points to measure bicarbonate (HCO₃-) levels:\n\nT0 (before anesthesia induction) T1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position) T9 (45 minutes postoperatively)\n\nEach HCO₃- measurement will be reported separately.', 'timeFrame': 'From 10 minutes before anesthesia induction to 45 minutes postoperatively.'}, {'measure': 'Peak Airway Pressure During Surgery (cmH₂O)', 'description': 'Peak airway pressure will be monitored intraoperatively using the Mindray WATO EX-65 anesthesia machine. Measurements will be recorded throughout the surgical procedure (from anesthesia induction to end of anesthesia).\n\nT1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position)\n\nEach measurement will be reported separately.', 'timeFrame': 'From T1 (10 minutes after anesthesia induction) to T8 (2 minutes after return to supine position).'}, {'measure': 'Positive End-Expiratory Pressure (PEEP) During Surgery (cmH₂O)', 'description': 'Positive end-expiratory pressure (PEEP) will be monitored intraoperatively using the Mindray WATO EX-65 anesthesia machine. Measurements will be recorded throughout the surgical procedure (from anesthesia induction to end of anesthesia).\n\nT1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position)\n\nEach measurement will be reported separately.', 'timeFrame': 'From T1 (10 minutes after anesthesia induction) to T8 (2 minutes after return to supine position).'}, {'measure': 'Plateau Pressure During Surgery (cmH₂O)', 'description': 'Plateau pressure will be monitored intraoperatively using the Mindray WATO EX-65 anesthesia machine. Measurements will be recorded throughout the surgical procedure (from anesthesia induction to end of anesthesia).\n\nT1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position)\n\nEach measurement will be reported separately.', 'timeFrame': 'From T1 (10 minutes after anesthesia induction) to T8 (2 minutes after return to supine position).'}, {'measure': 'Dynamic Pulmonary Compliance During Surgery (mL/cmH₂O)', 'description': 'Dynamic pulmonary compliance will be monitored intraoperatively using the Mindray WATO EX-65 anesthesia machine. Measurements will be recorded throughout the surgical procedure.\n\nT1 (10 minutes after induction) T2 (2 minutes after Trendelenburg positioning) T3 (2 minutes after carbon dioxide (CO₂) insufflation) T4 (1 hour after CO₂ insufflation) T5 (2 hours after CO₂ insufflation) T6 (3 hours after CO₂ insufflation) T7 (2 minutes after CO₂ desufflation) T8 (2 minutes after return to supine position)\n\nEach measurement will be reported separately.', 'timeFrame': 'From T1 (10 minutes after anesthesia induction) to T8 (2 minutes after return to supine position).'}]",15,,,MALE,False,Ataturk Training and Research Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:13.413560,v2_robust,True,True,True,False,False,
NCT03587142,Buspirone for Early Satiety and Symptoms of Gastroparesis,"Buspirone for Early Satiety and Symptoms of Gastroparesis: A Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial (BESST)",Buspirone,"['Buspirone', 'buspirone hydrochloride (HCl)', 'Buspar Dividose', 'Buspar', 'Placebo', 'Placebo (for buspirone)', 'Vanspar']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastroparesis,['Gastroparesis'],"['gastroparesis', 'early satiety', 'stomach', 'buspirone', '5-HT 1a receptor agonist']",COMPLETED,,2019-08-27,2022-04-30,"[{'measure': '4-Week Change in the Postprandial Fullness and Early Satiety Symptoms Severity', 'description': 'The outcome is assessed using the self-reported early satiety/postprandial fullness subscore (ES/PPF), which is computed as the average of 4 scores for 4-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: stomach fullness, inability to finish a normal-sized meal, feeling excessively full after meals, and loss of appetite. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.', 'timeFrame': 'baseline and 4-weeks'}]","[{'measure': '4-Week Change in Stomach Fullness Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of stomach fullness severity in the prior 2-weeks using the Gastroparesis Cardinal Symptoms Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Excessive Fullness Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of feeling excessively full after meals severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Inability to Finish a Normal-sized Meal Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of inability to finish a normal-sized meal severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Loss of Appetite Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of loss of appetite severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Total Overall GCSI Symptom Severity', 'description': 'The outcome is assessed using the self-reported Gastroparesis Cardinal Symptom Index (GCSI) total score, which is computed as the average of the 3 subscores on the GCSI survey: 3-item early satiety/postprandial fullness subscore, the nausea/vomiting subscore (average of 3-items: nausea, retching, vomiting), and bloating subscore (average of 2-items: bloating, stomach visibly larger). Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the total score ranges from 0 to 5. The change is computed as the total score at 4-weeks minus the baseline total score. A negative change indicates improved symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Nausea, Vomiting and Retching Symptoms Severity', 'description': 'The outcome is assessed using the self-reported nausea/vomiting subscore, which is computed as the average of 3 scores for 3-items on the Gastrointestinal Cardinal Symptom Index (GCSI) survey: nausea, retching, vomiting. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks. The change is computed as the subscore at 4-weeks minus the baseline subscore. Negative change indicates improvement in symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Nausea Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of nausea severity item from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Vomiting Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of vomiting severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates improvement in vomiting severity.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Bloating and Stomach Distention Symptoms Severity', 'description': 'The outcome is assessed using the self-reported bloating subscore, which is computed as the average of 2 scores for 2-items on the Gastroparesis Cardinal Symptom Index (GCSI) survey: bloating, stomach visibly larger. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative value for change indicates improvement in symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Bloating Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of bloating severity in the prior 2-weeks using the Gastroparesis Cardinal Symptom Index (GCSI) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Upper Abdominal Pain and Discomfort Symptoms Severity', 'description': 'The outcome is assessed using the self-reported upper abdominal pain subscore, which is computed as the average of 2 scores for 2-items on the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index (PAGI-SYM) survey: upper abdominal pain, upper abdominal discomfort. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Upper Abdominal Pain Symptom Severity', 'description': 'The outcome is assessed using self-reported assessment of upper abdominal pain severity in the prior 2-weeks using the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey. The item is scored from 0 (no) to 5 (very severe) symptoms; the change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Gastroesophageal (GERD) Symptoms Severity', 'description': 'The outcome is assessed using the self-reported GERD subscore, which is computed as the average of 7 scores for 7-items on the Patient Assessment of Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM) survey: heartburn during the day, heartburn when lying down, feeling of discomfort inside chest during the day, feeling of discomfort inside chest during sleep, regurgitation or reflux during the day, regurgitation when lying down, bitter, acid or sour taste in mouth. Each item is scored from 0 (no) to 5 (very severe) symptoms in the past 2-weeks; the subscore ranges from 0 to 5. The change is computed as the subscore at 4-weeks minus the baseline subscore.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Gastrointestinal Symptoms Rating Scale (GSRS) Global Score', 'description': 'The outcome is assessed using the self-reported GSRS total score which is computed as the mean of the 15 item scores on the Gastrointestinal Symptom Rating Scale (GSRS) survey. Each item is scored from 1 (no discomfort) to 7 (very severe discomfort) of the symptom in the past week. The change is computed as the score at 4-weeks minus the baseline score. A negative change indicates symptom improvement.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': ""4-Week Change in Participant's Rating of Symptom Relief"", 'description': 'The outcome is assessed using the participant-rated Clinical Patient Grading Assessment Scale (CPGAS) score which is scored from -3 (very considerably worse) to 3 (completely better) in the past week compared to the way the participant usually feels. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates patient feeling better.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Severity of Somatic Symptoms', 'description': 'The outcome is assessed using the self-reported Patient Health Questionnaire 15 Somatic Symptom Severity Scale (PHQ-15) total somatization score (ranges from 0 -30, with 30 being most bothered by symptoms in prior 4-weeks), calculated as the sum of 15-items, each scored from 0 (not bothered at all) to 2 (bothered a lot) by somatic symptoms in the prior 4-weeks. The change is computed as the score at 4-weeks minus the baseline score. A negative change indicates being less bothered by the symptoms.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Depression', 'description': 'The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) depression subscore, calculated as the sum of 7 items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative change indicates reduced depression.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Anxiety', 'description': 'The outcome is assessed using the self-reported Hospital Anxiety and Depression Scale (HADS) anxiety subscore, calculated as the sum of 7-items, each scored from 0 (not at all) to 3 (most of the time). The change is computed as the subscore at 4-weeks minus the baseline subscore. A negative change indicates reduced anxiety at 4-weeks.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change Overall Quality of Health Due to Gastroparesis Issues', 'description': ""The outcome is assessed using the self-reported Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL) total score which comprises 30 items scored from 0 (none of the time) to 5 (all of the time) the participant's QOL has been affected by their gastrointestinal issues in the prior two weeks. The total score is the mean of the 5 subscale scores and ranges from 0 (lowest QOL) to 5 (highest QOL) in past 2-weeks. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved QOL."", 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Overall Mental Quality of Life (QOL)', 'description': 'The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) mental health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved mental QOL.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Overall Physical Quality of Life (QOL)', 'description': 'The outcome is assessed using the self-reported 36-item Short Form Health Survey (SF-36v2) physical health QOL component score. The score ranges from 0 (poorest) to 100 (highest) QOL. The change is computed as the score at 4-weeks minus the baseline score. A positive change indicates improved Physical QOL.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': '4-Week Change in Gastric Retention', 'description': 'The outcome is assessed using the percent of gastric retention at 4-hours from the Gastric Emptying Scintigraphy (GES) test. The change is computed as the percent retention at 4-weeks minus the baseline percent retention. % retention is the amount of food remaining in the stomach at 4-hours of the GES test and ranges from 0% (no food) to 100% (all of the food).', 'timeFrame': 'baseline and 4-weeks'}, {'measure': 'Change at 4-weeks in the Intragastric Meal Distribution (IMD)', 'description': 'The Intragastric meal distribution (IMD) is assessed at baseline and 4-weeks during the Gastric Emptying Scintigraphy Test. The ratio of gastric counts of the meal in the proximal stomach to the distal stomach is used to compute the Intragastric meal distribution (IMD) which can be used as an indirect measure of Fundic Accommodation.', 'timeFrame': 'baseline and 4-weeks'}, {'measure': 'Change From Baseline at 4-weeks in the Water Load Satiety Test (WLST)', 'description': 'The Water Load Satiety Test (WLST) is the amount of water a patient can consume until full in 5 minutes. The volume of water is recorded. The change is computed as the volume of water ingested at baseline subtracted from the amount of water ingested at 4-weeks. A positive change indicates that the patient can ingest more water at 4-weeks than at baseline.', 'timeFrame': 'baseline and 4-weeks'}]",25,18 Years,85 Years,ALL,False,Johns Hopkins Bloomberg School of Public Health,OTHER,7,96.0,ACTUAL,2025-09-01T16:18:13.413794,v2_robust,True,True,True,False,False,
NCT01145586,"A Non-inferiority, Multicenter and Randomized, Multiple-Dose Study About a Treatment to Hypolactasia","A Phase III, Non-Inferiority, Randomized, Blind, Parallel-Group, Multicentre, Multiple-Dose, Comparative Clinical Study of Lactase Eurofarma and Lactaid®, Assessing the Efficacy and Safety in the Treatment of Patients With Lactose Intolerance""",Lactase Oral Tablets,['Lactase Oral Tablets'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Lactose Intolerance,['Lactose Intolerance'],[],COMPLETED,,2011-06,2012-05,"[{'measure': 'Hydrogen value in the expired air', 'description': 'Hydrogen value in the expired air for 3h after the patient exposure to the standardized Lactose 25g dose with interventional exogenous Lactase (comparative and test drugs).', 'timeFrame': '03 times'}]","[{'measure': 'Signs and Symptoms Diary', 'description': '* Signs and Symptoms Diary, registered for the period between V0 and V1 / V1 and V2;\n* The Specific Symptom Score registered during the tests of hydrogen in the expired air;\n* Global Evaluation of the Treatment Tolerance by the patient and the investigator; Frequency of adverse events noted.', 'timeFrame': '42 days'}]",2,18 Years,60 Years,ALL,False,Eurofarma Laboratorios S.A.,INDUSTRY,0,140.0,ACTUAL,2025-09-01T16:18:13.413964,v2_robust,True,True,True,False,True,
NCT05062486,A Study to Evaluate the Safety and Efficacy of RQC for AMD,"An Open-Label, Randomized, Double Arm, Phase 2 Study to Evaluate the Safety and Efficacy of C and RQC for Preventing Progression in Age-Related Macular Degeneration","Resveratrol, Quercetin, Curcumin (RQC)","['Curcumin', 'Resveratrol, Quercetin, Curcumin (RQC)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Age-related Macular Degeneration,['Age-related Macular Degeneration'],"['Curcumin', 'Resveratrol', 'Quercetin', 'Macular Degeneration, Age-Related', 'Age-Related Maculopathy', 'Adult Macular Degeneration']",COMPLETED,,2021-10-04,2024-11-07,"[{'measure': 'Change in Drusen Volume from Baseline', 'description': 'Macular drusen volume measured in µm3.', 'timeFrame': '24 months'}, {'measure': 'Geographic Atrophy (GA) Growth Rate', 'description': 'The annual growth rate of GA or nascent GA area measured in mm2.', 'timeFrame': '24 months'}, {'measure': 'Progression to Moderate Vision Loss', 'description': 'Progression defined as a decrease in ETDRS BCVA score of 15 or more letters.', 'timeFrame': '24 months'}, {'measure': 'Adverse Events', 'description': 'Safety outcomes include adverse and serious adverse events and vital sign/physical examination tests.', 'timeFrame': '24 months'}]","[{'measure': 'Progression to Advanced AMD', 'description': 'Progression defined as the development of geographic atrophy or choroidal neovascularization detected by OCT imaging using autofluorescence, infrared, and/or angiography modules.', 'timeFrame': '24 months'}]",5,50 Years,90 Years,ALL,False,"Paul A Knepper, MD PhD",OTHER,0,55.0,ACTUAL,2025-09-01T16:18:13.414005,v2_robust,True,True,True,False,True,
NCT03063086,Assess Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma.,"A Randomized, Double-blind, Double-dummy, Active-controlled, 3-period Complete Cross-over Study to Assess the Bronchodilator Effect and Safety of Two Doses of QVM149 Compared to a Fixed Dose Combination of Salmeterol/Fluticasone in Patients With Asthma",QVM149 150/50/80 μg o.d.,"['salmeterol/fluticasone FDC 50/500 μg b.i.d.', 'QVM149 150/50/160 μg o.d.', 'QVM149 150/50/80 μg o.d.']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Asthma,['Asthma'],[],COMPLETED,,2017-01-21,2018-08-02,"[{'measure': 'Peak FEV1 (L) Defined as the Highest Bronchodilatory Effect on FEV1 During a Period of 5 Min to 4 h After the Last Evening Dose of Each Treatment Period', 'description': 'The highest bronchodilator effect on FEV1 during a period of 5 min to 4 h after the last evening dose of each treatment period . To demonstrate superiority in peak bronchodilator effect of QVM149 at a dose of 150/50/160 μg o.d. and 150/50/80 μg o.d. compared to a FDC of salmeterol/fluticasone at a dose of 50/500 μg b.i.d. after 3 weeks of treatment in patients with asthma', 'timeFrame': '3 weeks'}]","[{'measure': 'FEV1 Over 24 h After 21 Days of Treatment in Relation to Evening Dose', 'description': 'To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.', 'timeFrame': '-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks'}, {'measure': 'FVC Over 24 h After 21 Days of Treatment in Relation to Evening Dose', 'description': 'To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.', 'timeFrame': '-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks'}, {'measure': 'FEV1/FVC Ratio Over 24 h After 21 Days of Treatment in Relation to Evening Dose', 'description': 'To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment at -45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min.', 'timeFrame': '-45 min, -15 min, 5 min, 15 min, 30 min, 1 h, 2 h, 3h, 4 h, 8 h, 10 h, 11 h 55 min, 14 h, 18 h, 21 h, 23 h 15 min, 23 h 45 min at 3 weeks'}, {'measure': 'FEV1 AUC 5 Min - 1 h (Day 21) FEV1 AUC 5 Min - 4 h (Day 21) and FEV1 AUC 5 Min - 23 h 45 Min (Day 21)', 'description': 'To evaluate the bronchodilator effect of each dose of QVM149 compared to salmeterol/ fluticasone FDC by measuring standardized FEV1 AUCs after 3 weeks of treatment respective period.', 'timeFrame': '3 weeks'}, {'measure': 'Trough FEV1 After 21 Days of Treatment', 'description': 'To evaluate post-dose trough bronchodilator effect of each dose of QVM149 compared to salmeterol/fluticasone FDC after 3 weeks of treatment in the respective treatment period. The trough FEV1 is the mean value of FEV1 at 23 h 15 min and 23 h 45 min post-dose', 'timeFrame': '3 weeks'}]",6,18 Years,75 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,116.0,ACTUAL,2025-09-01T16:18:13.414083,v2_robust,True,True,True,False,False,
NCT05776186,Fetal Heart Rate Pattern After Spinal Anesthesia for Scheduled Uncomplicated Cesarean Section,"Fetal Heart Rate Pattern Before, During, and After Spinal Anesthesia for Scheduled Uncomplicated Cesarean Section",Spinal anesthesia with heavy bupivacaine,['Spinal anesthesia with heavy bupivacaine'],1,OBSERVATIONAL,[],,,Continuous Fetal Heart Beat Monitor and Analysis After Spinal Anesthesia,['Continuous Fetal Heart Beat Monitor and Analysis After Spinal Anesthesia'],['cesarean section; spinal anesthesia ; fetal heart beat'],UNKNOWN,,2022-11-29,2023-12-31,"[{'measure': 'Fetal heart rate variability', 'description': 'Fetal heart rate deceleration (normal \\> 100 beats per minute)', 'timeFrame': '5 minutes after spinal anesthesia'}]","[{'measure': 'Neonatal outcome', 'description': 'APGAR score\\_1 minute, APGAR score\\_5 minute ( APGAR score: 0-10 points)', 'timeFrame': '1 minute and 5 minutes after delivery'}, {'measure': 'Neonatal intensive care rate', 'description': 'NICU admission rate', 'timeFrame': 'baseline (admission)'}, {'measure': 'Umbilical vein analysis', 'description': 'Umbilical vein blood gas analysis, including pH, O2, CO2, HgB, electrolyte', 'timeFrame': 'within 5 minutes after delivery'}, {'measure': 'Maternal pain score', 'description': 'Visual analog scale ( VAS score 0-10)', 'timeFrame': '0, 8, 24 hours after surgery'}]",5,20 Years,50 Years,FEMALE,True,Taichung Veterans General Hospital,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:13.414134,v2_robust,False,True,False,False,False,
NCT00626886,"Efficacy, Safety and Pharmacokinetic Profile of a Collagen Bupivacaine Implant in Men After Open Mesh Herniorrhaphy","A Phase II, Randomized, Single Dose, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety and Pharmacokinetic Profile of the CollaRx® Bupivacaine Implant in Men After Open Mesh Herniorrhaphy",Bupivacaine Collagen Sponge,"['CollaRx Bupivacaine Implant', 'placebo collagen sponge', 'Bupivacaine Collagen Sponge', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Postoperative Pain,"['Postoperative Pain', 'Inguinal Hernia']","['Herniorrhaphy', 'Inguinal Hernia Repair', 'Postoperative pain']",COMPLETED,,2008-03-11,2009-01-29,"[{'measure': 'Total Use of Opioid Rescue Analgesia Over 0 to 24 Hours', 'description': 'Total Use of Opioid Rescue Analgesia (mg) Over 0 to 24 Hour - number count - higher score means worse outcome', 'timeFrame': '0 to 24 hours postoperatively'}]","[{'measure': 'Total Use of Opioid Rescue Analgesia Over 0 to 48 Hours', 'description': 'Number count. Higher score means worse outcome', 'timeFrame': '0 to 48 hours postoperatively'}, {'measure': 'Total Use of Opioid Rescue Analgesia Over 0 to 72 Hours', 'description': 'Number count - higher score means worse outcome', 'timeFrame': '0 to 72 hours postoperatively'}, {'measure': 'Summed Pain Intensity VAS Scores (VAS at Rest and After Cough)', 'description': 'Summed pain intensity (SPI) (VAS at rest and after cough): - For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor. Each timepoint consist of two measurements (Resting \\& Coughing) - The lower the score the better outcome for the patient. The highest total score (worst possible score) for the 10 timepoints would be 2000.', 'timeFrame': '1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours after Time 0'}, {'measure': ""Patient's Global Evaluation of the Study Treatment on a 5 Point Likert Scale"", 'description': 'For the 5-point categorical scale global evaluation of study treatment, the patient was instructed to score his global evaluation of the pain control provided by the study treatment where: 0 = poor, 1 = fair, 2 = good, 3 = very good and 4 = excellent', 'timeFrame': 'At 72 hours after time 0'}, {'measure': 'VAS Pain Intensity Scores Over Time', 'description': 'For the VAS assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a horizontal 100-mm VAS scale labeled as follows: No Pain (0 mm) as the left anchor and Worst Pain Imaginable (100 mm) as the right anchor.', 'timeFrame': 'At 1, 1.5, 2,3,4,5,6,24,48,72 Hours'}, {'measure': 'Categorical Pain Intensity Scores Over Time - AT REST', 'description': 'For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = ""none,"" 1 = ""mild,"" 2 = ""moderate"" and 3 = ""severe.""', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}, {'measure': 'Categorical Pain Relief Scores Over Time - AT REST', 'description': 'For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}, {'measure': 'Categorical Pain Intensity Scores Over Time (After Cough)', 'description': 'For the 4-point categorical scale assessment, patients measured their pain intensity at rest and after aggravated movement (cough) using a numerical scale where: 0 = ""none,"" 1 = ""mild,"" 2 = ""moderate"" and 3 = ""severe."" Higher Score means a worse outcome', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}, {'measure': 'Categorical Pain Relief Scores Over Time (After Cough)', 'description': 'For the 5-point categorical scale assessment of pain relief, the patient was instructed to score his pain relief using a numerical scale where: 0 = no relief, 1 = a little relief, 2 = some relief, 3 = a lot of relief and 4 = complete relief.', 'timeFrame': 'At 0.5, 1, 1.5, 2, 3, 4, 5, 6, 24, 48 and 72 hours'}]",10,18 Years,,MALE,False,Innocoll,INDUSTRY,1,53.0,ACTUAL,2025-09-01T16:18:13.414152,v2_robust,True,True,True,False,False,
NCT02992886,Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly,"Multicenter, Phase II Study of Preoperative Chemoradiotherapy With Raltitrexed for Intermediate or Locally Advanced Rectal Cancer in the Fit Elderly",Raltitrexed,"['Raltitrexed', 'Raltitrexed Injection']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Rectal Neoplasms Malignant,['Rectal Neoplasms Malignant'],"['elderly patients', 'rectal cancer', 'preoperative chemoradiotherapy', 'comprehensive geriatric assessment']",COMPLETED,,2016-09,2021-08,"[{'measure': '2-year disease-free survival probability (%)', 'description': 'The probability of staying free from recurrence at 2 year after surgery or clinical complete response of tumor validated on imaging or pathological examination.', 'timeFrame': '2 year'}]","[{'measure': '5-year overall survival probability', 'description': 'The probability of staying alive at 5 year after surgery or end of CRT (for those who did not receive surgery).', 'timeFrame': '5 year'}, {'measure': '5-year cancer-specific survival probability', 'description': 'The probability of staying free from death caused by cancer at 5 year after surgery or end of CRT (for those who did not receive surgery).', 'timeFrame': '5 year'}, {'measure': 'The ratio of patients occured pCR', 'description': 'The ratio of patients occured pathological complete response of tumor.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'The ratio of patients occured Grade 3 or higher adverse events.', 'timeFrame': 'During chemoradiotherapy and within 180 days after surgery'}, {'measure': 'QOL', 'description': 'The quality of life assessment score by EORTC QLQ-C30 and EORTC QLQ-CR29.', 'timeFrame': 'Before and after chemoradiotherapy and surgery, and then follow up for 3 years'}]",6,71 Years,,ALL,False,Chinese Academy of Medical Sciences,OTHER,0,68.0,ACTUAL,2025-09-01T16:18:13.414224,v2_robust,True,True,True,False,True,
NCT05598086,Anti-fibrinolytic and Anti-inflammatory Effects of Local Infiltration of Tranexamic Acid in Patients With Calcaneal Fractures,Anti-fibrinolytic and Anti-inflammatory Effects of Local Infiltration of Tranexamic Acid in the Post-operation of Displaced Intra-articular Calcaneal Fractures: a Randomized Controlled Study,Tranexamic acid,"['Tranexamic acid', 'Normal saline']",2,INTERVENTIONAL,['NA'],,,Tranexamic Acid,"['Tranexamic Acid', 'Fibrinolysis', 'Inflammatory', 'Fracture']",[],COMPLETED,,2019-04-01,2022-05-15,"[{'measure': 'Incision drain output (mL)', 'description': 'Incision drain output of post-operative day 1 and 2', 'timeFrame': '2 days'}, {'measure': 'Outcomes of laboratory test', 'description': 'White blood cell (10\\^9/L)', 'timeFrame': '4 days'}, {'measure': 'Outcomes of laboratory test', 'description': 'Neutrophil count (10\\^9/L)', 'timeFrame': '4 days'}, {'measure': 'Outcomes of laboratory test', 'description': 'Hemoglobin (g/L)', 'timeFrame': '4 days'}]","[{'measure': 'Incidence of surgical related complications', 'description': 'Complications included oozing of the blood, hematoma, or deep infection etc.', 'timeFrame': '30 days'}]",5,18 Years,70 Years,ALL,False,Hebei Medical University Third Hospital,OTHER,0,113.0,ACTUAL,2025-09-01T16:18:13.414240,v2_robust,True,True,True,False,False,
NCT01257386,Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis,Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis,Asacol®,"['Marketed Mesalazine', 'Asacol®', 'Mesalazine', 'Import Mesalazine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Active Ulcerative Colitis,['Active Ulcerative Colitis'],[],COMPLETED,,2010-11,2013-03,"[{'measure': 'Reduction degree of UC-DAI', 'timeFrame': 'Week 8'}]","[{'measure': '1) Reduction degree of score of each UC-DAI item 2) Remission rate 3) Effective rate', 'timeFrame': 'Week 8'}]",2,18 Years,64 Years,ALL,False,Tillotts Pharma AG,INDUSTRY,1,251.0,ACTUAL,2025-09-01T16:18:13.414310,v2_robust,True,True,True,False,False,
NCT05340270,PD-1 Inhibitor Plus GP as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma,"PD-1 Inhibitor Plus GP Chemotherapy as Neoadjuvant Therapy for Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II, Multicenter, Randomized Controlled Clinical Trial",PD-1 inhibitor+GP,"['GP', 'PD-1 inhibitor+GP']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Nasopharyngeal Carcinoma,"['Nasopharyngeal Carcinoma', 'Neoadjuvant Therapy', 'PD-1 Inhibitor']",[],ACTIVE_NOT_RECRUITING,,2022-07-15,2026-03-29,"[{'measure': 'Failure-free survival', 'description': 'the time from registration to treatment failure or death from any cause, whichever is first.', 'timeFrame': 'up to 24 months'}]","[{'measure': 'Complete Response (CR)', 'description': 'the complete disappearance of the target and non-target lesion identified at baseline after radiological evaluation by MRI. Disease response was evaluated after the completion of the neoadjuvant therapy, according to RECIST 1.1.', 'timeFrame': 'up to 9 weeks'}, {'measure': 'Overall survival', 'description': 'the time from registration to death due to any cause, or censored at date last known alive.', 'timeFrame': 'up to 24 months'}, {'measure': 'Locoregional failure-free survival(LRRFS)', 'description': 'the time from registration to the first locoregional relapse or death from any cause.', 'timeFrame': 'up to 24 months'}, {'measure': 'Distant metastasis-free survival(DMFS)', 'description': 'the time from registration to the first distant metastasis or death from any cause.', 'timeFrame': 'up to 24 months'}, {'measure': 'Adverse events (AEs)', 'description': 'Analysis of adverse events (AEs) are based on treatment-related AEs (trAEs) and immune-related AEs (irAEs), and all-grade AEs and grade 3-4 AEs. AEs are evaluated by investigators according to the Common Terminology Criteria for Adverse Events, version 5.0', 'timeFrame': 'up to 24 months'}, {'measure': 'Quality of life（QOL）', 'description': ""Assessed by European Organization for Research and Treatment of Cancer's quality of life questionnaire(QLQ)-C30"", 'timeFrame': 'up to 24 months'}]",7,18 Years,65 Years,ALL,False,Guangxi Medical University,OTHER,9,146.0,ESTIMATED,2025-09-01T16:18:13.414387,v2_robust,True,True,False,False,True,
NCT00302770,Efficacy of Quetiapine in Generalised Social Anxiety Disorder,"Efficacy of Quetiapine in Generalised Social Anxiety Disorder, a Double-blind, Placebo-controlled Study",quetiapine,['quetiapine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Social Anxiety Disorder,['Social Anxiety Disorder'],['Patients with SAD'],TERMINATED,This study was terminated due to poor enrollment,2006-06,2006-12,[{'measure': 'Change on Lebowitz Social Anxiety Scale (LSAS) from baseline to endpoint'}],"[{'measure': 'Number of responders, time to onset of response of sustained response to treatment'}]",2,18 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,50.0,ESTIMATED,2025-09-01T16:18:13.414404,v2_robust,True,True,False,True,False,This study was terminated due to poor enrollment
NCT02816970,"Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)","Open Label, Randomized, Single Dose, Two-way Crossover Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)",Vildagliptin,"['Galvus', 'Gliptus', 'Vildagliptin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2014-02,2014-03,"[{'measure': 'Maximal measured plasma concentration (Cmax)', 'description': 'Serial blood samples for determination of study drug will be collected at 0.00, 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 12.00, 24.00 hours', 'timeFrame': 'Up to 24 hours post dose in each treatment period'}]","[{'measure': 'Time of the maximum plasma concentration (Tmax)', 'description': 'Serial blood samples for determination of study drug will be collected at 0.00, 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 4.00, 6.00, 8.00, 12.00, 24.00 hours', 'timeFrame': 'Up to 24 hours post dose in each treatment period'}]",2,18 Years,55 Years,ALL,True,"Genuine Research Center, Egypt",INDUSTRY,1,24.0,ACTUAL,2025-09-01T16:18:13.414413,v2_robust,True,True,True,False,False,
NCT02402270,Safety and Tolerability Study of an Edible Colon Preparation,"An Adaptive, Single-Blind, Parallel, Randomized, Phase 2, Formulation Screening/Proof of Concept, Safety, Tolerability and Efficacy Study of Three Formulations/Dosing Regimens of ECP (PEG 3350) Colon Prep Kit Compared to Comparators.",NuLYTELY® (PEG 3350),"['NuLYTELY® (PEG 3350)', 'ECP-019', 'MoviPrep® (PEG 3350)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Bowel Preparation,['Bowel Preparation'],"['Colonoscopy', 'Preparation']",COMPLETED,,2015-05,2016-06,"[{'measure': 'The proportion of patients with successful colon cleansing as assessed by the blinded gastroenterologists using the Aronchick Scale.', 'timeFrame': 'One year'}]","[{'measure': 'Percentage of patients who completed each of the ECP-019 formulation/dosing regimens', 'timeFrame': 'One year'}]",2,18 Years,74 Years,ALL,True,ColonaryConcepts LLC,INDUSTRY,0,69.0,ACTUAL,2025-09-01T16:18:13.414425,v2_robust,True,True,True,False,False,
NCT02679170,Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS),Observational Study to IDEntify Patients With Advanced/Metastatic NSCLC and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS),Crizotinib,['Crizotinib'],1,OBSERVATIONAL,[],,,Non-Small Cell Lung Cancer,['Non-Small Cell Lung Cancer'],"['ALK+, ROS1']",COMPLETED,,2016-06-29,2022-05-04,"[{'measure': 'Eastern Cooperative Oncology Group (ECOG) Quality of Life Score: ALK Treatment and ROS1 Sub-study Only', 'description': ""ECOG quality of life score is a rating of a participant's disease status, daily living activities and quality of life, where 0: fully active, 1: restricted in physically strenuous activity, 2: ambulatory and capable of self-care but unable to work, 3: capable only of limited self-care , 4: completely disabled; cannot carry on any self-care; totally confined to bed or chair, 5: dead. Higher scores indicated more severe disease, difficulty in performing daily activity and poor quality of life. Number of participants classified according to ECOG quality of life scores were reported in this outcome measure."", 'timeFrame': 'At baseline (for ALK treatment sub-study: at the beginning of diagnosis of ALK; for ROS1 treatment sub-study: at the beginning of diagnosis of ROS1 metastatic disease)'}, {'measure': 'Number of Participants Classified According to the Origin of Tumor Sample', 'description': 'Number of participants classified according to the origin of tumor sample (primary tumor or metastasis) were reported in this outcome measure.', 'timeFrame': 'At baseline (for ALK incidence sub-study: at the beginning of initial diagnosis of lung cancer; for ROS1 and ALK treatment sub-study: at the beginning of ALK and ROS1 initial diagnosis)'}, {'measure': 'Number of Participants Classified According to Type of Sample Collected for Tumor Analysis', 'description': 'Number of participants classified according to the type of sample collected (biopsy, cell block or cytology) were reported in this outcome measure.', 'timeFrame': 'At baseline (for ALK incidence sub-study: at the beginning of initial diagnosis of lung cancer; for ROS1 and ALK treatment sub-study: at the beginning of ALK and ROS1 initial diagnosis)'}, {'measure': 'Number of Participants Classified According to Histological Subtype of Tumor', 'description': 'Number of participants classified according to the histological subtype (adenocarcinoma, squamous, large cell, not otherwise specified \\[NOS\\], other) were reported in this outcome measure.', 'timeFrame': 'At baseline (for ALK incidence sub-study: at the beginning of initial diagnosis of lung cancer; for ROS1 and ALK treatment sub-study: at the beginning of diagnosis of ALK and ROS1 metastatic disease)'}, {'measure': 'Number of Participants Classified According to Stage of Tumor: ALK Treatment Sub-study and ROS1 Treatment Sub-study', 'description': 'Tumor Node Metastasis (TNM): based on tumor size, metastasis to nearby lymph nodes (LN), or distant metastasis. Stages were: stage IIIA (T0N2M0, T1N2M0,T2N3M0, T3N1 or N2M0), stage IIIB (T4 any NM0, any TN3M0), stage IV (any T any NM1), where T0 = early form of tumor, T1 = less than (\\<) 2 centimeter (cm), T2 = 2-5 cm, T3 = greater than (\\>) 5 cm, T4 = large sized, N0 = not spread to lymph nodes (LN), N1 = spread to 1 to 3 LN, N2 = spread to 4 to 9 LN, N3 = spread \\>10 axillary LN, M0 = no metastasis, M1 = metastasis. The number of participants classified according to stages of tumor (Stage IIIA, IIIB and IV) were reported in this outcome measure.', 'timeFrame': 'At baseline (for ALK incidence sub-study: at the beginning of initial diagnosis of lung cancer; for ROS1 and ALK treatment sub-study: at the beginning of ALK and ROS1 initial diagnosis of metastatic disease)'}, {'measure': 'Number of Participants Classified According to Molecular Alterations in Tumor: ALK Treatment Sub-Study and ROS1 Treatment Sub-Study', 'description': 'Number of participants classified according to molecular alterations (PD-L1+: programmed death-ligand 1 positive, MET+: mesenchymal epithelial transition factor receptor positive, TP53+: tumor protein 53 positive, AKT: serine/threonine-protein kinase) in tumors were reported in this outcome measure.', 'timeFrame': 'At baseline (for ALK treatment sub-study: at the beginning of diagnosis of ALK; for ROS1 treatment sub-study: at the beginning of diagnosis of ROS1 metastatic disease)'}, {'measure': 'Number of Participants Classified According to Location of Metastases: ALK Treatment Sub-Study and ROS1 Treatment Sub-Study', 'description': 'Number of participants classified according to the location of metastases were reported in this outcome measure. One participant may have more than one site of metastases.', 'timeFrame': 'At baseline (for ALK treatment sub-study: at the beginning of diagnosis of ALK; for ROS1 treatment sub-study: at the beginning of diagnosis of ROS1 metastatic disease)'}, {'measure': 'Number of Participants Categorized According to Number of Treatments Prior to Crizotinib: ALK Treatment Sub-Study and ROS1 Treatment Sub-Study', 'description': 'Number of participants classified according to number of treatments (1 or 2) prior to crizotinib were reported in this outcome measure.', 'timeFrame': 'At baseline (for ALK treatment sub-study: after initial diagnosis of ALK metastatic disease; for ROS1 treatment sub-study: after initial diagnosis of ROS1 metastatic disease)'}, {'measure': 'Number of Participants According to Treatment Response: ALK Treatment Sub-Study and ROS1 Treatment Sub-Study', 'description': 'Number of participants with treatment response as complete response (CR): disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size (\\<10 millimeter \\[mm\\] short axis), partial response (PR): at least 30 percent (%) decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits, stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD), progressive disease (PD): at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were reported in this outcome measure.', 'timeFrame': 'From date of inclusion until last date of follow-up (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}, {'measure': 'Number of Participants Classified According to Survival Data: ALK Treatment Sub-Study and ROS1 Treatment Sub-Study', 'description': 'The number of participants classified as dead or alive were reported in this outcome measure.', 'timeFrame': 'From date of inclusion until last date of follow-up (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}, {'measure': 'Percentage of Participants With European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire (EORTC QLQ-C30) Scores: ALK Treatment Sub-study', 'description': 'QLQ-C30: 30 item questionnaire consisted of a global health (GH) score, 5 functional domains, 8 symptom scales and single item about financial difficulties. All items were graded by severity experienced during previous week and used a 4-point-scale (1: not at all, 2: a little, 3: quite a bit, 4: very much). The scores were converted to health-related quality of life (HRQoL) scale ranging from 0 - 100. Higher GH and functional domain scores indicated better function and lower scores in symptom scales and single item indicated more severity. Positive changes from baseline indicated improvement and negative changes from baseline indicated worsening for GH and functional domains. Negative changes from baseline indicated improvement and higher levels of functioning and positive changes from baseline indicated worsening for symptom scale and single item. Stable indicated that the symptoms were neither improving nor worsening.', 'timeFrame': 'Baseline, End (day 28) of Cycles 1 and 3, and end of treatment (up to approximately 15.2 months)'}, {'measure': 'Percentage of Participants With European Organization For Research And Treatment Of Cancer Quality Of Life Questionnaire-Lung Cancer 13 (EORTC QLQ-LC13) Scores: ALK Treatment Sub-study', 'description': 'QLQ-LC13 consisted of 13 questions relating to disease symptoms specific to lung cancer \\& treatment side effects typical of treatment with chemotherapy and radiotherapy. It comprised of multi-item scale and single-item scale for symptoms and side effects (coughing, hemoptysis, sore mouth, dysphagia, peripheral neuropathy, alopecia, chest pain, arm pain, other pain, \\& medicine for pain). Response range - 1: Not at all to 4: Very much. The scores were converted to a HRQoL scale ranging from 0 - 100 where, higher scores = greater level of symptoms. Negative changes from baseline indicated improvement and positive changes from baseline indicated worsening. Stable indicated that the symptoms were neither improving nor deteriorating.', 'timeFrame': 'Baseline, End (day 28) of Cycles 1 and 3, and end of treatment (up to approximately 15.2 months)'}, {'measure': 'Percentage of Participants With Anaplastic Lymphoma Kinase Positive Translocations: ALK Incidence Sub-Study', 'description': 'The percentage of participants with ALK positive translocations were reported in this outcome measure.', 'timeFrame': 'At baseline (after initial diagnosis of lung cancer and until end of recruitment of ALK incidence sub study)'}, {'measure': 'Progression-Free Survival (PFS): ALK Treatment Sub-study and ROS1 Treatment Sub-Study', 'description': 'Progression-free survival (PFS) was defined as the period between the first day of treatment and the first day that progressive disease (PD) (at least a 20% increase \\[including an absolute increase of at least 5 mm\\] in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions) was observed according to response evaluation criteria in solid tumors (RECIST) criteria, or death. Participants who have not had an event at the time of the analysis of the study data were censored at the date of the last available follow-up.', 'timeFrame': 'From first day of treatment until date of progressive disease, death or censored, whichever was the earliest (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}, {'measure': 'Objective Response Rate (ORR): ALK Treatment Sub-study and ROS1 Treatment Sub-Study', 'description': 'ORR: percentage of participants who achieved CR : disappearance of all target and non-target lesions and normalization of tumor marker level, all lymph nodes must be non-pathological in size(\\<10 mm short axis), or PR : at least 30% decrease in sum of diameters of target lesions, taking as reference the baseline sum diameters persistence of one or more non-target lesion(s) and/or maintenance of tumor marker level above the normal limits. Additionally, the participants with SD : neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, PD: at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions were evaluated. The participants were evaluated in accordance with RECIST criteria.', 'timeFrame': 'From first day of treatment until date of CR, PR or SD (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}, {'measure': 'Duration of Response (DOR): ALK Treatment Sub-study and ROS1 Sub-Study', 'description': 'Duration of response (DOR) in participants with PR or CR was defined as the interval from the date the best response was documented to the first date that progressive disease (at least a 20% increase \\[including an absolute increase of at least 5 mm\\] in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of 1 or more new lesions) was observed.', 'timeFrame': 'From the date the best response was documented until the date of progressive disease (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}, {'measure': 'Overall Survival (OS): ALK Treatment Sub-study and ROS1 Treatment Sub-Study', 'description': 'Overall survival (OS) was defined as the period from the first day of treatment until death or censored up to the last date on which it was known that the participant was alive.', 'timeFrame': 'From first day of treatment until date of death or censored, whichever was earliest (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}, {'measure': 'Number of Participants With Adverse Events According to Seriousness: ALK Treatment Sub-study and ROS1 Treatment Sub-Study', 'description': 'An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship with the study treatment. SAE was defined as any untoward medical occurrence at any dose that: resulted in death, was life-threatening; resulted in persistent or significant disability/incapacity; constituted a congenital anomaly/birth defect; was important medical event; required hospitalization or prolongation of existing hospitalization. The number of participants with non-SAEs and SAEs were reported in this outcome measure.', 'timeFrame': 'From start of study treatment until end of follow-up (ALK treatment sub-study: maximum of 96.5 months and ROS1 treatment sub-study: maximum of 46.6 months)'}]",[],18,19 Years,,ALL,False,Pfizer,INDUSTRY,0,692.0,ACTUAL,2025-09-01T16:18:13.414434,v2_robust,False,True,True,False,True,
NCT04361370,Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer,A Single-arm Phase II Study of Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer (OPEB-01),Olaparib-Pembrolizumab-Bevacizumab,['Olaparib-Pembrolizumab-Bevacizumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer,['Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer'],"['BRCA wild type', 'ovarian cancer', 'Platinum-sensitive']",ENROLLING_BY_INVITATION,,2020-10-28,2026-08,"[{'measure': 'progression-free survival(6 months PFS rate)', 'description': 'To determine the clinical effectiveness of the study treatment assessed using progression free survival(6months) according to RECIST v1.1 criteria (Investigator determined)', 'timeFrame': '6 months'}]","[{'measure': 'Overall survival (OS)', 'timeFrame': 'Up to 1year'}, {'measure': 'Time to tumour progression (TTP)', 'timeFrame': 'Up to 1year'}, {'measure': 'Time to first subsequent treatment(or death)', 'timeFrame': 'The date of first documented first subsequent treatment or date of death, assessed up to 72 months'}, {'measure': 'Time to second subsequent treatment', 'timeFrame': 'The date of first documented second subsequent treatment assessed up to 72 months'}, {'measure': 'progression-free survival', 'timeFrame': 'Up to 1year'}]",6,20 Years,,FEMALE,False,Yonsei University,OTHER,0,44.0,ESTIMATED,2025-09-01T16:18:13.414563,v2_robust,True,True,False,False,False,
NCT01055470,Comparative Clinical Trial of Lornoxicam to Diclofenac in Patients of Osteoarthritis of Knee Joint.,"Open, Randomized, Controlled Clinical Trial of Lornoxicam as Compared to Diclofenac in Osteoarthritis of Knee Joint in Patients of Tertiary Care Hospital of Gujarat.",Diclofenac,"['Diclofenac', 'Lornoxicam']",2,INTERVENTIONAL,['NA'],,,Osteoarthritis of Knee Joint,['Osteoarthritis of Knee Joint'],[],COMPLETED,,2008-12,2009-06,"[{'measure': 'Difference in reduction in reading of Wong Baker face pain scale and in time of 100 meters walking test', 'timeFrame': '3 months'}]","[{'measure': 'To monitor side effects of study drugs.', 'timeFrame': '3 months'}]",2,25 Years,65 Years,ALL,False,"Government Medical College, Bhavnagar",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:13.414580,v2_robust,True,True,True,False,False,
NCT01475370,Study of OCV-501 in Patients With Acute Myeloid Leukemia (AML) (Extension From Study 311-10-001),,OCV-501,['OCV-501'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['Acute myeloid leukemia', 'WT1']",COMPLETED,,2012-01-24,2016-12-22,"[{'measure': 'Incidence of Relapse of Acute Myeloid Leukemia Based on the International Working Group Response Criteria', 'description': 'Bone marrow samples were taken by bone marrow aspiration, and the percentage of bone marrow blasts was calculated. The result was assessed according to the International Working Group Response Evaluation Criteria where a case was designated as relapse if any of the following occurred: reappearance of leukemic blasts in the peripheral blood or ≥ 5% blasts in the bone marrow after complete response (morphologic relapse).', 'timeFrame': 'Treatment period (from the first IMP administration until the time of discontinuation)'}]",[],1,60 Years,,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:13.414744,v2_robust,True,True,True,False,False,
NCT05870670,A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men,"Investigation of Pharmacokinetics, Safety, and Tolerability of Multiple Subcutaneous Doses of NNC0519-0130 in Japanese and Non-Japanese Male Participants",NNC0519-0130,"['NNC0519-0130', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2023-05-15,2023-10-16,"[{'measure': 'AUC0-24h,0130, SS: Area Under the NNC0519-0130 Plasma Concentration-Time Curve After the Last Dose in Each Treatment Period', 'description': 'Measured in h\\*nmol/L.', 'timeFrame': 'From pre-dose until 24 hours post-dose relative to last dose in each treatment period'}]","[{'measure': 'Cmax,0130, SS: Maximum Plasma Concentration of NNC0519- 0130 After the Last Dose in Each Treatment Period', 'description': 'Measured in nmol/L.', 'timeFrame': 'From pre-dose until 24 hours post-dose relative to last dose in each treatment period'}, {'measure': 'Number of Treatment Emergent Adverse Events (TEAEs)', 'description': 'Measured as number of events.', 'timeFrame': 'From time of dosing (day 1) until completion of the follow-up visit (day 105)'}]",3,18 Years,55 Years,MALE,True,Novo Nordisk A/S,INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:13.414838,v2_robust,True,True,True,False,True,
NCT04727073,Spironolactone in the Treatment of Heart Failure,"Spironolactone in the Treatment of Heart Failure- a Double-blind, Randomized, Placebo-controlled, Parallel Group Interventional Phase III Study to Determine Efficacy and Safety of Spironolactone on the Composite Endpoint of Recurrent Heart Failure Hospitalizations and Cardiovascular Death in Patients with Heart Failure with Mid-range or Preserved Ejection Fraction",Experimental: Spironolactone,"['Experimental: Spironolactone', 'Placebo Comparator']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Heart Failure with Mid-range Ejection Fraction,"['Heart Failure with Mid-range Ejection Fraction', 'Heart Failure with Preserved Ejection Fraction']","['heart failure', 'mid-range ejection fraction', 'preserved ejection fraction', 'diastolic dysfunction', 'Spironolactone', 'Mineralcorticoid Receptor Antagonist']",TERMINATED,"No extension of study funding by the DZHK following COVID-19 pandemic-induced prolongation of the recruitment period, also requiring manufacturing of further study drug batches",2018-11-01,2024-10-01,"[{'measure': 'Primary Objective: Cumulative number of primary composite events of cardiovascular (CV) death and total HF hospitalizations', 'description': 'Cumulative number of primary composite events of cardiovascular (CV) death and total (first and recurrent) HF hospitalizations in symptomatic HF patients (NYHA II-IV) with mid-range (LVEF 40- 49 %) or preserved (LVEF ≥ 50 %) ejection fraction.', 'timeFrame': 'Time Frame: Total follow up time (up to 48 months)'}]","[{'measure': 'Secondary Objective: Comparison of spironolactone to placebo in reducing the rate of hospitalisations and deaths', 'description': '* To compare Spironolactone to placebo in reducing the recurrent rate of heart failure Hospitalizations \\[Time Frame: Follow-up time up to 48month.\\]\n* To compare Spironolactone to placebo in reducing the rate of recurrent non-fatal hospitalizations from cardiovascular (CV) cause (i.e. hospitalization for non-fatal MI, non-fatal stroke, or the management of heart failure, whichever occurred first) \\[Time Frame: Total follow up time (up to 48 months)\\].\n* To compare Spironolactone to placebo in reducing the recurrent rate of hospitalizations from any cause \\[Time Frame: Total follow up time (up to 48 months)\\].\n* To compare Spironolactone to placebo in reducing the rate of death from cardiovascular (CV) cause \\[Time Frame: Total follow up time (up to 48 months)\\].\n* To compare Spironolactone to placebo in reducing the rate of death from any cause \\[Time Frame: Total follow up time (up to 48 months)\\].', 'timeFrame': 'Time Frame: Total follow up time (up to 48 months)'}]",2,50 Years,100 Years,ALL,False,"Charite University, Berlin, Germany",OTHER,7,743.0,ACTUAL,2025-09-01T16:18:13.414851,v2_robust,True,True,False,True,False,"No extension of study funding by the DZHK following COVID-19 pandemic-induced prolongation of the recruitment period, also requiring manufacturing of further study drug batches"
NCT05046873,A Research Study Looking Into Blood Levels of Semaglutide and NNC0480-0389 When Given in the Same Injection or in Two Separate Injections in Healthy People,A Study to Investigate the Pharmacokinetics of Semaglutide and NNC0480-0389 When Subcutaneously Administered as a Co-formulation or as Separate Injections in Healthy Participants,Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL,"['Semaglutide 1.34 mg/mL', 'NNC0480-0389 A 10 mg/mL', 'Co-formulation NNC0480 0389+Semaglutide A 10/1 mg/mL', 'semaglutide 1.34 mg/mL (placebo)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2021-09-06,2022-01-05,"[{'measure': 'AUC0-∞,sema,SD: Area under the semaglutide plasma concentration-time curve after a single dose', 'description': 'h\\*nmol/L', 'timeFrame': 'From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)'}, {'measure': 'AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve after a single dose', 'description': 'h\\*nmol/L', 'timeFrame': 'From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)'}]","[{'measure': 'Cmax,sema,SD: Maximum plasma concentration of semaglutide after a single dose', 'description': 'nmol/L', 'timeFrame': 'From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)'}, {'measure': 'Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 after a single dose', 'description': 'nmol/L', 'timeFrame': 'From baseline (visit 2/12, day 1, pre-dose) until completion of the assessment period (visit 11/21, day 36)'}]",4,18 Years,55 Years,ALL,True,Novo Nordisk A/S,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:13.414880,v2_robust,True,True,True,False,False,
NCT04166773,A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH),"A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)",Tirzepatide,"['LY3298176', 'Tirzepatide', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Nonalcoholic Steatohepatitis,['Nonalcoholic Steatohepatitis'],[],COMPLETED,,2019-11-19,2024-01-10,"[{'measure': 'Percentage of Participants With Absence of Nonalcoholic Steatohepatitis (NASH) With no Worsening of Fibrosis on Liver Histology', 'description': 'NASH resolution is defined as the absence of fatty liver disease or simple steatosis without steatohepatitis; the absence of hepatocellular ballooning (nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) 0 for ballooning); with or without mild lobular inflammation (NAS 0 or 1 for inflammation); and any value for steatosis. No worsening of fibrosis is defined as no increase in fibrosis stage from baseline to Week 52.', 'timeFrame': 'Week 52'}]","[{'measure': 'Percentage of Participants With ≥1 Point Decrease in Fibrosis Stage With No Worsening of NASH on Liver Histology', 'description': 'NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8 with the higher score indicating more aggressive disease. Evaluation of fibrosis stage was based on the nonalcoholic steatohepatitis clinical research network (NASH CRN) fibrosis staging system, which was scaled from 0 to 4 stages where, 0=None to 4=Cirrhosis. Participants were evaluated with the NASH CRN scoring system with ≥1-point reduction without worsening of NASH (defined as no increase in the NAS score).', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants With ≥1 Point Increase in Fibrosis Stage on Liver Histology', 'description': 'Participants were evaluated with the NASH CRN scoring system with ≥1 stage increase in fibrosis.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants That Achieve a ≥2 Point Decrease in NAFLD (Non-alcoholic Fatty Liver Disease) Activity Score (NAS) on Liver Histology, With ≥1 Point Reduction in at Least 2 NAS Components', 'description': 'Hepatic histological improvement in NAS was defined as a decrease (improvement) in NAS by ≥ 2 with at least a 1-point reduction in at least 2 NAS components (lobular inflammation, hepatocellular ballooning or steatosis). The NAS was derived as the unweighted sum of steatosis (0 to 3), lobular inflammation (0 to 3), and hepatocellular ballooning (0 to 2) scores. The NAS ranges from 0-8, with the higher score indicating more aggressive disease.', 'timeFrame': 'Week 52'}, {'measure': 'Mean Absolute Change From Baseline in Liver Fat Content by Magnetic Resonance Imaging - Proton Density Fat Fraction (MRI-PDFF)', 'description': 'MRI-PDFF is an established method that enables quantification of fat content in the liver. The value of whole liver fat as assessed by MRI-PDFF is expressed in percentage (%) and ranges from 0 to 100% with higher values representing higher liver fat level. Least square (LS) mean was calculated using mixed model repeated measures (MMRM) model for post-baseline measures: Variable = Baseline + Diabetes Flag (DIABFL) + REGION1 + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Mean Change From Baseline in Body Weight', 'description': 'Change in body weight at the end of 52 weeks measured in kilogram (kg) using a calibrated scale. LS mean was calculated using MMRM model for post-baseline measures: Variable = Baseline + DIABFL + REGION1 + Treatment + Time + Treatment\\*Time (Type III sum of squares). Variance-Covariance structure (Change from Baseline) = Unstructured.', 'timeFrame': 'Baseline to Week 52'}]",6,18 Years,80 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,190.0,ACTUAL,2025-09-01T16:18:13.414944,v2_robust,True,True,True,False,False,
NCT01059773,A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to Methotrexate,An Exploratory Trial to Assess Naturalistic Safety and Efficacy Outcomes in Patients With Moderate to Severe Plaque Psoriasis Transitiioned to Ustekinumab From Previous Methotrexate Therapy (TRANSIT),Ustekinumab,"['Methotrexate', 'Ustekinumab']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Psoriasis,['Psoriasis'],"['Psoriasis', 'Ustekinumab', 'Stelara', 'Methotrexate', 'Biologic']",COMPLETED,,2009-10,2011-08,"[{'measure': 'Number of Patients Experiencing One or More Adverse Events Occurring From Week 0 Through Week 12', 'timeFrame': 'from week 0 to week 12'}]","[{'measure': 'Rate of Adverse Events (AEs), Serious AEs (SAEs) and Deaths During the Study Period', 'description': 'The number of patients with any of the following Treatment Emergent AEs (TEAEs) were summarized through Week 12 and through Week 52, by treatment arm and body weight category (≤100 kg and \\>100 kg): AE; SAE and Death.', 'timeFrame': 'at week 12, 16, 28 40 and 52'}, {'measure': 'Rate of Severe AEs, Reasonably Related AEs, and AEs Leading to Discontination During the Study Period', 'description': ""The number of patients with any of the following TEAEs were summarized through Week 12 and through Week 52, by treatment arm and body weight category (≤100 kg and \\>100 kg): AE with severe intensity; AE or SAE reasonably related to ustekinumab (i.e., AEs classified by the investigator as 'possibly', 'probably', or 'very likely' related to study agent); AE or SAE leading to permanent discontinuation of ustekinumab."", 'timeFrame': 'at week 12, 16, 28 40 and 52'}, {'measure': 'Rate of Infections, Severe Infections and Infections Requiring Oral or Parenteral Antimicrobial Treatment During the Study Period', 'description': 'The number of patients with any of the following TEAEs were summarized through Week 12 and through Week 52, by treatment arm and body weight category (≤100 kg and \\>100 kg): infections, serious infections, and infections requiring oral or parenteral antimicrobial treatment (infections being considered any event that by the investigator was indicated as infection on the CRF).', 'timeFrame': 'at week 12, 16, 28 40 and 52'}, {'measure': 'Rate of Malignancies and Other Events of Clinical Interest (Tuberculosis, Serious Cardiovascular Events, Anaphylactic/Serum Sickness Reaction)', 'description': 'The number of patients with a malignancy and other event of clinical interest (tuberculosis, serious cardiovascular events, anaphylactic/serum sickness reaction) were summarized through Week 12 and through Week 52, by treatment arm and body weight category (≤100 kg and \\>100 kg)', 'timeFrame': 'at week 12, 16, 28 40 and 52'}, {'measure': 'Change in Mean Psoriasis Area-and-severity Index (PASI) Score Compared to Baseline', 'description': ""Change from baseline in Psoriasis Area and Severity Index (PASI) (0 \\[best\\] - 72 \\[worst\\]). The PASI is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score."", 'timeFrame': 'at Weeks 0, 2, 4, 12, 16, 28, 40 and 52'}, {'measure': 'Proportion of Patients Achieving PASI 50 Response', 'description': ""This is based on the number of participants achieving at least 50% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 \\[best\\] - 72 \\[worst\\]). The PASI is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score."", 'timeFrame': 'at Weeks 2, 4, 12, 16, 28, 40 and 52'}, {'measure': 'Proportion of Patients Achieving PASI 75 Response', 'description': ""This is based on the number of participants achieving at least 75% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 \\[best\\] - 72 \\[worst\\]). The PASI is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score."", 'timeFrame': 'at Weeks 2, 4, 12, 16, 28, 40 and 52'}, {'measure': 'Proportion of Patients Achieving PASI 90 Response', 'description': ""This is based on the number of participants achieving at least 90% improvement from baseline in Psoriasis Area and Severity Index (PASI) (0 \\[best\\] - 72 \\[worst\\]). The PASI is a test of how bad a person's psoriasis is. The combination of redness, scaling, and thickness, as well as overall body involvement determine the PASI score."", 'timeFrame': 'at Weeks 2, 4, 12, 16, 28, 40 and 52'}]",9,18 Years,,ALL,False,Janssen-Cilag International NV,INDUSTRY,0,490.0,ACTUAL,2025-09-01T16:18:13.415001,v2_robust,True,True,True,False,True,
NCT06114173,Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma,Efficacy and Safety Study of Cardunolizumab in Soft Tissue Sarcoma After Failure of at Least Anthracycline-based Chemotherapy: a Single-arm Clinical Trial,Cardunilizumab,"['PD-1/CTLA-4 Bispecific Antibody', 'Cardunilizumab']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Sarcoma, Soft Tissue","['Sarcoma, Soft Tissue']",[],ACTIVE_NOT_RECRUITING,,2022-11-01,2024-11-30,"[{'measure': 'Objective response rate，ORR', 'description': 'Tumor volume reduction of up to 30%（According to RECIST 1.1 efficacy evaluation criteria）', 'timeFrame': '24 months'}]","[{'measure': 'Incidence of adverse events', 'description': 'according to criteria CTCAE 5.0,the ratio of AE and SAE which were defined by the common terminology criteria for adverse events,CTCAE.', 'timeFrame': '24 months'}, {'measure': 'Incidence of immune-related adverse events', 'description': 'Adverse effects due to the use of immunotherapy', 'timeFrame': '24 months'}, {'measure': 'overall survival,OS', 'description': 'Time from initiation of immunotherapy to death or time lost to visit.', 'timeFrame': '24 months'}, {'measure': 'progression-free survival,PFS', 'description': 'Time from initiation of immunotherapy to disease progression or death from other causes.', 'timeFrame': '24 months'}]",5,18 Years,75 Years,ALL,False,Xiangya Hospital of Central South University,OTHER,0,15.0,ACTUAL,2025-09-01T16:18:13.415010,v2_robust,True,True,False,False,True,
NCT06393673,A Study to Find the Best Dose of HS-10384 to Treat Vasomotor Symptoms in Postmenopausal Women,"A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Investigate the Efficacy and Safety of HS-10384 in Postmenopausal Women Suffering From Vasomotor Symptoms (Hot Flashes)",HS-10384 tablet Dose 1,"['HS-10384-matched placebo tablets', 'HS-10384 tablet Dose 2', 'HS-10384 tablet Dose 1']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Vasomotor Symptoms,['Vasomotor Symptoms'],"['HS-10384', 'Vasomotor symptoms', 'postmenopausal women']",NOT_YET_RECRUITING,,2024-05-30,2025-09-30,"[{'measure': 'Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 4;', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Mean change in the frequency of moderate to severe vasomotor symptoms from baseline to Week 12;', 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 4;', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Mean change in the severity of moderate to severe vasomotor symptoms from baseline to Week 12.', 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Mean change in the frequency of moderate and severe vasomotor symptoms from baseline to each study week;', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Mean change in the severity of moderate and severe vasomotor symptoms from baseline to each study week;', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Mean change in the hot flash score of moderate and severe vasomotor symptoms from baseline to each study week;', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Mean percent reduction of 50% and 100% of moderate and severe vasomotor symptoms from baseline to each study week.', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Incidence and severity of treatment-emergent adverse events;', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Number of participants with clinical laboratory abnormalities;', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Number of participants with abnormalities of vital signs', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Number of participants with abnormalities of physical examinations', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Change from baseline in ECG parameters', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Change from baseline in plasma bone density marker concentrations', 'timeFrame': 'Baseline to Week 15'}, {'measure': 'Change from baseline in Endometrial health assessment.', 'timeFrame': 'Baseline to Week 15'}]",15,40 Years,65 Years,FEMALE,False,Hansoh BioMedical R&D Company,INDUSTRY,0,195.0,ESTIMATED,2025-09-01T16:18:13.415074,v2_robust,True,True,False,False,True,
NCT04975373,Intrauterine Hyaluronic Acid Gel for Prevention of Intrauterine Adhesions,Reduction of Intrauterine Adhesions by Intrauterine Hyaluronic Acid Gel After Hysteroscopic Removal of Retained Products of Conception: Multicenter Prospective Randomized Trial,Intrauterine injection of hyaluronic acid,"['diagnostic hysteroscopy', 'operative hysteroscopy -', 'Intrauterine injection of hyaluronic acid']",3,INTERVENTIONAL,['NA'],,,Prevenetion of Intrauterine Adhesions by Hyaluronic Acid Gel,['Prevenetion of Intrauterine Adhesions by Hyaluronic Acid Gel'],"['retained placenta', 'operative hysteroscopy', 'intrauterine adhesions', 'hyaluronic acid']",UNKNOWN,,2021-06-25,2022-07-25,"[{'measure': 'any adhesions', 'description': 'presence of any adhesions in uterine cavity during diagnostic hysteroscopy', 'timeFrame': '4-8 weeks after intervention'}]","[{'measure': 'adhesion scorring', 'description': 'American Fertility Society score for intrauterine adhesions', 'timeFrame': '4-8 weeks after intervention'}]",2,18 Years,45 Years,FEMALE,False,Barzilai Medical Center,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:13.415109,v2_robust,True,True,False,False,False,
NCT04918069,Capsaicin to Prevent Delayed Chemotherapy Induced Nausea and Vomiting (CapCIN),"Single-blinded, Randomized Study of Capsaicin to Prevent Delayed Chemotherapy-induced Nausea and Vomiting",Capsaicin,"['Capsaicin', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chemotherapy-induced Nausea and Vomiting,['Chemotherapy-induced Nausea and Vomiting'],"['Chemotherapy', 'Capsaicin', 'Nausea and Vomiting']",COMPLETED,,2019-10-18,2022-05-14,"[{'measure': 'Nausea', 'description': 'Number of participants with chemotherapy-induced nausea that occurs after 24 hours of the first cycle', 'timeFrame': 'Within 15 days of chemotherapy'}, {'measure': 'Vomiting', 'description': 'Number of participants with chemotherapy-induced vomiting that occurs after 24 hours of the first cycle', 'timeFrame': 'Within 15 days of chemotherapy'}]","[{'measure': 'Overall chemotherapy-induced nausea and vomiting', 'description': 'Number of participants with both immediate and delayed chemotherapy-induced nausea and vomiting', 'timeFrame': 'Within 15 days of chemotherapy'}, {'measure': 'Severity of chemotherapy-induced nausea and vomiting', 'description': 'Number of participants with severe, moderate and mild chemotherapy-induced nausea and vomiting', 'timeFrame': 'Within 15 days of chemotherapy'}, {'measure': 'Use of rescue medication', 'description': 'Number of participants requiring rescue medication for nausea and vomiting', 'timeFrame': 'Within 15 days of chemotherapy'}]",5,18 Years,,ALL,False,"Christian Medical College, Vellore, India",OTHER,0,160.0,ACTUAL,2025-09-01T16:18:13.415169,v2_robust,True,True,True,False,False,
NCT02561169,A Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza,A Randomized Controlled Trial of Oseltamivir in High-Risk Patients Presenting to the Emergency Department With Influenza,Oseltamivir,"['Oseltamivir', 'Tamiflu']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Influenza,['Influenza'],"['antiviral', 'oseltamivir']",TERMINATED,,2015-12,2016-03,"[{'measure': 'Non-elective Hospitalizations (number of hospitalizations)', 'timeFrame': '28 days'}, {'measure': 'Length of non-elective hospitalization (days)', 'timeFrame': '28 days'}]","[{'measure': 'Lower respiratory tract infection (LRTI), (number of LRTIs)', 'timeFrame': '28 days'}, {'measure': 'Pneumonia (number of episodes of pneumonia)', 'timeFrame': '28 days'}, {'measure': 'Acute Sinusitis (number of episodes of acute sinusitis)', 'timeFrame': '28 Days'}, {'measure': 'New antimicrobial prescription (number of antimicrobial prescriptions)', 'timeFrame': '28 Days'}, {'measure': 'Medical visits for acute respiratory illness (number of medical visits)', 'timeFrame': '28 Days'}, {'measure': 'Death', 'timeFrame': '3 months'}, {'measure': 'Adverse Events (number of adverse events)', 'timeFrame': '5 days'}, {'measure': 'Admission to intensive or critical care unit (number of admissions)', 'timeFrame': '28 days'}, {'measure': 'Duration of stay in intensive or critical care unit (days)', 'timeFrame': '28 days'}, {'measure': 'Need for mechanical ventilation (number of mechanical ventilation)', 'timeFrame': '28 days'}, {'measure': 'Duration of mechanical ventilation (days)', 'timeFrame': '28 days'}]",13,18 Years,,ALL,False,McMaster University,OTHER,2,1.0,ACTUAL,2025-09-01T16:18:13.415184,v2_robust,True,True,False,True,True,
NCT02328469,Aseptic Meningoencephalitis in Slovenia,"Prospective Study of the Etiology, Pathogenesis, Clinical Picture and Outcome of Aseptic Meningitis in Slovenia",symptomatic therapy,"['Acyclovir', 'symptomatic therapy', 'Ceftriaxone or Doxycycline']",3,OBSERVATIONAL,[],,,Aseptic Meningitis,['Aseptic Meningitis'],"['aseptic meningitis', 'tick-borne encephalitis', 'Lyme neuroborreliosis', 'inflammation', 'outcome']",UNKNOWN,,2014-06,2020-06,"[{'measure': 'Changes in selected clinical parameters in patients with acute aseptic meningitis/meningoencephalitis', 'description': 'Selected clinical parameters (presence or absence of headache, nausea, vomiting, neurologic symptoms, maximal temperature, etc) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and at follow-up visits: on day 7 or on day of discharge from hospital, on day 14, at 2, 6, and 12 months.', 'timeFrame': 'at enrollment and during 12 months follow-up'}, {'measure': 'Changes in selected laboratory parameters in patients with acute aseptic meningitis/meningoencephalitis', 'description': 'Selected laboratory parameters (complete blood count, biochemistry test results) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and at follow-up visits: on day 7 or on day of discharge from hospital, on day 14, at 2, 6, and 12 months.', 'timeFrame': 'at enrollment and during 12 months follow-up'}, {'measure': 'Changes in selected microbiologic parameters in patients with acute aseptic meningitis/meningoencephalitis', 'description': 'Selected microbiologic parameters (anti Borrelia burgdorferi immunoglobulin M and G in serum and cerebrospinal fluid results, polymerase chain reaction for enteroviruses, herpes simplex virus type 1 and 2 in cerebrospinal fluid results) in aseptic meningitis/meningoencephalitis patients at enrollment (at admission to hospital) and anti Borrelia burgdorferi immunoglobulin M and G in serum at follow-up visits: at 2, 6, and 12 months.', 'timeFrame': 'at enrollment and during 12 months follow-up'}]",[],3,18 Years,,ALL,True,University Medical Centre Ljubljana,OTHER,3,800.0,ESTIMATED,2025-09-01T16:18:13.415242,v2_robust,False,True,False,False,False,
NCT04166669,A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001,"A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study of APX001 to Evaluate the Effects of CYP3A4 Inhibition and Pan-CYP Induction in Two Parallel Groups of Healthy Male and Female Subjects",APX001,"['Sporanox', 'Rifampicin', 'Itraconazole', 'Fosmanogepix', 'APX001', 'Rifampin']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Fungal Infection,['Fungal Infection'],[],COMPLETED,,2019-11-12,2020-03-03,"[{'measure': 'Pharmacokinetics of APX001/APX001A as measured by area under the plasma concentration-time curve (AUC) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetics of APX001/APX001A as measured by maximum observed plasma concentration (Cmax) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetics of APX001/APX001A as measured by time to attain maximum observed plasma concentration (Tmax) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetics of APX001/APX001A as measured by terminal elimination rate constant (λz) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetics of APX001/APX001A as measured by terminal elimination half-life (t1/2) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetics of APX001/APX001A as measured by total clearance (CL) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Pharmacokinetics of APX001/APX001A as measured by the volume of distribution during the terminal phase (Vz) after multiple doses of a CYP3A4 inhibitor, itraconazole (oral solution) or multiple doses of a pan-CYP inducer, oral rifampin.', 'timeFrame': '6 weeks'}]","[{'measure': 'Number of subjects experiencing and frequency of occurrence of adverse events as rated by CTCAE v5.0 after dosing with APX001 IV alone and when co-administered with itraconazole (oral solution) or oral rifampin.', 'timeFrame': '6 weeks'}, {'measure': 'Occurrence and magnitude of clinical lab test values outside the normal range, clinically significant, and differing from baseline results after dosing with APX001 IV alone and when co-administered with itraconazole (oral solution) or oral rifampin.', 'description': 'The following parameters will be measured:\n\n* Clinical chemistry (serum quantitatively): total bilirubin, direct (conjugated) bilirubin, indirect (unconjugated) bilirubin (calculated), alkaline phosphatase, gamma-GT, ASAT, ALAT, LDH, p-amylase, lipase, CPK, creatinine, eGRF, urea, uric acid, cholesterol, triglycerides, total protein, albumin, globulin, glucose, inorganic phosphate, sodium, potassium, calcium, chloride, and bicarbonate.\n* Hematology (blood quantitatively): leukocytes, erythrocytes, hemoglobin, hematocrit, thrombocytes, partial automated absolute differentiation: lymphocytes, monocytes, eosinophils, basophils, neutrophils, MCV, MCH, and MCHC.\n* Coagulation (blood quantitatively): PT, aPTT, and fibrinogen.\n* Urinalysis (urine qualitatively): color, protein, glucose, bilirubin, urobilinogen, ketones, blood, pH, specific gravity, and leukocytes.', 'timeFrame': '6 weeks'}, {'measure': 'Occurrence of abnormal vital signs after dosing with APX001 IV alone and when co-administered with itraconazole (oral solution) or oral rifampin.', 'description': 'Systolic and diastolic blood pressure and pulse will be recorded after the subject has been resting supine or semi-recumbent for at least 5 minutes. Body temperature and respiratory rate will be measured subsequently.', 'timeFrame': '6 weeks'}, {'measure': 'Occurrence of abnormal, clinically significant results from 12-lead ECGs after dosing with APX001 IV alone and when co-administered with itraconazole (oral solution) or oral rifampin.', 'description': ""The following ECG parameters will be recorded: heart rate, PR interval, QRS duration, QT interval, and QTc interval (Fridericia's)."", 'timeFrame': '6 weeks'}, {'measure': 'Occurrence of changes in physical examinations which differ from baseline after dosing with APX001 IV alone and when co-administered with itraconazole (oral solution) or oral rifampin.', 'description': 'Physical examination will include: general appearance; skin/subcutaneous tissue; head; ears, nose, throat; neck and thyroid; thorax; lungs; cardiovascular; lymph nodes; abdomen; musculoskeletal; and neurological.', 'timeFrame': '6 weeks'}]",12,18 Years,60 Years,ALL,True,Basilea Pharmaceutica,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:13.415264,v2_robust,True,True,True,False,True,
NCT00609869,Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab,A Phase II Study of Lenalidomide (REVLIMID®) in Combination With Rituximab for Patients With CD5+/CD20+ Hematologic Malignancies Who Relapse or Progress After Rituximab,Lenalidomide,"['Lenalidomide', 'REVLIMID®', 'Rituximab', 'RITUXAN®']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphocytic Leukemia,"['Lymphocytic Leukemia', 'Mantle Cell Lymphoma']",[],COMPLETED,,2007-10,2015-08,"[{'measure': 'Overall Response Rate (ORR)', 'description': 'The sum of Complete Remission (CR) plus Partial Remission (PR) rates. Duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, and must be confirmed greater than 8 weeks after first meeting CR or PR criteria. Response and progression for Chronic Lymphocytic Leukemia (CLL) were evaluated using 2008 updated National Cancer Institute-Sponsored Working Group Guidelines (NCI-WG) for Chronic Lymphocytic Leukemia. CR: all of the criteria must be met, and patients have the lack disease-related constitutional symptoms: PR: at least two of the criteria of Group A plus one of the criteria of group B have to be met. Group A Parameters: Lymphadenopathy; Hepatomegaly; Splenomegaly; Blood; Lymphocytes; Marrow. Group B Parameters: Platelet count; Hemoglobin; Neutrophils.', 'timeFrame': 'Up to 6 years'}]","[{'measure': 'Clinical Benefit Rate', 'description': 'The ORR rate plus Stable Disease (SD). NCI-WG: SD is the absence of progressive disease (PD) and failure to achieve at least a PR; PD: at least one of the criteria of Group A or Group B has to be met.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Median Time to Treatment Failure (TTF)', 'description': 'The time from start of therapy to death, Progressive Disease (PD) or initiation of next therapy. PD: at least one of the NCI-WG criteria of Group A or Group B has to be met.', 'timeFrame': 'Up to 6 years'}]",3,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,29.0,ACTUAL,2025-09-01T16:18:13.415289,v2_robust,True,True,True,False,False,
NCT02652169,PRF With Topical Antibiotics or Antiseptics in Chronical Wounds Version 1.4,"Platelet Rich Fibrin in Combination With Topical Antibiotics or Antiseptics in the Treatment of Chronic Wounds - a Prospective, Randomized, Active Controlled, Double Blind Pilot Trial With an Observer-blinded Control Group",PRF mixed with amikacin and teicoplanin,"['PRF plus normal saline', 'PRF mixed with amikacin and teicoplanin', 'PRF plus Lavasorb', 'PRF plus sodium chloride 0.9%', 'PRF mixed with PHMB plus Macrogolol', 'PRF plus amikacin/teicoplanin']",6,INTERVENTIONAL,['NA'],,,Chronic Skin Ulcer,['Chronic Skin Ulcer'],[],RECRUITING,,2014-06,2027-04,"[{'measure': 'reduction in wound area', 'timeFrame': 'day 56'}]","[{'measure': 'Number of patients in necessity to initiate systemic antimicrobial therapy based on the opinion of a senior infectious disease consultant arises (subjective assessment based on wound inflammation, serum c-reactive protein levels and leucocyte count)', 'timeFrame': 'day 0, 7, 14, 21, 28, 35, 42, 49, 56'}, {'measure': 'Elevation of C-reactive protein over 7 mg/dl (normal value 0.5 mg/dl)', 'timeFrame': 'day 0, 7, 14, 21, 28, 35, 42, 49, 56'}, {'measure': 'time to sterility of the wound', 'timeFrame': 'day 0, 7, 14, 21, 28, 35, 42, 49, 56'}, {'measure': 'Relative wound volume and wound area reduction', 'timeFrame': 'on day 28 and 56'}, {'measure': 'Occurrence of drug resistant bacteria in the wound', 'timeFrame': 'day 0, 7, 14, 21, 28, 35, 42, 49, 56'}, {'measure': 'Occurrence of drug resistant bacteria in a swab of the tissue surrounding the wound or a Z-swab of the torso', 'timeFrame': 'on day 28 and 56'}]",7,18 Years,,ALL,False,Medical University of Vienna,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:13.415310,v2_robust,True,True,False,False,False,
NCT00989469,Sorafenib With Irinotecan in Metastatic Colorectal Cancer (mCRC) and K-RAS Mutation,SORAFENIB (NEXAVAR®) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.,Nexavar (Sorafenib) and irinotecan (Campto),['Nexavar (Sorafenib) and irinotecan (Campto)'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],[],COMPLETED,,2009-02,2012-02,"[{'measure': 'disease control', 'timeFrame': '6 months'}]","[{'measure': 'Assessment of adverse events by using the NCI-CTCAE version 3 scale', 'timeFrame': '6 months'}, {'measure': 'progression free survival', 'timeFrame': '24 months'}, {'measure': 'overall survival', 'timeFrame': '36 months'}]",4,18 Years,,ALL,False,Institut du Cancer de Montpellier - Val d'Aurelle,OTHER,1,64.0,ACTUAL,2025-09-01T16:18:13.415335,v2_robust,True,True,True,False,True,
NCT02303769,Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS,"A Multicenter, Randomized, Double -Blind, Parallel, Comparative, Phase III Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1 Tablet in BPH Patients With LUTS",Tamsulosin HCL 0.4mg,"['GL2702 GLARS-NF1 Tablet', 'Tamsulosin HCL 0.2mg', 'Tamsulosin HCL 0.4mg', 'Harmal D']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Benign Prostatic Hyperplasia,['Benign Prostatic Hyperplasia'],"['Lower Urinary Track Syndrome', 'Harnal', 'Tamsulosin HCL 0.4mg']",COMPLETED,,2014-03,2015-10,"[{'measure': 'Change from baseline to endpoint in total International Prostate Symptom Score', 'timeFrame': '8 weeks'}]","[{'measure': 'Change from baseline to endpoint in total International Prostate Symptom Score', 'timeFrame': '4 weeks'}, {'measure': 'Change from baseline to endpoint in voiding score', 'timeFrame': '4 weeks, 8 weeks'}, {'measure': 'Change from baseline to endpoint in IPSS QoL', 'timeFrame': '4 weeks, 8 weeks'}, {'measure': 'Change from baseline to endpoint in Qmax', 'timeFrame': '4 weeks, 8 weeks'}, {'measure': 'Change from baseline to endpoint in PVR', 'timeFrame': '4 weeks, 8 weeks'}, {'measure': 'Time to event/proportion of subjects with AUR', 'timeFrame': '8 weeks'}, {'measure': 'Time to event/proportion of subjects undergoing BPH related prostatic surgery', 'timeFrame': '8 weeks'}]",8,50 Years,,MALE,False,GL Pharm Tech Corporation,INDUSTRY,0,309.0,ACTUAL,2025-09-01T16:18:13.415374,v2_robust,True,True,True,False,False,
NCT03937869,Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g for the Treatment of Adolescent Girls With BV,"A Multi-Center, Open-Label Study to Evaluate the Safety of a Single Oral Dose of Solosec™ (Secnidazole) 2g Oral Granules for the Treatment of Adolescent Girls With Bacterial Vaginosis",Secnidazole,"['Solosec™', 'Secnidazole']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Bacterial Vaginoses,['Bacterial Vaginoses'],"['Adolescents', 'Vaginal fishy smell', 'Vaginal itching', 'off-white milky vaginal discharge']",COMPLETED,,2018-11-28,2020-11-05,"[{'measure': 'Clinical Outcome Responder', 'description': 'Defined as patients with resolution of abnormal vaginal , negative 10% KOF WHIFF test, and Clue cells less than 20% of the total epithelial cells', 'timeFrame': 'At TOC visit study day 7-14'}, {'measure': 'Nugent Score', 'description': 'All patients with a score of 0-3 will be considered normal; scores of 4 and above will considered abnormal.', 'timeFrame': 'At TOC visit study day 7-14'}, {'measure': 'Investigator Clinical Assessment', 'description': ""Investigator's opinion of the need for additional BV treatment. (Yes/No)"", 'timeFrame': 'At TOC visit study day 7-14'}, {'measure': ""Patient's Continued Clinical Response"", 'description': ""Investigator's opinion of the continued clinical response to treatment (Yes/No)"", 'timeFrame': 'At TOC visit study day 7-14'}]",[],4,12 Years,17 Years,FEMALE,True,Lupin Research Inc,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:13.415404,v2_robust,True,True,True,False,False,
NCT03282669,TC02 Obese Women Using It Morphine vs PCA IV Hydromorphone for Post-Cesarean Analgesia,Randomized Controlled Trial Evaluating the Transcutaneous Carbon Dioxide Measurements in Obese Women Using Intrathecal Morphine Versus Patient-Controlled Intravenous Hydromorphone for Post-Cesarean Analgesia,Intrathecal Morphine,"['Intrathecal Morphine', 'Intravenous hydromorphone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pain, Postoperative","['Pain, Postoperative', 'Obesity', 'Respiratory Insufficiency']","['Pregnancy', 'Transcutaneous Carbon Dioxide Monitoring', 'Pulse Oximetry', 'Cesarean Section', 'Postoperative pain control', 'High BMI', 'Hypercarbia', 'Hypoxemia']",WITHDRAWN,Change in institutional policy. Change in resources available.,2019-08,2021-12,"[{'measure': 'Incidence of hypercapnia', 'description': 'Incidence of hypercapnia (transcutaneous CO2 levels \\>50mmHg) in the intrathecal morphine versus patient controlled intravenous morphine groups', 'timeFrame': '24 hours post delivery'}]","[{'measure': 'Opioid consumption', 'description': 'Amount of opioids used during the time from delivery to 24 hours post delivery', 'timeFrame': '24 hours post delivery'}, {'measure': 'NSAID consumption', 'description': ""Amount of NSAID's used during the time from delivery to 24 hours post delivery."", 'timeFrame': '24 hours post delivery'}, {'measure': 'Respiratory rate', 'description': 'Hourly respiratory rates for the first 12 hours then every 2 hours for the next 12 hours.', 'timeFrame': '24 hours post delivery'}, {'measure': 'Sedation scores', 'description': 'Sedation scores as scored on the Richmond Agitation and Sedation Scale at 2 hours, 6 hour and 12 hours post delivery.', 'timeFrame': 'delivery to 12 hours post delivery'}, {'measure': 'Pain Scores', 'description': 'Pain scores on a scale of 0 (low)-10 (high) will be documented every hour for the first 24 hours after delivery.', 'timeFrame': '24 hours'}, {'measure': 'Pulse oximetry', 'description': 'Pulse oximetry will be collected using the transcutaneous Co2 monitor for 24 hours after deliuvery.', 'timeFrame': '24 hours post delivery'}]",7,18 Years,65 Years,FEMALE,False,Northwestern University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:13.415565,v2_robust,True,True,False,True,False,Change in institutional policy. Change in resources available.
NCT03899883,Uric Acid Lowering Trial in Youth Onset T2D,ULTRA-T2D Study: Uric Acid Lowering Trial in Youth Onset T2D,Pegloticase 8 MG/ML [Krystexxa],['Pegloticase 8 MG/ML [Krystexxa]'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetic Kidney Disease,"['Diabetic Kidney Disease', 'Hyperuricemia', 'Diabetes', 'Diabetes Mellitus, Type 2', 'Type2 Diabetes', 'Type 2 Diabetes Mellitus', 'Diabetic Nephropathies', 'Diabetes Complications']",[],UNKNOWN,,2020-01-01,2023-06-30,"[{'measure': 'Cardiovascular Markers', 'description': 'Measured by Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Mean Arterial Pressure (MAP)', 'timeFrame': '5 min'}, {'measure': 'Pulse Wave Velocity (PWV)', 'description': 'Measured by Aortic MRI renal MRI (4D Flow)', 'timeFrame': '2 hours (x2 study visits)'}, {'measure': 'Wall Shear Stress (WSS)', 'description': 'Measured by Aortic MRI renal MRI (4D Flow)', 'timeFrame': '2 hours (x2 study visits)'}, {'measure': 'Renal Blood Flow', 'description': 'Measured by 4D Flow renal MRI', 'timeFrame': '1 hour (x2 study visits)'}, {'measure': 'Glomerular Filtration Rate', 'description': 'Measured by Iohexol Clearance in Plasma', 'timeFrame': '4 hours (x2 study visits)'}, {'measure': 'Albumin Excretion Rate (AER)', 'description': 'Measured by albumin and creatinine concentrations in urine', 'timeFrame': '4 hours (x2 study visits)'}]","[{'measure': 'Calculated parameters of intrarenal hemodynamic function', 'description': 'Measured by using existing renal hemodynamic calculations', 'timeFrame': '1 hour'}, {'measure': 'Change in serum uric acid (sUA)', 'description': 'Measured by baseline sUA compared to sUA one week later', 'timeFrame': '1 hour'}]",8,18 Years,25 Years,MALE,False,"University of Colorado, Denver",OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:13.415655,v2_robust,True,True,False,False,False,
NCT05999383,Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration,Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration,Cannabis,"['Marijuana', 'Nicotine', 'Nicotine product', 'Cannabis']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,THC,"['THC', 'Cannabis', 'Cannabis Use', 'Cannabis Smoking', 'Tobacco Use', 'Vaping']","['THC', 'Cannabis', 'Marijuana', 'Nicotine', 'Vape']",NOT_YET_RECRUITING,,2025-06-15,2028-02-28,"[{'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Baseline to Day 1'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 1 to Day 2'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 2 to Day 3'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 3 to Day 4'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 4 to Day 5'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 5 to Day 6'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 6 to Day 7'}, {'measure': 'Change in peak plasma concentration of THC', 'description': 'To assess the differences between THC dosages, the study investigators will determine maximum plasma THC concentration (Cmax) using plasma THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 7 to Day 8'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Baseline to Day 1'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 1 to Day 2'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 2 to Day 3'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 3 to Day 4'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 4 to Day 5'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 5 to Day 6'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 6 to Day 7'}, {'measure': 'Change in Peak plasma concentration of nicotine', 'description': 'To assess the differences between nicotine dosages, the study investigators will determine maximum plasma nicotine concentration (Cmax) using plasma nicotine concentrations from the standardized sessions.', 'timeFrame': 'From Day 7 to Day 8'}]","[{'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Baseline to Day 1'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 1 to Day 2'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 2 to Day 3'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 3 to Day 4'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 4 to Day 5'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 5 to Day 6'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 6 to Day 7'}, {'measure': 'Cardiovascular effects among dosages using heart rate as a measure', 'description': 'The investigators will compare maximum change in heart rate as well as an integrated measure of heart rate over the first 180 minutes after the standardized session among dosages.', 'timeFrame': 'From Day 7 to Day 8'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Baseline to Day 1'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 1 to Day 2'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 2 to Day 3'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 3 to Day 4'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 4 to Day 5'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 5 to Day 6'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 6 to Day 7'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'To assess the differences of absorption among dosages, the study investigators will determine the AUC using plasma nicotine and THC concentrations from the standardized sessions.', 'timeFrame': 'From Day 7 to Day 8'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Baseline to Day 1'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased craving of marijuana.', 'timeFrame': 'From Day 1 to Day 2'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Day 2 to Day 3'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Day 3 to Day 4'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Day 4 to Day 5'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Day 5 to Day 6'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Day 6 to Day 7'}, {'measure': 'Change in subjective effects scores using the Marijuana Cravings Questionnaire (MCQ)', 'description': 'Self-assessed cravings will be measured using the MCQ. Questions on the MCQ are scored on a 7 point scale of 1 = Strongly Disagree and 7 = Strongly Disagree, with higher scores indicating increased cravings.', 'timeFrame': 'From Day 7 to Day 8'}]",40,21 Years,65 Years,ALL,True,"University of California, San Francisco",OTHER,3,48.0,ESTIMATED,2025-09-01T16:18:13.415675,v2_robust,True,True,False,False,False,
NCT00288483,Cholesterol-Lowering Effects of Policosanol,"Placebo-Controlled, Randomised, Double-Blind, Multi-Centre Clinical Trial on Dose-Dependent Cholesterol-Lowering Effects of Policosanol in Patients With Hypercholesterolaemia With 10 to 80 Mg Policosanol for 12 Weeks",Policosanol,['Policosanol'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,"['Hypercholesterolemia', 'Combined Hyperlipidemia']",[],TERMINATED,,2000-09,2001-07,[{'measure': 'Decrease in LDL cholesterol'}],[{'measure': 'Changes in other lipoproteins'}],2,18 Years,80 Years,ALL,False,Drug Commission of the German Medical Association,OTHER,1,,,2025-09-01T16:18:13.415749,v2_robust,True,True,False,True,False,
NCT03433183,SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors,SARC031: A Phase 2 Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors,Selumetinib,"['AZD6244', 'Sirolimus', 'Rapamycin', 'Selumetinib']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Malignant Peripheral Nerve Sheath Tumors,"['Malignant Peripheral Nerve Sheath Tumors', 'Neurofibromatosis 1']",[],COMPLETED,,2019-10-02,2023-10-01,"[{'measure': 'Clinical benefit rate of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.', 'description': 'An evaluable patient will be classified as a responder if the patient achieves a partial response (PR), complete response (CR) or stable disease (SD) ≥ 4 cycles.', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Progression free and overall survival', 'description': 'Determined using the Kaplan-Meier method with PFS at important time points reported along with 95% two sided confidence intervals.', 'timeFrame': 'Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of objective progression or death. [Time Frame: Up to 4 years]'}, {'measure': 'Define and describe the toxicities of selumetinib in combination with sirolimus in patients with unresectable or metastatic NF1 associated or sporadic MPNST.', 'description': 'This study will use CTEP Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 for toxicity and adverse event reporting. The toxicities will be graded and summarized descriptively and tabulations on the type, severity and relationship to study treatment will be performed.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Assess the impact on pain interference', 'description': 'Pain interference metrics will be assessed using the Patient Reported Outcomes Measurements Information System (PROMIS) scale to assess the impact of pain on daily activities. This is a self-report measure that assesses the degree to which pain has interfered with the ability to complete daily activities over the past 7 days. Items are rated on a 5-point Likert scale and the measures yield standardized T-scores.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Assess the impact on pain severity', 'description': 'Pain metrics will be assessed using the Numerical Rating Scale-11 (NRS-11) scale to assess pain severity. The scale consists of a horizontal line with 0 representing ""no pain"" and 10 representing ""worst pain you can imagine."" Patients will circle one number from 0 to 10 that best describes how much their tumor pain hurt during the past week.', 'timeFrame': 'Up to 6 months'}]",5,12 Years,,ALL,False,Sarcoma Alliance for Research through Collaboration,OTHER,2,21.0,ACTUAL,2025-09-01T16:18:13.415791,v2_robust,True,True,True,False,True,
NCT00370383,A Study Comparing Sequential Satraplatin & Erlotinib to Erlotinib in Unresectable Stage 3/4 Non-small-cell Lung Cancer (NSCLC),A Phase 2 Study Comparing Sequential Satraplatin and Erlotinib to Single-Agent Erlotinib in Patients ≥ 70 Years of Age With Unresectable Stage 3 OR 4 Non-Small Cell Lung Cancer as 1st-Line Therapy,Erlotinib,"['Satraplatin', 'Erlotinib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['Non Small Cell Lung Cancer', 'PATIENTS ≥ 70 YEARS WITH UNRESECTABLE STAGE 3 OR 4 NSCLC']",COMPLETED,,2006-07,2009-03,"[{'measure': 'To compare Progression-Free Survival (PFS) in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.', 'timeFrame': 'January, 2008'}]","[{'measure': 'To assess Overall Survival in patients ≥ 70 years of age, PS 0-1, with advanced or metastatic NSCLC in patients treated with a first-line regimen of either sequential satraplatin and erlotinib or continuous single-agent erlotinib.', 'timeFrame': 'January, 2008'}, {'measure': 'To compare response rates.', 'timeFrame': 'January, 2008'}, {'measure': 'To compare the toxicity profiles between patients treated with satraplatin and erlotinib and single-agent erlotinib', 'timeFrame': 'January, 2008'}]",4,70 Years,,ALL,False,Agennix,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:13.415843,v2_robust,True,True,True,False,False,
NCT02833883,"Use of an Experimental Drug, CC-115, With Enzalutamide in Men With Castration-Resistant Prostate Cancer",A Phase 1b Study of Enzalutamide Plus CC-115 in Men With Castration-Resistant Prostate Cancer (CRPC),Enzalutamide,"['CC-115', 'Enzalutamide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Prostate Cancer,"['Prostate Cancer', 'Castration Resistant Prostate Cancer']","['Enzalutamide', 'CC-115', '16-074']",COMPLETED,,2016-07,2023-01-13,"[{'measure': 'establish the maximum tolerated dose (MTD)', 'description': 'Subjects will be treated in cohorts of size three and six and the dosage will be escalated if the clinical toxicity is acceptable. The maximum tolerated dose is defined as the highest dose level with an observed incidence of DLT in no more than one out of six subjects treated at a particular dose level. A DLT will be determined by cycle 1 toxicity, although all-cycle toxicity will be recorded.', 'timeFrame': '1 year'}]",[],1,18 Years,,MALE,False,Memorial Sloan Kettering Cancer Center,OTHER,1,40.0,ACTUAL,2025-09-01T16:18:13.415895,v2_robust,True,True,True,False,False,
NCT03866083,Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics,Safety and Efficacy of Extracorporeal Cytokine Hemoadsorption in Septic Shock in Critically Ill Cirrhotics -A Prospective Randomized Controlled Trial,Extracorporeal Cytokine hemadsorption therapy,"['Standard Medical Treatment', 'Extracorporeal Cytokine hemadsorption therapy']",2,INTERVENTIONAL,['NA'],,,Septic Shock,['Septic Shock'],[],UNKNOWN,,2019-03-01,2019-06-30,"[{'measure': 'Reversal of shock in both groups', 'timeFrame': '72 hours'}]","[{'measure': 'Mortality in both groups', 'timeFrame': '28 days'}, {'measure': 'Duration of mechanical ventilation in both groups', 'timeFrame': '3 months'}, {'measure': 'Number of days in Intensive Care Unit stay in both groups', 'timeFrame': '3 months'}, {'measure': 'Reversal of Acute Kidney Injury', 'timeFrame': '5 days'}, {'measure': 'Lactate clearance in both groups', 'timeFrame': '1 day'}]",6,18 Years,,ALL,False,"Institute of Liver and Biliary Sciences, India",OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:13.415906,v2_robust,True,True,False,False,False,
NCT05233683,Caudal Block Versus Dorsal Penile Nerve Block Plus Ring Block for Pain Management of Different Surgical Techniques of Circumcision in Infants and Children,Caudal Block Versus Dorsal Penile Nerve Block Plus Ring Block for Pain Management of Different Surgical Techniques of Circumcision in Infants and Children,Caudal block,"['Caudal block', 'Dorsal penile nerve block plus ring block']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Anesthesia,"['Anesthesia', 'Anesthesia, Local', 'Analgesia', 'Pediatric ALL', 'Pain, Postoperative', 'Pain, Acute']",[],UNKNOWN,,2022-03,2023-03,"[{'measure': 'Efficacy of analgesia using FLACC Scale', 'description': 'Postoperatively in the PACU, the child will be observed in the recovery room by a senior nurse blinded to the anesthetic technique and the FLACC score will be used for pain assessment (copy attached). The FLACC scale is a uni-dimensional behavioral pain assessment instrument to measure pain in young children in the post-OP period. It includes five items (Face, Leg, Activity, Cry, and Consolability) and has good inter-rater reliability (Kappa 0.52-0.82), as well as good content and convergent validity. The scale is scored in a range of 0-10 with 0 = no pain and 10 = severe pain. The FLACC is reliable in critically ill young children. The severity of pain will be classified using the total score 0=no pain, and 10= severe pain. I.V fentanyl will be administered in the dose of 0.5 mic/kg if the pain score is \\>5 and the dose will be repeated if the FLACC score persisted \\>5 after five minutes.', 'timeFrame': 'First 12 hours after surgery/intervention (circumcision)'}, {'measure': 'Duration of analgesia', 'description': 'To compare the duration of post-OP analgesia produced by CB and DPNB plus RB in children undergoing circumcision with two different surgical techniques.', 'timeFrame': 'First 12 hours after surgery/intervention (circumcision)'}]","[{'measure': 'Number of participants that needed rescue analgesia', 'description': 'Number of participants that needed rescue analgesia in PACU and ward', 'timeFrame': 'first 12 hours after surgery (circumcision)'}, {'measure': 'Motor block score', 'description': 'Motor block score will be recorded (0=spontaneous movements of hips, knees and ankles, 1=movements of knees and ankles but no movements of hips, 2=only movements of ankles, and 3=no movements of lower limbs).', 'timeFrame': 'first 12 hours after surgery (circumcision)'}, {'measure': 'Blood pressure (mm/Hg)', 'description': 'Patients will receive fentanyl 0.5 mic/kg, if at any stage HR or BP increased 25% more than baseline value and the total dose of rescue analgesia received intra-operatively will be recorded.', 'timeFrame': 'during the surgery (from start time to end time of circumcision)'}, {'measure': 'Heart rate (beats/min)', 'description': 'Patients will receive fentanyl 0.5 mic/kg, if at any stage HR or BP increased 25% more than baseline value and the total dose of rescue analgesia received intra-operatively will be recorded.', 'timeFrame': 'during the surgery (from start time to end time of circumcision)'}, {'measure': 'Time to discharge from PACU', 'description': 'Amount of time the patient stays in PACU after the surgery. This will be a continuous variable (time).', 'timeFrame': 'First 12 hours after surgery (circumcision)'}, {'measure': 'Number of patients with infection', 'description': 'Number of patients experiencing infection at site of circumcision. It will be recorded as yes/no.', 'timeFrame': 'First 5 days after surgery (circumcision)'}, {'measure': 'Number of patients experiencing urinary retention', 'description': 'Measured as: no urine output after intervention.', 'timeFrame': 'First 12 hours after surgery (circumcision)'}, {'measure': 'Number of Participants with sedation', 'description': 'Sedation will be measured using the The Pasero Opioid-Induced Sedation Scale (POSS). POSS is a standardized approach to assessing opioid-induced sedation and instituting interventions. The POSS scores are S (""sleep, easy to arouse""), 1 (""awake and alert""), 2 (""slightly drowsy, easily aroused""), 3 (""frequently drowsy, arousable, drifts off to sleep during conversation""), and 4 (""somnolent, minimal, or no response to verbal or physical stimulation""). Scores of S, 1, or 2 are considered acceptable; the opioid dose may be increased if needed.', 'timeFrame': 'First 12 hours after surgery: assessed at 5, 15, and 30 minutes in PACU and hourly in the ward'}, {'measure': 'Number of Participants with nausea', 'description': 'Will be recorded as yes/no', 'timeFrame': 'First 12 hours after surgery: assessed at 5, 15, and 30 minutes in PACU and hourly in the ward'}, {'measure': 'Number of Participants with vomiting', 'description': 'Will be recorded as yes/no', 'timeFrame': 'First 12 hours after surgery: assessed at 5, 15, and 30 minutes in PACU and hourly in the ward'}, {'measure': 'Number of Participants with agitation', 'description': 'Will be recorded as yes/no', 'timeFrame': 'First 12 hours after surgery: assessed at 5, 15, and 30 minutes in PACU and hourly in the ward'}, {'measure': 'Number of Participants with penile hematoma', 'description': 'Will be recorded as yes/no', 'timeFrame': 'First 12 hours after surgery/intervention: assessed at 5, 15, and 30 minutes in PACU and hourly in the ward'}, {'measure': 'Total paracetamol doses administered', 'description': 'Amount of paracetamol required by the patient for pain control', 'timeFrame': 'first 5 days after surgery (circumcision)'}]",15,3 Months,4 Years,MALE,True,King Saud University,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:13.415942,v2_robust,True,True,False,False,False,
NCT05735483,A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis,"A Phase 3, Multicenter, Long-Term Extension Study to Assess the Safety and Efficacy of Lebrikizumab in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis",Lebrikizumab,"['LY3650150', 'Lebrikizumab', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Atopic Dermatitis,"['Atopic Dermatitis', 'Eczema']",[],ENROLLING_BY_INVITATION,,2023-03-09,2029-04,"[{'measure': 'Percentage of Participants Discontinued From Study Treatment due to Adverse Events (AEs)', 'timeFrame': 'Baseline through Week 52'}]","[{'measure': ""Percentage of Participants with an Investigator's Global Assessment (IGA) Score 0 or 1 and a Reduction ≥2 Points from Baseline of Study KGBI by Visit in Study KGBJ"", 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Percentage of Participants Achieving Eczema Area and Severity Index (EASI-75) (≥75% Reduction in EASI Score) from Baseline of Study KGBI by Visit in Study KGBJ', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Percentage of Participants Achieving EASI-90 (≥90% Reduction in EASI Score) from Baseline of Study KGBI by Visit in Study KGBJ', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Percentage of Participants with a Pruritus Numeric Rating Scale (NRS) of ≥4 points at Baseline of Study KGBI who Achieve a ≥4-point Reduction from Baseline of Study KGBI by Visit in Study KGBJ', 'timeFrame': 'Baseline to Week 52'}, {'measure': 'Percentage Change from Baseline of Study KGBI by Visit in Study KGBJ in Pruritus NRS Score', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Percentage Change from Baseline of Study KGBI by Visit in Study KGBJ in SCORing Atopic Dermatitis (SCORAD)', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Percentage Change from Baseline of Study KGBI by Visit in Study KGBJ in EASI', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change from Baseline of Study KGBI by Visit in Study KGBJ in EASI', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Change from Baseline of Study KGBI by Visit in Study KGBJ in Body Surface Area (BSA)', 'timeFrame': 'Baseline, Week 52'}]",10,6 Months,18 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,310.0,ESTIMATED,2025-09-01T16:18:13.416005,v2_robust,True,True,False,False,True,
NCT01601483,Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration,Phase II/III Study of the Efficacy and Safety of Macuclear MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration,MC-1101,"['MC-1101', 'MC-1101 Vehicle']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Nonexudative Age Related Macular Degeneration,['Nonexudative Age Related Macular Degeneration'],"['AMD', 'Dry AMD', 'Nonexudative AMD', 'MC-1101']",TERMINATED,Unmasked without Sponsor's prior knowledge or authorization by the PI.,2012-10,2013-03,"[{'measure': 'Visual Function', 'description': 'Primary efficacy assessment will be a comparison between groups of the change in visual function at 12 months with additional analyses at 18 and 24 months.', 'timeFrame': '12 months'}]","[{'measure': 'Safety and Tolerability (incidence and severity of adverse events, ocular irritability, ocular hyperemia)', 'description': 'Evaluate the safety and tolerability (incidence and severity of adverse events, ocular irritability,and ocular hyperemia) of MC-1101 compared to vehicle control at each study visit following treatment for 2 years', 'timeFrame': '24 months'}]",2,50 Years,85 Years,ALL,False,"MacuCLEAR, Inc.",INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:13.416020,v2_robust,True,True,False,True,True,Unmasked without Sponsor's prior knowledge or authorization by the PI.
NCT00219583,"Assessment Of Efficacy and Safety Of UK-390,957 In Men With Premature Ejaculation","A Phase 2b, Multi-Centre, Double-Blind, Placebo-Controlled, Parallel Group Dose Response Study To Assess The Efficacy and Safety Of Oral UK390,957 In Men With Premature Ejaculation","UK-390,957","['UK-390,957']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Ejaculation,['Ejaculation'],[],COMPLETED,,2004-08,2005-06,[{'measure': 'Assessment of efficacy and safety'}],[{'measure': 'Assessment of quality of sexual life'}],2,18 Years,,MALE,False,Pfizer,INDUSTRY,0,460.0,,2025-09-01T16:18:13.416122,v2_robust,True,True,True,False,True,
NCT01016483,Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer,Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects,Pimasertib,"['Gemcitabine', 'Pimasertib', 'MSC1936369B (MEK Inhibitor)', 'Placebo']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Pancreatic Adenocarcinoma,['Pancreatic Adenocarcinoma'],"['MEK inhibitor', 'cancer', 'pancreatic Adenocarcinoma', 'metastatic', 'chemo-naive', 'phase II']",COMPLETED,,2009-11-30,2015-04-30,"[{'measure': 'Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs)', 'description': 'DLT using the National Cancer Institute Common Terminology Criteria for Adverse Events(CTCAE) v3.0,was defined as any of the following toxicities at any dose level and judged to be possibly or probably related to trial medication by the Investigator and/or the Sponsor and relevant for the combination treatment: Grade 3/more non-hematological toxicity excluding: Subjects with liver involvement: Grade 4 asymptomatic increases in liver function tests and subject without liver involvement: Grade 3 asymptomatic increases in liver function tests reversible within 7 days. Grade 3 vomiting encountered despite adequate therapy. Grade 3 diarrhea encountered despite adequate anti diarrhea therapy. Grade 4 neutropenia greater (\\>) 5 days duration or febrile neutropenia lasting for more than 1 day. Grade 4 thrombocytopenia \\> 1 day/Grade 3 with bleeding. Grade 4 anemia: Any treatment delay \\> 2 weeks due to drug-related adverse effects.', 'timeFrame': 'Up to 28 days in Cycle 1'}, {'measure': 'Phase II: Progression-Free Survival (PFS) Time', 'description': 'PFS was defined as the time from randomization to the first documentation of objective tumor progression (Complete Response (CR): Disappearance of all target lesions, Partial Response (PR): At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline, Progressive Disease (PD): At least 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum of the longest diameter recorded since treatment started, or the appearance of 1 or more new lesions and stable disease: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started) or to death due to any cause, whichever occurred first. PFS calculated as (Months) = Date of first PD or death or censoring date minus date of randomization plus 1) divided by 30.4375.', 'timeFrame': 'From the time of randomization to every 8 weeks up to end of treatment (EOT) (6 years)'}]","[{'measure': 'Safety Run-In Part: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation', 'description': 'An adverse event (AE) was any untoward medical occurrence in a subjects who received study drug without regard to possibility of causal relationship. An serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.', 'timeFrame': 'From the first dose of study drug administration until EOT (6 years)'}, {'measure': ""Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) for Regimen 1"", 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': ""Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1"", 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': ""Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1"", 'description': 'Plasma decay half-life was the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': ""Safety Run-In Part: Area Under Curve (AUC: 0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 1"", 'description': 'AUC:0 to infinity was a measure of the serum concentration of the drug over time. It was used to characterize drug absorption.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine'}, {'measure': 'Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 1', 'description': 'Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) was influenced by the fraction of the dose absorbed.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 1', 'description': 'Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 1', 'description': 'Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 1', 'description': 'Apparent volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 1', 'description': 'ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.', 'timeFrame': 'pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1'}, {'measure': ""Safety Run-In Part: Maximum Concentration (Cmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2"", 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': ""Safety Run-In Part: Area Under Curve (AUC:0 to Infinity) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU) Regimen 2"", 'description': 'AUC:0 to infinity is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1 of Cycle 1 for MSC1936369B, 0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1 for Gemcitabine'}, {'measure': ""Safety Run-In Part: Time to Reach Maximum Concentration (Tmax) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2"", 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': ""Safety Run-In Part: Time to Reach Apparent Terminal Half-Life (t1/2) of Pimasertib (MSC1936369B), Gemcitabine (dFdC), and Gemcitabine Inactive Metabolite 2',2'-Difluorodeoxyuridine (dFdU): Regimen 2"", 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Apparent Oral Clearance (CL/f) of Pimasertib (MSC1936369B): Regimen 2', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Clearance obtained after oral dose (apparent oral clearance) is influenced by the fraction of the dose absorbed.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Total Clearance (CL) of Gemcitabine: Regimen 2', 'description': 'Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Apparent Volume of Distribution (V) of Gemcitabine: Regimen 2', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Oral Volume of Distribution (V/f) of Pimasertib (MSC1936369B): Regimen 2', 'description': 'Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.', 'timeFrame': '0 hour (pre-dose), 0.5, 1, 1.5, 2, 2.5, 4, 8, 12, 24 (post-dose) on Day 1, 22 of Cycle 1'}, {'measure': 'Safety Run-In Part: Levels of Pharmacodynamic (Pd) Markers (Phosphorylated- Extracellular Signal-Regulated Kinase (ERK) in Peripheral Blood Mononuclear Cells [PBMCs]): Regimen 2', 'description': 'ERK phosphoprotein in peripheral blood monocytes (PBMCs) was analyzed from blood samples of all subjects in the SAF analysis set (safety-run part) only.', 'timeFrame': 'pre-dose on Day 1, 2, 22 of Cycle 1; post-dose on Day 1, 22 of Cycle 1'}, {'measure': 'Phase II: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs Leading to Permanent Treatment Discontinuation', 'description': 'An AE was any untoward medical occurrence in a subject who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. All AEs (serious and non-serious) except AEs recorded with an onset date prior to the first day of drug administration unless a worsening of the event was recorded after the first dosing date, in which case the event was counted as a TEAE. TEAEs include both SAEs and non-SAEs.', 'timeFrame': 'From the first dose of study drug administration until EOT (6 years)'}, {'measure': 'Phase II: Percentage of Subjects With Best Overall Response (BOR)', 'description': 'Best overall response was defined as the presence of at least one complete response (CR), partial response (PR) or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.', 'timeFrame': 'Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)'}, {'measure': 'Phase II: Percentage of Subjects With Clinical Benefit', 'description': 'Clinical Benefit was defined as the presence of at least one CR, PR or Stable Disease (SD) (using RECIST v1.0) during treatment. CR: Disappearance of all target lesions, PR: At least 30% decrease in the sum of the longest diameter of target lesions, taking as reference the sum of the longest diameter at baseline and SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of the longest diameter since treatment started.', 'timeFrame': 'Baseline, every 8 weeks up to end of treatment (EOT i.e. 6 years)'}, {'measure': 'Phase II: Time to Progression (TTP)', 'description': 'Time to progression (TTP) is defined as the time (in months) from the randomization date to the date of progression prior to the start of any subsequent therapy for the primary disease, as reported and documented by the Investigator (i.e. radiological progression per RECIST).', 'timeFrame': 'From randomization every 8 weeks up to EOT (6 years)'}, {'measure': 'Phase II: Overall Survival (OS) Time', 'description': 'Overall survival (OS) time is defined as the time (in months) from randomization to death.', 'timeFrame': 'Baseline, every 8 weeks up to EOT (6 years)'}, {'measure': 'Phase II: Absorption Rate Constant (ka) of Pimasertib (MSC1936369B)', 'timeFrame': 'Baseline, every 8 weeks up to EOT (6 years)'}, {'measure': 'Phase II: Clearance From Central Compartment (CL/f) and Intercompartmental Clearance (Q/f) of Pimasertib (MSC1936369B)', 'timeFrame': 'Baseline, every 8 weeks up to EOT (6 years)'}, {'measure': 'Phase II: Volume of Central Compartment (V1/f) and Volume of Peripheral Compartment (V2/f) of Pimasertib (MSC1936369B)', 'timeFrame': 'Baseline, every 8 weeks up to EOT (6 years)'}]",29,18 Years,,ALL,False,EMD Serono,INDUSTRY,1,141.0,ACTUAL,2025-09-01T16:18:13.416137,v2_robust,True,True,True,False,True,
NCT02780141,A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With Anemia,"A Phase 3, Multi-center, Randomized, 2-arm, Open-label Study of Intermittent Oral Dosing of ASP1517 in Erythropoiesis Stimulating Agent-naive Hemodialysis Chronic Kidney Disease Patients With Anemia",roxadustat,"['ASP1517', 'roxadustat']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia,['ESA-naive Hemodialysis Chronic Kidney Disease Patients With Anemia'],"['Renal anemia', 'Roxadustat', 'ASP1517', 'Hemodialysis']",COMPLETED,,2016-06-02,2017-12-12,"[{'measure': 'Hemoglobin (Hb) Response rate', 'description': 'Hb response is defined as reaching target values for Hb and change of Hb from baseline', 'timeFrame': 'Up to Week 24'}]","[{'measure': 'Average Hb level from Week 18 to 24', 'timeFrame': 'Week 18 to 24'}, {'measure': 'Change from baseline in the average Hb level from Week 18 to 24', 'timeFrame': 'Baseline and Weeks 18 to 24'}, {'measure': 'Proportion of participants with the target Hb level from Week 18 to 24', 'timeFrame': 'Week 18 to 24'}, {'measure': 'Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment', 'timeFrame': 'Up to Week 4'}, {'measure': 'Proportion of measurement points with the target Hb level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Proportion of participants with the target Hb level at each week', 'timeFrame': 'Up to Week 24'}, {'measure': 'Proportion of participants with the lower limit of the target Hb level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Time to achieve the lower limit of the target Hb level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Change from baseline in Hb levels to each week', 'timeFrame': 'Baseline and Up to Week 24'}, {'measure': 'Average hematocrit level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average reticulocyte level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average iron (Fe) level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average ferritin level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average transferrin level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average total iron binding capacity level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average soluble transferrin receptor level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average transferrin saturation level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Average reticulocyte hemoglobin content level', 'timeFrame': 'Up to Week 24'}, {'measure': 'Quality of life assessed by EQ-5D-5L', 'description': 'EQ-5D-5L: EuroQol 5 Dimension 5 Levels', 'timeFrame': 'Up to Week 24'}, {'measure': 'Quality of life assessed by FACT-An', 'description': 'FACT-An: Functional Assessment of Cancer Therapy-Anemia', 'timeFrame': 'Up to Week 24'}, {'measure': 'Number of hospitalizations', 'timeFrame': 'Up to Week 24'}, {'measure': 'Duration of hospitalizations', 'timeFrame': 'Up to Week 24'}, {'measure': 'Safety assessed by incidence of adverse events', 'timeFrame': 'Up to Week 24'}, {'measure': 'Number of participants with abnormal Laboratory values and/or adverse events related to treatment', 'timeFrame': 'Up to Week 24'}, {'measure': 'Number of participants with abnormal Vital signs and/or adverse events related to treatment', 'timeFrame': 'Up to Week 24'}, {'measure': 'Safety assessed by standard 12-lead electrocardiogram', 'timeFrame': 'Up to Week 24'}, {'measure': 'Plasma concentration of unchanged ASP1517', 'timeFrame': 'Up to Week 24'}]",28,20 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,1,75.0,ACTUAL,2025-09-01T16:18:13.416204,v2_robust,True,True,True,False,True,
NCT00434941,Capecitabine Plus Radiotherapy for Local Relapse Breast Cancer With Negative Her2 Tumours,"Multicenter Phase IV.II Trial, for the Administration of Capecitabine Simultaneous to Radiotherapy for Local Relapse Breast Cancer Patients With Negative Her2 Tumours",Capecitabine,"['Xeloda', 'Capecitabine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['Administration of capecitabine concomitant to radiotherapy', 'Her2: negative']",TERMINATED,Due to the slow rate of recruitment the study was stopped.,2007-09,2009-01,"[{'measure': 'Complete clinical response rate', 'description': 'The disease evaluation will be measured by RECIST criteria in the 28 days after the end of the radiotherapy by Magnetic resonance imaging (MRI).', 'timeFrame': '28 days after the end of the radiotherapy'}]","[{'measure': 'Evaluation of the concomitant administration of capecitabine and radiotherapy as the first treatment', 'description': 'Safety will be assessed by standard clinical and laboratory tests. Adverse events grade will be defined by the National Cancer Institute Common Terminology Criteria for Adverse (NCI-CTCAE).', 'timeFrame': '28 days after the end of the radiotherapy'}]",2,18 Years,70 Years,FEMALE,False,Spanish Breast Cancer Research Group,OTHER,1,1.0,ACTUAL,2025-09-01T16:18:13.416268,v2_robust,True,True,False,True,True,Due to the slow rate of recruitment the study was stopped.
NCT04042441,"A Research Study, Looking at How Ryzodeg® (Insulin Degludec/Insulin Aspart) Works in People With Type 2 Diabetes in Local Clinical Practice",A Multi-centre Prospective Non-interventional Study Investigating the Clinical Effectiveness of Ryzodeg® (Insulin Degludec/Insulin Aspart) in Patients With Type 2 Diabetes Mellitus in a Real-world Setting,Insulin Degludec/Insulin Aspart,['Insulin Degludec/Insulin Aspart'],1,OBSERVATIONAL,[],,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2019-07-29,2020-12-11,"[{'measure': 'Change in local laboratory measured glycosylated haemoglobin (HbA1c)', 'description': 'Percentage point', 'timeFrame': 'From baseline (week 0) to end of study (week 26-36)'}]","[{'measure': 'HbA1c less than 7% (Yes/No)', 'description': 'Percentage of patients', 'timeFrame': 'At the end of study (week 26-36)'}, {'measure': 'HbA1c less than pre-defined individual treatment target (Yes/No)', 'description': 'Percentage of patients', 'timeFrame': 'At the end of study (week 26-36)'}, {'measure': 'Change in local laboratory measured fasting plasma glucose (FPG)', 'description': 'mg/dL', 'timeFrame': 'From baseline (week 0) to end of study (week 26-36)'}, {'measure': 'Change in local laboratory measured FPG', 'description': 'mmol/L', 'timeFrame': 'From baseline (week 0) to end of study (week 26-36)'}, {'measure': 'Change in insulin dose (total, basal, prandial)', 'description': 'units/day', 'timeFrame': 'From baseline (week 0) to end of study (week 26-36)'}, {'measure': 'Change in body weight', 'description': 'Kg', 'timeFrame': 'From baseline (week 0) to end of study (week 26-36)'}, {'measure': 'Number of patient recollection of non-severe hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'At baseline (week 0). Episodes occurring within 4 weeks prior to initiation of treatment with Ryzodeg®'}, {'measure': 'Number of patient recollection of non-severe hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'At the end of study (week 26-36). Episodes occurring within 4 weeks prior to end of study'}, {'measure': 'Number of patient recollection of nocturnal non-severe hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'At baseline (week 0). Episodes occurring within 4 weeks prior to initiation of treatment with Ryzodeg®'}, {'measure': 'Number of patient recollection of nocturnal non-severe hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'At end of study (week 26-36). Episodes occurring within 4 weeks prior to end of study'}, {'measure': 'Number of patient recollection of overall severe hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'At baseline (week 0). Episodes occurring within 26 weeks prior to initiation of treatment with Ryzodeg®'}, {'measure': 'Number of patient recollection of overall severe hypoglycaemic episodes', 'description': 'Number of episodes', 'timeFrame': 'At the end of study (week 26-36). Episodes occurring within 26 weeks prior to end of study'}, {'measure': 'Number of weekly self-measured plasma glucose (SMPG) measurements', 'description': 'Number of measurements', 'timeFrame': 'At baseline (week 0). Measurements occurring within 7 days prior to initiation of treatment with Ryzodeg®'}, {'measure': 'Number of weekly self-measured plasma glucose (SMPG) measurements', 'description': 'Number of measurements', 'timeFrame': 'At end of study (week 26-36). Measurements occurring within 7 days prior to end of study'}, {'measure': 'Reason for initiating Ryzodeg® (pre-specified response option(s))', 'description': 'Percentage of patients per response option', 'timeFrame': 'At baseline (week 0)'}, {'measure': 'Discontinue treatment with Ryzodeg® during the treatment period (Yes/No)', 'description': 'Percentage of patients', 'timeFrame': 'At treatment discontinuation (week 0-36) or at end of study (week 26-36). After initiation of treatment with Ryzodeg® until treatment discontinuation'}, {'measure': 'Reason for discontinuing treatment with Ryzodeg® during the treatment period, if applicable, (pre-specified response option(s))', 'description': 'Percentage of patients per response option', 'timeFrame': 'At treatment discontinuation (week 0-36). After initiation of treatment with Ryzodeg® until treatment discontinuation'}, {'measure': 'Time period from initiation to discontinuation of treatment with Ryzodeg®', 'description': 'Days', 'timeFrame': 'At treatment discontinuation (week 0-36). After initiation of treatment with Ryzodeg® until treatment discontinuation'}]",19,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,1122.0,ACTUAL,2025-09-01T16:18:13.416278,v2_robust,False,True,True,False,False,
NCT04224441,Repurposing Chlorpromazine in the Treatment of Glioblastoma,Repurposing the Antipsychotic Drug Chlorpromazine as a Therapeutic Agent in the Combined Treatment of Newly Diagnosed Glioblastoma Multiforme,Chlorpromazine Pill,"['Temozolomide', 'Chlorpromazine Pill']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Glioblastoma Multiforme,"['Glioblastoma Multiforme', 'MGMT-Unmethylated Glioblastoma']","['drug repurposing', 'antipsychotic drugs', 'glioblastoma']",UNKNOWN,,2019-12-15,2022-12-15,"[{'measure': 'Evaluation of toxicity', 'description': 'Toxicity evaluation of the combined treatment. Subjects will be evaluated for symptoms and adverse effects according to the NCI-CTCAE version 5.0 grading tool', 'timeFrame': '6 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Effect of of adding CPZ to the standard GBM therapy, when compared with the standard therapy alone', 'timeFrame': '6 months'}]","[{'measure': 'Evaluation of tumor response', 'description': 'Effect of of adding CPZ to the standard glioblastoma multiforme (GBM) therapy, when compared with the standard therapy alone', 'timeFrame': '6 months'}, {'measure': 'Overall survival (OS)', 'description': 'Effect of of adding CPZ to the standard glioblastoma multiforme (GBM) therapy, when compared with the standard therapy alone', 'timeFrame': '6 months'}]",4,18 Years,70 Years,ALL,False,"Marco G Paggi, MD, PhD",OTHER,3,41.0,ESTIMATED,2025-09-01T16:18:13.416340,v2_robust,True,True,False,False,True,
NCT04644354,The Efficacy of Nifedipine in the Management of Preterm Labor,The Tocolytic Efficacy of Nifedipine in the Management of Threatened and Advanced Preterm Labor: A Study on 444 Singleton Pregnant Women With Intact Membranes,Nifedipine 10 mg,['Nifedipine 10 mg'],1,OBSERVATIONAL,[],,,Preterm Labor,"['Preterm Labor', 'Preterm Birth', 'Preterm Labor Without Delivery', 'Preterm Labor With Preterm Delivery in Third Trimester', 'Calcium-Channel Blockers Toxicity', 'Side Effect of Drug']","['Nifedipine', 'Tocolytics']",UNKNOWN,,2020-12-15,2020-12-30,"[{'measure': 'Delay Delivery for 1 day', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is only 24 hours', 'timeFrame': '1 day'}, {'measure': 'Delay Delivery for 2 days', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is 48 hours', 'timeFrame': '2 days'}, {'measure': 'Delay Delivery for 3 days', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is 72 hours', 'timeFrame': '3 days'}, {'measure': 'Delay Delivery for 7 days', 'description': 'After start of tocolytic nifedipine, the delay recorded till delivery is 168 hours', 'timeFrame': '7 days'}, {'measure': 'Birth before 34 weeks', 'description': 'After start of tocolytic nifedipine, the preterm birth occurs before 34 weeks', 'timeFrame': 'till 34 weeks of gestation'}, {'measure': 'Birth before 37 weeks', 'description': 'After start of tocolytic nifedipine, the preterm birth occurs before 37 weeks', 'timeFrame': 'till 37 weeks of gestation'}, {'measure': 'Birth after 37weeks', 'description': 'After start of tocolytic nifedipine, the preterm birth occurs after 37 weeks (Normal birth)', 'timeFrame': 'after 37 weeks of gestation-normal birth'}]",[],7,,,FEMALE,False,"Ethem Unal, M.D., PhD, Associate Prof of Surgery & Surgic",OTHER_GOV,0,444.0,ESTIMATED,2025-09-01T16:18:13.416468,v2_robust,False,True,False,False,False,
NCT03318354,Bioequivalence Study of Torrent Pharmaceuticals Ltd.'s Olmesartan Medoxomil Tablet Under Fasting Conditions,"An Open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose BE of Olmesartan Medoxomil Tablets 40 mg [Torrent,India] Versus Benicar 40 mg Tablets [Daiichi Sankyo Inc., USA] in Healthy Subjects-Fasted Condition",Torrent's Olmesartan Medoxomil Tablets 40 mg,"[""Daiichi Sankyo Inc's Benicar Tablets 40 mg"", ""Torrent's Olmesartan Medoxomil Tablets 40 mg""]",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],[],COMPLETED,,2010-05,2010-07,"[{'measure': 'Cmax', 'timeFrame': 'Pre dose to 72 hours post dose.'}, {'measure': 'AUC', 'timeFrame': 'Pre dose to 72 hours post dose.'}]",[],2,18 Years,45 Years,MALE,True,Torrent Pharmaceuticals Limited,INDUSTRY,0,34.0,ACTUAL,2025-09-01T16:18:13.416505,v2_robust,True,True,True,False,False,
NCT02278354,Tau Imaging in Professional Fighters,18F-AV-1451 PET Imaging in Professional Fighters,Flortaucipir F18,"['[F-18]T807', 'LY3191748', 'Flortaucipir F18', '18F-AV-1451', 'Tauvid']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Alzheimer's Disease,"[""Alzheimer's Disease""]",[],COMPLETED,,2015-02-18,2017-02-03,"[{'measure': 'Flortaucipir Imaging (Quantitative) Between Cognitive Groups', 'description': 'Standard Uptake Value Ratio (SUVr) by subject enrollment group (cognitive impaired/normal) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.', 'timeFrame': 'baseline scan'}, {'measure': 'Flortaucipir Imaging (Quantitative) Between Fighter Groups', 'description': 'Standard Uptake Value Ratio (SUVr) by subject enrollment group (active fighter/retired fighter) across weighted cortical average, frontal, temporal, parietal, and occipital brain regions. For SUVr, a value of 1 or lower signifies no flortaucipir activity above background, values greater than 1 signify increasing flortaucipir activity in the brain.', 'timeFrame': 'baseline scan'}, {'measure': 'Flortaucipir Imaging (Qualitative) Between Cognitive Groups', 'description': 'Qualitative read results (no, mild, moderate, or intense uptake) compared between cognitively impaired (CI) and cognitively normal (CN) groups.', 'timeFrame': 'baseline scan'}, {'measure': 'Flortaucipir Imaging (Qualitative) Between Fighter Groups', 'description': 'Qualitative read results (no, mild, moderate, or intense uptake) compared between active and retired fighter groups', 'timeFrame': 'baseline scan'}]",[],4,18 Years,,MALE,False,Avid Radiopharmaceuticals,INDUSTRY,1,35.0,ACTUAL,2025-09-01T16:18:13.416526,v2_robust,True,True,True,False,False,
NCT01251354,Study of BN83495 in Post-menopausal Women With Endometrial Cancer Post-chemotherapy,"A Phase II, International, Multicenter, Open-label, Proof of Concept Study of BN83495 in Postmenopausal Women With Advanced, Metastatic or Recurrent Oestrogen Receptor (ER) Positive Endometrial Carcinoma Who Have Received One Line of Chemotherapy in the Adjuvant or Metastatic Setting.",BN83495,['BN83495'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Endometrial Cancer,['Endometrial Cancer'],[],TERMINATED,The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.,2010-11,2011-07,"[{'measure': 'Determination of Clinical Benefit (CB), Defined as Sum of Patients Who Present Complete Response (CR), Partial Response (PR) or Stable Disease (SD) ≥12 Weeks (CB=CR+PR+SD≥12 Weeks) Using Response Evaluation Criteria in Solid Tumors (RECIST Version1.1)', 'description': 'CR defined as: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm.\n\nPR defined as: At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.\n\nSD defined as: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease (PD), taking as reference the smallest sum diameters while on study.\n\nPD defined as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).', 'timeFrame': '12 weeks'}]","[{'measure': 'Number of Participants With Adverse Events', 'timeFrame': 'Up to 28 days after last dose'}, {'measure': 'Determination of Time to Progression (TTP) in This Patient Population', 'description': 'Time to Progression (TTP): Time from first study treatment to first documentation of objective tumour progression.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Progression Free Survival (PFS) in This Patient Population', 'description': 'Progression Free Survival (PFS): Time from first study treatment until objective tumour progression or death from any cause.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Overall Response Rate (ORR) in This Patient Population', 'description': 'Overall Response Rate (ORR): Defined as the sum of CR and PR.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Duration of Response in This Patient Population', 'description': 'Duration of Response (DR): Time from the first documentation of objective tumour response (defined as CR or PR) to the first documentation of objective tumour progression or death on study due to any cause.', 'timeFrame': 'After the last enrolled patient has been followed for at least 6 months or has progressed or died'}, {'measure': 'Determination of Overall Survival in This Patient Population', 'description': 'Overall Survival (OS): Defined as the time from first study treatment to death due to any cause.', 'timeFrame': '2 years after the last patient enrolled'}]",7,18 Years,,FEMALE,False,Ipsen,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:13.416616,v2_robust,True,True,False,True,True,The futility analysis of study NCT00910091 in patients with endometrial cancer shows that the primary endpoint will not be reached.
NCT00541554,"Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia","Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial",Abilify (aripiprazole),['Abilify (aripiprazole)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Hyperprolactinemia,"['Hyperprolactinemia', 'Weight Gain', 'Dyslipidemia']",[],UNKNOWN,,2007-10,2009-02,[],[],0,12 Years,65 Years,ALL,False,"Genovate Biotechnology Co., Ltd.,",INDUSTRY,0,,,2025-09-01T16:18:13.416689,v2_robust,True,True,False,False,False,
NCT05506605,Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance,"Open-label, Single-arm, Unicenter and Pilot Study of a Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance",Doravirine 100Mg Tab,['Doravirine 100Mg Tab'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV-1-infection,['HIV-1-infection'],"['HIV', 'Doravirine', 'Etravirine']",ACTIVE_NOT_RECRUITING,,2022-12-12,2024-12,"[{'measure': 'Percentage of participants with confirmed HIV viral load>50 copies/mL', 'description': 'Measured by blood HIV viral load', 'timeFrame': 'at week 24'}]","[{'measure': 'Percentage of participants with HIV viral load>50 copies/mL', 'description': 'Measured by blood HIV viral load', 'timeFrame': 'at week 12 and 48'}, {'measure': 'Percentage of participants with HIV viral load<50 copies/mL', 'description': 'Measured by blood HIV viral load', 'timeFrame': 'at week 12, 24 and 48'}, {'measure': 'Changes in CD4, CD8 cell counts and ratio CD4/CD8', 'description': 'Measured by blood CD4, CD8 and CD/4/CD8 ratio', 'timeFrame': 'at 48 weeks'}, {'measure': 'Incidence of Treatment-Emergent adverse events and serious adverse events', 'description': 'Measured by numer of AEs and SAEs related to the treatment', 'timeFrame': 'at week 48'}, {'measure': 'AUC during the dose interval (AUC0-24) of DRV/r and DRV/c with DOR', 'timeFrame': 'at weeks 2 and 4'}, {'measure': 'Maximum concentrations (Cmax) of DRV/r and DRV/c with DOR', 'timeFrame': 'at weeks 2 and 4'}, {'measure': 'Concentrations at the end of the dosing interval (C24) of DRV/r and DRV/c with DOR', 'timeFrame': 'at weeks 2 and 4'}, {'measure': 'Elimination half-life (t1/2) of DRV/r and DRV/c with DOR', 'timeFrame': 'at weeks 2 and 4'}]",9,18 Years,,ALL,False,Fundacion Clinic per a la Recerca Biomédica,OTHER,0,12.0,ACTUAL,2025-09-01T16:18:13.416800,v2_robust,True,True,False,False,True,
NCT06304805,TGRX-326 Pharmacokinetic Food Effect Bioavailability Study,"A Randomized, Open-label, Single-dose, 3-cycle, 6-sequence, Crossover Study Evaluating Food Effect on Pharmacokinetic Profiles of TGRX-326 in Chinese Healthy Subjects and Effect of Drug Specification on Bioavailability in Human",cycle 1: treatment drug,"['cycle 1: reference drug', 'cycle 2: treatment drug', 'cycle 1: treatment drug', 'cycle 3: treatment drug', 'cycle 2: reference drug', 'cycle 3: reference drug']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],[],COMPLETED,,2023-12-13,2024-01-19,"[{'measure': 'Plasma Cmax', 'description': 'Maximum concentration of TGRX-326 measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma AUC(0-t)', 'description': 'Area Under drug concentration-time curve (AUC) from time 0 to last measureable timepoint for TGRX-326 as measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma AUC(0-inf)', 'description': 'Area Under drug concentration-time curve from time 0 to infinity for TGRX-326 as measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}]","[{'measure': 'Plasma Tmax', 'description': 'Time to maximum concentration of TGRX-326 measured in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'terminal elimination rate constant (lambda-z)', 'description': 'terminal elimination rate constant calculated from plasma TGRX-326 concentrations', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Elimination half-life (T1/2-Z)', 'description': 'Time for TGRX-326 to decrease from maximum plasma concentration to half of maximum plasma concentration', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'AUC(%Extrap)', 'description': 'Calculated percentage of Area under curve for AUC(0-inf) that is from last measurable timepoint ot infinity, calculated based on TGRX-326 plasma concentration over time curve.', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma volume of distribution (Vz/F)', 'description': 'Apparent volume of distribution of TGRX-326 in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Plasma clearance (CL/F)', 'description': 'Apparent clearance of TGRX-326 in plasma', 'timeFrame': 'During treatment period on Day 1 of each of three cycles (each cycle is one day, and there is a 10-day washout period between two cycles)'}, {'measure': 'Adverse events/serious adverse events', 'description': 'to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'through completion of the study, a total duration of 37 days'}]",10,18 Years,55 Years,ALL,True,"Shenzhen TargetRx, Inc.",INDUSTRY,1,24.0,ACTUAL,2025-09-01T16:18:13.416816,v2_robust,True,True,True,False,True,
NCT00000705,Safety and Effectiveness of Azidothymidine (AZT) in HIV-Positive Patients With Hemophilia,A Phase I Trial to Evaluate Azidothymidine (AZT) in the Treatment of HIV Infections in Patients With Hemophilia,Zidovudine,['Zidovudine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,HIV Infections,"['HIV Infections', 'Hemophilia A']","['Drug Evaluation', 'Zidovudine', 'Hemophilia A']",COMPLETED,,,1989-03,[],[],0,12 Years,,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,24.0,,2025-09-01T16:18:13.416844,v2_robust,True,True,True,False,False,
NCT06320405,Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors,A Phase Ib/II Study of Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced Solid Tumors,Paclitaxel,"['Anzatax', 'Paclitaxel', 'Asotax', 'Taxol Konzentrat', 'Taxol', 'Praxel', 'Bristaxol']",7,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Advanced Malignant Solid Neoplasm,"['Advanced Malignant Solid Neoplasm', 'Metastatic Malignant Solid Neoplasm', 'Recurrent Malignant Solid Neoplasm', 'Refractory Malignant Solid Neoplasm']",[],RECRUITING,,2024-05-21,2029-04-01,"[{'measure': 'Incidence of dose limiting toxicities (phase Ib)', 'description': 'Will be coded by system organ class, MedDRA preferred term, and severity grade using Common Terminology Criteria for Adverse Events (version 5.0).', 'timeFrame': 'From the first dose of axatilimab (day -8) to the end of cycle 1 (cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'}, {'measure': 'Recommended phase 2 dose of the study drug combination (phase Ib)', 'timeFrame': 'From the first dose of axatilimab (day -8) to the end of cycle 1 (cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'}, {'measure': 'Clinical benefit rate (phase Ib/II)', 'description': 'Defined as percentage of participants with complete response or partial response confirmed by scans at least 4 weeks apart, or stable disease for \\> 4 months. Will be reported with exact 95% confidence interval.', 'timeFrame': 'From screening assessment to the end of cycle 6 assessment (each cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'}]","[{'measure': 'Incidence of ≥ grade 3 toxicities possibly or definitely related to study drugs', 'description': 'Will be categorized and tabulated for reporting. The analyses for reporting may include descriptive statistical analyses of the overall set of phase II adverse events.', 'timeFrame': 'From the first dose of axatilimab (day -8) to 90 days after the end of treatment visit (an average of 6 months)'}, {'measure': 'Changes in immune cell composition and functionality', 'description': 'Will be characterized in peripheral blood using flow cytometry (FC) and candidate protein biomarkers will be identified in tumor tissue using multiplexed immunohistochemistry. Changes in immune cell composition and functionality at the biopsy during cycle 2 will be assessed by paired t-test.', 'timeFrame': 'From screening until cycle 2 day 1 biopsy (each cycle is 28 days starting from cycle 1 day 1 [first dose of retifanlimab and paclitaxel])'}, {'measure': 'Change in immune cell population', 'description': 'To assess predictive biomarkers of response in peripheral blood, changes in immune cell populations in peripheral blood, including reduced presence of CD14dimCD16+ monocytes and increased presence of CD8+ T effector memory subsets, at the end of the study between responders and non-responders will be assessed using repeated measures of analysis of covariance over time to accommodate a longitudinal nature of peripheral blood draws for flow cytometry.', 'timeFrame': 'From screening to end of treatment visit (an average of 6 months)'}]",6,18 Years,,ALL,False,OHSU Knight Cancer Institute,OTHER,2,38.0,ESTIMATED,2025-09-01T16:18:13.416852,v2_robust,True,True,False,False,True,
NCT00506805,Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies,"A Phase 1, Open-label, Dose-escalation Study Of The Safety And Pharmacokinetics Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies Or Non-Hodgkin's Lymphoma",SNX-5422,['SNX-5422'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],['solid tumor malignancy; Hsp90'],COMPLETED,,2007-06,2010-03,"[{'measure': 'adverse events and other safety assessments', 'timeFrame': 'continuous'}]","[{'measure': 'tumor response measured by X-rays or scans', 'timeFrame': 'after every 2 cycles'}]",2,18 Years,,ALL,False,Esanex Inc.,INDUSTRY,2,44.0,ACTUAL,2025-09-01T16:18:13.416911,v2_robust,True,True,True,False,True,
NCT03713294,"Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma",Phase II Trial of Sequential Treatment of Multiple Myeloma With Antibody Therapy,Dexamethasone,"['TaperDex', 'Dexa-sine', 'Alin', 'Deronil', 'Desameton', 'Dexameth', 'Dexa-Rhinosan', 'Fluorodelta', 'ZoDex', 'Dinormon', 'Dexacortin', 'Dexinoral', 'Hexadrol', 'Mymethasone', 'Dexalocal', 'Cortidexason', 'Dexafluorene', 'Baycadron', 'Lokalison-F', 'Millicorten', 'Auxiloson', 'Methylfluorprednisolone', 'Desamethasone', 'Alin Depot', 'Aknichthol Dexa', 'Dexamethasone Intensol', 'Hexadecadrol', 'Pomalidomide', '4-Aminothalidomide', 'Orgadrone', 'Decacort', 'Dexa-Scheroson', 'Decalix', 'Dexapos', 'Pomalyst', 'Baycuten N', 'Gammacorten', 'CC-4047', 'Auricularum', 'Decadron', 'Dexafarma', 'Dexamecortin', 'Dexone', 'Visumetazone', 'Baycuten', 'Dxevo', 'Anemul mono', 'Dexa-Mamallet', 'Fortecortin', 'Actimid', 'Imnovid', 'Cortisumman', 'Alin Oftalmico', 'Aacidexam', 'Dexamethasone', 'Hemady', 'Alba-Dex', 'Decadrol', 'Decasone R.p.', 'Amplidermis', 'Spersadex', 'Dexacortal', 'Dectancyl', 'Loverine', 'Dexamethasonum', 'Decadron DP', 'Dexamonozon', 'Dekacort', 'Decameth', 'Deltafluorene', 'Adexone']",71,INTERVENTIONAL,['PHASE2'],PHASE2,,Refractory Plasma Cell Myeloma,['Refractory Plasma Cell Myeloma'],[],COMPLETED,,2019-01-14,2024-11-14,"[{'measure': 'Overall Response Rate', 'description': 'Overall response rate (ORR) defined as a partial response (PR), very good partial response (VGPR), complete response (CR) or stringent CR (sCR). CR and sCR are defined in Outcome 2. VGPR requires: serum and urine M-protein detectable by immunofixation but not on electrophoresis OR \\>= 90% reduction in serum M-protein and urine M-protein \\<100 mg/24 h. If the only measurable disease is FLC, a \\>90% reduction in the difference between involved and uninvolved FLC levels. PR requires: if present at baseline, \\>= 50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \\>= 90% or to \\<200 mg/24hrs. If the only measurable disease is FLC, a ≥50% reduction in the difference between involved and uninvolved FLC levels. If the only measurable disease is BM, a ≥ 50% reduction in BM PCs (provided the baseline PCs was ≥ 30%). If present at baseline, ≥ 50% reduction in the size (SPD) of soft tissue plasmacytomas.', 'timeFrame': '3 years'}]","[{'measure': 'Percentage of Patients Achieving CR', 'description': 'Will be estimated by the number of patients who achieve a sCR or CR divided by the total number of evaluable patients. Complete Response (CR) is defined by all of the following: negative immunofixation of serum and urine; disappearance of any soft tissue plasmacytoma; \\<5% PCs in bone marrow; and if the only measurable disease is Free Light Chain (FLC), a normal FLC ratio. Stringent Complete Response (sCR) is defined as CR plus normal FLC ratio and absence of clonal circulating plasma cells (PCs) immunohistochemistry or 2- to 4- color flow cytometry.', 'timeFrame': '3 years'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'PFS is defined as the time from registration to time of disease progression or death due to any cause.', 'timeFrame': '3 years'}, {'measure': 'Count of Patients That Experienced a Grade 3 or Greater Adverse Events', 'description': 'The maximum grade for each type of adverse event will be recorded for each patient, and frequency tables will be reviewed to determine patterns. The table of these events is located in the adverse events section of this report.', 'timeFrame': '37 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from registration to death due to any cause.', 'timeFrame': '62 months'}]",5,18 Years,,ALL,False,Mayo Clinic,OTHER,0,37.0,ACTUAL,2025-09-01T16:18:13.416953,v2_robust,True,True,True,False,True,
NCT02192294,Absolute Bioavailability Of Bosutinib,"An Open-label, Randomized, 2-period Crossover Study To Evaluate Absolute Bioavailability Of Bosutinib In Healthy Subjects",Oral Bosutinib,"['Oral Bosutinib', 'Intravenous infusion of bosutinib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bosutinib', 'absolute bioavailability']",COMPLETED,,2014-08,2014-10,"[{'measure': 'Area under the Concentration-Time Curve (AUC)', 'description': 'AUC is a measure of the serum concentration of the drug over time. It is used to characterize drug absorption.', 'timeFrame': '96 hours'}]","[{'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Maximum Observed Plasma Concentration', 'timeFrame': '96 hours'}, {'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)', 'timeFrame': '96 hours'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax)', 'description': 'Time to Reach Maximum Observed Plasma Concentration', 'timeFrame': '96 hours'}, {'measure': 'Plasma Decay Half-Life (t1/2)', 'description': 'Plasma decay half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '96 hours'}, {'measure': 'Systemic Clearance (CL)', 'description': 'CL is a quantitative measure of the rate at which a drug substance is removed from the body.', 'timeFrame': '96 hours'}, {'measure': 'Volume of Distribution at Steady State (Vss)', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.', 'timeFrame': '96 hours'}]",7,18 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:13.416992,v2_robust,True,True,True,False,False,
NCT00822094,Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML),"Phase IIB, Multicenter, Randomized, Open-Label Trial Of CPX-351 (Cytarabine : Daunorubicin) Liposome Injection Versus Intensive Salvage Therapy In Adult Patients ≤ 65 Years Old With AML In First Relapse Following An Initial CR > 1 Month Duration",CPX-351,"['CPX-351', 'Intensive Salvage Therapy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['Acute', 'Myeloid', 'Leukemia', 'Adult', 'First', 'Relapse', 'AML', 'Acute Myelogenous leukemia', 'Leukemia, Myeloid', 'Leukemia, Myeloid, Acute', 'Acute myelocytic leukemia']",COMPLETED,,2009-02,2012-01,"[{'measure': 'Proportion of Subjects Surviving at 1 Year', 'description': 'The proportion of subjects surviving at 1 year was evaluated separately for each arm by the number of subjects alive at 1 year divided by the total number of subjects.', 'timeFrame': 'Up to 1 year from randomization'}]","[{'measure': 'Complete Remission Rate', 'timeFrame': 'Following 1st induction, following 2nd induction if applicable'}, {'measure': 'Event Free Survival', 'description': 'Progression EFS median', 'timeFrame': 'Up to 1 year from randomization'}, {'measure': 'Remission Duration', 'description': 'Remission duration was measured from the time the criteria for CR were first met until the first date that disease relapse was objectively documented or until subject death.', 'timeFrame': 'Following achievement of CR and up to 1 year from randomization'}, {'measure': 'Rate of Aplasia', 'description': 'Patients with Aplasia During Study', 'timeFrame': 'Up to 1 year from randomization'}, {'measure': 'Rate of Stem Cell Transplant', 'description': 'Number of patients transferred for stem cell transplant', 'timeFrame': 'Up to 1 year from randomization'}]",6,18 Years,65 Years,ALL,False,Jazz Pharmaceuticals,INDUSTRY,1,126.0,ACTUAL,2025-09-01T16:18:13.417031,v2_robust,True,True,True,False,False,
NCT02583594,A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis,"A Phase 1, Exploratory, Randomized, Open-label, 2-Arm Study to Characterize the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Alemtuzumab 12mg Administered Subcutaneously or Intravenously in Patients With Progressive Multiple Sclerosis",Acyclovir,"['Loratadine', 'Paracetamol', 'Dexchlorpheniramine', 'Ceterizine', 'alemtuzumab GZ402673', 'Acyclovir', 'Methylprednisolone']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Progressive Multiple Sclerosis,['Progressive Multiple Sclerosis'],[],COMPLETED,,2015-12-06,2021-03-01,"[{'measure': 'Change from baseline in the CD3+ lymphocyte subset after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}]","[{'measure': 'Change from baseline in lymphocyte subsets after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}, {'measure': 'Change from baseline in total lymphocyte count after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}, {'measure': 'Change from baseline in helper/suppressor ratio after alemtuzumab administration', 'timeFrame': 'Baseline, 30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: maximum plasma concentration observed (Cmax)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: time to reach Cmax (Tmax)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration versus time curve from time zero until the last measurable concentration (AUClast)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: area under plasma concentration (AUC)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Assessment of pharmacokinetic parameter after alemtuzumab administration: terminal half-life (t1/2z)', 'timeFrame': '30 days after each treatment course'}, {'measure': 'Number of patients with adverse events', 'timeFrame': '4 years'}, {'measure': 'Number of patients with adverse events of special interest', 'timeFrame': '4 years'}, {'measure': 'Number of patients with injection site reactions', 'timeFrame': '2 years'}]",12,18 Years,,ALL,False,"Genzyme, a Sanofi Company",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:13.417051,v2_robust,True,True,True,False,True,
NCT03284294,Influence of Vitamin D Supplementation on Serum BDNF Level and Cognitive Function in Schizophrenia,The Influence of Vitamin D Supplementation on Serum Brain Derived Neurotrophic Factor Level and Cognitive Function in Schizophrenia Treated With Atypical Antipsychotic,Cholecalciferol,"['Cholecalciferol', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],[],UNKNOWN,,2020-04-15,2020-12,"[{'measure': 'Cognitive Function', 'description': 'cognitive function as measured with standard cognitive battery', 'timeFrame': 'At the end of week 8'}]","[{'measure': 'BDNF serum level', 'description': 'BDNF serum level as measured with ELISA method', 'timeFrame': 'At the end of week 8'}]",2,18 Years,45 Years,MALE,False,Universitas Padjadjaran,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:13.417117,v2_robust,True,True,False,False,False,
NCT01067794,Chemotherapy in Treating Patients With Lung Cancer,First-line Treatment of Non-Small Cell Lung Cancer Under Routine Conditions: Observational Study on Overall Survival,Any platinum-based doublet chemotherapy,['Any platinum-based doublet chemotherapy'],1,OBSERVATIONAL,[],,,Non Small Cell Lung Cancer,['Non Small Cell Lung Cancer'],"['Metastatic', 'Advanced', 'Stage IIIB-IV', 'daily', 'hospital', 'practice', 'setting']",COMPLETED,,2009-04,2012-07,"[{'measure': 'Overall survival', 'timeFrame': 'Treatment start to death from any cause (follow-up assessments until death or until end of study, up to 18 months from Last Patient Entered Treatment)'}]","[{'measure': 'One-year survival rate', 'timeFrame': '12 months'}, {'measure': 'Progression-free survival', 'timeFrame': 'Treatment start to progression or death (follow-up assessments until death or until end of study, up to 18 months from Last Patient Entered Treatment)'}, {'measure': 'Best tumor response', 'timeFrame': 'Treatment start to progression or treatment end'}]",4,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,1610.0,ESTIMATED,2025-09-01T16:18:13.417157,v2_robust,False,True,True,False,False,
NCT00515294,Acute and Residual Effects of Caffeinated Beer,Acute and Residual Effects of Beer VS. Caffeinated Beer On Simulated Driving,Caffeinated Alcoholic Beer,"['69mg caffeine/12oz glass of regular beer', '69mg caffeine/12oz glass of non-alcoholic beer', 'Caffeinated Alcoholic Beer', 'Caffeinated Non-Alcoholic Beer']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Neurobehavioral Manifestations,"['Neurobehavioral Manifestations', 'Drug Related Sleep Disturbance', 'Alcohol Intoxication']","['Caffeine', 'Alcohol', 'Alcohol Consumption', 'Residual Effects', 'Family History', 'Psychomotor Vigilance Test', 'Driving Simulation', 'Reaction Time']",COMPLETED,,2006-10,2009-10,"[{'measure': 'Lane Position Deviation', 'description': 'The reported lane position deviation indicates the position of the car relative to the center line in feet in the driver simulator. A deviation of 0 indicates no deviation from the center line (the car is positioned farthest from the road edge). Negative numbers indicate deviations to the right of the center line with the car positioned within the lane closer to the road edge. Positive numbers indicate deviations to the left of the center line with the car positioned in the lane of oncoming traffic closer to the road edge', 'timeFrame': '30 minutes post dosing'}]","[{'measure': 'Psycho-motor Vigilance Test (PVT)', 'description': 'Participants completed 10 test trials to assess their psycho-motor response using a hand held box that randomly starts a scroll of numbers in milliseconds and as soon as it starts to scroll the participant needs to press a button to stop the scrolling. The mean and standard deviations for the 10 tests were calculated as a single outcome score for each study arm. Response times were measured in milliseconds. The lower the number of milliseconds the faster the response to the random stimuli.', 'timeFrame': '30 minutes post dosing'}]",2,21 Years,30 Years,ALL,True,Boston University,OTHER,3,154.0,ACTUAL,2025-09-01T16:18:13.417170,v2_robust,True,True,True,False,False,
NCT05698394,Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth,Effect of Intravenous Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth in Women With Prenatal Depression: 3-year Follow-up of a Randomized Controlled Trial,Esketamine,"['0.9% sodium chloride', 'normal saline', 'Placebo', 'Esketamine']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Prenatal Depression,"['Prenatal Depression', 'Ketamine', 'Postpartum Depression']","['Prenatal Depression', 'Esketamine', 'Postpartum Depression', 'Long-Term Prognosis']",ACTIVE_NOT_RECRUITING,,2023-09-09,2025-11,"[{'measure': 'Incidence maternal depression at 3 years postpartum', 'description': 'Incidence of depression in women at 3 years postpartum. Diagnosis was made according to M.I.N.I. 6.0.', 'timeFrame': 'At 3 years postpartum (33-41 months)'}]","[{'measure': 'PHQ-9 scores and incidence of moderate-severe depression in women at 3 years postpartum.', 'description': 'PHQ-9 score and moderate-severe depression (PHQ-9 score ≥10) in women at 3 years postpartum.', 'timeFrame': 'At 3 years postpartum (33-41 months)'}, {'measure': 'Incidence of chronic pain in women at 3 years postpartum', 'description': 'Incidence of chronic pain in women at 3 years postpartum', 'timeFrame': 'At 3 years postpartum (33-41 months)'}, {'measure': 'Incidence of developmental delay in offspring at 3 years of age', 'description': 'Incidence of developmental delay in offspring at 3 years of age measured by the Ages \\& Stages Questionnaires 3rd edition (ASQ-3) in Chinese', 'timeFrame': 'At 3 years postpartum (33-41 months)'}]",4,18 Years,,FEMALE,False,Peking University First Hospital,OTHER,0,364.0,ACTUAL,2025-09-01T16:18:13.417280,v2_robust,True,True,False,False,False,
NCT01552694,Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation,"A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia for Reducing Inflammation and Increasing EPC Number in HIV Infected Men and Women With Insulin Resistance and Central Adiposity.",Sitagliptin,"['Sitagliptin', 'Januvia', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Inflammation,"['Inflammation', 'Macrophage Infiltration', 'Cardiovascular Disease']",['cardiometabolic complications'],COMPLETED,,2012-10,2014-12,"[{'measure': 'Inflammatory Biomarker 1: Plasma hsCRP Concentration', 'description': 'Fasting serum and plasma samples obtained at baseline and week 8 are batched for ELISA analysis (end of sudy) of hsCRP, IL-6 and D-dimer concentrations.', 'timeFrame': '2 months'}, {'measure': 'Inflammatory Biomarker 2: Plasma IL-6 Concentration', 'description': 'There are 3 levels of the primary outcome measure; hsCRP, IL-6, and D-dimer concentrations measured at baseline and week 8', 'timeFrame': '2 months'}, {'measure': 'Inflammatory Biomarker 3: Serum D-dimer Concentration', 'description': 'There are 3 levels of the primary outcome measure, hsCRP, IL-6, and D-dimer', 'timeFrame': '2 months'}]","[{'measure': 'Fold Change in Adipose Inflammation Marker CCL2 (MCP-1) mRNA Expression', 'description': 'Adipose tissue from obese, insulin resistant subjects is characterized by increased macrophage infiltration and overexpression of inflammatory cytokines/chemokines. In adipose samples, mRNA expression for the macrophage inflammation marker CCL2 (MCP-1) was quantified. Fold change between population averages from baseline to 2 months for adipose macrophage CCL2 (MCP-1) mRNA expression is the outcome measure.', 'timeFrame': 'Baseline to 2 months'}, {'measure': 'Percent Change in Blood Endothelial Progenitor Cells', 'description': 'Monocytes (PBMC) are isolated from 20 mL blood. CD34+/VEGFR2+/KDR+ monocytes represent cell markers for endothelial progenitor cells (EPC). CD34+/VEGFR2+/KDR+ monocytes are counted (flow cytometry) and expressed as a percentage of PBMC number. Percent change between population averages from baseline to 2 months for the EPC/PBMC ratio is calculated and reported as the outcome measure.', 'timeFrame': 'Baseline to 2 months'}]",5,18 Years,65 Years,ALL,False,Washington University School of Medicine,OTHER,0,38.0,ACTUAL,2025-09-01T16:18:13.417300,v2_robust,True,True,True,False,False,
NCT03320694,Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus,Comparison of Metformin and Insulin for Management of Gestational Diabetes Mellitus,Metformin,"['Insulin', 'Glucophage', 'Humulin R U 100 and Humulin N', 'Metformin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Gestational Diabetes Mellitus in Pregnancy,['Gestational Diabetes Mellitus in Pregnancy'],"['Gestational Diabetes Mellitus, Metformin, Insulin']",COMPLETED,,2016-02-01,2017-06-30,"[{'measure': 'maternal glycemic control', 'description': 'Maternal glycemic control was measured by blood sugar levels', 'timeFrame': 'From time of randomisation till 40 weeks'}]","[{'measure': 'Fetal macrosomia', 'description': 'Birth weight more than 4kg', 'timeFrame': 'at birth'}, {'measure': 'Apgar score', 'description': '\\<7 at 5min', 'timeFrame': 'at birth'}, {'measure': 'Neonatal intensive care unit (NICU) stay', 'description': 'Admitted to NICU', 'timeFrame': '>24 hours after birth'}, {'measure': 'Perinatal death', 'description': 'Fetal or neonatal death within 7 days', 'timeFrame': '7 days of delivery'}, {'measure': 'mode of delivery', 'description': 'Lower segment cesarean section , Spontaneous Vaginal Delivery, Instrumental delivery', 'timeFrame': 'at delivery'}, {'measure': 'Neonatal hypoglycemia', 'description': 'Neonatal blood sugar was checked at birth and if \\<2.2mmol/l, was labelled', 'timeFrame': 'at birth'}]",7,18 Years,45 Years,FEMALE,True,"Services Institute of Medical Sciences, Pakistan",OTHER_GOV,0,278.0,ACTUAL,2025-09-01T16:18:13.417329,v2_robust,True,True,True,False,False,
NCT00454194,Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer,Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer,pemetrexed disodium,"['pemetrexed disodium', 'sorafenib tosylate']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['recurrent non-small cell lung cancer', 'stage IIIB non-small cell lung cancer', 'stage IV non-small cell lung cancer', 'adenosquamous cell lung cancer', 'adenocarcinoma of the lung']",COMPLETED,,2007-09,2013-05,"[{'measure': 'Progression-free Survival', 'description': 'The progression-free survival (PFS) was defined as the time from date of randomization to the documentation of disease progression or death as a result of any cause, whichever comes first. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', 'timeFrame': 'Time from randomization to the disease progression or death (up to 5 years)'}]","[{'measure': 'Overall Survival', 'description': 'Overall survival was defined as the time from study enrollment (randomization) to the time of death from any cause or last follow-up.', 'timeFrame': 'Time from randomization to death or last follow-up (up to 5 years)'}, {'measure': 'Time to Treatment Failure', 'description': 'Time to treatment failure was defined as the time from date of randomization to the date at which the patient was removed from the treatment due to progression, toxicity, refusal or other medical problems.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Duration of Response', 'description': ""Duration of response was defined as the time from the date at which the patient's earliest best objective status was first noted to be either a complete response (CR) or partial response (PR) to the earliest date progression was documented.\n\nResponse was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:\n\n* Complete Response (CR): disappearance of all target lesions;\n* Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;"", 'timeFrame': 'Up to 5 years'}, {'measure': 'Number of Participants With at Least One Grade 3 or Above Adverse Events Assessed by NCI CTCAE v4.0', 'description': 'Adverse events were assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0. Grading: Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening, Grade 5=Death. The maximum grade for each type of adverse events were recorded for each patient.', 'timeFrame': 'Up to 3 years'}, {'measure': 'Confirmed Response Rate (Complete Response and Partial Response) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST)', 'description': 'A confirmed tumor response was defined as a complete response (CR) or partial response (PR) noted as the objective status on 2 consecutive evaluations at least 6 weeks apart.\n\nResponse was defined using Response Evaluation Criteria In Solid Tumors (RECIST) criteria:\n\n* Complete Response (CR): disappearance of all target lesions;\n* Partial Response (PR) 30% decrease in sum of longest diameter of target lesions;\n* Progressive Disease (PD): 20% increase in sum of longest diameter of target lesions;\n* Stable Disease (SD): small changes that do not meet above criteria.', 'timeFrame': 'Up to 5 years'}]",6,18 Years,120 Years,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,110.0,ACTUAL,2025-09-01T16:18:13.417346,v2_robust,True,True,True,False,True,
NCT01059266,PURETHAL Grasses Rush Study,"A Prospective, Randomized, Open, Multi-centre Study to Assess Safety of PURETHAL Grasses Given With a Rush Induction Schedule to Patients With Allergic Rhinoconjunctivitis","PURETHAL Grasses, 20.000 AUM/ml","['PURETHAL Grasses, 20.000 AUM/ml']",1,INTERVENTIONAL,['PHASE4'],PHASE4,,Allergic Rhinitis,"['Allergic Rhinitis', 'Allergic Rhinoconjunctivitis']","['immunotherapy', 'grass pollen', 'seasonal allergy', 'dose tolerability']",COMPLETED,,2010-02,2010-09,"[{'measure': 'systemic reactions > grade I or large local reactions related to injection', 'timeFrame': '24 hrs after injection'}]","[{'measure': 'specific serum IgE and IgG concentrations', 'timeFrame': '16 weeks'}]",2,18 Years,,ALL,False,HAL Allergy,INDUSTRY,0,150.0,ACTUAL,2025-09-01T16:18:13.417379,v2_robust,True,True,True,False,False,
NCT05171166,Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage HCC: a Multi-center Randomized Controlled Trial.,Neoadjuvant HAIC of TACE Plus Donafenib in BCLC B Stage Hepatocellular Carcinoma Out Up-to-seven: a Multi-center Randomized Controlled Trial.,FOLFOX,"['Dona', 'FOLFOX', 'leucovorin', 'cTACE or DEB-TACE', 'Donafenib', 'EPI', '5-fluorouracil', 'oxaliplatin']",8,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],RECRUITING,,2021-12-24,2027-12-31,"[{'measure': 'Progression-free survival', 'description': 'The date from the initiation of treatment to the date that disease progression or death due to any cause, whichever occurs firstly.', 'timeFrame': 'From date of treatment beginning until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.'}]","[{'measure': 'Overall Survival', 'description': 'The date from the initiation of treatment to the date of death.', 'timeFrame': 'From date of treatment beginning until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 100 months.'}, {'measure': 'Time To Progression', 'description': 'Time to progression is defined as time from treatment initiation to radiological progression.', 'timeFrame': 'Evaluation of tumor burden based on mRECIST criteria until first documented progress, assessed up to 100 months.'}, {'measure': 'Objective response rate', 'description': 'The proportion of participants in the analysis population who have complete response (CR) or partial response (PR) determined by investigators using mRECIST criteria at any time during the study.', 'timeFrame': 'Evaluation of tumor burden based on mRECIST criteria through study completion, an average of once per 3 months.'}, {'measure': 'Disease control rate', 'description': 'The proportion of participants in the analysis population who have CR, PR or stable disease (SD) determined by investigators using mRECIST criteria at any time during the study.', 'timeFrame': 'Evaluation of tumor burden based on mRECIST criteria through study completion, an average of once per 3 months.'}, {'measure': 'Number of paitents with treatment-related adverse events', 'description': 'Number of patients with AE, treatment-related AE (TRAE), serious adverse event (SAE) assessed by CTCAE v5.0.', 'timeFrame': 'Through study completion, an average of once per 1 month.'}]",6,18 Years,75 Years,ALL,False,Peking University,OTHER,0,156.0,ESTIMATED,2025-09-01T16:18:13.417414,v2_robust,True,True,False,False,True,
NCT00228566,Study to Assess Patient Reported Outcomes With Armodafinil Treatment for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome,"A Short-term (8 Week) Open-Label Study, Followed by a Long Term Evaluation, to Assess Patient-Reported Outcomes With Armodafinil Treatment (150 to 250 mg/Day) for Excessive Sleepiness in Adults With Narcolepsy or Obstructive Sleep Apnea/Hypopnea Syndrome",Armodafinil,['Armodafinil'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Excessive Daytime Sleepiness,"['Excessive Daytime Sleepiness', 'Narcolepsy', 'Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS)']",[],COMPLETED,,2005-10,2006-07,"[{'measure': 'Number of Responders to the Patient Global Impression of Change (PGI-C) Ratings', 'description': ""A subjective measure (PGI-C rating) of the patient's global health, ie, a patient's rating of disease severity, as compared with a pretreatment (baseline) evaluation assessment by the patient using the Patient Global Impression of Severity of illness (PGI-S). Responders at each visit were defined as having at least minimal improvement in the severity of excessive sleepiness as compared with a pretreatment evaluation made using the PGI-S."", 'timeFrame': 'Weeks 4, 8, and 12, at 3 month intervals thereafter, and at a Final Visit (or last postbaseline observation). Evaluation continues until the Final Visit, which occurs when the product is commercially available or the marketing application is withdrawn.'}]",[],1,18 Years,65 Years,ALL,False,Cephalon,INDUSTRY,0,247.0,ACTUAL,2025-09-01T16:18:13.417465,v2_robust,True,True,True,False,False,
NCT01958866,Study of Efficacy and Safety of Tinospora Crispa-extract Product Compared With the Acetaminophen,,Tinospora Crispa-extract Product,"['Tinospora Crispa-extract Product', 'Acetaminophen']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Patients With Body Temperature Between 37.8-38.5,"['Patients With Body Temperature Between 37.8-38.5', 'No Sign of Infection', 'No Liver and Kidney Problem']","['Fever', 'Body temperature']",COMPLETED,,2013-10,2014-12,"[{'measure': 'Body Temperature', 'timeFrame': 'Change from baseline in temperature at 1, 2, 3, 4, 6, 8, 12 and 24 hours'}]","[{'measure': 'Number of adverse events: diarrhea, elevated liver enzyme and elevated creatinine', 'description': 'Liver and kidney function will be randomly evaluated. Number of participants with soft stool will be recorded.', 'timeFrame': 'Participants will be followed for the duration of hospital stay (24 hours)'}]",2,18 Years,,ALL,False,Chulalongkorn University,OTHER,0,96.0,ACTUAL,2025-09-01T16:18:13.417529,v2_robust,True,True,True,False,True,
NCT01314066,Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS),Efficacy of Bevacizumab in Preventing Acute Respiratory Distress Syndrome (ARDS),Bevacizumab,"['Avastin', 'Bevacizumab', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Severe Sepsis,"['Severe Sepsis', 'Acute Respiratory Distress Syndrome']",[],WITHDRAWN,No funding,2010-07,2016-02,"[{'measure': 'Proportion of individuals progressing to meet RDS criteria as defined by the American- European ARDS consensus conference and as used by ARDSnet.', 'timeFrame': 'Day 28'}]","[{'measure': 'Ventilator-free days to Day 28', 'timeFrame': 'Day 28'}, {'measure': '28 day all-cause mortality', 'timeFrame': 'Day 28'}, {'measure': 'Proportion of subjects progressing to acute lung injury (who do not meet the definition at randomization)', 'timeFrame': 'Day 28'}, {'measure': 'Worst PaO2/FiO2 ratio recorded following enrollment', 'timeFrame': 'Day 3 and 28'}, {'measure': 'Change in PaO2/FiO2 ratio between Day 0 to Day 3', 'timeFrame': 'Day 0 and Day 3'}, {'measure': 'Change from baseline in number of non-lung organ failures using the Multi-Organ Dysfunction (MOD) score and Sepsis Organ Failure Assessment (SOFA) score', 'timeFrame': 'Day 0, Day 28'}, {'measure': 'Proportion of subjects surviving to hospital discharge', 'timeFrame': 'Hospital Discharge Day'}, {'measure': 'Vasopressor-free days', 'timeFrame': 'Day 28'}, {'measure': 'Reversal of shock if present at randomization.', 'timeFrame': 'Day 28'}]",10,18 Years,99 Years,ALL,False,Weill Medical College of Cornell University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:13.417566,v2_robust,True,True,False,True,False,No funding
NCT04205266,IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding,IV Iron vs Oral Iron for Treatment of Anemia in Women With Abnormal Uterine Bleeding,Ferumoxytol,"['Feraheme', 'Ferumoxytol', 'Ferrous Sulfate', 'oral iron']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Anemia, Iron Deficiency","['Anemia, Iron Deficiency', 'Heavy Menstrual Bleeding']",[],RECRUITING,,2020-02-14,2025-01,"[{'measure': 'Hemoglobin', 'description': 'Blood draw to check complete blood count', 'timeFrame': '60 days after initiation of treatment'}, {'measure': 'Hemoglobin', 'description': 'Blood draw with check complete blood count', 'timeFrame': '30 days after initiation of treatment'}, {'measure': 'Hemoglobin', 'description': 'Blood draw with check complete blood count', 'timeFrame': '14 days after initiation of treatment'}]","[{'measure': 'Participant satisfaction with treatment', 'description': 'Satisfaction with treatment, as measured on study-specific survey Higher scores indicate higher satisfaction', 'timeFrame': '60 days after initiation of treatment'}, {'measure': 'Quality of Life Score', 'description': 'Quality of life, as measured on the Duke Health Profile. Validated scale measuring physical health, mental health, anxiety, depression, pain, and disability; Minimum scores are 0; maximum score is 100 on each sub-scale Higher score indicates better outcome / status', 'timeFrame': '60 days after initiation of treatment'}]",5,18 Years,55 Years,FEMALE,True,Thomas Jefferson University,OTHER,1,76.0,ESTIMATED,2025-09-01T16:18:13.417630,v2_robust,True,True,False,False,False,
NCT04582266,PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US,Pharmacokinetics and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the United States,Remdesivir,['Remdesivir'],1,OBSERVATIONAL,[],,,COVID-19,['COVID-19'],"['COVID-19, Pregnancy']",COMPLETED,,2021-03-31,2022-04-13,"[{'measure': 'PK Outcome: Geometric Mean Area Under the Plasma Concentration-time Curve (AUC) of Remdesivir (RDV) in Arm 1', 'description': 'AUC calculated using non-compartmental methods with linear up-log down trapezoidal rule (Phoenix WinNonlin v 8.3, Certara®). Intensive PK sampling occurred once, on the day of the 3rd, 4th, or 5th infusion.', 'timeFrame': 'At 3rd, 4th, or 5th infusion. Collection timepoints included: pre-dose, end of infusion (EOI), EOI + 0.75 hours, EOI + 1.5 hours, EOI + 3 hours, EOI + 5 hours, EOI + 7 hours, EOI + 23 hours.'}, {'measure': 'PK Outcome: Geometric Mean Half-life (t1/2) of Remdesivir (RDV) in Arm 1', 'description': 't1/2 calculated using non-compartmental methods with linear up-log down trapezoidal rule (Phoenix WinNonlin v 8.3, Certara®). Intensive PK sampling occurred once, on the day of the 3rd, 4th, or 5th infusion.', 'timeFrame': 'At 3rd, 4th, or 5th infusion. Collection timepoints included: pre-dose, end of infusion (EOI), EOI + 0.75 hours, EOI + 1.5 hours, EOI + 3 hours, EOI + 5 hours, EOI + 7 hours, EOI + 23 hours.'}, {'measure': 'PK Outcome: Geometric Mean Trough Concentration (Ctrough) of GS-441524 in Arm 1', 'description': 'GS-441524 is a metabolite of remdesivir (RDV). Ctrough calculated using non-compartmental methods with linear up-log down trapezoidal rule (Phoenix WinNonlin v 8.3, Certara®). Intensive PK sampling occurred once, on the day of the 3rd, 4th, or 5th infusion.', 'timeFrame': 'At 3rd, 4th, or 5th infusion. Collection timepoints included: pre-dose, end of infusion (EOI), EOI + 0.75 hours, EOI + 1.5 hours, EOI + 3 hours, EOI + 5 hours, EOI + 7 hours, EOI + 23 hours.'}, {'measure': 'Safety Outcome: Proportion of Participants With Maternal Renal Adverse Event (AE) of Any Grade in Arm 1', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one maternal renal AE through 7 days post last infusion, bounded by an exact 95% confidence interval (CI). Renal AEs were defined using the MedDRA system organ class term ""Renal and urinary disorders"" and high level grouping term ""Renal and urinary tract investigations and urinalyses"". The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 7 Days post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Maternal Hepatic Adverse Event (AE) of Any Grade in Arm 1', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one maternal hepatic AE through 7 days post last infusion, bounded by an exact 95% confidence interval (CI). Hepatic AEs were defined using the MedDRA system organ class term ""Hepatobiliary disorders"" and high level grouping term ""Hepatobiliary investigations"". The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 7 Days post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Maternal Hematologic Adverse Event (AE) of Any Grade in Arm 1', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one maternal hematologic AE through 7 days post last infusion, bounded by an exact 95% confidence interval (CI). Hematologic AEs were defined using the MedDRA system organ class term ""Blood and lymphatic system disorders"" and high level grouping term ""Haematology investigations (incl blood groups)"". The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 7 Days post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Maternal Grade 3 or Higher Adverse Event (AE) in Arm 1', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: grade 1 indicates a mild event, grade 2 indicates a moderate event, grade 3 indicates a severe event, grade 4 indicates a potentially life-threatening event, and grade 5 indicates death. We present the proportion of participants with at least one maternal grade 3 or higher adverse event through 4 weeks post last infusion and delivery, bounded by an exact 95% confidence interval (CI). The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 4 Weeks post-last infusion and Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Serious Adverse Event (AE) in Arm 1', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one maternal serious AE through 4 weeks post last infusion and delivery, bounded by an exact 95% confidence interval (CI). The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 4 Weeks post-last infusion and Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Maternal Grade 3 or Higher Adverse Event (AE) Assessed as Related to Remdesivir (RDV) by the Clinical Management Committee (CMC) in Arm 1', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: grade 1 indicates a mild event, grade 2 indicates a moderate event, grade 3 indicates a severe event, grade 4 indicates a potentially life-threatening event, and grade 5 indicates death. We present the proportion of participants with at least one maternal grade 3 or higher AE assessed as related to RDV by the CMC through 4 weeks post last infusion and delivery, bounded by an exact 95% confidence interval (CI). The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 4 Weeks post-last infusion and Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Pregnancy Loss in Arm 1', 'description': 'We present the proportion of participants who had a pregnancy loss at delivery, bounded by an exact 95% confidence interval (CI).', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Congenital Anomalies in Arm 1', 'description': 'We present the proportion of participants who had a live infant born with congenital anomalies at delivery, bounded by an exact 95% confidence interval (CI).', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Preterm Birth, Defined as < 37 Weeks in Arm 1', 'description': 'We present the proportion of participants who had a live preterm birth defined as \\< 37 weeks, bounded by an exact 95% confidence interval (CI).', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Preterm Birth, Defined as < 34 Weeks in Arm 1', 'description': 'We present the proportion of participants who had a live preterm birth defined as \\< 34 weeks, bounded by an exact 95% confidence interval (CI).', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Proportion of Participants With Small for Gestational Age, Defined as < 10th Percentile in Arm 1', 'description': 'We present the proportion of participants who a live born infant who was small for gestational age defined as \\< 10th percentile, bounded by an exact 95% confidence interval (CI).', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Mean Newborn Birth Weight in Arm 1', 'description': 'We present the newborn mean weight among the participants who had live born infant, bounded by a 95% confidence interval (CI) calculated using the t distribution.', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Mean Newborn Length in Arm 1', 'description': 'We present the newborn mean length among the participants who had a live born infant, bounded by a 95% confidence interval (CI) calculated using the t distribution.', 'timeFrame': 'Delivery'}, {'measure': 'Safety Outcome: Mean Newborn Head Circumference in Arm 1', 'description': 'We present the newborn mean head circumference among the participants who had a live born infant, bounded by a 95% confidence interval (CI) calculated using the t distribution.', 'timeFrame': 'Delivery'}]","[{'measure': 'PK Outcome: Geometric Mean Area Under the Plasma Concentration-time Curve (AUC) of Remdesivir (RDV) in Arm 2', 'description': 'AUC calculated using non-compartmental methods with linear up-log down trapezoidal rule (Phoenix WinNonlin v 8.3, Certara®). Intensive PK sampling occurred once, on the day of the 3rd, 4th, or 5th infusion.', 'timeFrame': 'At 3rd, 4th, or 5th infusion. Collection timepoints included: pre-dose, end of infusion (EOI), EOI + 0.75 hours, EOI + 1.5 hours, EOI + 3 hours, EOI + 5 hours, EOI + 7 hours, EOI + 23 hours.'}, {'measure': 'PK Outcome: Geometric Mean Half-life (t1/2) of Remdesivir (RDV) in Arm 2', 'description': 't1/2 calculated using non-compartmental methods with linear up-log down trapezoidal rule (Phoenix WinNonlin v 8.3, Certara®). Intensive PK sampling occurred once, on the day of the 3rd, 4th, or 5th infusion.', 'timeFrame': 'At 3rd, 4th, or 5th infusion. Collection timepoints included: pre-dose, end of infusion (EOI), EOI + 0.75 hours, EOI + 1.5 hours, EOI + 3 hours, EOI + 5 hours, EOI + 7 hours, EOI + 23 hours.'}, {'measure': 'PK Outcome: Geometric Mean Trough Concentration (Ctrough) of GS-441524 in Arm 2', 'description': 'GS-441524 is a metabolite of remdesivir (RDV). Ctrough calculated using non-compartmental methods with linear up-log down trapezoidal rule (Phoenix WinNonlin v 8.3, Certara®). Intensive PK sampling occurred once, on the day of the 3rd, 4th, or 5th infusion.', 'timeFrame': 'At 3rd, 4th, or 5th infusion. Collection timepoints included: pre-dose, end of infusion (EOI), EOI + 0.75 hours, EOI + 1.5 hours, EOI + 3 hours, EOI + 5 hours, EOI + 7 hours, EOI + 23 hours.'}, {'measure': 'Safety Outcome: Proportion of Participants With Renal Adverse Event (AE) of Any Grade in Arm 2', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one renal AE through 7 days post last infusion, bounded by an exact 95% confidence interval (CI). Renal AEs were defined using the MedDRA system organ class term ""Renal and urinary disorders"" and high level grouping term ""Renal and urinary tract investigations and urinalyses"". The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 7 Days post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Hepatic Adverse Event (AE) of Any Grade in Arm 2', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one hepatic AE through 7 days post last infusion, bounded by an exact 95% confidence interval (CI). Hepatic AEs were defined using the MedDRA system organ class term ""Hepatobiliary disorders"" and high level grouping term ""Hepatobiliary investigations"". The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 7 Days post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Hematologic Adverse Event (AE) of Any Grade in Arm 2', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one hematologic AE through 7 days post last infusion, bounded by an exact 95% confidence interval (CI). Hematologic AEs were defined using the MedDRA system organ class term ""Blood and lymphatic system disorders"" and high level grouping term ""Haematology investigations (incl blood groups)"". The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 7 Days post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Grade 3 or Higher Adverse Event (AE) in Arm 2', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: grade 1 indicates a mild event, grade 2 indicates a moderate event, grade 3 indicates a severe event, grade 4 indicates a potentially life-threatening event, and grade 5 indicates death. We present the proportion of participants with at least one grade 3 or higher AE through 4 weeks post last infusion, bounded by an exact 95% confidence interval (CI).', 'timeFrame': 'First infusion through 4 Weeks post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Serious Adverse Event (AE) in Arm 2', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. We present the proportion of participants with at least one serious AE through 4 weeks post last infusion, bounded by an exact 95% confidence interval (CI). The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 4 Weeks post-last infusion'}, {'measure': 'Safety Outcome: Proportion of Participants With Grade 3 or Higher Adverse Event (AE) Assessed as Related to Remdesivir (RDV) by the Clinical Management Committee (CMC) in Arm 2', 'description': 'Graded according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Corrected Version 2.1, dated July 2017. The DAIDS grading table provides an AE severity grading scale ranging from grades 1 to 5 with descriptions for each AE based on the following general guidelines: grade 1 indicates a mild event, grade 2 indicates a moderate event, grade 3 indicates a severe event, grade 4 indicates a potentially life-threatening event, and grade 5 indicates death. We present the proportion of participants with at least one grade 3 or higher AE as related to RDV by the CMC through 4 weeks post last infusion, bounded by an exact 95% confidence interval (CI). The number of RDV infusions varied by participant.', 'timeFrame': 'First infusion through 4 Weeks post-last infusion'}]",26,,,FEMALE,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,1,54.0,ACTUAL,2025-09-01T16:18:13.417690,v2_robust,False,True,True,False,True,
NCT03410056,Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis,A Phase 1b/2a Study to Evaluate the Safety and Efficacy of Efavaleukin Alfa in Subjects With Active Rheumatoid Arthritis With Inadequate Response to Standard of Care Therapy,Efavaleukin alfa,"['AMG 592', 'Efavaleukin alfa', 'Placebo']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Rheumatoid Arthritis RA,['Rheumatoid Arthritis RA'],[],TERMINATED,Amgen made a business decision not to proceed with Phase 2.,2018-05-22,2020-05-13,"[{'measure': 'Phase 1b: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)', 'description': 'TEAEs were events with an onset after the administration of the first dose of study treatment.\n\nTEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).\n\nGrade 2 Moderate; minimal, local or noninvasive intervention indicated; limited age appropriate instrumental activities of daily life (ADL).\n\nGrade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.\n\nGrade 4 Life-threatening consequences; urgent interventions indicated.\n\nSerious adverse events (SAEs) were defined as meeting at least 1 of the following criteria:\n\n* Results in death (fatal)\n* Immediately life-threatening\n* Requires in-patient hospitalization or prolongation of existing hospitalization\n* Results in persistent or significant disability/incapacity\n* Is a congenital anomaly/birth defect\n* Other medically important serious event', 'timeFrame': 'Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs', 'description': 'Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.', 'timeFrame': 'Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests', 'description': 'Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit.\n\nGrade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.\n\nGrade 4 Life-threatening consequences; urgent interventions indicated.', 'timeFrame': 'Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 1b: Number of Participants Who Experienced a Clinically Significant Change in Electrocardiograms (ECGs)', 'description': 'Any changes in ECG parameters that were deemed clinically significant by the investigator were reported.', 'timeFrame': 'Baseline up to end of treatment maximum of 12 weeks'}, {'measure': 'Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 20 Percent Improvement Criteria (ACR 20) at Week 12', 'description': 'ACR 20 response defined as at least 20 percent improvement from baseline in both tender and swollen joint counts, and a 20 percent improvement or more in at least 3 of the following 5 criteria:\n\n* physician global assessment of disease activity (PGA)\n* subject global assessment of disease activity (SGA)\n* patient global assessment of joint pain\n* subject self-assessment of disability (HAQ-DI)\n* C-Reactive Protein (CRP)', 'timeFrame': 'Baseline and Week 12'}]","[{'measure': 'Phase 1b: Efavaleukin Alfa Serum Concentrations', 'description': 'A summary of mean serum concentrations of Efavaleukin alfa over time is presented. Any results below the lower limit of quantification were set to 0.00.', 'timeFrame': 'Day 1 (pre-dose), 6 and 12 hours post-dose, and days 2, 3, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and Day 85 (pre-dose), 6 and 12 hours post-dose and days 86, 87, 88, 92, 99, 113 and 127'}, {'measure': 'Phase 1b: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa', 'timeFrame': 'Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127'}, {'measure': 'Phase 1b: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa', 'timeFrame': 'Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92, 99, 113 and 127'}, {'measure': 'Phase 1b: Area Under the Concentration-time Curve From Time 0 to 14 Days (AUC0-14) Post Dose', 'description': 'AUC0-14 was only assessed for the participants who received Efavaleukin alfa using dosing schedule A.', 'timeFrame': 'Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4, 8, 11 and 15, Day 85 (pre-dose) and 6 to 72 hours post-dose, and days 92 and 99'}, {'measure': 'Phase 1b: Area Under the Concentration-time Curve From Time 0 to 7 Days (AUC0-7) Post Dose', 'description': 'AUC0-7 was only assessed for the participants who received Efavaleukin alfa using dosing schedule B.', 'timeFrame': 'Day 1 (pre-dose) and 6 to 48 hours post-dose, and days 4 and 8, Day 85 (pre-dose) and 6 to 72 hours post-dose, and Day 92'}, {'measure': 'Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Binding Antibodies and Anti-Interleukin (IL-2) Binding Antibodies', 'description': 'Number of participants who tested positive for anti-Efavaleukin alfa binding antibodies and number of those participants who cross-reacted with native human IL-2 (i.e. with anti-IL-2 binding antibodies) are reported.', 'timeFrame': 'Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 1b: Number of Participants With Anti-Efavaleukin Alfa Neutralizing Antibodies and Anti-IL-2 Neutralizing Antibodies', 'description': 'The number of participants who tested positive for anti-Efavaleukin alfa neutralizing antibodies and number of participants with anti-IL2 neutralizing antibodies who tested negative or no result at baseline are reported.', 'timeFrame': 'Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 2a: Number of Participants Who Achieved an American College of Rheumatology 50 Percent Improvement Criteria (ACR 50) or 70 Percent Improvement Criteria (ACR 70) at Week 12', 'description': 'ACR 50 and ACR 70 response defined as at least 50 percent or 70 percent improvement from baseline in both tender and swollen joint counts, and a 50 percent or 70 percent improvement or more in at least 3 of the following 5 criteria:\n\n* physician global assessment of disease activity (PGA)\n* subject global assessment of disease activity (SGA)\n* patient global assessment of joint pain\n* subject self-assessment of disability (HAQ-DI)\n* C-Reactive Protein (CRP)', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using The Erythrocyte Sedimentation Rate Formula (DAS28-ESR) at Week 12', 'description': ""Change from baseline in DAS28-ER at Week 12. DAS28-ESR was to assess disease activity in patients with rheumatoid arthritis. DAS28-ESR is a composite score that includes 4 variables: tender joint count (TJC) (based on 28 joints); swollen joint count (SJC) (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by ESR in mm/h. DAS28-ESR total score range from 0-10, higher score indicates more disease activity."", 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Phase 2a: Change From Baseline in Disease Activity Score (28 Joint) Calculated Using the C-reactive Protein Formula (DAS-28-CRP) at Week 12', 'description': ""Change from baseline in DAS28-CRP at Week 12. 2. DAS28-CRP was to assess disease activity in patients with rheumatoid arthritis. DAS28-CRP is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); participant's global assessment of health activity using 100 mm VAS: range 0 (no pain) to 100 (maximum pain imaginable); marker of inflammation assessed by CRP in mg/L. DAS28-CRP total score range from 0-10, higher score indicates more disease activity."", 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Phase 2a: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)', 'description': 'TEAEs were events with an onset after the administration of the first dose of study treatment.\n\nTEAEs were graded using the Common Terminology Criteria for Adverse Events (CTCAE).', 'timeFrame': 'Baseline up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Vital Signs', 'description': 'Any changes in systolic/diastolic blood pressure, heart rate, respiratory rate, and temperature that were deemed as clinically significant by the Investigator were reported.', 'timeFrame': 'Baseline up to Week 12'}, {'measure': 'Phase 2a: Number of Participants Who Experienced a Clinically Significant Change in Laboratory Safety Tests', 'description': 'Laboratory safety tests included chemistry and hematology parameters. Clinically significant laboratory safety tests were any events assessed as CTCAE Grade ≥3 at any post-baseline visit.\n\nGrade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolonged hospitalization indicated; disabling; limited self care ADL.\n\nGrade 4 Life-threatening consequences; urgent interventions indicated.', 'timeFrame': 'Day 1 up to end of study, maximum of 18 weeks (12-weeks double-blind treatment, 6-weeks safety follow-up)'}, {'measure': 'Phase 2a: Efavaleukin Alfa Serum Concentration', 'description': 'A summary of mean serum concentrations of Efavaleukin alfa over time.', 'timeFrame': 'Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12'}, {'measure': 'Phase 2a: Maximum Observed Serum Concentration (Cmax) of Efavaleukin Alfa', 'timeFrame': 'Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12'}, {'measure': 'Phase 2a: Time to Maximum Observed Serum Concentration (Tmax) of Efavaleukin Alfa', 'timeFrame': 'Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12'}, {'measure': 'Phase 2a: Area Under the Concentration-time Curve (AUC) of Efavaleukin Alfa', 'timeFrame': 'Day 1 (pre-dose) and weeks 2, 4, 6, 8, 10 and 12'}]",22,18 Years,70 Years,ALL,True,Amgen,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:13.417726,v2_robust,True,True,False,True,True,Amgen made a business decision not to proceed with Phase 2.
NCT02484456,Antidepressant Effects of the Glycine Receptor Antagonist AV-101 (4-chlorokynurenine) in Major Depressive Disorder,An Investigation of the Antidepressant Effects of the Glycine Receptor Antagonist AV 101 (4-chlorokynurenine) in Major Depressive Disorder,AV 101 (4-Chlorokynurenine),"['AV 101 (4-Chlorokynurenine)', '4-Cl-KYN']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Major Depression,['Major Depression'],"['Major Depression', 'Glycine Receptor Antagonist', '4-chlorokynurenine', 'Treatment Resistant', 'Glutamatergic System']",COMPLETED,,2015-10-14,2019-12-03,"[{'measure': 'Model Adjusted Means for Hamilton Depression Rating Score', 'description': 'The Hamilton Depression Rating scale is a 17-item global measure of depressive symptoms on a 5-point scale ranging from 0 = not present to 4 = severe (full score values = 0,1,2,3,4). Some items rated on a scale of 0-2 (0, 1, 2) with 0 = not present to 2 = more severe. Total scores are a sum of the individual items. The maximum total score being 52 on the 17-point scale, and the minimum score being 0.Total scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression.', 'timeFrame': 'Post Dose Day 0'}, {'measure': 'Model Adjusted Means for Hamilton Depression Rating Score', 'description': 'The Hamilton Depression Rating scale is a 17-item global measure of depressive symptoms on a 5-point scale ranging from 0 = not present to 4 = severe (full score values = 0,1,2,3,4). Some items rated on a scale of 0-2 (0, 1, 2) with 0 = not present to 2 = more severe. Total scores are a sum of the individual items. The maximum total score being 52 on the 17-point scale, and the minimum score being 0.Total scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression.', 'timeFrame': 'Post Dose Day 1'}, {'measure': 'Model Adjusted Means for Hamilton Depression Rating Score', 'description': 'The Hamilton Depression Rating scale is a 17-item global measure of depressive symptoms on a 5-point scale ranging from 0 = not present to 4 = severe (full score values = 0,1,2,3,4). Some items rated on a scale of 0-2 (0, 1, 2) with 0 = not present to 2 = more severe. Total scores are a sum of the individual items. The maximum total score being 52 on the 17-point scale, and the minimum score being 0.Total scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression.', 'timeFrame': 'Post Dose Day 2'}, {'measure': 'Model Adjusted Means for Hamilton Depression Rating Score', 'description': 'The Hamilton Depression Rating scale is a 17-item global measure of depressive symptoms on a 5-point scale ranging from 0 = not present to 4 = severe (full score values = 0,1,2,3,4). Some items rated on a scale of 0-2 (0, 1, 2) with 0 = not present to 2 = more severe. Total scores are a sum of the individual items. The maximum total score being 52 on the 17-point scale, and the minimum score being 0.Total scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression.', 'timeFrame': 'Post Dose Day 3'}, {'measure': 'Model Adjusted Means for Hamilton Depression Rating Score', 'description': 'The Hamilton Depression Rating scale is a 17-item global measure of depressive symptoms on a 5-point scale ranging from 0 = not present to 4 = severe (full score values = 0,1,2,3,4). Some items rated on a scale of 0-2 (0, 1, 2) with 0 = not present to 2 = more severe. Total scores are a sum of the individual items. The maximum total score being 52 on the 17-point scale, and the minimum score being 0.Total scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression.', 'timeFrame': 'Post Dose Day 7'}, {'measure': 'Model Adjusted Means for Hamilton Depression Rating Score', 'description': 'The Hamilton Depression Rating scale is a 17-item global measure of depressive symptoms on a 5-point scale ranging from 0 = not present to 4 = severe (full score values = 0,1,2,3,4). Some items rated on a scale of 0-2 (0, 1, 2) with 0 = not present to 2 = more severe. Total scores are a sum of the individual items. The maximum total score being 52 on the 17-point scale, and the minimum score being 0.Total scores of 0-7 are considered as being normal, 8-16 suggest mild depression, 17-23 moderate depression and scores over 24 are indicative of severe depression.', 'timeFrame': 'Post Dose Day 13'}]","[{'measure': 'Model Adjusted Means for Beck Depression Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item measure of depression with each question on a 4-point scale ranging from 0=minimal to 3 = more severe (full list score values = 0,1,2,3). Total scores are a sum of individual items. The minimal depression = 0-13, mild depression = 14-19, moderate depression = 20-28, and severe depression = 29-63. The maximum score being 63 and the minimum possible score = 0.', 'timeFrame': 'Post Dose Day 0'}, {'measure': 'Model Adjusted Means for Beck Depression Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item measure of depression with each question on a 4-point scale ranging from 0=minimal to 3 = more severe (full list score values = 0,1,2,3). Total scores are a sum of individual items. The minimal depression = 0-13, mild depression = 14-19, moderate depression = 20-28, and severe depression = 29-63. The maximum score being 63 and the minimum possible score = 0.', 'timeFrame': 'Post Dose Day 1'}, {'measure': 'Model Adjusted Means for Beck Depression Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item measure of depression with each question on a 4-point scale ranging from 0=minimal to 3 = more severe (full list score values = 0,1,2,3). Total scores are a sum of individual items. The minimal depression = 0-13, mild depression = 14-19, moderate depression = 20-28, and severe depression = 29-63. The maximum score being 63 and the minimum possible score = 0.', 'timeFrame': 'Post Dose Day 2'}, {'measure': 'Model Adjusted Means for Beck Depression Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item measure of depression with each question on a 4-point scale ranging from 0=minimal to 3 = more severe (full list score values = 0,1,2,3). Total scores are a sum of individual items. The minimal depression = 0-13, mild depression = 14-19, moderate depression = 20-28, and severe depression = 29-63. The maximum score being 63 and the minimum possible score = 0.', 'timeFrame': 'Post Dose Day 3'}, {'measure': 'Model Adjusted Means for Beck Depression Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item measure of depression with each question on a 4-point scale ranging from 0=minimal to 3 = more severe (full list score values = 0,1,2,3). Total scores are a sum of individual items. The minimal depression = 0-13, mild depression = 14-19, moderate depression = 20-28, and severe depression = 29-63. The maximum score being 63 and the minimum possible score = 0.', 'timeFrame': 'Post Dose Day 7'}, {'measure': 'Model Adjusted Means for Beck Depression Score', 'description': 'The Beck Depression Inventory (BDI) is a 21-item measure of depression with each question on a 4-point scale ranging from 0=minimal to 3 = more severe (full list score values = 0,1,2,3). Total scores are a sum of individual items. The minimal depression = 0-13, mild depression = 14-19, moderate depression = 20-28, and severe depression = 29-63. The maximum score being 63 and the minimum possible score = 0.', 'timeFrame': 'Post Dose Day 13'}, {'measure': 'Model Adjusted Means for Hamilton Anxiety Rating Score', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item global measure of anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) (full score list = 0,1,2,3,4), with a total score range of 0-56 (0 = minimum score and 56 = maximum), where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores are a sum of individual items.', 'timeFrame': 'Post Dose Day 0'}, {'measure': 'Model Adjusted Means for Hamilton Anxiety Rating Score', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item global measure of anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) (full score list = 0,1,2,3,4), with a total score range of 0-56 (0 = minimum score and 56 = maximum), where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores are a sum of individual items.', 'timeFrame': 'Post Dose Day 1'}, {'measure': 'Model Adjusted Means for Hamilton Anxiety Rating Score', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item global measure of anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) (full score list = 0,1,2,3,4), with a total score range of 0-56 (0 = minimum score and 56 = maximum), where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores are a sum of individual items.', 'timeFrame': 'Post Dose Day 2'}, {'measure': 'Model Adjusted Means for Hamilton Anxiety Rating Score', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item global measure of anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) (full score list = 0,1,2,3,4), with a total score range of 0-56 (0 = minimum score and 56 = maximum), where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores are a sum of individual items.', 'timeFrame': 'Post Dose Day 3'}, {'measure': 'Model Adjusted Means for Hamilton Anxiety Rating Score', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item global measure of anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) (full score list = 0,1,2,3,4), with a total score range of 0-56 (0 = minimum score and 56 = maximum), where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores are a sum of individual items.', 'timeFrame': 'Post Dose Day 7'}, {'measure': 'Model Adjusted Means for Hamilton Anxiety Rating Score', 'description': 'The Hamilton Anxiety Rating Scale (HAM-A) is a 14-item global measure of anxiety symptoms. Each item is scored on a scale of 0 (not present) to 4 (severe) (full score list = 0,1,2,3,4), with a total score range of 0-56 (0 = minimum score and 56 = maximum), where \\<17 indicates mild severity, 18-24 mild to moderate severity and 25-30 moderate to severe. Total scores are a sum of individual items.', 'timeFrame': 'Post Dose Day 13'}, {'measure': 'Model Adjusted Means for Montgomery-Asberg Depression Rating Score', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item global measure evaluating core symptoms of depression. Questions concern how the patient has felt over the past week. Each item is rated on a scale from 0 to 6, with 0 being ""normal/not present"" and 6 being ""extreme"" (full score list = 0,1,2,3,4,5,6). Maximum score = 60, minimum score = 0. Total scores are a sum of the individual items.', 'timeFrame': 'Post Dose Day 0'}, {'measure': 'Model Adjusted Means for Montgomery-Asberg Depression Rating Score', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item global measure evaluating core symptoms of depression. Questions concern how the patient has felt over the past week. Each item is rated on a scale from 0 to 6, with 0 being ""normal/not present"" and 6 being ""extreme"" (full score list = 0,1,2,3,4,5,6). Maximum score = 60, minimum score = 0. Total scores are a sum of the individual items.', 'timeFrame': 'Post Dose Day 1'}, {'measure': 'Model Adjusted Means for Montgomery-Asberg Depression Rating Score', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item global measure evaluating core symptoms of depression. Questions concern how the patient has felt over the past week. Each item is rated on a scale from 0 to 6, with 0 being ""normal/not present"" and 6 being ""extreme"" (full score list = 0,1,2,3,4,5,6). Maximum score = 60, minimum score = 0. Total scores are a sum of the individual items.', 'timeFrame': 'Post Dose Day 2'}, {'measure': 'Model Adjusted Means for Montgomery-Asberg Depression Rating Score', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item global measure evaluating core symptoms of depression. Questions concern how the patient has felt over the past week. Each item is rated on a scale from 0 to 6, with 0 being ""normal/not present"" and 6 being ""extreme"" (full score list = 0,1,2,3,4,5,6). Maximum score = 60, minimum score = 0. Total scores are a sum of the individual items.', 'timeFrame': 'Post Dose Day 3'}, {'measure': 'Model Adjusted Means for Montgomery-Asberg Depression Rating Score', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item global measure evaluating core symptoms of depression. Questions concern how the patient has felt over the past week. Each item is rated on a scale from 0 to 6, with 0 being ""normal/not present"" and 6 being ""extreme"" (full score list = 0,1,2,3,4,5,6). Maximum score = 60, minimum score = 0. Total scores are a sum of the individual items.', 'timeFrame': 'Post Dose Day 7'}, {'measure': 'Model Adjusted Means for Montgomery-Asberg Depression Rating Score', 'description': 'The Montgomery-Asberg Depression Rating Scale (MADRS) is a 10-item global measure evaluating core symptoms of depression. Questions concern how the patient has felt over the past week. Each item is rated on a scale from 0 to 6, with 0 being ""normal/not present"" and 6 being ""extreme"" (full score list = 0,1,2,3,4,5,6). Maximum score = 60, minimum score = 0. Total scores are a sum of the individual items.', 'timeFrame': 'Post Dose Day 13'}]",24,18 Years,65 Years,ALL,False,National Institute of Mental Health (NIMH),NIH,0,22.0,ACTUAL,2025-09-01T16:18:13.417785,v2_robust,True,True,True,False,False,
NCT03603756,SHR-1210 in Combination With Apatinib and Chemotherapy in Patients With Advanced Esophageal Squamous Cell Cancer,"SHR-1210, a Novel Anti-PD-1 Antibody, in Combination With Apatinib and Irinotecan/Paclitaxel Liposome Plus Nedaplatin in Patients With Previously Untreated Advanced or Metastatic Esophageal Squamous Cell Cancer: a Phase II Study",SHR-1210,"['Paclitaxel liposome', 'SHR-1210', 'Irinotecan Injection', 'Apatinib', 'Nedaplatin']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Squamous Cell Carcinoma,['Esophageal Squamous Cell Carcinoma'],[],UNKNOWN,,2018-07-31,2021-03-28,"[{'measure': 'objective response rate', 'description': 'objective response rate of the patients in cohort 1 and cohort 2', 'timeFrame': '24 months'}]","[{'measure': 'progression-free survival (PFS)', 'description': 'progression-free survival (PFS) of the patients in cohort 1 and cohort 2', 'timeFrame': '24 months'}, {'measure': 'overall survival', 'description': 'overall survival of the patients in cohort 1 and cohort 2', 'timeFrame': '24 months'}, {'measure': 'treatment-related adverse events', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '24 months'}]",4,18 Years,70 Years,ALL,False,Chinese Academy of Medical Sciences,OTHER,0,45.0,ESTIMATED,2025-09-01T16:18:13.417938,v2_robust,True,True,False,False,True,
NCT06488222,Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer,Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer,Docetaxel,"['Gemcitabine', 'Docetaxel']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Bladder Cancer,['Bladder Cancer'],"['bladder cancer', 'transurethral resection', 'gemcitabine', 'docetaxel']",RECRUITING,,2024-11-05,2027-08,"[{'measure': 'Recurrence free survival', 'description': 'Evaluate the recurrence free survival, as measured by cystoscopy', 'timeFrame': '12 months after start of induction'}]","[{'measure': 'Progression rate', 'description': 'Determine the progression rate at 12 months, for tumor grade and stage, based on pathologic assessment of tumors in patients with disease recurrence. Development of the following will be considered progression: high grade disease, ≥ T1 disease, CIS.', 'timeFrame': '12 months after start of induction'}, {'measure': 'Treatment compliance', 'description': ""Determine treatment compliance, as measured by how many planned study treatments were given. This will be measured by documented administration of study treatments in the subject's medical record."", 'timeFrame': '12 months after the start of induction'}]",3,18 Years,,ALL,False,University of Florida,OTHER,0,34.0,ESTIMATED,2025-09-01T16:18:13.418145,v2_robust,True,True,False,False,False,
NCT00318422,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Liraglutide Effect and Action in Diabetes (LEAD-1): Effect on Glycaemic Control After Once Daily Administration of Liraglutide in Combination With Glimepiride Versus Glimepiride Monotherapy Versus Glimepiride and Rosiglitazone Combination Therapy in Subjects With Type 2 Diabetes.,liraglutide,"['liraglutide', 'glimepiride', 'rosiglitazone']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2006-05,2007-05,"[{'measure': 'HbA1c', 'timeFrame': 'after 26 weeks of treatment'}]","[{'measure': 'body weight'}, {'measure': 'Safety and tolerability'}, {'measure': 'beta-cell function'}, {'measure': 'Glycemic control parameters (fasting plasma glucose, -glucose profiles)'}]",5,18 Years,80 Years,ALL,False,Novo Nordisk A/S,INDUSTRY,0,1041.0,ACTUAL,2025-09-01T16:18:13.418164,v2_robust,True,True,True,False,True,
NCT00282022,VNP40101M in Treating Patients With Relapsed or Refractory Locally Advanced or Metastatic Small Cell Lung Cancer,A Phase II Trial of Cloretazine™ (VNP40101M) for Patients With Relapsed or Refractory Small Cell Lung Cancer,laromustine,['laromustine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Lung Cancer,['Lung Cancer'],"['recurrent small cell lung cancer', 'extensive stage small cell lung cancer', 'limited stage small cell lung cancer']",COMPLETED,,2005-09,,"[{'measure': 'Overall response rate (complete and partial response)'}, {'measure': 'Toxicity'}]",[],2,18 Years,,ALL,False,Vion Pharmaceuticals,INDUSTRY,0,87.0,ESTIMATED,2025-09-01T16:18:13.418173,v2_robust,True,True,True,False,False,
NCT02087722,Efficacy and Safety of KI1001 in the Treatment of ≥ 55 Years Old Insomnia Patients,"A Double-blind, Parallel Group, Randomised, Placebo Controlled, Multicenter, Bridging Study of Efficacy and Safety of KI1001 in the Improvement of Sleep Quality in ≥ 55 Years Old Insomnia Patients",KI1001,"['KI1001', 'Placebo tablets 2mg', 'Prolonged release melatonin 2mg', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Sleep Initiation and Maintenance Disorders,['Sleep Initiation and Maintenance Disorders'],['Primary Insomnia'],COMPLETED,,2013-08,2014-01,"[{'measure': 'QOS in KMLSEQ', 'description': 'KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire QOS - Quality of Sleep', 'timeFrame': 'Three weeks'}]","[{'measure': 'GTS in KMLSEQ', 'description': 'KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire GTS - Getting to Sleep', 'timeFrame': 'Three weeks'}, {'measure': 'AFS in KMLSEQ', 'description': 'KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire AFS - Awakening from Sleep', 'timeFrame': 'Three weeks'}, {'measure': 'BFW in LSEQ', 'description': 'KMLSEQ - Korean Modified Leeds Sleep Evaluation Questionnaire BFW - Behavior following Wakefulness', 'timeFrame': 'Three weeks'}, {'measure': 'QOD', 'description': 'Quality of Day in Patient Diary', 'timeFrame': 'Three weeks'}, {'measure': 'QON', 'description': 'Quality of Night in Patient Diary', 'timeFrame': 'Three weeks'}, {'measure': 'QOL', 'description': 'WHO-5 Wellbeing Index QOL - Quality of Life', 'timeFrame': 'Three weeks'}, {'measure': 'PSQI', 'description': 'Pittsburgh Sleep Quality Index', 'timeFrame': 'Three weeks'}]",8,55 Years,,ALL,False,"Kuhnil Pharmaceutical Co., Ltd.",INDUSTRY,1,80.0,ACTUAL,2025-09-01T16:18:13.418190,v2_robust,True,True,True,False,False,
NCT04495322,"To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.","A Phase 1, Single-center, Randomized, Double-blind, Placebo-controlled, Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and to Evaluate the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.",TG-1000,"['TG-1000', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Chinese Volunteers,['Healthy Chinese Volunteers'],[],COMPLETED,,2020-07-17,2020-12-30,"[{'measure': 'Number of subjects of treatment-emergent adverse events', 'description': 'Any significant findings after dosing will be considered as adverse events.', 'timeFrame': '8 days'}, {'measure': 'Number of subjects of Significant Abnormal Vital Signs Findings', 'description': 'The systolic and diastolic blood pressure (mmHg), pulse/heart rate (beats/min), respiratory rate (breaths/min), and body temperature (oC) will be measured.', 'timeFrame': '8 days'}, {'measure': 'Number of subjects With Significant Abnormal Physical Examination Findings', 'description': 'A full general physical examination of the major body systems (General Appearance; Dermatological including skin and nails; Head and Neck; Chest region including Heart and Lung; Abdominal region including Gastrointestinal and Gastroenterology; Back region; Extremities; Psychiatric or Neurological; Lymph nodes; Other) will be performed by investigator.', 'timeFrame': '8 days.'}, {'measure': 'Number of subjects With Significant Abnormal 12-lead Electrocardiography (ECG) Findings', 'description': '12-lead ECG will be performed after a rest in a supine position. The following ECG parameters will be listed: heart rate, the time between QRS complexes (RR Interval) (ms), the beginning of the P wave to the first deflection of the QRS complex (PR Interval) (ms), first deflection of QRS complex to end of QRS complex at isoelectric line (QRS duration) (ms), first deflection of QRS complex to end of T wave at isoelectric line (QT interval) (ms), Corrected QT interval by Bazett (QTcB) (ms), and Corrected QT interval by - Fridericia (QTcF) (ms).', 'timeFrame': '8 days'}, {'measure': 'Number of subjects With Significant Abnormal Holter Electrocardiography (ECG) Findings', 'description': 'Holter ECG will be monitor continue from 12 hr pre-dose until 24 hr post-dose. The Investigator will determine whether the results of the Holter monitoring are normal or abnormal.', 'timeFrame': '12 hr pre-dose until 24 hr post-dose'}, {'measure': 'Number of Participants With Significant Abnormal Laboratory Values', 'description': 'Chemistry, Hematology, Coagulation, Urinalysis, Human Immunodeficiency Virus (HIV) test, Hepatitis A virus(HAV) test, Hepatitis B virus (HBV) test, Hepatitis C virus (HCV) test, syphilis, serum pregnancy tests and Breath Alcohol Test', 'timeFrame': '8 days'}, {'measure': 'Peak Plasma Concentration (Cmax)', 'description': 'Blood sample will be collected to evaluate PK profile and food effect of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'time to Cmax (Tmax)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'area under the curve from time zero to the time (AUC0-t)', 'description': 'Blood sample will be collected to evaluate PK profile and food effect of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-last)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'area under the concentration-time curve from time zero to infinity (AUC0-inf)', 'description': 'Blood sample will be collected to evaluate PK profile and food Effect of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'terminal elimination half-life (T1/2, z)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'apparent total body clearance (CL/F)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'apparent total volume distribution (V/F)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'plasma concentration 24 h after dosing (C24)', 'description': 'Blood sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}, {'measure': 'urinary excretion ratio relative to dose from time zero to the time (Feu0-t)', 'description': 'Urine sample will be collected to evaluate PK profile of TG-1000.', 'timeFrame': '15 days'}]",[],16,18 Years,45 Years,ALL,True,"TaiGen Biotechnology Co., Ltd.",INDUSTRY,1,66.0,ACTUAL,2025-09-01T16:18:13.418230,v2_robust,True,True,True,False,True,
NCT05433922,Efficacy and Safety of CSA and Avatrombopag for the Treatment of SAA in the Elderly,"A Multicenter, Single-arm Clinical Study of the Efficacy and Safety of CSA in Combination With Avatrombopag for the Treatment of Primary Treatment of Severe Aplastic Anemia in the Elderly",Avatrombopag,"['CSA', 'Avatrombopag']",2,INTERVENTIONAL,['NA'],,,Severe Aplastic Anemia,['Severe Aplastic Anemia'],"['Avatrombopag', 'Aplastic Anemia', 'elderly', 'sever']",UNKNOWN,,2022-06-01,2024-12-31,"[{'measure': 'OR rate at 24 weeks of treatment', 'description': 'Percentage of the total number of patients receiving treatment who received a response at 24 weeks of treatment', 'timeFrame': '24 weeks of treatment'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events as assessed by information on Common Toxicity Criteria (CTC) AE grading at 24 weeks of treatment', 'description': 'Incidence of Treatment-Emergent AE by CTCAE', 'timeFrame': '24 weeks of treatment'}, {'measure': 'Percentage of patients with transformation at 24 weeks', 'description': '% of patients with transformation to PNH or MDS,AML, or other disease', 'timeFrame': '24 weeks of treatment'}]","[{'measure': 'OR rate and CR rate at 12 weeks', 'description': 'Percentage of patients who received a response and who receive a complete response at 12 weeks of treatment', 'timeFrame': '12 weeks of treatment'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events as assessed by information on Common Toxicity Criteria (CTC) AE grading at 12 weeks', 'description': 'Incidence of Treatment-Emergent AE by CTCAE', 'timeFrame': '12 weeks of treatment'}, {'measure': 'Percentage of patients with transformation at 12 weeks', 'description': '% of patients with transformation to PNH or MDS,AML, or other disease at 12 weeks', 'timeFrame': '12 weeks of treatment'}]",6,60 Years,,ALL,False,"Institute of Hematology & Blood Diseases Hospital, China",OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:13.418238,v2_robust,True,True,False,False,True,
NCT04534322,Expanded Access Program for Melphalan Flufenamide (Melflufen) in Triple Class Refractory Multiple Myeloma,An Expanded Access Program Protocol for Melphalan Flufenamide in Combination With Dexamethasone in Patients With Triple Class Refractory Multiple Myeloma,Melphalan Flufenamide,"['Melphalan Flufenamide', 'melflufen', 'Dexamethasone']",3,EXPANDED_ACCESS,[],,,Relapsed and/or Refractory Multiple Myeloma,['Relapsed and/or Refractory Multiple Myeloma'],[],APPROVED_FOR_MARKETING,,,,[],[],0,18 Years,,ALL,,Oncopeptides AB,INDUSTRY,0,,,2025-09-01T16:18:13.418271,v2_robust,False,True,False,False,False,
NCT05059522,Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing,Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.,Avelumab,"['PF04518600', 'Axitinib', 'Talazoparib', 'Lorlatanib', 'Avelumab', 'CMP 001', 'Utomilumab', 'Pemetrexed']",8,INTERVENTIONAL,['PHASE3'],PHASE3,,Advanced Malignancies,"['Advanced Malignancies', 'NSCLC', 'Ovarian Cancer', 'Urothelial Cancer', 'Solid Tumors']","['BRCA Mutant Tumors', 'ATM Mutant Tumors']",ACTIVE_NOT_RECRUITING,,2021-09-29,2026-09-30,"[{'measure': 'Number of participants with adverse events leading to permanent discontinuation of study intervention', 'timeFrame': 'Baseline up to approximately 5 years'}, {'measure': 'Number serious adverse events reported for all participants', 'timeFrame': 'Baseline up to approximately 5 years'}]",[],2,18 Years,,ALL,False,Pfizer,INDUSTRY,0,68.0,ACTUAL,2025-09-01T16:18:13.418279,v2_robust,True,True,False,False,True,
NCT02256722,"In Vivo Specificity of KUC 7483 CL Co-administered With Bisoprolol, Propranolol, and Acipimox in Healthy Male Subjects","A Randomised, Open Label, Four-way Crossover Phase I Trial to Investigate the in Vivo Specificity of a Single Oral Dose of 320 mg KUC 7483 CL Co-administered With Bisoprolol (10 mg Daily), Propranolol (160 mg Daily), and Acipimox (500 mg Daily) Over 5 Days and a Single Inhalative Dose of 100 μg Salmeterol in Healthy Male Subjects",KUC 7483 CL,"['KUC 7483 CL', 'Propranolol', 'Bisoprolol', 'Acipimox', 'Salmeterol']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2005-10,,"[{'measure': 'Absolute change from baseline in glucose', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in glucose', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Absolute change from baseline in free fatty acids (FFA)', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in FFA', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Absolute change from baseline in insulin', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in insulin', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Absolute change from baseline in C-Peptide', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in C-Peptide', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Absolute change from baseline in Potassium', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in Potassium', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Absolute change from baseline in Magnesium', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in Magnesium', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Absolute change from baseline in cAMP', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Percentage change from baseline in cAMP', 'timeFrame': 'up to 24 hours after administration of study drug'}]","[{'measure': 'Number of subjects with adverse events', 'timeFrame': 'up to 80 days'}, {'measure': 'Number of subjects with clinically relevant changes in laboratory tests', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Number of subjects with clinically relevant changes in vital signs', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Number of subjects with clinically relevant findings in electrocardiogram', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Number of subjects with clinically relevant changes in physical examination', 'timeFrame': 'Baseline, within 10 days after last drug administration'}, {'measure': 'Maximum measured concentration of the analyte in plasma', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Time from dosing to the maximum concentration of the analyte in plasma', 'timeFrame': 'up to 24 hours after administration of study drug'}, {'measure': 'Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 4 hours', 'timeFrame': 'up to 24 hours after administration of study drug'}]",22,30 Years,60 Years,MALE,True,Boehringer Ingelheim,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:13.418307,v2_robust,True,True,True,False,True,
NCT05855122,Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients,Study of Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following High-dose Melphalan Conditioning in Patients With Multiple Myeloma,Tocilizumab,['Tocilizumab'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Multiple Myeloma,['Multiple Myeloma'],[],UNKNOWN,,2023-04-17,2024-12-31,"[{'measure': 'MDASI questionnaire', 'description': 'MDASI, also as the M. D. Anderson Symptom Inventory, is a brief measure of the severity and impact of cancer related symptoms. Each symptom is rated on an 11-point scale (0 -10) to indicate the presence and severity of the symptom, with 0 meaning ""not present"" and 10 meaning ""as bad as you can imagine."" Each symptom is rated at its worst in the last 24 hours.', 'timeFrame': 'day -7~day 100 after stem cells transfusion'}, {'measure': 'Adverse events', 'description': 'recording adverse events according to CTCAE5.0', 'timeFrame': 'day -7~day 100 after stem cells transfusion'}]",[],2,18 Years,70 Years,ALL,False,The First Affiliated Hospital of Soochow University,OTHER,0,48.0,ESTIMATED,2025-09-01T16:18:13.418337,v2_robust,True,True,False,False,True,
NCT01621022,Bupropion Alone or Combined With Nicotine Gum,Efficacy of Bupropion Alone and in Combination With Nicotine Gum,bupropion + nicotine gum,"['Placebo bupropion-Placebo gum', 'bupropion + nicotine gum', 'Active bupropion-Placebo gum']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Tobacco Dependence,['Tobacco Dependence'],"['smoking cessation', 'tobacco dependence']",COMPLETED,,2001-01,2002-10,"[{'measure': '7-day point prevalence abstinence measured at 6 months', 'description': 'No smoking, not evan a puff, during the 7 days prior to the 6 month follow-up', 'timeFrame': '6 months'}]",[],1,18 Years,,ALL,True,"University of Wisconsin, Madison",OTHER,1,608.0,ACTUAL,2025-09-01T16:18:13.418390,v2_robust,True,True,True,False,False,
NCT03523351,Study of Palliative Radiation Therapy vs. no Palliative Radiation Therapy for Patients With High Risk Bone Metastases That Are Not Causing Significant Pain,"A Randomized Trial of Early, Upfront Palliative Radiation Therapy Versus Standard of Care for Patients With Highest Risk Asymptomatic or Minimally Symptomatic Bone Metastases",Systemic Therapy,['Systemic Therapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Metastatic Solid Tumors of Metastatic Disease,['Metastatic Solid Tumors of Metastatic Disease'],"['Palliative Radiation', '18-196']",COMPLETED,,2018-05-01,2024-04-18,"[{'measure': 'Number of Participants With Skeletal Related Events (SREs)', 'description': 'which will be defined as pathological fractures, spinal cord compression, or palliative radiotherapy and orthopedic surgery to bone.', 'timeFrame': '1 year'}]",[],1,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,78.0,ACTUAL,2025-09-01T16:18:13.418492,v2_robust,True,True,True,False,False,
NCT04968951,Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC),REFOCUS: Refined Fecal Microbiota Transplantation (FMT) Delivered by Oral Capsules for Induction of Remission in Mild to Moderate Ulcerative Colitis - a Phase I Study,Metronidazole,"['Flagyl', 'Vancomycin', 'Metronidazole', 'Placebo']",4,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Ulcerative Colitis,"['Ulcerative Colitis', 'FMT', 'Fecal Microbiota Transplant']","['FMT', 'Fecal Microbiota Transplantation', 'Fecal Microbiota Transplant', 'Fecal Matter Transplant', 'Ulcerative colitis', 'UC']",TERMINATED,insufficient funding,2021-11-10,2022-08-22,"[{'measure': 'Proportion of participants with an adverse', 'description': 'Safety as measured by proportion of participants with an adverse event through week 8', 'timeFrame': '8 Weeks'}, {'measure': 'Proportion of participants with a severe adverse', 'description': 'Safety as measured by proportion of participants with a severe adverse event through week 8', 'timeFrame': '8 Weeks'}]","[{'measure': 'Number of patients requiring escalation of medical therapies', 'description': 'Number of patients requiring escalation of medical therapies based on clinical relapse. Clinical relapse is defined by requiring additional medical therapy.', 'timeFrame': '8 weeks'}, {'measure': 'Proportion of patients that achieve Mayo score 0 or 1', 'description': ""Proportion of patients with initial Mayo 2/3 disease at flexible sigmoidoscopy that achieve endoscopic improvement (Mayo score 0 or 1). The Mayo Score is a composite of subscores (each rated 0-3) from four categories, including stool frequency, rectal bleeding, findings of flexible proctosigmoidoscopy or colonoscopy, and physician's global assessment, with a total score ranging from 0-12, with higher score indicating worse health outcomes."", 'timeFrame': '8 weeks'}, {'measure': 'Number of patients with endoscopic remission', 'description': 'Number of patients with endoscopic remission as defined by a Mayo score of 0', 'timeFrame': '8 weeks'}, {'measure': 'Change in Nancy score', 'description': 'Change in histological score assessed by the Nancy score. The Nancy score includes 3 histologic items that define 5 grades of activity: absence of significant histologic disease, chronic inflammatory infiltrate with no acute inflammatory infiltrate, mildly active disease, moderately active disease, and severely active disease. The Nancy index is defined by a 5-level classification ranging from grade 0 (absence of significant histological disease activity) to grade 4 (severely active disease). higher score indicating worse health outcomes.', 'timeFrame': '8 weeks'}, {'measure': 'Fecal calprotectin level', 'description': 'Mean change fecal calprotectin levels', 'timeFrame': 'baseline and 8 weeks'}, {'measure': 'C-reactive protein levels', 'description': 'Mean change C-reactive protein levels', 'timeFrame': 'baseline and 8 weeks'}, {'measure': 'Hemoglobin levels', 'description': 'Mean change hemoglobin levels', 'timeFrame': 'baseline and 8 weeks'}, {'measure': 'Albumin levels', 'description': 'Mean change albumin levels', 'timeFrame': 'baseline and 8 weeks'}, {'measure': 'ESR level', 'description': 'Mean change erythrocyte sedimentation rate (ESR)', 'timeFrame': 'baseline and 8 weeks'}]",11,18 Years,75 Years,ALL,False,Ari M Grinspan,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:13.418500,v2_robust,True,True,False,True,True,insufficient funding
NCT02760251,Immunomodulation With Romiplostim in Young Adults With ITP,Thrombopoietin-receptor Agonist-immunomodulation in Young Adult Primary Immune Thrombocytopenia (ITP): A Multi-center Open Label Trial With Romiplostim,romiplostim,"['Nplate', 'romiplostim']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Immune Thrombocytopenia,['Immune Thrombocytopenia'],['immunomodulation'],COMPLETED,,2016-04,2020-03,"[{'measure': 'Change in Interleukin (IL)-4 concentrations (pg/ml) from baseline to week 22', 'description': 'The primary aim of the study is to demonstrate an immunomodulatory effect of the study drug. Investigators expect a shift in the Th1/Th2 balance towards Th2.\n\nThe primary outcome is to compare the pre- and post-treatment IL-4 concentrations (pg/ml) of all included patients (Th2 profile). Assessment of change in pre- and post-treatment IL-4 concentrations (pg/ml).', 'timeFrame': 'baseline and 22 weeks'}]","[{'measure': 'Change in immunomodulation as assessed by immune cell characteristics between baseline and week 22', 'description': 'Immunologic parameters will be investigated between baseline and week 22 of the study: immune cell characteristics\n\nfluorescence-activated cell sorting (FACS): B cells: cluster of Differentiation Antigen (CD)3- cluster of Differentiation Antigen (CD)19+ Memory B lymphocytes CD19+cluster of Differentiation Antigen (CD)10-cluster of Differentiation Antigen (CD)27+cluster of Differentiation Antigen (CD)38- Plasma cells: CD19+ CD10- cluster of Differentiation Antigen (CD)20- CD27++ cluster of Differentiation Antigen (CD)38++ Tcells and subpopulations: CD3+/ CD3+ CD4+/ CD3+ cluster of Differentiation Antigen (CD)8+ natural killer (NK) cells CD3- cluster of Differentiation Antigen (CD)16+ cluster of Differentiation (CD)56+ Monocytes CD56- cluster of Differentiation Antigen (CD)14 (low) CD16+ cluster of Differentiation Antigen (CD)33 Tregs CD4+ cluster of Differentiation Antigen (CD)25 superhigh FoxP3+', 'timeFrame': 'baseline and 22 weeks'}, {'measure': 'Change in immunomodulation as assessed by immune cell characteristics between baseline and week 10', 'description': 'Immunologic parameters will be investigated between baseline and week 10 of the study: immune cell characteristics\n\nFACS:\n\nB cells: CD3- CD19+ Memory B lymphocytes CD19+CD10-CD27+CD38- Plasma cells: CD19+ CD10- CD20- CD27++ CD38++ Tcells and subpopulations: CD3+/ CD3+ CD4+/ CD3+ CD8+ NK cells CD3- CD16+ CD56+ Monocytes CD56- CD14 (low) CD16+ CD33 Tregs CD4+ CD25 superhigh FoxP3+', 'timeFrame': 'baseline and 10 weeks'}, {'measure': 'Change in immunomodulation as assessed by messenger ribonucleic acid (mRNA) of cytokines between baseline and week 22', 'description': 'mRNA of cytokines will be investigated between baseline and week 22\n\nmRNA essays (real-time quantitative PCR): cytokine mRNA (interleucin (IL)2, interleucin (IL)4, interleucin (IL)6, interleucin (IL)10, IL17, interleucin (IL)35, IFNgamma, TNFalpha, transforming growth factor (TGF)-β)', 'timeFrame': 'baseline and 22 weeks'}, {'measure': 'Change in immunomodulation as assessed by mRNA of immune cells between baseline and week 22', 'description': 'mRNA of immune cells will be investigated between baseline and week 22\n\nmRNA essays (real-time quantitative PCR): mRNA Th1 (T-bet), Th2 (GATA-3), Th17 (RORγt), Tregs (Foxp3)', 'timeFrame': 'baseline and 22 weeks'}, {'measure': 'Change in immunomodulation as assessed by mRNA of cytokines between baseline and week 10', 'description': 'mRNA of cytokines will be investigated between baseline and week 10\n\nmRNA essays (real-time quantitative PCR): cytokine mRNA (IL2, IL4, IL6, IL10, IL17, IL35, IFNgamma, TNFalpha, TGF-β)', 'timeFrame': 'baseline and 10 weeks'}, {'measure': 'Change in immunomodulation as assessed by mRNA of immune cells between baseline and week 10', 'description': 'mRNA of immune cells will be investigated between baseline and week 10\n\nmRNA essays (real-time quantitative PCR): mRNA Th1 (T-bet), Th2 (GATA-3), Th17 (RORγt), Tregs (Foxp3)', 'timeFrame': 'baseline and 10 weeks'}, {'measure': 'Change in immunomodulation as assessed by cytokine concentrations between baseline and week 22', 'description': 'cytokine concentration will be investigated between baseline and week 22\n\nELISA Cytokines: IL2, IL4, IL6, IL10, IL17, IL35, IFNgamma, TNFalpha, TGF- β', 'timeFrame': 'baseline and 22 weeks'}, {'measure': 'Change in immunomodulation as assessed by cytokine concentrations between baseline and week 10', 'description': 'cytokine concentration will be investigated between baseline and week 10\n\nELISA Cytokines: IL2, IL4, IL6, IL10, IL17, IL35, IFNgamma, TNFalpha, TGF- β', 'timeFrame': 'baseline and 10 weeks'}, {'measure': 'Clinical response between baseline and week 52: number of severe bleeding', 'description': 'Clinical characterization of response to romiplostim therapy will be assessed additionally : measurement of severe bleeding (score Bolton-Maggs)', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Clinical response between baseline and week 52: number of days in hospital', 'description': 'Clinical characterization of response to romiplostim therapy will be assessed additionally : need of inpatient daycare', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Clinical response between baseline and week 52: platelet more than >100G/l', 'description': 'Clinical characterization of response to romiplostim therapy will be assessed additionally : assessment of platelet response to romiplostim, according to the definitions of Rodeghiero et al. (49).', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Change in immunomodulation as assessed by immune cell characteristics between baseline and week 52', 'description': 'Immunologic parameters will be investigated between baseline and week 52 of the study: immune cell characteristics\n\nFACS:\n\nB cells: CD3- CD19+ Memory B lymphocytes CD19+CD10-CD27+CD38- Plasma cells: CD19+ CD10- CD20- CD27++ CD38++ Tcells and subpopulations: CD3+/ CD3+ CD4+/ CD3+ CD8+ NK cells CD3- CD16+ CD56+ Monocytes CD56- CD14 (low) CD16+ CD33 Tregs CD4+ CD25 superhigh FoxP3+', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Change in immunomodulation as assessed by mRNA of immune cells between baseline and week 52', 'description': 'mRNA of immune cells will be investigated between baseline and week 52\n\nmRNA essays (real-time quantitative PCR): mRNA Th1 (T-bet), Th2 (GATA-3), Th17 (RORγt), Tregs (Foxp3)', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Change of immunomodulation as assessed by mRNA of cytokines between baseline and week 52', 'description': 'mRNA of cytokines will be investigated between baseline and week 52\n\nmRNA essays (real-time quantitative PCR): cytokine mRNA (IL2, IL4, IL6, IL10, IL17, IL35, IFNgamma, TNFalpha, TGF-β)', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Change in immunomodulation as assessed by cytokine concentrations between baseline and week 52', 'description': 'cytokine concentration will be investigated between baseline and week 52\n\nELISA Cytokines: IL2, IL4, IL6, IL10, IL17, IL35, IFNgamma, TNFalpha, TGF- β', 'timeFrame': 'baseline and 52 weeks'}, {'measure': 'Clinical response between baseline and week 52: frequency of use of rescue treatment', 'timeFrame': 'baseline and week 52'}]",17,18 Years,45 Years,ALL,False,"University Hospital, Basel, Switzerland",OTHER,1,15.0,ACTUAL,2025-09-01T16:18:13.418645,v2_robust,True,True,True,False,False,
NCT00513851,Phase 1 Study of OSI-930 in Cancer Patients,A Phase I Dose Escalation Study of Daily Oral OSI-930 in Patients With Advanced Solid Tumors,OSI-930,['OSI-930'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumors,['Advanced Solid Tumors'],"['Advanced Cancer', 'Non-small cell lung cancer', 'Small cell lung cancer', 'Uterine cancer', 'Ovarian cancer', 'Renal cancer', 'Head and neck cancer', 'Cervical cancer', 'Metastatic cancer', 'Colorectal cancer', 'Gastrointestinal stromal tumors']",COMPLETED,,2006-04,2009-09,"[{'measure': 'Determine the maximum tolerated dose (MTD) for both the once daily (QD) and twice daily (BID) dosing schedules and establish a recommended phase 2 dose of OSI-930', 'timeFrame': '2.5 years'}]","[{'measure': 'Safety, Pharmacokinetic profile, Pharmacodynamic relationships, Preliminary antitumor activity', 'timeFrame': '2.5 years'}]",2,18 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,1,60.0,ESTIMATED,2025-09-01T16:18:13.418792,v2_robust,True,True,True,False,True,
NCT03960151,Rolapitant Plus Olanzapine in Multiday Cisplatin Chemotherapy,"Phase II Study of Rolapitant Plus Olanzapine, Palonosetron, and Dexamethasone in Patients With Germ Cell Tumors Undergoing 5-day Cisplatin-based Chemotherapy.",Rolapitant,"['Palonosetron', 'Varubi', 'Olanzapine', 'Aloxi', 'Rolapitant', 'steroid', 'Zyprexa', 'Dexamethasone']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Germ Cell Tumor,['Germ Cell Tumor'],[],WITHDRAWN,Compound was sold by funder and development ceased.,2018-05,2022-03,"[{'measure': 'Complete Response Rate', 'description': 'Determine the complete response (CR) rate defined as no emesis and no use of rescue medications in germ cell tumor patients treated with rolapitant plus Olanzapine in combination with palonosetron a 5HT3RA and dexamethasone on Cycle 1 Day 1 through Day 8', 'timeFrame': '8 Days'}]","[{'measure': 'Complete Response Rate: Acute Phase', 'description': 'Determine the CR rate in the acute phase (Days 1-5) defined as no emesis and no use of rescue medications in germ cell tumor patients treated with rolapitant plus Olanzapine in combination with palonosetron a 5HT3RA and dexamethasone on Cycle 1 Day 1 through Day 5', 'timeFrame': '5 Days'}, {'measure': 'Complete Response Rate: Delayed Phase', 'description': 'Determine the CR rate in the delayed phase (Days 6-8) defined as no emesis and no use of rescue medications in germ cell tumor patients treated with rolapitant plus Olanzapine in combination with palonosetron a 5HT3RA and dexamethasone on Cycle 1 Day 6 through Day 8', 'timeFrame': '2 Days'}, {'measure': 'Frequency, intensity, and duration of nausea', 'description': 'Determine the frequency, intensity and duration of nausea on Days 1-8 in Cycle 1. The frequency, intensity and duration of nausea will be captured via daily self-assessment patient logs.', 'timeFrame': '8 Days'}, {'measure': 'Frequency of vomiting or retching.', 'description': 'Determine the frequency, intensity and duration of vomiting or retching on Days 1-8 in Cycle 1. The frequency of vomiting and retching will be captured via daily self-assessment patient logs.', 'timeFrame': '8 Days'}, {'measure': 'Intensity of Vomiting or retching.', 'description': 'Determine the intensity of vomiting or retching on Days 1-8 in Cycle 1. The intensity of vomiting and retching will be captured via daily self-assessment patient logs.', 'timeFrame': '8 Days'}, {'measure': 'Duration of Vomiting or retching', 'description': 'Determine the duration of vomiting or retching on Days 1-8 in Cycle 1. The duration of vomiting and retching will be captured via daily self-assessment patient logs.', 'timeFrame': '8 Days'}, {'measure': 'Rate of no nausea', 'description': 'Determine the rate of no nausea defined as \\< 5mm on a 0-100mm visual analog scale (VAS) on Days 1-5 and Days 6-8 on Cycle 1', 'timeFrame': '8 Days'}, {'measure': 'Use of rescue medications', 'description': 'Describe the use of rescue medications as defined in the protocol', 'timeFrame': '8 Days'}, {'measure': 'Assess adverse events of regimen using CTCAE v4.', 'description': 'Safety and toxicity will be assessed using CTCAE v4', 'timeFrame': '8 Days'}]",10,18 Years,,ALL,False,Costantine Albany,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:13.418802,v2_robust,True,True,False,True,True,Compound was sold by funder and development ceased.
NCT01469351,Identifying Potential Effects of Liraglutide on Degenerative Changes,Neurodegenerative Changes in Alzheimer's Disease: Identifying Potential Effects of Liraglutide on Degenerative Changes,Liraglutide,"['non-active study drug', 'Liraglutide']",2,INTERVENTIONAL,['NA'],,,Alzheimers Disease,['Alzheimers Disease'],['Alzheimers disease'],COMPLETED,,2012-01,2013-04,"[{'measure': 'PIB PET scan', 'description': ""Primarily to investigate whether 26 weeks of treatment with GLP-1 receptor liraglutide (Victoza ®) will change the intra-cerebral amyloid deposit in the CNS in patients with Alzheimer's disease assessed by PIB PET scan."", 'timeFrame': 'PIB PET-scan at baseline and after 26 weeks'}]","[{'measure': 'Neuro-psychological tests', 'description': 'To validate the cognitive functions using specific neuro-psychological test battery before and after treatment with liraglutide/placebo.', 'timeFrame': 'At baseline, after 12 weeks and after 26 weeks'}, {'measure': 'FDG PET Scan', 'description': 'To examine changes in glucose uptake in the CNS by FDG PET scan before and after 6 months of treatment with liraglutide/placebo', 'timeFrame': 'FDG PET-scan at baseline and after 26 weeks'}]",3,50 Years,80 Years,ALL,False,University of Aarhus,OTHER,0,34.0,ACTUAL,2025-09-01T16:18:13.418829,v2_robust,True,True,True,False,False,
NCT02560051,Hormone Therapy Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,Phase 2 Study of Androgen Deprivation Therapy (ADT) Plus Chemotherapy as Initial Treatment for Local Failures or Advanced Prostate Cancer,Doxorubicin,"['Adriamycin', 'Rubex', 'Emcyt', 'Nizoral', 'Degarelix', 'Doxorubicin', 'Taxotere', 'Docecad', 'Ketoconazole', 'Estramustine', 'Firmagon', 'Docetaxel']",12,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostatic Neoplasms,['Prostatic Neoplasms'],"['Prostate Cancer', 'Advanced', 'Local Failures']",TERMINATED,Slow accrual; resource re-allocation,2015-11,2017-09-14,"[{'measure': 'Efficacy as Measured by Number Who Progressed', 'description': 'Progression defined as increase in Prostate Specific Antigen (PSA) \\>0.3 ng/mL over 2 measurements or larger/new lesion', 'timeFrame': 'From the time the participant signs the informed consent until the participant was taken off-study or the study was stopped, an average of 10 months'}]","[{'measure': 'Efficacy as Measured by Number of Participants With Pathology/Biopsy Positive for Disease', 'timeFrame': 'about 10 months after treatment initiation'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood."", 'timeFrame': 'baseline'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood."", 'timeFrame': 'Cycle 1 Day 1, which is the day of treatment initiation'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood."", 'timeFrame': 'Cycle 2 Day 1, which is about 8 weeks after treatment initiation'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood."", 'timeFrame': 'Cycle 3 Day 1, which is about 16 weeks after treatment initiation'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood."", 'timeFrame': 'Cycle 4 Day 1, which is about 24 weeks after treatment initiation'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood."", 'timeFrame': 'Cycle 5 Day 1, which is about about 32 weeks after treatment initiation'}, {'measure': 'Efficacy as Measured by PSA Level', 'description': ""Prostate-specific antigen, or PSA, is a protein produced by normal, as well as malignant, cells of the prostate gland. The PSA test measures the level of PSA in a man's blood. For this test, a blood sample is sent to a laboratory for analysis. The results are reported as nanograms of PSA per milliliter (ng/mL) of blood.\n\nThe time point is the end of treatment, which is about about 8 weeks after the start of the last cycle. For the arm completing 3 cycles, the time point is 24 weeks after treatment initiation. For the arm completing 4 cycles, the time point is 32 weeks after treatment initiation. For the arm completing 5 cycles, the time point is 40 weeks after treatment initiation."", 'timeFrame': 'end of treatment, which is about about 8 weeks after the start of the last cycle'}, {'measure': 'Efficacy as Measured by Number Who PSA Progressed', 'description': 'PSA progression defined as increase in Prostate Specific Antigen (PSA) \\>0.3 ng/mL over 2 measurements', 'timeFrame': 'From the time the participant signs the informed consent until the participant was taken off-study or the study was stopped, an average of 10 months'}, {'measure': 'Quality of Life Measure by FACT-P Scale', 'description': 'The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.', 'timeFrame': 'post cycle 1, which is about 8 weeks after treatment initiation'}, {'measure': 'Quality of Life Measure by FACT-P Scale', 'description': 'The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.', 'timeFrame': 'post cycle 2, which is about 16 weeks after treatment initiation'}, {'measure': 'Quality of Life Measure by FACT-P Scale', 'description': 'The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.', 'timeFrame': 'post cycle 3, which is about 24 weeks after treatment initiation'}, {'measure': 'Quality of Life Measure by FACT-P Scale', 'description': 'The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.', 'timeFrame': 'post cycle 4, which is about 32 weeks after treatment initiation'}, {'measure': 'Quality of Life Measure by FACT-P Scale', 'description': 'The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.', 'timeFrame': 'post cycle 5, which is about about 40 weeks after treatment initiation'}, {'measure': 'Quality of Life Measure by FACT-P Scale', 'description': 'The Functional Assessment of Cancer Therapy-Prostate (FACT-P) scale is a tool used for assessing the health-related quality of life (QoL) in men with prostate cancer. It consists of 27 core items which assess patient function in four domains (Physical, Social/Family, Emotional, and Functional well-being), and it is further supplemented by 12 site specific items to assess for prostate-related symptoms. Each item is rated on a 0 to 4 Likert type scale, and then combined to produce a global QoL score, with a range of scores of 0 to 156. Higher scores represent better QoL.\n\nThe time point is about 12 weeks after completion of the last cycle. For the arm completing 3 cycles, the time point is 36 weeks after treatment initiation. For the arm completing 4 cycles, the time point is 44 weeks after treatment initiation. For the arm completing 5 cycles, the time point is 52 weeks after treatment initiation.', 'timeFrame': 'about 12 weeks after completion of the last cycle'}, {'measure': 'Safety of Drug Regimen as Measured by Number of Adverse Events', 'timeFrame': 'From the time the participant signs the informed consent until the participant was taken off-study or the study was stopped, an average of 10 months'}]",17,18 Years,,MALE,False,"The University of Texas Health Science Center, Houston",OTHER,0,19.0,ACTUAL,2025-09-01T16:18:13.418878,v2_robust,True,True,False,True,True,Slow accrual; resource re-allocation
NCT05866029,Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture,Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture,Denosumab,"['Denosumab', 'Teriparatide']",2,INTERVENTIONAL,['NA'],,,Osteoporotic Fractures,['Osteoporotic Fractures'],"['osteoporosis', 'osteoporotic fractures', 'bone turnover markers', 'imaging biomarkers']",RECRUITING,,2023-05-26,2026-09-30,"[{'measure': 'The incidence of new vertebral fractures', 'description': 'The incidence of new vertebral fractures (clinical and imaging) within 24 months of treatment', 'timeFrame': 'Within 24 months of treatment'}]",[],1,45 Years,90 Years,ALL,False,Peking Union Medical College Hospital,OTHER,0,2478.0,ESTIMATED,2025-09-01T16:18:13.418970,v2_robust,True,True,False,False,False,
NCT00686829,Vicriviroc (SCH 417690) Treatment Protocol in Human Immunodeficiency Virus (HIV)-Infected Participants: A Rollover Study for ACTG Protocol A5211 (P04100),Vicriviroc (SCH 417690) Treatment Protocol in HIV-Infected Subjects: A Rollover Study for ACTG Protocol A5211,Vicriviroc maleate,"['Vicriviroc maleate', 'SCH 417690']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV,"['HIV', 'HIV Infections']",['Treatment Experienced'],COMPLETED,,2005-06-30,2010-10-21,"[{'measure': 'Percentage of Participants With ≥1 Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which does not necessarily have a causal relationship with the treatment.', 'timeFrame': 'Up to discontinuation of commercial VCV availability (up to approximately 5.5 years)'}, {'measure': 'Percentage of Participants Discontinuing Study Therapy Due to AEs', 'description': 'An AE is any untoward medical occurrence in a participant administered a pharmaceutical product, biologic (at any dose), or medical device, which does not necessarily have a causal relationship with the treatment.', 'timeFrame': 'Up to discontinuation of commercial VCV availability (up to approximately 5.5 years)'}, {'measure': 'Percentage of Participants With ≥1 Serious Adverse Events (SAEs)', 'description': 'An SAE is any adverse occurrence that results in death; is life-threatening; results in a persistent disability; requires in-patient hospitalization or prolongs hospitalization; or is a congenital anomaly/birth defect.', 'timeFrame': 'Up to discontinuation of commercial VCV availability (up to approximately 5.5 years)'}, {'measure': 'Percentage of Participants With HIV Ribonucleic Acid (RNA) <50 Copies/mL', 'description': 'The percentage of participants with HIV RNA \\<50 copies/mL at each time point is reported. For this measure, ""month"" was defined as each 28-day period on study treatment. The Roche Amplicor® HIV-1 monitor test was used to quantify HIV RNA.', 'timeFrame': 'Every 12 months up to 60 months'}, {'measure': 'Percentage of Participants With HIV RNA >50 to <400 Copies/mL', 'description': 'The percentage of participants with HIV RNA \\>50 to \\<400 copies/mL at each time point is reported. For this measure, ""month"" was defined as each 28-day period on study treatment. The Roche Amplicor® HIV-1 monitor test was used to quantify HIV RNA.', 'timeFrame': 'Every 12 months up to 60 months'}, {'measure': 'Percentage of Participants With HIV RNA ≥400 Copies/mL', 'description': 'The percentage of participants with HIV RNA ≥400 copies/mL at each time point is reported. For this measure, ""month"" was defined as each 28-day period on study treatment. The Roche Amplicor® HIV-1 monitor test was used to quantify HIV RNA.', 'timeFrame': 'Every 12 months up to 60 months'}, {'measure': 'Number of Participants With Coreceptor Tropism Shifts From Baseline', 'description': 'The number of participants with non reportable (NR) tropism, CCR5 (R5) tropism, or dual/mixed CCR5/CXCR4 (DM/X4) tropism at baseline, who had NR, R5, or DM/X4 tropism at the time of virologic failure (VF) is reported. The definition of VF is an increase in HIV RNA level \\>0.5 log10 copies/mL compared to the baseline HIV RNA level.', 'timeFrame': 'Baseline (Week 48 of ACTG study A5211) and time of VF in P4100, assessed up to approximately 5.5 years'}, {'measure': 'Mean Change From Baseline in CD4/CD8 Cell Counts', 'description': 'The mean change from baseline in CD4/CD8 counts throughout P4100 until the time of VF is reported. ""Month"" was defined as each 28-day period on study treatment. A fluorescent-activated cell sorter (FACS) analysis was used to quantify CD4/CD8 lymphocytes. The definition of VF is an increase in HIV RNA level \\>0.5 log10 copies/mL compared to the baseline HIV RNA level.', 'timeFrame': 'Baseline (Week 48 of ACTG study A5211) and up to time of VF in P4100, assessed up to approximately 5.5 years'}, {'measure': 'Number of Participants With Reduced Susceptibility to VCV', 'description': 'The total number of participants with viruses having phenotypic resistance to VCV is reported. Viruses exhibiting both maximum percent inhibition (MPI) plateau values of \\<85% and relative MPI (R-MPI) values of \\<0.9 (based on the PhenoSense HIV entry assay) were considered to have phenotypic resistance to VCV.', 'timeFrame': 'Up to time of VF in P4100, assessed up to approximately 5.5 years'}, {'measure': 'Number of Participants With AIDS-defining Events (ADEs)', 'description': 'The number of participants with ADEs is reported. An ADE is an SAE that is expected in the course of disease and not considered related to study intervention. The sponsor identified events that met ADE criteria based on the 1993 Centers for Disease Control (CDC) Revised Classification System.', 'timeFrame': 'Up to discontinuation of commercial VCV availability (up to approximately 5.5 years)'}, {'measure': 'Number of Participants With New Infections', 'description': 'The number of participants with new infections is reported.', 'timeFrame': 'Up to discontinuation of commercial VCV availability (up to approximately 5.5 years)'}]",[],11,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,79.0,ACTUAL,2025-09-01T16:18:13.419379,v2_robust,True,True,True,False,True,
NCT02116231,The Role of Adding Concurrent Chemotherapy to IMRT in the Treatment of Stage II Nasopharyngeal Carcinoma,Phase II Study Comparing Intensity Modulated Radiotherapy (IMRT) in Combination With Concurrent Chemotherapy and IMRT Alone for Stage II Nasopharyngeal Carcinoma,Concurrent chemotherapy with cisplatin,['Concurrent chemotherapy with cisplatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Effects of Chemotherapy,['Effects of Chemotherapy'],['Nasopharyngeal neoplasm;IMRT; Concurrent chemotherapy'],UNKNOWN,,2014-04,2018-05,"[{'measure': 'Failure-free survival (FFS)', 'description': 'The time is calculated from the date of diagnosis to the date of occurrence of relapse or distant metastasis.', 'timeFrame': 'One year'}]","[{'measure': 'Overall survival (OS)', 'description': 'The time is calculated from the date of diagnosis to the date of patient death.', 'timeFrame': 'One year'}, {'measure': 'Loco-regional failure-free survival (LFFS)', 'description': 'The time is calculated from the date of diagnosis to the date of a relapse of local or nodal tumors.', 'timeFrame': 'One year'}, {'measure': 'Distant metastasis failure-free survival (DMFS)', 'description': 'The time is calculated from the date of diagnosis to the date of occurrence of relapse or distant metastasis.', 'timeFrame': 'One year'}, {'measure': 'Acute and late adverse events', 'description': 'The side effects will be evaluated according to CTCAE V 3.0.', 'timeFrame': 'Four months'}]",5,18 Years,70 Years,ALL,False,Cancer Hospital of Guangxi Medical University,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:13.419544,v2_robust,True,True,False,False,True,
NCT05465031,Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent (MAINSTREAM),Sacubitril/Valsartan in PriMAry preventIoN of the Cardiotoxicity of Systematic breaST canceR trEAtMent,Sacubitril-valsartan,"['Sacubitril-valsartan', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Breast Cancer,"['Breast Cancer', 'Neoplasm, Breast', 'Breast Diseases', 'Antihypertensive Agents', 'Sacubitril/Valsartan', 'Angiotensin II Type 1 Receptor Blockers', 'Angiotensin Receptor Antagonists', 'Molecular Mechanisms of Pharmacological Action', 'Heart Failure', 'Cardiac Toxicity', 'Cancer, Therapy-Related', 'Cancer Therapy-Related Cardiac Dysfunction', 'Cardiotoxicity']","['LCZ696', 'Sacubitril/Valsartan', 'Magnetic Resonance Imaging', 'Echocardiography', 'Cardio-oncology', 'Breast Cancer', 'Cardiotoxicity', 'Anthracyclines', 'Trastuzumab', 'Heart failure', 'Cardioprotection']",RECRUITING,,2024-04-17,2029-02,"[{'measure': 'Change in left ventricular ejection fraction (LVEF) by ≥5%', 'description': 'Reduction of LVEF assessed on transthoracic echocardiography (TTE)', 'timeFrame': 'Within 24 months from the randomization visit'}]","[{'measure': 'Death from any cause or hospitalization for heart failure', 'description': 'Composite clinical endpoint', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Death from any cause', 'description': 'Clinical endpoint', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Death from cardiovascular causes', 'description': 'Clinical endpoint', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Hospitalization for other cardiovascular causes', 'description': 'Clinical endpoint', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Change in left ventricular ejection fraction by ≥ 5%', 'description': 'Reduction of LVEF assessed on magnetic resonance imaging (MRI)', 'timeFrame': 'From Randomization till the end of blinded therapy - within 24 months'}, {'measure': 'Occurrence of diastolic dysfunction (TTE) within 24 months of randomization', 'description': 'Diastolic dysfunction assessed on echocardiography', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': '- Development of pathological pericardial fluid volume or increase in pericardial fluid volume from baseline', 'description': 'Assessed with any available clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Occurrence of cardiac tamponade', 'description': 'Assessed with any clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Occurrence of pericarditis', 'description': 'Assessed with any clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Occurrence of myocarditis', 'description': 'Assessed with any clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Development of ventricular arrhythmias', 'description': 'Assessed with any clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Development of supraventricular arrhythmias', 'description': 'Assessed with any clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Presence of conduction disturbances', 'description': 'Assessed with any clinical modality', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Changes in corrected QT interval', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Changes in B-type natriuretic peptide (BNP) or N-terminal prohormone of brain natriuretic peptide (NT pro-BNP) (pg/mL)', 'description': 'Assessed with serial laboratory measurements', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}, {'measure': 'Changes in cardiac troponins (cardiac troponin T preferred over troponin I) (ng/L)', 'description': 'Assessed with serial laboratory measurements', 'timeFrame': 'From Randomization till the end of blinded therapy - at 24 months'}]",17,18 Years,,FEMALE,False,Silesian Centre for Heart Diseases,OTHER,1,600.0,ESTIMATED,2025-09-01T16:18:13.419579,v2_robust,True,True,False,False,False,
NCT05142631,Fruquintinib in the Treatment of Soft Tissue Sarcoma,"Single Center, Open, Single Arm Phase II Clinical Study of Fruquintinib in the Treatment of Soft Tissue Sarcoma",Fruquintinib,['Fruquintinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Soft Tissue Sarcoma,['Soft Tissue Sarcoma'],"['soft tissue sarcoma', 'Fruquintinib']",UNKNOWN,,2021-11-21,2023-08-30,"[{'measure': 'PFS', 'description': 'progression free survival', 'timeFrame': '2 months'}]","[{'measure': 'ORR', 'description': 'objective response rat', 'timeFrame': '2 months'}, {'measure': 'OS', 'description': 'over survival', 'timeFrame': '6 months'}, {'measure': 'DCR', 'description': 'disease control rate', 'timeFrame': '2 months'}, {'measure': 'DoR', 'description': 'duration of response', 'timeFrame': '2 months'}, {'measure': 'TTR', 'description': 'time to response', 'timeFrame': '2 months'}, {'measure': 'AE', 'description': 'Adverse Events', 'timeFrame': '2 months'}]",7,18 Years,,ALL,False,Fudan University,OTHER,0,31.0,ESTIMATED,2025-09-01T16:18:13.419638,v2_robust,True,True,False,False,True,
NCT04141631,Transfusion Savings in Heart Surgery: Impact of Individual Strategy by Erythropoietin and Metabolic Adjustment (ScvO2),"Patient Blood Management in Cardiac Surgery by Erythropoietin, Ferric Carboxymaltose and Metabolic Adjustment (ScvO2): A Randomized Controlled Study","EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)","['EPO (600UI/Kg, sub-cutaneous) and Ferric Carboxymaltose (FCM) (20 mg/kg in 250 mL of saline solution 0.9% over 15 min)']",1,INTERVENTIONAL,['NA'],,,Cardiac Surgery,"['Cardiac Surgery', 'Transfusion', 'Perioperative Anemia']","['Perioperative Erythropoietin', 'Perioperative Iron', 'ScVO2', 'Patient blood Management', 'Blood Transfusion']",COMPLETED,,2020-01-13,2022-06-15,"[{'measure': 'Transfusion incidence at hospital discharge', 'description': 'Number of patients transfused of blood units', 'timeFrame': 'up to Day 28'}]","[{'measure': 'ICU transfusion incidence', 'description': 'Number of blood units transfused during ICU stay', 'timeFrame': 'at ICU discharge or up to Day 28'}, {'measure': 'total of blood units transfused', 'description': 'number of blood units administered per patient', 'timeFrame': 'up to day 28'}, {'measure': 'Hemoglobin level at surgery discharge and Hemoglobin level at 1 month after discharge from hospital', 'description': 'the last hemoglobin value at surgery discharge and the hemoglobin value at 1 month after discharge from hospital', 'timeFrame': 'at surgery discharge (or at Day 28) and at 1 month after discharge from hospital'}, {'measure': 'The total duration of mechanical ventilation', 'description': 'The total duration of mechanical ventilation in ICU', 'timeFrame': 'at ICU discharge or up to Day 28'}, {'measure': 'length of stay in ICU', 'description': 'numbers of days in ICU', 'timeFrame': 'up to day 28'}, {'measure': 'Length of hospital stay', 'description': 'Length of stay during hospitalization (Between 1 and 28 day)', 'timeFrame': 'at day 28'}, {'measure': 'Incidence of Mortality', 'description': 'Incidence of 28-day mortality', 'timeFrame': 'at day 28'}, {'measure': 'Incidence of postoperative events in ICU', 'description': 'AKI (KDIGO criteria), Cardiac dysfunction (acute heart failure requiring inotrope or extracorporeal life support (ECLS), arrythmia), vascular dysfunction (norepinephrine support without sepsis), respiratory dysfunction (non invasive ventilation devices, secondary intubation,mechanical ventilation more than 12 hours), septic complications (sepsis/septic shock)', 'timeFrame': 'at day 28'}]",9,18 Years,90 Years,ALL,False,"University Hospital, Montpellier",OTHER,0,128.0,ACTUAL,2025-09-01T16:18:13.419661,v2_robust,True,True,True,False,False,
NCT00179231,Olanzapine Versus Clozapine in Treatment Refractory Schizophrenia,,olanzapine vs. clozapine,['olanzapine vs. clozapine'],1,INTERVENTIONAL,['NA'],,,Schizophrenia,"['Schizophrenia', 'Schizoaffective Disorder']",[],COMPLETED,,2000-05,2004-02,"[{'measure': 'There has not been an adequate of test of whether olanzapine is as effective as clozapine in treatment'}, {'measure': 'resistant patients. Several recent studies suggest olanzapine may be effective in some clozapine responders as well as in treatment resistant patients. A head to head comparison is needed to clarify the relative efficacy'}]",[],2,18 Years,60 Years,ALL,False,Vanderbilt University,OTHER,0,80.0,,2025-09-01T16:18:13.419687,v2_robust,True,True,True,False,False,
NCT06173531,Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome,"A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome",Carbetocin,"['Carbetocin', 'Placebo', 'ACP-101']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Hyperphagia in Prader-Willi Syndrome,['Hyperphagia in Prader-Willi Syndrome'],"['Randomized', 'Placebo-controlled']",ACTIVE_NOT_RECRUITING,,2023-11-27,2025-11,"[{'measure': 'Change from Baseline at Week 12 in caregiver-rated Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score', 'description': ""The HQ-CT is a nine-item questionnaire designed to be completed by caregivers of subjects with PWS. It is a revision of the 11-item HPWSQ-R and has been further validated. The Foundation for Prader-Willi Research has made the HQ-CT available for clinical studies in PWS, and it is the consensus instrument within the PWS research community for measuring observable behaviors that stem from subjects' excessive drive to eat.\n\nThe HQ-CT should be completed by the same caregiver throughout the study. The HQ-CT will be administered to the caregiver by a rater using standardized prompts. The Food Safe Zone should be administered immediately before administration of the HQ-CT.\n\nA higher score on the HQ-CT indicates greater severity of hyperphagia."", 'timeFrame': 'Baseline to Week 12'}]","[{'measure': 'Change from Baseline at Week 12 in caregiver-rated Clinical Global Impression-Severity (CGI-S) score for PWS', 'description': ""The CGI-S is a rating scale that records a clinician's global impression of the current severity of illness on a seven-point scale, using a range of responses from 1 (normal) to 7 (among the most severely ill subjects)."", 'timeFrame': 'Baseline to Week 12'}, {'measure': 'Clinical Global Impression-Change (CGI-C) for PWS score at Week 12', 'description': ""The CGI-C is a rating scale that records a clinician's global impression of change in severity of illness, using a range of responses from 1 (very much improved) to 7 (very much worse)."", 'timeFrame': 'Score at Week 12'}]",3,5 Years,30 Years,ALL,False,ACADIA Pharmaceuticals Inc.,INDUSTRY,0,170.0,ESTIMATED,2025-09-01T16:18:13.419716,v2_robust,True,True,False,False,False,
NCT03742531,Does Induction Dosage in Latent Phase Affect Active Phase of Labor?,Does Induction Dosage in Latent Phase Affect Active Phase of Labor?A Randomized Study,oxytocin,"['synpitan', 'oxytocin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Oxytocin,"['Oxytocin', 'Induction of Labor']",[],COMPLETED,,2018-12-15,2019-12-01,"[{'measure': 'need for oxytocin retreatment', 'description': 'need for oxytocin retreatment due to inadequate uterine contractions and labor arrest', 'timeFrame': 'an average of one year'}]","[{'measure': 'length of active phase', 'description': 'duration of acive phase of labor', 'timeFrame': 'an average of one year'}, {'measure': 'ratio of caesarean section', 'description': 'caesaraen section rate in total delivery', 'timeFrame': 'an average of one year'}, {'measure': 'total oxytocin dose', 'description': 'total amount of oxytocin treatment in latent and active phase of labor', 'timeFrame': 'an average of one year'}, {'measure': 'APGAR scores', 'description': 'neonatal 1 minute and 5-minute-APGAR scores', 'timeFrame': 'an average of one year'}]",5,18 Years,40 Years,FEMALE,True,Zeynep Kamil Maternity and Pediatric Research and Training Hospital,OTHER,0,300.0,ACTUAL,2025-09-01T16:18:13.419739,v2_robust,True,True,True,False,False,
NCT03273231,The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection,The Effect of Ketamine on Immune Function and Prognosis in Patients Undergoing Colorectal Cancer Resection,Ketamine,"['Saline', 'Ketamine']",2,INTERVENTIONAL,['NA'],,,Colorectal Cancer,['Colorectal Cancer'],[],UNKNOWN,,2017-09-01,2020-07,"[{'measure': 'natural killer cell cytotoxicity', 'description': 'Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).', 'timeFrame': 'Baseline'}, {'measure': 'natural killer cell cytotoxicity', 'description': 'Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).', 'timeFrame': '1 hour after surgery'}, {'measure': 'natural killer cell cytotoxicity', 'description': 'Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).', 'timeFrame': 'postoperative day 1'}, {'measure': 'natural killer cell cytotoxicity', 'description': 'Natural killer cell cytotoxicity is measured with NK Vue Kit™(ATGen, Gyeonggi-do, Korea).', 'timeFrame': 'postoperative day 2'}]","[{'measure': 'proinflammatory cytokine', 'description': 'Inflammtory response is assesssed by measuring levels of proinflammtory cytokines.', 'timeFrame': 'Baseline'}, {'measure': 'proinflammatory cytokine', 'description': 'Inflammtory response is assesssed by measuring levels of proinflammtory cytokines.', 'timeFrame': '1 hour after surgery'}, {'measure': 'proinflammatory cytokine', 'description': 'Inflammtory response is assesssed by measuring levels of proinflammtory cytokines.', 'timeFrame': 'postoperative day 1'}, {'measure': 'proinflammatory cytokine', 'description': 'Inflammtory response is assesssed by measuring levels of proinflammtory cytokines.', 'timeFrame': 'postoperative day 2'}, {'measure': 'recurrence', 'description': 'Cancer recurrence is evaluated 1 year after surgery.', 'timeFrame': '1 year after surgery'}, {'measure': 'metastasis', 'description': 'Cancer metastasis is evaluated 1 year after surgery.', 'timeFrame': '1 year after surgery'}]",10,20 Years,80 Years,ALL,False,Yonsei University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:13.419760,v2_robust,True,True,False,False,False,
NCT00791102,Topical ASP-1001 (Contrast Media Formulation) and the Acute Response to Nasal Allergen Challenge (NAC),"A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Trial of Topical ASP-1001 (Contrast Media Formulation) in the Prevention of the Signs and Symptoms of the Acute Response to Nasal Allergen Challenge (NAC)",ASP-1001 nasal spray,"['Placebo for ASP-1001', 'ASP-1001 nasal spray']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Allergic Rhinitis,['Allergic Rhinitis'],[],COMPLETED,,2010-01,2010-12,"[{'measure': 'Change in Sneezing Symptom', 'description': 'Sneezes. The change is calculated by adding the number of sneezes following both antigen challenges minus twice the number of sneezes after the diluent challenge.', 'timeFrame': '10 minutes after diluent challenge and 10 minutes after each antigen challenge'}, {'measure': 'Change in Runny Nose Symptom', 'description': 'The nasal symptoms on a scale of 0-3 (0=no symptoms, 1=mild, 2= moderate, 3= severe). The change is calculated by adding the score of runny nose following both antigen challenges minus twice the score of runny nose after the diluent challenge.', 'timeFrame': '10 minutes after diluent challenge and 10 minutes after each antigen challenge'}, {'measure': 'Change in Stuffy Nose Symptom', 'description': 'The nasal symptoms on a scale of 0-3 (0=no symptoms, 1=mild, 2= moderate, 3= severe). The change is calculated by adding the score of stuffy nose following both antigen challenges minus twice the score of stuffy nose after the diluent challenge.', 'timeFrame': '10 minutes after diluent challenge and 10 minutes after each antigen challenge'}, {'measure': 'Change in Itching Symptom', 'description': 'The nasal symptoms on a scale of 0-3 (0=no symptoms, 1=mild, 2= moderate, 3= severe). The change is calculated by adding the score of itchy nose following both antigen challenges minus twice the score of itchy nose after the diluent challenge.', 'timeFrame': '10 minutes after diluent challenge and 10 minutes after each antigen challenge'}]","[{'measure': 'Nasal Peak Inspiratory Flow Measurements', 'description': 'The value of nasal peak inspiratory flow. The change is calculated by adding the values of nasal peak inspiratory flow following both antigen challenges minus twice the value of nasal peak inspiratory flow after the diluent challenge.', 'timeFrame': '15 minutes after diluent challenge and 15 minutes after each antigen challenge'}, {'measure': 'Change in Nasal Peak Inspiratory Flow Measurements From Before to After Treatment', 'timeFrame': '15 minutes prior to treatment and 15 minutes post antigen challenges'}]",6,18 Days,55 Years,ALL,True,University of Chicago,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:13.419791,v2_robust,True,True,True,False,False,
NCT02576002,Epidemiology and Treatment Patterns of Paediatric PAH (Pulmonary Arterial Hypertension),Study to Estimate the Incidence and Prevalence and Treatment Patterns of Pediatric Pulmonary Hypertension in the US,Assigned pulmonary hypertension medication,['Assigned pulmonary hypertension medication'],1,OBSERVATIONAL,[],,,"Hypertension, Pulmonary","['Hypertension, Pulmonary']",['Pulmonary Arterial Hypertension'],COMPLETED,,2015-10,2016-01,"[{'measure': 'Incidence rate of PAH (pulmonary arterial hypertension)', 'timeFrame': 'Retrospective analysis of three year period'}, {'measure': 'Prevalence rate of PAH', 'timeFrame': 'Retrospective analysis of three year period'}]","[{'measure': 'Assigned drug treatment for PAH measured using the MarketScan database', 'description': 'Description of pulmonary hypertension-targeted drugs prescribed in the study population and changes during the study period', 'timeFrame': 'Retrospective analysis of three year period'}, {'measure': 'Diagnostic procedures performed among PAH patients measured using the MarketScan database', 'timeFrame': 'Retrospective analysis of three year period'}, {'measure': 'Prevalence of comorbidities among PAH patients', 'timeFrame': 'Retrospective analysis of three year period'}]",5,,18 Years,ALL,False,Bayer,INDUSTRY,0,2691.0,ACTUAL,2025-09-01T16:18:13.419825,v2_robust,False,True,True,False,False,
NCT00354302,Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Who Are Receiving Treatment on Clinical Trial,The Influence of Five Years of Adjuvant Anastrozole or Exemestane on Bone Mineral Density In Postmenopausal Women With Primary Breast Cancer,alendronate sodium,"['risedronate sodium', 'alendronate sodium', 'calcium gluconate']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,"['Breast Cancer', 'Osteoporosis']","['osteoporosis', 'stage I breast cancer', 'stage II breast cancer', 'stage IIIA breast cancer']",COMPLETED,,2006-04-24,2012-01-06,"[{'measure': 'Percentage change of bone mineral density (BMD) measured at 2 years (from baseline) in the L1-L4 region of the spine and the hip', 'timeFrame': '5 years'}]","[{'measure': 'Percentage change in BMD at 5 years (from baseline)', 'timeFrame': '5 years'}, {'measure': 'Mean percentage change in BMD at 1, 3, and 5 years (from baseline)', 'timeFrame': '5 years'}, {'measure': 'Proportion of patients without osteopenia or osteoporosis (stratum I) who develop BMD below the absolute threshold for osteopenia (< -2.0 standard deviation below the mean), suffer any osteoporotic fracture, or have an asymptomatic fracture revealed ...', 'timeFrame': '5 years'}, {'measure': 'Percentage of patients with osteopenia or osteoporosis (stratum II) who have ≥ 5% improvement of BMD at 2 years post randomization on protocol CAN-NCIC-MA27 and who have clinically apparent osteoporosis-related fracture of the long bones', 'timeFrame': '5 years'}, {'measure': 'Pattern of change in bone biomarkers from baseline', 'timeFrame': '5 years'}, {'measure': 'Clinical safety and tolerability of study medications', 'timeFrame': '5 years'}]",7,45 Years,120 Years,FEMALE,False,NCIC Clinical Trials Group,NETWORK,3,497.0,ACTUAL,2025-09-01T16:18:13.419855,v2_robust,True,True,True,False,True,
NCT01253902,Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension,,bimatoprost ophthalmic solution 0.01%,"['bimatoprost ophthalmic solution 0.01%', 'Xalatan®', 'travoprost ophthalmic solution 0.004%', 'Lumigan® 0.01%, Lumigan® RC', 'Travatan Z®', 'latanoprost ophthalmic solution 0.005%']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,"Glaucoma, Open-Angle","['Glaucoma, Open-Angle', 'Ocular Hypertension']",[],COMPLETED,,2010-12,2011-10,"[{'measure': 'Mean Conjunctival Hyperemia at Week 12', 'description': 'Conjunctival hyperemia was analyzed using the average of the scores of both eyes. Hyperemia is engorgement of the blood vessels (redness) of the bulbar conjunctiva of the eye (the clear membrane covering the white surface of the eye). Hyperemia was graded on a 5 point scale where 0=none (normal), 0.5=trace (trace flush reddish pink), 1=Mild (mild flush reddish color), 2=Moderate (bright red color) and 3=severe (deep bright diffuse redness).', 'timeFrame': 'Week 12'}]","[{'measure': 'Mean Corneal Staining With Fluorescein at Week 12', 'description': 'Corneal staining was analyzed using the average of the scores of both eyes. The cornea is the transparent front part of the eye which covers the iris and pupil. To detect the presence or absence of corneal puncta (tiny disruptions in the surface of the eye), fluorescein dye is administered into the eye and the eye is graded using a 5-point scale where 0=None (no puncta), 0.5=Trace (1-5 puncta), 1=Mild (6-20 puncta), 2=Moderate (\\>20 puncta) and 3=Severe (too many puncta to count).', 'timeFrame': 'Week 12'}, {'measure': 'Mean Tear Break Up Time (TBUT) at Week 12', 'description': 'Tear Break Up Time was analyzed using the average of the readings of both eyes. TBUT is defined as the time (seconds) required for dry spots to appear on the surface of the eye after blinking. The longer it takes, the more stable the tear film.', 'timeFrame': 'Week 12'}]",3,18 Years,,ALL,False,Allergan,INDUSTRY,0,164.0,ACTUAL,2025-09-01T16:18:13.419908,v2_robust,True,True,True,False,False,
NCT05017402,Higher Dose of Alglucosidase Alpha for Pompe Disease,Higher Dose of Alglucosidase Alpha for Pompe Disease: Long-term Follow-up Study,Alglucosidase Alfa,['Alglucosidase Alfa'],1,OBSERVATIONAL,[],,,Glycogen Storage Disease Type II,['Glycogen Storage Disease Type II'],[],NOT_YET_RECRUITING,,2021-09-01,2026-12-31,"[{'measure': 'Forced vital capacity', 'description': 'Pulmonary function test (Units: percentage of predictive value)', 'timeFrame': 'For patient older than 3-year-old, first test before study, then every six months, up to 2-years.'}, {'measure': 'Peak expiratory flow', 'description': 'Pulmonary function test (Units: percentage of predictive value)', 'timeFrame': 'For patient older than 3-year-old, first test before study, then every six months, up to 2-years.'}, {'measure': 'Polysomnography', 'description': 'Comprehensive test used to diagnose sleep disorders.', 'timeFrame': 'For patient older than 6-month-old, first test before study, then every six months, up to 2-years.'}]","[{'measure': 'uGLC4', 'description': 'Urine glucose tetrasaccharide (Units: mmol/mol Creatinine).', 'timeFrame': 'uGLC4 will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'CK', 'description': 'Blood creatine kinase (Units: units per liter, U/L).', 'timeFrame': 'CK will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'AST', 'description': 'Blood aspartate aminotransferase (Units: units per liter, U/L).', 'timeFrame': 'AST will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'ALT', 'description': 'Blood alanine aminotransferase (Units: units per liter, U/L).', 'timeFrame': 'ALT will be tested before the treatment, then every three months, up to 2-years.'}, {'measure': 'Body weight', 'description': 'Change of body weight (Unit: kilogram, kg)', 'timeFrame': 'The body weight will be monitored before the treatment, then every two weeks, up to 2-years.'}, {'measure': 'Body height', 'description': 'Change of body height (Units: centimeter, cm)', 'timeFrame': 'The body height will be monitored before the treatment, then every two weeks, up to 2-years.'}, {'measure': 'Antibody titers', 'description': 'Alglucosidase alfa IgG antibody titer', 'timeFrame': 'First test will be one month later after first ERT, then every six months, up to 2-years.'}]",10,0 Years,60 Years,ALL,False,"Taipei Veterans General Hospital, Taiwan",OTHER_GOV,0,36.0,ESTIMATED,2025-09-01T16:18:13.419957,v2_robust,False,True,False,False,False,
NCT04678102,"Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)","A Phase I, Open-label, Dose-finding Study to Assess the Safety, Tolerability, and Pharmacokinetics of PHI-101 in Patients With Platinum-Resistance/Refractory Ovarian Cancer",PHI-101 administration,"['PHI-101', 'PHI-101 administration']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Platinum-resistant Ovarian Cancer,"['Platinum-resistant Ovarian Cancer', 'Platinum-refractory Ovarian Carcinoma', 'Platinum-Resistant Fallopian Tube Carcinoma', 'Platinum-Resistant Primary Peritoneal Carcinoma']","['PHI-101', 'Chk2 inhibitor', 'antineoplastic', 'Platinum-resistant Ovarian Cancer']",UNKNOWN,,2020-12-17,2023-12-31,"[{'measure': 'Proportion of patients with dose-limiting toxicity (DLT)', 'description': 'The frequency and percentage of DLT that occurs during 1 cycle (28 days) after administration of the IP will be presented by the cohort.', 'timeFrame': 'Subjects will be treated and observed for DLT through the end of the first cycle (Days 1-28)'}, {'measure': 'Maximum tolerated dose', 'description': 'The dose of PHI-101 will be escalated until an MTD is determined, and if the MTD is not determined at the MPD, dose escalation will be ended at that dose', 'timeFrame': 'Through the first cycle (Day1-28)'}]","[{'measure': 'Dose interruption (temporary discontinuation) percent (%)', 'description': 'Dose interruption percent (temporary discontinuation) of the IP due to adverse events (AEs) in each cohort will be presented using frequency and percentage, and 95% exact confidence intervals (CIs).', 'timeFrame': 'Through the first cycle (Day1-28)'}, {'measure': 'Dose reduction percent (%)', 'description': 'Dose reduction percent (%) of the IP due to adverse events (AEs) in each cohort will be presented using frequency and percentage, and 95% exact confidence intervals (CIs).', 'timeFrame': 'Through the first cycle (Day1-28)'}, {'measure': 'Dose termination (permanent discontinuation) percent (%)', 'description': 'Dose termination percent (%) of the IP due to adverse events (AEs) in each cohort will be presented using frequency and percentage, and 95% exact confidence intervals (CIs).', 'timeFrame': 'Through the first cycle (Day1-28)'}, {'measure': 'Cmax', 'description': 'Maximum plasma concentration after administration', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'AUCt', 'description': 'Area under the plasma concentration-time curve to the last measurable blood sampling time point, calculated by the trapezoidal method. AUC of the interval with increasing plasma concentration is calculated by a linear trapezoidal method, and AUC of the interval with decreasing plasma concentration is calculated by the log-linear trapezoidal summation. Concentrations below lower limit of quantification (LLOQ) will be excluded from calculation.', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'AUCτ', 'description': 'Area under the plasma concentration-time curve from time of administration to τ (AUCτ) (τ: dosing interval)', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'AUCinf', 'description': 'Area under the plasma concentration-time curve extrapolated from the time of a single dose to infinity. AUCinf = AUClast + Clast /λz', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'Tmax', 'description': 'Time to maximum plasma concentration after administration', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'Tmax,ss', 'description': 'Time to maximum plasma concentration at steady state', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 't1/2', 'description': 'Half-life obtained by calculating ln(2)/λz, where λz is the elimination rate constant obtained from the linear regression analysis of log-linear plot at the terminal phase of the plasma concentration-time curve', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'PTF', 'description': 'Fluctuation (%) between the maximum and minimum plasma concentrations at steady state', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'AR', 'description': 'Ratio of systemic exposure of the drug at steady state to systemic exposure of the drug after a single dose', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'CL/F', 'description': 'Apparent clearance CL/F = Dose/AUCinf', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'CLss/F', 'description': 'Apparent clearance at steady state', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'Vdz/F', 'description': 'Volume of distribution in the terminal phase', 'timeFrame': 'Cycle1Day1, Cycle1Day8, Cycle1Day15, Cycle2Day1, Cycle3Day1, Cycle6day1, and then, every 12 weeks until end of the study, up until 24 months (each cycle is 28 days)'}, {'measure': 'Objective response rate (ORR)', 'description': 'ORR = complete response (CR) + partial response (PR)\n\n: For subjects who have best overall response (BOR) of complete response (CR) or partial response (PR), frequency and percentage, and 95% exact CIs will be presented by cohort evaluated according to the RECIST criteria by CT imaging.', 'timeFrame': 'Until the end of the study or death, which may be up to 24 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'DCR=CR+PR+SD For subjects with BOR of CR, PR, or stable disease (SD), frequency and percentage, and 95% exact CIs will be presented by cohort and evaluated according to the RECIST criteria by CT imaging.', 'timeFrame': 'Until the end of the study or death, which may be up to 24 months'}, {'measure': 'Duration of response (DOR)', 'description': 'The time interval from response to progression or death', 'timeFrame': 'Until the end of the study or death, which may be up to 24 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'The time interval from enrollment to progression or death', 'timeFrame': 'Until the end of the study or death, which may be up to 24 months'}, {'measure': 'Overall survival (OS)', 'description': 'The time interval from enrollment to death', 'timeFrame': 'Until the end of the study or death, which may be up to 24 months'}, {'measure': 'Time to progression (TTP)', 'description': 'the time interval from enrollment date to disease recurrence or progression except death', 'timeFrame': 'Until the end of the study or death, which may be up to 24 months'}, {'measure': 'presence of genetic variation', 'description': 'homologous recombination deficiency \\[HRD\\] related genetic variation such as BRCA mutation', 'timeFrame': 'at the time of enrollment'}, {'measure': 'Number of of adverse events', 'description': 'The investigator should review the measurement, examination, and assessment results of vital signs, physical examination, laboratory tests, ECG, etc. performed for the safety assessment, and assess and record the clinical significance of abnormal results. Any clinically significant abnormal findings (medical condition or abnormal values) should be collected as AEs.', 'timeFrame': 'Up to 24 months from the start of the intervention'}]",25,19 Years,,FEMALE,False,Seoul National University Hospital,OTHER,1,36.0,ESTIMATED,2025-09-01T16:18:13.420004,v2_robust,True,True,False,False,True,
NCT04711902,Study of Efficacy and Safety of Secukinumab in Chinese Subjects With Active PsA Compared to Placebo.,"A Phase III Randomized, Double-blind, Placebo Controlled, Multicenter, Bridging Study of Subcutaneous Secukinumab, to Demonstrate Efficacy After Sixteen Weeks of Treatment and to Assess Safety, Tolerability and Long-term Efficacy Follow-up to One Year in Chinese Subjects With Active Psoriatic Arthritis",AIN457,"['AIN457', 'Secukinumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriatic Arthritis,['Psoriatic Arthritis'],"['PsA', 'immune-mediated chronic inflammatory disease', 'spondylarthritis', 'SpA', 'inflammatory musculoskeletal disease', 'China bridging study', 'AIN457', 'secukinumab']",COMPLETED,,2021-06-24,2023-03-10,"[{'measure': 'ACR20 Response at Week 16', 'description': ""Assessed the efficacy of secukinumab relative to placebo at week 16 using Non-responder imputation (NRI) and based on the percentage of participants achieving an ACR20 response (ACR = American College of Rheumatology). ACR20 response criteria is response ≥ 20% improvement based on:\n\nSwollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (Visual Analog Scale (VAS)), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI), and High-sensitivity C-reactive protein (hsCRP) or Erythrocyte sedimentation rate (ESR)."", 'timeFrame': '16 weeks'}]","[{'measure': 'ACR50 Response at Week 16', 'description': ""To assess the effect of secukinumab versus placebo on the composite endpoint ACR50 response and based on the percentage of participants achieving an ACR50 response at Week 16 using NRI. ACR50 response criteria is response ≥ 50% improvement based on: Swollen Joint Count (SJC)/Tender Joint Count (TJC), Patient's global assessment of disease activity (PaGA) (VAS), Physician's global assessment of disease activity (PhGA) (VAS), Patient's assessment of PsA pain intensity (VAS), HAQ-DI, and hsCRP or ESR."", 'timeFrame': '16 weeks'}, {'measure': 'Change From Baseline in DAS28-CRP Scores Using Mixed Model Repeated Scores (MMRM) at Week 16', 'description': 'To assess the effect of secukinumab versus placebo on change from BSL in DAS28-CRP. The assessment is based on the reduction in DAS28-CRP score.\n\nThe DAS28 is a measure of disease activity based on Swollen and Tender Joint Counts, ESR or CRP and the Patient Global Assessment of Disease Activity. The range of DAS28 score is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.', 'timeFrame': '16 weeks'}, {'measure': 'Change From Baseline in PASDAS Scores Using MMRM at Week 16', 'description': 'To assess the the effect of secukinumab versus placebo on change from Baseline in PASDAS. Assessment was based on reduction in PASDAS score.\n\nPASDAS is a measure of disease activity based on Patient reported measures (excluding mental component score (MCS) of the medical outcomes survey Short Form-36 (SF-36-PCS)), skin, peripheral joint counts (Tender and Swollen joint counts), Dactylitis (LDI), Enthesitis (LEI), acute phase response (CRP) and Patient \\& Physician global VAS scores. The range of PASDAS is 0-10. Higher score means more active disease. Negative change from baseline indicates a favorable outcome.', 'timeFrame': '16 weeks'}, {'measure': 'Change From Baseline in SF36-PCS Scores Using MMRM at Week 16', 'description': 'To assess the effect of secukinumab versus placebo on change from Baseline in SF-36 PCS.\n\nThe SF-36 is a widely used and extensively studied instrument to measure HRQoL among healthy participants and participants with acute and chronic conditions. Two overall summary scores, the Physical Component Score (PCS) and the Mental Component Score (MCS) also can be computed. SF36-PCS was used in this study. The range of SF36-PCS score is 0-100. Higher score means better health status. Negative change from baseline indicates a unfavorable outcome.', 'timeFrame': '16 weeks'}, {'measure': 'Change From Baseline in HAQ-DI Scores Using MMRM at Week 16', 'description': ""To assess the effect of secukinumab versus placebo on change from Baseline in HAQ-DI. Assessment was based on improvement in HAQ-DI PCS scores.\n\nThe HAQ-DI© is one of the most widely used measures to assess the long-term influence of chronic disease on a participant's level of functional ability and activity restriction, and calculated based on HAQ-DI questionnaire. There are 20 questions in eight categories of functioning including dressing, rising, eating, walking, hygiene, reach, grip, and usual activities. The range of score is 0-3. Higher score means more severe disability. Negative change from baseline indicates a favorable outcome."", 'timeFrame': '16 weeks'}]",6,18 Years,99 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,41.0,ACTUAL,2025-09-01T16:18:13.420019,v2_robust,True,True,True,False,False,
NCT00003453,Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer,Phase II Study of Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Adrenal Gland,Antineoplaston therapy (Atengenal + Astugenal),"['Antineoplaston therapy (Atengenal + Astugenal)', 'A10 (Atengenal); AS2-1 (Astugenal)ANP']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Stage IV Adrenocortical Carcinoma,['Stage IV Adrenocortical Carcinoma'],['recurrent adrenocortical carcinoma'],TERMINATED,Slow enrollment,1996-08-21,2011-07-05,"[{'measure': 'Number of Participants With Objective Response', 'description': 'Objective response rate per Response Assessment in Neuro-Oncology (RANO) for target lesions and assessed by MRI: Complete Response (CR), disappearance of all disease sustained for at least four weeks; Partial Response (PR), \\>=50% decrease in the sum of the products of of the greatest perpendicular diameters of all measurable enhancing lesions, sustained for at least four weeks.', 'timeFrame': '12 months'}]","[{'measure': 'Percentage of Participants Who Survived', 'description': '6 months, 12 months, 24 months, 36 months, 48 months, 60 months overall survival', 'timeFrame': '6 months, 12 months, 24 months, 36 months, 48 months, 60 months'}]",2,6 Months,99 Years,ALL,False,Burzynski Research Institute,OTHER,0,6.0,ACTUAL,2025-09-01T16:18:13.420348,v2_robust,True,True,False,True,False,Slow enrollment
NCT07008053,BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma,"BR (Bendamustine and Zuberitamab) Combined With OR (Orelabrutinib and Zuberitamab) in Treatment-naïve Marginal Zone Lymphoma: A Multicenter, Prospective Study",BR+OR,['BR+OR'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Marginal Zone Lymphomas,['Marginal Zone Lymphomas'],"['Lymphoma、Marginal zone lymphoma、Orelabrutinib', 'Bendamustine', 'Zuberitamab']",NOT_YET_RECRUITING,,2025-07,2028-11,"[{'measure': 'Complete response rate', 'description': 'Complete response rate is defined as the proportion of patients with a response of CR.', 'timeFrame': 'From enrollment to the end of induction therapy of cycle 6 (each cycle is 28 days)'}]","[{'measure': 'Overall response rate (ORR)', 'description': 'The ORR is defined as the proportion of patients with a response of CR or PR.', 'timeFrame': 'At the end of induction therapy (6 cycles; each cycle is 28 days)'}, {'measure': 'Time to response (TTR)', 'description': 'TTR is defined as the time from the start of therapy to the first response.', 'timeFrame': 'From the start of therapy to the first documentation of response, assessed up to 3 years.'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR is defined as the time from documentation of response to treatment to the first documentation of tumor progression or death due to any cause, whichever comes first.', 'timeFrame': 'From the first demonstration of response until disease progression/death, up to 3 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined as the time from enrollment to the first occurrence of progression or relapse as assessed by the investigator, or death from any cause. PFS for patients without disease progression, relapse, or death will be censored at the time of the last tumor assessment.', 'timeFrame': 'From the date of enrollment until the date of first documented progression, up to 3 years'}, {'measure': 'Overall survival (OS)', 'description': 'OS is defined as the enrollment to death from any cause. Patients who have not died until the time of the analysis will be censored at their last contact date.', 'timeFrame': 'From the date of enrollment until the date of death, up to 3 years'}, {'measure': 'The occurrence of adverse events (AEs)', 'description': 'AEs will be graded by the investigator according to the NCI-CTCAE Version 5.0.', 'timeFrame': 'From the date of enrollment until the date of death, up to 3 years'}]",7,18 Years,,ALL,False,Tianjin Medical University Cancer Institute and Hospital,OTHER,0,37.0,ESTIMATED,2025-09-01T16:18:13.420362,v2_robust,True,True,False,False,True,
NCT06380153,To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment,To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild and Moderate Renal Impairment and Normal Renal Function After a Single Oral Administration,Hemay005,"['Hemay005', 'Hemay005 tablet']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Psoriasis,['Psoriasis'],[],RECRUITING,,2024-05-07,2025-12-31,"[{'measure': 'Relevant pharmacokinetic parameters，Peak Plasma Concentration（Cmax）', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}, {'measure': 'Relevant pharmacokinetic parameters，Area under the plasma concentration versus time curve（AUC0-t）', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}, {'measure': 'Relevant pharmacokinetic parameters，Area under the curve from time 0 extrapolated to infinite time (AUC0-inf)', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}, {'measure': 'Relevant pharmacokinetic parameters，half-life (T1/2)', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}, {'measure': 'Relevant pharmacokinetic parameters，clearance (CL/F)', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}, {'measure': 'Relevant pharmacokinetic parameters，volume of distribution (Vz/F)', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}, {'measure': 'Relevant pharmacokinetic parameters ，Renal clearance rate（CLr）', 'description': 'All subjects who receive the drug will be analyzed for pharmacokinetic', 'timeFrame': 'Day1-Day6'}]",[],7,18 Years,70 Years,ALL,True,"Ganzhou Hemay Pharmaceutical Co., Ltd",INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:13.420385,v2_robust,True,True,False,False,False,
NCT04398953,A Study of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL),"A Single-arm, Multicenter Phase II Clinical Trial of TQ-B3525 Tablet in the Treatment of Relapsed / Refractory Mantle Cell Lymphoma (MCL)",TQ-B3525,['TQ-B3525'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapsed / Refractory Mantle Cell Lymphoma (MCL),['Relapsed / Refractory Mantle Cell Lymphoma (MCL)'],[],UNKNOWN,,2020-07-20,2021-09,"[{'measure': 'Objective response rate (ORR) assessed by Independent Review Committee (IRC)', 'description': 'Percentage of subjects achieving complete response (CR) and partial response (PR) based on investigator.', 'timeFrame': 'up to 12 months'}]","[{'measure': 'Disease control rate（DCR）', 'description': 'Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).', 'timeFrame': 'up to 12 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.', 'timeFrame': 'up to 12 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS was defined as the time from the date of study enrollment to the date of the first of the following events, objective disease progression or death due to any cause.', 'timeFrame': 'up to 12 months'}, {'measure': 'Overall survival (OS)', 'description': 'OS defined as the time from the first dose to death from any cause. Survival time was censored at the date of last contact for patients who were still alive or lost to follow-up.', 'timeFrame': 'up to 18 months'}, {'measure': 'Biomarkers', 'description': 'To assess the changes of genes related to PI3K pathway and bypass in the tissues and / or plasma of enrolled patients.', 'timeFrame': 'up to 12 months'}]",6,18 Years,,ALL,False,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,102.0,ESTIMATED,2025-09-01T16:18:13.420480,v2_robust,True,True,False,False,False,
NCT01081353,Pharmacokinetic Study Comparing Aspirin and Effervescent Aspirin,An Open Label 4-Way Crossover Pharmacokinetic Trial of New Formula Aspirin Versus Effervescent Aspirin in Healthy Adult Subjects,Acetylsalicylic Acid (Aspirin BAY1019036),"['Alka Seltzer Extra Strength', 'Aspirin Aspro', 'Aspirin Migraine', 'Acetylsalicylic Acid (Aspirin BAY1019036)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics,['Pharmacokinetics'],"['Aspirin', 'Acetylsalicylic Acid']",COMPLETED,,2010-02,2010-03,"[{'measure': 'Bioavailability of new formulation aspirin versus marketed effervescent tablets (500mg aspirin)', 'timeFrame': '24 hours'}]","[{'measure': 'Adverse event collection', 'timeFrame': '24 hours'}]",2,18 Years,55 Years,ALL,True,Bayer,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:13.420550,v2_robust,True,True,True,False,True,
NCT04044937,Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms,Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm,F-18 Fluoroethyltyrosine (FET),"['Fluoroethyltyrosine F18', 'O-(2[F18]fluoroethyl)-L-tyrosine', ""Fluorine-18 2''-Fluoroethyl-L-tyrosine"", '[18F]-Fluoro-ethyl-L-tyrosine', ""2''-[F18] Fluoro-ethyl-L-tyrosine"", 'F-18 Fluoroethyltyrosine (FET)', '18FET', '18F-FET']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Intracranial Neoplasm,"['Intracranial Neoplasm', 'Low Grade Glioma', 'Recurrent Glioblastoma', 'Recurrent World Health Organization (WHO) Grade II Glioma', 'Recurrent WHO Grade III Glioma']",[],COMPLETED,,2018-10-29,2024-03-31,"[{'measure': 'Misclassification rate for either having recurrent disease or not having recurrent disease for patients previously treated for glial and metastatic disease (Population 1)', 'description': 'Radiologists will classify lesions as having recurrent disease or not having recurrent disease. True Positives (TP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates tumor recurrence in at least one biopsy sample, False positives (FP) are defined as an FET PET read positive for tumor and pathology/follow-up demonstrates negative tumor recurrence in all of the biopsy samples, True negatives (TN) are defined as an FET PET read as negative for tumor and pathology/follow-up also negative tumor recurrence in all of the biopsy samples and a false negative (FN) is defined as an FET PET read as negative for tumor and pathology/follow-up demonstrates tumor recurrence in at least one biopsy sample. Misclassification rate = \\[FP+FN)\\]/\\[FP+FN+TP+TN\\]', 'timeFrame': 'Up to 6 months'}, {'measure': 'Misclassification rate for either high grade or low grade in patients with suspected neoplasms (Population 2)', 'description': 'Readers will have access only to FET PET images for participants with suspected glial neoplasms (Grade 2-4) planning to undergo biopsy or surgery prior to primary treatment during evaluation and will grade the lesions in a binary fashion as having Grade II glial neoplasms or having Grade III/IV glial neoplasms. True positive (TP2): FET PET read as positive for Grade III/IV neoplasm, pathology demonstrates Grade III/IV neoplasm. False positive (FP2): FET PET read as positive for Grade III/IV neoplasm, pathology demonstrates Grade II neoplasm. True negative (TN2): FET PET read as positive for Grade II neoplasm, pathology demonstrates Grade II neoplasm. False negative (FN2): FET PET read as positive for Grade II neoplasm, pathology demonstrates Grade III/IV neoplasm. Misclassification rate = \\[FP2+FN2\\]/\\[FP2+FN2+TP2+TN2\\]', 'timeFrame': 'Up to 6 months'}]","[{'measure': 'Binary characterization of follow-up imaging as positive/negative for tumor recurrence', 'description': 'Participants with available histology (performed within 4 weeks of FET scans) or follow-up imaging (performed within 6 months of FET scan) will be included and a composite truth standard for recurrence or treatment-related changes will be evaluated for each case. In the absence of pathology, the composite truth standard will use available clinical information to make a determination. Positive for tumor recurrence on follow-up imaging will be based on Response assessment in neuro-oncology criteria (RANO) criteria reads. Follow-up imaging has to be performed within six months of the FET PET imaging study to be considered for evaluation. Additionally, the composite truth standard may consider tumor board notes and subsequent management of the patient to make a determination.', 'timeFrame': 'Up to 6 months'}, {'measure': 'Misclassification rate for FET PET in the evaluation of recurrent low-grade gliomas (Population 1)', 'description': 'Low-grade glioma is defined by low uptake of FET. Radiologists will classify lesions based on imaging as either having recurrent disease or not having recurrent disease. True Positives (TP1L) are defined as an FET PET read positive for low-grade tumor and pathology/follow-up demonstrates low-grade tumor recurrence in at least one biopsy sample, False positives (FP1L) are defined as an FET PET read positive for low grade tumor recurrence and pathology/follow-up demonstrates negative low-grade tumor recurrence in all of the biopsy samples, True negatives (TN1L) are defined as an FET PET read as negative for low-grade tumor recurrence and pathology/follow-up also negative for low grade tumor recurrence in all of the biopsy samples and a false negative (FN1L) is defined as an FET PET read as negative for low grade tumor recurrence and pathology/follow-up demonstrates low grade tumor recurrence in at least one biopsy sample. Misclassification rate = \\[FP1L+FN1L)\\]/\\[FP1L+FN1L+TP1L+TN1L\\]', 'timeFrame': 'Up to 6 months'}, {'measure': 'Degree of inter-rater reliability for tracer uptake', 'description': ""Fleiss' kappa statistic will be used to determine the agreement between the assessment of FET-PET tumor targeting (tracer uptake in target lesion: yes/ no), as assessed by three independent blinded readers. Scores range from 0 to 1 with higher scores indicating a great degree of agreement"", 'timeFrame': 'Up to 6 months'}, {'measure': 'Degree of inter-rater reliability for radiological interpretations', 'description': ""Cohen's kappa statistics will be used to determine the reproducibility of the assessment by individual readers when analyzing the same data repeatedly and measures the agreement between two raters who each classify items into mutually exclusive categories."", 'timeFrame': 'Up to 6 months'}]",6,3 Years,,ALL,False,Thomas Hope,OTHER,0,143.0,ACTUAL,2025-09-01T16:18:13.420694,v2_robust,True,True,True,False,False,
NCT00943137,The Optimization of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer,The Optimisation of 5-Fluorouracil Dose by Pharmacokinetic Monitoring in Asian Patients With Advanced Stage Cancer,5-Fluorouracil,['5-Fluorouracil'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Cancer (Advanced Stage),['Cancer (Advanced Stage)'],[],UNKNOWN,,2009-06,2017-06,"[{'measure': 'AUC of 20-24 mg.h/L', 'description': 'If patient achieved target AUC for two consecutive cycles, therapeutic dose monitoring will performed every alternate cycle.', 'timeFrame': '28 days - 2 cycles'}]",[],1,21 Years,80 Years,ALL,False,"National University Hospital, Singapore",OTHER,0,55.0,ESTIMATED,2025-09-01T16:18:13.420762,v2_robust,True,True,False,False,False,
NCT05382637,Growth Hormone in a Patient With a Dominant-Negative GHR Mutation,Growth Hormone in a Patient With a Dominant-Negative GHR Mutation,Somatropin,['Somatropin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Growth Disorders,['Growth Disorders'],[],ACTIVE_NOT_RECRUITING,,2022-08-26,2028-09-01,"[{'measure': 'Growth Hormone Dose', 'description': 'Dose of growth hormone required in mg/kg/day to achieve an IGF-1 level above the mean', 'timeFrame': '1 year'}]","[{'measure': 'Growth Velocity', 'description': 'Growth velocity during 1st year of growth hormone treatment', 'timeFrame': '1 year'}, {'measure': 'Height Standard Deviation Score Using Center for Disease Control (CDC) Growth Chart', 'description': ""Change in age and sex adjusted height standard deviation score based on the US CDC growth charts over the course of the 1st year of treatment with growth hormone. Height standard deviation score based on the US CDC growth chart data. The CDC provides tables of both height percentiles and standard deviations of the distribution of heights by age and sex. The CDC has a SAS program that allows for calculation of an individual's height standard deviation score based on the population data. This is the standard way that height is recorded in many growth studies."", 'timeFrame': 'Baseline to 1 Year'}]",3,9 Years,,MALE,False,Children's National Research Institute,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:13.420832,v2_robust,True,True,False,False,False,
NCT03557437,High Dose of Amoxicillin and Metronidazole Plus Bismuth For Helicobacter Pylori Treatment,Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial,Esomeprazole,"['Esomeprazole', 'Amoxicillin, Metronidazole', 'Bismuth Potassium Citrate']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],['Helicobacter pylori Therapy'],COMPLETED,,2018-05-25,2019-06-10,"[{'measure': 'Helicobacter pylori eradication rate', 'description': 'Six weeks after completion of therapy, H. pylori eradication was assessed by ¹³C-urea breath test. Eradication was defined as negative result from urea breath test (\\<4‰) (4‰ as the cutoff value).', 'timeFrame': 'Six weeks after completion of therapy'}]","[{'measure': 'Rate of adverse effects', 'description': 'The subjects were asked to grade the severity of adverse events according to their influence on daily activities, experienced as ""mild"" (transient and well tolerated), ""moderate"" (causing discomfort and partially interfering with daily activities), or ""severe"" (causing considerable interference with daily activities)', 'timeFrame': 'Within 7 days after completion of therapy'}, {'measure': 'Compliance rate', 'description': 'Compliance was defined as poor when they had taken less than 80% of the total medication', 'timeFrame': 'Within 7 days after completion of therapy'}]",3,18 Years,80 Years,ALL,False,Shanghai Jiao Tong University School of Medicine,OTHER,0,216.0,ACTUAL,2025-09-01T16:18:13.420875,v2_robust,True,True,True,False,True,
NCT01261637,Abdominal Wall Local Anesthesia to Maximize Postoperative Pain Control After Cesarean Delivery,Ultrasound Guided 0.25% Ropivacaine Transversus Abdominis Plane Block in Addition to Intrathecal Morphine and Multimodal Analgesia for the Management of Postoperative Pain Among Women Undergoing Cesarean Delivery.,Saline placebo,"['Ropivicaine', 'Naropin', 'Saline placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Pain,['Postoperative Pain'],"['cesarean, pain, transversus abdominus plane block']",COMPLETED,,2009-07,2011-01,"[{'measure': 'The primary outcome will be postoperative pain, measured by an NRS, the quality of recovery score (QoR) and a Self Assessment Diary in the first 24h postoperative period.', 'timeFrame': '24 hours'}]","[{'measure': 'NRS / QoR - 48 hour Opioid Consumption Side effects - nausea, sedation', 'timeFrame': '48 hours'}, {'measure': 'TAP block success rates and duration of block effect will be assessed using a patient diary completed every 2 hours while the patient is awake.', 'timeFrame': '24 hours'}, {'measure': 'Persistant pain outcomes will be assessed at 30 days and 6 months using 5-minute SF-36 health survey.', 'timeFrame': '6 months'}]",4,18 Years,,FEMALE,True,IWK Health Centre,OTHER,0,86.0,ACTUAL,2025-09-01T16:18:13.420920,v2_robust,True,True,True,False,False,
NCT05968937,Vaginal Baclofen Suppositories in Chronic Pelvic Pain,"Baclofen in Chronic Pelvic Pain, a Randomized, Double-Blind, Placebo Controlled Trial",20 mg baclofen vaginal suppository daily per vagina,"['20 mg baclofen vaginal suppository daily per vagina', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Pelvic Pain Syndrome,['Chronic Pelvic Pain Syndrome'],"['Baclofen', 'vaginal suppository', 'pelvic floor muscle dysfunction']",RECRUITING,,2024-01-01,2026-06-01,"[{'measure': 'Visual analogue Score (VAS) 1-100 for pain', 'description': 'VAS is a 1-100mm scale with lower scores indicating less pain', 'timeFrame': 'at 8 weeks of suppository use'}]","[{'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference score', 'description': 'Patient-Reported Outcomes Measurement Information System (PROMIS) pain interference score is a 40-200 point scale with lower values indicating lower pain interference with quality of life', 'timeFrame': 'at baseline and at 4, 8 and 12 weeks'}, {'measure': 'Pelvic floor impact questionnaire', 'description': 'pelvic floor impact questionnaire is a 0-63 point composite scale consisting of questions concerning bladder/urinary, bowel/rectal, and vaginal/pelvic symptoms with higher values indicating higher symptoms', 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Pelvic floor disability index (PFDI) questionnaire', 'description': 'the pelvic floor disability index (PFDI) questionnaire is a composite questionnaire on a 0-80 point scale containing questions regarding pelvic organ prolapse, colorectal/anal distress, and urinary distress questions with higher scores indicating higher symptoms', 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Visual analogue Score (VAS) 1-100 for pain', 'description': 'VAS is a 1-100mm scale with lower scores indicating less pain', 'timeFrame': 'at baseline and at 4 and 12 week follow up'}, {'measure': ""O'Leary Sant questionnaire"", 'description': ""O'Leary Sant questionnaire is a 0 to 37 point score with higher points indicating increased symptoms"", 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) global health score', 'description': 'Patient-Reported Outcomes Measurement Information System (PROMIS) global health score is a 9-45 point scale with higher scores indicating better overall health and quality of life', 'timeFrame': 'at baseline and at 4, 8, and 12 week follow up'}, {'measure': 'Overall Satisfaction', 'description': 'Overall Satisfaction is a yes/no questionnaire with if ""yes"" is selected one selects choices from ""somewhat"" to ""quite a bit"" in satisfaction. ""quite a bit"" would indicate greater satisfaction.', 'timeFrame': 'at 4, 8, and 12 week follow up'}, {'measure': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual function score', 'description': 'Patient-Reported Outcomes Measurement Information System (PROMIS) Sexual function score is a 9-36 point score with higher scores indicating higher bother related to sexual function', 'timeFrame': 'at 0, 4, 8, and 12 week follow up'}, {'measure': 'Number of other treatments for chronic pelvic pain during the trial period', 'description': 'Number of other treatments for chronic pelvic pain during the trial period to determine if results are clouded by other, appropriate, evidence based treatments received for chronic pelvic pain.', 'timeFrame': 'at 4, 8, and 12 week follow up'}, {'measure': 'Pill Count', 'description': 'Pill Count to determine how many doses of the study medication have been missed', 'timeFrame': 'at 4, 8, and 12 week follow up'}]",11,18 Years,65 Years,FEMALE,True,University of Louisville,OTHER,0,44.0,ESTIMATED,2025-09-01T16:18:13.420950,v2_robust,True,True,False,False,False,
NCT02431637,Experimental Falciparum Transmission to Anopheles,Blood Stage Challenge Study to Asses Mosquito Transmissibility in Participants Inoculated With Plasmodium Falciparum,Piperaquine Phosphate 480 mg,['Piperaquine Phosphate 480 mg'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Malaria,['Malaria'],"['Induced blood stage malaria', 'Transmission', 'Standard membrane feeding assay']",COMPLETED,,2015-04,2016-09,"[{'measure': 'Successful Infection of Vector Mosquitoes Following Both Direct and Indirect Feeding on the Blood of Infected Participants', 'description': 'Seven to ten days after blood feeding, mosquitoes will be dissected to check for oocysts in midgut preparations. For permanent preparations, oocysts will be stained with 0.1% mercurochrome in PBS for 5 to 60 mins then fixed in 1%glutaraldehyde or formaldehyde. Oocysts will be counted per mosquito dissected and recorded. Relationship between parasitemia, gametocytemia and mosquito infection (both oocyst prevalence and intensity) will be determined using generalized-linear mixed models. The number of mosquitoes dying prior to dissection will be recorded.', 'timeFrame': '7-10 days after blood feeding'}]","[{'measure': 'Safety: Number of AEs', 'description': 'Adverse events incidence', 'timeFrame': 'Blood stage Plasmodium falciparum Challenge Inoculum up to Day 31'}]",2,18 Years,55 Years,ALL,True,Medicines for Malaria Venture,OTHER,5,6.0,ACTUAL,2025-09-01T16:18:13.421007,v2_robust,True,True,True,False,True,
NCT01941537,"Randomized Placebo Controlled Study to Determine Safety, Pharmacodynamics and Efficacy of ILV-094 in Atopic Dermatitis","A Randomized Placebo-controlled Study to Determine the Safety, Tolerability, Pharmacodynamics and Clinical Efficacy of ILV-094 (an IL-22 Antibody) Administered Intravenously to Subjects With Atopic Dermatitis (AD)",ILV-094,"['ILV-094', 'Placebo Comparator', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Atopic Dermatitis,['Atopic Dermatitis'],['Atopic Dermatitis'],COMPLETED,,2013-10,2019-01,"[{'measure': 'Percentage Change in SCORAD', 'description': 'Percentage Change in the Scoring of Atopic Dermatitis (SCORAD) at week 12 compared to baseline in both arms of the study in subjects with atopic dermatitis.\n\nSCORAD (Severity scoring of Atopic Dermatitis) is composite severity index comprising a) the amount/extent of body surface area affected, b) subjective symptom visual analog assessments \\[itchy 0 (no itching) to 3 (severe itching) and sleep disturbance 0(no sleep disturbance) to 3 (severe sleep disturbance)\\], and c) 6 disease intensity assessments \\[dryness/scaling, erythema, induration/papulation, excoriation, lichenification and oozing/weeping/crusting, each graded from 0 to (none) to 3 (severe). A SCORAD score ranges from 0 (no AD present) to 103 (severe).', 'timeFrame': '12 weeks'}]","[{'measure': 'The Percentage of Patients Who Achieve an Improvement of 50% or Greater From Their Baseline Objective SCORAD at Week 12 of ILV-094 Treatment', 'description': 'The SCORAD50 captures individuals who achieved 50% or greater improvement from baseline SCORAD score. This outcome measure is the percentage of participants who achieved SCORAD50 at week 12. This analysis will be performed using fisher exact test. Patients who drop-out will be considered treatment failures (non-responder approach). A sensitivity analysis will be carried out using data as observed.', 'timeFrame': '12 weeks'}, {'measure': 'The (Per-patient) Percent Improvement in the SCORAD Relative to Baseline.', 'description': 'The (per-patient) percent improvement in the SCORAD relative to baseline, which will be analyzed using the MMRM approach described for the primary efficacy endpoint. Improvement is measured as the reduction in the score.', 'timeFrame': '12 weeks'}, {'measure': 'Change in IGA Score', 'description': 'Change in Investigator Global Assessment score (IGA) at week 12 as compared to baseline for both arms of the study in subjects with atopic dermatitis.\n\nIGA is a score between 0-5, with 0 being all clear, 1 being almost clear, 2 being mild disease, 3 being moderate disease, 4 being severe disease and 5 being very severe disease.', 'timeFrame': '12 weeks'}]",4,18 Years,75 Years,ALL,False,Rockefeller University,OTHER,1,60.0,ACTUAL,2025-09-01T16:18:13.421037,v2_robust,True,True,True,False,False,
NCT01905137,Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain,Botulinum Toxin Type A Versus Saline Trigger Point Injections for Myofascial Pelvic Pain,Intervention-Botulinum Toxin Type A,"['Intervention-Botulinum Toxin Type A', 'Botox', 'saline', 'placebo']",4,INTERVENTIONAL,['NA'],,,Myofascial Pelvic Pain,['Myofascial Pelvic Pain'],['Myofascial pelvic pain'],UNKNOWN,,2013-07,2019-06,"[{'measure': 'To evaluate the change in patient-reported pelvic pain following pelvic floor injections of 200 units of Botox compared with 20cc of normal saline.', 'description': 'To test this hypothesis we will measure patient-reported pain on palpation of each levator ani muscle group at baseline and two weeks following the injection. Pain will be assessed on a 10-point visual analog scale. We will compare the baseline and two-week pain measurements for the most painful muscle group.', 'timeFrame': '2 weeks after pelvic floor injection'}]","[{'measure': 'To evaluate the change in patient-reported pelvic pain following Botox injections in conjunction with pelvic floor physical therapy compared to saline injections with physical therapy.', 'description': 'To test this we will measure patient-reported pain on palpation of each levator ani muscle group at baseline and 12 weeks following the injection. Pain will be assessed on a 10-point visual analog scale. We will compare the baseline and 12-week pain measurements for the most painful muscle group.', 'timeFrame': '12 weeks following pelvic floor injection'}]",2,18 Years,,FEMALE,False,Boston Urogynecology Associates,OTHER,1,64.0,ESTIMATED,2025-09-01T16:18:13.421078,v2_robust,True,True,False,False,False,
NCT07132645,An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer,An Exploratory Study of [68Ga]Ga-Fibroblast Activation Protein Inhibitor 4 ([68Ga]Ga-FAPI-04) in Patients With High-Grade Neuroendocrine Neoplasms,Gallium Ga 68-DOTA-FAPI-04,"['Gallium Ga 68-DOTA-FAPI-04', '68Ga-DOTA-FAPI-04', 'GALLIUM GA-68-DOTA-FAPI-04', '68Ga-FAPi-04', 'Gallium-68-FAPi-04']",5,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Neuroendocrine Tumor,['Neuroendocrine Tumor'],[],NOT_YET_RECRUITING,,2025-09-01,2027-09-01,"[{'measure': 'Biodistribution of Gallium Ga 68-DOTA-FAPI-04 ([68Ga]Ga-FAPI-04)', 'timeFrame': 'Day 1'}, {'measure': 'Pharmacokinetics of [68Ga] Ga-FAPI-04', 'description': 'We will monitor/measure the amount of Ga-FAPI-04 seen within different tissue in patients that have neuroendocrine tumors. We will specifically measure the ratio of uptake in the tumors in comparison to reference tissues such as liver or muscle.', 'timeFrame': 'Day 1'}]","[{'measure': 'Tissue concentrations of [68Ga] Ga-FAPI-04 retention in tumors', 'timeFrame': 'Day 1'}, {'measure': 'Standardized uptake values (SUV) of [68Ga] Ga-FAPI-04 retention in tumors', 'description': 'Will compare the difference in SUVmax uptake within each subject using a two-side, one-sample t-test.', 'timeFrame': 'Day 1'}, {'measure': 'Clinical diagnostic performance of [68Ga] Ga-FAPI-04', 'description': 'When a comparison Ga-DOTATATE scan is available, we will look at the uptake in the tumor in the SOC image related to reference tissue and then compare the FAPI-04 uptake.', 'timeFrame': 'Day 1'}]",5,18 Years,,ALL,False,University of Michigan Rogel Cancer Center,OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:13.421098,v2_robust,True,True,False,False,False,
NCT00003345,"Cisplatin Plus Irinotecan in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer","Phase II Trial of Cisplatin and Irinotecan in Patients With Suboptimally Debulked, Incompletely Responding Ovarian Cancer",cisplatin,"['irinotecan hydrochloride', 'cisplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Fallopian Tube Cancer,"['Fallopian Tube Cancer', 'Ovarian Cancer', 'Primary Peritoneal Cavity Cancer']","['stage I ovarian epithelial cancer', 'stage II ovarian epithelial cancer', 'stage III ovarian epithelial cancer', 'stage IV ovarian epithelial cancer', 'recurrent ovarian epithelial cancer', 'fallopian tube cancer', 'primary peritoneal cavity cancer']",COMPLETED,,1997-10,2001-10,[],[],0,18 Years,,FEMALE,False,Memorial Sloan Kettering Cancer Center,OTHER,1,35.0,ESTIMATED,2025-09-01T16:18:13.421226,v2_robust,True,True,True,False,False,
NCT06767345,Comparison of Moderate-Intensity Statin Plus Ezetimibe vs. High-Intensity Statin for Coronary Plaque Stabilization,Comparing the Moderate Intensity STatin With Ezetimibe COmbination TheraPy With High Intensity Statin Monotherapy on Coronary PLAQUE Stabilization,"statins, ezetimibe","['Combination therapy', 'statins, ezetimibe']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Coronary Artery Disease,"['Coronary Artery Disease', 'Atherosclerosis of Coronary Artery', 'Plaque, Atherosclerotic']",[],RECRUITING,,2025-05-12,2028-06-25,"[{'measure': 'percentage change in coronary atheroma volume (PAV) by gray-scale IVUS from baseline to week 52.', 'timeFrame': '52 weeks'}]","[{'measure': 'Change from baseline to week 52 in total lipid core BMI measured by NIRS (LCBItotal)', 'timeFrame': '52 weeks'}, {'measure': 'Change in maximum LCBI within a 4-mm bin measured by NIRS from baseline to week 52 (maxLCBI4mm)', 'timeFrame': '52 weeks'}, {'measure': 'Change in corrected total atherosclerotic plaque volume (NTAV) measured by IVUS from baseline to week 52', 'timeFrame': '52 weeks'}]",4,18 Years,,ALL,False,Korea University Anam Hospital,OTHER,2,330.0,ESTIMATED,2025-09-01T16:18:13.421271,v2_robust,True,True,False,False,False,
NCT00509145,Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS),"A Multinational, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Study, to Evaluate the Safety, Tolerability and Efficacy of Daily Oral Administration of Laquinimod 0.6 mg in Subjects With RRMS",Laquinimod,"['Laquinimod', 'TV-5600']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Multiple Sclerosis,['Multiple Sclerosis'],"['Relapsing', 'Remitting']",COMPLETED,,2007-11-13,2010-11-08,"[{'measure': 'Relapse Rate: Number of Confirmed Relapses During the Double Blind Study Period', 'description': ""A relapse was defined as the appearance of at least one new neurological abnormality or the reappearance of at least one previously observed neurological abnormalities lasting greater than or equal to 48 hours and immediately preceded by an improving neurological state of greater than or equal to 30 days from onset of previous relapse. An event was counted as a relapse only when the participant's symptoms were accompanied by observed objective neurological changes, consistent with one or more of the following: An increase of greater than or equal to 0.5 in the Expanded Disability Status Scale (EDSS) score as compared to previous evaluation, an increase of one grade in the actual score of greater than or equal to 2 of the 7 functional systems (FS), as compared to previous evaluation, or an increase of 2 grades in the actual score of one FS as compared to the previous evaluation."", 'timeFrame': 'Up to Month 24'}]","[{'measure': 'Composite Endpoint: Sum of the Number of T1 Gadolinium (Gd)-Enhanced Lesions on T1-Weighted MRI Images', 'description': 'Composite score was calculated as the sum of the number of gadolinium (Gd)-enhanced lesions at Month 12 and the number of gadolinium (Gd)-enhanced lesions at Month 24 on T1-Weighted MRI scans.', 'timeFrame': 'Month 12, Month 24'}, {'measure': 'Composite Endpoint: Sum of the Number of New/Enlarging T2 Lesions', 'description': 'Composite score calculated as the sum of T2 lesions at Months 12 and 24 that are new or enlarged.', 'timeFrame': 'Month 12, Month 24'}, {'measure': 'Accumulation of Physical Disability Measured by the Time to Confirmed Progression of Expanded Disability Status Scale (EDSS)', 'description': 'EDSS assesses disability in 8 functional systems with an overall score ranging from 0 (normal) to 10 (death due to multiple sclerosis \\[MS\\]). A confirmed progression of EDSS is defined as at least 1 point increase from baseline if baseline EDSS was between 0 and 5.0, or at least 0.5 point increase if baseline EDSS was 5.5 or higher, confirmed 3 months later. Participants were assessed between baseline and month 24 visit. Participants that met these criteria for any 3 consecutive months were counted in the progression category. Progression could not be confirmed during an MS relapse. Data is presented as a distribution of confirmed disease progression (CDP) events (number of participants with CDP).', 'timeFrame': 'Baseline to Month 24'}, {'measure': 'Change From Baseline in Disability as Assessed by the Multiple Sclerosis Functional Composite (MSFC) Score', 'description': ""The Multiple Sclerosis Functional Composite is an instrument assessing disability that consists of 3 clinical assessments. The 3 are Timed 25-Foot Walk, 9-Hole Peg Test which measures upper extremity (arm and hand) function, and PASAT (Paced Auditory Serial Addition Test) which is a measure of cognitive function that specifically assesses auditory information processing speed and flexibility, as well as calculation ability. A Z-score is used to define a common metric from the 3 assessments that constitute the MSFC score. The study's population at baseline was used as reference population for the Z-score calculation. A Z-score of 0 represents the population mean at baseline. Higher Z-scores correspond to an improved outcome."", 'timeFrame': 'Baseline, Month 24'}]",5,18 Years,55 Years,ALL,False,"Teva Branded Pharmaceutical Products R&D, Inc.",INDUSTRY,0,1106.0,ACTUAL,2025-09-01T16:18:13.421394,v2_robust,True,True,True,False,False,
NCT00969072,Extension Study of GI198745 to Treat Benign Prostatic Hyperplasia,A Long-term Extension Study of GI198745 in Subjects With Benign Prostatic Hyperplasia,GI198745 0.05mg,"['GI198745 2.5mg', 'GI198745 0.5mg', 'GI198745 0.05mg']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Benign Prostatic Hyperplasia,"['Benign Prostatic Hyperplasia', 'Prostatic Hyperplasia']","['GI198745', 'Long term extension study', 'BPH']",COMPLETED,,2003-08,2005-02,"[{'measure': 'adverse events, laboratory test values (hematology, serum chemistry, electrolyte, and urinalysis), prostate specific antigen (PSA), vital signs (blood pressure, pulse rate), and post-void residual volume.', 'timeFrame': 'a 28-week extension treatment in the subjects entered into the 24-week dose finding study (ARI20005: multicentre, double-blind, randomised, placebo-controlled, parallel-group)'}]","[{'measure': 'prostate volume, symptom scores (IPSS), maximum urinary flow (Qmax), serum dihydrotestosterone (DHT), and testosterone', 'timeFrame': 'a 28-week extension treatment in the subjects entered into the 24-week dose finding study (ARI20005: multicentre, double-blind, randomised, placebo-controlled, parallel-group)'}]",2,50 Years,,MALE,False,GlaxoSmithKline,INDUSTRY,0,121.0,ACTUAL,2025-09-01T16:18:13.421433,v2_robust,True,True,True,False,True,
NCT05275972,Descemet Endothelial Thickness Comparison Trial II,Descemet Endothelial Thickness Comparison Trials (DETECT I & II),Ripasudil,"['Placebo', 'Ripasudil']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Fuchs,"['Fuchs', 'Fuchs Dystrophy', ""Fuchs' Endothelial Dystrophy""]",[],RECRUITING,,2023-01-23,2028-08-31,"[{'measure': 'Best spectacle-corrected visual acuity (BSCVA)', 'description': 'Best spectacle-corrected visual acuity (BSCVA)', 'timeFrame': '12 months'}]","[{'measure': 'Best spectacle-corrected visual acuity (BSCVA)', 'description': 'Best spectacle-corrected visual acuity (BSCVA)', 'timeFrame': '3, 6 and 24 months'}, {'measure': 'Endothelial cell density', 'description': 'Endothelial cell density', 'timeFrame': '3, 6, and 24 months'}]",3,18 Years,,ALL,False,Stanford University,OTHER,8,60.0,ESTIMATED,2025-09-01T16:18:13.421453,v2_robust,True,True,False,False,False,
NCT02127372,"Maximum Tolerated Dose, Safety and Efficacy of Docetaxel / Cisplatin + STI571","A Phase I - II Open Label Study of the Maximum Tolerated Dose, Safety and Efficacy of Docetaxel and Cisplatin Plus STI571 in Advanced Non-Small Cell Lung Cancer","Docetaxel, Cisplatin and STI571","['Imatinib', 'Cisplatin', 'Platinol', 'Taxotere', 'Docetaxel, Cisplatin and STI571', 'Gleevec', 'Docetaxel']",7,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],"['non-small cell', 'lung cancer']",TERMINATED,The study was closed due to poor accrual,2004-11,2010-12,"[{'measure': 'Phase 1 - Maximum Tolerated Dose (MTD) of STI571', 'description': 'To determine the maximum tolerated dose (MTD) of STI571, docetaxel, and cisplatin, when administered in combination for the treatment of patients with chemo-naïve recurrent and metastatic (stage IV) NSCLC.', 'timeFrame': 'After cycle 1, day 22'}, {'measure': 'Phase 1 - Maximum Tolerated Dose (MTD) of Docetaxel and Cisplatin', 'description': 'To determine the maximum tolerated dose (MTD) of STI571, docetaxel, and cisplatin when administered in combination for the treatment of patients with chemo-naïve recurrent and metastatic (stage IV) NSCLC.', 'timeFrame': 'After cycle 1, day 22'}, {'measure': 'Phase II - Radiographic Response', 'description': 'The percentage of patients with a complete or partial response.\n\nResponses for the Phase II portion of the trial will be by Response Evaluation Criteria In Solid Tumors (RECIST) criteria as follows:\n\nComplete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.', 'timeFrame': 'After Cycle 6, approximately 18 weeks.'}]","[{'measure': 'Phase 2: 1 Year Survival', 'description': 'Phase II: Percentage of patients alive 1 year from the start of protocol treatment.', 'timeFrame': '1 year'}, {'measure': 'Change in Gd-MRI Measurement', 'description': 'The change in Gd-MRI perfusion/permeability measurement between pre and post 7-day of STI571 treatment.', 'timeFrame': 'Day 7'}]",5,18 Years,,ALL,False,Duke University,OTHER,0,43.0,ACTUAL,2025-09-01T16:18:13.421583,v2_robust,True,True,False,True,False,The study was closed due to poor accrual
NCT03266172,A Study to Compare the Pharmacokinetics (PK) of GSK2982772 Following Administration of Different Modified Release (MR) Formulations in Capsule and MR Tablet Formulations Relative to an Immediate Release (IR) Tablet Formulation and to Check the PK of MR Formulation in Capsule Following Repeat Doses,"A Three Part, Non-randomized, Open Label Study Designed to Assess the Pharmacokinetics of GSK2982772 Following Administration of Minitab Modified Release Formulations in a Capsule Relative to an Immediate Release Reference Tablet Formulation (Part A), the Pharmacokinetics of Escalating, Repeat Doses of a Selected Minitab Modified Release Prototype (Part B) , and the Pharmacokinetics of GSK2982772 Following Administration of Modified Release Tablet Formulations in the Fed and Fasted State (Part C) in Healthy Participants",GSK2982772 Modified Release,"['GSK2982772 Modified Release', 'GSK2982772 Immediate Release']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Autoimmune Diseases,['Autoimmune Diseases'],"['immediate release tablet', 'GSK2982772', 'Modified release', 'minitablet']",COMPLETED,,2017-09-27,2018-11-21,"[{'measure': 'Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A', 'description': ""Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf). Participants in the 'Safety Population' for whom a Pharmacokinetic (PK) sample was obtained and analyzed were part of PK Population."", 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose'}, {'measure': 'AUC(0-inf) of GSK2982772 in MT Formulation :Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-inf).', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Area Under the Curve From Time Zero to the Last Measurable Concentration (AUC[0-t]) of GSK2982772 in IR Formulation : Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose'}, {'measure': 'AUC(0-t) of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-t)', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Area Under the Curve From Time Zero to 24 Hours (AUC[0-24]) of GSK2982772 in IR Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose'}, {'measure': 'AUC(0-24) of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-24)', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Area Under the Curve From Time Zero to 12 Hours (AUC[0-12]) of GSK2982772 in IR Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 hours post-dose'}, {'measure': 'AUC(0-12) of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for AUC (0-12)', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose'}, {'measure': 'Maximum Observed Concentration (Cmax) of GSK2982772 in IR Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for Cmax', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose'}, {'measure': 'Cmax of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for Cmax', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Concentration at 12 Hours Post-dose (C12hour) of GSK2982772 in Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for C12hour.', 'timeFrame': '12 hours post-dose'}, {'measure': 'Concentration at 24 Hours Post-dose (C24hour) of GSK2982772 in Part A', 'description': 'Blood samples were collected from participants at indicated time points and analyzed for C24hour.', 'timeFrame': '24 hours post-dose'}, {'measure': 'Relative Bioavailability (Frelformulation) Based on AUC (0-inf) of GSK2982772 in Part A', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT (test) / Geometric mean of AUC (0-inf) of IR Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose (test)'}, {'measure': 'Frelformulation Based on AUC (0-24) of GSK2982772 in Part A', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation. Frelformulation for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MT (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose (reference); Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, and 24 hours post-dose (test)'}, {'measure': 'Frelformulation Based on Cmax of GSK2982772 in Part A', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation. Frel was calculated as Geometric mean of Cmax of MT Formulation (test)/ Geometric mean of Cmax of IR Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose(test)'}, {'measure': 'Ratio of Cmax to C12hour of GSK2982772 in IR Formulation: Part A', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Ratio of Cmax to C12hour of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hour has been presented.', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Ratio of Cmax to C24hour of GSK2982772 in IR Formulation: Part A', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.', 'timeFrame': 'Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose'}, {'measure': 'Ratio of Cmax to C24hour of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hour has been presented.', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Time to Cmax (Tmax) of GSK2982772 in IR Formulation: Part A', 'description': 'Blood samples were collected at indicated time points for analysis of Tmax.', 'timeFrame': 'Pre-dose 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, and 24 hours post-dose'}, {'measure': 'Tmax of GSK2982772 in MT Formulation: Part A', 'description': 'Blood samples were collected at indicated time points for analysis of Tmax.', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'AUC(0-inf) of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-inf)', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose'}, {'measure': 'AUC(0-inf) of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-inf).', 'timeFrame': 'Pre-dose, 2, 3, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'AUC(0-t) of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-t).', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose'}, {'measure': 'AUC(0-t) of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-t).', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'AUC(0-24) of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-24)', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose'}, {'measure': 'AUC(0-24) of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-24)', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose'}, {'measure': 'AUC (0-12) of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-12)', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, and 12 hours post-dose'}, {'measure': 'AUC (0-12) of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-12)', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, and 12 hours post-dose'}, {'measure': 'Cmax of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of Cmax', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose'}, {'measure': 'Cmax of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of Cmax', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'C12 of GSK2982772 in Part C: Fasted State', 'description': 'Blood samples was collected at indicated time point for analysis of C12', 'timeFrame': '12 hours post-dose'}, {'measure': 'C24 of GSK2982772 in Part C: Fasted State', 'description': 'Blood samples was collected at indicated time point for analysis of C24', 'timeFrame': '24 hours post-dose'}, {'measure': 'Ratio of Cmax to C12hour of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose'}, {'measure': 'Ratio of Cmax to C12hour of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C12hour. Mean and standard deviation of ratio of Cmax to C12 hours has been presented.', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Ratio of Cmax to C24hour of GSK2982772 for IR Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.', 'timeFrame': 'Pre-dose,0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose'}, {'measure': 'Ratio of Cmax to C24hour of GSK2982772 for MM Formulation in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of ratio of Cmax to C24hour. Mean and standard deviation of ratio of Cmax to C24 hours has been presented.', 'timeFrame': 'Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Frelformulation Based on AUC (0-t) of GSK2982772 in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-t) was calculated as Geometric mean of AUC (0-t) of MM formulation (test) / Geometric mean of AUC (0-t) of IR Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose(test)'}, {'measure': 'Frelformulation Based on AUC (0-24) of GSK2982772 in Part C: Fasted State', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation. Frel for AUC (0-24) was calculated as Geometric mean of AUC (0-24) of MM Fasted formulation (test) / Geometric mean of AUC (0-24) of IR Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose, 0.33, 0.66, 1, 1.5, 2, 3, 4, 6, 8, 10, 12 and 24 hours post-dose(reference); Pre-dose, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours post-dose(test)'}]","[{'measure': 'Frelformulation Based on AUC (0-inf) of GSK2982772 After a High Fat Meal in Part A', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after a high fat meal. Frel for AUC (0-inf) was calculated as Geometric mean of AUC (0-inf) of MT Fed formulation (test) / Geometric mean of AUC (0-inf) of MT Fasted Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Frelformulation Based on Cmax of GSK2982772 After a High Fat Meal in Part A', 'description': 'Blood samples were collected at indicated time points for analysis of FrelFE based on AUC of GSK2982772 after a high fat meal. Frel for Cmax was calculated as Geometric mean of Cmax of MT Fed formulation (test) / Geometric mean of Cmax of MT Fasted Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'AUC(0-24) of GSK2982772 in Part B', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-24)', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3'}, {'measure': 'Cmax of GSK2982772 in Part B', 'description': 'Blood samples were collected at indicated time points for analysis of Cmax', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3'}, {'measure': 'Tmax of GSK2982772 in Part B', 'description': 'Blood samples were collected at indicated time points for analysis of Tmax', 'timeFrame': 'Pre-dose 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24 hours on Day 1 and Day 3'}, {'measure': 'AUC (0-24) of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-24)', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, and 24 hours post-dose'}, {'measure': 'Cmax of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of Cmax', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours'}, {'measure': 'C12 of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of C12', 'timeFrame': '12 hours post-dose'}, {'measure': 'AUC(0-t) of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-t)', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'AUC(0-inf) of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-inf) after meal.', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'AUC(0-12) of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of AUC (0-12) after meal.', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, and 12 hours post-dose'}, {'measure': 'Frelformulation Based on AUC (0-t) of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation based on AUC of GSK2982772 after meal. Frel for Auc (0-t) was calculated as Geometric mean of AUC (0-t) of MM Fed formulation (fed) / Geometric mean of AUC (0-t) of MM Fasted Formulation (fasted) multiplied by 100.', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Frelformulation Based on Cmax of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of Frelformulation based on Cmax of GSK2982772 after meal. Frel for Cmax was calculated as Geometric mean of Cmax of MM Fed formulation (test) / Geometric mean of Cmax of MM Fasted Formulation (reference) multiplied by 100.', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Tmax of GSK2982772 After Meal in Part C', 'description': 'Blood samples were collected at indicated time points for analysis of Tmax of GSK2982772 after meal.', 'timeFrame': 'Pre-dose and at 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30 and 32 hours post-dose'}, {'measure': 'Number of Participants With Adverse Events (AE) and Serious AEs (SAE) in Part A', 'description': 'An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before. All participants who receive at least 1 dose of study treatment and were included in Safety Population. Participants will be analyzed according to the treatment they actually received.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants With AE and SAE in Part B', 'description': 'An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.', 'timeFrame': 'Up to Day 22'}, {'measure': 'Number of Participants With AE and SAE in Part C', 'description': 'An AE is any untoward medical occurrence in a clinical study participants, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. SAE is defined as any untoward medical occurrence that at any dose may result in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent disability/incapacity, is a congenital anomaly or birth defect and important medical events may jeopardize the participants or may require medical or surgical intervention to prevent one of the other outcomes listed before.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part A', 'description': 'Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the ""To Normal or No Change"" category. Participants are counted twice if the subject has values that changed \'To Low\' and \'To High\', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part A', 'description': 'Blood samples were collected to analyze hematology parameters like platelet count, white blood cell (WBC) count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the ""To Normal or No Change"" category. Participants are counted twice if the subject has values that changed \'To Low\' and \'To High\', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants Abnormal Urinalysis Dipstick Results: Part A', 'description': 'Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part B', 'description': 'Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the ""To Normal or No Change"" category. Participants are counted twice if the subject has values that changed \'To Low\' and \'To High\', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 22'}, {'measure': 'Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part B', 'description': 'Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the ""To Normal or No Change"" category. Participants are counted twice if the subject has values that changed \'To Low\' and \'To High\', so the percentages may not add to 100%. Participants with missing baseline value are assumed to have normal baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 22'}, {'measure': 'Number of Participants Abnormal Urinalysis Dipstick Results: Part B', 'description': 'Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.', 'timeFrame': 'Up to Day 22'}, {'measure': 'Number of Participants With Emergent Clinical Chemistry Results by Potential Clinical Importance Criteria: Part C', 'description': 'Blood samples were collected for analysis of clinical chemistry parameters like albumin, creatinine, glucose, potassium, sodium, AST, ALT, ALP, total bilirubin and calcium. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the ""To Normal or No Change"" category. Participants are counted twice if the participant has values that changed \'To Low\' and \'To High\', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Clinical chemistry parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants With Emergent Hematology Results by Potential Clinical Importance Criteria: Part C', 'description': 'Blood samples were collected to analyze hematology parameters like platelet count, WBC count, hemoglobin, hematocrit, total neutrophils, and lymphocytes. Participants are counted in the worst case category that their value changes to (Low, Normal or High), unless there is no change in their category. Participants whose value category was unchanged (e.g., High to High), or whose value became normal, are recorded in the ""To Normal or No Change"" category. Participants are counted twice if the participant has values that changed \'To Low\' and \'To High\', so the percentages may not add to 100%. Participants with missing Baseline value are assumed to have normal Baseline value. Hematology parameters with potential clinical importance data has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants Abnormal Urinalysis Dipstick Results: Part C', 'description': 'Urine samples were collected for analysis of specific gravity, potential of hydrogen ions, glucose, protein, blood and ketones by dipstick method. Microscopic examination were performed if blood or protein values were abnormal.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants Abnormal Electrocardiogram (ECG) Findings: Part A', 'description': 'Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and Corrected QT (QTc) intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Number of Participants Abnormal ECG Findings: Part B', 'description': 'Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 22'}, {'measure': 'Number of Participants Abnormal ECG Findings: Part C', 'description': 'Single 12-lead ECGs was obtained using an ECG machine. PR, QRS, QT and QTc intervals were measured in semi-supine or supine position. Number of participants with any visit post-Baseline abnormal clinically significant findings and abnormal not clinically significant findings in ECG results has been reported. Data for worst-case post-Baseline has been reported.', 'timeFrame': 'Up to Day 43'}, {'measure': 'Change From Baseline in Blood Pressure: Part A', 'description': 'Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Heart Rate: Part A', 'description': 'Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1 Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Respiration Rate: Part A', 'description': 'Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Body Temperature: Part A', 'description': 'Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Blood Pressure: Part B', 'description': 'SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours'}, {'measure': 'Change From Baseline in Heart Rate: Part B', 'description': 'Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours'}, {'measure': 'Change From Baseline in Respiration Rate: Part B', 'description': 'Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4 24 hours'}, {'measure': 'Change From Baseline in Body Temperature: Part B', 'description': 'Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1 and Day 3: 2 and 12 hours; Pre-dose on Days 2 and 3; Day 4: 24 hours'}, {'measure': 'Change From Baseline in Blood Pressure: Part C', 'description': 'SBP and DBP was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Heart Rate: Part C', 'description': 'Heart rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Respiration Rate: Part C', 'description': 'Respiration rate was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}, {'measure': 'Change From Baseline in Body Temperature: Part C', 'description': 'Body temperature was measured in semi-supine position. Baseline is defined as the latest pre-dose assessment before entering study. Change from Baseline was defined as post-dose visit value minus Baseline value.', 'timeFrame': 'Baseline (Day 1, Pre-dose), Day 1: 2 and 12 hours; Day 2: 24hours'}]",80,18 Years,65 Years,ALL,True,GlaxoSmithKline,INDUSTRY,1,45.0,ACTUAL,2025-09-01T16:18:13.421634,v2_robust,True,True,True,False,True,
NCT01373372,Corticotropin Releasing Hormone (CRH) Responsiveness in Children With Functional Dyspepsia,CRH Responsiveness in Children With Functional Dyspepsia: A Pilot Study,Acthrel,"['Corticorelin', 'Acthrel']",2,INTERVENTIONAL,['NA'],,,Functional Dyspepsia,['Functional Dyspepsia'],"['functional dyspepsia', 'GI']",WITHDRAWN,Funding not obtained.,2016-12,2017-03,"[{'measure': 'Heart rate variability', 'timeFrame': 'Over 90 minutes'}]","[{'measure': 'Stress profile', 'description': 'Surface Electromyograph readings, peripheral skin temperature readings, electrodermal response', 'timeFrame': 'over 90 minutes'}, {'measure': 'plasma protein levels', 'description': 'TNF-α, IL-4, IL-5, IL-8, eotaxin-3, MCP-1, MMP-9, ECP, MBP, cortisol, ACTH and CBG levels to be obtained at time of CRH infusion and 15, 30, 45 and 60 minutes after CRH infusion', 'timeFrame': 'change over 60 minutes'}, {'measure': 'BASC 2 profile', 'description': 'To be given 30 minutes prior to CRH infusion and 15, 30 and 60 minutes after CRH infusion', 'timeFrame': 'change over 90 minutes'}, {'measure': 'STICSA-C', 'description': 'To be given 30 minutes prior to CRH infusion and 15, 30 and 60 minutes after CRH infusion.', 'timeFrame': 'change over 90 minutes'}, {'measure': 'GI symptom severity scale', 'description': 'To be given 30 minutes prior to CRH infusion and 15, 30 and 60 minutes after CRH infusion.', 'timeFrame': 'change over 90 minutes'}]",6,8 Years,17 Years,ALL,True,Children's Mercy Hospital Kansas City,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:13.421644,v2_robust,True,True,False,True,False,Funding not obtained.
NCT06028672,Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6,"Efficacy and Safety of Actinomycin-D With or Without Toripalimab as Fist-Line Treatment in Patients With Gestational Trophoblastic Neoplasia With FIGO Score 5-6: A Multicenter, Open-label, Randomized Controlled Trial",Toripalimab,"['Toripalimab', 'Actinomycin-D']",2,INTERVENTIONAL,['NA'],,,Gestational Trophoblastic Neoplasia,['Gestational Trophoblastic Neoplasia'],"['Gestational Trophoblastic Neoplasia', 'International Federation of Gynecology and Obstetrics', 'Toripalimab', 'Actinomycin-D', 'Efficacy', 'Safety']",RECRUITING,,2023-09-12,2025-08,"[{'measure': 'Complete remission rate', 'description': 'The proportion of patients achieving complete remission. Complete remission is defined as normal serum β-hCG level measured for 4 consecutive weeks.', 'timeFrame': 'up to one year'}]","[{'measure': 'Objective response rate', 'description': 'The proportion of patients with complete or partial response according to serum β-hCG level.', 'timeFrame': 'up to one year'}, {'measure': 'Progression-free survival', 'description': 'The time from the treatment initiation to disease progression or death, whichever comes first. Disease progression is defined as any increase in serum β-hCG level from baseline after 2 cycles of treatment or the presence of new metastatic lesions.', 'timeFrame': 'up to one year'}, {'measure': 'Disease control rate', 'description': 'The proportion of patients with complete response, partial response, or stable disease according to serum β-hCG level.', 'timeFrame': 'up to one year'}, {'measure': 'Duration of response', 'description': 'The time from the first evidence of response to disease progression or death, whichever comes first.', 'timeFrame': 'up to one year'}, {'measure': 'Overall survival', 'description': 'The time from the treatment initiation to the date of death or last follow-up.', 'timeFrame': 'up to one year'}, {'measure': 'Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Determine frequency and severity of adverse events as assessed by NCI CTCAE (Version 5.0) .', 'timeFrame': 'up to one year'}, {'measure': 'Ovarian function', 'description': 'Ovarian function as assessed by anti-Müllerian hormone (AMH)', 'timeFrame': 'up to one year'}, {'measure': 'Quality of life of cancer patients', 'description': 'Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30(EORTC QLQ-C30)', 'timeFrame': 'up to one year'}, {'measure': 'Cancer specific rehabilitation', 'description': 'Assessed by Cancer rehabilitation evaluation system-short form (CARES-SF)', 'timeFrame': 'up to one year'}, {'measure': 'Reproductive concerns after cancer', 'description': 'Assessed by Reproductive Concerns After Cancer (RCAC) scale. The minimum and maximum values are 18 and 90 respectively, and a higher score means a higher level of reproductive concern or anxiety', 'timeFrame': 'up to one year'}]",11,18 Years,60 Years,FEMALE,False,Peking Union Medical College Hospital,OTHER,9,40.0,ESTIMATED,2025-09-01T16:18:13.421665,v2_robust,True,True,False,False,True,
NCT03632772,Comparison of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After TURP,Comparative Study of Solifenacin and Mirabegron in Treatment of Overactive Bladder Symptoms in Men After Transurethral Resection of the Prostate - A Randomized Prospective Study,Solifenacin 5Mg,"['Betmiga', 'Solifenacin 5Mg', 'Mirabegron 50 MG', 'Vesicare']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Overactive Bladder Syndrome,['Overactive Bladder Syndrome'],"['Overactive bladder', 'Transurethral Resection of the Prostate', 'Pharmacotherapy', 'Mirabegron', 'Solifenacin']",UNKNOWN,,2018-08-01,2019-07-31,"[{'measure': 'Urgency Severity Scale (USS)', 'description': 'The change of USS from baseline to 4 weeks after catheter removal and starting OAB medication.', 'timeFrame': 'from baseline to 4 weeks'}]","[{'measure': 'Overactive Bladder Symptom Score (OABSS)', 'description': 'The changes of OABSS', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}, {'measure': 'frequency episodes, urgency episodes, urgency urinary incontinence (UUI) episodes in the 3-day voiding diary', 'description': 'The changes of frequency episodes, urgency episodes, urgency urinary incontinence (UUI) episodes in the 3-day voiding diary', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}, {'measure': 'maximum flow rate (Qmax)', 'description': 'The changes of maximum flow rate (Qmax)', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}, {'measure': 'voided volume (Vol)', 'description': 'The changes of voided volume (Vol)', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}, {'measure': 'Postvoid residual volume (PVR)', 'description': 'The changes of Postvoid residual volume (PVR)', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}, {'measure': 'International Prostate Symptom Score (IPSS)', 'description': 'The changes of International Prostate Symptom Score (IPSS)', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}, {'measure': 'quality of life index (QoL-I)', 'description': 'The changes of quality of life index (QoL-I)', 'timeFrame': 'from baseline to 2 weeks and 4 weeks.'}]",8,20 Years,80 Years,MALE,False,Buddhist Tzu Chi General Hospital,OTHER,0,130.0,ESTIMATED,2025-09-01T16:18:13.421706,v2_robust,True,True,False,False,False,
NCT02078895,Randomization of Botox for Stent Pain and Irritative Voiding Symptoms,Prospective Randomized Evaluation of Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A for the Treatment of Ureteral Stent Related Pain and Irritative Voiding Symptoms,Botox,"['Botulinum Toxin Type A', 'Botox']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Lower Urinary Tract Discomfort,"['Lower Urinary Tract Discomfort', 'Stent Pain']","['Lower Urinary tract discomfort , ureteral stent pain']",TERMINATED,The study was terminated due to low enrollment,2014-02,2017-02,"[{'measure': 'Change in Lower Urinary Tract Discomfort between pre-operative visit date and the stent removal date and two week follow up.', 'description': ""Lower urinary tract symptoms (frequency, urgency, nocturia, dysuria) - Ureteral Stent Symptom Questionnaire (USSQ). The USSQ has different sections that pertain to different domains of a patient's life. Therefore, a total score from each section will be measured individually as described by Joshi et al (15). The different domains of the USSQ include urinary symptoms, body pain, general health, work performance, sexual matters. The total scores from each of these sections will be compared individually. In addition, the total score for the entire questionnaire will also be assessed."", 'timeFrame': 'At pre-operative visit (average of 7 days before stent placement), stent removal date (3-9 days after stent placement), and 2 week follow up (2 weeks after stent placement)'}]","[{'measure': 'Post-operative pain', 'description': 'Post-operative pain - visual analog scale (VAS).', 'timeFrame': 'At pre-operative visit (average of 7 days before stent placement), stent removal date (3-9 days after stent placement), and 2 week follow up (2 weeks after stent placement)'}, {'measure': 'Post-surgical analgesic requirements', 'description': 'Post-surgical analgesic requirements: Oral opiates/-patients to keep written record (number/duration\n\n-# of days)', 'timeFrame': 'post-operative to follow up day (2 weeks)'}]",3,18 Years,,ALL,True,"University of California, Irvine",OTHER,0,15.0,ACTUAL,2025-09-01T16:18:13.421765,v2_robust,True,True,False,True,False,The study was terminated due to low enrollment
NCT01076595,"Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period","Prospective Multicenter, Non Interventional Study to Evaluate the Patient's Characteristics Associated With Adherence to Treatment Regimen by Betaferon in the BetaPlus Program","Interferon beta-1b (Betaseron, BAY86-5046)","['Interferon beta-1b (Betaseron, BAY86-5046)']",1,OBSERVATIONAL,[],,,Multiple Sclerosis,['Multiple Sclerosis'],"['Multiple sclerosis', 'BetaPlus program', 'Recurrent/remittent multiple sclerosis patients', 'Adherence to treatment regimen']",COMPLETED,,2010-05,2014-07,"[{'measure': 'The adherence to treatment (rate of patients continuing with Betaferon® regimen after 24 months)', 'timeFrame': '24 months'}]","[{'measure': 'Compliance to Betaferon according physician (rate of patients with compliance rater > 94,5%)', 'timeFrame': '6 months, 12 months, 24 months'}, {'measure': 'Adherence to treatment (rate of patients continuing with the Betaferon® regimen at 6 and 12 months)', 'timeFrame': '6 months, 12 months'}, {'measure': 'Rate of patients with prematurely study discontinuation', 'timeFrame': '0-6 months, 6-12 months, 12-18 months, 18-24 months'}, {'measure': ""Patient's autonomy with regard to the Betaferon® injections (Number of injections realized by the patient alone/total number of injections)"", 'timeFrame': '24 months'}, {'measure': 'Tolerability of Betaferon injections (rate and number of injections)', 'timeFrame': '24 months'}, {'measure': ""Patient's Quality of Life (Mean total score of FAMS [Functional Assessment of Multiple Sclerosis])"", 'timeFrame': '24 months'}, {'measure': 'Fatigue (mean total score of FSS [Fatigue Severity scale])', 'timeFrame': '24 months'}, {'measure': 'Progression of clinical Condition( annual rate of Relapses)', 'timeFrame': '24 months'}, {'measure': 'Percentage of patients with change of in EDSS (Expanded Disability Status Scale) < 1 between M0 and end of the study', 'timeFrame': '24 months'}, {'measure': 'Percentage of patients with change in EDSS< 1 and no relapse between M0 and M24', 'timeFrame': '24 months'}]",11,18 Years,,ALL,False,Bayer,INDUSTRY,0,73.0,ACTUAL,2025-09-01T16:18:13.421830,v2_robust,False,True,True,False,False,
NCT04651595,Efficacy of Caudal Block on Intra-operative Anal Sphincter Muscle Tone and Post-operative Analgesia During Anal Sphincter Sparing Procedures Under General Anaesthesia,Efficacy of Caudal Block on Intra-operative Anal Sphincter Muscle Tone and Post-operative Analgesia During Anal Sphincter Sparing Procedures Under General Anaesthesia: A Randomized Control Trial,Morphine,['Morphine'],1,INTERVENTIONAL,['NA'],,,Efficacy of Caudal Block on Intra-operative Anal Sphincter Muscle Tone,['Efficacy of Caudal Block on Intra-operative Anal Sphincter Muscle Tone'],[],COMPLETED,,2021-01-01,2021-12-01,"[{'measure': 'The time to first request of rescue postoperative analgesic', 'description': 'the time interval between the end of surgery and the first request to postoperative morphine', 'timeFrame': 'in the first 24 hour'}]","[{'measure': 'Digital Rectal Examination Scoring System (DRESS', 'description': 'Digital Rectal Examination Scoring System to asses the anal tone', 'timeFrame': 'intraoperative'}]",2,18 Years,60 Years,ALL,False,Kasr El Aini Hospital,OTHER,0,26.0,ACTUAL,2025-09-01T16:18:13.421870,v2_robust,True,True,True,False,False,
NCT00927095,Continuous Oral Contraceptive Treatment in Premenstrual Dysphoric Disorder (PMDD),Continuous OC Treatment in PMDD: Steroid Hormone Mechanisms,Continuous OC (EE/DROS),"['Continuous OC (EE/DROS)', 'oral placebo', 'placebo', 'Yaz', 'Intermittent OC (EE/DROS)']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Premenstrual Dysphoric Disorder,['Premenstrual Dysphoric Disorder'],"['PMDD', 'Oral contraceptives', 'steroid hormones', 'neurosteroids']",COMPLETED,,2008-07,2014-07,"[{'measure': 'Pre-Post Change in Premenstrual Symptom Severity', 'description': 'Pre-post change (pre minus post) in mean premenstrual week severity of the worst emotional symptom as measured using the Daily Record of Severity of Problems items 1-8. Worst symptom for each individual was defined as the symptom in the baseline month demonstrating the highest mean severity during the premenstrual week. Mean premenstrual week severity scores were calculated to correspond to mean ratings; therefore, the mean premenstrual severity values ranged as follows: 1=Not at All, 2=Minimal, 3=Mild, 4=Moderate, 5=Severe, 6=Extreme. The change variable presented here is calculated as follows: ""mean rating on the individual\'s worst symptom during the premenstrual week at baseline"" minus ""mean rating during the premenstrual week during the last on-treatment cycle"". Therefore, higher values on this outcome variable correspond to greater reductions in premenstrual symptoms across the trial.', 'timeFrame': 'monthly'}]",[],1,18 Years,52 Years,FEMALE,False,"University of North Carolina, Chapel Hill",OTHER,1,67.0,ACTUAL,2025-09-01T16:18:13.421947,v2_robust,True,True,True,False,False,
NCT03651895,Metformin to Reduce Airway Glucose in COPD Patients,Metformin to Reduce Airway Glucose in COPD Patients,Metformin,"['Placebo', 'Metformin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Obstructive Pulmonary Disease,['Chronic Obstructive Pulmonary Disease'],['Chronic Obstructive Pulmonary Disease'],COMPLETED,,2022-05-17,2023-06-01,"[{'measure': 'Sputum Glucose Concentration', 'description': 'The median concentration of glucose in sputum following 3 months treatment with metformin or placebo.', 'timeFrame': '3 months'}]","[{'measure': 'Nasal Glucose Concentrations', 'description': 'The median concentration of glucose in nasal samples following 3 months treatment with metformin or placebo.', 'timeFrame': '3 months'}, {'measure': 'Sputum Bacterial Load', 'description': 'The bacterial load in sputum using qPCR was not measured. Therefore, data were not collected', 'timeFrame': '3 months'}, {'measure': 'Sputum Inflammatory Markers', 'description': 'The median concentration of inflammatory cells and cytokines in sputum was not measured. Therefore, data were not collected.', 'timeFrame': '3 months'}, {'measure': 'Quality of Life Score (COPD Assessment Test)', 'description': ""The COPD Assessment Test (CAT): the CAT features 8 questions ranked from 0-5 with a minimum score of 0 and maximum possible score of 40. Higher scores indicate a greater impact on patient health due to their COPD, a difference of ≥2 is considered meaningful.\n\nThe questionnaire's were completed by every participant at every visit up to 8 times: V1 is at the baseline, then V2-4 are at monthly intervals. V5 is at the baseline after crossing arms -1 month washout, V6-8 are monthly after that."", 'timeFrame': '1 month'}, {'measure': ""Quality of Life Score (St George's Respiratory Questionnaire)"", 'description': ""St George's Respiratory Questionnaire (SGRQ): the SGRQ contains 50 items with a minimum score of 0 and a maximum score of 100. Higher scores indicate a greater impact on quality of life due to COPD and a difference of ≥4 is meaningful\n\nThe questionnaire's were completed by every participant at every visit up to 8 times: V1 is at the baseline, then V2-4 are at monthly intervals. V5 is at the baseline after crossing arms -1 month washout, V6-8 are monthly after that."", 'timeFrame': '1 month'}, {'measure': 'Lung Function', 'description': 'FEV1(Forced Expiratory Volume Test) was performed up to 8 times: V1 is at the baseline, then V2-4 are at monthly intervals. V5 is at the baseline after crossing arms -1 month washout, V6-8 are monthly after that.', 'timeFrame': '1 month'}]",7,40 Years,75 Years,ALL,False,Imperial College London,OTHER,0,14.0,ACTUAL,2025-09-01T16:18:13.421975,v2_robust,True,True,True,False,False,
NCT02784795,A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors,A Phase 1b Study of LY3039478 in Combination With Other Anticancer Agents in Patients With Advanced or Metastatic Solid Tumors,LY3039478,"['Carboplatin', 'Cisplatin', 'LY3023414', 'LY2835219', 'Abemaciclib', 'Gemcitabine', 'Taladegib', 'LY3039478', 'LY2940680']",9,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,"['Solid Tumor', 'Breast Cancer', 'Colon Cancer', 'Cholangiocarcinoma', 'Soft Tissue Sarcoma']",['Notch Inhibitor'],TERMINATED,The study was terminated due to business considerations,2016-11-04,2020-02-13,"[{'measure': 'Number of Participants With LY3039478 Dose-Limiting Toxicities (DLT) in Part A, B, C, D and E', 'description': ""DLT is defined as an adverse event (AE) during Cycle 1 (28 days for Part A, B and C and 21 days for Part D, E) that was possibly related to the study drug and met 1 of the following criteria: According to the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0: ≥Grade 3 non-hematological toxicity except nausea/vomiting, diarrhea, or constipation that can be controlled with appropriate care; Grade 3 elevations of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) lasting fewer than 8 days (without evidence of other hepatic injury); Grade 3 rash that resolves or improves to a Grade 2 or less within 7 days; CTCAE Grade 4 hematological toxicity of \\>5 days duration; Grade 4 thrombocytopenia of any duration; Grade 3 thrombocytopenia with bleeding; Grade 3 febrile neutropenia."", 'timeFrame': 'Baseline to toxicity (up to end of Cycle 1 [1Cycle = 28 days for Part A, B and C and 21 days for Part D, E])'}]","[{'measure': 'Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Time 0 to Infinity (AUC[0-∞]) of LY3039478 in Combination With Taladegib, LY3023414, Abemaciclib, Cisplatin/Gemcitabine, and Gemcitabine/Carboplatin in Part A, B, C, D and E', 'description': 'AUC\\[0-∞\\] of LY3039478 in combination with taladegib, LY3023414, abemaciclib, cisplatin/gemcitabine, and gemcitabine/carboplatin in dose escalation parts of Part A, B, C, D and E was evaluated.', 'timeFrame': 'Parts A/B/C Day 22 (Cycle 1): pre-dose, 0.5, 1, 2, 4, 6, 8, 24-30 hours post-dose; Parts D/E Day 1 (Cycle 1) and 15 (Cycle 1): pre-dose, 0.5, 1, 2, 4, 6-8, 24-30 hours post-dose'}, {'measure': 'PK: AUC[0-∞] of Taladegib and Its Active Metabolite LSN3185556, in Combination With LY3039478 (Part A)', 'description': 'AUC\\[0-∞\\] of taladegib and its active metabolite LSN3185556, in combination with LY3039478 (Part A) was evaluated.', 'timeFrame': 'Day -3 (Lead in) : pre-dose, 0.5, 1, 2, 4, 6, 8, 24-30, 72 hours post-dose and Day 22 (Cycle 1): pre-dose, 0.5, 1, 2, 4, 6, 8, 24 hours post-dose'}, {'measure': 'PK: AUC[0-∞] of LY3023414 in Combination With LY3039478 on Day -3 (Part B)', 'description': 'AUC\\[0-∞\\] of LY3023414 in combination with LY3039478 (Part B) on day -3 was evaluated.', 'timeFrame': 'Day -3 (Lead in): pre-dose, 0.5, 1, 2, 4, 6, 8, 24-30, 72 hours post-dose'}, {'measure': 'PK: AUC[0-∞] of LY3023414 in Combination With LY3039478 on Day 22 (Part B)', 'description': 'AUC\\[0-∞\\] of LY3023414 in combination with LY3039478 (Part B) on day 22 was evaluated. LY3023414 PK data is summarized only for dose escalation patients in Part B with intensive PK sampling.', 'timeFrame': 'Day 22 (Cycle 1): pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose'}, {'measure': 'PK: AUC[0-∞] of Abemaciclib and AUC From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Its Major Active Metabolites LSN2839567 and LSN3106726, in Combination With LY3039478 on Day -3 (Part C)', 'description': 'AUC\\[0-∞\\] of abemaciclib and AUC\\[0-tlast\\] of its major active metabolites LSN2839567 and LSN3106726, in combination with LY3039478 on Day 3 (Part C) was evaluated.', 'timeFrame': 'Day -3 (Lead in): pre-dose, 0.5, 1, 2, 4, 6, 8, 24-30, 72 hours post-dose'}, {'measure': 'PK: AUC[0-∞] of Abemaciclib and AUC From Time Zero to the Last Measured Concentration Value (AUC[0-tlast]) of Its Major Active Metabolites LSN2839567 and LSN3106726, in Combination With LY3039478 on Day 22 (Part C)', 'description': 'AUC\\[0-∞\\] of abemaciclib and AUC\\[0-tlast\\] of its major active metabolites LSN2839567 and LSN3106726, in combination with LY3039478 on Day 22 (Part C) was evaluated.', 'timeFrame': 'Day 22 (Cycle 1): pre-dose, 0.5, 1, 2, 4, 6, 8 hours post-dose'}, {'measure': 'Duration of Response (DoR)', 'description': 'DoR was the time from the date of first evidence of complete response or partial response to the date of objective progression or the date of death due to any cause, whichever is earlier. CR and PR were defined using the RECIST v1.1. CR defined as the disappearance of all target and non-target lesions and no appearance of new lesions. PR defined as at least a 30% decrease in the sum of the LD of target lesions (taking as reference the baseline sum LD), no progression of non-target lesions, and no appearance of new lesions. If a responder was not known to have died or have objective progression as of the data inclusion cutoff date, duration of response was censored at the last adequate tumor assessment date.', 'timeFrame': 'Date of Complete Response (CR) or Partial Response (PR) to Date of Objective Disease Progression (Up To 12 Months)'}, {'measure': 'Progression Free Survival (PFS) Time in Part A, B, C, D and E', 'description': 'PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. PFS time was summarized using Kaplan-Meier estimates.', 'timeFrame': 'Baseline to Objective Disease Progression or Death (Up To 1.91 Months for Part A, 7.69 Months for Part B, 11.53 Months for Part C, 19.52 Months for Part D, 7.03 Months for Part E)'}]",9,18 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,94.0,ACTUAL,2025-09-01T16:18:13.422077,v2_robust,True,True,False,True,True,The study was terminated due to business considerations
NCT05916339,AWARE: Management of ADHD in Autism Spectrum Disorder,Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder,Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication,"['Randomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication', 'Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,ADHD,"['ADHD', 'Autism Spectrum Disorder']","['ADHD', 'Autism', 'ASD']",RECRUITING,,2023-10-01,2027-12-30,"[{'measure': 'The Vanderbilt Parent Rating Scale', 'description': 'The primary outcome measure is The Vanderbilt Parent Rating Scale for ADHD consists of 18 item, each scored from 0 to 3. It has a minimum score of 0, maximum score of 54. Higher scores indicate worse outcome.', 'timeFrame': '16 Weeks'}]","[{'measure': 'Parent reported Clinical Global Impression', 'description': 'Parent reported Clinical Global Impression - Improvement is a Likert scale ranging from 1 to 7. Higher scores indicate worse outcome.', 'timeFrame': '16 Weeks'}, {'measure': 'Aberrant Behavior Checklist- Hyperactivity/Impulsivity subscale', 'description': 'Aberrant Behavior Checklist- Hyperactivity/Impulsivity subscale consists of 16 items, each scored from 0 to 3. It has a minimum score of 0, maximum score of 48. Higher scores indicate worse outcome.', 'timeFrame': '16 Weeks'}]",3,4 Years,17 Years,ALL,False,Daniel Coury,OTHER,14,500.0,ESTIMATED,2025-09-01T16:18:13.422113,v2_robust,True,True,False,False,False,
NCT05261139,EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease,"A PHASE 2/3, INTERVENTIONAL SAFETY, PHARMACOKINETICS, AND EFFICACY, OPEN-LABEL, MULTI-CENTER, SINGLE-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332 (NIRMATRELVIR)/RITONAVIR IN NONHOSPITALIZED SYMPTOMATIC PEDIATRIC PARTICIPANTS WITH COVID-19 WHO ARE AT RISK OF PROGRESSION TO SEVERE DISEASE",nirmatrelvir,"['nirmatrelvir', 'ritonavir']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,COVID-19,['COVID-19'],"['Severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2)', 'Pediatrics']",RECRUITING,,2022-03-07,2026-07-30,"[{'measure': 'Cohort 1-2: Maximum Observed Plasma Concentration (Cmax) of nirmatrelvir and ritonavir', 'timeFrame': 'Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose'}, {'measure': 'Cohort 1-2: Area Under the Curve to the End of the Dosing Period (AUC0-tau) of nirmatrelvir and ritonavir', 'timeFrame': 'Day 1: 1 hour-post dose; Day 4: pre-dose; Day 5: pre-dose, and 1, and 2 hours post dose'}, {'measure': 'Incidence of Treatment Emergent Adverse Events (TEAEs) leading to discontinuations.', 'timeFrame': 'From Baseline up through Day 34'}, {'measure': 'Incidence of Serious Adverse Events (SAEs) leading to discontinuations.', 'timeFrame': 'From Baseline up through Day 34'}, {'measure': 'Incidence of Adverse Events (AEs) leading to discontinuations.', 'timeFrame': 'From Baseline up through Day 34'}, {'measure': 'Number of participants with change from Baseline in Vital Signs', 'timeFrame': 'From Baseline up through Day 34'}]","[{'measure': 'Viral load assessment titers measured via reverse transcription polymerase chain reaction (RT-PCR) in nasopharyngeal or nasal swabs over time', 'timeFrame': 'Baseline, Day 5, 6, 10, 14 and 28'}, {'measure': 'Proportion of participants with COVID-19 related hospitalization or death from any cause', 'timeFrame': 'From Baseline through Day 28'}, {'measure': 'Patient assessment on acceptability and palatability of nirmatrelvir/ritonavir (film-coated tablets and oral powder)', 'description': 'Frequency of responses to visual questionnaire on taste.', 'timeFrame': 'At baseline only for tablets and after each dose for powder formulation'}]",9,0 Years,17 Years,ALL,False,Pfizer,INDUSTRY,0,160.0,ESTIMATED,2025-09-01T16:18:13.422179,v2_robust,True,True,False,False,True,
NCT01787539,The Role of Postoperative Cycles in the Perioperative Chemotherapy for Gastric Cancer,The Role of Postoperative Chemotherapy Cycles in the Combined Modality Therapy of Gastric Cancer With Perioperative Chemotherapy and Surgery in Pathological Responders,Postoperative Chemotherapy,['Postoperative Chemotherapy'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Gastric Cancer,['Gastric Cancer'],"['gastric cancer', 'perioperative chemotherapy', 'combined modality therapy', 'gastrectomy']",UNKNOWN,,2013-02,2022-02,"[{'measure': 'cancer free and overall survival', 'timeFrame': '5 years'}]","[{'measure': 'overall and severe toxicity rate', 'timeFrame': '8 weeks'}, {'measure': 'chemotherapy related mortality', 'timeFrame': '8 weeks'}, {'measure': 'the rate of dose reduction for chemotherapeutics', 'timeFrame': '3 months'}, {'measure': 'the rate of chemotherapy cessation', 'timeFrame': '3 months'}]",5,18 Years,,ALL,False,Medical University of Lublin,OTHER,1,180.0,ESTIMATED,2025-09-01T16:18:13.422204,v2_robust,True,True,False,False,False,
NCT00393939,Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer,A Randomized Phase 3 Study Of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients,Sunitinib malate,"['Sunitinib malate', 'Taxotere']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Neoplasms,['Breast Neoplasms'],"['advanced breast cancer', 'sunitinib', 'docetaxel', 'Phase 3']",COMPLETED,,2007-02,2011-07,"[{'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS defined as time from date of randomization to date of the first documentation of objective tumor progression or death due to any cause, whichever occurred first. PFS calculated as (Months) = (first event date minus randomization date plus 1) divided by 30.4.', 'timeFrame': 'Baseline up to Month 33'}]","[{'measure': 'Percentage of Participants With Objective Response', 'description': 'Percentage of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all tumor lesions (target and non-target). PR defined as greater than or equal to 30 percent (≥30%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions with a non-progressive disease status of the non-target lesions.', 'timeFrame': 'Baseline up to Month 33'}, {'measure': 'Duration of Response (DR)', 'description': 'DR defined as time from first objective documentation of complete or partial response that was subsequently confirmed to first documentation of disease progression or to death due to any cause, whichever occurred first. DR calculated (Months) = (the date of the first documentation of objective tumor progression or death due to any cause minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 30.4.', 'timeFrame': 'Baseline up to Month 33'}, {'measure': 'Overall Survival (OS)', 'description': 'Time from randomization to date of death due to any cause. OS calculated as (Months) = (death date minus date of first dose of study medication plus 1) divided by 30.4. For participants who were alive, overall survival was censored at last contact.', 'timeFrame': 'Baseline to date of death from any cause (up to Month 33)'}, {'measure': 'Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionaire-C30 (EORTC- QLQ-C30) Score', 'description': 'EORTC QLQ-C30 measured 5 functional domains (physical, role, cognitive, emotional, and social), global health status, and symptom scales of fatigue, pain, nausea and vomiting, dyspnoea, loss of appetite, insomnia, constipation and diarrhea, and financial difficulties. For functional domains and global health status, scores ranged from 0 to 100 where higher scores represented a better level of functioning. For symptoms scales, scores ranged from 0 to 100 where higher scores represented a greater degree of symptoms. Change from baseline = score for Cycle/Day minus baseline score.', 'timeFrame': 'Baseline, every 6 weeks up to end of treatment or early termination (up to Month 33)'}, {'measure': 'Change From Baseline in EORTC-QLQ Breast Cancer Module (EORTC-QLQ-BR23) Score', 'description': 'EORTC-QLQ-BR23 measured multi-item functional scales for body image, sexual functioning, sexual enjoyment, and future perspective and measured single item symptoms scales which assessed systemic therapy side effects, breast symptoms, arm symptoms, and upset by hair loss. For functional scales, scores ranged from 0 to 100 where higher scores represented a better level of functioning. For symptoms scales, scores ranged from 0 to 100 where higher scores represented a greater degree of symptoms. Change from baseline = score for Cycle/Day minus baseline score.', 'timeFrame': 'Baseline, every 6 weeks up to end of treatment or early termination (up to Month 33)'}, {'measure': 'Change From Baseline European Quality of Life 5-dimensional Self-Report Questionnaire (EQ-5D) Score', 'description': ""EQ-5D: standardized, participant-administered 2 part measure of health outcome. Part 1: descriptive profile for 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), used 3 levels (no, some, extreme problems) and a single index value characterized current health status using formula that weighted the dimensions. Part 2: overall rating of participant's current health used Visual Analog Scale with endpoints labeled 'best imaginable health state' and 'worst imaginable health state'. Change from baseline = score for Cycle/Day minus baseline score."", 'timeFrame': 'Baseline, every 6 weeks up to end of treatment or early termination (up to Month 33)'}]",7,18 Years,,FEMALE,False,Pfizer,INDUSTRY,0,594.0,ACTUAL,2025-09-01T16:18:13.422250,v2_robust,True,True,True,False,False,
NCT00137839,Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung,A Phase II Study of Erlotinib (OSI-774); Tarceva in Women With Previously Untreated Advance Adenocarcinoma of the Lung,Erlotinib,"['Tarceva', 'Erlotinib', 'OSI-774']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma,"['Adenocarcinoma', 'Non-small Cell Lung Cancer']","['Tarceva', 'Erlotinib', 'OSI-774', 'Adenocarcinoma', 'Advanced Lung Cancer']",COMPLETED,,2004-11,2019-07,"[{'measure': 'Overall Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. Stable disease (SD) is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.', 'timeFrame': 'In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.'}]","[{'measure': 'Overall Response Rate (ORR) by EGFR Mutation Status', 'description': 'ORR is defined as the percentage of participants who achieve partial response (PR) or better on treatment based on RECIST 1.0 criteria: For target lesions, complete response (CR) is disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD (both require a minimum of 4 weeks). Progressive disease (PD) is at least a 20% increase in sum LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started, or appearance of one or more new target lesions. SD is neither PR nor PD. For non-target lesions, PD is the appearance of one or more new non-target lesions and/or unequivocal progression of existing non-target lesions.', 'timeFrame': 'In this study cohort, treatment duration which parallels the maximum observation time was up to 39 months.'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the time from study entry to death or date last known alive.', 'timeFrame': 'In this study cohort, participants were followed for survival up to 155 months.'}, {'measure': 'Overall Survival by EGFR Mutation Status', 'description': 'OS is defined as the time from study entry to death or date last known alive.', 'timeFrame': 'In this study cohort, participants were followed for survival up to 155 months.'}]",4,18 Years,,FEMALE,False,"Pasi A. Janne, MD, PhD",OTHER,5,84.0,ACTUAL,2025-09-01T16:18:13.422297,v2_robust,True,True,True,False,False,
NCT00253539,Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer,A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer,arzoxifene hydrochloride,"['tamoxifen citrate', 'arzoxifene hydrochloride']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'Hereditary Breast/Ovarian Cancer (brca1, brca2)']","['hereditary breast/ovarian cancer (BRCA1, BRCA2)', 'breast cancer']",COMPLETED,,2002-01,2005-04,"[{'measure': 'Ki67 in breast tissue of enrolled patients', 'description': 'The primary endpoint was changed in Ki67 in breast tissue of enrolled patients'}]",[{'measure': 'Toxicity'}],2,18 Years,,FEMALE,False,The Cleveland Clinic,OTHER,1,3.0,ACTUAL,2025-09-01T16:18:13.422321,v2_robust,True,True,True,False,False,
NCT00102739,SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Refractory Immune Thrombocytopenic Purpura (ITP),See Detailed Description,SB497115,['SB497115'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Purpura, Thrombocytopaenic, Idiopathic","['Purpura, Thrombocytopaenic, Idiopathic']","['thrombopoietin', 'immune thrombocytopenic purpura', 'platelets', 'chronic thrombocytopenia']",COMPLETED,,2005-02,2007-01,"[{'measure': 'Treatment response, assessed by the proportion of patients with platelet counts of =50, 000/µL (compared with baseline count of <30, 000/µL) after 42 days of treatment.'}]","[{'measure': 'Safety, tolerability, PK, PD, symptoms associated with ITP, and QoL, odds of response vs placebo during weeks 2 to 6 of the study.'}]",2,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,99.0,ACTUAL,2025-09-01T16:18:13.422329,v2_robust,True,True,True,False,True,
NCT00215839,HRN 004- Peginterferon a-2a Plus Ribavirin for Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy,"A Multi-Center, Randomized, Open-Label, Phase IIIb Study Investigating the Safety and Efficacy of Peginterferon a-2a Plus Ribavirin for the Treatment of Chronic Hepatitis C Infection in HIV Infected Persons Who Have Failed to Achieve a Sustained Virologic Response Following Previous Interferon Therapy",Peginterferon a-2a plus Ribavirin,['Peginterferon a-2a plus Ribavirin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Hepatitis C Infection in HIV Infected Persons,"['Chronic Hepatitis C Infection in HIV Infected Persons', 'HIV Infections']",['Treatment Experienced'],UNKNOWN,,,,"[{'measure': 'evaluate the safety, tolerability, and efficacy of Peginterferon a-2a plus Ribavirin for the treatment of chronic hepatitis C (CHC) infection in persons co-infected with human immunodeficiency virus (HIV) who have failed to achieve a sustained virologi'}]","[{'measure': 'To evaluate the virological response at weeks 12 and 24 as compared to baseline values.'}, {'measure': 'To evaluate the sustained virological response at post-treatment weeks 4, 12, and 24 as compared to baseline.'}]",3,18 Years,,ALL,False,Hepatitis Resource Network,OTHER,1,,,2025-09-01T16:18:13.422354,v2_robust,True,True,False,False,True,
NCT01495039,Antifungal Prophylaxis in Intensive Care Unit (ICU) Patients,The Role of Oral Nystatin Prophylaxis in ICU Surgical/Trauma Patients,Nystatin,"['Mycostatin', 'Nystatin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Fungal Prophylaxis,"['Fungal Prophylaxis', 'Candida Infection', 'Critical Illness', 'Surgery']",[],COMPLETED,,2008-11,2010-02,"[{'measure': 'course of the colonization index over time.', 'description': 'Fungal colonization will be defined as either the presence of the same yeast on one or more of the six distinct body sites tested (blood sample excepted), or on two consecutive specimens from the same body site. Candida Colonisation index (C.I.)was defined as the ratio of the number of distinct body sites colonised with genotypically identical strains of Candida spp (blood excepted) over the total number of sites tested.', 'timeFrame': 'AT 15 day from ICU admission'}]","[{'measure': 'The secondary evaluation criterion will be the occurrence of a fungal infection during the ICU stay', 'description': 'Fungal infection will be defined as either the presence of a candidemia or the identification of Candida spp. in a normally sterile body site associated with a severe sepsis with negative tests for bacteria or other causes.', 'timeFrame': 'At 15 day from ICU admission'}]",2,18 Years,,ALL,False,Policlinico Hospital,OTHER,0,99.0,ACTUAL,2025-09-01T16:18:13.422377,v2_robust,True,True,True,False,False,
NCT04940039,A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings,Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings,Risperidone 3 mg,"['R092670', 'Paliperidone Palmitate 175 mg eq.', 'Paliperidone Palmitate 263 mg eq.', 'Paliperidone Palmitate 100 mg eq.', 'Risperidone 3 mg', 'Paliperidone Palmitate 150 mg eq.', 'Paliperidone Palmitate 75 mg eq.', 'Paliperidone Palmitate 50 mg eq.', 'Paliperidone Palmitate 525 mg eq.', 'Paliperidone Palmitate 350 mg eq.']",10,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,['Schizophrenia'],"['Long-acting injectable antipsychotics', 'Low income countries', 'schizophrenia']",COMPLETED,,2021-07-22,2024-04-16,"[{'measure': 'Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])', 'description': 'The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).', 'timeFrame': 'Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])'}]","[{'measure': 'Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])', 'description': 'The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).', 'timeFrame': 'Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25)', 'description': 'The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).', 'timeFrame': 'Visit 2 (Week 1) to Visit 6 (Week 25)'}, {'measure': 'Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])', 'description': 'The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.', 'timeFrame': 'Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])', 'description': 'The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.', 'timeFrame': 'Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)', 'description': 'The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.', 'timeFrame': 'Visit 2 (Week 1) to Visit 6 (Week 25)'}, {'measure': 'Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])', 'description': 'The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \\[very dissatisfied\\] to 5 \\[very satisfied\\]) and 2 items are multiple-choice (example, ""select all that apply""). Higher score indicates greater satisfaction.', 'timeFrame': 'Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])', 'description': 'The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \\[very dissatisfied\\] to 5 \\[very satisfied\\]) and 2 items are multiple-choice (example, ""select all that apply""). Higher score indicates greater satisfaction.', 'timeFrame': 'Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)', 'description': 'The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \\[very dissatisfied\\] to 5 \\[very satisfied\\]) and 2 items are multiple-choice (example, ""select all that apply""). Higher score indicates greater satisfaction.', 'timeFrame': 'Visit 2 (Week 1) to Visit 6 (Week 25)'}, {'measure': 'Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])', 'description': 'The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \\[very dissatisfied\\] to 5 \\[very satisfied\\]) and 2 items are multiple-choice (example, ""select all that apply""). Higher score indicates greater satisfaction.', 'timeFrame': 'Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])', 'description': 'The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \\[very dissatisfied\\] to 5 \\[very satisfied\\]) and 2 items are multiple-choice (example, ""select all that apply""). Higher score indicates greater satisfaction.', 'timeFrame': 'Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)', 'description': 'The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 \\[very dissatisfied\\] to 5 \\[very satisfied\\]) and 2 items are multiple-choice (example, ""select all that apply""). Higher score indicates greater satisfaction.', 'timeFrame': 'Visit 2 (Week 1) to Visit 6 (Week 25)'}, {'measure': 'Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])', 'description': 'The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.', 'timeFrame': 'Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])', 'description': 'The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.', 'timeFrame': 'Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])'}, {'measure': 'Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25)', 'description': 'The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.', 'timeFrame': 'Visit 2 (Week 1) to Visit 6 (Week 25)'}, {'measure': 'Number of Participants with Treatment-emergent Adverse Events', 'description': 'An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts.', 'timeFrame': 'Up to Week 66'}, {'measure': 'Number of Participants with Abnormalities in Clinical Laboratory Measures', 'description': 'Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported.', 'timeFrame': 'Up to Week 66'}, {'measure': 'Number of Participants with Abnormalities in Vital Signs', 'description': 'Number of participants with abnormalities in vital signs (temperature \\[oral\\], pulse/heart rate, and blood pressure) will be reported.', 'timeFrame': 'Up to Week 66'}, {'measure': 'Number of Participants with Abnormalities in Electrocardiogram (ECG)', 'description': 'Number of participants with abnormalities in ECG will be reported.', 'timeFrame': 'Up to Week 66'}, {'measure': 'Number of Participants with Abnormalities in Physical Examination', 'description': 'Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported.', 'timeFrame': 'Up to Week 66'}, {'measure': 'Number of Participants With Pregnancy Outcome as a Safety Measure', 'description': 'Number of participants with pregnancy outcome will be reported.', 'timeFrame': 'Up to Week 66'}, {'measure': 'Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score', 'description': 'C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported.', 'timeFrame': 'Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])'}]",22,19 Years,34 Years,ALL,False,Janssen-Cilag International NV,INDUSTRY,0,93.0,ACTUAL,2025-09-01T16:18:13.422395,v2_robust,True,True,True,False,True,
NCT01856439,Long Term Safety and Efficacy Study of ProSavin in Parkinson's Disease,"A Multicentre, Open-label Study to Determine the Long Term Safety, Tolerability and Efficacy of ProSavin in Patients With Bilateral, Idiopathic Parkinson's Disease.",ProSavin,['ProSavin'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Parkinson's Disease,"[""Parkinson's Disease""]","['ProSavin', 'Gene therapy']",TERMINATED,"As a result of termination of development of Prosavin, it is no longer possible for Sio to either commence or to continue any related clinical trials.",2011-05,2022-04,"[{'measure': 'To assess the long term safety and tolerability of ProSavin', 'description': 'The number and severity of any adverse event', 'timeFrame': '10 years'}]","[{'measure': ""Patients' responses to ProSavin administration"", 'description': 'Assessed using Unified Parkinson\'s Disease Rating Score(UPDRS) Part III, evaluating percentage of time during waking day that patient is in the ""off"" state through patient diaries and activities of daily living using PDQ-39 at 36 months post administration.', 'timeFrame': '10 years'}]",2,,,ALL,False,Axovant Sciences Ltd.,INDUSTRY,1,15.0,ACTUAL,2025-09-01T16:18:13.422454,v2_robust,True,True,False,True,True,"As a result of termination of development of Prosavin, it is no longer possible for Sio to either commence or to continue any related clinical trials."
NCT00052039,"A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone","A Randomized, Double-Blind, Three-Arm, Phase IIIb Study Comparing the Safety and Efficacy of Interferon Gamma-1b Alone, IFN-Gamma 1b With Azathioprine, and Azathioprine Alone in Patients With Idiopathic Pulmonary Fibrosis Receiving Prednisone",interferon-gamma 1b,"['interferon-gamma 1b', 'azathioprine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Lung Disease,"['Lung Disease', 'Pulmonary Fibrosis']",['idiopathic pulmonary fibrosis'],TERMINATED,Study design changes were needed based on GIPF-001 results,2002-04,2002-06,"[{'measure': 'This study was terminated prior to enrollment.', 'timeFrame': 'This study was terminated prior to enrollment.'}]",[],1,20 Years,79 Years,ALL,False,InterMune,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:13.422462,v2_robust,True,True,False,True,False,Study design changes were needed based on GIPF-001 results
NCT04547439,"Sleep, Diabetic Retinopathy and Melatonin",Sleep and Circadian Regulation in Diabetic Retinopathy: The Role of Intrinsically Photosensitive Retinal Ganglion Cells and Melatonin Supplementation,Melatonin,['Melatonin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Diabetes Mellitus,"['Diabetes Mellitus', 'Diabetic Retinopathy']",[],RECRUITING,,2021-02-03,2026-06,"[{'measure': 'Sleep pattern', 'description': 'Sleep pattern: Sleep duration and sleep efficiency will be assessed by wrist actigraphy, to be worn by the participants for 14 days', 'timeFrame': '14 days'}, {'measure': 'Melatonin and Cortisol Rhythm', 'description': 'Melatonin and cortisol pattern (peak times of the levels, dim light melatonin onset) will be assessed from 24 hour blood sampling', 'timeFrame': '24 hours'}]",[],2,40 Years,65 Years,ALL,False,University of Illinois at Chicago,OTHER,1,42.0,ESTIMATED,2025-09-01T16:18:13.422494,v2_robust,True,True,False,False,False,
NCT01617577,Efficacy and Safety of Filgrastim in Alzheimer's Disease,Efficacy and Safety of Filgrastim as a Pro-Cognitive Agent in Alzheimer's Disease,G-CSF; filgrastim,"['Neupogen; granulocyte colony stimulating factor (GCSF)', 'G-CSF; filgrastim', 'Vehicle (5% dextrose water or D5W)', 'Placebo']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Alzheimer's Disease,"[""Alzheimer's Disease""]","['G-CSF', 'granulocyte colony stimulating factor', 'Filgrastim']",COMPLETED,,2009-06,2012-02,"[{'measure': 'Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )', 'description': 'Scores from each of the cognitive assessments:\n\nmean ADAScog: a decrease in total score units = improvement, min=0 max=31 mean PAL (memory): an increase in score = improvement, min= 0 max=12 mean PAL (total trial adj): a decrease in score = improvement,', 'timeFrame': 'Baseline and 2wk and 4 wk after Rx;'}, {'measure': 'Cognitive Measures Incluing ADAScog, Selected CANTABS Tests (Paired Associate Learning (PAL)and PAL )', 'description': 'Scores from each of the cognitive assessments:\n\nmean ADAScog: a decrease in total score units = improvement, min=0 max= mean PAL (memory): an increase in score = improvement, mean PAL (total trial adj): a decrease in score = improvement,', 'timeFrame': 'Baseline and final visit (14 wks)'}]",[],2,55 Years,,ALL,False,University of South Florida,OTHER,0,8.0,ACTUAL,2025-09-01T16:18:13.422505,v2_robust,True,True,True,False,False,
NCT00678977,"A Phase I, Open-label, Study of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors","A Phase I, Open-label, Study of the Safety, Tolerability and Pharmacokinetics of Pazopanib in Combination With Gemcitabine and Gemcitabine Plus Cisplatin for Advanced Solid Tumors",Pazopanib (GW786034),"['Gemcitabine', 'Pazopanib (GW786034)', 'Cisplatin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,"Lung Cancer, Non-Small Cell","['Lung Cancer, Non-Small Cell']","['pharmacokinetics', 'cisplatin', 'pazopanib (GW786034)', 'Solid tumors', 'anti-angiogenesis', 'gemcitabine']",COMPLETED,,2008-04-03,2011-06-30,"[{'measure': 'Optimum tolerated regimen (OTR) for each regimen in each arm of the study. OTR determined evaluation of AEs and change in lab values. OTR defined as the highest dosing regimen that results in dose limiting toxicity in no more than 1 of 6 subjects', 'timeFrame': 'Until disease progression'}]","[{'measure': 'Anti-tumor activity evaluated using RECIST criteria (if subjects have measurable disease). Assessments of disease every 6 to 12 weeks, recorded as complete response (CR), partial response (PR), stable disease (SD) or progressive disease (PD).', 'timeFrame': 'Until Disease progression'}, {'measure': 'Pharmacokinetic parameters AUC(0-24), Cmax, and tmax of pazopanib, gemcitabine, and ultrafilterable platinum.', 'timeFrame': 'Dose Expansion - Cycle; Dose-Expansion Cycle 2'}, {'measure': 'Levels of circulating cytokine and angiogenic factors (CAF) biomarkers (such as IL 2, IL-10, VEGF, sVEGFR2) in plasma will be determined', 'timeFrame': 'Day 1 of each cycle until disease progression'}, {'measure': 'Genetic variants in select candidate genes in the host DNA will be evaluated', 'timeFrame': 'Day 1 of first cycle'}]",5,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,22.0,ACTUAL,2025-09-01T16:18:13.422557,v2_robust,True,True,True,False,False,
NCT06751277,QL1706 Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer,"A Single-arm, Open-label, Multi-center Clinical Trial of Iparomlimab and Tuvonralimab (QL1706, Anti-PD-1 /CTLA-4 Combination Antibody) Combined with Chemotherapy in the Treatment of Recurrent or Metastatic Endometrial Cancer","QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706","[""QL1706 plus carboplatin plus paclitaxel for six to eight cycles at the investigator's discretion, followed by QL1706""]",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent or Metastatic Endometrial Cancer,['Recurrent or Metastatic Endometrial Cancer'],"['immunotherapy', 'anti-PD-1 antibody', 'anti-CTLA-4 antibody.', 'endometrial cancer']",NOT_YET_RECRUITING,,2025-02-01,2027-07-30,"[{'measure': 'ORR', 'description': 'The best overall response (BOR) was defined as the proportion of subjects who achieved a confirmed CR or PR (according to RECIST v1.1).', 'timeFrame': 'up to 5 months'}]","[{'measure': 'PFS', 'description': 'It was defined as the time from the first use of a study drug to documentation of disease progression (according to RECIST v1.1) or death from any cause, whichever occurred first. Subjects who were alive without disease progression at the time of data cutoff for analysis were censored at the last tumor assessment. Subjects who did not undergo postbaseline assessments were censored at the date of the first dose.', 'timeFrame': 'up to 13months'}, {'measure': 'DoR', 'description': 'It was defined as the time from the first documentation of an objective response (CR or PR) to the first documentation of objective disease progression (according to RECIST v1.1 criteria) or death from any cause, whichever occurred first. Subjects who were alive without disease progression at the time of data cutoff for analysis were censored at the date of the last tumor measurement. DoR was evaluated only in subjects who achieved CR or PR in response.', 'timeFrame': 'up to 5 months'}, {'measure': 'OS', 'description': 'time from first use of a study drug until death from any cause. For those subjects who were alive at the time of data cutoff, censoring will be performed at the last known date of survival. Subjects who did not provide any follow-up information were censored at the date of enrollment.', 'timeFrame': 'up to 45 months'}]",4,18 Years,75 Years,FEMALE,False,xiang yang,OTHER,1,26.0,ESTIMATED,2025-09-01T16:18:13.422656,v2_robust,True,True,False,False,False,
NCT00000577,Asthma Clinical Research Network (ACRN),Asthma Clinical Research Network (ACRN),Albuterol,"['Albuterol', 'Adrenal Cortex Hormones', 'Adrenergic-Beta Agonists', 'Colchicine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,"['Asthma', 'Lung Diseases']",[],WITHDRAWN,Record is an ACRN grant summary \& not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.,1993-09,2008-07,[],[],0,18 Years,75 Years,ALL,False,Milton S. Hershey Medical Center,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:13.422683,v2_robust,True,True,False,True,False,Record is an ACRN grant summary \& not reflective of an individual trial. All ACTs conducted by ACRN were individually registered on the PRS.
NCT06312475,Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors,"A Randomized, Open-label Study to Evaluate the Efficacy and Safety of KN057 Injection Prophylaxis in Patients With Hemophilia A or B With Inhibitors",KN057,['KN057'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hemophilia A With Inhibitor,"['Hemophilia A With Inhibitor', 'Hemophilia B With Inhibitor']",[],RECRUITING,,2024-01-09,2025-12-15,"[{'measure': 'Annualized bleeding rate (ABR) calculated based on treated spontaneous and traumatic bleeding episodes in Arm 1 and Arm 2.', 'description': 'Treated bleeding refers to the use of bypass agents and/or coagulation factors for hemostatic treatment of the bleeding.', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 183 (the end of the main trial), approximately 26 weeks in total'}]","[{'measure': 'ABR calculated based on bleeding episodes, treated spontaneous bleeding episodes, treated joint bleeding episodes, and treated target joint bleeding respectively in Arm 1 and Arm 2.', 'description': 'Bleeding episodes includes spontaneous and/or traumatic bleeding episodes, excluding surgery/procedure-related bleeding episodes. Treated bleeding refers to the use of bypass agents and/or coagulation factors for hemostatic treatment of the bleeding. Target joint are those with spontaneous bleeding ≥3 times in the 6 months prior to screening.', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 183 (the end of the main trial), approximately 26 weeks in total'}, {'measure': 'ABR calculated based on bleeding episodes and treated bleeding episodes respectively in Arm 2.', 'description': 'Bleeding episodes includes spontaneous and/or traumatic bleeding episodes, excluding surgery/procedure-related bleeding episodes. Treated bleeding refers to the use of bypass agents and/or coagulation factors for hemostatic treatment of the bleeding.', 'timeFrame': 'From Day 183 (the beginning of the extension period) to Day 365 (the end of the extension period), approximately 26 weeks in total'}, {'measure': 'ABR calculated based on bleeding episodes, treated bleeding episodes, treated spontaneous bleeding episodes, treated joint bleeding episodes, and treated target joint bleeding respectively in Arm 1.', 'description': 'Bleeding episodes includes spontaneous and/or traumatic bleeding episodes, excluding surgery/procedure-related bleeding episodes. Treated bleeding refers to the use of bypass agents and/or coagulation factors for hemostatic treatment of the bleeding. Target joint are those with spontaneous bleeding ≥3 times in the 6 months prior to screening.', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 365 (the end of the extension period), approximately 52 weeks in total'}, {'measure': 'Change from baseline in Hemophilia Joint Health Score (HJHS) scores in Arm 1 and Arm 2.', 'description': 'Hemophilia Joint Health Scores (HJHS) is a validated 11-item scoring tool developed for the assessment of joint health in participants with hemophilia. It comprised an evaluation of the elbows, knee and ankle joints: swelling (0 to 3), duration of swelling (0 and 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2) and strength (0 to 4), in each item 0 = none and higher score = severe damage and global gait (walking, stairs, running, hopping on 1 leg) scored on scale ranged from 0 to 4, where 0 = all skills in normal limit and 4 = no skills within normal limits). Total HJHS score = sum of joint totals (0 to 120) + general gait (1 to 4) and ranged from 0 (no joint damage) to 124 (severe joint damage), where higher score indicated severe joint damage.', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 183 (the end of the main trial), approximately 26 weeks in total'}, {'measure': 'Change in HJHS scores from baseline in Arm 1 and from the 26th week in Arm 2.', 'description': 'Hemophilia Joint Health Scores (HJHS) is a validated 11-item scoring tool developed for the assessment of joint health in participants with hemophilia. It comprised an evaluation of the elbows, knee and ankle joints: swelling (0 to 3), duration of swelling (0 and 1), muscle atrophy (0 to 2), crepitus on motion (0 to 2), flexion loss (0 to 3), extension loss (0 to 3), joint pain (0 to 2) and strength (0 to 4), in each item 0 = none and higher score = severe damage and global gait (walking, stairs, running, hopping on 1 leg) scored on scale ranged from 0 to 4, where 0 = all skills in normal limit and 4 = no skills within normal limits). Total HJHS score = sum of joint totals (0 to 120) + general gait (1 to 4) and ranged from 0 (no joint damage) to 124 (severe joint damage), where higher score indicated severe joint damage.', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 365 (the end of the extension period), approximately 52 weeks in total'}, {'measure': 'Change from baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) in Arm 1 and Arm 2.', 'description': 'The EQ-5D-5L questionnaire is made up for 2 components, health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; every dimension contains 5 levels (5L): no difficulty, a little difficulty, moderate difficulty, severe difficulty, very severe difficulty/inability to perform. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health).', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 183 (the end of the main trial), approximately 26 weeks in total'}, {'measure': 'Change in EQ-5D-5L from baseline in Arm 1 and from the 26th week in Arm 2.', 'description': 'The EQ-5D-5L questionnaire is made up for 2 components, health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D): mobility, self-care, usual activities, pain/discomfort, and anxiety/depression; every dimension contains 5 levels (5L): no difficulty, a little difficulty, moderate difficulty, severe difficulty, very severe difficulty/inability to perform. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health).', 'timeFrame': 'From Day 1 (the beginning of the main trial) to Day 365 (the end of the extension period), approximately 52 weeks in total'}, {'measure': 'Incidence of TEAE, TEAE related to the experimental drug and SAE.', 'description': ""TEAE refers to 'treatment emergent adverse event'. SAE refers to 'serious adverse event'."", 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Incidence of thromboembolic events, TMA and DIC.', 'description': ""TMA refers to 'thrombotic microangiopathy'. DIC refers to 'disseminated intravascular coagulation'."", 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Incidence of hypersensitivity type reactions.', 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Incidence of injection site reactions.', 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Incidence of clinically significant laboratory value abnormalities.', 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Number of participants with clinically significant changes from baseline in physical exam.', 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Number of participants with clinically significant changes from baseline in electrocardiograms.', 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'Number of participants with clinically significant changes from baseline in vital signs.', 'timeFrame': 'From the signing of informed consent to 4 weeks after the last dose of KN057 (the end of the trial), approximately 59 weeks in total'}, {'measure': 'KN057 plasma trough concentration.', 'description': 'pharmacokinetics', 'timeFrame': 'From start of KN057 treatment (Day 1 for KN057 prophylaxis group, Day 183 for no prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for KN057 prophylaxis group and 30 weeks for no prophylaxis group in total'}, {'measure': 'Levels of Free TFPI.', 'description': 'pharmacodynamics', 'timeFrame': 'From start of KN057 treatment (Day 1 for KN057 prophylaxis group, Day 183 for no prophylaxis group) to Day 365, approximately 52 weeks for KN057 prophylaxis group and 26 weeks for no prophylaxis group in total'}, {'measure': 'Levels of prothrombin fragment 1+2 (PF1+2).', 'description': 'pharmacodynamics', 'timeFrame': 'From start of KN057 treatment (Day 1 for KN057 prophylaxis group, Day 183 for no prophylaxis group) to Day 365, approximately 52 weeks for KN057 prophylaxis group and 26 weeks for no prophylaxis group in total'}, {'measure': 'Incidence of anti-KN057 antibody (ADA) and neutralizing antibody (Nab).', 'description': 'immunogenicity', 'timeFrame': 'From start of KN057 treatment (Day 1 for KN057 prophylaxis group, Day 183 for no prophylaxis group) to 4 weeks after the last dose of KN057, approximately 56 weeks for KN057 prophylaxis group and 30 weeks for no prophylaxis group in total'}]",20,12 Years,70 Years,MALE,False,"Suzhou Alphamab Co., Ltd.",INDUSTRY,0,51.0,ESTIMATED,2025-09-01T16:18:13.422697,v2_robust,True,True,False,False,True,
NCT04472975,Prescription Drug Safety and Effectiveness in Multiple Sclerosis,Disease-modifying Drug Safety and Effectiveness in Multiple Sclerosis [DRUMS],Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS,['Exposure to one or more disease-modifying drug(s)(DMDs) used to treat MS'],1,OBSERVATIONAL,[],,,Multiple Sclerosis,['Multiple Sclerosis'],"['disease-modifying drugs', 'health administrative data', 'population-based', 'Canada', 'cohort studies']",COMPLETED,,1996-01-01,2018-03-31,"[{'measure': 'Study 1: All-cause hospitalizations', 'description': 'The outcome (all-cause hospitalizations) will be derived from the comprehensive hospital data, excluding pregnancy-related events, in 5 Canadian provinces (British Columbia, Manitoba, Nova Scotia, Saskatchewan and Alberta).', 'timeFrame': 'As recurrent events from study entry to study end, up to 22 years.'}, {'measure': 'Study 2: All-cause mortality', 'description': 'The outcome (all-cause mortality) will be derived from the province-wide death data (e.g., Vital Statistics or the equivalent) in 5 Canadian provinces (British Columbia, Manitoba, Nova Scotia, Saskatchewan and Alberta).', 'timeFrame': 'Measured using Cox proportional hazards models (time from study entry to death), up to 22 years.'}, {'measure': 'Study 3: Change in disability (Expanded Disability Status Scale [EDSS]) over time', 'description': 'The outcomes (change in EDSS) will be derived from the MS clinical data in 3 Canadian provinces (British Columbia, Manitoba and Nova Scotia).', 'timeFrame': 'Assessed using mixed effects model from study entry to study end, up to 22 years.'}]","[{'measure': 'Study 1: Physician consultation rates (overall and by physician specialty)', 'description': 'The outcome (physician consultation) will be derived from the physician data, excluding pregnancy-related events, in 5 Canadian provinces (British Columbia, Manitoba, Nova Scotia, Saskatchewan and Alberta).', 'timeFrame': 'Overall numbers of physician consultations will be measured from study entry to study end, up to 22 years of follow-up.'}, {'measure': 'Study 3: MS disability, measured using the Expanded Disability Status Scale (EDSS) and assessed as time to sustained EDSS 6', 'description': 'The outcome (sustained EDSS 6) will be derived from the MS clinical data in 3 Canadian provinces (British Columbia, Manitoba and Nova Scotia).', 'timeFrame': 'Measured using Cox proportional hazards models (time from study entry to sustained EDSS 6 confirmed after at least 6 months with no subsequent improvement), up to 22 years of follow-up.'}, {'measure': 'Study 3: Sustained EDSS 4', 'description': 'The outcomes (sustained EDSS 4) will be derived from the MS clinical data in 3 Canadian provinces (British Columbia, Manitoba and Nova Scotia).', 'timeFrame': 'Measured using Cox proportional hazards models (time from study entry to sustained EDSS 4), up to 22 years of follow-up.'}, {'measure': 'Study 4: Explore the modifying effects', 'description': 'Effects of sex, age, comorbidity and DMD treatment duration on outcomes (all-cause hospitalizations, physician consultation rates, all-cause mortality, changes in EDSS) will be assessed.', 'timeFrame': 'From study entry to study end, up to 22 years of follow-up.'}, {'measure': 'Study 5: Potential incident adverse events', 'description': ""'Incident' event defined as not present in the year before DMD initiation. The outcomes (incident adverse events) will be identified using physician and hospital claims, coded using International Classification of Diseases \\[ICD\\]-9/10 and prescriptions filled (by ATC levels), in 5 Canadian provinces (British Columbia, Manitoba, Nova Scotia, Saskatchewan and Alberta). An additional, data mining, discovery approach will assess the associations between exposure and adverse events using unsupervised machine learning techniques. Cases of PML will be described."", 'timeFrame': 'Time from study entry to the incident adverse event of interest will be assessed using Cox proportional hazards with time-varying DMD exposure, up to 22 years of follow-up.'}, {'measure': 'Study 6: Characteristics associated with risk of adverse events', 'description': 'Examine demographic and clinical characteristics associated with risk of adverse events, including sex, age, comorbidity and DMD treatment duration.', 'timeFrame': 'From study entry to study end, up to 22 years of follow-up.'}]",9,18 Years,,ALL,True,University of British Columbia,OTHER,5,35000.0,ACTUAL,2025-09-01T16:18:13.422763,v2_robust,False,True,True,False,True,
NCT01234675,The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia,The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia,Milnacipran,"['Savella', 'Placebo', 'Sugar pill', 'Milnacipran']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Sleep Disorders,"['Sleep Disorders', 'Fibromyalgia', 'Sleep']","['Fibromyalgia', 'Sleep disorders', 'Forest Laboratories', 'Milnacipran']",COMPLETED,,2010-11,2014-02,"[{'measure': 'Number of Awakenings After Sleep Onset (NAASO)', 'description': 'Number of awakenings after defined sleep onset until lights on.', 'timeFrame': '4-Week maintenance treatment with milnacipran and placebo'}, {'measure': 'Sleep Efficiency (SE)', 'description': 'Percentage of time spent asleep while in bed', 'timeFrame': '4-Week maintenance treatment with milnacipran and placebo'}, {'measure': 'Wake After Sleep Onset (WASO)', 'description': 'Wake time after defined sleep onset until lights on.', 'timeFrame': '4-Week maintenance treatment with milnacipran and placebo'}]","[{'measure': 'Latency to Persistent Sleep Onset (LPS)', 'description': 'It is defined as time from lights out to the first consecutive 2 minutes of uninterrupted sleep.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Total Sleep Time (TST)', 'description': 'Total sleep of all Rapid Eye Movement (REM) and Non- Rapid Eye Movement Sleep (NTREM) from lights out to lights on.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Arousal Index (AI)', 'description': 'Number of arousals per hour of sleep', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Slow Wave Sleep (SWS)', 'description': 'Time spent in stage 3 of non-rapid eye movement sleep and often referred to as deep sleep.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)', 'description': 'This is a subjective index derived from the medical outcomes study sleep scale (MOS-SS) scored on a 0-100 possible range with higher scores indicating more severe sleep disruption. The scale is a self-report instrument consisting of 12 items that assess perceived initiation and maintenance of sleep, respiratory problems during sleep, sleep duration, perceived adequacy of sleep and daytime somnolence.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Sleep Quality Scale', 'description': 'Sleep quality measure derived from daily sleep diary rating ranging from 0 (""very poor"") to 10 (""excellent"")', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Fatigue Severity Scale (FSS) Total Score', 'description': 'The scale is a 9-item self-report of fatigue in the past week and scored on a 7-point scale with 1 = strongly disagree and 7 = strongly agree. Scores range from 9 to 63 with higher scores indicating higher fatigue severity. A total score greater or equal to 36 suggests fatigue.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Fibromyalgia Impact Questionnaire (FIQ) Total Score', 'description': ""The scale is composed of 10 items relating to fibromyalgia symptoms experienced in the past week. Score ranges from 0 to 100 with higher scores indicating a greater effect of fibromyalgia on a person's life."", 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Brief Pain Inventory (BPI) Mean Severity Score', 'description': 'The score is derived from the BPI scale and measures pain intensity in the past 24 hour. The pain severity score is derived as the average score of 4 pain items assessing pain at its ""worst"", ""least"", ""average"" and ""now"" and ranges from 0-10 with higher scores reflecting greater pain', 'timeFrame': '4-Week treatment with milnacipran and placebo'}, {'measure': 'Brief Pain Inventory (BPI) Mean Interference Score', 'description': 'The score is derived from the BPI scale and measures the effect of pain on functioning in the past 24 hour. It is the average score of 7 items interfering with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Score ranges from 0-10 with higher scores reflecting greater interference.', 'timeFrame': '4-Week treatment with milnacipran and placebo'}]",13,18 Years,,ALL,False,Mansoor Ahmed M.D.,OTHER,1,19.0,ACTUAL,2025-09-01T16:18:13.422800,v2_robust,True,True,True,False,False,
NCT02298075,Response Rate and Duration After Discontinuation Thrombopoietin Receptor Agonists Primary Immune Thrombocytopenia,Response Rate and Response Duration After Discontinuation of Treatment With Thrombopoietin Receptor Agonists in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study,Eltrombopag,"['Eltrombopag', 'Thrombopoietin Receptor Agonists (TPO-RAs)', 'Romiplostin']",3,OBSERVATIONAL,[],,,Immune Thrombocytopenia,['Immune Thrombocytopenia'],"['Immune thrombocytopenia', 'Primary', 'Thrombopoietin receptor agonist']",COMPLETED,,2016-04,2019-04-17,"[{'measure': 'Estimation of sustained response rate after discontinuation of treatment with TPO-RAs in terms of patients still alive in Complete Response or R at more than 4 weeks after discontinuation.', 'timeFrame': 'One year from start of recruitment.'}]","[{'measure': 'Frequency of the type of response in patients treated with TPO-RAs in absence of concomitant or rescue medication, in order to estimate the rate of Response (R) and Complete Response (CR).', 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Estimation of the suspension criteria in terms of frequency of discontinuation causes for each center.', 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Estimation of the duration of sustained response in terms of patients alive in CR or R at 6 and 12 months after sustained response achievement.', 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Estimation of incidence of relapse and loss of response at 6 and 12 months after sustained response achievement.', 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Estimation of treatment duration starting from the date of first dose of TPO-RAs.', 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Description of Platelet levels and TPO-RAs dosage at stop.', 'timeFrame': 'One year from start of recruitment.'}, {'measure': ""Description of patients' characteristics in term of: biological and clinical features, disease duration at the beginning of TPO-RAs, number and type of therapy lines preceding TPO-RAs treatment, platelet levels at TPO-RAs start."", 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Assessment of an association between previous splenectomy and sustained response after discontinuation of treatment with TPO-RAs.', 'timeFrame': 'One year from start of recruitment.'}, {'measure': 'Description of concomitant therapies since TPO-RAs start in terms of type and duration of therapies.', 'timeFrame': 'One year from start of recruitment.'}]",10,18 Years,,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,0,148.0,ACTUAL,2025-09-01T16:18:13.422840,v2_robust,False,True,True,False,False,
NCT06688175,IMRT Combined With Lobaplatin-based CCRT in Nasopharyngeal Carcinoma,Intensity-modulated Radiotherapy Combined With Lobaplatin-based Concurrent Chemotherapy in the Treatment of Elderly Patients With Nasopharyngeal Carcinoma,IMRT combined with lobaplatin-based concurrent chemotherapy,['IMRT combined with lobaplatin-based concurrent chemotherapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Nasopharyngeal Neoplasms,"['Nasopharyngeal Neoplasms', 'Elderly', 'Chemotherapy']",[],ENROLLING_BY_INVITATION,,2024-11-13,2027-12-31,"[{'measure': 'objective response rate (ORR)', 'description': 'ORR encompasses both CR and PR.', 'timeFrame': '6 months'}]","[{'measure': 'Safety', 'description': 'Number of participants with treatment-related adverse events as assessed by CTCAE v4.0', 'timeFrame': '3 months'}, {'measure': 'Overall survival (OS)', 'description': 'OS was defined as the time of NPC diagnosis until death from any cause.', 'timeFrame': '3 years'}, {'measure': 'Locoregional relapse-free survival (LRFS)', 'description': 'LRFS was measured as the duration time from the diagnosis of nasopharyngeal carcinoma to the occurrence of relapse in the nasopharynx or neck lymph nodes or until the last follow-up.', 'timeFrame': '3 years'}, {'measure': 'Distant metastasis-free survival (DMFS)', 'description': 'DMFS was defined as the duration time of nasopharyngeal carcinoma diagnosis to the time of distant metastasis or the last follow-up.', 'timeFrame': '3 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS was referred to as the time from nasopharyngeal carcinoma diagnosis to the date of disease progression.', 'timeFrame': '3 years'}]",6,65 Years,80 Years,ALL,False,The First Affiliated Hospital of Xiamen University,OTHER,0,32.0,ESTIMATED,2025-09-01T16:18:13.422870,v2_robust,True,True,False,False,True,
NCT03380975,Role of Montelukast in Asthma and Allergic Rhinitis Patients,Role of Montelukast in Asthma and Allergic Rhinitis Patients,Montelukast 10mg,"['Montelukast 10mg', 'Aireez']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Asthma and Allergic Rhinitis,['Asthma and Allergic Rhinitis'],"['MAAP', 'Asthma', 'Allergic rhinits']",COMPLETED,,2018-08-28,2019-06-30,"[{'measure': 'Efficacy of montelukast on asthma day and night symptoms changes from baseline after 4 weeks of treatment', 'description': 'To determine the efficacy of montelukast on asthma day and night symptoms changes from baseline after 4 weeks of treatment \\[Designated as safety issue: No\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}]","[{'measure': 'Efficacy of montelukast on allergic rhinitis symptoms changes from baseline after 4 weeks of treatment', 'description': 'To determine the efficacy of montelukast on allergic rhinitis symptoms changes from baseline after 4 weeks of treatment \\[Designated as safety issue: No\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}, {'measure': 'Effect of montelukast in change in individual quality of life using Quality of life questionnaire after 4 weeks of treatment', 'description': 'To determine the effect of montelukast in change in individual quality of life using Quality of life questionnaire after 4 weeks of treatment \\[Designated as safety issue: No\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}, {'measure': 'Proportion of participants experiencing an adverse event (AE)', 'description': 'Proportion of participants experiencing an adverse event (AE) \\[Designated as safety issue: Yes\\] \\[Time Frame: 0 days to 4 weeks\\]', 'timeFrame': '4 weeks'}]",4,18 Years,75 Years,ALL,False,Clinision,OTHER,0,600.0,ACTUAL,2025-09-01T16:18:13.422879,v2_robust,True,True,True,False,True,
NCT03131375,Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia,"Dexmedetomidine Reduces Emergence Delirium in Children Undergoing Tonsillectomy With Propofol Anesthesia: a Prospective, Randomized, Double-blind, Single-center Study.",Dexmedetomidine,"['alpha-2 agonist', 'Dexmedetomidine', 'Normal saline', 'placebo']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Emergence Delirium,"['Emergence Delirium', 'Extubation Time', 'Heart Rate', 'Postoperative Analgesia', 'Blood Pressure']","['dexmedetomidine', 'emergence delirium', 'anesthesia', 'propofol', 'children']",COMPLETED,,2017-05-01,2017-07-30,"[{'measure': 'Emergence delirium in PACU', 'description': 'Presence or absence of Emergence delirium with and without dexmedetomidine assessed by Watcha scale', 'timeFrame': 'up to 30 min'}]","[{'measure': 'Emergence delirium severity, assessed in PACU', 'description': 'Watcha score', 'timeFrame': 'up to 30 min'}, {'measure': 'Extubation time', 'description': 'time interval between discontinuation of anesthetics and extubation', 'timeFrame': 'up to15 min'}, {'measure': 'Heart rate', 'description': 'monitored intraoperatively ECG', 'timeFrame': 'up to 45 min'}, {'measure': 'Blood pressure', 'description': 'monitored intraoperatively NIBP', 'timeFrame': 'up to 45 min'}]",5,3 Years,14 Years,ALL,False,"Athens General Children's Hospital ""Pan. & Aglaia Kyriakou""",OTHER,0,60.0,ACTUAL,2025-09-01T16:18:13.422886,v2_robust,True,True,True,False,False,
NCT01781975,Imatinib Treatment in Recent Onset Type 1 Diabetes Mellitus,Safety and Efficacy of Imatinib for Preserving Beta-Cell Function in New-Onset Type 1 Diabetes Mellitus,Imatinib Mesylate,"['GLEEVEC', 'Imatinib Mesylate', 'Glivec', 'Placebo (For imatinib mesylate)']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Diabetes Mellitus, Type I","['Diabetes Mellitus, Type I', 'Diabetes Mellitus, Insulin-Dependent, 1', 'Type 1 Diabetes Mellitus', 'Insulin-Dependent Diabetes Mellitus 1', 'IDDM']",[],COMPLETED,,2014-01,2018-05,"[{'measure': 'Area Under the Stimulated C-peptide Curve (AUC) Mean Over the First 2 Hours of a 4 Hour Mixed Meal Tolerance Test at the 1 Year Visit', 'description': 'The primary outcome of each participant is the area under the stimulated c-peptide curve (AUC) mean based on data collected at time 0 to 2 hours of a 4-hour mixed meal tolerance test (MMTT) conducted at the primary endpoint visit. The timed measurements are done at: 0, 15, 30, 60, 90, and 120 minutes. The term ""AUC mean"" comes from the mean value theorem in calculus. It is the value on the scale of the y-axis that is equal to the AUC divided by the range on the x-axis (in this case 120 minutes).', 'timeFrame': 'Visit 9 (Week 52) at 0, 15, 30, 60, 90, 120 minutes post-dose'}]","[{'measure': 'Area Under the Stimulated C-peptide Curve (AUC) Mean Over 4 Hours at 24 Months', 'description': 'Area under the MMTT-stimulated peak, 4 hour C-peptide AUC mean at week 104. The units are reported as nano-moles/Liter because this is AUC mean (the AUC is divided by the time internal so that the units return to the c-peptide units of measure).', 'timeFrame': 'Visit 13 (Week 104)'}, {'measure': 'Change in HbA1c Levels Over Time', 'description': 'Change in HbA1c levels from Week 52 to Week 104', 'timeFrame': 'Visit 9 (Week 52) and Visit 13 (Week 104)'}, {'measure': 'Change in Insulin Dose (Units/kg) Over Time', 'description': 'Assess insulin use in units per kilogram body weight per day at weeks 52 and 104.', 'timeFrame': 'Visit 9 (Week 52) and Visit 13 (Week 104)'}, {'measure': 'Number of Severe Hypoglycemic Events', 'description': 'Major hypoglycemic events occurring from randomization at weeks 0, 52 and 104.', 'timeFrame': 'Visit 0 (Week 0), Visit 9 (Week 52), and Visit 13 (Week 104)'}, {'measure': 'Number of Adverse Events', 'description': 'Number of adverse events that were reported throughout the study.', 'timeFrame': 'Adverse Events will be assessed at Visit 0 (week 0), Visit 1 (Week 2), Visit 2 (Week 4), and every month thereafter.'}]",6,18 Years,45 Years,ALL,True,"University of California, San Francisco",OTHER,1,67.0,ACTUAL,2025-09-01T16:18:13.422912,v2_robust,True,True,True,False,True,
NCT00933075,Dermacyd Silver Frutal (Lactic Acid) - Photo Evaluation.,Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd Silver Frutal (Lactic Acid).,LACTIC ACID(ND),['LACTIC ACID(ND)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hygiene,['Hygiene'],[],COMPLETED,,2009-06,2009-07,"[{'measure': 'Measure of the photo irritation test and the photosensitivity by using UVA irradiation and evaluation according to International Contact Dermatitis Research Group (ICDRG) scale. Evaluation of the sensibility according to the skin type.', 'timeFrame': 'From the treatment start to the end of the study (treatment period 5 weeks)'}]",[],1,18 Years,60 Years,ALL,True,Sanofi,INDUSTRY,0,27.0,ACTUAL,2025-09-01T16:18:13.422937,v2_robust,True,True,True,False,False,
NCT06935175,A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in the Treatment of Advanced Hepatocellular Cancer,A Study of SHR-1826 Monotherapy or in Combination With Immunotherapy in Patients With Advanced Hepatocellular Cancer,SHR-1826,"['SHR-1826 and immunotherapy combination therapy', 'SHR-1826']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatocellular Cancer,['Hepatocellular Cancer'],['hepatocellular cancer'],NOT_YET_RECRUITING,,2025-05-01,2028-05-31,"[{'measure': 'Objective Response Rate (ORR) by RECIST V1.1', 'description': 'The ORR is defined as complete remission (CR) rate + partial remission (PR) rate by RECIST V1.1.', 'timeFrame': 'up 2 years'}]","[{'measure': 'Objective Response Rate (ORR) by mRECIST', 'description': 'The ORR is defined as complete remission (CR) rate + partial remission (PR) rate by mRECIST.', 'timeFrame': 'up 2 years'}, {'measure': 'Disease control rate (DCR) by RECIST V1.1', 'description': 'The DCR is defined as complete remission (CR) rate + partial remission (PR) rate + stable disease (SD).', 'timeFrame': 'up 2 years'}, {'measure': 'Progression-free survival (PFS)', 'description': 'The PFS is defined as Time from the date of enrollment to of disease.', 'timeFrame': 'up 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'The OS is defined as time from the date of enrollment to data of death from any cause, or date of lost follow-up, whichever comes first, and otherwise censored at time last known alive.', 'timeFrame': 'up 2 years'}]",5,18 Years,75 Years,ALL,False,Shanghai Zhongshan Hospital,OTHER,0,53.0,ESTIMATED,2025-09-01T16:18:13.422996,v2_robust,True,True,False,False,False,
NCT02275975,Drug-Drug Interaction Study in Healthy Adult Volunteers,,K-877,"['Fluconazole', 'K-877']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Adult Volunteers'],COMPLETED,,2014-07,,"[{'measure': 'Maximum concentration (Cmax)', 'timeFrame': '72 hours'}]","[{'measure': 'Area under concentration curve (AUC)', 'timeFrame': '72 hours'}]",2,18 Years,45 Years,ALL,True,"Kowa Research Institute, Inc.",INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:13.423021,v2_robust,True,True,True,False,False,
NCT00042575,"Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression","Protocol F1J-US-HMBY Dose Escalation, Double-Blind Treatment With Duloxetine Hydrochloride Once Daily Dosing for Evaluation of Safety in Major Depression",Duloxetine,['Duloxetine'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Major Depressive Disorder,['Major Depressive Disorder'],"['Sad, blue, lack of energy, depressed, hopelessness, guilt']",COMPLETED,,2002-06,2002-08,[],[],0,18 Years,,ALL,True,Eli Lilly and Company,INDUSTRY,0,120.0,,2025-09-01T16:18:13.423155,v2_robust,True,True,True,False,False,
NCT01762475,Sildenafil for Cerebrovascular Dysfunction in Chronic Traumatic Brain Injury.,Sildenafil for the Treatment of Cerebrovascular Dysfunction During the Chronic Stage After Traumatic Brain Injury.,Sildenafil,"['Sildenafil', 'Viagra']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Traumatic Brain Injury,"['Traumatic Brain Injury', 'Post-concussive Syndrome']","['Magnetic resonance imaging', 'Blood oxygen level dependent signal', 'Hypercapnia', 'Endothelial progenitor cells']",COMPLETED,,2013-01,2015-12,"[{'measure': 'Cerebrovascular reactivity', 'description': 'Single dose treatment with sildenafil (50 mg orally) is effective in increasing the global BOLD response to hypercapnia in symptomatic patients in the chronic stage after TBI.', 'timeFrame': '24 months'}]","[{'measure': 'Safety and tolerability', 'description': 'Sildenafil therapy (25 mg orally twice daily) is well tolerated in symptomatic patients in the chronic stage after TBI, with few adverse effects and treatment discontinuations in less than 10% of patients.', 'timeFrame': '24 months'}]",2,18 Years,55 Years,ALL,True,Uniformed Services University of the Health Sciences,FED,3,59.0,ACTUAL,2025-09-01T16:18:13.423171,v2_robust,True,True,True,False,True,
NCT02083575,Role of Vitamin C to Augment Iron Chelation With DFP or DFX,Study of Safty and Efficacy of Adjuvant Vitamin c in Augmenting Iron Chelation,"Vitamin C, Defriprone, deferisarox","['deferiprone , deferesarox', 'DFX', 'vitamin c', 'Vitamin C, Defriprone, deferisarox', 'DFP']",5,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Vitamin c,"['Vitamin c', 'Thalassemia Major', 'Iron Chelation']","['vitamin c', 'thalassemia major', 'iron chelation']",UNKNOWN,,2014-04,2014-04,"[{'measure': 'Vit C to Augment iron chelation', 'description': 'assess safety and efficacy of Vit C to Augment iron chelation with DFP or DFX in thalassemic patients.', 'timeFrame': '12 months'}, {'measure': 'vitamin c augmenting effect of iron chelator', 'description': 'better reduction in serum ferritin, LIC and cardiac T28 in group receiving vitamin c', 'timeFrame': '12 month'}]","[{'measure': 'adverse related events', 'description': 'safety and occurrence of AEs in both studied groups', 'timeFrame': '12 month'}]",3,6 Years,18 Years,ALL,False,Ain Shams University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:13.423182,v2_robust,True,True,False,False,True,
NCT06988475,DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations,"DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial):An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage/Young Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations.Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations",Capmatinib,['Capmatinib'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Solid Tumour,"['Solid Tumour', 'Haematological Malignancy', 'Malignant Neoplasm', 'Neoplasms by Histologic Type', 'Neoplasms by Site', 'Cancer', 'Malignancy', 'Glioma', 'Neuroblastoma', 'Gastric Cancer', 'Soft Tissue Sarcoma']","['adult', 'capmatinib', 'MET Tyrosine Kinase Receptor', 'MET exon 14 skipping', 'MET amplifications', 'MET fusions', 'MET activating mutations', 'MET dysregulations', 'Antineoplastic Agents', 'cancer', 'malignancy', 'Malignant Neoplasms', 'Molecular Targeted Therapy', 'Mutation', 'Neoplasms by Histologic Type', 'Neoplasms by Site', 'Precision Medicine', 'Protein Kinase Inhibitors', 'Rare', 'Tumour-agnostic', 'METex14 skipping']",RECRUITING,,2024-11-19,2029-10,"[{'measure': 'Objective Response (OR)', 'description': 'OR is defined as the confirmed occurrence of either a Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumours (RECIST) Version 1.1 criteria (or immune related \\[ir\\]-RECIST or standard imaging criteria for specific disease e.g. Response Evaluation in Neuro Oncology criteria \\[RANO\\]). In patients with leukaemia, OR will be defined as the occurrence of CR, CRi (CR incomplete neutrophil recovery) or CRp (CR with incomplete platelet recovery). The trial will report the proportion of patients with an OR and 95% credible interval.', 'timeFrame': 'Disease assessments to be performed up to 24 weeks from the start of trial treatment.'}, {'measure': 'Durable Clinical Benefit (DCB)', 'description': 'DCB is defined as the absence of disease progression for at least 24 weeks from the start of trial treatment according to RECIST Version 1.1 criteria (or ir-RECIST or standard imaging criteria for specific disease e.g. RANO criteria) and, where relevant (e.g. for haematological malignancies), by standard bone marrow response assessment criteria. Alternative definitions of DCB based on different time points may be pre-specified for particular sub-cohorts if 24 weeks is not clinically relevant. The trial will report the proportion of patients with a DCB and 95% credible interval.', 'timeFrame': 'Disease assessments to be performed up to 24 weeks from the start of trial treatment.'}]","[{'measure': 'Duration of response (DR)', 'description': 'DR is defined as the time from the date of the first confirmed CR or PR according to RECIST 1.1 or ir-RECIST or standard imaging criteria for specific disease, e.g. RANO criteria to the date of disease progression. The trial will report the median DR and 95% credible interval.', 'timeFrame': 'Disease assessment performed every 2 cycles of capmatinib (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose of capmatinib for up to 2 years.'}, {'measure': 'Best percentage change in sum of target lesion / index lesion diameters (PCSD)', 'description': 'PCSD is defined as the greatest decrease or least increase in the sum of target lesion diameters (RECIST) or index lesion diameters (irRECIST) as a percentage compared to the baseline measurement. The trial will report the mean PCSD and 95% credible interval.', 'timeFrame': 'Disease assessment performed every 2 cycles of capmatinib (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose of capmatinib for up to 2 years.'}, {'measure': 'Time to treatment discontinuation (TTD)', 'description': 'TTD is defined as the time from date of starting trial treatment to date of discontinuing trial treatment, in days estimated by the median of the posterior inverse gamma probability distribution. The trial will report the median TTD and 95% credible interval.', 'timeFrame': 'From first dose of capmatinib to discontinuation of trial treatment up to 5 years with an average calculated and presented with results entry.'}, {'measure': 'Progression-Free Survival time (PFS)', 'description': 'PFS is defined as the time from date of starting trial treatment to date of progression or date of death without a previous progression recorded estimated by the median of the posterior inverse gamma probability distribution.', 'timeFrame': 'Disease assessment performed every 2 cycles of capmatinib (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose of capmatinib for up to 2 years.'}, {'measure': 'Time to Progression (TTP)', 'description': 'TTP is defined as the time from date of starting trial treatment to date of progression or date of death without recorded progression censored rather than events. The trial will report the median TTP and 95% credible interval.', 'timeFrame': 'Disease assessment performed every 2 cycles of capmatinib (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose of capmatinib for up to 2 years.'}, {'measure': 'Growth Modulation Index (GMI)', 'description': 'GMI is defined as the ratio of TTP with the trial protocol treatment to TTP on the most recent prior line of therapy. The trial will report the mean GMI and 95% credible interval.', 'timeFrame': 'Disease assessment performed every 2 cycles of capmatinib (each cycle is 28 days) and at EoT. After 24 weeks, it can be done every 12 weeks, on discussion with Sponsor. Follow-up visits are every 3 months after last dose of capmatinib for up to 2 years.'}, {'measure': 'Overall Survival time (OS)', 'description': 'OS is defined as the time from date of starting trial treatment to date of death from any cause estimated by the median of the posterior normal probability distribution.', 'timeFrame': 'Time of death or up to 2 years after the EoT visit.'}, {'measure': 'Occurrence of at least one Suspected Unexpected Serious Adverse Reaction (SUSAR)', 'description': 'The trial will report the number of patients who experience at least one SUSAR to capmatinib.', 'timeFrame': 'From the time of consent until 28 days after last dose of capmatinib (up to 5 years) or until patient starts another anti-cancer therapy, whichever came first. An average time frame will be presented with results entry.'}, {'measure': 'Occurrence of at least one Grade 3, 4 or 5 capmatinib related AE', 'description': 'Number of patients who experience at least one capmatinib related Grade 3, 4 or 5 AE according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0', 'timeFrame': 'From the time of consent until 28 days after last dose of capmatinib (up to 5 years) or until patient starts another anti-cancer therapy, whichever came first. An average time frame will be presented with results entry.'}, {'measure': 'EORTC-QLQ-30-Standardised Area Under Summary Score Curve (QLQSAUC)', 'description': 'Multiple measures of Quality of Life (QoL) will be generated from patient completion of the European Organisation for Research and Treatment of Cancer QLQC30 (EORTC-QLQ-C30) questionnaire (15 measures). For each patient the Summary Score from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean QLQSAUC and 95% credible interval.', 'timeFrame': 'QoL surveys performed at baseline every cycle (every cycle is 28 days) and after interrupting treatment (up to 5 years).'}, {'measure': 'EQ-5D Standardised Area Under Index Value Curve (EQ5DSAUC)', 'description': 'Two measures of QoL will be generated from patient completion of the EQ-5D-5L questionnaire. For each measure, scores based on responses from the questionnaire will be generated at each time point and the area under the curve generated by these scores over time will be calculated and standardised by the time frame. The trial will report the mean EQ5DSAUC and 95% credible interval.', 'timeFrame': 'QoL surveys performed prior to inclusion, every cycle (each cycle is 28 days) and at EoT visit (up to 5 years).'}]",13,18 Years,,ALL,False,Cancer Research UK,OTHER,4,30.0,ESTIMATED,2025-09-01T16:18:13.423221,v2_robust,True,True,False,False,True,
NCT05041257,"Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO)","A Phase 2, Single Arm Study of Mirvetuximab Soravtansine in Recurrent Platinum-Sensitive, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (PICCOLO)",Mirvetuximab soravtansine,"['IMGN853', 'MIRV', 'Mirvetuximab soravtansine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,"['Ovarian Cancer', 'Peritoneal Cancer', 'Fallopian Tube Cancer']","['Platinum-sensitive', 'Ovarian cancer', 'Folate-receptor alpha expression', 'Antibody-drug conjugate', 'Cancer', 'Ovarian Neoplasma', 'Recurrent Platinum-Sensitive,', 'High-Grade Ovarian', 'PICCOLO']",COMPLETED,,2021-08-31,2024-12-12,"[{'measure': 'Assess Objective Response Rate', 'description': 'Objective response rate (ORR), which includes confirmed best response of complete response (CR) or partial response (PR) as assessed by the Investigator', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Assess Duration of response (DOR)', 'description': 'Duration of response (DOR), defined as the time from initial Investigator-assessed response (CR or PR) until progressive disease (PD) as assessed by the Investigator', 'timeFrame': 'up to 2 years'}, {'measure': 'Assess treatment emergent adverse events (TEAEs)', 'description': ""Adverse Events (AE's) will be evaluated according to the NCI CTCAE v5.0. AEs will be coded using the latest Medical Dictionary for Regulatory Activities (MedDRA) version and summarized per system organ class (SOC) and preferred term"", 'timeFrame': 'up to 2 years'}, {'measure': 'Assess Cancer Antigen-125', 'description': 'Cancer Antigen-125 response determined using the Gynecologic Cancer Intergroup (GCIG) criteria', 'timeFrame': 'up to 2 years'}, {'measure': 'Assess Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS), defined as the time from first dose of MIRV until Investigator-assessed radiological PD or death, whichever occurs first', 'timeFrame': 'up to 2 years'}, {'measure': 'Assess Overall survival (OS)', 'description': 'Overall survival (OS), defined as the time from first dose of MIRV until death', 'timeFrame': 'up to 2 years'}, {'measure': 'Sensitivity analysis', 'description': 'ORR, DOR, and PFS by blinded independent central review (BICR) will be summarized as sensitivity analysis', 'timeFrame': 'up to 2 years'}]",7,18 Years,,FEMALE,False,AbbVie,INDUSTRY,0,79.0,ACTUAL,2025-09-01T16:18:13.423338,v2_robust,True,True,True,False,True,
NCT00430157,Trial With Allergic Rhinitis Patients Taking GSK256066 Versus Placebo In A Pollen Challenge Chamber,"An 8 Day, Randomised, Double Blinded, Placebo-controlled 2-way Crossover Trial of Repeat Doses of Intranasal GSK256066 and Placebo in the Vienna Challenge Chamber in Subjects With Seasonal Allergic Rhinitis (SAR)",GSK256066,['GSK256066'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Rhinitis, Allergic, Seasonal","['Rhinitis, Allergic, Seasonal', 'Seasonal Allergic Rhinitis']","['Vienna Challenge Chamber', 'Seasonal Allergic Rhinitis', 'Inflammation']",COMPLETED,,2007-01,,"[{'measure': 'Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)', 'timeFrame': '1-4h post-dose period spent in the Vienna Challenge Chamber on Day 7'}]","[{'measure': 'Weighted mean total nasal symptom score (TNSS) (sneeze, itch, rhinorrhoea and obstruction)', 'timeFrame': '1-4h post morning dose period spent in the Vienna Challenge Chamber on Day 2.'}]",2,18 Years,50 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:13.423353,v2_robust,True,True,True,False,False,
NCT06247657,A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours,"A Phase I, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BL0006 as a Single Agent in Patients With Advanced Solid Tumors",BL0006,['BL0006'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],RECRUITING,,2024-01-03,2025-05,"[{'measure': 'Maximum Tolerated Dose(MTD)', 'description': 'Based on the incidence of Dose-Limiting Toxicity (DLT) of BL0006 in patients with advanced solid tumors, MTD is determined.', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Recommended Phase II Dose(RP2D)', 'description': 'RP2D will be evaluated according to all the available safety, PK and efficacy data.', 'timeFrame': 'Throughout the study for approximately 2 years'}]","[{'measure': 'Area under the plasma concentration-time curve (AUC)', 'description': 'Area under the plasma concentration time curve', 'timeFrame': 'Cycle 1 day 1 to Cycle 2 day 2（each cycle is 21 days）'}, {'measure': 'Half life (t1/2)', 'description': 'The elimination half-life time', 'timeFrame': 'Cycle 1 day 1 to Cycle 2 day 2（each cycle is 21 days）'}, {'measure': 'Disease Control Rate(DCR)', 'description': 'DCR is defined as the proportion of subjects who achieve a Complete Response (CR) 、Partial Response (PR) or Stable Disease (SD) as assessed by RECIST v1.1', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Objective response rate(ORR)', 'description': 'ORR is defined as the proportion of patients with the best responses of Complete Response (CR) and Partial Response (PR) observed after study treatment.', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS was defined as the the time from the start date of study treatment to the first documented disease progression or death due to any cause, whichever occurs first.', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'Duration of overall response (DOR)', 'description': 'DOR is defined as the time from the first documented CR or PR per RECIST v1.1 to disease recurrence or disease progression (PD) whichever occurs first.', 'timeFrame': 'Throughout the study for approximately 2 years'}, {'measure': 'One-year Overall Survival rate (OS 12)', 'description': 'OS 12 is defined as the proportion of patients alive at one year after the start date of study treatment.', 'timeFrame': 'Throughout the study for approximately 2 years'}]",9,18 Years,,ALL,False,"Shanghai Best-Link Bioscience, LLC",INDUSTRY,0,66.0,ESTIMATED,2025-09-01T16:18:13.423450,v2_robust,True,True,False,False,True,
NCT03299257,"Donepezil, Residual Excessive Daytime Sleepiness, Obstructive Sleep Apnea",Donepezil for Residual Symptoms in CPAP Treated Obstructive Sleepapnea Patients: A Controlled Study,donepezil treatment,['donepezil treatment'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,OSA,"['OSA', 'Sleepiness']","['OSA', 'CPAP', 'sleepiness', 'donepezil']",UNKNOWN,,2018-07-06,2019-03-02,"[{'measure': 'objective excessive daytime sleepiness', 'description': 'Maintenance Wakefulness Test', 'timeFrame': '40 days'}, {'measure': 'subjective excessive daytime sleepiness', 'description': 'Epworth Sleepiness Scale', 'timeFrame': '40 days'}]","[{'measure': 'cognitive improvement (executive functions)', 'description': 'standard cognitive tests to evaluate executive functions', 'timeFrame': '40 days'}]",3,35 Years,60 Years,ALL,False,Associação Fundo de Incentivo à Pesquisa,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:13.423489,v2_robust,True,True,False,False,False,
NCT03962101,Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake,"A Multicenter, Open-label, Uncontrolled Clinical Trial to Confirm the Tolerability of OPC-61815 in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake",OPC-61815 injection,['OPC-61815 injection'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Congestive Heart Failure,['Congestive Heart Failure'],[],COMPLETED,,2019-06-17,2020-06-30,"[{'measure': 'Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs', 'description': '""An AE is defined as any untoward medical occurrence in a patient or clinical trial subject administered a medicinal product and which does not necessarily have a causal relationship with this treatment. A serious AE (SAE) is an AE that leads to death, is life-threatening, results in persistent or significant disability/incapacity, requires in-patient or prolonged hospitalization, results in a congenital anomaly/birth defect, or any other important medical event which is medically significant.\n\nA TEAE is an AE that occurs only after a subject has received IMP.', 'timeFrame': 'From the start of IMP administration (Day 1) up to 15 days'}]","[{'measure': 'Change From Baseline in Body Weight', 'description': 'Change in body weight from baseline (before IMP administration on Day 1) at time of final IMP administration (day after final IMP administration). A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Day after final IMP administration'}, {'measure': 'Improvement Rate for Lower Limb Edema', 'description': 'The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated', 'timeFrame': 'Baseline, Day after final IMP administration'}, {'measure': 'Improvement Rate for Pulmonary Congestion', 'description': 'The improvement rate was defined as the percentage of subjects in whom a symptom was present at baseline and then markedly improved or improved after IMP administration. Improvement category is a 4-point scale below:\n\n* Markedly improved\n* Improved\n* Unchanged\n* Deteriorated', 'timeFrame': 'Baseline, Day after final IMP administration'}]",4,20 Years,85 Years,ALL,False,"Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:13.423540,v2_robust,True,True,True,False,True,
NCT05966701,The MAD Study of SSGJ-613 in Healthy Subjects,"A Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalation Phase I Clinical Study of Humanized Monoclonal Antibody Injection (SSGJ-613) in Healthy Adult Chinese Subjects",SSGJ-613,"['SSGJ-613', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Arthritis, Gouty","['Arthritis, Gouty']",[],UNKNOWN,,2023-08-10,2024-03-10,"[{'measure': 'Adverse events (AEs), measurement of vital signs，physical examination，electrocardiogram and laboratory tests at each visit.', 'description': 'The incidence and severity of treatment emergent adverse event (TEAE), including Serious Adverse Event (SAE), as well as clinical symptoms, and any abnormalities of vital signs, physical examinations，electrocardiogram，laboratory tests and, etc..', 'timeFrame': 'Up to Day 174'}]","[{'measure': 'SSGJ-613 Concentration in Serum', 'description': 'The concentration of SSGJ-613 in Serum.', 'timeFrame': 'Up to Day 174'}]",2,18 Years,45 Years,ALL,True,"Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.",INDUSTRY,0,36.0,ESTIMATED,2025-09-01T16:18:13.423691,v2_robust,True,True,False,False,True,
NCT00401401,Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer,"An Open-labeled Trial With a Dose-escalation Part and a Parallel Group Design(1) Investigating Zalutumumab, an Anti-EGF Receptor Antibody, in Combination With Chemo-Radiation as First Line Treatment of Patients With Cancer of the Head and Neck (1) The Parallel Group Part Was Cancelled",zalutumumab,"['cisplatin', 'zalutumumab']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Head and Neck Cancer,"['Head and Neck Cancer', 'Squamous Cell Cancer']",[],TERMINATED,MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.,2006-12,2010-10,"[{'measure': 'Adverse Events', 'description': 'Number of participants with at least one adverse event. All adverse events were collected during the 8 week treatment period and the following 4 weeks. Serious adverse events were collected during 3 years after the patient was allocated to the trial.', 'timeFrame': 'Overall Study'}]","[{'measure': 'Overall Response', 'description': 'Tumour response according to RECIST criteria J Natl Cancer Inst 2000;92:205-16 assessed by CT/MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR', 'timeFrame': 'Up to 3 years'}, {'measure': 'Time to Response', 'description': 'Tumour response according to RECIST criteria J Natl Cancer Inst 2000;92:205-16 assessed by CT/MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR', 'timeFrame': 'Up to 3 years'}, {'measure': 'Best Overall Tumor Response', 'description': 'Tumour response according to RECIST criteria J Natl Cancer Inst 2000;92:205-16 assessed by CT/MRI. Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the longest diameter of target lesions; Overall Response (OR), CR+PR', 'timeFrame': 'Up to 3 years'}]",4,18 Years,,ALL,False,Genmab,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:13.423720,v2_robust,True,True,False,True,True,MTD was established and patients completed 16 months safety f-up and response assessments. It is considered of limited value to follow patients for 3 years.
NCT05578001,Efficacy of Pilocarpine 1% in Presbyopia,Efficacy of Pilocarpine 1% in Pseudophakia Individuals With Presbyopia,Pilocarpine Ophthalmic,"['Pilocarpine Ophthalmic', 'Glaupin 1%']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Presbyopia,"['Presbyopia', 'Pseudophakia']","['Pilocarpine', 'Presbyopia', 'Pseudophakia']",UNKNOWN,,2022-07-01,2023-03-30,"[{'measure': 'Best Corrected Near Visual Acuity', 'description': 'Comparison of the BCNVA before and after instillation of Pilocarpine 1%', 'timeFrame': '20 minutes'}]","[{'measure': 'Best Corrected Distance Visual Acuity', 'description': 'Comparison of the BCDVA before and after instillation of Pilocarpine 1%', 'timeFrame': '20 minutes'}]",2,40 Years,,ALL,True,Isfahan University of Medical Sciences,OTHER,0,25.0,ESTIMATED,2025-09-01T16:18:13.423730,v2_robust,True,True,False,False,False,
NCT00482001,Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults,The Impact of Cholinesterase Inhibitors on Driving Ability in Healthy Older Adults: A Pilot Study,donepezil,"['Aricept', 'Placebo (cornstarch)', 'donepezil']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Mental Health,"['Mental Health', 'Geriatrics']","['Donepezil', 'Driving', 'Cholinesterase Inhibitors', 'Geriatric Psychiatry', 'Psychopharmacology', 'Aricept']",COMPLETED,,2007-06,2008-08,"[{'measure': 'Psychomotor Vigilance Test (PVT)', 'description': 'A measure of reaction time in milliseconds, using a handheld unit, in which participants respond to a visual simulus', 'timeFrame': 'Day 15'}, {'measure': 'Attention Network Test (ANT)', 'description': 'A measure of reaction time in milliseconds, based on the speed with which participants press a key in response to a visual stimulus', 'timeFrame': 'Day 15'}, {'measure': 'Speed Deviation', 'description': 'A measure of deviation from posted speed limit, measured in km/h', 'timeFrame': 'Day 15'}, {'measure': 'Deviation From Road Position', 'description': 'A measure of deviation from central road position, measured in cm', 'timeFrame': 'Day 15'}, {'measure': 'Reaction Time to Wind Gusts', 'description': 'Reaction time to wind gusts, measured in seconds', 'timeFrame': 'Day 15'}, {'measure': 'Percentage of Time in Safe Zone', 'description': 'Time spent in safe zone (within 10km/h of speed limit and within 0.838m of centre of driving lane), measured as %', 'timeFrame': 'Day 15'}, {'measure': 'Collisions', 'description': 'Number of collisions (on driving simulator)', 'timeFrame': 'Day 15'}]",[],7,65 Years,85 Years,ALL,True,Sunnybrook Health Sciences Centre,OTHER,1,22.0,ACTUAL,2025-09-01T16:18:13.423792,v2_robust,True,True,True,False,False,
NCT03988101,Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event,Role of Statin in Venous Dysfunction in Patients With Venous Thromboembolism Event,Rosuvastatin 20mg,"['Rosuvastatin 20mg', 'Control']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Venous Thromboembolism,"['Venous Thromboembolism', 'Dyslipidemias']",[],COMPLETED,,2019-09-19,2025-05-30,"[{'measure': 'The improvement rate of venous insufficiency', 'description': 'Venous function test (test items according to research) - DVT doppler(thrombus, spontaneous echo contrasts, compressibility)', 'timeFrame': '6months'}, {'measure': 'The improvement rate of venous insufficiency', 'description': 'Venous function test (test items according to research) - Venous insufficiency doppler (reflux, reflux site)', 'timeFrame': '6months'}]","[{'measure': 'Comparison of changes in lab data', 'description': 'Comparison of changes in blood lipid levels, inflammation, and blood coagulation\n\n\\- Test items according to standard treatment WBC, Hemoglobin, BUN, Creatinine, CRP, D-dimer, Fibrinogen, PAI-1', 'timeFrame': '6months'}, {'measure': 'Comparison of changes in lab data', 'description': 'Comparison of changes in blood lipid levels, inflammation, and blood coagulation\n\n\\- Test items according to research AST, ALT, CK, total cholesterol, triglyceride, HDL, LDL', 'timeFrame': '6months'}]",4,19 Years,70 Years,ALL,False,Yonsei University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:13.423825,v2_robust,True,True,True,False,False,
NCT02672501,A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia,"Open-labeled, Uncontrolled, Single-arm Pilot Study to Evaluate Cellular Immunotherapy Using CD19-targeted Chimeric Antigen Receptor Engineered T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia",anti-CD19-CAR-T cells,"['2nd CAR-T', 'anti-CD19-CAR-T cells']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Leukemia, B-Cell","['Leukemia, B-Cell']","['immunotherapy', 'CAR-T', 'leukemia']",UNKNOWN,,2016-01,2019-12,"[{'measure': 'Number of patients with adverse event', 'description': 'asverse event is evaluated with CTCAE, version 4.0', 'timeFrame': '6 weeks'}]","[{'measure': 'Number of patients with tumor response', 'description': 'summarize tumor response by overal response rates', 'timeFrame': '8 weeks'}, {'measure': 'Detection of transferred T cells in the circulation using quantitative -PCR', 'timeFrame': '6 weeks'}]",3,1 Year,70 Years,ALL,False,"Shanghai GeneChem Co., Ltd.",INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:13.423908,v2_robust,True,True,False,False,True,
NCT01382901,Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS),A Phase 2a Study Evaluating the Efficacy and Safety of a Novel Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS),Ferric Carboxymaltose (FCM),"['Placebo', 'VIT-45', 'Ferric Carboxymaltose (FCM)']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Restless Legs Syndrome (RLS),['Restless Legs Syndrome (RLS)'],[],COMPLETED,,2006-03,2007-07,"[{'measure': 'International Restless Legs Syndrome (IRLS) Total Score', 'description': 'The scale represents the patients symptoms of RLS. The patient rates his/her symptoms based on 10 questions with a maximum possible score of 40 representing the most severe symptoms while a score of 0 represents no symptoms at all.', 'timeFrame': 'Change from Baseline to Day 28'}]",[],1,18 Years,,ALL,False,"American Regent, Inc.",INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:13.423916,v2_robust,True,True,True,False,False,
NCT04453501,Anti Infective Agents Impact in COVID-19 Pneumonia,Interest of Azithromycin With or Without Hydroxychloroquine for the Treatment of COVID-19 Pneumonia : a Retrospective Observational Study,favorable outcome,['favorable outcome'],1,OBSERVATIONAL,[],,,COVID,"['COVID', 'Pneumonia, Viral']","['azithromycin', 'hydroxychloroquine', 'COVID-19', 'pneumonia', 'hospitalization']",COMPLETED,,2020-03-02,2020-04-25,"[{'measure': 'Favorable outcome', 'description': 'After being admitted, patient was monitored whether he does not required to be transferred in ICU or died because of a severe COVID-19 pneumonia within 7 days. The outcome was purely clinical. If patient was discharged at home after admission and/or was transferred into a rehabilitation center he was considered as a favorable outcome independently of any biological marker.', 'timeFrame': 'Assessed within 7 days after admission'}]","[{'measure': 'Risk factors 1', 'description': 'Studying if biological abnormalities (lymphocyte count or CRP) at admission were associated with an unfavorable outcome', 'timeFrame': 'Assessed at day 1'}, {'measure': 'Risk factors 2', 'description': 'Studying if comorbidities were associated with an unfavorable outcome', 'timeFrame': 'Assessed at day 1'}, {'measure': 'Interest of anti-infective agents', 'description': 'Studying whether any regimen was associated with a favorable outcome (including azithromycin)', 'timeFrame': 'From date of inclusion until the date of first documented progression to ICU or date of death from any cause, whichever came first, assessed up to 2 months'}]",4,18 Years,,ALL,False,Centre d'Investigation Clinique et Technologique 805,OTHER,0,132.0,ACTUAL,2025-09-01T16:18:13.423952,v2_robust,False,True,True,False,False,
NCT03135912,Three-Arm Trial of Novel Treatment for Tinea Pedis,Three-Arm Trial of Novel Treatment for Tinea Pedis,Experimental Drug SESC 01,"['Experimental Drug SESC 01', 'Terbinafine Hydrochloride', 'Lamisil AT', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Tinea Pedis,['Tinea Pedis'],"['Tinea Pedis', ""Athlete's Foot""]",COMPLETED,,2017-01-03,2017-08-02,"[{'measure': 'Effective Treatment (Mycological Cure and Minimal Symptoms)', 'description': 'Binary outcome measure defined as mycological cure AND a total clinical assessment score less than or equal to 2 (out of a possible 18). Mycological cure is defined as negative potassium hydroxide microscopy, while the clinical assessment is based on a sum of 6 symptoms (desquamation, vesiculation, erythema, fissuring, maceration, and pruritus) scored 0-3 by a physician.', 'timeFrame': '6 weeks'}]","[{'measure': 'Rate of Adverse Events', 'description': ""To examine treatment safety, we will calculate the rate of adverse events and serious adverse and compare them between the study's three arms using Chi-square tests to evaluate whether a statistically significant difference is present."", 'timeFrame': '6 weeks'}, {'measure': 'Effective Treatment (Mycological Cure and Minimal Symptoms)', 'description': 'Effective treatment as defined above, but measured at the end of treatment (4 weeks after the beginning of participation).', 'timeFrame': '4 weeks'}, {'measure': 'Patient Satisfaction Score', 'description': 'At the conclusion of treatment, patients complete a brief survey on their impressions of the treatment\'s tolerability, effectiveness, and convenience on a five-point scale, where 1 = poor, 2 = fair, 3 = good, 4 = very good, 5 = excellent, or they may answer with ""No answer/prefer not to say"". Scores will be compared for each of the three characteristics and as a sum of the three scores.', 'timeFrame': '4 weeks'}, {'measure': 'Self-Reported Patient Compliance', 'description': ""On the same experience questionnaire, patients are asked to estimate how many doses of treatment they missed or forgot to take. Possible answers are None, 1-2, 3-4, 5-6, 7-8, or 9 or more. This indicates whether there is a significant difference in patients' likelihood to adhere to a treatment regimen."", 'timeFrame': '4 weeks'}]",5,18 Years,,ALL,False,South End Skin Care,INDUSTRY,0,90.0,ACTUAL,2025-09-01T16:18:13.424138,v2_robust,True,True,True,False,True,
NCT04915612,"Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia",A Phase I Study of Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination With Gemtuzumab Ozogamicin (GO) in Relapsed Refractory Pediatric Patients With Acute Myeloid Leukemia (AML),Gemtuzumab Ozogamicin,"['hP67.6-Calicheamicin', 'gemtuzumab', 'Cytarabine-Daunorubicin Liposome for Injection', 'CPX-351', 'CMA-676', 'Daunorubicin and Cytarabine (Liposomal)', 'Liposomal AraC-Daunorubicin CPX-351', 'WAY-CMA-676', 'Liposomal Cytarabine-Daunorubicin', 'Vyxeos', 'Gemtuzumab Ozogamicin', 'Liposome-encapsulated Daunorubicin-Cytarabine', 'Mylotarg', 'Calicheamicin-Conjugated Humanized Anti-CD33 Monoclonal Antibody', 'CDP-771', 'Liposome-encapsulated Combination of Daunorubicin and Cytarabine']",16,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome,"['Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome', 'Recurrent Acute Myeloid Leukemia', 'Refractory Acute Myeloid Leukemia', 'Secondary Acute Myeloid Leukemia']",[],COMPLETED,,2021-05-21,2025-01-30,"[{'measure': 'Maximum tolerated dose', 'description': 'Will employ the Bayesian optimal interval (BOIN) design.', 'timeFrame': 'Up to 28 days'}, {'measure': 'Incidence of adverse events', 'description': 'The overall incidence and severity of all adverse events using Common Toxicity Criteria version 4.0.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Objective response', 'description': 'Will be summarized using descriptive statistics overall and per dose levels.', 'timeFrame': 'Up to 28 days'}, {'measure': 'Duration of response', 'description': 'Will be summarized using descriptive statistics overall and per dose levels.', 'timeFrame': 'Number of days from the date of initial response (partial response or better) to the date of first documented disease progression/relapse or death, whichever occurs first, assessed p to 28 days'}, {'measure': 'Overall survival', 'description': 'Will be estimated using Kaplan-Meier method.', 'timeFrame': 'Number of days from study enrollment to death due to any cause, assessed up to 28 days'}, {'measure': 'Event free survival', 'description': 'Will be estimated using Kaplan-Meier method.', 'timeFrame': 'Number of days from the date of treatment initiation to the date of documented treatment failure, relapses from complete response, or death from any cause, whichever occurs first, assessed up to 28 days'}]",6,,21 Years,ALL,False,M.D. Anderson Cancer Center,OTHER,0,1.0,ACTUAL,2025-09-01T16:18:13.424202,v2_robust,True,True,True,False,True,
NCT00143312,Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants,"Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).",voriconazole,['voriconazole'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Prophylaxis Of Invasive Fungal Infections,['Prophylaxis Of Invasive Fungal Infections'],"['Invasive Fungal Infection, Allogenic Stem Cell Transplant, prophylaxis, leukemia, voriconazole']",COMPLETED,,2005-02,2008-04,"[{'measure': 'Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 12-month Follow-up Visit', 'description': 'Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 12-month follow up', 'timeFrame': '12 months'}]","[{'measure': 'Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Prophylaxis Until 6-month Follow-up Visit', 'description': 'Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until 6-month follow up', 'timeFrame': '6 months'}, {'measure': 'Occurrence of Proven or Probable Invasive Fungal Infection (IFI): Start of Voriconazole Prophylaxis Until End of Prophylaxis Visit', 'description': 'Number of participants developing a proven or probable IFI from start of voriconazole prophylaxis until the End of Prophylaxis visit', 'timeFrame': '150 days'}, {'measure': 'Time to Occurrence of Proven or Probable Invasive Fungal Infection (IFI)', 'description': 'Time to occurrence of proven or probable IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI since the exact day on which the IFI began will not be known.', 'timeFrame': '12 months'}, {'measure': 'Time to Occurrence of Proven or Probable New (New Pathogen) Invasive Fungal Infection (IFI)', 'description': 'Time to occurrence of proven or probable new (new pathogen) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI.', 'timeFrame': '12 months'}, {'measure': 'Time to Occurrence of Proven or Probable Recurrent Invasive Fungal Infection (IFI) (Same Pathogen as Previous Baseline IFI)', 'description': 'Time to occurrence of proven or probable recurrent (same pathogen as baseline) IFI from the start of voriconazole prophylaxis. Time to occurrence is strictly time to recorded diagnosis of IFI. The pathogen identified as the positive culture recorded nearest to, but not after, the proven or probable IFI, was assumed to be responsible for the IFI.', 'timeFrame': '12 months'}, {'measure': 'Survival Without Proven or Probable Invasive Fungal Infection (IFI)', 'description': 'Number of participants who survive (ie., are alive) without proven or probable IFI at each of the 6 and 12 month follow-up visits', 'timeFrame': '6 months, 12 months'}]",7,18 Years,,ALL,False,Pfizer,INDUSTRY,1,45.0,ACTUAL,2025-09-01T16:18:13.424212,v2_robust,True,True,True,False,False,
NCT05387512,A Real World Study of Camrelizumab in the Treatment of Advanced Non-squamous Non-small-cell Lung Cancer,Efficacy，Safety and Cost-effectiveness Evaluation of Camrelizumab Plus Chemotherapy in First-line Treatment of Patients With Non-squamous Non-small-cell Lung Cancer,Camrelizumab,"['Airuika, S20190027', 'Camrelizumab']",2,OBSERVATIONAL,[],,,Lung Cancer,['Lung Cancer'],['lung cancer'],UNKNOWN,,2022-01-12,2024-08-31,"[{'measure': 'Progression free survival', 'description': 'Kaplan-meier method was used to estimate median PFS and its 95%CI, and survival curves were plotted.\n\nLog-rank test was used to compare PFS between groups, and COX proportional risk model was used to estimate the HR and 95%CI between groups. Random forebrain metastases (yes/no) and number of metastases (≤3 metastases / \\>3 metastases) were considered as important covariables in the model.', 'timeFrame': '2020-2022'}]",[],1,18 Years,100 Years,ALL,False,Affiliated Hospital of Nantong University,OTHER,1,100.0,ESTIMATED,2025-09-01T16:18:13.424246,v2_robust,False,True,False,False,False,
NCT06430112,Liposomal Bupivacaine vs Ropivacaine for TAPBs,Liposomal Bupivacaine vs Ropivacaine for Ultrasound-guided Transversus Abdominis Plane Blocks in Laparoscopic Lower Abdominal Tumor Resection: A Prospective Randomized Trial,Liposomal Bupivacaine,"['Liposomal Bupivacaine', 'Bupivacaine liposome', 'Ropivacaine', 'Ropivacaine Hydrochloride Injection']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Abdominal Tumor,"['Abdominal Tumor', 'Postoperative Analgesia', 'Liposomal Bupivacaine', 'Ropivacaine']","['liposomal bupivacaine', 'ropivacaine', 'transversus abdominis plane block', 'laparoscopic lower abdominal tumor resection', 'opioid consumption']",RECRUITING,,2023-11-01,2024-06,"[{'measure': 'Postoperative opioid use', 'description': 'The amount of drug used in the postoperative analgesia pump', 'timeFrame': '3 days postoperatively'}]","[{'measure': 'Postoperative pain score', 'description': 'Postoperative VAS score', 'timeFrame': '3 days postoperatively'}, {'measure': 'Postoperative adverse reactions', 'description': 'Postoperative adverse reactions were followed up', 'timeFrame': '3 days postoperatively'}]",3,18 Years,70 Years,ALL,False,Sun Yat-sen University,OTHER,0,74.0,ESTIMATED,2025-09-01T16:18:13.424357,v2_robust,True,True,False,False,True,
NCT06666712,Chronic CED of TPT for Recurrent Malignant Glioma,Chronic Convection Enhanced Delivery of Topotecan for Recurrent Malignant Glioma,Topotecan,"['TPT', 'Topotecan', 'Hycamtin']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,"Brain Tumor, Recurrent","['Brain Tumor, Recurrent', 'Malignant Glioma (WHO Grade III or IV)', 'IDH1/IDH2 Mutation']","['Brain Tumors', 'topotecan', 'Convection-Enhanced Delivery (CED)', 'Glioma', 'IDH Mutation']",NOT_YET_RECRUITING,,2025-10-04,2028-06,"[{'measure': 'Safety, defined as dose at which all patients have had no greater than grade 2 adverse reactions', 'description': 'The primary outcome of the study is to measure the safety of prolonged CED of Topotecan in patients with recurrent IDH-mutant malignant glioma. Safety is defined as the dose at which all patients have had no greater than grade 2 adverse reactions possibly, probably, or definitely related to CED of Topotecan as measured through physical and neurologic examination, laboratory studies, radiographic studies, and adverse effects, as defined by the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 out from Grade 1 (mild symptoms) to Grade 5 (death related to adverse event).', 'timeFrame': 'Up to 29 days'}]","[{'measure': 'Progression Free Survival (PFS), Overall Survival (OS)', 'description': 'Progression Free Survival is defined as the duration of time from start of Topotecan treatment to time of progression or death from any cause, whichever occurs first. Overall survival is defined as the duration of time from the start of Topotecan treatment to death from any cause. Patients will be contacted every 3-6 months, up to 5 years, by phone until death.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Tumor Response to Treatment', 'description': 'The response of the tumor to TPT treatment will be measured radiographically with MRI periodically throughout the 23-29 day treatment period and on follow up 4-6 weeks after treatment, per the international criteria proposed by the updated Response Assessment in Neuro-oncology (RANO) guidelines.', 'timeFrame': 'Up to 29 days of treatment, and 4-6 weeks post treatment period'}, {'measure': 'Clinical Toxicity Rate', 'description': 'This is defined by the number of serious adverse events occuring, which is projected to be ≤ 5% at 23-29 days. A clinical toxicity rate that exceeds 20% will be considered unacceptable for this procedure.', 'timeFrame': 'Up to 29 days'}]",4,18 Years,,ALL,False,Jeffrey N. Bruce,OTHER,0,6.0,ESTIMATED,2025-09-01T16:18:13.424411,v2_robust,True,True,False,False,True,
NCT01348412,Hepatic Arterial Chemotherapy With Raltitrexed and Oxaliplatin Versus Standard Chemotherapy in Unresectable Liver Metastases From Colorectal Cancer After Conventional Chemotherapy Failure,Phase II Randomized Study Comparing the Association of Intraarterial Perfusion of Raltitrexed and Oxaliplatin Versus Standard Chemotherapy Using Intravenous Perfusion for Colorectal Cancer Patient With Metastases Localized to Liver After Failure of Conventional Treatments.,oxaliplatin,"['other intravenous chemotherapy drugs', 'raltitrexed', 'oxaliplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,"['Colorectal Cancer', 'Liver Metastases']","['non resectable metastases', 'liver of colic or rectal origin', 'after failure of the conventional treatments']",COMPLETED,,2010-12-15,2018-04-18,"[{'measure': 'progression-free survival', 'timeFrame': 'for each patient after the 6 months of treatment'}]","[{'measure': 'Estimate the parameters of tumor perfusion using arterial CT Scan data', 'timeFrame': 'for each patient of experimental arm every 9 weeks after the six months of treatment or until progression'}, {'measure': 'Estimate the rate of objective response according to the criteria of CHOI and RECIST', 'timeFrame': 'for each patient every 9 weeks during the 6 months of treatment or until progression'}, {'measure': 'Estimate the overall survival which will be compared with the median of overall survival in other studies published in the literature', 'timeFrame': 'after all data completion after the end of all patient follow-up (december 2013-anticipated)'}, {'measure': 'Estimate the rate of secondary resectable hepatic metastases', 'timeFrame': 'after all data completion after the end of all patient follow-up (december 2013-anticipated)'}, {'measure': 'Estimate the tolerance of the treatment (NCI-CTCAE version 4.0)', 'timeFrame': 'For each patient every 21 days during the six months of treatment and for one year of follow up or until progression'}, {'measure': 'Estimate the quality of life (QLQ C30) and the fatigue MFI20', 'timeFrame': 'after all data completion after the end of all patient follow-up (december 2013-anticipated)'}]",7,18 Years,75 Years,ALL,False,Centre Georges Francois Leclerc,OTHER,2,31.0,ACTUAL,2025-09-01T16:18:13.424460,v2_robust,True,True,True,False,False,
NCT04059081,A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment,A Prospective Cohort of Obinutuzumab and Chlorambucil (GC) Chemotherapy for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia Including Next- Generation Sequencing (NGS)-Based Assessment,Obinutuzumab,['Obinutuzumab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Lymphocytic Leukemia,['Chronic Lymphocytic Leukemia'],[],UNKNOWN,,2019-07-09,2022-07-08,"[{'measure': 'Overall response rate', 'description': 'iwCLL criteria', 'timeFrame': '3 years'}]","[{'measure': 'Complete remission rate', 'description': 'No evidence of disease at the time of tumor assessment by NGS method', 'timeFrame': '3 years'}, {'measure': 'Progression free survival', 'description': 'the time from first dose to documented disease progression', 'timeFrame': '3 years'}, {'measure': 'Overall survival', 'description': 'the time from first dose to death from any cause', 'timeFrame': '3 years'}]",4,70 Years,,ALL,False,Deok-Hwan Yang,OTHER,1,31.0,ESTIMATED,2025-09-01T16:18:13.424478,v2_robust,True,True,False,False,False,
NCT03059381,Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures,Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures,Fycompa,['Fycompa'],1,OBSERVATIONAL,[],,,Partial Seizures (With or Without Secondary Generalized Seizures),"['Partial Seizures (With or Without Secondary Generalized Seizures)', 'Primary Generalized Tonic-clonic Seizures']","['adolescent epilepsy participants', 'partial seizures', 'primary generalized Tonic-clonic seizures']",COMPLETED,,2016-08-01,2021-03-21,"[{'measure': 'Number of participants with any serious adverse event', 'timeFrame': 'from 0 to 104 weeks'}, {'measure': 'Number of participants with any non-serious adverse event', 'timeFrame': 'from 0 to 104 weeks'}]","[{'measure': 'Number of participants experiencing seizures', 'timeFrame': 'from 0 to 104 weeks'}, {'measure': 'Overall improvement rating in seizure frequency', 'timeFrame': 'from 0 to 104 weeks'}]",4,12 Years,17 Years,ALL,False,"Eisai Co., Ltd.",INDUSTRY,0,519.0,ACTUAL,2025-09-01T16:18:13.424489,v2_robust,False,True,True,False,True,
NCT01667081,Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017),A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Clinical Trial,Grazoprevir,['Grazoprevir'],1,OBSERVATIONAL,[],,,Hepatitis C,['Hepatitis C'],[],COMPLETED,,2012-10-17,2021-03-31,"[{'measure': 'Time to Viral Relapse', 'description': 'Viral relapse is defined as any participant who has confirmed HCV Ribonucleic acid (RNA) ≥ Lower limit of quantification (LLoQ) of 15 IU/mL and had achieved sustained virologic response (SVR) in the follow up in the prior treatment study. Time to relapse is defined as the time from last dose of study therapy taken in the prior treatment study until the date where HCV RNA is ≥LLoQ.', 'timeFrame': 'Up to ~60 months after enrollment in this study'}, {'measure': 'Persistence of Treatment-Emergent Nonstructural Protein (NS)3 and NS5A Resistance-associated Substitutions (RASs) in Participants With HCV Genotype (GT) 1a Infections', 'description': 'In adult participants with HCV RNA ≥1000 IU/mL at entry or during the study period, HCV sequence analysis was performed to evaluate the presence of RASs and the persistence of RASs over time.', 'timeFrame': 'Up to ~60 months after enrollment in this study'}, {'measure': 'Persistence of Treatment-Emergent NS3 and NS5A RASs in Participants With HCV Genotype 1b Infections', 'description': 'In adult participants with HCV RNA ≥1000 IU/mL at entry or during the study period, HCV sequence analysis was performed to evaluate the presence of RASs and the persistence of RASs over time.', 'timeFrame': 'Up to ~60 months after enrollment in this study'}, {'measure': 'Persistence of Treatment-Emergent NS3 and NS5A RASs in Participants With Genotype 4 Infections', 'description': 'In adult participants with HCV RNA ≥1000 IU/mL at entry or during the study period, HCV sequence analysis was performed to evaluate the presence of RASs and the persistence of RASs over time.', 'timeFrame': 'Up to ~60 months after enrollment in this study'}, {'measure': 'Number of Participants Who Experienced a Drug-Related Adverse Event (AE) During the Long-Term Follow-Up', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The study investigator determined whether the adverse event was drug-related.', 'timeFrame': 'Up to ~ 60 months after enrollment in this study'}, {'measure': 'Number of Participants Who Experienced a Drug-Related Serious Adverse Event (SAE) During the Long-Term Follow-Up', 'description': 'A serious adverse event (SAE) is any adverse experience occurring at any dose that either results in death, is life threatening, results in a persistent or significant disability/incapacity, results in or prolongs an existing inpatient hospitalization, is a congenital anomaly/birth defect, is a cancer, is an overdose (whether accidental or intentional), or other important medical events that may not result in death, not be life threatening, or not require hospitalization may be considered a serious adverse experience when, based upon appropriate medical judgment, the event may jeopardize the participant and may require medical or surgical intervention to prevent one of the outcomes listed previously. The study investigator determined whether the adverse event was drug-related.', 'timeFrame': 'Up to ~60 months after enrollment in this study'}, {'measure': 'Number of Participants Who Experienced an Event of Clinical Interest (ECI) During the Long-Term Follow-Up', 'description': 'An ECI includes spontaneous bacterial peritonitis, variceal bleeding, ascites, encephalopathy, hepatorenal syndrome, hepatocellular carcinoma, liver transplant, cardiovascular disease limited to angina and myocardial infarction, neurologic disorders limited to transient ischemic attack (TIA) or stroke, graft rejection in participants who have undergone liver or kidney transplant, or one of the following in participants from the MK-5172-052 (NCT02092350) base study: kidney transplant, decreased estimated glomerular filtration rate (eGFR), new onset diabetes, cryoglobulinemia, or post transplantation glomerulonephritis.', 'timeFrame': 'Up to ~60 months after enrollment in this study'}]",[],7,3 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,2438.0,ACTUAL,2025-09-01T16:18:13.424522,v2_robust,False,True,True,False,True,
NCT01196481,Carvedilol + VSL#3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.,"A Prospective,Open Labeled, Randomized Controlled Trial Comparing Carvedilol + VSL# 3 Versus Endoscopic Variceal Ligation for Primary Prophylaxis of Esophageal Variceal Bleeding in Cirrhotic Patients Non Responder to Carvedilol.",Carvedilol+VSL#3,['Carvedilol+VSL#3'],1,INTERVENTIONAL,['NA'],,,Cirrhosis,['Cirrhosis'],[],COMPLETED,,2012-12,2015-08,"[{'measure': 'Development of first variceal bleeding', 'timeFrame': '1 Year'}]","[{'measure': 'Survival', 'timeFrame': '1 Year'}, {'measure': 'Reduction in Portal pressure', 'timeFrame': '1 Year'}, {'measure': 'Time to bleed', 'timeFrame': '1 Years'}, {'measure': 'Adverse events', 'timeFrame': '1 Year'}]",5,18 Years,75 Years,ALL,False,"Institute of Liver and Biliary Sciences, India",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:13.424621,v2_robust,True,True,True,False,True,
NCT07041281,Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories,Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories,spironolactone 25 mg orally once daily,"['spironolactone 25 mg orally once daily', 'Placebo tablet to match spironolactone']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Preeclampsia,"['Preeclampsia', 'Gestational Hypertension']","['preeclampsia', 'gestational hypertension', 'spironolactone', 'blood pressure', 'hypertension', 'pregnancy', 'echocardiography']",NOT_YET_RECRUITING,,2025-09-02,2029-03-02,"[{'measure': 'Mean 24-hour ambulatory diastolic blood pressure', 'description': '24-hour BP monitoring will be performed as part of end-of-study assessments using a validated ambulatory BP monitor.', 'timeFrame': '36 weeks'}]","[{'measure': 'Left ventricular relative wall thickness (main echocardiographic outcome)', 'description': 'Relative wall thickness is calculated as 2\\*posterior wall thickness/LV end-diastolic diameter as measured by transthoracic echocardiography.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Mean 24-hour ambulatory systolic blood pressure', 'description': '24-hour BP monitoring will be performed as part of end-of-study assessment using a validated ambulatory BP monitor. Mean 24-hour systolic BP will be calculated from the device data.', 'timeFrame': '36 weeks'}, {'measure': 'Mean diurnal ambulatory systolic blood pressure', 'description': '24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal systolic BP will be calculated from the device data.', 'timeFrame': '36 weeks'}, {'measure': 'Mean diurnal ambulatory diastolic blood pressure', 'description': '24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean diurnal ambulatory diastolic blood pressure will be calculated from the device data', 'timeFrame': '36 weeks'}, {'measure': 'Mean nocturnal ambulatory systolic blood pressure', 'description': '24-hour BP monitoring will be performed as part of the end-of-study assessment using a validated ambulatory BP monitor. Mean nocturnal ambulatory systolic blood pressure will be calculated from the device data.', 'timeFrame': '36 weeks'}, {'measure': 'Mean nocturnal ambulatory diastolic blood pressure', 'description': '24-hour BP monitoring will be performed as part of the post-treatment assessments using a validated ambulatory BP monitor. Mean nocturnal ambulatory diastolic blood pressure will be calculated from the device data.', 'timeFrame': '36 weeks'}, {'measure': 'Measured systolic blood pressure', 'description': 'At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit.', 'timeFrame': 'Baseline, 2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Measured diastolic blood pressure', 'description': 'At each visit, BP will be measured by study staff three times at one-minute intervals in accordance with multi-society guidelines for accurate measurement of blood pressure. The first measurement will be discarded, and the average of the second and third measurements will be recorded as the measured BP at each study visit.', 'timeFrame': 'Baseline, 2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Readmission for hypertension', 'description': 'Postpartum readmission for hypertension will be captured.', 'timeFrame': 'Through study completion (36 weeks post-randomization)'}, {'measure': 'All-cause readmission', 'description': 'All postpartum readmission will be captured', 'timeFrame': 'Through study completion (36 weeks post-randomization)'}, {'measure': 'Daily defined doses of antihypertensive medication', 'description': 'Daily defined doses of antihypertensive medication will be quantified in accordance with the World Health Organization classification.', 'timeFrame': 'Baseline, 2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Time to discontinuation of all non-study drug antihypertensive medications', 'description': 'All medication changes made by treating clinicians will be captured.', 'timeFrame': 'Through study completion (36 weeks post-randomization)'}, {'measure': 'Escalation of antihypertensive regimen', 'description': 'All medication changes made by treating clinicians will be captured.', 'timeFrame': 'Through study completion (36 weeks post-randomization)'}, {'measure': ""Ratio of mitral E velocity to e' [E/e']"", 'description': ""E/e', a measure of diastolic function, will be measured by transthoracic echocardiography."", 'timeFrame': 'Baseline and 36 weeks'}, {'measure': ""Early diastolic septal mitral annular velocity [septal e']"", 'description': ""Septal e', a measure of diastolic function, will be measured by transthoracic echocardiography using tissue Doppler"", 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Peak tricuspid regurgitant jet velocity', 'description': 'Peak tricuspid regurgitant jet velocity, a measure of diastolic function, will be measured by transthoracic echocardiography using continuous wave Doppler', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Left atrial volume index', 'description': 'Left atrial volume index will be measured by transthoracic echocardiogarphy using the biplane method and indexed for body surface area.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Ratio of E to A [E/A]', 'description': 'E/A, a measure of diastolic function, will be measured by transthoracic echocardiography.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Left ventricular mass index', 'description': 'Left ventricular mass will be calculated from transthoracic echocardiogarphy using the Devereux formula and indexed for body surface area', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Left ventricular ejection fraction', 'description': 'Left ventricular ejection fraction will be measured by transthoracic echocardiogarphy using the biplane method.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Left atrial reservoir strain', 'description': 'Left atrial strain, a sensitive measure of end- diastolic pressure and atrial remodeling, will be quantified using TOMTEC.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Peak global longitudinal strain', 'description': 'Left ventricular global longitudinal strain, a measure of subclinical cardiac dysfunction, will be quantified using TOMTEC.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Interventricular septal wall thickness', 'description': 'Interventricular septal wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'Posterior wall thickness', 'description': 'Posterior wall thickness will be measured by transthoracic echocardiography from the parasternal long axis view.', 'timeFrame': 'Baseline and 36 weeks'}, {'measure': 'High-sensitivity cardiac troponin I', 'description': 'High-sensitivity cardiac troponin will be measured using standard clinical assays.', 'timeFrame': 'Baseline, 12 weeks, and 36 weeks'}, {'measure': 'N-terminal pro-B-type natriuretic peptide', 'description': 'NT-proBNP will be measured using standard clinical assays.', 'timeFrame': 'Baseline, 12 weeks, and 36 weeks'}, {'measure': 'Urine microalbumin/creatinine', 'description': 'Urine microalbumin/creatinine will be measured using standard clinical assays.', 'timeFrame': '2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Activin A', 'description': 'Activin A will be measured by ELISA.', 'timeFrame': 'Baseline, 2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Soluble fms-like tyrosine kinase receptor-1', 'description': 'sFlt-1 will be measured by ELISA.', 'timeFrame': 'Baseline, 2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Placental growth factor', 'description': 'Placental growth factor will be measured by ELISA.', 'timeFrame': 'Baseline, 2 weeks, 12 weeks, and 36 weeks'}, {'measure': 'Procollagen type I carboxyterminal propeptide', 'description': 'PICP will be measured by enzyme immunoassay.', 'timeFrame': 'Baseline, 12 weeks, and 36 weeks'}]",32,18 Years,,FEMALE,False,Massachusetts General Hospital,OTHER,2,204.0,ESTIMATED,2025-09-01T16:18:13.424723,v2_robust,True,True,False,False,False,
NCT02942381,A Study of Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy,,Hydroxychloroquine Sulfate,"['Hydroxychloroquine Sulfate', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,IgA Patients,"['IgA Patients', 'Hydroxychloroquine']",[],COMPLETED,,2016-09-13,2018-01-08,"[{'measure': 'Proteinuria （g/d）', 'timeFrame': 'every two months(total six months)'}]","[{'measure': 'Albuminuria and creatinine ratio(mg/g)', 'timeFrame': 'every two months(total six months)'}]",2,18 Years,75 Years,ALL,False,Peking University First Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:13.424800,v2_robust,True,True,True,False,False,
NCT01264081,Lapatinib in Stage IV Melanoma With ERBB4 Mutations,A Phase II Study of Lapatinib for the Treatment of Stage IV Melanoma Harboring ERBB4 Mutations,Lapatinib,['Lapatinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Malignant Melanoma,['Malignant Melanoma'],"['Lapatinib', 'Melanoma', 'ERBB4 Mutation', 'Malignant Melanoma', 'Skin Cancer']",TERMINATED,Protocol would not be able to reach stated accrual.,2011-05-20,2013-11-22,"[{'measure': 'Count of Participants With a Partial Response (PR) and Complete Response (CR) to Lapatinib Who Have Metastatic Melanoma Harboring ERBB4 Mutations.', 'description': 'The count of participants with a partial response and complete response is defined by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria. Partial response is at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Complete response is disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \\<10 mm. Stable disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Progressive disease (PD) is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The appearance of one or more new lesions is also considered progressions.', 'timeFrame': '3 years'}]","[{'measure': 'Number of Participants With Serious and Non-Serious Adverse Events', 'description': 'Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.', 'timeFrame': 'Date treatment consent signed to date off study, approximately, 3 years'}]",2,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,34.0,ACTUAL,2025-09-01T16:18:13.424818,v2_robust,True,True,False,True,True,Protocol would not be able to reach stated accrual.
NCT05360381,HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid Tumors,"A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics and Initial Efficacy of HLX35 (Recombinant Human Anti-EGFR and Anti-4-1BB Bispecific Antibody) in Patients With Advanced or Metastatic Solid Tumors",HLX35,['HLX35'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Locally Advanced or Metastatic Solid Tumors,"['Locally Advanced or Metastatic Solid Tumors', 'Squamous-cell Non-small Cell Lung Cancer']",[],ACTIVE_NOT_RECRUITING,,2022-06-03,2024-12-30,"[{'measure': 'Incidence of Treatment-Related Adverse Events', 'timeFrame': '2 years'}, {'measure': 'The proportion of patients experiencing dose limiting toxicity (DLT) events', 'timeFrame': 'from first dose to the end of Cycle 2 (each cycle is 14 days)'}, {'measure': 'The maximum tolerated dose (MTD)', 'timeFrame': 'from first dose to the end of Cycle 2 (each cycle is 14 days)'}, {'measure': 'Recommended phase 2 dose (RP2D)', 'timeFrame': 'from first dose to the end of Cycle 2 (each cycle is 14 days)'}]","[{'measure': 'Peak plasma concentration (Cmax) of HLX35', 'timeFrame': '2 years'}, {'measure': 'Time to peak (Tmax) of HLX35', 'timeFrame': '2 years'}, {'measure': 'Area under the concentration-time curve (AUC) of HLX35', 'timeFrame': '2 years'}, {'measure': 'Elimination half-life (t1/2) of HLX35', 'timeFrame': '2 years'}, {'measure': 'Clearance (CL) of HLX35', 'timeFrame': '2 years'}, {'measure': 'Volume of distribution (Vz) of HLX35', 'timeFrame': '2 years'}, {'measure': 'Accumulation Index (Rac) of HLX35', 'timeFrame': '2 years'}, {'measure': '4-1BB receptor occupancy on circulating T cells', 'timeFrame': '2 years'}, {'measure': 'The level of 4-1BB in serum', 'timeFrame': '2 years'}, {'measure': 'Incidence of treatment-emergent anti-drug antibodies (ADA)', 'timeFrame': '2 years'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': '2 years'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': '2 years'}, {'measure': 'Duration of response (DOR)', 'timeFrame': '2 years'}]",17,18 Years,,ALL,False,Shanghai Henlius Biotech,INDUSTRY,0,82.0,ESTIMATED,2025-09-01T16:18:13.424885,v2_robust,True,True,False,False,True,
NCT02481219,Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure,"COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure",Senna tablets,"['Erythromycin', 'SUPREP oral sulfate solution with Gastrografin', 'Metoclopramide', 'PEG', 'SUPREP oral sulfate solution', 'Bisacodyl', 'Senna tablets']",7,INTERVENTIONAL,['NA'],,,Colorectal Cancer Screening,['Colorectal Cancer Screening'],"['Polyps', 'Capsule endoscopy', 'Bowel preparation regimen', 'Average risk patients for colorectal cancer screening']",COMPLETED,,2015-05,2016-02,"[{'measure': 'Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)', 'description': 'The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum).', 'timeFrame': 'Within two weeks of study procedure'}]","[{'measure': 'Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assessed from RAPID video in total and by segment', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assessed from RAPID video in total and by segment', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assesses by applicable case report form (CRF)', 'timeFrame': 'an expected average of 3 weeks from study procedure'}, {'measure': 'Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE', 'description': 'Will be assesses by applicable CRF', 'timeFrame': 'Adverse Events (AE) were collected starting from the screening visit and until 5-9 days following the PillCam procedure day.'}]",6,50 Years,75 Years,ALL,True,Medtronic - MITG,INDUSTRY,0,122.0,ACTUAL,2025-09-01T16:18:13.424894,v2_robust,True,True,True,False,True,
NCT02433119,The Efficacy and Safety of OROSARTAN® Versus CODIOVAN® in Patients With Essential Hypertension Uncontrolled With Monotherapy,"A Multi-center, Randomized, Double-blind, Phase IV Clinical Trial to Compare the Efficacy and Safety of OROSARTAN® Tablet 5/160mg Versus CODIOVAN® Tablet 160/12.5mg in Patients With Essential Hypertension Uncontrolled With Valsartan 160mg Monotherapy",OROSARTAN® 5/160mg,"['OROSARTAN® 5/160mg', 'CODIOVAN® 160/12.5mg']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],[],COMPLETED,,2015-03-16,2016-09-08,"[{'measure': 'Change from baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)', 'timeFrame': 'Baseline, Week 8'}]","[{'measure': 'Change from baseline in MSDBP', 'timeFrame': 'Baseline, Week 4'}, {'measure': 'Change from baseline in Mean Sitting Systolic Blood Pressure (MSSBP)', 'timeFrame': 'Baseline, Week 4 and 8'}, {'measure': 'Control rate in blood pressure', 'description': 'Rate of patients who achieved target blood pressure(MSDBP\\<90mmHg and MSSBP\\<140mmHg)', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Responder rate in blood pressure', 'description': 'Rate of patients who achieved MSDBP≥10mmHg and MSSBP≥20mmHg decrease compared to baseline', 'timeFrame': 'Baseline, Week 8'}]",5,19 Years,,ALL,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,238.0,ACTUAL,2025-09-01T16:18:13.424920,v2_robust,True,True,True,False,False,
NCT05533619,Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury,Analysis of Risk Factors of Proton Pump Inhibitor Related Acute Kidney Injury in Hospitalized Patients and Developments of Machine Learning Model,Proton pump inhibitor,['Proton pump inhibitor'],1,OBSERVATIONAL,[],,,Proton Pump Inhibitor,"['Proton Pump Inhibitor', 'Acute Kidney Injury']","['Proton pump inhibitor', 'Acute kidney injury', 'Pharmacoepidemiology', 'Miss diagnosis', 'Risk factors', 'Logic regression']",COMPLETED,,2022-07-01,2023-10-31,"[{'measure': 'The incidence of acute kidney injury in hospitalized patients treated with proton pump inhibitors', 'description': 'To analyze the incidence of acute kidney injury in hospitalized patients after using proton pump inhibitors, and to build a prediction model. To assess the risk factors before using proton pump inhibitors is helpful to the early prevention, diagnosis and treatment of AKI.', 'timeFrame': 'Through study completion，up to half a year.'}]",[],1,18 Years,100 Years,ALL,False,Qianfoshan Hospital,OTHER,0,30000.0,ACTUAL,2025-09-01T16:18:13.424962,v2_robust,False,True,True,False,False,
NCT01987219,The Effects Of Bronchodilator Therapy On Respiratory And Autonomic Function In Patients With Familial Dysautonomia,The Effects of Bronchodilator Therapy On Respiratory and Autonomic Function in Patients With Familial Dysautonomia,Albuterol-sulphate,"['(Proventil ®)', 'Albuterol-sulphate', 'Ipratropium-bromide', '(Atrovent ®)']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Familial Dysautonomia,['Familial Dysautonomia'],['familial dysautonomia'],COMPLETED,,2013-03,2014-12,"[{'measure': 'Change From Baseline of Forced Vital Capacity', 'description': 'FVC is a measure of the amount of air exhaled, and is measured in liters of air per second. The percentage in the change in the amount of air exhaled from baseline, measured in liters of air per second. Increase in the percentage of air exhaled from baseline indicates improvement in respiratory function.', 'timeFrame': 'Pre and 30 minutes post study drug administration'}, {'measure': 'Change in Respiratory Function (Airway Resistance at 5 Hz) From Baseline', 'description': 'The percentage change in respiratory function from baseline is measured in percentage change in Resistance, kPa/(L/s).', 'timeFrame': 'Pre and 30 minutes post study drug administration'}]","[{'measure': 'Change in Forced Expiratory Volume (FEV) From Baseline', 'description': 'Forced expiratory volume is measured in liters of air per second. FEV was measured during the first second of exhalation.', 'timeFrame': 'Pre and 30 post study drug admistration'}, {'measure': 'Change in Forced Expiratory Flow Between 25-75% (FEF25-75)', 'description': 'FEF25-75 is measured in liters of air per second at 25-75%', 'timeFrame': 'pre and 30 minutes post intervention'}]",4,12 Years,80 Years,ALL,False,NYU Langone Health,OTHER,0,15.0,ACTUAL,2025-09-01T16:18:13.425061,v2_robust,True,True,True,False,False,
NCT05260619,Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma,Phase II Trial of Lenalidomide Maintenance After High-dose Methotrexate-based Immunochemotherapy in Patients With Primary Central Nervous System Lymphoma,lenalidomide,"['lenalidomide', 'Lenalid®']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Central Nervous System Lymphoma,['Central Nervous System Lymphoma'],[],RECRUITING,,2022-04-01,2028-04-01,"[{'measure': 'PFS', 'description': 'progression-free survival', 'timeFrame': '2-year'}]","[{'measure': 'ORR', 'description': 'Overall response rate', 'timeFrame': '2-year'}, {'measure': 'OS', 'description': 'Overall survival', 'timeFrame': '2-year'}]",3,19 Years,,ALL,False,Seoul National University Bundang Hospital,OTHER,1,28.0,ESTIMATED,2025-09-01T16:18:13.425109,v2_robust,True,True,False,False,False,
NCT02015819,"Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas",A Phase I Study of Cytosine Deaminase-Expressing Neural Stem Cells in Combination With Oral 5-Fluorocytosine and Leucovorin for the Treatment of Recurrent High-Grade Gliomas,flucytosine,"['CFR', 'leucovorin calcium', 'flucytosine', 'CF', 'Ro 2-9915', '5-fluorocytosine', 'LV', '5-FC']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Adult Anaplastic Astrocytoma,"['Adult Anaplastic Astrocytoma', 'Adult Anaplastic Oligodendroglioma', 'Adult Giant Cell Glioblastoma', 'Adult Glioblastoma', 'Adult Gliosarcoma', 'Recurrent Adult Brain Tumor', 'Anaplastic Oligoastrocytoma']",[],COMPLETED,,2014-10-07,2017-10-07,"[{'measure': 'Number of Participants With Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD)', 'description': 'Number of DLTs per dose level and the MTD/MFD.', 'timeFrame': 'Day 28 of course 1'}, {'measure': 'Number of Participants With Mechanical Issues With Repeat Administrations of NSCs Via Rickham', 'description': 'Number of participants with mechanical issues with repeat administrations of NSCs via Rickham.', 'timeFrame': '28 days after last infusion of NSCs, up to 6 months total'}]","[{'measure': 'Number of Participants Developing Antibodies Against NSCs', 'description': 'Development of a antibody response to the NSCs will be evaluated by flow cytometry. Data from assessing for possible development of NSC immunogenicity with repeat exposure will be presented in an exploratory fashion using descriptive statistics.', 'timeFrame': 'While receiving treatment, up to 6 months.'}, {'measure': 'Average Steady State Levels of 5-FC and 5-FU in the Brain', 'description': 'Pharmacokinetic (PK) data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics. All summaries will be exploratory in spirit.', 'timeFrame': 'Following the first dose of 5-FC, samples were collected every hour for 24 hours and then every 3 hours thereafter until the end of the 7-day course of 5-FC or until the microdialysis catheter stopped functioning.'}, {'measure': 'Average Steady State Levels of 5-FC Concentrations in Plasma', 'description': 'PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using descriptive statistics.', 'timeFrame': 'Samples were obtained prior to the first dose of 5-FC then every 30 minutes for 3 hours, additional samples at 4 and 6 hours after the morning doses on days 4, 5. On days 6, 7, 8 blood samples were collected just before morning dose and 90 minutes later'}, {'measure': 'Comparison of 5-FC in the Brain to 5-FC in the Plasma', 'description': 'PK data from the patients who undergo intracerebral microdialysis (dose level 4) will be summarized using the mean ratio of average brain interstitial 5-FC concentrations to the average steady-state plasma levels.', 'timeFrame': 'The ratio of average brain interstitial 5-FC and 5-FU concentrations to average plasma steady-state levels was calculated using all measured data.'}, {'measure': 'Summary of Tumor Response Using the Response Assessment in Neuro-Oncology (RANO) Criteria', 'description': 'Per RANO criteria:\n\nComplete Response (CR): Complete disappearance of all enhancing disease that is sustained for at least 4 weeks, stable or improved non-enhancing FLAIR/T2 lesions, no new lesions, off corticosteroids, and neurologically stable or improved.\n\nPartial Response (PR): \\>= 50% decrease of all measurable enhancing lesions, sustained or at least 4 weeks, no progression of non-measurable disease, stable or improved non-enhancing FLAIR/T2 lesions, non new lesions, corticosteroid dose stable or reduced, and neurologically stable or improved.\n\nStable Disease (SD): Dose not qualify for CR, PR, or PD, stable non-enhancing FLAIR/T2 lesions, stable or reduced corticosteroids, clinically stable.\n\nProgressive Disease (PD): \\>=25% increase in enhancing lesion despite stable or increasing steroid dose, increase (significant) in non-enhancing T2/FLAIR lesions that is not attributable to other non-tumor causes, any new lesions, clinical deterioration', 'timeFrame': 'Up to 3 years post NSC infusion'}]",7,18 Years,,ALL,False,City of Hope Medical Center,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:13.425138,v2_robust,True,True,True,False,False,
NCT05832619,Intradermal Acupuncture Versus Sham Acupuncture and SSRI for Treating Adolescents With Major Depressive Disorder,Intradermal Acupuncture Versus Sham Acupuncture and SSRI for Treating Adolescents With Major Depressive Disorder: a Study Protocol for a Randomized Controlled Trial,SSRI,"['selective 5-hydroxytryptamine reuptake inhibitors', 'SSRI']",2,INTERVENTIONAL,['NA'],,,Major Depressive Disorder,['Major Depressive Disorder'],"['Major Depressive Disorder', 'Intradermal Acupuncture', 'Randomized Controlled Trial', 'Adolescent']",RECRUITING,,2022-11-01,2025-12-30,"[{'measure': 'Changes in the Hamilton Depression Scale-17 (HAMD-17) Scores', 'description': 'The HAMD scale is the most commonly used in the clinical assessment of depression, including 17 items. The higher the score, the more severe the depression. 0-7 means no depressive symptoms, 8-17 means mild depression, 18-24 was divided into moderate depression, and 25-52 was divided into severe depression.', 'timeFrame': '[Time Frame: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.]'}]","[{'measure': 'Changes in the Self-Rating Depression Scale (SDS) Scores', 'description': 'The standard score is the total of all scores multiplied by 1.25 to the nearest whole number on this scale, which has 20 questions. A standard score below 50 is normal; 50-60 is mild depression; 61-70 is moderate depression; 70 or more is severe depression.', 'timeFrame': 'Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up'}, {'measure': 'Changes in the Pittsburgh Sleep Quality Index (PSQI) Scores', 'description': 'The PSQI is used to assess the sleep quality of the participant in the last 1 month and consisted of 19 self-rated and 5 other rated items. The higher the score, the worse the sleep quality. Sleep quality is divided into 4 levels according to the total score.', 'timeFrame': 'Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up'}, {'measure': 'Changes in the Patient Health Questionaire-9 (PHQ-9)', 'description': 'The PHQ-9 was used to screen survey respondents for depression. The scale was developed according to the criteria for diagnosing depression in the American Diagnostic and Statistical Manual of Mental Disorders (4th edition) and is a concise, validated self-assessment and screening tool for depression. There are 9 questions, each with a score of 0-3 (none: 0; a few days: 1; more than half the time: 2; almost every day: 3), for a total score of 0-27.', 'timeFrame': 'Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up'}, {'measure': 'Changes in the Short Form 36 Questionnaire（SF-36）', 'description': ""The SF-36 scale has been developed by the American Medical Research Group as a universal scale for measuring quality of life and is widely recognized and used internationally. This scale has 8 dimensions to evaluate health-related quality of life, which are divided into two major categories: physical function (PF), physical function (RP), somatic pain (BP), general health (GH), energy (VT), social function (SF), emotional function (RE), and mental health (MH). the SF-36 scale is to a certain extent a better response to patients' quality of life."", 'timeFrame': 'Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up'}]",5,12 Years,17 Years,ALL,False,Xiaomei Shao,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:13.425301,v2_robust,True,True,False,False,False,
NCT00752219,Prospective Multicenter Doubleblind Randomized Study of NXL104/Ceftazidime + Metronidazole vs. Meropenem in Treatment of Complicated Intra-abdominal Infections,"A Prospective, Multicenter, Double-blind, Randomized, Comparative Study to Estimate the Safety, Tolerability and Efficacy of NXL104/Ceftazidime Plus Metronidazole vs. Meropenem in the Treatment of Complicated Intra-abdominal Infections in Hospitalized Adults",ceftazidime/NXL104 + metronidazole,"['ceftazidime/NXL104 + metronidazole', 'merrem', 'meropenem']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Complicated Intra-abdominal Infections,['Complicated Intra-abdominal Infections'],[],COMPLETED,,2009-03-31,2009-12-31,"[{'measure': 'Number of Participants With Clinical Response at the Test of Cure (TOC) Visit', 'description': 'Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were microbiologically evaluable (ME) at baseline.', 'timeFrame': 'Test of cure visit: 2 weeks post-therapy (Day 28)'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between first dose of study drug and up to 6 weeks after last dose of study treatment that were absent before treatment or that worsened relative to pretreatment state.', 'timeFrame': 'Baseline up to 6 weeks after last dose of study treatment (up to a maximum of 8 weeks)'}]","[{'measure': 'Number of Participants With Clinical Response at the End of Intravenous (IV) Therapy', 'description': 'Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline.', 'timeFrame': 'End of IV therapy: From Day 5 to Day 14'}, {'measure': 'Number of Participants With Clinical Response at the Late Follow-up Visit', 'description': 'Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required. This clinical response was measured in participants who were ME at baseline.', 'timeFrame': 'Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)'}, {'measure': 'Number of Participants With Microbiological Response at the Test of Cure Visit', 'description': 'Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline.', 'timeFrame': 'Test of cure visit: 2 weeks post-therapy (Day 28)'}, {'measure': 'Number of Participants With Microbiological Response at the End of IV Therapy', 'description': 'Microbiological response was defined as eradication of pathogen identified (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication of pathogens (absence of material to culture in a participant who had responded clinically to treatment). This clinical response was measured in participants who were ME at baseline.', 'timeFrame': 'End of IV therapy: From Day 5 to Day 14'}, {'measure': 'Number of Participants With Microbiological Response at the Late Follow-up Visit', 'description': 'Favorable: eradication (absence of causative pathogens from appropriately obtained specimens at site of infection) or presumptive eradication (absence of material to culture in a patient who had responded clinically to treatment)', 'timeFrame': 'Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)'}, {'measure': 'Number of Participants With Clinical Response in Clinically Evaluable (CE) Participants at the Test of Cure Visit', 'description': 'Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.', 'timeFrame': 'Test of cure visit: 2 weeks post-therapy (Day 28)'}, {'measure': 'Number of Participants With Clinical Response in CE Participants at the End of IV Therapy', 'description': 'Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.', 'timeFrame': 'End of IV therapy: From Day 5 to Day 14'}, {'measure': 'Number of Participants With Clinical Response in CE Participants at the Late Follow-up Visit', 'description': 'Clinical response was defined as complete resolution or significant improvement of signs and symptoms of the index infection. No further antimicrobial therapy or surgical or radiological intervention was required.', 'timeFrame': 'Late follow-up visit: 4 to 6 weeks post-therapy (up to 8 weeks)'}]",10,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,204.0,ACTUAL,2025-09-01T16:18:13.425341,v2_robust,True,True,True,False,True,
NCT04179019,Calcium Channel Blockade in Primary Aldosteronism,Calcium Channel Blockade in Primary Aldosteronism,Amlodipine,['Amlodipine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Primary Aldosteronism,"['Primary Aldosteronism', 'Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral)']","['primary aldosteronism', 'calcium channel blocker']",COMPLETED,,2020-09-01,2023-12-30,"[{'measure': 'Change in 24-hour Urinary Aldosterone Excretion Rate', 'description': 'Change in 24h urinary aldosterone excretion rate in response to maximal amlodipine therapy', 'timeFrame': 'Baseline and 2 weeks of amlodipine therapy'}, {'measure': 'Change in Plasma Aldosterone Concentration', 'description': 'Change in plasma aldosterone concentration in response to maximal amlodipine therapy', 'timeFrame': 'Baseline and 2 weeks of amlodipine therapy'}]","[{'measure': 'Acute Change in Plasma Aldosterone Concentration', 'description': 'Change in plasma aldosterone concentration after a single dose of amlodipine, before and after 2 weeks of amlodipine therapy', 'timeFrame': 'Baseline plasma aldosterone concentration before amlodipine therapy and 6 hours post-amlodipine dose, compared to baseline plasma aldosterone after 2 weeks of amlodipine therapy and 6 hours post-amlodipine therapy.'}]",3,18 Years,80 Years,ALL,False,Brigham and Women's Hospital,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:13.425363,v2_robust,True,True,True,False,False,
NCT05081219,SNIFF - Combo INI+EMPA Trial,Study of Nasal Insulin to Fight Forgetfulness - Combination Intranasal Insulin and Empagliflozin Trial,Insulin (Humulin® R U-100),"['Placebo (Insulin Diluent)', 'Placebo (Capsules)', 'Empagliflozin 10 MG', 'Insulin (Humulin® R U-100)']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Mild Cognitive Impairment,"['Mild Cognitive Impairment', 'Cognitive Impairment', 'Alzheimer Disease']","['Intranasal Delivery of Insulin', 'Cognitive Testing', 'Nasal Insulin']",COMPLETED,,2021-09-14,2024-09-17,"[{'measure': 'Number of Participants with Treatment-Related Serious Adverse Events as Assessed by CTCAE v5.0', 'description': 'Adverse events will be assessed using Common Terminology Criteria for Adverse Events (CTCAE v5.0). The number of participants with grade 3 or greater adverse events that were deemed to be possibly, probably, or definitely related to study treatment will be reported.', 'timeFrame': 'Week 8'}]","[{'measure': 'Change in the Preclinical Alzheimer Cognitive Composite 5 (PACC5) Z-Score', 'description': 'Cognition will be measured using the PACC5 scale, which includes the free/cued selective reminding test, delayed paragraph recall, digit-symbol substitution, mini mental state score, and the category fluency task. The PACC5 is a composite score comprised of measures of global cognition, memory, and executive function. The score reflects an averaged z-score, with higher scores indicating better cognitive performance.', 'timeFrame': 'Baseline to Week 4'}, {'measure': ""Change in the 14-item Alzheimer's Disease Assessment Scale-Cognitive subscale (ADAS-Cog 14) Score"", 'description': 'A psychometric instrument that evaluates memory, attention, reasoning, language, orientation, and praxis. A higher score indicates more impairment. Scores from the original portion of the test range from 0 (best) to 65 (worse), and are added to the mean of the words not immediately recalled (max of 10) and the number of items not recalled after a delay (ranging from 0-10) all total the maximum score of 85. A positive change indicates cognitive worsening.', 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Change in amyloid β-peptide (Aβ) 40 (Aβ40) in Cerebrospinal Fluid (CSF)', 'description': ""Cerebrospinal fluid (CSF) samples will be used to measure the levels of amyloid β-peptide (Aβ) 40. CSF Aβ40 is a key Alzheimer's disease (AD) biomarker that reflects pathological aggregation of amyloid in the brain."", 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Change in amyloid β-peptide (Aβ) 42 (Aβ42) in Cerebrospinal Fluid (CSF)', 'description': ""Cerebrospinal fluid (CSF) samples will be used to measure the levels of amyloid β-peptide (Aβ) 42. CSF Aβ42 is a key Alzheimer's disease (AD) biomarker that reflects pathological aggregation of amyloid in the brain."", 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Change in Cerebrospinal Fluid (CSF) Levels of Total Tau', 'description': ""Cerebrospinal fluid (CSF) samples will be used to measure the levels of total tau protein in the brain to assess impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker."", 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Change in Cerebrospinal Fluid (CSF) Levels of Phospho-Tau 181', 'description': ""Cerebrospinal fluid (CSF) samples will be used to measure the levels of phospho-tau 181 protein in the brain to assess impact on brain tau as a relevant Alzheimer's Disease (AD) biomarker."", 'timeFrame': 'Baseline to Week 4'}, {'measure': 'Change in Total Cerebral Blood Flow (CBF) Using MRI Pseudocontinuous Arterial Spin Labeling (ASL)', 'description': 'Change in CBF in mL/100g/min, calculated as the difference between the pre- and post- ASL flow in response to the study intervention.', 'timeFrame': 'Baseline to Week 4'}]",8,55 Years,85 Years,ALL,True,Wake Forest University Health Sciences,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:13.425378,v2_robust,True,True,True,False,True,
NCT05728619,HTMC0435 and Temozolomide in Treating Patients With Small Cell Lung Cancer,"A Phase 1b/2, Dose-finding and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HTMC0435 With Temozolomide in Patients With Small Cell Lung Cancer",HTMC0435,"['HTMC0435', 'Temozolomide']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Recurrent Extensive Stage Small Cell Lung Carcinoma,['Recurrent Extensive Stage Small Cell Lung Carcinoma'],[],UNKNOWN,,2023-02-03,2024-10,"[{'measure': 'Dose-limiting toxicities (DLT) of HTMC0435 combined with Temozolomide', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 21'}, {'measure': 'Adverse events (AE) of HTMC0435 combined with Temozolomide', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Maximum tolerable dose (MTD) and RP2D of HTMC0435 combined with Temozolomide', 'timeFrame': 'Through study completion, an average of 6 months'}]","[{'measure': 'Pharmacokinetic measures - the area under the concentration-time curve from dosing (time 0) to time infinity (AUC 0-inf)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - the area under the concentration-time curve from dosing (time 0) to time t (AUC 0-t)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - apparent clearance rate (CLz/F)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - maximum plasma concentrations (Cmax)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - time to reach Cmax (Tmax)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - trough concentrations at steady state (Css, min)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - peak concentrations at steady state (Css, max)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - accumulation ratio (Rac)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - terminal plasma half-life (T1/2)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Pharmacokinetic measures - apparent volume of distribution during terminal phase (Vz/F)', 'timeFrame': 'Cycle 1 Day 1 to Cycle 1 Day 9'}, {'measure': 'Objective response rate (ORR) by RECIST v1.1', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Disease control rate (DCR) by RECIST v1.1', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Progression-free survival (PFS) by RECIST v1.1', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Duration of response (DOR) by RECIST v1.1', 'timeFrame': 'Through study completion, an average of 6 months'}, {'measure': 'Overall survival (OS) by RECIST v1.1', 'timeFrame': 'Through study completion, an average of 6 months'}]",18,18 Years,75 Years,ALL,False,"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.",INDUSTRY,0,64.0,ESTIMATED,2025-09-01T16:18:13.425387,v2_robust,True,True,False,False,True,
NCT01465919,Efficacy Study of Mirtazapine to Treat Interferon-related Depression During Antiviral Therapy for Hepatitis C,Phase 4 Open-labeled Study to Compare the Anti-depressive Efficacy Between Mirtazapine and Psychotherapy for Patients With Interferon-related Depression During Antiviral Therapy for Hepatitis C,Mirtazapine,"['Mirtazapine', 'Remeron']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Depression,['Depression'],"['depression', 'interferon', 'chronic hepatitis C', 'mirtazapine']",TERMINATED,Due to the recent change in standard of care for hepatitis C.,2011-08,2018-03,"[{'measure': 'Change from baseline in Hamilton Depression Rating Scale (HAMD)-17 at 8 weeks', 'description': 'depression change', 'timeFrame': 'Baseline and 8-week of andi-depressive treatment'}]","[{'measure': 'Change from baseline in quality of life at 8 weeks', 'description': ""Psychometric assessment of quality of life using The Brief Form of the World Health Organization's Quality of Life Questionnaire (WHOQOL-BREF) and Liver Disease Quality of Life (LDQOL)"", 'timeFrame': 'Baseline and 8-week of andi-depressive treatment'}, {'measure': 'Genetic polymorphism', 'description': 'Determination of genetic factors (single nucleotide polymorphism) as predictors of clinical responses to mirtazapine in interferon-induced depression.', 'timeFrame': 'Baseline'}]",3,20 Years,75 Years,ALL,False,Seoul National University Boramae Hospital,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:13.425426,v2_robust,True,True,False,True,False,Due to the recent change in standard of care for hepatitis C.
NCT01855230,"Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)","A Randomized, Double-blind, Placebo-controlled, Two-Way Crossover Study to Evaluate the Safety, Tolerability and Clinical Activity of ASM-024 Administered by Dry Power Inhalation to Patients With GOLD 2 (Moderate) or GOLD 3 (Severe) Chronic Obstructive Pulmonary Disease (COPD)",ASM-024,"['ASM-024', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,COPD,['COPD'],[],COMPLETED,,2013-08,2014-12,"[{'measure': 'FEV₁ AUC (0 -6 h)', 'timeFrame': 'Day 14'}]","[{'measure': 'Change from baseline in Residual Volume (RV)', 'timeFrame': 'Days 1, 2, 3, & 14'}, {'measure': 'Peak change in FEV₁', 'timeFrame': 'Days 1, 2, 3, & 14'}, {'measure': 'Change from baseline in Inspiratory Capacity (IC)', 'timeFrame': 'Days 1, 2, 3, & 14'}, {'measure': 'Change from baseline in Functional Residual Capacity (FRC)', 'timeFrame': 'Days 1, 2, 3, &14'}, {'measure': 'Change from baseline in FEV₁', 'timeFrame': 'Day 14'}, {'measure': 'Change from baseline in FEV₁/FVC', 'timeFrame': 'Days 1, 2, 3, & 14'}, {'measure': 'FVC AUC (0-6 h)', 'timeFrame': 'Days 1, 2, 3, & 14'}, {'measure': 'Use of rescue medication', 'timeFrame': 'From Day 1 to Day 14'}]",9,40 Years,,ALL,False,Asmacure Ltée,INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:13.425544,v2_robust,True,True,True,False,False,
NCT01120730,Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury,Fluid Resuscitation With HES 200/0.5 10% in Severe Burn Injury,fluid resuscitation,"['fluid resuscitation', 'Fluid resuscitation']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Survival,"['Survival', 'Renal Failure']",[],COMPLETED,,1997-04,2009-03,"[{'measure': 'Intensive care unit mortality', 'description': '28 days', 'timeFrame': '28 days'}]","[{'measure': 'fluid amount during the first 72 hours', 'description': 'Fluid resuscitation after burn', 'timeFrame': '28 days'}]",2,18 Years,80 Years,ALL,False,University of Zurich,OTHER,0,28.0,ACTUAL,2025-09-01T16:18:13.425577,v2_robust,True,True,True,False,False,
NCT04794530,The COCOA-PAD II Trial,COCOA Flavanols to Improve Walking Performance in PAD: the COCOA-PAD II Trial,cocoa flavanols,"['cocoa flavanols', 'placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Peripheral Artery Disease,['Peripheral Artery Disease'],['cocoa flavanols'],RECRUITING,,2021-11-19,2027-01-31,"[{'measure': 'Six-month change in six-minute walk distance', 'description': 'Change in six-minute walk distance at six-month follow-up will be compared between those randomized to cocoa flavanols vs. those randomized to placebo.', 'timeFrame': 'Baseline to six-month follow-up'}]","[{'measure': 'Six-month change in gastrocnemius muscle perfusion (measured by magnetic resonance imaging (MRI))', 'description': 'Change in gastrocnemius muscle perfusion (measured by MRI) at six-month follow-up will be compared between those randomized to cocoa flavanols vs. those randomized to placebo.', 'timeFrame': 'Baseline to six-month follow-up'}, {'measure': 'Six-month change in brachial artery flow-mediated dilation (FMD)', 'description': 'Change in brachial artery flow-mediated dilation (FMD) at six-month follow-up will be compared between those randomized to cocoa flavanols vs. those randomized to placebo.', 'timeFrame': 'Baseline to six-month follow-up'}, {'measure': 'Six-month change in Actigraph-measured physical activity', 'description': 'Change in Actigraph-measured physical activity at six-month follow-up will be compared between those randomized to cocoa flavanols vs. those randomized to placebo.', 'timeFrame': 'Baseline to six-month follow-up'}, {'measure': 'Six-month change in calf muscle endothelial nitric oxide synthase (eNOS) and phosphorylated eNOS', 'description': 'Change in calf muscle biopsy measures of eNOS and phosphorylated eNOS at six-month follow-up will be compared between those randomized to cocoa flavanols vs. those randomized to placebo.', 'timeFrame': 'Baseline to six-month follow-up'}, {'measure': 'Six-month change in calf muscle characteristics (measured by calf muscle biopsy)', 'description': 'Change in calf muscle characteristics (measured by calf muscle biopsy) at six-month follow-up will be compared between those randomized to cocoa flavanols vs. those randomized to placebo.', 'timeFrame': 'Baseline to six-month follow-up'}, {'measure': 'Six minute walk at two and four week follow-up after intervention completion.', 'description': 'The trial will determine whether cocoa flavanols, compared to placebo, have a persistent effect on improved six-minute walk distance at two weeks and four weeks after the study intervention is completed', 'timeFrame': 'Six-month follow-up to 2- and 4-weeks post follow-up'}]",7,55 Years,,ALL,False,Northwestern University,OTHER,3,190.0,ESTIMATED,2025-09-01T16:18:13.425711,v2_robust,True,True,False,False,False,
NCT00520130,Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System,"Phase II Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation Using 8/8 and 7/8 HLA-matched Unrelated Donors and Utilizing Two Graft-versus-Host Disease Prophylaxis Regimens for the Treatment of Leukemias, Lymphomas, and Pre-malignant Blood Disorders",Cyclosporine,"['Allogenic stem cell transplant (ASCT)', 'Conditioning Chemotherapy', 'Fludarabine+high-dose cytarabine+G-CSF (Filgrastim))', 'Cyclosporine', 'FLAG', 'TMS', 'Prograf', 'EPOCH-F', 'Neoral']",9,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Myelodysplastic Syndrome,"['Myelodysplastic Syndrome', ""Hodgkin's Lymphoma"", ""Non-Hodgkin's Disease"", 'Acute Leukemia', 'Multiple Myeloma']","['Unrelated Donors', 'Reduced Intensity Stem Cell Transplant', 'Leukemia', 'Lymphoma', 'Allogeneic Stem Cell Transplant', 'Myelodysplastic Syndrome', 'Multiple Myeloma']",COMPLETED,,2007-10-30,2018-12-31,"[{'measure': 'Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD)', 'description': 'Acute GVHD is assessed by the 1994 Consensus Conference on Acute GVHD Grading criteria. See Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8., for grading criteria.', 'timeFrame': '6 months'}, {'measure': 'Percentage of Participants With Chronic Graft Versus Host Disease (cGVHD)', 'description': 'Chronic GVHD is assessed by the 2005 Chronic GVHD Consensus Project. First the individual organ scoring is done, and then based on that the Global score is determined (mild-moderate-severe). See Citation: Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005; 11:945-56., for grading criteria.', 'timeFrame': '2 years post transplant'}, {'measure': 'Recovery of Naïve Cluster of Differentiation 4 (CD4) T Cells', 'description': 'The percentage of C-C motif chemokine receptor 7 (CCR7)+CD45RA+ naïve T cells within the CD4 T cell populations was determined by flow cytometry.', 'timeFrame': 'Recipient recovery at 6, 12 and 24 months post transplant'}, {'measure': 'Recovery of Naïve Cluster of Differentiation 8 (CD8) T Cells', 'description': 'The percentage of CCR7+CD45RA+ naïve T cells within the CD4 and CD8 T cell populations was determined by flow cytometry.', 'timeFrame': 'Recipient recovery at 6, 12 and 24 months post transplant'}, {'measure': 'Changes in Cluster of Differentiation 4 (CD4) T Cell Receptor Vbeta Repertoire', 'description': ""Ribonucleic acid (RNA) was extracted from sorted CD4 and cluster of differentiation 8 (CD8) T cells and analyzed for Vbeta repertoire by nested polymerase chain reaction (PCR) analysis using Vbeta family specific primers and a labeled constant region primer (spectratyping). The receptor repertoire diversity was calculated from spectratyping data by creating a normal standard for repertoire diversity from healthy normal controls and assessing the divergence of individual patient's T cell receptor repertoire from these standard normal donor values. In this Vbeta repertoire divergence index, lower numbers are consistent with a more normal highly diverse repertoire, and high numbers represent a highly skewed, oligoclonal repertoire. The assay is described in Memon SA et al, J Immunol Methods, 2012, 375: 84-92. The repertoire diversity of the CD4 and CD8 T cells of the donor infusion is shown for comparison."", 'timeFrame': 'Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant'}, {'measure': 'Changes in CD8 T Cell Receptor Vbeta Repertoire', 'description': ""Ribonucleic acid (RNA) was extracted from sorted CD4 and cluster of differentiation 8 (CD8) T cells and analyzed for Vbeta repertoire by nested polymerase chain reaction (PCR) analysis using Vbeta family specific primers and a labeled constant region primer (spectratyping). The receptor repertoire diversity was calculated from spectratyping data by creating a normal standard for repertoire diversity from healthy normal controls and assessing the divergence of individual patient's T cell receptor repertoire from these standard normal donor values. In this Vbeta repertoire divergence index, lower numbers are consistent with a more normal highly diverse repertoire, and high numbers represent a highly skewed, oligoclonal repertoire. The assay is described in Memon SA et al, J Immunol Methods, 2012, 375: 84-92. The repertoire diversity of the CD4 and CD8 T cells of the donor infusion is shown for comparison."", 'timeFrame': 'Donor at time of collection and recipient at 1, 3, 6 and 12 months post transplant'}]","[{'measure': 'Percentage of Participants With Grade III-IV Acute Graft Versus Host Disease (GVHD)', 'description': 'Acute GVHD is assessed by the 1994 Consensus Conference on acute GVHD Grading criteria. See Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995; 15:825-8., for grading criteria.', 'timeFrame': '6 months'}, {'measure': 'Toxicities', 'description': 'Here are the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.', 'timeFrame': '103 months and 22 days'}, {'measure': 'Days to Engraftment of Neutrophils', 'description': 'Days to engraftment is defined as neutrophil recovery: designated by the first of 3 consecutive days with an absolute neutrophil count (ANC) above 500/mm(3).', 'timeFrame': '2 years'}, {'measure': 'Days to Engraftment of Platelets', 'description': 'Platelet recovery: designated by the first of 7 days where the platelet count remains above 20,000/mm(3) without transfusion support', 'timeFrame': '2 years'}, {'measure': 'Days to Engraftment of Lymphocytes', 'description': 'Lymphocyte recovery: designated by the first of 3 consecutive days with absolute lymphocyte count (ALC) above 500/mm(3).', 'timeFrame': '2 years'}, {'measure': 'Overall Survival', 'description': 'Time between the first day of transplant to the day of death.', 'timeFrame': 'Patients were followed for an average of up to 5 years.'}, {'measure': 'Early Treatment Related Mortality', 'description': 'Any death occurring within 28 days after transplantation in a patient in continuous remission.', 'timeFrame': 'Less than or equal to 28 days after transplantation'}, {'measure': 'Percentage of Participants With Late Treatment Related Mortality', 'description': 'Any death occurring 28 days or more after transplantation in a patient in continuous remission.', 'timeFrame': 'Greater than 28 days after transplantation'}, {'measure': 'Decline in Homeostatic Cytokine Interleukin 7 (IL-7) Post-Transplant', 'description': 'During depletion of lymphocytes during transplant conditioning, levels of homeostatic cytokines increase in the blood. These then decline with the expansion of new donor-derived cells. The rapidity of decline may predict acute graft versus host disease (AGVHD). Decline in cytokine IL-7 will be assessed by the enzyme-linked immunosorbent assay (ELISA).', 'timeFrame': 'Day 0, 1 week and 2 weeks'}, {'measure': 'Immune Reconstitution of Normal Killer (NK) Cells', 'description': 'Cluster of differentiation 3 (CD3) - cluster of differentiation 56 (CD56) + Natural Killer (NK) cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.', 'timeFrame': '2 weeks, and 1, 3, 6, 12, and 24 months post transplant'}, {'measure': 'Immune Reconstitution of Cluster of Differentiation 4 (CD4) T Cell Populations', 'description': 'Cluster of Differentiation 3 (CD3)+CD4+ and CD3+Cluster of Differentiation 8 (CD8)+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.', 'timeFrame': '2 weeks, and 1, 3, 6, 12 and 24 months post transplant'}, {'measure': 'Immune Reconstitution of Cluster of Differentiation 8 (CD8) T Cell Populations', 'description': 'Cluster of differentiation 3 (CD3)+cluster of differentiation 4 (CD4)+ and CD3+CD8+ T cells within the lymphocyte population were determined by flow cytometry. The absolute numbers of cells/µl were calculated from the absolute lymphocyte count.', 'timeFrame': '2 weeks, 1, 3, 6, 12 and 24 months post transplant'}]",18,18 Years,74 Years,ALL,False,National Cancer Institute (NCI),NIH,0,92.0,ACTUAL,2025-09-01T16:18:13.425737,v2_robust,True,True,True,False,True,
NCT02256930,Skin Safety Study to Evaluate the Sensitizing Potential in Healthy Volunteers,"A Phase 1, Randomized, Evaluator Blinded, Controlled Study to Evaluate the Sensitizing Potential of M518101 in Healthy Volunteers Using a Repeat Insult Patch Test Design",M518101,"['M518101 Vehicle', 'M518101']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2014-09,2015-08,"[{'measure': 'inflammatory skin response score', 'description': 'Drug application site will be evaluated for sign of inflammatory skin response (e.g. erythema, edema, papules)', 'timeFrame': '21 days'}]",[],1,18 Years,,ALL,True,Maruho North America Inc.,INDUSTRY,0,240.0,ACTUAL,2025-09-01T16:18:13.425948,v2_robust,True,True,True,False,False,
NCT04396730,Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction,Cannabidiol and Oral Contraceptive Pills: Exploring a Drug-Drug Interaction,Cannabidiol Oil,"['Placebo + OCP', 'Cannabidiol + OCP', 'Cannabidiol Oil', 'Placebo', 'Combined oral contraceptive pill']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Contraception,['Contraception'],"['Cannabidiol', 'Combined oral contraceptives']",COMPLETED,,2020-04-08,2022-03-02,"[{'measure': 'Maximum plasma concentration Ethinyl Estradiol', 'description': 'Area under the plasma concentration vs time curve of ethinyl estradiol (EE)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Maximum plasma concentration Ethinyl Estradiol', 'description': 'Area under the plasma concentration vs time curve of ethinyl estradiol (EE)', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}, {'measure': 'Maximum plasma concentration of Levonorgestrel', 'description': 'Area under the plasma concentration vs time curve of levonorgestrel (LNG)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Maximum plasma concentration of Levonorgestrel', 'description': 'Area under the plasma concentration vs time curve of levonorgestrel (LNG)', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}]","[{'measure': 'Time to maximum measured plasma concentration (Tmax)', 'description': 'Time to maximum measured plasma concentration of LNG and EE. (Tmax)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Time to maximum measured plasma concentration (Tmax)', 'description': 'Time to maximum measured plasma concentration of LNG and EE. (Tmax)', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}, {'measure': 'Time to maximum measured plasma concentration (Cmax)', 'description': 'Time to maximum measured plasma concentration of LNG and EE (Cmax)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Time to maximum measured plasma concentration (Cmax)', 'description': 'Time to maximum measured plasma concentration of LNG and EE (Cmax)', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}, {'measure': 'Final time taken for plasma concentration to be reduced by half (t1/2)', 'description': 'Final time taken for plasma concentration of LNG and EE to be reduced by half (t1/2)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'Final time taken for plasma concentration to be reduced by half (t1/2)', 'description': 'Final time taken for plasma concentration of LNG and EE to be reduced by half (t1/2)', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}, {'measure': 'The area under the plasma concentration of LNG and EE vs. time curve (AUC)', 'description': 'The area under the plasma concentration of LNG and EE vs. time curve (AUC)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'The area under the plasma concentration of LNG and EE vs. time curve (AUC)', 'description': 'The area under the plasma concentration of LNG and EE vs. time curve (AUC)', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}, {'measure': 'The first-order final elimination rate constant of EE and LNG', 'description': 'The first-order final elimination rate constant of EE and LNG', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}, {'measure': 'The first-order final elimination rate constant of EE and LNG', 'description': 'The first-order final elimination rate constant of EE and LNG', 'timeFrame': 'At the end of Cycle 3 (each cycle is 28 days)'}]",14,18 Years,35 Years,FEMALE,True,Oregon Health and Science University,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:13.426003,v2_robust,True,True,True,False,False,
NCT00187928,Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder,"A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Adjunctive Topiramate in the Treatment of Obsessive-Compulsive Disorder",Topiramate,['Topiramate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Obsessive-Compulsive Disorder,['Obsessive-Compulsive Disorder'],"['Obsessive-Compulsive Disorder', 'Obsessions', 'Compulsions', 'Adjunctive treatment']",COMPLETED,,2003-01,2006-03,[],[],0,18 Years,65 Years,ALL,False,University of Florida,OTHER,1,96.0,,2025-09-01T16:18:13.426066,v2_robust,True,True,True,False,False,
NCT04787328,A Study of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC),"A Single-arm, Open-Label, Multicenter Phase II Study to Evaluate the Efficacy and Safety of HA121-28 Tablets in Patients With Medullary Thyroid Carcinoma (MTC)",HA121-28 tablets,['HA121-28 tablets'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Medullary Thyroid Carcinoma,['Medullary Thyroid Carcinoma'],[],UNKNOWN,,2021-07-13,2025-03,"[{'measure': 'Objective remission rate (ORR)', 'description': 'assessed approximately every 8 weeks or 12 weeks based on the treatment cycle', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause,whichever came first, assessed up to 60 months'}]","[{'measure': 'Progression-free survival (PFS)', 'description': 'assessed approximately every 8 weeks or 12 weeks based on the treatment cycle', 'timeFrame': 'From date of randomization until the date of first documented progression, assessed up to 60 months'}, {'measure': 'Duration of response (DOR)', 'description': 'assessed approximately every 8 weeks or 12 weeks based on the treatment cycle', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause,whichever came first, assessed up to 60 months'}, {'measure': 'Overall survival (OS)', 'description': 'assessed approximately every 12 weeks', 'timeFrame': 'From date of randomization until date of death from any cause, assessed up to 60 months'}, {'measure': 'Disease control rate (DCR)', 'description': 'assessed approximately every 8 weeks or 12 weeks based on the treatment cycle', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause,whichever came first, assessed up to 60 months'}, {'measure': 'Changes in blood calcitonin', 'description': 'assessed approximately every 8 weeks', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, or date of death from any cause,whichever came first, assessed up to 60 months'}, {'measure': 'Adverse events incidence', 'description': 'assessed approximately every 4 weeks', 'timeFrame': 'From date of randomization until the date of death from any cause, assessed up to 60 months'}, {'measure': 'Plasma drug concentration', 'description': 'assessed approximately every 4 weeks', 'timeFrame': 'From date of randomization until the date of first documented progression or date of death from any cause, wihichever came first, assessed up to 60 months'}]",8,18 Years,,ALL,False,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:13.426153,v2_robust,True,True,False,False,True,
NCT00999128,A Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers,"An Open-Label, Two-Part Study to Determine the Relative Bioavailability of Capsule and Tablet Formulations of GDC-0941 and the Effect of Food and Proton Pump Inhibition on GDC-0941 Tablet Pharmacokinetics in Healthy Volunteers",GDC-0941,"['GDC-0941', 'rabeprazole']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['PI3K inhibitor', 'PI3 kinase', 'PI3 kinase inhibitor']",COMPLETED,,2009-10-26,2010-02-26,"[{'measure': 'Incidence, nature, and severity of adverse events', 'timeFrame': 'Through study completion or early study discontinuation'}, {'measure': 'PK parameters of GDC-0941 (total exposure, maximum and minimum plasma concentration)', 'timeFrame': 'Following administration of study drug'}]",[],2,18 Years,65 Years,ALL,True,"Genentech, Inc.",INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:13.426206,v2_robust,True,True,True,False,True,
NCT03961828,Hyalornic Acid Level in β-Thalassemic Children Treated for Hepatitis C Virus,Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy,Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni],"['Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]', 'Measuring level of Hyalornic Acid', 'Fibroscan of liver']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Beta-Thalassemia,"['Beta-Thalassemia', 'Hepatitis C']",[],COMPLETED,,2017-10-01,2019-03-01,"[{'measure': 'Treatment of Hepatitis C', 'description': 'Becoming PCR negative for Hepatitis C', 'timeFrame': '24 weeks'}]","[{'measure': 'Reduction of liver fibrosis', 'description': 'improvement of Fibroscan and Hyalornic Acid Level significantly after treatment', 'timeFrame': '6 months'}]",2,12 Years,18 Years,ALL,False,Tanta University,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:13.426333,v2_robust,True,True,True,False,False,
NCT00072228,Soblidotin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors,Phase I Study of Soblidotin and Gemcitabine in Patients With Locally Advanced or Metastatic Solid Tumors,gemcitabine,"['soblidotin', 'gemcitabine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']",[],WITHDRAWN,,,,[],[],0,18 Years,,ALL,False,Daiichi Pharmaceuticals,INDUSTRY,0,,,2025-09-01T16:18:13.426343,v2_robust,True,True,False,True,False,
NCT00327028,Study of Efficacy of Phenytoin in Therapy of Patients With Bronchial Asthma,"Randomised, Placebo Controlled, Double Blind, Parallel Group 3-Months Study of Phenytoin Efficacy in Bronchial Asthma Therapy",Diphenine,['Diphenine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Bronchial Asthma,['Bronchial Asthma'],"['Bronchial asthma', 'Phenytoin, Diphenine', 'Antiepileptic drugs', 'Efficacy']",COMPLETED,,2005-09,2005-12,"[{'measure': 'At 3 months of treatment'}, {'measure': 'Change from baseline of the PEFR and FEV1'}, {'measure': 'Number of patients without asthma symptoms'}]","[{'measure': 'At 3 months of treatment'}, {'measure': 'FEV1 before and after salbutamol inhalation'}, {'measure': 'The daily (daytime and night-time) symptoms scores'}, {'measure': 'Use of other antiasthmatic medication'}]",7,18 Years,65 Years,ALL,False,"Centre of Chinese Medicine, Georgia",OTHER,1,61.0,,2025-09-01T16:18:13.426401,v2_robust,True,True,True,False,False,
NCT00479128,Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors,Phase I Two-Dimensional Dose-Finding Study of Bortezomib in Combination With Gemcitabine/Doxorubicin in Metastatic Surgically Unresectable Urothelial Cancer or Other Solid Tumors,Bortezomib,"['Gemzar', 'PS-341', 'LDP-341', 'Adriamycin', 'AD', 'MLN341', 'Gemcitabine Hydrochloride', 'Doxorubicin', 'Gemcitabine', 'Hydroxydaunomycin hydrochloride', 'Bortezomib', 'Velcade']",12,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,"['Solid Tumor', 'Urethral Cancer']","['Solid Tumor', 'Bladder Cancer', 'Ureteral Cancer', 'Urothelial Cancer', 'Urethral Cancer', 'Renal Pelvis Tumor', 'Bortezomib', 'Gemcitabine', 'Doxorubicin', 'Gemzar', 'Adriamycin', 'Velcade', 'LDP-341', 'MLN341', 'PS-341', 'Gemcitabine Hydrochloride', 'AD', 'Hydroxydaunomycin hydrochloride']",ACTIVE_NOT_RECRUITING,,2006-09-28,2026-09-30,"[{'measure': 'Maximum Tolerated Dose (MTD) of Gemzar + Adriamycin Given with Velcade', 'timeFrame': 'Prior to each 2 week cycle'}]","[{'measure': 'Response of Gemzar + Adriamycin Given with Velcade', 'description': 'Participants be assessed for response on the basis of conventional response criteria for urothelial cancer.\n\nTumor status re-evaluated by CT scans and a bone scan.', 'timeFrame': '42 days'}]",2,,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:13.426415,v2_robust,True,True,False,False,False,
NCT02186665,Plaque Psoriasis Study in Pediatric Subjects,"A Multicenter, Randomized, Double Blind, Parallel Group, Vehicle Controlled, Study of the Safety and Efficacy of Calcitriol 3 mcg/g Ointment Applied Twice Daily for 8 Weeks in Pediatric Subjects (2 to 12 Years of Age) With Mild to Moderate Plaque Psoriasis",calcitriol ointment,"['placebo comparator', 'calcitriol ointment']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Plaque Psoriasis,['Plaque Psoriasis'],[],COMPLETED,,2014-07,2016-01,"[{'measure': ""Success of Investigator's Global Assessment (IGA)"", 'description': 'The number of subjects with a minimum improvement of 2 grades from baseline in the IGA score and a severity rating of 0 (clear) of 1 (almost clear) at Week 8 (LOCF).\n\nThe IGA was evaluated at each visit on the following 0 to 4 point scale:\n\n0 - Clear: No signs of psoriasis except for residual hypopigmentation / hyperpigmentation\n\n1. \\- Almost Clear: Just perceptible erythema, no induration, and no scaling\n2. \\- Mild: Mild erythema, no induration, and mild or no scaling\n3. \\- Moderate: Moderate erythema, mild induration, and mild or no scaling\n4. \\- Severe: Severe erythema, moderate to severe induration, and scaling of any degree', 'timeFrame': 'Baseline to Week 8'}]",[],1,2 Years,12 Years,ALL,False,Galderma R&D,INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:13.426432,v2_robust,True,True,True,False,False,
NCT05775965,HIP Fracture Oral ThromboPROphylaxis (Hip PRO Pilot),HIP Fracture Oral ThromboPROphylaxis: a Pilot Randomized Controlled Trial (Hip PRO Pilot),Rivaroxaban 10mg,"['Aspirin', 'Rivaroxaban', 'Rivaroxaban 10mg', 'acetylsalicylic acid (ASA) 81mg Oral Tablet']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Hip Fractures,['Hip Fractures'],[],RECRUITING,,2024-05-21,2026-03-01,"[{'measure': 'Recruitment Rate', 'description': 'Mean number of participants recruited per centre per month, calculated based on the total recruitment', 'timeFrame': '12 months'}]","[{'measure': 'Treatment fidelity', 'description': 'Adherence to study medication and pilot trial protocol', 'timeFrame': '12 months'}, {'measure': 'Retention rate', 'description': 'Participant completion of the pilot trial protocol', 'timeFrame': '12 months'}, {'measure': 'Consent rates', 'description': 'Consent rates for eligible participants who are approached, including reasons for non-consent', 'timeFrame': '12 months'}, {'measure': 'Trial implementation barriers Questionnaire', 'description': 'Trial implementation barriers will be assessed using an implementation barrier questionnaire developed for this study. The questionnaire will include questions about barriers and challenges related to the following: data capture, study management, study team infrastructure, participant-specific, site-specific, intervention, and study design. The implementation barriers will be summarized at the end of the study.', 'timeFrame': '12 months'}, {'measure': 'Healthcare cost', 'description': 'Direct and indirect healthcare costs including number of hospital admissions, and number of visits to healthcare providers.', 'timeFrame': '12 months'}, {'measure': 'Venous thromboembolism events', 'description': 'Number of venous thromboembolism events', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge, 2-week, 4-week, 6-week, 12-week'}, {'measure': 'Arterial thromboembolism events', 'description': 'Number of arterial thromboembolism events', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge, 2-week, 4-week, 6-week, 12-week'}, {'measure': 'Bleeding complications', 'description': 'Major bleeding, clinically relevant non-major bleeding', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge, 2-week, 4-week, 6-week, 12-week'}, {'measure': 'Mortality', 'description': 'Mortality within 90 days after hip fracture surgery', 'timeFrame': '90 days'}, {'measure': 'Frailty', 'description': ""Frailty is measured by Clinical Frailty Scale. A valid tool for evaluating these patients' frailty levels. The score ranges from 1 to 9. The higher scores mean better frailty (worse outcome)."", 'timeFrame': 'Baseline'}, {'measure': 'Complete Blood Counts', 'description': 'Complete Blood Counts', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge'}, {'measure': 'Partial thromboplastin time', 'description': 'Partial thromboplastin time', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge'}, {'measure': 'activated partial thromboplastin time', 'description': 'activated partial thromboplastin time', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge'}, {'measure': 'Cumulated Ambulation Score', 'description': ""A valid tool for evaluating these patients' basic mobility. The score ranges from 0 to 6. The higher scores mean better mobility."", 'timeFrame': 'Baseline and 2 weeks follow up'}, {'measure': 'Study Medication Adherence', 'description': 'Adherence to study medications', 'timeFrame': 'Baseline, Post-operative day 1, Post-operative day 2, Post-operative day 3, Post-operative day 4, Post-operative day 5, Post-operative day 6, or until hospital discharge, 2-week, 4-week, 6-week, 12-week'}]",16,50 Years,,ALL,False,University of Calgary,OTHER,1,250.0,ESTIMATED,2025-09-01T16:18:13.426465,v2_robust,True,True,False,False,False,
NCT04241965,"A Single-blind, Placebo-controlled, Outpatient Trial to Assess the Effects of Single Oral Tablet Dose of OPC-214870","A Phase 1b, Single-blind, Placebo-controlled, Adaptive Design, Outpatient Trial to Assess the Effects of Single Oral Tablet Doses of OPC-214870 on Photic-induced Paroxysmal Electroencephalogram Responses in Subjects Who Have Demonstrated Photoepileptiform Discharges on Electroencephalogram With or Without Seizures",OPC-214870,['OPC-214870'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Epilepsy,['Epilepsy'],[],COMPLETED,,2020-02-18,2021-10-28,"[{'measure': 'Change in Standardized Photosensitivity Range (SPR)', 'description': 'OPC-214870 in comparison to placebo', 'timeFrame': 'Up to 3 days'}]","[{'measure': 'Onset and duration of SPR', 'description': 'OPC-214870 in comparison to placebo', 'timeFrame': 'Up to 3 days'}]",2,18 Years,64 Years,ALL,False,"Otsuka Pharmaceutical Development & Commercialization, Inc.",INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:13.426504,v2_robust,True,True,True,False,False,
NCT06671665,Effect of Manual Therapy on Low Back Pain in Osteopenic Postmenopausal Women,Effect of Manual Therapy on Low Back Pain in Osteopenic Postmenopausal Women,calcium supplementation,"['665 mg calcium citrate', 'calcium supplementation']",2,INTERVENTIONAL,['NA'],,,Low Back Pain,"['Low Back Pain', 'Osteopenia']",[],RECRUITING,,2024-11-07,2025-06-07,"[{'measure': 'Assessment of Low back pain severity', 'description': 'Pain will be assessed by Visual analog scale (VAS). It is a scale that allows continuous data analysis and uses a 10cm line with 0 (0 = no pain) written at one end and 10 (10 = worst pain) on the other end. Subjects will be asked to place a mark along the line to denote their level of pain.', 'timeFrame': '12 weeks'}, {'measure': 'Measurement of lumbar curvature angle.', 'description': 'It will be measured, before and after treatment program, using a flexible ruler. The flexible ruler will be molded to the midline contour of the lumber spine from the spinous process of T12 to S2 to measure the degree of lordosis which carefully traced onto paper using pencil. Then, the lumbar curvature angle will be measured by the equation (theta angle = 4Arctang 2H/L). In this equation, the theta angle represents the magnitude of the lordotic curve, L is a straight line from the first vertebrae to the last vertebrae and the H letter is the distance between the deep point of L line and the lumbar curve.', 'timeFrame': '12 weeks'}, {'measure': 'Assessment of Lumbar Flexion', 'description': ""The examiner will stand behind the standing patient to identify the posterior superior iliac spines with thumbs, and then an ink mark will be drawn along the midline of the lumbar spine horizontal to the posterior superior iliac spines. Another ink mark will be made 15 cm above the original mark. The tape measure will be lined up between skin markings. With the tape pressed firmly against the subject's skin and while holding it with fingertips, the distance between superior and inferior skin marks will be measured. Then, the examiner will instruct the patient to bend forward into full lumbar flexion and the new distance between superior and inferior skin marks will be measured. The change in the difference between marks will be used to indicate the amount of lumbar flexion."", 'timeFrame': '12 weeks'}, {'measure': 'Assessment of Lumbar Extension', 'description': 'The examiner will follow the same procedure done previously in lumbar flexion except with the instruction. As the examiner will instruct the patient to bend backward into full extension and the new distance between superior and inferior skin marks will be measured as a straight line. The change in the difference between marks will be used to indicate the amount of lumbar extension.', 'timeFrame': '12 weeks'}, {'measure': 'Assessment of Lumbar Lateral bending to the right side', 'description': 'Measuring the distance between the tip of the middle finger and the floor when the patient stands upright, heels, buttocks and shoulders against the wall, and bends sideways without lifting the opposite foot off the ground.', 'timeFrame': '12 weeks'}, {'measure': 'Assessment of Lumbar Lateral bending to the left side', 'description': 'Measuring the distance between the tip of the middle finger and the floor when the patient stands upright, heels, buttocks and shoulders against the wall, and bends sideways without lifting the opposite foot off the ground.', 'timeFrame': '12 weeks'}, {'measure': 'Assessment of functional disability related to low back pain', 'description': 'Functional disability of each patient will be measured using Oswestry disability questionnaire. It is a valid and reliable tool consists of 10 multiple choice questions for back pain; subjects selected one sentence out of six that best describe her pain, higher scores indicated great pain. Scores of minimal disability:(0-20%), Scores of moderate disability: (20%- 40%), Scores of severe disability: (40% - 60%), Scores of crippled subjects: (60% - 80%), and Scores of patients confined to bed (80%-100%).', 'timeFrame': '12 weeks'}]","[{'measure': 'Measurement of lumbar Bone Mineral Density (BMD)', 'description': 'The lumbar BMD of each postmenopausal woman in both groups will be measured before entry into the study to confirm her diagnosis of osteopenia (from -1.1 to -2.49 SD) and also after 12 weeks of treatment, using DEXA, which represents the most preferable method for BMD calculation.', 'timeFrame': '12 weeks'}, {'measure': 'Assessment of quality of life', 'description': ""It will be assessed through Short Form 36 Health Survey Questionnaire (SF-36) for both groups before and after the treatment. It comprises eight domain scores including 'physical functioning'. This domain asks respondents to report limitations on ten mobility activities, such as walking specified distances, carrying groceries and bathing or dressing. It is an established and widely used health-related quality of life measure.It consists of ten multiple choice questions for back pain; patient will select one sentence out of six that best describe her pain, higher scores will indicate greater pain and disability. It will be used to measure the level of functional disability due to low back pain. The scores were scaled to a range where 0 denotes the lowest health status and 100 denotes the highest."", 'timeFrame': '12 weeks'}]",9,50 Years,60 Years,FEMALE,False,Cairo University,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:13.426513,v2_robust,True,True,False,False,False,
NCT05712265,Study to Evaluate the Effects of a Cytochrome P450 2C19 Inhibitor on the Pharmacokinetics of Miricorilant,"A Phase 1, Open-Label, Fixed-Sequence Crossover Study to Evaluate the Effect of a Strong Inhibitor of Cytochrome P450 2C19 on the Pharmacokinetics of Miricorilant in Healthy Subjects",Miricorilant,"['Fluvoxamine', 'Miricorilant', 'CORT118335']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Antipsychotic Induced Weight Gain,"['Antipsychotic Induced Weight Gain', 'Non-alcoholic Steatohepatitis (NASH)']",[],COMPLETED,,2023-01-24,2023-02-23,"[{'measure': 'Maximum observed plasma concentration of miricorilant (Cmax)', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, and 72 hours post-dose on Days 1 and 10'}, {'measure': 'Area under the curve from time zero to the time of last measurable plasma concentration of miricorilant (AUC0-last)', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, and 72 hours post-dose on Days 1 and 10'}, {'measure': 'Area under the curve from time zero extrapolated to infinity of plasma concentration of miricorilant (AUC0-inf)', 'timeFrame': 'Pre-dose and 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 6, 8, 12, 24, 48, and 72 hours post-dose on Days 1 and 10'}]","[{'measure': 'Number of participants with one or more treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Up to 30 days after study drug administration'}, {'measure': 'Number of participants with one or more serious adverse events (SAEs)', 'timeFrame': 'Up to 30 days after study drug administration'}, {'measure': 'Number of participants with a clinically-significant vital sign abnormality', 'timeFrame': 'Up to Day 13'}, {'measure': 'Number of participants with a clinically-significant laboratory test abnormality', 'timeFrame': 'Up to Day 13'}]",7,18 Years,60 Years,ALL,True,Corcept Therapeutics,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:13.426647,v2_robust,True,True,True,False,True,
NCT00041665,Recombinant Human Keratinocyte Growth Factor to Reduce Oral Mucositis in Hematologic Malignancy Patients Undergoing Peripheral Blood Stem Cell Transplantation After Radiation and High-dose Chemotherapy,"A Phase 3, Randomized, Double-blind, Placebo-controlled Trial of Recombinant Human Keratinocyte Growth Factor for Reduction of Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-dose Chemotherapy With Autologous PBPC Transplantation",Recombinant Human Keratinocyte Growth Factor,['Recombinant Human Keratinocyte Growth Factor'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Stomatitis,['Stomatitis'],[],COMPLETED,,,,[],[],0,18 Years,,ALL,False,Amgen,INDUSTRY,0,,,2025-09-01T16:18:13.426710,v2_robust,True,True,True,False,False,
NCT00253565,Imatinib Mesylate and Capecitabine in Treating Patients With Advanced Solid Tumors,A Phase I Dose Escalation Study of Imatinib Mesylate (Gleevec/STI571) Plus Capecitabine (Xeloda) in Advanced Solid Tumor Malignancies,capecitabine,"['capecitabine', 'imatinib mesylate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']","['unspecified adult solid tumor, protocol specific']",COMPLETED,,2003-08,2010-07,[],[],0,18 Years,,ALL,False,Herbert Hurwitz,OTHER,1,25.0,ACTUAL,2025-09-01T16:18:13.426727,v2_robust,True,True,True,False,False,
NCT06631365,PrEPsmart 2-1-1 Pilot,PrEPsmart Pilot: a Trial to Evaluate a Mobile App to Support the Safe and Effective Use of On-demand Pre-exposure Prophylaxis (PrEP) Among Sexual Minority Men in the US,Truvada,"['Emtricitabine', 'Tenofovir disoproxil fumarate', 'Truvada']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV-1-infection,['HIV-1-infection'],[],RECRUITING,,2023-10-02,2025-04-01,"[{'measure': 'Acceptability of the PrEPsmart mobile app', 'description': 'Acceptability will be measured using the Client Satisfaction Questionnaire (CSQ-8) adapted for use in PrEPsmart pilot. The study team will also assess interest in future use of the app at study completion.', 'timeFrame': '6 months'}, {'measure': 'Usability of the PrEPsmart mobile app', 'description': 'Usability will be measured using the System Usability Scale (SUS) adapted for use in PrEPsmart pilot. A score \\>50 (out of 100) on the SUS indicates the app is acceptable.', 'timeFrame': '6 months'}]","[{'measure': 'To compare PrEP coverage of sex acts as measured by weekly urine tenofovir test strips among SMM in the PrEPsmart vs. control arms', 'description': 'PrEP coverage will be primarily defined as self-reported sex acts in which the participant reported at least one pill taken within 24 hours before sex and one pill taken within 24 hours after sex, as defined in the Ipergay study. Additionally, the study team will conduct an analysis in which weekly PrEP dosing is confirmed by having a detectable TFV urine test within 7 days of reported sex.', 'timeFrame': '6 months'}, {'measure': 'To compare switching of PrEP regimens among SMM in the PrEPsmart vs. control arms', 'description': 'The proportion of participants who switch from on-demand PrEP to daily PrEP (or another regimen, e.g.\n\ninjectable PrEP) will be calculated and compared between arms using chi-square tests.', 'timeFrame': '6 months'}, {'measure': 'To compare rates of PrEP discontinuation among SMM in the PrEPsmart vs. control arm', 'description': 'PrEP discontinuation and retention rates will be calculated, with 95% binomial confidence intervals, and compared between arms using log-binomial models. The study team will also estimate and compare time to discontinuation using Kaplan Meier methods and the log-rank test, accounting for censoring by end of study or dropout.', 'timeFrame': '6 months'}, {'measure': 'Elicit feedback on areas for improvement for PrEPsmart to guide further app refinement', 'description': 'Ideas for improvement of PrEPsmart elicited through exit interviews will be tabulated, discussed with the protocol team, and prioritized for development.', 'timeFrame': '6 months'}]",6,18 Years,,MALE,True,"Public Health Foundation Enterprises, Inc.",OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:13.426758,v2_robust,True,True,False,False,False,
NCT02111265,THe Comparison of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients,The Comparison of Efficacy and Safety of Target Controlled Infusion of Propofol or Etomidate at General Anesthesia in Geriatric Patients --A Randomized Controlled Trial.,Remifentanil,"['Cisatracurium', 'Sufentanil', 'Remifentanil', 'Ruijie']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Adrenal Suppression,"['Adrenal Suppression', 'Hemodynamic Instability']",[],UNKNOWN,,2014-04,2014-07,"[{'measure': 'Effect Compartment Concentration', 'description': ""The effect compartment concentration of etomidate or propofol are recorded at three time points,including time that patient's loss of eyelash reflex,after 30 minutes of loss of eyelash reflex and when the patient is awake （call then open their eyes)."", 'timeFrame': ""From the beginning of induction to paitens'left of PACU, up to 4 hours""}]","[{'measure': 'vital signs', 'description': 'Systolic blood pressure, diastolic blood pressure, heart rate, respiration rate, pulse oxygen saturation recorded every 5 minutes during the operation.', 'timeFrame': 'From the beginning of induction to skin closure, up to 3 hours'}, {'measure': 'The amount of drugs', 'description': 'The amount of narcotics, sedation and muscle relaxation used in general anesthesia arr recorded when the operation is finished.', 'timeFrame': 'From the beginning of induction to skin closure, up to 3 hours'}, {'measure': 'Adrenal function', 'description': '1. 3 ml blood sample is collected at 5 time points including before induction,30 minutes,2 hours,24 hours, 48 hours after induction;\n2. to examine the concentration of Cortisol, Aldosterone and ACTH in serum:', 'timeFrame': 'From entering the operating room to 48 h after induction of anesthesia.'}]",4,60 Years,75 Years,ALL,False,Second Affiliated Hospital of Xi'an Jiaotong University,OTHER,1,90.0,ESTIMATED,2025-09-01T16:18:13.426794,v2_robust,True,True,False,False,False,
NCT03224767,Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma,Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas,Vemurafenib,"['Cobimetinib', 'Vemurafenib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,BRAF V600E Mutation Present,"['BRAF V600E Mutation Present', 'Papillary Craniopharyngioma']",[],ACTIVE_NOT_RECRUITING,,2018-01-05,2028-08-01,"[{'measure': 'Response rate', 'description': ""Defined as the number of responses achieved during treatment with BRAF and MEK inhibitors divided by the total number of evaluable patients and assessed by contrast-enhanced magnetic resonance imaging or computed tomography. Point estimates will be generated for response rates within each cohort with corresponding 95% binomial confidence intervals. Simon's two-stage design with one interim analysis for futility will be applied to evaluate response rate within each cohort."", 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Progression-free survival', 'description': 'Will be summarized for each cohort within each cohort with Kaplan-Meier curves and estimates.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall survival', 'description': 'Will be summarized for each cohort within each cohort with Kaplan-Meier curves and estimates.', 'timeFrame': 'Up to 5 years'}]",3,18 Years,,ALL,False,Alliance for Clinical Trials in Oncology,OTHER,1,24.0,ACTUAL,2025-09-01T16:18:13.426857,v2_robust,True,True,False,False,False,
NCT01617967,Safety and Tolerability of Patisiran (ALN-TTR02) in Transthyretin (TTR) Amyloidosis,"A Phase 2, Open-Label, Multi-Dose, Dose Escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous Infusions of ALN-TTR02 in Patients With TTR Amyloidosis",Patisiran,"['ALN-TTR02', 'Patisiran']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,TTR-mediated Amyloidosis,['TTR-mediated Amyloidosis'],['RNAi therapeutic'],COMPLETED,,2012-05,2014-01,"[{'measure': 'Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation', 'description': 'The number of participants experiencing at least one adverse event (AE), at least one serious adverse event (SAE) and study drug discontinuation (due to any reason).', 'timeFrame': 'Up to 56 days post first dose'}]","[{'measure': 'Percentage Change From Baseline in Serum Transthyretin (TTR) Protein', 'description': 'Percentage change of TTR relative to pretreatment/baseline levels is reported. For arms with a dosing regimen of Q4W TTR protein samples were measured on Days 28 and 56. For the arms with a dosing regimen of Q3W TTR protein samples were measured on Days 21 and 42.', 'timeFrame': 'Baseline to Day 21/28 and Day 42/56 depending on dosing regimen (Q3W/Q4W)'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Area Under the Concentration Curve From Time 0 to Last Measurable Time Point (AUC0-last)', 'description': 'Pharmacokinetic profiles for patisiran (ALN-TTR02) were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing regimen (Q3W/Q4W)'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Maximum Observed Plasma Concentration (Cmax)', 'description': 'Pharmacokinetic profiles for patisiran (ALN-TTR02) were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing regimen (Q3W/Q4W)'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Beta Elimination Half-life (t1/2 Beta)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing frequency'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Systemic Clearance (CL)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing frequency'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Apparent Volume of Distribution at Steady State (Vss)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose, end of infusion and post-infusion at 5 minutes (min), 10 min, 30 min, 1 hour (h), 2 h, 4 h, 6 h, 24 h and 48 h on Day 0 and Day 21/28 depending on dosing frequency'}, {'measure': 'Pharmacokinetic Parameters of Patisiran - Renal Clearance (CLR)', 'description': 'Pharmacokinetic profiles for patisiran were determined based on dosage and dosing frequency only, not premedication regimens. For arms with a dosing regimen of Q4W PK samples were taken on Days 0 and 28. For the arm with a dosing regimen of Q3W PK samples were taken on Days 0 and 21.', 'timeFrame': 'Predose (within 1 h of planned dosing start) and post-infusion at 0-6 h (pooled) on Day 0 and Day 21/28 depending on dosing frequency'}]",8,18 Years,85 Years,ALL,False,Alnylam Pharmaceuticals,INDUSTRY,0,29.0,ACTUAL,2025-09-01T16:18:13.426883,v2_robust,True,True,True,False,True,
NCT06754267,Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph+ B-ALL,"Venetoclax Combined With Olverembatinib and Predinisone in Treating Ph-positive Precursor B Cell Acute Lymphoblastic Leukemia: a Phase II, Single Arm and Multicenter Study",Venetoclax,"['Ven', 'Olverembatinib', 'Predinisone', 'Venetoclax', 'Olv']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Precursor B-Cell Acute Lymphoblastic Leukemia,['Precursor B-Cell Acute Lymphoblastic Leukemia'],"['acute lymphoblastic leukemia', 'Ph chromosome', 'BCL2 inhibitor', 'TKI']",RECRUITING,,2024-12,2027-12-30,"[{'measure': 'complete molecular response (CMR) after three cycles', 'description': 'BCR::ABL1≤0.01% detected by RT-qPCR', 'timeFrame': 'At the end of Cycle 3（each cycle is 28 days）'}]","[{'measure': 'Complete remission with or without incomplete PB cell recovery(CR/CRi) rate', 'description': 'Blast rate lower than 5% with or without peripheral blood cell recover', 'timeFrame': 'after Cycle 1(each cycle is 28 days)'}, {'measure': 'Event free survival (EFS)', 'description': 'Defined for all patients in a trial; measured from day 1 of treatment to the date of treatment failure, hematologic relapse from CR/CRi or death from any cause, whichever occurs first;', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'Defined for all patients in a trial; measured from day 1 of treatment to the date of death from any cause;', 'timeFrame': 'up to 2 years'}, {'measure': 'Minimal residual disease (MRD)', 'description': 'MRD level detected by flow cytometry which value \\<0.1% is defined as negtive; MRD level detected by RT-qPCR which BCR::ABL1 value \\<0.01% is defined as negtive', 'timeFrame': 'At the end of each cycle（each cycle is 28 days）, up to 2 years'}, {'measure': 'Relapse free survival(RFS)', 'description': 'Defined only for patients achieving CR or CRi; measured from the date of achievement of remission until the date of hematologic relapse or death from any cause;', 'timeFrame': 'up to 2 years'}, {'measure': 'Incidence of Adverse Events', 'description': 'The safety of the drug was evaluated by NCI-CTC AE 5.0 standard.Hematologic and non-hematologic toxicity.', 'timeFrame': 'From day 1 of treatment to 28 days after the last dose'}]",7,18 Years,,ALL,False,First Affiliated Hospital of Zhejiang University,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:13.426938,v2_robust,True,True,False,False,True,
NCT03939767,Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease,Evaluation of an eXtended and proacTive Dosing regimEn in Treatment-Naïve Patients With Wet Age-related Macular Degeneration (wAMD),"Aflibercept (Eylea, BAY86-5321)","['Aflibercept (Eylea, BAY86-5321)']",1,OBSERVATIONAL,[],,,Wet Age-related Macular Degeneration,['Wet Age-related Macular Degeneration'],[],COMPLETED,,2019-05-12,2023-10-17,"[{'measure': 'The change in BCVA (best corrected visual acuity)', 'description': 'In treatment-naïve wAMD patients treated with IVT aflibercept in a flexible proactive treatment pattern (fixed dosing or T\\&E (Treat and Extend Regimen)) by label regimen.', 'timeFrame': 'Baseline to 12 months'}]","[{'measure': 'The change in BCVA', 'timeFrame': 'Baseline to 24 and 36 months'}, {'measure': 'The change in BCVA by intended treatment regimen', 'timeFrame': 'Baseline to 12, 24 and 36 months'}, {'measure': 'The proportion of patients (eyes) gaining or losing a visual acuity compared to baseline', 'description': 'With letter score of ≥ 0 letters, ≥5 letters, ≥ 10 letters, ≥ 15 letters.', 'timeFrame': 'Baseline at 12, 24 and 36 months'}, {'measure': 'The proportion of patients (eyes) achieving a Snellen equivalent of 20/40 or better (approximately 73 ETDRS letters)', 'timeFrame': 'At 12, 24 and 36 months'}, {'measure': 'The changes in central retinal thickness (CRT)', 'timeFrame': 'Baseline to 12, 24 and 36 months'}, {'measure': 'The number of injections', 'timeFrame': 'Baseline to 12, 24 and 36 months'}, {'measure': 'The distribution of the intervals between injections', 'timeFrame': 'Up to 36 months'}]",8,50 Years,,ALL,False,Bayer,INDUSTRY,0,1563.0,ACTUAL,2025-09-01T16:18:13.427054,v2_robust,False,True,True,False,False,
NCT04645667,Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT),Development of a Population Pharmacokinetic Model to Optimize Tacrolimus Dosing in Adult Recipients of Allogeneic Hematopoietic Stem Cell Transplant.,Tacrolimus,"['Prograf', 'Tacrolimus']",2,OBSERVATIONAL,[],,,Acute GVHD,['Acute GVHD'],"['tacrolimus', 'aGVHD', 'pharmacokinetics', 'pharmacodynamics', 'pharmacogenomics', 'CYP3A5 genetic polymorphisms']",COMPLETED,,2021-02-01,2023-10-15,"[{'measure': 'Tacrolimus clearance', 'description': ""Patient's clearance calculated after the first day on tacrolimus and patient's clearance calculated after 5-6 doses of tacrolimus after they reach steady-state"", 'timeFrame': 'Day +1 of tacrolimus administration to Day +4 of tacrolimus administration'}]","[{'measure': 'Incidence and severity of aGVHD', 'description': 'The duration from the day of transplant to the first occurrence of aGVHD, censored at 100 days post-HCT.', 'timeFrame': 'Day +21 to Day +100 from HCT'}, {'measure': 'Incidence of tacrolimus-induced toxicities', 'description': 'The duration from the day of transplant to the first occurrence of tacrolimus-induced toxicities (AKI, hypertension, and metabolic abnormalities)', 'timeFrame': 'Day -3 to Day +100 from HCT'}, {'measure': 'Time to aGVHD', 'description': 'The duration from the day of transplant to the first occurrence of aGVHD, censored at 100 days post-HCT.', 'timeFrame': 'Day +21 to Day +100 from HCT'}, {'measure': 'Time to tacrolimus-induced toxicities (AKI, hypertension, metabolic panel abnormalities)', 'description': 'The duration from the day of transplant to the first occurrence of AKI, hypertension, and metabolic panel abnormalities, censored at 100 days post-HCT.', 'timeFrame': 'Day -3 to Day +100 from HCT'}]",5,18 Years,,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,1,38.0,ACTUAL,2025-09-01T16:18:13.427125,v2_robust,False,True,True,False,False,
NCT02927067,A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants,"A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients",Maribavir,"['Valganciclovir', 'Maribavir']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Cytomegalovirus (CMV),['Cytomegalovirus (CMV)'],[],COMPLETED,,2017-04-14,2022-07-01,"[{'measure': 'Number of Participants Who Achieved Confirmed Clearance of Plasma Cytomegalovirus (CMV) Deoxyribose Nucleic Acid (DNA) at the End of Study Week 8', 'description': 'Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. \\<137 International units per milliliter \\[IU/mL\\]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. To be considered a responder for the primary endpoint, the participant must have received exclusively study-assigned treatment (regardless of whether study-assigned treatment was completed).', 'timeFrame': 'Week 8'}]","[{'measure': 'Number of Participants Who Achieved Confirmed CMV Viremia Clearance and CMV Infection Symptom Control at the End of Week 8, Followed by Maintenance of Treatment Effect at Week 16', 'description': 'Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. \\<137 International units per milliliter \\[IU/mL\\]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. To be considered a responder for this key secondary endpoint, the participant must have received exclusively study-assigned treatment (regardless of whether study-assigned treatment was completed). CMV Infection Symptom Control is defined as no new clinical findings of CMV tissue invasive disease. Maintenance of Treatment Effect is defined as maintaining confirmed CMV viremia clearance and CMV infection symptom control through Week 16.', 'timeFrame': 'Week 8 up to Week 16'}, {'measure': 'Number of Participants Who Achieved Confirmed Clearance of Plasma CMV DNA (CMV Viremia Clearance) at Week 8 After Receiving 8 Weeks of Study Assigned Treatment', 'description': 'Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. \\<137 International units per milliliter \\[IU/mL\\]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. To be considered a responder for this secondary endpoint, the participant must have received exclusively study-assigned treatment for 8 weeks. Participants who discontinued treatment early were non-responders for this endpoint.', 'timeFrame': 'Week 8'}, {'measure': 'Number of Participants Who Achieved Confirmed CMV Viremia Clearance After Receiving 8 Weeks of Study-assigned Treatment Through Weeks 12, 16 and 20', 'description': 'Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. \\<137 International units per milliliter \\[IU/mL\\]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. To be considered a responder for this secondary endpoint, the participant must have received exclusively study-assigned treatment for 8 weeks.', 'timeFrame': 'Week 8 through Weeks 12, 16 and 20'}, {'measure': 'Number of Participants Who Maintained Confirmed CMV Viremia Clearance at Week 8 After Receiving Study-Assigned Treatment Through Study Weeks 12 and 20 Regardless of Whether Study Assigned Treatment Was Completed', 'description': 'Confirmed CMV viremia clearance is defined as plasma CMV DNA concentrations less than lower limit of quantification (LLOQ; i.e. \\<137 International units per milliliter \\[IU/mL\\]), when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive post baseline samples separated by at least 5 days. To be considered a responder for this secondary endpoint, the participant must have received exclusively study-assigned treatment (regardless of whether the 8-week study-assigned treatment was completed or discontinued early) and had no symptoms of tissue invasive CMV disease at Week 8, Week 8 through Week 12, and Week 8 through Week 20, respectively.', 'timeFrame': 'Week 8 through Weeks 12 and 20'}, {'measure': 'Number of Participants With Confirmed Recurrence of Viremia During First 8 Weeks of the Study', 'description': 'Recurrence of CMV viremia is defined as plasma CMV DNA concentration greater than or equal to (\\>=) lower limit of quantification (LLOQ, i.e. \\>=137 International units per milliliter \\[IU/mL\\]) when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable (\\<LLOQ, i.e. \\<137 IU/mL) for at least 5 days in 2 consecutive samples during the first 8 weeks of the study, during the 12 weeks of the follow up study phase, and at any time during the study.', 'timeFrame': 'Up to Week 8'}, {'measure': 'Number of Participants With Confirmed Recurrence of Viremia During the Follow-up Period', 'description': 'Recurrence of CMV viremia is defined as plasma CMV DNA concentration greater than or equal to (\\>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable (\\<LLOQ) for at least 5 days in 2 consecutive samples during the first 8 weeks of the study, during the 12 weeks of the follow up study phase, and at any time during the study.', 'timeFrame': 'From Week 9 up to Week 20'}, {'measure': 'Number of Participants With Confirmed Recurrence of Viremia at Any Time During the Study', 'description': 'Recurrence of CMV viremia is defined as plasma CMV DNA concentration greater than or equal to (\\>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable (\\<LLOQ) for at least 5 days in 2 consecutive samples during the first 8 weeks of the study, during the 12 weeks of the follow up study phase, and at any time during the study.', 'timeFrame': 'Up to Week 20'}, {'measure': 'Number of Participants With Confirmed Recurrence of Viremia While on Study Treatment and Off Treatment', 'description': 'Recurrence of CMV viremia is defined as plasma CMV DNA concentration greater than or equal to (\\>=) LLOQ when assessed by COBAS® AmpliPrep/COBAS® TaqMan® CMV Test in 2 consecutive plasma samples at least 5 days apart, after being unquantifiable (\\<LLOQ) for at least 5 days in 2 consecutive samples during the first 8 weeks of the study, during the 12 weeks of the follow up study phase, and at any time during the study.', 'timeFrame': 'Baseline up to Week 20'}, {'measure': 'Number of Participants With Grade 3 or 4 (Shift From Baseline Grade <3) and Grade 4 Neutropenia (Shift From Baseline Grade <4) While on Study Treatment', 'description': 'Grade 3 and grade 4 neutropenia are defined as absolute neutrophil count (ANC) \\<1000 per cubic millimeter (/mm\\^3) and ANC \\<500/mm\\^3 respectively. Incidence of Grade 3 or 4 neutropenia represents the percentage of participants with Grade \\<3 (or missing) neutropenia at baseline, but Grade 3 or 4 while on study treatment. Incidence of Grade 4 neutropenia represents the number of participants with Grade \\<4 (or missing) neutropenia at baseline, but Grade 4 while on study treatment.', 'timeFrame': 'From start of study drug to end of study drug + 1 day (up to approximately Week 8)'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events During the On-Treatment Period', 'description': 'An adverse event (AE) is any untoward medical occurrence in a clinical investigation participants administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE that has a start date on or after the first dose of study treatment, or that has a start date before the date of first dose of study treatment but increases in severity after the first dose of study treatment, will be considered a treatment-emergent AE (TEAE).', 'timeFrame': 'From the start of the study treatment to 7 days after the last dose of study treatment (up to approximately Week 9)'}, {'measure': 'Predose Concentration (Cmin) of Maribavir', 'description': 'The primary plasma maribavir concentration dataset (primary concentration dataset) includes all plasma maribavir concentrations. Missing PK sampling times are imputed according to the sparse sampling schedule in primary concentration dataset.', 'timeFrame': 'Weeks 1, 4, and 8: pre-morning dose'}, {'measure': 'Area Under the Concentration-Time Curve Over the 12-Hour Dosing Interval at Steady State AUC(0-tau) of Maribavir for Adolescent Participants Only', 'timeFrame': 'Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of Maribavir for Adolescent Participants Only', 'timeFrame': 'Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1'}, {'measure': 'Time When Maximum Concentration is Observed (Tmax) of Maribavir for Adolescent Participants Only', 'timeFrame': 'Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1'}, {'measure': 'Apparent Oral Clearance (CL/F) of Maribavir for Adolescent Participants Only', 'timeFrame': 'Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1'}, {'measure': 'Apparent Volume of Distribution (Vz/F) of Maribavir for Adolescent Participants Only', 'timeFrame': 'Pre-morning dose, 1, 2, 3, 4, 6, 8, and 12 hours post-morning dose of Week 1'}]",17,16 Years,,ALL,False,Shire,INDUSTRY,1,553.0,ACTUAL,2025-09-01T16:18:13.427143,v2_robust,True,True,True,False,True,
NCT00072267,"UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer",A Phase II Study of UCN-01 in Combination With Topotecan in Patients With Advanced Ovarian Cancer,7-hydroxystaurosporine,"['topotecan hydrochloride', '7-hydroxystaurosporine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Fallopian Tube Cancer,"['Fallopian Tube Cancer', 'Ovarian Cancer', 'Primary Peritoneal Cavity Cancer']","['stage IV ovarian epithelial cancer', 'recurrent ovarian epithelial cancer', 'primary peritoneal cavity cancer', 'fallopian tube cancer', 'stage III ovarian epithelial cancer']",COMPLETED,,2004-01,,[],[],0,18 Years,,FEMALE,False,"University Health Network, Toronto",OTHER,1,,,2025-09-01T16:18:13.427342,v2_robust,True,True,True,False,False,
NCT04051567,Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies,"Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies--A Multicenter, Prospective, Open, Randomized, Controlled Clinical Trial",Aspirin 100mg,['Aspirin 100mg'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Twin Pregnancy,"['Twin Pregnancy', 'Preeclampsia', 'Preterm Birth', 'Fetal Growth Restriction']",[],UNKNOWN,,2018-11-01,2020-12-01,"[{'measure': 'The incidence of preeclampsia, preterm birth, fetal growth restriction', 'timeFrame': 'after 30 weeks of gestional age'}]",[],1,18 Years,55 Years,FEMALE,True,Ministry of Science and Technology of the People´s Republic of China,OTHER_GOV,2,425.0,ESTIMATED,2025-09-01T16:18:13.427347,v2_robust,True,True,False,False,False,
NCT02447367,Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 in Healthy Male Volunteers,"Randomized, Open-label, Single Dose, Two-way Crossover, Clinical Trial to Investigate the Effect of Food on the Pharmacokinetic of JLP-1207 After Oral Administration in Healthy Male Volunteers",JLP-1207(Fasted),"['JLP-1207(Fed)', 'JLP-1207(Fasted)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,LUTS,"['LUTS', 'Benign Prostatic Hyperplasia', 'Overactive Bladder']","['α1-blockers', 'antimuscarinic agent']",COMPLETED,,2015-07,2015-12,"[{'measure': 'AUClast, Cmax, AUCinf', 'timeFrame': '192 hours'}]","[{'measure': 'Tmax', 'timeFrame': '192 hours'}, {'measure': 't1/2', 'timeFrame': '192 hours'}, {'measure': 'CL/F', 'timeFrame': '192 hours'}]",4,19 Years,45 Years,MALE,True,"Jeil Pharmaceutical Co., Ltd.",INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:13.427367,v2_robust,True,True,True,False,False,
NCT00514267,An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors,"A Phase I/II Multicenter, Open-Label Study of YM155 Plus Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors",YM 155,"['Prednisone', 'Docetaxel', 'YM 155']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Prostate Cancer,"['Prostate Cancer', 'Tumors']","['Prostate Cancer', 'HRPC', 'Hormone Refractory Prostate Cancer', 'YM155', 'Treatment Outcome', 'Solid Tumors']",COMPLETED,,2007-05,2010-03,"[{'measure': 'Occurrence of dose limiting toxicities (Part 1: Subjects with HRPC)', 'timeFrame': '2 cycles'}, {'measure': 'Occurrence of dose limiting toxicities (Part 2: Subjects with other solid tumors)', 'timeFrame': '1 cycle'}]","[{'measure': 'Assessment of safety and efficacy', 'timeFrame': '10 cycles'}, {'measure': 'Assessment of pharmacokinetics', 'timeFrame': 'Part 1 only'}]",4,18 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:13.427377,v2_robust,True,True,True,False,True,
NCT02947100,Omega-3 Fatty Acids in Sickle Cell Disease,Phase I/II Safety and Dose Escalation Trial of the Omega-3 Fatty Acids Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) in Children and Young Adults With Sickle Cell Disease (SCD),SCD-Omegatex™,"['SCD-Omegatex™', 'Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Sickle Cell Disease,['Sickle Cell Disease'],"['Sickle Cell Disease', 'omega-3 fatty acids', 'Docosahexaenoic Acid (DHA)', 'Eicosapentaenoic Acid (EPA)']",TERMINATED,manufacturing problem with study drug,2018-01-25,2018-10-15,"[{'measure': 'Clinical Safety, in a Dose Escalation Trial of SCD-Omegatex™ as Evidenced by an Absence of Adverse Events.', 'description': 'No results are available from any outcome measures as study was stopped early due to manufacturing issues with study drug and will not be reopened.', 'timeFrame': '6 months with continuous monitoring'}, {'measure': 'Determine Whether 6 Months of Supplementation With SCD-Omegatex™ Will Reduce Thermal Sensitivity by Quantitative Sensory Testing to Below Pre-treatment Levels', 'description': 'No results are available from any outcome measures as study was stopped early due to manufacturing issues with study drug and will not be reopened.', 'timeFrame': '6 months'}]","[{'measure': 'Health-associated Quality of Life', 'description': 'No results are available from any outcome measures as study was stopped early due to manufacturing issues with study drug and will not be reopened.', 'timeFrame': '6 months'}, {'measure': 'Number of Days With Pain Measured by iPad Daily Report Pain Calendar', 'description': 'No results are available from any outcome measures as study was stopped early due to manufacturing issues with study drug and will not be reopened.', 'timeFrame': '8 months'}, {'measure': 'Changes in Individual Thermal Sensitivity Thresholds by QST', 'description': 'No results are available from any outcome measures as study was stopped early due to manufacturing issues with study drug and will not be reopened.', 'timeFrame': '8 months'}]",5,8 Years,25 Years,ALL,False,Robin E. Miller,OTHER,3,4.0,ACTUAL,2025-09-01T16:18:13.427430,v2_robust,True,True,False,True,True,manufacturing problem with study drug
NCT01953900,iC9-GD2-CAR-VZV-CTLs/Refractory or Metastatic GD2-positive Sarcoma and Neuroblastoma,"Vaccination to Enhance the Anti-Tumor Activity of GD2 Chimeric Antigen Receptor-Expressing, VZV-Specific T Cells in Subjects With Advanced Sarcomas and Neuroblastoma (VEGAS)",Fludarabine,"['Fludara', 'Cyclophosphamide', 'Cytoxan', 'Fludarabine']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Osteosarcoma,"['Osteosarcoma', 'Neuroblastoma']","['Osteosarcoma', 'T-Cells', 'varicella zoster virus (VZV)', 'GD2', 'Neuroblastoma']",ACTIVE_NOT_RECRUITING,,2014-04,2034-10-31,"[{'measure': 'Number of patients with dose limiting toxicity', 'description': 'The primary objective is to evaluate the safety and feasibility of intravenous injections of autologous iC9-GD2-CAR-VZV-CTLs in combination with VZV vaccination in patients with advanced GD2-positive sarcomas or neuroblastoma.', 'timeFrame': '6-weeks'}]","[{'measure': 'Amount of T cells in the blood after the infusions', 'description': 'To assess the effects of VZV vaccination on the in vivo expansion and persistence of transgenic VZV-specific T cells\n\nTo assess the in vivo persistence of infused T cells using immunoassays and transgene detection', 'timeFrame': '15 years'}, {'measure': 'Number of patients with a response to the T cells', 'description': 'To assess the anti-tumor effects of the infused GD2-specific T cells\n\nTo assess the effect of of myeloid derived suppressor cells (MDSC) on expansion and persistence of infused T cells.\n\nEvaluations of tumor size will be performed within 4 weeks of beginning treatment and 6 weeks (before the vaccine) and 12 to 14 weeks after the iC9-GD2-CAR-VZV-CTL injection. All patients who receive the first infusion will be evaluable for response.', 'timeFrame': '14 weeks'}]",3,,,ALL,False,Baylor College of Medicine,OTHER,3,26.0,ESTIMATED,2025-09-01T16:18:13.427440,v2_robust,True,True,False,False,True,
NCT00634400,Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM Alternative),Candesartan in Heart Fail. Assess. of Reduction in Mortality & Morbidity. Candesartan in Patients With Heart Failure Who Are ACE Inhibitor Intolerant and Have Depressed Left Ventricular Systolic Function,Candesartan,"['Atacand', 'Candesartan', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Congestive Heart Failure,['Congestive Heart Failure'],"['Congestive Heart Failure', 'Atacand', 'Candesartan']",COMPLETED,,1999-03,2003-05,"[{'measure': 'Cardiovascular mortality or hospitalisation due to congestive heart failure', 'timeFrame': '2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months'}]","[{'measure': 'Cardiovascular mortality or hospitalisation for management of congestive heart failure, or non fatal MI', 'timeFrame': '2, 4, 6 weeks, 6 months, every 4 months thereafter until 24 months'}]",2,18 Years,,ALL,,AstraZeneca,INDUSTRY,0,6268.0,ESTIMATED,2025-09-01T16:18:13.427448,v2_robust,True,True,True,False,False,
NCT07118800,Study Evaluating Two Treatment Strategies for Rectal Cancer in Patients ≥75 Years Old,Randomized Phase III Study Evaluating Two Treatment Strategies for Locally Advanced Rectal Cancer in Patients ≥75 Years Old,FOLFOX4s,"['5FU + Oxaliplatin + folinic acid', 'FOLFOX4s', 'Chermotherapy']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Locally Advanced Rectal Adenocarcinoma,['Locally Advanced Rectal Adenocarcinoma'],"['Locally advanced', 'Rectum', 'Resectable', 'Adenocarcinoma', 'FOLFOX', 'Total neoadjuvant treatment', 'watch and wait', 'Non operative management', 'Short Course Radiotherapy']",NOT_YET_RECRUITING,,2025-12-15,2032-01-15,"[{'measure': 'TME-free survival', 'description': 'defined as proportion of patients without TME, or non-salvageable pelvic disease, and without permanent diversion stoma. Patients alive at the time of analysis or lost from follow-up will be censored at the date of the latest news.', 'timeFrame': '2 years'}]","[{'measure': 'Rate of clinical Complete Response', 'description': 'Defined as the percentage of CR confirmed by central review after 21 weeks divided by the number of patients.', 'timeFrame': '21 weeks'}, {'measure': 'Overall survival', 'description': 'The overall survival is the length of time from randomization that patients enrolled in the study are still alive.', 'timeFrame': 'From randomization to death from any cause, up to 2 years.'}, {'measure': 'Locoregional failure', 'description': 'Defined as either an unresectable rectal primary tumor following protocol neoadjuvant treatment, an R2 resection for the rectal primary tumor, or recurrence in the primary tumor bed after an R0-R1 resection. Tumor regrowth in the rectal wall or in regional lymph nodes after a cCR or near-complete response and a period of Watch \\& Wait or after local scar excision (for ypT0 and T1 tumor) will not be considered a locoregional failure if followed by an R0-R1 resection.', 'timeFrame': 'Time from randomization to locoregional failure, up to 2 years.'}, {'measure': 'Disease-free survival', 'description': 'Disease-free survival is defined as the delay between date of inclusion and tumor relapse (local, regional, or distant) or death from any cause, whichever occurs first.', 'timeFrame': '2 years'}, {'measure': 'Regrowth Rate', 'description': 'defined as the proportion of patients presenting tumor regrowth during their surveillance in the ""watch and wait"" strategy or after local scar excision after they achieved clinical complete response.', 'timeFrame': '2 years'}, {'measure': 'Metastasis-Free Survival', 'description': 'The metastases-free survival is the length of time during and after the treatment for cancer that a patient is still alive and the cancer has not spread to other parts of the body.', 'timeFrame': '2 years'}, {'measure': 'Rate of R0 resection', 'description': 'Defined as the percentage of R0 resection among patients with TME surgery (for patient with surgery only)', 'timeFrame': '3 years'}, {'measure': 'Rate of postoperative complications of initial surgery', 'description': 'Define as the percentage of patients having complication using Clavien-Dindo classification after initial surgery divided by the number of patients who undergo initial surgery', 'timeFrame': 'From initial surgery up to 3 months.'}, {'measure': 'Rate of postoperative complications of salvage surgey after initial non operative management (NOM)', 'description': 'Define as the percentage of patients having complication using Clavien-Dindo classification after salvage surgery after initial NOM divided by the number of patients who undergo salvage surgery', 'timeFrame': 'From salvage surgery up to 3 months.'}, {'measure': 'Acute and late toxicity during the study', 'description': 'The National Cancer Institute-Common Terminology Criteria for Adverse Events version 5 (NCI-CTCAE v5) is widely accepted in the community of oncology research as the leading rating scale for adverse events. This scale, divided into 5 grades (1 = ""mild"", 2 = ""moderate"", 3 = ""severe"", 4 = ""life-threatening"", and 5 = ""death"") determined by the investigator, will make it possible to assess the severity of the disorders.', 'timeFrame': 'Throughout study completion, up to 3 years.'}, {'measure': 'Bowel function', 'description': 'Defined by LARS score', 'timeFrame': 'At inclusion, 3 months post-radiotherapy, 12 months and 24 months post inclusion.'}, {'measure': 'Quality of life questionnaire - Core 30 (QLQ-C30)', 'description': 'Developed by the EORTC, this self-reported questionnaire assesses the health-related quality of life of cancer patients in clinical trials.\n\nThe questionnaire includes five functional scales (physical, everyday activity, cognitive, emotional, and social), three symptom scales (fatigue, pain, nausea and vomiting), a health/quality of life overall scale, and a number of additional elements assessing common symptoms (including dyspnea, loss of appetite, insomnia, constipation, and diarrhea), as well as, the perceived financial impact of the disease.\n\nAll of the scales and single-item measures range in score from 0 to 100. A high scale score represents a higher response level.', 'timeFrame': 'at inclusion, 3 months post-radiotherapy, 12 months and 24 months post inclusion.'}, {'measure': 'Quality of life questionnaire - Elderly cancer patients (QLQ-ELD14)', 'description': 'The EORTC QLQ-ELD14, a validated HRQOL questionnaire for cancer patients aged greater than or equal to70 years, is intended to supplement the QLQ-C30.\n\nThe QLQ-ELD14 contains 14 items incorporating five scales to assess mobility, worries about others, future worries, maintaining purpose, and illness burden. In addition, two single items assess joint stiffness and family support. All items are rated on a four-point Likert-type scale (1 = ""not at all"", 2 = ""a little"", 3 = ""quite a bit"", and 4 = ""very much""), and are linearly transformed to a 0-100 scale. High scores indicate poor mobility, good family support, much worry about the future, good maintenance of autonomy and purpose, and high burden of illness.', 'timeFrame': 'at inclusion, 3 months post-radiotherapy, 12 months and 24 months post inclusion.'}, {'measure': 'Geriatric Core Dataset (G-CODE)', 'description': 'The G-CODE was developed by the DIalog for personALization of management in geriatric OncoloGy (DIALOG) intergroup to assess the general health status of the older patient.\n\nThe G-Code contains 10 tools incorporating seven scales to assess social environment, functional status, mobility, nutritional status, cognitive status, depressive mood, and comorbidities. The total scale range 0-62. High score indicate better condition.', 'timeFrame': 'at 3 months post radiotherapy, 12 and 24 months post inclusion'}]",15,75 Years,,ALL,False,UNICANCER,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:13.427458,v2_robust,True,True,False,False,True,
NCT00382200,Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes,Phase I/II Study of Decitabine and All-Trans Retinoic Acid (Tretinoin) for Patients With Myelodysplastic Syndromes,decitabine,"['decitabine', 'tretinoin']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Myelodysplastic Syndromes,['Myelodysplastic Syndromes'],"['de novo myelodysplastic syndromes', 'previously treated myelodysplastic syndromes']",COMPLETED,,2006-07,2023-01-05,"[{'measure': 'Number of Participants Evaluated for Hematologic and Nonhematologic Toxicities as Measured by NCI CTC v2.0', 'timeFrame': 'Up to 1 year'}, {'measure': 'Maximum Tolerated Dose of Tretinoin When Administered With Decitabine as Determined by NCI CTC v2.0 (Phase II)', 'timeFrame': 'Up to 1 year'}, {'measure': 'Overall Response Rate', 'description': 'Overall Response Rate is defined as Complete Response + Partial Response', 'timeFrame': 'Up to 1 year'}, {'measure': 'Rate of Hematologic Improvement as Measured by Responding Cell Lines (Erythroid, Platelet, and Neutrophil Response) (Phase II)', 'timeFrame': 'After each cycle'}]","[{'measure': 'Change in Bone Marrow Function as Measured by Frequency of Transfusion, Bleeding, and Infection as Well as Changes in Bone Marrow Morphology and Cytogenetics', 'timeFrame': 'After each cycle'}, {'measure': 'Differentiation as Measured by Morphology and Flow Cytometry and Apoptosis as Measured by Flow Cytometry', 'timeFrame': 'After each cycle'}, {'measure': 'Gene Expression Changes as Measured by Affymetrix Gene Profiling Studies', 'timeFrame': 'After each cycle'}, {'measure': 'Demethylation of Specific Genes as Measured by Gene Promoter Methylation Studies', 'timeFrame': 'After each cycle'}, {'measure': 'Correlation of Clinical Response, With Gene Expression, Demethylation of Specific Genes, and Flow Cytometric Indicators of Differentiation and Apoptosis', 'timeFrame': 'After each cycle'}]",9,18 Years,120 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,54.0,ACTUAL,2025-09-01T16:18:13.427495,v2_robust,True,True,True,False,False,
NCT06496100,"Effect of Triticum Aestivum on Appetite, Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity","Effect of Triticum Aestivum on Appetite Regulation and the Ghrelin, Leptin, Adiponectin Hormonal Axis in Patients With Obesity",Triticum Aestivum,"['Placebo (calcined magnesia)', 'Calcined magnesia', 'Triticum Aestivum']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,"['Obesity', 'Leptin Deficiency', 'Ghrelin', 'Adiponectin']",[],RECRUITING,,2024-01-03,2024-12-24,"[{'measure': 'To evaluate the effect of Triticum aestivum on leptin in patients with obesity.', 'description': 'To quantify the serum concentrations of leptin ( pg/mL) before and after of treatment with 1000 mg of Triticum aestivum or placebo.', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on ghrelin in patients with obesity.', 'description': 'To quantify the serum concentrations of ghrelin ( pg/mL) before and after of treatment with 1000 mg of Triticum aestivum or placebo.', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on adiponectin in patients with obesity.', 'description': 'To quantify the serum concentrations of adiponectin ( pg/mL) before and after of treatment with 1000 mg of Triticum aestivum or placebo.', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on satiety regulation', 'description': 'To evaluate the effect on satiety by the visual analog scale for satiety and appetite', 'timeFrame': '120 days'}, {'measure': 'To evaluate the effect of Triticum aestivum on appetite regulation', 'description': 'To evaluate the effect on satiety by the visual analog scale for satiety and appetite', 'timeFrame': '120 days'}]",[],5,30 Years,50 Years,ALL,True,"Coordinación de Investigación en Salud, Mexico",OTHER_GOV,0,38.0,ESTIMATED,2025-09-01T16:18:13.427525,v2_robust,True,True,False,False,False,
NCT04175600,A Study of Selexipag as Add-On Treatment to Standard of Care in Children With Pulmonary Arterial Hypertension,"A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Period to Assess the Efficacy and Safety of Selexipag as Add-On Treatment to Standard of Care in Children Aged >=2 to <18 Years With Pulmonary Arterial Hypertension",Selexipag,"['JNJ-67896049', 'Selexipag', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Hypertension, Pulmonary","['Hypertension, Pulmonary']",[],ACTIVE_NOT_RECRUITING,,2020-01-16,2027-10-01,"[{'measure': 'Time to Disease Progression', 'description': ""Time to disease progression is the time from randomization up to 7 days after study treatment discontinuation. Disease progression is defined as the first occurrence of either of the following components: Death (all causes), Atrial septostomy or Potts' anastomosis, or registration on lung transplant list, Hospitalization due to worsening pulmonary arterial hypertension (PAH), Clinical worsening of PAH."", 'timeFrame': 'From randomization up to 7 days after study treatment discontinuation (up to 5 years)'}]","[{'measure': 'Percentage of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious AEs', 'description': 'An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. TEAEs are AEs with onset during the intervention period or that are a consequence of a pre-existing condition that has worsened since baseline. A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Percentage of Participants with AEs Leading to Premature Discontinuation of Study Treatment', 'description': 'Percentage of participants with AEs leading to premature discontinuation of study treatment will be reported.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Change from Baseline in Systolic and Diastolic Arterial Blood Pressure', 'description': 'Change from baseline in systolic and diastolic arterial blood pressure to all assessed time points will be reported.', 'timeFrame': 'Baseline up to end of treatment (EOT) (up to 8 years)'}, {'measure': 'Change from Baseline in Pulse Rate', 'description': 'Change from baseline in pulse rate to all assessed time points will be reported.', 'timeFrame': 'Baseline up to EOT (up to 8 years)'}, {'measure': 'Change from Baseline in Body Weight', 'description': 'Change from baseline in body weight to all assessed time points will be reported.', 'timeFrame': 'Baseline up to EOT (up to 8 years)'}, {'measure': 'Change from Baseline in Height', 'description': 'Change from baseline in height to all assessed time points will be reported.', 'timeFrame': 'Baseline up to EOT (up to 8 years)'}, {'measure': 'Sexual Maturation (Tanner Stage) Change from Baseline to all Assessed Time Points', 'description': 'The sexual maturation change as per Tanner stage will be assessed from baseline to all assessed time points. Tanner stage I is defined as no pubic hair at all (prepubertal Dominic state); stage II is defined as a small amount of long, downy hair with slight pigmentation at the base of the penis and scrotum (males) or on the labia majora (females); stage III is defined as when the hair becomes more coarse and curly, and begins to extend laterally; stage IV is defined as adult-like hair quality, extending across pubis but sparing medial thighs; and stage V is defined as when the: hair extends to medial surface of the thighs.', 'timeFrame': 'Up to 3 days after study treatment discontinuation (up to EOT) (multiple timepoints up to 8 years)'}, {'measure': 'Percentage of Participants with Treatment-emergent Electrocardiogram Abnormalities', 'description': 'Percentage of participants with treatment-emergent electrocardiogram abnormalities will be reported.', 'timeFrame': 'Baseline up to EOT (up to 8 years)'}, {'measure': 'Percentage of Participants with Treatment-emergent Marked Laboratory Abnormalities', 'description': 'Percentage of participants with treatment-emergent marked laboratory (serum chemistry \\[including pregnancy testing and thyroid markers\\] and hematology) abnormalities will be reported.', 'timeFrame': 'Baseline up to EOT (up to 8 years)'}, {'measure': 'Treatment-emergent Change from Baseline in Thyroid Stimulating Hormone', 'description': 'Treatment-emergent change from baseline in thyroid stimulating hormone over time will be reported.', 'timeFrame': 'Baseline up to EOT (up to 8 years)'}, {'measure': 'Time to First Clinical Event Committee (CEC)-confirmed Hospitalization or Death for PAH', 'description': 'Time to first CEC-confirmed hospitalization or death for PAH is the time (days) from randomization to first occurrence of CEC-confirmed hospitalization for PAH or death due to PAH up to 7 days after study intervention discontinuation.', 'timeFrame': 'Until 7 days after study treatment discontinuation (Up to 8 years)'}, {'measure': 'Trough Plasma Concentration at Steady-state (Ctrough,ss) of Selexipag and its Metabolite ACT-333679', 'description': 'Ctrough,ss is defined as the plasma concentration just prior to the morning dose, with the last study intervention administration one day prior to the pharmacokinetic sampling and will be reported for Selexipag and its metabolite ACT-333679.', 'timeFrame': 'Weeks 16, 24 and every 12 weeks thereafter (up to 8 years)'}, {'measure': 'Change from Baseline at Week 24 in Log2 N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)', 'description': 'The change from baseline at week 24 in log2 NT-proBNP will be reported.', 'timeFrame': 'Baseline up to Week 24'}]",14,2 Years,17 Years,ALL,False,Actelion,INDUSTRY,0,138.0,ACTUAL,2025-09-01T16:18:13.427548,v2_robust,True,True,False,False,True,
NCT04345900,Plinabulin vs. Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy Phase 2,"A Phase 2, Multicenter, Randomized Study to Evaluate Duration of Severe Neutropenia With Plinabulin Versus Pegfilgrastim in Patients With Solid Tumors Receiving Docetaxel Myelosuppressive Chemotherapy (Protective-1)",Plinabulin,"['Plinabulin', 'Pegfilgrastim', 'G-CSF']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Chemotherapy-induced Neutropenia,['Chemotherapy-induced Neutropenia'],[],COMPLETED,,2017-04-05,2018-04-20,"[{'measure': 'DSN', 'description': 'Duration of Grade 4 neutropenia (ANC \\< 0.5 × 109/L)', 'timeFrame': 'At the end of Cycle 1 (each cycle is 21 days)'}]","[{'measure': 'Peak Plasma Concentration (Cmax)', 'description': 'a parameter to establish the pharmacokinetic profile of plinabulin by evaluating the peak plasma concentration (Cmax) of the drug in the blood after administration of a single dose of the drug', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Area Under Curve (AUC)', 'description': 'A parameter to establish the pharmacokinetic profile of plinabulin to describe the variation of the drug concentration in blood plasma as a function of time', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Terminal Half-time (T1/2)', 'description': 'A parameter to establish the pharmacokinetic profile of plinabulin by measuring the time it takes for the concentration of the drug in the plasma to be reduced by 50%', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Volume of Distribution in the Terminal Elimination Phase (Vz)', 'description': 'A parameter to establish the pharmacokinetic profile of plinabulin by evaluating Vz.', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Clearance (Cl)', 'description': 'a parameter to establish the pharmacokinetic profile of plinabulin', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Systolic Blood Pressure', 'description': 'a parameter to establish the pharmacodynamic profile of plinabulin', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Diastolic Blood Pressure', 'description': 'a parameter to establish the pharmacodynamic profile of plinabulin', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}, {'measure': 'Area Over the Neutropenia Curve', 'description': 'a parameter to establish the pharmacodynamic profile of plinabulin', 'timeFrame': '0, 0.5, 1, 4.5, 24 hours post-dose'}]",9,18 Years,,ALL,False,BeyondSpring Pharmaceuticals Inc.,INDUSTRY,0,55.0,ACTUAL,2025-09-01T16:18:13.427567,v2_robust,True,True,True,False,False,
NCT03146000,Lidocaine-prilocaine Cream Versus Rectal Meloxicam on Relief of Post-episiotomy Pain,Effect of Topical Lidocaine-prilocaine Cream Versus Rectal Meloxicam Suppository on Relief of Post-episiotomy Pain: A Randomized Clinical Trial,lidocaine-prilocaine cream,"['lidocaine-prilocaine cream', 'meloxicam rectal suppository']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Postpartum,['Postpartum'],[],COMPLETED,,2017-05-01,2018-10-01,"[{'measure': 'The mean difference of visual analog scale after delivery', 'description': 'the scale is graded from 0 to 10', 'timeFrame': 'immediately'}]",[],1,,,FEMALE,False,Assiut University,OTHER,0,190.0,ACTUAL,2025-09-01T16:18:13.427593,v2_robust,True,True,True,False,False,
NCT05051007,Opioid-based Versus Lidocaine-based Induction of Anesthesia With Propofol in Elderly,Comparison of the Hemodynamic Effects of Opioid-based Versus Lidocaine-based Induction of Anesthesia With Propofol in Elderly: A Randomized Controlled Study,fentanyl,"['Lidocaine IV', 'fentanyl']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postinduction Hypotension,"['Postinduction Hypotension', 'Elderly']",[],UNKNOWN,,2021-10-01,2022-12,"[{'measure': 'total norepinephrine dose', 'description': 'mcg', 'timeFrame': '1 minute after induction of anesthesia until 15 minutes after induction or surgical incision'}]","[{'measure': 'Incidence of post-induction hypotension', 'description': 'mean arterial pressure ≤70% of baseline or \\< 60 mmHg', 'timeFrame': '1 minute after induction of anesthesia until 15 minutes after induction or surgical incision'}, {'measure': 'Incidence of severe post-induction hypotension', 'description': 'mean arterial pressure ≤60% of baseline', 'timeFrame': '1 minute after induction of anesthesia until 15 minutes after induction or surgical incision'}, {'measure': 'Incidence of hypertension', 'description': 'mean arterial pressure 120% of baseline', 'timeFrame': '1 minute after induction of anesthesia until 15 minutes after induction or surgical incision'}, {'measure': 'tachycardia', 'description': 'heart rate \\>120% of baseline', 'timeFrame': '1 minute after induction of anesthesia until 15 minutes after induction or surgical incision'}, {'measure': 'loss consciousness time', 'description': ""time to achieve no response to auditory command and disappearance of a patient's eyelash reflex"", 'timeFrame': '1 second after starting drug injection until one second after loss of consciousness'}, {'measure': 'total propofol dose', 'description': 'mg/kg', 'timeFrame': '1 second after starting drug injection until one second after loss of consciousness'}, {'measure': 'intubation time', 'description': 'second', 'timeFrame': '1 second after insertion of direct laryngoscopy into the mouth till one second after its removal after tracheal intubation'}, {'measure': 'incidence of postoperative delirium', 'description': 'Confusion assessment method will be assessed through a four-step algorithm identifying the following: 1) acute onset of mental status changes or a fluctuating course, 2) inattention, 3) disorganized thinking, 4) an altered level of consciousness. Patients will be diagnosed to be delirious if both features {(1) and (2)} will be present plus either feature (3) or (4)}', 'timeFrame': 'at 24 and 48 hour postoperatively'}]",9,60 Years,,ALL,False,Kasr El Aini Hospital,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:13.427697,v2_robust,True,True,False,False,False,
NCT02803307,Single-Dose Administration Trial of TLC599 in Osteoarthritis of the Knee,"A Randomized, Open-label, Parallel, Phase I/II Single-Dose Administration Trial of TLC599 in Subjects With Osteoarthritis of the Knee",TLC599,['TLC599'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Osteoarthritis of the Knee,['Osteoarthritis of the Knee'],"['osteoarthritis of the knee', 'TLC599', 'Dexamethasone', 'DSP']",COMPLETED,,2015-06,2016-11,"[{'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs)', 'description': 'Number of participants with at least one TEAE', 'timeFrame': 'up to 12 weeks after dosing'}]",[],1,20 Years,,ALL,False,Taiwan Liposome Company,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:13.427760,v2_robust,True,True,True,False,True,
NCT06278207,An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions,Finerenone Research of Outcomes and Drug Utilization,Finerenone (BAY 94-8862),"['Kerendia, Firialta', 'Finerenone (BAY 94-8862)']",2,OBSERVATIONAL,[],,,Chronic Kidney Disease,"['Chronic Kidney Disease', 'Type 2 Diabetes Mellitus']",[],RECRUITING,,2024-05-15,2026-03-31,"[{'measure': ""Participants' characteristics at baseline in a cohort of participants with CKD and T2D who initiate finerenone."", 'description': 'Sociodemographic characteristics such as age, sex, race and socio-economic status.', 'timeFrame': '12 months before first prescription/dispensation of finerenone (index date)'}, {'measure': ""Participants' comorbidities at baseline in a cohort of participants with CKD and T2D who initiate finerenone."", 'description': 'Including heart diseases, lipid diseases, liver disease, hospitalization for acute kidney injury, dementia, body mass index, smoking status, alcohol abuse, and other comorbidities measured using comorbidities indexes (such as the Charlson comorbidity index)', 'timeFrame': '12 months before first prescription/dispensation of finerenone (index date)'}, {'measure': ""Participants' comedications at baseline in a cohort of participants with CKD and T2D who initiate finerenone."", 'description': 'In subcohorts of participants in co-medication between finerenone and other hypertensive and diabetic medications (SGLT2i, RAASi, GLP-1 RA, etc.), characterized by CKD stage, including a 15-25 ml/min/1.73 m2 eGFR subgroup.', 'timeFrame': '12 months before first prescription/dispensation of finerenone (index date)'}]","[{'measure': 'Proportion of finerenone initiators with and without UACR measurements at baseline', 'description': 'UACR=Urinary Albumin-to-Creatinine Ratio', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until 12 months after index date'}, {'measure': 'Average UACR in the subcohort with UACR measurements', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until 12 months after index date'}, {'measure': 'Incidence rate of kidney failure in participants with CKD and T2D that initiate finerenone.', 'description': 'Any of the following:\n\n≥ 2 outpatient eGFR measurements of \\< 15 mL/min/1.73 m2 separated by at least 90 days; Record of dependence on dialysis (at least 3 sessions over at least 90 days); Diagnosis records of kidney failure or CKD stage 5; Record of kidney transplant', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}, {'measure': 'Incidence rate of a composite cardiovascular outcome in participants with CKD and T2D that initiate finerenone.', 'description': 'Acute myocardial infarction, identified as an inpatient hospital diagnosis of fatal or non-fatal acute myocardial infarction. Congestive heart failure, identified as an impatient hospital or emergency department diagnosis of heart failure and stratified by new-onset or recurrent heart failure.', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}, {'measure': 'Drug utilization patterns in a cohort of participants with CKD and T2D that initiate finerenone.', 'description': 'Depending on the database used, this includes incidence of drug use, initiation of treatment measured by drug prescription, drug dispensation, or a combination of both depending on data availability, dosing regimen, treatment persistence and non-persistence, and implementation measured as the proportion of days covered.', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}, {'measure': 'Number of participants who initiate finerenone at a 10 mg dose daily', 'timeFrame': 'At day 0 (first prescription/dispensation of finerenone)'}, {'measure': 'Proportion of participants who continue the original 10 mg dose daily at the 1, 3, 6, and 12 months mark', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until 12 months after index date'}, {'measure': 'Proportion of participants who up-titrate from 10 mg daily dose to a 20 mg dose daily at the 1, 3, 6, and 12 months mark', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until 12 months after index date'}, {'measure': 'Number of participants who initiate finerenone at a 20 mg dose daily', 'timeFrame': 'At day 0 (first prescription/dispensation of finerenone)'}, {'measure': 'Proportion of participants who continue the original 20 mg dose daily at the 1, 3, 6, and 12 months mark', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until 12 months after index date'}, {'measure': 'Proportion of participants who down-titrate from 20 mg daily dose to a 10 mg dose daily at the 1, 3, 6, and 12 months mark', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until 12 months after index date'}, {'measure': 'Incidence rate of hospitalization for heart failure in participants with CKD and T2D that initiate finerenone.', 'description': 'Congestive heart failure, identified as an impatient hospital or emergency department diagnosis of heart failure and stratified by new-onset or recurrent heart failure.', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}, {'measure': 'Incidence rate of atrial fibrillation or flutter in participants with CKD and T2D that initiate finerenone.', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}, {'measure': 'Incidence rate of hyperkalemia in participants with CKD and T2D that initiate finerenone.', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}, {'measure': 'Incidence rate of hospitalization associated with hyperkalemia in participants with CKD and T2D that initiate finerenone.', 'timeFrame': 'From first prescription/dispensation of finerenone (index date) until end of follow-up (death, disenrollment, development of either kidney failure or kidney cancer, or by the last available date in the corresponding database) up to 150 months'}]",18,18 Years,,ALL,False,Bayer,INDUSTRY,0,50000.0,ESTIMATED,2025-09-01T16:18:13.427768,v2_robust,False,True,False,False,False,
NCT05946707,Effects of Oxygen Supply After Lung Isolation in Thoracic Surgery,"Effects of Oxygen Supply on Hypoxic Pulmonary Vasoconstriction and Lung Collapse After Lung Isolation in Thoracic Surgery - a Prospective, Randomized Clinical Trial",restrictive oxygen supply,"['restrictive oxygen supply', 'liberal oxygen supply']",2,INTERVENTIONAL,['NA'],,,Mechanical Ventilation,"['Mechanical Ventilation', 'Thoracic Surgery', 'One-Lung Ventilation']","['Oxygen supply', 'Hypoxic pulmonary vasoconstriction', 'Lung collapse', 'Flow-controlled Ventilation']",COMPLETED,,2023-07-19,2024-03-07,"[{'measure': 'oxygenation of the blood', 'description': 'Oxygenation of the blood will be assessed by the paO2/FiO2 ratio and compared between groups.', 'timeFrame': 'Primary outcome timepoint is defined at 30 minutes after start of OLV'}]","[{'measure': 'lung collapse', 'description': 'Time to complete lung collapse will be recorded and compared between groups.', 'timeFrame': 'Lung collapse will be assessed and recorded as no collapse, partial collapse or complete collapse at 10, 20, 30 and 60 minutes after start of one-lung ventilation.'}, {'measure': 'postoperative pulmonary complication', 'description': 'Occurence of postoperative pulmonary complications will be assessed postoperatively', 'timeFrame': 'Follow-up will be completed after end of hospital stay or 30-days of hospital stay.'}]",3,18 Years,,ALL,False,Medical University Innsbruck,OTHER,0,55.0,ACTUAL,2025-09-01T16:18:13.427832,v2_robust,True,True,True,False,False,
NCT04324307,Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer,"Multicenter, Open-label Clinical Study of PD-L1/CTLA4 BsAb Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer",PD-L1/CTLA4 BsAb,['PD-L1/CTLA4 BsAb'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Locally Advanced and Metastatic Pancreatic Cancer,['Locally Advanced and Metastatic Pancreatic Cancer'],[],RECRUITING,,2019-11-26,2023-11,"[{'measure': 'ORR', 'description': 'objective response rate', 'timeFrame': '2 years'}]","[{'measure': 'DCR', 'description': 'Disease Control Rate', 'timeFrame': '2 years'}, {'measure': 'DOR', 'description': 'Duration of Response', 'timeFrame': '2 years'}, {'measure': 'TTP', 'description': 'Time to Response', 'timeFrame': '2 years'}, {'measure': 'PFS', 'description': 'Progression Free Survival', 'timeFrame': '2 years'}, {'measure': 'OS', 'description': 'Overall Survival', 'timeFrame': '2 years'}]",6,18 Years,80 Years,ALL,False,Changhai Hospital,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:13.427857,v2_robust,True,True,False,False,False,
NCT01478607,A Study to Evaluate the Long-term Safety of Repeated QUTENZA Administration for Treatment of Pain Caused by Nerve Damage in Diabetic Patients,"A Randomized, Controlled, Long-term Safety Study Evaluating the Effect of Repeated Applications of QUTENZATM Plus Standard of Care Versus Standard of Care Alone in Subjects With Painful Diabetic Peripheral Neuropathy",QUTENZA,"['QUTENZA', 'Capsaisin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Painful Diabetic Peripheral Neuropathy (PDPN),['Painful Diabetic Peripheral Neuropathy (PDPN)'],"['Painful Diabetic Peripheral Neuropathy', 'Qutenza']",COMPLETED,,2011-11,2014-02,"[{'measure': 'Percentage change in health related quality of life (HRQOL) total score as assessed by the disease specific Norfolk scale', 'timeFrame': 'Baseline till endpoint (discontinuation or End of Study visit) (up to 64 weeks)'}]","[{'measure': 'Neurological function as assessed by the Utah Early Neuropathy Scale (UENS) and sensory testing', 'description': 'Physicians measuring neurological function will be blinded to treatment', 'timeFrame': 'Baseline till End of Study (up to 64 weeks)'}, {'measure': 'Tolerability of patch application by dermal assessment', 'timeFrame': 'Screening till Last visit when QUTENZA patch is applied (up to 53 weeks)'}, {'measure': 'Tolerability of patch application by ""pain now"" Numeric Pain Rating Scale (NPRS) scores after patch application', 'description': 'Assessed within 15 minutes and 60 minutes after patch removal.', 'timeFrame': 'Baseline till Last visit when QUTENZA patch is applied (up to 52 weeks)'}, {'measure': 'Tolerability of patch application by rescue medication use', 'timeFrame': 'Days 1 through 5 after each patch application'}, {'measure': 'Adverse Events and serious adverse Events', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Vital Signs (heart rate and blood pressure)', 'description': 'In case of patch application to be performed within 15 minutes before topical anesthetic application and within 15 minutes after patch removal.', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Laboratory Analyses', 'description': 'The tests performed at the screening visit will include Hematology: Red Blood Cell Count, White Blood Cell Count, Lymphocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Hemoglobin, Hematocrit and Platelets. Biochemistry: Aspartate Aminotransferase (AST) and/or Alanine Aminotransferase (ALT), Alkaline Phosphatase, Sodium, Potassium, Blood Urea Nitrogen (BUN), Creatinine and Lipid profile. Subsequent HbA1c and lipid profile follow-up will be done at bi-monthly visits. The other tests will be performed if clinically indicated.', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Intensity of neuropathic pain using ""average pain"" NPRS scores', 'description': 'Question 5 of Brief Pain Inventory-Diabetic Neuropathy (BPI-DN)', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Brief Pain Inventory (BPI) pain severity index and pain interference index', 'timeFrame': 'Screening visit through End of study visit (up to 65 weeks)'}, {'measure': 'Patient Global Impression of Change', 'timeFrame': 'After each patch re-application, from first patch re-application through End of Study visit (up to 56 weeks)'}, {'measure': 'Generic HRQOL measured by European Quality of Life - 5 Dimensions (EQ-5D) questionnaire', 'timeFrame': 'After each patch application, from first patch application through End of Study (up to 64 weeks)'}, {'measure': 'Treatment satisfaction using the Self-Assessment of Treatment (SAT) questionnaire at week 12/End Of Study visit', 'timeFrame': 'End of Study (up to 65 weeks)'}]",13,18 Years,,ALL,False,Astellas Pharma Inc,INDUSTRY,0,468.0,ACTUAL,2025-09-01T16:18:13.427901,v2_robust,True,True,True,False,True,
NCT01759407,Femoral Nerve Block for Femur Fracture Repair in Pediatrics,"A Prospective, Double-blinded, Randomized Comparison of Ultrasound-guided Femoral Nerve Block With Lateral Femoral Cutaneous Nerve Block Versus Standard Anesthetic Management for Traumatic Femur Fracture Repair in the Pediatric Population",Ropivicaine,"['Ropivicaine', 'Naropin', 'Epinephrine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Traumatic Femur Fracture,['Traumatic Femur Fracture'],[],TERMINATED,Interim analysis showed no significant difference between study arms.,2013-05,2016-10,"[{'measure': 'Post-anesthesia Care Unit (PACU) Pain Scores', 'description': 'Hannallah et al developed the Objective Pain Scale (OPS) to monitor pain in children after surgery. Parameters: (1) systolic blood pressure, (2) crying, (3) movement, (4) agitation (confused, excited), (5) complains of pain (may not be possible in younger children). Interpretation: minimum score: 0; maximum score: 10; maximum score if too young to complain of pain: 8; the higher the score, the greater the degree of pain.', 'timeFrame': '30 mins after surgery'}]","[{'measure': 'Intraoperative End-tidal Isoflurane %', 'description': 'Median end-tidal isoflurane concentration per participant during the average 1 1/2 hr. surgery.', 'timeFrame': '1 1/2 hr.'}, {'measure': 'Time to First Opioid Dose', 'description': 'Median time between PACU discharge and first opioid dose on the ward.', 'timeFrame': 'From PACU discharge until first opioid dose on the ward, assessed up to 24 hours'}]",3,,18 Years,ALL,False,Nationwide Children's Hospital,OTHER,0,19.0,ACTUAL,2025-09-01T16:18:13.427928,v2_robust,True,True,False,True,False,Interim analysis showed no significant difference between study arms.
NCT01720407,Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face,Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face,Imiquimod cream + surgery,"['Placebo + surgery', 'Imiquimod cream + surgery']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Lentigo Maligna Melanoma (Head or Neck),['Lentigo Maligna Melanoma (Head or Neck)'],['Dermatology/ Skin cancers/Lentigo maligna melanoma'],COMPLETED,,2012-12,2022-11-10,"[{'measure': 'The primary endpoint is the margin of resection. Success is defined by an extralesional excision as from the first surgical procedure performed with a healthy tissue margin of 5 mm.', 'timeFrame': '10 weeks'}]","[{'measure': 'The number of surgical re-excisions required to obtain complete remission.', 'timeFrame': 'Baseline, 2 months till 3 years'}, {'measure': 'The number of recurrences, defined as the reappearance of pigmentation within 3 years of surgical excision.', 'timeFrame': 'Baseline, 2 months till 3 years'}, {'measure': 'The number of histologically confirmed complete remissions under imiquimod.', 'timeFrame': 'Baseline, 2 months till 3 years'}]",4,18 Years,,ALL,False,Nantes University Hospital,OTHER,1,259.0,ACTUAL,2025-09-01T16:18:13.427985,v2_robust,True,True,True,False,False,
NCT03761407,"A Clinical Study in Healthy Subjects Which Aims to Investigate the Safety, the Tolerability and the Effects of GRT0151Y and How the Compound is Taken up and Excreted From the Body","A Phase-I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Escalating Oral Doses of GRT0151Y in Healthy Male and Female Subjects",100 mg GRT0151Y,"['225 mg GRT0151Y', '150 mg GRT0151Y', '125 mg GRT0151Y', 'Matching placebo', '100 mg GRT0151Y']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Pain,['Acute Pain'],[],COMPLETED,,2004-12-30,2005-07-26,"[{'measure': 'Incidence of adverse events.', 'description': 'Number of adverse events and number of participants with adverse events.', 'timeFrame': 'From the first IMP administration (Day 1) to the Final Examination (Day 4 to 11 after last period).'}]","[{'measure': 'Pupillometry parameter: Initial pupil diameter', 'description': 'Pupil size (in mm) will be measured using a Compact Integrated Pupillograph (CIP). Measurements will be performed always in the same eye of the individual (preferably the left eye). The measurements will be performed under standard low-light conditions (10-15 lux).', 'timeFrame': 'Day 1 at 0 hour, 4, 11 and 23 hours, on Day 2 at 11 and 23 hours and on Day 5 at 0 hour, 1 hour, 4, 11, 23, 35 and 47 hours'}, {'measure': 'Pupillometry parameter: Amplitude of constriction', 'description': 'Amplitude of constriction (difference between initial pupil diameter and minimum pupil diameter \\[mm\\])', 'timeFrame': 'Day 1 at 0 hour, 4, 11 and 23 hours, on Day 2 at 11 and 23 hours and on Day 5 at 0 hour, 1 hour, 4, 11, 23, 35 and 47 hours'}, {'measure': 'Pupillometry parameter: Onset latency of miosis', 'description': 'Onset latency of miosis (the time between begin of light stimulus and the onset of constriction \\[ms\\])', 'timeFrame': 'Day 1 at 0 hour, 4, 11 and 23 hours, on Day 2 at 11 and 23 hours and on Day 5 at 0 hour, 1 hour, 4, 11, 23, 35 and 47 hours'}, {'measure': 'Pupillometry parameter: Constriction time', 'description': 'Constriction time (time for maximum pupil contraction \\[s\\])', 'timeFrame': 'Day 1 at 0 hour, 4, 11 and 23 hours, on Day 2 at 11 and 23 hours and on Day 5 at 0 hour, 1 hour, 4, 11, 23, 35 and 47 hours'}, {'measure': 'Minimum plasma concentration during dosing interval τ at steady-state (Css,min)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Maximum plasma concentration during dosing interval τ at steady-state (Css,max)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Time to reach maximum plasma concentration during dosing interval τ at steady-state (tss,max)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Area under the concentration vs. time curve after the last dose (AUC)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Average plasma concentration during dosing interval τ at steady-state (Css,ave)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Peak-trough fluctuation at steady-state (PTF%)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Rate constant for the terminal log-linear phase of the concentration time data, computed as the negative slope of the regression line for the terminal linear phase of the logarithmic concentration versus time plot (λss,z)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Half-life for the terminal log-linear phase of the concentration time data (tss,1/2,z)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Apparent terminal half-life after last dose (t1/2,Z)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Apparent terminal elimination rate constant after last dose (λz)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Area under the concentration vs. time curve in dosing interval τ at steady-state (AUCss,τ)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Extrapolated part to infinity of AUCss at steady-state (AUCextr)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Extrapolated part to infinity of AUCss in percent at steady-state (AUC%extr)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Area under the concentration-time data for dosing interval τ (AUC0-τ)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Total mean time in the total volume of distribution (MRTvsys)', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Relative total clearance (CL/F)ss', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Relative volume of distribution for the terminal log-linear phase of the concentration time data (Vz/F)ss', 'timeFrame': 'predose on Day 1, during 4 consecutive days of multiple dosing and up to 72 hours after the last dosing on Day 5'}, {'measure': 'Cold Pressor Test (CPT) (AUC of pain assessment)', 'description': 'The dominant hand will be plunged into a 1-3 degrees Celsius circulating cold water quench for 2 minutes. By using a computer mouse with the other hand, the participant adjusted a visual analogue scale on a computer screen facing them. The scale was labelled ""no pain"" at one end and ""maximum pain"" at the other end.', 'timeFrame': 'Day 1 at 0 hour, 4, 11 and 23 hours, on Day 2 at 11 and 23 hours and on Day 5 at 0 hour, 1, 4, 11, 23, 35 and 47 hours.'}]",23,40 Years,65 Years,ALL,True,Grünenthal GmbH,INDUSTRY,0,48.0,ACTUAL,2025-09-01T16:18:13.427999,v2_robust,True,True,True,False,True,
NCT01580592,Cold Urticaria Treatment With Xolair,"A Two-center, Double Blind, Placebo-controlled Study in Parallel Design to Assess the Efficacy and Safety of 150 and 300 mg Omalizumab in Subjects With Antihistamine-resistant Cold Contact Urticaria (CCU)",Omalizumab,"['Omalizumab', 'Xolair', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Cold Contact Urticaria,['Cold Contact Urticaria'],[],COMPLETED,,2012-04,2015-02,"[{'measure': 'Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo', 'description': 'The primary efficacy outcome was the change in trigger thresholds from baseline to week ten using TempTest® to assess critical temperature thresholds in °C.', 'timeFrame': 'day 70'}]","[{'measure': 'Number of Participants With Abnormal Physical Examinations, Laboratory Assessments, Vital Signs, and Adverse Events', 'description': 'This includes physical examination, routine safety laboratory assessments, vital signs and adverse event reporting', 'timeFrame': 'day 70'}]",2,18 Years,,ALL,False,"Charite University, Berlin, Germany",OTHER,1,31.0,ACTUAL,2025-09-01T16:18:13.428072,v2_robust,True,True,True,False,True,
NCT02342392,"Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study","Intralesional Ranibizumab on Pterygium Vascularity, Size and Recurrence Rate: a Pilot Study",ranibizumab,"['Lucentis', 'ranibizumab']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Pterygium,['Pterygium'],"['pterygium', 'ranibizumab', 'anti-VEGF', 'recurrence', 'vascularity', 'size']",COMPLETED,,2012-09,2014-09,"[{'measure': 'pterygium recurrence', 'description': 'pterygium recurrence is defined as true recurrence with a fibrovascular tissue invading the cornea (grade 4 lesion)', 'timeFrame': '1 year'}]","[{'measure': 'pterygium vessel area', 'description': 'Pterygium vesel area is defined as the as the ration of pixels occupied by the vessels within the pterygium area in percentage.', 'timeFrame': '1 week'}, {'measure': 'corneal pterygium area', 'description': 'Corneal pterygium area is defined as the as the ration of pixels occupied by the pterygium within the cornea area in percentage.', 'timeFrame': '1 week'}]",3,,,ALL,False,Universiti Sains Malaysia,OTHER,0,36.0,ACTUAL,2025-09-01T16:18:13.428090,v2_robust,True,True,True,False,False,
NCT05507892,Renal Mechanism of SGLT2 Inhibition,Molecular Mechanisms of SGLT2 Inhibition in Diabetic Kidney Disease,canagliflozin,"['-Sodium 4-amino hippurate (PAH) inj 20% 2g/10mL -Para-aminohippurate', 'canagliflozin', 'Invokana', 'Aminohippurate Sodium Inj 20%']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Type 2 Diabetes,"['Type 2 Diabetes', 'Diabetic Kidney Disease']",[],RECRUITING,,2022-10-10,2026-12-15,"[{'measure': 'Glomerular basement membrane (GBM) width and mesangial expansion', 'description': 'measured by morphometric examination of kidney tissue', 'timeFrame': '6 months'}, {'measure': 'Kidney Transcript Changes', 'description': 'Molecular changes measured by change in transcripts as assessed by single-cell RNA sequencing of kidney biopsy specimens', 'timeFrame': '6 months'}]","[{'measure': 'Cortical R2', 'description': 'Measured by Blood Oxygen Level Dependent (BOLD) MRI; Participants will be scanned in a supine position with a 3T MRI scanner. Spine array and body array receiver coils will be used to maximize image uniformity. Following initial localizer scans, coronal Sec T2-weighted MR images will be obtained to delineate cortical kidney regions. The image acquisition will be respiratory-gated to ensure accurate image co-registration with the respiratory-gated diffusion acquisitions.', 'timeFrame': '6 months'}, {'measure': 'Medullary R2', 'description': 'Measured by Blood Oxygen Level Dependent (BOLD) MRI; Participants will be scanned in a supine position with a 3T MRI scanner. Spine array and body array receiver coils will be used to maximize image uniformity. Following initial localizer scans, coronal Sec T2-weighted MR images will be obtained to delineate medullary kidney regions. The image acquisition will be respiratory-gated to ensure accurate image co-registration with the respiratory-gated diffusion acquisitions.', 'timeFrame': '6 months'}, {'measure': 'Renal Perfusion', 'description': 'Measured by Arterial Spin Labeling (ASL)', 'timeFrame': '6 months'}, {'measure': 'Glomerular Filtration Rate (GFR)', 'description': 'Measured by iohexol clearance; An intravenous (IV) line will be placed, and participants will be asked to empty their bladders. Spot plasma and urine samples will be collected prior to iohexol infusion. Iohexol will be administered through bolus IV injection (36 mg/kg/dose), followed by infusion (15mg/min over 180 min.) An equilibration period of 120 min was used and blood collections for iohexol plasma disappearance were drawn at +120, +150, +180 min.', 'timeFrame': '3 Hours'}, {'measure': 'Renal Plasma Flow (RPF)', 'description': 'Measured by para-aminohippurate (PAH) clearance; An intravenous (IV) line will be placed, and participants will be asked to empty their bladders. Spot plasma and urine samples will be collected prior to PAH infusion. PAH (2 g/10 mL, prepared by Basic Pharma, with a dose of (16 mg/kg or 12 mg/kg depending on eGFR) will be given slowly over 5 min followed by a continuous infusion of 8 mL of PAH and 42 mL of normal saline at a rate or 7.2 mg/kg/ hr or 5.0 mg/kg/hr for 2 h, depending on eGFR. After an equilibration period, blood will be drawn at 90, 120, and 150 min, and RPF will be calculated as PAH clearance divided by the estimated extraction ratio of PAH, which varies by the level of GFR.', 'timeFrame': '2.5 Hours'}]",7,18 Years,80 Years,ALL,False,"University of Colorado, Denver",OTHER,1,40.0,ESTIMATED,2025-09-01T16:18:13.428192,v2_robust,True,True,False,False,False,
NCT00231192,Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes,Repaglinide for Adolescents With Cystic Fibrosis-Related Diabetes,Repaglinide and Insulin,['Repaglinide and Insulin'],1,INTERVENTIONAL,['NA'],,,Diabetes,['Diabetes'],"['Diabetes', 'Adolescents', 'Cystic Fibrosis', 'Insulin', 'Repaglinide']",WITHDRAWN,Unable to recruit any subjects,2005-10,2007-08,"[{'measure': 'blood glucose'}, {'measure': 'insulin excursion during oral glucose tolerance test'}, {'measure': 'fasting blood glucose'}, {'measure': '2-hour post-prandial blood glucose'}, {'measure': 'hemoglobin A1C'}, {'measure': 'serum fructosamine'}]","[{'measure': 'weight'}, {'measure': 'body mass index'}, {'measure': 'lean body mass'}, {'measure': 'pulmonary function'}, {'measure': 'quality of life'}]",11,12 Years,20 Years,ALL,True,Children's Hospital of Philadelphia,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:13.428246,v2_robust,True,True,False,True,False,Unable to recruit any subjects
NCT04825392,A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors,A Phase Ib Study of Tolerance and Safety of a Recombinant Anti-PD-1 Monoclonal Antibody HX008 in Patients With Advanced Solid Tumors,HX008,['HX008'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],UNKNOWN,,2019-09-05,2021-12-30,"[{'measure': 'Number of participants with treatment-related adverse events as assessed by CTCAE v5.0', 'timeFrame': '24 months'}]","[{'measure': 'Objective Response Rate (ORR)', 'timeFrame': '24 months'}, {'measure': 'Disease Control Rate (DCR)', 'timeFrame': '24 months'}, {'measure': 'Duration of Response (DOR)', 'timeFrame': '24 months'}, {'measure': 'Progress Free Survival (PFS)', 'timeFrame': '24 months'}, {'measure': 'Overall Survival (OS)', 'timeFrame': '36 months'}]",6,18 Years,,ALL,False,Taizhou Hanzhong biomedical co. LTD,INDUSTRY,0,30.0,ESTIMATED,2025-09-01T16:18:13.428259,v2_robust,True,True,False,False,True,
NCT03682692,ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD),ACEI/CCB Versus ACEI/DIU Combination Antihypertensive Therapy in Chinese Hypertensive Patients (ACvAD),ACEI/CCB,"['ACEI/CCB', 'ACEI/DIU']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,['Hypertension'],[],COMPLETED,,2018-06-01,2022-03-31,"[{'measure': '24-hour ambulatory systolic blood pressure reduction', 'description': 'the change of 24-hour ambulatory systolic blood pressure in the ACEI/CCB group compared with the ACEI/DIU group after 6 months of antihypertensive treatment', 'timeFrame': '6 months'}]","[{'measure': 'reduction of other blood pressure measurements', 'description': 'the change of 24-hour, daytime, night-time, home and office systolic and diastolic blood pressure after 6 months of study medication treatment', 'timeFrame': '6 months'}]",2,18 Years,,ALL,True,Shanghai Jiao Tong University School of Medicine,OTHER,0,560.0,ACTUAL,2025-09-01T16:18:13.428318,v2_robust,True,True,True,False,False,
NCT01090492,PF-00489791 For The Treatment Of Raynaud's,"A Phase 2a Randomized Double-blinded, Placebo And Active Controlled Two Cohort Two Doses Cross-over Multi-center Clinical Study To Assess Efficacy Of A Once Daily Administration Of A Phosphodiesterase 5 Inhibitor (Pf-00489791) For The Treatment Of Vasospasm In Primary And Secondary Raynaud's Phenomenon",PF-00489791,['PF-00489791'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Raynaud's Disease,"[""Raynaud's Disease"", 'Peripheral Vascular Disease']","[""Raynaud's phenomenon"", 'vasospasm', 'scleroderma', 'systemic sclerosis', 'CREST', 'phosphodiesterase inhibitor']",COMPLETED,,2010-08-04,2011-05-31,"[{'measure': ""Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4"", 'description': ""The Raynaud's Condition score (RCS) is participant's rating of difficulty considering number of attacks, duration, amount of pain, numbness, or other symptoms caused in the fingers (including painful sores) due to the Raynaud's phenomenon every day and impact of Raynaud's alone on use of hands every day. An 11 point Likert scale is used to rate the difficulty caused by the condition each day with 0 = no difficulty and 10 = extreme difficulty. Participants were asked to select the number that best describes their difficulty, with higher score indicating worse condition. Average daily score was considered for participants completing more than 1 Raynaud's pain score scale on a day. Baseline value was calculated as mean of the scores over 7 days prior to treatment start. Week 4 value was calculated as mean of the scores over the 7-day period prior to Week 4."", 'timeFrame': 'Baseline, Week 4'}]","[{'measure': ""Change From Baseline in the Number of Raynaud's Attacks at Week 1, 2, 3 and 4"", 'description': ""Change from baseline in the number of Raynaud's attacks at Week 1, Week 2, Week 3 and Week 4 was calculated from the number of attacks reported over the 7-day period prior to each week from the patient diary, respectively."", 'timeFrame': 'Baseline, Week 1, Week 2, Week 3, Week 4'}, {'measure': ""Change From Baseline in Mean Duration of Raynaud's Attacks at Week 4"", 'description': ""Mean duration of Raynaud's attacks for a time period was calculated as sum of recorded durations of attacks in the time period divided by total number of attacks in the time period where duration was recorded."", 'timeFrame': 'Baseline, Week 4'}, {'measure': ""Change From Baseline in the Mean Raynaud's Pain Score at Week 1, 2, 3 and 4"", 'description': ""Participants were asked to rate their worst Raynaud's pain in the past 24 hours using an 11 point Likert scale, with 0 = no Raynaud's pain and 10 = the worst possible pain. Highest (most severe) response was considered for participants responding at more than 1 point on the scale. Average daily score was considered for participants completing more than 1 Raynaud's pain score scale on a day. Baseline value was calculated as mean of the scores over 7 days prior to treatment start. Post-baseline value was calculated as mean of the scores over the 7-day period prior to the visit."", 'timeFrame': 'Baseline, Week 1, 2, 3, 4'}, {'measure': ""Number of Participants With Decrease From Baseline in Digital Ulcers at Day 14 and 28: Secondary Raynaud's Phenomenon Cohort"", 'description': 'Presence of ulcer was assessed at baseline. At post-baseline visits, each ulcer was measured and scored: 1= smaller or improved compared to previous visit, 2= same as previous visit, 3= bigger or worse than previous visit, and 4= new. If a new digital ulcer develops during the course of the study, the measurement and scoring were initiated on this additional ulcer. Healed ulcers were not counted into the number of ulcers. Participants with SRP in the per-protocol population with at least 1 digital ulcer present at any assessment were evaluable for this measure. Results are reported for participants with presence of ulcer at baseline and decrease from baseline in ulcers at post-baseline visits.', 'timeFrame': 'Baseline, Day 14, 28'}, {'measure': 'Plasma Concentration of PF-00489791 and Its Metabolites', 'description': 'Only participants receiving PF-00489791 were to be analyzed for this outcome. Data have been calculated by setting plasma concentration values below the lower limit of quantification to 0. The lower limit of quantification is 0.0100 microgram per milliliter (mcg/mL). Data for plasma concentration of PF-00489791 metabolites was not analyzed, as it was not intended to be a secondary endpoint and was deemed optional.', 'timeFrame': 'Day 1, 15, 29 (Day 1, 15, 29 for first intervention period), 43, 57, 71 (Day 1, 15, 29 for second intervention period)'}, {'measure': 'Number of Participants With Laboratory Test Abnormalities', 'description': 'Criteria for laboratory tests abnormalities included: hemoglobin, hematocrit and red blood cells (less than \\[\\<\\] 0.8\\*lower limit of normal\\[LLN\\]); leukocytes (\\<0.6 LLN /greater than \\[\\>\\] 1.5\\*upper LN \\[ULN\\]; platelets (\\<0.5\\*LLN/\\>1.75\\*ULN); neutrophils, lymphocytes (\\<0.8\\* LLN/\\>1.2\\*ULN); eosinophils, basophils, monocytes (\\>1.2\\*ULN); bilirubin (\\>1.5\\*ULN); aspartate aminotransferase (AST), alanine aminotransferase (ALT), Gamma GT, alkaline phosphatase (\\>3\\*ULN); BUN, creatinine (\\>1.3\\*ULN); glucose (\\<0.6 LLN/\\>1.5\\*ULN); uric acid (\\>1.2\\*ULN); sodium (\\<0.95\\*LLN/\\>1.05\\*ULN); potassium, calcium, chloride, bicarbonate (\\<0.9\\*LLN/\\>1.1\\*ULN); albumin, total protein (\\<0.8\\*LLN/\\>1.2\\*ULN); creatine kinase (\\>2.0\\*ULN); Urine Specific Gravity, Urine pH, urine blood, urine glucose, urine protein, urine ketones, urine leukocytes esterase (\\>=1 high-powered field). Total number of participants with any laboratory abnormalities was reported.', 'timeFrame': 'Screening up to 28 days after last study dose (up to 98 days)'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs and Orthostatic Blood Pressure Measurements', 'description': ""Vital signs assessment included measurement of supine and standing pulse rate, systolic and diastolic blood pressures. Criteria for clinically significant vital signs and orthostatic blood pressure measurements were based on investigator's judgement."", 'timeFrame': 'Screening up to 28 days after last study dose (up to 98 days)'}, {'measure': 'Number of Participants With Abnormal Electrocardiogram (ECG) Values', 'description': ""ECG assessment included measurement of PR, QRS, QT,corrected QT interval (QTc)values. Criteria for clinically significant ECG values were based on investigator's judgement."", 'timeFrame': 'Screening up to 28 days after last study dose (up to 98 days)'}]",9,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,243.0,ACTUAL,2025-09-01T16:18:13.428330,v2_robust,True,True,True,False,False,
NCT06594692,"Node-Sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study","Node-sparing Modified Short-Course Radiation Combined with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer : a Randomized, Prospective, Multicenter, Open-label Clinical Trial",Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab,"['Node-Sparing Short-Course Radiotherapy Combined with CAPOX and Sintilimab', 'CAPOX Chemotherapy']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Microsatellite Stable (MSS) Colon Cancer,"['Microsatellite Stable (MSS) Colon Cancer', 'Locally Advanced Colon Cancer']","['Locally Advanced Colon Cancer', 'Microsatellite Stable (MSS) Colon Cancer', 'Node-Sparing Radiotherapy', 'Short-Course Radiotherapy', 'Sintilimab']",NOT_YET_RECRUITING,,2024-10,2026-09-30,"[{'measure': 'pathological complete response rate', 'description': 'The tumor specimen from node-sparing neoadjuvant chemoradiotherapy combined with immunotherapy, followed by sequential CME (complete mesocolic excision) surgery, showed no presence of cancer cells or lymph node metastasis under microscopic examination (ypT0N0M0).', 'timeFrame': '2 weeks after surgery'}]","[{'measure': 'R0 resection rate', 'description': 'which is the percentage of patients who undergo a surgical procedure in which the tumor is completely removed with no cancer cells detected at the margins (edges) of the resected tissue. Achieving an R0 resection is a critical goal in cancer surgery, as it indicates that all visible and microscopic tumor cells have been removed, reducing the likelihood of recurrence.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'Tumor downstaging rate', 'description': 'The tumor downstaging rate refers to the percentage of patients whose tumors decrease in size or extent (stage) following neoadjuvant treatment, compared to their initial stage at diagnosis. Downstaging means that the tumor has responded to treatment to the point where it moves from a more advanced stage (e.g., from stage III to stage II or I), which may improve the likelihood of successful surgical removal and lead to better prognosis.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'The 3-year Event-Free Survival', 'description': ""The 3-year Event-Free Survival (EFS) refers to the percentage of patients who remain free from certain negative events-such as cancer progression, recurrence, or death-within three years after treatment. In clinical trials, EFS is a critical measure of a treatment's long-term efficacy, indicating how long patients can live without the disease worsening or other significant events occurring during the follow-up period."", 'timeFrame': '3 years post-treatment'}, {'measure': 'Objective Response Rate', 'description': 'Objective Response Rate (ORR) refers to the percentage of patients in a clinical study whose cancer shows a measurable reduction in tumor size in response to treatment.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'The 3-year Local Recurrence Rate', 'description': 'The 3-year Local Recurrence Rate (LRR) refers to the percentage of patients whose cancer returns at the original tumor site or nearby lymph nodes within three years after completing treatment. This measure is important for evaluating the long-term effectiveness of a treatment in preventing the return of cancer in the localized area where it was initially detected. A lower LRR suggests better local control of the disease.', 'timeFrame': '3 years post-treatment'}, {'measure': '3-year Disease-Free Survival', 'description': '3-year Disease-Free Survival (DFS) refers to the percentage of patients who remain free from any signs or symptoms of cancer for three years after completing treatment. It measures the length of time during which patients experience no recurrence of the disease and are considered to be in remission. DFS is commonly used to assess the effectiveness of a treatment in preventing cancer from returning within a specified time frame.', 'timeFrame': '3 years post-treatment'}, {'measure': '3-year Overall Survival', 'description': '3-year Overall Survival (OS) refers to the percentage of patients who are still alive three years after the completion of treatment, regardless of whether the cancer has recurred or progressed. It is a key indicator of the effectiveness of a treatment in prolonging life. Unlike Disease-Free Survival (DFS), OS does not take into account whether the disease has returned, focusing solely on survival.', 'timeFrame': '3 years post-treatment'}, {'measure': 'The incidence of grade III/IV adverse events', 'description': 'The incidence of grade III/IV adverse events refers to the percentage of patients who experience severe or life-threatening side effects (classified as grade III or IV) during a clinical trial. Grade III adverse events are considered serious but not immediately life-threatening, often requiring medical intervention, while grade IV events are life-threatening and typically require urgent medical attention. This measure is crucial for assessing the safety and tolerability of a treatment.', 'timeFrame': '2 weeks after surgery'}, {'measure': 'EORTCQLQ-C30', 'description': ""The EORTC QLQ-C30 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30) is a standardized tool used to assess the quality of life of cancer patients. It contains 30 questions that cover a wide range of physical, emotional, and social aspects of well-being, including symptoms of cancer and treatment side effects, functioning (physical, role, emotional, cognitive, and social), and overall health. The questionnaire is widely used in clinical trials to evaluate how treatments impact the patient's quality of life during and after treatment."", 'timeFrame': '3 years post-treatment'}, {'measure': 'EORTCQLQ-CR29', 'description': ""The EORTC QLQ-CR29 (European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Colorectal Cancer Module) is a supplementary module to the QLQ-C30 designed specifically to assess quality of life in patients with colorectal cancer. It includes 29 questions that focus on colorectal cancer-specific symptoms and concerns, such as bowel function, body image, and sexual functioning, in addition to the general quality of life issues covered by the QLQ-C30. This questionnaire is used in clinical studies to evaluate the impact of colorectal cancer and its treatment on patients' quality of life."", 'timeFrame': '3 years post-treatment'}]",11,18 Years,,ALL,False,Sir Run Run Shaw Hospital,OTHER,0,140.0,ESTIMATED,2025-09-01T16:18:13.428420,v2_robust,True,True,False,False,True,
NCT03482492,Tramadol vs.Tramadol With Paracetamol,Comparison of Tramadol vs. Tramadol With Paracetamol for Efficacy of Postoperative Pain Management in Lumbar Discectomy: A Randomised Controlled Trial,Tramadol,"['Paracetamol', 'Tramadol']",2,INTERVENTIONAL,['NA'],,,Lumbar Disc Herniation,['Lumbar Disc Herniation'],"['Acetaminophen', 'Tramadol', 'Discogenic pain', 'Lumbar Discectomy']",COMPLETED,,2014-03-20,2015-04-03,"[{'measure': 'Severity of pain', 'description': 'Self reported pain intensity', 'timeFrame': '2 hours'}]","[{'measure': 'Tramadol consumption', 'description': 'Total tramadol consumption during time frame', 'timeFrame': '2 hours'}]",2,30 Years,60 Years,ALL,False,Yeditepe University Hospital,OTHER,0,60.0,ACTUAL,2025-09-01T16:18:13.428460,v2_robust,True,True,True,False,False,
NCT01133392,Bioequivalence of Two Lispro Formulations,Evaluation of the Bioequivalence of Two Formulations of Insulin Lispro in Healthy Subjects,Insulin lispro A,"['Insulin lispro B', 'LY275585', 'Insulin lispro A']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['insulin', 'lispro']",COMPLETED,,2010-05,2010-08,"[{'measure': 'Pharmacokinetic Parameter: Area Under the Serum Insulin Concentration Versus Time Curve From Time Zero to the Last Time Point With a Measurable Concentration [AUC0-tlast]', 'description': 'Primary outcome measure is based on the pharmacokinetic area under the concentration-time curve from time 0 to the last time point with a measurable concentration.', 'timeFrame': '0 up to 8 hours post dose'}]","[{'measure': 'Pharmacokinetic Parameter: Maximum Serum Insulin Concentration [Cmax]', 'description': 'The maximum observed insulin lispro concentration following dosing.', 'timeFrame': '0 to 8 hours post dose'}, {'measure': 'Pharmacodynamic Parameter: Maximum Glucose Infusion Rate (Rmax)', 'description': 'The maximum observed glucose infusion rate during the euglycemic clamp procedure.', 'timeFrame': '0 to 8 hours post dose'}, {'measure': 'Pharmacodynamic Parameter: Time of Maximum Glucose Infusion Rate (tRmax)', 'description': 'Time of maximal glucose infusion rate.', 'timeFrame': '0 to 8 hours post dose'}, {'measure': 'Pharmacodynamic Parameter: Total Amount of Glucose Infused (Gtot)', 'description': 'The total amount of glucose infused during the euglycemic clamp procedure.', 'timeFrame': '0 to 8 hours post dose'}]",5,21 Years,50 Years,ALL,True,Eli Lilly and Company,INDUSTRY,0,41.0,ACTUAL,2025-09-01T16:18:13.428469,v2_robust,True,True,True,False,False,
NCT04375436,Safety and Tolerability of NTRX-07 in Healthy Volunteers,"NTRX 07-C101: A Phase 1, Randomized, Placebo-Controlled, Modified Parallel Design Single Ascending Dose Study of NTRX 07 to Assess Safety and Tolerability and Pharmacokinetics in Adult Healthy Volunteers",NTRX-07-SDD,"['NTRX-07-SDD', 'MDA7']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Pain, Neuropathic","['Pain, Neuropathic']",[],COMPLETED,,2019-10-10,2020-06-30,"[{'measure': 'Number of subjects with treatment emergent adverse events of NTRX-07', 'description': 'Reported Treatment related Adverse Events', 'timeFrame': 'Seven days'}, {'measure': 'Number of subjects with Treatment related subjective effects of NTRX-07', 'description': 'Reported Treatment related subjective effects Events', 'timeFrame': 'Seven days'}, {'measure': 'Plasma levels of NTRX-07', 'description': 'Plasma levels of NTRX-07', 'timeFrame': '24 hours'}]",[],3,18 Years,60 Years,ALL,True,"NeuroTherapia, Inc.",INDUSTRY,2,48.0,ACTUAL,2025-09-01T16:18:13.428486,v2_robust,True,True,True,False,True,
NCT03887936,Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism,Testosterone Therapy and Bone Quality in Men With Diabetes and Hypogonadism,Testosterone gel 1.62%,"['Androgel', 'Testosterone gel 1.62%', 'Placebo']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 2 Diabetes Mellitus,"['Type 2 Diabetes Mellitus', 'Hypogonadism']","['diabetes mellitus', 'hypogonadism', 'testosterone', 'bone quality']",ACTIVE_NOT_RECRUITING,,2019-10-01,2025-09-30,"[{'measure': 'Finite element analysis of bone to measure bone strength', 'description': 'The FEA (or FEA) is a surrogate measure of strength using computational biomechanical principles and integrate bone morphology and bone mass to calculate bone strength under various loading conditions normally seen in daily living activities. In addition, the ratio of load to strength can be calculated by using patient information (i.e. weight and height) and FEA derived bone strength to mechanistically simulate bone failure and thus, whether fracture is likely during a given activity. Using high-resolution peripheral quantitative computer tomography we will compute for FEA, using finite element analysis software with images generated using Image Processing Language to estimate the biomechanical properties of the bone. Each bone voxel will be converted to hexahedral finite elements with linear-elastic and isotropic material behavior. The FEA model will be subject to uniaxial compression and stiffness and failure load will be estimated. FEA will be assessed at months 0, 6 and 12.', 'timeFrame': '5 years'}]","[{'measure': 'Markers of bone turnover to measure bone metabolism', 'description': 'Two markers of bone resorption, serum C-telopeptide (CTX) and tartrate-resistant acid phosphatase 5b (TRAP5b) and 2 markers of bone formation osteocalcin (OCN) and N-terminal propeptide of type 1 collagen (P1NP) will be evaluated. These markers will be obtained at months 0, 6, and 12. Enzyme-linked immunosorbent assay will be used to measure serum CTX (serum crosslaps, Osteometer, Hawthorne, CA), tartrate-resistant acid phosphatase 5b (TRAP5b) (EIA) (Microvue Bonehealth, Quidel Corporation, Biosource); and serum osteocalcin (ALPCO, Salem, NH). Serum P1NP will be measured by competitive radioimmunoassay (UniqTM P1NP RIA, Immunodiagnostic Systems, Scottsdale, AZ). Coefficients of variations for these assays are \\<10%.', 'timeFrame': '5 years'}, {'measure': 'Osteoblast and osteoclast progenitor cells which are cells found in bone', 'description': 'Osteoblast and osteoclast progenitor cells will be harvested from the serum at baseline, 6 and 12 months.', 'timeFrame': '5 years'}]",3,35 Years,70 Years,MALE,False,VA Office of Research and Development,FED,0,92.0,ACTUAL,2025-09-01T16:18:13.428549,v2_robust,True,True,False,False,False,
NCT04255836,Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC),A Pilot Study of Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC),Durvalumab,"['the first line chemotherapy for metastatic NSCLC', 'Durvalumab', 'IMFINZI']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung']",[],UNKNOWN,,2020-09-30,2023-07-30,"[{'measure': 'PFS', 'description': 'Progression-Free Survival (PFS) assessed according to RECIST 1.1 in subpopulation of patients with oligometastatic NSCLC', 'timeFrame': 'up to 2 years'}]","[{'measure': 'Safety (AESI, AEs/SAEs)', 'description': 'Incidence of Treatment-Emergent Adverse Events \\[Safety and Tolerability\\]', 'timeFrame': 'up to 2 years'}, {'measure': 'To assess the treat failure patterns', 'description': 'Treat failure patterns including local failure and distant metastasis', 'timeFrame': 'up to 2 years'}, {'measure': 'Objective response rate(ORR)', 'description': 'ORR was defined as the proportion of participants with partial response (PR) or complete response (CR) to treatment as defined by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.', 'timeFrame': 'up to 2 years'}, {'measure': 'and OS Overall Survival(OS)', 'description': 'OS was defined as the time from the date of enrollment until death by any cause. Participants still alive at the time of data analysis were censored at the date of last follow-up.', 'timeFrame': 'up to 2 years'}]",5,18 Years,80 Years,ALL,False,Zhejiang Cancer Hospital,OTHER,0,35.0,ESTIMATED,2025-09-01T16:18:13.428615,v2_robust,True,True,False,False,True,
NCT06120036,Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas,Dosing and Tolerability of Deoxycholic Acid Versus Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas,Kybella,"['Kybella', 'Asclera']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Neurofibromatosis 1,['Neurofibromatosis 1'],[],COMPLETED,,2022-12-06,2025-01-09,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]', 'description': 'Device based treatment will be considered tolerable if \\<40% of participants treated have a \\>grade 2 adverse event (AE). A grade 2 AE is defined as an adverse event that requires treatment.', 'timeFrame': '3 months after treatment'}]","[{'measure': 'Treatment specific patient reported outcomes (PRO)', 'description': 'NRS11, modality specific satisfaction assessment', 'timeFrame': 'Baseline, 1 day after treatment, 1 week after treatment, 1 month after treatment, 2 months after treatment, 3 months after treatment, 6 months after treatment, 12 months after treatment'}, {'measure': 'Clinician reported outcomes (ClinRO)', 'description': 'Clinician assessment of cNF via questionnaire. Physician rates degree of change of treated and control cNFs on a scale from -3 (no change) to 3 (very large improvement).', 'timeFrame': 'Baseline, 3 months after treatment, 6 months after treatment, 12 months after treatment'}, {'measure': 'Modified SkinDex for cNF', 'description': 'Health-related quality of life measure. Asks how much participants have been bothered by cNFs over the past week from 0 (never bothered) to 5 (always bothered).', 'timeFrame': 'Baseline, 3 months after treatment, 6 months after treatment, 12 months after treatment'}]",4,18 Years,85 Years,ALL,False,Massachusetts General Hospital,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:13.428624,v2_robust,True,True,True,False,True,
NCT04462536,Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis,"A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis",Placebo,"['NA-1', 'Nerinetide', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Stroke, Acute","['Stroke, Acute']",[],COMPLETED,,2020-12-06,2023-08-31,"[{'measure': 'Number of Participants With Independent Functioning on the Modified Rankin Scale (mRS), as Defined by a Score of 0-2', 'description': 'The modified Rankin Scale (mRS) is a valid and reliable clinician-reported measure of global disability that has been widely applied for evaluating recovery from stroke. It is a scale used to measure functional recovery (the degree of disability or dependence in daily activities) of people who have suffered a stroke. mRS scores range from 0 (best outcome) to 6 (worst outcome), with 0 indicating no residual symptoms; 5 indicating bedbound, requiring constant care; and 6 indicating death.', 'timeFrame': '90 days'}]","[{'measure': 'Mortality Rate, as Defined by Event Rate (Percent) for Mortality Over the 90-day Study Period.', 'description': 'The estimand of mortality rate was the adjusted unconditional population difference in the number of deaths observed divided by the number of participants observed over the 90-day study period (mortality proportions) between treatment conditions (nerinetide vs. placebo) in the target patient population at Day 90. Deaths occurring over the Day 90 period were considered as non-responses.', 'timeFrame': '90 days'}, {'measure': 'Number of Participants Exhibiting a Worsening of Their Index Stroke.', 'description': 'Worsening of stroke is defined as (A) progression, or hemorrhagic transformation of the index stroke, as documented by medical imaging that is (a) life-threatening requiring intervention and/or (b) results in increased disability as gauged by a ≥4 point increase from lowest NIHSS during hospitalization or (B) results in death from the index stroke.', 'timeFrame': '90 days'}, {'measure': 'Number of Participants With Good Neurological Outcome, as Defined by a Score of 0-2 on the NIHSS at Day 90 Post Randomization.', 'description': 'The National Institutes of Health Stroke Scale (NIHSS) is a standardized neurological examination score that is a valid and reliable measure of disability and recovery after acute stroke. Scores range from 0 to 42, with higher scores indicating increasing severity.', 'timeFrame': '90 days'}]",4,18 Years,,ALL,False,NoNO Inc.,INDUSTRY,1,850.0,ACTUAL,2025-09-01T16:18:13.428730,v2_robust,True,True,True,False,False,
NCT00478036,Comparing Acular LS and Pred Forte in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells,A Randomized Prospective Double Masked Controlled Trial Comparing Ketorolac Tromethamine 0.4% and Prednisolone Acetate 1% in Reducing Post-selective Laser Trabeculoplasty Anterior Chamber Flare and Cells.,Acular LS,"['KETOROLAC TROMETHAMINE 0.5% SOLUTION - OPHTHALMIC', 'Acular LS', 'Pred Forte', 'Prednisolone acetate ophthalmic suspension 1%']",4,INTERVENTIONAL,['NA'],,,Open Angle Glaucoma,['Open Angle Glaucoma'],"['glaucoma', 'selective laser trabeculoplasty', 'anterior chamber flare']",TERMINATED,insufficient enrollment,2007-05,2014-01,"[{'measure': 'Interocular Pressure', 'description': 'IOP, measured by Goldmann applanation tonometry', 'timeFrame': '8 weeks'}]",[],1,18 Years,,ALL,False,"University of Colorado, Denver",OTHER,0,31.0,ACTUAL,2025-09-01T16:18:13.428760,v2_robust,True,True,False,True,False,insufficient enrollment
NCT01024036,A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease,"A Randomized, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti IL 6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman's Disease",Siltuximab,"['Best Supportive Care (BSC)', 'Siltuximab', 'Placebo', 'CNTO 328']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Multicentric Castleman's Disease,"[""Multicentric Castleman's Disease""]","[""Multicentric Castleman's Disease"", 'MCD', 'CNTO 328', 'Best Supportive Care', 'Tumor', 'Symptomatic response', 'Pharmacokinetics', 'Interleukin-6', 'IL6']",COMPLETED,,2010-03-18,2017-02-24,"[{'measure': 'Percentage of Participants Who Achieved Durable Tumor and Symptomatic Response - by Independent Radiology Review', 'description': ""Durable tumor and symptomatic response is complete response (CR) + partial response (PR). CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion) and resolution of baseline symptoms attributed to multicentric Castleman's disease, sustained for at least 18 weeks. PR: \\>=50 percent decrease in sum of the product of the diameters of indicator lesion(s), with at least stable disease in all other evaluable disease in the absence of treatment failure sustained for at least 18 weeks. The statistical analysis shows difference in symptomatic response rate (siltuximab+best supportive care \\[BSC\\] minus Placebo+BSC)."", 'timeFrame': 'From Day 1 of Cycle 1 of treatment with study medication until treatment failure or discontinuation of treatment or withdrawal from study, or up to 48 weeks after last participant started study medication(approximately 3 years), whichever occurred earlier'}]","[{'measure': 'Median Duration of Tumor and Symptomatic Response - by Independent Radiology Review', 'description': ""Duration of tumor and symptomatic response is defined as time from first documentation of tumor and symptomatic response (CR or PR) to treatment failure. Whenever possible, treatment failure documented by the appearance of new lesions should be confirmed by histologic examination of the new lesions. Symptomatic response is complete response (CR) + partial response (PR). CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion) and resolution of baseline symptoms attributed to multicentric Castleman's disease, sustained for at least 18 weeks. PR: \\>=50 percent decrease in sum of the product of the diameters of indicator lesion(s), with at least stable disease in all other evaluable disease in the absence of treatment failure sustained for at least 18 weeks."", 'timeFrame': 'From the date when durable tumour and symptomatic response is achieved until treatment failure, as assessed until 48 weeks after the last participant started study treatment (approximately 3 years)'}, {'measure': 'Percentage of Participants Who Achieved Complete Response (CR) + Partial Response (PR) (Tumor Response Rate) - by Independent Radiology Review', 'description': 'Overall tumor response is CR + PR assessed according to Cheson criteria. CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion). PR: a \\>=50 percent decrease in sum of the product of the diameters of index lesion(s), with at least stable disease in all other evaluable disease. Statistical analysis shows difference of overall response rates (siltuximab+best supportive care \\[BSC\\] minus Placebo+BSC).', 'timeFrame': 'From Day 1 of Cycle 1 until the date when durable tumour and symptomatic response is achieved, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years)'}, {'measure': 'Median Duration of Tumor Response - by Independent Radiology Review', 'description': 'Duration of tumor response is defined as time from first documentation of tumor response to tumor progression. Tumour response is complete response (CR) + partial response (PR) as assessed according to Cheson criteria. CR: complete disappearance of all measurable and evaluable disease (eg, pleural effusion). PR: a \\>=50 percent decrease in sum of the product of the diameters of index lesion(s), with at least stable disease in all other evaluable disease. Statistical analysis shows difference of overall response rates (siltuximab+best supportive care \\[BSC\\] minus Placebo+BSC).', 'timeFrame': 'From the date when tumour response is achieved until tumour progression, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years)'}, {'measure': 'Time to Treatment Failure', 'description': ""Time to treatment failure was defined as the time from randomization until the participant fails treatment. Treatment failure was defined as any of the following: a sustained increase from baseline in disease related symptoms \\>=Grade 2 persisting for at least 3 weeks despite best supportive care (BSC); onset of any new disease related Grade 3 or higher symptom despite BSC; sustained (ie, at least 3 weeks) deterioration in performance status (increase from baseline in Eastern Cooperative Oncology Group Performance Status by more than 1 point) despite BSC; radiologic progression, as measured by modified Cheson criteria; Initiation of any other therapy intended to treat multicentric Castleman's disease ie, prohibited treatments. Statistical analysis shows difference in treatment failure rate (siltuximab+BSC minus Placebo+BSC)."", 'timeFrame': 'From the date of randomization until a participant fails treatment, as assessed up to 48 weeks after the last participant started study treatment (approximately 3 years), whichever occurred earlier'}, {'measure': 'Percentage of Participants Who Achieved Greater Than or Equal to (>=) 15 Gram Per Liter (g/L) Hemoglobin at Week 13 (Hemoglobin Response Rate)', 'description': 'Hemoglobin response rate is defined as percentage of participants who achieved \\>= 15 g/L hemoglobin at Week 13.', 'timeFrame': 'Week 13'}, {'measure': 'Percentage of Participants Who Achieved >= 20 g/L Hemoglobin at Week 13 (Hemoglobin Response Rate)', 'description': 'Hemoglobin response rate is defined as percentage of participants who achieved \\>= 20 g/L hemoglobin at Week 13.', 'timeFrame': 'Week 13'}, {'measure': 'Percentage of Participants Who Discontinued Corticosteroids', 'description': 'Percentage of participants who discontinued corticosteroids during blinded treatment period and who were dependent on corticosteroids at baseline (Day 1 of Cycle 1).', 'timeFrame': 'From Day 1 of Cycle 1 until 48 weeks after the after the last participant started study treatment (approximately 3 years)'}, {'measure': '6-year Survival Rate', 'description': 'Overall survival was defined as percent chance of survival of participants who were still alive at 6 years from time of first study treatment was analyzed.', 'timeFrame': 'until 6 years'}, {'measure': ""Median Time Required to Achieve >=1 Point Decrease in the Multicentric Castleman's Disease Symptom Scale (MCD-SS) Score From Baseline"", 'description': 'A patient-reported symptom scale. Symptom presence/absence and severity are noted on an anchor-based numeric scale. Scores range from 1 (very mild) to 5 (very severe).', 'timeFrame': 'From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)'}, {'measure': 'Median Time Required to Achieve >=3-point Increase in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scores From Baseline', 'description': 'The FACIT-F, a 13-item instrument, was designed to measure patient-reported fatigue. It is one of the suite of FACIT instruments developed for outcomes in cancer. Concepts measured in the scale include tiredness, weakness, and difficulty conducting usual functional activities or social interaction due to fatigue. Response options range from ""not at all"" (0) to ""very much"" (4), and yield a summary score. Total FACIT-F score is the sum of 13 items, ranging from 0 (not at all) to 52 (very much). Higher scores represent better outcomes.', 'timeFrame': 'From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)'}, {'measure': 'Median Time Required to Achieve >=5-point Increase in the Short-Form-36 (SF-36) Physical Component Summary (PCS) Scores From Baseline', 'description': 'SF-36 is a questionnaire and PCS is a part of subscale assessing physical functioning, role-physical, bodily pain, and general health. The scores range from 0 (worst score) to 100 (best score), with a higher score indicating better quality of life.', 'timeFrame': 'From Day 1 of Cycle 1 (baseline) until 48 weeks after the last participant started study treatment (approximately 3 years)'}]",12,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,79.0,ACTUAL,2025-09-01T16:18:13.428769,v2_robust,True,True,True,False,False,
NCT04550936,Patterns of Real-World Isavuconazole Use - a Study of Patients With Mucormycosis or Invasive Aspergillosis,"Patterns of Real-World Isavuconazole Use, Effectiveness, Safety, and Healthcare Resource Utilization-a Retrospective Chart Review Study of Patients With Mucormycosis or Invasive Aspergillosis (PRISMA)",Isavuconazole,"['Isavuconazole', 'Cresemba']",2,OBSERVATIONAL,[],,,Invasive Aspergillosis,"['Invasive Aspergillosis', 'Mucormycosis']",[],COMPLETED,,2021-03-10,2023-12-23,"[{'measure': 'Proportion of patients and their respective clinical outcomes of treatment with isavuconazole', 'description': 'overall response, including clinical response, mycological response, radiological response, and mortality', 'timeFrame': 'up to 6 months post-index'}, {'measure': 'Proportion of patients and their respective safety outcomes of treatment with isavuconazole', 'description': 'treatment related AEs and SAEs', 'timeFrame': 'up to 6 months post-index'}]","[{'measure': 'Proportion of patients for each indication and usage pattern of isavuconazole', 'description': 'formulation, dosage (loading and maintenance), duration, treatment changes (including dosage adjustments, switching, and discontinuation), and concomitant medication', 'timeFrame': 'up to 6 months post-index'}, {'measure': 'Proportion of patients and their respective healthcare resource utilization after treatment with isavuconazole', 'description': 'length of stay \\[LOS\\], emergency room \\[ER\\] visits, intensive care unit \\[ICU\\] visits and LOS, inpatient hospitalizations, and planned and unplanned outpatient visits', 'timeFrame': 'up to 6 months post-index'}]",4,18 Years,,ALL,False,Pfizer,INDUSTRY,0,307.0,ACTUAL,2025-09-01T16:18:13.428861,v2_robust,False,True,True,False,True,
NCT02556411,Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS),Comparison of E/P Therapy in Continuous Regimen Versus Combination of LNG-IUS Plus E/P,"LNG-IUS 13,5 mg Levonorgestrel","['LNG-IUS 13,5 mg Levonorgestrel', 'Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg']",2,INTERVENTIONAL,['NA'],,,Adenomyosis,"['Adenomyosis', 'Chronic Pelvic Pain']",[],UNKNOWN,,2021-06-01,2022-06-01,"[{'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 45 days of treatment'}]","[{'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 90 days of treatment'}, {'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 180 days of treatment'}, {'measure': 'Change of Pelvic pain as measured by visual analogue scale', 'timeFrame': 'Change from baseline pelvic pain at 365 days of treatment'}, {'measure': 'Quality of sexual life', 'timeFrame': 'Cases were administered and fulfilled the questionnaires at the moment of diagnosis of adenomyosis up to 4weeks; Change from baseline were evaluated 45 days after begin of treatment'}]",5,18 Years,40 Years,FEMALE,True,University of Cagliari,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:13.428881,v2_robust,True,True,False,False,False,
NCT00941811,Immunevasion of Human Papillomavirus (HPV) in Vulvar Intraepithelial Neoplasia 2/3 and Anogenital Warts and Efficiency and Mechanisms of Imiquimod Treatment,"An Explorative, Single Center and Controlled Study to Analyze the Immune Escape Mechanisms of HPV-associated Lesions and to Evaluate the Efficiency and Mechanisms of Imiquimod Treatment of Vulvar Intraepithelial Neoplasias 2/3 (VIN) and Anogenital Warts",Imiquimod,"['Imiquimod', 'Aldara']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,HPV,['HPV'],[],COMPLETED,,2008-12,2010-05,"[{'measure': 'Analysis of Cellular and Molecular Mechanisms of Imiquimod tretament and differences in HPV afeected and non affected tissue at cellular and molecular level', 'timeFrame': '16 weeks'}]","[{'measure': 'Proportion of histological and clinical response to therapy after 16 weeks of IMQ therapy', 'timeFrame': '16 weeks'}]",2,18 Years,,FEMALE,True,Medical University of Vienna,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:13.428894,v2_robust,True,True,True,False,False,
NCT00239811,Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients,"A Two-year Extension to a One-year, Multicenter, Partially Blinded, Double Dummy, Randomized Study to Evaluate the Efficacy and Safety of FTY720 Combined With Reduced-dose or Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids Versus Mycophenolate Mofetil Combined With Full-dose Cyclosporine, USP [Modified] (Novartis Brand) and Corticosteroids, in de Novo Adult Renal Transplant Recipients",FTY720,['FTY720'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Renal Transplantation,['Renal Transplantation'],"['Transplantation, kidney, and organ transplant.']",COMPLETED,,2004-04,,"[{'measure': 'IA, IB, IIA, IIB, III, or humoral rejection diagnosed by biopsy according to Banff 97 criteria within 36 months post transplant'}, {'measure': 'Permanent resumption of dialysis within 36 months post transplant'}, {'measure': 'Surgical removal of graft within 36 months post transplant'}, {'measure': 'Death within 36 months post transplant'}, {'measure': 'Withdrawal of consent, death, or lost to follow up within 36 months post transplant'}, {'measure': 'Serum creatinine, calculated creatinine clearance and urine-protein/creatinine ratio at Months 18, 24, 30 and 36'}, {'measure': 'FEV1 , FVC, FEV1/FVC, DLCO and FEF 25%-75% at Months 18, 24, 30 and 36'}, {'measure': 'Absolute lymphocyte count at Months 18, 24, 30 and 36.'}]","[{'measure': 'Physical examinations at Months 18, 24, 30 and 36'}, {'measure': 'Vital signs at Months 18, 24, 30 and 36'}, {'measure': 'Electrocardiogram at Months 24 and 36'}, {'measure': 'Chest X-ray Months 24 and 36'}, {'measure': 'Safety laboratory tests 18, 24, 30 and 36'}, {'measure': 'Ophthalmic evaluations 18, 24, 30 and 36'}, {'measure': 'AEs and SAEs'}, {'measure': 'FTY720/CsA levels at Months 18, 24, 30 and 36'}]",16,18 Years,65 Years,ALL,,Novartis Pharmaceuticals,INDUSTRY,0,684.0,,2025-09-01T16:18:13.428904,v2_robust,True,True,True,False,True,
NCT00482911,"Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma","A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid™), Oral Sunitinib (Sutent™) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma",cyclophosphamide,"['sunitinib malate', 'cyclophosphamide', 'cytoxan', 'lenalidomide', 'revlimid', 'sutent']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Intraocular Melanoma,"['Intraocular Melanoma', 'Malignant Conjunctival Neoplasm']","['recurrent intraocular melanoma', 'metastatic intraocular melanoma', 'ciliary body and choroid melanoma, medium/large size', 'extraocular extension melanoma', 'iris melanoma', 'conjunctival melanoma']",TERMINATED,Investigator left the institute.,2007-04,2009-04,"[{'measure': 'Response Rate (Complete and Partial Response)', 'description': 'Response was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST). Complete response is the disappearance of all target lesions. Partial response is at least a 30% decrease in the sum of the longest diameter (LD) of target lesions taking as reference the baseline sum LD.', 'timeFrame': '2 years'}, {'measure': 'Toxicity', 'description': 'Here is the number of participants with adverse events. For a detailed list of adverse events see the adverse event module.', 'timeFrame': '16 months'}, {'measure': 'Overall Survival', 'description': 'Time from date of on study to the date of death from any cause or last follow up', 'timeFrame': 'up to 16 months'}]","[{'measure': 'Progression Free Survival', 'description': 'Proportion of patients who progress or die after the start of treatment', 'timeFrame': 'up to 16 months'}, {'measure': 'Changes in Gene Expression, Methylation and Protein Modification', 'description': 'Ribonucleic acid (RNA), deoxyribonucleic acid (DNA) and protein obtained from blood, urine and/or tissue was to be evaluated for changes in gene expression, methylation and/or protein modification.', 'timeFrame': 'Baseline and end of treatment course 1 and 2, approximately 42 days'}]",5,18 Years,,ALL,False,National Institutes of Health Clinical Center (CC),NIH,1,12.0,ACTUAL,2025-09-01T16:18:13.428965,v2_robust,True,True,False,True,True,Investigator left the institute.
NCT04004611,A Study of Mirikizumab (LY3074828) in Children and Teenagers With Ulcerative Colitis (UC),"A Multicenter, Open-Label PK Study of Mirikizumab in Pediatric Patients With Moderately to Severely Active Ulcerative Colitis",Mirikizumab,"['Mirikizumab', 'LY3074828']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ulcerative Colitis,['Ulcerative Colitis'],"['Interleukin-23 (IL-23) antibody', 'IL-23p19', 'Pediatric']",COMPLETED,,2020-05-18,2023-03-15,"[{'measure': 'Pharmacokinetics (PK): Clearance of Mirikizumab', 'description': 'Clearance of mirikizumab was evaluated. The PK of mirikizumab is characterized at interim analysis points using mixed-effect (population PK) modelling approaches using the available induction and maintenance mirikizumab concentration data.', 'timeFrame': 'Predose on week 4, 8, 12,16, 24, 36, 52 and post dose on week 0 and 8'}]","[{'measure': 'Percentage of Participants in Clinical Remission', 'description': ""Clinical remission at week 52 is defined as achieving a 9-point modified Mayo score (MMS) for rectal bleeding (RB) = 0, stool frequency (SF) = 0 or 1 and endoscopy (ES) = 0 or 1 (excluding friability). The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding,ulceration."", 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants in Clinical Response', 'description': ""Clinical response at week 52 is defined as a decrease in the 9-point modified Mayo score (MMS) \\[rectal bleeding, stool frequency and the endoscopic findings\\] inclusive of ≥2 points and ≥30% from baseline with either a decrease of rectal bleeding subscore of ≥1 or rectal bleeding subscore of 0 or 1. The MMS is a composite score of ulcerative colitis disease activity calculated as the sum of three subscores: SF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal); RB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed); ES subscore, based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration)"", 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants Who Are in MMS Clinical Remission Without the Use of Corticosteroids', 'description': 'Corticosteroid-free clinical remission was defined as an SF subscore = 0 or 1, RB subscore = 0, ES ≤ 1 (excluding friability), and have not received corticosteroids for ≥ 12 weeks in the 52-Week Treatment Period. Each component subscore ranged from 0 to 3 and total score range of the MMS was from 0 to 9, with higher scores indicating more severe disease.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants in Clinical Remission Based on the Pediatric Ulcerative Colitis Activity Index (PUCAI)', 'description': ""The PUCAI is a clinician-administered, 6-item questionnaire that measures: abdominal pain; RB; stool consistency; number of stools; nocturnal stools; and activity level. For PUCAI score all items are answered as an average over the 'past 2 days'. A total disease activity score is calculated from 0 to 85, with Severe 65-85; Moderate:35-60; Mild:10-30, and None:\\<10. The clinician will record the participant or caregiver/legal guardian responses for the PUCAI electronically as source data in the tablet device at appropriate visits. PUCAI clinical remission is defined as a PUCAI score of \\<10 points."", 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants in Clinical Response Based on the PUCAI', 'description': 'PUCAI clinical response is defined as a reduction in baseline PUCAI score of ≥20 points.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants in Endoscopic Remission', 'description': 'Endoscopic remission at week 52 is defined as achieving a Mayo endoscopic subscore of 0 or 1 (excluding friability) at Week 52. ES subscore is based on colonoscopy or sigmoidoscopy and scored from 0 (normal or inactive disease) to 3 (severe disease, spontaneous bleeding, ulceration).', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants in Symptomatic Remission', 'description': ""Symptomatic remission at week 52 is defined as a Mayo score for RB=0, SF=0 or 1 with ≥ 1 point decrease from baseline.\n\nSF subscore, based on the participant's diary and scored from 0 (normal number of stools) to 3 (5 or more stools than normal).\n\nRB subscore, based on the participant's diary and scored from 0 (no blood seen) to 3 (blood alone passed)."", 'timeFrame': 'Week 52'}, {'measure': 'Height Velocity (in Centimeters/Year)', 'description': 'Observed height velocity by gender and age group was calculated. Age groups for which this was summarized were 2 to \\<8, 8 to \\<12, and 12 to \\<18. Observed height velocity by gender and age group was calculated at baseline according to the following formula: (Present Height \\[cm\\] - Previous Height \\[cm\\])/Interval (months) Between Measurements × 12.', 'timeFrame': 'Week 52'}, {'measure': 'Change From Baseline in Body Weight', 'description': 'Change from Baseline in body weight by gender and age group was calculated.', 'timeFrame': 'Baseline, Week 52'}, {'measure': 'Percentage of Participants With Histologic-Endoscopic Mucosal Remission', 'description': 'Histologic-endoscopic mucosal remission is defined as achieving both histologic remission and endoscopic remission. Histologic remission is defined as Geboes histological subscores of 0 for parameters: 2B (neutrophils in lamina propria), 3 (neutrophils in epithelium), 4 (crypt destruction), and 5 (erosion or ulceration).', 'timeFrame': 'Week 52'}, {'measure': 'Change From Baseline in 7-day Average of Abdominal Pain Numeric Rating Scale (NRS) Score at Week 12', 'description': 'The Abdominal Pain NRS is a single participant-reported item that measures the ""worst abdominal pain in the past 24 hours"" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \\< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant\'s Abdominal Pain NRS.', 'timeFrame': 'Baseline, Week 12'}, {'measure': 'Change From Baseline in 7-day Average of Abdominal Pain NRS Score at Week 52', 'description': 'The Abdominal Pain NRS is a single participant-reported item that measures the ""worst abdominal pain in the past 24 hours"" using a 6-point scale ranging from 0 (no pain) to 5 (worst possible pain) for 8-11 years old, and 11-point NRS ranging from 0 (no pain) to 10 (worst possible pain) for children \\< 8 years old as completed by a caregiver and those 12-17 years old. Abdominal Pain NRS Score is calculated by averaging data from all available daily diary entries of abdominal pain NRS for a 7 day period. A negative change from baseline indicates improvement in the participant\'s Abdominal Pain NRS.', 'timeFrame': 'Baseline, Week 52'}]",13,2 Years,17 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:13.429003,v2_robust,True,True,True,False,False,
NCT01326611,Efficacy of Clarithromycin Treatment in Prevention of Chronic Lung Disease in Premature Infants,,Clarithromycin,"['Dextrose', 'Clarithromycin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Lung Disease,['Chronic Lung Disease'],"['Chronic lung disease', 'Clarithromycin', 'Ureaplasma urealyticum']",COMPLETED,,2008-05,2010-12,"[{'measure': 'To evaluate the efficacy of clarithromycin in eradication of Ureaplasma urealyticum from premature nasopharynges', 'description': 'Efficacy of clarithromycin in eradication of Ureaplasma and incidence of CLD were the major outcomes of the study. Nasopharyngeal swabs for Ureaplasma were taken in postnatal first 3 days and on the 12th day only in culture positive infants, transported to the laboratory and cultured for Uu immediately.', 'timeFrame': '12 days after treatment by clarithromycin'}]","[{'measure': 'To evaluate the efficacy of clarithromycin in prevention of Chronic lung disease in premature infants with birthweight <1250 g and have Ureaplasma urealyticum colonization.', 'description': 'Efficacy of clarithromycin in eradication of Ureaplasma urealyticum and incidence of chronic lung disease were the major outcomes of the study. Chronic lung disease of newborn was defined as a persistent oxygen requirement at 36 weeks post menstrual age or death.', 'timeFrame': 'From first day of inclusion of study to at postpartum 36th week of day'}]",2,1 Hour,2 Days,ALL,False,Zekai Tahir Burak Women's Health Research and Education Hospital,OTHER,0,273.0,ACTUAL,2025-09-01T16:18:13.429146,v2_robust,True,True,True,False,False,
NCT02039011,Ultra-long Acting Bronchodilator Therapy in Asthmatics,Proof of Concept Study to Evaluate Single and Chronic Dosing Effects of Ultra-long Acting Bronchodilator Therapy on Mannitol Challenge in Asthmatic Patients Taking Inhaled Corticosteroids,Indacaterol,"['Indacaterol', 'Indacaterol and tiotropium']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Asthma,['Asthma'],"['Asthma', 'Long acting beta-agonists', 'Long acting muscarinic antagonists', 'Mannitol challenge']",COMPLETED,,2014-02,2016-07,"[{'measure': 'Change in provocation dose of mannitol causing 15% drop in forced expiratory volume in 1 second (PD15) between single and chronic dosing of ultra-long acting bronchodilator therapy', 'timeFrame': '2 to 4 weeks'}]","[{'measure': 'Mannitol Response-dose Ratio (RDR)', 'timeFrame': '2 to 4 weeks'}, {'measure': 'Salbutamol recovery time following mannitol challenge', 'timeFrame': '2 to 4 weeks'}, {'measure': 'Domiciliary peak expiratory flow (PEF)', 'timeFrame': '2 to 4 weeks'}, {'measure': 'Trough forced expiratory volume in 1 second (FEV1)', 'timeFrame': '2 to 4 weeks'}, {'measure': 'Exhaled nitric oxide (FeNO)', 'timeFrame': '2 to 4 weeks'}, {'measure': 'Trough impulse oscillometry (IOS)', 'timeFrame': '2 to 4 weeks'}, {'measure': 'Asthma Control Questionnaire (ACQ)', 'timeFrame': '2 to 4 weeks'}]",8,16 Years,,ALL,False,University of Dundee,OTHER,1,14.0,ACTUAL,2025-09-01T16:18:13.429238,v2_robust,True,True,True,False,False,
NCT04512911,Comparison of Ventricular Tachycardia Ablation Strategies in Patients With Ischemic Cardiomyopathy,Endocardial-Epicardial Radiofrequency Ablation of Ventricular Tachycardia in Patients With Ischemic Cardiomyopathy,Antiarrhythmic medications,['Antiarrhythmic medications'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Ventricular Tachycardia,['Ventricular Tachycardia'],"['Ventricular tachycardia', 'Catheter ablation', 'Epicardial ablation', 'arrhythmia recurrence']",WITHDRAWN,IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be reinitiated via progress report. No enrollment has taken place.,2023-01,2023-01-23,"[{'measure': 'Freedom from documented VT episodes', 'description': 'Freedom from documented VT episodes (greater than 30 seconds) at 12 months after the first ablation procedure or on antiarrhythmic medication.', 'timeFrame': '12 months'}, {'measure': 'Freedom from documented VT episodes after second intervention', 'description': 'Freedom from documented VT episodes (greater than 30 seconds) at 12 months after the second ablation procedure or on two antiarrhythmics combined.', 'timeFrame': '12 months after second intervention'}]","[{'measure': 'Incidence of peri-procedural and 12-month post procedural complications,', 'description': 'These complications include but not limited to ischemic stroke, cardiac perforation, rehospitalization, and death.', 'timeFrame': '12 months'}, {'measure': 'Procedure duration and fluoroscopy time', 'description': 'Procedure duration and fluoroscopy time', 'timeFrame': 'Up to 4 hours (During ablation procedure)'}, {'measure': 'Number of repeat procedures', 'description': 'Number of repeat ablations', 'timeFrame': '12, 24 months'}, {'measure': 'Cost-effectiveness analysis', 'description': ""The CEA will examine the cost of health care resources and health outcomes from the ablation procedure to 1-year postoperatively. The costs will include all health care utilization during this time. Health care utilization, and associated costs, related to the patients' condition, the procedure and adverse events will be the basis of a sensitivity analysis."", 'timeFrame': '12 months'}, {'measure': 'Long-term follow-up to evaluate freedom of documented VT episodes', 'description': 'Long-term follow-up at 24 and 60 months to evaluate freedom of documented VT episodes (\\>30 seconds)', 'timeFrame': '24 and 60 months'}]",7,18 Years,99 Years,ALL,False,Montefiore Medical Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:13.429253,v2_robust,True,True,False,True,True,IRB approval expired 1/23/2023 and eclipsed the 6 month institutional window where study can be reinitiated via progress report. No enrollment has taken place.
NCT03176771,Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia,"A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)",MT-5199,"['MT-5199', 'Placebo']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Tardive Dyskinesia,['Tardive Dyskinesia'],[],COMPLETED,,2017-06-21,2020-09-29,"[{'measure': 'Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6', 'description': 'Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.', 'timeFrame': 'Baseline and Week 6'}]","[{'measure': 'Percentage of Subjects With a ≥50% Improvement From Baseline in the AIMS Total Score (Central Assessment) at Week 6 (AIMS Responder)', 'description': 'Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)', 'timeFrame': 'Week 6'}, {'measure': 'Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Site Assessment) at Week 6', 'description': 'Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded site AIMS raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.', 'timeFrame': 'Baseline and Week 6'}, {'measure': 'Clinical Global Impression of Change - TD (CGI-TD) Score at Week 6', 'description': ""Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse)."", 'timeFrame': 'Week 6'}]",4,20 Years,85 Years,ALL,False,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,0,256.0,ACTUAL,2025-09-01T16:18:13.429274,v2_robust,True,True,True,False,False,
NCT03851471,Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma,"An Open-label, Single-institution, Non-randomized, Single-arm, Pilot Study of Jiu-wei-zhen-xiao Granule for the Treatment in Patients With Advanced Hepatocellular Carcinoma",Jiu-wei-zhen-xiao Granule,['Jiu-wei-zhen-xiao Granule'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],COMPLETED,,2019-04-07,2021-03-30,"[{'measure': 'Overall Survival', 'description': 'Overall Survival (OS) is defined as the percentage of people in a group who are alive after the 12-week use of drug.', 'timeFrame': 'Up to 12 weeks'}]","[{'measure': 'Progression-Free Survival', 'description': 'Progression-free survival (PFS) will be defined as the elapsed time from the first date of study treatment until documented disease progression (as per RECIST 1.1) or death from any cause, whichever is earlier. For patients who remain alive without progression, follow-up time will be censored at the date of last disease assessment .', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, 12 weeks'}, {'measure': 'European Organization for Reasearch and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) (Chinese version, Version 3.0)', 'description': 'EORTC QLQ-C30 is a 30-item questionnaire composed of multi-item scales and single items that reflect the multidimensionality of the QoL construct. It includes five functional scales (physical, role, cognitive, emotional, and social), three symptom scales (fatigue, pain, and nausea/vomiting), and a global health status/QoL scale. The remaining single items assess additional symptoms commonly reported by cancer patients (dyspnea, appetite loss, sleep disturbance, constipation, and diarrhea), as well as the perceived financial impact of the disease and treatment.', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, 12 weeks'}, {'measure': 'The level of the liver function', 'description': 'The biochemical indicators of the liver function include alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin(TBiL), direct bilirubin (DBiL), albumin (ALB), alkaline phosphatase (AKP), gamma-Glutamyltransferase (γ-GGT).', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, 12 weeks'}, {'measure': 'The level of AFP', 'description': 'AFP is the abbreviation of alpha fetoprotein, which could be the progress of the primary hepatocellular carcinoma', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, 12 weeks'}, {'measure': 'The level of coagulation function', 'description': 'The biochemical indicators of the coagulation function include prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (FIB).', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': 'The size of solid tumors', 'description': 'The size of solid tumors is measured by a professional film reader using MRI/CT.', 'timeFrame': 'Baseline, 12 weeks'}, {'measure': '""Du-tan-yu-jie Zheng"" symptoms score in Chinese medicine', 'description': '""Du-tan-yu-jie Zheng"" is a series of common symptoms in HCC，including distending pain in the hypochondrium,jaundice, a lump below the costal region,weak and lassitude, poor appetite,abdominal distension and fullness,dizziness and tinnitus, bitter or dry mouth,constipation, urinary yellow,upset and irritable,red or dark red tongue, stringy or rapid pulse', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, 12 weeks'}, {'measure': '10cm-VAS of the pain', 'description': 'The 10cm Visual Analogue Scale (VAS) of the pain is most commonly anchored by ""no pain"" (score of 0) and ""pain as bad as it could be"" or ""worst imaginable pain"" (score of 10) .', 'timeFrame': 'Baseline, 4 weeks, 8 weeks, 12 weeks'}]",9,18 Years,75 Years,ALL,False,Zhong Wang,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:13.429299,v2_robust,True,True,True,False,False,
NCT00961571,Sunitinib and Capecitabine for First Line Colon Cancer,"A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer",sunitinib and capecitabine,"['Capecitabine, Xeloda', 'Sunitinib, NSC 736511, Sutent', 'sunitinib and capecitabine']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Colorectal Cancer,['Metastatic Colorectal Cancer'],"['colorectal cancer', 'sunitinib', 'capecitabine']",TERMINATED,Unanticipated side effects and futility,2009-08,2011-03,"[{'measure': 'Progression-free Survival', 'description': ""Progression-free survival (PFS) will be measured as the number of months between each patient's enrollment and his/her date of progression or date of death."", 'timeFrame': '36 months'}]",[],1,18 Years,,ALL,False,Georgetown University,OTHER,1,50.0,ACTUAL,2025-09-01T16:18:13.429370,v2_robust,True,True,False,True,False,Unanticipated side effects and futility
NCT00706771,Bicarbonate and Lipocalin in Systemic Inflammatory Response Syndrome (SIRS) Study,"A Randomized Double-blind Controlled Pilot Feasibility and Safety Trial of NGAL-directed Sodium Bicarbonate to Protect Renal Function in Patients With the Systemic Inflammatory Response Syndrome, Oliguria and Elevated Lipocalin Levels",Sodium bicarbonate,"['Sodium bicarbonate', 'Sodium chloride']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Systemic Inflammatory Response Syndrome,"['Systemic Inflammatory Response Syndrome', 'Oliguria', 'Renal Impairment']","['sodium bicarbonate', 'serum neutrophil gelatinase associated lipocalin', 'renal impairment', 'renal failure', 'systemic inflammatory response syndrome', 'defined', 'by serum NGAL ≥ 100 ng/ml.']",COMPLETED,,2010-02,2012-09,"[{'measure': 'The ability to deliver the study protocol safely and rapidly with a trend to improved renal outcomes', 'timeFrame': '28 days'}]","[{'measure': 'Attenuation in lipocalin levels', 'timeFrame': '28 days'}, {'measure': 'Decrease in the magnitude in serum creatinine rise', 'timeFrame': '28 days'}, {'measure': 'Ability to deliver the study protocol without significant biochemical side effects', 'timeFrame': '28 days'}]",4,18 Years,,ALL,False,Austin Health,OTHER_GOV,0,70.0,ESTIMATED,2025-09-01T16:18:13.429379,v2_robust,True,True,True,False,False,
NCT00641771,4-Week Study to Assess the Effect of Alendronate and Vitamin D3 Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women (0217A-230),"A Double-Blind, Randomized, Placebo-Controlled, Multicenter 4-Week Study to Assess the Effect of Alendronate 70 mg and Vitamin D3 2800 IU Once Weekly on Fractional Calcium Absorption in Postmenopausal Osteoporotic Women",alendronate sodium (+) cholecalciferol,"['alendronate sodium (+) cholecalciferol', 'MK0217A', 'Comparator: Placebo (unspecified)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Osteoporosis,['Osteoporosis'],[],COMPLETED,,2004-05,2005-08,"[{'measure': 'To compare change in fractional calcium absorption following administration of MK0217A relative to matching placebo, in postmenopausal women with osteoporosis', 'timeFrame': '4 Weeks'}]",[],1,50 Years,80 Years,FEMALE,False,Organon and Co,INDUSTRY,0,56.0,ACTUAL,2025-09-01T16:18:13.429450,v2_robust,True,True,True,False,False,
NCT03733171,Platelet Rich Plasma in Bleeding Peptic Ulcer,Role of Platelet Rich Plasma in the Treatment of Actively Bleeding Peptic Ulcer,PLATELET RICH PLASMA,"['PRP', 'diluted epinephrine', 'Hemostasis', 'PLATELET RICH PLASMA']",4,INTERVENTIONAL,['NA'],,,Bleeding Ulcer,['Bleeding Ulcer'],['platelet rich plasma'],UNKNOWN,,2018-09-20,2019-06-30,"[{'measure': 'bleeding', 'description': 'control of peptic ulcer bleeding', 'timeFrame': '3 months'}]","[{'measure': 'improved iron indices', 'description': 'imroved complete blood count element', 'timeFrame': '3 months'}]",2,18 Years,70 Years,ALL,False,Zagazig University,OTHER_GOV,0,80.0,ESTIMATED,2025-09-01T16:18:13.429457,v2_robust,True,True,False,False,False,
NCT03961971,Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM,A Phase I Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM,MBG453,"['stereotactic radiosurgery', 'MBG453', 'spartalizumab']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Glioblastoma Multiforme,['Glioblastoma Multiforme'],['Immunotherapy'],ACTIVE_NOT_RECRUITING,,2020-02-18,2025-09,"[{'measure': 'Number of participants with serious adverse events (SAE) graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 5.0', 'description': 'Number of participants experiencing SAEs, as defined by NCI CTC v5.0', 'timeFrame': 'Up to 12 weeks after first dose of study treatment'}]","[{'measure': 'Proportion of participants who experience grade 3 or higher toxicity, graded according to the NCI CTC v5.0', 'description': 'Proportion of participants who experience grade 3 or higher toxicity, graded according to the NCI CTC v5.0', 'timeFrame': 'Up to 100 days after completion of study treatment'}, {'measure': 'Progression-free survival', 'description': 'Progression-free survival estimated using the Kaplan-Meier method. Progression as defined by Response Assessment in Neuro-oncology (RANO) criteria: Complete Response (CR)= no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; Partial Response (PR)= ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Stable Disease (SD)= \\<50% reduction to \\<25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Progressive Disease (PD)= ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.', 'timeFrame': 'From the date of initial diagnosis (at surgery) until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}, {'measure': 'Overall survival', 'description': 'Overall survival as estimated using the Kaplan-Meier method.', 'timeFrame': 'From the date of initial diagnosis until the date of death from any cause assessed up to 24 months'}, {'measure': 'Objective Response', 'description': 'Proportion of participants who have objective PR or CR during the course of treatment and a measurable disease indicated in baseline scan. Progression is defined by Response Assessment in Neuro-oncology (RANO) criteria: Complete Response (CR)= no change in size of T1-gadolinium-enhancing (T1-Gd+) disease, stable or reduced T2/FLAIR signal, no new lesion, no corticosteroid use, and stable or improved clinical status; Partial Response (PR)= ≥50% change in size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Stable Disease (SD)= \\<50% reduction to \\<25% increase size of T1-Gd+ disease, stable or reduced T2/FLAIR signal, no new lesion, stable or reduced corticosteroid use, and stable or improved clinical status; Progressive Disease (PD)= ≥25% increase size of T1-Gd+ disease, or increased T2/FLAIR signal, or presence of new lesion, or worsening clinical status.', 'timeFrame': 'From date of baseline scan until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months'}]",5,18 Years,,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,1,16.0,ACTUAL,2025-09-01T16:18:13.429532,v2_robust,True,True,False,False,True,
NCT07014371,Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA),"Alternative vs. Once-Daily Oral Iron Supplementation in Iron Deficiency Anemia (IDA): A Multicenter, Randomized, Open-Label, Non-Inferiority Trial",Ferrous Fumarate Oral Tablet,"['Ferrous Fumarate 200 mg tablet', 'Ferrous Fumarate Oral Tablet', 'Oral iron supplement']",3,INTERVENTIONAL,['NA'],,,Iron Deficiency Anemia Treatment,['Iron Deficiency Anemia Treatment'],"['Iron deficiency anemia', 'Ferrous fumarate', 'Alternate day dosing', 'Hemoglobin']",RECRUITING,,2025-06-09,2027-12-31,"[{'measure': 'Hemoglobin Level at Week 8 After Oral Iron Supplementation', 'description': 'Hemoglobin concentration (g/dL) measured at Week 8 following oral ferrous fumarate supplementation. Participants are stratified by sex and baseline Hb level. Comparison between once-daily and alternate-day dosing groups will be analyzed using a linear mixed-effects model.', 'timeFrame': '8 weeks'}]","[{'measure': 'Change in Reticulocyte Count at Weeks 4 and 8', 'description': 'Mean change in reticulocyte count (%) from baseline to Week 4 and Week 8.', 'timeFrame': '4 and 8 weeks'}, {'measure': 'Change in Serum Ferritin at Weeks 4 and 8', 'description': 'Mean change in serum ferritin concentration (ng/mL) from baseline to Week 4 and Week 8.', 'timeFrame': '4 and 8 weeks'}, {'measure': 'Adverse Effects of Ferrous Fumarate', 'description': 'Incidence and type of adverse effects experienced by participants during treatment with ferrous fumarate oral tablets.', 'timeFrame': 'During the 8-week treatment period'}]",4,20 Years,,ALL,False,Phramongkutklao College of Medicine and Hospital,OTHER,0,114.0,ESTIMATED,2025-09-01T16:18:13.429614,v2_robust,True,True,False,False,True,
NCT02204371,Evaluation of Pazopanib on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia,A Phase II Study to Evaluate the Effects of up to 12 Weeks of Pazopanib Dosing on Bleeding in Subjects With Hereditary Haemorrhagic Telangiectasia,Pazopanib,"['Pazopanib', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Telangiectasia, Hereditary Hemorrhagic","['Telangiectasia, Hereditary Hemorrhagic']","['Pazopanib', 'hereditary haemorrhagic telangiectasia', 'bleeding']",TERMINATED,The study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug.,2015-02-25,2016-02-10,"[{'measure': 'Change From Baseline in Epistaxis Severity Score at the Indicated Time Points', 'description': 'The Epistaxis (nose bleeding) severity score (ESS) is a 6-item par-reported outcome measure designed to be a uniform epistaxis severity scoring system to assess the effectiveness of specific treatments on HHT-related epistaxis. Four questions document epistaxis frequency, duration, intensity and need for treatment, whereas two additional questions detail the presence of anemia and if a par has required a blood transfusion as a consequence of their epistaxis. Questions are variably weighted and results are tabulated on a 0-10 scale (0=no disease, 10 = severe disease). The minimum important difference is 0.71. Baseline is the Day1 pre-dose assessment value. Change from Baseline is calculated as the Post dose value at the indicated visit minus the Baseline value. Par were evaluated at Baseline, Treatment period (Weeks 6 and 12) and Follow-up period (Weeks 16, 20, 24 and 28). Only those par available at the indicated timepoints were analysed (specified by n=X in the category titles).', 'timeFrame': 'Baseline, Week 6, Week 12, Week 16, Week 20, Week 24 and Week 28'}, {'measure': 'Change From Baseline in the Average of the Last 3 Hemoglobin Measures in the Dosing Period (Week 9, Week 10.5 and Week 12)', 'description': 'For post-Baseline hemoglobin assessments, average of the last 3 measurements of the dosing period (Weeks 9, 10.5 and 12) was computed. Only pre-transfusion hemoglobin values have been included in the analyses. Baseline hemoglobin value is the average of the last two measurements during the run-in period. . Average of the last two measurements during the run-in period was calculated as sum of the last 2 measured values of hemoglobin divided by 2. Change from Baseline was calculated as the average of the last 3 measured values of hemoglobin minus the Baseline value. Average of the last 3 measurements was calculated as sum of the last 3 measured values of hemoglobin divided by 3. If measurements were missing at one or two of the 3 visits at Weeks 9, 10.5 and 12, then the average was based on the available measurements.', 'timeFrame': 'Baseline, Week 9, Week 10.5 and Week 12'}, {'measure': 'Change From Baseline in Hemoglobin at the Indicated Time Points', 'description': 'Only pre-transfusion hemoglobin values have been included in the analyses. All hemoglobin values that fall within 5 days of packed red blood cells (PRBC) transfusion are considered as post-transfusion values. Baseline hemoglobin value is defined as the average of the last two measurements during the run-in period. Average of the last two measurements during the run-in period was calculated as sum of the last 2 measured values of hemoglobin divided by 2. Change from Baseline was calculated as the Post dose value at the indicated visit minus the Baseline value. Par. were evaluated at Treatment period (Weeks 1.5, 3, 4.5, 6, 7.5, 9, 10.5 and 12) and Follow-up period (Weeks 16, 20, 24 and 28).', 'timeFrame': 'Baseline, Week 1.5, Week 3, Week 4.5, Week 6, Week 7.5, Week 9, Week 10.5, Week 12, Week 16, Week 20, Week 24 and Week 28'}, {'measure': 'Duration of Epistaxis Over the Last 2 Weeks of the Dosing Period and by Time Over the Entire Dosing and Follow-up Period by 2 Week Interval (From Daily Diaries)', 'description': 'Duration of epistaxis based on daily diaries has been reported over Baseline, On-Therapy (OT) to Follow-up (F). Individual participant data from the daily diaries has been reported.', 'timeFrame': 'Over last 2 weeks of the run-in phase and then 2 week intervals throughout treatment period and follow-up period (from daily diaries)'}, {'measure': 'Frequency of Epistaxis Over the Last 2 Weeks of the Dosing Period and by Time Over the Entire Dosing and Follow-up Period by 2 Week Interval (From Daily Diaries)', 'description': 'Frequency of epistaxis based on daily diaries has been reported over Baseline, On-Therapy (OT) to Follow-up (F). Individual participant data from the daily diaries has been reported.', 'timeFrame': 'Over last 2 weeks of the run-in phase and then 2 week intervals throughout treatment period and follow-up period (from daily diaries)'}, {'measure': 'Intensity of Epistaxis Over the Last 2 Weeks of the Dosing Period and by Time Over the Entire Dosing and Follow-up Period by 2 Week Interval (From Daily Diaries)', 'description': 'Intensity of epistaxis based on daily diaries has been reported as total gushing and total non gushing from Baseline, On-Therapy (OT) to Follow-up (F). Individual participant data from the daily diaries has been reported.', 'timeFrame': 'Over last 2 weeks of the run-in phase and then 2 week intervals throughout treatment period and follow-up period (from daily diaries)'}, {'measure': 'Total Iron Intake Over the Last 4 Weeks of the Dosing Period', 'description': 'Total iron intake at Baseline is defined as the sum total of iron intake (oral + intravenous infusion) during the last 4 weeks of run-in period (i.e., Day -28 to Day -1). Total iron intake over the last 4 weeks of run-in and during last 4 weeks of dosing period was listed. Individual participant data has been reported.', 'timeFrame': 'Last 4 weeks of run-in and during last 4 weeks of dosing period'}, {'measure': 'Total Iron Intake Over the Entire Dosing and Follow-up Period by 4 Week Interval', 'description': 'Total iron intake at Baseline is defined as the sum total of iron intake (oral + intravenous infusion) during the last 4 weeks of run-in period (i.e., Day -28 to Day -1). Total iron intake over the entire dosing and follow-up period was listed by 4 week interval. Individual participant data has been reported.', 'timeFrame': 'Last 4 weeks of run-in and during last 4 weeks of dosing period'}, {'measure': 'Total Units of Packed Red Blood Cells (PRBCs) Transfused During the Entire Dosing and Follow-up Period by 4 Week Interval', 'description': 'Baseline PRBC transfused is defined as the number of units of PRBC transfused during the last 4 weeks of run-in period (i.e., Day -28 to Day -1). Total units of PRBCs transfused during the entire dosing and follow-up period was listed by 4 week interval. Individual participant data been reported.', 'timeFrame': 'Over the last 4 weeks of run-in and at 4 week intervals during dosing and follow-up'}]","[{'measure': 'Change From Baseline in the Average of the Last 3 Ferritin Measures in the Dosing Period (Week 9, Week 10.5 and Week 12)', 'description': 'For post-Baseline ferritin assessments, average of the last 3 measurements of the dosing period (Weeks 9, 10.5 and 12) was computed. Only pre-infusion ferritin values have been included in the analyses. Baseline ferritin value is the average of the last two measurements during the run-in period. Average of the last two measurements during the run-in period was calculated as sum of the last 2 measured values of ferritin divided by 2. Change from Baseline was calculated as the average of the last 3 measured values of ferritin minus the Baseline value. Average of the last 3 measurements was calculated as sum of the last 3 measured values of ferritin divided by 3. If measurements were missing at one or two of the 3 visits at Weeks 9, 10.5 and 12, then the average was based on the available measurements.', 'timeFrame': 'Baseline, Week 9, Week 10.5 and Week 12'}, {'measure': 'Change From Baseline in Ferritin at the Indicated Time Points', 'description': 'Only pre-infusion ferritin values have been included in the analyses. All ferritin measurements that fall within 5 days of iron infusion date are considered post-infusion. Baseline ferritin value is defined as the average of the last two measurements during the run-in period. Average of the last two measurements during the run-in period was calculated as sum of the last 2 measured values of ferritin divided by 2. Change from Baseline is calculated as the difference between the Post dose value at indicated visit minus Baseline value. Par. were evaluated at baseline, treatment period (Weeks 1.5, 3, 4.5, 6, 7.5, 9, 10.5 and 12) and follow-up period (16, 20, 24 and 28).', 'timeFrame': 'Baseline, Week 1.5, Week 3, Week 4.5, Week 6, Week 7.5, Week 9, Week 10.5, Week 12, Week 16, Week 20, Week 24 and Week 28'}, {'measure': 'Overall Health-related (HR) Quality of Life (QOL) Score Measured Using SF-36v2 at Day 1, Week 6 and Week 12', 'description': 'SF-36v2 is a generic HR QOL instrument with 36 items covering 8 subscales (SS) clustering into 2 global scores, the physical component summary score (PCS: physical functioning (PF), role physical (RP), bodily pain (BP), and general health (GH)) and mental component summary score (MCS: vitality (VT), social functioning (SF), role emotional (RE) and mental health (MH)). All scores are normalized so that mean score for a representative US population = 50, with a standard deviation = 10. Information was used to observe a direction in overall QOL. Ranges are shown below. Higher scores represent better QOL and minimum important differences are PF, 3; RP, 3; BP, 3; GH, 2; VT, 2; SF, 3; RE, 4; and MH, 3 PCS, 2; MCS, 3. Response Consistency Index (RCI) measures the consistency of responses to individual survey responses. Lower the score the more consistent the individual responses. SF-6D Health Utility Index (HUI) Score = 0 (worst measured health state) to 1 (best measured health state).', 'timeFrame': 'Day (D) 1, Week (W) 6 and Week 12'}, {'measure': 'Number of Participants With the Indicated Clinical Chemistry Values of Potential Clinical Concern', 'description': 'The following laboratory parameters were analyzed: hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, total neutrophils, lymphocytes; alanine amino transferase (ALT), alkaline phosphatase (ALP), aspartate amino transferase (AST), gamma glutamyl transferase (GGT), total bilirubin, albumin, total protein, blood urea nitrogen, creatinine, uric acid, sodium, potassium, chloride, calcium, total carbondioxide, glucose, magnesium, and ferritin. Only those parameters for which at least one value of clinical concern are reported in the table. Values above upper limit of normal and below lower limit to normal have been presented as high and low respectively.', 'timeFrame': 'Up to Week 16'}, {'measure': 'Number of Participants With Vital Signs Data Meeting Criteria of Potential Clinical Concern', 'description': 'The following laboratory parameters were analyzed in supine position after 10 minutes rest: Diastolic blood pressure (DBP), Systolic blood pressure (SBP) and Heart rate (HR). Values above upper limit of normal and below lower limit to normal have been presented as high and low respectively.', 'timeFrame': 'Up to Week 16'}, {'measure': 'Number of Participants With Electrocardiogram (ECG) Data Meeting Criteria of Potential Clinical Concern', 'description': 'The following ECG parameters were analyzed: PR, QRS, QT, corrected QT \\[QTc\\] intervals. Criteria for clinical concern:. QT where value is \\> 450, QT\\[QTc\\] where value is \\> 450, PR where value is \\< 110 or \\> 220, QRS where value is \\< 75 or \\>110.', 'timeFrame': 'Up to Week 16'}, {'measure': 'Number of Participants With Urinalysis Data Meeting Criteria of Potential Clinical Concern', 'description': 'Protein - values of clinical concern if change from ""trace"" at baseline to 3+ any time on-therapy or from 0 at baseline to 2+ any time on-therapy.', 'timeFrame': 'Up to Week 16'}, {'measure': 'Number of Participants With Any Adverse Events (AE) or Serious Adverse Event (SAE)', 'description': 'An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.', 'timeFrame': 'From start of investigational product (IP) through the Study Phase (12 weeks post-dose) (assessed up to 28 weeks)'}, {'measure': 'Plasma Concentration of GW786034 at the Indicated Time Points', 'description': 'Predose (trough) blood samples were collected at weeks 3, 6, 9, and 12. Blood samples for pharmacokinetic (PK) profile were collected at pre-dose, 1, 2, 3, 4, 6 and 8 hours post dose. Area under the curve (0-tau), Concentration tau (Ctau), and maximum concentration (Cmax) following repeat administration was to be studied if data permitted.', 'timeFrame': 'Weeks 3, 6, 9 and 12'}, {'measure': 'Graphical Exploration of PK/Pharmacodynamic (PD) Relationships Between Pazopanib Exposure and Selected PD', 'description': 'Graphical exploration of PK/PD relationships between pazopanib exposure and selected parameters was to be explored if data permitted. Due to the small sample size and the fact that only one dose was studied these analyses were not performed.', 'timeFrame': 'Weeks 3, 6, 9 and 12'}, {'measure': 'PK/PD Modeling Analysis to Characterize the Relationship Between Pazopanib Trough Concentrations and Epistaxis Frequency and Duration/Severity', 'description': 'A repeated categorical event per time interval PK/PD modeling analysis was planned (data permitting) to characterize the relationship between pazopanib trough concentrations and epistaxis frequency and duration/severity. Due to the small sample size and the fact that only one dose was studied these analyses were not performed.', 'timeFrame': 'Weeks 3, 6, 9 and 12'}]",20,18 Years,75 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,7.0,ACTUAL,2025-09-01T16:18:13.429637,v2_robust,True,True,False,True,True,The study was terminated as the asset was sold to another company who decided not to pursue this indication with this drug.
NCT00456144,Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone Agonist Therapy for Prostate Cancer,Prospective Observation Study of Insulin Sensitivity During and After Gonadotropin Releasing Hormone (GnRH) Agonist Therapy for Prostate Cancer,Gonadotropin Releasing Hormone Agonist Therapy,['Gonadotropin Releasing Hormone Agonist Therapy'],1,OBSERVATIONAL,[],,,Prostate Cancer,['Prostate Cancer'],"['GnRH', 'Insulin sensitivity']",COMPLETED,,2006-08,2012-09,[],[],0,18 Years,,MALE,False,Massachusetts General Hospital,OTHER,1,36.0,ACTUAL,2025-09-01T16:18:13.429773,v2_robust,False,True,True,False,False,
NCT01737944,Exposure Study Comparing 3 Routes of Methotrexate (MTX) Administration,"Exposure, Safety and Local Tolerance Study Comparing 3 Routes of Methotrexate (MTX) Administration: Vibex-MTX Device, Subcutaneous (SC)and Intramuscular (IM) in Adult Subjects With Rheumatoid Arthritis",Methotrexate (MTX),"['Methotrexate (MTX)', 'Device with MTX']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],"['methotrexate injection, subcutaneous, autoinjector']",COMPLETED,,2011-01,2011-06,"[{'measure': 'Bioequivalence Based Upon Dose-Normalized AUC[0-Inf] for MTX', 'description': 'Dose-normalized area under the curve from time zero to infinity (AUC\\[0-inf\\]/Dose) for each treatment', 'timeFrame': '24 Hour period'}, {'measure': 'Bioequivalence Based Upon Dose-Normalized AUC[0-24] for MTX', 'description': 'Dose-normalized area under the curve from time zero to 24 hours post-dose (AUC\\[0-24\\]/Dose) for each treatment', 'timeFrame': '24 Hour period'}, {'measure': 'Bioequivalence Based Upon Dose-Normalized Cmax for MTX', 'description': 'Dose-normalized maximum observed concentration for each treatment', 'timeFrame': '24 Hour period'}]",[],3,18 Years,,ALL,False,Antares Pharma Inc.,INDUSTRY,0,38.0,ACTUAL,2025-09-01T16:18:13.429824,v2_robust,True,True,True,False,False,
NCT01360944,Exploratory Study to Investigate Efficacy of LAS41004 in a Psoriasis Plaque Test,"An Investigator-blind, Controlled Exploratory Study to Assess the Efficacy and Safety of Different Concentrations of Active Ingredients in the Project LAS 41004 Compared to a Bland Ointment and to Active Control in a Psoriasis- Plaque- Test",LAS41004,"['LAS41004', 'reference']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Psoriasis,['Psoriasis'],"['PPT, topical, psoriasis']",COMPLETED,,2011-05,2011-06,"[{'measure': 'Decrease in thickness of infiltration', 'description': 'measurement will be performed by ultrasound, comparing data from baseline (day1) vs end of trial (day15)', 'timeFrame': 'Day 1 (baseline) vs day 15 day (final)'}]","[{'measure': 'Change in clinical score', 'description': 'scoring of total symptom score (0 - 12)will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)', 'timeFrame': 'day 1 (baseline) vs day 15 (final)'}, {'measure': 'Change in erythema score', 'description': 'scoring of erythema (0-4) will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)', 'timeFrame': 'day1 (baseline) vs day 15 (final)'}, {'measure': 'Change in Induration score', 'description': 'scoring of induration (0-4) will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)', 'timeFrame': 'day 1 (baseline) vs day 15 (final)'}, {'measure': 'Change in Scaling score', 'description': 'scoring of scaling (0-4) will be performed by investigator, comparing data from baseline (day1) vs end of trial (day15)', 'timeFrame': 'day 1 (baseline) vs day 15 (final)'}]",5,18 Years,75 Years,ALL,False,"Almirall, S.A.",INDUSTRY,1,22.0,ACTUAL,2025-09-01T16:18:13.429858,v2_robust,True,True,True,False,False,
NCT04908644,MS-20 on Patients With Ulcerative Colitis(UC),Study to Evaluate Efficacy and Safety of MS 20 on Patients With Ulcerative Colitis,MS-20 oral solution,"['Chemo young', 'MS-20 oral solution']",2,INTERVENTIONAL,['NA'],,,Ulcerative Colitis,['Ulcerative Colitis'],"['Ulcerative Colitis', 'MS-20', 'Postbiotics', 'Gut microbiota']",RECRUITING,,2021-08-18,2024-11-30,"[{'measure': 'Change from baseline structural of gut microbiota at 16 weeks', 'timeFrame': 'Baseline, week 16'}, {'measure': 'Change from baseline in the abundance and variability of gut microbiota at 16 weeks', 'timeFrame': 'Baseline, week 16'}]","[{'measure': 'Change from baseline of Partial Mayo Score at 12 weeks', 'description': 'Partial Mayo score consisted of 3 sub-scores: stool frequency, most severe rectal bleeding of the day, endoscopic findings and global assessment by physician, each graded from 0 to 3 with higher scores indicating more severe disease. These scores are summed to give a total score range of 0 to 9. Here, higher scores indicated more severe disease.', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of IL-6 level in blood at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of TNF-α level in blood at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of IL-1β level in blood at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of IL-23 level in blood at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of IL-33 level in blood at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of C-reactive protein(CRP) level in blood at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of erythrocyte sedimentation rate(ESR) at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of fecal calprotectin result at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Change from baseline of fecal occult blood result at 12 weeks', 'timeFrame': 'Baseline, week 12'}, {'measure': 'Adverse events', 'timeFrame': 'up to 16 weeks'}]",13,20 Years,65 Years,ALL,False,National Taiwan University Hospital,OTHER,1,40.0,ESTIMATED,2025-09-01T16:18:13.429874,v2_robust,True,True,False,False,True,
NCT01892644,Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome,Deferasirox Versus Venesection in Patients With Hemochromatosis and for Treatment of Transfusional Siderosis in Myelodysplastic Syndrome: Diagnostics and New Biomarkers.,Deferasirox,"['Exjade', 'Deferasirox']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hemochromatosis,"['Hemochromatosis', 'Myelodysplastic Syndromes']","['Hemochromatosis', 'Myelodysplastic syndromes', 'Iron overload', 'Deferasirox', 'Chelation therapy', 'Venesection', 'Phlebotomy', 'Ferritin', 'Transfusional siderosis']",WITHDRAWN,Failure to recruit patients with hemochromatosis to the Deferasirox arm,2013-05,2017-01,"[{'measure': 'Changes from baseline in liver iron concentration (LIC) and heart iron concentration (HIC) determined by Magnetic Resonance Imaging (MRI), and in bone marrow iron content determined by microscopy after treatment with deferasirox.', 'timeFrame': '0, 6 and 12 months'}]","[{'measure': 'Change of hepcidin concentration in serum', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Change of non-transferrin bound iron (NTBI) concentration in serum', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Change of multiple trace metals in serum', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Change of intracellular signal molecules, mTOR, NFkB and stress sensor p53 in blood cells', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Change of 8-oxodG in urine', 'description': 'Marker of oxidative DNA damage', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Change of Cu,Zn-SOD activity in erythrocyte hemolysate', 'description': 'Cu,Zn-Super Oxid Dismutase (SOD)is an antioxidant enzyme', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Clinical chemistry: Na, K, Ca, Creatinine, creatinine kinase, CRP, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GT), lactate dehydrogenase (LD), albumin, bilirubin.', 'description': 'Serum analysis', 'timeFrame': '0, 2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks posttreatment'}, {'measure': 'Urine routine test strip for detection of blood, protein, and nitrite', 'description': 'Morning spot urine sample.', 'timeFrame': '0,2,4,6,8 weeks and 3,4,5,6,7,8,9,10,11,12 months'}, {'measure': 'Ferritin concentration in serum', 'timeFrame': '0,2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks post treatment'}, {'measure': 'Transferrin saturation in serum', 'timeFrame': '0,2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks post treatment'}, {'measure': 'HbA1c', 'timeFrame': '0, 2,6,12 months'}, {'measure': 'INR ( International normalized ratio)', 'timeFrame': '0,2,6,12 months'}, {'measure': 'Analysis of hemoglobin, reticulocytes, hematocrit, MCV, leukocyte count (total and differential), and platelets', 'timeFrame': '0, 2,4,6,8 weeks, 3,4,5,6,7,8,9,10,11,12 months, 5 weeks posttreatment'}, {'measure': 'Urine trace metals', 'timeFrame': '0, 6 and 12 months'}, {'measure': 'Bone marrow sample', 'timeFrame': '0, 6 and 12 months'}]",16,18 Years,80 Years,ALL,True,Haukeland University Hospital,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:13.429934,v2_robust,True,True,False,True,False,Failure to recruit patients with hemochromatosis to the Deferasirox arm
NCT05072444,Drug-Drug Interaction Study of IV QPX2014 Combined With QPX7728 in Healthy Adult Subjects,"A Phase 1, Randomized, Double-Blind, Single-Dose, Drug-Drug Interaction Study to Determine the Impact of Co-administration of QPX7728 on the Pharmacokinetics of QPX2014 in Healthy Adult Subjects",QPX7728,"['QPX2014', 'IV', 'QPX7728']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Bacterial Infections,['Bacterial Infections'],['beta-lactam antibiotic'],COMPLETED,,2021-11-15,2021-11-23,"[{'measure': 'Area under the plasma concentration versus time curve (AUC) between dosing groups', 'description': 'Comparison will be performed between the dosing groups for AUC. Mean graphical presentation of the data will be reported.\n\nStatistical analysis of exposure parameters will be performed.', 'timeFrame': 'up to 9 days'}, {'measure': 'Peak plasma Concentration measurements by subject and by dosing group', 'description': 'Comparison will be performed between the dosing groups. Mean graphical presentation of the data will be reported.\n\nStatistical analysis of exposure parameters will be performed.', 'timeFrame': 'up to 9 days'}, {'measure': 'Urine Pharmacokinetic (PK) amount excreted by subject and by dosing group', 'description': 'Urine PK parameters such as amount excreted will be calculated from urinary excretion data', 'timeFrame': 'up to 9 days'}, {'measure': 'Urine PK % dose excreted by subject and by dosing group', 'description': 'Urine PK parameters such as amount of % dose excreted will be calculated from urinary excretion data', 'timeFrame': 'up to 9 days'}, {'measure': 'Incidence of Treatment -Emergent Adverse events (AEs) by subject and by dosing group', 'description': 'Number of patients with Treatment-Emergent AEs by treatment arm, severity and relationship to treatment', 'timeFrame': 'up to 9 days'}, {'measure': 'Number of patients with changes from baseline in safety parameters', 'description': 'Number of patients with changes in safety parameters before and after dosing by subject and treatment arm', 'timeFrame': 'up to 9 days'}]",[],6,18 Years,55 Years,ALL,True,"Qpex Biopharma, Inc.",INDUSTRY,1,12.0,ACTUAL,2025-09-01T16:18:13.429963,v2_robust,True,True,True,False,True,
NCT03754244,A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics,A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics,TQB3456,['TQB3456'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],[],TERMINATED,"The enrolment task cannot be gotten within the planned time.It mainly includes patients with non-small cell lung cancer failed in standard treatment,with a short survival period.It is hard to obtain observational endpoints for bone-related events.",2020-09-24,2022-02-28,"[{'measure': 'Dose-Limiting Toxicities（DLT）', 'description': 'an adverse event cccurring after initiation of TQ-B3456 that met any following criteria：\n\n1. \\>=Grade 3 of non-hematology toxicity\n2. Grade 4 hematology toxicity', 'timeFrame': 'Baseline up to 28 days'}]",[],1,18 Years,70 Years,ALL,False,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:13.430038,v2_robust,True,True,False,True,True,"The enrolment task cannot be gotten within the planned time.It mainly includes patients with non-small cell lung cancer failed in standard treatment,with a short survival period.It is hard to obtain observational endpoints for bone-related events."
NCT00872144,Sativex for Treatment of Chemotherapy Induced Neuropathic Pain,A Double Blind Placebo Controlled Crossover Pilot Trial of Sativex With Open Label Extension for Treatment of Chemotherapy Induced Neuropathic Pain,Sativex,['Sativex'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Neuropathic Pain,['Neuropathic Pain'],[],COMPLETED,,2010-06,2013-03,"[{'measure': 'Change in the NRS-PI from baseline to the final week of stable dose treatment)', 'timeFrame': 'Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)'}, {'measure': 'Participants gaining a 30% or greater reduction in the NRS-PI', 'timeFrame': 'Patients will titrate the dose to a level where they obtain an analgesic effect without limiting side effects (week 3)'}]","[{'measure': 'Secondary outcome measures will include measures in the remaining domains (suggested by IMMPACT). These include SF36, Quantitative sensory examination, Global Impression of Change, PGIC and Patient Satisfaction Scale, PSS', 'timeFrame': 'After stable dosing is achieved (week 3)'}]",3,18 Years,,ALL,False,Mary Lynch,OTHER,0,16.0,ACTUAL,2025-09-01T16:18:13.430069,v2_robust,True,True,True,False,False,
NCT02789644,"Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Elderly After UDCA Administration","A Randomized, Open-label Clinical Trial to Investigate Pharmacokinetics, Metabolomics and Biomarker in Healthy Elderly Subjects After Ursodeoxycholic Acid Administration",Ursodeoxycholic Acid,"['Ursa tab.', 'Ursodeoxycholic Acid']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Aged,['Aged'],"['Ursodeoxycholic acid', 'Metabolomics/biomarker', 'Pharmacokinetics']",UNKNOWN,,2016-05,2016-07,"[{'measure': 'Area under the plasma concentration-time curve (AUC) of ursodeoxycholic acid', 'timeFrame': 'predose and 2, 4, 5, 7, 9, 10, 12, 24h postdose'}]",[],1,70 Years,84 Years,ALL,True,Seoul National University Hospital,OTHER,0,16.0,ESTIMATED,2025-09-01T16:18:13.430081,v2_robust,True,True,False,False,False,
NCT03300544,"Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer",A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum,Capecitabine,"['RP-54780', '5 Fluorouracilum', 'Fluroblastin', 'Ro 2-9757', 'Fluouracil', '1-OHP', 'Leucovorin', 'Ro-2-9757', 'Fluracil', '5-Fu', 'Fluracedyl', '5 Fluorouracil', 'Dacplat', 'Xeloda', 'SR-96669', '5FU', 'Folinic acid', '5 FU', 'Oxalatoplatin', 'Oxaliplatin', 'Ro 09-1978/000', 'Eloxatin', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', 'Ai Heng', 'Eloxatine', 'Aiheng', 'Flurablastin', 'Fluoro Uracil', 'Ribofluor', 'Fluril', 'Carac', '5-Fluracil', 'Diaminocyclohexane Oxalatoplatinum', 'Capecitabine', 'Fluorouracil', 'AccuSite', 'Oxalatoplatinum', 'RP 54780', '5-Fluorouracil', 'Dacotin', 'JM-83']",41,INTERVENTIONAL,['PHASE1'],PHASE1,,Locally Advanced Rectal Adenocarcinoma,"['Locally Advanced Rectal Adenocarcinoma', 'Metastatic Rectal Adenocarcinoma', 'Rectal Adenocarcinoma', 'Stage III Rectal Cancer AJCC v7', 'Stage IIIA Rectal Cancer AJCC v7', 'Stage IIIB Rectal Cancer AJCC v7', 'Stage IIIC Rectal Cancer AJCC v7', 'Stage IV Rectal Cancer AJCC v7', 'Stage IVA Rectal Cancer AJCC v7', 'Stage IVB Rectal Cancer AJCC v7']",[],TERMINATED,Inadequate accrual rate,2019-05-14,2022-03-22,"[{'measure': 'Determination of Dose Limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD) of Talimogene Laherparepvec in Combination With Chemotherapy and Radiation in Rectal Cancer.', 'description': 'Assessed using the National Cancer Institute (NCI) Common Terminology for Adverse Events (CTCAE) version 5.0.', 'timeFrame': '4 weeks after surgery'}]","[{'measure': 'To Establish Safety and Feasibility of the Combination', 'description': 'Feasibility will be reported in all patients who have started therapy as percent of planned dose intensity. The scale for dose intensity will range from 0 - 100% with a higher score being better.\n\nThe result will be reported using descriptive statistics.', 'timeFrame': '4 weeks after surgery'}, {'measure': 'Determine the Neoadjuvant Rectal (NAR) Score of Talimogene Laherparepvec With Chemotherapy and Radiation.', 'description': 'The NAR score has been validated in clinical trials as a surrogate endpoint for overall survival. The score is designed to be particularly sensitive to changes in factors that are affected by neoadjuvant. NAR is calculated based on the clinical T stage (cT), pathological T (pT) and pN stages as:\n\nNAR = \\[5pN- 3 (cT- pT) + 12\\] \\^2 / 9.61 and will be reported using descriptive statistics\n\nScale: The NAR score is a pseudo-continuous variable with 24 possible discrete scores from 0 to 100 with higher scores representing a poorer prognosis.', 'timeFrame': '4 weeks after surgery'}]",3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,3.0,ACTUAL,2025-09-01T16:18:13.430121,v2_robust,True,True,False,True,True,Inadequate accrual rate
NCT04865744,The Effect of Semaglutide on Pituitary Function,The Effect of Semaglutide on Pituitary Function,Semaglutide 7 MG Oral Tablet,"['Semaglutide 7 MG Oral Tablet', 'Rybelsus 7 mg', 'Rybelsus 14 mg', 'Placebo', 'Semaglutide 14 MG Oral Tablet']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Healthy,['Healthy'],[],COMPLETED,,2021-05-19,2021-09-30,"[{'measure': 'Growth hormone peak', 'description': 'Maximum concentration measured after study medication administration.', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}]","[{'measure': 'Cortisol peak', 'description': 'Maximum concentration measured after study medication administration.', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}, {'measure': 'Adrenocorticotropin (ACTH) peak', 'description': 'Maximum concentration measured after study medication administration.', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}, {'measure': 'Aldosterone peak', 'description': 'Maximum concentration measured after study medication administration.', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}, {'measure': 'Glucose nadir', 'description': 'Lowest glucose concentration measured after study medication administration', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}, {'measure': 'C-peptide peak', 'description': 'Maximum concentration measured after study medication administration.', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}, {'measure': 'Copeptin peak', 'description': 'Maximum concentration measured after study medication administration', 'timeFrame': '60, 90, 120, 150, 180 and 240 minutes after study medication administration'}]",7,18 Years,50 Years,ALL,True,University of Tartu,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:13.430132,v2_robust,True,True,True,False,False,
NCT06943534,Omalizumab Weight-Based Dosing Efficacy Trial,Omalizumab Weight-Based Dosing Efficacy Trial,5mg/kg omalizumab injection,"['15mg/kg omalizumab injection', 'Xolair', '5mg/kg omalizumab injection']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Allergies,"['Allergies', 'Food Allergy']",['omalizumab'],RECRUITING,,2025-06-01,2028-04-01,"[{'measure': 'Proportion of participants that tolerate the 600 mg dose after treatment.', 'description': 'The primary analysis of outcome is on the proportion of subjects tolerating at least 600 mg at the post-treatment OFC in either group against the expected outcome without treatment based on OUTMATCH data.', 'timeFrame': '16 Weeks'}]","[{'measure': 'Other measures of omalizumab treatment effect on food allergy', 'description': 'Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment:\n\n● The proportion of participants that tolerate a single dose 1000 mg allergen', 'timeFrame': '16 Weeks'}, {'measure': 'Other measures of omalizumab treatment effect on food allergy', 'description': 'Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment:\n\n● The proportion of participants that tolerate a single dose 2000 mg allergen', 'timeFrame': '16 Weeks'}, {'measure': 'Other measures of omalizumab treatment effect on food allergy', 'description': 'Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment:\n\n● The proportion of participants that tolerate two doses of 2000 mg allergen', 'timeFrame': '16 Weeks'}, {'measure': 'Other measures of omalizumab treatment effect on food allergy', 'description': 'Secondary efficacy endpoint analysis will also be determined at OFC following 16-weeks of treatment:\n\n● Reaction severity of positive post treatment reactions using the CoFAR grading scale ranging from 1 (mild) to 5 (death)', 'timeFrame': '16 Weeks'}]",5,1 Year,55 Years,ALL,False,Massachusetts General Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:13.430207,v2_robust,True,True,False,False,False,
NCT00002234,Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients,"A Phase II, 48 Week, Open-Label Study Designed to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Simplified Dosing Regimen of Preveon (Adefovir Dipivoxil; bis-POM PMEA), Videx (Didanosine; ddI), Sustiva (Efavirenz; DMP-266), and Epivir (Lamivudine; 3TC) Administered Once Daily for the Treatment of HIV-1 Infection",Efavirenz,"['Adefovir dipivoxil', 'Didanosine', 'Efavirenz', 'Lamivudine']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infections,['HIV Infections'],"['Drug Therapy, Combination', 'Reverse Transcriptase Inhibitors', 'Anti-HIV Agents']",COMPLETED,,,,[],[],0,13 Years,,ALL,False,Gilead Sciences,INDUSTRY,3,25.0,,2025-09-01T16:18:13.430243,v2_robust,True,True,True,False,False,
NCT00840034,A Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder,A Study of Augmentation With LY2216684 for Patients With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor Treatment,LY2216684,"['LY2216684', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Depressive Disorder, Major","['Depressive Disorder, Major']",[],COMPLETED,,2009-02,2010-01,"[{'measure': 'Change From Baseline to 8 Weeks in Montgomery-Asberg Depression Rating Scale (MADRS)', 'description': 'The MADRS is a rating scale for severity of depressive mood symptoms. The MADRS is a 10-item checklist with items rated on a scale of 0-6, for a total scores range of 0 (low severity of depressive symptoms) to 60 (high severity of depressive symptoms). Least Squares (LS) means are calculated using mixed model repeating measures (MMRM) and adjusted for investigator, treatment-by-visit, baseline score, and baseline-by-visit.', 'timeFrame': 'Baseline, 8 weeks'}]","[{'measure': 'Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Total Score', 'description': 'QIDS-SR16 is a 16-item, participant-rated measure of depressive symptomatology with 4 possible answers per question that are specific to the question. Each question (Q) is scored from 0 (no problems) to 3 (increased symptoms). The total score for each visit is the sum of 9 of the 16 items: the highest number from Q1-4 (sleep), number from Q5 (feeling sad), highest number from Q6-9 (appetite and weight), total for Q10-14 (concentration, view of self, thoughts of death or suicide, general interest and energy level respectively) and the highest number from Q15-16 (psychomotor changes). The total score ranges from 0 to 27 with higher scores indicating greater severity of depression. Least Squares (LS) means are calculated using mixed model repeating measures (MMRM) and adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.', 'timeFrame': 'Baseline, 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in 16-Item Quick Inventory of Depressive Symptomatology-Self Rated (QIDS-SR16) Individual Items', 'description': 'QIDS-SR16 is a 16-item, participant-rated measure of depressive symptomatology with 4 possible answers per question that are specific to the question. Each question (Q) is scored from 0 (no problems) to 3 (increased symptoms). The total score for each visit is the sum of 9 of the 16 items: the highest number from Q1-4 (sleep), number from Q5 (feeling sad), highest number from Q6-9 (appetite and weight), total for Q10-14 (concentration, view of self, thoughts of death or suicide, general interest and energy level respectively) and the highest number from Q15-16 (psychomotor changes). Least Squares (LS) means are calculated using mixed model repeated measure (MMRM) and adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit.', 'timeFrame': 'Baseline, 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Hospital Anxiety and Depression Scale (HADS)', 'description': ""HADS is a 14-item questionnaire with 2 subscales: anxiety and depression. Each item is rated on a 4-point scale (0-3), giving maximum scores of 21 for each subscale. Scores of 11 or more on either subscale are considered to be a significant 'case' of psychological morbidity, while scores of 8-10 represent 'borderline' and 0-7 is 'normal.' Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, visit, treatment-by-visit, investigator, and baseline score."", 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Clinical Global Impression of Severity (CGI-S)', 'description': 'CGI-S measures severity of illness at the time of assessment. Scores range from 1 (normal, not at all ill) to 7 (among the most extremely ill participants). Least Squares (LS) means are calculated using mixed model repeated measures (MMRM) and adjusted for treatment, investigator, visit, treatment-by visit, baseline score, and baseline-by-visit.', 'timeFrame': 'Baseline, 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ)', 'description': ""The CPFQ is a 7-item participant-rated questionnaire pertaining to a participant's cognitive and physical well-being. It assesses motivation, wakefulness, energy, focus, recall, word-finding difficulty, and mental acuity. Each item is scored on a 6-point scale ranging from 1 (greater than normal) to 6 (totally absent). Total score ranges from 7 to 42. Higher scores indicate greater disease severity. Least Squares (LS) means are calculated using mixed model repeated measures (MMRM) and adjusted for treatment, investigator, visit, treatment-by-visit, baseline score, and baseline-by-visit."", 'timeFrame': 'Baseline, 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Fatigue Associated With Depression Participant-Reported Outcome (FAsD PRO)', 'description': 'The FAsD PRO is a 16-item participant-rated scale. Seven items ask how often the participants experience different aspects of fatigue with each item rated on a 5-point scale: 1 (Never) to 5 (Always). Nine items ask how often fatigue impacts various aspects of the participants lives with each item rated on a 5-point scale: 1 (Not at all) to 5 (Very much). The Fatigue Experience Score is the mean of Items 1-5, and 7, the Fatigue Impact Score is the mean of Items 8-12, 14, and 16, and the Overall Average Score is the mean of Items 1-5, 7-12, 14 and 16. The Experience, Impact and Overall Mean Scores range from 1 to 5, lower scores indicate less experience/impact. Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, and baseline score.', 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Visual Analog Scale for Fatigue (VAS-F)', 'description': 'VAS-F is a self-rated assessment on 2 items: the overall severity of fatigue and the interferences with daily activities due to fatigue. For the overall severity of fatigue the participant is asked to place a vertical mark on a 100 millimeter (mm) line between 2 anchors: 0 (not at all) and 100 (as severe as I can imagine). For the interference with daily activities due to fatigue, the participant is asked to place a vertical mark on a 100 mm line between 2 anchors: 0 (not at all) and 100 \\[complete disability (unable to do any activities)\\]. Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, and baseline score.', 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Visual Analog Scale for Pain (VAS-P)', 'description': 'VAS-P is a self-rated assessment for 2 items: the overall severity of pain and the interferences with daily activities due to pain. For the overall severity of pain the participant is asked to place a vertical mark on a 100 millimeter (mm) line between 2 anchors: 0 (not at all) and 100 (as severe as I can imagine). For the interference with daily activities due to pain, the participant is asked to place a vertical mark on a 100-mm line between 2 anchors: 0 (not at all) and 100 \\[complete disability (unable to do any activities)\\]. Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, and baseline score.', 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Sheehan Disability Scale (SDS)', 'description': ""The SDS is a 3-item, participant completed assessment and is used to assess the effect of the participant's symptoms on their work/social/family life. The Global Functional Impairment Total Score is a total of the 3 individual item scores, each with a scores range from 0 (not at all) to 10 (extremely). The Global Functional Impairment Total Scores range from 0 to 30 with higher values indicating greater disruption in the participant's work/social/family life. Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, and baseline score."", 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks in Quality of Life Enjoyment and Satisfaction Survey-Short Form (Q-LES-Q-SF)', 'description': 'The Q-LES-Q-SF is a self-administered 16-item questionnaire measuring degree of enjoyment and satisfaction experienced in various areas of daily life during the past week, and is rated on a 5-point Likert scale: 1 (very poor) to 5 (very good). The Q-LES-Q-SF Total Raw Score is the sum of Items 1 to 14 and ranges from 14 to 70. The Q-LES-Q-SF Raw Scores are converted to, and expressed as the percentage of the maximum possible score. Higher scores indicate higher levels of enjoyment/satisfaction. Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, and baseline score.', 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Change From Baseline to 8 Weeks Massachusetts General Hospital Sexual Functioning Questionnaire (MGH-SFQ)', 'description': 'The MGH-SFQ is a 6-item participant-rated scale quantifying sexual interest, arousal (subjective excitement), ability to reach orgasm, erectile function (for males), and overall satisfaction and are scored on a 6-point scale: 1 (greater than normal) to 6 (totally absent); and overall improvement since last medication change is scored on a 6-point scale: 1 (very much improved) to 6 (much worse). Least Squares (LS) means are calculated using analysis of covariance (ANCOVA) and adjusted for treatment, investigator, and baseline score.', 'timeFrame': 'Baseline, up to 8 weeks'}, {'measure': 'Colombia-Suicide Severity Rating Scale (C-SSRS)', 'description': 'Percent of participants with suicidal ideation, behavior and acts based on C-SSRS. The C-SSRS scale captures occurrence, severity, and frequency of suicide-related thoughts and behaviors. Suicidal behavior: a ""yes"" answer to any 1 of 5 suicidal behavior questions (preparatory acts or behavior, aborted attempt, interrupted attempt, actual attempt, and completed suicide). Suicidal ideation: a ""yes"" answer to any 1 of 5 suicidal ideation questions (wish to be dead, and 4 different categories of active suicidal ideation). Suicidal act: a ""yes"" answer to actual attempt or completed suicide.', 'timeFrame': 'Baseline, 8 weeks'}]",13,18 Years,65 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,227.0,ACTUAL,2025-09-01T16:18:13.430248,v2_robust,True,True,True,False,False,
NCT00134134,Efficacy and Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa,An Open-Label Assessment of the Efficacy & Safety of Efalizumab in the Treatment of Moderate-Severe Hydradenitis Suppurativa,efalizumab,['efalizumab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Hidradenitis Suppurativa,['Hidradenitis Suppurativa'],"['hidradenitis suppurativa', 'efalizumab', 'biologic', 'Raptiva']",COMPLETED,,2005-02,2006-08,[{'measure': 'Reduction in number of inflammatory lesions 12 weeks post-baseline'}],"[{'measure': 'Time to the reduction of lesions during 12 weeks of treatment'}, {'measure': 'Percent of disease activity at various weeks after baseline'}]",3,18 Years,65 Years,FEMALE,False,NYU Langone Health,OTHER,1,5.0,,2025-09-01T16:18:13.430480,v2_robust,True,True,True,False,False,
NCT00278434,Zoledronate in Treating Patients With Cervical Intraepithelial Neoplasia 2/3 or 3,An Exploratory Clinical Trial of Zoledronic Acid in Women With CIN 2/3 or 3,Zoledronate,['Zoledronate'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Cervical Cancer,"['Cervical Cancer', 'Precancerous Condition']","['cervical cancer', 'cervical intraepithelial neoplasia grade 2', 'cervical intraepithelial neoplasia grade 3']",TERMINATED,Accrual was insufficient to meet study endpoints,2005-04,2008-07,"[{'measure': 'Impact of Zoledronic Acid (ZA) on clinical response', 'description': 'The primary objective is to determine whether Zoledronic Acid (ZA), when given to women with CIN 2/3 or 3 for two months prior to surgical excision, has a measurable impact on clinical response (lesion size and histological grade).', 'timeFrame': '10 weeks from start of treatment'}]",[],1,18 Years,120 Years,FEMALE,False,"University of California, San Francisco",OTHER,1,12.0,ACTUAL,2025-09-01T16:18:13.430507,v2_robust,True,True,False,True,False,Accrual was insufficient to meet study endpoints
NCT04898634,"A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer","A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer",JNJ-78278343,['JNJ-78278343'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Prostatic Neoplasms,['Prostatic Neoplasms'],"['Metastatic castration-resistant prostate cancer (mCRPC)', 'Advanced prostate cancer']",ACTIVE_NOT_RECRUITING,,2021-07-13,2026-02-16,"[{'measure': 'Part 1 and 2: Number of Participants With Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Part 1 and 2: Number of Participants With AEs by Severity', 'description': 'Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (Death). Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. Cytokine release syndrome (CRS) and immune effector cell associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) guidelines.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)', 'description': 'Number of participants with DLT will be reported. The DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.', 'timeFrame': 'Up to 1 year and 10 months'}]","[{'measure': 'Serum Concentration of JNJ-78278343', 'description': 'Serum concentrations of JNJ-78278343 will be determined.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Systemic Cytokine Concentrations', 'description': 'Cytokine concentrations will be determined for biomarker assessment.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Serum Prostate Specific Antigen (PSA) Concentration', 'description': 'Serum PSA concentration will be measured.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Number of Participants With Anti-JNJ-78278343 Antibodies', 'description': 'Serum samples will be analyzed for the detection of anti-JNJ-78278343 antibodies using a validated assay method.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants who have a partial response (PR) or better according to the response evaluation criteria in solid tumors (RECIST) version 1.1 response criteria without evidence of bone progression according to prostate cancer working group 3 (PCWG3).', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Radiographic Progression-free Survival (rPFS)', 'description': 'rPFS is defined as time from the date of first dose of JNJ-78278343 until the date of objective disease progression or death, whichever comes first.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'PSA Response Rate', 'description': 'PSA response rate is defined as the percentage of participants with a decline of PSA of 50 percent (%) or more from baseline. The maximum reduction from baseline in PSA will also be calculated during the treatment.', 'timeFrame': 'Up to 1 year and 10 months'}, {'measure': 'Duration of Response (DOR)', 'description': 'DOR will be calculated among responders (PR or better) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the PCWG3 or RECIST version 1.1 response criteria, or death due to any cause, whichever occurs first.', 'timeFrame': 'Up to 1 year and 10 months'}]",11,18 Years,,MALE,False,"Janssen Research & Development, LLC",INDUSTRY,0,216.0,ACTUAL,2025-09-01T16:18:13.430550,v2_robust,True,True,False,False,True,
NCT05096234,18F-F-AraG PET Imaging to Evaluate Immunological Response to CAR T Cell Therapy in Lymphoma,Pilot Study of [18F]F-AraG PET Imaging to Evaluate Immunological Response to Chimeric Antigen Receptor (CAR) T Cell Therapy in Lymphoma,[ 18F]F-AraG PET,"[""[ 18F]F-AraG (2'-deoxy-2'-fluoro-9-β-D- arabinofuranosylguanine; trade name VisAcT)"", '[ 18F]F-AraG PET']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Non-Hodgkin's Lymphoma,"[""Non-Hodgkin's Lymphoma""]",[],TERMINATED,loss of sponsor support,2021-09-28,2023-10-09,"[{'measure': 'Primary outcome measure', 'description': 'Spearman correlation between changes in SUV in \\[18F\\]F-AraG signal on PET imaging to changes in T-cell infiltrates in biopsy samples', 'timeFrame': 'values obtained on Day 0 and Day 4 (± 2 days)'}]",[],1,18 Years,,ALL,False,Stanford University,OTHER,1,2.0,ACTUAL,2025-09-01T16:18:13.430559,v2_robust,True,True,False,True,False,loss of sponsor support
NCT01361334,Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible,Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible,Pazopanib,"['Votrient(R)', 'Pazopanib']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],['(other than AML M3)'],COMPLETED,,2011-06,2016-03,"[{'measure': 'Cumulative response rate (CR, CRp, CRi, PR) within up to one year of pazopanib treatment', 'timeFrame': '12 months'}, {'measure': 'Reduction of BM microvessel density on day 28', 'timeFrame': '28 days'}]","[{'measure': 'Safety and Tolerability (Rate of adverse events)', 'description': 'Rate of adverse events', 'timeFrame': '12 months'}, {'measure': 'Cumulative incidence and degree of inhibition of target receptor phosphorylation (PDGFR, VEGFR, and c-KIT) and correlation with clinical response', 'timeFrame': '12 months'}, {'measure': 'Reduction of BM microvessel density on day 14', 'timeFrame': '14 days'}, {'measure': 'Relapse-free survival in relationship to historical control patients, Overall survival in relationship to historical control patients, Duration of response', 'timeFrame': '12 months'}]",6,18 Years,,ALL,False,University Hospital Muenster,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:13.430570,v2_robust,True,True,True,False,True,
NCT00509834,A Study on the Tolerability and Early Efficacy of hLF1-11 in Patients With Proven Candidaemia,"A Phase-IIa, Double-blind, Randomized Study on the Tolerability and Early Efficacy of hLF1-11 in Hospitalized Patients With Proven Candidaemia. (SLIC: Study of Lactoferrin Peptide in Infections With Candida)",hLF1-11,"['hLF1-11', 'Placebo', 'human lactoferrin 1-11']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Candidaemia,['Candidaemia'],"['hLF1-11', 'Candida', 'candidaemia', 'lactoferrin']",WITHDRAWN,Patient population not available,2008-07,2009-01,"[{'measure': 'Haematology, biochemistry, and microbiological evaluation Adverse event monitoring.', 'timeFrame': '28 Days'}]","[{'measure': 'Test of Cure (TOC): Clinical: complete resolution of clinical signs and symptoms or resolution to a point where no further antifungal therapy is judged necessary; and Microbiological: eradication of Candida identified at baseline.', 'timeFrame': '28 Days'}]",2,18 Years,70 Years,ALL,False,AM-Pharma,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:13.430667,v2_robust,True,True,False,True,True,Patient population not available
NCT03016234,IOP Changes With Different Anesthetic Agents During Laparoscopic Colorectal Surgery,Intraocular Pressure Changes During Laparoscopic Colorectal Surgery: Propofol Versus Desflurane Anesthesia,Desflurane,"['Desflurane', 'Propofol', 'Fresofol medium-chain triglyceride (MCT) 2% inj. 50mL', 'Suprane soln. 240ml/Bottle']",4,INTERVENTIONAL,['NA'],,,Intraocular Pressure,['Intraocular Pressure'],"['intraocular pressure', 'trendelenburg position', 'pneumoperitoneum']",COMPLETED,,2016-09-29,2017-03-08,"[{'measure': 'changes in intraocular pressure (IOP) in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T1 (baseline: initial IOP before anesthesia induction), T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 minutes after position change to head down and right tilt), T5 (10 minutes after position change to head up and right tilt), T6 (30 minutes after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'before anesthesia induction, immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}]","[{'measure': 'changes in mean arterial pressure (MAP) in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T1 (baseline: initial MAP before anesthesia induction), T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 minutes after position change to head down and right tilt), T5 (10 minutes after position change to head up and right tilt), T6 (30 minutes after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'before anesthesia induction, immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}, {'measure': 'changes in end tidal carbon dioxide in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 mins after position change to head down and right tilt), T5 (10 mins after position change to head up and right tilt), T6 (30 mins after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}, {'measure': 'changes in peak airway pressure in different positions during laparoscopic colorectal surgery under desflurane or propofol anesthesia.', 'description': 'T2 (immediately after endotracheal intubation), T3(after pneumoperitoneum in supine position), T4 (30 mins after position change to head down and right tilt), T5 (10 mins after position change to head up and right tilt), T6 (30 mins after position change to head down and right tilt) and T7 (5 minutes before endotracheal extubation)', 'timeFrame': 'immediately after intubation, after pneumoperitoneum, 30 minutes after head down and right tilt position, 10 minutes after head up and right tilt, 30 minutes after head down and right tilt and 5 minutes before extubation'}]",4,30 Years,80 Years,ALL,False,"Saint Vincent's Hospital, Korea",OTHER,0,50.0,ACTUAL,2025-09-01T16:18:14.657149,v2_robust,True,True,True,False,False,
NCT04489134,P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release,P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release,Treatment A,"['Treament C', 'Treatment A', 'Treatment B', 'Treatment D']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Pharmacokinetics,['Pharmacokinetics'],[],COMPLETED,,2022-02-15,2023-05-16,"[{'measure': 'Area under the curve', 'description': 'Change in area under the curve of tacrolimus blood concentrations between 0 and 24h.', 'timeFrame': 'Between 0 and 24 hours'}]","[{'measure': 'Cmax', 'description': 'Blood pharmacokinetic parameters: peak concentration (Cmax)', 'timeFrame': 'Cmax Advagraf: 2-3 hours, Cmax Envarsus: 6-8 hours'}, {'measure': 'Trough concentration', 'description': 'Blood pharmacokinetic parameters: trough concentration (Cmin)', 'timeFrame': '24 hours'}, {'measure': 'Apparent clearance', 'description': 'Blood pharmacokinetic parameters: apparent clearance (Cl/F)', 'timeFrame': '0-24 hours'}, {'measure': 'Half-life', 'description': 'Blood pharmacokinetic parameters: half-life (T1/2)).', 'timeFrame': '0-24 hours'}, {'measure': 'AUC', 'description': 'Intracellular pharmacokinetic parameters: AUC', 'timeFrame': '0-24 hours'}, {'measure': 'Cmax', 'description': 'Intracellular pharmacokinetic parameters: Cmax', 'timeFrame': 'Cmax Advagraf: 2-3 hours, Cmax Envarsus: 6-8 hours'}, {'measure': 'Cmin', 'description': 'Intracellular pharmacokinetic parameters:Cmin', 'timeFrame': '24 hours'}, {'measure': 'CI/F', 'description': 'Intracellular pharmacokinetic parameters: Cl/F', 'timeFrame': '0-24 hours'}, {'measure': 'T1/2', 'description': 'Intracellular pharmacokinetic parameters:T1/2', 'timeFrame': '0-24 hours'}, {'measure': 'ABCB1 genotypes', 'description': 'ABCB1 genotypes', 'timeFrame': 'Day 0'}, {'measure': 'Others genotypes', 'description': 'Other genotypes of interest coding for metabolism (CYP3A4, CYP3A5…) or drug transport (CNT3…).', 'timeFrame': 'Day 0'}]",12,18 Years,,ALL,True,Rennes University Hospital,OTHER,0,27.0,ACTUAL,2025-09-01T16:18:14.657221,v2_robust,True,True,True,False,False,
NCT02014064,Safety Study to Assess Atomoxetine With MA Abusers and Healthy Controls,"A Study to Assess the Cardiovascular, Cognitive and Subjective Effects of Atomoxetine in Combination With Intravenous Methamphetamine",Atomoxetine,"['Strattera', 'Atomoxetine']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Continuous Methamphetamine Dependence,"['Continuous Methamphetamine Dependence', 'Methamphetamine Dependence in Remission']","['Methamphetamine, Atomoxetine, Clinical Pharmacology']",COMPLETED,,2009-08,2012-08,"[{'measure': 'Cardiovascular & Subjective Effects of Methamphetamine & Atomoxetine', 'description': 'Participants will be followed for the duration of the study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}]","[{'measure': 'The effects of administration of atomoxetine on the preference of MA-using subjects for MA (0 and 15mg, IV) versus escalating doses of money, from $0.25 to $64 in a Multiple-Choice Procedure.', 'description': 'Participants will be followed for the duration of study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'The effects of atomoxetine administration on cognitive function, as determined by measures of performance on cognitive tests, such as working memory tasks and reaction time tests', 'description': 'Participants will be followed for the duration of study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}, {'measure': 'The effects of administration of atomoxetine on BOLD fMRI signals in the brain in MA users and normal controls.', 'description': 'Participants will be followed for the duration of study, an expected average of 4 weeks', 'timeFrame': '4 weeks'}]",4,18 Years,50 Years,ALL,True,"University of California, Los Angeles",OTHER,0,41.0,ACTUAL,2025-09-01T16:18:14.657350,v2_robust,True,True,True,False,False,
NCT00824564,Study Of Tranexamic Acid For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture,Prospective Randomized Phase IV Open Label Comparative Study Of Tranexamic Acid Plus Standard Of Care Versus Standard Of Care For The Reduction Of Blood Loss In Patients Undergoing Surgery For Long Bone Fracture,Tranexamic Acid plus standard of care,['Tranexamic Acid plus standard of care'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Femoral Fractures,['Femoral Fractures'],"['Tranexamic Acid', 'Blood Loss', 'Long Bone Fracture Surgery']",COMPLETED,,2009-04,2010-06,"[{'measure': 'Total Blood Loss', 'description': 'Total blood loss was defined as the sum of intra-operative and post-operative blood loss. It was measured by weighing the drapes/ dressings or swabs prior to soaking to measure difference in weight and checking drain collectors until drains were removed.', 'timeFrame': 'Baseline through Day 7 post-surgery'}]","[{'measure': 'Intra-operative Blood Loss', 'description': 'Intra-operative blood loss was measured by weighing the drapes/ dressings or swabs prior to soaking to measure difference in weight and checking drain collectors until drains were removed.', 'timeFrame': 'Day 1 (End of surgery)'}, {'measure': 'Post-operative Blood Loss', 'description': 'Post-operative blood loss was defined as the sum of the drainage volumes measured over post-operative days 1, 2, and at drain removal. It was measured by weighing the drapes/ dressings or swabs prior to soaking to measure difference in weight and checking drain collectors until drains were removed.', 'timeFrame': '1, 4, 8 and 24 hours post-surgery'}, {'measure': ""Total Blood Loss Assessed by Gross' Formula"", 'description': ""Gross's formula for estimating total blood loss: Estimated blood volume\\*\\[(Hematocrit initial - Hematocrit final)/ Hematocrit average\\]; where estimated blood volume equals body weight in kilograms (kg) \\*70 mL/kg."", 'timeFrame': 'Day 7 post-surgery'}, {'measure': 'Number of Participants Receiving Transfusions', 'description': 'A uniform transfusion protocol was maintained for all participants in the study. Transfusion to be triggered at 8.0 milligram/deciliter (mg/dl) hemoglobin or haematocrit value of 24 percent.', 'timeFrame': 'Up to day 7 post-surgery'}, {'measure': 'Change From Baseline in Hemoglobin Levels at End of Surgery, 1 hr Post-surgery, and Mornings of Day 1, Day 2, Day 4, Day 7 or Early Termination (ET) Post-surgery', 'timeFrame': 'Baseline through end of surgery, 1 hr post-surgery, and mornings of Day 1, Day 2, Day 4, Day 7 or ET post-surgery'}, {'measure': 'Number of Participants With Deep Vein Thrombosis (DVT) Post Surgery', 'description': 'DVT was defined if a segment of the deep vein of the lower limb was not compressible or a previous compressive vein became non compressive or there was no flow in the underlying vessel. Symptoms of DVT included pain in the lower limb, localized tenderness, swelling and warmth.', 'timeFrame': 'Day 5 post-surgery'}]",7,18 Years,50 Years,ALL,False,Pfizer,INDUSTRY,0,82.0,ACTUAL,2025-09-01T16:18:14.657428,v2_robust,True,True,True,False,False,
NCT03221764,Intraoperative Amiodarone to Prevent Atrial Fibrillation in Lung Transplant Patients,The Intra-Operative Application of Amiodarone Releasing Hydrogel to Prevent Postoperative Atrial Fibrillation in Patients Undergoing Lung Transplantation,Amiodarone with CoSeal,"['Amiodarone with CoSeal', 'Amiodarone with CoSealadministered with CO2 driver']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Atrial Fibrillation,"['Atrial Fibrillation', 'Lung Transplant; Complications']",[],COMPLETED,,2017-10-19,2019-04-01,"[{'measure': 'Post Operative Atrial Fibrillation', 'description': 'Patient that developed atrial fibrillation after undergoing lung transplantation', 'timeFrame': 'Patients will be monitored for up to one year following lung transplant'}]","[{'measure': 'Atrial Fibrillation Requiring Intervention', 'description': 'Patients that underwent cardioversion or ablation due to post operative atrial fibrillation', 'timeFrame': 'From transplant to discharge from hospital, up to 1 year'}, {'measure': 'Anti-Arrhythmic Medication at Discharge', 'description': 'Patients that required anti-arrhythmic medication at the time of discharge for post operative atrial fibrillation.', 'timeFrame': '1 year'}]",3,18 Years,,ALL,False,University of Louisville,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:14.657473,v2_robust,True,True,True,False,False,
NCT00928564,Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia,Addition of Pudendal Blocks to Pelvic Floor Physical Therapy for the Treatment of Pelvic Floor Tension Myalgia: A Randomized Controlled Trial,Pudendal block,"['Pudendal block', 'saline', 'Placebo', 'regional nerve block anesthesia (drug)']",4,INTERVENTIONAL,['NA'],,,Pelvic Floor Muscle Spasm,['Pelvic Floor Muscle Spasm'],"['Pelvic floor muscle spasm', 'Pelvic pain', 'physical therapy', 'pudendal block']",COMPLETED,,2009-04,2016-05,"[{'measure': 'Visual Analog Pain Score After 6 Weekly Injections', 'description': '10 point likert scale to report pain a score from zero for no pain to ten for the worst possible pain', 'timeFrame': 'up to 8 weeks'}]","[{'measure': 'Improvement in Pelvic Floor Symptoms as Assessed Through Validated Questionnaires', 'description': 'The Pelvic Floor Distress Inventory (PFDI) has 20 items and 3 scales, the response scale is from 0-4. Summary scores range from 0-300 with higher scores indicating more distress.', 'timeFrame': 'up to 6 months'}]",2,18 Years,,FEMALE,False,"University of California, Irvine",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:14.657504,v2_robust,True,True,True,False,False,
NCT05919264,FOG-001 in Locally Advanced or Metastatic Solid Tumors,A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors,FOG-001,"['Nivolumab', 'Leucovorin, 5-fluorouracil, Oxaliplatin', 'Opdivo', 'Avastin', 'Trifluridine/tipiracil', 'Lonsurf', 'FOG-001', 'mFOLFOX-6', 'Bevacizumab']",9,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cancer,"['Cancer', 'Colorectal Cancer', 'Solid Tumor', 'Locally Advanced Solid Tumor', 'Metastatic Cancer', 'WNT Pathway', 'β-catenin', 'Beta-catenin', 'Adenomatous Polyposis Coli', 'APC', 'HCC', 'Desmoid', 'Microsatellite Stable Colorectal Cancer', 'Metastatic Castration-resistant Prostate Cancer', 'FAP', 'Endometrial Carcinoma', 'Prostate Cancer', 'Microsatellite Instability-High Colorectal Cancer', 'CTNNB1', 'Adamantinomatous Craniopharyngioma']","['Cancer', 'Solid Tumor', 'Locally Advanced Solid Tumor', 'Metastatic Cancer', 'WNT Pathway Activating Mutation (WPAM)', 'Colorectal Cancer (CRC)', 'Microsatellite Stable (MSS)']",RECRUITING,,2023-05-23,2027-08-31,"[{'measure': 'During dose escalation and dose expansion measure incidence and severity of treatment emergent adverse events by CTCAE v5.0', 'description': 'Number and severity of treatment emergent adverse events as assessed by CTCAE v5.0', 'timeFrame': 'Through study completion, an average of 10 months'}, {'measure': 'During dose escalation characterize dose-limiting toxicities (DLTs)', 'description': 'Incidence of DLTs', 'timeFrame': '1 treatment cycle (28 days)'}, {'measure': 'During dose expansion describe the Overall Response Rate using RECIST v1.1', 'description': 'The rate of objective responses (Partial \\& Complete) using RECIST v1.1', 'timeFrame': 'Every 63 days until study completion, approximately 10 months on average'}, {'measure': 'During dose expansion describe the Disease Control Rate using RECIST v1.1 (Part 2a only)', 'description': 'The rate of objective responses (Stable, Partial, \\& Complete) using RECIST v1.1', 'timeFrame': '4 months'}, {'measure': 'During dose expansion describe the PSA30 response rate for participants with prostate cancer', 'description': 'The response to treatment as a 30% or greater reduction in PSA levels from baseline', 'timeFrame': 'Baseline, weekly during the first 2 cycles (56 days), bi-weekly during the Cycle 3 (28 days), and then monthly (up to approximately 7 months)'}]","[{'measure': 'Maximum observed plasma concentration (Cmax) of FOG-001 and associated metabolites', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'Time to achieve Cmax (Tmax) of FOG-001 and associated metabolites in plasma', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'Area under the plasma concentration-time curve (AUC) of FOG-001 and associated metabolites', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'Plasma trough concentration (Ctrough) of FOG-001 and associated metabolites', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'Clearance (CL) of FOG-001 from the plasma', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'Volume of distribution of FOG-001', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'During dose escalation select the preliminary recommended Phase 2 dose and dosing schedule of study drug Rate of DLTs across dose levels', 'timeFrame': 'During Cycle 1 (28 days)'}, {'measure': 'During dose escalation Part 1b to evaluate the pharmacodynamic activity in tumors', 'description': 'Change in tumor Myc expression (on-study compared to baseline)', 'timeFrame': 'During first 2 cycles (56 days)'}, {'measure': 'During dose escalation and expansion to describe Best Overall Response Rate using RECIST v1.1', 'description': 'Best response to treatment using RECIST v1.1', 'timeFrame': 'Every 63 days until study completion, approximately 10 months on average'}, {'measure': 'During dose escalation and expansion to describe Duration of Response using RECIST v1.1', 'description': 'Time from initial objective response (partial response or complete response) to disease progression', 'timeFrame': 'Every 63 days until study completion, approximately 10 months on average'}, {'measure': 'During dose escalation and expansion describe Progression Free Survival', 'description': 'Progression Free Survival (PFS) using RECIST v1.1', 'timeFrame': 'From date of randomization until the date of first disease progression, an average of 10 months'}, {'measure': 'During dose escalation and expansion describe the Disease Control Rate using RECIST v1.1', 'description': 'The rate of objective responses (Stable, Partial, \\& Complete) using RECIST v1.1', 'timeFrame': 'Every 63 days until study completion, approximately 10 months on average'}, {'measure': 'During dose escalation and expansion describe the Time To Progression using RECIST v1.1', 'description': 'Time To Progression (TTP) using RECIST v1.1', 'timeFrame': 'From date of randomization until the date of first disease progression, an average of 10 months'}, {'measure': 'During dose escalation and expansion describe radiographic Progression Free Survival for participants with prostate cancer', 'description': 'Radiographic Progression Free Survival (rPFS) using PCWG3 assessment criteria', 'timeFrame': 'From date of randomization until the date of first disease progression, an average of 10 months'}]",19,18 Years,,ALL,False,"Parabilis Medicines, Inc.",INDUSTRY,0,480.0,ESTIMATED,2025-09-01T16:18:14.657521,v2_robust,True,True,False,False,True,
NCT03891264,Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain,Investigation of Cannabidiol for Reduction of NeuroInflammation in Chronic Back Pain,Cannabidiol,"['Cannabidiol', 'Epidiolex']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Back Pain, Low","['Back Pain, Low']",[],TERMINATED,Funding obtained to do a larger placebo-controlled trial,2019-11-13,2020-11-23,"[{'measure': 'Changes in Brain Positron Emission Tomography Signal', 'description': 'The investigators will test for the presence of a significant treatment effect in the brain \\[11C\\]PBR28 signal.', 'timeFrame': '4 weeks'}]","[{'measure': 'Changes in Pain Outcomes as Measured by Self Report on a 0-10 Numerical Pain Rating Scale (Worst Pain in the Past 24 Hours).', 'description': 'The investigators will test for the presence of a significant treatment effect in pain outcomes on a self reported numerical (0-10) pain rating scale. Higher number indicates worse pain.', 'timeFrame': '4 weeks'}]",2,18 Years,75 Years,ALL,False,Massachusetts General Hospital,OTHER,0,7.0,ACTUAL,2025-09-01T16:18:14.657617,v2_robust,True,True,False,True,False,Funding obtained to do a larger placebo-controlled trial
NCT06272409,Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children.,"Phase III, Multicenter, Double-blind, Planned, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children Aged Between 6 and 11 Years",DEP114,"['Desloratadine 0.5 MG/ML', 'DEP114']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Allergic Rhinitis,['Allergic Rhinitis'],[],NOT_YET_RECRUITING,,2025-02-15,2027-04-15,"[{'measure': 'To demonstrate the superiority of DEP114 in relation to desloratadine 0.5 mg/mL in relieving the nasal symptoms of moderate to severe persistent allergic rhinitis in children, five days after starting treatment.', 'description': 'Global improvement in nasal symptoms (absolute variation in total nasal symptoms score obstruction, runny nose, itching and sneezing, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) five days after the start of treatment.', 'timeFrame': '5 days'}]","[{'measure': 'To evaluate the effectiveness of DEP114 in relieving nasal symptoms of moderate to severe persistent allergic rhinitis in children, throughout the treatment.', 'description': 'Global improvement in nasal symptoms throughout treatment (absolute variation in the total score of nasal symptoms, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) on days 1, 2, 3, 4 and 5.\n\nImprovement of nasal symptoms three days after the start of the treatment (proportion of participants with improvement in total nasal symptoms score, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) three days after the start of treatment, with improvement in total nasal symptoms score change of at least 4 points on day 3 compared to at baseline).', 'timeFrame': '1-5 days'}, {'measure': 'Evaluate the efficacy of DEP114 to relieve nasal obstruction present in moderate to severe persistent allergic rhinitis in children through the treatment.', 'description': 'Improvement of nasal obstruction throughout treatment (absolute variation in total nasal symptoms score obstruction, where 0=no symptoms, 1=mild symptoms, 2=moderate symptoms and 3=severe symptoms) on days 1, 2, 3, 4 and 5.', 'timeFrame': '1-5 days'}, {'measure': 'Evaluate the efficacy of DEP114 to relieve coryza present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment.', 'description': 'Improvement of the runny nose three and five days after the start of the treatment (distribution of participants according to intensity of coryza at baseline, three and five days after the start of treatment).', 'timeFrame': '3 and 5 day'}, {'measure': 'Evaluate the efficacy of DEP114 to relieve nasal itching present in moderate to severe persistent allergic rhinitis in children, three and five days after the start of treatment.', 'description': 'Improvement of nasal itching three and five days after the onset treatment (distribution of participants according to intensity of nasal itching at baseline, three and five days after starting treatment).', 'timeFrame': '3 and 5 day'}, {'measure': 'Evaluate the efficacy of DEP114 to relieve sneezing present in persistent allergic rhinitis moderate to severe in children, three and five days after the start of treatment.', 'description': 'Improvement in sneezing three and five days after the start of the treatment (distribution of participants according to intensity of sneezing at baseline, three and five days after starting treatment).', 'timeFrame': '3 and 5 day'}, {'measure': 'Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the perception of the person responsible for the participant.', 'description': 'Overall assessment of the treatment by the person responsible for the treatment participant five days after the start of treatment (distribution of participants according to a 5-point categorical scale, where 0=very bad, 1=bad, 2=neither good nor bad, 3=good, 4=very good).', 'timeFrame': '5 day'}, {'measure': ""Evaluate the efficacy of DEP114 to relieve symptoms of moderate to severe persistent allergic rhinitis in children according to the investigator's perception."", 'description': 'Overall assessment of treatment by the investigator five days after the start of treatment (distribution of participants according to a 5-point categorical scale, where 0=very bad 1=bad, 2=neither good nor bad, 3=good, 4=very good).', 'timeFrame': '5 day'}]",8,6 Years,11 Years,ALL,False,EMS,INDUSTRY,0,318.0,ESTIMATED,2025-09-01T16:18:14.657656,v2_robust,True,True,False,False,False,
NCT04309409,"Adjuvant Nivolumab Treatment in Stage II (IIA, IIB, IIC) High-risk Melanoma","Adjuvant Nivolumab Treatment in Stage II High-risk Melanoma - A Randomized, Controlled, Phase III Trial With Biomarker-based Risk Stratification",Nivolumab,"['Nivolumab', 'Opdivo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Malignant Melanoma Stage II,['Malignant Melanoma Stage II'],"['Stage II malignant melanoma', 'patients having undergone surgery', 'IIA melanoma', 'IIB melanoma', 'IIC melanoma']",ACTIVE_NOT_RECRUITING,,2020-07-01,2028-01,"[{'measure': 'Relapse-Free Survival (RFS) rates', 'description': 'Determination of efficacy of nivolumab in a biomarker-selected high-risk-enriched stage II melanoma patient population in comparison to control receiving observation only in a 2 (Arm A=nivolumab) : 1 (Arm B=observation) randomization, as measured by Relapse-Free Survival (RFS) rates at 36 and 60 months.\n\nRFS is defined as the time from date of registration until documented tumor progression date or date of death of any cause, whichever occurs first in all patients tested with the MelaGenix gene expression profiling (GEP).', 'timeFrame': '5 years'}]","[{'measure': 'Distant metastasis-free survival (DMFS) rates', 'description': 'DMFS rates at 36 and 60 months', 'timeFrame': '5 years'}, {'measure': 'Melanoma-specific survival (MSS) rates', 'description': 'MSS rates at 36 and 60 months', 'timeFrame': '5 years'}, {'measure': 'Overall survival (OS) rates', 'description': 'OS rates at 36 and 60 months', 'timeFrame': '5 years'}, {'measure': 'Adverse events ≥ Grade 3 according to CTCAE Version 5.0 criteria (Safety / Toxicity)', 'description': 'All adverse events ≥ Grade 3 according to CTCAE Version 5.0 criteria, that are definitely, probably, or possibly related to the administration of the investigational agent', 'timeFrame': 'Arm A: Until 100 days after discontinuation of dosing of the investigational product; Arm B: Until 1 year after patient´s written consent'}, {'measure': 'Clinical utility/decision impact of the MelaGenix Gene Expression Profiling (GEP) Score in stratifying patients for adjuvant therapy', 'description': 'Patients with a risk score of \\> 0.0 (HR 1.48, 1.11-1.98) will be classified as high risk for relapse. It is expected, that 61% of screened patients will belong to this group.\n\nPatients with a risk score of score of ≤ 0.0 will be classified as low risk for relapse.', 'timeFrame': '5 years'}]",6,18 Years,80 Years,ALL,False,"University Hospital, Essen",OTHER,0,374.0,ESTIMATED,2025-09-01T16:18:14.657738,v2_robust,True,True,False,False,True,
NCT00920309,Rapamycin as Treatment for Autosomal Dominant Polycystic Kidney Disease (ADPKD): The Role of Biomarkers in Predicting a Response to Therapy,Rapamycin as Treatment for ADPKD: The Role of Biomarkers in Predicting a Response to Therapy,Rapamycin,"['sirolimus', 'Rapamycin']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Autosomal Dominant Polycystic Kidney Disease,['Autosomal Dominant Polycystic Kidney Disease'],"['Autosomal Dominant Polycystic Kidney Disease', 'rapamycin', 'ADPKD']",TERMINATED,This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD,2009-06,2010-07,"[{'measure': 'Total Kidney Volume (mL)', 'timeFrame': '2 years'}]","[{'measure': 'Glomerular Filtration Rate (Kidney Function)', 'timeFrame': '2 years'}]",2,18 Years,70 Years,ALL,True,Yale University,OTHER,0,21.0,ACTUAL,2025-09-01T16:18:14.657796,v2_robust,True,True,False,True,False,This study was stopped after larger studies published in the NEJM failed to show a benefit in treating ADPKD
NCT04705909,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer,Pitavastatin,"['HMG CoA reductase inhibitor "" Lipovastatin""', 'Pitavastatin', 'placebo']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Breast Cancer,['Breast Cancer'],[],UNKNOWN,,2021-01-15,2021-12-15,"[{'measure': 'clinical response rate', 'description': 'Response to preoperative therapy as per ultrasonographic tumor size assessment. A responder will have \\> 50% decrease in the size of the primary tumor without appearance of new lesions.', 'timeFrame': '6 months'}, {'measure': 'Relative reduction of Ki67 in tumor samples', 'description': 'It will be described as average pre-post differences in percent positive cells with 95% Wilson confidence intervals.', 'timeFrame': '6 months'}]","[{'measure': 'The change in Cyclin D1 (candidate marker associated with breast tumor proliferation)', 'timeFrame': 'Baseline up to 6 months'}, {'measure': 'The change in Cleaved caspase-3 (CC3) (candidate marker associated with tumor apoptosis)', 'timeFrame': 'Baseline up to 6 months'}]",4,18 Years,,FEMALE,False,Mansoura University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:14.657807,v2_robust,True,True,False,False,False,
NCT00500409,Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis,Safety and Efficacy of OSTEOFORM (rhPTH [1-34]) in Increasing Bone Mineral Density in Osteoporosis. A Randomized Controlled Open-label Multicentre Study in India,Osteoform,"['Calcium and vitamin D', 'Osteoform', 'SHELCAL']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Osteoporosis,['Osteoporosis'],"['rhPTH(1-34)', 'Osteoporosis']",COMPLETED,,2005-12,2007-07,"[{'measure': 'Percentage of change in Bone Mineral Density at lumber spine (L1-L4) in postmenopausal women with osteoporosis at the end of 6 and 12 months.', 'timeFrame': '6 and 12 months'}]","[{'measure': 'Percentage of change from baseline in biomarkers of bone formation and bone resorption at the end of 3, 6 and 12 months.', 'timeFrame': '3, 6 and 12 months'}]",2,45 Years,75 Years,FEMALE,False,Virchow Group,INDUSTRY,0,82.0,ACTUAL,2025-09-01T16:18:14.657824,v2_robust,True,True,True,False,False,
NCT05189509,EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT),"EXtending the tIme Window of Thrombolysis by ButyphThalide up to 6 Hours After Onset (EXIT-BT): a Prospective, Randomized, Blinded Assessment of Outcome and Open Label Multi-center Study",TNK-Tissue Plasminogen Activator,['TNK-Tissue Plasminogen Activator'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Stroke, Ischemic","['Stroke, Ischemic']",[],COMPLETED,,2022-02-11,2022-12-28,"[{'measure': 'symptomatic intracerebral hemorrhage', 'description': 'any evidence of bleeding on the head CT scan associated with clinically significant neurological deterioration (NIHSS score ≥4 points increase)', 'timeFrame': '36 hours'}]","[{'measure': 'The proportion of excellent prognosis (mRS 0-1)', 'description': 'the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome', 'timeFrame': 'Day 90'}, {'measure': 'The proportion of favourable prognosis (mRS 0-2)', 'description': 'the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome', 'timeFrame': 'Day 90'}, {'measure': 'Distribution of modified Rankin Score', 'description': 'the minimum and maximum values of modified Rankin Score are 0 and 6, respectively; higher score mean a worse outcome', 'timeFrame': 'Day 90'}, {'measure': 'Changes in National Institute of Health stroke scale (NIHSS)', 'description': 'the minimum and maximum values of NIHSS are 0 and 42, respectively; higher NIHSS mean a worse outcome', 'timeFrame': '24 hours, 2 weeks'}, {'measure': 'any intracerebral hemorrhage', 'description': 'the evidence of bleeding on the head CT scan', 'timeFrame': '36 hours'}, {'measure': 'any cerebral microbleeding(CMB)', 'description': 'CMB is measured by SWI sequence', 'timeFrame': '48 hours'}, {'measure': 'infarct volume', 'description': 'infarct volume is measured by DWI sequence', 'timeFrame': '48 hours'}, {'measure': 'proportion of death', 'description': 'death due to any cause', 'timeFrame': 'Day 90'}]",9,18 Years,80 Years,ALL,False,General Hospital of Shenyang Military Region,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:14.657938,v2_robust,True,True,True,False,False,
NCT00474409,A Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation,"A Multicenter, Placebo-Controlled, Double-Blind Study To Evaluate The Efficacy And Safety Of Betahistine Mesilate In The Treatment Of Patients With Vertigo Caused By Cerebral Infarction In Posterior Circulation",Merislon,['Merislon'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Vertigo,['Vertigo'],"['Vertigo', 'Posterior circulation infarction']",WITHDRAWN,"Due to poor enrollment, this study was withdrawn/ terminated.",2007-05,,"[{'measure': 'Changes in the European Evaluation of Vertigo (EEV) scale in 4 weeks.', 'timeFrame': '4 weeks'}]",[{'measure': 'The duration of the vertigo symptom.'}],2,18 Years,80 Years,ALL,False,Eisai Inc.,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:14.658239,v2_robust,True,True,False,True,False,"Due to poor enrollment, this study was withdrawn/ terminated."
NCT06712199,Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery,"Effect of Oxalidine Combined with Reduced-opioid Anesthesia on Multimodal Analgesia in Morbidly Obese Patients Undergoing Bariatric Surgery: a Prospective, Single-center, Randomized, Parallel Controlled Study",oxalidine,"['Less opioids for anesthesia', 'oxalidine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Morbid Obesity,['Morbid Obesity'],"['Oxeridine', 'Hypopiate anesthesia', 'Multimodal analgesia', 'Morbid obesity']",NOT_YET_RECRUITING,,2025-01-01,2026-12-31,"[{'measure': 'Oral morphine equivalent (OME) opioid consumption in the 24 hours prior to surgery', 'timeFrame': '24 hours after surgery'}]","[{'measure': 'Area under the NRS score curve at rest and exercise 72 hours after surgery (AUC)', 'description': 'Area under the NRS score curve at rest and exercise 72 hours after surgery (AUC)', 'timeFrame': 'Within 72 hours after surgery'}]",2,18 Years,,ALL,True,Yongtao Sun,OTHER,1,124.0,ESTIMATED,2025-09-01T16:18:14.658264,v2_robust,True,True,False,False,False,
NCT00334399,Double-Blind Trial of Miglitol in Type 2 Diabetic Patients Treated With Biguanide,,Miglitol,['Miglitol'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],"['alpa-glucosidase inhibitor,Biguanide']",COMPLETED,,,,[],[],0,20 Years,69 Years,ALL,False,"Sanwa Kagaku Kenkyusho Co., Ltd.",INDUSTRY,0,,,2025-09-01T16:18:14.658391,v2_robust,True,True,True,False,False,
NCT05341999,Effect of Cryotherapy Versus Post-operative Ibuprofen Medication on Post-operative Pain in Mandibular Molar Teeth With Symptomatic Irreversible Pulpitis,Evaluation of the Effect of Cryotherapy Versus Post-operative Ibuprofen Medication on Post-operative Pain in Mandibular Molar Teeth With Symptomatic Irreversible Pulpitis: a Randomized Controlled Trial,Ibuprofen 400 mg,['Ibuprofen 400 mg'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Symptomatic Irreversible Pulpitis,['Symptomatic Irreversible Pulpitis'],[],UNKNOWN,,2022-04,2023-05,"[{'measure': 'Post-operative pain', 'description': 'The pain will be recorded using the modified visual analogue scale (VAS). • 0, ""no pain""\n\n* 1-3, ""mild pain""\n* 4-6, ""moderate pain""\n* 7-10, ""severe pain"" ""10"" being the most intense pain conceivable.', 'timeFrame': '6 hours post-operatively'}, {'measure': 'Post-operative pain', 'description': 'The pain will be recorded using the modified visual analogue scale (VAS). • 0, ""no pain""\n\n* 1-3, ""mild pain""\n* 4-6, ""moderate pain""\n* 7-10, ""severe pain"" ""10"" being the most intense pain conceivable.', 'timeFrame': '24 hours post-operatively'}, {'measure': 'Post-operative pain', 'description': 'The pain will be recorded using the modified visual analogue scale (VAS). • 0, ""no pain""\n\n* 1-3, ""mild pain""\n* 4-6, ""moderate pain""\n* 7-10, ""severe pain"" ""10"" being the most intense pain conceivable.', 'timeFrame': '48 hours post-operatively'}]",[],3,18 Years,60 Years,ALL,True,Cairo University,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:14.658417,v2_robust,True,True,False,False,False,
NCT05024799,Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation,Effect of Different Sedation and Analgesia Strategies on Patients With Mechanical Ventilation,"Fentanyl, propofol","['Butorphanol and dexmedetomindine', 'fentanyl and dexmedetomindine', 'Butorphanol and propofol', 'Fentanyl, propofol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Respiratory Insufficiency,['Respiratory Insufficiency'],[],UNKNOWN,,2022-01,2024-12,"[{'measure': 'ventilator-free days at 28 days', 'timeFrame': 'at 28 days'}]",[],1,18 Years,,ALL,False,The Affiliated Hospital of Qingdao University,OTHER,0,300.0,ESTIMATED,2025-09-01T16:18:14.658461,v2_robust,True,True,False,False,False,
NCT00206999,The Effect of Imipramine on Early Information Processing,Early Information Processing in Healthy Controls: Studies on the Relation Between Two Different Paradigms (PPI and P50ERP) and Effects of Pharmacological Interventions,imipramine,['imipramine'],1,INTERVENTIONAL,['NA'],,,Healthy Volunteers,['Healthy Volunteers'],"['Psychophysiology', 'PPI', 'P50 suppression', 'Imipramine']",COMPLETED,,2004-09,2006-01,"[{'measure': 'Sensory gating', 'timeFrame': 'Once, 1 hour after administration of capsule'}]","[{'measure': 'PPI of the startle reflex', 'timeFrame': 'once, one hour after administration'}, {'measure': 'P50 suppression', 'timeFrame': 'once, one hour after administration'}]",3,18 Years,35 Years,MALE,True,Birte Glenthoj,OTHER,4,20.0,ACTUAL,2025-09-01T16:18:14.658483,v2_robust,True,True,True,False,False,
NCT04157699,An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b,"An Open-Label Phase 2 Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b: a Multicenter, Randomized, Positive Controlled Clinical Trial",TDF tablet,"['TDF tablet', 'Tenofovir disoproxil fumarate tablet', 'QL-007']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Hepatitis b,['Chronic Hepatitis b'],['HBeAg-positive chronic hepatitis B'],UNKNOWN,,2019-07-26,2022-10,"[{'measure': 'To evaluate the efficacy of QL-007 in combination with TDF in patients with HBeAg-positive chronic hepatitis b: HBV DNA level', 'description': 'The change of HBV DNA level at week 24 of treatment compared to baseline', 'timeFrame': '24 weeks'}]","[{'measure': 'serological indexs', 'description': 'The changes of HBsAg and HBeAg level from baseline at week 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96', 'timeFrame': '96 weeks'}, {'measure': 'serological indexs', 'description': 'The percentage of subjects with HBsAg and HBeAg serological clearance and/or seroconversion at week 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96', 'timeFrame': '96 weeks'}, {'measure': 'Virological indexs', 'description': 'The changes of HBV DNA level compared to baseline at week 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96', 'timeFrame': '96 weeks'}, {'measure': 'Virological indexs', 'description': 'The rate of HBV DNA negative subjects (HBV DNA \\<60 IU/mL) at week 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96', 'timeFrame': '96 weeks'}, {'measure': 'biochemistry index', 'description': 'The changes of ALT at week 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84, 96 compared to baseline', 'timeFrame': '96 weeks'}, {'measure': 'biochemistry index', 'description': 'The percentage of subjects with normal ALT level at weeks 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84 and 96', 'timeFrame': '96 weeks'}, {'measure': 'Other evaluation indexes of pharmacodynamics exploration', 'description': 'The changes of HBV RNA and HBcrAg level compared with baseline at week 4, 8, 12, 16, 20, 24, 36, 48, 60, 72, 84 and 96', 'timeFrame': '96 weeks'}, {'measure': 'To evaluate the tolerance of QL-007 in combination with TDF: incidence of adverse events', 'description': 'The incidence of adverse events', 'timeFrame': '96 weeks'}]",9,18 Years,70 Years,ALL,False,"Qilu Pharmaceutical Co., Ltd.",INDUSTRY,0,100.0,ESTIMATED,2025-09-01T16:18:14.658496,v2_robust,True,True,False,False,True,
NCT02067299,A Study to Investigate the Effect of JNJ-42847922 on Polysomnography Measures in Patients With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants,"A Single Dose, 4-way Crossover, Placebo-controlled, Randomized Study to Investigate the Effect of JNJ-42847922 on Polysomnography (PSG) Measures in Subjects With Major Depressive Disorder With Insomnia Who Are Stably Treated With Antidepressants",JNJ-42847922,['JNJ-42847922'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,"Depressive Disorder, Major","['Depressive Disorder, Major']","['Depressive Disorder, Major', 'Major Depressive Disorder', 'Insomnia', 'JNJ-42847922', 'Placebo']",COMPLETED,,2014-02,2014-12,"[{'measure': 'Latency to Persistent Sleep (LPS) on Day 1', 'description': 'LPS is with lights off, appearance of first epoch of Stage 1 (light sleep), Stage 2 (light sleep), Stage 3 (deep sleep), and Stage 4 (rapid eye movement sleep) sleep followed by at least 20 consecutive epochs without any Stage 0 sleep (awake but sleepy). LPS will be accessed on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Day 1'}]","[{'measure': 'Number of participants with adverse events', 'timeFrame': 'Up to Week 10'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-42847922', 'description': 'Cmax is defined as maximum observed analyte concentration. This will be measured on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Predose, and postdose Day 1 (20 minutes, 8 hours 20 minutes, and 12 hours)'}, {'measure': 'Time to Reach Maximum Observed Plasma Concentration (Tmax) of JNJ-42847922', 'description': 'Tmax is defined as actual sampling time to reach maximum observed analyte concentration. This be measured on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Predose, and postdose Day 1 (20 minutes, 8 hours 20 minutes, and 12 hours)'}, {'measure': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Time 12 (AUC[12])', 'description': 'Area Under the Plasma Concentration-Time Curve From Time Zero to Time 12 is area under the plasma concentration-time curve from 0 to 12 hours post dosing. This will be measured on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Predose, and postdose Day 1 (20 minutes, 8 hours 20 minutes, and 12 hours)'}, {'measure': 'Total amount of JNJ-42847922 excreted in urine (Ae12)', 'description': 'Total amount of JNJ-42847922 excreted in urine is expressed as a percentage of dose administered. This will be measured overnight after the administration of the study medication on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Predose and postdose Day 1'}, {'measure': 'Renal clearance (CLR)', 'description': 'CLR will be measured overnight after the administration of the study medication on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Predose and postdose Day 1'}, {'measure': 'Number of participants with suicidal ideation or behavior measured using Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'C-SSRS is a clinician rated assessment of suicidal behavior and / or intent. Scale consists of 28 items in 4 sections: suicide behavior, actual attempts, suicidal ideation, and intensity of ideation. Suicidal ideation consists of 5 yes/no items: wish to be dead, non-specific active suicidal thoughts, active suicidal ideation with any methods (not plan) without intention to act, active suicidal ideation with some intent to act without specific plan, active suicidal ideation with specific plan and intent. Only items with yes responses are listed. Worsening of suicidal ideation was an increase in severity of suicidal ideation from baseline. This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Total sleep time in participants', 'description': 'This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Sleep efficiency in participants', 'description': 'This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Next-day residual effect of JNJ-42847922 measured using visual analogue scale (VAS) for sleepiness', 'description': 'VAS scale is ued to measure subjective characteristics or attitudes that cannot be measured directly for sleepiness. VAS will assess whether the participants were feeling sleepy during the first hour after wake-up by using a 10 cm line, having sleepy/tired and awake at either end. The scores ranged from 0 to 100, with a high score reflecting a high level of anxiety. This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Next-day residual effect of JNJ-42847922 measured using the Bond and Lader visual analogue scale (VAS) to rate subjective feelings', 'description': 'The Bond-Lader Visual Analogue Scale (VAS) is made up of 16 pairs of alternative descriptors of mood and attention at either end of a 10 cm line. Participants were asked to rate their feelings at the time of assessment by indicating the point on the line which best represent their mood. Each item was scored by measuring the position relative to the left hand end of the line and levels of anxiety, sedation, and dysphoria were then calculated from the combined scores of selected items. The scores ranged from 0 to 100, with a high score reflecting a high level of anxiety, sedation or dysphoria. This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Next-day residual effect of JNJ-42847922 on body movements measured using a pot string meter and a stabilometric platform', 'description': 'A pot string meter includes a string attached the waist of the participant and all body movements over a period of time are integrated and expressed as mm sway. In a stabilometric platform, the participant will be made to sleep on a firm surface for about 51.2 seconds each with first eyes open and then eyes closed. This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Next-day residual effect of JNJ-42847922 on saccadic eye movements', 'description': 'Saccadic eye movements will be assessed using a computer-based system connected to electrodes placed lateral of the eyes or using infra-red technology. This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Number of participants with depressive symptoms measured using Quick Inventory of Depressive Symptomatology - Self Report 14-item (QIDS-SR14)', 'description': 'The QIDS-SR14, s a version of the QIDS-SR16 with a shorter, 24-hour recall period that has been developed for this trial. The total score ranges from 0 to 27. Using a scale of severity of depression of none, mild, moderate, severe, and very severe, corresponding QIDS-SR16 total scores are none 1-5, mild 6-10, moderate 11-15, severe 16-20 and very severe 21-27. Higher scores indicate worsening. This will be assessed on Days 1 and 2 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2), Day 1, and Day 2'}, {'measure': 'Concentration of cortisol in saliva', 'description': 'This will be measured on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Predose Day 1 (30 minutes and 90 minutes) and postdose Day 2 (at wake-up and 30 minutes after wake-up)'}, {'measure': 'Time spent awake by the participants', 'description': 'This will be assessed on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2) and Day 1'}, {'measure': 'Total time spent deep sleep by the participants', 'description': 'This will be assessed on Day 1 of each treatment period (Periods 1, 2, 3, and 4).', 'timeFrame': 'Screening (Day -28 to Day -2) and Day 1'}]",18,18 Years,64 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:14.658523,v2_robust,True,True,True,False,True,
NCT00420199,A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate,"A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate",Abatacept,"['(BMS-188667)', 'Abatacept', 'Orencia', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Active Rheumatoid Arthritis,['Active Rheumatoid Arthritis'],[],COMPLETED,,2007-05,2010-05,"[{'measure': 'Double-blind Period: Mean Synovitis Scores at Baseline As Measured by the Rheumatoid Arthritis Clinical Trials 6 (OMERACT 6) Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS)', 'description': 'Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\\*3 wrist regions), indicating most severe damage. Change in synovitis = Follow-up synovitis score - baseline score.', 'timeFrame': 'At baseline'}, {'measure': 'Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Planned Analysis Using Non-Parametric ANCOVA', 'description': 'Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\\*3 wrist regions), indicating most severe damage. Change in synovitis=Follow-up synovitis score-baseline score.', 'timeFrame': 'Baseline to Day 113'}, {'measure': 'Double-blind Period: Mean Change From Baseline in OMERACT 6 Wrist Synovitis Score: Post Hoc Sensitivity Analysis Using Parametric ANCOVA Analysis', 'description': 'Wrist synovitis was assessed by postgadolinium MRI enhancement according to OMERACT 6 RAMRIS in 3 wrist regions: distal radioulnar, radiocarpal, and intercarpal and carpometacarpal joints. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3\\*3 wrist regions), indicating most severe damage. Change in synovitis score=Follow-up synovitis score-baseline synovitis score.', 'timeFrame': 'Baseline to Day 113'}]","[{'measure': 'Double-blind Period: Baseline Mean Erosion OMERACT 6 Scores', 'description': 'Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.', 'timeFrame': 'At baseline'}, {'measure': 'Double-blind Period: Adjusted Mean Change From Baseline in Erosion OMERACT 6 Scores', 'description': 'Bone erosion assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached hand. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage), indicating erosion (each unit=10% bone loss) of original articular bone. Total erosion score for hands/wrists is sum of the individual scores for each location. Thus the maximum score per hand/wrist is 230. Increasing score=greater severity. Adjusted change from baseline in erosion score=mean score at Day 113-mean erosion score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.', 'timeFrame': 'Baseline to Day 113'}, {'measure': 'Double-blind Period: Baseline Mean Osteitis OMERACT 6 Scores', 'description': 'Osteitis assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) \\* 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity.', 'timeFrame': 'At baseline'}, {'measure': 'Double-blind Period: Adjusted Mean Change From Baseline in Osteitis OMERACT 6 Scores', 'description': 'Osteitis assessed at 23 anatomic locations: 15 in 1 wrist and 8 in attached. Each site scored in 1.0 increments, indicating involvement of original articular bone (0=none to 3=severe). Total score for hands/wrists is sum of scores for each location. Maximum score per hand/wrist is 23 (total anatomic locations)\\*3 (maximum score per joint)=69. Minimum score=0(normal). Increasing score=greater severity. Adjusted mean change from baseline in osteitis score=mean score at Day 113-mean score at baseline. Adjustment based on ANCOVA model with treatment=factor and baseline value=covariate.', 'timeFrame': 'Baseline to Day 113'}, {'measure': 'Double-blind Period: Number of Participants With Newly Involved Joints in Bone Erosion, Edema/Osteitis, and Synovitis', 'description': 'Bone erosion and osteitis were assessed at a total of 23 anatomic locations according to erosion (for bone erosion) or involvement (for osteitis) of the original articular bone. Synovitis assessed as above-normal post-gadolinium enhancement in 3 wrist regions: distal radioulnar joint, radiocarpal joint, and intercarpal and carpometacarpal joints.', 'timeFrame': 'Baseline to Day 113'}, {'measure': 'Double-blind Period: Baseline Mean RAMRIS Scores', 'description': 'RAMRIS score is the sum of its core components: Synovitis Score, Osteitis Score, and Erosion Score. Synovitis scored from 0 (normal) to 9 (maximum distension of synovial cavity). Osteitis scored 0 (normal) to 69 (maximum articular bone involvement). Erosion scored from 0 (normal) to 230 (maximum erosion of articular bone). RAMRIS=Synovial Score + Osteitis Score + Erosion Score. Minimum RAMRIS score=0 (normal), maximum RAMRIS score=308 (severe structural damage). For Synovial Score, Osteitis Score, Erosion Score, and RAMRIS score, increasing number=increasing severity.', 'timeFrame': 'Baseline'}, {'measure': 'Double-blind Period: Adjusted Mean Change From Baseline in RAMRIS Scores', 'description': 'RAMRIS Score=sum of core components: Synovitis (S), Osteitis (O), and Erosion (E) Scores. S scored 0 (none) to 9 (maximum distension of synovial cavity); O scored 0 (none) to 69 (maximum articular bone involvement); E scored 0 (none) to 230 (maximum erosion of articular bone). RAMRIS=S+O+E Scores. RAMRIS minimum score=0 (normal), maximum=308 (severe structural damage). Adjusted change from baseline in RAMRIS=mean RAMRIS at Day 113-mean RAMRIS at baseline. Adjustment based on ANCOVA model: treatment=factor, baseline value=covariate.', 'timeFrame': 'Baseline to Day 113'}, {'measure': 'Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Formation: Osteocalcin and Serum Intact N-terminal Propeptide of Type I Procollagen (PINP)', 'description': 'PINP and osteocalcin are markers of bone formation. Osteocalcin is synthesized by osteoblasts and is associated with osteoblast synthetic activity. Osteoblasts secrete type 1 procollagen, and cleavage of large fragments from the carboxy and amino terminal ends result in formation of mature type 1 collagen and production of PINP fragments.', 'timeFrame': 'Baseline to Days 15, 29, 57, 85, and 113'}, {'measure': 'Double-blind Period: Median Percent Change From Baseline in Systemic Markers of Bone Destruction (Serum Carboxy-terminal Cross-linking Telopeptide of Type I Collagen [CTX-I] and Serum Pyridinoline Cross-linked Telopeptide Domain of Type I Collagen [ICTP])', 'description': 'CTX-I and ICTP are biochemical markers of bone resorption or bone degradation', 'timeFrame': 'Baseline to Days 15, 29, 57, 85, and 113'}, {'measure': 'Double-blind Period: Median Percent Change From Baseline in a Systemic Marker of Cartilage Degradation (Creatinine-corrected Urinary Carboxyterminal Crosslinking Telopeptide of Type II Collagen [UCTX2C])', 'description': 'Urinary CTX-II is a biochemical marker of type II collagen breakdown. In participants with early rheumatoid arthritis, increased levels of CTX-II can be predictive of rapid radiographic progression over periods of 1 to 5 years. These markers of cartilage destruction can predict progression of joint damage, independent of clinical and biologic indices of disease activity and baseline joint damage.', 'timeFrame': 'Baseline to Days 15, 29, 57, 85, and 113'}, {'measure': 'Double-blind Period: Median Percent Change From Baseline in Systemic Marker of Synovial Tissue Metabolism (Creatinine-corrected Urinary Glucosyl-Galactosyl-Pyridinoline [UGGPC])', 'description': 'Glucosyl-galactosyl-pyridinoline (Glc-Gal-PYD) is a specific biochemical marker reflecting the degradation of the synovial tissue membrane. It is a glycosylated derivative of the collagen crosslink pyridinoline, and it is present in significant amounts only in the synovial membrane; it is absent from bone and present in minutes amounts in cartilage and other soft tissues. Increased urinary levels of Glc-Gal-PYD have been found in early and long-standing rheumatoid arthritis, high levels being associated with rapid destruction.', 'timeFrame': 'Baseline to Days 15, 29, 57, 85, and 113'}, {'measure': 'Double-blind Period: Number of Participants With Death, Serious Adverse Events (SAEs), Treatment-related SAEs, SAEs Leading to Discontinuation, Adverse Events (AEs), Treatment-related AEs, and AEs Leading to Discontinuation', 'description': 'An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. An SAE is any unfavorable medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency or abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=possibly, probably, or certainly related to and of unknown relationship to study treatment.', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With AEs of Special Interest', 'description': 'An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs of special interest are those AEs that may be associated with the use of immunomodulatory drugs, including serious, opportunistic, and all other infections; autoimmune disorders; neoplasms; acute infusional AEs (prespecified AEs occurring within 1 hour of start of infusion) and peri-infusional AEs (prespecified AEs occurring within 24 hours of start of infusion).', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Infections/Infestations of Special Interest', 'description': 'Infections/Infestations of Special Interest are AEs and SAEs considered possibly, probably, or certainly related to study treatment, graded according to Common Terminology Criteria for Adverse Events Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death). AE=any new untoward medical occurrence or worsening of a preexisting medical condition which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Acute Infusional AEs of Special Interest', 'description': 'Acute infusional AEs are AEs with onset during the first hour after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events ,Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Peri-infusional AEs of Special Interest', 'description': 'Peri-infusional AEs are AEs occurring during the first 24 hours after the start of study drug infusion. An AE is any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that does not necessarily have a causal relationship with treatment. AEs considered possibly, probably, or certainly related to study treatment were graded according to Common Terminology Criteria for Adverse Events, Version 3.0 (Grade 1=Mild, Grade 2=Moderate, Grade 3=Severe, Grade 4=Life-threatening or disabling, Grade 5=Death).', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Laboratory Test Results in Hematology Meeting the Criteria for Marked Abnormality', 'description': 'BL=baseline; LLN=lower limit of normal; ULN=upper limit of normal. Marked abnormality criteria: Hemoglobin: \\>3 g/dL decrease from BL. Hematocrit: \\<0.75\\*BL. Erythrocytes: \\<0.75\\*BL. Platelets: \\<0.67\\*LLN/\\>1.5\\*ULN, or if BL \\<LLN, use 0.5\\*BL/\\<100,000 mm\\^3. Leukocytes: \\<0.75\\*LLN/\\>1.25\\*ULN, or if BL\\<LLN, use \\<0.8\\*BL/\\>ULN, or if BL\\>ULN, use \\>1.2\\*BL/\\<LLN. Neutrophils+bands: \\<1.0\\*10\\^3 c/uL. Eosinophils: \\>0.750\\*10\\^3 c/uL. Basophils: \\> 400 mm\\^3. Monocytes: \\>2000 mm\\^3. Lymphocytes: \\<0.750\\*10\\^3 c/uL/\\>7.50\\*10\\^3 c/uL.', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Laboratory Test Results for Liver and Kidney Function Meeting Criteria for Marked Abnormality', 'description': 'ULN=upper limit of normal; BL=baseline. Marked abnormality criteria: Alkaline phosphatase: \\>2\\*ULN, or if BL\\>ULN, use \\>3\\*BL; aspartate aminotransferase: \\>3\\*ULN, or if BL\\>ULN,use \\>4\\*BL; alanine aminotransferase: \\>3\\*ULN, or if BL\\>ULN, use \\>4\\*BL; G-Glutamyl transferase: \\>2\\*ULN, or if BL\\>ULN, use \\>3\\*BL; Bilirubin: \\>2\\*ULN, or if BL\\>ULN, use \\>4\\*BL; blood urea nitrogen: \\>2\\*BL; creatinine: \\>1.5\\*BL.', 'timeFrame': 'From Day 1 to Day 113, and including up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Laboratory Test Results for Electrolytes Meeting the Criteria for Marked Abnormality', 'description': 'LLN=lower limit of normal; ULN=upper limit of normal; BL=baseline. Marked abnormality: Sodium: \\<0.95\\*LLN/\\>1.05\\*ULN,or if BL\\<LLN, use 0.95\\*BL or \\>ULN,or if BL\\>ULN, use\\>1.05\\*BL or \\<LLN. Potassium: \\<0.9\\*LLN/\\>1.1\\* ULN,or if BL\\<LLN, use 0.9\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.1\\*BL or \\<LLN. Chloride: \\<0.9\\*LLN/\\>1.1\\*ULN, or if BL\\<LLN, use 0.9\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.1\\*BL or \\<LLN. Calcium: \\<0.8\\*LLN/\\>1.2\\*ULN, or if BL\\<LLN, use 0.75\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.25\\*BL or \\<LLN. Phosphorous: \\<0.75\\*LLN/\\>1.25\\*ULN, or if BL\\<LLN, use 0.67\\*BL or \\>ULN, or if BL\\>ULN, use\\>1.33\\*BL or \\<LLN.', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period: Number of Participants With Laboratory Test Results in Other Chemistries and Urinalysis Meeting the Criteria for Marked Abnormality', 'description': 'LLN=lower limit of normal; ULN=upper limit of normal; BL-baseline. Marked abnormality c: serum glucose:\\<65 mg/dL/\\>220 mg/dL; fasting serum glucose: \\<0.8\\* LLN/\\>1.5\\* ULN, or if BL\\<LLN, use 0.8\\*BL or \\>ULN, or if BL\\>ULN, use \\>2.0\\*BL or \\<LLN; total protein: \\<0.9\\*LLN/\\>1.1\\* ULN; albumin: \\<0.9\\*LLN,or if BL\\<LLN, use \\<0.75 BL; uric acid: \\>1.5\\* ULN, or if BL\\>ULN, use \\>2\\*BL. Urinalysis (Urine protein, urine Glu, urine blood, leukocyte esterase, red blood cells, white blood cells):Use ≥2 when BL value missing or value ≥4,or when predose=0 or 0.5. Use ≥3 when predose=1. Use ≥4 when predose=2 or 3', 'timeFrame': 'From Day 1 to Day 113, and up to 56 days post last dose of double-blind period, or start of first dose of open-label period'}, {'measure': 'Double-blind Period:Number of Participants With Significantly Abnormal Changes in Vital Signs', 'description': 'Vital signs, which included blood pressure, heart rate, respiration, and temperature, were monitored predose and 1 hour after start of infusion. Changes in vital signs were determined to be significantly abnormal at the discretion of the investigator but were generally those that either exceeded, or failed to reach, normal parameters. Normal vital sign parameter ranges varied by site.', 'timeFrame': 'Days 1, 15, 29, 57, 85, and 113'}, {'measure': 'Double-blind Period: Number of Participants With Positive Antibodies to Abatacept by Electrochemiluminescence (ECL) Assay', 'description': 'On-Rx=on treatment; post-Rx=post treatment. ECL screened sera for drug-specific antibodies; immunocompetition was used to identify specific anti-Abatacept reactivity. Cytotoxic leukocyte antigen 4 (CTLA4) and Possibly Immunoglobulin (Ig) Category=reactivity against extracellular domain of human CTLA4, constant regions of human IgG1, or both (CTLA4Ig; Abatacept molecule). Ig and/or Junction Category=reactivity against constant regions and/or hinge region of human IgG1.', 'timeFrame': 'Day 1 to Day 113'}]",25,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:14.658564,v2_robust,True,True,True,False,True,
NCT03263299,Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol,Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET Using Microdose GnRH Agonist Flare-Up-Protocol,cabergoline,"['Aspirin', 'cabergoline', 'GnRH agonist']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Invitro Fertilization,['Invitro Fertilization'],[],UNKNOWN,,2017-08,2018-09,"[{'measure': 'clinical pregnancy', 'description': 'Intrauterine gestational sac detection by transvaginal ultrasound', 'timeFrame': '4 weeks after embryo transfer'}]",[],1,20 Years,39 Years,FEMALE,False,Cairo University,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:14.658701,v2_robust,True,True,False,False,False,
NCT04291599,Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid,Initial Pain Management in Pediatric Pancreatitis: Opioid vs. Non-Opioid,Ketorolac,"['Opioid', 'Morphine, hydromorphone', 'Ketorolac', 'Toradol']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Pancreatitis,['Acute Pancreatitis'],['Pancreatitis'],RECRUITING,,2022-03-15,2024-06-30,"[{'measure': 'Efficacy: amount of opioid analgesia (mg/kg/hr) from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA', 'description': 'The primary endpoint for efficacy is the amount of opioid analgesia (mg/kg/hr) from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA.', 'timeFrame': 'time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA'}]","[{'measure': 'Safety: number of hours from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA', 'description': 'The secondary endpoint for safety is defined as the total number of incident adverse events, grade 2 or higher, from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA.', 'timeFrame': 'time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA'}, {'measure': 'Length of stay', 'description': 'The secondary endpoint for length of stay is defined as the number of hours from the time of enrollment until discharge home, transfer to the ICU, or initiation of PCA.', 'timeFrame': 'time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA'}, {'measure': 'Time to initiation of oral or enteral diet', 'description': 'The secondary endpoint for time to initiation of oral or enteral diet is defined as the number of hours from the time of enrollment until first oral or enteral intake. The number of hours will be expressed to two decimal places to account for fractions of an hour.', 'timeFrame': 'time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA'}, {'measure': 'Predefined Feasibility Outcomes to Assess Trial Success', 'description': 'The secondary endpoint for feasibility is defined as (1) ≥80% of eligible patients approached for consent during the trial, and (2) ≥20% of eligible patients randomized into the trial.', 'timeFrame': 'duration of trial, approximately 1 year from the start of enrollment'}, {'measure': 'Pain resolution: pain scores', 'description': 'To compare pain resolution from time of enrollment throughout hospital stay by comparing pain scores in patients receiving opioid-sparing therapies to those receiving standard of care opioid analgesics.', 'timeFrame': 'time of enrollment through study completion (approximately 5 days), or transfer to the ICU or initiation of PCA'}]",6,,21 Years,ALL,False,Boston Children's Hospital,OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:14.658713,v2_robust,True,True,False,False,True,
NCT06404099,"RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)",RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC),Modafinil,"['Modafinil Placebo', 'Solriamfetol Placebo', 'Solriamfetol', 'Modafinil']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Long COVID,"['Long COVID', 'Long COVID-19', 'Hypersomnia']",['PASC'],RECRUITING,,2024-08-12,2025-12-31,"[{'measure': 'Change in total score of the PROMIS 8a SRI to assess sleep-related impairment', 'description': 'The PROMIS 8a SRI form includes a total of 8 items that ask participants to reflect on their sleep-related daytime impairment over the past 7 days with questions rated not at all to very much. T-Scores range from 0 to 100, with a score of 55 being 1 standard deviation above population mean. Higher scores indicate greater sleep-related impairment.', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}]","[{'measure': 'Change in total score of the PROMIS 8b SD to assess sleep disturbance', 'description': 'The PROMIS 8b SD form includes a total of 8 items that ask participants to reflect on their sleep over the past 7 days with one question rated very poor to very good and the remaining questions rated not at all to very much. T-Scores range from 0 to 100, with \\> 55 1 SD above population mean.', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in PROMIS 10a Fatigue score', 'description': ""The PROMIS 10a Fatigue is a 10-item questionnaire that assesses a participant's fatigue on a scale of 1 (not at all fatigued) to 5 (very much)."", 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in an objective neurocognitive battery score', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in ECog2 measure', 'description': ""Everyday Cognition 2 (ECog2) is a self-report, 41-item questionnaire used to measure measure the participant's perceived capacity to perform activities related to cognitive function, which could impact major activities of daily living and independence. It has been used for patients with mild cognitive impairment, Alzheimer's Disease, and dementia. It takes 5 minutes to complete."", 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in PASC Symptom Questionnaire responses', 'description': 'Participants will be asked to complete a questionnaire that asks about the presence of PASC symptoms at Baseline and at follow-up visits. This questionnaire includes symptoms that have been associated with PASC.', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in total score on the Insomnia Severity Index (ISI)', 'description': 'The ISI is a 7-item, self-report questionnaire that assesses the nature, severity, and impact of insomnia, on a 5-point Likert scale (eg, 0 = not at all, 4 = extremely; scores: from 0 to 28). The ISI asks patients to recall their insomnia symptoms over the past 2 weeks.', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in within-person variability (over a 7-day period) in sleep onset time, assessed by sleep diary', 'description': 'Sleep onset time will be assessed by sleep diary', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) nocturnal sleep duration, assessed by sleep diary', 'description': 'Nocturnal sleep duration will be assessed by sleep diary', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) 24-hour sleep duration, assessed by sleep diary', 'description': '24-hour sleep duration will be assessed by sleep diary', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) sleep midpoint, assessed by sleep diary', 'description': 'Sleep midpoint is the time half way between start and end of sleep, as assessed by sleep diary', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) nocturnal sleep duration, assessed by activity tracker', 'description': 'Nocturnal sleep duration will be assessed by activity tracker', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) 24-hour sleep duration, assessed by activity tracker', 'description': '24-hour sleep duration will be assessed by activity tracker', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) sleep efficiency, assessed by activity tracker', 'description': 'Sleep Efficiency is the percentage of the sleep period spent asleep, as measured by activity tracker', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}, {'measure': 'Change in average (over a 7-day period) sleep midpoint, assessed by activity tracker', 'description': 'Sleep midpoint is the time half way between start and end of sleep, as assessed by sleep diary', 'timeFrame': 'Baseline, End of Intervention (Day 77)'}]",15,18 Years,,ALL,False,Duke University,OTHER,0,474.0,ESTIMATED,2025-09-01T16:18:14.658726,v2_robust,True,True,False,False,False,
NCT04974099,Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease,Personalized Infliximab Induction Strategy With Model-informed Dosing in Patients With Crohn's Disease,Precision dosing with a dashboard,['Precision dosing with a dashboard'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Crohn Disease,['Crohn Disease'],[],TERMINATED,"This was the Pilot study. The larger, confirmatory study has started",2021-10-01,2024-08-01,"[{'measure': 'Obtain safety data for optimal dosing strategy and sample size estimation', 'description': 'Number of adverse and/or serious adverse events', 'timeFrame': '2 years'}, {'measure': 'Enrollment feasibility', 'description': 'Evaluate the rate of recruitment', 'timeFrame': '2 years'}, {'measure': 'Completion feasibility', 'description': 'Number of patients that complete the study', 'timeFrame': '2 years'}, {'measure': 'Rate of patient adherence to stool and blood sample collections', 'description': 'patient adherence to stool and blood sample collections', 'timeFrame': '2 years'}, {'measure': 'RoadMAB Usability', 'description': 'Evaluate rate of physician adherence to RoadMAB dosing recommendation', 'timeFrame': '2 years'}, {'measure': 'RoadMAB Efficacy', 'description': 'Rate of achieving infus3 (Visit 4) infliximab concentration between 16-24 μg/ml as a dichotomous outcome', 'timeFrame': '2 years'}]","[{'measure': 'Evaluate accuracy of infliximab concentration targets - Median difference infus3', 'description': 'Median difference of infus3 (Visit 4) levels between cases and controls', 'timeFrame': '2 years'}, {'measure': 'Evaluate accuracy of infliximab concentration targets - Incidence', 'description': 'Incidence of achieving infus2 (Visit 3) level between target range of 26-34 μg/ml as a dichotomous outcome', 'timeFrame': '2 years'}, {'measure': 'Evaluate accuracy of infliximab concentration targets - Median difference infus2', 'description': 'Median difference of infus2 (Visit 3) levels between cases and controls', 'timeFrame': '2 years'}, {'measure': 'Evaluate accuracy of infliximab concentration targets - Maintenance', 'description': 'Rates of achieving maintenance targets infus4-6 (Visits 5-7) between 5-10 μg/ml', 'timeFrame': '2 years'}, {'measure': 'Evaluate accuracy of infliximab concentration targets', 'description': 'Rate of development of antiinfliximab antibodies at any infusion between cases and controls', 'timeFrame': '2 years'}, {'measure': 'Infus4 (Visit 5) and infus6 (Visit 7): Clinical Response', 'description': 'Improvement in baseline wPCDAI by \\>17.5 or a wPCDAI\\<12.5', 'timeFrame': '2 years'}, {'measure': 'Infus4 (Visit 5) and infus6 (Visit 7): Clinical Remission', 'description': 'wPCDAI \\<12.5 and off corticosteroids', 'timeFrame': '2 years'}, {'measure': 'Sustained Remission', 'description': 'wPCDAI \\<12.5 and off prednisone for all visits from infus4 (Visit 5) to infus6 (Visit 7)', 'timeFrame': '2 years'}, {'measure': 'Infus4 (Visit 5) and Infus6 (Visit 7): Fecal Biochemical Response', 'description': '≥50% improvement in fecal calprotectin', 'timeFrame': '2 years'}, {'measure': 'Infus4 (Visit 5) and Infus6 (Visit 7): Fecal Biochemical Remission', 'description': 'fecal calprotectin \\<250 μg/g', 'timeFrame': '2 years'}, {'measure': 'Infus6 (Visit 7): Rate of transmural ileal', 'description': 'ileum subscore stage 0 (score = 0)', 'timeFrame': '2 years'}, {'measure': 'Infus6 (Visit 7): Rate of colonic healing', 'description': 'all segments of colon subscore stage 0 (score = 0)', 'timeFrame': '2 years'}, {'measure': 'Infus6 (Visit 7): Rate of total bowel healing', 'description': 'total ileum and colonic subscore is not greater than stage 0 on either individual score', 'timeFrame': '2 years'}]",19,6 Years,22 Years,ALL,False,"Children's Hospital Medical Center, Cincinnati",OTHER,1,6.0,ACTUAL,2025-09-01T16:18:14.658774,v2_robust,True,True,False,True,True,"This was the Pilot study. The larger, confirmatory study has started"
NCT01066832,The Valentines Trial,The Valentines Trial,Paclitaxel,['Paclitaxel'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Instent Restenosis,['Instent Restenosis'],"['Drug-eluting balloon', 'Paclitaxel', 'DIOR', 'short term registry', 'Valentines Trial', 'Drug-eluting balloon treatment of in-stent restenosis']",COMPLETED,,2010-02,2011-03,"[{'measure': 'Clinical success at 6-9 month defined as freedom from MACE, death, MI,TLR and stent thrombosis', 'timeFrame': '6-9 month'}]","[{'measure': 'In-stent and in-segment late loss and binary restenosis', 'timeFrame': '6-9 month'}]",2,18 Years,,ALL,False,Eurocor GmbH,INDUSTRY,0,276.0,ACTUAL,2025-09-01T16:18:14.658843,v2_robust,True,True,True,False,False,
NCT01841632,Safety Study of Multipotent Progenitor Cells for Immunomodulation Therapy After Liver Transplantation,Safety and Feasibility of Multipotent Adult Progenitor Cells for Immunomodulation Therapy After Liver Transplantation: A Phase I Study of the MiSOT Study Consortium,MultiStem,['MultiStem'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Liver Transplantation,['Liver Transplantation'],"['Liver transplantation', 'Allogeneic liver transplantation', 'Solid organ transplantation']",TERMINATED,,2013-04,2016-12,"[{'measure': 'Infusional and Acute Toxicity, Using Toxicity Scoring Mechanism', 'description': '* For the description of intraportal toxicity a doppler ultrasound examination will be performed to assess various parameters that describe velocity of flow and flow pattern.\n* For pulmonary toxicity the assessment begins with an arterial blood gas. If this reveals pathological findings, a chest X-ray is required for clinical reasons independent of the study enrolment. In addition, clinical data describing the need for postoperative re-intubation will be recorded and the patient is assessed for the occurrence of a pulmonary embolism according to clinical guidelines.\n* For systemic toxicity, the occurrence of anaphylactic shock due to standard clinical guidelines is recorded.', 'timeFrame': 'up to day 30 (+10)'}]","[{'measure': 'Time to First Biopsy-proven Acute Rejection', 'description': 'Per protocol biopsies will be performed on days 1, 4, 10. Additional biopsies will be taken whenever clinically necessary.', 'timeFrame': 'up to day 90 (+/-30)'}, {'measure': 'Evidence Confirming That MultiStem Does Not Promote Malignant Transformation or Tumor Growth', 'description': 'Four additional outpatient visits are planned to further evaluate the study patients (including screening for malignancies).', 'timeFrame': 'up to day 365 (+/-30)'}, {'measure': 'Evaluation of Data From Routine Examinations Following Last Study Visit for Evidence of Long Term Safety From MultiStem Administration', 'description': 'The results of routine examinations, which are necessary for all transplant patients, will be used once a year and analyzed retrospectively.', 'timeFrame': 'up to six years'}]",4,18 Years,65 Years,ALL,False,"Prof. Dr. Marc-H. Dahlke, Ph. D.",OTHER,2,3.0,ACTUAL,2025-09-01T16:18:14.658852,v2_robust,True,True,False,True,True,
NCT06088732,"Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression","Effects of Acute Exercise and Ibuprofen on Symptoms, Immunity, and Neural Circuits in Bipolar Depression",Ibuprofen 800 mg,"['Ibuprofen 800 mg', 'Placebo']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Bipolar Depression,['Bipolar Depression'],[],RECRUITING,,2024-03-12,2026-12-31,"[{'measure': 'Inflammation', 'description': 'Serum concentrations of interleukin 6 (IL-6)', 'timeFrame': 'Difference between IL-6 at baseline and two hours post intervention'}, {'measure': 'Neural Response to Reward Anticipation', 'description': 'Percent Signal Change in Ventral Striatum During Monetary Incentive Delay', 'timeFrame': 'One hour post intervention'}]","[{'measure': 'Neural Response to Reward Receipt', 'description': 'Percent Signal Change in Ventral Striatum During Monetary Incentive Delay (MID) task', 'timeFrame': 'One hour post intervention'}, {'measure': 'Brain Volume', 'description': 'Gray Matter Volume of the Hippocampus', 'timeFrame': 'One hour post intervention'}, {'measure': 'Inflammation', 'description': 'Serum concentrations of tumor necrosis factor (TNF)', 'timeFrame': 'Difference between TNF at baseline and two hours post intervention'}, {'measure': 'Inflammation', 'description': 'Serum concentrations of interleukin 10 (IL-10)', 'timeFrame': 'Difference between IL-10 at baseline and two hours post intervention'}, {'measure': 'Anhedonia', 'description': 'Score on the Snaith-Hamilton Pleasure Scale (SHAPS). Higher scores indicate greater anhedonia. Score range from 0-14.', 'timeFrame': 'Difference between SHAPS scores at baseline and two hours post intervention'}]",7,18 Years,55 Years,ALL,False,"Laureate Institute for Brain Research, Inc.",OTHER,0,20.0,ESTIMATED,2025-09-01T16:18:14.658873,v2_robust,True,True,False,False,False,
NCT02339532,"Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status","Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer",FEC100,"['FEC100', 'Carboplatin', 'Trastuzumab', 'Docetaxel', 'Pertuzumab']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['HER2-positive', 'non-metastatic', 'TOP2A']",COMPLETED,,2015-01,2024-07-08,"[{'measure': 'Pathological complete response according to Chevallier classification', 'description': 'on surgical specimen and lymph nodes at the time of the surgery', 'timeFrame': '20 weeks'}]","[{'measure': 'Predictive factors of response to both treatment regimens (anthracycline-based and non anthracycline-based regimens)', 'description': 'on surgical specimen and lymph nodes at the time of the surgery', 'timeFrame': '20 weeks'}, {'measure': ""Pathological complete response (pCR), according to Sataloff's classification"", 'description': 'on surgical specimen and lymph nodes at the time of the surgery', 'timeFrame': '20 weeks'}, {'measure': 'Clinical and radiological response according to the WHO criteria', 'description': 'on mammography and breast echography', 'timeFrame': 'after two cycles of treatment and after the end of treatment'}, {'measure': 'Toxicity according to NCI CTC-AE v4.0 criteria', 'description': 'according the occurrence of adverse events and toxicities assessed every week', 'timeFrame': 'during on-treatment period (defined as the period from the first dose of study medication up to 30 days of the last dose'}, {'measure': 'Progression-free survival', 'description': 'The PFS is defined as the time from the first administration of treatment to progression or death of any cause, if progression has not been documented.', 'timeFrame': 'up to 60 months'}, {'measure': 'Overall survival', 'description': 'The OS is defined as the time from the first administration of treatment to death from any cause.', 'timeFrame': 'up to 60 months'}]",7,18 Years,,FEMALE,False,UNICANCER,OTHER,0,86.0,ACTUAL,2025-09-01T16:18:14.659092,v2_robust,True,True,True,False,True,
NCT01619332,"Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763","A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763 Following Single and Multiple Ascending Doses in Healthy Subjects and Patients With Type 2 Diabetes",Placebo,"['Sitagliptin', 'LEZ763', 'Placebo']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Type II Diabetes,['Type II Diabetes'],"['Healthy volunteers,', 'Diabetes', 'Glucose', 'Pharmacokinetics']",COMPLETED,,2012-03,2013-09,"[{'measure': 'Number of Patients with adverse events, serious adverse events and death', 'description': 'An adverse event is the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. Adverse events will also be determined on the basis of clinical laboratory assessments, electrocardiographic evaluations and vital signs determinations.', 'timeFrame': 'Day 28'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to infinity (AUCinf)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): area under the plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUClast)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): Terminal elimination half-life (T1/2)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): Apparent systemic (or total body) clearance from plasma following extravascular administration (CL/F)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I) : Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part I): time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single dose', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1; 24 and 36 hours Day 2; Day 3, Day 4'}, {'measure': 'Pharmacokinetics of LEZ763 (Part II) : Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10'}, {'measure': 'Pharmacokinetics of LEZ763 (Part II): time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 10'}, {'measure': 'Pharmacokinetics of LEZ763 (Part II): Accumulation ratio(Racc)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III) : Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III): time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 (Part III): Accumulation ratio(Racc)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after single and multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 4, 6, 8, 12 hours post-dose on Day 1 and Day 27'}, {'measure': 'Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Observed maximum plasma concentration (Cmax) following drug administration', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28'}, {'measure': 'Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Area under the plasma concentration-time curve from time zero to the end of the dosing interval tau (AUCtau)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28'}, {'measure': 'Pharmacokinetics of LEZ763 and Sitagliptin (Part III): Time to reach the maximum concentration after drug administration (Tmax)', 'description': 'Blood will be collected at multiple timepoints and will be analyzed for LEZ736 concentrations after multiple doses', 'timeFrame': 'pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day 28'}, {'measure': 'Area under the effect curve (AUC0-4h) over the 4-hour post-dose period to measure glucose response following a standard mixed meal test', 'timeFrame': '4 hour post-dose Day 27'}]","[{'measure': 'Area under the serum Glucagon-like-peptide 1 (GLP-1) curve (AUC0-24 hours)', 'description': 'GLP-1 Biomarker measures will be evaluated at pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose', 'timeFrame': 'Pre-dose, and 0.5, 0.66, 0.75, 1, 1.5, 2, 2.5, 3, 3.5 and 4 hours post-dose on Day -1, Day 1, Day 27, and Day 28'}, {'measure': '2-hour value of post-prandial glucose', 'timeFrame': 'Day 1 of Part I, Day 1 and day 10 of Part II'}, {'measure': 'Change from baseline in Fasting C-peptide at Day 27 (Part III)', 'timeFrame': 'Baseline, Day 27'}, {'measure': 'Change from baseline in Fasting Insulin at Day 27 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change from baseline in fasting plasma glucose at Day 27 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change From Baseline in peak glucose level following meal Test at Day 27 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Peak effect (Emax) on postprandial GLP-1 (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change from baseline in Peptide YY (PYY) (Part III)', 'timeFrame': 'Baseline , Day 27'}, {'measure': 'Change from baseine in Gastric inhibit polypeptide (GIP) (Part III)', 'timeFrame': 'Baseline , Day 27'}]",27,18 Years,65 Years,ALL,True,Novartis Pharmaceuticals,INDUSTRY,0,220.0,ACTUAL,2025-09-01T16:18:14.659115,v2_robust,True,True,True,False,True,
NCT04689932,Triferic AVNU Infusion Via Freedom Pump During Hemodialysis,Triferic AVNU Infusion Via Freedom Pump During Hemodialysis,Triferic AVNU,"['FPC', 'Triferic AVNU']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,End Stage Renal Disease,['End Stage Renal Disease'],[],COMPLETED,,2021-04-19,2021-06-19,"[{'measure': 'Time for Complete Infusion of 4.5 mL Triferic AVNU Pre-Dialyzer', 'description': 'The syringe pump and flow restrictor tubing has a nominal flow rate of 2 mL/hour. When the tubing is connected to the pre-dialyzer or post dialyzer blood circuit the administration time will vary due to the pressure in the dialyzer blood lines. For a 4.5 mL volume the target administration rate is 2.25 hours. The Product labeling for Triferic AVNU advises the dose (4.5 mL) to be administered over 3 to 4 hours.', 'timeFrame': 'On Days 1, 3, and 5, up to 3 hours'}, {'measure': 'Time for Complete Infusion of 4.5 mL Triferic AVNU Post-Dialyzer', 'description': 'The syringe pump and flow restrictor tubing has a nominal flow rate of 2 mL/hour. When the tubing is connected to the pre-dialyzer or post dialyzer blood circuit the administration time will vary due to the pressure in the dialyzer blood lines. For a 4.5 mL volume the target administration rate is 2.25 hours. The Product labeling for Triferic AVNU advises the dose (4.5 mL) to be administered over 3 to 4 hours.', 'timeFrame': 'On Days 2, 4, and 6, up to 3 hours'}]","[{'measure': 'Mean TSAT Max Pre-Dialyzer', 'description': 'The maximum Transferrin saturation (TSATmax) for the infusion of FPC into the pre-dialyzer blood line when compared to the TSATmax when FPC is infused into the post-dialyzer blood line is an index of any loss of FPC during transit through the dialyzer (artificial kidney', 'timeFrame': 'up to 3 hours'}, {'measure': 'Mean TSAT Max Post-Dialyzer', 'description': 'The maximum Transferrin saturation (TSATmax) for the infusion of FPC into the pre-dialyzer blood line when compared to the TSATmax when FPC is infused into the post-dialyzer blood line is an index of any loss of FPC during transit through the dialyzer (artificial kidney', 'timeFrame': 'up to 3 hours'}]",4,18 Years,,ALL,False,"Rockwell Medical Technologies, Inc.",INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:14.659157,v2_robust,True,True,True,False,False,
NCT00175032,A Comparison of Safety and Treatment in Subjects With Osteoarthritis Taking Low Dose Aspirin,"A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of Lansoprazole 30 mg QD and Naproxen 500 mg BID Versus Celecoxib 200 mg QD in Risk Reduction of Non Steroidal Anti-Inflammatory-Associated Ulcers in Osteoarthritis Subjects Taking Low Dose Aspirin",Lansoprazole and naproxen and aspirin,"['Celecoxib and aspirin', 'Lansoprazole and naproxen and aspirin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Osteoarthritis,"['Osteoarthritis', 'Peptic Ulcer']","['Low dose aspirin', 'Peptic Ulcer', 'gastric ulcer', 'duodenal ulcer', 'NSAIDs']",COMPLETED,,2003-07,2004-07,"[{'measure': 'Gastroduodenal ulcers at final visit', 'timeFrame': 'Week 12'}]","[{'measure': 'Proportion of subjects with GI complications (GI bleeding, perforation and gastric outlet obstruction)', 'timeFrame': 'Week 12'}, {'measure': 'Severity of each dyspepsia symptom (abdominal pain, nausea, vomiting, heartburn, fullness, and belching) and combined dyspepsia scores.', 'timeFrame': 'Weeks 4,8, and 12'}, {'measure': 'Proportion of subjects with dyspepsia at weeks 4, 8, and 12 that did not have dyspepsia at baseline.', 'timeFrame': 'Weeks 4,8, and 12'}, {'measure': 'Proportion of subjects without dyspepsia at weeks 4, 8, and 12 who had dyspepsia at baseline.', 'timeFrame': 'Weeks 4, 8, and 12'}, {'measure': 'Scores of each SODA scale (pain intensity, non-pain symptoms, and satisfaction) for subjects with dyspepsia.', 'timeFrame': 'Weeks 4, 8, and 12'}, {'measure': 'The change from baseline SODA scale for subjects with dyspepsia at baseline.', 'timeFrame': 'Weeks 4, 8, and 12'}]",7,18 Years,,ALL,False,Takeda,INDUSTRY,0,1045.0,ACTUAL,2025-09-01T16:18:14.659214,v2_robust,True,True,True,False,False,
NCT03918798,The Efficacy and Safety of Chloroprocaine 1% and 2% in Pediatric Population,"Randomized, Multi-center, Double-blind, Two-armed, Parallel Active Groups, Prospective Trial, to Evaluate, in Pediatric Population, the Efficacy and Safety of Chloroprocaine 1% and 2% for Peripheral Nerve Block.",Chloroprocaine 1% Injectable Solution,"['Chloroprocaine 2% Injectable Solution', 'ARM 2', 'Chloroprocaine 1% Injectable Solution', 'ARM 1']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Hernia, Inguinal","['Hernia, Inguinal', 'Flat Foot']","['Surgery', 'Hernia, Inguinal', 'Flat Foot', 'Pediatric population', 'Peripheral nerve block']",RECRUITING,,2019-02-14,2024-12-30,"[{'measure': 'Overall proportion of patients, in each of the two dosage level groups, not requiring rescue anesthesia during surgery.', 'description': 'The primary efficacy endpoint of the study will be represented by the overall proportion of patients, in each of the two dosage level groups, not requiring rescue anesthesia during surgery.', 'timeFrame': 'Visit 2 (Day 1; surgery/discharge)'}]","[{'measure': 'Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia (fentanyl) during the two surgical procedures separately', 'description': ""Proportion of patients, in both of the two dosage level groups, not requiring rescue anaesthesia (fentanyl) during the two surgical procedures separately; Time to onset of sensory block, defined as the time period from completion of the injection (time 0 min) to the achievement of complete sensory block, assessed by pinprick test associated with heart rate measurement, and evaluated for both surgeries; Time to regression of motor block evaluated in 'calcaneo stop' surgery only and assessed by a grade I of the standard Bromage scale (i.e. free movement of legs and feet). Pain intensity evaluated five times in the first 3 hours after patient's awakening andduring the home discharge visit (V2). The technique and appropriate scale for pain measurement are age-dependent therefore, different tools will have to be used for the evaluation: COMFORT scale for patients \\<2 months of age; FLACC scale for patients aged \\_ 2 months \\_ 6 years; Wong-Baker scale for patients over 6 years of age"", 'timeFrame': 'Visit 2 (Day 1; surgery/discharge); FU phone call I( 24 hrs from Visit 2); FU phone call II (7 days from Visit 2)'}]",2,,17 Years,ALL,False,Sintetica SA,INDUSTRY,0,174.0,ESTIMATED,2025-09-01T16:18:14.659286,v2_robust,True,True,False,False,False,
NCT00451698,Erythropoietin and Pediatric Cardiac Surgery,Erythropoietin and Pediatric Cardiac Surgery,acyanotic erythropoietin,"['acyanotic placebo', 'acyanotic erythropoietin']",2,INTERVENTIONAL,['NA'],,,Congenital Heart Defect,['Congenital Heart Defect'],"['Erythropoietin', 'Congenital heart surgery']",TERMINATED,Inadequate patient enrollment,2007-10,2011-12,"[{'measure': 'Biochemical Markers of Heart Damage', 'description': 'Troponin I levels (ng/ml) measured at 4 time points', 'timeFrame': '4 postoperative time points up to 48 hours'}, {'measure': 'Biochemical Markers of Neuron Damage', 'timeFrame': '4 postoperative time points'}, {'measure': 'Echocardiographic Assessment of Heart Function', 'timeFrame': '24 hours postop'}]","[{'measure': 'Inotropic Support', 'timeFrame': '24 and 48 hours post operative'}, {'measure': 'Length of Hospitalization', 'timeFrame': 'At hospital discharge, up to 30 days'}]",5,6 Weeks,18 Years,ALL,False,Medical College of Wisconsin,OTHER,2,9.0,ACTUAL,2025-09-01T16:18:14.659311,v2_robust,True,True,False,True,False,Inadequate patient enrollment
NCT06681298,"A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab","A Multi-center, Two-arm, Phase 2 Clinical Study on the Perioperative Treatment of HER2-positive Resectable Esophagogastric Junctional Adenocarcinoma With Nabulimab Combined With FLOT and Trastuzumab VS FLOT Combined With Trastuzumab",The experimental group received Nivolumab,"['Trastuzumab', 'FLOT', 'The experimental group received Nivolumab']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Adenocarcinoma of the Esophagogastric Junction,"['Adenocarcinoma of the Esophagogastric Junction', 'Perioperative Period']","['Nivolumab', 'adenocarcinoma of the esophagogastric junction', 'FLOT']",ACTIVE_NOT_RECRUITING,,2024-05-01,2029-05-01,"[{'measure': 'Pathological complete response rate (pCR)', 'description': 'Pathological complete response rate refers to the proportion of primary tumor sites and surgical specimens with no viable tumor cells (ypT0N0) in all resected lymph nodes to the total number of patients evaluated centrally by the study pathologist', 'timeFrame': '30 days'}]","[{'measure': 'Objective response rate (ORR)', 'description': 'Objective response rate (ORR) : ORR is the proportion of subjects who achieved partial and complete response on imaging assessment (RECIST v1.1) after the end of neoadjuvant therapy', 'timeFrame': '30 days'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Progression-free survival (PFS) : PFS is the time from the date of enrollment in the study to the date of death from all causes', 'timeFrame': '1,3,5 years'}, {'measure': 'Overall survival (OS)', 'description': 'Overall survival (OS) : OS is the amount of time a patient can survive treatment without dying from any condition', 'timeFrame': '1,3,5 years'}, {'measure': 'Major pathological response rate (MPR)', 'description': 'Major pathological response rate (MPR) : MPR refers to the proportion of patients with residual tumor cells \\< 10% after surgery to determine the pathological status of the primary lesion', 'timeFrame': '30 days'}, {'measure': 'Duration of response (DOR)', 'description': 'Duration of response (DOR) : The DOR is the time from the first response until disease progression is first recorded or death occurs', 'timeFrame': '5 years'}, {'measure': 'Adverse Event Rate (AE)', 'description': 'Adverse Event Rate (AE) : Any adverse events that may be related to the investigational drug that occur while receiving neoadjuvant therapy', 'timeFrame': '5 years'}]",7,18 Years,75 Years,ALL,False,xiaohua li,OTHER,0,36.0,ESTIMATED,2025-09-01T16:18:14.659326,v2_robust,True,True,False,False,True,
NCT01710098,Treatment of Prostate Cancer With Firmagon®,"Effectiveness and Safety as Well as Adherence of the ""S3 Guidelines for the Treatment of Prostate Cancer"" in the Treatment of Patients of Patients With Firmagon®",Degarelix,"['Firmagon®', 'Degarelix']",2,OBSERVATIONAL,[],,,Prostate Cancer,['Prostate Cancer'],"['testosterone', 'S3-Adherence', 'Quality of Life']",COMPLETED,,2012-06,2015-09-24,"[{'measure': 'PSA-/Testosterone Level', 'timeFrame': '12 months'}]","[{'measure': 'S3 Guideline', 'description': 'Percentage of patients who have been treated in accordance with the grade A recommendations of the S3 guideline for treatment of prostate cancer', 'timeFrame': '12 months'}, {'measure': 'Anxiety', 'description': 'Anxiety score', 'timeFrame': '12 Months'}]",3,18 Years,95 Years,MALE,False,United Clinic Management GmbH,INDUSTRY,0,100.0,ACTUAL,2025-09-01T16:18:14.659352,v2_robust,False,True,True,False,False,
NCT00731198,Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During Endoscopic Retrograde Cholangiopancreatography (ERCP),"Drotaverine Hydrochloride Versus Hyoscine-N-butylbromide for Duodenal Antimotility During ERCP: a Prospective, Multicenter Randomized Controlled Trial",Drotaverine hydrochloride,"['No-spa', 'Drotaverine hydrochloride', 'Scopolamine Butylbromide', 'Hyoscine-N-butylbromide']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,ERCP,"['ERCP', 'Pancreatic Diseases', 'Bile Duct Diseases']","['ERCP', 'Drotaverine hydrochloride', 'Hyoscine-N-butylbromide']",COMPLETED,,2008-08,2009-07,"[{'measure': 'The Grades of the Number of Duodenal Contractions', 'description': 'a duodenal motility grade was determined as follows: 0 = no motility; 1 = less than five contractions/minute; 2 = 5 to 10/minute; 3 = 11 to 15/minute; 4 = continuous.', 'timeFrame': 'Intra-procedure'}]","[{'measure': 'Cannulation Time', 'timeFrame': 'Intra-procedure'}, {'measure': 'Percentage of Successful Selective Cannulation', 'timeFrame': 'Intra-procedure'}, {'measure': 'Frequency of Post-ERCP Complications', 'timeFrame': '48 hours after ERCP'}, {'measure': 'Side Effects', 'timeFrame': 'Intra-procedure and 24 hours after ERCP'}]",5,18 Years,90 Years,ALL,False,Changhai Hospital,OTHER,0,650.0,ACTUAL,2025-09-01T16:18:14.659365,v2_robust,True,True,True,False,False,
NCT03708198,Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks,Pharmacokinetics of Single-Dose Liposomal Bupivacaine in Surgeon Performed Intercostal Nerve Blocks,Liposomal Bupivacaine,['Liposomal Bupivacaine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Thoracic,['Thoracic'],[],COMPLETED,,2018-06-11,2020-08-11,"[{'measure': 'Tmax, or the Time Until the Maximum Concentration', 'description': 'the tmax, or the time until the maximum concentration', 'timeFrame': 'until study completion, which is 6 months on average'}]",[],1,18 Years,,ALL,False,University of Virginia,OTHER,0,15.0,ACTUAL,2025-09-01T16:18:14.659380,v2_robust,True,True,True,False,False,
NCT01145898,Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data,Trusopt and Cosopt; Ocular Perfusion Pressure and Blood Flow: New Long-term Prospective Data,"(Cosopt®, prostaglandin)","['(Cosopt®, prostaglandin)', 'Cosopt is a trade name drug which is a combination of dorzolamide and timolol.']",2,OBSERVATIONAL,[],,,Glaucoma,['Glaucoma'],"['Glaucoma', 'Cosopt', 'blood flow', 'progression']",COMPLETED,,2010-06,2012-10,"[{'measure': '6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV)', 'description': 'Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '6-month Change inOphthalmic Artery (OA) End Diastolic Velocity (EDV)', 'description': 'Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '6-month Change in Ophthalmic Artery (OA) Vascular Resistance (RI)', 'description': 'Measurement of change in ocular blood flow - ophthalmic artery resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '6-month Change in Central Retinal Artery (CRA) Peak Systolic Velocity (PSV)', 'description': 'Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '6-month Change in Central Retinal Artery (CRA) End Diastolic Velocity (EDV)', 'description': 'Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '6-month Change in Central Retinal Artery (CRA) Vascular Resistance (RI)', 'description': 'Measurement of change in ocular blood flow - central retinal arteries resistance index, this is a measure of the amount of resistance to blood flow within the selected blood vessel.', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '6-month Change in Ocular Perfusion Pressures (OPP)', 'description': 'Measurement of change in ocular perfusion pressure, the pressure of blood flow to the eye minus the pressure of within the eye.', 'timeFrame': 'Baseline and 6 month visits'}, {'measure': '3-year Change in OA PSV', 'description': 'Measurement of change in ocular blood flow - ophthalmic artery peak systolic velocity', 'timeFrame': 'Baseline and 36 month visits'}, {'measure': '3-year Change in OA EDV', 'description': 'Measurement of change in ocular blood flow - ophthalmic artery end diastolic velocity', 'timeFrame': 'Baseline and 36 month visits'}, {'measure': '3-year Change in OA RI', 'description': 'Measurement of change in ocular blood flow - ophthalmic artery resistance index', 'timeFrame': 'Baseline and 36 month visits'}, {'measure': '3-year Change in CRA PSV', 'description': 'Measurement of change in ocular blood flow - central retinal arteries peak systolic velocity', 'timeFrame': 'Baseline and 36 month visits'}, {'measure': '3-year Change in CRA EDV', 'description': 'Measurement of change in ocular blood flow - central retinal arteries end diastolic velocity', 'timeFrame': 'Baseline and 36 month visits'}, {'measure': '3-year Change in CRA RI', 'description': 'Measurement of change in ocular blood flow - central retinal arteries resistance index', 'timeFrame': 'Baseline and 36 month visits'}, {'measure': '3-year Change in OPP', 'description': 'Measurement of change in ocular perfusion pressure', 'timeFrame': 'Baseline and 36 month visits'}]",[],14,30 Years,,ALL,False,Indiana University,OTHER,0,56.0,ACTUAL,2025-09-01T16:18:14.659487,v2_robust,False,True,True,False,False,
NCT02796898,"Study of the Efficacy, Safety, and Pharmacokinetics of SM88 in Patients With Prostate Cancer","A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer",SM88 (Cohort 1),"['SM88', 'SM88 (Cohort 1)', 'SM88 (Cohort 2)']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Prostate Cancer,"['Prostate Cancer', 'Rising Prostate Specific Antigen (PSA)']","['Prostate Cancer', 'PSA', 'Androgen Deprivation Therapy (ADT)']",COMPLETED,,2016-06,2019-05-30,"[{'measure': 'The dose limiting toxicity (DLT), and maximum tolerated dose (MTD) or minimum effective optimum dose of SM88, when 2 dose levels of SM88 are evaluated.', 'description': 'During 4 days of single dose PK evaluations \\[Phase 1b only\\], and six 4-week treatment cycles, we will determine if patients in consecutive cohorts experience any dose limiting toxicity to determine MTD, or a complete response with no DLTs observed to determine the optimum dose.', 'timeFrame': 'Six months'}]","[{'measure': 'Single dose pharmacokinetics (PK) of tyrosine based isomer alone and as a component of SM88 in patients with prostate cancer.', 'description': 'After a single dose of tyrosine based isomer alone on PK Day 1, and a single dose of SM88 on PK Day 3, the plasma concentrations of tyrosine isomers in patients with prostate cancer will be assayed.', 'timeFrame': 'Six months'}, {'measure': 'Multi-dose PK of the individual isomers of tyrosine.', 'description': 'The plasma concentrations of tyrosine isomers associated with morning and evening doses of tyrosine isomers on PK Day 1, and also associated with morning and evening doses of SM88, in patients with prostate cancer will be assayed.', 'timeFrame': 'Six months'}, {'measure': 'Multi-dose steady state PK of all 4 components of SM88 in patients with prostate cancer.', 'description': 'After approximately 2 weeks of daily dosing of SM88, the plasma concentrations of tyrosine isomers as well as the other 3 drugs of SM88 in patients with prostate cancer will be assayed.', 'timeFrame': 'Six months'}, {'measure': 'Safety and tolerability of SM88 in patients with prostate cancer.', 'description': 'Changes from baseline in blood work results and incidence of adverse events associated with treatment of SM88 in patients with prostate cancer.', 'timeFrame': 'Six months'}, {'measure': 'Anti-cancer activities of SM88 in patients with prostate cancer.', 'description': 'Changes from baseline in CTCs, and PSA level per Prostate Cancer Working Group 3 (PCWG3) criteria and radiography per RECIST 1.1 criterial, stratified by circulating tumor cells (CTC) and other blood-based markers including lactate dehydrogenase (LDH), total alkaline phosphatase, bone-specific alkaline phosphatase, urine N-telopeptide, hemoglobin, and neutrophil:lymphocyte ratio (NLR).', 'timeFrame': 'Six Months'}, {'measure': 'Correlation of toxicity and efficacy with cutaneous hyperpigmentation', 'description': 'The incident and severity (as assessed by CTCAE v4.0) of treatment-related adverse events and anticancer activities of SM88 are correlated with the degree of cutaneous pigmentation (measured by quantitative image analysis of subject skin color). The total number of subjects with adverse events and efficacy with changes in skin pigmentation during treatment will be reported in aggregate. We will evaluate cutaneous pigmentation as a biomarker in the treatment of prostate cancer by SM88 and stratify pigmentation and known risk factors for outcome analysis.', 'timeFrame': 'Six Months'}, {'measure': 'Radiographic progression-free-survival (rPFS)', 'description': 'Duration of survival since treatment initiation with SM88 of study subjects who are without disease progression according to radiology, stratified by PSA level, CTC, and other blood-based markers (including LDH, total alkaline phosphatase, bone-specific alkaline phosphatase, urine N-telopeptide, hemoglobin, and NLR).', 'timeFrame': 'Six Months'}, {'measure': 'PSA doubling time before, during and after SM88', 'description': 'PSA doubling time before, during and after SM88 treatment will be compared to evaluate disease progression rate associated with SM88 treatment.', 'timeFrame': 'Six Months'}, {'measure': 'Effect of SM88 on patient-reported outcomes including quality of life (as measured by the EORTC QLQ-30 and EORTC QLQ-PR25) in patients with prostate cancer.', 'description': 'Changes from baseline in the Quality-of-Life, as measured by EORTC QLQ-30 and QLQ-PR25, stratified by PSA level, CTC, and other blood-based markers (including LDH, total alkaline phosphatase, bone-specific alkaline phosphatase, urine N-telopeptide, hemoglobin, and NLR in patients with prostate cancer).', 'timeFrame': 'Six Months'}, {'measure': 'Effect of SM88 on performance status in patients with prostate cancer.', 'description': 'Changes from baseline in the performance status (as measured by Eastern Cooperative Oncology Group (ECOG) score) in patients with prostate cancer.', 'timeFrame': 'Six months'}]",11,18 Years,,MALE,False,"Tyme, Inc",INDUSTRY,0,23.0,ACTUAL,2025-09-01T16:18:14.659523,v2_robust,True,True,True,False,True,
NCT06072898,A Randomized Neuroimaging Trial of Psilocybin in Depression,Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression,Psilocybin,['Psilocybin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Depressive Disorder,"['Depressive Disorder', 'Major Depressive Disorder']","['Psilocybin', 'Neuroimaging', 'MRI', 'Depression', 'Psychotherapy', 'Psychedelic']",RECRUITING,,2025-03-25,2028-06,"[{'measure': 'Regional Blood Flow', 'description': 'Changes in cerebral blood flow within three a priori-defined brain regions relevant to mood regulation and depression as assessed by arterial spin labeling acutely at expected peak drug concentration during treatment visits.', 'timeFrame': 'Up to 3 weeks'}, {'measure': 'Change in Montgomery-Asberg Depression Rating Scale (MADRS)', 'description': 'Changes in the MADRS relative to baseline at study follow-up visits. Higher scores with respect to the MADRS minimum (0) and maximum (60) values represent a worse treatment outcome .', 'timeFrame': 'Up to 6 weeks'}]","[{'measure': 'Functional Network Connectivity', 'description': 'Changes in voxel-wise functional connectivity within four a priori-defined and established functional networks relevant to mood regulation and depression as assessed by resting state functional magnetic resonance imaging acutely at the time of expected peak drug concentration during treatment visits.', 'timeFrame': 'Up to 3 weeks'}, {'measure': '17-item Hamilton Depression Rating Scale (GRID-HAMD-17)', 'description': 'Baseline grid-version of the 17-item Hamilton Depression Rating Scale score. The GRID-HAMD is a 17-item clinician-administered rating scale designed to assess severity of depressive symptoms. The score range is 0 to 52, with higher score indicating more severe depression .', 'timeFrame': '24 hours'}, {'measure': 'Incidence of response', 'description': 'Incidence of response, calculated as the proportion of participants with a response (defined as a ≥ 50% improvement in MADRS total score from Baseline) at at follow-up after psilocybin administration.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Incidence of remission', 'description': 'Incidence of remission, calculated as the proportion of participants with remission (defined as MADRS total score \\<11) at week 3 and 6 following the initial psilocybin/niacin administration.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Patient Health Questionnaire 9-item (PHQ-9)', 'description': 'The PHQ-9 will be collected at baseline as well as week 3 and 6 post-psilocybin administration. The PHQ-9 is a self-rated measure of depressive symptom severity in the past two weeks. Each of the nine items is rated on a Likert scale, ranging from 0 (not at all) to 3 (nearly every day), and summed for a total score between 0 (no symptoms) to 27 (most severe).', 'timeFrame': 'up to 6 weeks'}, {'measure': '16-item Quick Inventory of Depressive Symptomatology-Self-Report (QIDS-SR-16)', 'description': 'The QIDS-SR-16 will be collected at baseline as well as week 3 and 6 post-psilocybin administration. The QIDS-SR-16 is a self-report scale with scores that range from 0 to 27. Higher scores indicate greater depression .', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'The C-SSRS will be collected at baseline as well as week 3 and 6 post-psilocybin administration. The C-SSRS evaluates suicidal ideation and behaviour. The suicidal ideation score ranges from 0 (no ideation) to 5 (active suicidal ideation with specific plan and intent). Suicidal ideation intensity score ranges from 0 (no ideation) to 25 (most severe). The presence of suicidal behaviour is rated as a binary response; the lethality of previous actual attempts is rated on a scale of 0 (no or very minor physical damage) to 5 (death) and the potential lethality of actual attempts are rated on a scale of 0 (behaviour not likely to result in injury) to 2 (behaviour likely to result in death despite available medical care) .', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Brief Psychiatric Rating Scale (BPRS)', 'description': 'The BPRS will be collected at baseline as well as week 3 and 6 post-psilocybin administration. The BPRS rating scale has 18 items, each item rated on a severity scale of 1 (not present) to 7 (extremely severe). 0 is entered if the item is not assessed.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Sheehan Disability Scale (SDS)', 'description': 'The SDS will be collected at baseline as well as week 3 and 6 post-psilocybin administration. The SDS total score ranges from 0 to 30, with 0 representing no impairment and 30 representing severe impairment. The last two items of the scale (Days Lost and Days Unproductive) range from 0 to 7 (higher number denotes greater impairment) .', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Generalized Anxiety Disorder-7 (GAD-7)', 'description': 'The GAD-7 will be collected at baseline as well as week 3 and 6 post-psilocybin administration. Scores from 0 (""Not at all"") to 3 (""Nearly every day""), and total score ranges from 0 to 21; a higher score denotes greater symptom severity.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Snaith-Hamilton Pleasure Scale (SHAPS)', 'description': 'The SHAPS will be collected at baseline as well as week 3 and 6 post-psilocybin administration. The SHAPS is rated on a 4-point Likert scale from 0 (""strongly disagree"") to 3 (""strongly agree""). Total score ranges from 14 to 56, wherein a higher score indicates greater hedonic capacity (lower anhedonic severity) .', 'timeFrame': 'up to 6 weeks'}, {'measure': '6-Item Clinician Administered Dissociative Symptom Scale (CADSS-6)', 'description': 'The CADSS-6 is a simplified 6-item scale that will be collected at both treatment visits as well as week 3 and 6 post-psilocybin administration. Responses range from 0 (""not at all"") to 4 (""extremely""). Total scores range from 0-24, wherein a higher score indicates greater dissociation.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Montreal Cognitive Assessment (MoCA)', 'description': 'The MoCA total score will be collected at baseline as well as week 6 (3 weeks after second treatment visit). This is scale is a cognitive screening assessment tool that tests six domains of cognition, with scores ranging from 0-30, wherein a higher score indicates better cognitive performance: 18-25 points (""Mild cognitive impairment""), 10-17 points (""Moderate cognitive impairment""), less than 10 points (""Severe cognitive impairment"").', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Hopkins Verbal Learning Test-Revised (HVLT-R)', 'description': 'The revised HVLT-R total Score will be collected at baseline as well as week 6 (3 weeks after second treatment visit). A list learning test that contains 12 nouns that are read to a participant for three consecutive trials. After each trial, a participant is asked to recall the words that were read to them. The number of words recalled on each trial is summed together to produce a total score. The higher total score equates to a better outcome.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB Rapid Visual Information Processing', 'description': 'We will use the CANTAB software program for evaluating cognitive domains baseline as well as week 6 (3 weeks after second treatment visit). Sustained attention will be measured by the Rapid Visual Information Processing task. Responses will be scored as the number of responses recorded as having occurred within 1800 milliseconds of the final digit presentation for each of the target sequences, with more responses reflecting better sustained attention.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB Reaction Time', 'description': 'We will use the CANTAB software program for evaluating cognitive domains at baseline as well as week 6 (3 weeks after second treatment visit). Psychomotor speed will be measured by the Reaction Time (RTI) task. Simple reaction time will be the outcome of interest, with faster reaction time (lower latency) reflecting better psychomotor speed.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB Spatial Working Memory', 'description': 'The CANTAB software program for evaluating cognitive domains is used at baseline as well as week 6 (3 weeks after second treatment visit). Executive function will be measured by the Spatial Working Memory (RTI) task. This is a search task that stresses executive function and spatial working memory, requiring subjects to use heuristic search strategies. A higher score indicates better performance in spatial working memory.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB One Touch Stockings of Cambridge', 'description': ""We will use the CANTAB software program for evaluating cognitive domains at baseline as well as week 6 (3 weeks after second treatment visit). Executive function will be measured by the One Touch Stockings of Cambridge (OTS) task. This is a spatial planning task that stresses executive function, requiring subjects to use reordered stacked objects to match a presented pattern. Fewer 'moves' indicates better executive function."", 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB Delayed Matching to Sample', 'description': 'We will use the CANTAB software program for evaluating cognitive domains at baseline as well as week 6 (3 weeks after second treatment visit). Memory will be measured by the Delayed Matching to Sample (DMS) task. This is a memory task that stresses encoding, requiring subjects to remember and differentiate complex patterns when presented after a delay. More correct responses, or greater accuracy, reflects better memory.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB Paired-Associates Learning', 'description': 'We will use the CANTAB software program for evaluating cognitive domains at baseline as well as week 6 (3 weeks after second treatment visit). Memory will be measured by the Paired-Associates Learning (PAL) task. This is a memory task =sensitive to changes in functioning of the medial temporal lobe, requiring subjects to remember and identify previous locations of complex patterns when presented after a delay. More correct responses, or greater accuracy, reflects better memory.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'CANTAB Emotion Recognition Task', 'description': 'We will use the CANTAB software program for evaluating cognitive domains at baseline as well as week 6 (3 weeks after second treatment visit). Social/emotional cognition will be assessed by the Emotion Recognition Task (ERT). Subjects are briefly shown faces morphed to display various emotions of varying intensities, and then required to identify the emotion. Better accuracy defined as number of correct responses reflects better emotional cognition.', 'timeFrame': 'up to 6 weeks'}, {'measure': 'Revised Mystical Experience Questionnaire (MEQ30)', 'description': 'The MEQ30 is a validated self-report revised 30-item questionnaire recording elements that comprise the mystical experience. 0 (""none (not at all)"") to 5 (""extreme (more than any other time in my life and stronger than 4)""), with a total scoring range from 0 to 150. Higher scores indicate a more profound mystical experience.', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Persistent Effects Questionnaire (PEQ)', 'description': 'The PEQ is a non-validated self-report 145-item questionnaire that describe any changes in the participants\' lives that may be attributed to the psilocybin treatment. Comprises of 6 categories with items rated on a 6-point scale from 0 (""none"") to 5 (""extreme""). Higher scores indicate a greater magnitude of the persistent effects following their psilocybin experience.', 'timeFrame': '24 hours'}]",25,18 Years,64 Years,ALL,False,Sunnybrook Health Sciences Centre,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:14.659548,v2_robust,True,True,False,False,False,
NCT04580498,A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC,"An Open-label, Multicenter Phase II Clinical Trial of SHR-1701 With or Without Chemotherapy in the Treatment of Unresectable Stage III Non-small Cell Lung Cancer",SHR-1701+Paclitaxel+carboplatin,"['SHR-1701', 'SHR-1701+Paclitaxel+carboplatin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Non-Small-Cell Lung Cancer,['Non-Small-Cell Lung Cancer'],[],UNKNOWN,,2020-11-10,2025-03-01,"[{'measure': 'ORR', 'description': 'Objective response rate', 'timeFrame': 'From the initiation of the first dose to 3 years'}, {'measure': 'EFS', 'description': 'event free survival', 'timeFrame': 'From the initiation of the first dose to 3 years'}]","[{'measure': 'OS', 'description': 'overall survival', 'timeFrame': 'From the initiation of the first dose to 3 years'}, {'measure': 'EFS rate', 'description': 'event free survival rate', 'timeFrame': 'From the initiation of the first dose to 3 years'}, {'measure': 'TDDM', 'description': 'time to death or distant metastasis', 'timeFrame': 'From the initiation of the first dose to 3 years'}, {'measure': 'Adverse events(AEs)', 'description': 'Incidence of treatment-related AEs', 'timeFrame': 'From the initiation of the first dose to 90 days after the last dose'}]",6,18 Years,70 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,107.0,ACTUAL,2025-09-01T16:18:14.659702,v2_robust,True,True,False,False,True,
NCT04991298,Efficacy of iv Fentanyl Citrate Administered Oral as a Pediatric Premedication,Efficacy of the Intravenous Formulation of Fentanyl Citrate Administered Orally as Premedication in Paediatric Patients Undergoing Open Cardiac Surgery,Oral premedication,"['Oral premedication', 'Midazolam , fentanyl']",2,INTERVENTIONAL,['NA'],,,"Anesthesia, Local","['Anesthesia, Local']",[],UNKNOWN,,2021-06-01,2022-07-25,"[{'measure': ""Patient's acceptance of the medication (score from 1 to 3)"", 'description': 'Response of the child to acceptance of premedication will be assessed on a three-point scale:\n\n1. = Spits/vomits the premedication.\n2. = Accepts it/but dislikes the taste.\n3. = Accepts it/likes the taste.', 'timeFrame': '1 year'}, {'measure': 'Reaction to separation from parents (score from 1 to 4)', 'description': 'The response of the children when taken away from the parents will be recorded as the end point of premedication. It will be assessed on a four point scale:\n\n1. = Inconsolable cry.\n2. = Complaining.\n3. = Quiet but awake.\n4. = Sleepy.', 'timeFrame': '1 year'}, {'measure': 'Sedation score ( score from 1 to 6)', 'description': 'The degree of sedation, when the child will be first seen in the operating room (OR), will be scaled from 1 to 6 according to the Ramsay Sedation Scale.\n\n1. =Anxious and agitated or restless, or both.\n2. =Cooperative, oriented, and calm.\n3. =Responsive to commands only.\n4. =Exhibiting brisk response to light glabellar tap or loud auditory stimulus.\n5. =Exhibiting a sluggish response to light glabellar tap or loud auditory stimulus.\n6. =Unresponsive.', 'timeFrame': '1 year'}, {'measure': 'Ease of Induction of general anaesthesia (score from 1 to 4)', 'description': ""A 4-point scoring system will used to evaluate the child's behaviour at anaesthesia induction and mask acceptance\n\n1= Calm and cooperating 2 =Anxious but without resistance 3 =Anxious with slight resistance 4 =Crying and/or struggling against mask"", 'timeFrame': '1 year'}]","[{'measure': 'Hemodynamic effects', 'description': 'Heart rate (beats/min)', 'timeFrame': '1 year'}, {'measure': 'Adverse effects', 'description': 'nausea, vomiting, illusion, pruritis, paradoxical hyperactive reactions', 'timeFrame': '1 year'}]",6,1 Year,7 Years,ALL,False,University of Alexandria,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:14.659738,v2_robust,True,True,False,False,True,
NCT04469998,Evaluation of AXR-270 for the Treatment of Posterior Blepharitis Associated With Meibomian Gland Dysfunction,"A Phase I/II, Randomized, Double-Masked, Vehicle-Controlled Study of the Safety, Tolerability, and Efficacy of AXR-270 Topical Eyelid Cream in Treating Posterior Blepharitis Associated With Meibomian Gland Dysfunction",AXR-270 Low Dose,"['AXR-270 Low Dose', 'AXR-270 Vehicle', 'AXR-270 High Dose']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Posterior Blepharitis,"['Posterior Blepharitis', 'Meibomian Gland Dysfunction']","['Meibomian Gland Dysfunction', 'Posterior Blepharitis']",COMPLETED,,2020-06-16,2020-12-31,"[{'measure': 'Adverse Events', 'description': 'Incidence of treatment emergent ocular and systemic adverse events (TEAE)', 'timeFrame': '22 Days'}]","[{'measure': 'Total Meibomian Gland Dysfunction Score', 'description': 'Change from Baseline in total MGD score (Study Eyelid):\n\nThe total MGD score is the sum of secretion of 5 central glands on the upper and lower eyelids. Each gland orifice was scored from 0-3. The total score range was from 0-15 per eyelid. The numbers reported are for the Study Eyelid of each subject (=eyelid with higher sum score of the Total MGD score and Vascularity of Eyelid Margin score at baseline). Greater negative scores indicate a better outcome.\n\nScores: 0 = clear/slightly yellow; 1 = opaque/yellow, whitish, particulate; 2 = paste; 3 = none/occluded.', 'timeFrame': '22 Days'}]",2,18 Years,100 Years,ALL,False,"AxeroVision, Inc.",INDUSTRY,0,129.0,ACTUAL,2025-09-01T16:18:14.659809,v2_robust,True,True,True,False,True,
NCT07132398,Slow vs. Rapid Glucocorticoids Tapering With Inebilizumab in NMOSD,"The Efficacy of Slow - Tapering Versus Rapid - Tapering Glucocorticoid Strategies in Preventing Relapses of Neuromyelitis Optica Spectrum Disorder (NMOSD) When Combined With Inebilizumab: A Multicenter, Open - Label, Randomized Parallel - Controlled Clinical Trial",Slow-tapering glucocorticoids + Inebilizumab,"['Rapid-tapering glucocorticoids + Inebilizumab', 'Slow-tapering glucocorticoids + Inebilizumab']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Neuromyelitis Optica (NMO),"['Neuromyelitis Optica (NMO)', 'Neuromyelitis Optica Spectrum Disorders (NMOSD)']","['NMO', 'NMOSD', 'Inebilizumab', 'Glucocorticoids']",NOT_YET_RECRUITING,,2025-09-01,2028-08-31,"[{'measure': 'First adjudicated relapse event within 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}]","[{'measure': 'Change in Expanded Disability Status Scale (EDSS) score from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Low-contrast Visual Acuity (LCVA) from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Timed 25-Foot Walk (T25-FW) test from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Expanded Disability Status Scale (EDSS) score from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Low-contrast Visual Acuity (LCVA) from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Timed 25-Foot Walk (T25-FW) test from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in serum Neurofilament Light chain (sNfL) levels at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in serum Glial Fibrillary Acidic Protein (sGFAP) levels at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in serum AQP4-IgG titer at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in serum Neurofilament Light chain (sNfL) levels at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in serum Glial Fibrillary Acidic Protein (sGFAP) levels at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in serum AQP4-IgG titer at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Visual Analogue Scale (VAS) score from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Visual Analogue Scale (VAS) score from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Change in Quality of Life (QoL) score from baseline at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Change in Quality of Life (QoL) score from baseline at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Proportion of Relapse-free Participants at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Proportion of Relapse-free Participants at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Percentage of patients in glucocorticoid-free remission between 54 and 106 weeks', 'timeFrame': '54 Weeks, 106 Weeks'}, {'measure': 'Annualized Relapse Rate (ARR) at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Annualized Relapse Rate (ARR) at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Daily and acumulate dose of glucocorticoids at relapse before 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Adverse events (AEs) and Serious AEs (SAEs) at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Immunoglobulin levels at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Pelvic X-ray at 54 weeks', 'timeFrame': 'Baseline, 54 Weeks'}, {'measure': 'Adverse events (AEs) and Serious AEs (SAEs) at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Immunoglobulin levels at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}, {'measure': 'Pelvic X-ray at 106 weeks', 'timeFrame': 'Baseline, 106 Weeks'}]",29,18 Years,,ALL,False,Tianjin Medical University General Hospital,OTHER,0,170.0,ESTIMATED,2025-09-01T16:18:14.659892,v2_robust,True,True,False,False,True,
NCT05355298,ACCENT: AMP945 in Combination with Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer,"A Phase 1b/2a, Multicentre, Open Label Study of the Pharmacokinetics, Safety and Efficacy of AMP945 in Combination with Nab-paclitaxel and Gemcitabine in Pancreatic Cancer Patients",AMP945 ascending doses,"['AMP945 ascending doses', 'AMP945 RP2D']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Pancreatic Cancer,"['Pancreatic Cancer', 'PDAC', 'Pancreatic Ductal Adenocarcinoma']",[],ACTIVE_NOT_RECRUITING,,2022-05-31,2026-05-01,"[{'measure': 'Number of Participants with Treatment-Emergent Adverse Events (TEAEs) from Baseline to End of Study', 'description': 'TEAEs during study treatment and follow up periods', 'timeFrame': 'From first dose of study drug to end of study, an expected average of 6 months'}, {'measure': 'Part A: Determination of RP2D', 'description': 'The RP2D of AMP945 will be determined based on either the maximum tolerated dose or maximum pharmacodynamic effect, which ever is reached first', 'timeFrame': 'After Cycle 1 (28 days) for each Part A cohort'}, {'measure': 'Part B: efficacy of AMP945', 'description': 'Overall response rate based on RECIST 1.1', 'timeFrame': 'Imaging every 56 days per participant, with an expected average duration of 6 months'}]","[{'measure': 'Part A: efficacy of AMP945', 'description': 'Overall response rate based on RECIST 1.1', 'timeFrame': 'Imaging every 56 days per participant, with an expected average duration of 6 months'}, {'measure': 'AMP945 levels in plasma', 'description': 'Measurement of maximum concentration (cmax) of AMP945', 'timeFrame': 'Days -8, -7, 1, 3, 4, 8 and 10'}, {'measure': 'AMP945 levels in plasma', 'description': 'Measurement of time to cmax (tmax)', 'timeFrame': 'Days -8, -7, 1, 3, 4, 8 and 10'}, {'measure': 'AMP945 levels in plasma', 'description': 'Measurement of clearance (CL)', 'timeFrame': 'Days -8, -7, 1, 3, 4, 8 and 10'}]",7,18 Years,,ALL,False,Amplia Therapeutics Limited,INDUSTRY,0,62.0,ESTIMATED,2025-09-01T16:18:14.659957,v2_robust,True,True,False,False,True,
NCT05931263,A Randomized Clinical Trial Comparing Chi-BEAM With BEAM Regimen Combined With ASCT for the Treatment of ND PTCL,"A Randomized Controlled Clinical Trial Comparing Chidamide,Carmustine,Etoposide,Cytarabine and Melphalan With BEAM Regimen Combined With Autologus Hematopoietic Stem Cell Transplantation for the Treatment of Newly Diagnosed PTCL",C-BEAM Regimen,"['C-BEAM Regimen', 'BEAM Regimen']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Newly Diagnosed Peripheral T-cell Lymphoma,['Newly Diagnosed Peripheral T-cell Lymphoma'],"['PTCL', 'Chidemide']",RECRUITING,,2023-06-01,2028-02,"[{'measure': '2-y PFS', 'description': '2-year PFS', 'timeFrame': '2 years'}]","[{'measure': '2-year OS', 'timeFrame': '2 years'}, {'measure': 'CR rate at 3 months post-transplant evalutation', 'timeFrame': '2 years'}, {'measure': 'hematopoietic reconstitution time', 'timeFrame': '2 years'}, {'measure': 'Non-recurrent mortality', 'timeFrame': '2 years'}]",5,18 Years,65 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,104.0,ESTIMATED,2025-09-01T16:18:14.659967,v2_robust,True,True,False,False,False,
NCT03415763,Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy,"Efficacy of Adjuvant Chemotherapy in Patients With Clinical Stage III Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Pathology-oriented, Prospective, Multicenter, Randomized, Open-label, Parallel Group Clinical Trial",Capecitabine,"['5-Fu-leucovorin-oxaliplatin or xeloda-oxaliplatin', 'mFOLFOX6 or CAPOX', 'Xeloda', 'Capecitabine']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Rectal Neoplasms,['Rectal Neoplasms'],"['Rectal Neoplasms', 'Adjuvant Chemotherapy', 'Neoadjuvant Chemoradiotherapy']",RECRUITING,,2018-11-05,2025-12,"[{'measure': 'Disease free survival', 'description': 'Calculated from the date of surgery to the date of recurrence', 'timeFrame': '3-year'}]","[{'measure': 'Overall survival', 'description': 'Calculated from the date of diagnosis to the date of death from any cause', 'timeFrame': '3-year, 5-year'}, {'measure': 'Disease free survival', 'description': 'Calculated from the date of surgery to the date of recurrence', 'timeFrame': '5-year'}, {'measure': 'The rate of local recurrence', 'description': 'The ratio of the number of local recurrence to the total patients', 'timeFrame': '3-year'}, {'measure': 'The rate of adverse events resulted from chemotherapy', 'description': 'The ratio of the number of patients experienced adverse events to the total patients', 'timeFrame': '3-year'}, {'measure': 'The quality of life postoperatively', 'description': 'The European Organization for Research and Treatment (EORTC)-QLQ-C30 HRQL questionnaire was assessed with repeated measures at regular intervals postoperatively at months 3, 6, 9, 12, 18, and 24', 'timeFrame': '3-month, 6-month, 9-month, 12-month, 18-month, 24-month'}]",6,18 Years,75 Years,ALL,False,LI XIN-XIANG,OTHER,0,764.0,ESTIMATED,2025-09-01T16:18:14.659997,v2_robust,True,True,False,False,True,
NCT05060263,A Study of of HOT1030 in Patients With Advanced Solid Tumors,"A Phase 1, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HOT1030 in Patients With Advanced Solid Tumors",HOT-1030,"['no other interventions', 'HOT-1030']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Solid Tumor, Adult","['Solid Tumor, Adult']",[],UNKNOWN,,2021-03-12,2023-06-30,"[{'measure': 'Safety and tolerability as measured by incidence of AEs (Adverse Events)', 'description': 'Incidence and severity of AEs, Adverse events were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v4.0.', 'timeFrame': 'through study completion， an average of 1 year'}]","[{'measure': 'Area Under Curve (AUC) of HOT-1030', 'description': 'Area under the concentration-time curve of HOT-1030 in plasma over the time interval from 0 extrapolated to infinity', 'timeFrame': '42 days'}, {'measure': 'Maximum Serum Concentration (Cmax) of HOT-1030', 'description': 'Maximum Serum Concentration (Cmax) in plasma', 'timeFrame': '42 days'}, {'measure': 'Antitumor Activity of HOT-1030 in Patients With advanced Solid Tumors', 'description': 'Response is defined as a Complete Response + Partial Response and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.', 'timeFrame': 'through study completion， an average of 1 year'}]",4,18 Years,75 Years,ALL,False,"Huabo Biopharm Co., Ltd.",INDUSTRY,0,42.0,ESTIMATED,2025-09-01T16:18:14.660040,v2_robust,True,True,False,False,True,
NCT00437463,Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor,Treatment of Early Immunoglobulin A Nephropathy by ACE Inhibitor - a Randomized Controlled Trial,Ramipril,['Ramipril'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Glomerulonephritis,['Glomerulonephritis'],[],COMPLETED,,2004-07,2010-09,"[{'measure': 'Development of hypertension (defined as blood pressure above 140/90 mm Hg and require anti-hypertensive therapy)', 'timeFrame': 'From the beginning to the end of the study'}, {'measure': 'Development of proteinuria', 'timeFrame': 'From the beginning to the end of the study'}, {'measure': '20% decline in creatinine clearance, as determined by 24-hour urine collection or estimated by the Gault-Cockroft equation', 'timeFrame': 'From the beginning to the end of the study'}, {'measure': 'body weight, blood pressure, pulse', 'timeFrame': 'From the beginning to the end of the study'}, {'measure': 'Adverse effects of treatment', 'timeFrame': 'From the beginning to the end of the study'}]",[],5,18 Years,65 Years,ALL,False,Sanofi,INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:14.660139,v2_robust,True,True,True,False,True,
NCT01851863,Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia,Compliance With Antidepressant Medication in Treatment of Functional Dyspepsia: A Randomized Comparison of Different Prescribing Behaviors,Omeprazole,"['Flupentixol-Melitracen(without explanation) + Omeprazole', 'Flupentixol-Melitracen(psychological and GI) + Omeprazole', 'Flupentixol and Melitracen Tablets brand name: Deanxit(produced by H.Lundbeck A/S, Copenhagen, Denmark )', 'Brand name: Aoke (produced by Changzhou Siyao Pharm, China)', 'Flupentixol-Melitracen(psychological) + Omeprazole', 'Omeprazole', 'Omeprazole brand name: Aoke (produced by Changzhou Siyao Pharm, China)']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Dyspepsia,"['Dyspepsia', 'Compliance', 'Depression']","['functional dyspepsia', 'depression', 'compliance']",COMPLETED,,2013-05,2014-06,"[{'measure': 'Compliance of Flupentixol-Melitracen', 'description': 'The patients were asked to keep a diary to record their medication intake. At each visit (weeks 1, 2, 4, 8), the patient bring back the drug bottle and the diary, then the physician recorded the number of pills remaining in the bottle. Pills remained more than 20% at any visit or seven days of consecutive abstinence were adopted as the criterion for identifying therapy noncompliance.', 'timeFrame': 'weeks 1, 2, 4, 8'}]","[{'measure': 'Change From Baseline in Dyspepsia Symptom Questionnaire at Week 8', 'description': ""The severity of patients' dyspeptic symptoms were assessed using the Leeds Dyspepsia Questionnaire (LDQ) at week 0 and 8. The LDQ contains eight items about epigastric pain, retro-sternal pain, regurgitation, nausea, vomiting, belching, early satiety and dysphagia with six grades for each item and a sum of the eight symptom scores make the LDQ score.LDQ scores of 0 - 4 were classified as very mild dyspepsia, 4 - 8 as mild dyspepsia, 9 -15 as moderate dyspepsia, and \\> 15 as severe or very severe dyspepsia. The change of LDQ scores was calculated by LDQ scores of 8 weeks minus baseline, with lower values represent a better outcome."", 'timeFrame': 'week 0 and 8'}, {'measure': 'Change From Baseline in Psychiatric Symptom on Hospital Anxiety and Depression Scale at Week 8', 'description': 'Each patient was surveyed using the Hospital Anxiety and Depression Scale to assess the psychiatric symptom at week 0 and 8.The HADS consists of 14 items, seven of which assess anxiety, and seven assess depression. The anxiety and depression subscales were calculated independently. The patients were asked to answer each item on a four-point (0 - 3) scale. Scores of 0 to 7 on either subscale can be regarded as within the normal range, scores of 8 to 10 are suggestive of the presence of the respective state, and scores of 11 or higher indicate the probable presence of the respective mood disorder. The change of HADS scores was calculated by HADS anxiety and depression scores of 8 weeks minus baseline, with lower values indicate better outcome.', 'timeFrame': 'week 0 and 8'}]",3,18 Years,75 Years,ALL,False,RenJi Hospital,OTHER,0,262.0,ACTUAL,2025-09-01T16:18:14.660159,v2_robust,True,True,True,False,False,
NCT05898087,Subpectoral Bupivacaine for Pain Management in Adolescent Reduction Mammaplasty,Subpectoral Bupivacaine for Pain Management in Adolescent Reduction Mammaplasty,Marcaine 0.25 % Injectable Solution,"['Saline', 'bupivacaine 0.25% injectable solution', 'injectable saline', 'Marcaine 0.25 % Injectable Solution']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Macromastia,"['Macromastia', 'Post-operative Pain']","['macromastia', 'post-operative pain', 'bupivacaine']",RECRUITING,,2022-04-01,2026-04-01,"[{'measure': 'Patient Reported Pain Score', 'description': 'Post-operative pain score will be patient reported on a rating scale of 1-10. This will be recorded by the PACU nurse upon admission and upon discharge from the PACU. Patients will subsequently record a daily pain score in a home log daily until their 1 week follow-up visit. Scores will be recorded using the home log provided by the patient. We will also utilize chart review to record PACU pain score from the immediate post-operative time period.', 'timeFrame': 'Measured on day of surgery'}]","[{'measure': 'Demographics', 'description': 'Demographics including age, race, ethnicity will be collected and recorded for all patients approached to enter the study.', 'timeFrame': 'Recorded when patient is enrolled'}, {'measure': 'Total Amount of Narcotic Use', 'description': 'Narcotic use will be determined by chart review of the PACU record. The amount of narcotic pain medication will be recorded for each patient. Prescription narcotic use upon discharge will be patient-reported in their patient log.', 'timeFrame': 'Measured up until 4 weeks post-op'}, {'measure': 'Days to Return to full activity', 'description': 'Return to full activity- will be categorized as returning to school, returning to light activity, or returning to full activity/heavy exercise.', 'timeFrame': 'Measured for 4 weeks post-op'}, {'measure': 'Length of stay in post-anesthesia care unit (hours)', 'description': 'Length of stay in post-anesthesia care unit will be determined by chart review from time entering the PACU to time of discharge from the hospital.', 'timeFrame': 'Measured on day of surgery'}]",5,13 Years,25 Years,ALL,True,Connecticut Children's Medical Center,OTHER,0,128.0,ESTIMATED,2025-09-01T16:18:14.660407,v2_robust,True,True,False,False,False,
NCT05021887,A Bioequivalence Study Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions,"A Randomized, Single-dose, Open Label, Two-treatment, Two-sequence, Two-period, Crossover Study Under Fasting Conditions to Examine the Bioequivalence Between Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 100 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers",Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals,"['FLOVENT DISKUS', 'Fluticasone Propionate 100 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals', 'Reference', 'Test']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Asthma,"['Asthma', 'Bioequivalence']","['bioequivalence', 'asthma', 'fluticasone propionate', 'FLOVENT']",UNKNOWN,,2021-08-13,2021-11-30,"[{'measure': 'Cmax', 'description': 'Maximum plasma concentration, it is read directly from the raw data', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}, {'measure': 'AUC(0-t)', 'description': 'Area under the plasma concentration curve from time 0 to the last measured', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}]","[{'measure': 'AUC0-∞', 'description': 'Area under the plasma concentration-time curve extrapolated to infinity', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}, {'measure': 'Tmax', 'description': 'Time until Cmax is reached, it is read directly from the observed concentrations', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}, {'measure': 't1/2', 'description': 'Plasma concentration halflife, it is calculated from the ratio 0.693/λZ', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}, {'measure': 'λz', 'description': 'Terminal elimination rate constant, calculated from the slope of the final phase of the ln-concentration curve versus time with regression analysis', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}, {'measure': 'Residual Area', 'description': '\\[AUC(0-∞)-AUC(0-t)\\]/AUC(0-∞)\\]', 'timeFrame': '3, 5, 10, 15, 30, 45 minutes, 1.00 hour, 1 hour and 20 minutes, 1 hour and 40 minutes, 2.00 hours, 2 hours and 30 minutes, 3.00, 4.00, 6.00, 8.00, 12.00, 14.00, 16.00, 24.00 and 36:00 hours post-administration'}]",7,18 Years,60 Years,ALL,True,Respirent Pharmaceuticals Co Ltd.,INDUSTRY,1,50.0,ESTIMATED,2025-09-01T16:18:14.660473,v2_robust,True,True,False,False,False,
NCT01013987,Maraviroc (Celsentri) With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients,"A Phase 4, Single Arm, Open Label, Pilot Study of Maraviroc (Celsentri) in Combination With Raltegravir and Darunavir/Ritonavir for the Treatment of Triple Class Failure in Adult HIV-1 Infected Patients.",maraviroc,"['Celsentri', 'maraviroc', 'Darunavir/ritonavir', 'Raltegravir', 'Issentres']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV-1 Adults Patients,"['HIV-1 Adults Patients', 'AIDS', 'Triple Class Failure']","['HIV-1', 'triple class failure', 'Maraviroc', 'Raltegravir', 'Darunavir/ritonavir', 'Maraviroc with raltegravir and darunavir/ritonavir']",UNKNOWN,,2010-02,,"[{'measure': 'Proportion of patients with HIV RNA levels of less than 50 copies/ml in an intent to treat analysis at week 24', 'timeFrame': 'week 24'}]","[{'measure': 'Proportion of patients with HIV RNA levels of less than 50 copies/ml at week 24 and with HIV RNA levels of less than 400 copies/ ml at weeks 24 and 48.', 'timeFrame': 'week 24 and week 48'}]",2,21 Years,,ALL,False,Fundación Huésped,OTHER,1,60.0,ESTIMATED,2025-09-01T16:18:14.660525,v2_robust,True,True,False,False,False,
NCT02978287,New Transporting Solution in Parathyroid Allotransplantation,The Effects of Cold Ischemia Time With a New Transporting Solution to Parathyroid Cell Viability and Calcium Sensing Receptor in Parathyroid Allotransplantation,BAVU Solution,['BAVU Solution'],1,INTERVENTIONAL,['NA'],,,Parathyroid Allotransplantation,['Parathyroid Allotransplantation'],"['Calcium sensing receptor', 'Parathyroid cell viability', 'Parathyroid allotransplantation', 'Transporting solution']",UNKNOWN,,2016-09,2016-12,"[{'measure': 'Cell viability of Parathyroid cells', 'description': 'The investigators will measure the viability of Parathyroid cells at 0 hour at the BAVU solution', 'timeFrame': '0 hour'}, {'measure': 'Cell viability of Parathyroid cells', 'description': 'The investigators will measure the viability of Parathyroid cells at 6 hours at the BAVU solution', 'timeFrame': '6 hours'}, {'measure': 'Cell viability of Parathyroid cells', 'description': 'The investigators will measure the viability of Parathyroid cells at 12 hours at the BAVU solution', 'timeFrame': '12 hours'}, {'measure': 'Cell viability of Parathyroid cells', 'description': 'The investigators will measure the viability of Parathyroid cells at 18 hours at the BAVU solution', 'timeFrame': '18 hours'}, {'measure': 'Cell viability of Parathyroid cells', 'description': 'The investigators will measure the viability of Parathyroid cells at 24 hours at the BAVU solution', 'timeFrame': '24 hours'}]",[],5,18 Years,80 Years,ALL,False,Sisli Hamidiye Etfal Training and Research Hospital,OTHER,1,7.0,ESTIMATED,2025-09-01T16:18:14.660595,v2_robust,True,True,False,False,False,
NCT02944487,A Study to Assess the Safety and Pharmacokinetics of Lucerastat (OGT 923) in Healthy Subjects,"A Randomised, Double-blind, Placebo-controlled Ascending Dose Tolerance Study of OGT 923 in Healthy Male Volunteers",Lucerastat,"['Placebo', 'OGT-923', 'ACT-434964', 'Lucerastat']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],"['safety', 'pharmacokinetics']",COMPLETED,,2002-10,2002-12,"[{'measure': 'Number of participants with Adverse Events (AEs)', 'description': 'An AE was defined as any untoward medical occurrence in a clinical investigation subject, which did not necessarily have a causal relationship with the treatment.', 'timeFrame': 'From baseline up to 7 days post-administration'}, {'measure': 'Maximum plasma concentration (Cmax) of lucerastat after single ascending doses of lucerastat', 'description': 'Cmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving a single dose.', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration'}, {'measure': 'Maximum plasma concentration (Cmax) of lucerastat after two daily doses of lucerastat', 'description': 'Cmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving lucerastat twice daily.', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration'}, {'measure': 'Time to reach Cmax (tmax) of lucerastat after single ascending doses of lucerastat', 'description': 'tmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving a single dose.', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration'}, {'measure': 'Time to reach Cmax (tmax) of lucerastat after two daily doses of lucerastat', 'description': 'tmax was determined directly from the observed plasma concentration-time curves of lucerastat in subjects receiving lucerastat twice daily.', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration'}, {'measure': 'Area under the plasma concentration-time curves (AUC) of lucerastat after single ascending doses of lucerastat', 'description': 'AUC was calculated from time zero to time t (last PK blood sample in which drug was detected) and extrapolated to infinity for subjects receiving a single dose.', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration'}, {'measure': 'Area under the plasma concentration-time curves (AUC) of lucerastat after two daily doses of lucerastat', 'description': 'AUC was calculated from time zero to time t (last PK blood sample in which drug was detected) and extrapolated to infinity for subjects receiving lucerastat twice daily', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration'}, {'measure': 'Terminal elimination half-life (t1/2) of lucerastat after single ascending doses of lucerastat', 'description': 't1/2 was calculated from the corresponding plasma concentrations-time curves for subjects receiving a single dose', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 24 hours post administration'}, {'measure': 'Terminal elimination half-life (t1/2) of lucerastat after two daily doses of lucerastat', 'description': 't1/2 was calculated from the plasma concentrations-time curves for subjects receiving lucerastat twice daily', 'timeFrame': 'PK Blood samples were collected at pre-dose and at scheduled time points up to 48 hours after the first administration'}]","[{'measure': 'Change from baseline in heart rate', 'timeFrame': 'Up to 24 hours post administration'}, {'measure': 'Change from baseline in blood pressure', 'timeFrame': 'Up to 24 hours post administration'}, {'measure': 'Change from baseline in electrocardiogram (ECG) variables', 'timeFrame': 'Up to 24 hours post administration'}, {'measure': 'Change from baseline in laboratory tests', 'timeFrame': 'Up to 24 hours post administration'}]",13,18 Years,45 Years,MALE,True,Idorsia Pharmaceuticals Ltd.,INDUSTRY,0,39.0,ACTUAL,2025-09-01T16:18:14.660611,v2_robust,True,True,True,False,True,
NCT02544087,Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction,Heat-clearing and Blood-activating Chinese Medicinal Components in Acute Cerebral Infarction: Mechanisms of Multi-target Anti-inflammatory Action,Ixeris of sonchifolia Hance,"['Ixeris of sonchifolia Hance', 'Ixeris of sonchifolia Hance combined with Panax notoginseng saponins', 'Panax notoginseng saponins', 'Xueshuantong injections', 'KDZ injection']",5,INTERVENTIONAL,['NA'],,,Ischemic Stroke,['Ischemic Stroke'],"['fire-heat syndrome', 'blood stasis syndrome', 'method of clearing heat', 'method of promoting blood circulation']",UNKNOWN,,2015-04,2018-04,"[{'measure': 'modified Rankin scale', 'timeFrame': '180 days'}]","[{'measure': 'Barthel index', 'timeFrame': '180 days'}, {'measure': 'national institute of health stroke scale', 'timeFrame': '180 days'}, {'measure': 'Glasgow coma scale', 'timeFrame': '180 days'}, {'measure': 'scores of Chinese medicine symptoms', 'timeFrame': '180 days'}, {'measure': 'mortality rate', 'timeFrame': '180 days'}, {'measure': 'disability rate', 'timeFrame': '180 days'}]",7,40 Years,80 Years,ALL,False,Yunling Zhang,OTHER,2,120.0,ESTIMATED,2025-09-01T16:18:14.660622,v2_robust,True,True,False,False,False,
NCT03478787,Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis,"A Multicenter, Randomized, Open Label, Efficacy Assessor-Blinded Study of Risankizumab Compared to Secukinumab for the Treatment of Adult Subjects With Moderate to Severe Plaque Psoriasis Who Are Candidates for Systemic Therapy",risankizumab,"['Cosentyx', 'risankizumab', 'SKYRIZI', 'BI 655066', 'ABBV-066', 'secukinumab']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriasis,['Psoriasis'],['Plaque Psoriasis'],COMPLETED,,2018-05-08,2020-07-08,"[{'measure': 'Percentage of Participants With a 90% Reduction From Baseline Psoriasis Area and Severity Index (PASI 90) at Week 16', 'description': 'The Psoriasis Area and Severity Index (PASI) is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \\* 100. Non-responder imputation (NRI) was used for missing data.', 'timeFrame': 'Week 16'}, {'measure': 'Percentage of Participants With a PASI 90 at Week 52', 'description': 'The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 90 is defined as at least a 90% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \\* 100.', 'timeFrame': 'Week 52'}]","[{'measure': 'Percentage of Participants With a 100% Reduction From Baseline Psoriasis Area and Severity Index (PASI 100) at Week 52', 'description': 'PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 100 is defined as 100% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \\* 100.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of Clear or Almost Clear at Week 52', 'description': 'The sPGA is an assessment by the investigator of the overall disease severity at the time of evaluation. Erythema, induration, and scaling of psoriatic lesions are scored on a 5-point scale ranging from 0 (none) to 4 (severe). The sPGA ranges from 0 to 4, and is calculated as Clear (0) = 0 for all 3; Almost clear (1) = mean \\> 0, \\< 1.5; Mild (2) = mean ≥ 1.5, \\< 2.5; Moderate (3) = mean ≥ 2.5, \\< 3.5; and Severe (4) = mean ≥ 3.5.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants With a 75% Reduction From Baseline Psoriasis Area and Severity Index (PASI 75) at Week 52', 'description': 'The PASI is a composite score based on the degree of effect on body surface area of psoriasis and the extension of erythema (reddening), induration (thickness), desquamation (scaling) of the lesions and area affected as observed on the day of examination. The PASI score ranges from 0 to 72, where 0 indicates no psoriasis and 72 indicates very severe psoriasis. PASI 75 is defined as at least a 75% reduction in PASI score compared with the Baseline PASI score. The percent reduction in score is calculated as (PASI score at Baseline - score at follow-up visit) / PASI score at Baseline \\* 100.', 'timeFrame': 'Week 52'}]",5,18 Years,,,False,AbbVie,INDUSTRY,0,327.0,ACTUAL,2025-09-01T16:18:14.660639,v2_robust,True,True,True,False,False,
NCT04781387,Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection,"A Phase 2, Randomized, Double-Blind, Comparator-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of CRS3123 Compared With Oral Vancomycin in Adults With Clostridioides Difficile Infection",CRS3123,"['CRS3123', 'Active Comparator']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Clostridioides Difficile Infection,['Clostridioides Difficile Infection'],"['CDI', 'Cdiff Infection', 'Clostridiodes difficile infection', 'Cdiff']",COMPLETED,,2021-01-05,2024-04-16,"[{'measure': 'Rate of Clinical Cure at the Test of Cure [TOC] Visit in the Intent-to-treat [ITT] Population', 'description': 'Clinical cure is defined as survival through TOC/Day 12 and resolution of diarrhea (i.e., \\<3 unformed bowel movements \\[UBM\\] \\[Bristol Stool Scale score of 5, 6, or 7\\] at end-of-treatment (EOT)/Day 10 with maintenance of resolution through TOC/Day 12 and no further requirement for treatment of CDI through TOC/Day 12. Numbers reported below indicate participants from each cohort that were clinical cures, clinical failures, or indeterminate at the TOC/Day 12 visit.', 'timeFrame': 'TOC/Day 12'}]","[{'measure': 'Rate of Clinical Cure at Test of Cure (TOC) in the Microbiological-ITT (mITT) Population', 'description': 'Clinical cure is defined as survival through TOC/Day 12 and resolution of diarrhea (i.e., \\<3 unformed bowel movements \\[UBM\\] \\[Bristol Stool Scale score of 5, 6, or 7\\] at end-of-treatment (EOT)/Day 10 with maintenance of resolution through TOC/Day 12 and no further requirement for treatment of CDI through TOC/Day 12. Numbers reported below indicate participants from each cohort that were clinical cures, clinical failures, or indeterminate at the TOC/Day12 visit.', 'timeFrame': 'TOC/Day 12'}, {'measure': 'Rate of Clinical Cure at Test of Cure (TOC) in the Per Protocol (PP) and Microbiologically Evaluable (ME) Populations', 'description': 'Clinical cure is defined as survival through TOC/Day 12 and resolution of diarrhea (i.e., \\<3 unformed bowel movements \\[UBM\\] \\[Bristol Stool Scale score of 5, 6, or 7\\] at end-of-treatment (EOT)/Day 10 with maintenance of resolution through TOC/Day 12 and no further requirement for treatment of CDI through TOC/Day 12. Numbers reported below indicate participants from each cohort that were clinical cures, clinical failures, or indeterminate at the TOC/Day12 visit.', 'timeFrame': 'TOC/Day 12'}, {'measure': 'Rate of Total Relief of Symptoms of Clostridioides Difficile Infection at Test of Cure (TOC) in the Microbiological-ITT (mITT) Population', 'description': ""Total relief of symptoms at TOC/Day 12 is defined as resolution (\\< 3 per day) of unformed bowel movements, an investigator's assessment of clinical cure, and the resolution of signs or symptoms of CDI recorded at baseline. Numbers reported below indicate participants from each cohort that had total relief of symptoms at TOC/Day 12 and those that did not."", 'timeFrame': 'TOC/Day 12'}, {'measure': 'Rate of Total Relief of Symptoms of Clostridioides Difficile Infection at Test of Cure (TOC) in the Per Protocol (PP) and Microbiologically Evaluable (ME) Populations', 'description': ""Total relief of symptoms at TOC/Day 12 is defined as resolution (\\< 3 per day) of unformed bowel movements, an investigator's assessment of clinical cure, and the resolution of signs or symptoms of CDI recorded at baseline. Numbers reported below indicate participants from each cohort that had total relief of symptoms at TOC/Day 12 and those that did not."", 'timeFrame': 'TOC/Day 12'}, {'measure': 'Time to Resolution of Diarrhea Through Test of Cure (TOC) in the Microbiological-ITT (mITT) Population', 'description': 'The time to resolution of diarrhea is defined as the time elapsed from the first dose of study treatment to the last unformed bowel movement before 2 consecutive days of \\< 3 unformed bowel movements (Bristol Stool Scale score of 5, 6, or 7) per day through TOC/Day 12. Values reported below are median days to resolution for each cohort.', 'timeFrame': 'Study Day 1 until the date of documented resolution, assessed up to TOC/Day 12'}, {'measure': 'Time to Resolution of Diarrhea Through Test of Cure (TOC) in the Per Protocol (PP) and Microbiologically Evaluable (ME) Populations', 'description': 'The time to resolution of diarrhea is defined as the time elapsed from the first dose of study treatment to the last unformed bowel movement before 2 consecutive days of \\< 3 unformed bowel movements (Bristol Stool Scale score of 5, 6, or 7) per day through TOC/Day 12. Values reported below are median days to resolution for each cohort.', 'timeFrame': 'Study Day 1 until the date of documented resolution, assessed up to TOC/Day 12'}, {'measure': 'Rate of Early Recurrence of Clostridioides Difficile Infection Through Day 40 in the Microbiological-ITT (mITT) Population', 'description': 'Rate of early recurrence of C. difficile infection (CDI) is defined as a new episode of diarrhea (≥ 3 unformed bowel movements \\[Bristol Stool Scale score of 5, 6, or 7\\] in a 24-hour period) with a positive toxin result and requires retreatment for CDI before Day 40. The table below shows the number of participants per cohort that experienced a recurrence before Day 40 and those that did not. Only participants that were clinical cures at TOC/Day 12 were included in the analysis.', 'timeFrame': 'Post TOC/Day 12 visit through Day 40'}, {'measure': 'Rate of Early Recurrence of Clostridioides Difficile Infection Through Day 40 in the Microbiologically Evaluable (ME) Population', 'description': 'Rate of early recurrence of C. difficile infection (CDI) is defined as a new episode of diarrhea (≥ 3 unformed bowel movements \\[Bristol Stool Scale score of 5, 6, or 7\\] in a 24-hour period) with a positive toxin result and requires retreatment for CDI before Day 40. The table below shows the number of participants per cohort that experienced a recurrence before Day 40 and those that did not. Only participants that were clinical cures at TOC/Day 12 were included in the analysis.', 'timeFrame': 'Post TOC/Day 12 visit through Day 40'}, {'measure': 'Rate of Late Recurrence of Clostridioides Difficile Infection (Between Day 40 and Day 70) in the Microbiological-ITT (mITT) Population', 'description': 'Rate of late recurrence of CDI is defined as a new episode of diarrhea (≥ 3 unformed bowel movements \\[Bristol Stool Scale score of 5, 6, or 7\\] in a 24-hour period), with a positive toxin result and requires retreatment of CDI between Day 40 and Day 70. The table below shows the number of participants per cohort that experienced a recurrence between Day 40 and Day 70 and those that did not. Analysis populations for this assessment only includes participants that had an investigator assessment of clinical cure at TOC/Day 12. Participants that were indeterminate at TOC/Day 12 or recurrent prior to Day 40 were excluded.', 'timeFrame': 'Day 40 - Day 70'}, {'measure': 'Rate of Late Recurrence of Clostridioides Difficile Infection (Between Day 40 and Day 70) in the Microbiologically Evaluable (ME) Population', 'description': 'Rate of late recurrence of CDI is defined as a new episode of diarrhea (≥ 3 unformed bowel movements \\[Bristol Stool Scale score of 5, 6, or 7\\] in a 24-hour period), with a positive toxin result and requires retreatment of CDI between Day 40 and Day 70. The table below shows the number of participants per cohort that experienced a recurrence between Day 40 and Day 70 and those that did not. Analysis populations for this assessment only includes participants that had an investigator assessment of clinical cure at TOC/Day 12. Participants that were indeterminate at TOC/Day 12 or recurrent prior to Day 40 were excluded.', 'timeFrame': 'Day 40 - Day 70'}, {'measure': 'Rate of Recurrence of Clostridioides Difficile Infection Through Day 70 in the Microbiological-ITT (mITT) Population', 'description': 'Rate of recurrence of CDI is defined as a new episode of diarrhea (≥3 unformed bowel movements \\[Bristol Stool Scale score of 5, 6, or 7\\] in a 24-hour period) with a positive toxin result and requires retreatment for CDI at any point between TOC/Day 12 and Day 70. The table below shows the number of participants per cohort that experienced a recurrence between TOC/Day 12 and Day 70 and those that did not. Analysis populations for this assessment only includes participants that had an investigator assessment of clinical cure at TOC/Day 12.', 'timeFrame': 'Post TOC/Day 12 visit through Day 70'}, {'measure': 'Rate of Recurrence of Clostridioides Difficile Infection Through Day 70 in the Microbiologic Evaluable (ME) Population', 'description': 'Rate of recurrence of CDI is defined as a new episode of diarrhea (≥3 unformed bowel movements \\[Bristol Stool Scale score of 5, 6, or 7\\] in a 24-hour period) with a positive toxin result and requires retreatment for CDI at any point between TOC/Day 12 and Day 70. The table below shows the number of participants per cohort that experienced a recurrence between TOC/Day 12 and Day 70 and those that did not. Analysis populations for this assessment only includes participants that had an investigator assessment of clinical cure at TOC/Day 12.', 'timeFrame': 'Post TOC/Day 12 visit through Day 70'}, {'measure': 'Rate of Global Cure in the Microbiological-ITT (mITT) Population', 'description': 'Global cure is defined as a clinical cure at TOC/Day 12 without recurrence through Day 40. The table below shows the number of participants per cohort that experienced a recurrence between TOC/Day 12 and Day 40 and those that did not.', 'timeFrame': 'Post TOC/Day 12 visit through Day 40'}, {'measure': 'Rate of Global Cure in the Per Protocol (PP) and Microbiologically Evaluable (ME) Populations', 'description': 'Global cure is defined as a clinical cure at TOC/Day 12 without recurrence through Day 40. The table below shows the number of participants per cohort that experienced a recurrence between TOC/Day 12 and Day 40 and those that did not.', 'timeFrame': 'Post TOC/Day 12 visit through Day 40'}]",15,18 Years,,ALL,False,"Crestone, Inc",INDUSTRY,1,43.0,ACTUAL,2025-09-01T16:18:14.660694,v2_robust,True,True,True,False,False,
NCT02260687,Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization,Special Drug Use Investigation of EYLEA for Myopic Choroidal Neovascularization,"Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)","['Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)']",1,OBSERVATIONAL,[],,,Choroidal Neovascularization,['Choroidal Neovascularization'],"['Aflibercept', 'Anti-VEGF']",COMPLETED,,2014-12-05,2018-08-22,"[{'measure': ""Number of episodes of Adverse drug reaction (ADR's)"", 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of episodes of Infections', 'timeFrame': 'Up to 12 months'}, {'measure': ""Number of episodes of Serious Adverse Events(SAE's)"", 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of episodes of Ocular Adverse events', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Mean changes in visual acuity', 'timeFrame': 'Baseline up to 12 months'}, {'measure': 'Mean changes in retina thickness', 'timeFrame': 'Baseline up to 12 months'}]",6,,,ALL,False,Bayer,INDUSTRY,1,353.0,ACTUAL,2025-09-01T16:18:14.660896,v2_robust,False,True,True,False,True,
NCT05214287,Multiple N-of-1 Trials of (Intermittent) Hypoxia Therapy in Parkinson's Disease,An N-of-1 Double-blind Randomized Phase 1 Trial of the Safety and Feasibility of (Intermittent) Hypoxia Therapy in Parkinson's Disease (TALISMAN),Hypoxic Gas Mixture,"['Hypoxicator', 'Hypoxic Gas Mixture']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Parkinson Disease,"['Parkinson Disease', 'Effect of Drug']","[""Parkinson's disease"", 'Treatment', 'Intermittent hypoxia therapy', 'IHT', 'Disease-modifying treatment', 'Symptomatic therapy', 'Neurodegenerative Diseases', 'Synucleinopathies', 'Oxygen Deficiency', 'Hypoxia, Brain', 'Movement Disorders']",COMPLETED,,2022-02-22,2023-07-12,"[{'measure': 'Nature and number of adverse events', 'description': 'Actively reported during intervention and passively for up to 3 days after the intervention, adverse events will be collected.', 'timeFrame': 'Until 3 days post-intervention'}, {'measure': 'Self-reported dizziness, discomfort and stress on a ten-point scale', 'description': 'Every 10 minutes up to one hour post-intervention, one time next morning post-intervention, 10-point Likert scale, lower is better.', 'timeFrame': 'Until 3 days post-intervention'}, {'measure': 'Blood pressure', 'description': 'Systolic and diastolic blood pressure', 'timeFrame': 'Baseline and every 5 mins until 30 mins post-intervention'}, {'measure': 'Heartrate', 'description': 'Beats/min', 'timeFrame': 'Baseline and every 5 mins until 30 mins post-intervention'}, {'measure': 'Respiratory rate', 'description': 'Breaths/min', 'timeFrame': 'Baseline and every 5 mins until 30 mins post-intervention'}, {'measure': 'Oxygen saturation', 'description': 'Percentage', 'timeFrame': 'Baseline and every 5 mins until 30 mins post-intervention'}, {'measure': 'Feasibility questionnaire', 'description': '17-item scale, scored 1-10, lower is better. Subscores and total score', 'timeFrame': 'After 1st, 5th, 10th post-intervention test'}]","[{'measure': 'Participant-selected motor symptom', 'description': 'Change from (pre-treatment) baseline in the symptom that improved most during previous positive altitude effect (if applicable), or other symptom of choice. Self-reported severity scores on a Likert-scale. 10-point Likert scale allowing half points. Lower is better.', 'timeFrame': 'Directly after, as well as 30 and 60 minutes after the intervention and four times once every hour after that. In addition, these will be measured once every morning (i.e. in OFF) for the next three mornings after the intervention.'}, {'measure': 'General impression of PD symptoms', 'description': 'Change from (pre-treatment) baseline on 10-point Likert scale allowing half points. Lower is better.', 'timeFrame': 'Directly after, as well as 30 and 60 minutes after the intervention and four times once every hour after that. In addition, these will be measured once every morning (i.e. in OFF) for the next three mornings after the intervention.'}, {'measure': 'Urge to take dopaminergic medication', 'description': 'Change from (pre-treatment) baseline on 10-point Likert scale allowing half points. Lower is better.', 'timeFrame': 'Directly after, as well as 30 and 60 minutes after the intervention and four times once every hour after that. In addition, these will be measured once every morning (i.e. in OFF) for the next three mornings after the intervention.'}, {'measure': 'Timed Up & Go Test', 'description': 'Change from (pre-treatment) baseline in total time and steps. The Timed Up \\& Go Test is a test that evaluates primarily gait functioning. Lower is better.', 'timeFrame': '30 minutes'}, {'measure': 'MiniBESTest', 'description': 'Change from (pre-treatment) baseline in item subscores and total score. The MiniBESTest is a concise balance test. Higher is better.', 'timeFrame': '30 minutes'}, {'measure': ""Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III"", 'description': ""The MDS-UPDRS part III is the gold standard for motor assessment in Parkinson's disease. Change form (pre-treatment) baseline in item subscores and total scores. Lower is better."", 'timeFrame': '30 minutes'}, {'measure': 'Finger tapping', 'description': 'Change from (pre-treatment) baseline in number of taps during 10-second trials on both hands, one session each. Finger tapping is considered a measure of bradykinesia. Higher is better.', 'timeFrame': '30 minutes'}, {'measure': 'MDS Non-Motor Symptoms Scale (only items related to stress, fatigue, mood, anxiety, pain)', 'description': 'The most important potentially adaptive non-motor symptoms mentioned in this gold standard for non-motor symptom screening are selected. Likert scale 1-10 (allowing half points). Change from (pre-treatment) baseline. Lower is better.', 'timeFrame': '30 minutes'}, {'measure': 'Accelerometry during MDS-UPDRS part III, items on pronation-supination and tremor', 'description': 'During the MDS-UPDRS part III, accelerometry allows for quantification of therapeutic effects in addition to the MDS-UPDRS part III. Lower amplitude is better in tremor, higher frequency and rotational power is better in pronation-supination. Change from (pre-treatment) baseline.', 'timeFrame': '30 minutes'}, {'measure': 'Heart Rate Variability (HRV)', 'description': 'Average HRV during intervention and post intervention. HRV is a marker of cardiovascular stress. Change form (pre-treatment) baseline. Lower equals more stress.', 'timeFrame': '30 minutes'}, {'measure': 'Modified Purdue pegboard test', 'description': 'Change from (pre-treatment) baseline in number of pins per side. The Purdue pegboard test is primarily a measure of bradykinesia, hypokinesia and fine motor skills. Higher is better.', 'timeFrame': '30 minutes'}]",18,18 Years,,ALL,False,Radboud University Medical Center,OTHER,1,29.0,ACTUAL,2025-09-01T16:18:14.660932,v2_robust,True,True,True,False,True,
NCT04373187,Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects,"A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of Two Different Dose Concentrations of CC-93538 in Healthy Adult Subjects",CC-93538,['CC-93538'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],"['CC-93538', 'Healthy Subjects', 'PK comparability between two different dose concentrations']",COMPLETED,,2020-06-22,2021-05-26,"[{'measure': 'Pharmacokinetic - AUC0-∞', 'description': 'Area under the concentration-time curve calculated from time zero to infinity', 'timeFrame': 'From Day 0 to Day 105'}, {'measure': 'Pharmacokinetic - Cmax', 'description': 'Maximum observed concentration of drug', 'timeFrame': 'From Day 0 to Day 105'}]","[{'measure': 'Adverse Events (AEs)', 'description': ""An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE."", 'timeFrame': 'From enrollment to Day 105'}, {'measure': 'Pharmacokinetic - AUC0-last', 'description': 'Area under the concentration-time curve calculated from time zero to the last measured time point', 'timeFrame': 'From Day 0 to Day 105'}, {'measure': 'Pharmacokinetic - tmax', 'description': 'Time to Cmax', 'timeFrame': 'From Day 0 to Day 105'}, {'measure': 'Pharmacokinetic - t½', 'description': 'Terminal elimination half-life', 'timeFrame': 'From Day 0 to Day 105'}, {'measure': 'Pharmacokinetic - CL/F', 'description': 'Apparent clearance of drug from serum after extravascular administration', 'timeFrame': 'From Day 0 to Day 105'}, {'measure': 'Pharmacokinetic - Vz/F', 'description': 'Apparent volume of distribution during the terminal phase', 'timeFrame': 'From Day 0 to Day 105'}]",8,18 Years,55 Years,ALL,True,Celgene,INDUSTRY,0,52.0,ACTUAL,2025-09-01T16:18:14.660941,v2_robust,True,True,True,False,True,
NCT00087087,Pemetrexed Disodium in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer,"A Phase II Evaluation Of Pemetrexed (ALIMTA LY231514, IND #40061) In The Treatment Of Recurrent Or Persistent Platinum-Resistant Ovarian Or Primary Peritoneal Carcinoma",pemetrexed disodium,['pemetrexed disodium'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,"['Ovarian Cancer', 'Primary Peritoneal Cavity Cancer']","['recurrent ovarian epithelial cancer', 'primary peritoneal cavity cancer']",COMPLETED,,2004-07,,"[{'measure': 'Antitumor activity'}, {'measure': 'Toxicity'}]",[],2,,,FEMALE,False,Gynecologic Oncology Group,NETWORK,2,51.0,ESTIMATED,2025-09-01T16:18:14.660989,v2_robust,True,True,True,False,False,
NCT02681887,Effect of Melatonin on Cardiometabolic Risk- FULL,Effect of Melatonin on Cardiometabolic Risk- FULL,Melatonin,"['Circadian', 'Melatonin', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,"['Obesity', 'Prediabetic State']",[],UNKNOWN,,2016-09,2021-12,"[{'measure': 'change in insulin sensitivity', 'description': 'measure insulin sensitivity using hyperinsulinemic clamp', 'timeFrame': '12 weeks'}, {'measure': 'change in beta-islet cell function', 'description': 'measure beta-iset cell function measured using a hyperglycemic clamp', 'timeFrame': '12 weeks'}]","[{'measure': 'change in 24 hour ambulatory blood pressure', 'description': 'evaluate the effect of supplementation on 24-hour ambulatory blood pressure', 'timeFrame': '12 weeks'}, {'measure': 'change in nocturnal blood pressure', 'description': 'evaluate the effect of supplementation nocturnal blood pressure', 'timeFrame': '12 weeks'}, {'measure': 'change in endothelial dependent vasodilation', 'description': 'Measurements of the brachial diameter will be made under basal conditions and during reactive hyperemia following five minutes of ischemic stimulus', 'timeFrame': '12 weeks'}, {'measure': 'change in endothelial independent vasodilation', 'description': 'measuring brachial artery diameter under basal conditions and 3 minutes following the administration of sublingual nitroglycerine (0.4mg)', 'timeFrame': '12 weeks'}, {'measure': 'change in catecholamine production', 'description': 'using 24 hour urine collection, measure catecholamines from (epinephrine, norepinephrine and dopamine) using a RIA', 'timeFrame': '12 weeks'}, {'measure': 'change in plasma renin level', 'description': 'effect of melatonin on RAS', 'timeFrame': '12 weeks'}, {'measure': 'change in angiotensin II level', 'description': 'effect of melatonin on RAS', 'timeFrame': '12 weeks'}, {'measure': 'change in cellular cytokine level', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in CC family chemokine expression', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in high sensitivity CRP', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in IL-6 level', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}, {'measure': 'change in TNF-alpha', 'description': 'effect of melatonin on inflammatory markers', 'timeFrame': '12 weeks'}]",14,18 Years,,ALL,True,Brigham and Women's Hospital,OTHER,0,120.0,ESTIMATED,2025-09-01T16:18:14.661029,v2_robust,True,True,False,False,False,
NCT00947687,Safety and Efficacy Study of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects,"A Randomized, Phase 1B, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Inhaled PUR003 on a Controlled Influenza Virus Challenge in Healthy Adult Subjects",PUR003,"['PUR003', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['influenza', 'healthy subject', 'virus inoculation', 'symptom scores', 'viral shedding', 'bioaerosol output']",COMPLETED,,2009-07,2009-10,"[{'measure': 'Safety and tolerability of PUR003 as determined by incidence of adverse events (AEs); changes in physical examination, chest examination; pulmonary function; vital signs; electrocardiogram (ECG) and clinical laboratory assessments.', 'timeFrame': 'Day 6'}]","[{'measure': 'Subjected-reported symptom scores assessed both individually and as a composite score evaluating severity overall and at the time of peak symptom score', 'timeFrame': 'Day 6 of study'}, {'measure': 'Quantitative viral shedding from nasal viral inoculation until day 6', 'timeFrame': 'Day 0 to day 6'}, {'measure': 'Change in bioaerosol output with treatment and after viral inoculation', 'timeFrame': 'Day -2 to day 6'}]",4,18 Years,45 Years,ALL,True,Pulmatrix Inc.,INDUSTRY,2,24.0,ACTUAL,2025-09-01T16:18:14.661068,v2_robust,True,True,True,False,True,
NCT05159193,Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer,"A Multicentre, Open-label, Randomised Trial of Neoadjuvant Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer",pegylated liposomal doxorubicin (PLD),"['pegylated liposomal doxorubicin (PLD)', 'duoxitasai', 'Doxorubicin Hydrochloride Liposome Injection', 'trastuzumab (H)', 'huanlinxianan', 'qutuozhudankang', 'carboplatin (Cb)', 'kabo', 'pertuzumab (P)', 'cyclophosphamide (C)', 'docetaxel (T)', 'patuozhudankang', 'duomeisu']",13,INTERVENTIONAL,['PHASE3'],PHASE3,,Breast Cancer,['Breast Cancer'],[],RECRUITING,,2021-12-20,2028-01-31,"[{'measure': 'Pathological complete response (pCR) rate', 'description': 'The percentage of participants without residual invasive cancer (ypT0/Tis ypN0 in the current AJCC staging system) when the complete resected breast specimen and all sampled regional lymph nodes were evaluated with hematoxylin and eosin staining after completion of systemic neoadjuvant therapy.', 'timeFrame': 'Within 2 to 5 weeks after completion of neoadjuvant therapy'}]","[{'measure': 'Objective response rate (ORR) at the end of neoadjuvant chemotherapy', 'description': 'The number of participants who achieved complete response and partial response at the end of neoadjuvant chemotherapy as a percentage of the overall evaluable participants.', 'timeFrame': 'After the last dose to before surgery or within 21 days'}, {'measure': '5-year disease-free survival (DFS) rate', 'description': 'DFS is defined as the time from randomization to tumor recurrence or death from any cause. 5-year DFS rate is the percentage of participants with DFS from enrollment through 5 years.', 'timeFrame': '5 years'}, {'measure': 'Breast conservation rate at surgery', 'description': 'Percentage of participants receiving breast-conserving surgery after neoadjuvant therapy.', 'timeFrame': 'Within 2 to 5 weeks after completion of neoadjuvant therapy'}, {'measure': 'Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V5.0, including overall and Grade 3/4 adverse events.', 'description': 'Number of participants with treatment-related adverse events as assessed by NCI-CTCAE V5.0, including overall and Grade 3/4 adverse events.', 'timeFrame': '5 years'}, {'measure': 'Percentage of Participants with dose reductions of chemotherapy due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0', 'description': 'Percentage of Participants with dose reductions of chemotherapy due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0', 'timeFrame': '1 year'}, {'measure': 'Percentage of Participants with chemotherapy delay due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0', 'description': 'Percentage of Participants with chemotherapy delay due to Grade 3/4 adverse events as assessed by NCI-CTCAE V5.0', 'timeFrame': '1 year'}, {'measure': 'Relative dose intensity (RDI)', 'description': 'RDI=actual dose intensity\\* / standard dose intensity# actual dose intensity\\* = drug standard dose (mg/m\\^2) / weeks of administration per cycle (week) standard dose intensity# = actual standard dose (mg/m\\^2) / actual dosing weeks (week)', 'timeFrame': '1 year'}]",8,18 Years,70 Years,FEMALE,False,Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University,OTHER,1,372.0,ESTIMATED,2025-09-01T16:18:14.661164,v2_robust,True,True,False,False,True,
NCT07137793,Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients,Clinical Study to Evaluate The Cardioprotective Effect of Pentoxifylline Against Doxorubicin Induced Cardiotoxicity in Breast Cancer Patients,Pentoxifylline 400mg plus chemotherapy,['Pentoxifylline 400mg plus chemotherapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Doxorubicin Induced Cardiotoxicity,"['Doxorubicin Induced Cardiotoxicity', 'Breast Cancer']","['pentoxyfillne', 'breast cancer', 'cardioprotective', 'Doxorubicin Induced Cardiotoxicity']",RECRUITING,,2025-05-25,2026-12,"[{'measure': 'change in ejection fraction', 'timeFrame': '3 MONTHS'}]","[{'measure': 'changes in serum levels of the measured biological markers', 'timeFrame': '3 MONTHS'}]",2,18 Years,60 Years,FEMALE,True,Tanta University,OTHER,0,46.0,ESTIMATED,2025-09-01T16:18:14.661252,v2_robust,True,True,False,False,False,
NCT00822393,Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC),Clinical Phase III Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Reduced-intensity Conditioning (RIC) Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Patients With AML or MDS Considered Ineligible to Standard Conditioning Regimens,Busulfan,"['Busulfan', 'Treosulfan']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Acute Myeloid Leukemia,"['Acute Myeloid Leukemia', 'Myelodysplastic Syndrome']","['Treosulfan', 'Busulfan', 'Conditioning', 'Allogeneic', 'Transplantation']",COMPLETED,,2008-11-24,2018-01-25,"[{'measure': 'Event-free survival (EFS)', 'timeFrame': 'within 2 years after transplantation'}]","[{'measure': 'Comparative evaluation of incidence of CTC grade III/IV mucositis/stomatitis between day -6 and day +28', 'timeFrame': 'between day -6 and day +28'}]",2,18 Years,70 Years,ALL,False,medac GmbH,INDUSTRY,0,570.0,ACTUAL,2025-09-01T16:18:14.661354,v2_robust,True,True,True,False,False,
NCT00611793,PTK787/ZK222584 With Bevacizumab in Patients With Refractory and/or Advanced Malignancies,A Phase I Trial of PTK787/ZK222584 in Combination With Bevacizumab (Avastin) in Patients With Refractory and/or Advanced Malignancies,PTK787/ZK222584 and Bevacizumab,['PTK787/ZK222584 and Bevacizumab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Refractory Malignancy,"['Refractory Malignancy', 'Advanced Malignancies']","['Refractory Malignancy', 'Advanced Malignancies', 'PTK787/ZK222584', 'Bevacizumab']",COMPLETED,,2004-10,2009-01,"[{'measure': 'Maximum tolerated dose', 'timeFrame': '18 months'}]",[],1,18 Years,,ALL,False,"SCRI Development Innovations, LLC",OTHER,1,50.0,ESTIMATED,2025-09-01T16:18:14.661377,v2_robust,True,True,True,False,False,
NCT02820493,Effectiveness of Vedolizumab in CD Patients Naïve to Anti-TNF,Effectiveness of Vedolizumab Therapy in Inducing Clinical Remission in CD Patients Naïve to Anti-TNF and Its Capability to Halt Disease Progression,vedolizumab,['vedolizumab'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Crohn Disease,['Crohn Disease'],[],WITHDRAWN,Internal problems,2016-09,2019-03,"[{'measure': 'Harvey Bradshaw index', 'description': 'Primary responders will defined as by a decrease of Harvey Bradshaw Index at week 14 of 3 point from the Harvey Bradshaw Index calculate at week 0.', 'timeFrame': 'Week 0-14'}]","[{'measure': 'Lèmann Index', 'timeFrame': 'Week 0 and Week 54'}, {'measure': 'VDZ trough levels', 'timeFrame': 'Week 0-2-6-14-22-30-38-46-54'}, {'measure': 'anti-drug antibodies', 'timeFrame': 'Week 0-2-6-14-22-30-38-46-54'}, {'measure': 'fecal VDZ loss', 'description': 'The investigators will evaluated the VDZ quantity (microgram) that a patients with mucosal ulcers could loss in patients feces.', 'timeFrame': 'Week 0-2-6-14-22-30-38-46-54'}]",5,18 Years,80 Years,ALL,False,Universita degli Studi di Genova,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.661385,v2_robust,True,True,False,True,False,Internal problems
NCT00002993,Combination Chemotherapy in Treating Patients With Recurrent or Advanced Cancer of the Uterus,"Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas",cisplatin,"['mitomycin C', 'doxorubicin hydrochloride', 'cisplatin']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Sarcoma,['Sarcoma'],"['stage III uterine sarcoma', 'stage IV uterine sarcoma', 'recurrent uterine sarcoma']",TERMINATED,,1997-08,,[],[],0,,,FEMALE,False,Gynecologic Oncology Group,NETWORK,1,30.0,ESTIMATED,2025-09-01T16:18:14.661403,v2_robust,True,True,False,True,False,
NCT01048593,Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery,"A Multicenter, Randomized, Double-masked, Dose-ranging, Phase 2 Study to Evaluate the Efficacy and Safety of IBI-10090 in Cataract Surgery Patients",IBI-10090,['IBI-10090'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Inflammatory Reaction Due to Ocular Lens Prosthesis,['Inflammatory Reaction Due to Ocular Lens Prosthesis'],"['ocular inflammation cataract surgery', 'post cataract surgery inflammation']",TERMINATED,Study was terminated in order to examine study data.,2010-01,2010-06,"[{'measure': 'Clearance of Anterior Chamber Cells', 'description': 'Efficacy was assessed by slit lamp biomicroscopy to evaluate the anterior chamber cells (ACC) graded on a scale of 0 to 4. The primary efficacy endpoint was complete clearing of ACC, where grade 0 = 0 cells in the anterior chamber on POD 8.', 'timeFrame': 'Day 8 post treatment'}]","[{'measure': 'Anterior Chamber Flare (ACF) Grade', 'description': 'Efficacy was assessed by slit lamp biomicroscopy to evaluate the anterior chamber flare (ACF) graded on a scale of 0 to 4.', 'timeFrame': 'Day 90 post-treatment'}, {'measure': 'Conjunctival Erythema Grade', 'description': 'Conjunctival erythema was evaluated by slit lamp biomicroscopy graded on a scale of 0 to 3.', 'timeFrame': 'Day 90 post-treatment'}, {'measure': 'Corneal Edema Grade', 'description': 'Cornea edema was evaluated by slit lamp biomicroscopy graded on a scale of 0 to 3.', 'timeFrame': 'Day 90 post-treatment'}, {'measure': 'Anterior Chamber Cell Grade', 'description': 'Anterior chamber cells (ACC) grade was evaluated by slit lamp biomicroscopy graded on a scale of 0 to 4.', 'timeFrame': 'Day 90 post-treatment'}]",5,40 Years,,ALL,False,ICON Bioscience Inc,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:14.661418,v2_robust,True,True,False,True,False,Study was terminated in order to examine study data.
NCT07007793,A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism,"A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism",Baxdrostat,"['CIN-107', 'Baxdrostat', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Primary Hyperaldosteronism,['Primary Hyperaldosteronism'],"['Primary hyperaldosteronism', 'Primary aldosteronism', 'PA', 'Baxdrostat', 'CIN-107', 'Aldosterone']",NOT_YET_RECRUITING,,2025-08-07,2028-02-18,"[{'measure': 'Change from baseline in seated Systolic Blood Pressure (SBP) at Week 8', 'description': 'To assess the effect of baxdrostat versus placebo on seated Systolic Blood Pressure (SBP) at Week 8', 'timeFrame': 'At week 8'}, {'measure': 'Achieving normalization of the Renin Angiotensin Aldosterone system (RAAS) at week 8', 'description': 'To assess the effect of baxdrostat versus placebo on achieving normalization of the Renin Angiotensin Aldosterone system (RAAS) at week 8, in participants with dysregulated RAAS at baseline', 'timeFrame': 'At week 8'}]","[{'measure': 'Change from Randomised withdrawal (RWD) baseline (Week 44) in seated Systolic Blood Pressure (SBP) at Week 52', 'description': 'To assess the effect of baxdrostat versus placebo on seated Systolic Blood Pressure (SBP) 8 weeks after Randomised withdrawal (RWD)', 'timeFrame': 'At week 52'}, {'measure': 'Percent change from RWD baseline (Week 44) in Plasma Renin Activity (PRA) at Week 52', 'description': 'To assess the effect of baxdrostat versus placebo on the percent change in PRA 8 weeks after RWD', 'timeFrame': 'At week 52'}, {'measure': 'Achieving serum potassium ≥ 3.7 mmol/L without potassium supplementation at Week 8 in participants with serum potassium < 3.7 mmol/L or potassium supplementation at baseline', 'description': 'To assess the effect of baxdrostat versus placebo on achieving serum potassium ≥ 3.7 mmol/L without potassium supplementation at Week 8 in participants with serum potassium \\< 3.7 mmol/L or potassium supplementation at baseline', 'timeFrame': 'At week 8'}, {'measure': 'Percent change from baseline in PRA at Week 8', 'description': 'To assess the effect of baxdrostat versus placebo on the percent change from baseline in PRA at Week 8', 'timeFrame': 'At week 8'}, {'measure': 'Achieving 24-hour urine aldosterone < 10 μg at Week 8 in participants with 24-hour urine aldosterone ≥ 10 μg at baseline', 'description': 'To assess the effect of baxdrostat versus placebo on achieving 24-hour urine aldosterone \\< 10 μg at Week 8 in participants with 24-hour urine aldosterone\n\n≥ 10 μg at baseline', 'timeFrame': 'At week 8'}, {'measure': 'Change from baseline in 24-hour urine albumin at Week 8', 'description': 'To assess the effect of baxdrostat versus placebo on 24-hour urine albumin at Week 8', 'timeFrame': 'At week 8'}]",8,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,180.0,ESTIMATED,2025-09-01T16:18:14.661437,v2_robust,True,True,False,False,False,
NCT02778893,Conmana Combined With Thalidomide to Treat NSCLC,"A Phase Ⅳ,Open,Multicenter,Single Arm Study to Evaluate the Efficacy of the Combination Conmana With Thalidomide in Patients With NSCLC(Non-Small-Cell-Lung-Cancer)",Conmana,"['Celgene Brand of Thalidomide', 'Sedoval', 'Icotinib', 'Icotinib Hydrochloride Tablets', 'Thalomid', 'Thalidomide', 'Conmana']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,NSCLC,['NSCLC'],"['Conmana', 'Thalidomide', 'NSCLC', 'EGFR mutation']",UNKNOWN,,2016-03,2020-03,"[{'measure': '5 years the progression-free survival (PFS) rate of the combination of thalidomide with gefitinib in patients who harbors EGFR mutations.', 'timeFrame': '5 years'}]",[],1,18 Years,75 Years,ALL,False,Henan Provincial People's Hospital,OTHER,0,67.0,ESTIMATED,2025-09-01T16:18:14.661523,v2_robust,True,True,False,False,False,
NCT04685421,Liposomal Bupivacaine Pharmacokinetic Study After Median Sternotomy Incision Infiltration in a Pediatric Cardiac Surgery,Liposomal Bupivacaine Pharmacokinetic Study After Median Sternotomy Incision Infiltration in a Pediatric Cardiac Surgery,Bupivacaine liposome,"['Bupivacaine liposome', 'Bupivacaine liposome PKs']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cardiac Conditions,['Cardiac Conditions'],"['pediatric cardiac surgery', 'median sternotomy incision']",TERMINATED,"PI, Christopher Tirotta, no longer at NCH as of 5-26-23.",2021-07-15,2023-06-01,"[{'measure': 'Bupivacaine-Exparel levels', 'description': 'To determine plasma bupivacaine levels after the use of Exparel 1.3% admixed with 0.25% bupivacaine and 0.9% Normal Saline in pediatric cardiac surgery patients ages two through seventeen years of age (Cohort I). Cohort II covers ages 2 \\< 6.', 'timeFrame': '96 hours'}]",[],1,2 Years,17 Years,ALL,False,Nicklaus Children's Hospital f/k/a Miami Children's Hospital,OTHER,0,15.0,ACTUAL,2025-09-01T16:18:14.661594,v2_robust,True,True,False,True,False,"PI, Christopher Tirotta, no longer at NCH as of 5-26-23."
NCT05107921,Bromfenac Sodium Hydrate Eye Drops in Familial Exudative Vitreoretinopathy,Efficacy of Bromfenac Sodium Hydrate Eye Drops in Children With Familial Exudative Vitreoretinopathy After Diode Laser Photocoagulation,Bromfenac Sodium,"['Bronuck', 'Bromfenac Sodium']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Familial Exudative Vitreoretinopathies,['Familial Exudative Vitreoretinopathies'],[],RECRUITING,,2021-11-01,2024-10-20,"[{'measure': 'Macular edema response rate', 'description': 'Presence of macular edema', 'timeFrame': '4 weeks after the diode laser photocoagulation'}]","[{'measure': 'Conjunctival injection response rate', 'description': 'Presence of conjunctival injection', 'timeFrame': '4 weeks after the diode laser photocoagulation'}]",2,1 Month,7 Years,ALL,False,Seoul National University Hospital,OTHER,0,39.0,ESTIMATED,2025-09-01T16:18:14.661605,v2_robust,True,True,False,False,False,
NCT03300921,A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer,A Phase Ib Pharmacodynamic Study of Neoadjuvant Paricalcitol in Resectable Pancreatic Cancer,Paricalcitol,['Paricalcitol'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pancreatic Cancer,['Pancreatic Cancer'],[],TERMINATED,Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery,2017-09-28,2022-03-23,"[{'measure': 'Number of Adverse Events', 'timeFrame': '18 months'}]",[],1,18 Years,,ALL,False,Abramson Cancer Center at Penn Medicine,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:14.661792,v2_robust,True,True,False,True,True,Newer research suggested that paricalcitol may be harmful to a subset of pancreatic cancer patients and it is not feasible to subtype patients in the short time frame before surgery
NCT00043121,Combination Chemotherapy in Treating Patients With Advanced Cancer That is Metastatic or Cannot Be Removed By Surgery,"A Phase I Study of Oxaliplatin, 5-Fluorouracil, and Leucovorin in Combination With Oral Capecitabine in Patients With Advanced Malignancy",oxaliplatin,"['CFR', 'fluorouracil', 'leucovorin calcium', '5-fluorouracil', 'Dacplat', 'Ro 09-1978/000', '5-Fluracil', 'CAPE', 'Xeloda', 'Eloxatin', 'capecitabine', 'L-OHP', 'CF', '1-OHP', 'LV', 'Dacotin', '5-FU', 'oxaliplatin']",18,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']",[],COMPLETED,,2002-06,,"[{'measure': 'MTD, defined as the highest dose level which results in DLT in fewer than 2/6 patients, graded according to the NCI CTC version 2.0', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Incidence of adverse events, graded according to NCI CTC version 2.0', 'timeFrame': 'Up to 6 years'}, {'measure': 'Overall survival', 'description': 'Estimated using the product-limit method of Kaplan and Meier.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Time to progression', 'description': 'Estimated using the product-limit method of Kaplan and Meier.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Duration of response', 'description': 'Estimated using the product-limit method of Kaplan and Meier.', 'timeFrame': 'Up to 6 years'}]",5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,50.0,ACTUAL,2025-09-01T16:18:14.661805,v2_robust,True,True,True,False,True,
NCT00330421,Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07),"A Phase II Clinical and Correlative Study of BAY 43-9006 (Sorafenib) IND 69,896 in Sarcoma",sorafenib tosylate,"['BAY 43-9006', 'Nexavar', 'BAY 54-9085', 'sorafenib tosylate', 'SFN', 'BAY 43-9006 Tosylate Salt']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor,"['Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor', 'Metastatic Osteosarcoma', 'Recurrent Adult Soft Tissue Sarcoma', 'Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor', 'Recurrent Osteosarcoma', 'Stage I Adult Soft Tissue Sarcoma', 'Stage II Adult Soft Tissue Sarcoma', 'Stage III Adult Soft Tissue Sarcoma', 'Stage IV Adult Soft Tissue Sarcoma']",[],COMPLETED,,2006-06,2008-07,"[{'measure': 'Change in Fludeoxyglucose (FDG) Uptake (Maximal Standardized Uptake Value, or SUVmax)', 'description': 'Paired comparison made using a Wilcoxon signed rank test with one-sided type I error of 5%.', 'timeFrame': 'Baseline to up to 1 month post-treatment'}, {'measure': 'Change in Interstitial Fluid Pressure (IFP)', 'description': 'Paired comparison made using a Wilcoxon signed rank test with one-sided type I error of 5%.', 'timeFrame': 'Baseline to up to 1 month post-treatment'}, {'measure': 'Change in White Blood Cell Count (WBC)', 'description': 'Paired comparison made using a Wilcoxon signed rank test with one-sided type I error of 5%.', 'timeFrame': 'Baseline to up to 1 month post-treatment'}, {'measure': 'Change in Pericyte Coverage of Endothelial Cells (Alpha-SMA)', 'description': 'Paired comparison made using a Wilcoxon signed rank test with one-sided type I error of 5%.', 'timeFrame': 'Baseline to up to 1 month post-treatment'}, {'measure': 'Clinical Benefit as Measured by 50% Reduction in IFP', 'timeFrame': 'Baseline to surgery'}, {'measure': 'Clinical Benefit, Measured by Any Reduction in Tumor Dimensions on CT Scan as Measured by RECIST Criteria', 'timeFrame': 'Up to 1 month'}, {'measure': 'Incidence of Adverse Events', 'timeFrame': 'Up to 1 month'}]",[],7,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,15.0,ACTUAL,2025-09-01T16:18:14.661817,v2_robust,True,True,True,False,True,
NCT04469621,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,"A Phase 1b, Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Safety and Immunomodulatory Effect of the RIPK1 Inhibitor SAR443122 in Hospitalized Patients With Severe COVID-19",SAR443122,"['SAR443122', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Corona Virus Infection,['Corona Virus Infection'],[],COMPLETED,,2020-07-17,2020-10-23,"[{'measure': 'Relative change from baseline in CRP level', 'description': 'Relative change from baseline in CRP level on Day 7', 'timeFrame': 'Day 7'}]","[{'measure': 'Time to 50% decrease from baseline in CRP level', 'description': 'The time to 50% decrease from baseline in CRP level', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Time to improvement of oxygenation', 'description': 'The time to improvement of oxygenation as measured by oxygen saturation \\>/=92% breathing room air over 48 hrs or until discharge', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Change from baseline in SPO2/FiO2 ratio', 'description': 'Change from baseline in SPO2/FiO2 ratio at Day 7', 'timeFrame': 'Day 7'}, {'measure': 'Number of Days without need for oxygen support and alive', 'description': 'Number of Days without need for oxygen support and alive (oxygen saturation \\>=92% breathing room air) up to Day 28', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Numbers of Ventilator-free days and alive', 'description': 'Numbers of Ventilator-free days and alive up to Day 28', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Change from baseline in markers of inflammation: white blood cell count and differential blood lymphocytes', 'description': 'Change from baseline in white blood cell count and differential blood lymphocytes at Day 7 and End of treatment (EOT)', 'timeFrame': 'Day 7 and Day 15'}, {'measure': 'Change from baseline in marker of inflammation: neutrophil to lymphocyte ratio', 'description': 'Change from baseline in neutrophil to lymphocyte ratio at Day 7 and EOT', 'timeFrame': 'Day 7 and Day 15'}, {'measure': 'Change from baseline in marker of inflammation: interleukin 6 (IL-6)', 'description': 'Change from baseline in IL-6 at Day 7 and EOT', 'timeFrame': 'Day 7 and Day 15'}, {'measure': 'Change from baseline in D-Dimer', 'description': 'Change from baseline in D-Dimer at Day 7 and EOT', 'timeFrame': 'Day 7 and Day 15'}, {'measure': 'Incidence of Deaths', 'description': 'Incidence of Deaths up to Day 28', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Percentage of participants receiving thrombolytic treatment', 'description': 'Percentage of participants receiving thrombolytic treatment up to Day 28', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Percentage of participants receiving vasopressor treatment', 'description': 'Percentage of participants receiving vasopressor treatment up to Day 28', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Incidence of serious adverse events (SAEs), adverse events of special interest (AESI) and treatment-emergent adverse events (TEAEs) leading to treatment discontinuation', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Incidence of TEAEs leading to study discontinuation (primary reason)', 'timeFrame': 'Baseline to Day 28'}, {'measure': 'Numbers of Respiratory Failure-Free Days (RFFD) and alive', 'description': 'Numbers of Respiratory Failure-Free Days (RFFD) and alive up to Day 28', 'timeFrame': 'Baseline to Day 28'}]",16,18 Years,80 Years,ALL,False,Sanofi,INDUSTRY,0,68.0,ACTUAL,2025-09-01T16:18:14.661859,v2_robust,True,True,True,False,True,
NCT02882321,Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia,Phase 1 Study of IACS-010759 in Subjects With Relapsed or Refractory AML,Oxidative Phosphorylation Inhibitor IACS-010759,"['Oxidative Phosphorylation Inhibitor IACS-010759', 'IACS-010759', 'OXPHOS Inhibitor IACS-010759']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Recurrent Acute Myeloid Leukemia,"['Recurrent Acute Myeloid Leukemia', 'Refractory Acute Myeloid Leukemia']",[],TERMINATED,The study was terminated by the Sponsor for apparent lack of effectiveness.,2016-09-29,2022-04-15,"[{'measure': 'Maximum Tolerated Dose (MTD) Defined as the Highest Dose Studied for Which the Observed Incidence of Dose Limiting Toxicities (DLT) is Less Than 33%', 'description': 'Will be assessed according to National Cancer Institute Common Toxicity Criteria version 4.03.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'Participants With a Response', 'description': 'Response is Complete Response (CR) + Complete Response with Incomplete Blood Count Recovery (CRi) + Partial Response (PR) + Morphologic Leukemia -Free State (MLFS): CR is Bone marrow blasts \\< 5%; absence of circulating blasts and blasts with Auer rods; absence of extra-medullary disease; ANC \\> 1.0 x 10\\^9/L; platelet count \\>/= 100 x 10\\^9/L. CRi is CR except for ANC \\</= 1.0 x 10\\^9 or platelet count , 100 x 10\\^9/L. PR is decreased bone marrow blast % by at least 50% to a value of 5% to 25% and ANC \\>/= 1.0 x 10\\^9/L; platelet count \\>/= 100 x 10\\^9/L. MLFS is Bone marrow blasts \\< 5%; abcence of blasts with Auer rods; absence of extra-medullary disease; no hematologic recovery required.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Duration of Response', 'description': 'Duration of Response: length of time from the first objective evidence of response to the first objective evidence of disease progression.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Progression-free Survival', 'description': 'Progression-Free Survival: length of time (up to 5 years) from the date of first treatment to the first objective evidence of disease progression or death, whichever is earlier.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall Survival', 'description': 'Overall Survival: length of time from the date of first administration of study drug to the date of death from any cause.', 'timeFrame': 'Up to 5 years'}]",5,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,17.0,ACTUAL,2025-09-01T16:18:14.661897,v2_robust,True,True,False,True,False,The study was terminated by the Sponsor for apparent lack of effectiveness.
NCT05331521,A Clinical Study to Improve Brain Function and Quality of Life of Patients With Newly Diagnosed Brain Tumors (Gliomas).,Improvement of Functional Outcome for Patients With Newly Diagnosed Grade 2 or 3 Glioma With Co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 Trial,CETEG,"['PCV', 'CETEG', 'Procarbazine, Lomustine and Vincristine', 'Lomustine (CCNU) and Temozolomide']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Oligodendroglioma,['Oligodendroglioma'],"['Radiotherapy', 'Chemotherapy', 'Temozolomide']",RECRUITING,,2021-04-07,2031-03-31,"[{'measure': 'Qualified overall survival (qOS)', 'description': 'The primary efficacy endpoint is the overall survival without functional and/or cognitive and/or quality of life deterioration over a period of 90 days, coined qualified overall survival (qOS).', 'timeFrame': 'Counted as event starting 12 months (365 days) after randomization on 2 consecutive study visits with an interval of 3 months (90 days) till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}, {'measure': 'Short-term qOS deterioration in NeuroCogFX®', 'description': 'The primary efficacy endpoint is overall survival without functional and/or cognitive and/or quality of life deterioration over a period of 90 days, coined qualified overall survival (qOS). Short-term qOS is defined as detriment of ≥ 1.5 standard deviations below the normative mean (i.e. percentile rank ≤ 6.68) in two or more NeuroCog FX® subtests AND Related to baseline: 90%-confidence intervals of NeuroCog FX® subtests indicate a clinically and statistically meaningful individual change (i.e. deterioration) in two or more NeuroCog FX® subtest raw scores', 'timeFrame': 'Counted as event starting 12 months (365 days) after randomization on 2 consecutive study visits with an interval of 3 months (90 days) till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}, {'measure': 'Short-term qOS deterioration in KPI', 'description': 'The primary efficacy endpoint is overall survival without functional and/or cognitive and/or quality of life deterioration over a period of 90 days, coined qualified overall survival (qOS). Short-term qOS is defined as a decrease in the KPI from 100 or 90 to 70 or less, a decrease in KPI of at least 20 from 80 or less, or a decrease in KPI from any baseline to 50 or less. Fulfilment of one of these criteria is considered neurological deterioration unless attributable to comorbid events or changes in corticosteroid dose.', 'timeFrame': 'Counted as event starting 12 months (365 days) after randomization on 2 consecutive study visits with an interval of 3 months (90 days) till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}, {'measure': 'Short-term qOS deterioration in HrQoL', 'description': 'The primary efficacy endpoint is overall survival without functional and/or cognitive and/or quality of life deterioration over a period of 90 days, coined qualified overall survival (qOS). Short-term qOS is defined as a worsening of at least 10 points, which is the minimal clinically relevant difference, in at least one of the five selected domains of the HrQoL (global health status (GHS), physical functioning (PF), social functioning (SF), determined in the QLQ-C30 with higher scores indicate better HRQoL; communication deficits (CD) \\& motor dysfunction (MD) determined by QLQ-BN20 with lower scores indicate better HRQoL).', 'timeFrame': 'Counted as event starting 12 months (365 days) after randomization on 2 consecutive study visits with an interval of 3 months (90 days) till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}, {'measure': 'Short-term qOS deterioration in NANO scale', 'description': 'The primary efficacy endpoint is overall survival without functional and/or cognitive and/or quality of life deterioration over a period of 90 days, coined qualified overall survival (qOS). Short-term qOS is defined as a decline in the NANO scale defined as a ≥2 level worsening from baseline within ≥1 domain or worsening to the highest score within ≥1 domain that is felt to be related to underlying tumor progression and not attributable to a comorbid event or change in concurrent medication.', 'timeFrame': 'Counted as event starting 12 months (365 days) after randomization on 2 consecutive study visits with an interval of 3 months (90 days) till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}, {'measure': 'Short-term qOS deterioration due to death', 'description': 'Death due to any cause.', 'timeFrame': 'From start of randomization until death from any cause till the end of follow up at 120 months.'}]","[{'measure': 'Short-term qOS', 'description': 'Defined qOS defined as qOS as described above, but neglecting the subsequent time interval of 3 months (90 days).', 'timeFrame': 'From 3 months after start of treatment, every 3 months till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as the time from randomization until death due to any cause.', 'timeFrame': 'From start of randomization until death from any cause till the end of follow up at 120 months.'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Defined as the time from randomization to the day of first documentation of clinical or radiographic tumor progression or death of any cause.', 'timeFrame': 'From randomization until the day of first documentation of clinical or radiographic tumor progression or death of any cause till the end of follow up at 120 months or date of death from any cause, whatever occurs first.'}]",9,18 Years,,ALL,False,University Hospital Heidelberg,OTHER,2,406.0,ESTIMATED,2025-09-01T16:18:14.662028,v2_robust,True,True,False,False,False,
NCT03310021,"A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects","A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Andexanet Alfa Administered to Healthy Japanese and Caucasian Subjects",Apixaban,"['Apixaban', 'Xarelto', 'Rivaroxaban', 'Placebo', 'Savaysa, Lixiana', 'Edoxaban', 'Eliquis']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Bleeding,['Bleeding'],[],COMPLETED,,2017-08-28,2019-08-13,"[{'measure': 'Percent Change in Anti-Fxa Activity From Baseline to the End of Infusion (EOI) Nadir.', 'description': 'The primary efficacy endpoint is the percent change in the anti-FXa activity from baseline to the end of infusion (EOI) nadir.', 'timeFrame': 'Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours'}]","[{'measure': 'Percent Change in Anti-Fxa Activity From Baseline to the End of Bolus (EOB) Nadir.', 'description': 'The percent change from baseline in anti-FXa activity at its end of bolus (EOB) nadir.', 'timeFrame': 'Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours'}, {'measure': 'Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Bolus (EOB) Nadir.', 'description': 'The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOB nadir.', 'timeFrame': 'Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours'}, {'measure': 'Percent Change in Free Fxa Inhibitor Concentration From Baseline to the End of Infusion (EOI) Nadir.', 'description': 'The percent change from baseline in free FXa inhibitors concentration (ng/mL) at its EOI nadir.', 'timeFrame': 'Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours'}, {'measure': 'Change in Thrombin Generation From Baseline to the End of Bolus (EOB) Nadir.', 'description': 'The change in thrombin generation from baseline to its EOB peak.', 'timeFrame': 'Baseline to the end of bolus (EOB) nadir, approximately 2.5 hours'}, {'measure': 'Change in Thrombin Generation From Baseline to the End of Infusion (EOI) Nadir.', 'description': 'The change in thrombin generation from baseline to its EOI peak.', 'timeFrame': 'Baseline to the end of infusion (EOI) nadir, approximately 2.5 hours'}]",6,18 Years,75 Years,ALL,True,Portola Pharmaceuticals,INDUSTRY,0,108.0,ACTUAL,2025-09-01T16:18:14.662165,v2_robust,True,True,True,False,False,
NCT06415214,Efficacy and Safety of HRS-7535 Tablets in Adults With Type 2 Diabetic Kidney Disease,"A Multicenter, Randomized, Double-blinded, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of HRS-7535 in Adults With Type 2 Diabetic Kidney Disease",Placebo,"['HRS-7535', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Type 2 Diabetic Kidney Disease,['Type 2 Diabetic Kidney Disease'],[],NOT_YET_RECRUITING,,2024-06,2025-09,"[{'measure': 'Ratio of UACR at week 16 to UACR at baseline', 'timeFrame': 'at Week 16'}]","[{'measure': '24 hour urine analysis results at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Proportion of subjects with a 30% decrease in UACR from baseline at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Change from baseline in eGFR at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Change from baseline in HbA1c at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Proportion of subjects reaching the target of HbA1c (<7.0%、<6.5%) at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Change from baseline in FPG at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Change from baseline in insulin at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Change from baseline in c-peptide at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Change from baseline in body weight at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'Proportion of subjects receiving glycemic rescue medicine at Week 16', 'timeFrame': 'at Week 16'}, {'measure': 'A summary of adverse events, including serious adverse events (SAEs), and hypoglycemic event at Week 16', 'timeFrame': 'at Week 16'}]",12,18 Years,75 Years,ALL,False,"Shandong Suncadia Medicine Co., Ltd.",INDUSTRY,0,186.0,ESTIMATED,2025-09-01T16:18:14.662316,v2_robust,True,True,False,False,True,
NCT01874314,Effects of SQ109 on QTc Interval in Healthy Subjects,Phase 1 Crossover Study to Assess the Effects of SQ109 on QTc Interval in Healthy Subjects,SQ109,"['Moxifloxacin', 'SQ109']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Tuberculosis,['Tuberculosis'],"['tuberculosis, SQ109, QTc, moxifloxacin, crossover, placebo, pharmacokinetic, randomized, single-center']",WITHDRAWN,,,2015-12,"[{'measure': 'Solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing, holter monitor and ECG changes for 300mg/day SQ109', 'timeFrame': 'Days 1-7 of each dosing period and 30 days after last dosing period.'}, {'measure': 'Electrocardiogram and holter monitor data (QTc, T wave forms, QRS, RR and PR intervals) for 300mg/day SQ109', 'timeFrame': 'Days 1-7 of each dosing period and 30 days after last dosing period.'}]","[{'measure': 'Solicited and unsolicited adverse events, including symptoms, physical findings, laboratory testing, holter monitor and ECG changes for 450mg/day SQ109', 'timeFrame': 'Days 1-7 of each dosing period and 30 days after last dosing period.'}, {'measure': 'Pharmacokinetics of SQ109 at doses of 300 or 450mg/day; AUC0-, (Cmax), time to maximum concentration (Tmax), elimination rate constant, elimination half-life, clearance, volume of distribution, and urinary excretion', 'timeFrame': 'Day 1 and Day 6 of each dosing period'}, {'measure': 'Electrocardiogram and holter monitor data (QTc, T wave forms, QRS, RR and PR intervals) for 450mg/day SQ109', 'timeFrame': 'Days 1-7 of each dosing period and 30 days after last dosing period.'}]",5,18 Years,45 Years,ALL,True,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,0.0,ACTUAL,2025-09-01T16:18:14.662432,v2_robust,True,True,False,True,True,
NCT05393414,Efficacy of NSAID and Acetaminophen in the Control of Post-Operative Pain in Patients Undergoing Total Knee Replacement,Efficacy of NSAID and Acetaminophen in the Control of Post-Operative Pain in Patients Undergoing Total Knee Replacement,Opioid based protocol,"['percocet oral', 'acetaminophen oral', 'ketorolac injection', 'Opioid based protocol', 'morphine injection', 'Opioid sparing protocol']",6,INTERVENTIONAL,['NA'],,,Pain,"['Pain', 'Hispanics', 'Opioid Use', 'Multimodal Analgesia', 'Total Knee Arthroplasty']","['Total Knee Arthroplasty', 'Postoperative Pain', 'Opioid Use', 'Hispanics', 'Clinical Outcomes', 'Multimodal Analgesia']",COMPLETED,,2019-11-25,2020-03-12,"[{'measure': 'Pain scores using numerical rating scale (NRS, 0 to 10)', 'description': 'The amount of pain intensity reported will be measure throughout the numerical rating scale. Each patient will rate their pain intensity on a scale from 0 to 10, where zero represents ""no pain,"" whereas 10 represents the ""most intense pain"" (e.g., ""the most intense pain imaginable,"" ""the maximum pain intensity as it could be""); during the 12 hours postoperative period', 'timeFrame': 'Post-operative 12 hours after surgery'}, {'measure': 'Pain scores using numerical rating scale (NRS, 0 to 10)', 'description': 'The amount of pain intensity reported will be measure throughout the numerical rating scale. Each patient will rate their pain intensity on a scale from 0 to 10, where zero represents ""no pain,"" whereas 10 represents the ""most intense pain"" (e.g., ""the most intense pain imaginable,"" ""the maximum pain intensity as it could be""); during the 24 hours postoperative period', 'timeFrame': 'Post-operative 24 hours after surgery'}, {'measure': 'Pain scores using numerical rating scale (NRS, 0 to 10)', 'description': 'The amount of pain intensity reported will be measure throughout the numerical rating scale. Each patient will rate their pain intensity on a scale from 0 to 10, where zero represents ""no pain,"" whereas 10 represents the ""most intense pain"" (e.g., ""the most intense pain imaginable,"" ""the maximum pain intensity as it could be""); during the 48 hours postoperative period', 'timeFrame': 'Post-operative 48 hours after surgery'}]","[{'measure': 'Hospital Length of Stay', 'description': 'The number of days per patient from the time of admission to discharge up to 30 days', 'timeFrame': 'up to 30 days'}, {'measure': 'Drug-related adverse events', 'description': 'nausea, dizziness, vomit, tachycardia, pruritus and headache', 'timeFrame': 'From the time of surgery after being discharge (0 to 72 hours after surgery)'}]",5,18 Years,110 Years,ALL,False,University of Puerto Rico,OTHER,0,81.0,ACTUAL,2025-09-01T16:18:14.662443,v2_robust,True,True,True,False,True,
NCT02270814,"Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma","Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)",nab-paclitaxel,"['nab-paclitaxel', 'DDP', 'Paraplatin®', 'cis-DDP', 'Carboplatin', 'Cisplatin', 'CBDCA', 'Cisplatinum', 'cis-Diamminedichloroplatinum', 'Albumin-bound paclitaxel', 'cis-Platinum II', 'Abraxane', 'Paclitaxel protein-bound', 'CDDP']",14,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,"['Head and Neck Cancer', 'Head and Neck Squamous Cell Carcinoma', 'Cancer of the Head and Neck']",[],ACTIVE_NOT_RECRUITING,,2015-02-02,2025-12-31,"[{'measure': 'Progression-free survival (PFS) - with first line therapy', 'description': 'PFS is defined as the time from randomization to first radiologic confirmation of disease progression, or death from any cause.', 'timeFrame': '8 months (estimated median length of treatment)'}]","[{'measure': 'Overall survival (OS)', 'description': 'OS is defined as the time from randomization to death.', 'timeFrame': 'Until death (estimated 24 months)'}, {'measure': 'Overall response rate', 'description': 'Overall response rate = complete response + partial response\n\nEvaluated using RECIST 1.1.', 'timeFrame': '8 months (estimated median length of treatment)'}, {'measure': 'Grade 3 and 4 adverse events', 'description': 'Adverse events will be recorded from the date of first dose of study drug (nab-paclitaxel) until 28 days after the last dose of study drug.\n\nThe descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 will be utilized for all toxicity reporting.', 'timeFrame': '9 months (28 days from last dose of study drug with estimated median length of treatment of 8 months)'}, {'measure': 'Quality of life', 'description': 'Using the EORTC QLQ-C30, MDADI, FACT-H\\&N, and FACT/GOG-NTX-4.\n\n* The EORTC-QLQ-C30 has a total score, one general QOL and one ""within the last week"" subscale, as well as a single ""overall general health"" item and a single ""overall QOL"" item. Scale is from 1-4 with 1 = not at all and 4 = very much on 28 questions. The scale is from 1-7 on 2 questions with 1 = very poor and 7 = excellent.\n* The MDADI has 1 global dysphagia item, physical, function and emotional subscales and one summary scale, which is the sum of the 3 subscales rescaled to 0-100.\n* The FACT instruments have four subscales (physical, social, emotional and functional), as well as 11-12 head and neck cancer-specific questions. The scale goes from 1-4 with 1 = not at all and 4 = very much.', 'timeFrame': 'Baseline, End of cycle 2, End of cycle 6, and End of treatment (estimated median length of treatment is 8 months)'}, {'measure': 'Progression-free survival (PFS) - with maintenance therapy', 'description': 'PFS on maintenance therapy is defined as time from first dose of maintenance therapy to first radiologic confirmation of disease progression, or death from any cause.', 'timeFrame': '8 months (estimated median length of treatment)'}, {'measure': 'Disease control', 'description': 'Disease control = complete response + partial response + stable disease\n\nEvaluated using RECIST 1.1', 'timeFrame': '8 months (estimated median length of treatment)'}]",7,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,74.0,ACTUAL,2025-09-01T16:18:14.662467,v2_robust,True,True,False,False,True,
NCT05266014,This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease,"Phase 1/2, Open-Label, Dose-Finding Followed by 2-Year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease",tinlarebant,['tinlarebant'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Stargardt Disease,['Stargardt Disease'],[],COMPLETED,,2021-03-12,2023-08-15,"[{'measure': 'To evaluate systemic and ocular safety and tolerability of tinlarebant.', 'description': 'To evaluate safety and tolerability of daily dosing of tinlarebant assessed by incidence and/or severity of ocular and non-ocular adverse events.', 'timeFrame': 'From baseline to 24 months'}, {'measure': 'The optimal dose for Phase 2.', 'description': 'To determine optimal dose of tinlarebant administered orally in adolescent patients with Stargardt Disease.', 'timeFrame': 'Up to 24 months'}]","[{'measure': 'Change in atrophic lesion size.', 'timeFrame': 'From baseline to 24 months.'}, {'measure': 'Maximum Plasma Concentration (Cmax) of tinlarebant in plasma.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Time to Maximum Plasma Concentration (Tmax) of tinlarebant in plasma.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Half-life (t1/2) of tinlarebant in plasma.', 'timeFrame': 'Up to 24 months'}, {'measure': 'Time to minimal plasma RBP4 level (Tmin)', 'timeFrame': 'Up to 24 months'}, {'measure': 'Minimum concentration of RBP4 (Cmin)', 'timeFrame': 'Up to 24 months'}]",8,12 Years,18 Years,ALL,False,RBP4 Pty Ltd,INDUSTRY,1,13.0,ACTUAL,2025-09-01T16:18:14.662498,v2_robust,True,True,True,False,True,
NCT04688814,SEQ Block for Perioperative Analgesia in Acetabular Surgery,(SEQ Block): Single Puncture Combined Lumbar Erector Spinae Plane Block and Quadratus Lumborum Block for Perioperative Analgesia in Acetabular Surgeries,Morphine Sulfate,"['Morphine Sulfate', 'MOR group']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Anesthesia, Local","['Anesthesia, Local', 'Nerve Pain', 'Pain, Postoperative', 'Acetabular Fracture']",[],COMPLETED,,2020-12-25,2022-02-15,"[{'measure': 'Total postoperative morphine consumption', 'description': 'Compare the total postoperative opioid (morphine) consumption after posterior column acetabular surgery when providing ultrasound guided SEQ block: single puncture combined lumbar erector spinae plane block and paraspinous sagittal shift (PSSS) quadratus lumborum block versus conventional intravenous morphine analgesia. Morphine 0.05 mg/kg will be given intravenously when VAS score is ≥ 4. The total postoperative morphine consumption in milligrams will be recorded.', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Heart rate (HR)', 'description': 'HR (beats/minute) will be recorded preoperatively (baseline), every 30 minutes during the surgery, and every hour postoperatively for the first 4 hours, then every 4 hours for the remaining 24 hour postoperative follow up. Hemodynamic measurement will be done using multichannel Mindray monitor MEC-1000, mindray Ltd, Shenzhen, China', 'timeFrame': '24 hours'}, {'measure': 'Mean arterial blood pressure (MABP)', 'description': 'MABP (mmHg) will be recorded preoperatively (baseline), every 30 minutes during the surgery, and every hour postoperatively for the first 4 hours, then every 4 hours for the remaining 24 hour postoperative follow up. Hemodynamic measurement will be done using multichannel Mindray monitor MEC-1000, mindray Ltd, Shenzhen, China', 'timeFrame': '24 hours'}, {'measure': 'Resting and dynamic visual analogue score', 'description': 'Every patient will be asked postoperatively according to a visual analogue scale (VAS) score from 0 -10 about his experience with pain. Zero is equal to the best pain relief and 10 is referring to the worst pain experience. This will be also asked about during active movement of the hip joint and will be interpreted as the dynamic pain score. This will be done every hour during the 1st 4 postoperative hours and every 4 hours later for the rest 24 hour follow up period.', 'timeFrame': '24 hours'}, {'measure': 'Postoperative complications', 'description': 'Block or opioid related complications Nausea and vomiting: Incidence and frequency Urine retention: Incidence and frequency Any manifestation of nerve injury like the presence of paresthesia: Incidence and frequency', 'timeFrame': '24 hours'}]",5,18 Years,70 Years,ALL,False,Alexandria University,OTHER,0,52.0,ACTUAL,2025-09-01T16:18:14.662522,v2_robust,True,True,True,False,False,
NCT03494114,Imaging Activated Macrophages in the Lungs,Imaging Activated Macrophages in the Lungs,Ga-EC2115,['Ga-EC2115'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,COPD,['COPD'],[],TERMINATED,Funding has ended and unable to recruit due to COVID 19,2018-11-29,2021-01-13,"[{'measure': 'Determine whether the PET signal in the lungs correlates with inflammation in bronchoalveolar lavage (BAL).', 'description': 'We will compare the PET signal from 68 Ga-EC2115 in the lungs (opposite lung to the one containing a lung nodule) to the number of macrophages and other inflammatory cells obtained by BAL, particularly those expressing folate receptor beta.', 'timeFrame': '1 day (at the time of bronchoscopy following PET scanning)'}]","[{'measure': 'Determine whether the PET signal in lungs can identify differences between patients with COPD and control subjects without COPD.', 'description': 'We will compare the PET signal from 68 Ga-EC2115 in the lungs (opposite lung to the one containing a lung nodule) of patients with COPD and control subjects without COPD (based on pulmonary function testing).', 'timeFrame': '1 day (at the time of the PET scan)'}]",2,45 Years,,ALL,True,Vanderbilt University Medical Center,OTHER,1,13.0,ACTUAL,2025-09-01T16:18:14.662631,v2_robust,True,True,False,True,False,Funding has ended and unable to recruit due to COVID 19
NCT04456816,"A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","An Exploratory, Randomized, Double-blind, Multicenter, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AP1189 Versus Placebo Administered for 12 Weeks as an add-on to Patients, in ACE Inhibitor or Angiotensin II Receptor Blocker Treatment, With Idiopathic Membranous Nephropathy and Severe Proteinuria",100 mg AP1189,"['100 mg AP1189', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy,"['Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy', 'Severe Proteinuria Due to Idiopathic Membranous Nephropathy']",[],RECRUITING,,2020-08-31,2026-06-30,"[{'measure': 'Adverse Event', 'description': 'Evaluation of Adverse Event', 'timeFrame': 'Week 12'}, {'measure': 'Serious Adverse Events', 'description': 'Evaluation of Serious Adverse Events', 'timeFrame': 'Week 12'}, {'measure': 'ALAT change in plasma samples', 'description': 'Evaluation of ALAT compared with baseline', 'timeFrame': 'Week 12'}, {'measure': 'ASAT change in plasma samples', 'description': 'Evaluation of ASAT compared with baseline', 'timeFrame': 'Week 12'}, {'measure': 'Total bilirubin change in plasma samples', 'description': 'Evaluation of total bilirubin compared with baseline', 'timeFrame': 'Week 12'}, {'measure': 'Alkaline phosphatase change in plasma samples', 'description': 'Evaluation of alkaline phosphatase compared with baseline', 'timeFrame': 'Week 12'}, {'measure': 'Protein change in 24 hours urinary protein excretion', 'description': 'Change of protein in urine excretion compared to baseline measured in 24 h urinary protein excretion', 'timeFrame': 'Week 12'}]","[{'measure': 'Albumin change in 24 hours urinary protein excretion', 'description': 'Change of albumin in urine excretion compared to baseline measured in 24 h urinary protein excretion', 'timeFrame': 'Week 12'}]",8,18 Years,85 Years,ALL,False,SynAct Pharma Aps,INDUSTRY,0,23.0,ESTIMATED,2025-09-01T16:18:14.662812,v2_robust,True,True,False,False,True,
NCT03528616,Management of Supraventricular Tachycardia of Children,Management of Supraventricular Tachycardia of Children Admitted to Assiut University Children Hospital(Clinical Audit),"adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.","['adenosine,Propranolol,flecainide, amiodarone, propranolol, digoxin and procainamide.']",1,OBSERVATIONAL,[],,,Supraventricular Tachycardia,['Supraventricular Tachycardia'],[],UNKNOWN,,2018-05-15,2019-11-30,"[{'measure': 'Evaluate management of SVT in the cardiology unit of Assiut University Children Hospital according to international guidelines by using pharmacological and non pharmacological treatments.', 'description': 'Descriptive sheet of the study checklist that will be asked about in all cases: Clinical examination and ECG at presentation,Physical maneuvers(vagal stimulation),Drug therapy including:adenosine and other antiarrythmic drugs as Flecainide,propranolol,amiodarone,digoxin and verapamil.\n\nAppropriate dose of drugs,Putting on monitor ECG during treatment,Synchronized DC cardioversion in hemodynamically unstable cases.\n\nYes ,No ,℅ of the folowing, Clinical examination and ECG at presentation Vagal manoeuvers,diving reflex,One side carotid massage,Valsalva manoeuvre Drug therapy Adenosine only,Flecainide only,Propranolol and Amiodarone,Amiodarone only Digoxin only,Digoxin then Amiodarone, Verapamil Maintain ECG monitoring,Synchronized DC cardioversion. These data will be collected and revised to show how would doctors in the cardiology unit of Assiut University Children Hospital manage SVT according to the international guinternational guidelines.', 'timeFrame': 'one year'}]",[],1,1 Month,12 Years,ALL,False,Assiut University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:14.662820,v2_robust,False,True,False,False,False,
NCT00069316,Omr-IgG-am(Trademark) for Treating Patients With or at High Risk for West Nile Virus Disease,"A Phase I/II Randomized, Placebo-Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin G (Omr-IgG-am) Containing High Anti-West Nile Virus Antibody Titers in Patients With, or at High Risk for Progression to West Nile Virus(WNV)",Omr-IgG-am,['Omr-IgG-am'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,West Nile Virus,['West Nile Virus'],"['West Nile Virus', 'Encephalitis', 'Virus', 'Mosquito', 'Fever', 'WNV', 'Myelitis']",COMPLETED,,2003-09-22,2007-06-27,[],[],0,18 Years,,ALL,False,National Institutes of Health Clinical Center (CC),NIH,0,2.0,ACTUAL,2025-09-01T16:18:14.662854,v2_robust,True,True,True,False,False,
NCT06993116,A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors,"A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4712 in Patients With Advanced Solid Tumors",SHR-4712 Injection,['SHR-4712 Injection'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],RECRUITING,,2025-06-09,2027-05,"[{'measure': 'Dose Limited Toxicity (DLT)', 'timeFrame': 'First 21 days of treatment.'}, {'measure': 'Adverse Events (AEs)', 'timeFrame': 'Approximately 24 months.'}]","[{'measure': 'Time to peak concentration (Tmax)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Peak concentration (Cmax)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Trough concentration (Ctrough)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Area under the concentration-time curve from time zero to the last measurable time point (AUC0-t)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Area under the concentration-time curve from time zero to infinity (AUC0-∞)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Elimination half-life (t1/2)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Apparent clearance (CL/F)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Apparent volume of distribution (Vz/F)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Duration of objective tumor response (DoR)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Disease control rate (DCR)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Progression-free survival (PFS)', 'timeFrame': 'Approximately 24 months.'}, {'measure': 'Overall survival (OS)', 'timeFrame': 'Approximately 24 months.'}]",15,18 Years,75 Years,ALL,False,"Guangdong Hengrui Pharmaceutical Co., Ltd",INDUSTRY,0,126.0,ESTIMATED,2025-09-01T16:18:14.662861,v2_robust,True,True,False,False,True,
NCT00723216,Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery,"Multicenter, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Enoxaparin Sodium (RP54563) 20mg Bid for 14 Days for Prevention of Venous Thromboembolism in Patients With Curative Abdominal Cancer Surgery. Physical Prophylaxis Only Arm [Intermittent Pneumatic Compression (IPC)] Will be Used as an Indicator of Event Rates.",enoxaparin,['enoxaparin'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Abdominal Neoplasms,['Abdominal Neoplasms'],"['Prevention', 'venous thromboembolism', 'curative surgery']",COMPLETED,,2007-03,2007-12,"[{'measure': 'Venous thromboembolism incidence', 'timeFrame': '28 days'}]","[{'measure': 'Incidence of deep vein thrombosis, pulmonary thromboembolism, and venous thromboembolism incidence except patients with thrombus only in muscle veins, and incidence of proximal vein thrombosis', 'timeFrame': '28 days'}]",2,40 Years,,ALL,False,Sanofi,INDUSTRY,0,151.0,ACTUAL,2025-09-01T16:18:14.663034,v2_robust,True,True,True,False,False,
NCT03319316,Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC),Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC),Durvalumab,"['Tremelimumab', 'Durvalumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Squamous Non-small Cell Lung Cancer,"['Squamous Non-small Cell Lung Cancer', 'Non-Squamous Non-small Cell Lung Cancer']",[],WITHDRAWN,Interest withdrawn,2018-11-01,2022-11,"[{'measure': 'Progression free survival (PFS)', 'description': 'The time interval between the date of randomization and the date of disease progression or death, whichever comes first.', 'timeFrame': '4.3 years from FPI'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Overall Survival (OS) is defined as the time interval between the date of randomization and the date of death from any cause.', 'timeFrame': '5 years from FPI'}, {'measure': 'Objective response rate according to RECIST 1.1;', 'description': 'Patients with response categories progression, early death and unknown will be considered as failing to respond to treatment. The response rates in each arm and their 95% confidence intervals will be provided.', 'timeFrame': '5 years from FPI'}, {'measure': 'Progression-free survival -2', 'description': 'PFS-2 calculated as the time between randomization and the 2nd PD or death, not of the maintenance treatment/observation but the PD after the subsequent treatment thus taking into account the influence of the treatment under investigation on the following treatment line.', 'timeFrame': '5 years from FPI'}, {'measure': 'Time to failure of 2nd treatment', 'description': 'Defined as the time between randomization and the permanent treatment interruption of the subsequent/second treatment (treatment received after progression of the first treatment) due to progressive disease, PS worsening, unacceptable toxicity that does not allow continuing the treatment according to the investigator.', 'timeFrame': '5 years from FPI'}, {'measure': 'Safety', 'description': 'All adverse events will be recorded according to CTCAE version 4.', 'timeFrame': '5 years from FPI'}, {'measure': 'Quality of life', 'description': 'The hypothesis to test is whether the possible benefit with respect to PFS/OS of the intense maintenance treatment will also translate in a better QoL or will the higher risk of Adverse events cause a reduction in QoL. (methodology: quality of life questionnaires)', 'timeFrame': '5 years from FPI'}]",7,18 Years,,ALL,False,European Organisation for Research and Treatment of Cancer - EORTC,NETWORK,0,0.0,ACTUAL,2025-09-01T16:18:14.663044,v2_robust,True,True,False,True,True,Interest withdrawn
NCT05247216,A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis,"A Multicenter, Randomized, Double-blind Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Hemay007 in Patients With Moderate to Severe Rheumatoid Arthritis",Hemay007 800 mg QD group,"['Hemay007 placebo group', 'Hemay007 800 mg QD group', 'Hemay007 600 mg QD group', 'Hemay007 1200 mg QD group']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],['moderate to severe Rheumatoid Arthritis'],COMPLETED,,2021-03-26,2023-06-22,"[{'measure': 'ACR20', 'description': 'The proportion of subjects who achieved ACR 20 remission at the week 4.', 'timeFrame': 'week 4'}, {'measure': 'ACR20', 'description': 'The proportion of subjects who achieved ACR 20 remission at the week 8.', 'timeFrame': 'week 8'}, {'measure': 'ACR20', 'description': 'The proportion of subjects who achieved ACR 20 remission at the week 12.', 'timeFrame': 'week 12'}, {'measure': 'ACR20', 'description': 'The proportion of subjects who achieved ACR 20 remission at the week 16.', 'timeFrame': 'week 16'}]",[],4,18 Years,75 Years,ALL,False,"Tianjin Hemay Pharmaceutical Co., Ltd",INDUSTRY,0,140.0,ACTUAL,2025-09-01T16:18:14.663164,v2_robust,True,True,True,False,False,
NCT05274516,A Trial of HRS-2261 in Healthy Subjects After Single and Multiple Oral Administration,"Phase I Clinical Study on the Safety, Tolerability, and Pharmacokinetics of HRS-2261, the Effects of Food on the Pharmacokinetics of HRS-2261, and the Effects of HRS-2261 on CYP3A4 Metabolic Enzymes in Healthy Subjects After Single and Multiple Oral Administration",HRS-2261 tablet、placebo,['HRS-2261 tablet、placebo'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Chronic Cough,['Chronic Cough'],[],COMPLETED,,2022-03-28,2022-10-25,"[{'measure': 'Number and severity of treatment emergent adverse events (TEAEs)', 'description': 'Number and severity of TEAEs collected from dosing until follow up 7 days after last dose', 'timeFrame': 'up to 7 days after the last dose'}]","[{'measure': 'Area under the curve (AUC)', 'description': 'To assess AUC of single and multiple ascending oral doses of HRS-2261', 'timeFrame': 'up to 7 days after the last dose'}, {'measure': 'Maximum plasma concentration (Cmax)', 'description': 'To assess Cmax of single and multiple ascending oral doses of HRS-2261', 'timeFrame': 'up to 7 days after the last dose'}, {'measure': 'Area under the curve (AUC) under fed conditions', 'description': 'To assess AUC of a single oral dose of HRS-2261 under fed conditions', 'timeFrame': 'up to 7 days after the last dose'}, {'measure': 'Maximum plasma concentration (Cmax) under fed conditions', 'description': 'To assess Cmax of a single oral dose of HRS-2261 under fed conditions', 'timeFrame': 'up to 7 days after the last dose'}]",5,18 Years,55 Years,ALL,True,"Guangdong Hengrui Pharmaceutical Co., Ltd",INDUSTRY,0,92.0,ACTUAL,2025-09-01T16:18:14.663195,v2_robust,True,True,True,False,True,
NCT05993416,Treatment of Primary Hyperoxaluria Type 1 With Nedosiran,Treatment of Primary Hyperoxaluria Type 1 With Nedosiran,Nedosiran,['Nedosiran'],1,EXPANDED_ACCESS,[],,,Primary Hyperoxaluria Type 1 (PH1),['Primary Hyperoxaluria Type 1 (PH1)'],[],NO_LONGER_AVAILABLE,,,,[],[],0,2 Years,,ALL,,"Dicerna Pharmaceuticals, Inc., a Novo Nordisk company",INDUSTRY,0,,,2025-09-01T16:18:14.663370,v2_robust,False,True,False,False,False,
NCT04965506,A Study of IBI362 in Chinese Patients With Type 2 Diabetes,A Randomized Phase II Study to Evaluate the Efficacy and Safety of IBI362 Versus Placebo and Dulaglutide in Chinese Patients With Type 2 Diabetes,IBI362,['IBI362'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Type 2 Diabetes,['Type 2 Diabetes'],[],COMPLETED,,2021-09-06,2022-06-11,"[{'measure': 'The change in HbA1c from baseline to 20 weeks', 'timeFrame': 'Baseline,20 weeks'}]","[{'measure': 'Percentage of Participants Achieving HbA1c Target of <7.0%', 'timeFrame': 'Baseline,20 weeks'}, {'measure': 'Number of participants with treatment-related adverse events', 'timeFrame': 'Baseline,25 weeks'}]",3,18 Years,75 Years,ALL,False,Innovent Biologics (Suzhou) Co. Ltd.,INDUSTRY,0,252.0,ACTUAL,2025-09-01T16:18:14.663377,v2_robust,True,True,True,False,True,
NCT02006706,A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy,An Open-label Study to Evaluate the Effect of MabThera in Combination With Methotrexate on Disease Activity in Patients With Active Rheumatoid Arthritis After DMARD Treatment Failure,rituximab [MabThera/Rituxan],"['methotrexate', 'rituximab [MabThera/Rituxan]', 'methylprednisolone']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2006-08-10,2007-11-23,"[{'measure': 'Change From Baseline Disease Activity Score Based on 28-Joint Count (DAS28) at Week 24', 'description': ""DAS28 was calculated from the number of swollen joints and painful joints using the 28 joints count, the erythrocyte sedimentation rate (ESR) (millimeters per hour \\[mm/hour\\]) and patient's global assessment (PGA) of disease activity (participant-rated arthritis activity assessment using visual analog scale \\[VAS\\]) with transformed scores ranging 0 to 10; higher scores indicated greater affectation due to disease activity). DAS28 less than or equal to (≤)3.2 equals (=) low disease activity, DAS28 greater than (\\>)3.2 to 5.1 = moderate to high disease activity."", 'timeFrame': 'Baseline, Week 24'}]","[{'measure': 'Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.', 'timeFrame': 'Baseline, Week 24'}]",2,18 Years,80 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,15.0,ACTUAL,2025-09-01T16:18:14.663426,v2_robust,True,True,True,False,False,
NCT00059306,Secondary Prevention of Small Subcortical Strokes Trial,Secondary Prevention of Small Subcortical Strokes (SPS3) Trial,aspirin,"['clopidogrel', 'aspirin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Cerebrovascular Accident,"['Cerebrovascular Accident', 'Hypertension']","['stroke', 'hypertension', 'high blood pressure', 'lacunar stroke', 'subcortical stroke', 'aspirin', 'clopidogrel']",COMPLETED,,2003-02,2012-04,"[{'measure': 'Evidence of clinically defined ischemic stroke (focal neurological deficits persisting for more than 24 hours) confirmed by non-investigational CT or MRI', 'timeFrame': 'Mean follow up of 4 years'}, {'measure': 'Evidence of hemorrhagic stroke; a neurologic deficit associated with intraparenchymal or subarachnoid space lesion on CT/MRI or cerebral hemorrhage demonstrated by surgery or autopsy.', 'timeFrame': 'within mean follow-up of 4 years'}]","[{'measure': 'The difference in the rate of cognitive decline among SPS3 participants assigned to receive aspirin alone versus combination of aspirin and clopidogrel, assessed through repeated neuropsychological tests; and major vascular events.', 'timeFrame': 'within mean follow-up of 4 years'}]",3,30 Years,,ALL,False,University of British Columbia,OTHER,1,3020.0,ACTUAL,2025-09-01T16:18:14.663485,v2_robust,True,True,True,False,False,
NCT07071506,New Methods for Evaluating Preventive Migraine Treatment,New Methods for Evaluating Preventive Migraine Treatment,Active drug for chronic migraine treatment.,"['Placebo Subcutaneous injection', 'Active drug for chronic migraine treatment.']",2,INTERVENTIONAL,['NA'],,,Migraine,"['Migraine', 'Migraine With or Without Aura', 'Headache Disorders', 'Chronic Migraine, Headache']","['Headache', 'Chronic migraine', 'Balanced placebo design', 'Treatment effects', 'Adverse events']",RECRUITING,,2025-03-04,2028-09,"[{'measure': 'Moderate/severe headache days', 'description': 'Total number of moderate/severe headache days will be measured 28 days before and after each treatment administration. Headache days will be recorded by the presence of headache (yes/no), peak pain intensity (mild/moderate/severe), and duration (\\< 4h or ≥ 4h), acute medication intake type (triptan/ergotamine/other) and migraine associated symptoms.', 'timeFrame': 'Through study completion, an average of 8 months'}, {'measure': 'Headache/pain intensity', 'description': 'Headache/pain intensity rated on a 11-point Numerical Rating Scale (0=no pain; 10=worst pain intensity) will also be measured 28 days before and after each treatment administration.', 'timeFrame': '8 months'}, {'measure': 'Adverse events', 'description': 'Occurrence of adverse events in each treatment condition recorded by the presence of adverse events ascribed to the treatment, measured by free recall and by prompting.', 'timeFrame': '24 hours, 14 and 28 days after each treatment administration'}]","[{'measure': 'Migraine days', 'description': 'Total number of migraine days will be measured 28 days before and after each treatment condition.', 'timeFrame': 'Through study completion, an average of 8 months'}, {'measure': 'Intensity of migraine', 'description': 'A categorical, four-point rating scale will be used to rate each migraine day as absent, mild, moderate, or severe. It is is graded mild when it does not inhibit work or other activities, moderate when it inhibits but does not prohibit work or other activities, and severe when it prohibits work and other activities.', 'timeFrame': 'Through study completion, an average of 8 months'}, {'measure': 'Acute treatment utilization', 'description': 'The use of acute migraine medication will be recorded, including the number of days and the specific drug used.', 'timeFrame': 'Through study completion, an average of 8 months'}, {'measure': 'Positive and negative affect (PANAS)', 'description': 'PANAS will be used to measure positive and negative emotions or feelings pre- and post-treatment of each treatment condition. Positive affectivity refers to positive emotions and expressions. Negative affectivity, on the other hand, refers to negative emotions and expressions. This scale consists of words that describe different emotions and is scored on a Likert scale ranging from 1 to 5 (1= Very slightly or Not at all, 2=little, 3=moderately, 4=quite a bit and 5 =extremely).', 'timeFrame': 'Pre-treatment and 28 days after each treatment administration'}, {'measure': 'Hospital Anxiety and Depression Scale (HADS)', 'description': 'It is a 14-item measure designed to assess anxiety and depression symptoms. It is rated on a 4-point Likert scale. It will be measured pre- and post-treatment of each treatment condition.', 'timeFrame': 'Pre-treatment and 28 days after each treatment administration'}, {'measure': 'Quality of life (SF-12)', 'description': ""Short-form-12 (SF-12) is a self-reported outcome measure assessing the impact of health on an individual's everyday life. It consists of two components- physical (PCS-12) and mental (MCS-12). The summary scores are scored using norm-based scoring, where means of 50 and standard deviations of 10 are achieved."", 'timeFrame': 'Pre-treatment and 28 days after each treatment administration'}, {'measure': 'HIT-6', 'description': 'Headache impact test (HIT-6) measures the impact that headache has on social functioning, role functioning, vitality, cognitive functioning, and psychological distress. It consists of 6 questions. Each question can be answered with 5 responses (never, rarely, sometimes, very often, or always), which has the following numerical values (6, 8, 10, 11, and 13, respectively).', 'timeFrame': 'Pre-treatment and 28 days after each treatment administration'}, {'measure': 'Intensity of experienced adverse events', 'description': 'Intensity of the experienced adverse events will be measured on a 11-point Numerical Rating Scale (e.g., ""To what extent have you been feeling fatigue/dizziness?""; 0=not at all; 10=worst imaginable)', 'timeFrame': '24 hours, 14 days and 28 days after each treatment administration'}]",11,18 Years,65 Years,ALL,False,University of Aarhus,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:14.663603,v2_robust,True,True,False,False,True,
NCT04526106,"REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors","A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors",RLY-4008,['RLY-4008'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,FGFR2 Amplification,"['FGFR2 Amplification', 'FGFR2 Gene Mutation', 'FGFR2 Gene Fusion/Rearrangement', 'FGFR2 Gene Translocation', 'FGFR2 Gene Activation', 'Intrahepatic Cholangiocarcinoma', 'Cholangiocarcinoma', 'Other Solid Tumors, Adult']",[],ACTIVE_NOT_RECRUITING,,2020-09-02,2027-12,"[{'measure': 'Part 1 and Part 4: Number of patients with adverse events and serious adverse events', 'timeFrame': 'Every cycle (4-week cycles) until study discontinuation, approximately 24 months'}, {'measure': 'Part 1: Determination of maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of RLY-4008', 'timeFrame': 'Cycle 1 (4-week cycle) of treatment for MTD and at the end of every cycle (4-week cycles) for RP2D until study discontinuation, approximately 24 months'}, {'measure': 'Part 2 and Part 3: Objective Response Rate (ORR) assessed by Independent Review Committee per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Part 4: Number of patients with dose interruptions', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}, {'measure': 'Part 4: Number of patients with dose reductions', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}, {'measure': 'Part 4: Number of patients with dose discontinuations', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}]","[{'measure': 'Part 1: FGFR2 gene status in plasma circulating tumor deoxyribonucleic acid (ctDNA) and tumor tissue', 'timeFrame': 'Every cycle (4-week cycles) through Cycle 3 and every other cycle thereafter until study discontinuation, approximately 24 months'}, {'measure': 'Part 1: Duration of Response (DOR) assessed by Investigator per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Part 1: Disease Control Rate (DCR) as assessed by Investigator per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Part 1, Part 2, and Part 3: Objective Response Rate (ORR) as assessed by Investigator per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Pharmacokinetic parameters including maximum plasma drug concentration (Cmax)', 'timeFrame': 'Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)'}, {'measure': 'Pharmacokinetic parameters including area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)'}, {'measure': 'Pharmacokinetic parameters including half-life (t1/2)', 'timeFrame': 'Approximately every 2 weeks in Cycle 1 (4-week cycle) and every cycle through Cycle 4 (4-week cycles)'}, {'measure': 'Part 1: Pharmacodynamic parameters including changes in fibroblast growth factor 23 (FGF-23)', 'timeFrame': 'Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months'}, {'measure': 'Part 1: Pharmacodynamic parameters including changes in carcinoembryonic antigen (CEA)', 'timeFrame': 'Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months'}, {'measure': 'Part 1: Pharmacodynamic parameters including changes in cancer antigen 19-9 (CA 19-9)', 'timeFrame': 'Approximately every 2 weeks in Cycle 1 (4-week cycle) and every other cycle (4-week cycles) from Cycle 3, approximately 24 months'}, {'measure': 'Part 2 and Part 3: Duration of response (DOR) assessed by Investigator and Independent Review Committee per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Part 2 and Part 3: Progression-free survival (PFS) assessed by Investigator and Independent Review Committee per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Part 2 and Part 3: Disease control rate (DCR) assessed by Investigator and Independent Review Committee per RECIST v1.1', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}, {'measure': 'Part 2 and Part 3:Overall survival (OS)', 'timeFrame': 'Up to approximately 36 months.'}, {'measure': 'Part 2 and Part 3:Change from baseline in quality of life as assessed by EORTC QLQ-C30', 'timeFrame': 'Approximately every 4 weeks during treatment, approximately 24 months'}, {'measure': 'Part 2 and Part 3:Dose intensity', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}, {'measure': 'Part 2 and Part 3: Number of patients with dose interruptions', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}, {'measure': 'Part 2 and Part 3: Number of patients with dose reductions', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}, {'measure': 'Part 2 and Part 3: Number of patients with dose discontinuations', 'timeFrame': 'Every 28-day cycle until end of treatment, approximately 24 months.'}, {'measure': 'Part 2 and Part 3: Correlation between FGFR2 genotype by central tissue assessment and antitumor response, as measured by ORR', 'timeFrame': 'Approximately every 8 weeks during treatment and every 12 weeks after the last dose in the absence of progressive disease, approximately 36 months'}]",26,18 Years,,ALL,False,Elevar Therapeutics,INDUSTRY,0,490.0,ACTUAL,2025-09-01T16:18:14.663647,v2_robust,True,True,False,False,True,
NCT01680406,Ethiopia Antimalarial in Vivo Efficacy Study 2012,Ethiopia Antimalarial in Vivo Efficacy Study 2012: Evaluating the Efficacy of Artemether-lumefantrine Alone Compared to Artemether-lumefantrine Plus Primaquine and Chloroquine Alone Compared to Chloroquine Plus Primaquine for Plasmodium Vivax Infection,Artemether-lumefantrine combination,"['Artemether-lumefantrine combination', 'Primaquine', 'Chloroquine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Plasmodium Vivax Infection,['Plasmodium Vivax Infection'],"['Plasmodium vivax', 'malaria', 'Ethiopia', 'Sub-Saharan Africa', 'primaquine', 'artemether lumefantrine', 'chloroquine']",COMPLETED,,2012-10,2014-12,"[{'measure': 'P. vivax treatment failures following treatment with AL compared to AL+PQ', 'timeFrame': 'day 28 and 42'}, {'measure': 'P. vivax treatment failures following treatment with CQ compared to CQ+PQ', 'timeFrame': 'day 28 and 42'}]","[{'measure': 'Number of episodes of P. vivax parasitemia over one year following initial effective therapy against P. vivax (i.e. parasite clearance)', 'timeFrame': '1 year after day 0 of enrollment'}]",3,1 Year,,ALL,False,Centers for Disease Control and Prevention,FED,6,398.0,ACTUAL,2025-09-01T16:18:14.663670,v2_robust,True,True,True,False,False,
NCT05683704,Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma,Phase 2 Multi-center Randomized Study to the Efficacy and Safety of AK105 Combined With Anrotinib Hydrochloride in Patients With Recurrent/Refractory Classical Hodgkin's Lymphoma,AK105，Anrotinib hydrochloride,['AK105，Anrotinib hydrochloride'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent/Refractory Classical Hodgkin's Lymphoma,"[""Recurrent/Refractory Classical Hodgkin's Lymphoma""]",[],ENROLLING_BY_INVITATION,,2022-09-01,2026-05-31,"[{'measure': 'Complete response rate (CRR)', 'description': ""To evaluate the efficacy of AK105 combined with androtinib hydrochloride capsule in the treatment of patients with recurrent/refractory classical Hodgkin's lymphoma."", 'timeFrame': 'from May 2022 to May 2024'}]",[],1,18 Years,75 Years,ALL,False,Tianjin Medical University Cancer Institute and Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:14.663682,v2_robust,True,True,False,False,False,
NCT05951504,The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin,The Prospective Evaluation of Peri-Operative Glucocorticoid Use in the Management of Cervicofacial Infections of Odontogenic Origin,Methylprednisolone,"['Solumedrol', 'Methylprednisolone']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Odontogenic Infection of Jaw (Disorder),['Odontogenic Infection of Jaw (Disorder)'],['Glucocorticoid'],COMPLETED,,2022-06-22,2023-07-01,"[{'measure': 'Length of Hospital Admission', 'description': 'Length of Hospital Admission in days from the date of admission to the date of discharge.', 'timeFrame': 'Entire length of hospital admission (in days), total average length less than 14 days'}, {'measure': 'White Blood Cell Count', 'description': 'Hematologic Biomarker of Infection', 'timeFrame': 'Daily for entire length of hospital admission (in days), total average length less than 14 days'}, {'measure': 'C-Reactive Protein Level', 'description': 'Acute phase reactant that is a hematologic biomarker of infection', 'timeFrame': 'Daily for entire length of hospital admission (in days), total average length less than 14 days'}, {'measure': 'Improvement in Mouth Opening (Trismus)', 'description': 'Trismus is a marker of both pain and resolution of soft tissue swelling', 'timeFrame': 'Daily for entire length of hospital admission (in days), total average length less than 14 days'}]",[],4,,,ALL,False,University of Manitoba,OTHER,0,29.0,ACTUAL,2025-09-01T16:18:14.663802,v2_robust,True,True,True,False,False,
NCT03785704,Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer,Clinical Study of Xinmailong Injection on Reducing Cardiovascular Toxicity in Adjuvant Chemotherapy in Breast Cancer,Xinmailong Injection,['Xinmailong Injection'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Neoplasms,"['Breast Neoplasms', 'Cardiac Event', 'Chemotherapeutic Toxicity']","['Xinmailong injection', 'anthracycline induced cardiac toxicity']",UNKNOWN,,2019-01-01,2025-03-01,"[{'measure': 'The rate of no cardiac events during chemotherapy', 'description': 'Adverse events (AEs) and laboratory tests graded according to the NCI CTCAE (version 4.0) .No cardiac events were defined until all relevant indicators (Electrocardiograph, Echcardiography and myocardial enzyme) were normal during chemotherapy.', 'timeFrame': 'up to 12 months'}]","[{'measure': 'Disease-free survival (DFS)', 'description': 'The time between the start of a randomized clinical trial and the onset of disease recurrence or death from any cause', 'timeFrame': '5 years'}]",2,18 Years,,ALL,False,Peking Union Medical College,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:14.663820,v2_robust,True,True,False,False,True,
NCT02782104,A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression,An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression,Esketamine Nasal Spray,"['JNJ-54135419', 'Esketamine Nasal Spray']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Depressive Disorder, Treatment-Resistant","['Depressive Disorder, Treatment-Resistant']","['Depressive Disorder, Treatment-Resistant', 'Esketamine', 'JNJ-54135419']",COMPLETED,,2016-06-09,2022-12-30,"[{'measure': 'Change From Study Baseline in Computerized Cognitive Battery Domain Score: Detection Test (DET) Score', 'description': 'This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. The DET is a measure of psychomotor function and uses a well-validated simple reaction time. In this outcome measure, speed of performance of subjects (calculated as mean of the logarithmic base 10 transformed reaction times) for correct responses was reported. Total score ranged from 2 to 3.3 log 10 milliseconds (msec). Lower score indicated better performance. Higher change from baseline indicated better performance.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Study Baseline in Computerized Cognitive Battery Domain Score: Identification Test (IDN) Score', 'description': 'This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. IDN test is a measure of visual attention (choice reaction time) and scored for speed of response (mean of the log10 transformed reaction times for correct responses). Total score ranged from 2 to 3.3 log 10 msec. Lower score indicated better performance. Higher change from baseline indicated better performance.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Card Learning Test (OCL) Score', 'description': 'This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. OCL test is a measure of visual episodic memory and visual recall test scored using arcsine transformation of the percentage of correct responses (CR). The range for OCL is 0 to 100 percent (%) accuracy; presented as an arcsin transformation, the range is 0 to 1.57. Higher score indicated better performance. Higher change from baseline indicated better performance.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Study Baseline in Computerized Cognitive Battery Domain Score: One Back Test (ONB) Score', 'description': 'The ONB is a measure of working memory and scored for speed of correct response (mean of the log10-transformed reaction times for correct responses). Total score ranged from 2 to 3.54 log10 msec. Lower score indicated better performance. Higher change from baseline indicated better performance.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Study Baseline in Computerized Cognitive Battery Domain Score: Groton Maze Learning Test (GMLT) Score', 'description': 'This battery is a series of computerized cognition tests (detection, identification, one card learning, one back and groton maze learning) designed to measure reaction time, visual learning and memory, and executive function/sequencing. GMLT measures executive function; maze/sequencing test, scored for total number of errors. Total score ranged from 0 to 999 number of errors. Lower score indicated better performance. Higher change from baseline indicated better performance.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Study Baseline in Hopkins Verbal Learning Test-Revised (HVLT-R) Score', 'description': 'The HVLT-R measures performance in verbal memory, learning, and long-term recall in which a list of words is read up to three times. Approximately 20-25 minutes later, a delayed recall trial and a recognition trial are completed. The delayed recall requires free recall of any words remembered. The recognition trial is composed of 24 words, including the 12 target words and 12 false-positives. When scoring the HVLT, the three learning trials are combined to calculate a total recall score (0-36); the delayed recall trial creates the delayed recall score (0-12); the total number of true-positive errors (0-12); and the range of recognition discrimination index is comprised by subtracting the total number of false positives from the total number of true positives. A higher total recall score indicated higher cognition. The range of the recognition discrimination index is -12 to 12. Higher score indicated better performance and higher change from baseline indicated better performance.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Percentage of Participants Based on Columbia-Suicide Severity Rating Scale (C-SSRS) Score', 'description': 'C-SSRS: interview-based instrument to systematically assess suicidal ideation (SI) and behavior, to assess whether participant experienced any of following: completed suicide, suicide attempt (response of ""yes"" on ""actual attempt""), preparatory acts toward imminent suicidal behavior (""yes"" on ""preparatory acts or behavior"", ""aborted attempt"" or ""interrupted attempt""), suicidal ideation (""yes"" on ""wish to be dead"", ""non-specific active suicidal thoughts"", ""active SI with methods without intent to act or some intent to act, without or with specific plan and intent), any self-injurious behavior with no suicidal intent (""yes"" on ""has participant engaged in non-suicidal self-injurious behavior""). Here, percentage of participants with \\>=1 positive behavior, participants with \\>=1 positive ideations; no event were reported.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs)', 'description': 'An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. Any AE occurring at or after the initial administration of study intervention up to end of study was considered as treatment-emergent.', 'timeFrame': 'IND Phase: up to 4 weeks; OP/MA Phase: up to 78 months'}, {'measure': 'Change From Baseline in Heart Rate', 'description': 'Change from baseline (predose) in heart rate were reported.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Systolic and Diastolic Blood Pressure', 'description': 'Change from baseline in systolic and diastolic blood pressure were reported.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Respiratory Rate', 'description': 'Change from baseline in respiratory rate were reported.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Blood Oxygen Saturation', 'description': 'Change from baseline in blood oxygen saturation (predose) were reported.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}]","[{'measure': 'Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score', 'description': 'MADRS measures depression severity, detects changes due to AD treatment. It consists of 10 items (evaluate apparent sadness, reported sadness, inner tension, sleep, appetite, concentration, lassitude, interest level, pessimistic thoughts, suicidal thoughts), scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), summed for a total possible score of 0 to 60. Higher scores indicate more severe conditions. Negative change in score indicates improvement. Missing data was imputed using last observation carried forward (LOCF) method.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Participant-Reported Depressive Symptoms Using the Patient Health Questionnaire - 9 (PHQ-9) Total Score', 'description': ""Change from baseline in PHQ-9 total score were reported. The PHQ-9 was a 9-item, patient-reported outcome measure to assess depressive symptoms. The scale scores each of the 9 symptom domains of the Diagnostic and Statistical Manual of Mental Disorders. Each item was rated on a 4-point scale (0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day). The participant's item responses were summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms."", 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Clinical Global Impression-severity (CGI-S) Score', 'description': ""Change from baseline in clinical global impression-severity (CGI-S) score were reported. The CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 1 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 1 = normal (not at all ill); 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; 7 = among the most extremely ill participants. Negative change in score indicates improvement."", 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Sheehan Disability Scale (SDS) Total Score', 'description': 'Change from baseline in SDS total score were reported. The SDS, a patient-reported outcome measure, was a 5 item questionnaire which had been widely used and accepted for assessment of functional and associated disability impairment. The first three items assessed disruption of (1) work/school, (2) social life, and (3) family life/home responsibilities using a 0-10 rating scale. The score for the first three items were summed to create a total score of 0-30 where a higher score indicated greater impairment.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Participant-Reported Health-related Quality of Life as Assessed by EuroQol-5 Dimension-5 Level (EQ-5D-5L) Valuation Index Score (VAS)', 'description': ""Change from baseline in participant-reported health-related quality of life as assessed by EQ-5D-5L VAS was reported. The EQ-5D-5L is a standardized 2-part instrument for use as a measure of health outcome, primarily designed for self-completion by respondents. It essentially consists of the EQ-5D-5L descriptive system and the EQ-VAS. EQ-VAS self-rating records the respondent's own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Positive change in score indicates improvement."", 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline as Assessed by EQ 5D-5L: Sum Score', 'description': 'EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ-VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health ""today"". Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \\*5. Higher score indicates worst health state.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}, {'measure': 'Change From Baseline in Participant- Reported Health Related Quality of Life Using the Quality of Life in Depression Scale (QLDS)', 'description': 'Change from baseline in participant- reported health related quality of life using the QLDS. The QLDS is a disease-specific validated patient-reported outcome (PRO) measure which assesses the impact that depression has on a participant\'s quality of life. It is a 34-item self-rated questionnaire which consists of dichotomous response questions, with the response being either True/Not True. Each statement on the QLDS is given a score of ""1"" or ""0"". A score of ""1"" is indicative of adverse quality of life. All item scores are summed to give a total score that ranges from 0 (good quality of life) to 34 (very poor quality of life). A higher score indicates a more severe condition.', 'timeFrame': 'IND Phase: Baseline up to 4 weeks; OP/MA Phase: Baseline up to 78 months'}]",19,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,1148.0,ACTUAL,2025-09-01T16:18:14.663841,v2_robust,True,True,True,False,True,
NCT06393504,Database Study to Provide Information on Pregnancy and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant),"Healthcare Claims Database Study to Provide Safety Information on Maternal, Fetal and Infant Outcomes Among Women Exposed to QUVIVIQ (Daridorexant) During Pregnancy",Daridorexant,"['Daridorexant', 'QUVIVIQ', 'Non-orexin receptor antagonist insomnia medication']",3,OBSERVATIONAL,[],,,Insomnia Disorder,['Insomnia Disorder'],['Pregnancy'],ACTIVE_NOT_RECRUITING,,2023-11-30,2028-04,"[{'measure': 'Prevalence of major congenital malformations (MCMs)', 'description': ""MCMs will be identified as pre-specified diagnostic codes for malformations included in the National Birth Defects Prevention Network's birth defects descriptions (identified through maternal and infant claims).\n\nMCMs with etiologies presumed not to be associated with drug exposure, such as chromosomal abnormalities, genetic syndromes, prematurity-related defects, and positional effects, will be excluded from the definition of MCMs."", 'timeFrame': 'From May 2022 to April 2028 (6 years)'}]","[{'measure': 'Prevalence of spontaneous abortions (SABs)', 'description': 'An SAB is defined as the loss of an embryo before 20 gestational weeks (identified through maternal claims).', 'timeFrame': 'From May 2022 to April 2028 (6 years)'}, {'measure': 'Prevalence of stillbirths (SBs)', 'description': 'An SB is defined as the loss of a fetus at or after 20 gestational weeks (identified through maternal claims).', 'timeFrame': 'From May 2022 to April 2028 (6 years)'}, {'measure': 'Prevalence of small for gestational age infants (SGAs)', 'description': 'SGA is defined as birth weight less than or equal to the tenth percentile for gestational age (identified through maternal and infant claims).', 'timeFrame': 'From May 2022 to April 2028 (6 years)'}, {'measure': 'Prevalence of preterm births (PTBs)', 'description': 'PTB is defined as a live birth before 37 gestational weeks (identified through maternal and infant claims).', 'timeFrame': 'From May 2022 to April 2028 (6 years)'}, {'measure': 'Prevalence of induced abortions (IABs)', 'description': 'An IAB is defined as the elective termination of the pregnancy (identified through maternal claims).', 'timeFrame': 'From May 2022 to April 2028 (6 years)'}]",6,15 Years,50 Years,FEMALE,False,Idorsia Pharmaceuticals Ltd.,INDUSTRY,1,2095.0,ESTIMATED,2025-09-01T16:18:14.663903,v2_robust,False,True,False,False,False,
NCT00410904,AZD2171 and Pemetrexed Disodium in Treating Patients With Relapsed Non-Small Cell Lung Cancer,Phase 2 Study of AZD2171 (NSC 732208) in Combination With Pemetrexed in Relapsed Non-Small Cell Lung Cancer (NOS: 10029514),cediranib maleate,"['pemetrexed disodium', 'cediranib maleate', 'AZD2171', 'Recentin', 'MTA', 'LY231514', 'ALIMTA']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Non-small Cell Lung Cancer,['Recurrent Non-small Cell Lung Cancer'],[],COMPLETED,,2006-10,2014-03,"[{'measure': 'Response Rate (Complete and Partial) 2 Separate Cohorts of Relapsed NSCLC Cohort A: Pts Who Have Received Prior Chemo w/o Ever Having Received Bevacizumab. Cohort B: Pts Who Have Received Prior Bevacizumab.', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v 1.0) for target lesions and assessed by MRI or CT:\n\nComplete Response (CR): Disappearance of all target lesions\n\nPartial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD\n\nOverall Response (OR) = CR + PR, the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for PD the smallest measurements recorded since the treatment started)', 'timeFrame': 'Up to 4 years'}]","[{'measure': 'Progression-free Survival', 'description': 'Estimated with the standard Kaplan-Meier method, from which summary statistics of interest (median, 1-year rate, etc.) will be derived. Both point and 95% confidence interval estimates of all PFS and OS statistics will be calculated. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', 'timeFrame': 'The duration of time from start of treatment to time of progression, assessed up to 4 years'}, {'measure': 'Overall Survival', 'description': 'Estimated with the standard Kaplan-Meier method, from which summary statistics of interest (median, 1-year rate, etc.) will be derived. Both point and 95% confidence interval estimates of all PFS and OS statistics will be calculated.', 'timeFrame': 'The time from start of treatment to time of death, assessed up to 4 years'}]",3,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,60.0,ACTUAL,2025-09-01T16:18:14.663942,v2_robust,True,True,True,False,False,
NCT04481204,"New and Emerging Therapies for the Treatment of Resectable, Borderline Resectable, or Locally Advanced Pancreatic Cancer, PIONEER-Panc Study",PIONEER-Panc: Phase II Investigations of New and Emerging Therapies for Pancreatic Cancer,Cisplatin,"['Paclitaxel Albumin', 'Neoplatin', 'Placis', 'Platinum Diamminodichloride', 'Ro-2-9757', 'Difluorodeoxycytidine', '5 Fluorouracil', 'Cysplatyna', '5FU', 'Plastistil', ""Peyrone''s Salt"", 'Lederplatin', 'Abiplatin', 'Cisplatin', 'paclitaxel albumin-stabilized nanoparticle formulation', 'Platamine', 'Briplatin', 'Albumin-Stabilized Nanoparticle Paclitaxel', 'Platiblastin-S', 'Platinol- AQ', 'Flurablastin', 'Ribofluor', 'Diaminocyclohexane Oxalatoplatinum', 'AccuSite', '5-Fluorouracil', 'Cismaplat', 'Cis-platinum II Diamine Dichloride', 'Metaplatin', 'Gemcitabine', 'Citoplatino', 'Platistin', '5-Fu', 'Platinum', 'Cis-platinous Diamine Dichloride', 'Platinex', 'Oxalatoplatin', 'Cis-platinum II', 'Cisplatinum', 'dFdCyd', 'Cis-diamminedichloro Platinum (II)', 'Cis-diammine-dichloroplatinum', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', 'Aiheng', 'Protein-bound Paclitaxel', 'Fluoro Uracil', 'Platiblastin', 'Irinotecan', 'Cis-dichloroammine Platinum (II)', 'RP 54780', 'JM-83', 'Fluroblastin', 'Platinol', '1-OHP', 'Leucovorin', 'Albumin-bound Paclitaxel', 'ABI 007', 'Dacplat', 'SR-96669', 'Folinic acid', 'ABI-007', 'Platiran', 'Oxaliplatin', 'Nanoparticle Albumin-bound Paclitaxel', 'Eloxatin', 'Cis-platinum', 'Cisplatina', 'Nab-paclitaxel', 'Oxalatoplatinum', 'dFdC', 'Nanoparticle Paclitaxel', 'DDP', 'RP-54780', 'Cisplatyl', '5 Fluorouracilum', 'Ro 2-9757', 'Fluouracil', 'Platinoxan', 'Cis-diamminedichloridoplatinum', 'Fluracil', 'Fluracedyl', '5 FU', 'Blastolem', 'Platinol-AQ', ""Peyrone''s Chloride"", 'Eloxatine', 'Ai Heng', 'Cis-diamminedichloroplatinum', 'Abraxane', 'CDDP', 'Platinol-AQ VHA Plus', 'Fluril', 'Carac', '5-Fluracil', 'Citosin', 'Platosin', 'Fluorouracil', 'Dacotin']",97,INTERVENTIONAL,['PHASE2'],PHASE2,,Borderline Resectable Pancreatic Adenocarcinoma,"['Borderline Resectable Pancreatic Adenocarcinoma', 'Locally Advanced Pancreatic Ductal Adenocarcinoma', 'Resectable Pancreatic Ductal Adenocarcinoma']",[],ACTIVE_NOT_RECRUITING,,2023-04-18,2027-04-06,"[{'measure': 'Major pathological response rate', 'description': 'Major pathological response is any patient who has grade I or II treatment response. Grade I - 0% residual tumor cells in the specimen (pathologic complete response, grade II - 1 to \\< 5% residual tumor cells in the specimen.', 'timeFrame': '12 weeks'}, {'measure': 'Disease control rate', 'description': 'Measured as the proportion of patients without progression.', 'timeFrame': '6 months'}]","[{'measure': 'Progression free survival', 'description': 'Will be estimated using the Kaplan-Meier method. Comparisons of these time-to-event endpoints by important covariate subgroups will be made using the log-rank tests. Cox proportional hazards regression models will be explored to evaluate the associations between the time-to-event endpoints and covariates of interest.', 'timeFrame': 'From the date of treatment initiation to the date of disease progression, recurrence after surgery or death from any cause whichever occurs first, assessed up to 5 years'}, {'measure': 'Overall survival', 'description': 'Will be estimated using the Kaplan-Meier method. Comparisons of these time-to-event endpoints by important covariate subgroups will be made using the log-rank tests. Cox proportional hazards regression models will be explored to evaluate the associations between the time-to-event endpoints and covariates of interest.', 'timeFrame': 'From treatment start till death or last follow-up if the patient is alive, assessed up to 5 years'}]",4,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,105.0,ACTUAL,2025-09-01T16:18:14.664006,v2_robust,True,True,False,False,False,
NCT06142604,Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery,Single Dose Flecainide for Early Sinus Rhythm Conversion of Perioperative Atrial Fibrillation After Noncardiac Surgery (FLIP-AF): a Pilot Randomized Controlled Trial,Flecainide,['Flecainide'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Atrial Fibrillation,"['Atrial Fibrillation', 'Surgery']",['Flecainide'],WITHDRAWN,Feasibility,2024-07-01,2025-12-31,"[{'measure': 'Recruitment rate', 'description': 'Minimum recruitment rate of at least 1.5 patients per site per month', 'timeFrame': 'through study completion, an average of six months'}, {'measure': 'Follow-up completion rate', 'description': 'Completion rate of at least 90%', 'timeFrame': 'through study completion, an average of six months'}]",[],2,18 Years,,ALL,False,Population Health Research Institute,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.664043,v2_robust,True,True,False,True,False,Feasibility
NCT03928704,A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis,"A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis",Bimekizumab,"['BKZ', 'UCB4940', 'Bimekizumab']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Nonradiographic Axial Spondyloarthritis,['Nonradiographic Axial Spondyloarthritis'],"['Nonradiographic axial spondyloarthritis', 'Axial spondyloarthritis', 'Nr-axSpA', 'Bimekizumab']",COMPLETED,,2019-04-25,2023-04-17,"[{'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response at Week 16', 'description': ""ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component."", 'timeFrame': 'Week 16'}]","[{'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 40% Response Criteria (ASAS40) Response in TNFα Inhibitor-naïve Subjects at Week 16', 'description': ""ASAS40 response is defined as relative improvements of at least 40% and absolute improvement of at least 2 units in at least 3 of the 4 following components:1) Patient's Global Assessment of Disease Activity (PGADA) assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) Bath Ankylosing Spondylitis Functional Index (BASFI) assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component."", 'timeFrame': 'Week 16'}, {'measure': 'Change From Baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Total Score at Week 16', 'description': 'BASDAI is a well-established patient-reported endpoint assessing severity of AS symptoms. It is made of 6 items assessing severity of fatigue, spinal pain, peripheral joint pain \\& swelling, enthesitis, \\& morning stiffness (both severity and duration). Each question is rated using a numerical rating scale ranging from 0 (none) to 10 (very severe), higher score=higher symptom severity.BASDAI score is calculated by computing mean of questions 5 and 6 \\& adding it to sum of questions 1 to 4.This score is then divided by 5.Total BASDAI score ranges from 0=no disease activity to 10=maximal disease activity, higher score indicates higher symptom severity. A negative change reflects improvement.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society 20% Response Criteria (ASAS20) Response at Week 16', 'description': ""ASAS20 response is defined as relative improvements of at least 20% and absolute improvement of at least 1 unit in at least 3 of the 4 following components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities, 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI, each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity; and no worsening at all in the remaining component."", 'timeFrame': 'Week 16'}, {'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) Partial Remission (PR) at Week 16', 'description': ""The Assessment of SpondyloArthritis International Society partial remission (ASAS-PR) is defined as a score of less than or equal to (\\<=) 2 units in each of the 4 following components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity,2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most severe pain\\], higher score= higher pain intensity, 3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities, and 4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \\[none / 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity."", 'timeFrame': 'Week 16'}, {'measure': 'Percentage of Participants With Ankylosing Spondylitis Disease Activity Score Major Improvement (ASDAS-MI) at Week 16', 'description': ""ASDAS-MI is achieved when there is a reduction (improvement) greater or equal to (\\>=) 2.0 in ASDAS relative to Baseline. ASDAS is calculated by adding the 5 following components: 1) 0.121 × Neck, back or hip pain (BASDAI Q2), 2) 0.058 × Duration of morning stiffness (BASDAI Q6), 3) 0.110 × Patient's Global Assessment of Disease Activity (PGADA), 4) 0.073 × Peripheral pain/swelling in joints (BASDAI Q3), 5) 0.579 × (natural logarithm of the C-reactive protein (CRP) \\[mg/L\\] + 1). Q2, Q3 and Q6 from BASDAI and PGADA, are all assessed on a numerical scale from 0 \\[none / not active\\] to 10 \\[very severe / very active\\]. There is a minimum score of 0.980 for ASDAS (as a fixed value of 2 is assumed for values of hs-CRP below the lower limit of quantification (LLOQ)), but no defined upper score. Higher ASDAS scores reflect higher disease activity and participants achieving ASDAS-MI are considered to have a major improvement in their disease."", 'timeFrame': 'Week 16'}, {'measure': 'Percentage of Participants With Assessment of SpondyloArthritis International Society (ASAS) 5/6 Response at Week 16', 'description': ""ASAS 5/6 response is defined as achieving at least 20% improvement in 5 of the following 6 components:1) PGADA assessed on a scale ranging from 0 \\[not active\\] to 10 \\[very active\\], higher score=higher disease activity, 2) Spinal Pain assessed on a scale ranging from 0 \\[no pain\\] to 10 \\[most intense pain\\], higher score=higher pain intensity,3) BASFI assessing participant's level of ability on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\] on 10 physical activities,4) morning stiffness, assessed as the mean of Q5 (intensity) and Q6 (duration) from the BASDAI scale, each assessed on a scale ranging from 0 \\[none/ 0 hour\\] to 10 \\[very severe / 2 or more hours\\], higher score=higher severity;5) spinal mobility (ie, lateral spinal flexion component of Bath Ankylosing Spondylitis Disease Metrology Index) on a scale ranging from 0 \\[no limitation of movement\\] to 10 \\[very severe limitation of movement\\] and 6) high sensitivity C-reactive protein (hs-CRP)."", 'timeFrame': 'Week 16'}, {'measure': 'Change From Baseline in Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16', 'description': ""The BASFI is a well-established PRO measure of physical functioning used in AxSpA trials. It assesses participants' level of ability during the past week in conducting 10 physical activities on a scale ranging from 0 \\[easy\\] to 10 \\[impossible\\]. The BASFI score is the mean of the 10 item scores and ranges from 0 to 10, with lower scores indicating better physical function. A negative change in BASFI indicates improvement. The higher the negative value the better the improvement."", 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Nocturnal Spinal Pain Score Using Numeric Rating Scale (NRS) at Week 16', 'description': 'Nocturnal spinal pain experienced by participants with axial spondyloarthritis (axSpA) was assessed on a numerical rating scale ranging from 0 (no pain) to 10 (most severe pain). A lower score indicates less pain and a negative change represents an improvement.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Total Score at Week 16', 'description': 'The Ankylosing Spondylitis Quality of Life (ASQoL) is an 18-item PRO measure developed specifically for measuring health-related quality of life (HRQoL) in participants with ankylosing spondylitis and validated in the full spectrum of axial spondyloarthritis (axSpA). Each item is given a score of 1 for positive responses indicating impaired quality of life, and a score of 0 for negative responses. All item scores are summed to generate the total score ranging from 0 to 18 with a higher score indicating worse HRQoL. A negative change represents an improvement.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in the Short Form 36-Item Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 16', 'description': ""SF-36 is a 36-item HRQoL instrument with recall period of 4 weeks. Items are grouped into 8 domains: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items) and 1 item for Health Transition during last year. PCS and Mental Component Summary (MCS) scores are calculated from 8 domains (excluding Health Transition item). Each of SF-36 derived raw scores range from 0 to 100; higher score = better function. PCS score is calculated from 8 domain scores. It is standardized score ranging from 7.3 to 70.1, with a mean of 50 and SD of 10 in general US population, higher values = better function, and positive change reflects improvement. A PCS score mean below 47 indicates impaired physical functioning. Individual respondent's score that falls outside T-score range of 45 to 55 are outside average general US population range."", 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in Bath Ankylosing Spondylitis Disease Metrology Index (BASMI) at Week 16', 'description': ""The BASMI characterizes the spinal mobility of participants with axial Spondyloarthritis (SpA) and Ankylosing Spondylitis. It is a disease-specific measure consisting of 5 clinical measures to reflect participant axial status: cervical rotation; tragus to wall distance; lateral lumbar flexion; lumbar flexion (modified Schober test); intermalleolar distance. According to the linear definition of the BASMI a score of 0 to 10 was calculated for each item based on the measurement. The mean of the 5 scores provides the total BASMI score (ranging from 0 to 10). The higher the BASMI score, the more severe the participant's limitation of movement due to their axial SpA. A negative value in BASMI change from Baseline indicates an improvement from Baseline. The higher the negative value, the better the improvement."", 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Change From Baseline in the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline at Week 16', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. A higher score reflects higher severity and a negative change represents an improvement.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Percentage of Participants With Enthesitis-free State at Week 16 Based on the Maastricht Ankylosing Spondylitis Enthesitis (MASES) Index in the Subgroup of Participants With Enthesitis at Baseline', 'description': 'The Maastricht Ankylosing Spondylitis Enthesitis is an index that measures the severity (ie, intensity and extent) of enthesitis through the assessment of 13 entheses (bilateral costochondral 1, costochondral 7, anterior superior iliac spine, posterior iliac spine, iliac crest and proximal insertion of the Achilles tendon sites, and the fifth lumbar vertebral body spinous process), each scored as 0 or 1 and then summed for a possible score of 0 to 13. Enthesitis free state is defined as having a MASES score of 0. A higher score reflects higher severity and a negative change represents an improvement.', 'timeFrame': 'Baseline, Week 16'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study', 'description': 'TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week Safety follow up (SFU)). TEAEs were analyzed and have been reported separately for Double-Blind Treatment Period (Safety set),Maintenance Period (MP) (Maintenance Set) and Overall Period (Safety set) which includes all participants who received BKZ 160 mg Q4W during the study. The overall period arm reports repeated TEAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, Maintenance Period (MP) included AEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.', 'timeFrame': 'From Baseline (Day 1) until Safety-Follow-Up (up to Week 68) (Week 48 last IMP intake + 20 weeks SFU)'}, {'measure': 'Percentage of Participants With Treatment-emergent Serious Adverse Events (SAEs) During the Study', 'description': 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose resulted in 1) Death, 2) Life-threatening (Life-threatening does not include a reaction that might have caused death had it occurred in a more severe form.), 3) Significant or persistent disability/incapacity, 4) Congenital anomaly/birth defect (including that occurring in a fetus), 5) Important medical event that, based upon appropriate medical judgment, may jeopardize the participant or participant may require medical or surgical intervention to prevent any of the above, 6) Initial inpatient hospitalization or prolongation of hospitalization. The overall period arm reports repeated SAEs from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included SAEs of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.', 'timeFrame': 'From Baseline (Day 1) until Safety Follow-Up (up to Week 68)'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the Study', 'description': 'TEAEs are defined as those AEs that have a start date on or following the first dose of study treatment through the final dose of study treatment + 140 days (covering the 20-week SFU period). The overall period arm reports repeated events from the double blind treatment period arm and maintenance period arm. As pre-specified in SAP, MP included events of Safety follow up period for participants who did not enter the open label extension or discontinued early in MP.', 'timeFrame': 'From Baseline (Day 1) until Safety-Follow-Up (up to Week 68)'}]",17,18 Years,,ALL,False,UCB Biopharma SRL,INDUSTRY,0,274.0,ACTUAL,2025-09-01T16:18:14.664054,v2_robust,True,True,True,False,True,
NCT02206984,Endocrine Response in Women With Invasive Lobular Breast Cancer,A Trial of Endocrine Response in Women With Invasive Lobular Breast Cancer,Tamoxifen,"['Tamoxifen', 'Anastrozole', 'Fulvestrant']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2015-09-30,2024-07-19,"[{'measure': 'Change in Ki67 proliferative index', 'description': 'Ki67 proliferative index is measured as the percent of positively staining cells. As a proliferation marker to measure the growth fraction of cells in human tumors, the expression of Ki67 is strongly associated with cell proliferation and used in routine pathology. pKi67 is well characterized at the molecular level and extensively used as a prognostic and predictive marker in cancer. Index values will be log- transformed (Ki67Day 21/Ki67BL).', 'timeFrame': 'Baseline (prior to treatment) to Day 21-24'}]","[{'measure': 'Estrogen receptor (ER) protein expression', 'description': 'ER protein expression in Invasive lobular carcinoma (ILC) tissues will be measured as the percent of positively staining cells. ER protein is a biomarker of endocrine response to estrogen receptor inhibiting/blocking treatment. ILC tumors can contain high amounts of estrogen receptors.', 'timeFrame': 'Baseline (prior to treatment) to Day 21-24'}, {'measure': 'Estrogen receptor (ER) related gene expression', 'description': 'Invasive lobular carcinoma (ILC)-specific target gene mRNA expression in tissues will be measured will be measured as the percent of positively staining cells.in an effort to identify biomarkers of endocrine response and putative drivers of endocrine resistance. ILC tumors can contain increased amounts of estrogen receptors.', 'timeFrame': 'Baseline (prior to treatment) to Day 21-24'}, {'measure': 'Change in Ki67', 'description': 'Ki67 marker in tissues will be measured as the percent of positively staining cells. Ki67 is strongly associated with cell proliferation and is widely used in routine pathology as a prognostic and predictive marker in cancer. The presence of Ki67 is associated with aggressive disease.', 'timeFrame': 'Baseline (prior to treatment) to Day 21-24'}, {'measure': 'Progesterone receptor (PR) protein expression', 'description': 'Invasive lobular carcinoma (ILC)-specific target gene mRNA expression in tissues will be measured will be measured as the percent of positively staining cells to identify biomarkers of endocrine response and putative drivers of endocrine resistance. ILC tumors can contain increased amounts of progesterone receptors.', 'timeFrame': 'Baseline (prior to treatment) to Day 21-24'}]",5,,,FEMALE,False,Priscilla McAuliffe,OTHER,0,201.0,ACTUAL,2025-09-01T16:18:14.664243,v2_robust,True,True,True,False,False,
NCT03384784,Effect of Galantamine on Inflammation and Cognition,Targeting the Cholinergic Pathway in HIV-associated Inflammation and Cognitive Dysfunction,Galantamine,"['Sugar Pill', 'Razadyne ER', 'Galantamine', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Associated Cognitive Motor Complex,['HIV Associated Cognitive Motor Complex'],"['HIV', 'Neurocognition', 'Inflammation', 'Galantamine', 'Nicotine', 'Tobacco Use']",COMPLETED,,2017-10-30,2022-05-31,"[{'measure': 'Change in Cognition', 'description': 'Cognitive function will be assessed 4 times at Lab Visits. Executive function was measured by the task switch cost from the Color shape task, measured in ms. Executive function was also measured via response time (ms) and accuracy (# correct) on an N-back working memory task. Verbal learning and memory were measured by the Total Recall and Delayed Recall, respectively, from the Hopkins Verbal Learning Test. Response inhibition was measured by the stop signal reaction time (ms) from the Stop Signal Task. A composite score will be created by computed standardized z-scores for each measure (where the mean is 0 and the standard deviation is 1) and then averaging the z-scores. Measures of response time were reverse coded such that higher z-scores indicate better cognitive performance. The primary outcome is the change from baseline cognitive function after 12 weeks of treatment. Change in cognition will be measured during each treatment arm.', 'timeFrame': 'Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)'}, {'measure': 'Change in Inflammation (MCP-1)', 'description': 'Cellular markers of immune activation will be measured in whole blood and soluble markers of immune activation will be measured in plasma at Lab Visits. The primary outcome is the change in monocyte and T cell surface activation and soluble markers after 12 weeks of treatment. Because this is a within-subject crossover study, changes in cellular markers will be measured during each treatment arm.', 'timeFrame': 'Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)'}, {'measure': 'Change in Inflammation (Percentage of CD14+ Monocytes Expressing CD8)', 'description': 'Cellular markers of immune activation will be measured in whole blood and soluble markers of immune activation will be measured in plasma at Lab Visits. The primary outcome is the change in monocyte and T cell surface activation and soluble markers after 12 weeks of treatment. Because this is a within-subject crossover study, changes in cellular markers will be measured during each treatment arm.', 'timeFrame': 'Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)'}, {'measure': 'Change in Inflammation (CD14)', 'description': 'Cellular markers of immune activation will be measured in whole blood and soluble markers of immune activation will be measured in plasma at Lab Visits. The primary outcome is the change in monocyte and T cell surface activation and soluble markers after 12 weeks of treatment. Because this is a within-subject crossover study, changes in cellular markers will be measured during each treatment arm.', 'timeFrame': 'Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)'}, {'measure': 'Change in Inflammation (Percentage of CD14+ Monocytes Expressing CD163)', 'description': 'Cellular markers of immune activation will be measured in whole blood and soluble markers of immune activation will be measured in plasma at Lab Visits. The primary outcome is the change in monocyte and T cell surface activation and soluble markers after 12 weeks of treatment. Because this is a within-subject crossover study, changes in cellular markers will be measured during each treatment arm.', 'timeFrame': 'Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)'}, {'measure': 'Change in Inflammation (Percentage of CD14+ Monocytes Expressing CD16)', 'description': 'Cellular markers of immune activation will be measured in whole blood and soluble markers of immune activation will be measured in plasma at Lab Visits. The primary outcome is the change in monocyte and T cell surface activation and soluble markers after 12 weeks of treatment. Because this is a within-subject crossover study, changes in cellular markers will be measured during each treatment arm.', 'timeFrame': 'Period1 Lab 1 (Week 0), Period 1 Lab 2 (Week 12), Period 2 Lab 1 (Week 16), Period 2 Lab 2 (Week 28)'}]",[],6,30 Years,,ALL,False,University of Pennsylvania,OTHER,1,63.0,ACTUAL,2025-09-01T16:18:14.664271,v2_robust,True,True,True,False,False,
NCT06277284,Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects,"A Randomized, Open, Parallel, Phase I Clinical Trial Comparing the Pharmacokinetics of MG-K10 Humanized Monoclonal Antibody in Healthy Adults",MG-K10 humanized monoclonal antibody injection (prefilled syringe),"['MG-K10 （Penicillin bottle）', 'MG-K10 humanized monoclonal antibody injection (prefilled syringe)', 'MG-K10 humanized monoclonal antibody injection（Penicillin bottle）', 'MG-K10 (prefilled syringe)']",4,INTERVENTIONAL,['NA'],,,Pharmacokinetics,['Pharmacokinetics'],[],ACTIVE_NOT_RECRUITING,,2023-10-23,2024-08,"[{'measure': 'Pharmacokinetic: the maximum concentration (Cmax)', 'description': 'Concentration and exposure', 'timeFrame': '57 days'}, {'measure': 'Pharmacokinetic: area under the curve of o~t', 'description': 'Concentration and exposure', 'timeFrame': '57 days'}, {'measure': 'Pharmacokinetic: area under the curve of o~∞', 'description': 'Concentration and exposure', 'timeFrame': '57 days'}]","[{'measure': 'Safety evaluation index', 'description': 'Any adverse medical events that occur during a clinical study', 'timeFrame': '57 days'}]",4,18 Years,50 Years,ALL,True,Shanghai Mabgeek Biotech.Co.Ltd,OTHER_GOV,1,60.0,ESTIMATED,2025-09-01T16:18:14.664329,v2_robust,True,True,False,False,True,
NCT06591884,Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus,Evaluation of the Efficacy of 0.08% Tacrolimus Nanoencapsulated Aqueous Solution Spray Vs. 0.1% Free Tacrolimus Commercial Ointment in the Treatment of Oral Lichen Planus - a Randomized Clinical Trial,Tacrolimus modified-release,"['tacrolimus ointment 0.1%', 'Tacrolimus modified-release']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Oral Erosive Lichen Planus,['Oral Erosive Lichen Planus'],"['Oral Lichen Planus', 'Tacrolimus']",RECRUITING,,2024-09-03,2028-12,"[{'measure': 'Oral Disease Severity Score (ODSS) - 50%', 'description': 'Number of patients achieving a reduction of at least 50% in ODSS score compared to baseline and the percentage and absolute reduction in ODSS score in both groups at the end of treatment (30 days).\n\nODSS score ranges from 0 to 106, lower score mean a better outcome.', 'timeFrame': '30 days'}, {'measure': 'VAS (visual analogical score) pain score - 50%', 'description': 'number of patients achieving a reduction of at least 50% in VAS score of reported pain compared to baseline and the percentage and absolute reduction in VAS score in both groups at the end of treatment (30 days).\n\nVAS score ranges from 0 to 10, lower score mean a better outcome.', 'timeFrame': '30 days'}]","[{'measure': 'OHIP-14 quality of life score', 'description': 'the percentage and absolute reduction in OHIP-14 scale score in both groups at mid-treatment and end of treatment (15 and 30 days) and at the 30 and 60-day follow-ups after treatment completion (follow-up 1 and follow-up 2).\n\nOHIP-14 score ranges from 0 to 56, lower score mean a better outcome.', 'timeFrame': '15-90 days'}, {'measure': 'Beck scale scores (anxiety levels)', 'description': 'The percentage and absolute reduction in Beck scale score in both groups at mid-treatment and end of treatment (15 and 30 days) and at the 30 and 60-day follow-ups after treatment completion (follow-up 1 and follow-up 2).\n\nOHIP-14 score ranges from 0 to 63, lower score mean a better outcome.', 'timeFrame': '15-90 days'}, {'measure': 'hedonic scale satisfaction scores', 'description': 'Comparison of hedonic scale scores of satisfaction reported by the participants in regards of treatment received in both groups at the end of treatment (30 days) and at the 30 and 60-day follow-ups after treatment completion (follow-up 1 and follow-up 2).\n\nHedonic scale satisfaction score ranges from 0 to 9, higher score mean a better outcome.', 'timeFrame': '30-90 days'}]",5,18 Years,,ALL,False,Hospital de Clinicas de Porto Alegre,OTHER,0,46.0,ESTIMATED,2025-09-01T16:18:14.664652,v2_robust,True,True,False,False,False,
NCT01257984,Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function,"A Multicenter, Open-label, Randomized, Controlled, Two-arm Study to Assess Compliance With Daily Tablet Intake of Women on Treatment With the Oral Contraceptive SH T00186D/BAY 86-5300 (0.02 mg Ethinyl Estradiol as Betadex Clathrate and 3 mg Drospirenone) in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function Over 12 Months",BAY86-5300,['BAY86-5300'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Contraception,['Contraception'],[],COMPLETED,,2010-12,2012-09,"[{'measure': 'Mean daily delay of tablet release, i.e. the time of tablet-release which will be compared to the reference tablet release time', 'timeFrame': '12 months'}]","[{'measure': 'Number of delayed and missed pills', 'timeFrame': '12 months'}, {'measure': 'Bleeding pattern and cycle control parameters', 'timeFrame': '12 months'}, {'measure': 'Length of the tablet break and the length of the bleeding episode preceding the tablet break', 'timeFrame': '12 months'}]",4,18 Years,35 Years,FEMALE,True,Bayer,INDUSTRY,0,508.0,ACTUAL,2025-09-01T16:18:14.664682,v2_robust,True,True,True,False,False,
NCT05148884,"Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in L-dopa-induced Dyskinesia","A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Preliminary Efficacy of NLX-112 Versus Placebo in Levodopa-induced Dyskinesia in Parkinson's Disease",NLX-112,"['(2E)-2-butenedioate', 'NLX-112', 'befiradol', 'Placebo', '4-piperidinemethanamine', 'F13640', '1-(3-chloro-4-fluorobenzoyl)-4-fluoro-N-[(5-methyl-2-pyridinyl)-methyl]']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Medication-Induced Dyskinesia,['Medication-Induced Dyskinesia'],"['Levodopa', 'Dyskinesia', 'Parkinson´s disease', 'L-dopa', 'NLX-112', 'Befiradol', 'LID']",COMPLETED,,2021-11-09,2023-01-18,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'Number of patients with Adverse events (AEs) divided into categories of severity/intensity (grade 1 to grade 5 following the common terminology criteria for AEs (CTCAE) v5.0) and assessed relationship to IMP (unlikely, possibly or probably related). AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit.', 'timeFrame': 'AEs (including SAEs) were collected from the start of IMP administration until the end-of-study visit. Through study completion, an average of 10 weeks.'}, {'measure': 'Number of Participants With Any Clinically Significant Changes From Baseline in Electrocardiogram (ECG)', 'description': 'Number of patients with clinically significant changes from baseline in Electrocardiogram (Rate, PR interval, QRS duration, QT, QTcB, and QTcF). Any abnormalities were specified and documented as either clinically significant or not clinically significant.', 'timeFrame': 'Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).'}, {'measure': 'Number of Patients With Any Clinically Significant Changes From Baseline in Vital Signs', 'description': 'Number of patients with clinically significant changes from baseline in vital signs (Systolic blood pressure (mmHg), diastolic blood pressure (mmHg), Heart rate, respiratory rate, body temperature). Any vital signs outside the normal ranges at each site were judged as either not clinically significant or clinically significant by the clinician.', 'timeFrame': 'Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).'}, {'measure': 'Number of Patients With Any Clinically Significant Changes From Baseline in Safety Laboratory Parameters', 'description': 'Number of patients with clinically significant changes from baseline in safety laboratory parameters. Any lab values outside the normal ranges at each site were judged as not clinically significant or clinically significant.', 'timeFrame': 'Visit 1 (Screening), Visit 2 (Baseline, Day 1), Visit 4 (Clinic Safety Visit, Day 14), Visit 5 (Clinic Safety Visit, Day 21), Visit 6 (Clinic Efficacy Visit, Day 28), Visit 7 (Clinic Efficacy Visit, Day 42) and Visit 9 (Follow-up Clinic Visit, Day 70).'}, {'measure': 'Number of Patients With Clinically Significant Abnormalities in Physical Examinations', 'description': 'Number of patients with clinically significant abnormalities in physical examination investigated by general appearance, head, ears, eyes, nose, throat, neck, skin, cardiovascular system, respiratory system, abdominal system, and nervous system. Any abnormalities were specified and documented as either clinically significant or not clinically significant.', 'timeFrame': 'Visit 1 (Screening) and Visit 9 (Follow-up Clinic Visit, Day 70).'}, {'measure': 'Number of Patients With Suicidal Ideation/Behavior as Assessed by the Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'Number of patients with change from baseline in suicidal ideation/behavior as assessed by C-SSRS questionnaire with no total score summation. The scale contains 6 ""yes"" or ""no"" questions in which respondents were asked to indicate whether they have experienced several thoughts or feelings relating to suicide over the past 3 months and behavior over their lifetime using a baseline scale at visit 1 and any cahnges since last visit using a follow-up scale at subsequent visits. Each question addresses a different component of the respondent\'s suicide ideation severity and behavior. Q1: wish to be dead, Q2: non-specific suicidal thoughts, Q3-5: more specific suicidal thoughts and intent to act, Q6: suicidal behavior over the respondent\'s lifetime and past 3 months or since last visit for visits after the visit 1.', 'timeFrame': 'The baseline scale was used at screening (Visit 1) and the follow-up scale at all subsequent visits (Visit 2, 4-7, 9)'}]","[{'measure': 'Change From Baseline at the Final Efficacy Clinic Visit (Day 42), After a 150% L-dopa Dose Challenge, in the Unified Dyskinesia Rating Scale (UDysRS) Total Score - Change From Baseline', 'description': ""The Unified Dyskinesia Rating Scale (UDysRS) is a rating instrument designed to assess the core features of dyskinesia in Parkinson´s Disease. The UDysRS consists of 4 parts:\n\n* Part 1, historical disability with regard to the patient's perceptions of the impact on activities of daily living (ADL) of on-dyskinesia (11 items).\n* Part 2, historical disability with regard to the patient's perceptions of the impact on ADL of off-dystonia (4 items).\n* Part 3, objective impairment, which assesses severity of dyskinesia, affected body parts, and type of impairment (choreic vs. dystonic) (7items).\n* Part 4, objective disability, based on an evaluation of Part 3 activities (4 items).\n\nEach item in the UDysRS was scored from 0 to 4, with a possible maximum total score sum of 104 where a higher score indicates a worse outcome.\n\nThe UDysRS Parts 3 and 4 were repeated 3 times after each L-dopa challenge, and the timepoint with the worst outcome was used to calculate total score sum"", 'timeFrame': 'At baseline (Day 1, Visit 2), and Day 42 (Visits 7)'}, {'measure': 'Change From Baseline in UDysRS Total Score at Day 28, After a 150% L-DOPA Dose Challenge - Change From Baseline', 'description': ""The Unified Dyskinesia Rating Scale (UDysRS) is a rating instrument designed to assess the core features of dyskinesia in Parkinson´s Disease. The UDysRS consists of 4 parts:\n\n* Part 1, historical disability with regard to the patient's perceptions of the impact on activities of daily living (ADL) of on-dyskinesia (11 items).\n* Part 2, historical disability with regard to the patient's perceptions of the impact on ADL of off-dystonia (4 items).\n* Part 3, objective impairment, which assesses severity of dyskinesia, affected body parts, and type of impairment (choreic vs. dystonic) (7items).\n* Part 4, objective disability, based on an evaluation of Part 3 activities (4 items).\n\nEach item in the UDysRS was scored from 0 to 4, with a possible maximum total score sum of 104 where a higher score indicates a worse outcome.\n\nThe UDysRS Parts 3 and 4 were repeated 3 times after each L-dopa challenge, and the timepoint with the worst outcome was used to calculate total score sum"", 'timeFrame': 'At baseline (Day 1, Visit 2) and Day 28 (Visits 6)'}, {'measure': 'Change From Baseline in Total Objective Score (Parts 3, 4) of the UDysRS at Day 28 and Day 42, After a 150% L-DOPA Dose Challenge - Change From Baseline', 'description': ""The Unified Dyskinesia Rating Scale (UDysRS) is a rating instrument designed to assess the core features of dyskinesia in Parkinson´s Disease. The UDysRS consists of 4 parts:\n\n* Part 1, historical disability with regard to the patient's perceptions of the impact on activities of daily living (ADL) of on-dyskinesia (11 items).\n* Part 2, historical disability with regard to the patient's perceptions of the impact on ADL of off-dystonia (4 items).\n* Part 3, objective impairment, which assesses severity of dyskinesia, affected body parts, and type of impairment (choreic vs. dystonic) (7items).\n* Part 4, objective disability, based on an evaluation of Part 3 activities (4 items).\n\nEach item in the UDysRS was scored from 0 to 4, with a possible total score sum for parts 3 and 4 of 44, where a higher score indicates a worse outcome.\n\nThe UDysRS Parts 3 and 4 were repeated 3 times after each levodopa challenge, and the timepoint with the worst outcome was used to calculate total score sum."", 'timeFrame': 'At baseline (Day 1, Visit 2), Day 28 and Day 42 (Visits 6 and 7)'}, {'measure': 'Change From Baseline in ON Time Without Troublesome Dyskinesia (ON Without Dyskinesia Plus ON With Non-troublesome Dyskinesia) Based on a PD Home Dyskinesia Diary - Change From Baseline', 'description': 'A PD Home Dyskinesia Diary (electronic) as completed by the patient and/or caregiver with concordance in ON time with dyskinesia between study staff and patient. The diary was integrated in the Kinesia 360 wearable dyskinesia assessment system and was based on the PD Home Diary developed by Hauser et al 2004. The diary was used to score 5 different conditions in 30-minute time intervals during 2x24 hours prior to Visit 2 (Baseline), Visit 6 (Titration) and Visit 7 (Steady state):\n\n* ASLEEP;\n* OFF;\n* ON (i.e., adequate control of PD symptoms) without dyskinesia;\n* ON with non-troublesome dyskinesia;\n* ON with troublesome dyskinesia.\n\nPresented as the ratio of ON Time without troublesome dyskinesia (the sum of the time in ON without dyskinesia together with the time in ON with non-troublesome dyskinesia) compared with the total awake time (ON and OFF).', 'timeFrame': 'Baseline - prior to Day 1 (Visit 2), Titration - prior to Day 28 (Visit 6), and Steady state prior to Day 42 (Visit 7).'}, {'measure': ""Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Scores (Part III, Motor Examination) - Change From Baseline"", 'description': 'The UPDRS is one of the most widely-used rating scales employed in the assessment of PD. The UPDRS consists of 4 parts:\n\n* Part I assesses non-motor experiences of daily living, such as cognitive impairment and depressed mood (4 items).\n* Part II assesses motor experiences of daily living, such as speech and eating tasks (13 items).\n* Part III is a motor examination conducted by the clinician, including assessments of symptoms such as rigidity and tremor (27 items).\n* Part IV is an assessment of motor complications, such as time spent with dyskinesia and functional impact of dyskinesias (11 items).\n\nEach item in the UPDRS was scored from 0 to 4 (7 items in Part IV was scored 0 to 1), and the individual scores were summed to give a total score that indicates the severity of the disease, with a score of 0 indicating no disability and a score of 199 being the most severe (indicating total disability). Total score sum for Part III alone is 108.', 'timeFrame': 'At baseline (Day 1, Visit 2), Day 28 (Visit 6), Day 42 (Visit 7) and Day 70 (Visit 9).'}, {'measure': 'Change From Baseline in UPDRS Combined Scores (Parts I, II, III and IV) - Change From Baseline', 'description': 'The UPDRS is one of the most widely-used rating scales employed in the assessment of PD. The UPDRS consists of 4 parts:\n\nPart I assesses non-motor experiences of daily living, such as cognitive impairment and depressed mood (4 items).\n\nPart II assesses motor experiences of daily living, such as speech and eating tasks (13 items).\n\nPart III is a motor examination conducted by the clinician, including assessments of symptoms such as rigidity and tremor (27 items).\n\nPart IV is an assessment of motor complications, such as time spent with dyskinesia and functional impact of dyskinesias (11 items).\n\nEach item in the UPDRS was scored from 0 to 4 (7 items in Part IV was scored 0 to 1), and the individual scores were summed to give a total score that indicates the severity of the disease, with a score of 0 indicating no disability and a score of 199 being the most severe (indicating total disability).', 'timeFrame': 'At baseline (Day 1, Visit 2), Day 28 (Visit 6), Day 42 (Visit 7) and Day 70 (Visit 9).'}, {'measure': 'Number of Patients in Each Category of Clinical Global Impression of Change (CGI-C) in Overall PD Symptoms', 'description': ""The CGI-C is a clinician-oriented scale that assesses the total improvement in the patient's condition relative to the clinical global impression of severity (CGI-S) scale conducted at baseline.\n\n1 - Normal not ill, 2 - Borderline ill, 3 - Mildly ill, 4 - Moderately ill, 5 - Markedly ill, 6- Severely ill, 7 - Among the most extremely ill patients The CGI-C rates the patient's condition from 1 to 7: 1 - Very much improved, 2 - Much improved, 3 - Minimally improved, 4 - No change, 5 - Minimally worse, 6 - Much worse, 7 - Very much worse"", 'timeFrame': 'Clinician rated the patient´s global condition using CGI-S at baseline (Day 1, Visit 2) and CGI-C at Day 28 (Visit 6) and Day 42 (Visit 7).'}, {'measure': 'Change From Baseline in Dyskinesia Scores Measured by the Kinesia 360 (Great Lakes Neurotechnologies, Inc) Wearable Dyskinesia Assessment System - Absolute Change From Baseline', 'description': 'The Kinesia 360 (Great Lakes Neurotechnologies, Inc) wearable dyskinesia assessment system was used to monitor dyskinesias. Sensors worn on the wrist and ankle combined with a mobile application continuously record data for assessment dyskinesia. Algorithms were used to detect symptoms from the motion sensors data and calculate a severity score (0 to 1 where score 0 corresponds to no dyskinesia and score 1 corresponds to dyskinesia) every 2 minutes. Wearable data collection of dyskinesia took place during a 2-day period prior to Visit 2 (Baseline), Visit 6 (Titration) and Visit 7 (Steady state). Outcome is presented as the mean ratio at baseline and absolute ratio change from baseline.', 'timeFrame': 'Baseline - prior to Day 1 (Visit 2), Titration - prior to Day 28 (Visit 6), and Steady state prior to Day 42 (Visit 7).'}]",14,30 Years,85 Years,ALL,False,Neurolixis SAS,INDUSTRY,3,27.0,ACTUAL,2025-09-01T16:18:14.664796,v2_robust,True,True,True,False,True,
NCT06558084,Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy,Real-World Clinical Outcomes and Toxicity in Metastatic Breast Cancer Patients Treated With First or Second Line CDK 4/6 Inhibitors and Endocrine Therapy,CDK4/6 Inhibitor,['CDK4/6 Inhibitor'],1,OBSERVATIONAL,[],,,"Toxicity, Drug","['Toxicity, Drug', 'Progression, Disease']","['Breast cancer', 'CDK4/6 inhibitor', 'toxicity', 'PFS']",COMPLETED,,2022-07-06,2024-08-10,"[{'measure': 'Adverse effect', 'description': 'assess the toxicity profile', 'timeFrame': '2 years'}]","[{'measure': 'PFS', 'description': 'PFS in patient receiving CDK4/6i in Egypt', 'timeFrame': '2 years'}]",2,18 Years,,FEMALE,False,Ain Shams University,OTHER,0,64.0,ACTUAL,2025-09-01T16:18:14.664821,v2_robust,False,True,True,False,True,
NCT06161584,"A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration","A Prospective, Multicenter, Open-Label, Observational Phase 4 Study to Evaluate Real-World Safety, Tolerability, and Treatment Patterns of Pegcetacoplan (Syfovre) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration",Pegcetacoplan,"['Pegcetacoplan', 'Syfovre']",2,OBSERVATIONAL,[],,,Geographic Atrophy,['Geographic Atrophy'],[],RECRUITING,,2023-09-28,2028-06,"[{'measure': 'Incidence of ocular AEs in treated eyes overall and according to physician-directed treatment interval based on US prescribing information', 'timeFrame': 'Up to 36 months'}, {'measure': 'Incidence of other events of interest', 'timeFrame': 'Up to 36 months'}]","[{'measure': 'Assess real-world treatment patterns and use of pegcetacoplan considering the proportion of participants with bilateral GA treated with pegcetacoplan in both eyes', 'timeFrame': 'Up to 36 months'}, {'measure': 'If only one eye is treated, the criteria for determination of the eye to be treated', 'timeFrame': 'Up to 36 months'}, {'measure': 'The treatment interval (mean days between injections) over time', 'timeFrame': 'Up to 36 months'}, {'measure': 'The frequency of imaging on treated eyes (color fundus photography, spectral domain optical coherence tomography [SD-OCT], fundus autofluorescence, optical coherence tomography angiography [OCT-A', 'timeFrame': 'Up to 36 months'}, {'measure': 'The treatment adherence to planned dosing frequency: the number of injections administered divided by the number of injections planned', 'timeFrame': 'Up to 36 months'}, {'measure': 'The duration of persistence on treatment: continuous medication usage until a gap of ≥3 months', 'timeFrame': 'Up to 36 months'}, {'measure': 'The treatment discontinuation and/or switching to other agents approved for treatment of GA', 'timeFrame': 'Up to 36 months'}, {'measure': 'The management of new-onset exudative age-related macular degeneration (eAMD) events in eyes treated with pegcetacoplan in clinical practice', 'timeFrame': 'Up to 36 months'}, {'measure': 'The proportion of treated eyes that develop eAMD that receive anti-vascular endothelial growth factor (VEGF) injections', 'timeFrame': 'Up to 36 months'}, {'measure': 'The number of anti-VEGF injections per month from diagnosis of eAMD', 'timeFrame': 'Up to 36 months'}, {'measure': 'The proportion of anti-VEGF injections given on same day in the same eye as pegcetacoplan', 'timeFrame': 'Up to 36 months'}]",13,60 Years,,ALL,False,"Apellis Pharmaceuticals, Inc.",INDUSTRY,0,300.0,ESTIMATED,2025-09-01T16:18:14.664857,v2_robust,False,True,False,False,False,
NCT06808984,"Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease","A Phase 2, Randomized, Double-blind, Three-Arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of Orally Administered BMS-986368, a FAAH/MAGL Inhibitor, for the Treatment of Agitation in Participants With Alzheimer's Disease (BALANCE-AAD-1)",BMS-986368,"['BMS-986368', 'CC-97489', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Agitation,"['Agitation', 'Alzheimer Disease']",[],RECRUITING,,2025-06-09,2027-09-08,"[{'measure': 'Change in Cohen-Mansfield Agitation Inventory (CMAI) total score from baseline', 'description': 'The CMAI is a scale administered by qualified rater based on caregiver\'s input on 29 items that assess the frequency of manifestations of agitated behaviors in older adults. Each item is rated on a 7-point scale: 1 = ""never"", 2 = ""less than once a week"", 3 = ""once or twice a week"", 4 = ""several times a week"", 5 = ""once or twice a day"", 6 = ""several times a day"" and 7 = ""several times per hour."" Ratings pertain to the period of time over the previous 2 weeks preceding administration of the CMAI. CMAI total scores range from 29 to 203.', 'timeFrame': 'Up to Week 8'}]","[{'measure': 'Change in Clinical Global Impression-Severity (CGI-S)', 'timeFrame': 'Up to Week 8'}, {'measure': 'Change in CMAI-International Psychogeriatric Association (CMAI-IPA) Total Score', 'timeFrame': 'Up to Week 8'}, {'measure': 'CMAI sub-score change in Aggressive Behaviors', 'timeFrame': 'Up to Week 8'}, {'measure': 'CMAI sub-score change in Physically Non-aggressive Behaviors', 'timeFrame': 'Up to Week 8'}, {'measure': 'CMAI sub-score change in Verbally Agitated Behaviors', 'timeFrame': 'Up to Week 8'}, {'measure': 'Change in Neuropsychiatric Inventory Nursing Home Version (NPI-NH) Total Score', 'timeFrame': 'Up to Week 8'}, {'measure': 'Change in NPI-NH Agitation/Aggression Domain Score', 'timeFrame': 'Up to Week 8'}, {'measure': 'Change in NPI-NH Occupational Disruptiveness for Agitation/aggression Domain', 'timeFrame': 'Up to Week 8'}, {'measure': 'Number of Participants with Treatment-Emergent Adverse Events (TEAEs)', 'timeFrame': 'Up to Day 28 After Last Dose'}, {'measure': 'Number of Participants with Serious Adverse Events (SAEs)', 'timeFrame': 'Up to Day 28 After Last Dose'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'timeFrame': 'Up to Day 28 After Last Dose'}, {'measure': 'Number of Participants with Clinically Significant Laboratory Abnormalities', 'timeFrame': 'Up to 28 Days After Last Dose'}, {'measure': 'Change in Suicidal Ideation Assessed by Sheehan-Suicidality Tracking Scale (S-STS)', 'timeFrame': 'Up to Day 28 After Last Dose'}, {'measure': 'Change in Behaviour Assessed by Sheehan-Suicidality Tracking Scale (S-STS)', 'timeFrame': 'Up to Day 28 After Last Dose'}, {'measure': 'Abuse Potential Assessed by the Cannabis Withdrawal Scale (CWS)', 'timeFrame': 'Up to Day 21 After Last Dose'}, {'measure': 'Withdrawal Symptoms Assessed by the Cannabis Withdrawal Scale (CWS)', 'timeFrame': 'Up to Day 21 After Last Dose'}, {'measure': 'Plasma Concentrations of BMS-986368', 'timeFrame': 'Up to Week 14'}]",18,55 Years,90 Years,ALL,False,Celgene,INDUSTRY,0,120.0,ESTIMATED,2025-09-01T16:18:14.664925,v2_robust,True,True,False,False,True,
NCT00001384,"A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients","A Pilot Trial of AC (Adriamycin, Cyclophosphamide) Chemotherapy With G-CSF (Granulocyte Colony-Stimulating Factor) Followed by Infusional Taxol (Paclitaxel) as Adjuvant Treatment for High Risk Stage II and Stage III Breast Cancer Patients",Adriamycin,"['Adriamycin', 'paclitaxel', 'cyclophosphamide', 'G-CSF']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'Breast Neoplasms']","['14-Day Cycle', 'Dose Intensity', 'Filgrastim', 'Lymph Node Positive', 'Non-Cross Resistant']",COMPLETED,,1994-05,2001-02,[],[],0,,,ALL,False,National Cancer Institute (NCI),NIH,0,35.0,,2025-09-01T16:18:14.665073,v2_robust,True,True,True,False,False,
NCT00482833,Phase III Trial in Acute Promyelocytic Leukemia Patients,"A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia",arsenic trioxide,"['all-trans retinoic acid (ATRA)', 'arsenic trioxide', 'idarubicin', 'methotrexate', 'mercaptopurine', 'all-trans retinoic acid']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Leukemia,['Leukemia'],"['adult acute promyelocytic leukemia (M3)', 'adult acute myeloid leukemia with t(15;17)(q22;q12)', 'untreated adult acute myeloid leukemia']",COMPLETED,,2007-08,2019-10-17,"[{'measure': 'Event-free survival', 'description': 'As of 14th september 2010, all patients needed to evaluate the primary endpoint have been recruited.', 'timeFrame': 'At maximum 3.5 years from study entry'}]","[{'measure': 'Rate of hematological complete remission', 'timeFrame': 'At maximum 60 days from induction therapy start'}, {'measure': 'Overall survival rate', 'timeFrame': 'At 2 years from study entry'}, {'measure': 'Rate of cumulative incidence of relapse', 'timeFrame': 'At 2 years from study entry'}, {'measure': 'Incidence of hematological and non-hematological toxicity episodes during treatment as assessed by CTC-NCI', 'timeFrame': 'At maximum 60 days from induction therapy start and at maximum 225 days from consolidation therapy start'}, {'measure': 'Rate of molecular remission after 3rd consolidation course', 'timeFrame': 'At maximum 225 days grom consolidation therapy start'}, {'measure': 'Assessment of acute promyelocytic leukemia/RARa transcript level reduction after induction and during consolidation therapy', 'timeFrame': 'At maximum 60 days from induction therapy start and at maximum 225 days from consolidation therapy start'}, {'measure': 'Quality of life at the end of induction therapy and at the end of the 3rd consolidation course', 'timeFrame': 'At maximum 60 days from induction therapy start and at maximum 225 days from consolidation therapy start'}, {'measure': 'Event free survival', 'timeFrame': 'At 2 years from study entry'}, {'measure': 'Total hospitalization days during study therapy', 'timeFrame': 'At maximum 3.5 years from study entry'}, {'measure': 'Event-free survival rate in the two arms', 'timeFrame': 'At 2 years from study entry'}]",11,18 Years,70 Years,ALL,False,Gruppo Italiano Malattie EMatologiche dell'Adulto,OTHER,1,276.0,ACTUAL,2025-09-01T16:18:14.665082,v2_robust,True,True,True,False,False,
NCT00907933,Intranasal SB-705498 in Healthy Volunteers,"A Randomized, Double-blind, Placebo-controlled Study in Healthy Volunteers to Examine the Safety, Tolerability and Pharmacokinetics of a) Single, Ascending and b) Twice-daily Repeat Doses of Intranasal SB-705498",SB-705498,"['Placebo', 'SB-705498']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Rhinitis,['Rhinitis'],[],COMPLETED,,2008-11-10,2009-02-11,"[{'measure': 'Safety and tolerability (Electrocardiogram, vital signs, lab tests, AEs and nasal tolerability', 'timeFrame': 'Various'}]","[{'measure': 'Part 1: Single dose derived pharmacokinetics (Cmax, tmax, AUC(0-4) and AUC(o-infinity); Part 2: Repeat dose derived pharmacokinetics (Cmax, tmax, AUC(0-4) and AUC(o-infinity)', 'timeFrame': 'Part 1: Various timepoints through the day; Part 2: Various timepoints over 14 days'}]",2,18 Years,60 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,44.0,ACTUAL,2025-09-01T16:18:14.665170,v2_robust,True,True,True,False,True,
NCT01638533,"Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction","A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients With, Lymphomas, Chronic Lymphocytic Leukemia, and Select Solid Tumors and Varying Degrees of Liver Dysfunction",Romidepsin,"['N-[(3S,4E)-3-Hydroxy-7-mercapto-1-oxo-4-heptenyl]-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoyl-L-valine, (4->1) Lactone, Cyclic', 'FK-228', 'FR-901228', 'FR901228', 'Antibiotic FR 901228', 'FR 901228', 'Depsipeptide', 'Romidepsin', 'FK228', 'Istodax', 'FK 228']",11,INTERVENTIONAL,['PHASE1'],PHASE1,,Glioma,"['Glioma', 'Hematopoietic and Lymphoid Cell Neoplasm', 'Lymphoma', 'Metastatic Malignant Solid Neoplasm', 'Neuroendocrine Neoplasm', 'Recurrent Adult Soft Tissue Sarcoma', 'Recurrent Bladder Carcinoma', 'Recurrent Breast Carcinoma', 'Recurrent Chronic Lymphocytic Leukemia', 'Recurrent Colorectal Carcinoma', 'Recurrent Head and Neck Carcinoma', 'Recurrent Lung Carcinoma', 'Recurrent Malignant Solid Neoplasm', 'Recurrent Melanoma', 'Recurrent Pancreatic Carcinoma', 'Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Recurrent Prostate Carcinoma', 'Recurrent Renal Cell Carcinoma', 'Recurrent Thyroid Gland Carcinoma', 'Refractory Chronic Lymphocytic Leukemia', 'Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma', 'Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma', 'Stage III Breast Cancer AJCC v7', 'Stage III Colorectal Cancer AJCC v7', 'Stage III Cutaneous Melanoma AJCC v7', 'Stage III Lung Cancer AJCC v7', 'Stage III Pancreatic Cancer AJCC v6 and v7', 'Stage III Prostate Cancer AJCC v7', 'Stage III Renal Cell Cancer AJCC v7', 'Stage III Soft Tissue Sarcoma AJCC v7', 'Stage IIIA Breast Cancer AJCC v7', 'Stage IIIA Colorectal Cancer AJCC v7', 'Stage IIIA Cutaneous Melanoma AJCC v7', 'Stage IIIB Breast Cancer AJCC v7', 'Stage IIIB Colorectal Cancer AJCC v7', 'Stage IIIB Cutaneous Melanoma AJCC v7', 'Stage IIIC Breast Cancer AJCC v7', 'Stage IIIC Colorectal Cancer AJCC v7', 'Stage IIIC Cutaneous Melanoma AJCC v7', 'Stage IV Breast Cancer AJCC v6 and v7', 'Stage IV Colorectal Cancer AJCC v7', 'Stage IV Cutaneous Melanoma AJCC v6 and v7', 'Stage IV Lung Cancer AJCC v7', 'Stage IV Pancreatic Cancer AJCC v6 and v7', 'Stage IV Prostate Cancer AJCC v7', 'Stage IV Renal Cell Cancer AJCC v7', 'Stage IV Soft Tissue Sarcoma AJCC v7', 'Stage IVA Colorectal Cancer AJCC v7', 'Stage IVB Colorectal Cancer AJCC v7', 'Unresectable Solid Neoplasm']",[],COMPLETED,,2012-08-03,2020-09-01,"[{'measure': 'Maximum tolerated dose of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0', 'description': 'Analyses will be descriptive in nature. The observed toxicities will be characterized by dose level within each category of liver dysfunction (mild, moderate, severe, and liver transplant). These results will be summarized in relation to what is known about romidepsin in a population without liver dysfunction (as defined in this protocol).', 'timeFrame': '28 days'}, {'measure': 'Dose-limiting toxicity of romidepsin in groups of patients with varying degree of hepatic dysfunction according to the National Cancer Institute Common Toxicity Criteria for Adverse Events version 5.0', 'description': 'In order to define levels of hepatic impairment at which dose modifications of romidepsin are required, data will be combined across hepatic dysfunction groups to evaluate the association between toxicity, dose, and liver assay level(s). The outcome variable, drug tolerance and dose-limiting toxicities will be modeled as function of dose and liver assay using multivariate linear regression. Higher order terms of the predictor variables and interactions will be included if there is evidence of non-linear and/or non-additive associations.', 'timeFrame': '28 days'}, {'measure': 'Pharmacokinetic (PK) profile of romidepsin in patients with varying degrees of hepatic dysfunction using liquid chromatography-electrospray ionization tandem mass spectrometric method', 'description': 'Pharmacokinetic variables will be tabulated and descriptive statistics calculated for each function group. Geometric means and coefficients of variation will be presented for maximum concentration and area under the curve for each group.', 'timeFrame': '0, 1, 2, 3, 4, 4.25, 4.5, 5, 6, 8, 10, 24, and 48 hours after initiation of the infusion on day 1'}]","[{'measure': 'Child-Pugh classification of hepatic dysfunction', 'description': 'Correlations of the Child-Pugh classification of hepatic dysfunction with the observed toxicities and plasma PK of romidepsin administration will be explored.', 'timeFrame': 'Baseline'}, {'measure': 'Antitumor activity assessed using Response Evaluation Criteria in Solid Tumors and the International Workshop Lymphoma Response Criteria', 'description': 'Association of antitumor activity and romidepsin treatment will be documented.', 'timeFrame': 'Up to 30 days'}]",5,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,1,37.0,ACTUAL,2025-09-01T16:18:14.665219,v2_robust,True,True,True,False,True,
NCT02294552,Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT,High-dose Post-transplantation Cyclophosphamide as Graft Versus-host Disease Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation,Cyclophosphamide,"['Mycophenolate mofetil', 'Busulfan', 'Fludarabine monophosphate', 'Cyclophosphamide', 'Tacrolimus']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myeloid Leukemia,"['Acute Myeloid Leukemia', 'Acute Lymphoid Leukemia', 'Lymphoma', 'Myelodysplastic Syndromes', 'Chronic Lymphocytic Leukemia', 'Immune System Diseases']","['Cyclophosphamide', 'Leukemia', 'Lymphoma', 'Myelodysplastic Syndromes', 'Chronic Lymphocytic Leukemia', 'Immunosuppressive Agents', 'Immune System Diseases', 'Busulfan', 'Fludarabine', 'Tacrolimus', 'Mycophenolate mofetil', 'Antineoplastic Agents, Alkylating', 'Myeloablative Agonists', 'Hematopoietic Stem Cell Transplantation', 'Allogeneic']",COMPLETED,,2014-10,2017-11,"[{'measure': 'Incidence of acute and chronic GVHD, requiring treatment', 'timeFrame': '365 days'}]","[{'measure': 'Incidence of primary graft failure', 'timeFrame': '60 days'}, {'measure': 'Non-relapse mortality analysis', 'timeFrame': '365 days'}, {'measure': 'Overall survival analysis', 'timeFrame': '365 days'}, {'measure': 'Event-free survival analysis', 'timeFrame': '365 days'}, {'measure': 'Relapse rate analysis', 'timeFrame': '365 days'}, {'measure': 'Toxicity based NCI CTC grades', 'timeFrame': '100 days'}, {'measure': 'Infectious complications, including analysis of severe bacterial, fungal and viral infections incidence', 'timeFrame': '100 days'}]",8,18 Years,65 Years,ALL,False,Ivan S Moiseev,OTHER,0,200.0,ACTUAL,2025-09-01T16:18:14.665304,v2_robust,True,True,True,False,False,
NCT03269552,Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone Lymphoma,A Response-Adapted Clinical Trial of Weekly Carfilzomib With or Without Rituximab for Waldenström's Macroglobulinemia and Marginal Zone Lymphoma,Carfilzomib,"['PR-171', 'Kyprolis', 'Carfilzomib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Marginal Zone Lymphoma,"['Marginal Zone Lymphoma', 'Recurrent Marginal Zone Lymphoma', 'Recurrent Waldenstrom Macroglobulinemia', 'Refractory Marginal Zone Lymphoma', 'Refractory Waldenstrom Macroglobulinemia', 'Waldenstrom Macroglobulinemia']",[],TERMINATED,Terminated due to low accrual.,2017-12-18,2018-12-28,"[{'measure': 'Overall Response Rate', 'description': 'Descriptive statistics will be used for baseline characteristics, and responses to treatment.', 'timeFrame': 'Up to 1 year'}]","[{'measure': 'Overall Survival', 'description': 'Estimated using Kaplan-Meier analysis.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Time to Best Response', 'description': 'Estimated using Kaplan-Meier analysis.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Time to Progression', 'description': 'Estimated using Kaplan-Meier analysis.', 'timeFrame': 'Up to 1 year'}]",4,18 Years,,ALL,False,University of Washington,OTHER,1,4.0,ACTUAL,2025-09-01T16:18:14.665321,v2_robust,True,True,False,True,False,Terminated due to low accrual.
NCT01706952,Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery,Comparison of Topical Vasoconstriction in Endoscopic Sinus Surgery: Cocaine Versus Adrenaline,Cocaine,"['Special feature: Latex Free Stopper', 'Code: 1200', 'Cocaine', 'Adrenaline', 'Generic Name: Cocaine Hydrochloride Sterile Topical Solution', 'UPC: 057513012006', 'Preservative: Yes', 'Brand Name: Cocaine Hydrochloride Sterile Topical Solution', 'Format: 5 x 5 mL', 'DIN: 01962388', 'Active Ingredients: Cocaine hydrochloride', 'Concentration: 4%', 'Epinephrine']",13,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Sinusitis,['Chronic Sinusitis'],"['Endoscopic sinus surgery', 'Bleeding', 'Topical Vasocontriction', 'Cocaine', 'Adrenaline']",COMPLETED,,2012-12,2013-12,"[{'measure': 'To Estimate the Change in Bleeding Category (Surgical Field Improvement) as Measured on a Six-point Scale, Measured From 0 (Best Case) to 5 (Worst Case).', 'description': '0 No bleeding.\n\n1. Slight bleeding - no suctioning of blood required.\n2. Slight bleeding - occasional suctioning required. Surgical field not threatened.\n3. Slight bleeding - frequent suctioning required. Bleeding threatens surgical field a few seconds after suction is removed.\n4. Moderate bleeding - frequent suctioning required. Bleeding threatens surgical field directly after suction is removed.\n5. Severe bleeding - constant suctioning required. Bleeding appears faster than can be removed by suction. Surgical field severely threatened and surgery not possible.\n\nFor the primary objective of surgical field grade, we calculated the mean within sides treated with cocaine vs adrenaline and assessed its difference', 'timeFrame': 'Every 15 minutes until 300 minutes'}]","[{'measure': 'Heart Rate', 'description': 'The heart rate (heart beats for minutes) will be recorded every 15 minutes, until the surgery is over or until 300 minutes.\n\nThe Co-investigator will record this data in a special data sheeet For the secondary objective of Heart rate, we calculated the average within sides treated with cocaine vs adrenaline and assessed its difference', 'timeFrame': 'Every 15 minutes until 300 minutes'}, {'measure': 'Blood Pressure', 'description': 'The mean blood pressure, defined as the average arterial pressure during a single cardiac cycle, will be recorded every 15 minutes, until the surgery is over or until 300 minutes.\n\nFor the secondary objective of blood pressure, we calculated the mean within sides treated with cocaine vs adrenaline and assessed its difference', 'timeFrame': 'Every 15 minutes or until 300 minutes'}, {'measure': 'End Tidal CO2', 'description': 'The concentration of carbon dioxide (CO2) in the respiratory gases will be recorded every 15 minutes or until 300 minutes.\n\nFor the secondary objective of concentration of carbon dioxide, we calculated the mean within sides treated with cocaine vs adrenaline and assessed its difference', 'timeFrame': 'Every 15 minutes or until 300 minutes'}]",4,18 Years,,ALL,False,Marc Tewfik,OTHER,0,45.0,ACTUAL,2025-09-01T16:18:14.665397,v2_robust,True,True,True,False,False,
NCT02836652,Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy,Prevention of Non-Surgical Bleeding by Management of HeartMate II Patients Without Antiplatelet Therapy,Warfarin,"['Warfarin', 'acetylsalicylic acid (ASA) therapy', 'Coumadin', 'Aspirin']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure,['Heart Failure'],"['HeartMate II (HMII)', 'Left Ventricular Assist Device (LVAD)']",COMPLETED,,2016-11,2019-07-18,"[{'measure': 'Safety Endpoint: % of Patients With Non-surgical Bleeding at 6 Months Post HeartMate II Implant', 'description': 'Composite incidence of non-surgical bleeding at 6 months post initial implantation, including but not limited to gastrointestinal, genitourinary, epistaxis, subdural hematoma, and primary hemorrhagic stroke (not due to ischemic conversion, or due to the treatment of a hemolysis/suspected thrombosis event).', 'timeFrame': '6 months post initial implantation'}, {'measure': 'Efficacy Endpoint: % of Patients With Thromboembolic Events at 6 Months Post HeartMate II Implant', 'description': 'Composite incidence of pump thrombosis and thromboembolic stroke at 6 months post initial implantation, including ischemic stroke, or hemorrhagic stroke due to an ischemic conversion/treatment of hemolysis/pump thrombosis event.', 'timeFrame': '6 months post initial implantation'}]",[],2,50 Years,,ALL,False,Abbott Medical Devices,INDUSTRY,0,72.0,ACTUAL,2025-09-01T16:18:14.665431,v2_robust,True,True,True,False,True,
NCT03633552,Efficacy of Two Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma,"A Single-blind, Randomized, Clinical Trial Comparing the Efficacy of 6 Cycles Versus 12 Cycles Temozolomide Regimens in Adjuvant Treatment of Patients With Brain High Grade Glioma",Temozolomide,"['Temozolomide', 'Temodar, Temodal, Temcad, Glidar']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Glioblastoma Multiforme of Brain,"['Glioblastoma Multiforme of Brain', 'Anaplastic Astrocytoma of Brain']","['Glioblastoma Multiforme', 'Anaplastic Astrocytoma', 'Adjuvant treatment', 'Extended chemotherapy']",UNKNOWN,,2018-03-03,2021-04-03,"[{'measure': 'Overall survival', 'description': 'The time interval between the diagnosis and death.', 'timeFrame': 'up to 1 year from start of treatment'}, {'measure': 'Progression-free survival', 'description': 'The time interval between the diagnosis and disease progression based on radiologic criteria or symptoms', 'timeFrame': 'up to 1 year from start of treatment'}]","[{'measure': 'Anemia', 'description': 'blood hemoglobin lower than 10 grams per deciliter', 'timeFrame': 'monthly, up to 12 months during treatment'}, {'measure': 'Neutropenia', 'description': 'Blood almost mature neutrophils count lower than 1500/mm3', 'timeFrame': 'monthly, up to 12 months during treatment'}, {'measure': 'Presence of alopecia', 'description': 'A condition in which hair is lost', 'timeFrame': 'monthly, up to 12 months during treatment'}, {'measure': 'Presence of nausea', 'description': 'An unpleasant sense of unease, discomfort, and revulsion towards food', 'timeFrame': 'monthly, up to 12 months during treatment'}, {'measure': 'Presence of vomiting', 'description': 'Eject matter from the stomach through the mouth.', 'timeFrame': 'monthly, up to 12 months during treatment'}]",7,18 Years,70 Years,ALL,False,Mashhad University of Medical Sciences,OTHER,0,62.0,ESTIMATED,2025-09-01T16:18:14.665440,v2_robust,True,True,False,False,False,
NCT01134952,Study of Sirolimus Versus Mycophenolate Liver Transplant Recipients With Recurrent Hepatitis C Virus (HCV),A Prospective Cross-over Study Comparing the Effect of Sirolimus Versus Mycophenolate on Viral Load in Liver Transplant Recipients With Recurrent Chronic HCV Infection,Mycophenolate to sirolimus switch,"['Mycophenolate to sirolimus switch', 'rapamune', 'mycophenolic acid', 'mycophenolic mofetil', 'rapamycin', 'cellcept']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Hepatitis C,['Hepatitis C'],"['sirolimus', 'everolimus', 'mycophenolic acid', 'hepatitis C virus', 'tacrolimus', 'viral load']",COMPLETED,,2010-06,2014-12,"[{'measure': 'Delta Hepatitis C Viral Load', 'description': 'Percent change in HCV load determined 3 months after switch from MMF to SRL.', 'timeFrame': '3 month'}]","[{'measure': 'Final Hepatitis C Viral Load', 'description': 'Percent change in HCV load determined 3 months after switch from SRL to MMF', 'timeFrame': '3 month'}, {'measure': 'Sirolimus Trough Level', 'timeFrame': '3 month'}, {'measure': 'Delta Tacrolimus Trough Level', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Bilirubin', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Alkaline Phosphatase', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Alanine Aminotransferase', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Hemoglobin', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Platelet Count', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Cholesterol Fasting Level', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}, {'measure': 'Delta Triglyceride Fasting Level', 'description': 'Percent change determined 3 months after switch from MMF to SRL', 'timeFrame': '3 month'}]",11,18 Years,,ALL,False,London Health Sciences Centre,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:14.665461,v2_robust,True,True,True,False,False,
NCT03296852,Study: SONAS Ultrasound for Detecting Stroke SONAS Ultrasound for Detecting Stroke,SONAS Ultrasound Device for the Detection of Ischemic and Hemorrhagic Stroke,Lumason,['Lumason'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,"Stroke, Acute","['Stroke, Acute']",[],COMPLETED,,2018-04-19,2019-01-20,"[{'measure': 'Blood brain barrier impairment by extravasation of Gadolinium into the brain tissue', 'description': 'BBB impairment will be assessed by extravasation of Gadolinium into the brain tissue. Because of its molecular weight Gadolinium cannot enter the extravascular space, unless the BBB integrity is impaired. BBB impairment causes leakage of Gadolinium in into the extravascular space which, in turn, can be visualized by T1-weighted sequences.', 'timeFrame': '5 hours'}]",[],1,18 Years,,ALL,True,"University of California, Los Angeles",OTHER,1,12.0,ACTUAL,2025-09-01T16:18:14.665522,v2_robust,True,True,True,False,False,
NCT03118947,A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease,A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease,Pimavanserin,['Pimavanserin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Agitation and Aggression in Alzheimer's Disease,"[""Agitation and Aggression in Alzheimer's Disease""]",[],COMPLETED,,2017-02-23,2019-02-25,"[{'measure': 'Treatment Emergent Adverse Events (TEAEs)', 'description': ""Safety and tolerability of pimavanserin after 52 weeks of treatment in patients with probable Alzheimer's disease who have symptoms of agitation and Aggression, in terms of occurrence of TEAEs"", 'timeFrame': '52 weeks'}]",[],1,50 Years,,ALL,False,ACADIA Pharmaceuticals Inc.,INDUSTRY,0,79.0,ACTUAL,2025-09-01T16:18:14.665568,v2_robust,True,True,True,False,True,
NCT00249847,Study of PET Scans and Serotonin in Hot Flashes Treatment,A Feasibility Study of Positron Emission Tomography (PET) of the Serotonin Transporter (SERT) Before and After Treatment With Conjugated Equine Estrogen or Paroxetine for Hot Flashes,Paroxetine controlled-release,"['Paxil CR', 'Paroxetine controlled-release', 'Premarin', 'Conjugated equine estrogen']",4,INTERVENTIONAL,['NA'],,,Hot Flashes,['Hot Flashes'],"['Hot flashes, vasomotor symptoms, estrogen, paroxetine']",TERMINATED,Unable to complete accrual; elected to close the study in April 2008.,2005-10,2008-04,"[{'measure': 'To estimate the proportion of women who have a 50% or greater reduction in frequency of hot flashes following 4 weeks of paroxetine or conjugated equine estrogen.', 'timeFrame': 'Following 4 weeks of study medication'}, {'measure': 'To evaluate baseline and change in binding of the serotonin transporter in postmenopausal women who suffer hot flashes before and after 4 weeks of paroxetine or conjugated equine estrogen using PET.', 'timeFrame': 'Following 4 weeks of study medication'}, {'measure': 'To correlate baseline and change in binding of the serotonin transporter using PET with reduction of hot flashes after 4 weeks of conjugated equine estrogen or paroxetine.', 'timeFrame': 'Following 4 weeks of study medication'}]",[],3,18 Years,,FEMALE,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:14.665576,v2_robust,True,True,False,True,False,Unable to complete accrual; elected to close the study in April 2008.
NCT05141747,A Study of MRG002 in the Treatment of HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer.,"An Open-label, Multi-center, Phase II Clinical Study to Evaluate the Safety, Efficacy and Pharmacokinetics of MRG002 in Patients With HER2-positive/HER2-low Locally Advanced or Metastatic Gastric/ Gastroesophageal Junction Cancer.",MRG002,['MRG002'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Locally Advanced Gastric Cancer,"['Locally Advanced Gastric Cancer', 'Metastatic HER2 Positive Gastroesophageal Junction Cancer']","['MRG002', 'Antibody Drug Conjugate (ADC)', 'HER2', 'Gastric/Gastroesophageal Junction Cancer']",UNKNOWN,,2022-01-19,2023-12,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of patients with a complete response (CR) and partial response (PR) according to RECIST v1.1.', 'timeFrame': 'Baseline to study completion, up to 24 months'}, {'measure': 'Adverse Events (AEs)', 'description': 'Any reaction, side effect, or untoward event that occurs during the course of the clinical trial whether or not the event is considered related to the study drug.', 'timeFrame': 'Baseline to 45 days after the lase dose of study treatment.'}]","[{'measure': 'Progression Free Survival (PFS)', 'description': 'PFS is defined as the duration from the start of treatment to the onset of tumor progression or death of any cause.', 'timeFrame': 'Baseline to study completion, up to 24 months.'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the duration from the start of treatment to death of any cause.', 'timeFrame': 'Baseline to study completion, up to 24 months.'}, {'measure': 'Duration of Response (DoR)', 'description': 'DOR is defined as the time from first documented objective response to the first onset of tumor progression or death of any cause.', 'timeFrame': 'Baseline to study completion, up to 24 months.'}, {'measure': 'Disease Control Rate (DCR)', 'description': 'DCR is defined as the percentage of patients who achieve CR, PR, and stable disease (SD) after treatment.', 'timeFrame': 'Baseline to study completion, up to 24 months.'}, {'measure': 'Pharmacokinetics (PK) Parameter of MRG002: concentration-time curve', 'description': 'Plot of drug concentration changing with time after drug administration.', 'timeFrame': 'Baseline to 30 days after the last dose of study treatment'}, {'measure': 'Immunogenicity (ADA)', 'description': 'The proportion of patients with positive ADA results.', 'timeFrame': 'Baseline to 30 days after the last dose of study treatment.'}]",8,18 Years,,ALL,False,Shanghai Miracogen Inc.,INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:14.665589,v2_robust,True,True,False,False,True,
NCT00587847,Campath Maintenance in Chronic Lymphocytic Leukemia,Maintenance Alemtuzumab in Refractory Chronic Lymphocytic Leukemia,Campath,"['Alemtuzumab', 'Campath']",2,INTERVENTIONAL,['NA'],,,Chronic Lymphocytic Leukemia,['Chronic Lymphocytic Leukemia'],['leukemia'],TERMINATED,Insufficient recruitment.,2005-08,2009-11,"[{'measure': 'Time to Progression (Months)', 'description': 'Time to progression calculated as the period, in months, between the date of the first dose of alemtuzumab and the first date of documented disease progression (NCI 1996 criteria) or death. Duration of response of all other participants who did not progress nor expire, had their event times calculated at the last date of follow-up.', 'timeFrame': 'Every 8 weeks'}]","[{'measure': 'Rate of Infections', 'description': 'Number of participants who developed clinical or laboratory evidence of infection.', 'timeFrame': 'Weekly then every 2 weeks then every 3 weeks'}]",2,18 Years,,ALL,False,Northwell Health,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:14.665600,v2_robust,True,True,False,True,False,Insufficient recruitment.
NCT05677347,"Phase 1, Single and Repeat Dose Study to Assess Safety, Tolerability, and Pharmacokinetics (PK) of GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)","A Randomized, Double-blind, Placebo Controlled, Single and Repeat Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Inhaled GSK3923868 in Participants With Chronic Obstructive Pulmonary Disease (COPD)",GSK3923868,"['GSK3923868', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Pulmonary Disease, Chronic Obstructive","['Pulmonary Disease, Chronic Obstructive']","['Single ascending dose', 'Repeat dose', 'Phosphatidylinositol 4-kinase beta (PI4KB) inhibitor', 'Chronic Obstructive Pulmonary Disease (COPD)']",COMPLETED,,2023-01-23,2023-07-20,"[{'measure': 'Number of Participants With Non-serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Following Single Dose of GSK3923868', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Adverse events which were not serious, were considered as non-serious adverse events.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Number of Participants With Non-SAEs and SAEs Following Repeat Dose of GSK3923868', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. An SAE is any untoward medical occurrence that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or any other situation according to medical or scientific judgment. Adverse events which were not serious, were considered as non-serious adverse events.', 'timeFrame': 'Up to 29 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Hematology and Clinical Chemistry Laboratory Parameters Following Single Dose of GSK3923868', 'description': 'The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were Basophil, Eosinophil, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Lymphocyte, Monocyte, Neutrophils, Platelets and Reticulocytes, Alanine Aminotransferase, Albumin, Alkaline phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Sodium and Urea. Number of participants with clinically significant changes in hematology and clinical chemistry and were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Hematology and Clinical Chemistry Laboratory Parameters Following Repeat Dose of GSK3923868', 'description': 'The laboratory measurements included hematology and clinical chemistry. The parameters evaluated were Basophil, Eosinophil, Erythrocyte Mean Corpuscular Hemoglobin, Erythrocyte Mean Corpuscular Volume, Erythrocytes, Hematocrit, Hemoglobin, Lymphocyte, Monocyte, Neutrophils, Platelets and Reticulocytes, Alanine Aminotransferase, Albumin, Alkaline phosphatase, Aspartate Aminotransferase, Bilirubin, Calcium, Creatinine, Direct Bilirubin, Glucose, Potassium, Sodium and Urea. Number of participants with clinically significant changes in hematology and clinical chemistry and were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 29 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Urinalysis Parameters Following Repeat Dose of GSK3923868', 'description': 'Urine samples were collected at indicated time points for the analysis of urinalysis parameters including specific gravity, potential of hydrogen (pH) of urine, presence of glucose, protein, erythrocytes, ketones, bilirubin, urobilinogen, nitrite, leukocyte esterase in urine by dipstick. Number of participants with clinically significant changes in urinalysis parameters were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 29 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs and 12-lead Electrocardiogram (ECG) Findings Following Single Dose of GSK3923868', 'description': 'Vital signs included systolic and diastolic blood pressure, pulse rate and respiratory rate were measured with the participant in semi-supine position after at least 10 minutes rest. Tympanic Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Twelve-lead electrocardiogram were performed in a semi-supine position after at least 10 minutes rest using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, QT and corrected QT intervals (QTc) intervals. Number of participants with clinically significant changes in vital signs and ECG parameters were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Vital Signs and 12-lead Electrocardiogram (ECG) Findings Following Repeat Dose of GSK3923868', 'description': 'Vital signs included systolic and diastolic blood pressure, pulse rate and respiratory rate were measured with the participant in semi-supine position after at least 10 minutes rest. Tympanic Temperature was also measured as a vital sign but did not require positioning or rest prior to measuring. Twelve-lead electrocardiogram were performed in a semi-supine position after at least 10 minutes rest using an ECG machine that automatically calculates the heart rate and measures PR interval, QRS duration, QT and corrected QT intervals (QTc) intervals. Number of participants with clinically significant changes in vital signs and ECG parameters were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 29 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Spirometry Measurements Following Single Dose of GSK3923868', 'description': 'Spirometry included forced expiratory volume in 1 second (FEV1) for lung function assessment. FEV1 is an important measure of pulmonary function and is the maximum amount of air that can be forced out in one second after taking a deep breath. Spirometry assessments were performed in triplicate with the highest value reported. Number of participants with clinically significant changes in spirometry measurements were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 18 days'}, {'measure': 'Number of Participants With Clinically Significant Changes in Spirometry Measurements Following Repeat Dose of GSK3923868', 'description': 'Spirometry included forced expiratory volume in 1 second (FEV1) for lung function assessment. FEV1 is an important measure of pulmonary function and is the maximum amount of air that can be forced out in one second after taking a deep breath. Spirometry assessments were performed in triplicate with the highest value reported. Number of participants with clinically significant changes in spirometry measurements were reported. Clinical significance was determined by the investigator.', 'timeFrame': 'Up to 29 days'}]","[{'measure': 'Area Under the Plasma-concentration Time Curve From Time Zero (Pre-dose) to 24 Hours (AUC [0-24]) of GSK3923868 for Single Dose', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of GSK3923868. Pharmacokinetic analysis was conducted using standard non-compartmental method with WinNonlin.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6, 24 hours post-dose on Day 1 in Treatment Periods 1 and 2'}, {'measure': 'Area Under the Plasma-concentration Time Curve From Time Zero (Pre-dose) to Time of the Last Quantifiable Concentration (AUC[0-t]) of GSK3923868 for Single Dose', 'description': 'Blood samples were collected at the indicated time points for PK analysis of GSK3923868. Area under the concentration-time curve from time zero to the time of the last quantifiable concentration values were reported.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6, 24 hours post-dose on Day 1 in Treatment Periods 1 and 2'}, {'measure': 'Area Under the Plasma-concentration Time Curve From Time Zero (Pre-dose) to 6 Hours (AUC [0-6]) of GSK3923868 for Repeat Dose', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of GSK3923868. Pharmacokinetic analysis was conducted using standard non-compartmental method with WinNonlin.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6 hours post-dose on Day 1 and Day 14 in Treatment Period 3'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) of GSK3923868 for Single Dose', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of GSK3923868. Pharmacokinetic analysis was conducted using standard non-compartmental method with WinNonlin.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6, 24 hours post-dose on Day 1 in Treatment Periods 1 and 2'}, {'measure': 'Time to Reach Cmax (Tmax) of GSK3923868 for Single Dose', 'description': 'Blood samples were collected at the indicated time points for analysis of tmax of GSK3923868. The tmax was obtained directly from the concentration-time data. The tmax was analyzed with the non-compartmental methods with WinNonlin.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6, 24 hours post-dose on Day 1 in Treatment Periods 1 and 2'}, {'measure': 'Cmax of GSK3923868 for Repeat Dose', 'description': 'Blood samples were collected at the indicated time points for pharmacokinetic (PK) analysis of GSK3923868. Pharmacokinetic analysis was conducted using standard non-compartmental method with WinNonlin.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6 hours post-dose on Day 1 and Day 14 in Treatment Period 3'}, {'measure': 'Tmax of GSK3923868 for Repeat Dose', 'description': 'Blood samples were collected at the indicated time points for analysis of tmax of GSK3923868. The tmax was obtained directly from the concentration-time data. The tmax was analyzed with the non-compartmental methods with WinNonlin.', 'timeFrame': 'Pre-dose and 5, 15, 30, 45 minutes, 1, 2, 4, 6 hours post-dose on Day 1 and Day 14 in Treatment Period 3'}]",16,40 Years,70 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:14.665613,v2_robust,True,True,True,False,True,
NCT01534247,A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately,"A Phase I, Open-Label, 3-way Crossover, Pharmacokinetic and Drug-Drug Interaction Study of Ceftazidime Avibactam (CAZ-AVI) and Metronidazole When Administered Alone and in Combination in Healthy Subjects",CAZ-AVI,"['CAZ-AVI + metronidazole', 'metronidazole', 'CAZ-AVI']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Phase I', 'drug to drug', 'CAZ-AVI', 'Healthy volunteer', 'pharmacokinetics', 'open label', 'metronidazole', 'safety']",COMPLETED,,2012-02,2012-07,"[{'measure': 'Profile of pharmacokinetic of ceftazidime, avibactam and metronidazole when administering CAZ-AVI plus metronidazole in combination compared to administration of individual components', 'timeFrame': 'CAZ-AVI: pre-dose, 0.5, 1, 1.5, 2, 2.25, 2.5, 2.75, 3, 4, 5, 7, 11, 23, 73, 73.5, 74, 74.5, 75, 75.25, 75.5, 75.75, 76, 77, 78, 80, 84 and 95 hours post-dose'}, {'measure': 'Profile of pharmacokinetic of ceftazidime, avibactam and metronidazole when administering CAZ-AVI plus metronidazole in combination compared to administration of individual components', 'timeFrame': 'Metronidazole: pre-dose, 0.5, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 72, 72.5, 73, 73.25, 73.5, 74, 75, 76, 78, 80, 84 and 96 hours post-dose'}, {'measure': 'Profile of pharmacokinetic of ceftazidime, avibactam and metronidazole when administering CAZ-AVI plus metronidazole in combination compared to administration of individual components', 'timeFrame': 'CAZ-AVI and metronidazole: pre-dose, 0.5, 1, 1.25, 1.5, 2.5, 3, 3.25, 3.5, 3.75, 4, 5, 6, 8, 12, 24, 72, 72.5, 73, 73.25, 73.5, 74, 74.5, 75, 75.25, 75.5, 75.75, 76, 77, 78, 80, 84 and 96 hours post-dose'}]","[{'measure': 'To assess safety and tolerability of CAZ-AVI and metronidazole when administered as a 2- and 1-hour infusion, respectively, every 8 hours by assessment of adverse events, lab, vital signs, ECG, physical examination', 'timeFrame': 'Screening up to 26 days after first dose'}]",4,18 Years,50 Years,ALL,True,Pfizer,INDUSTRY,1,28.0,ACTUAL,2025-09-01T16:18:14.665647,v2_robust,True,True,True,False,True,
NCT04217447,Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease,Assessment of Quitting Versus Using Aspirin Therapy In Patients Treated With Oral Anticoagulation for Atrial Fibrillation or Other Indication With Stabilized Coronary Artery Disease,OAC + Aspirin 100mg od,"['OAC + placebo of Aspirin 100mg od', 'OAC + Aspirin 100mg od']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Coronary Artery Disease,['Coronary Artery Disease'],"['atrial fibrillation', 'oral anticoagulation', 'antithrombotic therapy']",TERMINATED,"The sponsor's decision to stop the study follows the DSMB's recommendations (end of enrolment and experimental treatment, post-treatment/end-of-study visit within 3 months of stopping treatment), regarding the benefit-risk balance.",2020-05-25,2024-10-28,"[{'measure': 'Primary efficacy outcome : rate of composite of cardiovascular mortality and thrombotic cardiovascular events', 'description': 'The primary efficacy outcome is the incidence of the adjudicated composite of (within 24-48 months):\n\n* CV mortality\n* Thrombotic cardiovascular events\n\n  * Myocardial infarction\n  * Stroke\n  * Any coronary revascularization\n  * Systemic embolism\n  * Acute limb ischemia\n\nAn Independent Clinical Events Committee (ICEC) will adjudicate all events (ischemic and bleeding events).', 'timeFrame': 'within 24-48 months'}, {'measure': 'Primary safety outcome : rate of major bleeding', 'description': 'The primary safety outcome is the occurrence of major bleeding according to the ISTH (International Society of Thrombosis and Haemostasis) definition', 'timeFrame': 'within 24-48 months'}]","[{'measure': 'Secondary efficacy outcomes : rate of composite of CV mortality, MI, stroke; CV mortality; all cause of death; thrombotic cardiovascular events.', 'description': 'The secondary efficacy outcomes are the occurrence of any of the following events:\n\n* The composite of CV mortality, MI, stroke\n* CV mortality\n* All cause death\n* Thrombotic cardiovascular events:\n\n  * Myocardial infarction\n  * Stent thrombosis alone (definite or probable)\n  * Stroke (ischemic, hemorrhagic, or stroke of uncertain cause, TIA)\n  * Any coronary revascularization\n  * Systemic embolism\n  * Acute limb ischemia', 'timeFrame': 'within 24-48 months'}, {'measure': 'Secondary safety outcomes : rate of major and clinically relevant non major bleeding', 'description': 'The secondary safety outcome are the occurrence of :\n\nMajor and clinically relevant non major bleeding according to the ISTH definition (ISTH : International Society of Thrombosis and Haemostasis) Major bleeding (TIMI : Thrombolysis in Myocardial Infarction) Major bleeding (BARC ≥3 : Bleeding Academic Research Consensus)', 'timeFrame': 'within 24-48 months'}]",4,18 Years,,ALL,False,"University Hospital, Brest",OTHER,1,874.0,ACTUAL,2025-09-01T16:18:14.665723,v2_robust,True,True,False,True,True,"The sponsor's decision to stop the study follows the DSMB's recommendations (end of enrolment and experimental treatment, post-treatment/end-of-study visit within 3 months of stopping treatment), regarding the benefit-risk balance."
NCT03513549,Observational Study Evaluating the Safety of ADASUVE® in Agitation Associated With Schizophrenia or Bipolar I Disorder,A Postmarketing Observational Study to Evaluate the Safety of ADASUVE® (STACCATO® Loxapine for Inhalation) in Patients With Agitation Associated With Schizophrenia or Bipolar I Disorder,Loxapine 10 MG,"['Loxapine 10 MG', 'ADASUVE (loxapine) inhalation powder, NDA 022549']",2,OBSERVATIONAL,[],,,"Agitation,Psychomotor","['Agitation,Psychomotor']","['Agitation', 'Schizophrenia', 'Bipolar I disorder']",UNKNOWN,,2014-11-04,2022-03,"[{'measure': 'Evaluating frequency and nature of adverse events, serious adverse events and respiratory adverse events of special interest (AESIs) after administration of ADASUVE treatment in real-world clinical settings', 'description': 'Safety will be assessed by evaluating adverse events, serious adverse events, and respiratory AESIs within the study follow-up period after administration of ADASUVE treatment in real-world clinical settings.', 'timeFrame': '24 hours'}]","[{'measure': 'Patient demographics', 'description': 'The secondary measure of this study is patient characteristics, including demographic characteristics, after administration of ADASUVE treatment in real-world clinical settings.', 'timeFrame': '24 hours'}, {'measure': 'Patient baseline characteristics - medical history', 'description': 'The secondary measure of this study is patient characteristics, including baseline characteristic of medical history, after administration of ADASUVE treatment in real-world clinical settings.', 'timeFrame': '24 hours'}, {'measure': 'Patient baseline characteristics - prior medications', 'description': 'The secondary measure of this study is patient characteristics, including baseline characteristic of prior medications, after administration of ADASUVE treatment in real-world clinical settings.', 'timeFrame': '24 hours'}]",4,18 Years,,ALL,False,"Alexza Pharmaceuticals, Inc.",INDUSTRY,1,10000.0,ESTIMATED,2025-09-01T16:18:14.665791,v2_robust,False,True,False,False,True,
NCT05854849,Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC,"A Multicenter, Phase 3 Clinical Trial of Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma",Camrelizumab,"['Gemcitabine', 'Apatinib', 'Cisplatin', 'Camrelizumab']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Nasopharyngeal Carcinoma,['Nasopharyngeal Carcinoma'],"['Nasopharyngeal Carcinoma', 'PD-1', 'metastatic']",RECRUITING,,2023-05-01,2027-12-01,"[{'measure': 'Progression-free survival', 'description': 'the time from treatment initiation to disease progression or death from any cause.', 'timeFrame': '2 years'}]","[{'measure': 'Overall survival', 'description': 'the survival time until death from any cause', 'timeFrame': '2 years'}, {'measure': 'Objective response rate', 'description': 'the proportion of patients with complete response (CR) or partial response (PR) according to RECIST v1.1', 'timeFrame': '2 years'}, {'measure': 'Disease control rate', 'description': 'the proportion of patients who achieved CR, PR, or stable disease', 'timeFrame': '2 years'}, {'measure': 'Duration of response', 'description': 'the time from the first evidence of response to disease progression or death', 'timeFrame': '2 years'}, {'measure': 'Safety evaluation', 'description': 'incidence of adverse events', 'timeFrame': '2 years'}]",6,18 Years,75 Years,ALL,False,Sun Yat-sen University,OTHER,0,244.0,ESTIMATED,2025-09-01T16:18:14.665800,v2_robust,True,True,False,False,True,
NCT05380349,Personalized Cancer Stem Cell High-Throughput Drug Screening for Glioblastoma,A Phase 1 Study of Combination Drug Therapy Based on Personalized Cancer Stem Cell (CSC) High-Throughput Drug Screening (HTS) With Standard of Care for Newly Diagnosed Glioblastoma,combinations of up to 3 FDA approved drugs from a panel of compounds,['combinations of up to 3 FDA approved drugs from a panel of compounds'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Newly Diagnosed Glioblastoma,['Newly Diagnosed Glioblastoma'],[],RECRUITING,,2024-04-19,2027-12,"[{'measure': 'determine safety of CSC/HTS-based combination drug therapy', 'description': 'incidence of treatment-related AEs, laboratory abnormalities, and SAEs as assessed by CTCAE version 5.0', 'timeFrame': 'From date of first dose of investigational drug regimen until date of first documented progression or death from any cause, whichever came first, assessed up to 24 months.'}]","[{'measure': 'Efficacy of CSC/HTS-based combination drug therapy', 'description': 'Response assessment per Response Assessment in Neuro-Oncology (RANO) criteria', 'timeFrame': 'From inclusion in the study up to approximately 36 months'}, {'measure': 'Efficacy of CSC/HTS-based combination drug therapy', 'description': 'Progression-free survival (PFS)', 'timeFrame': 'From inclusion in the study until the date of first documented progression or date of death from any cause, whichever came first, assessed up to approximately 36 months'}, {'measure': 'Efficacy of CSC/HTS-based combination drug therapy', 'description': 'Median overall survival (OS)', 'timeFrame': 'From inclusion in the study until date of death from any cause, assessed up to approximately 36 months'}]",4,18 Years,,ALL,False,Swedish Medical Center,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:14.666117,v2_robust,True,True,False,False,True,
NCT01436149,Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder,"The SPD489-322 Phase 3, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Flexible Dose Titration, Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder With Inadequate Response to Prospective Treatment With an Antidepressant",SPD489 (Lisdexamfetamine dimesylate ),"['SPD489 (Lisdexamfetamine dimesylate )', 'Vyvanse', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2011-10-27,2013-12-23,"[{'measure': 'Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at up to 8 Weeks', 'description': 'MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.', 'timeFrame': '8 weeks'}]","[{'measure': 'Change From Baseline in Sheehan Disability Scale (SDS) Total Score at up to 8 Weeks', 'description': ""Designed to evaluate the extent to which illness symptoms impact a subject's life in 3 areas: work/school, social, and family/home. Each area is scored on a scale from 0 (no impairment) to 10 (highly impaired) with a total score ranging from 0 (unimpaired) to 30 (highly impaired). Lower scores translate into less impairment."", 'timeFrame': '8 weeks'}, {'measure': 'Percentage of Participants Achieving a 25% Response on the MADRS', 'description': 'The percentage of subjects who achieved a 25% response (i.e., ≥25% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/Early Termination (ET) (Week 16/ET).', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Percentage of Participants Achieving a 50% Response on the MADRS', 'description': 'The percentage of subjects who achieved a 50% response (i.e., ≥50% reduction in MADRS total score from Lead-in Baseline, Visit 2; Week 0). A comparison was performed at Visit 14/ET (Week 16/ET).', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Percentage of Participants Achieving Remission on the MADRS', 'description': 'MADRS remission was defined as a MADRS total score of ≤10. A comparison was performed at Visit 14/ET (Week 16/ET).', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Mean Change From Baseline Over Time in MADRS Total Score', 'description': 'MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.', 'timeFrame': 'Baseline and up to 8 weeks'}, {'measure': 'Mean Change From Baseline in the Quick Inventory of Depressive Symptomatology - Self Report (QIDS SR)', 'description': 'The QIDS-SR is a self-administered questionnaire designed to rate depressive symptoms. The scale contains 16 items, each scored using a 4-point scale ranging from 0 (representing the most favorable response \\[low amount of symptom\\]) to 3 (representing the least favorable response \\[frequent/intense symptom\\]). The total score could range from 0 (no depression) to 27 (very severe depression). Higher scores represent more severe depressive symptoms.', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Mean Change From Baseline in the Short Form-12 Health Survey V2 (SF-12V2)', 'description': 'Total score ranges from 0 (lowest level of health) - 100 (highest level of health) on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability (i.e. a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability). Higher scores are associated with better quality of life.', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Mean Change From Baseline in the Quality of Life Enjoyment Satisfaction Questionnaire Short Form (Q-LES-Q-SF)', 'description': 'The short form is a 16-item self-report questionnaire which evaluates general subject satisfaction with health, mood, relationships, functioning in daily life, and the treatment being taken. Overall level of satisfaction is evaluated on a 5-point scale from 1 (very poor) to 5 (very good). The total score ranges from 14-70 (last two items on the form are not included in the total score). A higher score indicates a better quality of life.', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Clinical Global Impressions - Global Improvement (CGI-I)', 'description': 'Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale.', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Columbia Suicide Severity Rating Scale (C-SSRS)', 'description': 'C-SSRS is a semi-structured interview that captures the occurrence, severity, and frequency of suicide-related thoughts and behaviors during the assessment period. The interview includes definitions and suggested questions to solicit the type of information needed to determine if a suicide-related thought or behavior occurred. The assessment is done by the nature of the responses, not by a numbered scale.', 'timeFrame': 'up to 8 weeks'}, {'measure': 'Amphetamine Cessation Symptom Assessment (ACSA)', 'description': 'ACSA scale has 16 symptom items rated on a scale from 0 (not at all) to 4 (extremely) with a possible total score range of 0 to 64. Higher scores indicate greater withdrawal symptom severity.', 'timeFrame': 'up to 8 weeks'}]",12,18 Years,65 Years,ALL,False,Shire,INDUSTRY,0,1262.0,ACTUAL,2025-09-01T16:18:14.666128,v2_robust,True,True,True,False,False,
NCT05319249,Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia,Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid Leukemia,Talazoparib 1 MG [Talzenna],"['Talazoparib 1 MG [Talzenna]', 'Talzenna']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],[],NOT_YET_RECRUITING,,2024-06,2028-06,"[{'measure': 'complete remission (CR/CRi)', 'description': 'response defined as complete remission (CR/CRi) for patients with overt leukemia at time of inclusion and MRD decrease \\>1log10 for patients with rising MRD at time of inclusion.', 'timeFrame': 'Collected at a minimum at baseline, day 28 and latest on day 42'}]","[{'measure': 'EFS - Event-free survival', 'description': 'Event-free survival', 'timeFrame': 'EFS is defined as the time of entry into the study to the date of primary refractory disease, or relapse from CR, or CRi, or death from any cause, whichever comes first, assessed up to 42 days.'}, {'measure': 'RFS -Relapse-free survival', 'description': 'RFS is defined only for patients achieving CR or CRi', 'timeFrame': 'Defined as the time from achieving a remission until the date of relapse or death from any cause, whichever comes first, assessed up to 42 days.'}, {'measure': 'OS - Overall survival', 'description': 'Overall survival', 'timeFrame': 'OS is defined as the time from entry into the trial to the date of death from any cause, assessed up to 42 days.'}, {'measure': 'MRD', 'description': 'Measurable Residual Disease', 'timeFrame': 'Collected at a minimum at baseline, day 28 and latest on day 42'}, {'measure': 'QoL - Quality of life - QLQ-C30', 'description': 'Validated 30-item self-assessment questionnaire to assess quality of life aspects. The items are rated on a 4-point Likert scale ranging from 1 (not at all) to 4 (very much) with higher scores meaning a higher level of fatigue.', 'timeFrame': 'QoL is assessed at baseline and latest on day 42.'}]",6,18 Years,,ALL,False,German Cancer Research Center,OTHER,0,54.0,ESTIMATED,2025-09-01T16:18:14.666294,v2_robust,True,True,False,False,False,
NCT00002949,Vinorelbine and Paclitaxel Plus Radiation Therapy in Treating Patients With Advanced Cancer Arising in the Pelvis,Phase I Study of Concomitant Chemoradiotherapy With Vinorelbine and Paclitaxel in Patients With Advanced Pelvic Malignancies,paclitaxel,"['paclitaxel', 'vinorelbine tartrate']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Bladder Cancer,"['Bladder Cancer', 'Cervical Cancer', 'Endometrial Cancer', 'Vaginal Cancer']","['stage II cervical cancer', 'stage III cervical cancer', 'stage IV cervical cancer', 'stage II vaginal cancer', 'stage III vaginal cancer', 'stage IVA vaginal cancer', 'stage IVB vaginal cancer', 'stage II endometrial carcinoma', 'stage III endometrial carcinoma', 'stage IV endometrial carcinoma', 'stage II bladder cancer', 'stage III bladder cancer', 'stage IV bladder cancer']",COMPLETED,,1996-07,2001-05,"[{'measure': 'Maximum tolerated dose', 'timeFrame': '4 years'}]",[],1,18 Years,,ALL,False,University of Chicago,OTHER,1,33.0,ACTUAL,2025-09-01T16:18:14.666317,v2_robust,True,True,True,False,False,
NCT01242449,Oral Vinorelbine in Combination With Trastuzumab for Metastatic Breast Cancer,A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer,Trastuzumab,"['Trastuzumab', 'Vinorelbine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],"['Breast cancer', 'Metastatic', 'HER2 positive', 'vinorelbine']",COMPLETED,,2010-11,2014-10,"[{'measure': 'Objective Response Rate', 'description': 'CT scan and MUGA scan', 'timeFrame': 'Every 9 weeks. Up to 2 years'}]","[{'measure': 'Progression free survival', 'description': 'CT scan', 'timeFrame': 'Every 9 weeks from date of first treatment until progression or death. Up to 2 years'}, {'measure': 'Overall Survival', 'timeFrame': 'From date of inclusion until date of death. Up to 2 years.'}]",3,18 Years,,FEMALE,False,Vejle Hospital,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:14.666325,v2_robust,True,True,True,False,False,
NCT01568749,A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations,A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations,Paracetamol,"['Paracetamol', 'Paracetamol formulation 1', 'Paracetamol Formulation 2', 'Paracetamol formulation 4', 'Paracetamol formulation 3']",5,INTERVENTIONAL,['PHASE1'],PHASE1,,Analgesia,['Analgesia'],"['otc', 'Analgesia', 'Paracetamol']",COMPLETED,,2008-12,2009-08,"[{'measure': 'Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.', 'timeFrame': 'Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.'}]","[{'measure': 'Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.', 'timeFrame': 'Disclosure of this information is being delayed to protect business sensitive information. It will be disclosed when it is not longer business sensitive.'}]",2,18 Years,50 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:14.666339,v2_robust,True,True,True,False,False,
NCT03120949,Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis,"A Multicenter, Open-Label, Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis",Olokizumab 64 mg SC q4w,"['Olokizumab 64 mg SC q2w', 'Olokizumab 64 mg SC q4w', 'Concomitant treatment']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],"['Rheumatoid Arthritis', 'moderate', 'severe', 'subcutaneous', 'Olokizumab', 'open-label']",COMPLETED,,2017-07-04,2021-09-01,"[{'measure': 'Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred Term (Safety Population)', 'description': 'Incidence of Treatment-Emergent Adverse Events Reported for ≥5% of Subjects in Any Treatment Group by System Organ Class or Preferred Term', 'timeFrame': 'up to Week 126'}, {'measure': 'Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred Term (Safety Population)', 'description': 'Incidence of Serious Treatment-Emergent Adverse Events by System Organ Class or Preferred Term.\n\nDeaths are included.', 'timeFrame': 'up to Week 126'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI)', 'timeFrame': 'up to Week 126'}, {'measure': 'Incidence of Treatment-Emergent AEs Leading to Withdrawal of the Study Treatment', 'timeFrame': 'up to Week 126'}, {'measure': 'Incidence Rate of Treatment Emergent AEs Per Patient-years of Exposure', 'description': 'Incidence Rate of all Subjects with at Least One Treatment Emergent AE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.', 'timeFrame': 'up to Week 126'}, {'measure': 'Incidence Rate of Treatment Emergent SAEs Per Patient-years of Exposure', 'description': 'Incidence Rate of all Subjects with at Least One Treatment Emergent SAE. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.', 'timeFrame': 'up to Week 126'}, {'measure': 'Incidence Rate of Treatment Emergent AESIs (Safety Population)', 'description': 'Incidence Rate of all Subjects with at Least One Treatment Emergent AESI. Subject Incidence Rate (IR) is summarized per 100 subject years (SY) of follow-up (/100 SY) based on the OLE safety population and presented by study treatments.', 'timeFrame': 'up to Week 126'}]","[{'measure': 'American College of Rheumatology 20% (ACR20) Response Rates Compare Against Core Baseline Through Week 82', 'description': 'Number and Proportion of subjects achieving an ACR20 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82.\n\nAmerican College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:\n\n* Patient Global Assessment of Disease Activity (VAS)\n* Patient Assessment of Pain (VAS)\n* HAQ-DI\n* Physician Global Assessment (VAS)\n* Level of acute phase reactant (CRP)', 'timeFrame': 'up to Week 82'}, {'measure': 'American College of Rheumatology 50% (ACR50) Response Rates Compare Against Core Baseline Through Week 82', 'description': 'Number and Proportion of subjects achieving an ACR50 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82\n\nAmerican College of Rheumatology 50 % response is a composite defined as a ≥ 50% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 50% improvement from baseline in at least 3 of the 5 remaining core set measures:\n\n* Patient Global Assessment of Disease Activity (VAS)\n* Patient Assessment of Pain (VAS)\n* HAQ-DI\n* Physician Global Assessment (VAS)\n* Level of acute phase reactant (CRP)', 'timeFrame': 'up to Week 82'}, {'measure': 'American College of Rheumatology 70% (ACR70) Response Rates Compare Against Core Baseline Through Week 82', 'description': 'Number and Proportion of subjects achieving an ACR70 response who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82\n\nAmerican College of Rheumatology 70 % response is a composite defined as a ≥ 70% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥ 70% improvement from baseline in at least 3 of the 5 remaining core set measures:\n\n* Patient Global Assessment of Disease Activity (VAS)\n* Patient Assessment of Pain (VAS)\n* HAQ-DI\n* Physician Global Assessment (VAS)\n* Level of acute phase reactant (CRP)', 'timeFrame': 'up to Week 82'}, {'measure': 'Proportion of Subjects With Simplified Disease Activity Index (SDAI) Remission Through Week 82', 'description': 'The number and proportion of subjects with SDAI score ≤ 3.3 (considered to be in remission).\n\nThe SDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), CRP (mg/dL), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS) + CRP (mg/dL)', 'timeFrame': 'up to week 82'}, {'measure': 'Disease Activity Score 28-joint Count (DAS28) Response Rates Through Week 82', 'description': 'Number and Proportion of subjects with DAS28 low disease activity (based on DAS28 C-reactive protein (CRP) \\< 3.2), who remain on randomized open-label treatment and in the study, assessed at several timepoints up to Week 82.\n\nThe DAS28 (CRP) was calculated in the statistical database for analysis purposes using the Swollen joint count (SJC) (28 joints), Tender joint count (TJC) (28 joints), CRP level, and the Patient Global Assessment of Disease Activity Visual Analog Scale (VAS) (100 mm VAS, where 0 is ""no disease activity"" and 100 was ""maximal disease activity"") according to the following formula: \\[0.56 × square root of TJC\\] + \\[0.28 × square root of SJC\\] + \\[0.36 × natural log (CRP+1)\\] + \\[0.014 × VAS\\] + 0.96.', 'timeFrame': 'up to Week 82'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 12', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 12'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 20', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 20'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 28', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 28'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 40', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 40'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 52', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 52'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 64', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 64'}, {'measure': 'Change in Health Assessment Questionnaire-Disability Index (HAQ-DI) From Core Baseline at Week 82', 'description': 'HAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'Core baseline, Week 82'}, {'measure': 'Proportion of Subjects With Health Assessment Questionnaire - Disability Index (HAQ-DI) Improvement Through Week 82', 'description': 'The number and proportion of subjects with HAQ-DI improvement ≥ 0.22 Against OLE Baseline.\n\nHAQ-DI Range: 0 (the best outcome) - 3 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain (activity) consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3, where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question (i.e., question in each category with the highest score for that category). The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered.', 'timeFrame': 'up to week 82'}, {'measure': 'Changes From Core Baseline Over Time in Clinical Disease Activity Index (CDAI)', 'description': 'CDAI Range: 0 (the best outcome) - 76 (the worst outcome), with a decrease from baseline indicating improvement.\n\nThe CDAI was calculated in the statistical database for analysis purposes using the SJC (28 joints), TJC (28 joints), the Patient Global Assessment of Disease Activity (VAS) (in cm), and the Physician Global Assessment (VAS) (in cm) according to the following formula: CDAI = SJC + TJC + Patient Global Assessment of Disease Activity (VAS) + Physician Global Assessment (VAS)', 'timeFrame': 'up to week 82'}]",21,18 Years,,ALL,False,"R-Pharm International, LLC",INDUSTRY,2,2106.0,ACTUAL,2025-09-01T16:18:14.666384,v2_robust,True,True,True,False,True,
NCT06814938,A Study of a Novel Precision Medicine Approach for Obesity,"A Novel Precision Medicine Approach for Obesity: a Randomized, Multi-Center Trial",Semaglutide,"['Semaglutide', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Obesity,['Obesity'],[],RECRUITING,,2025-02-21,2028-11,"[{'measure': 'Change in Total Body Weight at 24 weeks', 'description': 'Percent change in body weight in biomarker positive participants vs. biomarker negative participants taking semaglutide vs placebo.', 'timeFrame': 'Baseline, 24 weeks'}]","[{'measure': 'Percentage of Responders >5%', 'description': 'Percentage of participants who loss 5% of more of total body weight', 'timeFrame': '24 weeks'}, {'measure': 'Percentage of Responders >10%', 'description': 'Percentage of participants who loss 10% of more of total body weight', 'timeFrame': '24 weeks'}, {'measure': 'Percentage of Responders >15%', 'description': 'Percentage of participants who loss 15% of more of total body weight', 'timeFrame': '24 weeks'}, {'measure': 'Percentage of Responders >20%', 'description': 'Percentage of participants who loss 20% of more of total body weight', 'timeFrame': '24 weeks'}, {'measure': 'Change in Total Body Weight at 3 months', 'description': 'Percent change in body weight', 'timeFrame': 'Baseline, 3 months'}, {'measure': 'Change in Total Body Weight at 6 months', 'description': 'Percent change in body weight', 'timeFrame': 'Baseline, 6 months'}, {'measure': 'Change in Waist Circumference', 'description': 'Reported in centimeters (CM)', 'timeFrame': 'Baseline, 24 weeks'}]",8,18 Years,65 Years,ALL,False,Mayo Clinic,OTHER,3,135.0,ESTIMATED,2025-09-01T16:18:14.666397,v2_robust,True,True,False,False,False,
NCT01230138,Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis,"A Randomised, Double Blind, Placebo Controlled Efficacy and Safety Trial of Different Doses/Dose Regimens of FP187 Compared to Placebo in Moderate to Severe Plaque Psoriasis (Pivotal Registration Study)",Placebo,"['FP187', 'Placebo of FP187', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Plaque Psoriasis,['Plaque Psoriasis'],[],COMPLETED,,2010-09,2012-05,"[{'measure': 'Proportion of patients achieving PASI 75 compared to placebo', 'description': 'Proportion of patients achieving PASI75 (a reduction in the PASI score of 75% or more)', 'timeFrame': 'After 20 weeks of treatment'}]","[{'measure': 'PASI 75', 'description': 'Proportion of patients achieving PASI75 (a reduction of the PASI score of 75% or more compared to baseline)', 'timeFrame': 'At week 4, 8, 12 and 16'}, {'measure': 'PASI 50', 'description': 'Proportion of patients who achieves PASI 50 (a reduction of the PASI score of 50% or more compared to baseline)', 'timeFrame': 'At week 4, 8, 12, 16 and 20'}, {'measure': 'PASI 90', 'description': 'Proportion of patients achieving PASI90 (a reduction of the PASI score of 90% or more compared to baseline', 'timeFrame': 'At week 4, 8, 12, 16 and 20'}, {'measure': 'PGA (Physicians Global Assessment)', 'description': 'On a 5-point scale from 0 (abscence or very mild disease) to 4 (very severe disease) proportion of patients being responders - defined as patients achieving either a score of 0 or 1 or a two point improvement', 'timeFrame': 'At week 4, 8, 12, 16 and 20'}, {'measure': 'PaGA (Patients Global Assessment', 'description': 'Patients evaluation on a 5-point Likert scale 1 (very good) - 5 (very poor)based on the evaluation of: ""Considering all the ways your psoriasis affects you, how have you been doing in the last 24 hours?""', 'timeFrame': 'At week 4,8,12,16 and 20'}, {'measure': 'Pruritus', 'description': 'Patient evaluation of pruritus measured on a VAS (Visual Analog Scale) from 0mm (no pruritus) to 100mm (worst possible pruritus)', 'timeFrame': 'At week 4, 8, 12, 16 and 20'}, {'measure': 'Patient rated QoL (Quality of Life)', 'description': 'Patient filling in 10 questions on the DLQI QoL system with a calculated summary score and analysis of the improvement from baseline', 'timeFrame': 'At week 4, 8, 12, 16 and 20'}, {'measure': 'Adverse events (AEs)', 'description': 'Summary of incidense and severity of AEs and ADRs (Adverse Drug Reactions)/SAEs (Serious Adverse Events)/SUSARs (Suspected Unexpected Serious Adverse Reactions)', 'timeFrame': 'At week 4, 8, 12, 16 and 20'}, {'measure': 'Safety lab test', 'description': 'Summary of lab parameters and clinically relevant changes over the treatment period in standard clinical chemistry tests, standard haematology tests and urin dip stick test', 'timeFrame': 'At week 20'}]",10,18 Years,90 Years,ALL,False,Forward-Pharma GmbH,INDUSTRY,0,252.0,ACTUAL,2025-09-01T16:18:14.666419,v2_robust,True,True,True,False,True,
NCT06395038,IL-2 Plus Abatacept in FTD,"A Phase I Clinical Trial, Using Interleukin-2 (IL-2) and Abatacept in Patients with Frontotemporal Disorders",Abatacept plus Aldesleukin,['Abatacept plus Aldesleukin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Frontotemporal Degeneration,['Frontotemporal Degeneration'],[],RECRUITING,,2024-05-06,2026-04-30,"[{'measure': 'To assess the safety and the tolerability of abatacept plus IL-2 in FTD patients', 'description': 'Number of participants with adverse events and with abnormal laboratory findings (serum chemistry, hematology).', 'timeFrame': '6 months treatment phase'}]","[{'measure': 'To investigate the impact of low dose IL-2 plus abatacept administration on the blood Treg population in FTD patients', 'description': 'Change in Treg percentage out of total # of CD4 cells from baseline to month 6', 'timeFrame': '6 months treatment phase'}]",2,18 Years,86 Years,ALL,False,The Methodist Hospital Research Institute,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:14.666447,v2_robust,True,True,False,False,True,
NCT00967538,Safety and Efficacy of Etanercept in Patients With Psoriasis Who Failed to Respond to Other Biologic Treatments,Safety and Efficacy of Etanercept in Patients With Moderate to Severe Plaque Psoriasis Who Have Shown an Unsatisfactory Response to Adalimumab or Infliximab,etanercept 50 mg,"['etanercept 50 mg', 'Enbrel']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Psoriasis,['Psoriasis'],"['psoriasis', 'etanercept', 'efficacy', 'response', 'anti-TNF alpha', 'treatment efficacy']",COMPLETED,,2009-09,2014-07,"[{'measure': ""Proportion of patients who reach a Physician's Global Assessment (PGA) of clear or almost clear after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg every other week (EOW)."", 'timeFrame': '24 weeks'}]","[{'measure': 'Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Proportion of patients who reach a PGA of clear or almost clear after 12 and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}, {'measure': 'Mean Body Surface Area (BSA) after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}, {'measure': 'Mean BSA after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Mean BSA after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Mean Psoriasis Area and Severity Index (PASI) score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}, {'measure': 'Mean PASI score after 12 weeks and 24 weeks of etanercept for patients who have lost their satisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Mean PASI score after 12 and 24 weeks of etanercept for patients who have shown an unsatisfactory response to adalimumab 40 mg EOW.', 'timeFrame': '24 weeks'}, {'measure': 'Safety of etanercept in patients who have shown an unsatisfactory response to adalimumab, who have lost their satisfactory response to adalimumab or who have lost their satisfactory response to infliximab.', 'timeFrame': '24 weeks'}]",10,18 Years,80 Years,ALL,False,Innovaderm Research Inc.,OTHER,1,89.0,ACTUAL,2025-09-01T16:18:14.666475,v2_robust,True,True,True,False,True,
NCT06673238,"A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants","A First-In-Human Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-722 Following Single and Multiple Ascending Doses in Healthy Adult Subjects and Single Doses in Healthy Adult Asian Subjects",ABBV-722,"['ABBV-722', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteer,['Healthy Volunteer'],"['Healthy Volunteer', 'ABBV-722']",RECRUITING,,2024-10-29,2026-04,"[{'measure': 'Number of Participants with Adverse Events Reported During Safety Evaluations', 'description': 'Safety evaluations will include AE monitoring, vital sign measurements (including orthostatic blood pressure and pulse rate), ECG variables, and clinical laboratory testing (hematology, chemistry, and urinalysis) as a measure of safety and tolerability for the entire study duration. Clinically significant abnormal changes in physical examination findings will be reported as AEs.', 'timeFrame': 'Up to Day 44'}, {'measure': 'Maximum Plasma Concentration (Cmax) of ABBV-722', 'description': 'Cmax of ABBV-722.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Time to Cmax (Tmax) of ABBV-722', 'description': 'Tmax of ABBV-722.', 'timeFrame': 'Up to Day 21'}, {'measure': 'For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Time t (AUCt) of ABBV-722', 'description': 'AUCt of ABBV-722.', 'timeFrame': 'Up to Day 8'}, {'measure': 'For Parts 1 and 2: Area Under the Concentration-Time Curve (AUC) from Time 0 to Infinity (AUCinf) of ABBV-722', 'description': 'AUCinf of ABBV-722', 'timeFrame': 'Up to Day 8'}, {'measure': 'For Part 3: Observed Plasma Concentration at the End of the Dosing Interval (Ctrough) of ABBV-722', 'description': 'Ctrough of ABBV-722.', 'timeFrame': 'Up to Day 21'}, {'measure': 'For Part 3: AUC from Time 0 to the End of Dosing Interval (AUCtau) Following the First and Last Doses of ABBV-722', 'description': 'AUC from AUCtau following the first and last doses of ABBV-722.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Terminal Phase Elimination Rate Constant (Beta) of ABBV-722', 'description': 'Beta of ABBV-722.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Terminal Phase Elimination Half-Life (t1/2) of ABBV-722', 'description': 't1/2 of ABBV-722.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Dose Normalized Cmax', 'description': 'Dose normalized Cmax.', 'timeFrame': 'Up to Day 21'}, {'measure': 'Dose Normalized AUCs', 'description': 'Dose normalized AUCs.', 'timeFrame': 'Up to Day 21'}]",[],11,18 Years,65 Years,ALL,True,AbbVie,INDUSTRY,0,96.0,ESTIMATED,2025-09-01T16:18:14.666498,v2_robust,True,True,False,False,True,
NCT00717938,A Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer,A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer,cisplatinum or carboplatin and e.g.etoposide.,"['cisplatinum', 'cisplatinum or carboplatin and e.g.etoposide.', 'etoposide', 'cisplatinum or carboplatin and e.g.etoposide+enoxaparin', 'carboplatin', 'enoxaparin']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Small Cell Lung Cancer,['Small Cell Lung Cancer'],[],COMPLETED,,2008-06,2017-05,"[{'measure': 'Significant increase of overall survival', 'timeFrame': 'At follow up 1 year after treatment'}]","[{'measure': 'Toxicity', 'timeFrame': 'During treatment'}]",2,18 Years,,ALL,False,Lund University Hospital,OTHER,1,390.0,ACTUAL,2025-09-01T16:18:14.666652,v2_robust,True,True,True,False,False,
NCT00121238,Cilengitide in Treating Patients With Prostate Cancer,"Phase II Evaluation of EMD 121974 (NSC 707544, Cilengitide) in Patients With Non-Metastatic Androgen Independent Prostate Cancer",cilengitide,"['cilengitide', 'EMD 121974']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Prostate Cancer,"['Recurrent Prostate Cancer', 'Stage I Prostate Cancer', 'Stage IIA Prostate Cancer', 'Stage IIB Prostate Cancer', 'Stage III Prostate Cancer']",[],COMPLETED,,2005-01,2015-11,"[{'measure': 'The Number of Patients With a PSA Decline of ≥50%', 'description': 'To assess the rate of Prostate Specific Antigen response associated with EMD121974 therapy in patients with non-metastatic androgen-independent prostate cancer.\n\nThis measure defined as a drop in PSA of at least 50% from the final pre-treatment value.', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Median PSA Slope Difference', 'description': 'Median PSA slope difference was calculated between baseline and 6 months.', 'timeFrame': 'Baseline to 6 months'}, {'measure': 'The Number of Participants With at Least One Incident of Toxicity', 'description': 'Toxicity was evaluated by NCI-CTCAE (ver. 3) criteria in all 15 treated patients (16 patients were enrolled however one progressed prior to treatment) including the two ineligible patients.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Median Survival Time', 'description': '6 of 13 patients were alive at five years. The Median survival time was calculated for all patients.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Mean Time to Progression of Prostate Cancer', 'description': 'Kaplan-Meier estimates of time to progression will be reported.', 'timeFrame': 'Up to 5 years'}]",5,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,16.0,ACTUAL,2025-09-01T16:18:14.666783,v2_robust,True,True,True,False,False,
NCT04627038,Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis,"Randomized, Placebo-Controlled, Phase 2 Clinical Trial to Evaluate LY3556050 for the Treatment of Osteoarthritis Pain",LY3556050,"['LY3556050', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Osteoarthritis,['Osteoarthritis'],[],COMPLETED,,2020-11-12,2021-10-21,"[{'measure': 'Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS)', 'description': 'The NRS was used to describe pain severity. Participants were asked to describe their average pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine.\n\nPosterior mean change from baseline, 95 percent (%) credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Baseline, Week 8'}]","[{'measure': 'Change From Baseline on the Western Ontario and McMaster University Arthritis Index (WOMAC®) Pain Subscale', 'description': 'The WOMAC® is a validated instrument that is extensively used to evaluate the response to medications for the treatment of Osteoarthritis pain. There are 5 questions on the pain subscale, and participants used a 0 to 4 Likert scale to answer each question for the current day: 0 = no pain, and 4 = extreme pain. The scores for the pain subscale were calculated by summing the scores of the 5 questions for each participant at each time point. The range of possible scores is 0 to 20 with higher scores representing worse outcome.\n\nPosterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Change From Baseline on the WOMAC® Stiffness Subscale', 'description': 'The WOMAC® is a validated instrument that is extensively used to evaluate the response to medications for the treatment of Osteoarthritis pain. There are 2 questions in the stiffness subscale and participants used a 0 to 4 Likert scale to answer each question for the current day: 0 = no stiffness, and 4 = extreme stiffness. The scores for the stiffness subscale was calculated by summing the scores of the 2 questions for each participant at each time point. The range of possible scores is 0 to 8 with higher scores representing worse outcome.\n\nPosterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Change From Baseline on the WOMAC® Physical Function Subscale', 'description': 'The WOMAC® is a validated instrument that is extensively used to evaluate the response to medications for the treatment of Osteoarthritis pain. There are 17 questions in the physical function subscale, and participants used a 0 to 4 Likert scale to answer each question for the current day: 0 = no difficulty, and 4 = extreme difficulty. The score for physical function subscale was calculated by summing the scores of the 17 questions for each participant at each time point. The range of possible scores is 0 to 68 with higher scores representing worse outcome.\n\nPosterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Baseline, Week 8'}, {'measure': ""Change From Baseline for Overall Improvement as Measured by Patient's Global Impression of Change"", 'description': ""Patients Global Impression of Change captured the participant's perspective of treatment apart from sub-aspects of the general improvement. This is a numeric scale from 1 to 7: 1 = very much better, and 7 = very much worse.\n\nPosterior mean, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval."", 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Change From Baseline for Worst Pain Intensity as Measured by NRS', 'description': 'The NRS was used to describe pain severity. Participants were asked to describe their worst pain over the past 24 hours, on a scale of 0 to 10: 0 = no pain, and 10 = pain as bad as you can imagine.\n\nPosterior mean, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Change From Baseline on the Visual Analog Scale (VAS) for Pain', 'description': 'VAS was a graphic, single-item scale where participants were asked to describe their pain intensity over the past week, on a scale of 0 to 100: 0 = no pain, and 100 = worst imaginable pain. Participants completed the VAS by placing a line perpendicular to the VAS line at a point that described their pain intensity.\n\nPosterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Change From Baseline on the Sleep Scale From the Medical Outcomes Study (MOS Sleep Scale) - Average Hours of Sleep', 'description': ""The MOS Sleep Scale consists of 12 questions addressing the past week. Question 1 asks time to fall asleep and it is reported in 5-point timeframe categories. Question 2 asks average hours of sleep. In the remaining 10 questions participants report how often a sleep symptom or problem was present on a scale ranging from '0=all of the time' to '5=none of the time.' MOS Sleep scale dimension scores range from 0 to 100 with lower score indicating improvement, except for the dimension of sleep adequacy, where higher scores indicate improvement. Here, the average hours of sleep (i.e., Question 2) is reported as the average number of hours slept each night during the past week (range 0 to 24 hours). Higher number of hours slept indicates improvement.\n\nPosterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval."", 'timeFrame': 'Baseline, Week 8'}, {'measure': 'Total Amount of Rescue Medication Use as Measured by Average Daily Dosage', 'description': 'Total amount of rescue medication use as measured by average daily dosage. Posterior mean change from baseline, 95% credible interval was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval.', 'timeFrame': 'Week 8'}, {'measure': 'Change From Baseline on the EuroQuality of Life Five Dimensions (5D) Five Level (5L) Questionnaire (EQ-5D-5L) Health State Index (United States Algorithm)', 'description': ""The EQ-5D-5L assessed quality of life based on 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The participant was asked to 'check the ONE box that best describes your health TODAY,' choosing from 5 options (no problems, slight problems, moderate problems, severe problems, extreme problems) provided under each dimension. The scores in the 5 dimensions were summarized into a health state index score using the United States algorithm. The health state index value is a single value on a scale from less than 0 to 1 (negative values are valued as worse than dead) with higher scores indicating better health: 0=a health state equivalent to death, and 1=perfect health.\n\nPosterior mean change from baseline, 95% credible intervals was derived using Bayesian mixed model repeated measures. Data presented are posterior mean with 95% credible interval."", 'timeFrame': 'Baseline, Week 8'}]",10,40 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,202.0,ACTUAL,2025-09-01T16:18:14.666807,v2_robust,True,True,True,False,False,
NCT04394858,"Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer","A Prospective, Multi-Institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma",Olaparib,"['Methazolastone', 'SCH 52365', 'KU 0059436', 'Olaparib', 'Temizole', 'M and B 39831', 'Olanib', 'KU0059436', 'AZD-2281', 'PARP Inhibitor AZD2281', 'AZD2281', 'RP-46161', 'Olaparix', 'Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-', 'CCRG-81045', 'TMZ', 'Temomedac', 'Gliotem', 'Lynparza', 'M & B 39831', 'Temodal', 'Temcad', 'AZD 2281', 'KU-0059436', 'Temozolomide', 'Temodar']",26,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Adrenal Gland Pheochromocytoma,"['Advanced Adrenal Gland Pheochromocytoma', 'Advanced Paraganglioma', 'Metastatic Adrenal Gland Pheochromocytoma', 'Metastatic Paraganglioma', 'Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8', 'Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8', 'Unresectable Adrenal Gland Pheochromocytoma', 'Unresectable Paraganglioma']",[],ACTIVE_NOT_RECRUITING,,2021-03-17,2026-02-28,"[{'measure': 'Progression-free survival (PFS)', 'description': 'Will be compared between treatment arms using the un-stratified log-rank test at one-sided level of 0.11 and the p-value will be used for decision making. The hazard ratio will be estimated using a Cox proportional hazards model and the 95% confidence interval for the hazard ratio will be provided. Results from a stratified analysis will also be provided. Kaplan-Meier methodology will be used to estimate the median PFS for each treatment arm, and Kaplan-Meier curves will be produced. Brookmeyer-Crowley methodology will be used to construct the 95% confidence interval for the median PFS for each treatment arm.', 'timeFrame': 'From randomization to the first documentation of disease progression (per Response Evaluation Criteria in Solid Tumors [RECIST] version 1.1) or death, assessed up to 5 years'}]","[{'measure': 'Overall survival (OS)', 'description': 'Patients who are alive will be censored at last follow-up. The distribution of survival time will be estimated using the method of Kaplan-Meier. OS will be compared between treatment arms using the log-rank test. OS medians, survival rates and hazard ratio will be estimated along with 95% confidence intervals.', 'timeFrame': 'From randomization to death due to any cause, assessed up to 5 years'}, {'measure': 'Objective response', 'description': 'Will be assessed by RECIST version 1.1 criteria. Will be estimated using objective response rate where objective response rate is defined as the number of evaluable patients achieving a response (partial response or complete response per RECIST version 1.1) during treatment with study therapy divided by the total number of evaluable patients. Rates of response will be compared across arms using a Chi-Square Test for Proportion. Point estimates will be generated for objective response rates within each arm along with 95% binomial confidence intervals.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Incidence of adverse events', 'description': 'Will be assessed per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The term toxicity is defined as adverse events that are classified as possibly, probably, or definitely related to study treatment. Toxicities will be evaluated via the ordinal Common Terminology Criteria for Adverse Events standard toxicity grading. Similarly, scores (0-4) and the maximum score for each Patient-Reported Outcomes-CTCAE item will be recorded for each patient.', 'timeFrame': 'Up to 5 years'}]",4,12 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,46.0,ESTIMATED,2025-09-01T16:18:14.666916,v2_robust,True,True,False,False,True,
NCT02427958,A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants,"An Open Label, Multicenter Study to Assess the Safety and Efficacy of Leuprorelin in the Treatment of Central Precocious Puberty",Leuprorelin,"['Enantone', 'Leuprorelin']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Central Precocious Puberty,['Central Precocious Puberty'],['Drug Therapy'],COMPLETED,,2015-08-07,2018-11-23,"[{'measure': 'Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)', 'timeFrame': 'Day 1 up to Week 100'}]","[{'measure': 'Percentage of Participants With Regression or no Progression in Tanner Staging at Week 96', 'description': 'Tanner assessment score was used to document the stage of development of puberty through the assessment of secondary sexual characteristics. Female pubertal development staged by pubic hair development and breast size; male pubertal development staged by size of the genitalia and development of pubic hair. Rated in 5 stages: stage 1 (no development) to 5 (adult-like development in quantity and size). Regression or no progression was defined as negative change (improvement) or no change in Tanner score at Week 96 compared to baseline.', 'timeFrame': 'Week 96'}]",2,1 Year,9 Years,ALL,False,Takeda,INDUSTRY,0,307.0,ACTUAL,2025-09-01T16:18:14.666962,v2_robust,True,True,True,False,True,
NCT00483158,First Time in Man Study of Finafloxacin Hydrochloride,"A Double-Blind, Placebo-Controlled, Randomized, Dose-Escalating Study of Single and Multiple Oral Doses of Finafloxacin Hydrochloride in Healthy Subjects and a Study of H. Pylori Treatment in Healthy Carriers",Finafloxacin hydrochloride,['Finafloxacin hydrochloride'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Helicobacter Infections,"['Helicobacter Infections', 'Urinary Tract Infection']","['Helicobacter pylori', 'Fluoroquinolones', 'First in Man']",COMPLETED,,2007-08,2008-05,"[{'measure': 'To evaluate the safety and tolerability of single and multiple oral doses of Finafloxacin HCl by assessing adverse events, physical examinations, clinical chemistry examination, hematology, ECG and urinalysis.', 'timeFrame': '7 days'}]","[{'measure': 'To determine the pharmacokinetic profile of single and multiple oral doses of Finafloxacin HCl in healthy subjects', 'timeFrame': '7 days'}, {'measure': 'To determine the bactericidal activity of urine obtained from healthy subjects after administration of Finafloxacin HCl', 'timeFrame': '7 days'}, {'measure': 'To explore the activity of multiple oral doses of Finafloxacin HCl against Helicobacter pylori using the effect on the urease breath test in healthy carriers as a model', 'timeFrame': '7 days'}]",4,18 Years,55 Years,ALL,True,MerLion Pharmaceuticals GmbH,INDUSTRY,0,95.0,ACTUAL,2025-09-01T16:18:14.666970,v2_robust,True,True,True,False,True,
NCT03787758,"A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B","A Phase 1, Double-blind, Placebo-controlled, Multiple Ascending Dose Study to Determine the Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Healthy Adults With an Open-label Cohort of Patients With Huntington's Disease",SAGE-718,['SAGE-718'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Huntington Disease,['Huntington Disease'],[],COMPLETED,,2019-02-28,2019-10-07,"[{'measure': 'Number of Participants with the Incidence of Adverse Events and Serious Adverse Events.', 'timeFrame': '21 Days'}, {'measure': 'Percentage of participants with change from baseline in vital signs.', 'timeFrame': '21 Days'}, {'measure': 'Change from baseline in electrocardiograms (ECGs) including PR interval, QT interval, QTc interval, QTcF, and rhythm abnormalities', 'timeFrame': '21 Days'}, {'measure': 'Percentage of participants with change from baseline in clinical laboratory parameters.', 'timeFrame': '21 Days'}, {'measure': 'Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS).', 'timeFrame': '21 Days'}]","[{'measure': 'PK profile of SAGE-718 following administration of multiple doses of SAGE-718 Oral Solution as assessed by area under the curve [AUC].', 'timeFrame': '17 Days'}, {'measure': 'PK profile of SAGE-718 following administration of multiple doses of SAGE-718 Oral Solution as assessed by maximum observed concentration [Cmax].', 'timeFrame': '17 Days'}, {'measure': 'PK profile of SAGE-718 following administration of multiple doses of SAGE-718 Oral Solution as assessed by time of occurrence of Cmax [tmax].', 'timeFrame': '17 Days'}]",8,18 Years,70 Years,ALL,False,Sage Therapeutics,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:14.666977,v2_robust,True,True,True,False,True,
NCT04472858,A Study of CS1001 in Combination With Donafenib in Subjects With Advanced Solid Tumors,"A Phase I, Multicenter,Open-label,Dose-Escalation and Expansion Study of CS1001 in Combination With Donafenib in Patients With Advanced Solid Tumors",Donafenib,"['Donafenib', 'CS1001']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Tumor,['Advanced Solid Tumor'],[],UNKNOWN,,2020-10-15,2023-12,"[{'measure': 'Number of participants with adverse events', 'timeFrame': 'From the day of first dose to 21 days after last dose'}, {'measure': 'To determine the dose limiting toxicity (DLT)', 'timeFrame': 'In the dose escalation part, from the day of first dose to 21 days after last dose'}, {'measure': 'To determine the maximum tolerated dose(MTD)', 'timeFrame': 'In the dose escalation part, from the day of first dose to 21 days after last dose'}, {'measure': 'To determine the recommended dose of phase II', 'timeFrame': 'In the dose escalation part, from the day of first dose to 21 days after last dose'}, {'measure': 'Objective response rate as determined by the Invertigator using RECIST V1.1', 'timeFrame': 'In the dose escalation part, from the day of first dose to 21 days after last dose'}]","[{'measure': 'Anti-CS1001 antibody', 'timeFrame': 'From the day of first dose to 21 days after last dose'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': 'From the day of first dose to 21 days after last dose'}, {'measure': 'Overall survival(OS)', 'timeFrame': 'From the day of first dose to 21 days after last dose'}, {'measure': 'Progression free survival(PFS)', 'timeFrame': 'From the day of first dose to 21 days after last dose'}, {'measure': 'Duration of remission (DOR)', 'timeFrame': 'From the day of first dose to 21 days after last dose'}]",10,18 Years,75 Years,ALL,False,"Suzhou Zelgen Biopharmaceuticals Co.,Ltd",INDUSTRY,1,30.0,ESTIMATED,2025-09-01T16:18:14.666984,v2_robust,True,True,False,False,True,
NCT00636558,Coxsackie Virus A21 Administered Intravenously (IV) for Solid Tumour Cancers (PSX-X04),"A Phase I, Open-Label, Cohort Study of Multiple Doses of Cavatak™ (Coxsackie Virus A21) Given Intravenously to Stage IV Solid Tumour Cancer Patients Bearing ICAM-1 With or Without DAF Expressing Tumours (PSX-X04)",CVA21,"['CVA21', 'CAVATAK']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Melanoma,"['Melanoma', 'Breast Cancer', 'Prostate Cancer']","['coxsackie virus', 'melanoma', 'breast cancer', 'prostate cancer']",COMPLETED,,2008-02-29,2012-01-12,"[{'measure': 'The primary objective of the study is to determine the safety and tolerability of CVA21 given by intravenous infusion in multiple escalating doses.', 'timeFrame': 'Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84'}]","[{'measure': 'To obtain preliminary efficacy data, determine the time course of viraemia and its elimination post-administration of CVA21', 'timeFrame': 'Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84'}, {'measure': 'To characterise the time course of the anti-CVA21 antibody response', 'timeFrame': 'Days 1, 2, 5, 6, 7, 8, 12, 16, 20, 28, 42, 56, 84'}]",3,18 Years,,ALL,False,Viralytics,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:14.667036,v2_robust,True,True,True,False,True,
NCT02483858,Study of Oral PQR309 in Patients With Advanced Solid Tumors,Phase I Study of Oral PQR309 in Patients With Advanced Solid Tumors,PQR 309,"['PQR 309', 'PI3K/mTOR/AKT Inhibitor']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],"['oncology, solid tumors']",COMPLETED,,2019-03-21,2019-03-21,"[{'measure': 'To identify the Maximum Tolerated Dose (MTD) of PQR309 administered in different (continuous and intermittent) dosing schedules. To evaluate efficacy of PQR309 in selected patient population: • Solid tumors with PI3K/mTOR activation • Human Papilloma', 'description': 'MTD based on the rate of dose-limiting toxicities. The MTD is defined as the maximum dose level at which ≤ 1/6 patients have dose limiting toxicities (DLTs).', 'timeFrame': 'In average 1 year'}, {'measure': 'Objective response rate (ORR) according to the response evaluation• Solid tumors with PI3K/mTOR activation • Human Papilloma Virus (HPV) positive Head and neck squamous cell carcinoma (HNSCC) containing activating PIK3CA mutations', 'description': 'Expansion part criteria in solid tumors (RECIST), version 1.1', 'timeFrame': 'in average 2 years'}]","[{'measure': 'Number of patients with adverse Events and serious adverse events', 'description': 'Continous Dosing and intermittent dosing ""2days on/5days off', 'timeFrame': 'Cycle1 on Day1,8,15, Cycle 2 and subsequent cycles on Day 1, End of the treatment up to 3 days and as follow up 30 days after last dosing'}, {'measure': 'Number of patients with adverse Events and serious adverse events', 'description': '""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1 after basline, Cycle1 on Day 8,15, Cycle 2 and subsequent cycles on Day 1, End of the treatment up to 3 days and as follow up 30 days after last dosing'}, {'measure': 'Physical examination according to ECOG (Eastern Cooperative Oncology Group) Performance Status', 'description': 'Continous Dosing', 'timeFrame': 'Cycle 1 on Day 8,15, Cycle 2 and subsequent cycles on Day1 , end of treatment up to 3 days after'}, {'measure': 'Physical examination according to ECOG (Eastern Cooperative Oncology Group) Performance Status', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1 , end of treatment up to 3 days after'}, {'measure': 'Physical examination according to ECOG (Eastern Cooperative Oncology Group) Performance Status', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day1,2, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Change in Pulse Rate', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3 after baseline, Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Pulse Rate', 'description': 'Intermittent Dosing ""2 days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Pulse Rate', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day1,2,Cycle 1 on Day 4,8,9,15'}, {'measure': 'Change in Temperature', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3 after baseline, Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Temperature', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Temperature', 'description': 'Intermittent Dosing "" Assessment on Day1,2,Cycle 1 on Day 4,8,9,15', 'timeFrame': 'Assessment on Day1,2,Cycle 1 on Day 4,8,9,15'}, {'measure': 'Change in Respiratory Rate', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3 after baseline, Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Respiratory Rate', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Respiratory Rate', 'description': 'Intermittent Dosing "" Monday/ Thursday""', 'timeFrame': 'Assessment on Day1,2,Cycle 1 on Day 4,8,9,15'}, {'measure': 'Change in Blood Pressure', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3 after baseline, Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Blood Pressure', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Blood Pressure', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day1,2,Cycle 1 on Day 4,8,9,15'}, {'measure': 'Change in Blood Body Weight', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3 after baseline, Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Blood Body Weight', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1,8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in Blood Body Weight', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day1,2,Cycle 1 on Day 4,8,9,15'}, {'measure': 'Change in ECG', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3 after baseline, Cycle 1 on Day 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Change in ECG', 'description': 'Intermittent Dosing ""2days on/5days off"" and ""Monday/ Thursday""', 'timeFrame': 'After Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Depression test (PHQ-9)', 'description': 'Continous Dosing', 'timeFrame': 'After Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Depression test (PHQ-9)', 'description': 'Intermittent Dosing ""2days on/5days off"" and ""Monday/ Thursday""', 'timeFrame': 'Cycle 1 on Day 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Generalized anxiety disorder mood scale score (GAD7)', 'description': 'Continous Dosing and Intermittent Dosing ""2days on/5days off"" and ""Monday/ Thursday""', 'timeFrame': 'Cycle 1 on Day 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Changes in routine blood chemistry', 'description': 'Continous Dosing and Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1, 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Changes in routine blood chemistry', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1 after baseline, Cycle 1 on Day 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Changes of hematology', 'description': 'Continous Dosing and Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1, 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Changes of hematology', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1 after baseline, Cycle 1 on Day 8,15, Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Changes of insulin/Glucose/ C-peptide', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3, ,2,1 after baseline, Cycle 1 on Day 1, Cycle 2 and subsequent cycles on Day1'}, {'measure': 'Changes of insulin/Glucose/ C-peptide', 'description': '"" Intermittent Dosing ""2days on/5days off""""', 'timeFrame': 'Assessment on Day 3, 2,1 after baseline, Cycle 8,9,15 on Day 1'}, {'measure': 'Changes of insulin/Glucose/ C-peptide', 'description': '"" Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle1 on Day 4, 8,9,15'}, {'measure': 'Changes of haemostasis', 'description': 'Continous Dosing and Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Cycle 1 on Day 1, 8, 15 Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Changes of haemostasis', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1 after baseline, Cycle 1 on Day 1,15 Cycle 2 and subsequent cycles on Day1, end of treatment up to 3 days after last medication'}, {'measure': 'Determination of Cmax', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of Cmax', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of Cmax', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determination of AUC 0-24', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of AUC 0-24', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of AUC 0-24', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determination of tmax', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of tmax', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of tmax', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determination of AUClast (area under the curve)', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of AUClast', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of AUClast', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determination of AUC0-∞', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of AUC0-∞', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of AUC0-∞', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determination of t 1/2', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of t 1/2', 'description': 'Intermittent Dosing ""2days on/5days off""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of t 1/2', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determination of RAC (Accumulation Ratio)', 'description': 'Continous Dosing', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,15, Cycle 2 on Day1'}, {'measure': 'Determination of RAC (Accumulation Ratio)', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 3,2,1 after baseline, Cycle 1 on Day 8,9,15'}, {'measure': 'Determination of RAC (Accumulation Ratio)', 'description': 'Intermittent Dosing ""Monday/ Thursday""', 'timeFrame': 'Assessment on Day 1,2 after baseline, Cycle 1 on Day 4,8,9,15'}, {'measure': 'Determine Time to Response (TTR)', 'description': 'Efficacy', 'timeFrame': 'up to 2 years'}, {'measure': 'Determine Duration of Response (DOR)', 'description': 'Defined as the time from the date of the first confirmed response to the first documentation of relapse or progressive disease, whichever occurs first', 'timeFrame': 'baseline and on Day 1 of every subsequential cycle which can be up to 24 months'}, {'measure': 'Time to Treatment Failure (TTF)', 'description': 'Defined as the time from study entry to any treatment failure including disease progression or discontinuation of treatment for any reason (e.g., disease progression, AE, patient preference, initiation of new treatment without documented progression, death)', 'timeFrame': 'Tumor Measurement preferably with a ruler and/or MRI scans e.g. and incorporated clinical signs will be assesses at baseline and on Day 1 of every subsequential cycle which can be up to 24 months'}, {'measure': 'Determine Progression Free Survival (PFS)', 'description': 'Defined as the time from study entry to progression or death due to any cause', 'timeFrame': 'baseline and on Day 1 of every subsequential cycle which can be up to 24 months'}, {'measure': '1- year Survival Rate', 'description': 'Defined as the time from study entry to death as a result of any cause at 1-year cutoff date', 'timeFrame': 'baseline and on Day 1 of every subsequential cycle which can be up to 36 months'}]",62,18 Years,,ALL,False,PIQUR Therapeutics AG,INDUSTRY,8,70.0,ACTUAL,2025-09-01T16:18:14.667055,v2_robust,True,True,True,False,True,
NCT02257658,"Efficacy of Doxycycline Prophylaxis to Reduce Syphilis in High-Risk, HIV-Positive MSM","Doxycycline Prophylaxis or Incentive Payments to Reduce Incident Syphilis Among HIV- Infected Men Who Have Sex With Men Who Continue to Engage in High Risk Sex: A Randomized, Controlled Pilot Study",Doxycycyline,['Doxycycyline'],1,INTERVENTIONAL,['NA'],,,Syphilis,['Syphilis'],"['Men who have Sex with Men', 'HIV-positive', 'Syphilis', 'Contingency Management']",COMPLETED,,2011-09,2013-01,"[{'measure': 'Measure changes in the incidence of Syphilis, Gonorrhea and Chlamydia at 12 weeks, 24 weeks, 26 weeks and 48 weeks in the Doxycycline Arm and Contingency Management Arms', 'timeFrame': '12 Weeks, 24 Weeks, 36 Weeks and 48 Weeks'}]","[{'measure': 'Measure adherence to study visits in the Doxycycline and Contingency Management Arms at Weeks 12, 24, 36 and 48', 'timeFrame': '12 Weeks, 24 Weeks, 36 Weeks and 48 Weeks'}, {'measure': 'Measure adherence to daily Doxycycline Use using Blood Samples in the Doxycycline Arm at Weeks 12, 24 and 36', 'description': 'At Weeks 12, 24 and 36, blood samples were drawn from participants in the Doxycycline arm and sent to a lab to measure doxycyline levels in each participant in the Doxycyline Arm. The purpose of this outcome is to determine if individuals in the Doxycycline Arm are consistently adhering to the daily regimen of the drug.', 'timeFrame': '12 Weeks, 24 Weeks and 36 Weeks'}, {'measure': 'Measure changes in self-report sexual risk behaviors (e.g., condom use, drug use and number of partners) in the Doxycycline and Contingency Management Arms at Weeks 12, 24 and 36', 'description': 'Prior to having labs drawn, participants in both the Doxycycline and Contingency Management Arms were asked about their risk behaviors in the past three months including: meth use, condom use with casual partners, condom use with regular partners, condom use with a main partner, number of casual sexual partners and number of regular sexual partners.', 'timeFrame': '12 Weeks, 24 Weeks and 36 Weeks'}]",4,18 Years,,MALE,True,Los Angeles LGBT Center,OTHER,1,30.0,ACTUAL,2025-09-01T16:18:14.667108,v2_robust,True,True,True,False,False,
NCT02457858,Islet Isolation Using MnTE-2-PyP (BMX-010) - Pilot Study,Manganese Porphyrin MnTE-2-PyP (BMX - 010) Preservation of Islet Cell Mass and Function for Clinical Islet Transplantation,Islet isolation using BMX-010,"['Islet isolation using BMX-010', 'MnTE-2-PyP']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 1 Diabetes,['Type 1 Diabetes'],"['Type 1 Diabetes', 'Islet Transplant']",COMPLETED,,2014-08,2016-08,"[{'measure': 'Islet yield using BMX-010, compared to current standard islet isolation data', 'description': 'To assess the safety of treating pancreata using BMX-010 prior to islet transplantation, treated islet isolation data will be measured and recorded, compared to current standard islet isolation data.', 'timeFrame': 'Day -1 pre-transplant (Islet yield will be recorded as standard-of-care routine practice)'}]","[{'measure': 'Islet isolation quantity and quality using BMX-010, compared to current standard islet isolation data', 'description': 'To demonstrate efficacy of BMX-010 to improve islet isolation quantity and quality prior to islet transplantation, treated islet isolation data will be measured and recorded, compared to current standard islet isolation data.', 'timeFrame': 'Day -1 pre-transplant (Islet isolation quantity and quality will be recorded as standard-of-care routine practice)'}, {'measure': 'AE/SAE morbidity within 1 month post-transplant', 'description': 'To demonstrate safety of BMX-010 in islet transplantation, Adverse Event/Serious Adverse Event morbidity within 1 month post-transplant will be recorded.', 'timeFrame': 'up to 1 month post-transplant'}]",3,18 Years,68 Years,ALL,False,University of Alberta,OTHER,1,5.0,ACTUAL,2025-09-01T16:18:14.667195,v2_robust,True,True,True,False,True,
NCT04336748,HCQ for Primary Prophylaxis Against COVID19 in Health-care Workers,"Low-dose Hydroxychloroquine for Primary Prophylaxis Against SARS-CoV-2 in Health-care Workers - a Randomized, Double-blind, Controlled Trial",Hydroxychloroquine,"['Placebo', 'Hydroxychloroquine']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Sars-CoV2,"['Sars-CoV2', 'Infection Viral', 'Healthcare Worker', 'Prophylaxis']",[],WITHDRAWN,Not feasible,2020-04,2020-08,"[{'measure': 'Symptomatic or asymptomatic SARS-CoV-2 infection confirmed by PCR', 'timeFrame': '4 weeks'}]","[{'measure': 'Viral load during SARS-CoV-2 infection', 'timeFrame': '4 weeks'}, {'measure': 'Seroconversion during the study period', 'timeFrame': '4 weeks'}, {'measure': 'Incidence of any acute respiratory infection', 'timeFrame': '4 weeks'}, {'measure': 'Days of sick leave', 'timeFrame': '4 weeks'}]",5,18 Years,,ALL,True,Medical University of Vienna,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.667245,v2_robust,True,True,False,True,False,Not feasible
NCT00077948,Enoximone Plus Extended-Release Metoprolol Succinate in Subjects With Advanced Chronic Heart Failure,"A Phase III, Randomized, Double-Blind, Double Placebo-Controlled, Multicenter, Three Parallel Group Study of Enoximone Plus Extended-Release Metoprolol Succinate in Advanced CHF Subjects Previously Intolerant to Beta-Blocker Treatment",Enoximone,"['Metoprolol succinate', 'Placebo to match metoprolol succinate', 'Placebo to match enoximone', 'Enoximone']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Heart Failure, Congestive","['Heart Failure, Congestive']","['positive inotrope', 'enoximone', 'beta-blocker', 'intolerant']",TERMINATED,,2003-07,2005-06,"[{'measure': 'Proportion of participants experiencing improved metoprolol tolerability when coadministered with enoximone', 'description': 'Improved tolerability measured by increased left ventricular ejection fraction (LVEF), improvement of heart failure symptoms, and improvement in submaximal exercise tolerance.', 'timeFrame': 'Baseline to Week 36'}]",[],1,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,1,175.0,,2025-09-01T16:18:14.667344,v2_robust,True,True,False,True,False,
NCT00132548,A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children,A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children,Pyrimethamine/sulfadoxine,"['Amodiaquine', 'Artesunate', 'Pyrimethamine/sulfadoxine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Malaria,['Malaria'],"['Malaria', 'Children', 'Intermittent preventive treatment', 'Senegal']",COMPLETED,,2004-06,2004-12,[{'measure': 'Prevalence of drug resistance'}],"[{'measure': 'Incidence of clinical malaria'}, {'measure': 'Side effects'}]",3,1 Year,5 Years,ALL,False,London School of Hygiene and Tropical Medicine,OTHER,3,2200.0,,2025-09-01T16:18:14.667363,v2_robust,True,True,True,False,False,
NCT00210548,A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia,"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (50 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Subjects With Schizophrenia",paliperidone palmitate,['paliperidone palmitate'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],"['schizophrenia', 'intramuscular injection', 'antipsychotic agents', 'dementia praecox', 'paliperidone palmitate', 'mental disorders', 'PANSS.']",COMPLETED,,2005-04,2006-06,[{'measure': 'The change in the total score of the Positive and Negative Syndrome Scale for Schizophrenia (PANSS) from the beginning to the end of the double-blind treatment period or to the last post-randomization assessment.'}],"[{'measure': ""The investigator's Clinical Global Impression of the Severity (CGI-S) of schizophrenia and rating of mental function on a Personal and Social Performance Scale (PSP). Evaluations of adverse events, laboratory tests, and other measures of drug safety.""}]",2,18 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,366.0,ACTUAL,2025-09-01T16:18:14.667373,v2_robust,True,True,True,False,True,
NCT00448955,Open-Label Study of ARD-0403 in Testosterone Deficient Men,"A Phase III Open-Label Study of the Efficacy and Safety of ARD-0403, a Testosterone Cream, in Testosterone Deficient Men",ARD-0403,['ARD-0403'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypogonadism,['Hypogonadism'],[],COMPLETED,,2007-05,2008-02,[{'measure': 'Pharmacokinetic'}],[{'measure': 'Safety and tolerability'}],2,18 Years,,MALE,False,Ardana Bioscience Ltd,INDUSTRY,0,150.0,ESTIMATED,2025-09-01T16:18:14.667583,v2_robust,True,True,True,False,True,
NCT04450355,Effects of Continuous Infusion of Intravenous Nefopam on Postoperative Pain and Opioid Consumption After VATS,Effects of Continuous Infusion of Intravenous Nefopam on Postoperative Pain and Opioid Consumption After Video Assisted Thoracic Surgery: A Double Blind Randomized Controlled Trial,Nefopam 80mg/day,"['Nefopam 80mg/day', 'Normal saline']",2,INTERVENTIONAL,['NA'],,,Postoperative Pain,['Postoperative Pain'],['Postoperative Pain'],COMPLETED,,2020-07-30,2021-11-10,"[{'measure': 'Total fentanyl consumption during 24 hours', 'description': 'postoperative fentanyl consumption (mcg) via IV patient controlled analgesia', 'timeFrame': 'postoperative 24 hours'}]","[{'measure': 'Total fentanyl consumption', 'description': 'postoperative fentanyl consumption (mcg) via IV patient controlled analgesia', 'timeFrame': 'postoperative 48 hours'}, {'measure': 'Postoperative pain score', 'description': '11-pointed NRS pain score at resting/coughing/movement NRS (0-10): 0, ""no pain""; 10, ""worst pain imaginable""', 'timeFrame': 'postoperative 24, 48 hours'}, {'measure': 'Postoperative nausea and vomiting', 'description': 'Incidence of postoperative nausea and vomiting (%)', 'timeFrame': 'postoperative 24, 48 hours'}, {'measure': 'chronic postsurgical pain', 'description': 'Incidence of chronic postsurgical pain (NRS ≥ 3) (%)', 'timeFrame': '3-months after surgery'}]",5,19 Years,70 Years,ALL,False,Seoul National University Hospital,OTHER,1,90.0,ACTUAL,2025-09-01T16:18:14.667591,v2_robust,True,True,True,False,False,
NCT00187655,"Effect of, OAT3, on the Renal Secretion of Cefotaxime","Effect of Genetic Variation in the Transporter, OAT3, on the Renal Secretion of Cefotaxime",Cefotaxime,"['Cefotaxime', 'Claforan', 'Cefotaxime Sodium']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Focus Groups,['Focus Groups'],['Healthy volunteers willing to be dosed with cefotaxime'],COMPLETED,,2004-01,2013-12,"[{'measure': 'Effect of OAT3 on Renal Secretion of Cefotaxime IV Based on Genotype', 'description': 'Participants were stratified by their OCT3 genotype, heterozygous vs homozygous. The renal clearance of cefotaxime was measured by urine content of cefotaxime metabolites in participants after the single IV push administration of 2 grams of cefotaxime.', 'timeFrame': 'post dose up to 24 hours'}]",[],1,18 Years,45 Years,ALL,True,"University of California, San Francisco",OTHER,0,24.0,ACTUAL,2025-09-01T16:18:14.667650,v2_robust,True,True,True,False,False,
NCT00420355,Pharmacokinetic Study of Two HIV Protease Inhibitors in Patients,The Pharmacokinetics of Lopinavir/Ritonavir in Combination With Atazanavir in HIV-Infected Subjects,atazanavir,"['lopinavir/ritonavir', 'Reyataz 300 mg capsules', 'atazanavir', 'Kaletra 200 mg/50 mg tablets']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,HIV Infection,['HIV Infection'],"['antiretroviral therapy', 'protease inhibitors', 'drug interactions', 'HIV infection', 'acquired immunodeficiency syndrome', 'Treatment Experienced']",TERMINATED,Unexpected adverse event,2007-04,2008-09,"[{'measure': 'Mean pharmacokinetic parameters (Cmax, Cmin, AUC) for lopinavir, ritonavir, atazanavir', 'timeFrame': 'Day 6, Day 12 or 16, Day 20'}]","[{'measure': 'Safety (e.g., GI tolerance, lab abnormalities, ECG changes)', 'timeFrame': 'Day 6, Day 12 or Day 16, Day 20'}]",2,18 Years,60 Years,ALL,False,University of Oklahoma,OTHER,1,19.0,ACTUAL,2025-09-01T16:18:14.667698,v2_robust,True,True,False,True,True,Unexpected adverse event
NCT01813955,Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia,PDE Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia,Papaverine or placebo,"['Papaverine', 'Papaverine or placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Schizophrenia,"['Schizophrenia', 'Cognitive Deficits']","['phosphodiesterase inhibitor', 'Psychophysiology', 'Cognition', 'Schizophrenia', 'Papaverine']",TERMINATED,Patient recruitment insufficient,2011-06,2013-06,"[{'measure': 'psychophysiology', 'description': 'Prepulse inhibition of the startle reflex, Mismatch negativity, P300 amplitude', 'timeFrame': '1 hour after intake of capsule with papaverine or placebo'}]","[{'measure': 'Hemodynamic changes', 'description': 'Changes in Hemodynamics, as observed by MR techniques', 'timeFrame': '1 hour after intake of capsule with papaverine or placebo'}]",2,18 Years,60 Years,MALE,True,University of Copenhagen,OTHER,1,5.0,ACTUAL,2025-09-01T16:18:14.667708,v2_robust,True,True,False,True,False,Patient recruitment insufficient
NCT02995655,CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia,A Pilot Study of CX-01 Combined With Azacitidine in the Treatment of Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia,CX-01,"['ODSH', 'Azacitidine', 'CX-01', 'Vidaza®', 'Ladakamycin', '2-O, 3-O desulfated heparin']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Myelodysplastic Syndromes,"['Myelodysplastic Syndromes', 'Acute Myeloid Leukemia', 'AML', 'MDS']",[],COMPLETED,,2017-04-07,2019-04-29,"[{'measure': 'Overall response rate (partial response or higher)', 'description': '* Overall response rate = the percentage of patients obtaining partial response or higher\n* Patients will be assessed for response according to modified International Working Group (IWG) criteria', 'timeFrame': '30 days following completion of treatment (estimated to be 28 weeks)'}]","[{'measure': 'Progression-free survival (PFS)', 'description': '* The interval from the date of first dose of study drug to disease progression or death.\n* Described by median time-to-event and a 95% confidence interval, if estimable, using Kaplan-Meier models', 'timeFrame': 'Up to 5 years'}, {'measure': 'Disease-free survival (DFS)', 'description': '* The interval from the date of first documentation of a CR to date of recurrence or death. This is determined only for patients achieving a CR\n* Described by median time-to-event and a 95% confidence interval, if estimable, using Kaplan-Meier models', 'timeFrame': 'Up to 5 years'}, {'measure': 'Overall survival (OS)', 'description': '* The date of first dose of study drug to the date of death from any cause.\n* Described by median time-to-event and a 95% confidence interval, if estimable, using Kaplan-Meier models', 'timeFrame': 'Up to 5 years'}, {'measure': 'Safety and tolerability of regimen as measured by adverse events tabulated by patient', 'description': '-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 will be utilized for all toxicity reporting.', 'timeFrame': '30 days following completion of therapy (estimated to be 28 weeks)'}]",5,18 Years,,ALL,False,Washington University School of Medicine,OTHER,1,20.0,ACTUAL,2025-09-01T16:18:14.667748,v2_robust,True,True,True,False,True,
NCT03571126,Olanzapine for the Prevention and Treatment of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer,"Olanzapine as First Line Treatment for Prevention of Nausea and Vomiting Induced by Chemotherapy of Lung Cancer: a Multicenter, Double-blind and Randomized Trial",Olanzapine,"['Placebos', 'Olanzapine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Chemotherapy-induced Nausea and Vomiting,"['Chemotherapy-induced Nausea and Vomiting', 'Lung Cancer']",[],UNKNOWN,,2019-05-09,2023-08-01,"[{'measure': 'Incidence rate of no delayed nausea and vomiting', 'description': 'Number of participants with nausea and vomiting occuring within 24 hours after chemotherapy in all participants.', 'timeFrame': '1 week'}]","[{'measure': 'Complete response of acute nausea and vomiting', 'description': 'Number of participants with no nausea and vomiting occuring within 24 hours after chemotherapy as assessed by CTCAE v4.0.', 'timeFrame': '1 week'}, {'measure': 'Complete response of delayed nausea and vomiting', 'description': 'Number of participants with no nausea and vomiting occuring in 24 hours to 120 hours after chemotherapy as assessed by CTCAE v4.0.', 'timeFrame': '1 week'}, {'measure': 'Disease control rate', 'description': 'Number of participants who reach complete response or partial response.', 'timeFrame': '1 week'}, {'measure': 'Quality of life of participants by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 13 scale', 'description': 'Quality of life of participants is measured with The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13(QLQ-LC13) scale which is filled by participants themselves. The questionnaire is consist of several symptoms measured by scores range from 1 to 7, the higher the symptoms are scored, the worse the quality of life is.', 'timeFrame': '1 week'}, {'measure': 'Quality of life of participants by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Lung Cancer 30 scale', 'description': 'Quality of life of participants is measured with EORTC QLQ-LC30 scale which is filled by participants themselves. The questionnaire is consist of several symptoms measured by scores range from 1 to 7, the higher the symptoms are scored, the worse the quality of life is.', 'timeFrame': '1 week'}, {'measure': 'Quality of life of participants by Functional Assessment of Cancer Therapy-Lung cancer scale', 'description': 'Quality of life of participants is measured with Functional Assessment of Cancer Therapy-Lung cancer (FACT-L) scale which is filled by participants themselves. The FACT-L, version 4, is a combination of the 27-item FACT-General (FACT-G) and the 9-item Lung Cancer Subscale (LCS) which measures multidimensional quality of life. The FACT-L score ranges from 0 to 136. The higher the score obtained by each patient in question, the greater the final score of the subscale and the better the quality of life.', 'timeFrame': '1 weeks'}]",7,18 Years,70 Years,ALL,False,Zunyi Medical College,OTHER,5,156.0,ESTIMATED,2025-09-01T16:18:14.668023,v2_robust,True,True,False,False,False,
NCT03493126,"Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function","A Pilot Randomized Controlled Trial of Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function",Estradiol,"['Estradiol', 'Estrace']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Vaginal Atrophy,['Vaginal Atrophy'],"['postpartum, local estrogen']",COMPLETED,,2018-10-15,2020-09-01,"[{'measure': 'Vulvar Assessment Scale (VUAS)', 'description': 'The VUAS is a four-item measurement administered by a clinical provider that quantifies and rates the patient\'s responses to questions of dryness, soreness, irritation and pain to external stimulation. Patients are asked whether they have experienced specific symptoms (""yes/no"") during the past 4 weeks and rate symptom severity (""none,"" ""mild,"" ""moderate,"" ""severe""). The first 3 items assess dryness, soreness, and irritation during routine activities excluding sexual intercourse and the fourth item assesses pain with external manual stimulation. An option for ""no attempt"" indicates a patient has not been sexually active within the past 4 weeks. Each item in the VuAS is scored from 0 (none) to 3 (severe) with composite scores calculated by taking the mean of the items when at least two of four items are not missing. Higher scores indicate worse symptoms. The minimum composite score is 0 and maximum composite score is 3.', 'timeFrame': '3 months'}]","[{'measure': 'Depression', 'description': 'Edinburgh Postnatal Depression Scale (EPDS) The EPDS is a validated 10-question depression assessment for postpartum women, which includes anxiety symptoms and excludes constitutional symptoms associated with depression common in the postpartum period, such as changes in sleeping patterns. Questions 1, 2, \\& 4 are scored 0, 1, 2 or 3 with top box scored as 0 and the bottom box scored as 3. Questions 3 and 5--10 are reverse scored, with the top box scored as a 3 and the bottom box scored as 0. Minimum total score: 0 Maximum total score: 30. Total score of 10 or higher may be indicative of postpartum depression.', 'timeFrame': '3 months'}, {'measure': 'Urinary Symptoms', 'description': 'Urinary Distress Inventory (UDI-6) The UDI-6 is a questionnaire that includes 6 items evaluating bother from urinary symptoms with higher scores indicating more disability. Each item is scored from 0-3. The total score is the average individual score multiplied by 25. The minimal score is 0 and maximum score is 100.', 'timeFrame': '3 months'}, {'measure': 'Fecal Incontinence', 'description': 'Fecal Incontinence Severity Index (FISI) for bowel symptoms The FISI evaluates patient responses symptom severity to fecal incontinence with higher scores indicating more bothersome anal incontinence symptoms. The FISI score ranges from 0 to 61 with higher score indicating higher severity of the fecal incontinence.', 'timeFrame': '3 months'}, {'measure': 'Sexual Function', 'description': 'Female Sexual Function Index (FSFI) The FSFI is a validated questionnaire to assess sexual function in six domains of sexual function, including desire, arousal, lubrication, orgasm, satisfaction, and pain over the 4 weeks prior to administration of questionnaire with lower scores indicating more sexual dysfunction. The FSFI score ranges from 2-36 with LOWER score indicating worse sexual dysfunction.', 'timeFrame': '3 months'}, {'measure': 'Satisfaction Via Likert Scale', 'description': 'Likert scale Satisfaction will be assessed using the patient satisfaction questionnaire in response to the question, ""How satisfied were you with your progress with this treatment?""', 'timeFrame': '3 months'}, {'measure': 'Adverse Outcomes', 'description': 'At each clinical/research visit the participant will be asked about any adverse events (AEs). AEs will be reported with study outcomes.', 'timeFrame': '3 months'}]",7,18 Years,,FEMALE,True,Ohio State University,OTHER,1,59.0,ACTUAL,2025-09-01T16:18:14.668114,v2_robust,True,True,True,False,True,
NCT00503126,Bivalirudin as a Procedural Anticoagulant in Pediatrics,Bivalirudin (Angiomax®) As A Procedural Anticoagulant In The Pediatric Population Undergoing Intravascular Procedures For Congenital Heart Disease,bivalirudin,"['Angiomax/Angiox', 'bivalirudin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cardiology,['Cardiology'],"['pediatrics', 'bivalirudin']",COMPLETED,,2007-08,2008-07,"[{'measure': 'PK/PD and safety', 'timeFrame': '30 days'}]",[],1,,16 Years,ALL,False,The Medicines Company,INDUSTRY,0,110.0,ACTUAL,2025-09-01T16:18:14.668203,v2_robust,True,True,True,False,True,
NCT04505826,"A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer","A Phase I Dose Escalation and Dose Expansion and Phase II Monotherapy Open-label, First-in-Human, Multicenter Study of OP-1250 in Adult Subjects With Advanced and/or Metastatic Hormone Receptor (HR)-Positive, HER2-negative Breast Cancer",OP-1250,['OP-1250'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Hormone Receptor Positive Breast Carcinoma,"['Hormone Receptor Positive Breast Carcinoma', 'HER2-negative Breast Cancer']",[],COMPLETED,,2020-08-13,2024-07-30,"[{'measure': 'Dose Limiting Toxicities (DLT)', 'description': 'To determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of OP-1250, the incidence of DLTs will be assessed.', 'timeFrame': 'The first 28 days of treatment'}, {'measure': 'Characterize the incidence, nature and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) of OP-1250', 'description': 'Characterize the incidence, nature and severity of TEAEs and SAEs of OP-1250 according to NCI-CTCAE version 5.0', 'timeFrame': 'Up to 42 days after end of treatment'}, {'measure': 'Pharmacokinetics of OP-1250', 'description': 'Plasma concentrations of OP-1250 will be assessed at predefined intervals', 'timeFrame': 'Every 28 days'}, {'measure': 'Anti-tumor activity of OP-1250', 'description': 'Tumor response will be evaluated in patients with measurable or evaluable disease, using RECISTv1.1 guidelines', 'timeFrame': 'Every 8 weeks'}]",[],4,18 Years,,ALL,False,"Olema Pharmaceuticals, Inc.",INDUSTRY,0,153.0,ACTUAL,2025-09-01T16:18:14.668211,v2_robust,True,True,True,False,True,
NCT02011126,Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors,"A Phase II Study of Imetelstat (GRN163L, NSC# 754228) in Children With Relapsed or Refractory Solid Tumors",Imetelstat Sodium,"['GRN163L, Sodium Salt', 'GRN163L', 'Imetelstat Sodium']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hepatoblastoma,"['Hepatoblastoma', 'Previously Treated Childhood Rhabdomyosarcoma', 'Recurrent Childhood Liver Cancer', 'Recurrent Childhood Rhabdomyosarcoma', 'Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor', 'Recurrent Neuroblastoma', 'Recurrent Osteosarcoma', 'Rhabdomyosarcoma']",[],WITHDRAWN,IND no longer available.,2014-06-30,,"[{'measure': 'Objective response (complete response [CR] or partial response [PR]) according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria or MIBG scoring criteria', 'description': 'Response rates will be calculated as the percent of evaluable patients who are responders, and confidence intervals will be constructed accounting for the two-stage design. Each disease stratum will be reported separately.', 'timeFrame': 'Up to 126 days (6 courses)'}, {'measure': 'Incidence of grade 3 or higher adverse events using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0', 'description': 'Toxicity tables will be constructed to summarize the observed incidence in each reporting period by type of toxicity and grade. The relative frequency of each type of toxicity will be quantified as the number of toxicity-evaluable cycles in which the adverse event (AE) was noted at grade 3 or higher considered by the treating physician to be possibly, probably or definitely related to one of the agents in the regimen divided by the number of toxicity-evaluable courses administered to patients enrolled on the trial.', 'timeFrame': 'Up to 126 days (6 courses)'}]","[{'measure': 'Progression-free survival', 'description': 'The probability of remaining progression-free as a function of days since enrollment will be calculated according to the method of Gray accounting for censoring and the competing events.', 'timeFrame': 'Date of enrollment until the end progression-free interval (PFI) date, calculated as the date of disease progression, date of death, date of removal of all tumor by surgery or last patient contact, whichever occurs first, assessed up to 3 years'}]",3,1 Year,30 Years,ALL,False,Children's Oncology Group,NETWORK,1,0.0,ACTUAL,2025-09-01T16:18:14.668224,v2_robust,True,True,False,True,True,IND no longer available.
NCT01223326,N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection,A Randomized Controlled Trial of N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection Performed Under Ischemic Preconditioning and Intermittent Portal Triad Clamping,Acetylcysteine (NAC),"['Saline', 'Acetylcysteine (NAC)', 'Flumil']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Hepatectomy,"['Hepatectomy', 'Reperfusion Injury']",['Acetylcysteine'],COMPLETED,,2003-01,2007-12,"[{'measure': 'Laboratory results', 'description': 'Coagulation + cytolysis + cholestasis + lactic acid', 'timeFrame': '24 hours'}]","[{'measure': 'Inflammation', 'description': 'Cytokines, adhesion molecules (P-selectin and ICAM-1) and nuclear factor kappaB (NF-kappaB). Circulating neutrophils/platelets. Oxidative stress of neutrophils and apoptosis.', 'timeFrame': '24 hours'}]",2,18 Years,70 Years,ALL,False,"Clinica Universidad de Navarra, Universidad de Navarra",OTHER,0,46.0,ACTUAL,2025-09-01T16:18:14.668250,v2_robust,True,True,True,False,False,
NCT06238778,Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec,"A Phase 2b Randomized, Double-blind Trial Comparing HDV-Insulin Lispro Versus Insulin Lispro Alone in Adults With Type 1 Diabetes Receiving Insulin Degludec",HDV-Lispro,"['LIS', 'HDV-L', 'Lispro', 'HDV-Lispro']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Diabetes Mellitus, Type 1","['Diabetes Mellitus, Type 1']","['Diabetes Mellitus Type 1', 'CGM', 'Randomized', 'HDV', 'Lispro']",ACTIVE_NOT_RECRUITING,,2024-01-23,2025-12,"[{'measure': 'hypoglycemia events', 'description': 'CGM-measured rates of nocturnal level 2 hypoglycemia events', 'timeFrame': 'during the first 6 weeks of the maintenance period'}, {'measure': 'hypoglycemia percentage of time', 'description': 'CGM-measured nocturnal percent time', 'timeFrame': 'during the first 6 weeks of maintenance period'}]","[{'measure': 'blood chemistry values', 'description': 'Triglyceride levels, Liver enzymes', 'timeFrame': 'baseline through study completion, an average of 7 months'}]",3,18 Years,79 Years,ALL,False,"Diasome Pharmaceuticlas, Inc.",INDUSTRY,0,227.0,ACTUAL,2025-09-01T16:18:14.668391,v2_robust,True,True,False,False,False,
NCT00479778,Study Of Pharmacokinetic (PK) Profile of Bazedoxifene (BZA) in 2 BZA/Conjugated Estrogen Forms,"An Open Label, Randomized, Multicenter Study To Compare Bazedoxifene Steady-State Exposures Obtained With 2 Bazedoxifene Acetate/Conjugated Estrogen Formulations In Postmenopausal Women",Bazedoxifene/conjugated estrogens,['Bazedoxifene/conjugated estrogens'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Postmenopause,['Postmenopause'],['Postmenopause'],COMPLETED,,2007-04,2007-07,[{'measure': 'Pharmacokinetic analyses.'}],[],1,40 Years,65 Years,FEMALE,True,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,72.0,,2025-09-01T16:18:14.668511,v2_robust,True,True,True,False,False,
NCT01983878,A Study of Ramucirumab in Treating Japanese Participants With Metastatic Gastric or Gastroesophageal Junction Cancer,A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients,Ramucirumab,"['IMC-1121B', 'Ramucirumab', 'LY3009806']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastric Cancer,['Gastric Cancer'],[],COMPLETED,,2013-12,2016-02,"[{'measure': 'Percentage of Participants Who Are Progression-Free at 12 Weeks (Progression-Free Survival [PFS] Rate at 12 Weeks)', 'description': 'The 12-week PFS rate is the probability of participants who survived during the first 12 weeks in the study without disease progression. It was estimated using the Kaplan-Meier method for the main analysis of the 12-week PFS rate.', 'timeFrame': '12 Weeks'}]","[{'measure': 'Progression-Free Survival (PFS)', 'description': 'The time from baseline to measured Progressive Disease (PD) as defined by RECIST v.1.1 \\[defined as \\> 20% increase from smallest sum of longest diameter recorded since treatment started (best response)\\], or death due to any cause, whichever is first.', 'timeFrame': 'Baseline to Measured PD or Death from Any Cause (Up to 30.3 weeks)'}, {'measure': 'Percentage of Participants Achieving Complete Response (CR) or Partial Response (PR) [Objective Response Rate (ORR)]', 'description': 'Participants achieved an objective response if they had a best overall response of CR or PR. According to RECIST v1.1, PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter; CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all nontarget lesions, and the normalization of tumor marker levels \\[if tumor markers were initially above the upper limit of normal (ULN)\\]. The percentage of participants who achieved an objective response = (number of participants with CR or PR)/(number of participants assessed)\\*100.', 'timeFrame': 'Baseline to Measured PD or Death from Any Cause (Up to 38.0 Weeks)'}, {'measure': 'Percentage of Participants Achieving Stable Disease (SD) or a Confirmed CR or PR [Disease Control Rate (DCR)]', 'description': 'Participants achieved disease control if they had a best overall response of CR, PR or SD. According to RECIST v1.1, CR was the disappearance of all non-nodal target lesions, with the short axes of any target lymph node reduced to \\<10 mm, the disappearance of all non-target lesions, and the normalization of tumor marker levels (if tumor markers were initially above the ULN); PR was defined as at least a 30% decrease in the sum of the diameters of target lesions (including the short axes of any target lymph node), taking as reference the baseline sum diameter. SD was neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as PD, taking as reference the smallest sum diameter since treatment started. The percentage of participants who achieved disease control = (number of participants with CR, PR, or SD)/(number of participants assessed)\\*100.', 'timeFrame': 'Baseline to Measured PD or Death from Any Cause (Up to 12 Months)'}, {'measure': 'Overall Survival (OS)', 'description': 'The OS time is defined as the time from baseline to the date of death from any cause. If a participant is not known to have died on or before the date of data cut-off, OS data will be censored on the last date (on or before the cut-off date) the participant was known to be alive.', 'timeFrame': 'Baseline to Death from Any Cause (Up to 13 Months)'}, {'measure': 'Number of Participants With Anti-Ramucirumab Antibodies', 'description': 'A sample will be considered positive for circulating anti-ramucirumab antibodies if it exhibits a post-baseline antibody level that exceeds the upper 95% confidence interval of the mean determined from the normal anti-ramucirumab level seen in healthy untreated individuals. A participant will be considered to have an anti-ramucirumab response if there are 2 consecutive positive samples or if the final sample tested is positive.', 'timeFrame': 'Cycle 1: Pre-infusion, Cycle 2: Pre-infusion, Cycle 3: Pre-infusion, Follow Up'}, {'measure': 'Pharmacokinetics (PK): Maximum Concentration (Cmax) of Ramucirumab', 'timeFrame': 'Cycle 1 Day 1: Pre-Dose, End of Infusion. 1, 4, 23, 47, 95, 167, 263, and 335 Hours Post-Dose'}, {'measure': 'PK: Area Under the Curve Time Zero to Infinity (AUC[0-∞]) of Ramucirumab', 'timeFrame': 'Cycle 1 Day 1: Pre-Dose, End of Infusion: 1, 4, 23, 47, 95, 167, 263, and 335 Hours Post-Dose'}]",8,20 Years,,ALL,False,Eli Lilly and Company,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:14.668540,v2_robust,True,True,True,False,False,
NCT02203578,Romidepsin in Treating Patients With Steroid-Refractory Graft-versus-Host Disease,A Pilot Study of Romidepsin for Therapy of Graft-versus-Host Disease,romidepsin,"['romidepsin', 'Istodax', 'FR901228', 'FK228']",4,INTERVENTIONAL,['NA'],,,Graft Versus Host Disease,['Graft Versus Host Disease'],[],TERMINATED,slow accrual,2014-11,2016-06-14,"[{'measure': 'Incidence of aGVHD', 'timeFrame': 'At 28 days after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 1 month after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 3 months after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 6 months after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 9 months after initiation of romidepsin'}, {'measure': 'Incidence of cGVHD', 'timeFrame': 'At 12 months after initiation of romidepsin'}]","[{'measure': 'Total Duration of Immunosuppressive Therapy', 'timeFrame': 'Up to 12 months after initiation of romidepsin'}, {'measure': 'Rate of Documented Infection', 'timeFrame': 'Up to 12 months after initiation of romidepsin'}, {'measure': 'T Cell Kinetics - Reconstitution', 'timeFrame': 'Up to 12 months after initiation of romidepsin'}]",9,18 Years,,ALL,False,"Rutgers, The State University of New Jersey",OTHER,2,1.0,ACTUAL,2025-09-01T16:18:14.668607,v2_robust,True,True,False,True,False,slow accrual
NCT05115578,Remifentanil Effect-site Prediction by Algometry,Remifentanil Pharmacodynamics During Conscious Sedation From the Algometry Perspective. An Essential Standpoint to be Considered in Opioids Time-course Modelling Validation,Remifentanil 1 MG Injection [Ultiva],"['Remifentanil 1 MG Injection [Ultiva]', 'Opioid', 'Benzodiazepine', 'Saline solution', 'Midazolam 1 MG/ML Prefilled Syringe', '0.9% Sodium Chloride Injection']",6,OBSERVATIONAL,[],,,Conscious Sedation Failure During Procedure,['Conscious Sedation Failure During Procedure'],"['Remifentanil', 'Algometry', 'Pharmacodynamics', 'TCI Infusion system', 'Conscious Sedation']",COMPLETED,,2017-03-01,2020-09-30,"[{'measure': 'Pressure pain threshold (PPT) Baseline', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry before starting the administration of remifentanil.', 'timeFrame': 'Baseline'}, {'measure': 'Pressure pain threshold (PPT) 1.5 minutes', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 1.5 minutes after starting the administration of remifentanil.', 'timeFrame': '1.5 minutes'}, {'measure': 'Pressure pain threshold (PPT) 5 minutes', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 5 minutes after starting the administration of remifentanil.', 'timeFrame': '5 minutes'}, {'measure': 'Pressure pain threshold (PPT) 10 minutes', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 10 minutes after starting the administration of remifentanil.', 'timeFrame': '10 minutes'}, {'measure': 'Pressure pain threshold (PPT) 15 minutes', 'description': 'Measurement of pressure pain threshold(0 - 1.000 kPa) by algometry 15 minutes after starting the administration of remifentanil.', 'timeFrame': '15 minutes'}, {'measure': 'Pressure pain threshold (PPT) 18 minutes', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 18 minutes after starting the administration of remifentanil.', 'timeFrame': '18 minutes'}, {'measure': 'Pressure pain threshold (PPT) 20 minutes', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 20 minutes after starting the administration of remifentanil.', 'timeFrame': '20 minutes'}, {'measure': 'Pressure pain threshold (PPT) 25 minutes', 'description': 'Measurement of pressure pain threshold (0 - 1.000 kPa) by algometry 25 minutes after starting the administration of remifentanil.', 'timeFrame': '25 minutes'}, {'measure': 'Infusion rate', 'description': 'Remifentanil infusion rate (ml/h) administered during the experiment to the patient provided by the TCI system.', 'timeFrame': 'Continous measurements every 1 second for the whole experiment of 25 minutes'}, {'measure': 'Remifentanil Plasma Concentration (Cp)', 'description': ""Patient's remifentanil plasma concentration (ng/ml) evolution during the experiment given by Minto's model implemented in the TCI system."", 'timeFrame': 'Continous measurements every 1 second for the whole experiment of 25 minutes'}, {'measure': 'Remifentanil Effect Concentration (Ce)', 'description': ""Patient's remifentanil effect concentration (ng/ml) evolution during the experiment given by Minto's model implemented in the TCI system."", 'timeFrame': 'Continous measurements every 1 second for the whole experiment of 25 minutes'}]","[{'measure': 'Age', 'description': 'Apart from standard anthropometric data (Weight, Height, etc), age is of significant relevance for evaluating the possible effect of age on the pharmacodynamic properties of remifentanil and the algometry.', 'timeFrame': 'Single annotation.'}, {'measure': 'Mean arterial pressure (MAP) Baseline', 'description': 'Baseline mean arterial pressure (mmHg) from standard hemodynamic monitor.', 'timeFrame': 'Baseline'}, {'measure': 'Mean arterial pressure (MAP) 1.5 min', 'description': 'Measurement of mean arterial pressure (mmHg) 1.5 minutes after starting the administration of remifentanil.', 'timeFrame': '1.5 minutes'}, {'measure': 'Mean arterial pressure (MAP) 5 min', 'description': 'Measurement of mean arterial pressure (mmHg) 5 minutes after starting the administration of remifentanil.', 'timeFrame': '5 minutes'}, {'measure': 'Mean arterial pressure (MAP) 10 min', 'description': 'Measurement of mean arterial pressure (mmHg) 10 minutes after starting the administration of remifentanil.', 'timeFrame': '10 minutes'}, {'measure': 'Mean arterial pressure (MAP) 15 min', 'description': 'Measurement of mean arterial pressure (mmHg) 15 minutes after starting the administration of remifentanil.', 'timeFrame': '15 minutes'}, {'measure': 'Mean arterial pressure (MAP) 18 min', 'description': 'Measurement of mean arterial pressure (mmHg) 18 minutes after starting the administration of remifentanil.', 'timeFrame': '18 minutes'}, {'measure': 'Mean arterial pressure (MAP) 20 min', 'description': 'Measurement of mean arterial pressure (mmHg) 20 minutes after starting the administration of remifentanil.', 'timeFrame': '20 minutes'}, {'measure': 'Mean arterial pressure (MAP) 25 min', 'description': 'Measurement of mean arterial pressure (mmHg) 25 minutes after starting the administration of remifentanil.', 'timeFrame': '25 minutes'}, {'measure': 'Heart Rate (HR) Baseline', 'description': 'Baseline measurement of heart rate (beats/min)', 'timeFrame': 'Baseline'}, {'measure': 'Heart Rate (HR) 1.5 min', 'description': 'Measurement of heart rate (beats/min) 1.5 minutes after starting the administration of remifentanil.', 'timeFrame': '1.5 minutes'}, {'measure': 'Heart Rate (HR) 5 min', 'description': 'Measurement of heart rate (beats/min) 5 minutes after starting the administration of remifentanil.', 'timeFrame': '5 minutes'}, {'measure': 'Heart Rate (HR) 10 min', 'description': 'Measurement of heart rate (beats/min) 10 minutes after starting the administration of remifentanil.', 'timeFrame': '10 minutes'}, {'measure': 'Heart Rate (HR) 15 min', 'description': 'Measurement of heart rate (beats/min) 15 minutes after starting the administration of remifentanil.', 'timeFrame': '15 minutes'}, {'measure': 'Heart Rate (HR) 18 min', 'description': 'Measurement of heart rate (beats/min) 18 minutes after starting the administration of remifentanil.', 'timeFrame': '18 minutes'}, {'measure': 'Heart Rate (HR) 20 min', 'description': 'Measurement of heart rate (beats/min) 20 minutes after starting the administration of remifentanil.', 'timeFrame': '20 minutes'}, {'measure': 'Bispectrum (BIS) Baseline', 'description': 'Baseline measurement of EEG Bispectral index (adimensional index from 0- to 100).', 'timeFrame': 'Baseline'}, {'measure': 'Bispectrum (BIS) 1.5 minutes', 'description': 'EEG Bispectral index (adimensional index from 0- to 100) 1.5 minutes after starting the administration of remifentanil.', 'timeFrame': '1.5 minutes'}, {'measure': 'Bispectrum (BIS) 5 minutes', 'description': 'EEG Bispectral index (adimensional index from 0- to 100) 5 minutes after starting the administration of remifentanil.', 'timeFrame': '5 minutes'}, {'measure': 'Bispectrum (BIS) 10 minutes', 'description': 'EEG Bispectral index (adimensional index from 0- to 100) 10 minutes after starting the administration of remifentanil.', 'timeFrame': '10 minutes'}, {'measure': 'Bispectrum (BIS) 15 minutes', 'description': 'EEG Bispectral index (adimensional index from 0- to 100) 15 minutes after starting the administration of remifentanil.', 'timeFrame': '15 minutes'}, {'measure': 'Bispectrum (BIS) 20 minutes', 'description': 'EEG Bispectral index (adimensional index from 0- to 100) 20 minutes after starting the administration of remifentanil.', 'timeFrame': '20 minutes'}, {'measure': 'Bispectrum (BIS) 25 minutes', 'description': 'EEG Bispectral index (adimensional index from 0- to 100) 25 minutes after starting the administration of remifentanil.', 'timeFrame': '25 minutes'}]",34,18 Years,80 Years,FEMALE,True,Hospital Universitari Vall d'Hebron Research Institute,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:14.668673,v2_robust,False,True,True,False,False,
NCT01205178,G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine),A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects With Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium Vivax Malaria Patients With Glucose-6-phosphate Dehydrogenase Deficiency,Chloroquine,"['Tafenoquine', 'Primaquine', 'Chloroquine']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Malaria,['Malaria'],[],COMPLETED,,2009-07-02,2013-04-01,"[{'measure': 'To evaluate the safety, tolerability, and hemolytic potential of TQ in G6PD-deficient female healthy volunteers compared with G6PD-normal female healthy volunteers. This will be done by measuring maximum absolute decline in Haemoglobin from baseline', 'timeFrame': '2 years'}]","[{'measure': 'Maximum absolute decline in Hgb (or Hct) from baseline for TQ in G6PD-deficient healthy volunteers compared to G6PD-normal healthy volunteers.', 'timeFrame': '1 year'}]",2,18 Years,45 Years,ALL,True,GlaxoSmithKline,INDUSTRY,1,192.0,ACTUAL,2025-09-01T16:18:14.668739,v2_robust,True,True,True,False,True,
NCT04433078,RepurpoSing Old Drugs TO SuppRess a Modern Threat: COVID-19 STORM,RepurpoSing Old Drugs TO SuppRess a Modern Threat: The STORM Trial,Doxycycline,"['Doxycycline', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cytokine Storm,"['Cytokine Storm', 'SARS-CoV-2']","['Doxycycline', 'Cytokine Storm', 'SARS-CoV-2']",WITHDRAWN,No Participants Enrolled,2020-06-22,2021-04-13,"[{'measure': 'Time Free of Either Hospitalization, Hypoxemia, ICU Admission or Death', 'description': 'Days Alive and Out of Hospital (Composite Endpoint)', 'timeFrame': '21 days'}]","[{'measure': 'NP SARS-CoV-2 PCR', 'description': 'Change From Baseline of Nasopharyngeal Luminex NxTAG CoV (Positive/Negative)', 'timeFrame': '21 days'}, {'measure': 'SARS-CoV-2 Serum Quantitative Viral Load', 'description': 'Change From Baseline of SARS-CoV-2 Serum Quantitative Viral Load', 'timeFrame': '21 days'}, {'measure': 'SARS-CoV-2 IgM/IgG Antibodies', 'description': 'Change From Baseline of SARS-CoV-2 IgM/IgG Antibodies (Positive/Negative)', 'timeFrame': '21 days'}, {'measure': 'White Blood Cell Count (WBC)', 'description': 'Change From Baseline of White Blood Count (CBC) K/mm3', 'timeFrame': '21 days'}, {'measure': 'Absolute Lymphocyte Count (ALC)', 'description': 'Change From Baseline of Absolute Lymphocyte Count (ALC) K/mm3', 'timeFrame': '21 days'}, {'measure': 'C-Reactive Protein (CRP)', 'description': 'Change From Baseline of C-Reactive Protein (CRP) mg/dL', 'timeFrame': '21 days'}, {'measure': 'N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP)', 'description': 'Change From Baseline of N-Terminal Pro-B-Type Natriuretic Peptide (Pro-BNP) pg/mL', 'timeFrame': '21 days'}, {'measure': 'High Sensitivity Troponin I (hsTnT)', 'description': 'Change From Baseline of High Sensitivity Troponin I (hsTnT) ng/mL', 'timeFrame': '21 days'}, {'measure': 'Tumor Necrosis Factor Alpha (TNF-a)', 'description': 'Change From Baseline of Tumor Necrosis Factor Alpha (TNF-a)', 'timeFrame': '21 days'}, {'measure': 'IL-1', 'description': 'Change From Baseline of IL-1', 'timeFrame': '21 days'}, {'measure': 'IL-1B', 'description': 'Change From Baseline of IL-1B', 'timeFrame': '21 days'}, {'measure': 'IL-6', 'description': 'Change From Baseline of IL-6', 'timeFrame': '21 days'}]",13,18 Years,,ALL,False,Temple University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.668747,v2_robust,True,True,False,True,False,No Participants Enrolled
NCT05578378,Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL,Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in Refractory/Relapsed Acute Lymphoblastic Leukemia,Cladribine,"['G-CSF', 'Cytarabine', 'Cladribine', 'methotrexate', 'cytosine arabinoside', 'Fludarabine']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Acute Lymphoblastic Leukemia,['Acute Lymphoblastic Leukemia'],[],UNKNOWN,,2022-01-01,2024-12-31,"[{'measure': 'CR (complete remission rate)', 'description': 'Response to CLAG regimen.', 'timeFrame': 'the first cycle (4 weeks)'}]","[{'measure': 'Overall survival(OS)', 'description': 'The time from randomization to death from any cause.', 'timeFrame': 'From the 1st day to the 365th day after enrollment.'}, {'measure': 'Progression-Free Survival （PFS）', 'description': 'It is defined as the total survival of a patient after CR until the tumor recurrence or death from any cause.', 'timeFrame': 'From the 1st day to the 365th day after enrollment.'}]",3,14 Years,,ALL,False,The First Affiliated Hospital of Soochow University,OTHER,3,32.0,ESTIMATED,2025-09-01T16:18:14.668775,v2_robust,True,True,False,False,False,
NCT06588478,A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma,"A Phase 2, Open-Label, Randomized Study Evaluating the Efficacy and Safety of 3 Doses of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Previously Received Treatment With a Covalent Bruton Tyrosine Kinase Inhibitor",Pirtobrutinib,['Pirtobrutinib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Lymphocytic Leukemia,"['Chronic Lymphocytic Leukemia', 'Small Lymphocytic Lymphoma']",[],RECRUITING,,2025-01-03,2028-12,"[{'measure': 'Overall Response Rate', 'description': 'Overall response rate is defined as the proportion of participants who achieve the best overall response at or before the initiation of subsequent anticancer therapy of CR, CRi, nPR, or PR. ORR will be assessed using International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 response criteria.', 'timeFrame': 'Baseline up to 3 years'}]","[{'measure': 'Duration of Response', 'description': 'Duration of response is defined as the time from the date of the first documented CR, CRi, nPR, or PR to disease progression (per iwCLL 2018) or death from any cause.', 'timeFrame': 'Baseline up to 3 years'}]",2,18 Years,,ALL,False,"Loxo Oncology, Inc.",INDUSTRY,1,249.0,ESTIMATED,2025-09-01T16:18:14.668792,v2_robust,True,True,False,False,False,
NCT01345578,Hepatocyte Transplantation for Liver Based Metabolic Disorders,Hepatocyte Transplantation for Liver Based Metabolic Disorders,human hepatocyte transplantation,"['hepatocyte transplant', 'human hepatocyte transplantation']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Metabolic Diseases,['Metabolic Diseases'],"['Urea Cycle Disorders', 'Carbamoyl-Phosphate Synthase I Deficiency Disease', 'Citrullinemia', 'Ornithine Carbamoyltransferase Deficiency Disease', 'Crigler-Najjar Syndrome']",TERMINATED,seeking additional funding,2011-03,2022-03-31,"[{'measure': 'Improvement in enzyme physiologic function at 6 months', 'description': 'After infusing donor allogeneic hepatocytes through the portal vein following preparative hepatic irradiation, improvement in enzyme physiologic function will be assessed at 6 months.', 'timeFrame': '6 months post hepatocyte transplant'}]",[],1,,21 Years,ALL,False,Ira Fox,OTHER,0,5.0,ACTUAL,2025-09-01T16:18:14.668805,v2_robust,True,True,False,True,False,seeking additional funding
NCT01518985,The Impact of Intravenous Bendavia™ on Endothelial Reactivity Dysfunction in Cigarette Smoking,"A Phase 1, Placebo-Controlled Trial to Evaluate the Impact of Intravenous (IV) Bendavia™ (MTP-131) on Endothelial Reactivity Dysfunction Induced by Cigarette Smoking",Bendavia,"['Bendavia', 'Sterile saline (0.9%)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2012-01,2012-03,"[{'measure': 'Analysis of variance (ANOVA) between group mean endothelial function (EndoPAT Index) following smoking a single cigarette with and without Bendavia', 'description': 'Endothelial function will be determined using EndoPAT 2000 (Itamar Medical Ltd) prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of endothelial function (EndoPAT Index) between placebo and active study drug within a subject will be performed.\n\nEndoPAT quantifies the endothelium-mediated changes in vascular tone. A post-occlusion to pre-occlusion ratio is calculated providing the EndoPAT index.', 'timeFrame': 'Baseline, +30, +60, +90 minutes post-study-drug administration start'}]","[{'measure': 'Anova between group mean inflammatory laboratory marker (hs-CRP; mg/L) after smoking one cigarette with and without Bendavia', 'description': 'hs-CRP will be evaluated prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of hs-CRP levels between placebo and active study drug within a subject will be performed.', 'timeFrame': 'Baseline to 24 hours post-study-drug administration'}, {'measure': 'ANOVA between group means of urinary 8-isoprostane (ng/mg of creatinine) after smoking one cigarette with and without Bendavia', 'description': '8-isoprostane will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed.', 'timeFrame': 'Baseline to 48 hours post-study-drug administration'}, {'measure': 'Number adverse events with and without Bendavia', 'description': 'Adverse events will be tabulated by treatment group. No statistical analysis will be preformed.', 'timeFrame': 'Baseline to Study Day 10'}, {'measure': 'Assessment of Bendavia exposure measured by area Under the Curve (AUC; ng*hr/mL)', 'description': 'Bendavia levels will be measured and pharmacokinetic parameters reported.', 'timeFrame': 'Baseline to 48 hours post-study-drug administration'}, {'measure': ""ANOVA between group means of urinary 8-hydroxy-2'-deoxyguanosine (pg/mL) after smoking one cigarette with and without Bendavia"", 'description': ""8-hydroxy-2'-deoxyguanosine will be measured prior to and after smoking of one unfiltered cigarette and prior to and after initiation of study drug. Group comparison of laboratory results between placebo and active study drug within a subject will be performed."", 'timeFrame': 'Baseline to 48 hours post-study-drug administration'}]",6,18 Years,65 Years,MALE,True,Stealth BioTherapeutics Inc.,INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:14.668828,v2_robust,True,True,True,False,True,
NCT01811485,Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy,"A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 14 Weeks Treatment With LMF237 Bid to Placebo in Patients With Type 2 Diabetes Inadequately Controlled With Vildagliptin 50 mg Bid Monotherapy",LMF237 50/250 mg,"['LMF237 50/250 mg', 'LMF237 50/500 mg', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2013-05,2014-02,"[{'measure': 'Change From Baseline in Glycosylated Hemoglobin (HbA1c) at 14 Weeks Between Treatment Groups', 'description': 'HbA1c was performed on a blood sample obtained and measured by High performance liquid chromatography (HPLC). HPCL was performed at a central laboratory.', 'timeFrame': 'Baseline to 14 weeks'}]","[{'measure': 'Change From Baseline in HbA1c at 14 Weeks Within LMF237 Treatment Groups', 'description': 'HbA1c will be performed on a blood sample obtained and measured by HPLC. HPCL was performed at a central laboratory.', 'timeFrame': 'Baseline to 14 weeks'}, {'measure': 'Percentage of Patients Meeting Responder Rates in HbA1c', 'description': ""Responder rate was analyzed in categories: 1. Endpoint HbA1c ≤ 6.5% 2. Endpoint HbA1c \\< 7% 3. Endpoint HbA1c \\< 7% in patients with baseline HbA1c ≤ 8% 4. Endpoint HbA1c \\< 6.9% 5. HbA1c reduction from baseline at endpoint ≥ 1% 6. HbA1c reduction from baseline at endpoint ≥ 0.5%.\n\nCategories 1, 2, and 4 - 'n' includes only patients with baseline HbA1c \\> 6.5%, ≥ 7%, ≥ 6.9% and endpoint HbA1c measurement. Category 3, 'n' includes only patients with 7% ≤ baseline HbA1c ≤ 8% and endpoint HbA1c. Category 5 and 6, 'n' indicates number of patients with both baseline and endpoint HbA1c measurements."", 'timeFrame': 'Baseline, 14 weeks'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at 14 Weeks', 'description': 'FPG was performed on a blood sample obtained and analyzed at a central laboratory.', 'timeFrame': 'Baseline to 14 weeks'}, {'measure': 'Number of Patients With Adverse Events (Including Hypoglycemia), Serious Adverse Events and Death', 'description': 'The occurrence of adverse events were sought by non-directive questioning of the patient at each visit. Adverse events are defined as appearance or worsening of any undesirable symptom, sign (including an abnormal laboratory finding), or medical conditions. Serious adverse events are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital anomalies or birth defects, or are other conditions which in judgment of investigators represent significant hazards.', 'timeFrame': '14 weeks'}]",5,20 Years,74 Years,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,171.0,ACTUAL,2025-09-01T16:18:14.668854,v2_robust,True,True,True,False,True,
NCT02894385,"Effect of Hepatic and Renal Impairment on the Pharmacokinetics, Safety and Tolerability of BAY1841788 (ODM-201)","A Phase I, Non-randomized, Open-label, Single-dose Study to Investigate the Pharmacokinetics, Safety and Tolerability of BAY 1841788 (ODM-201) in Male Subjects With Hepatic Impairment, Renal Impairment and Normal Hepatic and Renal Function",BAY1841788,['BAY1841788'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics,"['Pharmacokinetics', 'Hepatic Insufficiency', 'Renal Insufficiency']",[],COMPLETED,,2016-09-13,2017-12-15,"[{'measure': 'Area under the concentration-time curve of darolutamide from time zero to 48 hours (AUC(0-48)) in plasma', 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': 'Maximum drug concentration (Cmax) of darolutamide in plasma', 'timeFrame': 'Pre-dose up to 48 h post dose'}]","[{'measure': ""Area under the concentration-time curve of darolutamide's diastereomer ((S,R)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma"", 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': ""Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,R)-darolutamide) in plasma"", 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': ""Area under the concentration-time curve of darolutamide's diastereomer ((S,S)-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma"", 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': ""Maximum drug concentration (Cmax) of darolutamide's diastereomer ((S,S)-darolutamide) in plasma"", 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': ""Area under the concentration-time curve of darolutamide's major metabolite (keto-darolutamide) from time zero to 48 hours (AUC(0-48)) in plasma"", 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': ""Maximum drug concentration (Cmax) of darolutamide's major metabolite (keto-darolutamide) in plasma"", 'timeFrame': 'Pre-dose up to 48 h post dose'}, {'measure': 'Number of subjects with study drug-related treatment-emergent adverse events (TEAEs)', 'timeFrame': 'From first application of study medication up to 30 days after end of treatment with study medication.'}]",9,45 Years,79 Years,MALE,True,Bayer,INDUSTRY,1,29.0,ACTUAL,2025-09-01T16:18:14.668907,v2_robust,True,True,True,False,True,
NCT00777985,Preventive Effects of Bosentan on the Systemic Cardiovascular Consequence of Sleep Apnea,Cardiovascular Consequences of Obstructive Sleep Apnea (OSA): Role of Endothelin and Preventive Effects of Bosentan,bosentan,"['bosentan', 'TRACLEER']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Obstructive Sleep Apnea,"['Obstructive Sleep Apnea', 'Hypertension']","['Cardiovascular system', 'Sleep', 'Endothelial function', 'Endothelin system']",COMPLETED,,2007-12,2012-01,"[{'measure': '24 hour mean diastolic blood pressure', 'timeFrame': 'before and after each treatment completion (4 weeks)'}]","[{'measure': 'Peripheral Arterial Tonometry measure', 'timeFrame': 'before and after each treatment completion (4 weeks)'}, {'measure': 'mean 24 hour systemic systolic blood pressure', 'timeFrame': 'before and after each treatment completion (4 weeks)'}, {'measure': 'mean 24 hour nocturnal blood pressure', 'timeFrame': 'before and after each treatment completion (4 weeks)'}, {'measure': 'carotid Intima Media Thickness', 'timeFrame': 'before and after each treatment completion (4 weeks)'}, {'measure': 'Circulating inflammation markers (RANTES, MCP-1, TNF-alpha, INF-gamma, IL-6, IL-10 and TGF-gamma', 'timeFrame': 'before and after each treatment completion (4 weeks)'}, {'measure': 'Circulating Big ET1 and ET1 levels', 'timeFrame': 'before and after each treatment completion (4 weeks)'}]",7,18 Years,80 Years,ALL,False,"University Hospital, Grenoble",OTHER,2,19.0,ACTUAL,2025-09-01T16:18:14.668946,v2_robust,True,True,True,False,False,
NCT03526185,A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes,A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Melanoma,Tumor Infiltrating Lymphocytes,"['Tumor Infiltrating Lymphocytes', 'Nivolumab and Ipilimumab', 'Young TIL', 'Autologous TIL', 'Unselected TIL']",5,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Metastatic Melanoma,['Metastatic Melanoma'],[],TERMINATED,lack of funds,2018-02-06,2020-12-01,"[{'measure': 'Adverse Events', 'description': 'To determine the safety of administering a regimen of TIL/IL-2, incidence of drug-related adverse events (AEs) will be summarized across adverse event type in terms of frequency by event type.', 'timeFrame': 'up to 12 months'}, {'measure': 'Serious Adverse Events', 'description': ""To determine the safety of administering a regimen of TIL/IL-2, serious adverse events (SAEs) will be summarized across event type in terms of frequency by event type. SAE's will include events leading to discontinuation, deaths and clinical laboratory test abnormalities"", 'timeFrame': 'up to 12 months'}]","[{'measure': 'Objective response rate to TIL', 'description': 'Objective response rate (ORR) of the TIL/IL-2 regimen based on investigator review of radiographic images using RECIST 1.1 criteria', 'timeFrame': 'up to 12 months'}]",3,18 Years,,ALL,False,Yale University,OTHER,0,6.0,ACTUAL,2025-09-01T16:18:14.669008,v2_robust,True,True,False,True,True,lack of funds
NCT01309685,Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive Impairment,Effect of Varenicline on a Laboratory Model of Tobacco Addiction and on Withdrawal-Induced Cognitive Impairment,Varenicline,['Varenicline'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Drug Addiction,['Drug Addiction'],"['Cognition', 'Smoking', 'Nicotine', 'Varenicline', 'Withdrawal']",WITHDRAWN,,2011-02-13,2014-11-26,"[{'measure': 'Tobacco craving, nicotine reinforcement, cognitive performance'}]","[{'measure': 'Nicotine dependence, smoking history, mood'}]",2,18 Years,50 Years,ALL,True,National Institute on Drug Abuse (NIDA),NIH,0,0.0,ACTUAL,2025-09-01T16:18:14.669016,v2_robust,True,True,False,True,False,
NCT04362085,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to the COVID-19 Pandemic (RAPID COVID COAG),Therapeutic Anticoagulation,['Therapeutic Anticoagulation'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,COVID-19,['COVID-19'],"['coagulopathy', 'anticoagulation']",COMPLETED,,2020-05-11,2021-10-14,"[{'measure': 'Composite Outcome of ICU Admission, Non-invasive Positive Pressure Ventilation, Invasive Mechanical Ventilation, or All-cause Death up to 28 Days.', 'description': 'Composite outcome of ICU admission, non-invasive positive pressure ventilation, invasive mechanical ventilation, or all-cause death up to 28 days.', 'timeFrame': 'Up to 28 days'}]","[{'measure': 'All-cause Death', 'description': 'All-cause death', 'timeFrame': 'Up to 28 days'}, {'measure': 'Composite Outcome of ICU Admission or All-cause Death', 'description': 'Composite outcome of ICU admission or all-cause death', 'timeFrame': 'Up to 28 days'}, {'measure': 'Composite Outcome of Mechanical Ventilation or All-cause Death', 'description': 'Composite outcome of mechanical ventilation or all-cause death', 'timeFrame': 'Up to 28 days'}, {'measure': 'Major Bleeding', 'description': 'Major bleeding as defined by the ISTH Scientific and Standardization Committee (ISTH-SSC) recommendation', 'timeFrame': 'Up to 28 days'}, {'measure': 'Red Blood Cell Transfusion', 'description': 'Red Blood Cell transfusion (greater than or equal to 1 unit)', 'timeFrame': 'Up to 28 days'}, {'measure': 'Transfusion of Platelets, Frozen Plasma, Prothrombin Complex Concentrate, Cryoprecipiate and/or Fibrinogen Concentrate', 'description': 'Transfusion of platelets, frozen plasma, prothrombin complex concentrate, cryoprecipiate and/or fibrinogen concentrate', 'timeFrame': 'Up to 28 days'}, {'measure': 'Renal Replacement Therapy', 'description': 'Renal replacement therapy defined as continuous renal replacement therapy or intermittent hemodialysis', 'timeFrame': 'Up to 28 days'}, {'measure': 'Hospital-free Days Alive up to Day 28', 'description': 'Hospital-free days alive up to day 28', 'timeFrame': 'Up to 28 days'}, {'measure': 'ICU-free Days Alive up to Day 28', 'description': 'ICU-free days alive up to day 28', 'timeFrame': 'Up to 28 days'}, {'measure': 'Ventilator-free Days Alive up to Day 28', 'description': 'Ventilator-free days alive up to day 28', 'timeFrame': 'Up to 28 days'}, {'measure': 'Organ Support-free Days Alive up to Day 28', 'description': 'Organ support-free days alive up to day 28', 'timeFrame': 'Up to 28 days'}, {'measure': 'Venous Thromboembolism', 'description': 'Venous thromboembolism', 'timeFrame': 'Up to 28 days'}, {'measure': 'Arterial Thromboembolism', 'description': 'Arterial thromboembolism', 'timeFrame': 'Up to 28 days'}, {'measure': 'Heparin Induced Thrombocytopenia', 'description': 'Heparin induced thrombocytopenia', 'timeFrame': 'Up to 28 days'}, {'measure': 'Changes in D-dimer', 'description': 'Geometric mean ratio defined as ratio of geometric means of D-dimer ratios (D-dimer×ULN) of day 2 ±24 hours post-randomisation, adjusted for baseline geometric means of D-dimer ratios using analysis of covariance.', 'timeFrame': 'Up to day 3'}]",16,18 Years,,ALL,False,Unity Health Toronto,OTHER,24,465.0,ACTUAL,2025-09-01T16:18:14.669025,v2_robust,True,True,True,False,False,
NCT00471185,ACY-6 Oral Administration of Acyline,Oral Administration of the GnRH Antagonist Acyline in Normal Men,Acyline,['Acyline'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Contraception,['Contraception'],"['Male Contraception', 'Acyline']",COMPLETED,,2007-06,2007-08,"[{'measure': 'To evaluate the suppressive effects of GIPET-enhanced oral Acyline on pituitary gonadotropin and testosterone secretion in normal men and to assess any potential side effects of GIPET enhanced oral Acyline', 'timeFrame': '28-days'}]","[{'measure': 'To define the pharmacokinetics of GIPET enhanced oral Acyline', 'timeFrame': '28-days'}, {'measure': 'Assess any potential side effects of GIPET enhanced oral Acyline', 'timeFrame': '28-days'}]",3,18 Years,50 Years,MALE,True,University of Washington,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:14.669083,v2_robust,True,True,True,False,False,
NCT00856843,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects,BLI800,"['Polyethylene glycol 3350 based bowel preparation', 'BLI800']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Colonoscopy,['Colonoscopy'],"['colonoscopy', 'bowel preparation']",COMPLETED,,2009-02,,"[{'measure': 'Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale', 'description': 'Blinded colonoscopists rated cleansing quality as either Excellent, Good, Fair or Poor. Scores of Excellent or Good were considered Successful preparations.', 'timeFrame': '2 days'}]","[{'measure': 'Assessment of Residual Stool - Cecum', 'description': 'The blinded colonoscopist rated residual stool in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Stool - Ascending Colon', 'description': 'The blinded colonoscopist rated residual stool in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Stool - Transverse Colon', 'description': 'The blinded colonoscopist rated residual stool in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Stool - Descending Colon', 'description': 'The blinded colonoscopist rated residual stool in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Stool - Sigmoid Colon/Rectum', 'description': 'The blinded colonoscopist rated residual stool in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Fluid - Cecum', 'description': 'The blinded colonoscopist rated residual fluid in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Fluid - Ascending Colon', 'description': 'The blinded colonoscopist rated residual fluid in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Fluid - Transverse Colon', 'description': 'The blinded colonoscopist rated residual fluid in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Fluid - Descending Colon', 'description': 'The blinded colonoscopist rated residual fluid in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Assessment of Residual Fluid - Sigmoid Colon/Rectum', 'description': 'The blinded colonoscopist rated residual fluid in specific colon sections as Absent, Small, Moderate or Excess.', 'timeFrame': '2 days'}, {'measure': 'Subject Symptom Scores', 'description': 'Expected preparation related symptoms of Abdominal Cramping, Abdominal Bloating, Nausea and Overall discomfort were rated by each subject from 1 - 5 (1=none, 2=mild, 3=bothersome, 4=distressing, 5=severely distressing).', 'timeFrame': '2 days'}, {'measure': 'Mean Change in Serum Chemistry (mg/dL)', 'description': 'Mean changes from Baseline to Post-preparation for the following analytes will be compared between treatment groups: blood urea nitrogen, calcium, creatinine, phosphorus. Baseline lab samples were allowed to be drawn within 15 days of the post-preparation (Visit 2) lab draw.', 'timeFrame': 'up to 15 days'}, {'measure': 'Mean Change in Serum Chemistry (mEq/L)', 'description': 'Mean changes from Baseline to Post-preparation for the following analytes will be compared between treatment groups: bicarbonate, chloride, magnesium, potassium, sodium. Baseline lab samples were allowed to be drawn within 15 days of the post-preparation (Visit 2) lab draw.', 'timeFrame': 'up to 15 days'}]",14,18 Years,,ALL,False,Braintree Laboratories,INDUSTRY,0,136.0,ACTUAL,2025-09-01T16:18:14.669335,v2_robust,True,True,True,False,False,
NCT01976143,A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety,A Phase 1 Study to Evaluate the Effect of Nktr-102 for Injection (Etirinotecan Pegol) on the QT/QTC Interval in Patients With Advanced or Metastatic Solid Tumors,NKTR-102,['NKTR-102'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Cancer,"['Advanced Cancer', 'Metastatic Solid Tumors']",[],COMPLETED,,2014-02,2016-09,"[{'measure': 'QTcF interval values', 'description': '10 pre-dose and 18 post-dose ECG measurements to evaluate the effect of NKTR-102', 'timeFrame': 'Day -1 through Day 42'}]","[{'measure': 'Pharmacokinetics (PK) and ECG Parameters', 'description': '1 pre-dose and 18 post-dose blood samples to measure concentrations of NKTR-102 and its metabolites', 'timeFrame': 'Day 1 through Day 42'}]",2,18 Years,,ALL,False,Nektar Therapeutics,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:14.669370,v2_robust,True,True,True,False,False,
NCT00890643,Effect of Prazosin on Neurophysiology and Cognition in Post-Traumatic Stress Disorder (PTSD),Effect of Prazosin on Neurophysiologic Responses and Cognitive Performance in PTSD,prazosin hydrochloride,"['prazosin hydrochloride', 'Minipress', 'placebo']",3,INTERVENTIONAL,['NA'],,,Posttraumatic Stress Disorder,['Posttraumatic Stress Disorder'],"['Stress disorders, post-traumatic', 'Combat Disorders', 'prazosin', 'cognition', 'neurophysiology']",WITHDRAWN,Primary investigator left VA employment,2009-12,2011-09,"[{'measure': 'Responses to acoustic startle and prepulse inhibition of acoustic startle', 'timeFrame': 'baseline, week 2, week 8'}]","[{'measure': 'Heart rate variability', 'timeFrame': 'baseline, week 2, week 8'}, {'measure': 'Pennsylvania Computerized Neurocognitive Battery (CNB)', 'timeFrame': 'baseline, week 8'}]",3,18 Years,65 Years,ALL,False,US Department of Veterans Affairs,FED,0,0.0,ACTUAL,2025-09-01T16:18:14.669382,v2_robust,True,True,False,True,False,Primary investigator left VA employment
NCT01664143,A Single-Center Study of RO5508887 in Healthy Volunteers,"A Single-Center, Randomized, Investigator/Subject-Blind, Multiple Ascending-Dose, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO5508887 Following Oral Administration in Healthy Subjects",Placebo,"['RO5508887', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteer,['Healthy Volunteer'],[],COMPLETED,,2012-07,2012-09,"[{'measure': 'Safety: incidence of adverse events', 'timeFrame': '30 days'}]","[{'measure': 'Correlation of the age on pharmacokinetics of RO5508887', 'timeFrame': '30 days'}, {'measure': 'Correlation of the age on pharmacodynamics of RO5508887', 'timeFrame': '30 days'}, {'measure': 'Pharmacokinetics: plasma levels of RO5508887', 'timeFrame': 'Predose and up to 144 hours post last dose, and at follow-up'}, {'measure': 'Pharmacodynamics: Plasma levels of amyloid deposition markers', 'timeFrame': 'Predose and up to 144 hours post last dose'}, {'measure': 'Correlation of the age on safety of RO5508887', 'timeFrame': '30 days'}]",6,18 Years,,ALL,True,Hoffmann-La Roche,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:14.669406,v2_robust,True,True,True,False,True,
NCT00135343,A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen,A Pilot Study of Atazanavir/Ritonavir/Efavirenz as a Nucleoside Sparing Regimen,Atazanvir/ritonavir + efavirenz,"['Atazanvir/ritonavir + efavirenz', 'Reyataz & Sustiva']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV Infections,['HIV Infections'],['HIV/AIDS'],COMPLETED,,2004-04,2005-10,[{'measure': 'Mean percent change from baseline in fasting plasma triglycerides at Week 8'}],"[{'measure': 'Incidence of grade 2-4 elevation of fasting plasma triglycerides at Week (Wk) 8, 24 and 48'}, {'measure': 'The mean percent change from baseline in fasting plasma triglycerides at Wk 24 and 48'}]",3,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,60.0,,2025-09-01T16:18:14.669415,v2_robust,True,True,True,False,False,
NCT03917043,APG-2449 in Patients With Advanced Solid Tumors,"A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors",APG-2449,"['APG-2449 Capsule', 'APG-2449']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Solid Cancer,"['Advanced Solid Cancer', 'Non Small Cell Lung Cancer', 'Esophageal Cancer', 'Ovarian Cancer', 'Malignant Pleural Mesothelioma']",[],RECRUITING,,2019-05-27,2028-01,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'To determine the maximum tolerated dose (MTD) of APG-2449 in subjects with advanced solid tumors', 'timeFrame': '28 days'}, {'measure': 'Recommended Phase 2 dose (RP2D)', 'description': 'To determine the tentative recommended Phase 2 dose (RP2D) of APG-2449 in subjects with advanced solid tumors', 'timeFrame': '28 days'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'description': 'Maximum plasma concentration (Cmax) will be assessed on all participants with APG-2449 treatments', 'timeFrame': '28 days'}, {'measure': 'Area under the plasma concentration versus time curve (AUC)', 'description': 'Area under the plasma concentration versus time curve (AUC) will be assessed on all participants with APG-2449 treatments', 'timeFrame': '28 days'}, {'measure': 'Phosphorylation of FAK protein', 'description': 'Phosphorylation of FAK protein will be assessed in peripheral blood mononuclear cells on all participants with APG-2449 treatments', 'timeFrame': '28 days'}, {'measure': 'Preliminary efficacy assessment: Response Evaluation Criteria In Solid Tumors (RECIST) 1.1', 'description': 'To assess preliminary efficacy in subjects with solid tumors using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1', 'timeFrame': '4 weeks'}]",6,18 Years,,ALL,False,Ascentage Pharma Group Inc.,INDUSTRY,1,165.0,ESTIMATED,2025-09-01T16:18:14.669425,v2_robust,True,True,False,False,False,
NCT02571543,Can Ibuprofen Delay Ovulation in Natural Cycle-IVF?,Investigation of Ibuprofen in the Delay of Ovulation in NC-IVF (Natural Cycle in Vitro Fertilisation) Therapy With the Objective of Reducing Premature Ovulation and Thus Improving Effectivity (Off Label Use),Ibuprofen,"['Ibuprofen', 'Brufen®']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovulation,"['Ovulation', 'Ovulation Inhibition', 'Ovulation Inhibition/Drug Effects', 'Pregnancy', 'Fertilization in Vitro/Methods']","['Ibuprofen', 'IVF', 'minimal stimulation', 'modified natural-cycle', 'nonsteroidal anti-inflammatory drug (NSAID)', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Oocyte Retrieval', 'Ovarian Follicle/drug effects']",COMPLETED,,2016-01,2022-08-09,"[{'measure': 'Percentage of non ovulated follicles', 'description': 'The primary outcome of this study is whether Ibuprofen delays ovulation in the test subjects. It will be measured in the percentage of non-ovulated follicles exactly 42h after HCG administration with Ibuprofen.', 'timeFrame': '42 hours after HCG injection'}]","[{'measure': 'Comparison of ovulation rates between the intervention and the control groups', 'description': 'Measured using ultrasound.', 'timeFrame': '42 hours after HCG injection, up to end of study duration.'}, {'measure': 'Percentage of oocytes obtained from aspirated follicles', 'description': 'Compared to whether this differs from regular NC-IVF without the investigational product', 'timeFrame': '42 hours after HCG injection'}, {'measure': 'E2 (Estradiol) concentration in the follicular fluid', 'description': 'To assess whether Ibuprofen has altered these levels', 'timeFrame': '42 hours after HCG injection'}, {'measure': 'Incidence and severity of gastrointestinal and of other side effects', 'description': 'To assess whether Ibuprofen has caused these known side effects', 'timeFrame': 'Throughout study duration, expected to be up to 11 months'}]",5,18 Years,42 Years,FEMALE,True,"Insel Gruppe AG, University Hospital Bern",OTHER,1,51.0,ACTUAL,2025-09-01T16:18:14.669462,v2_robust,True,True,True,False,False,
NCT01508143,Comparitive Study of Two Misoprostol Regimen in Early Pregnancy Termination,A Comparative Study of Vaginal Misoprostol Two Dosing Regimen for First Trimester Pregnancy Termination in Patients Admitted at Bandarabbas in Shariati Hospital in 2009,Misoprostol 400 micrograms,"['Misoprostol 800 micrograms', 'Misoprostol 400 micrograms', 'Cytotec']",3,INTERVENTIONAL,['NA'],,,Termination,['Termination'],"['Abortion', 'Pregnancy', 'Termination', 'Misoprostol']",COMPLETED,,2012-01,2012-09,"[{'measure': 'Abortion', 'description': 'After 48 hours after treatment each patient is assessed for abortion. Patients are devided into three groups including complete, partial or no abortion.', 'timeFrame': '48 hours after treatment'}]","[{'measure': 'Duration of abortion', 'description': 'Duration of abortion Form the begining of treatment to complete abortion', 'timeFrame': 'Form the begining of treatment to complete abortion'}, {'measure': 'Adverse Effects', 'description': 'including nausea, vomiting, fever and chill, diarhea, abdominal cramp, skin rash', 'timeFrame': '48 hours after treatment'}, {'measure': 'Need for surgery', 'description': 'Dilatation \\& cartage', 'timeFrame': '48 hours after treatment'}]",4,,,FEMALE,False,Hormozgan University of Medical Sciences,OTHER,0,41.0,ACTUAL,2025-09-01T16:18:14.669503,v2_robust,True,True,True,False,True,
NCT00140543,European Trial of Immunosuppression in SPK Tx,"A European Multicenter Open-Label Randomised Trial to Evaluate the Efficacy and Safety of Sirolimus and Tacrolimus Compared to MMF and Tacrolimus With Short-Course Induction Therapy, Short-Term Steroids Application in de Novo SPK Transplanted Diabetic Patients",sirolimus versus mycophenolate mofetil,['sirolimus versus mycophenolate mofetil'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,"Diabetes Mellitus, Type 1","['Diabetes Mellitus, Type 1', 'Diabetic Nephropathy']","['simultaneous pancreas/kidney transplantation', 'Immunosuppression']",COMPLETED,,2002-02,2005-09-30,[{'measure': 'At 1 year:Incidence of biopsy-proven (kidney) rejection episodes.'}],"[{'measure': 'SECONDARY ENDPOINTS: At 6 months and 1 year'}, {'measure': '* Kidney/Pancreas function (at 6 months and 1 year):'}, {'measure': '- Kidney function will be measured by:'}, {'measure': '- S- creatinine'}, {'measure': '- Creatinine clearance'}, {'measure': '- Pancreas function will be measured by:'}, {'measure': '- Fasting Glucose level (< 123 mg/dl)'}, {'measure': '- HbA1C'}, {'measure': '- Need for insulin therapy'}, {'measure': '- Need for oral drugs'}, {'measure': '* At 6 months and 1 year:'}, {'measure': '- Patient and graft survival'}, {'measure': '- Lipid profile'}, {'measure': '- Infections'}, {'measure': '- Side effects'}, {'measure': '- Blood Pressure'}, {'measure': '- Treatment failure for any reason, such as permanent discontinuation of a drug, graft loss or death.'}, {'measure': '* % of steroid free patients: at 6 months and 1 year.'}]",19,18 Years,55 Years,ALL,False,EUROSPK Study Group,OTHER,5,228.0,,2025-09-01T16:18:14.669539,v2_robust,True,True,True,False,False,
NCT04355143,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),"Randomized, Open-Label, Controlled Trial of Colchicine to Reduce Cardiac Injury in Hospitalized COVID-19 (Coronavirus Disease 2019) Patients (COLHEART-19)",Colchicine Tablets,"['AR 374', 'Colchicine Tablets', 'COLCRYS']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,COVID-19,['COVID-19'],[],COMPLETED,,2020-05-01,2021-07-21,"[{'measure': 'Composite of All-cause Mortality, Need for Mechanical Ventilation, or Need for Mechanical Circulatory Support (MCS)', 'description': 'Number of participants experiencing any of the following: All-cause mortality, need for mechanical ventilation, or need for mechanical circulatory support (MCS)', 'timeFrame': '90 Days'}]","[{'measure': 'Delta (Peak Minus Baseline) Troponin Level', 'description': 'Change from initial troponin level to maximum level of troponin among measures taken during hospitalization and at 30 days', 'timeFrame': 'Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized'}, {'measure': 'Delta (Baseline to Peak) Brain Natriuretic Peptide (BNP) Level', 'description': 'Change from baseline BNP level (Day 1) to maximum level of BNP among measures taken during hospitalization and at 30 days', 'timeFrame': 'Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized'}, {'measure': 'Change in Left Ventricular Ejection Fraction (LVEF) on Echocardiography', 'description': 'Number of participants experiencing LVEF of \\< 50% on echocardiogram with failure to show an improvement of ≥ 5% at 30 days', 'timeFrame': 'Baseline, Day 30'}, {'measure': 'Delta (Peak Minus Baseline) C-Reactive Protein (CRP) Inflammatory Biomarker Level', 'description': 'Change from baseline CRP level (Day 1) to maximum level of CRP among measures taken during hospitalization and at 30 days', 'timeFrame': 'Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized'}, {'measure': 'Delta (Peak Minus Baseline) D-Dimer Inflammatory Biomarker Level', 'description': 'Change from baseline D-Dimer level (Day 1) to maximum level among measures taken during hospitalization and at 30 days. D-Dimer is a small protein fragment present in the blood after a blood clot is degraded by fibrinolysis, so named because it contains two D fragments of the fibrin protein joined by a cross-link.', 'timeFrame': 'Baseline (Day 1), Day 30, Days 3 and 7 if hospitalized'}, {'measure': 'Composite Event-Free Survival Over Time (Days)', 'description': 'Participants reaching primary (composite) endpoint were subtracted from event-free survival reported at 10-day intervals', 'timeFrame': 'Days 0, 10, 20, 30, 40, 50, 60, 70, 80, and 90'}, {'measure': 'Number of Participants Requiring Mechanical Ventilation', 'timeFrame': '90 days'}, {'measure': 'Number of Participants Requiring Mechanical Circulatory Support (MCS)', 'timeFrame': '90 days'}, {'measure': 'Re-hospitalization at 90 Days', 'description': 'Number of participants released and re-admitted to the hospital within 90 days of enrollment', 'timeFrame': '90 days'}, {'measure': 'All-cause Mortality', 'timeFrame': '90 days'}]",11,18 Years,,ALL,False,"University of California, Los Angeles",OTHER,0,93.0,ACTUAL,2025-09-01T16:18:14.669569,v2_robust,True,True,True,False,False,
NCT00037843,"Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening","Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening",I-131 Iodocholesterol,['I-131 Iodocholesterol'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Adrenal Gland Diseases,"['Adrenal Gland Diseases', 'Adrenal Gland Neoplasms']",['adrenal diseases'],COMPLETED,,1988-12,2007-08,[],[],0,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,114.0,ACTUAL,2025-09-01T16:18:14.669629,v2_robust,True,True,True,False,False,
NCT04711343,Comparative Study to Evaluate the Pharmacokinetics of BAT2306 vs Cosentyx® in Healthy Subjects,"A Randomized, Double-blinded, Single-dose, 3-arms Parallel, Comparative Study to Evaluate the Pharmacokinetics and Safety of BAT2306 Injection vs Secukinumab Injection (Cosentyx®) in Healthy Chinese Male Subjects",BAT2306,"['Cosentyx (EU-licensed)', 'Secukinumab', 'Cosentyx (US-licensed)', 'BAT2306']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Psoriasis,['Psoriasis'],[],COMPLETED,,2022-06-08,2023-06-05,"[{'measure': 'Pharmacokinetics Endpoint：Peak plasma concentration (Cmax)', 'description': 'Pharmacokinetics Endpoint：Peak plasma concentration (Cmax)', 'timeFrame': '0-5months'}, {'measure': 'Pharmacokinetics Endpoint：Area under the plasma concentration versus time curve (AUC0-inf)', 'description': 'Pharmacokinetics Endpoint：Area under the plasma concentration versus time', 'timeFrame': '0-5months'}]",[],2,18 Years,55 Years,MALE,True,Bio-Thera Solutions,INDUSTRY,0,216.0,ACTUAL,2025-09-01T16:18:14.669652,v2_robust,True,True,True,False,False,
NCT00373243,A Study Of GW406381 In Volunteers With Moderate Hepatic Impairment,"An Open-label, Non-randomised Study of 20 mg GW406381 Single Dose Pharmacokinetics in Healthy Subjects and in Volunteers With Moderate Hepatic Impairment",GW406381,['GW406381'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pain,['Pain'],['hepatic impairment pharmacokinetics'],COMPLETED,,2005-10-19,2006-09-26,"[{'measure': 'GW406381 pharmacokinetic parameters AUC and Cmax', 'timeFrame': 'throughout the study'}]","[{'measure': 'GW406381 pharmacokinetic parameters Tmax, Total plasma clearance, and if data permits the t1/2 of GW406381 GW404347 pharmacokinetic parameters AUC and Cmax Ex vivo protein binding Clinical laboratory values, adverse events, vital signs and 12 lead ECG', 'timeFrame': 'throughout the study'}]",2,18 Years,65 Years,ALL,True,GlaxoSmithKline,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:14.669668,v2_robust,True,True,True,False,True,
NCT04602143,Effect of Testosterone Pretreatment in POR,Therapeutic Effect of Prolonged Testosterone Pretreatment in Women With Poor Ovarian Response: a Randomized Control Trial,Testosterone gel,"['Testosterone gel', 'Androgel 1% Transdermal Gel']",2,INTERVENTIONAL,['NA'],,,Infertility,['Infertility'],[],COMPLETED,,2018-02-16,2020-06-30,"[{'measure': 'Number of oocytes retrieved', 'description': 'The main outcomes of our study were the total number of retrieved', 'timeFrame': '30 minutes after oocyte retrieval complete'}]","[{'measure': 'Pregnancy rates.', 'description': 'Pregnancy was defined as positive when the serum beta-hCG level was ≥ 50 IU/L', 'timeFrame': '14 days after embryo transfer'}, {'measure': 'clinical pregnancy rates.', 'description': 'Clinical pregnancy was defined as the presence of a gestational sac identified by transvaginal ultrasound', 'timeFrame': '4 weeks after embryo transfer'}, {'measure': 'Ongoing pregnancy rates', 'description': 'Ongoing pregnancy was defined as a viable intrauterine pregnancy after 12 weeks of gestation.', 'timeFrame': 'after 12 weeks of gestation'}]",4,20 Years,47 Years,FEMALE,False,Hanoi Medical University,OTHER,1,165.0,ACTUAL,2025-09-01T16:18:14.669709,v2_robust,True,True,True,False,False,
NCT06860243,A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009),"An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Moderate Hepatic Impairment",Opevesostat,"['Prednisone', 'Fludrocortisone acetate', 'Opevesostat', 'MK-5684']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatic Impairment,"['Hepatic Impairment', 'Healthy Participants']",[],RECRUITING,,2025-05-13,2025-10-27,"[{'measure': 'Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC0-inf) of Opevesestat', 'description': 'Plasma samples will be collected to determine the AUC0-inf of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}, {'measure': 'Area Under the Concentration Versus Time Curve from 0 to the Last Quantifiable Sample (AUC0-last) of Opevesestat', 'description': 'Plasma samples will be collected to determine the AUC0-last of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}, {'measure': 'Area Under the Concentration Versus Time Curve from 0 to 24 hours (AUC0-24) of Opevesestat', 'description': 'Plasma samples will be collected to determine the AUC0-24 of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 24 hours post-dose)'}, {'measure': 'Maximum Observed Concentration (Cmax) of Opevesestat', 'description': 'Plasma samples will be collected to determine the Cmax of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}, {'measure': 'Time to Maximum Concentration (Tmax) of Opevesestat', 'description': 'Plasma samples will be collected to determine the Tmax of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}, {'measure': 'Apparent Terminal Half-life (t1/2) of Opevesestat', 'description': 'Plasma samples will be collected to determine the t1/2 of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}, {'measure': 'Apparent Clearance (CL/F) of Opevesestat', 'description': 'Plasma samples will be collected to determine the CL/F of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}, {'measure': 'Apparent Volume of Distribution During Terminal Phase (Vz/F) of Opevesestat', 'description': 'Plasma samples will be collected to determine the Vz/F of opevesostat.', 'timeFrame': 'At designated timepoints (up to approximately 96 hours post-dose)'}]","[{'measure': 'Number of Participants Who Experience One or More Adverse Events (AEs)', 'description': 'An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.', 'timeFrame': 'Up to approximately 2 weeks'}, {'measure': 'Number of Participants Who Discontinue Study Due to an AE', 'description': 'An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.', 'timeFrame': 'Up to approximately 2 weeks'}]",10,18 Years,,MALE,True,Merck Sharp & Dohme LLC,INDUSTRY,0,16.0,ESTIMATED,2025-09-01T16:18:14.669747,v2_robust,True,True,False,False,True,
NCT01149915,Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias,"A Phase I Open-Label Study to Assess the Safety, Tolerability and Preliminary Efficacy of TH-302, a Hypoxia-Activated Prodrug, in Patients With Advanced Leukemias",TH-302,['TH-302'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myelogenous Leukemia,"['Acute Myelogenous Leukemia', 'Acute Lymphoblastic Leukemia', 'Chronic Myelogenous Leukemia', 'High-risk Myelodysplastic Syndrome', 'Chronic Lymphocytic Leukemia', 'Advanced Myelofibrosis']","['Advanced Leukemias', 'Relapsed/Refractory Leukemias', 'AML', 'ALL', 'CML', 'MDS', 'CLL', 'MF', 'Evofosfamide']",COMPLETED,,2010-06,2013-08,"[{'measure': 'To determine the maximum tolerated dose of TH-302', 'timeFrame': '2 years'}, {'measure': 'To determine the dose-limiting toxicity of TH-302', 'timeFrame': '2 years'}, {'measure': 'TO determine the number of participants with Adverse Events as a measure of safety and tolerability', 'timeFrame': '2 years'}]","[{'measure': 'To determine the efficacy of TH-302 via specific response criteria', 'timeFrame': '2 years'}]",4,18 Years,,ALL,False,Threshold Pharmaceuticals,INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:14.669944,v2_robust,True,True,True,False,True,
NCT00805415,Ovulation Inhibition of Two 4-phasic Oral Contraceptive Regimens,"Multicenter, Open-label, Randomized, Comparative Study to Evaluate Ovulation Inhibition With Two 4-phasic Oral Contraceptive Regimens Containing Estradiol Valerate and Dienogest Applied Daily for Three Cycles to 200 Healthy Female Volunteer","EV/DNG (Qlaira, BAY86-5027, SH T00658K)","['EV/DNG (Qlaira, BAY86-5027, SH T00658K)', 'EV/DNG (SH T00658L)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovulation Inhibition,['Ovulation Inhibition'],"['Oral Contraceptive', 'Ovulation Inhibition']",COMPLETED,,2003-03,2004-02,"[{'measure': 'Proportion of subjects with a Hoogland score of 5-6 (luteinized unruptured follicle [LUF] or ovulation)', 'timeFrame': 'Treatment cycles 2 and 3'}]","[{'measure': 'Proportion of subjects with a Hoogland score of 5-6 (LUF or ovulation)', 'timeFrame': 'Treatment cycles 2 or 3'}, {'measure': 'Measurements of endometrial thickness', 'timeFrame': 'Treatment cycles 2 and 3'}, {'measure': 'Visibility of cervical mucus', 'timeFrame': 'Treatment cycles 2 and 3'}, {'measure': 'Ovarian activity (Hoogland score)', 'timeFrame': 'Posttreatment cycle (only subjects from center 2)Treatment cycles 2 and 3'}, {'measure': 'Measurements of follicle size', 'timeFrame': 'Treatment cycles 2 and 3'}, {'measure': 'Measurements of hormone levels (follicle-stimulating hormone [FSH], luteinizing hormone [LH], progesterone and estradiol)', 'timeFrame': 'Treatment cycles 2 and 3'}, {'measure': 'Compliance', 'timeFrame': 'Throughout whole study'}, {'measure': 'Medical, surgical and medication history, concomitant medication, general physical and gynecological examination, cervical smear, pregnancy test, adverse events, safety laboratory determinations, cycle control, vital signs', 'timeFrame': 'Various timepoint throughout the study'}]",9,18 Years,35 Years,FEMALE,True,Bayer,INDUSTRY,0,209.0,ACTUAL,2025-09-01T16:18:14.669956,v2_robust,True,True,True,False,True,
NCT06282315,Real World Evaluation of an Albendazole-Ivermectin Coformulation Safety and Effectiveness,A Pragmatic Phase III Multicentre Clinical Trial to Evaluate the Safety and Effectiveness of a Single Dose of an Albendazole-Ivermectin Coformulation Vs Albendazole for Preventive Chemotherapy of Soil-Transmitted Helminth Infections in School-Aged Children,Pre-screening Phase,"['Baseline Effectiveness Cohort', 'Day 0 Trial Intervention', 'Passive Surveillance', 'Screenig Phase', 'Post-Treatment Effectiveness Evaluation', 'Pre-screening Phase', 'Active Surveillance (study visit Day 1, Day 2 and Day 7)', 'Randomization', 'Mass Drug Administration (MDA)']",9,INTERVENTIONAL,['PHASE3'],PHASE3,,Soil-Transmitted Helminths,['Soil-Transmitted Helminths'],"['STH', 'albendazole', 'ivermectin', 'hookworms']",NOT_YET_RECRUITING,,2025-03,2026-07,"[{'measure': 'AEs and SAEs record of participants treated with FDC compared to ALB.', 'description': ""Adverse events will be recorded in the source documents and the electronic Case Report Form during the trial. The nature of the AE, its date and time of onset, duration and severity, therapy employed (only for SAEs) and the investigator's opinion of causality to the study drug with an alternate aetiology, if appropriate, will be documented.\n\nChanges in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of intensity.\n\nClassification of the AEs and SAEs according to their frequency will be performed by the Sponsor at the end of the trial."", 'timeFrame': '7 days, active surveillance (Day 0 (1 hour), Day 1, Day 2 and Day 7 post-intervention) and passive surveillance (From Day 0 up to Day 6 post-intervention)'}]","[{'measure': 'Reduction in T. trichiura prevalence in participants treated with FDC compared with ALB.', 'description': 'At each time point, one stool sample will be requested from each selected participant, and the presence and number of STH eggs will be determined by a single Kato Katz method (WHO gold standard for STH diagnosis) using microscopy. T. trichiura prevalence will be considered as the number of participants infected divided by the total number of participants in the effectiveness cohort.\n\nSTH diagnosis by Kato-Katz on fresh stool (samples analysed up to a maximum of 24 hours after sample collection). The stool sample will be analysed in the local laboratory to estimate STH prevalence at baseline in each school as part of evaluating the STH effectiveness of the treatment arms.', 'timeFrame': 'Baseline, 21 days and 11 months post-intervention'}]",2,5 Years,17 Years,ALL,True,Insud Pharma,INDUSTRY,8,20000.0,ESTIMATED,2025-09-01T16:18:14.670020,v2_robust,True,True,False,False,True,
NCT00068315,Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia,A Phase I Trial of PS-341 and Fludarabine for Relapsed and Refractory Indolent Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia,bortezomib,"['Fludara', 'VELCADE', '2-F-ara-AMP', 'bortezomib', 'LDP 341', 'Beneflur', 'MLN341', 'fludarabine phosphate']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue,"['Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue', 'Hematopoietic/Lymphoid Cancer', 'Nodal Marginal Zone B-cell Lymphoma', 'Recurrent Adult Diffuse Small Cleaved Cell Lymphoma', 'Recurrent Grade 1 Follicular Lymphoma', 'Recurrent Grade 2 Follicular Lymphoma', 'Recurrent Mantle Cell Lymphoma', 'Recurrent Marginal Zone Lymphoma', 'Recurrent Small Lymphocytic Lymphoma', 'Refractory Chronic Lymphocytic Leukemia', 'Splenic Marginal Zone Lymphoma', 'Waldenström Macroglobulinemia']",[],COMPLETED,,2003-07,,"[{'measure': 'Maximum tolerated dose (MTD) assessed by Common Toxicity Criteria version 2.0', 'timeFrame': '3 weeks'}]",[],1,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,18.0,ACTUAL,2025-09-01T16:18:14.670119,v2_robust,True,True,True,False,False,
NCT00749515,Pilot Study for Patients With Poor Response to Deferasirox,Pilot Pharmacokinetic Study In Patients With Inadequate Response To Deferasirox (Exjade),Deferoxamine,"['Exjade', 'ICL670', 'Deferoxamine', 'Deferasirox', 'Desferal']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Transfusion-dependent Hemachromatosis,"['Transfusion-dependent Hemachromatosis', 'Thalassemia Major', 'Sickle Cell Disease']","['Thalassemia', 'Iron', 'Chelation']",COMPLETED,,2008-03,2008-11,"[{'measure': 'Area Under the Curve of Deferasirox After a Dose of 35 mg/kg', 'description': 'Area Under the Curve (AUC) 0 to 24 hours post dose', 'timeFrame': '0, 1, 2, 4, 6, 8, 12, and 24 hours post dose'}, {'measure': 'Half-Life of Deferasirox', 'description': 'All patients received the same interventions of deferoxamine challenge, deferasirox dose with pharmacokinetic monitoring. Then we compared responses between patients who were known to be slow responders to deferasirox and those who were known to be rapid responders (chelated well).\n\nDeferoxamine: After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and Total Iron Binding Capacity (TIBC) by atomic absorption.', 'timeFrame': '0, 1, 2, 4, 6, 8, 12, and 24 hours post dose.'}, {'measure': 'Volume of Distribution/Bioavailability of Deferasirox After a Dose of 35 mg/kg', 'description': 'Volume of distribution/bioavailability (Vd/F)', 'timeFrame': '0, 1, 2, 4, 6, 8, 12, and 24 hours post dose'}, {'measure': 'Volume of Distribution/Bioavailability of Deferasirox After a Dose of 35 mg/kg', 'description': 'Volume of distribution/bioavailability (Vd/F), adjusted per kilogram body weight', 'timeFrame': '0, 1, 2, 4, 6, 8, 12, and 24 hours post dose'}, {'measure': 'Clearance/Bioavailability of Deferasirox in Patients With Poor Response to Deferasirox Compared to Patients With Good Response After a Dose of 35 mg/kg', 'description': 'Clearance/bioavailability (CL/F)', 'timeFrame': '0, 1, 2, 4, 6, 8, 12, and 24 hours post dose.'}]","[{'measure': 'Number of Participants With Polymorphisms in Genes Known to be, or Potentially Involved, in Deferasirox Disposition', 'description': 'Polymorphisms in genes known to be, or potentially involved, in deferasirox disposition: UGT1a1 (including the Gilbert syndrome promoter polymorphism, (TA)nTAA),UGT1a3, BRCP/ABCG2, MRP2/ABCC2. These genes were chosen because deferasirox is primarily eliminated by glucuronidation and subsequent biliary excretion.', 'timeFrame': '3 months'}]",6,6 Years,,ALL,False,Boston Children's Hospital,OTHER,1,15.0,ACTUAL,2025-09-01T16:18:14.670166,v2_robust,True,True,True,False,False,
NCT01872715,Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea,Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea,Oracea,"['Oracea', 'doxycycline USP, 40 mg (30 mg immediate release/ 10 mg delayed release beads)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Papulopustular Rosacea,['Papulopustular Rosacea'],"['Papulopustular Rosacea', 'Oracea', 'anti inflammatory doxycycline']",COMPLETED,,2013-03,2013-06,"[{'measure': 'Rosacea Score on the Visual Analog Scale', 'description': 'VAS = visual analog scale, 10 cm scale in which 0 = no rosacea, 10 = worst rosacea imaginable', 'timeFrame': 'Baseline, Weeks 2, 6, and 12'}]","[{'measure': 'Rosacea-Specific Quality of Life Index', 'description': 'ROSACEA-SPECIFIC QUALITY OF LIFE INDEX©: average of scores to 22 questions on a 5 point scale (1 = never, 5 = all the time)', 'timeFrame': 'Baseline, Weeks 2, 6, and 12'}, {'measure': 'Patient Global Assessment (PGA) of Rosacea Scores', 'description': 'Patient Global Assessment (PGA) of Rosacea: 0 = clear, no signs or symptoms present; 1 = Near clear, 1 or 2 papules; 2 = mild, some (3 to 10) papules/pustules; 3 = moderate, moderate (11 to 19) number of papules and pustules; 4 = severe, numerous (≥ 20) papules/pustules; nodules', 'timeFrame': 'Baseline, Weeks 2, 6, and 12'}, {'measure': 'Patient Satisfaction Question', 'description': 'The patient satisfaction question was answered by the subject at week 2, week 6, and week 12. The subject was asked how satisfied they were with this treatment (doxycycline MR) for rosacea.', 'timeFrame': 'Week 2, 6, and 12'}]",4,25 Years,70 Years,ALL,False,Galderma R&D,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:14.670279,v2_robust,True,True,True,False,False,
NCT05511415,In Vitro Evaluation of Spontaneous and Oxytocin-induced Contractility of Pregnant Human Myometrium During Exposure to Dexmedetomidine,In Vitro Evaluation of Spontaneous and Oxytocin-induced Contractility of Pregnant Human Myometrium During Exposure to Dexmedetomidine,Oxytocin,"['pitocin', 'Dexmedetomidine', 'Oxytocin']",3,INTERVENTIONAL,['NA'],,,Postpartum Hemorrhage,['Postpartum Hemorrhage'],"['uterine contraction', 'oxytocin', 'dexmedetomidine']",COMPLETED,,2022-11-02,2024-11-22,"[{'measure': 'Motility index', 'description': 'Motility index (MI) is a calculated outcome, based on the formula: frequency/(10 x amplitude).\n\nFrequency and amplitude are secondary outcome measures as described below.\n\nThe analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.', 'timeFrame': '4 hours'}]","[{'measure': 'Amplitude of contraction', 'description': 'The maximum extent of uterine muscle contraction, measured in grams (g). The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.', 'timeFrame': '4 hours'}, {'measure': 'Frequency of contraction', 'description': 'The number of contractions in uterine muscle (myometrium) over 10 minutes, spontaneously and in response to an agonist. The analysis is undertaken by attaching myometrial strips between an isometric force transducer and the base of an organ bath chamber.', 'timeFrame': '4 hours'}, {'measure': 'Integrated area under response curve (AUC)', 'timeFrame': '4 hours'}]",4,18 Years,50 Years,FEMALE,True,"Samuel Lunenfeld Research Institute, Mount Sinai Hospital",OTHER,0,50.0,ACTUAL,2025-09-01T16:18:14.670312,v2_robust,True,True,True,False,False,
NCT04030715,The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study,The Associations Between the Gastric Mucosal Pathology and the Eradication Rate of H.Pylori :A Multicenter Study,bismuth-containing quadral therapy based on antibiotic susceptibility,"['gastric mucosal pathology', 'bismuth-containing quadral therapy based on antibiotic susceptibility']",2,INTERVENTIONAL,['NA'],,,Helicobacter Pylori,['Helicobacter Pylori'],"['Gastric Mucosal Pathology', 'Eradication Rate']",UNKNOWN,,2018-09-01,2020-09-30,"[{'measure': 'Eradication Rate of H.Pylori', 'description': 'evaluate the eradication rate of H.Pylori and analysis the association between the gastric mucosal pathology and the eradication rate', 'timeFrame': '2months'}]",[],1,18 Years,70 Years,ALL,False,Shandong University,OTHER,0,1200.0,ESTIMATED,2025-09-01T16:18:14.670345,v2_robust,True,True,False,False,False,
NCT00740415,"Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma","First-line Treatment of Mantle Cell Lymphoma of Old Patients . Evaluate the Efficacy, Toxicity, and Molecular Prognostic Factors of Velcade®) in Association With Chemotherapy and Immunotherapy With Rituximab",bortezomib,"['bortezomib', 'Levact ®', 'dexamethasone', 'Bendamustine', 'Velcade']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,['Lymphoma'],"['contiguous stage II mantle cell lymphoma', 'noncontiguous stage II mantle cell lymphoma', 'stage III mantle cell lymphoma', 'stage IV mantle cell lymphoma']",COMPLETED,,2007-06,2015-08,"[{'measure': 'Overall response rate after 4 courses of therapy', 'timeFrame': '4 months'}]",[],1,65 Years,80 Years,ALL,False,French Innovative Leukemia Organisation,OTHER,2,39.0,ACTUAL,2025-09-01T16:18:14.670366,v2_robust,True,True,True,False,False,
NCT06225115,"A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of KYN-5356 in Healthy Subjects Aged 18 to 55 Years","A First in Human Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of KYN-5356 in Adult, Healthy Subjects",KYN-5356,"['KYN-5356', 'placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cognitive Dysfunction,"['Cognitive Dysfunction', 'Schizophrenia']",[],COMPLETED,,2023-12-21,2024-10-07,"[{'measure': 'Treatment-Emergent Adverse Events', 'description': 'All cohorts', 'timeFrame': 'Initiation of dosing through the last follow-up visit after the last dose, approximately 8 days in the MAD and 5 days after dosing in the SAD and the Food Effect parts of the study'}]","[{'measure': 'PK parameters: Cmax [SAD]', 'description': 'Maximum plasma concentration determined directly from the concentration-time profile. For each dose in SAD part.', 'timeFrame': 'Baseline (predose) through 72 hours post dosing'}, {'measure': 'PK parameters: tmax [SAD]', 'description': 'Time of maximum plasma concentration determined directly from the concentration-time profile. For each dose in SAD part.', 'timeFrame': 'Baseline (predose) through 72 hours post dosing'}, {'measure': 'PK parameters: AUCinf [SAD]', 'description': 'Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time calculated using the linear-log trapezoidal rule. For each dose in SAD part.', 'timeFrame': 'Baseline (predose) through 72 hours post dosing'}, {'measure': 'PK parameters: Cmax on Day 1 [MAD]', 'description': 'Maximum plasma concentration determined directly from the concentration-time profile. For each dose in MAD part', 'timeFrame': 'Baseline (predose) through 24 hours post first dosing'}, {'measure': 'PK parameters: tmax on Day 1 [MAD]', 'description': 'Time of maximum plasma concentration determined directly from the concentration-time profile. For each dose in MAD part.', 'timeFrame': 'Baseline (predose) through 24 hours post first dosing'}, {'measure': 'PK parameters: Cmax,ss [MAD]', 'description': 'Maximum observed plasma concentration during a dosing interval at steady state. For each dose in MAD part.', 'timeFrame': 'Baseline (predose) through 96 hours post dosing on Day 7.'}, {'measure': 'PK parameters: tmax,ss [MAD]', 'description': 'Time of maximum plasma concentration determined directly from the concentration-time profile at steady state. For each dose in MAD part.', 'timeFrame': 'Baseline (predose) through 96 hours post dosing on Day 7.'}, {'measure': 'PK parameters: AUCtau on Days 1 and 7 [MAD]', 'description': 'Area under the concentration-time curve over the dosing interval. For each dose in MAD part', 'timeFrame': 'Baseline (predose) through 96 hours post dosing on Day 7.'}, {'measure': 'PK parameters: AUCinf [MAD]', 'description': 'Area under the concentration-time curve from pre-dose (time 0) extrapolated to infinite time calculated using the linear-log trapezoidal rule. For each dose in MAD part.', 'timeFrame': 'Baseline (predose) through 96 hours post dosing on Day 7.'}]",10,18 Years,55 Years,ALL,True,Kynexis B.V.,INDUSTRY,1,72.0,ACTUAL,2025-09-01T16:18:14.670383,v2_robust,True,True,True,False,True,
NCT02947815,Safety and Efficacy of NABOTA in Treatment of Essential Blepharospasm,"A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase II/III Clinical Trial to Compare the Safety and Efficacy of NABOTA Versus BOTOX in Treatment of Essential Blepharospasm",Clostridium Botulinum Toxin Type A,"['Clostridium Botulinum Toxin Type A', 'NABOTA', 'BOTOX']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Blepharospasm,['Blepharospasm'],[],COMPLETED,,2016-10,2018-01,"[{'measure': ""The change from baseline in Scott's Scale Score"", 'timeFrame': 'At 4 weeks'}]",[],1,18 Years,,ALL,False,Daewoong Pharmaceutical Co. LTD.,INDUSTRY,0,234.0,ESTIMATED,2025-09-01T16:18:14.670399,v2_robust,True,True,True,False,False,
NCT01498835,Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma,Phase 1 Trial of Concurrent Sunitinib and Radiation Therapy as Preoperative Treatment for Locally Advanced or Recurrent Soft Tissue Sarcoma.,Sunitinib,"['Radiation therapy', 'Sunitinib']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Soft Tissue Sarcoma,['Soft Tissue Sarcoma'],"['Soft tissue sarcoma', 'Radiation therapy', 'Sunitinib']",COMPLETED,,2012-02,2015-02,"[{'measure': 'To evaluate the dose limiting toxicity and maximal tolerated dose of sunitinib given concurrently with irradiation as neoadjuvant treatment in soft tissue sarcoma.', 'description': 'Toxicity of the study treatment will be documented according to CTCAE 4.0 during and until 4 weeks after study treatment.', 'timeFrame': '12 weeks'}]","[{'measure': 'To evaluate the response to sunitinib given concurrently with radiation as neoadjuvant treatment in soft tissue sarcoma.', 'description': 'Imaging response will be determined according to RECIST criteria comparing magnetic resonance imaging performed prior to and 6 weeks after completion of study treatment. Pathologic response will be determined evaluating the the fraction of non-viable tumor in the resection specimen.', 'timeFrame': '6 weeks after completion of study treatment.'}]",2,18 Years,,ALL,False,Heidelberg University,OTHER,1,9.0,ACTUAL,2025-09-01T16:18:14.670717,v2_robust,True,True,True,False,False,
NCT00614835,Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus,A Pilot Study of Adjuvant Docetaxel Plus Gemcitabine in Patients With Completely Resected Leiomyosarcoma (LMS) of the Uterus,Docetaxel plus Gemcitabine,['Docetaxel plus Gemcitabine'],1,INTERVENTIONAL,['NA'],,,Uterine Leiomyosarcoma,"['Uterine Leiomyosarcoma', 'Uterine Cancer']","['Gemcitabine', 'Docetaxel', 'uterine sarcoma']",COMPLETED,,2001-08,2012-01,"[{'measure': 'To determine the tolerability of delivering 4 cycles of docetaxel plus gemcitabine.', 'timeFrame': 'conclusion of the study'}]","[{'measure': 'Determine the percentage of pts with completely resected uterine LMS tx with the regimen that remain progression-free at 2 years, & compare this rate with historical controls to establish an estimate of the efficacy of the adjuvant treatment strategy.', 'timeFrame': 'conclusion of the study'}]",2,18 Years,,FEMALE,False,Memorial Sloan Kettering Cancer Center,OTHER,0,25.0,ACTUAL,2025-09-01T16:18:14.670778,v2_robust,True,True,True,False,False,
NCT05570708,The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training,The Role of Personal Experience for the Therapeutic Attitude in the Context of Substance-assisted Therapy Training,"MDMA, LSD, psilocybin","['MDMA, LSD, psilocybin']",1,INTERVENTIONAL,['NA'],,,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD","['Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD']",[],ENROLLING_BY_INVITATION,,2022-10-25,2029-06-01,"[{'measure': 'TASC-2 scale', 'description': 'The primary endpoint is changes on the TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)', 'timeFrame': 'Three weeks after last PE'}]","[{'measure': 'semi-structured interview', 'description': 'A semi-structured interview will be used to explore the range of effects and systematically collect and record subjective effects of the personal experience', 'timeFrame': 'Five months after last PE'}, {'measure': 'TASC-2 scale', 'description': 'TASC-2 scale of the Therapeutic attitude questionnaire (ThAT)', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'SOCS-S', 'description': 'Compassion with self', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'SPCS-O', 'description': 'Compassion with others', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'SPF/IRI', 'description': 'Empathy questionnaire', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': '5D-ASC', 'description': '5 dimensions of altered states of consciousness questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'CEQ', 'description': 'Challenging experience questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'APEQ', 'description': 'Acceptance /avoidance-promoting experiences questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'PIQ', 'description': 'Psychological insights questionnaire', 'timeFrame': 'Directly after each PE'}, {'measure': 'CSOWD', 'description': 'Connectedness scale', 'timeFrame': 'Directly after each PE'}, {'measure': 'EBI', 'description': 'Emotional breakthrough inventory', 'timeFrame': 'Directly after each PE'}, {'measure': 'BFW/E', 'description': 'Berner Subjective Well-Being questionnaire', 'timeFrame': 'Three weeks after each PE and six months after last PE'}, {'measure': 'PEQ', 'description': 'Persisting effects questionnaire', 'timeFrame': 'Three weeks after each PE and six months after last PE'}]",14,27 Years,,ALL,True,Felix Mueller,OTHER,1,48.0,ESTIMATED,2025-09-01T16:18:14.670960,v2_robust,True,True,False,False,False,
NCT01860508,A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers,Advanced Metastatic Non-small Cell Lung Cancer Patients Aged or PS Score 2 Points for First Line Application Pemetrexed/Carboplatin Chemotherapy Regimens Sequential Pemetrexed Single Drug Maintenance Treatment of Clinical Research and Related Predictive Biomarkers of Exploratory Research,pemetrexed /carboplatin,['pemetrexed /carboplatin'],1,INTERVENTIONAL,['NA'],,,Non-small Cell Lung Cancer,['Non-small Cell Lung Cancer'],['Progression free Survival'],UNKNOWN,,2013-02,,"[{'measure': 'PFS', 'timeFrame': 'from the first cycle of treatment (day one) to two month after the last cycle'}]",[],1,70 Years,,ALL,False,Fudan University,OTHER,0,94.0,ESTIMATED,2025-09-01T16:18:14.670991,v2_robust,True,True,False,False,False,
NCT06917508,"A Study to Evaluate the Drug-Drug Interaction of EDP-323 With Midazolam, Caffeine, and Rosuvastatin in Healthy Participants","A Non-Randomized, Multiple-Dose, Open-Label, Single Sequence Study to Evaluate the Effect of Concomitant Administration of EDP-323 on the Pharmacokinetics and Safety of Midazolam, Caffeine, and Rosuvastatin in Healthy Participants",EDP-323,"['Caffeine', 'Midazolam', 'EDP-323', 'Rosuvastatin']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,RSV Infection,"['RSV Infection', 'Drug Drug Interaction']",['Drug Drug Interaction'],COMPLETED,,2025-03-13,2025-06-13,"[{'measure': 'Cmax of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323', 'timeFrame': 'Up to 17 Days'}, {'measure': 'AUC of midazolam, caffeine, and rosuvastatin with and without the coadministration of EDP-323', 'timeFrame': 'Up to 17 Days'}]","[{'measure': 'Safety measured by adverse events', 'timeFrame': 'Up to 22 days'}]",3,18 Years,65 Years,ALL,True,"Enanta Pharmaceuticals, Inc",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:14.671003,v2_robust,True,True,True,False,True,
NCT02871908,Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial,Lactobacillus Reuteri DSM 17938 in the Prevention of Antibiotic-associated Diarrhea in Children: Protocol of a Randomized Controlled Trial,Lactobacillus reuteri DSM 17938,"['Lactobacillus reuteri DSM 17938', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diarrhea,"['Diarrhea', 'Antibiotic Associated Diarrhea']",[],COMPLETED,,2016-12,2018-03,"[{'measure': 'frequencies of diarrhea and antibiotic associated diarrhea', 'description': 'Three different definitions of diarrhea will be used, as the definitions of diarrhea/AAD in published studies vary. These will include diarrhea defined as: (a) ≥3 loose or watery stools per day for a minimum of 48 hours during antibiotic treatment; (b) ≥3 loose or watery stools per day for a minimum of 24 hours during antibiotic treatment, and (c) ≥2 loose or watery stools per day for a minimum of 24 hours during antibiotic treatment. AAD will be diagnosed in cases of diarrhea, defined clinically as above, caused by C. difficile or for otherwise unexplained diarrhea (i.e., negative laboratory stool tests for infectious agents). In all cases, loose or watery stools will correspond to scores of 5 to 7 on the BSF scale or A-consistency on the AISS.', 'timeFrame': 'during antibiotic treatment, an average of 10 days and 7 days of follow up'}]","[{'measure': 'infectious diarrhea', 'description': 'rotavirus, adenovirus, norovirus, Salmonella, Shigella, Campylobacter, Yersinia and C. difficile', 'timeFrame': 'during antibiotic treatment, an average of 10 days and 7 days of follow up'}, {'measure': 'the need for discontinuation of the antibiotic treatment', 'timeFrame': 'during antibiotic treatment, an average of 10 days'}, {'measure': 'the need for hospitalization to manage the diarrhea (in outpatients)', 'timeFrame': 'during antibiotic treatment, an average of 10 days and 7 days of follow up'}, {'measure': 'the need for intravenous rehydration in any of the study groups', 'timeFrame': 'during antibiotic treatment, an average of 10 days and 7 days of follow up'}, {'measure': 'adverse events', 'timeFrame': 'during antibiotic treatment, an average of 10 days and 7 days of follow up'}]",6,,18 Years,ALL,False,Medical University of Warsaw,OTHER,0,250.0,ACTUAL,2025-09-01T16:18:14.671039,v2_robust,True,True,True,False,True,
NCT00353808,"A Trial Assessing The Long Term Safety And Tolerability Of [S,S]-Reboxetine In Patients With Post-Shingles Pain.","An Open-Label Extension Trial Assessing The Safety And Tolerability Of [S,S]-Reboxetine In Patients With Postherpetic Neuralgia (PHN).","[S,S]-Reboxetine","['[S,S]-Reboxetine']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Pain,['Pain'],[],TERMINATED,This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.,2006-07,2007-10,"[{'measure': 'Vital signs'}, {'measure': 'Physical examination'}, {'measure': '12-lead ECG'}, {'measure': 'Hematology/Biochemistry'}, {'measure': 'Adverse events'}]","[{'measure': 'Pain Visual Analogue Scale'}, {'measure': 'Patient Global Impression of Change'}]",7,18 Years,,ALL,False,Pfizer,INDUSTRY,0,112.0,ACTUAL,2025-09-01T16:18:14.671119,v2_robust,True,True,False,True,True,This study has been terminated early as the esreboxetine development program is being discontinued. There are no safety or efficacy concerns.
NCT01227408,"Neoadjuvant Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer","Phase II Clinical Trial of Neoadjuvant Weekly Doxorubicin, Polyglutamate Paclitaxel, Capecitabine and Metronomic Chemotherapy in Breast Cancer","doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate","['doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate']",1,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],['Patients with confirmed breast cancer for neoadjuvant chemotherapy'],WITHDRAWN,Sponsor withdrew due to funding issues,2009-02,2011-02,"[{'measure': 'Response', 'timeFrame': 'At surgical resection on about week 30'}]","[{'measure': 'Toxicity', 'timeFrame': 'Every 4 weeks'}]",2,18 Years,,FEMALE,False,University of Southern California,OTHER,1,0.0,ACTUAL,2025-09-01T16:18:14.671403,v2_robust,True,True,False,True,False,Sponsor withdrew due to funding issues
NCT03568708,Primary Ovarian Insufficiency: Phenotype and Optimal Treatment,Primary Ovarian Insufficiency: Phenotype and Optimal Treatment,Transdermal Estrogen,"['Transdermal Estrogen', 'Estradiol-estradiol patch']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Primary Ovarian Insufficiency,['Primary Ovarian Insufficiency'],"['Primary Ovarian Insufficiency', 'Hormone Replacement Therapy', 'Estrogen Deficiency']",COMPLETED,,2018-11-01,2023-01-05,"[{'measure': 'Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine', 'description': 'Change in height adjusted areal BMD Z-score of the lumbar spine from baseline to 24 months within groups. BMI Z-score, calcium intake, vitamin D intake and physical activity were included in the analysis. As DXA BMD Z-scores already include race, age, and sex, these variables were not included in the analysis.\n\nZ-scores ranging between -2.0 and 2.0 are considered normal. A Z-score \\<-2.0 is considered low. This analysis considers change in Z-score, therefore a high value reflects a greater increase in BMD Z-score.', 'timeFrame': 'Change in bone mineral density and body composition from baseline to 24 months'}]","[{'measure': 'Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) at the Whole Body Less Head, Total Hip, and Femoral Neck', 'description': 'To assess changes in bone mineral density DXA height adjusted BMD Z-scores of the whole body less head, total hip and femoral neck were measured. BMI, calcium intake, vitamin D intake and physical activity were included in the analysis. As DXA BMD Z-scores already include race, age, and sex, these variables were not included in the analysis.\n\nZ-scores ranging between -2.0 and 2.0 are considered normal. A Z-score \\<-2.0 is considered low. This analysis considers change in Z-score, therefore a high value reflects a greater increase in BMD Z-score.', 'timeFrame': 'baseline to 24 months'}, {'measure': 'Change in Volumetric Bone Mineral Density (vBMD) at the Distal Radius as Measured by Peripheral Quantitative Computed Tomography (pQCT)', 'description': 'To assess the appendicular (peripheral) skeleton, pQCT (Stratec XCT 2000, Orthometrix, Inc., White Plains, NY) bone measures were obtained of the non-dominant radius at the 3% and 66% sites. Measurements were acquired with a voxel size of 0.4 mm, slice thickness of 2.3 mm, and scan speed of 25 mm/sec, and analyzed with manufacturer software version 6.', 'timeFrame': 'Change from baseline to 24 months'}, {'measure': 'Anthropometrics', 'description': 'The mean BMI in kg/m\\^2 is presented for each study group at baseline and at the 24 months follow up visit to show that there was no significant difference between groups nor a significant change in BMI over the duration of the study.', 'timeFrame': 'Baseline and 24 months'}, {'measure': 'Change in Lean Mass as Measured by DXA Body Composition', 'description': 'Lean mass was obtained from the whole body DXA scan. Change in baseline to 24 months was assessed.', 'timeFrame': 'Change in lean mass from baseline to 24 months'}, {'measure': 'Change in Symptoms of Anxiety as Measured by Screen for Child Anxiety Related Disorders (SCARED)', 'description': 'A 41 item self-report tool to assess for anxiety where each question receives a score of either 0, 1 or 2. Range of scores is 0 to 82. A total score of ≥ 25 may indicate the presence of an Anxiety Disorder. A higher score indicates there are more endorsed symptoms of anxiety.', 'timeFrame': 'Change from SCARED score baseline to 24 months'}, {'measure': 'Change in Symptoms of Depression as Measured by Child Depression Inventory-II (CDI-II)', 'description': 'A brief self-report test that helps assess cognitive, affective and behavioral signs of depression in children and adolescents 7 to 17 years old. Scales include Emotional and Functional Problems, along with subscales of Negative mood/Physical symptoms, Negative Self-Esteem, Interpersonal Problems, and Ineffectiveness. The total score is converted into a T-score (mean=50, standard deviation=10) where a result \\>64 is considered elevated. A higher score indicates there are more endorsed symptoms of depression.', 'timeFrame': 'Change from CDI-II score from baseline to 24 months'}, {'measure': 'Change in Memory as Assessed by the Children and Adolescent Memory Profile (CHAMP) Total Memory Index Score', 'description': 'The ChAMP is a norm-referenced test of memory and learning that was designed for use with children, adolescents, and young adults ranging from 5 through 21 years. The ChAMP includes 4 Subtests of visual and verbal memory to generate a total memory index score as a measure of overall memory. The total memory index score ranges from 50-150 with a mean=100 and standard deviation=15. Higher scores indicating better memory. The data presented here is the change in the total memory index score from baseline visit to the 24 month follow up time.', 'timeFrame': 'Change from score from baseline to 24 months'}, {'measure': 'Change in Quality of Life as Assessed by the Child Health Questionnaire-Child Self-Report Form (CHQ-CF87)', 'description': 'The CHQ-87 is an 87-item self-report survey is designed to measure the physical and psychosocial health of adolescents. The total score ranges from 0-100. Higher scores indicate better quality of life. This instrument is reliable and valid for evaluating aspects of health pertinent across age, gender, health condition, and socioeconomic status in adolescents.', 'timeFrame': 'Change from baseline to 24 months'}, {'measure': 'Compliance With Transdermal Estrogen Patch', 'description': 'Participants with primary ovarian insufficiency (POI) were prescribed weekly transdermal estrogen (TDE2) patches and asked to log on a patch calendar when they changed the patch. Patch calendars were reviewed for compliance and weeks where at least one patch was applied were considered to be in compliance. Weeks in compliance generated the numerator whereas total weeks of participation in the study constituted the numerator.', 'timeFrame': 'Patch Calendars were collected at 6 months, 12 months, 18 months and 24 months. Data presented is through study completion.'}, {'measure': 'Study Medications - Serum Estradiol', 'description': 'Mean serum estradiol levels as measured in participants with POI.', 'timeFrame': 'Baseline, 12 months, 24 months'}]",11,11 Years,18 Years,FEMALE,True,"Children's Hospital Medical Center, Cincinnati",OTHER,1,19.0,ACTUAL,2025-09-01T16:18:14.671456,v2_robust,True,True,True,False,False,
NCT00157508,Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy,"A Pilot, Randomised, Double-blind, Cross-over Study to Assess the Renal and Systemic Effects of NCX4016 in Patients With Type 2 Diabetes and Early Nephropathy",nitroaspirin,['nitroaspirin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Type 2 Diabetes,"['Type 2 Diabetes', 'Early Nephropathy']",[],TERMINATED,,2003-03,2004-08,"[{'measure': 'Albuminuria after 4 weeks of treatment'}, {'measure': 'Insulin sensitivity after 4 weeks of treatment'}, {'measure': 'Cardiac and renal hemodynamics after 4 weeks of treatment'}]",[],3,18 Years,75 Years,ALL,False,Mario Negri Institute for Pharmacological Research,OTHER,0,13.0,,2025-09-01T16:18:14.671534,v2_robust,True,True,False,True,False,
NCT04443608,Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management,"A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Phase 4 Study of the Efficacy & Safety of Patiromer for Oral Suspension in Combination With Standard of Care Treatment in ED Patients With Hyperkalemia",Patiromer Powder for Oral Suspension [Veltassa],"['Patiromer Powder for Oral Suspension [Veltassa]', 'Inactive substance', 'Placebo', 'Active drug']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Hyperkalemia,['Hyperkalemia'],"['potassium', 'dialysis', 'emergency department']",TERMINATED,Recruitment window ended,2020-10-08,2023-06-03,"[{'measure': 'The need for additional potassium-lowering medical interventions', 'description': 'Net clinical benefit (mean difference in number of interventions less change in serum potassium)', 'timeFrame': ""Duration of patient's emergency department visit, up to 6 hours""}]","[{'measure': 'Potassium level trends after receiving study drug', 'description': 'Proportion of subjects without post-baseline potassium-related medical interventions at Hours 4, 6 and 8', 'timeFrame': 'Up to 24 hours after study drug dose is given'}, {'measure': 'Potassium level trends after receiving study drug', 'description': 'Net clinical benefit at Hour 4', 'timeFrame': '4 hours'}, {'measure': 'Potassium level trends after receiving study drug', 'description': 'Number of post-baseline potassium-related medical interventions up until Hours 4, 6, and 8 and ED discharge', 'timeFrame': 'ED visit, up to 10 hours'}, {'measure': 'Potassium level trends after receiving study drug', 'description': 'Proportion of subjects with sustained potassium reduction (defined as K+ ≤5.5 mEq/l and 4 hours without potassium-related medical intervention) at Hours 6 and 8', 'timeFrame': '8 hours'}, {'measure': 'Potassium level trends after receiving study drug', 'description': 'K+ 24 hours after ED discharge', 'timeFrame': 'Up to 24 hours after study drug dose is given'}]",6,18 Years,,ALL,False,Comprehensive Research Associates,INDUSTRY,0,115.0,ACTUAL,2025-09-01T16:18:14.671546,v2_robust,True,True,False,True,False,Recruitment window ended
NCT03824808,Effect of Perioperative Intravenous Lidocaine Infusion in Robotic-Assisted Urologic Surgery,"A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy",Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution,"['Normal Saline', 'Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution', '0.9% Sodium Chloride Injection', 'Lidocaine']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Kidney Cancer,"['Kidney Cancer', 'Prostate Cancer']","['prostatectomy', 'partial nephrectomy', 'robotic surgery', 'intravenous lidocaine', 'lidocaine hydrochloride']",TERMINATED,Challenges with recruitment of surgical research subjects in the target population.,2019-02-26,2020-03-26,"[{'measure': 'Difference in Post-operative Pain Scores Measured by Visual Analog Scale', 'description': '10-cm Visual Analog Scale (VAS), score of 0 ""no pain"" to a score of 10 ""worst pain ever""', 'timeFrame': 'Through study completion, assessed at 1h, 2h, 4h, 6h, 12h and 24h post operatively, then every 24 hours until discharge, and at the post operative visit which occurred within 21-days post-operatively.'}]","[{'measure': 'Opioid Consumption', 'description': 'Difference in opioid consumption in first 24 hours, discharge and 21 days post-operatively (morphine equivalents)', 'timeFrame': 'Through study completion, assessed for first 24-hours post operatively, then every 24 hours until discharge, and at the post operative visit which occurred within 21-days post-operatively.'}, {'measure': 'Length of Hospital Stay', 'description': 'Difference in length of hospital stay determined by surgeon excluding social factors that may delay discharge', 'timeFrame': 'At participant discharge, assessed up to 14 days (+/-) 7 days'}, {'measure': 'Duration of Post-operative Ileus', 'description': 'Difference in post-operative Ileus duration', 'timeFrame': 'Through study completion, assessed at 1h, 2h, 4h, 6h, 12h and 24h post operatively, then every 24 hours until discharge, and at the post operative visit which occurred within 21-days post-operatively.'}, {'measure': 'Post-operative PACU Time', 'description': 'Difference in time in the Post Anesthesia Care Unit (PACU) after surgery', 'timeFrame': 'During hospitalization, approximately 2 hours post-surgery'}, {'measure': 'Return of Flatus', 'description': 'Difference in return of flatus after surgery', 'timeFrame': 'During hospitalization at 1h, 2h, 4h, 6h, 12h, and 24h post operatively, then every 24 hours thereafter until discharge.'}, {'measure': 'Time to Out of Bed', 'description': 'Difference in time to out of bed to chair after surgery', 'timeFrame': 'During hospitalization regular intervals for the first 24 hours, then every 24 hours until discharge.'}, {'measure': 'First Ambulation in the Hallway', 'description': 'Difference in time to first ambulation in the hallway after surgery', 'timeFrame': 'During hospitalization at 1h, 2h, 4h, 6h, 12h, and 24h post operatively, then every 24 hours until discharge.'}]",8,18 Years,,ALL,False,University of Missouri-Columbia,OTHER,0,21.0,ACTUAL,2025-09-01T16:18:14.671582,v2_robust,True,True,False,True,False,Challenges with recruitment of surgical research subjects in the target population.
NCT04599725,Feasibility of Telemedicine Medical Abortion,TelAbortion: Medical Abortion by Direct-to-patient Telemedicine and Mail,medical abortion,['medical abortion'],1,OBSERVATIONAL,[],,,Pregnancy,['Pregnancy'],[],COMPLETED,,2020-10-01,2021-10-01,"[{'measure': 'Number of participants with adverse events', 'timeFrame': '2 years'}]",[],1,10 Years,50 Years,FEMALE,True,Gynuity Health Projects,OTHER,0,413.0,ACTUAL,2025-09-01T16:18:14.671698,v2_robust,False,True,True,False,True,
NCT01707225,Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD),Safety and Efficacy of Octreotide LAR Depot in Left Ventricular Assist Device (LVAD) Associate Gastrointestinal (GI),Octreotide LAR Depot,['Octreotide LAR Depot'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Gastrointestinal Bleeding,['Gastrointestinal Bleeding'],"['GI Bleeding', 'Gastrointestinal bleeding', 'LVAD']",COMPLETED,,2013-02,2014-10,"[{'measure': 'Number of Participants With Side-Effects', 'description': 'Cardiovascular:\n\nSinus bradycardia (19% to 25%) Hypertension (≤13%) conduction abnormalities (9% to 10%)\n\nCentral nervous system:\n\nFatigue (1% to 32%) headache (6% to 30%) malaise (16% to 20%) fever (16% to 20%) dizziness (5% to 20%) Pain (4% to 15%)\n\nDermatologic:\n\nPruritus (≤18%) Rash (15%; depot formulation) alopecia (≤13%)\n\nEndocrine \\& metabolic:\n\nHyperglycemia (2% to 27%)\n\nGastrointestinal:\n\nAbdominal pain (5% to 61%) loose stools (5% to 61%) nausea (5% to 61%) diarrhea (34% to 58%) flatulence (≤38%) cholelithiasis (13% to 38%; length of therapy dependent) constipation (9% to 21%) vomiting (4% to 21%)\n\nHematologic Anemia (5-15%)\n\nLocal:\n\nInjection site pain (2% to 50%; dose and formulation related)\n\nNeuromuscular \\& skeletal:\n\nBack pain (1% to 27%) arthropathy (8% to 19%) myalgia (≤18%)\n\nRenal Kidney Stones (5-15%)\n\nRespiratory:\n\nUpper respiratory infection (10% to 23%)\n\nMiscellaneous:\n\nflu symptoms (1% to 20%)', 'timeFrame': '24 weeks'}]","[{'measure': 'Need for Blood Transfusion and Hospital Admission for GI Bleed', 'timeFrame': '24 weeks'}]",2,18 Years,,ALL,False,Virginia Commonwealth University,OTHER,2,10.0,ACTUAL,2025-09-01T16:18:14.671707,v2_robust,True,True,True,False,False,
NCT05275725,Finding Solutions to Thrive After Birth Asphyxia in Africa,Finding Solutions to Thrive After Birth Asphyxia in Africa: An Open-label Dose-finding Clinical Trial (Phase Ib Study),Sildenafil,['Sildenafil'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Birth Asphyxia,['Birth Asphyxia'],[],ACTIVE_NOT_RECRUITING,,2022-07-01,2025-01-31,"[{'measure': 'Maximum tolerable dose of sildenafil', 'timeFrame': 'within 30 days of drug administration'}]","[{'measure': 'Incidence of adverse events (Safety and Tolerability)', 'description': 'safety, assessed through the reporting of adverse events, such as death, hypotension, persistent pulmonary hypertension, altered hepatic function, seizures, intraventricular and/or intraparenchymal hemorrhage', 'timeFrame': 'within 30 days of drug administration'}, {'measure': 'Sildenafil concentrations', 'timeFrame': 'within 30 days of drug administration'}]",3,0 Days,18 Months,ALL,False,Pia Wintermark,OTHER,3,18.0,ACTUAL,2025-09-01T16:18:14.671744,v2_robust,True,True,False,False,True,
NCT01379625,Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder,Phase 2 Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders,Triheptanoin,"['IND 113386', 'Triheptanoin', 'C7']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency,"['Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency', 'Carnitine Palmitoyltransferase 2 (CPT2) Deficiency', 'Mitochondrial Trifunctional Protein (TFP) Deficiency', 'Long-chain 3 hydroxyacylCoA Dehydrogenase (LCHAD) Deficiency']","['fatty acid oxidation', 'triheptanoin', 'long-chain fatty acid oxidation disorders', 'LCHADD', 'VLCADD', 'CPT2', 'TFP']",COMPLETED,,2011-09,2015-04,"[{'measure': 'Energy Expenditure', 'description': 'Total energy expenditure will be measured by doubly labeled water and resting energy expenditure will be measured by indirect calorimetry at baseline and again after 4 months of either MCT or trihpetanoin treatment.', 'timeFrame': 'change from baseline after 4 months of treatment'}, {'measure': 'Ejection Fraction', 'description': 'Change in resting ejection fraction over 4 month treatment period', 'timeFrame': '4 months'}]","[{'measure': 'Exercise Heart Rate', 'description': 'Subjects will complete a submaximal treadmill exercise study at baseline. Exercise heart heart, ventilation and perceived exertion will be measured. Subjects will be randomized to MCT or triheptanoin supplementation for 4 months. At the end of treatment, the exercise test will be repeated keeping work performed constant. Change in exercise heart rate, ventilation and exertion will be compared between groups.', 'timeFrame': 'change from baseline to 4 months of treatment'}]",3,7 Years,,ALL,False,Oregon Health and Science University,OTHER,1,32.0,ACTUAL,2025-09-01T16:18:14.671823,v2_robust,True,True,True,False,False,
NCT00298025,A Study to Compare the Safety and Efficacy of Cetrotide® 3 Milligram (mg) Versus Antagon™ in Women Undergoing Ovarian Stimulation,"A Phase IV, Multicenter, Open-label, Randomized Study to Compare the Safety and Efficacy of Cetrotide® 3 mg Versus Antagon™ in the Inhibition of a Premature LH Surge in a r-hFSH/hMG Stimulation Cycle With OCP Programming in Women Undergoing Ovarian Stimulation Prior to ART",Cetrotide®,"['Pergonal®', 'Antagon ™', 'Recombinant human follicle stimulating hormone (r-hFSH)', 'Human Menopausal Gonadotropin (hMG)', 'Choriogonadotropin alfa', 'Ganirelix acetate', 'Ovidrel®', 'Recombinant Human Choriogonadotropin (r-hCG)', 'Cetrorelix acetate', 'Cetrotide®', 'Gonal-f®']",11,INTERVENTIONAL,['PHASE4'],PHASE4,,Infertile Women Undergoing Assisted Reproductive Technology (ART),['Infertile Women Undergoing Assisted Reproductive Technology (ART)'],"['Infertility', 'Cetrotide', 'Antagon', 'Recombinant human follicle stimulating hormone (r-hFSH)', 'Human Menopausal Gonadotropin (hMG)', 'Recombinant Human Choriogonadotropin (r-hCG)']",COMPLETED,,2003-09,2004-05,"[{'measure': 'Percentage of subjects without premature luteinizing hormone (LH) surge', 'timeFrame': 'r-hCG administration day (end of stimulation cycle {approximately 4 days})'}]","[{'measure': 'Duration of study treatment', 'timeFrame': 'Stimulation Day 1 (S1) up to r-hCG administration day (end of stimulation cycle {approximately 4 days})'}, {'measure': 'Total dose of recombinant human follicle stimulating hormone/human menopausal gonadotropin (r-hFSH/hMG) administered', 'timeFrame': 'Stimulation Day 1 (S1) up to r-hCG administration day (end of stimulation cycle {approximately 4 days})'}, {'measure': 'Duration of gonadotropin therapy', 'timeFrame': 'Stimulation Day 1 (S1) up to r-hCG administration day (end of stimulation cycle {approximately 4 days})'}, {'measure': 'Number of follicles greater than or equal to (>=) 14 millimeter (mm) on day of recombinant human chorionic gonadotropin (r-hCG) administration', 'timeFrame': 'r-hCG administration day (end of stimulation cycle {approximately 4 days})'}, {'measure': 'Number of oocytes retrieved', 'timeFrame': 'Ovum pick-up (OPU) day (34-38 hours post r-hCG administration day [end of stimulation cycle {approximately 4 days}])'}, {'measure': 'Number of mature oocytes retrieved', 'timeFrame': 'OPU day (34-38 hours post r-hCG administration day [end of stimulation cycle {approximately 4 days}])'}, {'measure': 'Number of fertilized oocytes', 'timeFrame': 'Day 1 post OPU day (34-38 hours post r-hCG administration day [end of stimulation cycle {approximately 4 days}])'}, {'measure': 'Number and Quality of Embryos', 'timeFrame': 'Day 2-3 post OPU (34-38 hours post r-hCG administration day [end of stimulation cycle {approximately 4 days}])'}, {'measure': 'Implantation rate', 'timeFrame': 'Day 35-42 post r-hCG administration day (end of stimulation cycle {approximately 4 days})'}, {'measure': 'Total number of transferred and cryopreserved embryos', 'timeFrame': 'Day 2-3 post OPU (34-38 hours post r-hCG administration day [end of stimulation cycle {approximately 4 days}])'}, {'measure': 'Percentage of subjects with clinical and biochemical pregnancies', 'timeFrame': 'Day 35-42 post r-hCG administration day (end of stimulation cycle {approximately 4 days})'}, {'measure': 'Quality of Life assessed by Short Form- 36 (SF-36) Questionnaire', 'timeFrame': 'Stimulation Day 1 (S1) and Day 15-18 post r-hCG administration (end of stimulation cycle {approximately 4 days})'}]",13,18 Years,39 Years,FEMALE,False,EMD Serono,INDUSTRY,0,185.0,ACTUAL,2025-09-01T16:18:14.671944,v2_robust,True,True,True,False,False,
NCT05255276,PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.,"A Phase 1 Open-label, Two-cohort, One-sequence Crossover Study to Investigator the Effect of P-glycoprotien Inhibitor (Itraconazole) and Inducer (Rifampin) on the Pharmacokinetics, Safety, and Tolerability of Sitravatinib in Health Subjects",Sitravatinib 50 mg,"['Protonix', 'Itraconazole', 'Sitravatinib 50 mg', 'Pepcid', 'MGCD516', 'Sitravatinib 100 mg', 'Rifampin']",7,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Adults,['Healthy Adults'],[],COMPLETED,,2022-02-02,2023-02-10,"[{'measure': 'Pharmacokinetics - Cmax (sitravatinib)', 'description': 'Maximum observed plasma concentration', 'timeFrame': 'Up to Day 168 hours after dosing'}, {'measure': 'Pharmacokinetics - AUC∞ (sitravatinib)', 'description': 'Area under the plasma concentration-time curve from time zero extrapolated to infinity', 'timeFrame': 'Up to 168 hours after dosing'}, {'measure': 'Pharmacokinetics - AUClast (sitravatinib)', 'description': 'Area under the curve from time zero to the last measured time point', 'timeFrame': 'Up to 168 hours after dosing'}, {'measure': 'Pharmacokinetics - tmax (sitravatinib)', 'description': 'Terminal elimination half-life', 'timeFrame': 'Up to 168 hours after dosing'}, {'measure': 'Pharmacokinetics - CL/F (sitravatinib)', 'description': 'Apparent total plasma clearance when dosed orally', 'timeFrame': 'Up to 168 hours after dosing'}, {'measure': 'Pharmacokinetics - Vz/F (sitravatinib)', 'description': 'Apparent volume of distribution when dosed orally', 'timeFrame': 'Up to 168 hours after dosing'}, {'measure': 'Pharmacokinetics - uf (sitravatinib)', 'description': 'Unbound fraction', 'timeFrame': 'Up to 168 hours after dosing'}]","[{'measure': 'Adverse Events (AEs)', 'description': 'Incidence and severity of AEs', 'timeFrame': 'Up to 12 weeks from screening'}]",8,18 Years,55 Years,ALL,True,Mirati Therapeutics Inc.,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:14.672022,v2_robust,True,True,True,False,True,
NCT00953576,"Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer","A Phase I/II Trial of Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Castration Resistant Prostate Cancer With Pre- and Post-therapy Tumor Biopsies",ketoconazole,"['Hydrocortone', 'Nizoral', 'dutasteride', 'lapatinib', 'Tyverb', 'lapatinib ditosylate', 'hydrocortisone', 'Cortef', 'ketoconazole', 'Avodart']",10,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Prostate Cancer,['Prostate Cancer'],"['castration resistant prostate cancer', 'KHAD']",TERMINATED,The study terminated early due to concerns about drug toxicity.,2009-09-29,2013-04-11,"[{'measure': 'Lapatinib Maximum Tolerated Dose (MTD) [Phase I]', 'description': 'The MTD of lapatinib in combination with KHAD is determined by the number of participants who experience a dose limiting toxicity (DLT) at the various dose levels of lapatinib under evaluation. See subsequent primary outcome measure for the DLT definition. The MTD is defined as the lapatinib dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached and the Recommended Phase II Dose (RP2D) will be based on safety and pharmacokinetic results.', 'timeFrame': 'The evaluation for MTD occurred continuously through one cycle of KHLAD treatment (28 days).'}, {'measure': 'Lapatinib Dose Limiting Toxicity (DLT) [Phase I]', 'description': 'A DLT is defined as an adverse event (AE) occurring during the first cycle of KHLAD treatment that are determined to related to the Lapatinib or the combination as follows:\n\n1. Any Grade 3 or greater non-hematological treatment related (possible, probable, or definite attribution) including diarrhea\n2. Grade 4 or greater for hematological toxicities, regardless of attribution.\n3. Grade 3 skin reactions, pulmonary reactions, regardless of attribution.', 'timeFrame': 'The evaluation for DLT occurred continuously through one cycle of treatment (28 days).'}, {'measure': 'Plasma Lapatinib Levels [Phase I]', 'description': 'Plasma lapatinib levels were measured after day 28 of KHLAD treatment. Participants were instructed to fast prior to samples being taken.', 'timeFrame': 'After first 28 days of KHLAD treatment'}]","[{'measure': 'Grade 3-4 Treatment-Related Adverse Events Rate', 'description': 'All grade 3-4 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEv4 as reported on case report forms were counted to calculate the proportion of participants experiencing at least one treatment-related grade 3 or 4 AE of any type on treatment.', 'timeFrame': 'Assessed each cycle throughout treatment. Treatment duration in months was a median (range) of 5.4 months (range 1 day-8.3 months). Thus, AEs were evaluated up to 8.3 months.'}]",4,18 Years,,MALE,False,Dana-Farber Cancer Institute,OTHER,5,11.0,ACTUAL,2025-09-01T16:18:14.672064,v2_robust,True,True,False,True,True,The study terminated early due to concerns about drug toxicity.
NCT03731117,FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU,FURosemide Stress Test to Predict Need of Renal Replacement THERapy in Ischemic Acute Tubular Necrosis in ICU,Furosemide,"['Furosemide', 'furosemide stress test']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Acute Kidney Injury,['Acute Kidney Injury'],"['Ischemic Acute Kidney Injury', 'Intensive care units', 'AKI', 'ICU', 'FST', 'FUROSEMIDE STRESS TEST', 'RRT', 'Renal Replacement Therapy', 'sepsis', 'Cardio-pulmonary bypass']",TERMINATED,Study end date exceeded and insufficient number of subjects needed for analysis. 11 patients included / 70 theoretical patients,2019-07-15,2020-12-07,"[{'measure': 'Need for renal replacement therapy or death', 'description': 'Need for renal replacement therapy will be define according to the AKIKI study (Gaudry S, Hajage D, Schortgen F, Martin-Lefevre L, Pons B, Boulet E, et al. Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit. N Engl J Med. 2016 Jul 14;375(2):122-33). Need for RRT following AKIKI delayed initiation criteria.\n\nFST performance will be compared to the need of RRT or death.', 'timeFrame': 'Before day 7'}, {'measure': 'sensitivity', 'description': 'FST will be positive if patient is non responder : 2-hour urine output \\< 200mL', 'timeFrame': '3 hour after FST'}]","[{'measure': '6 hour urine output', 'description': 'measurement of urine out', 'timeFrame': '6 hour after FST'}, {'measure': 'percentage of effective renal replacement therapy', 'description': 'Initiation of RRT', 'timeFrame': 'daily up to day 7'}, {'measure': 'death', 'timeFrame': 'daily up to day 7'}, {'measure': 'hemodynamic safety: noradrenaline dose', 'description': 'noradrenaline dose', 'timeFrame': '6 hour after FST'}, {'measure': 'clinical safety: arterial pressure', 'description': 'modification of systolic, diastolic or mean arterial blood pressure', 'timeFrame': '6 hour after FST'}]",7,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:14.672161,v2_robust,True,True,False,True,True,Study end date exceeded and insufficient number of subjects needed for analysis. 11 patients included / 70 theoretical patients
NCT00469417,Metvix Photodynamic Therapy (PDT) Versus Cryotherapy in Participants With Primary Superficial Basal Cell Carcinoma,"A Multicenter, Phase III, Randomised Study of Photodynamic Therapy With Metvix Cream 160 mg/g in Comparison With Cryotherapy in Patients With Primary Superficial Basal Cell Carcinoma",Metvix® cream,"['Metvix® cream', 'Methyl 5-aminolevulinate hydrochloride']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Superficial Basal Cell Carcinoma,['Superficial Basal Cell Carcinoma'],"['Methyl aminolevulinate', 'Photodynamic therapy', 'Primary Superficial Basal Cell Carcinoma']",COMPLETED,,1999-10-18,2005-04,"[{'measure': 'Percentage of Participants With Histologically Confirmed Patient Complete Response (CR) 3 Months After Last Metvix PDT or Cryotherapy Cycle', 'description': 'Patient Complete Response (CR) was defined as 100 percentage of the lesions within the participant having negative findings for nodular basal cell carcinoma (BCC) in the histological examination.', 'timeFrame': '3 months after last Metvix PDT or Cryotherapy cycle, up to 6 months'}]","[{'measure': 'Number of Lesion With Complete Response 3 Months After Last Metvix PDT or Cryotherapy Cycle', 'description': 'Complete response was defined as no clinically visible BCC lesions in the treatment area.', 'timeFrame': '3 months after last Metvix PDT or Cryotherapy cycle, up to 6 months'}, {'measure': 'Overall Cosmetic Outcome Assessed by Investigator 3 Months After the Last Metvix PDT or Cryotherapy Cycle', 'description': 'Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.', 'timeFrame': '3 months after the last metvix PDT or Cryotherapy cycle (Up to 6 months)'}, {'measure': 'Overall Cosmetic Outcome Assessed by Participants 3 Months After the Last Metvix PDT or Cryotherapy Cycle', 'description': 'Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The participants graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.', 'timeFrame': '3 months after the last metvix PDT or Cryotherapy cycle (Up to 6 months)'}, {'measure': 'Recurrence Rate in Complete Clearance Group', 'description': 'Recurrence rate in complete clearance group was analyzed.', 'timeFrame': '12, 24, 36, 48 and 60 months after last Metvix PDT cycle or Cryotherapy (Up to 5 years)'}, {'measure': 'Overall Cosmetic Outcome Assessed by Investigator 24, 36, 48, and 60 Months After the Last Metvix PDT or Cryotherapy Cycle', 'description': 'Cosmetic outcome was assessed by both investigator and participants in participants with 100% of lesions in complete response. Overall cosmetic outcome was assessed with regard to occurrence of the following signs or symptoms; scarring, atrophy, induration, redness or change in pigmentation. The investigator graded the cosmetic outcome as:\n\n* excellent: no scarring, atrophy or induration, and no or slight occurrence of redness or change in pigmentation compared lo adjacent skin\n* good: no scarring, atrophy or induration but moderate redness or change in pigmentation compared to adjacent skin\n* fair: slight to moderate occurrence of scarring, atrophy or induration\n* poor: extensive occurrence of scarring, atrophy or induration.', 'timeFrame': '24, 36, 48, and 60 Months After the Last Metvix PDT Cycle (Up to 5 years)'}]",6,18 Years,,ALL,False,Galderma R&D,INDUSTRY,0,120.0,ACTUAL,2025-09-01T16:18:14.672290,v2_robust,True,True,True,False,False,
NCT02216617,Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy,A Phase I Study Evaluating the Combination Afatinib With Docetaxel and Cisplatin (TPA) in Induction Chemotherapy in Locally Advanced Squamous Cell Carcinoma of the Upper Aerodigestive Tract,"Taxotere, Cisplatin, Afatinib","['Taxotere, Cisplatin, Afatinib']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,HNSCC,['HNSCC'],[],COMPLETED,,2014-08-06,2015-09-15,"[{'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'The main objective is to determine the Maximum Tolerated Dose (MTD) of afatinib in combination with docetaxel and cisplatin chemotherapy TPA induction in locally advanced head and neck carcinomas in order to move a phase II for comparison with induction chemotherapy ""of reference ""TPF (Taxotere, cisplatin and 5-fluorouracil).', 'timeFrame': 'During the first 4 weeks of treatment for each patient of the bearing.'}]","[{'measure': 'Tolerance', 'description': 'Tolerance: Toxicity will be evaluated by NCI CTCAE V4.03. scale', 'timeFrame': '12 weeks'}, {'measure': 'Efficacy', 'description': 'Efficacy: Objective tumor response will be evaluated through RECIST V1.1', 'timeFrame': '12 weeks'}]",3,18 Years,70 Years,ALL,False,Groupe Oncologie Radiotherapie Tete et Cou,OTHER,0,8.0,ACTUAL,2025-09-01T16:18:14.672335,v2_robust,True,True,True,False,False,
NCT01136317,Comparison of Antisecretory Effect of a Single Dose of Rabeprazole 20 mg and Omeprazole 20 mg in Obese Subjects,,Omeprazole,"['Rabeprazole', 'Lactose', 'Omeprazole']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastroesophageal Reflux,['Gastroesophageal Reflux'],[],COMPLETED,,2010-04,2010-07,"[{'measure': 'In order to measure antisecretory effect, the main outcome criteria of analysis will be the percentage of time with gastric pH above 3 and measured during 24hours following rabeprazole administration in comparison with omeprazole administration.'}]",[],1,18 Years,55 Years,ALL,True,Nantes University Hospital,OTHER,0,,,2025-09-01T16:18:14.672350,v2_robust,True,True,True,False,False,
NCT01306617,"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) When Given Together With ABT-333 and Ribavirin (RBV) in Treatment-Naïve and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection","An Open-Label Pilot Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-333 and Ribavirin (RBV) in Treatment-Naive and Non-responder Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection",ABT-450,"['ABT-333', 'dasabuvir', 'ABT-450', 'ribavirin', 'ritonavir', 'Norvir']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Hepatitis C Infection,"['Chronic Hepatitis C Infection', 'Hepatitis C', 'Hepatitis C Virus']",[],COMPLETED,,2011-02,2012-10,"[{'measure': 'Percentage of Participants With Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Suppressed Below the Lower Limit of Detection (LLOD) From Week 4 Through Week 12', 'description': 'Analysis of the percentage of participants with hepatitis C virus ribonucleic acid less than the lower limit of detection (\\< 15 IU/mL).', 'timeFrame': 'Week 4 through Week 12'}]","[{'measure': 'Percentage of Participants With HCV RNA < 1000 International Units Per Milliliter (IU/mL)', 'description': 'Analysis of participants with HCV RNA levels below 1000 IU/mL at Week 2.', 'timeFrame': 'Week 2'}, {'measure': 'Percentage of Participants With HCV RNA Below the Lower Limit of Quantitation (LLOQ; <25 IU/mL) at Week 4', 'description': 'Analysis of percentage of participants with hepatitis C virus ribonucleic acid less than the lower limit of quantitation (\\< 25 IU/mL).', 'timeFrame': 'Week 4'}, {'measure': 'Percentage of Participants With Sustained Virologic Response 12 Weeks (SVR12) Post-treatment', 'description': 'Sustained virologic response 12 (SVR12) is defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ; \\< 25 IU/mL) 12 weeks after the last dose of study drug.', 'timeFrame': 'Post-treatment Day 1 to Post-treatment Week 12'}, {'measure': 'Percentage of Participants With Sustained Virologic Response 24 Weeks (SVR24) Post-Treatment', 'description': 'Sustained virologic response 24 (SVR24) is defined as plasma hepatitis C virus ribonucleic acid (HCV RNA) less than the lower limit of quantification (LLOQ; \\< 25 IU/mL) 24 weeks after the last dose of study drug.', 'timeFrame': 'Post-treatment Day 1 to Post-treatment Week 24'}, {'measure': 'Time to Failure to Suppress or Rebound During Treatment', 'description': 'Time to failure to achieve a 2 log10 IU/mL HCV RNA decrease at Week 1, failure to achieve HCV RNA \\< Lower Limit of Detection (LLOD) at Week 6, or a confirmed increase of at least 0.5 log10 IU/mL above nadir (local minimum value) or confirmed HCV RNA \\> lower limit of quantitation (LLOQ) for participants who previously achieved HCV RNA \\< LLOQ.', 'timeFrame': 'Day 1 through Week 12'}, {'measure': 'Time to Virologic Relapse Post-treatment', 'description': 'Time to the first of 2 consecutive measurements of confirmed HCV RNA ≥ lower limit of quantitation (LLOQ) at any point in the post-treatment period among participants with HCV RNA \\< LLOQ at the end of treatment.', 'timeFrame': 'Post-treatment Day 1 to post-treatment week 48'}, {'measure': 'Resistance-Associated Variants and Phenotypic Resistance', 'description': 'Baseline samples were analyzed for resistance-associated amino acid variants using population sequencing. Phenotypic resistance to ABT-450 or ABT-333 at baseline was assessed by calculating the fold difference in the half maximal effective concentration (EC50) compared with the EC50 for the appropriate reference replicon (1a-H77 or 1b-Con1). Participants not achieving SVR12 were analyzed for resistance-associated variants at the time of failure using population sequencing and were compared with the baseline and appropriate reference sequences to assess amino acid changes. Phenotypic resistance to ABT-450 or ABT-333 at the time of failure was assessed by calculating the fold difference in the EC50 compared with the EC50 for the corresponding baseline sample. The number of participants with variants at resistance-associated amino acid positions and phenotypic resistance at baseline and at the time of failure are presented.', 'timeFrame': 'Day 1 to post-treatment week 48'}, {'measure': 'Pharmacokinetics (C Trough) of ABT 450 in HCV Infected Participants', 'description': 'Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.', 'timeFrame': 'Day 1 to Week 12'}, {'measure': 'Pharmacokinetics (C Trough) of ABT-333 in HCV Infected Participants', 'description': 'Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.', 'timeFrame': 'Day 1 to Week 12'}, {'measure': 'Pharmacokinetics (C Trough) of Ritonavir in HCV Infected Participants', 'description': 'Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.', 'timeFrame': 'Day 1 to Week 12'}, {'measure': 'Pharmacokinetics (C Trough) of Ribavirin in HCV Infected Participants', 'description': 'Trough concentration (C trough) is the concentration 24 hours after once daily (QD) dose and 12 hours after twice daily (BID) dose.', 'timeFrame': 'Day 1 to Week 12'}]",12,18 Years,65 Years,ALL,False,"AbbVie (prior sponsor, Abbott)",INDUSTRY,0,50.0,ACTUAL,2025-09-01T16:18:14.672384,v2_robust,True,True,True,False,False,
NCT01283217,Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected Stage IIIB/IV Gastric Cancer,"A Randomized, Multicenter, Open-label, Phase III Trial of Docetaxel and S1 (DS) Versus S1 and Cisplatin (SP) in Curatively Resected (D2) Gastric Cancer of Stage IIIB/IV (M0)",DS,"['Test group : DS * 8 cycles', '(S-1 70mg/m2/D, D1~14 plus Docetaxel 35 mg/m2 D1,8 q 3weeks)', 'Control group : SP * 8 cycles', '(S-1 70mg/m2/D, D1~14 + Cisplatin 60mg2 D1, q 3 weeks)', 'SP', 'DS']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Gastric Adenocarcinoma,['Gastric Adenocarcinoma'],[],UNKNOWN,,2010-03,2016-03,"[{'measure': '3-year disease free survival(DFS)', 'description': 'Tumor assessments with chest X-rays and CT or MRI scan will be done at 6 months after randomization (after the end of the treatment period), then every 3 months for the first 2 years after randomization and then every 6 months for coming 3 years then one year basis until completion of the study.', 'timeFrame': '3 years'}]",[],1,20 Years,,ALL,False,Yonsei University,OTHER,0,166.0,ESTIMATED,2025-09-01T16:18:14.672466,v2_robust,True,True,False,False,False,
NCT04513717,"Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial",Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*),Apalutamide,"['Fluken', 'Fugerel', 'Flutacan', 'Sch 13521', 'CL-118532', 'Flutan', 'Orgovyx', ""4'-Nitro-3'-trifluoromethylisobutyranilide"", 'Buserelin', 'S74 6766', 'Prostadirex', 'Cytomid', 'Utamide', 'Flutamex', 'Cebatrol', 'Grisetin', 'Relugolix', 'TAK385', 'Flucinome', ""N-(4-(1-((2,6-Difluorophenyl)methyl)-5-((dimethylamino)methyl)-1,2,3,4-tetrahydro-3-(6-methoxy-3-pyridazinyl)-2,4-dioxothieno(2,3-d)pyrimidin-6-yl)phenyl)-N'-methoxyurea"", 'AY25650', 'Prostica', '6-[O-(1,1-Dimethylethyl)-D-serine]-9-(N-ethyl-L-prolinamide)-10-deglycinamide-luteinizing Hormone-releasing Factor (Pig)', 'Chimax', 'Etilamide', 'Busereline', 'ARN509', 'HOE 766', 'S746766', 'TAK-385', 'HOE-766', 'Cassotide', 'AY-25650', 'Tecnoflut', 'Flulem', 'Testotard', 'CL-118,532', 'Apalutamide', 'CL 118532', 'Tiloryth', 'ASP3550', 'Prostacur', 'Flucinom', 'HOE766', 'ARN-509', 'Eulexine', 'BSRL', 'JNJ-56021927', 'ASP 3550', 'CL118532', 'AY 25650', 'ICI-123215', 'ASP-3550', 'Propanamide, 2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-', 'Euflex', 'Relumina', 'Leuprorelin', 'ICI 123215', 'FLUT', 'ICI 176334', 'Casodex', 'Flutaplex', 'Profamid', 'Fluta-Gry', 'Bicalutamide', 'Oncosal', 'FE-200486', 'Firmagon', '6-D-Tryptophan-LH-RH', 'ICI-118630', 'Drogenil', 'ARN 509', 'Degarelix', 'ICI 176,334', 'Flutamide', 'JNJ 56021927', 'FE 200486', 'Detryptoreline', 'Leuprolide', 'Erleada', 'Histrelin', 'ICI123215', 'Niftolide', 'Triptorelin', 'Flugerel', 'Goserelin', 'TAK 385', 'FE200486', '6-D-Tryptophanluteinizing Hormone-releasing Factor', 'Flutabene', 'S74-6766', 'Cosudex', 'Prostogenat', 'Flutamin', 'Apimid', 'Tafenil']",96,INTERVENTIONAL,['PHASE3'],PHASE3,,Prostate Adenocarcinoma,"['Prostate Adenocarcinoma', 'Stage III Prostate Cancer AJCC v8', 'Stage IVA Prostate Cancer AJCC v8']",[],RECRUITING,,2021-01-21,2033-12-31,"[{'measure': 'Metastasis-free survival (MFS)', 'description': 'Assessed based on conventional imaging. MFS will be estimated using the Kaplan-Meier method (Kaplan 1958).', 'timeFrame': 'From randomization to the date of detection of distant metastasis on standard imaging or date of death from any cause, assessed up to 13 years'}, {'measure': 'Sexual quality of life (De-intensification study)', 'description': 'Measured by Expanded Prostate Cancer Index Composite-26 sexual domain', 'timeFrame': 'Up to 13 years'}, {'measure': 'Hormonal quality of life (De-intensification study)', 'description': 'Measured by EPIC-26 hormonal domain', 'timeFrame': 'Up to 13 years'}, {'measure': 'Fatigue (Intensification study)', 'description': 'Measured by Patient Reported Outcomes Measurement Information Systems (PROMIS) Fatigue short form (SF)', 'timeFrame': 'Up to 13 years'}]","[{'measure': 'MFS', 'description': 'Assessed based on standard or molecular, if available, imaging. MFS will be estimated using the Kaplan-Meier method (Kaplan 1958)', 'timeFrame': 'From randomization to the date of detection of distant metastasis on standard imaging or date of death from any cause, assessed up to 13 years'}, {'measure': 'Overall survival', 'description': 'Will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test (Kaplan 1958).', 'timeFrame': 'From the date of randomization to the date of death or last known follow-up date, with patients alive at the last known follow-up time treated as censored, assessed up to 13 years'}, {'measure': 'Prostate cancer specific mortality (PCSM)', 'timeFrame': 'From the date of randomization to the date of prostate cancer death, assessed up to 13 years'}, {'measure': 'Prostate specific antigen (PSA) failure-free survival with non-castrate testosterone and no additional therapies', 'description': 'PSA failure-free survival will be estimated using the Kaplan-Meier method and treatment arms compared using the stratified log-rank test (Kaplan 1958).', 'timeFrame': 'From the date of randomization to the date event, or death or censored at the last known follow-up date, assessed up to 13 years'}, {'measure': 'Time to testosterone recovery', 'description': 'Defined as testosterone that is non-castrate.', 'timeFrame': 'Up to 13 years'}, {'measure': 'Time to PSA failure or salvage therapy', 'timeFrame': 'Up to 13 years'}, {'measure': 'Testosterone levels at the time of PSA failure and metastases', 'timeFrame': 'Up to 13 years'}, {'measure': 'Incidence of adverse events', 'description': 'Measured by the Common Terminology Criteria for Adverse Events (CTCAE ) version (v) 5.0 and Patient Reported Outcomes (PRO)-CTCAE.', 'timeFrame': 'Up to 13 years'}, {'measure': 'Depression (De-intensification study)', 'description': 'Measured by the PROMIS Depression', 'timeFrame': 'Up to 13 years'}, {'measure': 'Depression (Intensification study)', 'description': 'Measured by the PROMIS Depression', 'timeFrame': 'Up to 13 years'}]",14,18 Years,,MALE,False,NRG Oncology,OTHER,1,2753.0,ESTIMATED,2025-09-01T16:18:14.672504,v2_robust,True,True,False,False,True,
NCT02269540,A New Treatment Approach for Major Depressive Disorder Based Upon Targeting Monoamine Oxidase A (MAO-A),A New Biomarker-Based Approach Towards Developing Improved Treatment for Major Depressive Disorder (MDD) Based Upon Targeting Monoamine Oxidase A (MAO-A),Sertraline,"['Celexa', 'N-acetylcysteine (NAC)', 'Citalopram', 'Existing depression medication treatment', 'Sertraline', 'Zoloft']",6,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Major Depressive Disorder,['Major Depressive Disorder'],[],COMPLETED,,2014-10,2018-07,"[{'measure': 'MAO-A distribution volume with positron emission tomography', 'description': 'Treatment take 1 week for titration and 6 weeks at full dose=7weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}]","[{'measure': 'Hamilton Depression Rating Scale Score', 'description': 'Treatment takes 1 week for titration and 6 weeks at full dose=7 weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}, {'measure': 'Magnetic Resonance Spectroscopy (n-acetylaspartate and glutathione levels)', 'description': 'Treatment takes 1 week for titration and 6 weeks at full dose=7 weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}, {'measure': 'Blood markers of monoamine oxidase-A fragment level and glutathione level', 'description': 'Treatment takes 1 week for titration and 6 weeks at full dose=7 weeks average', 'timeFrame': 'before and after treatment, 7 weeks on average between measures'}]",4,18 Years,49 Years,ALL,False,Centre for Addiction and Mental Health,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:14.672540,v2_robust,True,True,True,False,False,
NCT02985840,Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department,Ondansetron Versus Dexamethasone/Ondansetron to Treat Acute Nausea in the Emergency Department,Ondansetron,"['Ondansetron', 'Dexamethasone', 'Zofran', 'Decadron']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Nausea,"['Nausea', 'Abdominal Pain']","['ondansetron', 'dexamethasone']",TERMINATED,Unable to access EMR for patients enrolled prior to 8/2015 for data collection,2014-01-28,2016-11-15,"[{'measure': 'Number of Participants With Need for Additional Nausea Medications', 'description': 'Effectiveness of intervention will be assessed by the need for additional medications via chart review', 'timeFrame': '1 hour post intervention'}]","[{'measure': 'Number of Participants With Resolution of Nausea and Abdominal Pain Symptoms', 'description': 'Effectiveness of intervention will be assessed by the resolution of symptoms via chart review', 'timeFrame': '1 hour post intervention'}]",2,18 Years,,ALL,False,OhioHealth,OTHER,0,127.0,ACTUAL,2025-09-01T16:18:14.672563,v2_robust,True,True,False,True,False,Unable to access EMR for patients enrolled prior to 8/2015 for data collection
NCT02884440,Transverse Abdominis Plane Block for Anterior Approach Spine Surgery,Transverse Abdominis Plane Block for Anterior Approach Spine Surgery: A Prospective Randomized Study,TAP block ropivacaine,"['TAP block ropivacaine', 'General anesthesia', 'TAP block placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Spine Surgery,"['Spine Surgery', 'Low Back Pain', 'Spondylolisthesis']",[],COMPLETED,,2016-11-07,2019-05-25,"[{'measure': 'Morphine consumption in the first 24 hours after spine surgery by anterior approach', 'timeFrame': '24 hours'}]","[{'measure': 'Morphine consumption in the first 48 hours after spine surgery by anterior approach', 'timeFrame': '48 hours'}, {'measure': 'Assessment of pain', 'description': 'Numerical Analogue score', 'timeFrame': '1, 6, 12, 24 and 48 hours'}, {'measure': 'Assessment of post operative nausea or vomiting', 'description': 'Occurence of nausea or vomiting episodes over 48 hours', 'timeFrame': '48 hours'}, {'measure': 'Delay before first morphine administration', 'description': 'Number of hours between end of surgery and first morphine administration', 'timeFrame': 'Day 1'}, {'measure': 'Delay before the first lift', 'description': 'Number of hours between end of surgery and the first lift', 'timeFrame': 'Day 1'}, {'measure': 'Delay before resumption of transit', 'description': 'Number of days between end of surgery and resumption of transit', 'timeFrame': 'Day 1'}, {'measure': 'Duration of hospitalization', 'timeFrame': 'Day 1'}, {'measure': 'Patient satisfaction', 'description': 'Satisfaction questionnaire', 'timeFrame': '48 hours'}]",9,18 Years,,ALL,False,Rennes University Hospital,OTHER,0,43.0,ACTUAL,2025-09-01T16:18:14.672615,v2_robust,True,True,True,False,False,
NCT00120640,Treatment of Preterm Labor With 17 Alpha-hydroxyprogesterone Caproate,,17 hydroxyprogesterone caproate intramuscular injections,['17 hydroxyprogesterone caproate intramuscular injections'],1,INTERVENTIONAL,['NA'],,,Premature Birth,"['Premature Birth', 'Premature Labor']","['Premature birth', 'Premature labor', 'Progesterone']",WITHDRAWN,funding,2005-07,,"[{'measure': ""Delivery <37 weeks' gestation""}, {'measure': ""Delivery <34 weeks' gestation""}, {'measure': ""Delivery <32 weeks' gestation""}]",[{'measure': 'Neonatal outcomes'}],4,18 Years,,FEMALE,False,Yale University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.672704,v2_robust,True,True,False,True,False,funding
NCT00541840,Phase I-II Trial of Sorafenib in Combination With Ifosfamide in Soft Tissue Sarcoma,"Phase I-II, Not-Randomized, Multicenter Clinical Trial to Evaluate Safety and Efficacy of Sorafenib (BAY-43-9006) in Combination With Ifosfamide in Soft Tissue Sarcoma.",Sorafenib,"['Sorafenib', 'BAY 43-9006']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Soft Tissue Sarcoma,['Soft Tissue Sarcoma'],"['Sarcoma', 'Sorafenib', 'GEIS']",UNKNOWN,,2007-10,2010-04,"[{'measure': 'Phase I: Safety profile and to determine maximum tolerated dose (MTD) / Recommended Dose (DR) of Sorafenib in combination with Ifosfamide. Phase II: Activity profile evaluating of the combination in patients with advanced soft tissue sarcoma.', 'timeFrame': 'Phase II: Progression free rate: at 3 and 6 months'}]","[{'measure': 'Phase II: Efficacy evaluation', 'timeFrame': 'Phase II: Progression free rate at 3 and 6 months'}]",2,18 Years,72 Years,ALL,False,Grupo Espanol de Investigacion en Sarcomas,OTHER,0,24.0,ESTIMATED,2025-09-01T16:18:14.672736,v2_robust,True,True,False,False,True,
NCT05620940,"A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.","A Phase 1, Open-Label, Exploratory, Fixed-Sequence, Pharmacokinetic Single Dose Study of IVL3004 Versus Vivitrol® (Naltrexone) Long-Acting Injectable (LAI) and IVL4002 in Healthy Subjects",Vivitrol Injectable Product,"['IVL3004', 'Vivitrol Injectable Product', 'IVL4002']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Opioid Dependence,"['Opioid Dependence', 'Alcohol Dependence']",[],RECRUITING,,2024-09-11,2025-05-06,"[{'measure': 'AUC0-240', 'description': 'Area under the concentration-time curve from time zero to 240hrs', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'Cmax', 'description': 'The maximal observed concentration', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'AUC240-672', 'description': 'Area under the concentration-time curve from time 240 to 672hrs', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'AUC0-672', 'description': 'Area under the concentration-time curve from time zero to 672hrs', 'timeFrame': 'Pre-dose, up to Day 57'}, {'measure': 'AUC0-inf', 'description': 'Area under the concentration-time curve from time zero to infinity', 'timeFrame': 'Pre-dose, up to Day 57'}]",[],5,18 Years,55 Years,MALE,True,"Inventage Lab., Inc.",INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:14.672744,v2_robust,True,True,False,False,False,
NCT06832540,Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects,Mass Balance Study of [14C] TJ0113 in Healthy Chinese Subjects,[14C]TJ0113,['[14C]TJ0113'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Chinese Subjects,['Healthy Chinese Subjects'],[],ACTIVE_NOT_RECRUITING,,2025-02-19,2025-08-15,"[{'measure': 'The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and feces', 'description': 'The excretion ratio of total radioactivity at each time interval and the cumulative recovery of total radioactivity in urine and feces', 'timeFrame': 'Predose up to 240 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: Cmax', 'description': 'Maximum concentration', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: Tmax', 'description': 'Time to Maximum Concentration', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: t1/2', 'description': 'Half Life', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: MRT', 'description': 'Mean Residence Time', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}, {'measure': 'Pharmacokinetic parameters of total radioactivity in plasma: AUC', 'description': 'Area Under the Plasma Concentration-time Curve', 'timeFrame': 'Predose up to 168 hours after administration of [14C]TJ0113'}]",[],6,18 Years,45 Years,MALE,True,"Hangzhou PhecdaMed Co., Ltd.",INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:14.672776,v2_robust,True,True,False,False,False,
NCT03059940,Smoking Cessation Intervention During Low Dose CT (LDCT) Screening for Lung Cancer,Optimizing Effectiveness of Smoking Cessation Intervention During Low Dose CT Screening for Lung Cancer,Nicotine Patch,"['Anti-Smoking Drug', 'Nicotine Patch']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Smoking Cessation,['Smoking Cessation'],"['Smoking Cessation', 'Low Dose computed tomography', 'LDCT', 'Quitline', 'Questionnaires', 'Surveys', 'Counseling', 'Smoking cessation drugs', 'Anti-Smoking Drug', 'Nicotine replacement therapy', 'NRT', 'Nicotine Patch']",ACTIVE_NOT_RECRUITING,,2017-06-16,2026-06-01,"[{'measure': 'Smoking Abstinence Rate', 'description': 'Statistical power will focus on primary objective. Primary analyses use intention-to-treat (ITT) principles, with missing observations imputed as smoking.', 'timeFrame': '6 months'}]",[],1,50 Years,,ALL,True,M.D. Anderson Cancer Center,OTHER,2,630.0,ACTUAL,2025-09-01T16:18:14.672795,v2_robust,True,True,False,False,False,
NCT03917940,Omega 3 Fatty Acids on Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride,"The Effect of Omega 3 Fatty Acids on Blood Glucose, Lipids Profile, Serum Irisin and Sirtuin-1 in Type 2 Diabetic Mellitus Patients Treated With Glimepiride",Glimepiride,"['Amaryl', 'Glimepiride']",2,INTERVENTIONAL,['NA'],,,Diabetic Patients,['Diabetic Patients'],"['Irisin', 'sirtuin-1', 'Omega 3 fatty acids']",COMPLETED,,2019-01-31,2020-05-10,"[{'measure': 'serum Irisin concentration (ng/ml)', 'description': 'Myokines have anti- inflammatory properties', 'timeFrame': 'three months'}, {'measure': 'serum sirtuin-1 concentration (ng/ml)', 'description': 'class III protein deacetylase that is associated with aging, inflammation and CVD', 'timeFrame': 'three months'}]","[{'measure': 'Fasting Blood Sugar', 'description': 'Serum Glucose (mg/dl)', 'timeFrame': 'Three Months'}]",3,30 Years,60 Years,ALL,False,Damanhour University,OTHER,0,70.0,ACTUAL,2025-09-01T16:18:14.672812,v2_robust,True,True,True,False,False,
NCT00418340,Manipulation of Visceral Sensitivity and Immune System in IBS,Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity,probiotic (bacterial/dietary supplement),['probiotic (bacterial/dietary supplement)'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Irritable Bowel Syndrome,['Irritable Bowel Syndrome'],"['Irritable Bowel Syndrome,', 'Visceral hypersensitivity,', 'probiotic therapy,', 'immune response']",UNKNOWN,,2007-12,,"[{'measure': 'The primary outcome measure is the change in physiological rectal sensitivity and before and after probiotic'}, {'measure': 'therapy.'}]","[{'measure': 'Secondary outcome measures are the change symptoms and QOL induced by probiotic therapy and the'}, {'measure': 'change in the immune response after probiotic therapy.'}]",4,18 Years,,ALL,True,London North West Healthcare NHS Trust,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:14.672830,v2_robust,True,True,False,False,False,
NCT04051840,Safely and Efficacy of ClinOleic-based Lipid Parenteral Nutrition,Safely and Efficacy of ClinOleic-based Lipid Parenteral Nutrition After Pancreatectomy:a Prospective Study of Real World Clinical Research in China,"ClinOleic (Baxter Healthcare, Deerfield, IL, USA)","['ClinOleic (Baxter Healthcare, Deerfield, IL, USA)']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Nutritional Supplement Toxicity,['Nutritional Supplement Toxicity'],[],UNKNOWN,,2017-07-01,2020-06-30,"[{'measure': 'biomarkers of liver functions', 'description': 'Concentration of AST, ALT, TBIL, DBIL in the blood', 'timeFrame': '48 hours after operation.'}]","[{'measure': 'markers of infection and inflammation', 'description': 'Concentration of CRP, PCT in the blood', 'timeFrame': '48 hours after operation.'}, {'measure': 'Trenal function', 'description': 'Concentration of Crea, Urea in the blood', 'timeFrame': '48 hours after operation.'}, {'measure': 'lipids and lipid upper derivatives', 'description': 'Concentration of arachidonic acid, eicosapentaenoic acid, linoleic acid, oleic acid in the blood', 'timeFrame': '48 hours after operation.'}]",4,18 Years,80 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,1,200.0,ESTIMATED,2025-09-01T16:18:14.672841,v2_robust,True,True,False,False,False,
NCT05332340,"Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered","Phase 1 Clinical Trial Study to Evaluate Pharmacokinetics and Safety Profile of BZ371A in a Gel Formulation, Applied on Healthy Men and Women Genitals",BZ371A,['BZ371A'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Erectile Dysfunction Following Radical Prostatectomy,"['Erectile Dysfunction Following Radical Prostatectomy', 'Erectile Dysfunction', 'Prostate Cancer', 'Radical Prostatectomy']","['Erectile Dysfunction', 'Radical Prostatectomy', 'Prostate Cancer']",COMPLETED,,2022-11-16,2022-11-30,"[{'measure': 'Cmax', 'description': 'Peak Plasma Concentration', 'timeFrame': '0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose'}, {'measure': 'T1/2', 'description': 'Terminal half-life of BZ371A', 'timeFrame': '0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose'}, {'measure': 'AUC', 'description': 'Area under the curve (AUC) of plasma/serum/blood drug concentration-time curve', 'timeFrame': '0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose'}, {'measure': 'Clearance (CL)', 'description': 'Clearance of BZ371A', 'timeFrame': '0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose'}, {'measure': 'Vd', 'description': 'Distribution Volume of BZ371A', 'timeFrame': '0 (Pre-dose), 15, 30, 60, 180 and 360 minutes post dose'}, {'measure': 'Adverse Effects Evaluation', 'description': 'Number of Adverse Effects after compound application', 'timeFrame': 'All adverse effect will be collected from the beginning of the study up to one week after drug administration'}, {'measure': 'Physical Exam', 'description': 'Number of participants with abnormal physical exam findings', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Change in SBP', 'description': 'Number of participants with a significant change in Systolic Blood Pressure', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Change in DBP', 'description': 'Number of participants with a significant change in Diastolic Blood Pressure', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Change in Heart Rate', 'description': 'Change in Heart Rate (HR).\n\nThe data from this measure reflect changes calculated from the baseline.', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Change in Respiratory Rate', 'description': 'Change in Respiratory Rate (RR).\n\nThe data from this measure reflect changes calculated from the baseline.', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Change in Temperature', 'description': 'Temperature measurements.\n\nThe data from this measure reflect changes calculated from the baseline.', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Basal Chest Electrocardiogram (ECG)', 'description': 'Number of participants with abnormal ECG readings', 'timeFrame': 'Baseline and 1 week'}, {'measure': 'Blood Evaluation', 'description': 'Number of participants with abnormal laboratory test results', 'timeFrame': 'Baseline and 1 day'}, {'measure': 'Urine Evaluation', 'description': 'Number of participants with abnormal urinalysis', 'timeFrame': 'Baseline and 1 week'}]",[],15,18 Years,,ALL,True,Biozeus Biopharmaceutical S.A.,INDUSTRY,1,12.0,ACTUAL,2025-09-01T16:18:14.672886,v2_robust,True,True,True,False,True,
NCT02819089,Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant,Recovery Profiles After c Spine Surgery: With or Without Dexmedetomidine as an Anesthetic Adjuvant,Dexmedetomidine,"['Precedex', 'Dexmedetomidine']",2,INTERVENTIONAL,['NA'],,,Cervical Spondylosis,['Cervical Spondylosis'],"['anterior cervical spine surgery', 'ACDF', 'Dexmedetomidine', 'Anesthesia', 'Agitation', 'Riker sedation agitation scores']",UNKNOWN,,2016-05,2018-04,"[{'measure': 'Riker sedation agitation scores', 'description': 'After finish the operation, Desflurane will be stopped. All patients will be received the neuromuscular reversal drugs and TOF ratio \\> 0.9. All patients will be evaluated by Riker sedation agitation score before extubation and re-evaluated again at 15 minutes after extubation.\n\nRiker sedation agitation scores\n\n1. Dangerous agitation: trying to get out of bed, pulling out tube, thrashing\n2. Very agitated: may require physical restraint, unable to calm with verbal instructions.\n3. Agitated: mild agitation and anxiety but calm down with verbal instructions.\n4. Calm and cooperative: aroused easily and follows commands\n5. Sedated: difficult to aroused, but does arouse to verbal or physical stimuli, able to follow simple commands\n6. Very sedated: does not follow commands but arouses to physical stimulation\n7. Unarousable: little or no response to noxious stimuli', 'timeFrame': 'before extubation'}]","[{'measure': 'Fentanyl consumption', 'description': 'After finish the operation, the total of fentanyl consumption during the operation will be recorded.', 'timeFrame': 'during surgery'}]",2,18 Years,70 Years,ALL,False,Mahidol University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:14.672931,v2_robust,True,True,False,False,False,
NCT00079989,Study Evaluating Tigecycline in Selected Serious Infections Due to Resistant Gram-Negative Organisms,"A Phase 3, Open-label, Noncomparative Study of Tigecycline for the Treatment of Subjects With Selected Serious Infections Due to Resistant Gram-negative Organisms Such as Enterobacter Species, Acinetobacter Baumannii, and Klebsiella Pneumoniae",tigecycline,['tigecycline'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Gram-Negative Bacterial Infections,['Gram-Negative Bacterial Infections'],['Bacterial Infections'],COMPLETED,,2003-12,2005-11,[],[],0,18 Years,,ALL,False,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,115.0,ACTUAL,2025-09-01T16:18:14.672971,v2_robust,True,True,True,False,False,
NCT00706589,Aripiprazole in Children and Adolescents With Chronic Tic Disorder or Tourette's Disorder,"A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder",aripiprazole,"['Abilify', 'aripiprazole', 'placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Chronic Motor or Vocal Tic Disorder,"['Chronic Motor or Vocal Tic Disorder', ""Tourette's Disorder""]","['Chronic Motor Tic disorder', 'Chronic Phonic Tic disorder', ""Tourette's disorder"", 'Aripiprazole', 'Abilify', 'Children', 'Adolescent']",COMPLETED,,2008-10,2010-04,"[{'measure': 'Mean Change of Total Tic Scores in K-YGTSS From Randomization (Baseline, Visit 2) to the Final Visit (Visit 7)', 'description': 'The meaning of the total tic scores is a sum of the total motor tic score and total phonic tic score and the total tic score will be indicated from zero point to 50 points. And also, for the global tic severity scale is sum of the total tic scores and impairment score and it will be indicated from zero point to 100 points. Additionally, for the imparment score is also indicated from zero to 50 points same as total tic scores. And it is divided as 0 point, 10 point, 20 point and etc… Lastly, someone who gets a high score, it will be considered worse result.', 'timeFrame': '10 week'}]","[{'measure': '1)Percent Change of Total Tic Scores on the Korean Version of YaleGlobalTicseverity Scale.2)Response Rate Assessed With the Tic Score ClinicalGlobalImpressionImprovementScale.3)Mean Change in Scores on the Tic Score ClinicalGlobal ImpressionSeverityScale.', 'timeFrame': '10 weeks'}]",2,6 Years,18 Years,ALL,False,"Korea Otsuka Pharmaceutical Co., Ltd.",INDUSTRY,1,61.0,ACTUAL,2025-09-01T16:18:14.672978,v2_robust,True,True,True,False,False,
NCT02033889,A Study To Evaluate The Efficacy And Safety Of Ertugliflozin In Participants With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy (MK-8835-007).,"A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 26-Week Multicenter Study With a 78-Week Extension To Evaluate The Efficacy And Safety Of Ertugliflozin In Subjects With Type 2 Diabetes Mellitus And Inadequate Glycemic Control On Metformin Monotherapy.",Ertugliflozin 5 mg,"['Ertugliflozin 15 mg', 'Fortamet', 'Diabex', 'Dianben', 'Siofor', 'Carbophage SR', 'Gluformin', 'Metfogamma', 'Diaformin', 'Placebo to Glimepiride', 'Riomet', 'Ertugliflozin 5 mg', 'Glucophage XR', 'Glumetza', 'Placebo to Ertugliflozin', 'Obimet', 'MK-8835', 'Metformin']",18,INTERVENTIONAL,['PHASE3'],PHASE3,,Type 2 Diabetes Mellitus,['Type 2 Diabetes Mellitus'],[],COMPLETED,,2013-12-13,2017-08-03,"[{'measure': 'Change From Baseline in A1C at Week 26 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 26 A1C minus the Week 0 A1C (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants Experiencing An Adverse Event (AE) (Including Rescue Approach)', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.', 'timeFrame': 'Up to Week 106'}, {'measure': 'Percentage of Participants Discontinuing Study Treatment Due to an AE (Including Rescue Approach)', 'description': 'An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Per protocol, participants who met pre-specified glycemic criteria were rescued with open-label glimepiride or basal insulin according to Investigator judgment.', 'timeFrame': 'Up to Week 104'}]","[{'measure': 'Change From Baseline in Fasting Plasma Glucose at Week 26 (Excluding Rescue Approach)', 'description': 'Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 26 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 26 minus FPG at Week 0) which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Change From Baseline in Body Weight at Week 26 (Excluding Rescue Approach)', 'description': 'The change in body weight from baseline reflects the Week 26 body weight minus the Week 0 body weight (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Week 26'}, {'measure': 'Change From Baseline in Sitting Systolic Blood Pressure at Week 26 (Excluding Rescue Approach)', 'description': 'This change from baseline reflects the Week 26 sitting systolic blood pressure (SBP) minus the Week 0 sitting SBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Change From Baseline in Sitting Diastolic Blood Pressure at Week 26 (Excluding Rescue Approach)', 'description': 'This change from baseline reflects the Week 26 sitting diastolic blood pressure (DBP) minus the Week 0 sitting DBP (which is estimated on average for each treatment group using a constrained longitudinal data analysis model, which allows for participants with missing data to be included in the analysis). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 26 (Logistic Regression Using Multiple Imputation: Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Week 26'}, {'measure': 'Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 26', 'description': 'Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.', 'timeFrame': 'Up to Week 26'}, {'measure': 'Time to Glycemic Rescue Therapy at Week 26', 'description': 'Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.', 'timeFrame': 'Week 26'}, {'measure': 'Change From Baseline in A1C at Week 52 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 52 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose at Week 52 (Excluding Rescue Therapy)', 'description': 'Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 52 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 52 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 52 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 52 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Week 52'}, {'measure': 'Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 52', 'description': 'Per protocol, participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Change From Baseline in Body Weight at Week 52 (Excluding Rescue Approach)', 'description': 'The change in body weight from baseline reflects the Week 52 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in Sitting Systolic Blood Pressure at Week 52 (Excluding Rescue Approach)', 'description': 'This change from baseline reflects the Week 52 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in Sitting Diastolic Blood Pressure at Week 52 (Excluding Rescue Approach)', 'description': 'This change from baseline reflects the Week 52 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Change From Baseline in A1C at Week 104 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Thus, this change from baseline reflects the Week 104 A1C minus the Week 0 A1C. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Change From Baseline in Fasting Plasma Glucose at Week 104 (Excluding Rescue Approach)', 'description': 'Blood glucose was measured on a fasting basis. Blood was drawn at predose on Day 1 and after 104 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 104 minus FPG at Week 0). Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percentage of Participants With an A1C of <7% (53 mmol/Mol) at Week 104 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Week 104'}, {'measure': 'Percentage of Participants With an A1C of <6.5% (48 mmol/Mol) at Week 104 (Excluding Rescue Approach)', 'description': 'A1C is blood marker used to report average blood glucose levels over prolonged periods of time. Percentage A1C is the ratio of glycated hemoglobin to total hemoglobin x 100. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Week 104'}, {'measure': 'Percentage of Participants Receiving Glycemic Rescue Therapy up to Week 104', 'description': 'Per protocol participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment.', 'timeFrame': 'Up to Week 104'}, {'measure': 'Change From Baseline in Body Weight at Week 104 (Excluding Rescue Approach)', 'description': 'The change in body weight from baseline reflects the Week 104 body weight minus the Week 0 body weight. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Change From Baseline in Sitting Systolic Blood Pressure at Week 104 (Excluding Rescue Approach)', 'description': 'This change from baseline reflects the Week 104 sitting SBP minus the Week 0 sitting SBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Change From Baseline in Sitting Diastolic Blood Pressure at Week 104 (Excluding Rescue Approach)', 'description': 'This change from baseline reflects the Week 104 sitting DBP minus the Week 0 sitting DBP. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Ertugliflozin Plasma Concentrations (ng/mL): Summary Statistics Over Time (Excluding Rescue Approach)', 'description': ""Pharmacokinetic samples were collected at approximately 24 hours following the prior day's dose and before administration of the current day's dose. The lower limit of quantitation (LLOQ) was 0.500 mg/mL. Participants who met pre-specified glycemic criteria were rescued with oral tablets of open-label glimepiride or basal insulin injected subcutaneously, and dosed according to Investigator judgment. Per protocol, this data set excludes data for any participant after the initiation of glycemic rescue therapy."", 'timeFrame': 'Pre-dose and/or 60 minutes post-dose on Weeks 6, 12, 18, and 30'}, {'measure': 'Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the femoral neck was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the total hip was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in BMD at Week 26 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the distal forearm was assessed by DXA at Week 0 and Week 26. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in Bone Biomarker Carboxy-Terminal Cross-Linking Telopeptides of Type I Collagen (CTX) at Week 26 (Excluding Bone Rescue Approach)', 'description': 'CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in Bone Biomarker Procollagen Type I N-terminal Propeptide (P1NP) at Week 26 (Excluding Bone Rescue Approach)', 'description': 'P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in Bone Biomarker Parathyroid Hormone (PTH) at Week 26 (Excluding Bone Rescue Approach)', 'description': 'PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 26'}, {'measure': 'Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the femoral neck was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the total hip was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in BMD at Week 52 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the distal forearm was assessed by DXA at Week 0 and Week 52. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in Bone Biomarker CTX at Week 52 (Excluding Bone Rescue Approach)', 'description': 'CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in Bone Biomarker P1NP at Week 52 (Excluding Bone Rescue Approach)', 'description': 'P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in Bone Biomarker PTH at Week 52 (Excluding Bone Rescue Approach)', 'description': 'PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 52'}, {'measure': 'Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Lumbar Spine (L1-L4) Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Femoral Neck Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the femoral neck was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percent Change From Baseline in BMD at Week 104 as Measured by DXA at the Total Hip Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the total hip was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percent Change From BMD at Week 104 as Measured by DXA at the Distal Forearm Using Raw Data (Excluding Bone Rescue Approach)', 'description': 'BMD at the distal forearm was assessed by DXA at Week 0 and Week 104. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percent Change From Baseline in Bone Biomarker CTX at Week 104 (Excluding Bone Rescue Approach)', 'description': 'CTX is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percent Change From Baseline in Bone Biomarker P1NP at Week 104 (Excluding Bone Rescue Approach)', 'description': 'P1NP is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}, {'measure': 'Percent Change From Baseline in Bone Biomarker PTH at Week 104 (Excluding Bone Rescue Approach)', 'description': 'PTH is a biochemical marker of bone resorption. Participants who exhibited a significant reduction in BMD according to the protocol defined criteria completed an unscheduled DXA scan and, if required, received bone-active therapy. This table excludes measurements obtained after initiation of bone rescue medications.', 'timeFrame': 'Baseline and Week 104'}]",49,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,1,621.0,ACTUAL,2025-09-01T16:18:14.673177,v2_robust,True,True,True,False,True,
NCT02876289,Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon),Retrospective Evaluation of Perampanel in a French Neurology and Epileptology Department (Hospices Civil de Lyon),Perampanel,['Perampanel'],1,OBSERVATIONAL,[],,,Refractory Epilepsy,['Refractory Epilepsy'],[],COMPLETED,,2014-05,2015-09,"[{'measure': 'Retention rate', 'description': 'Proportion of patient still treated with Perampanel 6 months after its initiation', 'timeFrame': '6 months'}]","[{'measure': 'Retention rate', 'description': 'Proportion of patients still treated with Perampanel 12 months after its initiation', 'timeFrame': '12 months'}, {'measure': 'Seizure freedom', 'description': 'Proportion of seizure-free patients during at least 6 months', 'timeFrame': '6 months'}, {'measure': 'Responder rates', 'description': 'Responder rates is defined as a reduction in seizure frequency of 50% or more compared with the three months before the initiation of perampanel.', 'timeFrame': '6 months'}, {'measure': 'Responder rates', 'description': 'Responder rates is defined as a reduction in seizure frequency of 50% or more compared with the three months before the initiation of perampanel.', 'timeFrame': '12 months'}, {'measure': 'Total withdrawal rate', 'description': 'Discontinuation rates at 6 months due to inefficiency or adverse effects', 'timeFrame': '6 months'}, {'measure': 'Total withdrawal rate', 'description': 'Discontinuation rates at 12 months due to inefficiency or adverse effects', 'timeFrame': '12 months'}, {'measure': 'Observed adverse effects during the observation period', 'timeFrame': '12 months'}]",8,16 Years,86 Years,ALL,False,Hospices Civils de Lyon,OTHER,0,110.0,ACTUAL,2025-09-01T16:18:14.673217,v2_robust,False,True,True,False,True,
NCT03097068,Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis,Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis,Lucentis,"['Aqueous Tap', 'Lucentis']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetic Macular Edema,['Diabetic Macular Edema'],[],COMPLETED,,2017-04-19,2018-02-02,"[{'measure': 'Vascular Endothelial Growth Factor Levels', 'description': 'An aqueous humor specimen was obtained at baseline and at 12 weeks to determine if the levels of VEGF had decreased with treatment.', 'timeFrame': '12 weeks'}]",[],1,18 Years,,ALL,False,"Vitreo-Retinal Associates, Michigan",OTHER,2,10.0,ACTUAL,2025-09-01T16:18:14.673319,v2_robust,True,True,True,False,False,
NCT05851768,Efficacy of Dexmedetomidine VS Magnesium Sulphate With Bupivacaine in Erector Spinae Block for Thoracotomy Pain,Analgesic Efficacy of Adding Dexmedetomidine VS Magnesium Sulphate as Adjuvants With Bupivacaine in Ultrasound-guided Erector Spinae Plane Block for Post Thoracotomy Pain,Bupivacaine,"['Bupivacaine + Magnesium', 'Bupivacaine + Dexmedetomidine', 'Bupivacaine']",3,INTERVENTIONAL,['NA'],,,Analgesia,['Analgesia'],[],RECRUITING,,2023-05-15,2024-04-27,"[{'measure': 'Total postoperative morphine consumption', 'description': 'Total dose of morphine needed postoperatively in the first 24 h', 'timeFrame': 'First 24 hours postoperatively'}]","[{'measure': 'Time to first postoperative rescue analgesia.', 'description': 'Time to first postoperative rescue analgesia.', 'timeFrame': 'First 24 hours postoperatively'}]",2,18 Years,65 Years,ALL,False,"National Cancer Institute, Egypt",OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:14.673346,v2_robust,True,True,False,False,False,
NCT02493868,A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression,"A Randomized, Double-blind, Multicenter, Active-Controlled Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Treatment-resistant Depression",Esketamine,"['Venlafaxine Extended Release (XR) (Oral Antidepressant)', 'Escitalopram (Oral antidepressant)', 'Esketamine', 'Duloxetine (Oral Antidepressant)', 'Placebo', 'Sertraline (Oral Antidepressant)']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,"Depressive Disorder, Treatment-Resistant","['Depressive Disorder, Treatment-Resistant']","['Treatment-resistant Depression', 'Esketamine', 'Placebo', 'Oral Antidepressant', 'Relapse prevention']",COMPLETED,,2015-10-01,2018-02-16,"[{'measure': 'Time to Relapse in Participants With Stable Remission (Maintenance Phase)', 'description': 'Relapse is defined as any of following: Montgomery-asberg depression rating scale (MADRS) total score greater than or equal to (\\>=) 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable remission: MADRS total score less than or equal to (\\<=) 12 for at least 3 of last 4 weeks of OP phase, with 1 excursion total score greater than (\\>) 12 or one missing assessment at OP week 13 or 14.', 'timeFrame': 'Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)'}]","[{'measure': 'Time to Relapse in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': 'Relapse is defined as any of following: MADRS total score \\>= 22 for 2 consecutive assessments separated by 5-15 days and/or hospitalization for worsening depression or any other clinically relevant event to be suggestive of a relapse of depressive illness such as suicide attempt/completed suicide/hospitalization for suicide prevention; If hospitalized, start date of hospitalization will be date of relapse, if not hospitalized date of event will be used. MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal-severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. Stable response is defined as \\>= 50 percent (%) reduction in MADRS total score from baseline (Day 1 of induction phase, prior to first intranasal dose) in each of the last 2 weeks of the OP phase, but without meeting criteria for stable remission.', 'timeFrame': 'Time from randomization to the first relapse during the maintenance phase (up to 92 Weeks)'}, {'measure': 'Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': 'MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (last observation carried forward \\[LOCF\\] data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in MADRS Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': 'MADRS: clinician-rated scale to measure depression severity and to detect changes due to antidepressant treatment. It has 10 items, scored from 0-6 (not present/normal - severe/continuous symptoms), with total score of 60. Higher scores mean more severe condition. The change from baseline in MADRS total score (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Patient Health Questionnaire-9 (PHQ-9) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': ""PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint."", 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in PHQ-9 Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': ""PHQ-9 is a 9-item, self-report scale assessing depressive symptoms. Each item is rated on a 4-point scale (0 = Not at all, 1 = Several Days, 2 = More than half the days, and 3 = Nearly every day). The participant's item responses are summed to provide a total score (range of 0 to 27) with higher scores indicating greater severity of depressive symptoms. The severity of the PHQ-9 is categorized as follows: None-minimal (0-4), mild (5-9), moderate (10-14), moderately severe (15-19) and severe (20-27). The change from baseline in PHQ-9 total score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint."", 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': ""CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint."", 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Clinical Global Impression-Severity Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': ""CGI-S provides an overall clinician-determined summary measure of the severity of the participant's illness that takes into account all available information, including knowledge of the participant's history, psychosocial circumstances, symptoms, behavior, and the impact of the symptoms on the participant's ability to function. The CGI-S evaluates the severity of psychopathology on a scale of 0 to 7. Considering total clinical experience, a participant is assessed on severity of mental illness at the time of rating according to: 0=not assessed; 1=normal (not at all ill); 2=borderline mentally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most extremely ill patients. The change from baseline in CGI-S score, (LOCF data) at endpoint was reported. The last post baseline observation was carried forward as the endpoint."", 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Generalized Anxiety Disorder-7 Items (GAD-7) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': 'GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Generalized Anxiety Disorder-7 Items Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': 'GAD-7 is a brief and validated 7-item self-report assessment of overall anxiety. Participants respond to each item using a 4-point scale with response categories of 0=not at all, 1=several days, 2=more than half the days, and 3=nearly every day. Item responses are summed to yield a total score with a range of 0 to 21, where higher scores indicate more anxiety. The recall period is 2 weeks. The severity of the GAD-7 is categorized as follows: None (0-4), Mild (5-9), Moderate (10-14) and Severe (15 -21). Item responses are summed to yield a total score (range of 0 to 21), with higher scores indicating more anxiety. The change from baseline in GAD-7 total score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in EuroQol-5 Dimension-5 Level (EQ-5D-5L) Sum Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': 'EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ visual analogue scale (EQ VAS). EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health ""today"". Responses were used to generate a Health Status Index (HSI). HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent\'s own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \\*5. Higher score indicates worst health state.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': ""EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine)."", 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': 'EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health ""today"". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health).', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in EuroQol-5 Dimension-5 Level Sum Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': 'EQ-5D-5L consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health ""today"". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health). EQ VAS self-rating records the respondent\'s own assessment of his/her overall health status at time of completion, on a scale of 0 (worst health you can imagine) to 100 (best health you can imagine). Sum score ranges from 0 to 100 where, sum score = (sum of the scores from the 5 dimensions minus 5) \\*5. Higher score indicates worst health state.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in EQ-5D-5L EQ Visual Analogue Scale Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': ""EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. The EQ VAS self-rating records the respondent's own assessment of his or her overall health status at the time of completion, on a scale of 0 (the worst health you can imagine) to 100 (the best health you can imagine)."", 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in EQ-5D-5L Health Status Index at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': 'EQ-5D-5L is a 2-part instrument for use as a measure of health outcome, designed for self-completion by respondents. It consists of EQ-5D-5L descriptive system and EQ VAS. EQ-5D-5L descriptive system comprises of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels of perceived problems (1-no problem, 2-slight problems, 3-moderate problems, 4-severe problems, 5-extreme problems). Participant selects answer for each of 5 dimensions considering response that best matches his/her health ""today"". Responses were used to generate a HSI. HSI ranges from 0 (dead) to 1.00 (full health).', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Sheehan Disability Scale (SDS) Total Score at Endpoint in Participants With Stable Remission (Maintenance Phase)', 'description': 'The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores \\<= 4 for each item and \\<= 12 for the total score are considered response. Scores \\<= 2 for each item and \\<= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}, {'measure': 'Change From Baseline in Sheehan Disability Total Score at Endpoint in Participants With Stable Response (But Not in Stable Remission) (Maintenance Phase)', 'description': 'The SDS is a participant-reported outcome measure and is a 5-item questionnaire used and accepted for assessment of functional impairment and associated disability. The first 3 items assess disruption of 1: work/school 2: social life 3: family life/home responsibilities using a 0-10 rating scale. It also has one item on days lost from school or work and one item on days when underproductive. The score for the first 3 items are summed to create a total score of 0-30 where a higher score indicates greater impairment. The recall period is 7 days. Scores \\<= 4 for each item and \\<= 12 for the total score are considered response. Scores \\<= 2 for each item and \\<= 6 for the total score are considered remission. The change from baseline in SDS total Score, (LOCF data), at endpoint was reported. The last post baseline observation was carried forward as the endpoint.', 'timeFrame': 'Baseline and Endpoint (Up to 92 Weeks)'}]",18,18 Years,64 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,719.0,ACTUAL,2025-09-01T16:18:14.673395,v2_robust,True,True,True,False,False,
NCT03516968,Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Deficit in Obese Children and Adolescents,Treatment of Vitamin D Deficit in Obese Children and Adolescents: an Open Label Randomized Controlled Study Comparing the Efficacy of Two Oral Supplementation Regimens: Monthly Boluses Versus Daily Doses for Correcting Blood Vitamin D Level: OBEVIDOS,Monthly bolus of cholecalciferol per os,"['Monthly bolus of cholecalciferol per os', 'Daily dose of cholecalciferol per os']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Obesity, Childhood","['Obesity, Childhood']","['Obesity', 'Vitamin D deficiency,', 'supplementation,', 'Child', 'Adolescent']",RECRUITING,,2023-12-04,2027-03,"[{'measure': 'Proportion of patients reaching the therapeutic target defined as vitamin D (25(OH)D) serum level ≥ 50 nmol/L and < 120 nmol/L', 'description': 'Vitamin D (25OH)D) serum level', 'timeFrame': 'Month 3'}]","[{'measure': 'calcium dosages', 'description': 'blood safety dosages', 'timeFrame': 'Month 3'}, {'measure': 'phosphore dosages', 'description': 'blood safety dosages', 'timeFrame': 'Month 3'}, {'measure': 'vitamin D (25(OH)D) dosages', 'description': 'blood safety dosages', 'timeFrame': 'Month 3'}, {'measure': 'urinary calcium', 'description': 'urinary safety dosages', 'timeFrame': 'Month 3'}, {'measure': 'creatinin', 'description': 'urinary safety dosages', 'timeFrame': 'Month 3'}, {'measure': 'Treatment compliance', 'description': 'amount of treatment taken (Daily arm: patient diary and weighting of returned treatment at M3. Bolus arm: description of taken ampoules after hospital dosing (number taken, empty or not))', 'timeFrame': 'Month 3'}, {'measure': 'Evaluation of influence of type of skin on study results', 'description': 'assessed a questionnaire', 'timeFrame': 'Month 3'}, {'measure': 'Evaluation of influence of physical activity on study results', 'description': 'assessed by a questionnaire', 'timeFrame': 'Month 3'}, {'measure': 'Evaluation of influence of sun exposure on study results', 'description': 'assessed by a questionnaire', 'timeFrame': 'Month 3'}, {'measure': 'Evaluation of influence of alimentary intakes on study results', 'description': 'assessed by questionnaires', 'timeFrame': 'Month 3'}, {'measure': 'Bone mineral density description (DXA)', 'description': 'Bone mineral density', 'timeFrame': 'Day 1'}, {'measure': 'Evaluation of the PTH variation', 'description': 'PTH serum level', 'timeFrame': 'Month 3'}, {'measure': 'Comparison bone mineral density (DXA) with a preexisting cohort', 'description': 'Bone mineral density (DXA)', 'timeFrame': 'Day 1'}]",14,5 Years,18 Years,ALL,False,Hospices Civils de Lyon,OTHER,0,68.0,ESTIMATED,2025-09-01T16:18:14.673564,v2_robust,True,True,False,False,True,
NCT00909168,"Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)","Induction, Consolidation and Intensification Therapy for Patients Younger Than 66 Years With Previously Untreated CD33 Positive Acute Myeloid Leukemia (AML)","FLAIMy - Fluda, Ida, Ara-C, Mylotarg","['FLAIMy - Fluda, Ida, Ara-C, Mylotarg']",1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Acute Myeloid Leukemia,['Acute Myeloid Leukemia'],"['Induction chemotherapy', 'Fludarabine', 'Gemtuzumab Ozogamicin']",COMPLETED,,2008-03,2013-03,"[{'measure': 'Feasibility, Efficacy (CR+PR rate) and Toxicity of FLAI + Gemtuzumab-Ozogamicin.', 'timeFrame': 'one year'}, {'measure': 'RFS, DFS and OS.', 'timeFrame': 'one year'}]","[{'measure': 'Evaluation of Minimal Residual Disease by WT1 (and other biologic markers) expression and monitoring.', 'timeFrame': 'one year'}, {'measure': 'Evaluation of prognostic clinical relevance of biological features at onset.', 'timeFrame': 'one year'}, {'measure': 'Feasibility and outcome of consolidation with BMT.', 'timeFrame': 'one year'}]",5,18 Years,65 Years,ALL,False,"University Hospital, Udine, Italy",OTHER,0,130.0,ACTUAL,2025-09-01T16:18:14.673597,v2_robust,True,True,True,False,False,
NCT03501368,Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma,Phase 1 Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma,Ceritinib,"['Ceritinib', 'MEKINIST', 'Trametinib', 'ZYKADIA']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Melanoma,"['Melanoma', 'Unresectable Melanoma', 'Advanced Melanoma']","['cutaneous', 'refractory', 'melanoma', 'ceritinib']",ACTIVE_NOT_RECRUITING,,2018-06-27,2026-01,"[{'measure': 'Maximum Tolerated Dose (MTD) and recommended Phase 2 Dose (RP2D)', 'description': 'Maximum Tolerated Dose and recommended phase 2 dose of trametinib + ceritinib, determined by number and frequency of treatment related adverse events', 'timeFrame': 'Up to 12 months'}, {'measure': 'Overall Response Rate (ORR)', 'description': 'ORR will be defined by proportion of patients who have achieved a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD.', 'timeFrame': 'Up to 6 months post treatment'}]","[{'measure': 'Median Progression-free Survival (PFS)', 'description': 'PFS is defined from the time of on-treatment to time of progression, censoring at last clinical follow up or if no longer followed at Moffitt, then based on date of last medical documentation of no progression. Progressive Disease (PD): At least a 20% increase in the sum of the longest diameter (LD) of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.', 'timeFrame': 'Up to 5 years post treatment'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as from the time of on-treatment to the time of death, censoring at last date known alive.', 'timeFrame': 'Up to 5 years post treatment'}]",4,18 Years,,ALL,False,H. Lee Moffitt Cancer Center and Research Institute,OTHER,1,27.0,ACTUAL,2025-09-01T16:18:14.673678,v2_robust,True,True,False,False,True,
NCT04846868,Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1),"A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-1)",Iclepertin,"['Iclepertin', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],[],COMPLETED,,2021-09-08,2024-10-01,"[{'measure': 'Change from baseline in overall composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) after 26 weeks of treatment', 'description': 'MCCB comprises 10 tests, which assess 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition', 'timeFrame': 'at baseline and at week 26'}]","[{'measure': 'Change from baseline in the Schizophrenia Cognition Rating Scale (SCoRS) interviewer total score after 26 weeks of treatment', 'description': 'SCoRS is a 20-item interview-based assessment of cognitive deficits and the degree to which they affect day-to-day functioning. Each item is rated on a 4-point scale. Higher ratings reflect a greater degree of impairment.', 'timeFrame': 'at baseline and at week 26'}, {'measure': 'Change from baseline to Week 26 in the adjusted total time T-score in the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)', 'timeFrame': 'at baseline and at week 26'}, {'measure': 'Change from baseline to Week 26 in the T-score of the number of correct responses on Tower of London (ToL) test', 'timeFrame': 'at baseline and at week 26'}, {'measure': 'Change from screening visit 1a to Week 24 in Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) total score', 'description': ""PRECIS is a patient reported outcome (PRO) for recording patients' subjective experience of Cognitive Impairment Associated with Schizophrenia (CIAS). The questionnaire contains 28 items covering 6 domains: Memory (6 items), communication (4 items), self-control (3 items), executive function (4 items), attention (6 items), and sharp thinking (3 items). Two additional items assess the overall degree of bother associated with all domains. Questions are answered via a 5-category Likert scale, with higher scores corresponding to worse patient experience. The Total Score is derived by calculating the simple average score of the first 26 items."", 'timeFrame': 'up to 24 weeks'}]",5,18 Years,50 Years,ALL,False,Boehringer Ingelheim,INDUSTRY,0,620.0,ACTUAL,2025-09-01T16:18:14.673689,v2_robust,True,True,True,False,False,
NCT02963168,"A DRF Study to Evaluate Safety, Tolerability, PK, and Activity of Oradoxel Monotherapy in Subjects w Adv. Malignancies","A Dose Regimen-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Activity of Oradoxel Monotherapy in Subjects With Advanced Malignancies",Oradoxel,"['oral docetaxel + oral HM30181A', 'Oradoxel']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,['Solid Tumor'],[],UNKNOWN,,2017-04-20,2020-04-30,"[{'measure': 'The maximum tolerated dose (MTD) of Oradoxel based on dose-limiting toxicity (DLT) in subjects with advanced malignancies', 'description': 'The MTD will be the highest dose at which no more than 1 of 6 subjects experience a DLT during treatment and Oradoxel pharmacokinetics are acceptable.', 'timeFrame': '3 weeks'}]","[{'measure': 'Safety assessment using AEs of Oradoxel', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Safety assessment using SAEs of Oradoxel', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Laboratory evaluation for hematology', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Blood chemistry', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Urine analysis', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'Periodic measurements of ECGs', 'timeFrame': 'Screening, Day 1, every 6 weeks thereafter up to 24 months'}, {'measure': 'Periodic measurements of vital signs', 'timeFrame': 'Weekly, up to 24 months'}, {'measure': 'The incidence of unacceptable toxicity with Oradoxel', 'description': 'Unacceptable toxicity graded according to CTCAE v4.03', 'timeFrame': '24 months'}, {'measure': 'The recommended Phase 2 dose (RP2D) of Oradoxel', 'description': 'Upon determination of the overall MTD for Oradoxel, the safety and PK profile of the study treatment from all Treatment Periods will be reviewed to determine the recommended Phase 2 dose.', 'timeFrame': '24 months'}, {'measure': 'The amount of docetaxel and HM30181A in blood stream by Area under the plasma concentration versus time curve (AUC)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The peak plasma concentration (Cmax) and Minimum plasma concentration (Cmin)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'A biological half-life or elimination half-life (t1/2)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The accumulation ratio (R)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The apparent total clearance of the drug from plasma (CL/F)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'The apparent volume of distribution (Vd/F)', 'timeFrame': 'Part 1: 16 timepoints over 504 hours; Part 2: 26 timepoints over 480 hours'}, {'measure': 'To evaluate tumor response', 'description': 'Tumor response will be evaluated according to RECIST v1.1', 'timeFrame': 'Every 12 weeks, up to 24 months'}]",17,18 Years,,ALL,False,"Athenex, Inc.",INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:14.673735,v2_robust,True,True,False,False,True,
NCT05769868,"Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments","Prospective, Multicenter and Open Study to Evaluate the Efficacy of Esmolol in the Early Identification of Cardiovascular Disorders Induced by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments",Esmolol Injection [Brevibloc],"['Esmolol Hydrochloride', 'Anatomical Therapeutic Chemical (ATC) code: C07AB09', 'Esmolol Injection [Brevibloc]']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Cirrhosis,"['Cirrhosis', 'Diabetes Mellitus', 'Oncologic Disorders']","['beta blockers', 'echocardiography', 'esmolol', 'systolic function', 'cardiovascular diagnosis', 'biomarkers', 'diagnostic techniques', 'medical imaging']",RECRUITING,,2023-04-18,2027-09,"[{'measure': 'Left Ventricle (LV) ejection fraction', 'description': 'Estimated with 3D echocardiography (Both: convectional and with esmolol administration)', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Peak measurement of global LV systolic longitudinal strain', 'description': 'Estimated with 3D echocardiography (Both: convectional and with esmolol administration)', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Ejection Intraventricular Pressure Difference (EIVPD) measure', 'description': 'Estimated with M-mode echocardiography (Both: convectional and with esmolol administration)', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}]","[{'measure': 'Ejection fraction', 'description': ""Obtained with 2D echocardiography (Simpson's biplane method)"", 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Interleukin (IL)-1β', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'High-sensitivity IL-6 (hsIL-6)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Soluble Suppression of Tumorigenicity 2 (ST-2)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'N-terminal fragment of brain natriuretic peptide (NT-proBNP)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Ultrasensitive troponin I (hsTnI)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Procollagen type I terminal propeptide (PICP)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'C-terminal telopeptide collagen type I (CITP)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}, {'measure': 'Matrix metalloproteinase-1 (MMP-1)', 'description': 'Biochemical variables in blood in relation to the alteration of the different components of the myocardium', 'timeFrame': 'At Baseline (Day 1) until Month-24 according to cohort'}]",12,18 Years,,ALL,True,Consorcio Centro de Investigación Biomédica en Red (CIBER),OTHER_GOV,1,1000.0,ESTIMATED,2025-09-01T16:18:14.673852,v2_robust,True,True,False,False,False,
NCT04205968,Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers,Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma,Fluorouracil,"['Folinate Calcium', 'Tonofolin', 'Ro-2-9757', 'Paclitaxel', '5 Fluorouracil', '5FU', 'Dalisol', 'Taxol', 'Citrec', 'Flurablastin', 'Ribofluor', 'Folinoral', 'Leucovorin Calcium', 'AccuSite', 'Calcium Folinate', '5-Fluorouracil', 'Rescuvolin', 'Citofolin', 'Irinotecan Hydrochloride Trihydrate', 'Taxol Konzentrat', '5-FU', 'Citrovorum Factor', 'Folaxin', 'Folinic Acid Calcium Salt Pentahydrate', 'Camptosar', 'Irinotecan Monohydrochloride Trihydrate', 'Calfolex', 'CPT-11', 'Calinat', '5-Fluoro-2,4(1H, 3H)-pyrimidinedione', 'Fluoro Uracil', 'Irinotecan', 'Divical', 'Calcium (6S)-Folinate', 'Disintox', 'Emovis', 'Fluroblastin', 'Wellcovorin', 'Leucovorin', 'Rescufolin', 'Asotax', 'Cehafolin', 'Folinic acid', 'leucovorin', 'Imo', 'Irinomedac', 'Folix', 'Camptothecin-11', 'Folidar', 'Factor, Citrovorum', 'Folaren', 'Praxel', 'Lederfolat', 'Ecofol', 'Folinac', '5 Fluorouracilum', 'Flynoken A', 'Ro 2-9757', 'U-101440E', 'Fluouracil', 'CPT 11', 'Campto', 'Bristaxol', 'Fluracil', 'Fluracedyl', '5 FU', 'Camptothecin 11', 'FOLI-cell', 'Irinotecan Hydrochloride', 'Anzatax', 'folinic acid', 'Lederfolin', 'Cromatonbic Folinico', 'Calcifolin', 'Foliben', 'Fluril', 'Carac', 'Leucosar', '5-Fluracil', 'Adinepar', 'Foliplus', 'Calcium Leucovorin', 'Fluorouracil', 'Folidan', 'Folinvit']",85,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Small Intestinal Adenocarcinoma,"['Metastatic Small Intestinal Adenocarcinoma', 'Stage III Small Intestinal Adenocarcinoma AJCC v8', 'Stage IIIA Small Intestinal Adenocarcinoma AJCC v8', 'Stage IIIB Small Intestinal Adenocarcinoma AJCC v8', 'Stage IV Small Intestinal Adenocarcinoma AJCC v8']",[],RECRUITING,,2020-06-01,2027-08-01,"[{'measure': 'Progression free survival (PFS)', 'description': 'PFS will be assessed in all eligible and evaluable (received at least one dose of protocol therapy) patients using the Kaplan-Meier method, with statistical differences in event rates between treatment arms assessed via stratified Cox regression model.', 'timeFrame': 'From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 3 years'}]","[{'measure': 'Overall survival (OS)', 'description': 'Probabilities of OS will be estimated using the method of Kaplan-Meier, with statistical differences in event rates between treatment arms assessed via stratified Cox regression model.', 'timeFrame': 'From date of registration to date of death due to any cause, assessed up to 3 years'}, {'measure': 'Overall response rate', 'description': 'Will be assessed by Response Evaluation Criteria in Solid Tumors 1.1. Will be compared across treatment arms via chi-square tests.', 'timeFrame': 'Up to 3 years after registration'}, {'measure': 'Incidence of adverse events', 'description': 'Will be compared across treatment arms via chi-square tests.', 'timeFrame': 'Up to 3 years after registration'}]",4,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,94.0,ESTIMATED,2025-09-01T16:18:14.673928,v2_robust,True,True,False,False,True,
NCT02359968,PReoperative Chemoradiation (Paclitaxel-carboplatin or FOLFOX) for Resectable Esophageal and Junctional Cancer,PReoperative Chemoradiation With Paclitaxel-carboplatin or With Fluorouracil-oxaliplatine-acide Folinique (FOLFOX) for Resectable Esophageal and Junctional Cancer - A Randomized Phase II Trial,FOLFOX,"['paclitaxel', 'Oxaliplatin', 'FOLFOX', 'Elvorine', 'Carboplatine', 'Folinic acid', 'Fluorouracil', 'CarboP-pacliT']",8,INTERVENTIONAL,['PHASE2'],PHASE2,,Esophageal Neoplasms,"['Esophageal Neoplasms', 'Gastro-esophageal Junction Cancer']","['resectable esophageal', 'junctional cancer', 'FOLFOX', 'paclitaxel-carboplatin']",COMPLETED,,2015-02-26,2024-02-09,"[{'measure': 'Short-term benefit of 2 preoperative regimen: complete resection rate AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification', 'description': 'Complete resection rate (R0, that is ""complete removal of all tumor with microscopic examination of margins showing no tumor cells"") AND severe (grade ≥ 3) postoperative morbidity/mortality according to the Clavien-Dindo classification. Severe postoperative complication is defined by grade ≥III per-operative or post-operative complication occurring in the 30 days after surgery.', 'timeFrame': 'up to 30 days after surgery'}]","[{'measure': 'Rate of completion of full treatment without modification', 'timeFrame': 'up to 58 days'}, {'measure': 'Evaluation of the efficacy of both regimen in term of overall survival', 'description': 'Overall survival using Kaplan-Meier method', 'timeFrame': 'From date of inclusion until the date of death from any cause assessed up to 36 months after the last surgery'}, {'measure': 'Evaluation of the efficacy of both regimen in term of disease-free survival', 'description': 'Disease-free survival using Kaplan-Meier method', 'timeFrame': 'From date of inclusion until the date of first documented progression whichever came first, assessed up to 36 months after the last surgery'}, {'measure': 'Evaluation of the safety of the evaluated regimens in terms of preoperative mortality.', 'description': 'Preoperative mortality (grade 5) rate, according to NCI-CTCAE v4.0 criteria', 'timeFrame': 'From registration to surgery'}, {'measure': 'Evaluation of the safety of the evaluated regimens in terms of preoperative morbidities, postoperative morbidities, respiratory morbidities.', 'description': 'Pre-operative morbidities according to NCI-CTCAE v4.0 criteria, post-operative morbidities occurring in the 30 days after surgery with the main post-operative complication graded according to Clavien-Dindo, post-operative morbidities occurring more than 30 days after surgery graded according to NCI-CTCAE V4.0, postoperative respiratory morbidity rate according to the Clavien-Dindo classification.', 'timeFrame': 'From start of treatment to end of study'}, {'measure': 'Evaluation of the efficacy of both regimen in term of Pathological response rate', 'description': 'Complete pathological response (ypCR) rate', 'timeFrame': 'Surgery'}, {'measure': 'Evaluation of the efficacy of both regimen in term of quality of life', 'description': 'Quality of life: QLQC30 and OES18', 'timeFrame': 'Up to 3 years after surgery'}]",8,18 Years,,ALL,False,Centre Oscar Lambret,OTHER,1,106.0,ACTUAL,2025-09-01T16:18:14.673953,v2_robust,True,True,True,False,True,
NCT02960568,Genetic Variability in CYP2D6 in U.S Active Duty Population,Genetic Variability in the Cytochrome P-450 Isoenzyme 2D6 (CYP2D6) in an Active Duty U.S. Military Population and the Impact of CYP2D6 Phenotype on Primaquine Metabolism.,Primaquine,['Primaquine'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacologic Action,['Pharmacologic Action'],"['primaquine', 'metabolism', 'malaria', 'hypnozoite', 'vivax', 'CYP2D6', 'active duty personnel']",COMPLETED,,2016-01-08,2017-08,"[{'measure': 'Description of CYP2D6 alleles in an active duty population', 'description': 'Genotyping of CYP2D6 alleles will be analyzed by a multiplexed cytometric bead array assay, Luminex xTAG® CYP2D6 Kit v3 (Austin, TX) which allows for detection of the 16 major alleles of 2D6 in the United States: 1,2,3,4,5,6,7,8,9,10,11,15, 17,29, 35,41. Subjects will then be categorized by CYP2D6 phenotype according to standard definitions of enzyme metabolic activity of specific 2D6 alleles using the published activity score model: AS Model A (1): ""poor"" (PM), ""intermediate"" (IM), ""extensive"" (EM) or ""ultra (UM)"" enzyme activity compared to the general population. Alleles known to have no activity are scored ""0"", intermediate activity alleles are scored as 0.5, while alleles with normal activity are scored as 1. Scores of both alleles making up the genotype are then added together to give the AS-Model A score and range from 0 to 2, with 0 indicating little or no CYP2D6 activity and 1 or 2 indicating normal levels of CYP2D6. Data will be descriptively analyzed.', 'timeFrame': '1 hour'}, {'measure': 'Measure concentrations of plasma primaquine and its major metabolites.', 'timeFrame': '24 hours'}, {'measure': 'Develop pharmacokinetic curves of primaquine and its major metabolites with determinations of Area under the curve (AUC)', 'timeFrame': '1 month'}]",[],3,18 Years,60 Years,ALL,True,Walter Reed Army Institute of Research (WRAIR),FED,0,550.0,ACTUAL,2025-09-01T16:18:14.674071,v2_robust,True,True,True,False,False,
NCT01343368,Preservation of Ovarian Function After Hematopoietic Cell Transplant,A Phase II Trial of GnRH Agonist for the Preservation of Ovarian Function After Hematopoietic Cell Transplantation (HCT),Leuprolide,"['Leuprolide', 'Lupron Depot-3(R)', 'Leuprolide acetate']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,"['Multiple Myeloma', 'Non-Hodgkin Lymphoma', 'Hodgkin Disease', 'Acute Myeloid Leukemia', 'Myeloproliferative Disorders']",['Post-menarchal'],TERMINATED,,2011-07,2015-04,"[{'measure': 'Comparison of Number of Patients With Ovarian Failure', 'description': 'Comparison of treatment arms; interventional versus observational. Ovarian failure rate is based on FSH measured at 180 days after HCT; to determine the effect of GnRH agonists on the incidence of ovarian failure (i.e. FSH \\>40 IU/L) after transplant.', 'timeFrame': 'Through Day 180 Post Transplant'}]","[{'measure': 'Comparison of Number of Patients Who Stopped Menstrual Bleeding', 'description': 'Comparison of treatment arms; interventional versus observational. Count of patients who stopped menstrual bleeding; to determine how the effect of GnRH agonists are at suppressing menses during hematopoietic cell transplant', 'timeFrame': 'From Baseline Through Day 365'}, {'measure': 'Comparison of Follicle Stimulating Hormone (FSH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average FSH levels.', 'timeFrame': 'Baseline'}, {'measure': 'Comparison of Follicle Stimulating Hormone (FSH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average FSH levels.', 'timeFrame': 'Day 100'}, {'measure': 'Comparison of Follicle Stimulating Hormone (FSH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average FSH levels.', 'timeFrame': 'Day 180'}, {'measure': 'Comparison of Follicle Stimulating Hormone (FSH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average FSH levels.', 'timeFrame': '1 year'}, {'measure': 'Comparison of Follicle Stimulating Hormone (FSH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average FSH levels.', 'timeFrame': '2 years'}, {'measure': 'Comparison of Number of Patients Who Resumed Menstrual Cycles', 'description': 'Comparison of treatment arms; interventional versus observational. Count of patients who resumed menses after hematopoietic cell transplant', 'timeFrame': 'Day 365 Post Transplant'}, {'measure': 'Comparison of Lutineizing Hormone (LH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average LH levels during study.', 'timeFrame': 'Baseline'}, {'measure': 'Comparison of Luteinizing Hormone (LH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average LH levels during study.', 'timeFrame': 'Day 100'}, {'measure': 'Comparison of Luteinizing Hormone (LH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average LH levels during study.', 'timeFrame': 'Day 180'}, {'measure': 'Comparison of Luteinizing Hormone (LH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average LH levels during study.', 'timeFrame': '1 year'}, {'measure': 'Comparison of Leuprolide Hormone (LH) Levels', 'description': 'Comparison of treatment arms; interventional versus observational average LH levels during study.', 'timeFrame': '2 years'}, {'measure': 'Comparison of Antimullerian Hormone (AMH) Levels After Transplant', 'description': 'Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.', 'timeFrame': 'Day Prior to Transplant'}, {'measure': 'Comparison of Antimullerian Hormone (AMH) Levels After Transplant', 'description': 'Comparison of treatment arms; interventional versus observational average AMH levels after receiving transplant.', 'timeFrame': 'Day 180 after Transplant'}]",15,50 Years,,FEMALE,False,"Masonic Cancer Center, University of Minnesota",OTHER,1,19.0,ACTUAL,2025-09-01T16:18:14.674233,v2_robust,True,True,False,True,False,
NCT00352950,Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer,An Open-Label Clinical Trial Evaluating the Safety and Pharmacodynamics of Sirolimus and Panitumumab in Subjects With Advanced Non-Small Cell Lung Cancer,AMG 954/Panitumumab,['AMG 954/Panitumumab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Oncology,"['Oncology', 'Non-Small Cell Lung Cancer']","['NSCLC, Lung cancer', 'Panitumumab', 'Sirolimus', 'mTOR', 'Monoclonal antibody']",WITHDRAWN,,2006-03,2008-02,[{'measure': 'safety within the first 3 weeks'}],[{'measure': 'pharmacodynamic analysis of mTOR'}],2,18 Years,,ALL,False,Amgen,INDUSTRY,0,0.0,ACTUAL,2025-09-01T16:18:14.674272,v2_robust,True,True,False,True,True,
NCT03943550,"Double-Blinded, Placebo-Controlled Phase 1b Study for Safety, PK, Efficacy, PD of RO7049665 in Participants With Ulcerative Colitis (UC)","A Multicenter, Randomized, Double-Blind, Placebo Controlled Phase Ib Study to Investigate the Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy, and Pharmacodynamics of Subcutaneously Administered RO7049665 in Participants With Active Ulcerative Colitis",RO7049665,"['RO7049665', 'Placebo']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Ulcerative Colitis,['Ulcerative Colitis'],[],TERMINATED,"The decision to terminate study WP40161 was based on that treatment with RO7049665 showed trends in efficacy, however these data were below expectations and would not have supported superiority over standard of care.",2019-05-13,2021-07-22,"[{'measure': 'Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', 'description': 'An AE was defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A SAE was defined as any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect. Severity of AEs were graded according to NCI CTCAE v4.0.', 'timeFrame': 'From baseline up to safety follow-up visit on Day 99'}]","[{'measure': 'Time to Maximum Concentration (Tmax) of RO7049665', 'timeFrame': 'Day 1 to Day 15 (predose) and Day 43 (post-dose)'}, {'measure': 'Maximum Serum Concentration Observed (Cmax) of RO7049665', 'timeFrame': 'Days 1 and 43: Pre-dose, 6 h and 12 h post-dose'}, {'measure': 'Area Under the Serum Concentration-time Curve Extrapolated to Infinity (AUCinf) of RO7049665', 'timeFrame': 'Days 1 and 43: Pre-dose, 6 h and 12 h post-dose'}, {'measure': 'Change From Baseline in the Endoscopy Subscore of the Mayo Clinic Score (MCS-ES)', 'description': 'The Mayo Clinic Score (MCS) ranges from 0 to 12 and is a composite of 4 assessments, each rated from 0-3: stool frequency, rectal bleeding, endoscopy (i.e., centrally read MCS-ES) and Physician Global Assessment (PGA). Flexible sigmoidoscopy (or colonoscopy) was centrally read and scored using the MCS-ES scoring systems. The disease was considered as endoscopic normal or inactive if the MCS-ES (centrally read) was 0, mild (erythema, decreased vascular pattern) if MCS-ES was 1, moderate (marked erythema, absent vascular pattern, erosions) if MCS-ES was 2 and severe (spontaneous bleeding, ulceration) if MCS-ES was 3. The Endoscopy Subscore of the Mayo Score was modified so that a value of 1 did not include friability. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Days 29 and 57'}, {'measure': 'Change From Baseline in the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)', 'description': 'Flexible sigmoidoscopy (or colonoscopy) were centrally read and scored using the UCEIS scoring systems. The UCEIS total score is a sum of 3 assessments: Bleeding (scored 0-3), Erosion and Ulcers (scored 0-3), and Vascular Pattern (scored 0-2). The total score ranges from 0-8, with higher score indicating more severe disease. A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Days 29 and 57'}, {'measure': 'Change From Baseline in Histology Score of Sigmoid Colon Biopsies Using Geboes Score (GS)', 'description': 'Mucosal biopsies were obtained during flexible sigmoidoscopy from the most affected area 10 to 20 centimeters (cm) from the anal verge. Biopsies were assessed by standard histology for changes in the inflammatory activity as measured using GS. The GS is a stepwise grading system used for the evaluation of microscopic inflammation and histopathologic disease activity in UC. The microscopic appearance of the mucosa is categorized into 6 grades: Grade 0: architectural changes, Grade 1: chronic inflammatory infiltrate, Grade 2: lamina propria neutrophils and eosinophils, Grade 3: neutrophils in epithelium, Grade 4: crypt destruction and erosions or Grade 5: ulcerations, and each grade of the score is divided in 4 subcategories. A decrease of the Geboes grading system to Grades 0 or 1 would indicate mucosal healing.', 'timeFrame': 'Baseline, Days 29 and 57'}, {'measure': 'Change From Baseline in Histology Score of Sigmoid Colon Biopsies Using Robarts Histology Index (RHI)', 'description': 'Mucosal biopsies were obtained during flexible sigmoidoscopy from the most affected area 10 to 20 cm from the anal verge. Biopsies were assessed by standard histology for changes in the inflammatory activity as measured using RIH. The RHI is an evaluative index, derived from the Geboes score and is designed to be reproducible and responsive to clinically meaningful change in disease activity over time. The total RHI score ranges from 0 (no disease activity) to 33 (severe disease activity). A negative change from baseline indicates improvement.', 'timeFrame': 'Baseline, Days 29 and 57'}, {'measure': 'Change From Baseline in Histology Score of Sigmoid Colon Biopsies Using Nancy Histology Index (NHI)', 'description': 'Mucosal biopsies were obtained during flexible sigmoidoscopy from the most affected area 10 to 20 cm from the anal verge. Biopsies were assessed by standard histology for changes in the inflammatory activity as measured using NHI. NHI is a validated index for assessing histological disease activity in UC. It is composed of three histological items defining five grades of disease activity: absence of significant histological disease (Grade 0), chronic inflammatory infiltrate with no acute inflammatory infiltrate (Grade 1), mildly active disease (Grade 2), moderately active disease (Grade 3), and severely active disease (Grade 4). The presence of ulceration on the biopsy specimen corresponds to severely active disease (Grade 4). A decrease of the NHI grading system to Grades 0 or 1 would indicate improvement.', 'timeFrame': 'Baseline, Days 29 and 57'}, {'measure': 'Percentage of Participants With Mayo Clinic Score (MCS) Clinical Response', 'description': 'The MCS ranges from 0 to 12 and is a composite of 4 assessments: stool frequency, rectal bleeding, endoscopy (i.e., centrally read MCS-ES) and Physician Global Assessment (PGA). Each assessment was rated from 0-3, with higher score indicating more severe disease. Clinical response was defined as a decrease in the MCS of at least 3 points and at least 30% decrease from baseline.', 'timeFrame': 'Baseline, Days 29 and 57'}, {'measure': 'Number of Participants With Anti-Drug Antibodies (ADAs)', 'description': 'ADA assays was used to detect anti-drug antibodies against RO7049665. Samples which were positive for anti-drug antibodies were further assessed using a neutralizing antibody assay. Participants were considered ADA positive if they were ADA negative at baseline but developed an ADA response following study drug administration (treatment-induced ADA response), or if they were ADA positive at baseline and the titer of one or more post-baseline samples was greater than the titer of the baseline sample by a scientifically reasonable margin such as at least 4-fold (treatment-enhanced ADA response).', 'timeFrame': 'Baseline; Post-dose on Days 8, 22, 57, 71 and 99; Pre-dose on Days 15, 29 and 43'}, {'measure': 'Change From Baseline in White Blood Cells (Tregs, Teffs)', 'timeFrame': 'Baseline; Pre-dose: Days 15, 29 and 43; Post-dose: Days 2, 6, 8, 10, 22, 36, 48, 50, 52, 57, 71'}, {'measure': 'Change From Baseline in White Blood Cells (Natural Killer (NK) Cells)', 'timeFrame': 'Baseline; Pre-dose: Days 15, 29 and 43; Post-dose: Days 2, 6, 8, 10, 22, 36, 48, 50, 52, 57, 71'}, {'measure': 'Change From Baseline in White Blood Cells (B Cells)', 'timeFrame': 'Baseline; Pre-dose: Days 15, 29 and 43; Post-dose: Days 2, 6, 8, 10, 22, 36, 48, 50, 52, 57, 71'}, {'measure': 'Change From Baseline in Eosinophils', 'timeFrame': 'Baseline; Pre-dose: Days 15, 29 and 43; Post-dose: Days 2, 8, 22, 36, 57, 71 and follow-up visit on Day 99'}]",15,18 Years,70 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,45.0,ACTUAL,2025-09-01T16:18:14.674286,v2_robust,True,True,False,True,True,"The decision to terminate study WP40161 was based on that treatment with RO7049665 showed trends in efficacy, however these data were below expectations and would not have supported superiority over standard of care."
NCT06503250,A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization,Effectiveness and Safety of Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization as Conversion Therapy Among Patients With Initially Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice in China,Atezolizumab,"['Tecentriq', 'Atezolizumab', 'Avastin', 'Bevacizumab']",4,OBSERVATIONAL,[],,,Unresectable Hepatocellular Carcinoma,['Unresectable Hepatocellular Carcinoma'],[],COMPLETED,,2024-07-19,2024-11-27,"[{'measure': 'Median Time to Real-World Progression-Free Survival (rwPFS)', 'description': 'rwPFS is defined as time from the index date to the first evidence of clinician-assessed progressive disease (may include but are not limited to local tumor progression, disease recurrence, new metastasis, or clinical progression anchored by clinicians) or death from any cause.', 'timeFrame': 'up to approximately 12 months'}]","[{'measure': 'Median Time to Real-World Overall Survival (rwOS)', 'description': 'rwOS is defined as time from the index date to death from any cause.', 'timeFrame': 'up to approximately 3 years'}, {'measure': 'Median Time to Real-World Overall Response Rate (rwORR)', 'description': 'rwORR is defined as the percentage of patients who achieved complete response (CR) or partial response (PR) after the initiation of both Atezo+Bev and TACE among patients with at least one response assessment result after the initiation of both Atezo+Bev and TACE, with reference to the assessment of tumor lesions within 60 days prior to the later initiation of Atezo+Bev or TACE.', 'timeFrame': 'up to approximately 3 years'}, {'measure': 'Percentage of Participants with Serum Alpha-Fetoprotein (AFP) Reduction', 'description': 'AFP reduction is defined as \\> 50% reduction in AFP level after 3 months (± 4 weeks) of the later initiation of Atezo+Bev or TACE.', 'timeFrame': 'up to approximately 4 years'}, {'measure': 'Percentage of Participants with Prothrombin Induced by the Absence of Vitamin K or Antagonist-II (PIVKA-II) Reduction:', 'description': 'PIVKA-II reduction is defined as \\> 50% reduction in PIVKA-II level after 3 months (± 4 weeks) of the later initiation of Atezo+Bev or TACE.', 'timeFrame': 'up to approximately 4 years'}, {'measure': 'Percentage of Participants with Surgical Resection', 'description': 'Conversion rate (surgical resection) is defined as the percentage of patients who underwent surgical resection of tumor among patients who completed the Atezo+Bev plus TACE treatment by the end of observation period.', 'timeFrame': 'up to approximately 4 years'}, {'measure': 'Percentage of Participants with Adverse Events', 'description': 'The adverse events of interest include liver function abnormality, renal function abnormality, hemorrhage, hypertension, hepatitis virus reactivation and immune-related adverse events.', 'timeFrame': 'up to approximately 4 years'}]",7,18 Years,,ALL,False,Hoffmann-La Roche,INDUSTRY,0,113.0,ACTUAL,2025-09-01T16:18:14.674315,v2_robust,False,True,True,False,True,
NCT02884050,Physiologic Effects of Topiramate on Cognition,Physiologic Effects of Topiramate on Cognition,Topiramate,"['Topamax', 'Topiramate', 'Placebo']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Alteration of Cognitive Function,['Alteration of Cognitive Function'],[],COMPLETED,,2009-04,2011-01,"[{'measure': 'Controlled Oral Word Association test', 'description': 'generative verbal fluency', 'timeFrame': '6 hours'}]",[],1,18 Years,50 Years,ALL,True,University of Florida,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:14.674356,v2_robust,True,True,True,False,False,
NCT03760250,Imiquimod for Preventing Keloid Recurrence,"Open-label, Single-arm Pilot Study of the Effects of Topical 5% Imiquimod Cream on Preventing Keloid Recurrence After Surgical Keloidectomy",Imiquimod 5% cream,"['Imiquimod 5% cream', 'Aldara']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Keloid,['Keloid'],[],TERMINATED,Investigator decision,2019-02-05,2020-09-01,"[{'measure': 'Keloid Recurrence', 'description': 'To assess the efficacy of 5% Imiquimod cream on decreasing keloid recurrence after excision when initiated prior to excision', 'timeFrame': '12 weeks after surgical excision'}]","[{'measure': 'Tolerability - Local Site Reaction Rated on a Scale', 'description': 'tolerability of 5% imiquimod cream - clinical evaluation of local site reactions by clinicians for symptoms such as redness, discomfort, swelling, and ulceration at the site of drug application on the following scale with none being the best and severe the worst: none (no reaction in application site), mild (slight redness in application site), moderate (redness with swelling and pain in application site), severe (redness, swelling, ulceration in application site)', 'timeFrame': '12 weeks after surgical excision'}]",2,18 Years,,ALL,False,University of Pennsylvania,OTHER,0,6.0,ACTUAL,2025-09-01T16:18:14.674443,v2_robust,True,True,False,True,False,Investigator decision
NCT00722150,Artemisinin Resistance in Cambodia II,Artemisinin Resistance in Cambodia II,Artesunate,['Artesunate'],1,INTERVENTIONAL,['NA'],,,Falciparum Malaria,['Falciparum Malaria'],"['Artesunate', 'Plasmodium Falciparum', 'Cambodia']",COMPLETED,,2008-07,2009-08,"[{'measure': 'Primary clinical outcome is cure (Adequate Clinical and Parasitological Response - ACPR as defined by WHO criteria) on Day 28 and 42', 'timeFrame': 'Day 28 and 42'}, {'measure': 'Safety and tolerability of oral artesunate', 'timeFrame': 'Up to 42 days'}]","[{'measure': 'Secondary outcome measures are time until parasite, fever, and gametocyte clearance (PCT, FCT, and GCT).', 'timeFrame': 'Day 3'}]",3,18 Years,65 Years,ALL,False,"Armed Forces Research Institute of Medical Sciences, Thailand",OTHER_GOV,2,143.0,ACTUAL,2025-09-01T16:18:14.674488,v2_robust,True,True,True,False,True,
NCT05695950,A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis,"A Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered GLPG3667 Once Daily for 24 Weeks in Adult Subjects With Dermatomyositis",GLPG3667,"['GLPG3667', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Dermatomyositis,['Dermatomyositis'],[],ACTIVE_NOT_RECRUITING,,2023-02-27,2026-04,"[{'measure': 'Total improvement score [TIS] according to the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) criteria', 'description': ""The TIS is a score derived from the evaluation of the results from 6 core set measurements (CSMs) of myositis disease activity: Physician's Global Disease Activity Assessment; Patient's Global Disease Activity Assessment; Muscle Manual Test-8 (MMT-8); Health Assessment Questionnaire-Disability Index (HAQ-DI); Enzymes (aldolase, creatine kinase (CK), alanine aminotransferase (ALT), aspartate aminotransferase (AST), and lactate dehydrogenase (LDH); and Extra-muscular disease activity. The TIS is a scale from 0 to 100 that allows for the discrimination between minimal, moderate and major responders depending on their improvement in the combined 6 CSM."", 'timeFrame': 'Week 24'}]","[{'measure': 'Percentage of Participants With at Least Minimal Improvement According to the ACR/EULAR Criteria', 'description': ""Minimal improvement per ACR/EULAR was defined as TIS of ≥ 20 points. The TIS is a score derived from the evaluation of the results from 6 CSMs of myositis disease activity: Physician's Global Disease Activity Assessment; Patient's Global Disease Activity Assessment; MMT-8; HAQ-DI; Enzymes (aldolase, CK, ALT, AST, and LDH; and Extra-muscular disease activity. The TIS is a scale from 0 to 100 that allows for the discrimination between minimal, moderate and major responders depending on their improvement in the combined 6 CSM."", 'timeFrame': 'Week 24'}, {'measure': 'Change From Baseline in Modified-Cutaneous DM Disease Area and Severity Index Activity Score (m-CDASI-A) at Week 24', 'description': ""The CDASI is a clinician-scored single page instrument that separately measures activity (m-CDASI-A) and damage (m-CDASI-D) in the skin of DM participants. The m-CDASI-A consists of 3 activity measures (erythema, scale, and erosion/ulceration) assessed over 15 body areas along with the activity of Gottron's papules on hands and activity of periungual changes and alopecia. m-CDASI-A ranges from 0-100. Higher scores indicate more disease activity."", 'timeFrame': 'Week 24'}, {'measure': 'Change from baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 24', 'description': 'The HAQ-DI is a generic rather than a disease-specific instrument, comprised of 8 sections: dressing, arising, eating, walking, hygiene, reach, grip, and activities. There are 2 or 3 questions for each section. Scoring within each section is from 0 \\[without any difficulty\\] to 3 \\[unable to do\\]. For each section the score given to that section is the worst score within the section. The 8 scores of the 8 sections are summed and divided by 8.', 'timeFrame': 'Week 24'}, {'measure': 'Change from baseline in the manual muscle test (MMT-8) at Week 24', 'description': 'MMT-8 is a set of 8 designated muscles, 7 of them being tested bilaterally (potential score 0-140). Axial (neck flexors) testing is included, so that potential maximum MMT-8 score = 150.', 'timeFrame': 'Week 24'}, {'measure': 'Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Serious Adverse Events (SAEs), and TEAEs Leading to Treatment Discontinuation', 'timeFrame': 'Baseline (Day 1) up to Week 24'}, {'measure': 'Maximum Plasma Concentration (Cmax) of GLPG3667', 'timeFrame': 'Week 4'}, {'measure': 'Area Under the Plasma Concentration-Time Curve (AUC) of GLPG3667', 'timeFrame': 'Week 4'}, {'measure': 'Plasma Trough Concentration (Ctrough) at Steady State of GLPG3667', 'timeFrame': 'Week 2 predose until Week 24'}]",9,18 Years,75 Years,ALL,False,Galapagos NV,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:14.674497,v2_robust,True,True,False,False,True,
NCT01763450,Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer,LIAONING CANCER HOSPITAL&INSTITUTE,bevacizumab plus chemotherapy,['bevacizumab plus chemotherapy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Liver Metastases,"['Liver Metastases', 'Colorectal Cancer']","['Bevacizumab', 'conversion therapy', 'liver metastases', 'colorectal cancer', 'objective response rate']",UNKNOWN,,2012-09,2014-09,"[{'measure': 'To assess the objective response rate(ORR)', 'timeFrame': '8 weeks after chemotherapy'}]","[{'measure': 'To assess the R0 resection rate of liver metastases', 'timeFrame': '8 weeks after chemotherapy、every three months follow-up 1 time in R0 postoperative 1-2 years、Every six months follow-up 1 time in R0 postoperative 2-5 years'}]",2,18 Years,80 Years,ALL,False,Liaoning Cancer Hospital & Institute,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:14.674550,v2_robust,True,True,False,False,False,
NCT04018950,Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects,"Single Period, Open Label, Phase 1 Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects",ETX2514,"['14C-ETX2514', 'ETX2514']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Acinetobacter Baumannii-calcoaceticus Complex Infections,['Acinetobacter Baumannii-calcoaceticus Complex Infections'],"['Acinetobacter baumannii-calcoaceticus', 'complex infections', 'ETX2514', 'excretion', 'metabolism']",COMPLETED,,2019-06-21,2019-07-26,"[{'measure': 'Cumulative urinary recovery of total radioactivity', 'timeFrame': '-12-0 hours (pre-dose), and at 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the intravenous (IV) dose'}, {'measure': 'Cumulative fecal recovery of total radioactivity', 'timeFrame': '-12-0 hours (pre-dose), and at 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the IV dose'}, {'measure': 'Mass balance as a sum of the percent of total radioactivity recovered in urine and feces', 'timeFrame': 'urine: -12-0 hours (pre-dose), and at 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the IV dose; feces: -12-0 hours (pre-dose), and at 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the IV dose'}, {'measure': 'Metabolite profiles in plasma', 'timeFrame': 'pre-dose (-30 minutes) and at 1, 2 (± 2 minutes), 3 (just prior to shutting off infusion), 4, 6, 8, 10, 12 (± 5 minutes), 18, 24, 36, 48, 72, 96, 120, 144, and 168 hours (± 10 minutes) after the initiation of the IV dose or early termination'}, {'measure': 'Metabolite profiles in urine samples', 'timeFrame': '-12-0 hours (pre-dose) and over the following collection periods: 0-6, 6-12, 12-24, 24-48, 48-72, 72-96, 96-120,120-144, and 144-168 hours after the initiation of the IV dose'}, {'measure': 'Metabolite profiles in fecal samples', 'timeFrame': '-12-0 hours (pre-dose) and over the following collection periods: 0-24, 24-48, 48-72, 72-96, 96-120, 120-144, and 144-168 hours after the initiation of the IV dose'}]","[{'measure': 'Number of participants with any treatment-emergent adverse event', 'timeFrame': 'up to Day 8'}, {'measure': 'Number of participants with any clinically significant clinical laboratory evaluation', 'timeFrame': 'up to Day 8'}, {'measure': 'Number of participants with any clinically significant vital sign measurement', 'timeFrame': 'up to Day 8'}, {'measure': 'Number of participants with any clinically significant electrocardiogram finding', 'timeFrame': 'up to Day 8'}, {'measure': 'Number of participants with any clinically significant physical examination finding', 'timeFrame': 'up to Day 8'}]",11,18 Years,55 Years,MALE,True,Entasis Therapeutics,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:14.674584,v2_robust,True,True,True,False,True,
NCT00338650,Treatment of the Human Anti-TNF Monoclonal Antibody Adalimumab in Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab (CHOICE),"A Multi-Center, Open-Label Treatment Protocol of the Human Anti-TNF Monoclonal Antibody Adalimumab in Patients With Moderate to Severe Crohn's Disease With Previous Exposure to Infliximab",adalimumab,['adalimumab'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Crohn's Disease,"[""Crohn's Disease""]",[],COMPLETED,,2006-06,2007-05,"[{'measure': 'AEs, laboratory data, physical examinations and vital signs'}]",[{'measure': 'Efficacy variables will be assessed from Outcomes Questionnaires'}],2,18 Years,75 Years,ALL,False,Abbott,INDUSTRY,0,1000.0,,2025-09-01T16:18:14.674611,v2_robust,True,True,True,False,False,
NCT00950391,Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus,Enhancement of Functional Recovery After Peripheral Nerve Injury With Tacrolimus,Tacrolimus,"['FK506, Prograf', 'Tacrolimus']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Peripheral Nerve Injury,['Peripheral Nerve Injury'],"['peripheral nerve injury', 'peripheral nerve surgery', 'nerve repair', 'nerve graft']",WITHDRAWN,PI unable to secure funding for the project so study was not pursued.,2010-08,2015-09,"[{'measure': 'Functional Recovery', 'timeFrame': '1-1.5 years'}, {'measure': 'Incidence of adverse events.', 'timeFrame': '1 year'}]","[{'measure': 'Recovery time.', 'timeFrame': '1.5 years'}, {'measure': 'Recovery of sensation.', 'timeFrame': '1 year'}]",4,18 Years,50 Years,ALL,False,Washington University School of Medicine,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.674802,v2_robust,True,True,False,True,True,PI unable to secure funding for the project so study was not pursued.
NCT00796991,"Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine","A Randomized, Parallel, 3-arm Study to Characterize the Effect of Ipilimumab + Chemotherapy in Patients With Untreated Advanced Melanoma",Ipilimumab,"['Ipilimumab', 'Paclitaxel', 'BMY-26575', 'Dacarbazine', 'TAXOL', 'Carboplatin', 'BMS-734016', 'BMS-181339', 'PARAPLATIN', 'MDX-010']",10,INTERVENTIONAL,['PHASE1'],PHASE1,,Advanced Melanoma,['Advanced Melanoma'],['Untreated Advanced Melanoma'],COMPLETED,,2009-02,2012-10,"[{'measure': 'Pharmacokinetic Parameter Maximum Observed Serum Concentration (Cmax) for Ipilimumab, Paclitaxel, Dacarbazine and the Active Metabolite for Dacarbazine, 5-aminoimidazole-4carboxamide (AIC)- Pharmacokinetic Analysis Population', 'description': 'Cmax=micrograms per milliliter (µg/mL): drug concentration versus time for ipilimumab (Day 43) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma by Enzyme-linked Immunosorbent Assay (ELISA); lower level of quantitation (LLOQ)=0.8 µg/mL; upper limit of quantitation (ULOQ)=25.6 µg/mL; Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; from Day 162 on every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined using liquid chromatography tandem mass spectrometry (LC/MS/MS) detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography atmospheric pressure ionization (API) tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.', 'timeFrame': 'Day 1 (0 h) to Day 43'}, {'measure': 'Area Under the Concentration Time Curve (AUC) From Time Zero to 21 Days [AUC(0-21d)] for Ipilimumab and AUC Time Zero Extrapolated to Infinity [AUC(INF)] for Paclitaxel, Dacarbazine and the Active Metabolite AIC - Pharmacokinetic Analysis Population', 'description': 'AUC=micrograms\\*hour(h) per mL (µg\\*h/mL): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.', 'timeFrame': 'Day 1 (0 h) to Day 43'}]","[{'measure': 'Pharmacokinetic Parameter of Time of Maximum Observed Concentration (Tmax) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population', 'description': 'Tmax reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..', 'timeFrame': 'Day 1 (0 h) to Day 43'}, {'measure': 'Pharmacokinetic Parameter of Terminal Elimination Half Life (T-HALF) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population', 'description': 'T(HALF) reported in hours (h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.', 'timeFrame': 'Day 1 (0 h) to Day 43'}, {'measure': 'Pharmacokinetic Parameter of Clearance (CLT) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population', 'description': 'CLT reported in milliliters/hour (mL/h): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose..', 'timeFrame': 'Day 1 (0 h) to Day 43'}, {'measure': 'Pharmacokinetic Parameter Volume of Distribution at Steady State (Vss) for Ipilimumab, Paclitaxel, Dacarbazine and Active Metabolite AIC - Pharmacokinetic Analysis Population', 'description': 'Vss reported in liters(L): derived from drug concentration versus time for ipilimumab (Day 43 only) and paclitaxel, dacarbazine, and AIC (Days 1, 43). Ipilimumab determined from plasma ELISA; LLOQ=0.8 µg/mL; ULOQ=25.6 µg/mL; sample times on Day 43=0 hour (h) predose, 1.5, 4.0, 24, 72, 168, 336, 504 h post dose; starting Day 162 every 12 weeks (Day 1 and 22= 0 h). Paclitaxel determined from plasma using LC/MS/MS detection; LLOQ=10 nanograms per milliliter (ng/mL); ULOQ=5000 ng/mL; sample times Day 1 and Day 43=0 h predose, 1.5, 3.0, 3.5, 5,5, 9.5, 24, 48 h postdose. Dacarbazine (DTIC) and AIC determined from plasma using liquid chromatography API tandem mass spectrometry (LC-API/MS/MS) detection; LLOQ for dacarbazine=10.0 ng/mL; ULOQ=5000 ng/mL; AIC LLOQ=0.05 µg/mL; ULOQ=25.0 µg/mL; sample times Day 1: 0 h predose, 1, 1.5, 2.5, 3.5, 5.5, 9.5, 24 h post dose.', 'timeFrame': 'Day 1 (0 h) to Day 43'}, {'measure': 'Number of Participants in Best Overall Response Categories Based on Modified World Health Organization (mWHO) Criteria - All Treated Participants', 'description': 'Assessments for antitumor activity by physical exam and routine anatomic imaging were at Week 12 and confirmatory imaging at Weeks 16, 20, and 24. Participants with resected index or new lesions were considered progressed in their disease. Complete Response (CR): Complete disappearance of all index lesions; Partial Response (PR): Decrease, relative to baseline, of 50% or greater in the sum of the products of the two largest perpendicular diameters of all index lesions, in the absence of Complete Response; Stable Disease (SD): Does not meet criteria for complete or partial response, in the absence of progressive disease. Participants with PR or CR that was not confirmed after at least 4 weeks are scored as SD unless they have new primary lesions; Progressive Disease: At least 25% increase in the sum of products of all index lesions and/or the appearance of any new lesion(s). Unknown=the participants overall response was not known.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants in Best Overall Response Categories Based on Immune Related (ir) Response Criteria (RC) - All Treated Participants', 'description': 'Assessments: Weeks 12, 16, 20, and 24. Participants with resected index or new lesions considered progressed in their disease. The immune-related (ir) response criteria (irRC) represents further modifications of mWHO criteria reflecting clinical experience with ipilimumab in which objective and durable responses (as per mWHO) were observed in participants following progression and without intervening alternative anti-cancer therapy. Immune-related (ir)Complete Response (irCR): Complete disappearance of all index lesions; ir Partial Response (irPR): Decrease, relative to baseline, of 50% or greater in sum of products of the two largest perpendicular diameters of all index and all new measurable lesions, in the absence of irCR; ir Stable Disease (irSD): Does not meet criteria for irCR or irPR, in the absence of progressive disease (PD); ir PD: At least 25% increase in Tumor Burden compared to sum of product diameters (SPD) at nadir. ir Unknown=participants overall response not known.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants With Objective Response to Treatment and Disease Control Using mWHO Criteria - All Randomized Participants', 'description': 'Number of participants with an objective response to treatment excluded participants with a best overall response (BOR) of Stable Disease (SD). Disease control is non-progression of disease while on treatment. A participant was considered to have achieved disease control if he/she had a BOR of CR, PR, or SD in the absence of resected index lesions or new lesions while the participant was considered to have an objective response to treatment in he/she had a BOR of CR or PR in the absence of resected index lesions or new lesions.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants With Adverse Events, Serious Adverse Events, Deaths, and Discontinuation Due to Adverse Events From Day 1 to Week 48 - All Treated Population', 'description': 'Adverse events (AEs) and Serious AEs (SAEs) were graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse events version 3.0. Week 48 database lock was 27 July 2010.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Mean Absolute Lymphocyte Count (ALC) at Each Nominal Ipilimumab Induction Dose and at End of the Induction Period - Pharmacodynamic Population', 'description': 'Absolute lymphocyte counts were obtained from routine hematology panels from 28 days prior to the first treatment with any study medication through the end of the Induction-Dosing Period and were reported as number\\*10\\^3 cells per micro liter (x10\\^3 c/µL).', 'timeFrame': 'Day to Week 12'}, {'measure': 'Mean Change From Baseline at Weeks 16 and 48 in Diastolic and Systolic Blood Pressure - All Treated Population', 'description': 'Blood pressure was obtained while the participant was sitting down and was measured in millimeters of mercury (mmHg). During the induction phase blood pressure was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Orthostatic blood pressure was to be measured when clinically indicated (for example, participant was experiencing lightheadedness, dizziness, syncope). Blood pressures were recorded at Weeks 1, 4, 7, 10,13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Mean Change From Baseline in Pulse Rate at Weeks 16 and 48 - All Treated Population', 'description': 'Pulse rate was obtained while the participant was sitting down and measured in beats per minute (bpm). During the induction phase pulse rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Pulse rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Mean Change From Baseline in Respiration Rate at Weeks 16 and 48 - All Treated Population', 'description': 'Respiration rate was obtained while the participant was sitting down and measured in breaths per minute (bpm). During the induction phase respiration rate was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Respiration rate was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Mean Baseline Change in Body Temperature at Weeks 16 and 48 - All Treated Population', 'description': 'Temperature was obtained while the participant was sitting down and was measured in degrees Fahrenheit (F). During the induction phase this vital sign was collected 30 minutes prior to dosing and every 30 minutes for the duration of the ipilimumab infusion. Temperature was recorded at Weeks 1, 4, 7, 10, 13, 16, 19, and 22 during the Induction Phase, and at Weeks 24, 36, and 48 during the Maintenance Phase.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Hemoglobin - All Treated Population', 'description': 'Hemoglobin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 10.0 - less than (\\<) lower limit of normal (LLN); GRADE (2): 8.0 - \\< 10.0; GRADE (3): 6.5 - \\< 8.0; GRADE (4): \\< 6.5', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Leukocytes - All Treated Population', 'description': 'Leukocytes are measured as \\*10\\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 3.0 - \\< LLN; GRADE (2): 2.0 - \\< 3.0; GRADE (3): 1.0 - \\< 2.0; GRADE (4): \\< 1.0.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst Common Terminology Criteria (CTC) Grade for Lymphocytes - All Treated Population', 'description': 'Lymphocytes (absolute) were measured as \\*10\\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) version (v) 3.0 was used to determine Grade. GRADE (1): 0.8 - \\< 1.5; GRADE (2): 0.5 - \\< 0.8; GRADE (3): 0.2 - \\< 0.5; GRADE (4): \\< 0.2', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils - All Treated Population', 'description': 'Neutrophils (absolute) are measured as \\*10\\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \\< 2.0; GRADE (2): 1.0 - \\< 1.5; GRADE (3): 0.5 - \\< 1.0; GRADE (4): \\< 0.5', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Neutrophils Plus Bands - All Treated Population', 'description': 'Neutrophils plus bands (absolute) were measured as \\*10\\^3 cells per microliter (c/µL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 1.5 - \\< 2.0; GRADE (2): 1.0 - \\< 1.5; GRADE (3): 0.5 - \\< 1.0; GRADE (4): \\< 0.5.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Platelet Count - All Treated Population', 'description': 'Platelets were measured as \\*10\\^9 cells per liter (c/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 75.0 - \\< LLN; GRADE (2): 50.0 - \\< 75.0; GRADE (3): 25.0 - \\< 50.0; GRADE (4): \\< 25.0.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alanine Aminotransferase (ALT) - All Treated Population', 'description': 'ALT was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 - 2.5 \\* upper limits of normal (ULN); GRADE (2): \\> 2.5 - 5.0 \\* ULN; GRADE (3): \\> 5.0 - 20.0 \\* ULN; GRADE (4): \\> 20.0 \\* ULN.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Aspartate Aminotransferase (AST) - All Treated Population', 'description': 'AST was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 - 2.5 \\* upper limits of normal (ULN); GRADE (2): \\> 2.5 - 5.0 \\* ULN; GRADE (3): \\> 5.0 - 20.0 \\* ULN; GRADE (4): \\> 20.0 \\* ULN.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Albumin - All Treated Population', 'description': 'Albumin was measured in grams per deciliter (g/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\< LLN - 3.0; GRADE (2): \\< 3.0 - 2.0; GRADE (3): \\< 2.0 g/dL.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Alkaline Phosphatase - All Treated Population', 'description': 'Alkaline Phosphatase was measured as Units per Liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 - 2.5 \\* upper limits of normal (ULN); GRADE (2): \\> 2.5 - 5.0 \\* ULN; GRADE (3): \\> 5.0 - 20.0 \\* ULN; GRADE (4): \\> 20.0 \\* ULN.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Bilirubin - All Treated Population', 'description': 'Total Bilirubin was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 - 1.5 \\* upper limits of normal (ULN); GRADE (2): \\> 1.5 - 3.0 \\* ULN; GRADE (3): \\> 3.0 - 10.0 \\* ULN; GRADE (4): \\> 10.0 \\* ULN.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Serum Potassium (High) - All Treated Population', 'description': 'Serum potassium was measured as milliequivalents per liter (mEq/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 3.0 - \\< LLN OR \\> ULN - 5.5;; GRADE (2): \\> 5.5 - 6.0; GRADE (3): 2.5 - \\< 3.0 \\> 6.0 - 7.0; GRADE (4): \\< 2.5 mEq/L.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Amylase - All Treated Population', 'description': 'Amylase was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 - 1.5 \\* upper limits of normal (ULN); GRADE (2): \\> 1.5 - 2.0 \\* ULN; GRADE (3): \\> 2.0 - 5.0 \\* ULN; GRADE (4): \\> 5.0 \\* ULN.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Calcium (High) - All Treated Population', 'description': 'Total Calcium was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): 8.0 - \\< LLN OR \\> ULN - 11.5; GRADE (2): 7.0 - \\< 8.0 \\> 11.5 - 12.5; GRADE (3): 6.0 - \\< 7.0 \\> 12.5 - 13.5; GRADE (4): \\< 6.0 \\> 13.5 mg/dL.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Total Lipase - All Treated Population', 'description': 'Total Lipase (as measured with a turbidimetric assay) was measured as units per liter (U/L). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 - 1.5 \\* ULN; GRADE (2): \\> 1.5 - 2.0 \\* ULN; GRADE (3): \\> 2.0 - 5.0 \\* ULN; GRADE (4): \\> 5.0 X ULN.', 'timeFrame': 'Day 1 to Week 48'}, {'measure': 'Number of Participants on Treatment With Toxicity Changes From Baseline by Worst CTC Grade for Uric Acid - All Treated Population', 'description': 'Uric acid was measured as milligrams per deciliter (mg/dL). National Cancer Institute Common Terminology Criteria (CTC) v3.0 was used to determine Grade. GRADE (1): \\> 1.0 \\* ULN - 10.0; GRADE (4): \\> 10.0 mg/dL.', 'timeFrame': 'Day 1 to Week 48'}]",31,18 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,1,72.0,ACTUAL,2025-09-01T16:18:14.674813,v2_robust,True,True,True,False,True,
NCT00250991,Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial,Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke (CLEAR Stroke) Trial,activase,"['integrilin', 'activase']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Stroke,['Stroke'],"['stroke', 'integrilin', 'eptifibatide', 'activase', 'recombinant tissue plasminogen activator', 'rt-PA', 'recombinant t-PA', 'SPOTRIAS']",COMPLETED,,2003-07,2007-07,"[{'measure': 'The primary safety endpoint in this safety study will be the incidence of symptomatic intracranial hemorrhage .', 'timeFrame': 'within 36 hours'}, {'measure': 'The primary measure of early beneficial drug activity will be the incidence of early neurological improvement, as measured by the NIHSSS </= 2', 'timeFrame': 'at 24 hours from symptom onset'}]",[],2,18 Years,80 Years,ALL,False,University of Cincinnati,OTHER,1,94.0,ACTUAL,2025-09-01T16:18:14.675038,v2_robust,True,True,True,False,True,
NCT00137891,Study Comparing Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone,Phase I Study Comparing Pharmacokinetics and Safety Profile of Thyrogen Versus a Modified Release of Recombinant Human Thyroid Stimulating Hormone,Modified Release rhTSH,['Modified Release rhTSH'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Multinodular goiter'],COMPLETED,,2005-06,2005-08,[{'measure': 'To assess and compare the pharmacokinetics (PK) of a single intramuscular (IM) administration of 0.1 mg of Thyrogen versus a single IM administration of 0.1 mg modified release formulation of rhTSH in healthy subjects'}],[],1,18 Years,40 Years,ALL,True,"Genzyme, a Sanofi Company",INDUSTRY,0,46.0,,2025-09-01T16:18:14.675046,v2_robust,True,True,True,False,False,
NCT06165991,Efficacy and Safety of Liposomal Bupivacaine in Thoracic Paravertebral Nerve Block,Efficacy and Safety of Liposomal Bupivacaine for Thoracic Paravertebral Nerve Block Combined With Drainage Tube Analgesia for Postoperative Analgesia After Thoracoscopic Lobectomy,"Liposomal bupivacaine, Bupivacaine","['Liposomal bupivacaine, Bupivacaine', 'drainage tube analgesia technique', 'liposomal bupivacaine']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Thoracic Paravertebral Block,"['Thoracic Paravertebral Block', 'Postoperative Analgesia', 'Thoracoscopic Lobectomy']","['liposomal bupivacaine(LB)', 'Thoracic paravertebral nerve block', 'Postoperative analgesia', 'thoracoscopic lobectomy']",NOT_YET_RECRUITING,,2024-06-01,2025-12-31,"[{'measure': 'Numerical Rating Scale (NRS) for pain at rest', 'description': 'Numerical Rating Scale (NRS) for pain at rest for 72h (The average of the three 24h time points: 24, 48, and 72h). The Numeric Pain Scale (NRS) pain numerical score(0-10 score, 0: no pain, 10: worst imaginable pain). A pain measurement list about quiet NRS score at different postoperative time will be used.', 'timeFrame': '24hour,48hour, 72hour postoperative'}]","[{'measure': '15 quality of recovery assessments (QoR15)', 'description': '15 quality of recovery assessments (QoR15) at 24, 48, and 72 hours after surgery. Its scores range from 0 to 150, with higher scores indicating better recovery.Based on the scores, QoR can be classified into excellent (QoR-15 \\> 135), good (122 ≤ QoR-15 ≤ 135), moderate (90 ≤ QoR-15 ≤ 121), and poor (QoR-15 \\<90).', 'timeFrame': 'at 24, 48, and 72 hours after surgery'}, {'measure': 'area under the NRS score curve (AUC) for resting and exercise', 'description': 'area under the NRS score curve (AUC) for resting and exercise 72 hours after surgery', 'timeFrame': '72 hours after surgery'}, {'measure': 'cumulative opioid consumption (morphine milligram equivalent, MME', 'description': 'cumulative opioid consumption at 72 hours after surgery (morphine milligram equivalent, MME', 'timeFrame': 'at 72 hours after surgery'}]",4,18 Years,,ALL,False,Yongtao Sun,OTHER,0,228.0,ESTIMATED,2025-09-01T16:18:14.675107,v2_robust,True,True,False,False,False,
NCT00720291,Inflammation and Treatment of Bacterial Vaginosis Near Term,Inflammation and Treatment of Bacterial Vaginosis Near Term,Metronidazole,"['Placebo', 'Metronidazole', 'Flagyl, CAS# 443-48-1']",3,INTERVENTIONAL,['NA'],,,Bacterial Vaginosis,['Bacterial Vaginosis'],"['Metronidazole', 'BV', 'Pregnancy']",COMPLETED,,2006-02,2010-11-23,"[{'measure': 'Levels of Interleukins 1 and 6 as well as Tumor Necrosis Factor Alpha', 'timeFrame': '3-5 days after start of treatment'}]",[],1,18 Years,45 Years,FEMALE,False,Medical University of South Carolina,OTHER,0,59.0,ACTUAL,2025-09-01T16:18:14.675138,v2_robust,True,True,True,False,False,
NCT06791291,Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 Diabetes,"Efficacy and Safety of Teplizumab in the Treatment of Japanese Pediatric and Adult Participants Aged 8 to 34 Years With Stage 2 Type 1 Diabetes: A Multicenter, Randomized, Open-label, Controlled Study.",Teplizumab,"['SAR446681', 'Teplizumab', 'TZIELD']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Type 1 Diabetes Mellitus,['Type 1 Diabetes Mellitus'],[],RECRUITING,,2025-07-25,2028-03-06,"[{'measure': 'Number of participants with Stage 3 Type 1 Diabetes based on American Diabetes Association criteria', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Change from baseline in area under the curve (AUC) of C-peptide', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Change from baseline in endogenous insulin', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Number of participants with TEAEs, SAEs, AEs leading to permanent study intervention- or study discontinuation; AEs of special interest; number of participants with clinically significant changes in vital signs, ECG, and/or safety laboratory test', 'description': 'TEAE: treatment-emerged adverse event; SAE: serious adverse event; AE: adverse event', 'timeFrame': 'Throughout the study, approximately 756 days'}]","[{'measure': 'Change from baseline in fasting plasma glucose (FPG) from an oral glucose tolerance test', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Change from baseline in 2-hour plasma glucose from an oral glucose tolerance test', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Change from baseline of hemoglobin A1c (HbA1c)', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Serum concentration of teplizumab', 'timeFrame': 'From Day 1 to Day 28'}, {'measure': 'CD3 receptor occupancy', 'timeFrame': 'From baseline to Day 28'}, {'measure': 'Number of participants with anti-drug antibodies', 'timeFrame': 'From baseline up to Week 104'}, {'measure': 'Number of participants with neutralizing antibodies', 'timeFrame': 'From baseline up to Week 104'}]",11,8 Years,34 Years,ALL,False,Sanofi,INDUSTRY,0,10.0,ESTIMATED,2025-09-01T16:18:14.675171,v2_robust,True,True,False,False,True,
NCT05037591,Effect of Sea Grapes-antioxidants Extract in Obese Men : 4 Weeks Randomized-Double Blind Controlled Trial,Effect of Sea Grapes-antioxidants Extract in Obese Men,Sea grapes extract 1.68 g/70kg BW,"['Sea grapes extract 1.68 g/70kg BW', 'Placebo']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Obesity,"['Obesity', 'Aging', 'Diabetes']","['Obesity', 'Aging', 'Functional Food', 'Diabetes', 'Dyslipidemia']",COMPLETED,,2021-08-01,2021-09-15,"[{'measure': 'Peroxisome proliferator-activated receptor (PPAR)-γ coactivator 1 alpha (PGC-1α) Levels ""change"" is being assessed', 'description': 'Evaluate PGC-1α level in pg/dL', 'timeFrame': 'Change from Baseline PGC-1α Levels at 4th weeks of the intervention period'}, {'measure': 'Total Cholesterol ""change"" is being assessed', 'description': 'Evaluate total Cholesterol level in mg/dL', 'timeFrame': 'Change from Baseline Total Cholesterol at 4th weeks of the intervention period'}, {'measure': 'Blood Glucose ""change"" is being assessed', 'description': 'Evaluate total blood sugar level in mg/dL', 'timeFrame': 'Change from Baseline Blood Glucose at 4th weeks of the intervention period'}]","[{'measure': 'Body Mass Index (BMI)', 'description': 'Body Mass Index (BMI) weight and height will be combined to report BMI in kg/m\\^2', 'timeFrame': 'Change from Baseline Body Mass Index (BMI) at 4th weeks of the intervention period'}, {'measure': 'Triglycerides', 'description': 'Triglycerides in mg/dL', 'timeFrame': 'Change from Baseline Triglycerides Levels at 4th weeks of the intervention period'}, {'measure': 'high-density lipoprotein (HDL)', 'description': 'high-density lipoprotein (HDL) in mg/dL', 'timeFrame': 'Change from Baseline high-density lipoprotein (HDL) Levels at 4th weeks of the intervention period'}, {'measure': 'low-density lipoprotein (LDL)', 'description': 'low-density lipoprotein (LDL) in mg/dL', 'timeFrame': 'Change from Baseline low-density lipoprotein (LDL) Levels at 4th weeks of the intervention period'}, {'measure': 'Body Weight', 'description': 'Weight in kilograms (kg)', 'timeFrame': 'Change from Baseline Body Weight at 4th weeks of the intervention period'}, {'measure': 'Body Height', 'description': 'Height in meters (M)', 'timeFrame': 'Change from Baseline Body Height at 4th weeks of the intervention period'}, {'measure': 'waist-to-hip ratio (WHR)', 'description': 'This is calculated as waist measurement divided by hip measurement (W⁄H). For example, a person with a 30"" (76 cm) waist and 38"" (97 cm) hips has a waist-hip ratio of about 0.78.', 'timeFrame': 'Change from Baseline waist-to-hip ratio (WHR) at 4th weeks of the intervention period'}]",10,19 Years,60 Years,MALE,False,State Islamic University of Sunan Kalijaga Yogyakarta,OTHER,0,70.0,ACTUAL,2025-09-01T16:18:14.675196,v2_robust,True,True,True,False,False,
NCT06956391,Ultralow Dose PET Imaging of 18F-FDG Uptake,Evaluation of Ultralow Dose PET Imaging for Detecting 18F-FDG Uptake,18F-FDG,"['18F-FDG', 'blood collection', 'CT scan', 'PET scan']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Healthy Volunteer,"['Healthy Volunteer', 'Cancer']",[],RECRUITING,,2025-05-12,2030-06-30,"[{'measure': 'Signal-to-Noise Ratio (SNR)', 'description': 'Measurement of signal-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: SNR (unitless, numeric ratio)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}, {'measure': 'Contrast-to-Noise Ratio (CNR)', 'description': 'Measurement of contrast-to-noise ratio for image quality assessment across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: CNR (unitless, numeric ratio)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}, {'measure': 'Coefficient of Variation (COV)', 'description': 'Measurement of the coefficient of variation in selected regions for evaluating image consistency across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Percentage (%)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}, {'measure': 'Spatial Resolution (Full Width at Half Maximum - FWHM)', 'description': 'Assessment of spatial resolution using full width at half maximum (FWHM) across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Millimeters (mm)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}, {'measure': 'Target-to-Background Ratio (TBR)', 'description': 'Assessment of target-to-background ratio for evaluating PSMA-expressing tissue contrast across different scan durations, reconstruction techniques, and AI-enhanced image reconstructions. Unit of Measure: Ratio (unitless numeric ratio)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}, {'measure': 'Qualitative Image Quality Score (Likert Scale)', 'description': 'Independent qualitative evaluation of overall image quality, lesion detectability, image noise, and artifacts by nuclear medicine physicians, assessed using a 5-point Likert scale. Unit of Measure: Score on Likert Scale (1-5; 1 = worst, 5 = best)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}, {'measure': 'Inter-reader Agreement (Weighted Kappa Statistics)', 'description': 'Measurement of agreement among readers evaluating qualitative image quality scores, analyzed using weighted kappa statistics. Unit of Measure: Weighted kappa statistic (numeric value ranging from 0 to 1, 0 = no agreement, 1 = perfect agreement)', 'timeFrame': 'Evaluated annually (once per year), based on pooled images acquired during the preceding 12-month period.'}]",[],7,18 Years,120 Years,ALL,True,Akiva Mintz,OTHER,0,200.0,ESTIMATED,2025-09-01T16:18:14.675252,v2_robust,True,True,False,False,False,
NCT04360174,"CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension","A Prospective, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of OTX-TIC (Travoprost) Implant in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension",OTX-TIC,['OTX-TIC'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Ocular Hypertension,"['Ocular Hypertension', 'Open Angle Glaucoma']",[],COMPLETED,,2018-04-25,2021-05-24,"[{'measure': 'Ocular Treatment Emergent Adverse Events', 'description': 'All adverse events will be captured throughout the study', 'timeFrame': 'Through study completion, 6 months'}, {'measure': 'Efficacy Outcome', 'description': 'IOP measurements at 8 am', 'timeFrame': 'Diurnal IOP [12 Week Visit]'}]",[],2,18 Years,,ALL,False,"Ocular Therapeutix, Inc.",INDUSTRY,0,19.0,ACTUAL,2025-09-01T16:18:14.675343,v2_robust,True,True,True,False,True,
NCT05371574,Clonidine Versus Tranexamic Acid in Reduction of Blood Loss,Premedication With Oral Clonidine Versus Intraoperative Intravenous Tranexamic Acid in Reduction of Blood Loss During Elective Cesarean Section in Abakaliki - a Randomized Control Trial,clonidine group,"['oral clonidine', 'clonidine group']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Blood Loss,['Blood Loss'],[],UNKNOWN,,2022-01-03,2022-08-03,"[{'measure': 'Blood loss', 'description': 'Estimated blood loss following Caesarean Section', 'timeFrame': '6 months'}]","[{'measure': 'Bleeding tendency', 'description': 'Change in haematocrit 48 hours after delivery', 'timeFrame': '6 months'}]",2,18 Years,45 Years,FEMALE,True,Uwakwe Emmanuel Chijioke,OTHER,0,112.0,ESTIMATED,2025-09-01T16:18:14.675383,v2_robust,True,True,False,False,False,
NCT02980874,Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO,"SAPPHIRE: A Randomized, Masked, Controlled Trial To Study The Safety And Efficacy Of Suprachoroidal CLS-TA In Conjunction With Intravitreal Aflibercept In Subjects With Retinal Vein Occlusion",suprachoroidal CLS-TA,"['Aflibercept', 'suprachoroidal CLS-TA', 'IVT aflibercept', 'Triamcinolone acetonide', 'suprachoroidal sham']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Macular Edema,"['Macular Edema', 'Retinal Vein Occlusion']","['RVO', 'ME', 'Central Subfield Thickness', 'OCT', 'Optical Coherence Tomography', 'Cystoid Macular Edema', 'Subretinal Fluid', 'Eylea', 'Aflibercept', 'Anti-VEGF', 'Suprachoroidal', 'Triamcinolone acetonide']",TERMINATED,"Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent.",2017-01-31,2018-12-10,"[{'measure': 'Proportion of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Early Treatment of Diabetic Retinopathy Study (ETDRS)', 'description': 'Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. An increase from the pre-treatment state in BCVA of 15 letters or more represents a clinically meaningful improvement.', 'timeFrame': '2 months'}]","[{'measure': 'Mean Change From Baseline in Best Corrected Visual Acuity', 'description': 'Best corrected visual acuity (BCVA) refers to the measurement of the best possible vision that can be achieved following refraction or correction. BCVA was assessed following the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol and was measured in the number of letters read correctly on an ETDRS eye chart. A positive change from baseline value represents an improvement in vision.', 'timeFrame': '6 months'}, {'measure': 'Mean Change From Baseline in Central Subfield Thickness', 'description': 'Central subfield thickness (CST) is a diagnostic measurement used in identifying the presence of edema in the circular area 1 mm in diameter centered around the fovea. CST was measured using spectral domain optical coherence tomography (SD-OCT). A masked reading center graded the SD-OCT digital images. A negative change from baseline value represents a reduction in macular edema.', 'timeFrame': '6 months'}]",3,18 Years,,ALL,False,"Clearside Biomedical, Inc.",INDUSTRY,0,460.0,ACTUAL,2025-09-01T16:18:14.675463,v2_robust,True,True,False,True,False,"Primary, 8-week efficacy endpoint not achieved. No additional benefit for subjects receiving a corticosteroid together with an intravitreal anti-VEGF agent."
NCT04280874,Induction of Labor in Term Pregnancies With Unfavourable Cervix,Comparison of Intracervical and Intravaginal Application of Prostaglandin E2 for Induction of Labour in Term Pregnancies With Unfavourable Cervix,Dinoprostone 0.5 MG,"['Dinoprostone 0.5 MG', 'PREPIDIL', 'Dinoprostone 2 MG/2.5 ML Vaginal Gel/Jelly', 'PROSTIN']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Induction of Labor Affected Fetus / Newborn,"['Induction of Labor Affected Fetus / Newborn', 'Prostaglandins Causing Adverse Effects in Therapeutic Use']","['dinoprostone', 'Bishop score', 'labor induction', 'term pregnancy']",COMPLETED,,2018-12-10,2020-07-01,"[{'measure': 'time period between beginning of labor induction to delivery', 'description': 'hours (difference of 4 hours or more is considered significant)', 'timeFrame': '5 days'}]","[{'measure': 'number of births within 24h of start of labor induction', 'description': 'N (%)', 'timeFrame': '7 days'}, {'measure': 'number of deliveries by caesarean section or instrumental deliveries', 'description': 'N (%)', 'timeFrame': '7 days'}, {'measure': 'number of uterus hyperstimulation', 'description': 'N (%)', 'timeFrame': '7 days'}]",4,,,FEMALE,True,Clinical Hospital Merkur,OTHER,0,212.0,ACTUAL,2025-09-01T16:18:14.675490,v2_robust,True,True,True,False,False,
NCT02767674,Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma,"Phase III,Randomized Controlled Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma",Rituximab,"['Oxaliplatin', 'Rituximab', 'Gemcitabine', 'Vindesine', 'Cyclophosphamide', 'Epirubicin Injectable Product', 'Prednisone']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Diffuse Large B Cell Lymphoma,['Diffuse Large B Cell Lymphoma'],"['R-Gemox', 'R-miniCHOP', 'elderly patients with diffuse large B cell lymphoma']",UNKNOWN,,2016-05,2020-12,"[{'measure': '2-year overall survival rate', 'description': 'from the date of inclusion to date of death, irrespective of cause', 'timeFrame': 'One year'}]","[{'measure': '2-year progression free survival rate', 'description': 'from date of inclusion to date of progression, relapse, or death from any causePFS：from date of inclusion to date of progression, relapse, or death from any cause', 'timeFrame': 'One year'}, {'measure': 'overall response rate', 'description': 'overall response rate after treated by R-GemOx or R-miniCHOP overall response rate after treated by R-GemOx or R-miniCHOP regimen', 'timeFrame': 'One year'}]",3,70 Years,90 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,0,258.0,ESTIMATED,2025-09-01T16:18:14.675504,v2_robust,True,True,False,False,False,
NCT03680274,Lessening Organ Dysfunction With VITamin C,Lessening Organ Dysfunction With VITamin C (LOVIT),Vitamin C,"['Ascorbic acid', 'Vitamin C']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Sepsis,"['Sepsis', 'Vitamin C', 'Intensive Care Unit', 'COVID-19', 'Pandemic', 'Coronavirus']",[],COMPLETED,,2018-11-08,2022-01-24,"[{'measure': 'Number of deceased participants or with persistent organ dysfunction', 'description': 'Defined as death or dependency on mechanical ventilation, renal replacement, or vasopressors', 'timeFrame': 'Both assessed at 28 days'}]","[{'measure': 'Number of participants with persistent organ dysfunction-free days in intensive care unit', 'description': 'Persistent organ dysfunction-free days in intensive care unit', 'timeFrame': 'Up to day 28'}, {'measure': 'Number of participants deceased at 6 months', 'description': 'Mortality at 6 months', 'timeFrame': '6 months'}, {'measure': 'Score of health related quality of life in 6-month survivors', 'description': ""Assessed by the questionnaire EuroQol-5D (EQ-5D-5L). The EQ-5D-5L essentially consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS).\n\nThe descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.\n\nThe EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'."", 'timeFrame': '6 months'}, {'measure': 'Global tissue dysoxia', 'description': 'Assessed by serum lactate concentration', 'timeFrame': 'Days 1, 3, 7'}, {'measure': 'Organ function (including renal function)', 'description': ""Assessed by the Sequential Organ Failure Assessment (SOFA) score. Used to track a person's status during the stay in an intensive care unit to determine the extent of a person's organ function or rate of failure. The score is based on 6 different sub-scores, one each for the respiratory (PaO2/FiO2 mmHg), cardiovascular (mean arterial pressure OR administration of vasopressors required), hepatic (liver bilirubin (mg/dl) \\[μmol/L\\]), coagulation (platelets×103/µl), renal (kidneys creatinine (mg/dl) \\[μmol/L\\] (or urine output)) and neurological (Glasgow coma scale). The sub-score of each system ranges from 0 (best) to +4 (worst)."", 'timeFrame': 'Days 1, 2, 3, 4, 7, 10, 14, 28'}, {'measure': 'Rate of inflammation', 'description': 'Assessed by interleukin-1 beta (IL-1ß), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP).', 'timeFrame': 'Days 1, 3, 7'}, {'measure': 'Rate of infection', 'description': 'Assessed by procalcitonin (PCT)', 'timeFrame': 'Days 1, 3, 7'}, {'measure': 'Rate of endothelial injury', 'description': 'Assessed by thrombomodulin (TM) and angiopoietin-2 (ANG-2)', 'timeFrame': 'Days 1, 3, 7'}, {'measure': 'Occurrence of stage 3 acute kidney injury', 'description': 'Assessed by KDIGO (Kidney Disease: Improving Global Outcomes) criteria', 'timeFrame': 'Up to day 28'}, {'measure': 'Acute hemolysis', 'description': '* clinician judgment of hemolysis, as recorded in the chart, OR\n* hemoglobin drop of at least 25 g/L within 24 hours of a dose of investigational product PLUS 2 of the following:\n\n  * reticulocyte count \\>2 times upper limit of normal at clinical site lab;\n  * haptoglobin \\< lower limit of normal at clinical site lab;\n  * indirect (unconjugated) bilirubin \\>2 times upper limit of normal at clinical site lab;\n  * Lactate dehydrogenase (LDH) \\>2 times upper limit of normal at clinical site lab.\n\nSevere hemolysis:\n\n\\- hemoglobin \\< 75 g/L AND at least 2 of the above criteria AND requires 2 units of packed red blood cells', 'timeFrame': 'Up to day 28'}, {'measure': 'Hypoglycemia', 'description': 'Core lab-validated glucose level of less than 3.8 mmol/L', 'timeFrame': 'During the time participants receive the 16 doses of the investigational product and the 7 days following the last dose'}, {'measure': 'Vitamin C volume of distribution', 'description': 'Assessed by chromatography-tandem mass spectrometry', 'timeFrame': '8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy)'}, {'measure': 'Vitamin C clearance', 'description': 'Assessed by chromatography-tandem mass spectrometry', 'timeFrame': '8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy)'}, {'measure': 'Vitamin C plasma concentration', 'description': 'Assessed by chromatography-tandem mass spectrometry', 'timeFrame': '8th dose of vitamin C at time 0 (immediately prior to the dose) and then after administration at times 1 hour, 2 hours, 4 hours and 6 hours (Pharmacokynetic substudy)'}]",15,18 Years,,ALL,False,Université de Sherbrooke,OTHER,1,872.0,ACTUAL,2025-09-01T16:18:14.675552,v2_robust,True,True,True,False,False,
NCT07134218,Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer,"A National Multicenter, Prospective, Randomized Controlled Study of Serplulimab Injection Combined With Bevacizumab to Improve the Complete Response Rate of Neoadjuvant Therapy for Locally Advanced Stage Intermediate and Low Rectal Cancer",serplulimab、bevacizumab,['serplulimab、bevacizumab'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Rectal Cancer,['Rectal Cancer'],[],NOT_YET_RECRUITING,,2025-10,2027-10,"[{'measure': 'The rate of cCR', 'description': 'Rate of patients who achieve clinical complete response', 'timeFrame': '2 years'}]","[{'measure': 'Major Pathological Response', 'description': 'Rate of major pathological response assessed by postoperative pathology', 'timeFrame': '2 years'}, {'measure': 'Objective Response Rate', 'description': 'Objective response rate assessed by RECIST 1.1 criteria', 'timeFrame': '2 years'}, {'measure': 'Disease-Free Survival (DFS)', 'description': 'DFS was defined as the duration from the date of randomization to the date of the first recurrence (local, distant, or mixed) or death.', 'timeFrame': '2 years'}, {'measure': 'Overall Survival (OS)', 'description': 'Time from randomization to death due to any cause', 'timeFrame': '2 years'}, {'measure': 'Organ Preservation Rate (OPR)', 'description': 'Proportion of patients who achieve organ preservation by choosing a watch-and-wait strategy or local excision after attaining clinical or pathological complete response', 'timeFrame': '2 years'}, {'measure': 'Neoadjuvant Rectal Score (NAR)', 'description': 'Neoadjuvant rectal score assessed by postoperative pathology', 'timeFrame': '2 years'}, {'measure': 'Quality of Life Score (QoL)', 'description': 'Quality of life score during treatment and follow-up', 'timeFrame': '2 years'}, {'measure': 'Safety and Tolerability', 'description': 'Incidence of adverse events (AEs), incidence of abnormal laboratory values, and dose adjustments during treatment and follow-up', 'timeFrame': '2 years'}]",9,18 Years,75 Years,ALL,False,Changhai Hospital,OTHER,0,180.0,ESTIMATED,2025-09-01T16:18:14.675658,v2_robust,True,True,False,False,True,
NCT03170518,A Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (>=10 to <18 Years) With Type 2 Diabetes Mellitus,"A Randomized, Multicenter, Double-Blind, Parallel-Group, Placebo-Controlled Study to Investigate the Efficacy and Safety of Canagliflozin in Children and Adolescents (≥10 to <18 Years) With Type 2 Diabetes Mellitus",Canagliflozin 100 mg,"['Canagliflozin 300 mg', 'JNJ-28431754', 'Canagliflozin 100 mg', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2017-07-21,2023-09-20,"[{'measure': 'Change From Baseline in Glycated Hemoglobin (HbA1c) at Week 26', 'description': 'Change from baseline in HbA1c at Week 26 was analyzed using a pattern mixture model with multiple imputation. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1) and Week 26'}, {'measure': 'Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)', 'description': 'An AE was any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non investigational) product. An AE did not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAE was defined as the AEs occurring after first administration of double blind study intervention up to 30 days post last dose of study intervention.', 'timeFrame': 'Baseline (Day 1) up to 30 days post last dose at Week 52 (up to Week 56)'}]","[{'measure': 'Change From Baseline in Fasting Plasma Glucose (FPG) at Weeks 26 and 52', 'description': 'Change from baseline in FPG at Weeks 26 and Week 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26 and 52'}, {'measure': 'Percentage of Participants With HbA1c Less Than (<)7.5 Percent (%), <7%, and <6.5% at Weeks 26 and 52', 'description': 'The percentage of participants with HbA1c \\<7.5%, \\<7.0%, and \\<6.0% at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Weeks 26 and 52'}, {'measure': 'Percentage of Participants Who Received Rescue Therapy', 'description': 'Percentage of participants who received rescue therapy was reported. Participants who met glycemic rescue criteria that is with baseline HbA1c less than (\\<) 9.0 percent (%) and greater than (\\>) 0.8% change from baseline in HbA1c or with baseline HbA1c \\>=9% and \\>0.5% change from baseline in HbA1c received the glycemic rescue therapy. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1) up to Week 52'}, {'measure': 'Time to Rescue Therapy', 'description': 'Time to rescue therapy was planned to be reported. Participants who met glycemic rescue criteria that is with baseline HbA1c less than (\\<) 9.0 percent (%) and greater than (\\>) 0.8% change from baseline in HbA1c or with baseline HbA1c greater than or equal to (\\>=)9% and \\>0.5% change from baseline in HbA1c received the glycemic rescue therapy. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1) up to Week 52'}, {'measure': 'Percent Change From Baseline in Body Weight at Weeks 26 and 52', 'description': 'The percent change from baseline in body weight at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26 and 52'}, {'measure': 'Change From Baseline in Body Mass Index (BMI) at Weeks 26 and 52', 'description': 'Change from baseline in BMI at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26, and 52'}, {'measure': 'Percent Change From Baseline in Fasting Plasma Lipids Levels at Weeks 26 and 52', 'description': 'The percentage change from baseline in fasting plasma lipids (low-density lipoprotein-cholesterol \\[LDL-C\\], high-density lipoprotein-cholesterol \\[HDL-C\\], total cholesterol, non-HDL-C, and triglycerides) at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26, and 52'}, {'measure': 'Percent Change From Baseline in LDL-C to HDL-C Ratio and Non-HDL-C to LDL-C Ratio at Weeks 26 and 52', 'description': 'The percentage change from baseline in LDL-C to HDL-C ratio and non-HDL-C to LDL-C ratio at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26, and 52'}, {'measure': 'Change From Baseline in Systolic Blood Pressure at Weeks 26 and 52', 'description': 'Change from baseline in systolic blood pressure at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26 and 52'}, {'measure': 'Change From Baseline in Diastolic Blood Pressure at Weeks 26 and 52', 'description': 'Change from baseline in diastolic blood pressure at Weeks 26 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 26, and 52'}, {'measure': 'Change From Baseline in HbA1c at Weeks 12 and 52', 'description': 'Change from baseline in HbA1c at Weeks 12 and 52 was reported. Data for this outcome measure was planned to be collected and analyzed for the combined population of arm Canagliflozin 100 mg and Canagliflozin 300 mg.', 'timeFrame': 'Baseline (Day 1), Weeks 12, and 52'}, {'measure': 'Growth Velocity at Weeks 26 and 52', 'description': 'Growth velocity (increase in height per year) at Weeks 26 and 52 was reported. Growth velocity was derived from height measurements taken at baseline (Day 1), Week 26 and Week 52 visit. Growth velocity at Week 26 was derived as: (height at Week 26 - height at baseline)/(time from baseline to week 26. Similarly, growth velocity at Week 56 was derived.', 'timeFrame': 'Baseline (Day 1) and Weeks 26 and 52'}, {'measure': 'Number of Participants With Changes in Tanner Staging (Females) From Baseline at Weeks 26 and 52', 'description': ""Tanner pubertal staging was assessed in female (F) for pubic hair growth and for breast development in stages (S) 1 to 5. If a participant had reached tanner S 5, no further Tanner pubertal S assessments were to be completed and reported as 'not done (ND)'. Tanner S Pubic hair growth: Pubic hair (1: No hair, 2: Downy hair, 3: More coarse and curly hair, 4: Adult-like hair quality; 5: Hair extends to medial surface of the thighs); Breast development: (1: The nipple is raised a little in this stage. The rest of the breast is still flat, 2: Breast bud forms,3: More elevated, outside areola, 4: Increased breast size, 5: Final adult-size breasts). Categories with at least 1 non-zero data values are reported. Baseline=B, Week=W."", 'timeFrame': 'Baseline (Day 1), Weeks 26, and 52'}, {'measure': 'Number of Participants With Changes in Tanner Staging (Males) From Baseline at Weeks 26 and 52', 'description': 'Tanner pubertal staging was assessed in male (M) for pubic hair growth and for genitalia development in S 1 to 5. If a participant had reached Tanner S5, no further Tanner pubertal S assessments were to be completed and reported as ND. Tanner S pubic hair growth: Pubic hair (1: No hair, 2: little soft, long, lightly curled hair at penis 3: More coarse and curly hair covered larger area, 4: Adult-like hair quality; 5: Hair extends to medial surface of the thighs); Genitalia development: (1: Testes, scrotum, and penis about same size, 2: Enlargement of scrotum, testes, and penis, 3: Enlargement of penis, 4: The penis and glans became larger, 5: Genitalia size and shape same an adult male). Categories with at least 1 non-zero data values are reported. GD: genitalia development.', 'timeFrame': 'Baseline (Day 1), Weeks 26, and 52'}, {'measure': 'Change From Baseline in Bone Turnover Marker: Serum Osteocalcin and Serum Collagen Type 1 Carboxy-Telopeptide (CTx) at Weeks 26 and 52', 'description': 'Change from baseline in bone turnover marker: serum osteocalcin and CTx at Weeks 26 and 52 was reported.', 'timeFrame': 'Baseline (Day 1), Weeks 26 and 52'}, {'measure': 'Urinary Albumin/Creatinine Ratio (ACR) at Weeks 26 and 52', 'description': 'Urinary ACR at Weeks 26 and 52 was reported.', 'timeFrame': 'Weeks 26 and 52'}]",18,10 Years,17 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,171.0,ACTUAL,2025-09-01T16:18:14.675711,v2_robust,True,True,True,False,True,
NCT02671318,Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence,Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus),Drug conversion to sirolimus,"['Myfortic', 'Immuran', 'Rapamune', 'Maintenance of the current regimen', 'Drug conversion to sirolimus']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Cytomegalovirus Infections,['Cytomegalovirus Infections'],"['cytomegalovirus', 'sirolimus', 'cytomegalovirus recurrence', 'kidney transplant', 'conversion']",UNKNOWN,,2015-09,2020-08,"[{'measure': 'Cytomegalovirus infection/disease recurrence', 'description': 'Cytomegalovirus infection/disease recurrence', 'timeFrame': 'One year'}]",[],1,18 Years,,ALL,False,Hospital do Rim e Hipertensão,OTHER,0,250.0,ESTIMATED,2025-09-01T16:18:14.675760,v2_robust,True,True,False,False,False,
NCT05432518,Pilot Trial for Treatment of Recurrent Glioblastoma,Biomarker and Tumor Cell Culture-Driven Pilot Trial for Treatment of Recurrent Glioblastoma,Afatinib,"['Giotrif', 'Palbociclib', 'Olaparib', 'Teva-everolimus', 'Afatinib', 'Everolimus', 'Lynparza', 'Ibrance', 'Sprycel', 'Dasatinib']",10,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Glioblastoma,"['Glioblastoma', 'Recurrent Disease', 'Recurrent Glioblastoma']","['Glioblastoma', 'Recurrent Disease', 'Recurrent Glioblastoma', 'GBM']",RECRUITING,,2023-06-27,2027-12-01,"[{'measure': 'Success rate of personalized GBM treatment based on molecular characterization of recurrent tumor', 'description': 'Percentage of patients, interested in participating, consented and detected with target mutations and completed the treatment with one of the 5 study drugs', 'timeFrame': 'From date of initial consent to participate to the end of follow up period (24 months)'}]","[{'measure': 'Overall survival (OS)', 'description': 'OS is calculated as the period from the day of starting administration of the study drug to the day of death from any cause.', 'timeFrame': 'From date of study drug administration until date of death from any cause (approximately 24 months)'}, {'measure': 'Progression free survival (PFS)', 'description': 'PFS is calculated as the period from the day of starting administration of the study drug to the date that disease progression is confirmed by radiographic assessment and RANO criteria.', 'timeFrame': 'From date of study drug administration until date of radiographic confirmed progression (approximately 2 years)'}, {'measure': 'Quality of Life (QoL) EORTC QLQ-C30', 'description': 'The EORTC QLQ-C30 is a questionnaire to assess the overall quality of life of cancer patients. Participant responses to the questions ""How would you rate your overall health during the past week?"" and ""How would you rate your overall quality of life during the past week?"" are scored on a 7-point scale (1= Very poor to 7=Excellent). Using linear transformation, raw scores are standardized, so that scores range from 0 to 100. A higher score indicates a better overall health status. The change from baseline in EORTC QLQ-C30 Items 29 and 30 combined score will be presented.', 'timeFrame': 'Baseline until the end of treatment'}, {'measure': 'Quality of Life (QoL) EORTC QLQ BN-20', 'description': ""Quality of Life measures are recorded according to EORTC QLQ BN-20 module, which is validated for brain tumor patients and measured as a unit of scale. This is a standard tool for assessing patient reported quality of Life along time during treatment. EORTC QLQ BN-20 (BN-20): 4 scales comprised of multiple items and 7 single items. All items are rated on a 4-point Likert-type scale, 1=not at all' to 4=very much, and linearly transformed to a 0-100 scale, higher scores indicating more severe symptoms.\n\nThe scores across all time points were averaged to obtain the mean."", 'timeFrame': 'Baseline until the end of treatment'}]",5,18 Years,,ALL,False,AHS Cancer Control Alberta,OTHER,1,10.0,ESTIMATED,2025-09-01T16:18:14.675867,v2_robust,True,True,False,False,False,
NCT00042718,"A Study of the Effectiveness and Safety of High Dose, Short-course Levofloxacin in the Treatment of Acute Bacterial Exacerbation (Worsening) of Chronic Bronchitis.",,"levofloxacin, azithromycin, amoxicillin/clavulanate","['levofloxacin, azithromycin, amoxicillin/clavulanate']",1,INTERVENTIONAL,['PHASE3'],PHASE3,,Bronchitis,"['Bronchitis', 'Chronic Bronchitis']","['Chronic Bronchitis', 'Acute Bacterial Exacerbation of Chronic Bronchitis']",COMPLETED,,2001-11,2003-08,[{'measure': 'Clinical response rates based on signs and symptoms at posttherapy visit.'}],[{'measure': 'Microbiologic eradication rates at posttherapy visit'}],2,18 Years,,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,1,659.0,ACTUAL,2025-09-01T16:18:14.675902,v2_robust,True,True,True,False,False,
NCT00805818,Study of NNZ-2566 in Patients With Traumatic Brain Injury,"A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of NNZ-2566 in Patients With Traumatic Brain Injury",NNZ-2566,"['Sodium Chloride 0.9% Injection', 'NNZ-2566', 'Glycyl-L-2-Methylprolyl-L-Glutamic Acid', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Brain Injuries,['Brain Injuries'],[],COMPLETED,,2010-04,2016-01,"[{'measure': 'Reduced incidence, compared to placebo, of adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'AEs to discharged or Day 30 post randomization, whichever occurs first, and SAEs through to 3 months (defined as 12-14 weeks), post randomization.'}]","[{'measure': 'Evidence of efficacy in modifying global outcomes by evaluating Glasgow Outcome Scale - Extended (GOS-E) and activities of daily living (Mayo-Portland Adaptability Inventory - 4th Edition (MPAI-4))', 'timeFrame': '1 month (defined as 4-6 weeks) and 3 months (defined as 12-14 weeks), post randomization.'}, {'measure': 'Improvement in cognitive and neuropsychological functioning.', 'timeFrame': '1 month (defined as 4-6 weeks) and at 3 months (defined as 12-14 weeks), post randomization.'}, {'measure': 'Modification of the acute physiological processes in TBI by evaluating electroencephalographic (EEG) determinants in patients with moderate to severe TBI (defined as GCS 4-12), and biomarker levels.', 'timeFrame': 'Baseline through to 72 hours post-start of infusion.'}, {'measure': 'Blood pharmacokinetics (PK) of an intravenous (i.v) dose of NNZ-2566 when administered as a 10-minute infusion immediately followed by a 72-hour infusion.', 'timeFrame': 'Start of infusion through to 12 hours post infusion.'}]",5,18 Years,70 Years,MALE,False,Neuren Pharmaceuticals Limited,INDUSTRY,0,261.0,ACTUAL,2025-09-01T16:18:14.675964,v2_robust,True,True,True,False,True,
NCT04500418,Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Cenicriviroc (CVC),"['Cenicriviroc Mesylate', 'Cenicriviroc (CVC)', 'Placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Covid19,['Covid19'],"['COVID-19', 'Cenicriviroc', 'CVC', 'SARS-CoV-2']",TERMINATED,"Despite multiple efforts, no further patient could be enrolled since 03/05/2021. A continuation of the study is therefore no longer justified",2020-08-25,2021-07-27,"[{'measure': 'Subject´s Responder status (score on the 7-point ordinal scale on Day 15)', 'description': 'The Primary Endpoint will be the subject\'s responder status defined by achieving a score of ""1"" or ""2"" (discharged from hospital e.g.) on Day 15 on the following 7-point scale:\n\n1. Not hospitalized, no limitations on activities;\n2. Not hospitalized, limitation on activities;\n3. Hospitalized, not requiring supplemental oxygen;\n4. Hospitalized, requiring supplemental oxygen;\n5. Hospitalized, on non-invasive ventilation or high-flow oxygen devices;\n6. Hospitalized, on invasive mechanical ventilation or ECMO (Extracorporeal membrane oxygenation);\n7. Death.', 'timeFrame': '14 days after enrollment (Day 15)'}]","[{'measure': 'Evaluation of change in clinical condition based on the 7-point ordinal scale', 'description': '7-point ordinal scale to be assessed on Day 15 (and Day 1 for baseline comparison), analyses of\n\n* ordinal change of 2 or more, compared with baseline\n* ordinal change of 1 or more, compared with baseline', 'timeFrame': 'day of enrollment and 15 days after enrollment'}, {'measure': 'Evaluation of change in clinical condition based on the 7-point ordinal scale and Responder Status', 'description': '7-point ordinal scale assessed on: Days 8, 22, 29 (and Day 1 for baseline comparison), analyses of:\n\n* Responder status (achieving a score of a ""1"" or a ""2"")\n* ordinal change of 2 or more, compared with baseline\n* ordinal change of 1 or more, compared with baseline', 'timeFrame': 'day of enrollment, 8 days, 22 days and 29 days after enrollment'}, {'measure': 'Hospital resource utilization comparison', 'description': 'Analysis of:\n\n* Length of time spent in the ICU (days)\n* Length of time spent in the hospital (days)\n* Days alive and out of hospital through Day 29\n* Days free of endotracheal tube-based ventilation through Day 29', 'timeFrame': '29 days after enrollment, 85 days after enrollment'}]",4,18 Years,,ALL,False,"Charite University, Berlin, Germany",OTHER,1,45.0,ACTUAL,2025-09-01T16:18:14.675972,v2_robust,True,True,False,True,False,"Despite multiple efforts, no further patient could be enrolled since 03/05/2021. A continuation of the study is therefore no longer justified"
NCT04425018,MARGetuximab Or Trastuzumab (MARGOT),MARGetuximab Or Trastuzumab (MARGOT): A Phase II Study Comparing Neoadjuvant Paclitaxel/Margetuximab/Pertuzumab to Paclitaxel/Trastuzumab/Pertuzumab in Patients With Stage II-III HER2-positive Breast Cancer,Paclitaxel,"['Paclitaxel', 'Margetuximab', 'Margenza', 'Perjeta', 'Onxal', 'Herzuma', 'Taxol', 'Herceptin', 'Ogivri', 'Trastuzumab', 'Pertuzumab', 'Kanjinti']",12,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,"['Breast Cancer', 'Stage II Breast Cancer', 'Stage III Breast Cancer', 'HER2-positive Breast Cancer']","['Breast Cancer', 'Stage II Breast Cancer', 'Stage III Breast Cancer', 'HER2-positive Breast Cancer']",ACTIVE_NOT_RECRUITING,,2020-07-13,2027-07-01,"[{'measure': 'Rate of pathologic complete response (pCR)', 'description': 'Compare rate of pathologic complete response (pCR, defined as RCB 0) in patients with the FF or FV CD16A genotype and anatomic stage II-III HER2+ breast cancer treated with 4 cycles of neoadjuvant TMP or THP', 'timeFrame': '12 weeks'}]","[{'measure': 'Rate of pathologic complete response', 'description': 'Compare rate of pCR (RCB 0) in patients treated with TMP or THP, according to hormone receptor-positive (HR+) or hormone receptor-negative (HR-) status', 'timeFrame': '12 weeks'}, {'measure': 'Residual Cancer Burden (RCB) scores', 'description': 'Assess Residual Cancer Burden (RCB) scores1 in patients treated with TMP or THP, overall and according to HR+ or HR- status. reported using the Residual Cancer Burden calculator from M.D Anderson:', 'timeFrame': '12 weeks'}, {'measure': 'Number of Participants with Treatment Related Adverse Events according to CTCAE v5.0', 'description': 'Assessment of DLTs on Arm A during the first 21 days of treatment Maximum grade of all treatment-related adverse events according to CTCAE v5.0 Patient-reported outcomes', 'timeFrame': 'From first treatment to 12 weeks'}, {'measure': 'Event-free survival rate (EFS)', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Event-free survival rate (EFS) Patients with RCB 0 or 1', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Event-free survival rate (EFS)Patients with RCB 2 or 3', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Event-free survival rate (EFS) Patients randomized to neoadjuvant TMP', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Event-free survival rate (EFS) patients randomized to neoadjuvant THP', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Event-free survival rate (EFS) -Patients with pCR', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Event-free survival rate (EFS) -Patients without pCR', 'description': ""The distribution of the survival function and cumulative incidence function for EFS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'From enrollment to occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI)', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI) RCB 0 or 1', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI) RCB 2 or 3', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI) Patients randomized to neoadjuvant TMP', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI) Patients randomized to neoadjuvant THP', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI) Patients with pCR', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence ror death from breast cancer or up to 10 years'}, {'measure': 'Recurrence-free interval rate (RFI) Patients without pCR', 'description': ""The distribution of the survival function and cumulative incidence function for RFI summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'patients who undergo surgery for breast cancer as the interval from the time of surgery until the occurrence of invasive local/regional recurrence distant recurrence or death from breast cancer or up to 10 years'}, {'measure': 'Overall survival Rate (OS)', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}, {'measure': 'Overall survival Rate (OS) Patients with RCB 0 or 1', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}, {'measure': 'Overall survival Rate (OS) Patients with RCB 2 or 3', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}, {'measure': 'Overall survival Rate (OS) Patients randomized to neoadjuvant TMP', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}, {'measure': 'Overall survival Rate (OS) randomized to neoadjuvant THP', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}, {'measure': 'Overall survival Rate (OS) Patients with pCR', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}, {'measure': 'Overall survival Rate (OS) Patients without CR', 'description': ""The distribution of the survival function and cumulative incidence function for OS, summarized using the Kaplan Meier product limit estimator and 90% confidence interval (CI) using Greenwood's formula for the standard error"", 'timeFrame': 'up to 10 years from definitive surgery.'}]",25,18 Years,,ALL,False,Dana-Farber Cancer Institute,OTHER,2,174.0,ACTUAL,2025-09-01T16:18:14.676006,v2_robust,True,True,False,False,True,
NCT04885218,Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in Patients With Hypercholesterolemia,"A Multicentre, Randomized, Double-blind, Placebo-controlled, Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 Combined With Lipid-lowering Agents in the Stable Treatment of Patients With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia .",SHR-1209 ;placebo,['SHR-1209 ;placebo'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Non-familial Hypercholesterolemia,"['Non-familial Hypercholesterolemia', 'Mixed Hyperlipidemia']",[],COMPLETED,,2021-07-30,2023-05-23,"[{'measure': 'Percentage change in LDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment'}]","[{'measure': 'The value of change in LDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment'}, {'measure': 'Percentage change in LDL-C relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'The value of change in LDL-C relative to baseline ,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in non-HDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in non-HDL-C relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in ApoB relative to baseline', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in ApoB relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in TC/HDL-C relative to baseline', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in TC/HDL-C relative to baseline,', 'timeFrame': 'at 48 weeks of treatment'}, {'measure': 'Percentage change in ApoB/ApoA1 relative to baseline,', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in ApoB/ApoA1 relative to baseline,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in LP (a) relative to baseline,', 'timeFrame': 'at 24 weeks of treatment;'}, {'measure': 'Percentage change in LP (a) relative to baseline,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage change in TG relative to baseline', 'timeFrame': 'at 24 weeks of treatment'}, {'measure': 'Percentage change in TG relative to baseline', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage of patients who achieved LDL-C goal according to presence of ASCVD at baseline,', 'timeFrame': 'at 48 weeks of treatment;'}, {'measure': 'Percentage of patients who achieved LDL-C goal according to presence of ASCVD at baseline,', 'timeFrame': 'at 48 weeks of treatment.'}]",18,18 Years,80 Years,ALL,False,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,692.0,ACTUAL,2025-09-01T16:18:14.676030,v2_robust,True,True,True,False,False,
NCT01223690,Clarithromycin as Immunomodulator for the Management of Sepsis,A Double-blind Randomized Placebo-controlled Clinical Trial of the Safety and Efficacy of Intravenous Clarithromycin as Immunomodulatory Therapy for the Management of Sepsis,Clarithromycin,"['Klaricid IV', 'Dextrose solution', 'Clarithromycin', 'Dextrose 5%']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Sepsis,"['Sepsis', 'Severe Sepsis', 'Septic Shock']","['sepsis', 'infection', 'bacteremia', 'clarithromycin']",COMPLETED,,2007-07,2011-04,"[{'measure': 'Effect of clarithromycin in mortality and risk for death by severe sepsis/shock and multiple organ dysfunction compared with placebo', 'description': 'Survival analysis for 28 days will be done between placebo-treated patients and clarithromycin-treated patients separately for patients with sepsis; for patients with severe sepsis; and for patients with septic shock. Odds ratios for death by septic shock and/or multiple organ dysfunction will be assessed separately for each arm. Comparison of odds ratios will be done.', 'timeFrame': '28 days'}]","[{'measure': 'Effect of clarithromycin compared with placebo in time to resolution of infection', 'description': 'Time analysis between placebo-treated patients and clarithromycin-treated patients will be done', 'timeFrame': '28 days'}, {'measure': 'Effect of clarithromycin compared with placebo in time to resolution of sepsis', 'description': 'Time analysis between placebo-treated patients and clarithromycin-treated patients will be done', 'timeFrame': '28 days'}, {'measure': 'Effect of clarithromycin compared with placebo in time to progression to severe sepsis or septic shock and multiple organ failure', 'description': 'Time analysis between placebo-treated patients and clarithromycin-treated patients will be done', 'timeFrame': '28 days'}, {'measure': 'Influence of administration of clarithromycin compared with placebo on systemic inflammatory response', 'description': 'Comparative analysis of serum markers estimated at consecutive time intervals over the first 10 days of follow-up', 'timeFrame': '10 days'}]",5,18 Years,,ALL,False,University of Athens,OTHER,0,600.0,ACTUAL,2025-09-01T16:18:14.676144,v2_robust,True,True,True,False,False,
NCT04021290,Regimen Switch to Dolutegravir/Lamivudine Fixed Dose Combination From Current Antiretroviral Regimen in HIV-1 Infected and Virologically Suppressed Adults (SALSA),"A Phase III, Randomized, Multicenter, Open-label, Non-inferiority Study Evaluating the Efficacy, Safety and Tolerability of Switching to Dolutegravir/Lamivudine Fixed Dose Combination in HIV-1 Infected Adults Who Are Virologically Suppressed",DTG/3TC FDC,"['DTG/3TC FDC', 'CAR']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV Infections,['HIV Infections'],"['Current antiretroviral regimen (CAR)', 'HIV-1', 'Long-term antiviral activity', 'Dolutegravir/lamivudine', 'Fixed dose combination']",COMPLETED,,2019-11-11,2022-09-09,"[{'measure': 'Number of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) >=50 Copies/Milliliter (c/mL) as Per Food and Drug Administration (FDA) Snapshot Category at Week 48', 'description': 'Number of participants with plasma HIV 1 RNA \\>=50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the non-inferior antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant\'s virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \\>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot (""No virologic data"") is not pre-defined as an endpoint and therefore not reported separately.', 'timeFrame': 'Week 48'}]","[{'measure': 'Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 48', 'description': 'Number of participants with plasma HIV 1 RNA \\<50 c/mL were evaluated using FDA snapshot algorithm at Week 48 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 48 weeks. The FDA snapshot algorithm defines a participant\'s virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \\<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot (""No virologic data"") is not pre-defined as an endpoint and therefore not reported separately.', 'timeFrame': 'Week 48'}, {'measure': 'Number of Participants With Plasma HIV-1 RNA >=50 c/mL as Per FDA Snapshot Category at Week 24', 'description': 'Number of participants with plasma HIV 1 RNA \\>=50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant\'s virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \\>=50 c/mL were termed as subjects with virologic failure. The third category of the FDA snapshot (""No virologic data"") is not pre-defined as an endpoint and therefore not reported separately.', 'timeFrame': 'Week 24'}, {'measure': 'Number of Participants With Plasma HIV-1 RNA <50 c/mL Using the FDA Snapshot Algorithm at Week 24', 'description': 'Number of participants with plasma HIV 1 RNA \\<50 c/mL were evaluated using FDA snapshot algorithm at Week 24 to demonstrate the antiviral activity of switching to DTG/3TC FDC once daily compared to continuation of CAR over 24 weeks. The FDA snapshot algorithm defines a participant\'s virologic response status using only the viral load at the predefined time point within a window of time (HIV-RNA equal to or above 50 copies/mL and HIV-RNA below 50 copies/mL ), along with study drug discontinuation status. Participants with plasma HIV 1 RNA \\<50 c/mL were termed as subjects with virologic success. The third category of the FDA snapshot (""No virologic data"") is not pre-defined as an endpoint and therefore not reported separately.', 'timeFrame': 'Week 24'}, {'measure': 'Change From Baseline in Cluster of Differentiation 4 (CD4+) Cell Count for Week 24', 'description': 'CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in CD4+ Cell Count for Week 48', 'description': 'CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+ lymphocyte count was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.', 'timeFrame': 'Baseline (Day 1) and Week 48'}, {'measure': 'Change From Baseline in CD4+/ Cluster of Differentiation 8 (CD8+) Cell Counts Ratio for Week 24', 'description': 'CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 24 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in CD4+/CD8+ Cell Counts Ratio for Week 48', 'description': 'CD4+/CD8+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Baseline value is defined as the latest pre-dose assessment with a non-missing value (Day 1). Change from Baseline is defined as post-dose visit value minus Baseline value. Lymphocyte subsets were collected for assessment of this outcome measure by flow cytometry. Change from Baseline in CD4+/CD8+ lymphocyte cell count ratio was assessed at Week 48 to evaluate the immune effects of DTG/3TC FDC once daily compared to continuation of CAR. Plasma samples for lymphocyte subsets were collected.', 'timeFrame': 'Baseline (Day 1) and Week 48'}, {'measure': 'Number of Participants With Disease Progression Through Week 24', 'description': 'Participants with disease progression included incidences of HIV-associated conditions, Acquired Immuno Deficiency Syndrome (AIDS) and death. HIV-associated conditions were assessed according to the 2014 HIV infection by Centers for Disease Control and Prevention (CDC) classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.', 'timeFrame': 'Up to Week 24'}, {'measure': 'Number of Participants With Disease Progression Through Week 48', 'description': 'Participants with disease progression included incidences of HIV-associated conditions, AIDS and death. HIV-associated conditions were assessed according to the 2014 HIV infection by CDC classification system for HIV Infection in adults to evaluate the immune effects of DTG /3TC FDC once daily compared to continuation of CAR.', 'timeFrame': 'Up to Week 48'}, {'measure': 'Number of Participants With Adverse Events (AEs) and AEs Leading to Discontinuation', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With AEs by Severity Grades', 'description': 'An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks', 'description': 'Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\\[ALT/ALT ULN\\]/\\[ALP/ALP ULN\\]) \\>= 5 and ALT \\>=3xULN.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Number of Participants With Any AEs and AEs by Severity Grades for Those Participants With Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Number of participants with any AE were presented and AEs were graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Number of Participants With Any AEs Leading to Discontinuation Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2', 'description': 'An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.', 'timeFrame': 'Up to 52 weeks'}, {'measure': 'Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of 30-49 mL/Min/1.73m^2', 'description': 'Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\\[ALT/ALT ULN\\]/\\[ALP/ALP ULN\\]) \\>= 5 and ALT \\>=3xULN.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Number of Participants With Hepatobiliary Abnormalities Through 52 Weeks Based on Baseline Creatinine Clearance of >=50 mL/Min/1.73m^2', 'description': 'Blood samples were collected to evaluate hepatobiliary abnormalities. Number of participants with Bilirubin (BIL), Alkaline phosphatase (ALP), Alanine Aminotransferase (ALT)/combination of these with levels more than the defined hepatobiliary abnormality criteria were presented. Hepatocellular injury is defined as (\\[ALT/ALT ULN\\]/\\[ALP/ALP ULN\\]) \\>= 5 and ALT \\>=3xULN.', 'timeFrame': 'Up to Week 52'}, {'measure': 'Change From Baseline in Fasting Lipids at Week 24', 'description': 'Lipid parameters included total cholesterol, high density lipoprotein (HDL) cholesterol, low density lipoprotein (LDL) cholesterol and triglycerides.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Fasting Lipids at Week 48', 'description': 'Lipid parameters included total cholesterol, HDL cholesterol, LDL cholesterol and triglycerides.', 'timeFrame': 'Baseline (Day 1) and Week 48'}, {'measure': 'Number of Participants With Observed Genotypic and Phenotypic Resistance to Antiretrovirals (ARVs) for Participants Meeting Confirmed Virologic Withdrawal (CVW) Criteria', 'description': 'Genotypic and phenotypic testing was conducted for participants who met the CVW criteria, i.e., one assessment with HIV-1 RNA ≥200 c/mL after Day 1 with an immediately prior HIV-1 RNA ≥50 c/mL at any point in the study.', 'timeFrame': 'Up to week 48'}, {'measure': 'Change From Baseline in Health Status by HIV Treatment Satisfaction Questionnaire (TSQ) at Week 24', 'description': 'The HIV Treatment Satisfaction Questionnaire (HIVTSQ) is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Health Status by HIV TSQ at Week 48', 'description': 'The HIVTSQ is a 10-item self-reported scale that consists of a total score ranging from 0 to 60. Higher scores indicate a greater level of patient-reported satisfaction with their current therapy.', 'timeFrame': 'Baseline (Day 1) and Week 48'}, {'measure': 'Change From Baseline in Health Status by Symptom Distress Module (SDM) at Week 24', 'description': 'SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).', 'timeFrame': 'Baseline (Day 1) and Week 24'}, {'measure': 'Change From Baseline in Health Status by SDM at Week 48', 'description': 'SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).', 'timeFrame': 'Baseline (Day 1) and Week 48'}, {'measure': 'Change From Baseline in Health Status by SDM in Continuation Phase', 'description': 'SDM is a 20-item self-reported measure that addresses the presence and perceived distress linked to symptoms commonly associated with HIV or its treatment. Each item is rated from 0 to 4 where 0 (complete absence of symptom) and 4 (very bothersome symptom). Overall score calculated as the sum of the scores for each of the 20 items of the questionnaire and ranged from 0 (best health) and 80 (worst health).', 'timeFrame': 'Baseline (Day 1) and Week 76, Week 100, and Week 132'}]",27,18 Years,,ALL,False,ViiV Healthcare,INDUSTRY,2,493.0,ACTUAL,2025-09-01T16:18:14.676163,v2_robust,True,True,True,False,True,
NCT03137290,Comparing Reversal With Neostigmine and Sugammadex in Paediatric,Comparison Between the Efficacy of Neostigmine Versus Sugammadex Reversal of Rocuronium Induced Neuromuscular Blockade In Paediatric Patients.,Neostigmine,"['Neostigmine', 'Prostigmine', 'Bridion', 'Sugammadex Sodium']",4,INTERVENTIONAL,['NA'],,,Neuromuscular Blockade,['Neuromuscular Blockade'],"['Paediatric general anaesthesia', 'Rocuronium', 'Neostigmine', 'Sugammadex']",COMPLETED,,2014-12-01,2016-06-30,"[{'measure': 'Recovery time', 'description': 'To assess the recovery time from TOF count of 2 or 3 to TOF ratio of more than 0.9 between neostigmine or sugammadex in reversal of rocuronium induced neuromuscular blockade in paediatric patients.', 'timeFrame': 'From the time the reversal drugs (neostigmine or sugammadex) were given at TOF count of 2-3 till the TOF ratio is more than 0.9 up to 5 minutes after the operation finished'}]","[{'measure': 'Adequate ventilation', 'description': 'To evaluate the time from administration of reversal to adequate ventilation (tidal volume at least 6mls/kg and adequate respiratory rate for age)', 'timeFrame': 'From the time of the reversal drugs (neostigmine or sugammadex) were given till patient achieved good ventilation (tidal volume 6 ml/kg) up to 5 minutes after the operation finished'}, {'measure': 'Extubation time', 'description': 'To evaluate the time from administration of reversal to extubation', 'timeFrame': 'From the time of the reversal drugs (neostigmine or sugammadex) were given till the patient is extubated up to 5 minutes after the operation finished.'}, {'measure': 'Blood Pressure', 'description': 'Blood pressure was documented in 5 minute intervals upon administration of the reversal agent and in the the recovery bay.', 'timeFrame': 'From the time of the reversal drugs (neostigmine or sugammadex) were given till the patient is discharged throughout the time the patient stays at the recovery bay up to 30 minutes.'}, {'measure': 'Heart Rate', 'description': 'Heart rate was documented in 5 minute intervals upon administration of the reversal agent and in the the recovery bay.', 'timeFrame': 'From the time of the reversal drugs (neostigmine or sugammadex) were given till the patient is discharged throughout the time the patient stays at the recovery bay up to 30 minutes.'}, {'measure': 'Oxygen saturation', 'description': 'Oxygen saturation was documented in 5 minute intervals upon administration of the reversal agent and in the the recovery bay.', 'timeFrame': 'From the time of the reversal drugs (neostigmine or sugammadex) were given till the patient is discharged throughout the time the patient stays at the recovery bay up to 30 minutes.'}, {'measure': 'Number of patients with treatment related-adverse event as assessed by clinical observation', 'description': 'To monitor any incidence of treatment related-adverse event post extubation', 'timeFrame': 'From the time of the patient extubated until the patient is discharged throughout the time the patient stays at the recovery bay up to 30 minutes.'}]",7,2 Years,12 Years,ALL,False,Universiti Sains Malaysia,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:14.676238,v2_robust,True,True,True,False,True,
NCT06677190,Belzutifan in Recurrent Clear Cell Ovarian Carcinoma,A Phase II Trial of Belzutifan in Patients With Recurrent or Persistent Clear Cell Carcinoma of the Ovary,Belzutifan,"['NSC#825217', 'MK-6482', 'PT2977', 'C17H12F3NO4S', 'Belzutifan', '3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5-fluorobenzonitrile']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,"['Ovarian Cancer', 'Ovarian Carcinoma']","['Ovarian Cancer', 'Ovarian Carcinoma', 'Persistent Clear Cell Ovarian Carcinoma', 'Recurrent Clear Cell Ovarian Carcinoma']",RECRUITING,,2024-12-20,2029-06-30,"[{'measure': 'Objective Response Rate (ORR)', 'description': 'ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) on treatment based on RECIST 1.1 criteria. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete', 'timeFrame': 'ORR expected to be observed up to 3 years.'}, {'measure': 'Progression Free Survival at 6 months (PFS6)', 'description': 'Progression-Free Survival at 6 Months (PFS6) is defined as the proportion of participants who are alive without disease progression for at least 6 months after initiating study treatment.', 'timeFrame': 'Disease will be evaluated at baseline and every 2 cycles on treatment, where each cycle is 4 weeks. Relevant to this endpoint is the 6 month timepoint.'}]","[{'measure': 'Grade 4 Treatment-Related Toxicity Rate', 'description': 'The percentage of participants who experienced a maximum grade 4 treatment-related adverse event based on the Common Toxicity Criteria for Adverse events Version 5.0 (CTCAEv5) as reported on case report forms.', 'timeFrame': 'AEs expected to be observed up to 3 years.'}, {'measure': 'Median Progression Free Survival (PFS)', 'description': 'PFS based on Kaplan Meier method is defined as the duration of time from study entry to documented disease progression (PD) requiring removal from the study or death. Participants alive without PD were censored at the earliest of the date of the last disease evaluation or start of new anticancer therapy.', 'timeFrame': 'Disease is evaluated at baseline, every 2 cycles on treatment (each cycle is 4 weeks), and in follow-up every 3 months (if off not due to PD), up to 3 years.'}, {'measure': 'Median Overall Survival (OS)', 'description': 'Overall Survival (OS) is defined as the time from or registration to death due to any cause, or censored at date last known alive.', 'timeFrame': 'Survival is evaluated in follow-up every 6 months (off due to PD) or every 3 months (off not due to PD), up to 3 years.'}, {'measure': 'Clinical Benefit Rate (CBR)', 'description': 'ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) or stable disease (SD) and last more than 6 months on treatment based on RECIST 1.1 criteria.', 'timeFrame': 'Disease will be evaluated every 2 cycles on treatment (each cycle is 4 weeks); Treatment continues until disease progression or unacceptable toxicity. Treatment duration is expected to be up to 3 years.'}]",6,18 Years,,FEMALE,False,Dana-Farber Cancer Institute,OTHER,1,32.0,ESTIMATED,2025-09-01T16:18:14.676264,v2_robust,True,True,False,False,True,
NCT00119990,Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis,Changes in Cardiovascular Hemodynamics During Peritoneal Dialysis; the Effect of Different Dialysates,Icodextrin (dialysate),"['Icodextrin (dialysate)', 'Physioneal (dialysate) 1.36% and 2.27%']",2,INTERVENTIONAL,['NA'],,,Peritoneal Dialysis,['Peritoneal Dialysis'],"['vasopressin', 'icodextrin', 'cardiac output']",TERMINATED,,2006-01,2010-01,"[{'measure': 'Changes in cardiac hemodynamics. (Cardiac Output, stroke volume, pulse rate, blood pressure and total peripheral resistance)', 'timeFrame': '4 hours'}]",[],1,18 Years,85 Years,ALL,False,University of Aarhus,OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:14.676282,v2_robust,True,True,False,True,False,
NCT00199290,A Phase2 Clinical Trial of Trafermin in Patients With Marginal Periodontitis in Japan,"A Phase 2, Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and the Safety of Trafermin in Patients With Marginal Periodontitis in Japan",Trafermin (genetical recombination),['Trafermin (genetical recombination)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Periodontitis,['Periodontitis'],"['Trafermin', 'Periodontitis']",COMPLETED,,2005-08,2007-12,"[{'measure': 'rate of increase in alveolar bone height', 'timeFrame': '36 weeks after administration'}]","[{'measure': 'clinical attachment level regained', 'timeFrame': '36 weeks after administration'}, {'measure': 'time course of increase rate in alveolar bone height', 'timeFrame': 'within 36 weeks after administration'}, {'measure': 'time course of clinical attachment level regained', 'timeFrame': 'within 36 weeks after administration'}, {'measure': 'occurrence and level of adverse reaction', 'timeFrame': 'within 36 weeks after administration'}, {'measure': 'serum anti-Trafermin antibody level', 'timeFrame': 'within 4 weeks'}, {'measure': 'serum Trafermin level', 'timeFrame': 'within 24 hours'}]",7,20 Years,,ALL,False,Kaken Pharmaceutical,INDUSTRY,0,267.0,ACTUAL,2025-09-01T16:18:14.676289,v2_robust,True,True,True,False,True,
NCT00637390,A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.,A Phase I Study of Alemtuzumab in Patients With Relapsed Ovarian/Primary Peritoneal Cancer.,Alemtuzumab,['Alemtuzumab'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Ovarian Cancer,"['Ovarian Cancer', 'Fallopian Tube Cancer', 'Peritoneal Cancer']",[],TERMINATED,Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.,2008-03,2010-10,"[{'measure': 'safety & maximally tolerated dose', 'timeFrame': 'Maybe 2 years'}]","[{'measure': 'Effectiveness of Alemtuzumab to eliminate VLCs.', 'timeFrame': 'Maybe 2 years'}, {'measure': 'Assess molecular markers associated with reduction in VLCs.', 'timeFrame': 'Maybe 2 years'}, {'measure': 'Anti-tumor activity measured by decline or stabilization of CA125(a protein that is a tumor marker)or radiological(ie. CT, MRI, X-Ray)improvement or improvement in progression free survival.', 'timeFrame': 'Maybe 2 years'}, {'measure': ""Alemtuzumab effect on patients' response rates to chemotherapy given after the discontinuation of chemotherapy."", 'timeFrame': 'Maybe 2 years'}]",5,18 Years,,FEMALE,False,University of Michigan Rogel Cancer Center,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:14.676301,v2_robust,True,True,False,True,True,Genzyme will no longer supply the study drug for this trial as it does not believe the study will not fully enroll within an appropriate time frame.
NCT01023490,Vitamin D Treatment to Patients Suffering From Chronic Pain and Vitamin D Hypovitaminosis,"A Randomised, Double-blind, Placebo-controlled Study to Check Whether Vitamin D Will Lead to a Decrease in Pain Intensity in Patients Suffering From Chronic Pain and Hypovitaminosis D",Vitamin D,"['Vitamin D', 'Placebo']",2,INTERVENTIONAL,['NA'],,,Back Pain,"['Back Pain', 'Hypovitaminosis D']","['back pain', 'hypovitaminosis D']",COMPLETED,,2010-01,2012-10,"[{'measure': 'The objective of this study is to check whether vitamin D will lead to a decrease in pain intensity compare to placebo, in patients suffering from chronic pain.', 'timeFrame': 'one year'}]",[],1,18 Years,90 Years,ALL,False,Tel-Aviv Sourasky Medical Center,OTHER_GOV,0,12.0,ACTUAL,2025-09-01T16:18:14.676399,v2_robust,True,True,True,False,False,
NCT01855490,Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes,A Pilot Study to Determine the Effects of a Single Dose of Exenatide (Byetta ®) on the Acute Metabolic Responses to a Mixed Meal or Intravenous Glucose Tolerance Test in Patients With Type 1 Diabetes,Exenatide,['Exenatide'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 1 Diabetes,['Type 1 Diabetes'],[],COMPLETED,,2012-01,2013-10,"[{'measure': 'Effect of exenatide on metabolic responses to an oral (as a mixed meal) or intravenous glucose challenge in subjects with established T1D with or without residual insulin production.', 'description': 'We will measure the hormonal and metabolic changes during a mixed meal and intravenous glucose tolerance test with and without exenatide pretreatment in subjects with and without residual insulin production.', 'timeFrame': 'Each patients is estimated to finish the study within 4-6 weeks'}]","[{'measure': 'Effect of exenatide on insulin secretion, glucagon secretion, GLP-1 and GIP levels, and gastric emptying in these patients with T1D. - effect of exenatide on residual insulin production', 'description': 'In addition to measuring the levels of glucose and gastric emptying, we will measured glucagon levels, insulin secretion rates, GLP-1 and GIP hormonal levels during the provocative tests.', 'timeFrame': '4-6 weeks'}]",2,18 Years,56 Years,ALL,False,Yale University,OTHER,0,17.0,ACTUAL,2025-09-01T16:18:14.676407,v2_robust,True,True,True,False,False,
NCT01491490,Treatment on Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine,"A Randomised, Doubleblind,Placebo Controlled, Parallel Group, Pilot Study of 40:1 Ratio of Formulated GW42003 :GW42004 in the Treatment of Iatrogenic Weight Gain and Dyslipidaemia Associated With Olanzapine Treatment in Subjects With Functional Psychosis",GWP42003 : GWP42004 (40:1),"['GWP42003 : GWP42004 (40:1)', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'Functional psychosis', 'Schizophreniform', 'Acute psychosis']",TERMINATED,The Chief Investigator and the Sponsor have concluded that it will not be possible to complete the enrolment in any meaningful timeframe.,2011-10,2012-10,"[{'measure': 'Change in Bodyweight.', 'description': 'Efficacy of a 40:1 ratio of GWP42003:GWP42004 compared with placebo in the change from baseline in body weight after 42 days (6 weeks) in subjects currently being treated with olanzapine for schizophrenia or other non-affective psychosis.', 'timeFrame': '6 weeks from Baseline.'}]",[],1,18 Years,,ALL,False,GW Research Ltd,INDUSTRY,0,2.0,ACTUAL,2025-09-01T16:18:14.676428,v2_robust,True,True,False,True,False,The Chief Investigator and the Sponsor have concluded that it will not be possible to complete the enrolment in any meaningful timeframe.
NCT03769090,A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma,"A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in Symptomatic Adults and Children 4 Years of Age or Older With Asthma",Albuterol sulfate metered-dose inhaler 180 μg,['Albuterol sulfate metered-dose inhaler 180 μg'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Asthma,['Asthma'],[],COMPLETED,,2018-12-13,2022-02-07,"[{'measure': 'Number of Participants With a Severe Asthma Exacerbation Event', 'description': 'Time to first severe asthma exacerbation will be calculated as the time from randomization until the start date of the first severe asthma exacerbation. An asthma exacerbation will be considered severe if it results in at least one of the following: a temporary bolus/burst of systemic corticosteroids for at least 3 consecutive days to treat symptoms of asthma worsening (a single depo-injectable dose of corticosteroids will be considered equivalent), an emergency room or urgent care visit (\\<24 hours in the facility for evaluation and treatment) due to asthma that required systemic corticosteroids, or an in-patient hospitalization (admission to an in-patient facility and/or ≥ 24 hours in a healthcare facility) due to asthma. The descriptive summary shows the number of participants with a severe exacerbation event, occurring between the date of randomization up to the date of randomized treatment discontinuation or a change in maintenance therapy.', 'timeFrame': 'From randomization up to a discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.'}]","[{'measure': 'Annualized Severe Exacerbation Rate', 'description': 'The annualized severe exacerbation rate (severe exacerbations per year) is estimated from a negative binomial model with treatment, age group, region, and number of severe exacerbations in the last 12 months prior to randomization as categorical covariates. The logarithm of the time at risk is included as an offset variable.', 'timeFrame': 'From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.'}, {'measure': 'Total Annualized Dose of Systemic Corticosteroid (SCS)', 'description': 'This endpoint includes all systemic corticosteroids (SCS) taken in response to a severe exacerbation event from randomization up to randomized treatment discontinuation or a change in maintenance therapy. All SCS are standardized to equipotent doses of prednisone before deriving the total dose. The total annualized dose is calculated as the total dose of SCS divided by the duration of the randomized treatment period.', 'timeFrame': 'From randomization up to discontinuation of randomized treatment or a change in maintenance therapy. The mean and median reporting period for all participants was 44 and 48 weeks, respectively.'}, {'measure': 'Asthma Control Questionnaire-5 (ACQ-5) - Number of Participants Who Were Responders at Week 24', 'description': 'The ACQ-5 consists of 5 questions on symptom control, with each scored on a 7-point scale (0 = excellent asthma control; 6 = extremely poor control). The overall score (0 = excellent asthma control; 6 = extremely poor control, so a lower score is the better outcome) is the mean of the 5 symptom items. A responder is defined as a participant with a decrease from baseline to Week 24 overall ACQ-5 score of 0.5 or more. ACQ-5 is not validated for children less than 6 years old, data for participants who were 4 or 5 years old was excluded from the analysis of ACQ-5.', 'timeFrame': 'From baseline to Week 24'}, {'measure': 'Asthma Quality of Life Questionnaire for Participants Aged 12 Years and Older (AQLQ+12) - Number of Participants Who Were Responders at Week 24', 'description': 'The AQLQ+12 consists of 32 questions in 4 domains and is assessed on separate 7-point Likert scales from 1 to 7, with higher values indicating better health-related quality of life. The overall score is the mean of all responses. A responder is defined as a participant with an increase from baseline to week 24 AQLQ-12 score of at least 0.5.', 'timeFrame': 'From baseline to 24 weeks'}]",5,4 Years,,ALL,False,Bond Avillion 2 Development LP,INDUSTRY,0,3132.0,ACTUAL,2025-09-01T16:18:14.676436,v2_robust,True,True,True,False,False,
NCT00971997,A Study of Insulin Lispro Mix in Type 2 Diabetic Asian Patients,The Study of Stepwise Introduction of Insulin Analog Mixture as a Post-marketing Clinical Trial of Lispro Mix 50/50 to Evaluate Efficacy and Safety in Type 2 Diabetic Patients With Inadequate Glycemic Control on Oral Therapy. (SIMPLE Study),Lispro Mix 50/50,"['LY275585', 'Lispro Mix 50/50', 'Humalog Mix50']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,"Diabetes Mellitus, Type 2","['Diabetes Mellitus, Type 2']",[],COMPLETED,,2009-09,2011-04,"[{'measure': 'Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 48 Endpoint', 'description': 'Hemoglobin A1c (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The 6.5% HbA1c is the Japan Diabetes Society (JDS) value, and is equivalent to the National Glycohemoglobin Standardization Program (NGSP) HbA1c value of 6.9%.', 'timeFrame': 'Week 48'}]","[{'measure': 'Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 6.5% at Week 16 and Week 32 Endpoints', 'description': 'Hemoglobin A1c (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The 6.5% HbA1c is the Japan Diabetes Society (JDS) value, and is equivalent to the National Glycohemoglobin Standardization Program (NGSP) HbA1c value of 6.9%.', 'timeFrame': 'Week 16 and Week 32'}, {'measure': 'Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Below 7.0% at Week 16, 32 and 48 Endpoints', 'description': 'Hemoglobin A1c (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. The 7.0% HbA1c is the Japan Diabetes Society (JDS) value, and is equivalent to the National Glycohemoglobin Standardization Program (NGSP) HbA1c value of 7.4%.', 'timeFrame': 'Week 16 and Week 32 and Week 48'}, {'measure': 'Percentage of Participants Achieving Hemoglobin A1c (HbA1c) Level Below 6.5% and Below 7.0% by Regimen at Week 48 Endpoint', 'description': 'Hemoglobin A1c (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time. 6.5% and 7.0% HbA1c are the Japan Diabetes Society (JDS) values, and are equivalent to the National Glycohemoglobin Standardization Program (NGSP) HbA1c values of 6.9% and 7.4%, respectively.', 'timeFrame': 'Week 48'}, {'measure': 'Change From Baseline in Hemoglobin A1c (HbA1c) at Week 48 Endpoint', 'description': 'Hemoglobin A1c (HbA1c) is a form of hemoglobin which is measured primarily to identify the average plasma glucose concentration over prolonged periods of time.', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Change From Baseline in Fasting Glucose at Week 48 Endpoint', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Change From Baseline in Blood Glucose Profile at Week 48 Endpoint', 'description': 'Time course of changes in blood glucose was determined by 7-point self-monitoring of blood glucose (SMBG) during the day (before breakfast, lunch, and dinner, 2 hours after the start of each meal, and at bedtime).', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Change From Baseline in Fasting C-Peptide at Week 48 to Endpoint', 'description': 'C-peptide is a protein that is produced in the body along with insulin.', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Change From Baseline in Fasting Serum Lipids at Week 48 Endpoint', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Change From Baseline in Body Weight at Week 48 Endpoint', 'timeFrame': 'Baseline, Week 48'}, {'measure': 'Total Daily Dose of Insulin at Baseline, Week 16, Week 32 and Week 48', 'timeFrame': 'Baseline and Weeks 16, 32 and 48'}, {'measure': 'Percentage of Participants Developing Hypoglycemia at Any Time From Baseline Through Week 48', 'description': 'Results are reported as the percentage of participants experiencing hypoglycemia, which was considered any hypoglycemic event in which participants themselves recognized hypoglycemia-related signs and symptoms, or they had a blood glucose level below 50 milligram/deciliter (mg/dL) regardless of signs, symptoms or the relationship to treatment.', 'timeFrame': 'Baseline through Week 48'}, {'measure': 'Number of Hypoglycemia Episodes Participants Experienced at Any Time From Baseline Through Week 48', 'description': 'A hypoglycemic episode was considered any hypoglycemic event in which participants themselves recognized hypoglycemia-related signs and symptoms, or participants had a blood glucose level below 50 mg/dL regardless of signs, symptoms or the relationship to treatment.', 'timeFrame': 'Baseline through Week 48'}]",13,20 Years,80 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,135.0,ACTUAL,2025-09-01T16:18:14.676524,v2_robust,True,True,True,False,False,
NCT02227797,MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients,MT2013-37R: Voriconazole Therapeutic Drug Monitoring in Pediatric Hematopoietic Stem Cell Transplant Patients,Voriconazole,['Voriconazole'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Fungal Infection,['Fungal Infection'],"['stem cell transplant', 'hematopoietic stem cell transplant', 'fungal infection', 'voriconazole', 'pediatric']",COMPLETED,,2015-01-19,2019-03-01,"[{'measure': 'Maximum tolerated, minimum efficacious dose for 3 different pediatric age groups', 'timeFrame': 'Seven days after starting voriconazole'}]","[{'measure': 'Correlation of initial dose of voriconazole with voriconazole blood concentration in 3 different pediatric age groups', 'timeFrame': 'After starting voriconazole: Day 5, between Days 12-15, between Days 19-22'}, {'measure': 'Correlation of voriconazole dose with elevations to 5 times the upper limit of normal in liver enzymes', 'timeFrame': 'After starting voriconazole: Twice a week Days 1-30 and 1 week after the last dose of voriconazole ~ Day 35-42'}, {'measure': 'Incidence of fungal infection', 'timeFrame': '6-month period after transplant'}]",4,,21 Years,ALL,False,"Masonic Cancer Center, University of Minnesota",OTHER,0,66.0,ACTUAL,2025-09-01T16:18:14.676568,v2_robust,True,True,True,False,False,
NCT02602197,Intravenous Paracetamol Compared Dexketoprofen for Postoperative Analgesia After Septoplasty,The Efficacy of Intravenous Paracetamol Versus Dexketoprofen for Postoperative Pain Management After Septoplasty: A Prospective Randomized Double Blind Study,Paracetamol,"['Paracetamol', 'Parol', 'Dexketoprofen', 'Arveles']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Postoperative Pain,['Postoperative Pain'],"['Paracetamol', 'Dexketoprofen', 'postoperative pain', 'septoplasty']",UNKNOWN,,2013-08,2016-02,"[{'measure': 'Change from pain scores until postoperative 24 hours', 'description': 'Pain scores as measured by Visual Analog Scale (VAS) at 15 and 30 minutes, 1h, 2h, 4h, 6h, 12h, and 24 h after surgery', 'timeFrame': 'Pain scores recorded during postoperative 24 hours.'}]","[{'measure': 'Cumulative tramadol consumption during postoperative 24 hours.', 'description': 'Cumulative tramadol consumption was recorded during postoperative 24 hours.', 'timeFrame': 'First postoperative 24 hours'}]",2,18 Years,65 Years,ALL,True,Baskent University,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:14.676582,v2_robust,True,True,False,False,False,
NCT02455297,Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL),"A Single-arm, Open-label Phase IIa Study to Evaluate the Efficacy and Safety of Copanlisib Monotherapy in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL), Who Failed Ibrutinib Treatment or Were Unable to Tolerate Ibrutinib",Copanlisib (BAY80-6946),['Copanlisib (BAY80-6946)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,"Lymphoma, Mantle-Cell","['Lymphoma, Mantle-Cell']",[],TERMINATED,,2015-08-24,2016-08-31,"[{'measure': 'Objective response rate (ORR)', 'description': 'ORR is defined as the proportion of patients who have a best overall response of complete response (CR) or partial response (PR) during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014.', 'timeFrame': '24 weeks'}]","[{'measure': 'Complete response rate (CRR)', 'description': 'Defined as the proportion of patients who have a best overall response of CR during study conduct according to the criteria defined by the Lugano response criteria in NHL 2014', 'timeFrame': '24 weeks'}, {'measure': 'Disease control rate (DCR)', 'description': 'Defined as the proportion of patients who have a best response of CR, PR, or stable disease (SD)', 'timeFrame': '24 weeks'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Defined as the time (in days) from the date of first administration of study treatment to radiological disease progression or death from any cause (if death occurs before radiological progression is documented). PFS for patients without radiological progression or death at the time of analysis will be censored at the last date of evaluable tumor assessment. PFS for alive patients who have no tumor assessments after baseline will be censored at day 1.', 'timeFrame': '24 weeks'}, {'measure': 'Duration of response (DOR)', 'description': 'Defined as the time (in days) from the date of first observed tumor response of CR or PR, whichever was noted earlier, to radiological disease progression or death from any cause (if death occurs before radiological progression is documented)', 'timeFrame': '24 weeks'}, {'measure': 'Overall survival (OS)', 'description': 'Defined as the time (in days) from the date of first administration of study treatment to death from any cause. The OS time for patients alive at the time of analysis will be censored at their last known alive date.', 'timeFrame': '24 weeks'}, {'measure': 'Number of participants with treatment emergent adverse events (TEAEs) as a measure of safety and tolerability', 'timeFrame': 'Approximately 7 months'}]",7,18 Years,,ALL,False,Bayer,INDUSTRY,0,4.0,ACTUAL,2025-09-01T16:18:14.676592,v2_robust,True,True,False,True,True,
NCT00013897,"A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine",A Phase III Study Comparing the Antiviral Efficacy and Safety of BMS-232632 With Efavirenz; Each in Combination With Fixed Dose Zidovudine-Lamivudine,Atazanavir,"['Lamivudine/Zidovudine', 'Efavirenz', 'Atazanavir']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,HIV Infections,['HIV Infections'],"['Placebos', 'Drug Therapy, Combination', 'Zidovudine', 'HIV Protease Inhibitors', 'Lamivudine', 'RNA, Viral', 'Reverse Transcriptase Inhibitors', 'Anti-HIV Agents', 'Viral Load', 'BMS 232632', 'efavirenz']",COMPLETED,,2001-02,2003-04,[],[],0,16 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,,,2025-09-01T16:18:14.676620,v2_robust,True,True,True,False,False,
NCT05970497,A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors,"A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study of KB707 in Subjects With Locally Advanced or Metastatic Solid Tumor Malignancies",Opdualag,"['KEYTRUDA ®( Pembrolizumab)', 'Opdualag']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cancer,"['Cancer', 'Melanoma Stage III', 'Melanoma Stage IV', 'Cutaneous Melanoma']","['Krystal Biotech', 'cancer', 'melanoma']",RECRUITING,,2023-10-31,2027-07,"[{'measure': 'Percentage of adverse events (AEs)', 'description': 'Percentage of subjects with adverse events (AEs)', 'timeFrame': 'up to 36 months'}, {'measure': 'Percentage of serious adverse events (SAEs)', 'description': 'Percentage of subjects with serious adverse events (SAEs)', 'timeFrame': 'up to 36 months'}]","[{'measure': 'Maximum tolerated dose (MTD)', 'description': 'Assess whether the tested doses include the maximum tolerated dose (MTD) of KB707 based on the safety and response data collected during the dose escalation portion of the study', 'timeFrame': 'up to 36 months'}, {'measure': 'Percentage of overall response rate (ORR)', 'description': 'Percentage of ORR', 'timeFrame': 'up to 36 months'}]",4,18 Years,,ALL,False,"Krystal Biotech, Inc.",INDUSTRY,0,240.0,ESTIMATED,2025-09-01T16:18:14.676642,v2_robust,True,True,False,False,True,
NCT00895297,Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia,Phase II Efficacy and Safety Study of Dasatinib in Patients With Chronic and Accelerated Phase Chronic Myeloid Leukemia Relapsing After Allogeneic Blood or Bone Marrow Transplantation,Dasatinib (Sprycel),['Dasatinib (Sprycel)'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Myeloid Leukemia,['Chronic Myeloid Leukemia'],"['Relapsing after allogeneic transplantation', 'Dasatinib', 'Sprycel', 'Philadelphia Chromosomes']",TERMINATED,Slow recruitment. No safety concerns during this study.,2010-02,2011-11,"[{'measure': 'CMR as determined by two consecutive (-) RT-PCR tests for the presence of BCR-ABL transcripts in peripheral blood samples 1 year after starting Dasatinib therapy. The expected CMR of >30% would be regarded as being clinically relevant', 'timeFrame': '4 years'}]","[{'measure': 'Complete haematological response (CHR) at 3 months post commencing Dasatinib for those that have relapsed at the haematological level.', 'timeFrame': '4 years'}, {'measure': 'Complete cytogenetic response (CCyR) at 6 and 12 months post commencing Dasatinib for those that have relapsed at the cytogenetic level.', 'timeFrame': '4 years'}, {'measure': 'Major molecular response (MMR) at 12 months post commencing Dasatinib for all patients.', 'timeFrame': '4 years'}, {'measure': 'Proportion of patients requiring DLI during the first 12 months', 'timeFrame': '4 years'}, {'measure': 'Overall survival (OS) - Limited to 3 years.', 'timeFrame': '4 years'}, {'measure': 'Progression free survival (PFS).', 'timeFrame': '4 years'}, {'measure': 'Adverse event (AE) rate.', 'timeFrame': '4 years'}, {'measure': 'Rate of dose reductions, interruptions and discontinuations.', 'timeFrame': '4 years'}]",9,18 Years,,ALL,False,European Society for Blood and Marrow Transplantation,NETWORK,1,50.0,ESTIMATED,2025-09-01T16:18:14.676657,v2_robust,True,True,False,True,True,Slow recruitment. No safety concerns during this study.
NCT01515397,Comparison of Two Gelatine Solutions,Efficacy and Safety of a Balanced Gelatine Solution in Combination With a Balanced Electrolyte Solution Versus a Standard Gelatine Solution in Combination With a Non-balanced Electrolyte Solution in Patients Scheduled for Abdominal Surgery,Gelofusine balanced,"['Gelofusine 4%', 'Gelofusine balanced']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypovolemia,['Hypovolemia'],[],COMPLETED,,2011-12,2013-01,"[{'measure': 'base excess [mmol/l]', 'timeFrame': 'Change from baseline at end of surgery, an expected average of 2 hours surgery'}, {'measure': 'chloride [mmol/l]', 'timeFrame': 'Change from baseline at end of surgery, an expected average of 2 hours surgery'}]","[{'measure': 'arterial blood gase analyses', 'timeFrame': 'until 12 hours after surgery'}, {'measure': 'coagulation status', 'timeFrame': 'until 12 hours after surgery'}, {'measure': 'renal function', 'timeFrame': 'until 12 hours after surgery'}, {'measure': 'adverse events', 'timeFrame': 'until 12 hours after surgery'}, {'measure': 'hemodynamics (systolic and diastolic blood pressure)', 'timeFrame': 'until 12 hours after surgery'}, {'measure': 'time on ventilation', 'timeFrame': 'until 12 hours after surgery'}]",8,18 Years,90 Years,ALL,False,B. Braun Melsungen AG,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:14.676695,v2_robust,True,True,True,False,True,
NCT03534297,Study of Dapansutrile Capsules in Heart Failure,"A Phase 1b, Randomized, Double-Blinded, Dose Escalation, Single Center, Repeat-Dose Safety and Pharmacodynamics Study of Orally Administered Dapansutrile Capsules in Subjects With NYHA II-III Systolic Heart Failure",dapansutrile capsules,"['dapansutrile capsules', 'OLT1177 capsules', 'Placebo capsules']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Systolic Heart Failure,['Systolic Heart Failure'],"['heart failure', 'systolic heart failure']",COMPLETED,,2018-05-16,2019-11-21,"[{'measure': 'Adverse events', 'description': 'Adverse events experienced by the patient will be recorded.', 'timeFrame': 'Screening through Day 42 follow-up'}]","[{'measure': 'Cardiopulmonary exercise test', 'description': 'Physician-supervised maximal aerobic exercise test will be administered using a metabolic cart that is interfaced with a motorized treadmill. Change in peak oxygen consumption in each group will be assessed.', 'timeFrame': 'Day 14'}, {'measure': 'Transthoracic Doppler ECG - Left Ventricle Ejection Fraction', 'description': 'Changes in left ventricular ejection fraction will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Transthoracic Doppler ECG - Left Ventricular Filling Pressure', 'description': ""Changes in estimated left ventricular filling pressure, measured as ratio of early diastolic transmitral pulsed wave Doppler flow velocity (E) to tissue Doppler velocity of the mitral annulus (e') will be analyzed."", 'timeFrame': 'Day 14'}, {'measure': 'Bioimpedance analysis', 'description': 'Bioimpedance is a non-invasive, quick and safe technique that allows to estimate body composition compartments (total body water, intracellular water, extracellular water, fat mass, fat-free mass, lean mass). Change in total body water will be assessed.', 'timeFrame': 'Day 14'}, {'measure': 'Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score', 'description': ""Change in KCCQ score, a 23-item, self-administered instrument that independently measures a patient's perception of their health status, which includes heart failure symptoms. This scale is quantified in six domains: physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Each domain is scored on a 0-100 scale with 100 being better and 0 being worse. Two summary scores are calculated: the Clinical Summary Score (mean of symptom and physical function domain scores) and the Overall Summary Score (mean of the symptom, physical function, social limitations and quality of life scores)."", 'timeFrame': 'Day 14'}, {'measure': 'Kansas City Cardiomyopathy Questionnaire - Overall Summary Score', 'description': ""Change in KCCQ score, a 23-item, self-administered instrument that independently measures a patient's perception of their health status, which includes heart failure symptoms. This scale is quantified in six domains: physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Each domain is scored on a 0-100 scale with 100 being better and 0 being worse. Two summary scores are calculated: the Clinical Summary Score (mean of symptom and physical function domain scores) and the Overall Summary Score (mean of the symptom, physical function, social limitations and quality of life scores)."", 'timeFrame': 'Day 14'}, {'measure': 'Duke Activity Status Index', 'description': 'Change in Duke Activity Status Index, a self-administered questionnaire that measures a patient\'s functional capacity. The index consists of 12 ""yes or no"" questions, which are summed and used to calculate VO2peak and METS.', 'timeFrame': 'Day 14'}, {'measure': 'Vital signs - Pulse', 'description': 'Changes in pulse will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Vital signs - Blood Pressure', 'description': 'Changes in systolic and diastolic blood pressure will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Vital signs - Temperature', 'description': 'Changes in body temperature will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Vital signs - Respiratory Rate', 'description': 'Changes in respiratory rate will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Safety Laboratory Measurements - Chemistry', 'description': 'Changes in blood chemistry will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Safety Laboratory Measurements - Hematology', 'description': 'Changes in complete blood count will be analyzed.', 'timeFrame': 'Day 14'}, {'measure': 'Physical Examination', 'description': ""A full or targeted physical examination of the patient's major body systems"", 'timeFrame': 'Day 14'}, {'measure': '12-lead electrocardiogram', 'description': 'Electrodes will be placed on the patient to obtain a recording of the electrical activity of the heart.', 'timeFrame': 'Day 8'}]",16,18 Years,,ALL,False,Olatec Therapeutics LLC,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:14.676707,v2_robust,True,True,True,False,True,
NCT03475810,The Effect of Virtual Reality Glasses on Anxiety During Surgery Under Spinal Anesthesia,The Effect of Virtual Reality Glasses on Anxiety During Surgery Under Spinal Anesthesia: A Randomize Controlled Study,Midazolam,"['Demizolam', 'Midazolam']",2,INTERVENTIONAL,['NA'],,,VIRTUAL REALITY,['VIRTUAL REALITY'],"['VIRTUAL REALITY', 'ANXIETY', 'SPINAL ANESTHESIA']",COMPLETED,,2017-11-07,2018-07-01,"[{'measure': 'State Anxiety Test', 'description': 'State Anxiety test will be perform at postop care unit', 'timeFrame': 'postoperative 20th min.'}]","[{'measure': 'Total tolerance time of Virtual Reality glasses', 'description': 'Total tolerance to VR glasses will be recorded', 'timeFrame': 'intraoperative'}, {'measure': 'incidence of vomiting', 'description': 'incidence of vomiting due to VR glasses', 'timeFrame': 'intraoperative'}, {'measure': 'incidence of nausea', 'description': 'incidence of nausea due to VR glasses', 'timeFrame': 'intraoperative'}, {'measure': 'incidence of dizziness', 'description': 'incidence of dizziness due to VR glasses', 'timeFrame': 'intraoperative'}, {'measure': 'incidence of headache', 'description': 'incidence of headache due to VR glasses', 'timeFrame': 'intraoperative'}, {'measure': 'Postoperative Visual Analog Scale Score', 'description': 'Patient will be asked his anxiety level by Visual analog scale (VAS) from 0 to 10. 0(= no anxiety), 10(= highest level of anxiety)', 'timeFrame': 'postoperative 20 th min.'}, {'measure': 'change in mean arterial pressure', 'description': 'blood pressure of the patient will be measured noninvasively from proper extremity in the operating room', 'timeFrame': '5th min. intraoperative'}, {'measure': 'change in mean arterial pressure', 'description': 'blood pressure of the patient will be measured noninvasively from proper extremity in the operating room', 'timeFrame': '10th min. intraoperative'}, {'measure': 'change in mean arterial pressure', 'description': 'blood pressure of the patient will be measured noninvasively from proper extremity in the operating room', 'timeFrame': '15th min. intraoperative'}, {'measure': 'change in mean arterial pressure', 'description': 'blood pressure of the patient will be measured noninvasively from proper extremity in the operating room', 'timeFrame': '20th min. intraoperative'}, {'measure': 'change in heart rate', 'description': 'heart rate of the patient will be monitored and recorded', 'timeFrame': '5th min. intraoperative'}, {'measure': 'change in heart rate', 'description': 'heart rate of the patient will be monitored and recorded', 'timeFrame': '10th min. intraoperative'}, {'measure': 'change in heart rate', 'description': 'heart rate of the patient will be monitored and recorded', 'timeFrame': '15th min. intraoperative'}, {'measure': 'change in heart rate', 'description': 'heart rate of the patient will be monitored and recorded', 'timeFrame': '20th min. intraoperative'}, {'measure': 'change in respiratory rate', 'description': 'respiratory rate of the patient will be monitored and recorded', 'timeFrame': '5th min. intraoperative'}, {'measure': 'change in respiratory rate', 'description': 'respiratory rate of the patient will be monitored and recorded', 'timeFrame': '10th min. intraoperative'}, {'measure': 'change in respiratory rate', 'description': 'respiratory rate of the patient will be monitored and recorded', 'timeFrame': '15th min. intraoperative'}, {'measure': 'change in respiratory rate', 'description': 'respiratory rate of the patient will be monitored and recorded', 'timeFrame': '20th min. intraoperative'}]",19,18 Years,,ALL,False,Derince Training and Research Hospital,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:14.676852,v2_robust,True,True,True,False,False,
NCT04745910,Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome,Effect of Pegloticase on Reduction of Uric Acid in Patients With Tumor Lysis Syndrome: A Pilot Pragmatic Clinical Trial,Pegloticase,"['SR 29142', 'SR-29142', 'Krystexxa', 'Oxidase, Urate (Synthetic Sus scrofa variant pigks-DN subunit), homotetramer, amide with alpha-carboxy-omega-methoxypoly(oxy-1,2-ethanediyl)', 'Elitek', 'Des-(1-6)-(7-threonine,46-threonine,291-lysine,301-serine)uricase (EC 1.7.3.3, urate oxidase) Sus scrofa (pig) tetramer, Non Acetylated, Carbamates with alpha-carboxy-omega-methoxypoly(oxyethylene)', 'Rasburicase', 'Pegloticase', 'Methoxypolyethylene Glycol Uricase', 'Puricase', 'Urate Oxidase', 'Recombinant Urate Oxidase', 'Polyethylene Glycol-uricase']",13,INTERVENTIONAL,['PHASE4'],PHASE4,,Hematopoietic and Lymphoid Cell Neoplasm,"['Hematopoietic and Lymphoid Cell Neoplasm', 'Malignant Solid Neoplasm', 'Tumor Lysis Syndrome']",[],RECRUITING,,2022-04-05,2025-12-31,"[{'measure': 'Response rate', 'description': 'Will estimate the 24-hour response rate along with the corresponding 90% confidence interval. In addition, the report will present plots of uric acid levels across all time points.', 'timeFrame': 'Within 24 hours of single dose of pegloticase'}]","[{'measure': 'Time from pegloticase infusion until serum uric acid levels drop to 6 mg/dL', 'description': 'Will display results in frequency tables and plots of serum uric acid levels across time.', 'timeFrame': 'Up to 14 days after pegloticase administration'}, {'measure': 'Renal function', 'description': 'Will summarize serum creatinine and estimated glomerular filtration rate at each time point and plot these lab values across time. Finally, will calculate the rate and 90% confidence interval for the initiation of renal replacement therapy within the 14-day observation window.', 'timeFrame': 'Up to 14 days after pegloticase administration'}]",3,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:14.676904,v2_robust,True,True,False,False,False,
NCT00570310,Neuropathic Pain Syndrome Patient Study (MK-0000-072),"A Double-Blind, Placebo-Controlled, Enriched-Enrollment, Randomized Withdrawal Study to Evaluate an Optimal Methodology for Conducting Proof of Concept Trials in Patients With Chronic Neuropathic Pain Syndromes Using Pregabalin as a Test Drug",Comparator: pregabalin,"['Comparator: Placebo (unspecified)', 'Comparator: pregabalin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Neuralgia, Postherpetic","['Neuralgia, Postherpetic', 'Diabetic Neuropathy', 'Painful Small-Fiber Neuropathy', 'Idiopathic Distal Sensory Polyneuropathy']",[],COMPLETED,,2007-12,2008-09,"[{'measure': 'Daily Evening Patient Reported Pain Intensity Scores', 'description': 'Change from mean of last 3 days of maintenance period to last 3 days of double-blind period; Pain Intensity was rated on a 0-10 numeric rating scale (NRS: 0=no pain, 10=worst pain you can imagine)', 'timeFrame': 'Baseline and 6 Weeks'}]","[{'measure': ""'Time to Efficacy Failure' During the Randomized Withdrawal Portion of the Study"", 'description': 'Time to treatment failure (3 day mean of average 24 hour pain intensity ≥ 4 with at least a 30% increase relative to the last 3 days prior to randomization)', 'timeFrame': '6 Weeks'}]",2,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,104.0,ACTUAL,2025-09-01T16:18:14.676918,v2_robust,True,True,True,False,False,
NCT03289910,Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia,NCI 10147: A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML),Carboplatin,"['PARP-1 inhibitor ABT-888', 'Topotecan Hydrochloride', 'ABT-888', 'Topotecan HCl', 'Blastocarb', 'Carboplatinum', 'Potactasol', 'Paraplatin', 'Carboplatino', 'Paraplatine', 'Topotec', 'Ribocarbo', 'Ercar', 'Novoplatinum', 'Carbotec', 'Topotecan Lactone', 'Carboplat', 'SKF S-104864-A', 'Carboplatin', 'Hycamptamine', 'Hycamtin', 'Carbosol', 'topotecan hydrochloride (oral)', 'Carbosin', 'Nogitecan Hydrochloride', 'ABT888', 'Veliparib', 'Platinwas', 'JM8', 'Nealorin', 'Displata', 'CBDCA', 'SKF S104864A', 'JM-8', 'SKF S 104864 A', 'Paraplatin AQ', 'Carboplatin Hexal', 'Topotecan', 'ABT 888', 'Evotopin']",40,INTERVENTIONAL,['PHASE2'],PHASE2,,Acute Myeloid Leukemia,"['Acute Myeloid Leukemia', 'Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome', 'Atypical Chronic Myeloid Leukemia', 'Chronic Myelomonocytic Leukemia', 'Essential Thrombocythemia', 'Myelodysplastic/Myeloproliferative Neoplasm', 'Myelofibrosis', 'Polycythemia Vera', 'Recurrent Acute Myeloid Leukemia', 'Refractory Acute Myeloid Leukemia']",[],ACTIVE_NOT_RECRUITING,,2018-09-24,2025-12-19,"[{'measure': 'Number of Participants With a Response', 'description': 'Based on published standards for acute leukemias, Complete Response (CR) means less than 5% leukemic blasts in the bone marrow, no blasts in the blood, no longer presence of cytogenetic abnormalities, no longer presence of extramedullary disease, with or without absolute neutrophil count or platelet count recovery; Partial Remission (PR) includes the criteria for Complete Remission except there are 5-25% leukemic blasts in the bone marrow and there is absolute neutrophil count and platelet count recovery; Hematologic Improvement (HI) means the disease has not gotten worse and there is at least a 20% decrease in the leukemic blasts in the bone marrow and/or a decrease in leukemia symptoms. Response = CR, PR, or HI.', 'timeFrame': 'Up to 7 months'}]","[{'measure': 'The Highest Grade Adverse Event Experienced', 'description': 'Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0.', 'timeFrame': 'Up to 7 months'}, {'measure': 'Number of Participants Without Disease at Study Completion', 'description': 'Study completion was either death or completion of all protocol-specified activities, whichever came first. Participants who came off study due to disease-related death were counted as having disease.', 'timeFrame': 'Up to 7 months'}, {'measure': 'Duration of Disease-free Survival', 'description': 'Disease-free survival is defined as participants who are still alive and without disease at study completion. Study completion was either death or completion of all protocol-specified activities, whichever came first.', 'timeFrame': 'Up to 7 months'}, {'measure': 'Number of Participants Still Alive at Study Completion', 'description': 'Study completion was either death or completion of all protocol-specified activities, whichever came first.', 'timeFrame': 'Up to 7 months'}, {'measure': 'Duration of Overall Survival at the Time of Study Completion', 'description': ""Study completion was either death or completion of all protocol-specified activities, whichever came first. Duration was measured from the date of registration to the participant's study completion date."", 'timeFrame': 'Up to 7 months'}, {'measure': 'Number of Participants With Minimal Residual Disease (MRD) After Treatment', 'description': 'Minimal residual disease (MRD) refers to a small number of leukemic cells that remain after treatment.', 'timeFrame': 'Up to 7 months'}, {'measure': 'Distribution of Mutations in Deoxyribonucleic Acid (DNA) Repair Defects Via Assessment in Leukemia Mutation Panel', 'description': ""Will be summarized using descriptive statistics. The association response will be described with appropriate tests for continuously measured biomarkers (t tests, Wilcoxon rank sum tests) and categorical biomarkers (Fisher's exact test). Descriptive analyses will be performed for the whole cohort and also separately for Arms A and B. Differential treatment outcomes for patient subgroups may be explored using appropriate tests for interactions."", 'timeFrame': 'Baseline'}, {'measure': 'Frequency of Patients With Functional Impairment of DNA Damage Response Via Assessment With RAD51 Assay', 'description': ""Will be reported with exact binomial 95% confidence intervals. The association response will be described with appropriate tests for continuously measured biomarkers (t tests, Wilcoxon rank sum tests) and categorical biomarkers (Fisher's exact test). Descriptive analyses will be performed for the whole cohort and also separately for Arms A and B. Differential treatment outcomes for patient subgroups may be explored using appropriate tests for interactions."", 'timeFrame': 'Baseline'}, {'measure': 'Topotecan-induced Stabilization of Topoisomerase I-DNA Covalent Complexes', 'description': 'Topotecan-induced stabilization of topoisomerase I-DNA covalent complexes from peripheral blood', 'timeFrame': 'Up to 7 months'}, {'measure': 'Pharmacokinetic Sampling Studies Measured Using a Validated Liquid Chromatography/Tandem Mass Spectrometric Method in Plasma and Bone Marrow', 'description': 'Plasma trough levels will be obtained weekly through the first cycle to provide a steady-state assessment. Steady-state plasma concentrations will be calculated for each patient. Exploratory correlative studies between veliparib exposure (plasma and bone marrow) with pharmacodynamic (biological endpoints, toxicity and efficacy) will be analyzed using nonparametric statistics. Significance for comparisons will be at the p \\< 0.05 level.', 'timeFrame': 'Pre-treatment, day 1, day 8, day 14, day 15, and day 22 (approximately 24 hours post last dose)'}]",11,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,25.0,ACTUAL,2025-09-01T16:18:14.676941,v2_robust,True,True,False,False,True,
NCT05451810,A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma,"A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) When Administered in the Outpatient Setting",Epcoritamab,"['ABBV-GMAB-3013', 'Epcoritamab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Diffuse Large B-Cell Lymphoma,"['Diffuse Large B-Cell Lymphoma', 'Classic Follicular Lymphoma']","['Relapsed or Refractory Diffuse Large B-Cell Lymphoma', 'Relapsed or Refractory Classic Follicular Lymphoma', 'Non-Hodgkins Lymphoma', 'Cancer', 'Epcoritamab', 'ABBV-GMAB-3013', 'EPCORE']",ACTIVE_NOT_RECRUITING,,2022-08-17,2027-03,"[{'measure': 'Percentage of Participants Experiencing Grade 3 or Higher Cytokine Release Syndrome (CRS) Events', 'description': 'Cytokine Release Syndrome events will be graded using American Society for Transplantation and Cellular Therapy (ASTCT), with a higher grade indicating higher severity.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Percentage of Participants Experiencing Grade 3 or Higher Immune Cell-Associated Neurotoxicity Syndrome (ICANS) Events', 'description': 'ICANS events will be graded using ASTCT, with a higher grade indicating higher severity.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Percentage of Participants Experiencing Grade 3 or Higher Neurotoxicity (Ntox) Events', 'description': 'Ntox is defined as the percentage of participants who developed at least 1 Grade 3 or higher Ntox since the initiation of epcoritamab treatment.', 'timeFrame': 'Up to 3 Months'}]","[{'measure': 'Best Overall Response (BOR) Determined by Lugano 2014 Criteria Per Investigator Assessment', 'description': 'BOR is defined as the percentage of participants who achieved best overall response of complete response (CR) or partial response (PR) determined by Lugano 2014 criteria as assessed by investigators.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'CR Determined by Lugano 2014 Criteria Per Investigator Assessment', 'description': 'Complete response is defined as the percentage of participants who achieved best overall response of CR determined by Lugano 2014 criteria as assessed by investigator.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Incidence of Treatment-Emergent Adverse Events (TEAEs) by Severity Level', 'description': 'Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Severity of TEAEs by Severity Level', 'description': 'Treatment-emergent events (TEAEs) are defined as any event that began or worsened in severity after the first dose of study drug.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Incidence of Serious Adverse Events (SAEs) by Severity Level', 'description': 'A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Severity of SAEs by Severity Level', 'description': 'A serious adverse event (SAE) is an event that results in death, is life-threatening, requires or prolongs hospitalization, results in a congenital anomaly, persistent or significant disability/incapacity or is an important medical event that, based on medical judgment, may jeopardize the participant and may require medical or surgical intervention to prevent any of the outcomes listed above.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Median Time to Onset of CRS of Grade 3 or Higher', 'description': 'Median time to onset of CRS of Grade 3 or higher.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Median Time to Resolution of CRS of Grade 3 or Higher', 'description': 'Median time to resolution of CRS of Grade 3 or higher.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Median Time to Onset of ICANS of Grade 3 or Higher', 'description': 'Median time to onset of ICANS of Grade 3 or higher.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Median Time to Resolution of ICANS of Grade 3 or Higher', 'description': 'Median time to resolution of ICANS of Grade 3 or higher.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Median Time to Onset of Ntox of Grade 3 or Higher', 'description': 'Median time to onset of Ntox of Grade 3 or higher.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Median Time to Resolution of Ntox of Grade 3 or Higher', 'description': 'Median time to resolution of Ntox of Grade 3 or higher.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Percentage of Participants Experiencing Any Adverse Events (AE)s', 'description': 'An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of CRS After the First Full Dose of Epcoritamab', 'description': 'Percentage of participants receiving various interventions for the management of CRS after the first full dose of epcoritamab.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of ICANS After the First Full Dose of Epcoritamab', 'description': 'Percentage of participants receiving various interventions for the management of ICANS after the first full dose of epcoritamab.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Percentage of Participants Receiving Various Interventions for the Management of Ntox After the First Full Dose of Epcoritamab', 'description': 'Percentage of participants receiving various interventions for the management of Ntox after the first full dose of epcoritamab.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Duration of response (DOR)', 'description': ""Duration of response is defined for participants who achieved BOR of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause."", 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Progression-free survival (PFS)', 'description': 'Progression-free survival is defined as the time in months from the first dose of study drug to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Overall survival (OS)', 'description': 'Overall survival is defined for as the time in months from first dose of epcoritamab to death from any cause.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Time-to-response (TTR)', 'description': ""Time to response is defined for participants who achieved BOR of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by investigator, as the time in months from first dose of study drug to initial CR/PR."", 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Duration of CR (DOCR)', 'description': 'The duration of complete response is defined for participants who achieved BOR of CR (Complete Responders), as the duration from the first CR response to the earliest date of disease progression determined per Lugano 2014 criteria, as assessed by the investigator, or death, whichever occurs first.', 'timeFrame': 'Up to 3 Months'}, {'measure': 'Diversity Enriched Cohort: Time to Next Treatment', 'description': 'Time to next treatment is defined as the time from the date of the first dose of study drug to the start of new non-protocol-specified treatment or death from any cause.', 'timeFrame': 'Up to 3 Months'}]",25,18 Years,,ALL,False,Genmab,INDUSTRY,1,184.0,ESTIMATED,2025-09-01T16:18:14.677008,v2_robust,True,True,False,False,True,
NCT04768010,Misoprostol for Bloating and Distension,Misoprostol for the Management of Bloating and Gaseous Distension in Patients With Cirrhosis: an Open Label Trial,Misoprostol,"['Misoprostol', 'Cytotec (brand name)']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Distension,"['Distension', 'Gas Bloat Syndrome', 'Constipation']",[],WITHDRAWN,After significant delays study was never initiated. No participants enrolled,2023-08,2023-09-18,"[{'measure': 'Change in Patient Assessment of Gastrointestinal Symptoms (PAGI-SYM) Questionnaire Score', 'description': 'The PAGI-SYM is a validated 20 item self-report questionnaire divided in to six domains: heartburn/regurgitation, fullness/early satiety, nausea/vomiting, bloating, upper abdominal pain, and lower abdominal pain. Scores for each question range from 0 (none absent) to 5 (very severe). This questionnaire obtains subscale scores derived from the average scores across these six domains. The original questionnaires asks ""How severe have each of these following symptoms been in the past two weeks?"" For the purpose of this study, we have obtained manufacturer approval to modify the questionnaire to ask about symptoms severity in the past day.', 'timeFrame': 'Baseline, Day 2, and Day 3'}, {'measure': 'Change in Patient Assessment of Constipation Symptoms (PAC-SYM) Questionnaire Score', 'description': 'The PAC-SYM is a validated 12 item self-report questionnaire divided into abdominal, rectal, and stool domains. The questionnaire has 4 items for abdominal symptoms, 3 items for rectal symptoms, and 5 items for stool symptoms. Scores range from 0 (none or absent) to 4 (very severe). The total score is the mean of the individual item scores.The original questionnaires asks ""How severe have each of these following symptoms been in the past two weeks?"" For the purpose of this study, we have obtained manufacturer approval to modify the questionnaire to ask about symptoms severity in the past day.', 'timeFrame': 'Baseline, Day 1, Day 2, and Day 3'}]","[{'measure': 'Change in intestinal gas volume from baseline to post-intervention', 'description': 'Measured by low dose abdominal CT', 'timeFrame': 'Baseline and Day 3'}, {'measure': 'Change in stool burden from baseline to post-intervention', 'description': 'Scored using abdominal X-ray', 'timeFrame': 'Baseline and Day 3'}, {'measure': 'Change in Abdominal Girth', 'description': 'Abdominal girth will be measured in centimeters using a tape measure.', 'timeFrame': 'Baseline, Day 1, Day 2, and Day 3'}, {'measure': 'Change in Psychometric Hepatic Encephalopathy Score (PHES)', 'description': ""The PHES is a series of five neuropsychological tests used in the diagnosis of minimal hepatic encephalopathy. The tests used in this score include the digit-symbol test, number connection tests A and B, the serial dotting test, and the line-drawing test. The final score for the PHES is derived from the sum of the scores of these individual tests. To determine individual test scores, the difference between the predicted and observed results for each test are divided by the corresponding standard deviation (SD) for the reference population to obtain the deviation from 'normal' as a multiple of the SD. Final scores range from -15 to +5. Lower scores are found in patients with encephalopathy, with a score \\<-4 SD being considered to represent the presence of minimal hepatic encephalopathy."", 'timeFrame': 'Baseline, Day 2, and Day 3'}, {'measure': 'Change in Abdominal Pain', 'description': 'The severity of abdominal pain will de determined from the individual Likert score derived from the Patient Assessment of Gastrointestinal Symptoms (PAGI-SYM). The Likert scale ranges from Scores for each question range from 0 (none absent) to 5 (very severe).', 'timeFrame': 'Baseline, Day 2, and Day 3'}]",7,18 Years,,ALL,False,Montefiore Medical Center,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:14.677044,v2_robust,True,True,False,True,False,After significant delays study was never initiated. No participants enrolled
NCT03250910,Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients,Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus,Sofosbuvir and Velpatasvir,"['Sofosbuvir and Velpatasvir', 'Ribavirin', 'Sofosvel', 'Robatrol']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,"Hepatitis C Virus Infection, Response to Therapy of","['Hepatitis C Virus Infection, Response to Therapy of', 'Human Immunodeficiency Virus']","['hepatitis C virus', 'human immunodeficiency virus', 'Direct acting antiviral agent']",COMPLETED,,2016-08-01,2017-10-31,"[{'measure': 'Sustained virologic response', 'description': 'HCV RNA \\< LLOQ 12 weeks off therapy', 'timeFrame': '24 weeks'}]",[],1,20 Years,,ALL,False,National Taiwan University Hospital,OTHER,0,228.0,ACTUAL,2025-09-01T16:18:14.677128,v2_robust,True,True,True,False,False,
NCT00010413,Phase II Study of High-Dose Cyclophosphamide in Patients With Refractory Pemphigus,,cyclophosphamide,"['filgrastim', 'cyclophosphamide']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pemphigus,['Pemphigus'],"['immunologic disorders and infectious disorders', 'pemphigus', 'rare disease']",COMPLETED,,1999-04,,[],[],0,18 Years,70 Years,ALL,False,Johns Hopkins University,OTHER,0,35.0,,2025-09-01T16:18:14.677304,v2_robust,True,True,True,False,False,
NCT04544813,A Study of JNJ-77474462 in Healthy Participants,A Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of JNJ-77474462 in Healthy Participants,JNJ-77474462,"['Bermekimab', 'JNJ-77474462', 'Anakinra']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2020-10-13,2021-05-30,"[{'measure': 'Maximum Observed Plasma Concentration (Cmax) of JNJ-77474462', 'description': 'Cmax is the maximum observed plasma concentration.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve from Time Zero to Infinity with Extrapolation of the Terminal Phase (AUC[0-infinity]) of JNJ-77474462', 'description': 'AUC(0-infinity) is defined as area under the plasma concentration versus time curve from time zero to infinity with extrapolation of the terminal phase of JNJ-77474462.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Area Under the Plasma Concentration Versus Time Curve from Time Zero to the Time Corresponding to the Last Quantifiable Concentration (AUC[0-last]) of JNJ-77474462', 'description': 'AUC(0-last) is defined as area under the plasma concentration versus time curve from time zero to the time corresponding to the last quantifiable concentration of JNJ-77474462.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Terminal Half-Life (T1/2) of JNJ-77474462', 'description': 'T1/2 is defined as the time measured for the plasma concentration to decrease by 1 half of its original concentration.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Absolute Subcutaneous (SC) Bioavailability (F%)', 'description': '(F%) is defined as absolute SC bioavailability to be calculated using the following equation: AUC(0-infinity) SC/mean AUC(0-infinity) IV \\* 100 percent (%).', 'timeFrame': 'Up to Week 12'}]","[{'measure': 'Percentage of Participants with Treatment-emergent Adverse Events (TEAE)', 'description': 'An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as adverse events (AEs) with onset or worsening on or after date of first dose of study treatment.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Percentage of Participants with Serious Adverse Events (SAE)', 'description': 'A SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Number of Participants with Clinically Significant Changes in Vital Signs', 'description': 'Number of participants with clinically significant changes in vital signs (including body temperature, resting \\[supine\\] pulse/heart rate, respiratory rate and blood pressure) will be reported.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Number of Participants with Clinically Significant Changes in Electrocardiogram (ECG)', 'description': 'Number of participants with clinically significant changes ECG will be reported.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Number of Participants with Clinically Significant Changes in Laboratory Findings', 'description': 'Number of participants with clinically significant changes in laboratory findings (that is, hematology, clinical chemistry, urinalysis) will be reported.', 'timeFrame': 'Up to Week 12'}, {'measure': 'Number of Participants with Anti-JNJ-77474462 Antibodies', 'description': 'Number of participants with anti-drug antibodies to JNJ-77474462 will be reported.', 'timeFrame': 'Up to Week 12'}]",11,18 Years,60 Years,ALL,True,"Janssen Research & Development, LLC",INDUSTRY,0,78.0,ACTUAL,2025-09-01T16:18:14.677569,v2_robust,True,True,True,False,True,
NCT00485160,Ibuprofen vs. Continuous Indomethacin in the Treatment of PDA,Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus,Continuous indomethacin,"['Continuous indomethacin', 'ibuprofen']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Patent Ductus Arteriosus,['Patent Ductus Arteriosus'],"['Patent Ductus Arteriosus', 'Indomethacin', 'Ibuprofen', 'Renal effects']",COMPLETED,,2002-02,2006-09,"[{'measure': 'To show no differences in urine output and/or in serum creatinine between the treatment groups', 'timeFrame': 'Up to one day after completion of therapy'}]","[{'measure': 'To show no other clinical differences, eg. NEC, IVH or ROP between the groups; to study doppler flow velocities to these areas; to correlate with BNP levels.', 'timeFrame': 'Until end of primary hospitalization'}]",2,36 Hours,3 Weeks,ALL,False,Shaare Zedek Medical Center,OTHER,0,70.0,ESTIMATED,2025-09-01T16:18:14.677591,v2_robust,True,True,True,False,False,
NCT03584360,Role of Topical Treatments in the Modulation of Skin Microbiome in Psoriatic Skin,"Study Role of the Local Treatments on the Microbiome Modulation in the Psoriatic Skin. Study Monocentric, Interventional, Randomized and Single-blind",Betamethasone-Calcipotriene Topical,['Betamethasone-Calcipotriene Topical'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Psoriasis Vulgaris,['Psoriasis Vulgaris'],[],COMPLETED,,2018-09-24,2019-03-07,"[{'measure': 'Quantitative evaluation of bacterial microbiota on psoriasis lesions and surrounding healthy skin by 16S rRNA (ribosomal ribonucleic acid 16S) amplification coupled with high throughput sequencing', 'timeFrame': 'after 4 weeks of treatment'}, {'measure': 'Qualitative evaluation of bacterial microbiota on psoriasis lesions and surrounding healthy skin by 16S rRNA (ribosomal ribonucleic acid 16S) amplification coupled with high throughput sequencing', 'timeFrame': 'after 4 weeks of treatment'}]","[{'measure': 'Targetted Psoriasis Area and Severity Index for the effectiveness of the products tested.', 'description': 'Evaluated by PASI score (PASI= Psoriasis Area Severity Index) minimum = 0 = Absence of psoriasis maximum = 4 = very severe psoriasis', 'timeFrame': 'after 4 weeks of treatment'}, {'measure': 'Number of ILCs and NKs on skin biopsies using immunohistochemistry', 'timeFrame': 'after 4 weeks of treatment'}, {'measure': 'Types of ILCs and NKs on skin biopsies using immunohistochemistry', 'timeFrame': 'after 4 weeks of treatment'}, {'measure': ""Score of overall evaluation of the investigator's treatment"", 'description': 'Evaluated by physician global assessment (PGA) score PGA = physician global assessment minimum = 0 = healing maximum = 5 = very severe psoriasis', 'timeFrame': 'after 4 weeks of treatment'}, {'measure': 'Evaluation of tolerance', 'description': 'evaluated numbers of serious adverse events', 'timeFrame': 'after 4 weeks of treatment'}, {'measure': 'Occurrence of possible adverse effects', 'timeFrame': 'after 4 weeks of treatment'}]",8,18 Years,,ALL,False,Centre Hospitalier Universitaire de Nice,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:14.677612,v2_robust,True,True,True,False,True,
NCT02162160,Microbiological Impact of an Intimate Cream and Its Suitability to Contribute to the Feeling of Softness and Freshness in the Intimate Area of Women,Microbiological Impact of a Cream and the Feeling of Softness and Freshness in the Intimate Area of Women,Placebo,['Placebo'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Post Menopausal Dryness in the Intimate Area of Women,['Post Menopausal Dryness in the Intimate Area of Women'],"['probiotic', 'post-menopausal', 'atrophic vaginitis']",COMPLETED,,2013-09,2014-03,"[{'measure': 'Presence of at least one LN bacteria strain in the intimate area of women in the intervention group', 'description': 'Bacterial Culture of LN bacterial strains', 'timeFrame': 'the end of a 10 days crème-usage'}]","[{'measure': 'Obtain information about the coliform bacteria flora in respect to E. coli flora in the external intimate area', 'description': 'Measured by bacterial Culture and subtyping by PCR', 'timeFrame': 'at the end of creme usage and 10 days after finished crème-usage (9-11 days after).'}, {'measure': 'subjective feeling of dryness and freshness in the intimate of women', 'description': 'Assessed through self adminstered questionnair with grading of feeling of dryness and freshness on a scale from 0 (no dryness and feeling fresh) to 5 (max dryness and absolutely not feeling fresh)', 'timeFrame': 'the end of the 10 days crème-usage (Day 8-10) and 10 days after finished crème-usage (9-11 days after)'}]",3,45 Years,65 Years,FEMALE,False,Karolinska Institutet,OTHER,0,18.0,ACTUAL,2025-09-01T16:18:14.677677,v2_robust,True,True,True,False,False,
NCT02245360,Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis,"A Randomized, Double-blind, Placebo-controlled Study Investigating the Immunologic Effects and Safety of 60-day Treatment of the SQ Grass SLIT-tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis",Phleum pratense grass pollen allergen extract,"['GRAZAX/GRASTEK', 'Phleum pratense grass pollen allergen extract', 'placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],['GRAZAX'],COMPLETED,,2014-10,2015-03,"[{'measure': 'The Primary Efficacy Endpoint is Change From Baseline to End of Treatment of Phleum Pratense Specific Immunoglobulin G4 (IgG4) in Serum', 'description': 'measurement of IgG4 in serum', 'timeFrame': 'baseline versus end of treatment (approx. 60 days)'}]","[{'measure': 'Change of Phleum Pratense Specific Immunoglobulin E (IgE) From Baseline to End of Treatment', 'description': 'measurement of IgE in serum', 'timeFrame': 'baseline versus end of treatment (approx. 60 days)'}]",2,18 Years,65 Years,ALL,False,Abbott,INDUSTRY,0,107.0,ACTUAL,2025-09-01T16:18:14.677759,v2_robust,True,True,True,False,False,
NCT06146660,A Study to Assess the Safety of Mavacamten in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy,CAMZYOS® (Mavacamten) Post-Marketing Surveillance in Korean Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM),Mavacamten,['Mavacamten'],1,OBSERVATIONAL,[],,,Obstructive Hypertrophic Cardiomyopathy,['Obstructive Hypertrophic Cardiomyopathy'],[],RECRUITING,,2024-07-24,2026-11-30,"[{'measure': 'Number of participants with adverse events', 'timeFrame': 'Up to 12 months'}]",[],1,19 Years,,ALL,False,Bristol-Myers Squibb,INDUSTRY,0,600.0,ESTIMATED,2025-09-01T16:18:14.677783,v2_robust,False,True,False,False,True,
NCT05022160,Preventing Catheter Related Bladder Discomfort (CRBD) With Bilateral Pudendal Nerve Block,Preventing Catheter Related Bladder Discomfort (CRBD) in Male Patients Undergoing Lower Urinary Tract Surgery With Bilateral Pudendal Nerve Block: a Randomized Control Trial,pudendal nerve block,['pudendal nerve block'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Bladder Neoplasm,"['Bladder Neoplasm', 'Prostatic Neoplasms']","['Bupivacaine', 'pudendal nerve block', 'CRBD']",UNKNOWN,,2021-08-10,2021-11-10,"[{'measure': 'Catheter related bladder discomfort', 'description': 'Frequency of catheter related bladder discomfort at 3,8,12 and 24 hours after surgery', 'timeFrame': '24 hours post surgery'}]","[{'measure': 'average intensity of Catheter related bladder discomfort', 'description': 'average intensity of CRBD using numeric rating scale for pain at 3,8,12 and 24 hours after surgery', 'timeFrame': '24 hours post surgery'}]",2,18 Years,60 Years,MALE,True,"Armed Forces Hospital, Pakistan",OTHER,0,250.0,ESTIMATED,2025-09-01T16:18:14.677928,v2_robust,True,True,False,False,False,
NCT01526460,Evaluation of Platelet Function After Statin Loading Dose in Patients Before Percutaneous Coronary Intervention,"Prospective, Randomized, Single Center, Open Label Study Designed to Evaluate the Effect on Platelet Reactivity in Response to High Doses of Atorvastatin or Rosuvastatin Administered Before Percutaneous Coronary Intervention (PCI)",Atorvastatin,"['TORVAST', 'TOTALIP', 'Atorvastatin', 'CRESTOR', 'Rosuvastatin', 'Placebo', 'NO STATIN DRUGS']",7,INTERVENTIONAL,['PHASE2'],PHASE2,,Platelet Dysfunction,['Platelet Dysfunction'],"['Platelet', 'Atorvastatin', 'Rosuvastatin', 'Multiplate', 'reactivity']",COMPLETED,,2011-08,2014-02,"[{'measure': 'Area Under the Aggregation Curve (AUC) measured with the Multiplate 5.0 Analyzer', 'description': 'Evaluation of the effect of a loading dose (LD) of two different statins on platelet reactivity (atorvastatin and rosuvastatin) in terms of difference between AUC value before statin LD and after 12 hrs statin LD. The Area Under the Aggregation Curve (AUC) will be measured with the Multiplate 5.0 system.', 'timeFrame': 'Evaluation of platelet reactivity (in terms of AUC) two time points.'}]","[{'measure': 'Incidence of periprocedural myocardial infarction', 'description': 'To evaluate if the loading dose of statin prevent the periprocedural myocardial damage measured by CK and CK-MB The measurments will be done once before the procedure and at 6 and 12 hours after.', 'timeFrame': 'CK and CK-MB evaluated before the procedure and two time points up to 12 hours'}]",2,18 Years,75 Years,ALL,False,IRCCS San Raffaele,OTHER,0,146.0,ACTUAL,2025-09-01T16:18:14.677944,v2_robust,True,True,True,False,False,
NCT04586660,Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone,"An Open-label, Multi-center, Phase 4 Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone",XGEVA®,"['Denosumab', 'XGEVA®']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Giant Cell Tumor of Bone,['Giant Cell Tumor of Bone'],"['Giant cell tumor of bone (GCTB)', 'XGEVA®']",ACTIVE_NOT_RECRUITING,,2023-08-17,2028-03-07,"[{'measure': 'Objective tumor response', 'description': 'Objective tumor response is defined as the percentage of participants with complete response (CR) or partial response (PR) evaluated based on European Organisation for Research and Treatment of Cancer (EORTC) criteria and Response Evaluation Criteria in Solid Tumors (RECIST).', 'timeFrame': 'Up to 36 months'}]","[{'measure': 'Time to disease progression or recurrence in participants with unsalvageable giant cell tumor of bone (GCTM) (Cohort 1 only)', 'timeFrame': 'From baseline until end of treatment, up to a maximum of 36 months'}, {'measure': 'Number of participants with surgically salvageable giant cell tumor of bone (GCTB) after treatment (Cohort 1 only)', 'timeFrame': 'Month 36'}, {'measure': 'Time to disease progression or recurrence for participants with complete response (CR) from time of surgery (Cohort 2 only)', 'timeFrame': 'From time of surgery until end of treatment, up to a maximum of 36 months'}, {'measure': 'Number of participants who do not require surgery in participants with salvageable giant cell tumor of bone (GCTB) (Cohort 2 only)', 'timeFrame': 'Up to 36 months'}, {'measure': 'Number of participants with surgically downstaging in participants with salvageable giant cell tumor of bone (GCTB) (Cohort 2 only)', 'timeFrame': 'Up to 36 months'}, {'measure': 'Change from baseline in bone turnover markers (urinary N-telopeptide [uNTX]/creatinine ratio)', 'timeFrame': 'Baseline to Month 36'}, {'measure': 'Change from baseline in severity of pain assessed by Brief Pain Inventory - Short Form (BPI-SF) score', 'description': 'Pain severity will be assessed using Brief Pain Inventory - Short Form. The minimum score is 0 (no pain) and the maximum score is 10 (worst pain imaginable). The higher the score means a worse outcome of more pain.', 'timeFrame': 'Baseline to Month 36'}, {'measure': 'Number of participants who experience one or more treatment-emergent adverse events (TEAEs)', 'timeFrame': 'Baseline to end of safety follow-up, up to approximately 37 months'}, {'measure': 'Number of participants who experience adverse events of special interest', 'description': 'Adverse events of special interest include hypocalcemia, hypercalcemia following investigational product discontinuation, atypical femoral fracture, and osteonecrosis of the jaw.', 'timeFrame': 'Baseline to end of safety follow-up, up to approximately 37 months'}, {'measure': 'Serum XGEVA concentration levels', 'timeFrame': 'Up to 36 months'}]",11,12 Years,,ALL,False,Amgen,INDUSTRY,0,36.0,ACTUAL,2025-09-01T16:18:14.677976,v2_robust,True,True,False,False,True,
NCT00002060,A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC),A Multi-Center Randomized Double-Blind Placebo-Controlled Study To Investigate the Effect of Isoprinosine in Patients With AIDS Related Complex (ARC),Inosine pranobex,['Inosine pranobex'],1,INTERVENTIONAL,['NA'],,,HIV Infections,['HIV Infections'],"['AIDS-Related Opportunistic Infections', 'Inosine Pranobex', 'Homosexuality', 'Acquired Immunodeficiency Syndrome', 'AIDS-Related Complex']",COMPLETED,,,,[],[],0,18 Years,75 Years,MALE,False,Newport Pharmaceuticals International,INDUSTRY,0,,,2025-09-01T16:18:14.677998,v2_robust,True,True,True,False,False,
NCT02550860,Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function,Influence of Fish Oil Based Intravenous Fat Emulsions on the Epidermal Barrier Function,soybean oil (SO)-based IVFE (Medialipide),"['fish oil (FO)-containing IVFE (Lipidem)', 'soybean oil (SO)-based IVFE (Medialipide)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Intestinal Diseases,['Intestinal Diseases'],"['intravenous fat emulsions', 'parenteral nutrition', 'skin barrier function', 'essential fatty acids', 'transepidermal water loss']",TERMINATED,problem of enrollment,2015-01,2017-09-08,"[{'measure': 'Measurement of the transepidermal water loss (TEWL).', 'description': 'Measurement will be performed in a horizontal plane on the dominant volar forearm, which is the reference site for TEWL measurement because of its low content of sebaceous glands and pilosity. The TEWL will be measured using the latest generation of closed chamber system, combined to a vapor water condenser (Aquaflux 200®), which offers the advantage of a reduced TEWL value sensitivity to ambient humidity and temperature during measurement.', 'timeFrame': 'at Day 0 (at recruitment time)'}, {'measure': 'Measurement of the transepidermal water loss (TEWL).', 'description': 'Measurement will be performed in a horizontal plane on the dominant volar forearm, which is the reference site for TEWL measurement because of its low content of sebaceous glands and pilosity. The TEWL will be measured using the latest generation of closed chamber system, combined to a vapor water condenser (Aquaflux 200®), which offers the advantage of a reduced TEWL value sensitivity to ambient humidity and temperature during measurement.', 'timeFrame': 'at Day 90'}, {'measure': 'Measurement of the transepidermal water loss (TEWL).', 'description': 'Measurement will be performed in a horizontal plane on the dominant volar forearm, which is the reference site for TEWL measurement because of its low content of sebaceous glands and pilosity. The TEWL will be measured using the latest generation of closed chamber system, combined to a vapor water condenser (Aquaflux 200®), which offers the advantage of a reduced TEWL value sensitivity to ambient humidity and temperature during measurement.', 'timeFrame': 'at Day 180'}]","[{'measure': 'Determination of erythrocyte fatty acids ω-6', 'description': 'Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.', 'timeFrame': 'at Day 0'}, {'measure': 'Determination of erythrocyte fatty acids ω-3', 'description': 'Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.', 'timeFrame': 'at Day 0'}, {'measure': 'Determination of erythrocyte fatty acids ω-6', 'description': 'Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.', 'timeFrame': 'at Day 90'}, {'measure': 'Determination of erythrocyte fatty acids ω-3', 'description': 'Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.', 'timeFrame': 'at Day 90'}, {'measure': 'Determination of erythrocyte fatty acids ω-6', 'description': 'Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.', 'timeFrame': 'at Day 180'}, {'measure': 'Determination of erythrocyte fatty acids ω-3', 'description': 'Essential fatty acid red blood cell monitoring more properly reflect the global membrane fatty acid composition of the body. Monitoring will be achieved at biochemistry laboratory of recruiting centers on a blood sample.', 'timeFrame': 'at Day 180'}, {'measure': 'Determination of Stratum corneum (SC) ω-3', 'description': 'Stratum corneum lipids will be collected using the minimally invasive and painless ""Tape Stripping"" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.', 'timeFrame': 'at Day 0'}, {'measure': 'Determination of Stratum corneum (SC) ω-6', 'description': 'Stratum corneum lipids will be collected using the minimally invasive and painless ""Tape Stripping"" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.', 'timeFrame': 'at Day 0'}, {'measure': 'Determination of Stratum corneum (SC) ω-3', 'description': 'Stratum corneum lipids will be collected using the minimally invasive and painless ""Tape Stripping"" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.', 'timeFrame': 'at Day 90'}, {'measure': 'Determination of Stratum corneum (SC) ω-6', 'description': 'Stratum corneum lipids will be collected using the minimally invasive and painless ""Tape Stripping"" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.', 'timeFrame': 'at Day 90'}, {'measure': 'Determination of Stratum corneum (SC) ω-3', 'description': 'Stratum corneum lipids will be collected using the minimally invasive and painless ""Tape Stripping"" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.', 'timeFrame': 'at Day 180'}, {'measure': 'Determination of Stratum corneum (SC) ω-6', 'description': 'Stratum corneum lipids will be collected using the minimally invasive and painless ""Tape Stripping"" method, which consists of applying a scotch on the skin. Quantitative and qualitative composition of the SC lipid matrix will be determined using high-performance thin-layer chromatography.', 'timeFrame': 'at Day 180'}]",15,18 Years,,ALL,False,Hospices Civils de Lyon,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:14.678003,v2_robust,True,True,False,True,False,problem of enrollment
NCT05730920,IV Methadone Vs EXPAREL Erector Spinae Plane Blockade in Pediatric Subjects Undergoing Idiopathic Scoliosis Correction,"A Single-center, Randomized, Single-blind Pilot Study to Evaluate Intravenous Methadone Versus EXPAREL Erector Spinae Plane Blockade in Pediatric Subjects Undergoing Adolescent and Juvenile Idiopathic Scoliosis Correction",Methadone,"['Liposomal bupivacaine (LB, Exparel)', 'Methadone']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Adolescent Idiopathic Scoliosis,"['Adolescent Idiopathic Scoliosis', 'Juvenile Idiopathic Scoliosis']","['scoliosis', 'methadone', 'exparel', 'regional anesthesia', 'erector spinae plane block', 'pediatric']",COMPLETED,,2022-10-19,2024-09-21,"[{'measure': 'Successful Enrollment and Data Collection of 30 Subjects', 'description': 'Assess the feasibility of completing a prospective randomized trial pilot study comparing Erector Spinae Plane Blockade (ESPB) with liposomal bupivacaine (LB) to intravenous methadone at a single institution in two years', 'timeFrame': '2 years'}]","[{'measure': 'Opioid Consumption', 'description': 'Assess whether there is a difference in post-operative opioid consumption between the two study groups. This will evaluated by converting all long-acting opioids to daily morphine equivalents per unit of weight.', 'timeFrame': '2 years'}, {'measure': 'Pain Scores', 'description': 'Assess whether there is a difference in post-operative pain scores between the two study groups. Visual analog scale (VAS) scores with a minimum of 0 and a maximum of 10 will be used where 0 is no pain and 10 is the worst pain imaginable', 'timeFrame': '2 years'}, {'measure': 'Length of Stay', 'description': 'Assess whether there is a difference in hospital length of stay between the two study groups', 'timeFrame': '2 years'}]",4,11 Years,17 Years,ALL,False,"Dr. Casey Stondell, MD",OTHER,1,30.0,ACTUAL,2025-09-01T16:18:14.678118,v2_robust,True,True,True,False,False,
NCT00993720,"Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes","Effect of GLP-1 on Insulin-dose, Risk of Hypoglycemia and Gastric Emptying Rate in Patients With Type 1 Diabetes",Liraglutide,['Liraglutide'],1,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Diabetes Mellitus,['Diabetes Mellitus'],['patients with type 1 diabetes mellitus'],COMPLETED,,2009-10,2010-10,"[{'measure': 'insulin-dose', 'timeFrame': '4 weeks'}]","[{'measure': '24-hours glucose profiles with and without treatment of Victoza', 'timeFrame': 'three days'}, {'measure': 'risk of hypoglycemia during physical activity with and without Victoza', 'timeFrame': 'one day'}, {'measure': 'gastric emptying rate during hypoglycemia with and without Victoza', 'timeFrame': 'one day'}, {'measure': 'weight change from baseline, change in fructosamine from baseline', 'timeFrame': 'four weeks'}]",5,18 Years,50 Years,ALL,False,Hvidovre University Hospital,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:14.678160,v2_robust,True,True,True,False,False,
NCT07037420,ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly,"A Phase 2, Randomized, Double-blinded, Placebo-controlled, Dose Range-finding, Multicenter Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALXN2420, a Growth Hormone Receptor Antagonist, Administered Subcutaneously in Combination With Somatostatin Analogs in Adult Participants With Acromegaly",ALXN2420,"['ALXN2420', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Acromegaly,['Acromegaly'],"['Acromegaly', 'ALXN2420', 'Somatostatin Analog', 'insulin-like growth factor 1', 'IGF-1', 'SSA therapy', 'GHRA', 'Growth Hormone Receptor Antagonist']",NOT_YET_RECRUITING,,2025-10-17,2027-11-02,"[{'measure': 'Percentage Change From Baseline in Serum IGF-1 Level at Week 15', 'timeFrame': 'Baseline, Week 15'}]","[{'measure': 'Number of Participants Who Achieve Serum IGF-1 Level ≤1.3 Upper Limit of Normal (ULN) at Week 15', 'timeFrame': 'Week 15'}, {'measure': 'Number of Participants Who Achieve of Serum IGF-1 Level ≤1.0 ULN at Week 15', 'timeFrame': 'Week 15'}, {'measure': 'Change from Basline in Symptoms as assessed by disease specific questionnaire, at Week 15', 'timeFrame': 'Baseline, Week 15'}, {'measure': 'Change From Baseline in Serum IGF-1 Level at Week 15', 'timeFrame': 'Baseline, Week 15'}, {'measure': 'Change From Baseline in 36-item Short Form Survey (SF-36) Summary Scores and Subscores at Week 15', 'timeFrame': 'Baseline, Week 15'}, {'measure': 'Change From Baseline in EuroQol 5-Dimension 5-Level (EQ-5D-5L) at Week 15', 'timeFrame': 'Baseline, Week 15'}, {'measure': 'Change From Baseline in Acromegaly Quality of Life (AcroQoL) at Week 15', 'timeFrame': 'Baseline, Week 15'}, {'measure': 'Change From Baseline in Global Impression of Severity at Week 15 as Assessed by Patient Global Impression of Severity (PGIS) Scale', 'timeFrame': 'Baseline, Week 15'}, {'measure': 'Global Impression of Change at Week 15 as Assessed by Patient Global Impression of Change (PGIC) Scale', 'timeFrame': 'Week 15'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and Adverse Events (AEs) Leading to Study Intervention Discontinuation or Interruption', 'timeFrame': 'Baseline (Day 1) through Week 15'}, {'measure': 'Plasma Concentration of ALXN2420', 'timeFrame': 'Baseline (Day 1) through Week 15'}, {'measure': 'Number of Participants With Antidrug Antibodies (ADAs)', 'timeFrame': 'Baseline (Day 1) through Week 15'}]",13,18 Years,80 Years,ALL,False,"Alexion Pharmaceuticals, Inc.",INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:14.678191,v2_robust,True,True,False,False,True,
NCT04612920,Towards Enhanced Recovery After Cesarean,Towards Enhanced Recovery After Cesarean: Scheduled Post-operative Medication: a Randomized Controlled Trial,"Ibuprofen, acetaminophen, oxycodone","['Ibuprofen, acetaminophen, oxycodone']",1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Cesarean Section Complications,['Cesarean Section Complications'],[],COMPLETED,,2020-12-12,2023-03-08,"[{'measure': 'Amount of morphine milligram equivalents used from 25-72 hours post-op', 'description': ""Patient's inpatient chart will be reviewed to calculate the amount of oxycodone the patient used, converted to morphine milligram equivalents and recorded."", 'timeFrame': '25-72 hours post-op'}, {'measure': ""Patient's morphine milligram equivalent usage from day of discharge to outpatient post-operative visit"", 'description': 'The patient will be discharged home with 20 tablets of oxycodone 5mg. When they return to their post-operative visit, we will count the number of tablets left in the pill bottle. A low number of remaining tablets would mean increased medication usage outpatient.', 'timeFrame': 'post-discharge day #8-12'}]","[{'measure': ""Patient's pain rating on post-operative day #2 and #3 with and without ambulation"", 'description': 'The patient will be asked to rate her pain on post-operative day #2 and #3 with and without ambulation on a scale from 1-10 with 1 representing severe pain and 10 representing well controlled pain.', 'timeFrame': 'post-op days #2 and #3'}, {'measure': ""Patient's pain satisfaction scale on day of post-operative visit"", 'description': 'Patient will be asked to mark on a line how satisfied she is with her pain management outpatient with the left side of the line representing poor satisfaction and the right side of the line representing good satisfaction with pain control. The place she marks on the line will be measured and recorded in centimeters.', 'timeFrame': '1 day of post-operative visit'}, {'measure': ""Patient's pain satisfaction scale on day of discharge"", 'description': 'Patient will be asked to mark on a line how satisfied she is with her pain management during admission with the left side of the line representing poor satisfaction and the right side of the line representing good satisfaction with pain control. The place she marks on the line will be measured and recorded in centimeters.', 'timeFrame': '1 day of discharge'}, {'measure': 'Amount of acetaminophen used on post-operative day #2 and #3', 'description': 'Chart will be reviewed to calculate the amount of acetaminophen in milligrams the patient required on post-operative day #2 and #3 from 0000 to 2359.', 'timeFrame': 'post-operative day #2 and #3'}, {'measure': 'Amount of ibuprofen used on post-operative day #2 and #3', 'description': 'Chart will be reviewed to calculate the amount of ibuprofen in milligrams the patient required on post-operative day #2 and #3 from 0000 to 2359.', 'timeFrame': 'post-operative days #2 and #3'}, {'measure': 'Amount a patient ambulates on post-operative day #2 and #3', 'description': 'The patient will be given a fitness tracker after surgery and the number of steps the patient takes on post-operative day #2 and #3 will be recorded from 0000 to 2359.', 'timeFrame': 'post-operative day #2 and #3'}, {'measure': ""Patient's readiness to be discharged"", 'description': ""A validated questionnaire will be administered on post-operative day #2 and #3 by a research nurse assessing the patient's perceived readiness to be discharged home."", 'timeFrame': 'post-operative day #2 and #3'}, {'measure': ""Patient's ambulation on outpatient day #1-3"", 'description': 'The patient will be given a fitness tracker after surgery and the number of steps the patient takes on outpatient day #1-3 will be recorded daily from 0000 to 2359.', 'timeFrame': ""information from outpatient day #1-3 will be recorded at the patient's post-operative visit""}, {'measure': ""Patient's ambulation on outpatient day #4-5"", 'description': 'The patient will be given a fitness tracker after surgery and the number of steps the patient takes on outpatient day #4-5 will be recorded daily from 0000 to 2359.', 'timeFrame': ""information from outpatient day #4-5 will be recorded at the patient's post-operative visit""}, {'measure': ""Patient's sleep pattern on outpatient night #1-3"", 'description': 'The patient will be given a fitness tracker and asked to wear it while sleeping. The amount of time spent in deep sleep, light sleep, and awake will be recorded in hours and minutes on outpatient night #1-3.', 'timeFrame': ""information from outpatient night #1-3 will be recorded at the patient's post-operative""}, {'measure': ""Patient's sleep pattern on outpatient night #4-5"", 'description': 'The patient will be given a fitness tracker and asked to wear it while sleeping. The amount of time spent in deep sleep, light sleep, and awake will be recorded in hours and minutes on outpatient night #4-5.', 'timeFrame': ""information from outpatient night #4-5 will be recorded at the patient's post-operative visit""}, {'measure': ""Patient's acetaminophen usage from discharge to outpatient post-operative visit"", 'description': 'The patient will be discharged home with acetaminophen 500mg. When they return to their post-operative visit, we will count the number of tablets left in the pill bottle. A low number of remaining tablets would mean increased medication usage outpatient.', 'timeFrame': 'information will be collected at the outpatient post-operative 1 day visit'}, {'measure': ""Patient's ibuprofen usage from discharge to outpatient post-operative visit"", 'description': 'The patient will be discharged home with ibuprofen 800mg. When they return to their post-operative visit, we will count the number of tablets left in the pill bottle. A low number of remaining tablets would mean increased medication usage outpatient.', 'timeFrame': 'information will be collected at the outpatient post-operative 1 day visit'}, {'measure': ""Patient's pain rating on day of post-operative visit with and without ambulation"", 'description': 'The patient will be asked to rate her pain at post-operative day with and without ambulation on a scale from 1-10 with 1 representing severe pain and 10 representing well controlled pain.', 'timeFrame': '1 day of post-operative visit'}, {'measure': ""Patient's pain rating at 12 hours post-op"", 'description': 'The patient will be asked to rate her pain at 12 hour post-op on a scale from 1-10 with 1 representing severe pain and 10 representing well controlled pain.', 'timeFrame': '12 hours post-op'}]",17,18 Years,50 Years,FEMALE,False,University of Oklahoma,OTHER,0,33.0,ACTUAL,2025-09-01T16:18:14.678223,v2_robust,True,True,True,False,False,
NCT01602120,An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy,"A Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Lampalizumab (FCFD4514S) in Patients With Geographic Atrophy Who Have Completed Genentech-Sponsored Lampalizumab Studies",Lampalizumab,"['Lampalizumab', 'FCFD4514S']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Geographic Atrophy,['Geographic Atrophy'],[],TERMINATED,The study was terminated early by the Sponsor due to lack of efficacy.,2012-05-29,2018-02-09,"[{'measure': 'Percentage of Participants With Ocular and Non-ocular Adverse Events (AEs)', 'description': 'An AE was defined as any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether considered related to the medicinal product, any new disease or exacerbation of an existing disease, recurrence of an intermittent medical condition, or any deterioration in a laboratory value or other clinical test. Ocular AEs are events localized to the eye. Non-ocular events include all other events.', 'timeFrame': 'From Day 1 up to the last study visit (up to approximately 62 months)'}]",[],1,60 Years,89 Years,ALL,False,"Genentech, Inc.",INDUSTRY,0,159.0,ACTUAL,2025-09-01T16:18:14.678311,v2_robust,True,True,False,True,True,The study was terminated early by the Sponsor due to lack of efficacy.
NCT00235820,Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis,"A Phase 3, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Study Comparing the Safety and Efficacy of Adalimumab to Methotrexate in Subjects With Moderate to Severe Chronic Plaque Psoriasis",adalimumab,"['ABT-D2E7', 'MTX', 'Humira', 'placebo', 'adalimumab', 'placebo adalimumab, placebo MTX']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriasis,['Psoriasis'],"['Psoriasis', 'adalimumab']",COMPLETED,,2005-07,,"[{'measure': 'Proportion of subjects achieving clinical response at Week 16 relative to the Baseline (Week 0) PASI score.', 'timeFrame': 'Week 16'}, {'measure': 'Safety parameters', 'timeFrame': 'Every Study Visit'}]","[{'measure': 'Physician Global Assessment', 'timeFrame': 'Baseline - Week 16'}, {'measure': 'PASI 50/90/100', 'timeFrame': 'Baseline - Week 16'}, {'measure': 'DLQI', 'timeFrame': 'Baseline - Week 16'}]",5,18 Years,,ALL,False,Abbott,INDUSTRY,0,271.0,ACTUAL,2025-09-01T16:18:15.890627,v2_robust,True,True,True,False,True,
NCT04779320,A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD),"A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy",Vedolizumab IV,"['KYNTELES', 'Vedolizumab IV', 'MLN0002', 'ENTYVIO']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Crohn's Disease (CD),"[""Crohn's Disease (CD)""]",['Drug Therapy'],RECRUITING,,2022-04-30,2026-05-22,"[{'measure': ""Percentage of Participants With Clinical Remission at Week 54 Based on Pediatric Crohn's Disease Activity Index (PCDAI) Score ≤10"", 'description': 'Clinical remission is defined by PCDAI score ≤10. The PCDAI was specifically designed for use in children. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: hematocrit (HCT) (adjusted for age and sex), erythrocyte sedimentation rate (ESR), and albumin level. The PCDAI score ranges from 0 to 100, with higher scores indicating more active disease. A score of \\<10 will be consistent with inactive disease, 11 to 30 will indicate mild disease, and \\>30 will indicate moderate to severe disease. A decrease of 12.5 points is taken as evidence of improvement.', 'timeFrame': 'Week 54'}, {'measure': ""Percentage of Participants With Endoscopic Response at Week 54 Based on Simple Endoscopic Score for Crohn's Disease [SES-CD] Score"", 'description': 'Endoscopic response is defined as at least a 50% reduction in SES-CD score from Baseline. The overall SES-CD score ranges from 0 to 56 and is the sum of 4 variables (ie, size of ulcers \\[cm\\], ulcerated surface, affected surface \\[%\\], and presence of narrowing) across 5 bowel segments (ie, rectum, descending and sigmoid colon, transverse colon, ascending colon, and ileum). Each variable is coded from 0 to 3 based on severity, where 0 is none or not severe and 3 is the most severe case, with the sum of the scores for each variable ranging from 0 to 15, except for presence of narrowing. Presence of narrowing ranges from 0 to 11 since a severity of 3 represents a narrowing which a colonoscope cannot be passed and, thus, can only be observed once among the bowel segments. The segmental SES-CD score is the sum of the 4 variables for each bowel segment and can range from 0 to 12, where each individual variable score ranges from 0 to 3.', 'timeFrame': 'Week 54'}]","[{'measure': 'Percentage of Participants with Clinical and Endoscopic Remission at Week 14 Based on Both PCDAI Score and SES-CD Score', 'description': 'Clinical and endoscopic remission is where participant achieves both clinical and endoscopic remission. Clinical remission is defined by PCDAI score ≤10. Endoscopic remission is defined by SES-CD score of ≤4 with at least a 2-point reduction from Baseline and no sub-score \\>1. PCDAI includes child-specific item: height velocity variable as well as three laboratory parameters: HCT, ESR, albumin level. PCDAI score ranges from 0 to 100, with higher scores indicating more active disease. The SES-CD score ranges from 0 to 56 and is the sum of 4 variables, size of ulcers \\[cm\\], ulcerated surface, affected surface \\[%\\], and presence of narrowing) across 5 bowel segments (ie, rectum, descending and sigmoid colon, transverse colon, ascending colon, and ileum), where higher scores indicate more severe disease.', 'timeFrame': 'Week 14'}, {'measure': 'Percentage of Participants with Clinical and Endoscopic Remission at Week 54 Based on Both PCDAI Score and SES-CD Score', 'description': 'Clinical and endoscopic remission is where participant achieves both clinical and endoscopic remission. Clinical remission is defined by PCDAI score ≤10. Endoscopic remission is defined by SES-CD score of ≤4 with at least a 2-point reduction from Baseline and no sub-score \\>1. PCDAI includes child-specific item: height velocity variable as well as three laboratory parameters: HCT, ESR, albumin level. PCDAI score ranges from 0 to 100, with higher scores indicating more active disease. The SES-CD score ranges from 0 to 56 and is the sum of 4 variables, size of ulcers \\[cm\\], ulcerated surface, affected surface \\[%\\], and presence of narrowing) across 5 bowel segments (ie, rectum, descending and sigmoid colon, transverse colon, ascending colon, and ileum), where higher scores indicate more severe disease.', 'timeFrame': 'Week 54'}, {'measure': 'Percentage of Participants with Sustained Clinical and Endoscopic Remission at Week 54', 'description': 'Sustained clinical and endoscopic remission is where a participant achieved clinical and endoscopic remission based on PCDAI and SES-CD scores at Weeks 14 and 54. Clinical remission is defined by PCDAI score ≤10. Endoscopic remission is defined as ≤4 with at least a 2-point reduction from Baseline and no sub-score \\>1 by SES-CD. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score ranges from 0 to 100, with higher scores indicating more active disease. The SES-CD score ranges from 0 to 56 and is the sum of 4 variables, size of ulcers \\[cm\\], ulcerated surface, affected surface \\[%\\], and presence of narrowing) across 5 bowel segments (ie, rectum, descending and sigmoid colon, transverse colon, ascending colon, and ileum), where higher scores indicate more severe disease.', 'timeFrame': 'Week 54'}, {'measure': 'Percentage of Participants with Corticosteroid-free Remission at Week 54 Based on PCDAI Score', 'description': 'Corticosteroid-free clinical remission is where participants achieves corticosteroid-free clinical remission based on PCDAI at Week 54 and has been off corticosteroids at least 12 weeks prior to and at Week 54. Clinical remission is defined by PCDAI score ≤10. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score ranges from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Week 54'}, {'measure': 'Percentage of Participants with Sustained Endoscopic Remission Based on SES-CD Score', 'description': 'Sustained endoscopic remission is where participants achieves endoscopic remission based on SES-CD ≤4 with at least a 2-point reduction from Baseline and no sub-score \\>1. The SES-CD evaluates 4 endoscopic variables (Size of ulcers, Ulcerated surface, Affected surface and Presence of narrowing). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the four endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.', 'timeFrame': 'Week 14'}, {'measure': 'Percentage of Participants with Sustained Endoscopic Remission Based on SES-CD Score', 'description': 'Sustained endoscopic remission is where participants achieves endoscopic remission based on SES-CD ≤4 with at least a 2-point reduction from Baseline and no sub-score \\>1. The SES-CD evaluates 4 endoscopic variables (Size of ulcers, Ulcerated surface, Affected surface and Presence of narrowing). The score for each endoscopic variable is sum of values obtained for each segment. The SES-CD total is the sum of the four endoscopic variable scores from 0 to 56, where higher scores indicate more severe disease.', 'timeFrame': 'Week 54'}, {'measure': 'Percentage of Participants with Sustained Clinical Remission at Week 14 Based on PCDAI Score', 'description': 'Sustained Clinical Remission is where participants will achieve clinical remission based on PCDAI at Weeks 14 and 54. Clinical remission is defined by PCDAI score ≤10. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score will range from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Week 14'}, {'measure': 'Percentage of Participants with Sustained Clinical Remission at Week 54 Based on PCDAI Score', 'description': 'Sustained Clinical Remission is where participants will achieve clinical remission based on PCDAI at Weeks 14 and 54. Clinical remission is defined by PCDAI score ≤10. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score will range from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Week 54'}, {'measure': 'Serum Trough Concentrations of Vedolizumab Over Time', 'timeFrame': 'Predose and postdose at multiple time points (up to 54 weeks)'}, {'measure': 'Percentage of Participants With Positive Antivedolizumab Antibodies', 'timeFrame': 'Pre-dose (up to 54 weeks)'}, {'measure': 'Percentage of Participants With Positive Neutralizing Antivedolizumab Antibody Titers', 'timeFrame': 'Pre-dose (up to 54 weeks)'}, {'measure': 'Sustained Clinical Response at Week 14 Based on PCDAI Score', 'description': 'Sustained clinical response is where a participant achieve clinical response based on PCDAI score ≤30 and reduction of the PCDAI by ≥15 points from Baseline. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score will range from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Week 14'}, {'measure': 'Sustained Clinical Response at Week 54 Based on PCDAI Score', 'description': 'Sustained clinical response is where a participant achieve clinical response based on PCDAI score ≤30 and reduction of the PCDAI by ≥15 points from Baseline. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score will range from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Week 54'}, {'measure': 'Percentage of Participants with Clinical Remission at Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54', 'description': 'Clinical remission is defined by PCDAI score \\< 10. The PCDAI was specifically designed for use in children. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT (adjusted for age and sex), ESR, and albumin level. The PCDAI score will range from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54'}, {'measure': 'Percentage of Participants with Change in Baseline in Clinical Response at Weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54', 'description': 'Clinical Response is where participants achieves clinical response if PCDAI ≤30 with reduction in the PCDAI of ≥15 points from Baseline. The PCDAI includes a child-specific item: the height velocity variable as well as three laboratory parameters: HCT, ESR, and albumin level. The PCDAI score will range from 0 to 100, with higher scores indicating more active disease.', 'timeFrame': 'Baseline, weeks 2, 6, 10, 14, 22, 30, 38, 46, and 54'}, {'measure': 'Percentage of Participants with at Least One Adverse Event (AE), Serious Adverse Event (SAE), and AE of special interest (AESI)', 'description': 'An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have causal relationship with this treatment. AE can be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a drug whether it is considered related to drug. SAE is any untoward medical occurrence that at any dose: results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, leads to congenital anomaly/birth defect and/or is important medical event. An AESI (serious or non-serious) is one of scientific and medical concern specific to compound or program, for which ongoing monitoring and rapid communication by investigator. AESIs include- opportunistic infection, such as progressive multifocal leukoencephalopathy (PML), liver injury, malignancies, infusion-related reactions, hypersensitivity.', 'timeFrame': 'From first dose of study drug before each dose on dosing days through the Week 72'}, {'measure': 'Change from Baseline in Weight', 'description': 'Change from in Baseline in weight will be calculated as: Weight at each study visit (up to Week 54) - Weight at Baseline.', 'timeFrame': 'Baseline up to Week 54'}, {'measure': 'Change from Baseline in Linear Growth Z-score', 'description': 'Linear growth Z-score will be calculated as: Z-score = (observed value - median value of the reference population)/ standard deviation value of reference population.', 'timeFrame': 'Baseline up to Week 54'}, {'measure': 'Change from Baseline in Tanner Stages at Week 54', 'description': 'Tanner Stage is used to define physical measurements of sexual development based on external primary and secondary sex characteristics. Female and male participants are evaluated for breast development and genital development respectively and both genders for pubic hair distribution based on a 5-stage scale ranging from Stage I (prepubertal/preadolescent characteristics) to Stage V (mature or adult characteristics).', 'timeFrame': 'Week 54'}]",21,2 Years,17 Years,ALL,False,Takeda,INDUSTRY,0,120.0,ESTIMATED,2025-09-01T16:18:15.890639,v2_robust,True,True,False,False,True,
NCT05093920,Role of DEB-TACE Versus c-TACE in Treatment of HCC,Role of Drug Eluting Bead Transarterial Chemoebolization Versus Conventional Transarterial Chemoembolization in Treatment of Hepatocellular Carcinoma,Doxorubicin-Eluting Beads,"['Doxorubicin-Eluting Beads', 'Lipidol-Doxorubicin emulsion']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],UNKNOWN,,2022-01-01,2024-01-30,"[{'measure': 'Tumor size', 'description': 'Triphasic CT scan of the liver measures the maximum diameter of tumor according to modified RECIST (mRecist) criteria.', 'timeFrame': 'four-six weeks after treatment'}]","[{'measure': 'Serum Alpha-fetoprotein level ng/ml.', 'description': 'Laboratory test of Serum alpha-fetoprotein level (AFP) ng/ml.', 'timeFrame': 'four-six weeks after treatment'}]",2,,,ALL,False,Sohag University,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:15.890925,v2_robust,True,True,False,False,False,
NCT03505320,A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer,A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive,zolbetuximab,"['IMAB362', 'fluorouracil', 'Pembrolizumab', 'folinic acid', 'nivolumab', 'leucovorin', 'Docetaxel', 'zolbetuximab', 'oxaliplatin']",9,INTERVENTIONAL,['PHASE2'],PHASE2,,Pharmacokinetics of Zolbetuximab,"['Pharmacokinetics of Zolbetuximab', 'Gastric Cancer', 'Gastro-esophageal Junction (GEJ) Cancer', 'Pharmacokinetics of Oxaliplatin', 'Pharmacokinetics of Fluorouracil Bolus (5-FU)']","['zolbetuximab', 'oxaliplatin', 'fluorouracil', 'docetaxel', 'claudiximab', 'IMAB362', 'Gastro-Esophageal Junction cancer', 'locoregional gastric cancer', 'Pembrolizumab', 'Gastric cancer']",ACTIVE_NOT_RECRUITING,,2018-06-29,2027-02-28,"[{'measure': 'Objective Response Rate (ORR) of zolbetuximab as a single agent by central review (Cohort 1)', 'description': 'The ORR is defined as the proportion of participants with complete or partial objective response based on Response Evaluation Criteria in Solid Tumors (RECIST) V1.1 (assessed by an independent review committee (IRC)).', 'timeFrame': 'Up to 3 months'}]","[{'measure': 'Pharmacokinetics (PK) of zolbetuximab: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity (AUCinf) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'AUCinf will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Area Under the Concentration-time Curve from the Time of Dosing Extrapolated to Time Infinity Percentage (AUCinf (%extrap)) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'AUCinf (%extrap) will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Area Under the Concentration-time Curve from the Time of Dosing Until the Last Measurable Concentration (AUClast) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'AUClast will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Area Under the Concentration-Time Curve from the Time of Dosing to the Start of the Next Dosing Interval (AUCtau) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'AUCtau will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Maximum Concentration (Cmax) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Cmax will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Concentration Immediately Prior to Dosing (Ctrough) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Ctrough will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Time of Maximum Concentration (Tmax) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Tmax will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Terminal Elimination Half-life (T1/2) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'T1/2 will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Time of the last measurable concentration (Tlast) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Tlast will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Clearance (CL) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'CL will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of zolbetuximab: Volume of Distribution During the Terminal Phase (Vz) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Vz will be derived from the PK serum samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: AUCinf (Cohort 2)', 'description': 'AUCinf will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: AUCinf (%extrap) (Cohort 2)', 'description': 'AUCinf (%extrap) will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: AUClast (Cohort 2)', 'description': 'AUClast will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: Cmax (Cohort 2)', 'description': 'Cmax will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: Tmax (Cohort 2)', 'description': 'Tmax will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: T1/2 (Cohort 2)', 'description': 'T1/2 will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: Tlast (Cohort 2)', 'description': 'Tlast will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: CL (Cohort 2)', 'description': 'TL will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of oxaliplatin: Vz (Cohort 2)', 'description': 'Vz will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): AUCinf (Cohort 2)', 'description': 'AUCinf will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): AUCinf (%extrap) (Cohort 2)', 'description': 'AUCinf (%extrap) will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): AUClast (Cohort 2)', 'description': 'AUClast will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): Cmax (Cohort 2)', 'description': 'Cmax will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): Tmax (Cohort 2)', 'description': 'Tmax will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): T1/2 (Cohort 2)', 'description': 'T1/2 will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): Tlast (Cohort 2)', 'description': 'Tlast will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): CL (Cohort 2)', 'description': 'CL will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'PK of fluorouracil bolus (5-FU): Vz (Cohort 2)', 'description': 'Vz will be derived from the PK plasma samples collected.', 'timeFrame': 'Up to 16 months'}, {'measure': 'Safety and tolerability assessed by adverse events (AEs) (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'An AE is any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product.', 'timeFrame': 'Up to 16 months'}, {'measure': 'Number of participants with electrocardiogram (ECG) abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Number of participants with potentially clinically significant ECG values.', 'timeFrame': 'Up to 14 months'}, {'measure': 'Number of participants with vital signs abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Number of participants with potentially clinically significant vital sign values.', 'timeFrame': 'Up to 14 months'}, {'measure': 'Number of participants with European Cooperative Oncology Group (ECOG) performance status abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Number of participants with potentially clinically significant ECOG performance status values. ECOG grades 0-5, where 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair and 5 = Dead.', 'timeFrame': 'Up to 14 months'}, {'measure': 'Number of participants with laboratory assessments abnormalities and or adverse events (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Number of participants with potentially clinically significant laboratory values.', 'timeFrame': 'Up to 14 months'}, {'measure': 'Number of anti-drug antibody (ADA) Positive Participants (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Immunogenicity will be measured by the number of participants that are ADA positive.', 'timeFrame': 'Up to 16 months'}, {'measure': 'Health Related Quality of Life (HRQoL) measured by the Quality of Life Questionnaire - Core Questionnaire (QLQ-C30) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'The EORTC-QLQ-C30 is a cancer-specific instrument consisting of 5 functional domain scales: physical, role, emotional, social and cognitive.', 'timeFrame': 'Up to 16 months'}, {'measure': 'HRQoL measured by the Oesophago-Gastric Module (EORTC QLQ-OG-25) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'The EORTC-QLQ-OG25 instrument evaluates GC- and GEJC-specific symptoms such as stomach discomfort, difficulties eating and swallowing and indigestion.', 'timeFrame': 'Up to 16 months'}, {'measure': 'HRQoL measured by the Global Pain (GP) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'The GP instrument is a single assessment of overall pain.', 'timeFrame': 'Up to 16 months'}, {'measure': 'HRQoL measured by the EuroQOL Five Dimensions Questionnaire 5L (EQ-5D-5L) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)', 'description': ""The EQ-5D-5L is a standardized instrument developed by the EuroQol Group for use as a generic, preference-based measure of health outcomes. The EQ-5D-5L is a 5-item self-reported measure of functioning and wellbeing, which assesses 5 dimensions of health, including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension comprises 5 levels (no problems, slight problems, moderate problems, severe problems, extreme problems). A unique EQ-5D-5L health state is defined by combining 1 level from each of the 5 dimensions. This questionnaire also records the respondent's self-rated health status on a vertical graduated (0 = the worst health a participant can imagine to 100 = the best health a participant can imagine) visual analogue scale. Responses to the 5 items will also be converted to a weighted health state index (utility score) based on values derived from general population samples."", 'timeFrame': 'Up to 16 months'}, {'measure': 'HRQoL measured by the Health Resource Utilization (HRU) questionnaire (Cohorts 1A, 2, 3A, 4 and 5)', 'description': 'Health resource utilization questionnaire to assess the number of office visits, hospital stays and other healthcare resource utilization that occur outside of the clinical trial.', 'timeFrame': 'Up to 16 months'}, {'measure': 'Disease Control Rate (DCR) of zolbetuximab as a single agent by investigator assessment (Cohort 1A)', 'description': 'The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.', 'timeFrame': 'Up to 3 months'}, {'measure': 'DCR of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)', 'description': 'The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.', 'timeFrame': 'Up to 13 months'}, {'measure': 'DCR of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)', 'description': 'DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.', 'timeFrame': 'up to 13 months'}, {'measure': 'DCR of zolbetuximab as a single agent by independent central reader (Cohort 1A)', 'description': 'The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.', 'timeFrame': 'Up to 3 months'}, {'measure': 'DCR of zolbetuximab in combination with mFOLFOX6 by Independent central reader (Cohort 2)', 'description': 'The DCR is defined as the proportion of subjects with complete or partial objective response, or stable disease based on RECIST V1.1.', 'timeFrame': 'Up to 13 months'}, {'measure': 'Duration of Response (DOR) of zolbetuximab as a single agent by investigator assessment (Cohort 1A)', 'description': 'DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.', 'timeFrame': 'Up to 3 months'}, {'measure': 'DOR of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)', 'description': 'DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.', 'timeFrame': 'Up to 13 months'}, {'measure': 'DOR of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)', 'description': 'DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.', 'timeFrame': 'up to 13 months'}, {'measure': 'DOR of zolbetuximab as a single agent by independent central reader (Cohort 1A)', 'description': 'DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.', 'timeFrame': 'Up to 3 months'}, {'measure': 'DOR of zolbetuximab in combination with mFOLFOX6 by independent central reader (Cohort 2)', 'description': 'DOR is defined as the time from the date of the first response CR/PR (whichever is first recorded) to the date of radiographical progression/death or date of censoring.', 'timeFrame': 'Up to 13 months'}, {'measure': 'Progression Free Survival (PFS) of zolbetuximab as a single agent by investigator assessment (Cohort 1A)', 'description': 'PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.', 'timeFrame': 'Up to 3 months'}, {'measure': 'PFS of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)', 'description': 'PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.', 'timeFrame': 'Up to 13 months'}, {'measure': 'PFS of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)', 'description': 'PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.', 'timeFrame': 'up to 13 months'}, {'measure': 'PFS of zolbetuximab as a single agent by independent central review (Cohort 1A)', 'description': 'PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.', 'timeFrame': 'Up to 3 months'}, {'measure': 'PFS of zolbetuximab in combination with mFOLFOX6 by independent central review (Cohort 2)', 'description': 'PFS is defined as the time from date of treatment start until the date of radiological disease progression assessed by independent radiographic reviewer (IRR), or until death due to any cause.', 'timeFrame': 'Up to 13 months'}, {'measure': 'ORR of zolbetuximab as a single agent by investigator assessment (Cohort 1A)', 'description': 'The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.', 'timeFrame': 'Up to 3 months'}, {'measure': 'ORR of zolbetuximab in combination with mFOLFOX6 by investigator assessment (Cohort 2)', 'description': 'The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.', 'timeFrame': 'Up to 13 months'}, {'measure': 'ORR of zolbetuximab in combination with mFOLFOX6 (with nivolumab) by investigator assessment (Cohort 4)', 'description': 'The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.', 'timeFrame': 'up to 13 months'}, {'measure': 'ORR of zolbetuximab in combination with mFOLFOX6 by independent central reader (Cohort 2)', 'description': 'The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.', 'timeFrame': 'Up to 13 months'}, {'measure': 'ORR of zolbetuximab in combination with pembrolizumab by independent central reader (Cohort 3A)', 'description': 'The ORR is defined as the proportion of subjects with complete or partial objective response based on RECIST V1.1.', 'timeFrame': 'Up to 5 months'}, {'measure': 'Overall Survival (OS) of zolbetuximab as a single agent (Cohort 1A)', 'description': 'OS is defined as the time from the date of treatment start until the documented date of death from any cause.', 'timeFrame': 'Up to 7 months'}, {'measure': 'OS of zolbetuximab in combination with mFOLFOX6 and nivolumab (Cohort 4B)', 'description': 'OS is defined as the time from the date of treatment start until the documented date of death from any cause.', 'timeFrame': 'up to 56 Months'}, {'measure': 'OS of zolbetuximab in combination with FLOT (Cohort 5)', 'description': 'OS is defined as the time from the date of treatment start until the documented date of death from any cause.', 'timeFrame': 'Up to 72 months'}, {'measure': 'Percentage of participants with surgical complications (Cohort 5)', 'description': 'Percentage of participants with surgical complications will be reported.', 'timeFrame': 'Up to 8 months'}, {'measure': 'Percentage of participants with surgical mortality as defined by death within 30 days of surgery (Cohort 5)', 'description': 'Percentage of participants with surgical mortality as defined by death within 30 days of surgery will be reported.', 'timeFrame': 'Up to 30 days'}, {'measure': 'Percentage of participants able to complete preoperative chemotherapy (Cohort 5)', 'description': 'Percentage of participants able to complete preoperative chemotherapy will be reported.', 'timeFrame': 'Up to 2 months'}, {'measure': 'Percentage of participants with perioperative mortality and morbidity at 30 days and 90 days post last dose (Cohort 5)', 'description': 'Percentage of participants with perioperative mortality and morbidity at 30 days and 90 days post last dose will be reported.', 'timeFrame': 'Up to 3 months'}, {'measure': 'Percentage of participants able to start postoperative chemotherapy (Cohort 5)', 'description': 'Percentage of participants able to start postoperative chemotherapy will be reported.', 'timeFrame': 'Up to 7 months'}, {'measure': 'Percentage of participants able to complete postoperative chemotherapy (Cohort 5)', 'description': 'Percentage of participants able to complete postoperative chemotherapy will be reported.', 'timeFrame': 'Up to 9 months'}, {'measure': 'Percentage of participants with radiological response at restaging (Cohort 5)', 'description': 'Radiological response will include complete response and partial response.', 'timeFrame': 'Up to 5 months'}, {'measure': 'Percentage of subjects with pathological response (ypTNM) (Cohort 5)', 'description': 'Pathological response (ypTNM) will include ypCR, ypPR', 'timeFrame': 'Up to 5 months'}, {'measure': 'Disease-free Survival (DFS) (Cohort 5)', 'description': 'DFS is defined as the time from date of treatment start until the date of radiological disease recurrence or until death due to any cause, whichever is earliest.', 'timeFrame': 'Up to 70 months'}, {'measure': 'Minimal Residual Disease (Cohort 5)', 'description': 'Minimal residual disease and disease recurrence as measured by circulating tumor DNA (ctDNA) will be summarized.', 'timeFrame': 'Up to 37 months'}]",74,18 Years,,ALL,False,"Astellas Pharma Global Development, Inc.",INDUSTRY,0,143.0,ACTUAL,2025-09-01T16:18:15.891018,v2_robust,True,True,False,False,True,
NCT03112720,Therapeutic Epidural Patch Versus Pain Block in the Midface for Headache,A Comparison of the Efficacy of Sphenopalatine Ganglion (SPG) Block With 5% Lidocaine Versus Epidural Blood Patch (EBP) for the Treatment of Post-Dural Puncture Headache (PDPH),Sphenopalatine Ganglion Block,['Sphenopalatine Ganglion Block'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Postdural Puncture Headache,['Postdural Puncture Headache'],[],TERMINATED,no enrollment after covid pandemic,2016-09,2020-09,"[{'measure': 'Number of Headaches With a VAS Score >8/10 Prior to Initiation of Either Therapy', 'description': 'Outcome measure will entail recording patient self-reported pain scores to quantify the level of headache pain using the Visual analog scale, meaning 0 - No pain, 1-3 - Mild Pain, 4-6 - Moderate Pain, 7-10 - Severe Pain, by way of in person assessment by pain questionnaire just prior to initiation of either therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).', 'timeFrame': 'Prior to initiation of therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).'}, {'measure': 'Number of Participants With a Headache Vas 8/10 at 30 Minutes Following Either Therapy.', 'description': 'Self-reported pain scores to quantify the level of headache pain using the Visual analog scale (as defined within the description of outcome 1 above) by way of in person assessment by pain questionnaire at 30 minutes following either therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).', 'timeFrame': 'At 30 minutes following either therapy.'}, {'measure': 'Number of Participants With a Headache Vas 8/10 at 60 Minutes Following Either Therapy.', 'description': 'Self-reported pain scores to quantify the level of headache pain using the Visual analog scale (as defined within the description of outcome 1 above) by way of in person assessment by pain questionnaire at 60 minutes following either therapy (Epidural blood patch vs Sphenopalatine Ganglion Block).', 'timeFrame': 'At 60 minutes following either therapy.'}]",[],3,13 Years,92 Years,ALL,True,"Rutgers, The State University of New Jersey",OTHER,1,8.0,ACTUAL,2025-09-01T16:18:15.891075,v2_robust,True,True,False,True,False,no enrollment after covid pandemic
NCT01777620,A Study of Subject Satisfaction With BOTOX® Cosmetic Treatment in Facial Rhytides,,Normal Saline,['Normal Saline'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Facial Rhytides,['Facial Rhytides'],[],COMPLETED,,2013-01-31,2013-07-31,"[{'measure': 'Percentage of Participants Satisfied With Treatment of Glabellar Lines Assessed Using the Facial Line Satisfaction Questionnaire (FLSQ)', 'description': 'Participants assessed their overall satisfaction with their glabellar (frown) lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.', 'timeFrame': 'Day 60'}]","[{'measure': ""Percentage of Participants Satisfied With Treatment of Crow's Feet Lines (CFL) and Glabellar Lines Assessed Using the FLSQ"", 'description': 'Participants assessed their overall satisfaction with both their CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants mostly or very satisfied is reported.', 'timeFrame': 'Day 60'}, {'measure': 'Percentage of Participants Satisfied With Duration of Treatment of Glabellar Lines Assessed Using the FLSQ', 'description': 'Participants assessed their overall satisfaction with duration of treatment of glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.', 'timeFrame': 'Day 90'}, {'measure': 'Percentage of Participants Where Treatment of Glabellar Lines Met Expectation Assessed Using the FLSQ', 'description': 'Participants assessed whether treatment of their glabellar lines met expectation using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.', 'timeFrame': 'Day 60'}, {'measure': 'Percentage of Participants Satisfied With Duration of Treatment of CFL and Glabellar Lines Assessed Using the FLSQ', 'description': 'Participants assessed their overall satisfaction with duration of treatment of both CFL and glabellar lines using the FLSQ 5-point scale where: -2=Very dissatisfied, -1=Mostly dissatisfied, 0=Neither dissatisfied nor satisfied, 1=Mostly satisfied and 2=Very satisfied. The percentage of participants with responses mostly or very satisfied is reported.', 'timeFrame': 'Day 90'}, {'measure': 'Percentage of Participants Where Treatment of CFL and Glabellar Lines Met Expectation Assessed Using the FLSQ', 'description': 'Participants assessed whether treatment of glabellar lines met expectations using the FLSQ 3-point scale where: 1=Worse than expected, 2=Met expectations and 3=Better than expected. The percentage of participants with responses Met expectations and Better than expected is reported.', 'timeFrame': 'Day 60'}, {'measure': 'Percentage of Participants Who Were Likely to Continue Treatment of Glabellar Lines Assessed Using the FLSQ', 'description': 'Participants assessed how likely they were to continue treatment of glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.', 'timeFrame': 'Day 90'}, {'measure': 'Percentage of Participants Who Were Likely to Continue Treatment of CFL and Glabellar Lines Assessed Using the FLSQ', 'description': 'Participants assessed how likely they were to continue treatment of CFL and glabellar Lines using the FLSQ 5-point scale where: 1=Not at all, 2=A little bit, 3=Moderately, 4=Quite a bit and 5=Extremely. The percentage of participants with responses Moderately, Quite a bit and Extremely is reported.', 'timeFrame': 'Day 90'}, {'measure': ""Percentage of Participants With a Score of None or Mild in the Investigator's Assessment of the Severity of Glabellar Lines at Maximum Frown Assessed Using the FWS"", 'description': ""The Investigator assessed the severity of the patient's glabellar lines at maximum frown using the 4-point Facial Wrinkle Scale (FWS) where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with a score of none or mild is reported."", 'timeFrame': 'Day 30'}, {'measure': ""Percentage of Participants With at Least a 1-Grade Improvement in the Investigator's Assessment of the Severity of CFL at Maximum Smile Assessed Using the FWS"", 'description': ""The Investigator assessed the severity of the patient's CFL at maximum smile using the 4-point FWS where: 0=none, 1=mild, 2=moderate, and 3=severe. The percentage of participants with at least a 1-Grade improvement from Baseline is reported."", 'timeFrame': 'Baseline, Day 30'}]",10,18 Years,65 Years,ALL,False,Allergan,INDUSTRY,0,125.0,ACTUAL,2025-09-01T16:18:15.891110,v2_robust,True,True,True,False,False,
NCT06952920,Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer,Electroacupuncture for Managing Chemotherapy-Induced Gastrointestinal Symptom Clusters in Patients With Breast Cancer,standard quadruple antiemetic therapy,['standard quadruple antiemetic therapy'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Standard Quadruple Antiemetic Therapy,"['Standard Quadruple Antiemetic Therapy', 'Electroacupuncture', 'Chemotherapy-induced Gastrointestinal Symptom Cluster']","['breast cancer', 'chemotherapy', 'standard quadruple antiemetic therapy', 'electroacupuncture', 'chemotherapy-induced gastrointestinal symptom cluster']",NOT_YET_RECRUITING,,2025-08-01,2028-06-30,"[{'measure': 'The incidence of chemotherapy-induced gastrointestinal symptom clusters, including nausea, vomiting, poor appetite, and xerostomia, within 120 hours after chemotherapy.', 'timeFrame': '120 hours'}]","[{'measure': 'Improvement in other gastrointestinal symptom clusters after the first cycle of chemotherapy.', 'timeFrame': '120 hours'}, {'measure': 'The incidence of no nausea during the acute and delayed phases following the first chemotherapy cycle.', 'timeFrame': '120 hours'}, {'measure': 'The incidence of no vomiting during the overall, acute, and delayed phases following the first chemotherapy cycle.', 'timeFrame': '120 hours'}, {'measure': 'Complete response rates in the overall, acute, and delayed phases following the first chemotherapy cycle.', 'timeFrame': '120 hours'}, {'measure': 'Complete protection rates in the overall, acute, and delayed phases following the first chemotherapy cycle.', 'timeFrame': '120 hours'}, {'measure': 'Quality of life assessed by the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L).', 'description': 'The EQ-5D-5L evaluates five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is scored from 1 (""no problems"") to 5 (""extreme problems""), with health states expressed as 5-digit codes (e.g., 11111=no impairment; 55555=extreme impairment across all dimensions). Index scores were calculated using the Chinese value set (Luo et al., 2017), yielding a theoretical range of -0.391 (worse than death) to 1.0 (perfect health). The visual analogue scale (VAS) component records self-rated health status from 0 (""worst imaginable health"") to 100 (""best imaginable health"").', 'timeFrame': '120 hours'}]",7,18 Years,75 Years,ALL,False,Jiuda Zhao,OTHER,0,388.0,ESTIMATED,2025-09-01T16:18:15.891171,v2_robust,True,True,False,False,False,
NCT03124420,Intraluminal Therapy for Helicobacter Pylori Infection,Intraluminal Therapy for Helicobacter Pylori Infection,Lansoprazole,"['Takepron', 'Lansoprazole', 'Clarithromycin', 'Amoxicillin', 'Klaricid', 'Supercillin']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Helicobacter Pylori Infection,['Helicobacter Pylori Infection'],"['Helicobacter Infection', 'Eradication therapy', 'Antibiotics']",COMPLETED,,2017-04-28,2018-04-30,"[{'measure': 'Eradication rate in the intraluminal therapy', 'description': 'C13-UBT will be used to assess the existence of H. pylori 6 weeks after the intraluminal therapy', 'timeFrame': '6 weeks after finishing therapy'}]","[{'measure': 'Eradication rates in the two groups of rescue oral antibiotics therapies.', 'description': 'C13-UBT will be used to assess the existence of H. pylori 6 weeks after finishing rescue oral antibiotics therapies.', 'timeFrame': '6 weeks after finishing therapy'}, {'measure': 'Overall eradication rates', 'description': 'Overall eradication rates after the first line intraluminal therapy and the oral antibiotics rescue therapies. Overall eradication rates after the first line intraluminal therapy and the oral antibiotics rescuOverall eradication rates after the first line intraluminal therapy and the oral antibiotics rescue therapies. e therapies.', 'timeFrame': '3-6 months after finishing intraluminal therapy'}, {'measure': 'Short term recurrent rate', 'description': 'To assess the short term recurrent rate 3-6 months after successful intraluminal therapy.\n\nStool H. Pylori Ag will be used to assess the short term recurrence of H. pylori 3-6 months after successful intraluminal therapy .', 'timeFrame': '3-6 months after intraluminal therapy.'}, {'measure': 'Incidence of adverse effects in the intraluminal therapy.', 'description': 'Incidence of adverse effects were evaluated for Participants who had or had not finished the intraluminal therapy', 'timeFrame': 'within 7 days after finishing the intraluminal therapy'}]",5,20 Years,75 Years,ALL,False,Mackay Memorial Hospital,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:15.891228,v2_robust,True,True,True,False,True,
NCT00535782,A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis,"A Mechanism of Action Study to Evaluate the Effects of IL-6 Receptor Blockade With Tocilizumab (TCZ) on Lipids, Arterial Stiffness, and Markers of Atherogenic Risk in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA).",Tocilizumab,"['Methotrexate', 'Placebo', 'RoActemra', 'Actemra', 'Tocilizumab']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Rheumatoid Arthritis,['Rheumatoid Arthritis'],[],COMPLETED,,2007-10-31,2011-01-31,"[{'measure': 'Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers', 'description': 'Small LDL particles are associated with an increased risk of cardiovascular disease: more of these small particles lead to a greater risk. The concentration of fasting small LDL particles was determined using the Nuclear Magnetic Resonance (NMR) methodology.', 'timeFrame': 'Baseline and Week 12'}, {'measure': 'Change From Baseline to Week 12 in Aortic Pulse Wave Velocity (PWV)', 'description': 'Aortic (central) arterial stiffness was assessed with Pulse Wave Analysis (PWA) of the radial artery and carotid-femoral PWV using applanation tonometry after the patient had rested in a supine position for at least 10 minutes.', 'timeFrame': 'Baseline and Week 12'}]","[{'measure': 'Change From Baseline to Week 24 in Small Low Density Lipoprotein (sLDL) Particle Numbers', 'description': 'Small LDL particles are associated with an increased risk of cardiovascular disease: more of these small particles lead to a greater risk. The concentration of fasting small LDL particles was determined using the Nuclear Magnetic Resonance (NMR) methodology.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Change From Baseline to Week 24 in Aortic Pulse Wave Velocity (PWV)', 'description': 'Aortic (central) arterial stiffness was assessed with Pulse Wave Analysis (PWA) of the radial artery and carotid-femoral PWV using applanation tonometry after the patient had rested in a supine position for at least 10 minutes.', 'timeFrame': 'Baseline and Week 24'}, {'measure': 'Number of Participants Experiencing Adverse Events (AEs)', 'description': 'A severe AE is an event in which the intensity of the event results in an inability to work or perform normal daily activity.\n\nA Serious AE is fatal, life-threatening, requires in-patient hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically significant or requires intervention to prevent one of the above outcomes.\n\nAEs of special interest include infection, gastrointestinal, infusion reaction (occurring during or within 24 hours of infusion), hepatic disorder, myocardial infarction and stroke.', 'timeFrame': 'Up to Week 24'}]",5,18 Years,75 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,0,132.0,ACTUAL,2025-09-01T16:18:15.891376,v2_robust,True,True,True,False,True,
NCT06630624,"Dose Finding, Efficacy and Immunological Response of IP-001 Following MWA or IRE for CRLM","INJECTABL-II: Dose Finding, Efficacy and Immunological Response of a Novel Immuno-Adjuvant (IP-001) Following Microwave Ablation or Irreversible Electroporation for Colorectal Liver Metastases.",IP-001,['IP-001'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Colorectal Cancer,"['Colorectal Cancer', 'Liver Metastases', 'Liver Metastasis Colon Cancer']","['Colorectal liver metastases', 'Colorectal hepatic metastases', 'irreversible electroporation', 'Microwave ablation', 'Immunotherapy']",RECRUITING,,2024-07-10,2031-08-01,"[{'measure': 'Maximum Tolerated Dose (MTD) (Phase 1)', 'description': 'The highest dose of IP-001 that does not cause unacceptable side effects defined as the dose level below the dose level that caused 2 or more Dose Limiting Toxicites (DLTs).', 'timeFrame': 'During the 10-day DLT-monitoring period.'}, {'measure': '1-Year Distant Progression Free Survival (DPFS) (Phase 2 part 1)', 'description': 'Overall DPFS is defined as the time from inclusion to the time of disease progression (according to the RECIST 1.1 guideline) or death (events). Death related to other causes is considered a failure event for DPFS.', 'timeFrame': '1 year'}, {'measure': 'Disease Control Rate (DCR) (Phase 2 part 2)', 'description': 'DCR is calculated as the percentage of patients experiencing either iSD (Stable Disease), iPR (Partial Response) or iCR (Complete Response) as best response in target lesions at 16 weeks after treatment according to iRECIST.', 'timeFrame': '16 weeks'}]","[{'measure': 'Elimination half-life of the study drug IP-001 in the blood (t1/2 ) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as elimination half-life of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}, {'measure': 'Overall Survival (OS; per patient analysis) (All phases)', 'description': 'OS is defined as the time from focal therapy to the time of death due to any cause, assessed up to 5 years;', 'timeFrame': 'Up to 5 years'}, {'measure': '(Serious) Adverse Events ((S)AEs) (All phases)', 'description': '(Serious) adverse events according to CTCAE v5.0, assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Duration of best overall response (DoR, per patient analysis) (Phase 2 part 2)', 'description': 'DoR is defined from when the time measurement criteria are first met for CR/iCR or PR/iPR until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years;', 'timeFrame': 'Up to 3 years'}, {'measure': 'Local Tumor Progression Free Survival (LTPFS, per lesion analysis) (All phases)', 'description': 'LTPFS is defined as the time from focal therapy to the time of local tumor progression or death from any cause, whichever occurs first. Local tumor is defined as the treated tumor, assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Distant Progression Free Survival (DPFS; per patient analysis) (All phases)', 'description': 'DPFS is defined as the time from focal therapy to the time of distant disease progression or death from any cause, whichever occurs first, assessed up to 5 years. Distant disease is defined as extra-hepatic lesions and untreated, hepatic lesions;', 'timeFrame': 'Up to 5 years'}, {'measure': 'Hepatic progression free survival (HPFS; per patient analysis) (All phases)', 'description': 'HPFS is defined as the time from focal therapy to the time of progression of any tumor in the liver (treated or untreated) or death from any cause, whichever occurs first, assessed up to 5 years;', 'timeFrame': 'Up to 5 years'}, {'measure': 'Time to progression (TTP; per patient analysis) (All phases)', 'description': 'TTP is defined as the time from focal therapy to the time of unequivocal disease progression (events); the date of death from any cause or death without established RECIST progressive disease is considered to be a competing risk. TTP will be analysed with and without competing risks. Assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Progression-free survival (PFS; per patient analysis) (All phases)', 'description': 'The time until the date of unequivocal disease progression (local site recurrence or metastatic disease) or death from any cause, whichever occurs first, assessed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Disease-free survival (DFS; per patient analysis) (All phases)', 'description': 'DFS is defined as the time from focal therapy until the appearance or worsening of signs or symptoms of the disease or death from any cause, whichever occurs first, assesed up to 5 years.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Pain assessment (Per procedure analysis)', 'description': 'Pain assessment using visual analogue scale questionnaires (VAS; per procedure analysis). Assessed prior to, directly after and every three months after local treatment, and up to 1 year.', 'timeFrame': 'Up to 1 year'}, {'measure': 'Ablative Success (All phases)', 'description': 'Ablative success (or technical success rate) is defined as the primary efficacy rate; the percentage of successfully eradicated tumor tissue after the local treatment, assessed directly after the treatment.', 'timeFrame': 'Directly after treatment'}, {'measure': 'Quality of Life using EORCT QLQ-C30 questionnaireS (QoL; per patient analysis) (Phase 2)', 'description': 'The quality of life is assessed using EORCT QLQ-C30 questionnaires, prior to, and every three months after treatment during a total follow-up time of 1 year.', 'timeFrame': '1 year'}, {'measure': 'Quality of Life using EQ-5D questionnaires (QoL; per patient analysis) (Phase 2)', 'description': 'The quality of life is assessed using EQ-5D questionnaires, prior to, and every three months after treatment during a total follow-up time of 1 year.', 'timeFrame': '1 year'}, {'measure': 'Quality of Life using PRODISQ questionnaires(QoL; per patient analysis) (Phase 2)', 'description': 'The quality of life is assessed using PRODISQ questionnaires, prior to, and every three months after treatment during a total follow-up time of 1 year.', 'timeFrame': '1 year'}, {'measure': 'Time of maximum observed concentration of the study drug IP-001 in the blood (Tmax) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as time of maximum observed concentration of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}, {'measure': 'Maximum observed concentration of the study drug IP-001 in the blood (Cmax) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as maximum observed concentration of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}, {'measure': 'Area under the curve from time 0 to the time of the last measurable concentration of the study drug IP-001 in the blood (AUC 0-t) (Phase 1 and phase 2 part 2)', 'description': 'Blood samples will be taken prior to and at different timepoints after the procedure for pharmacokinetic analysis defined as the area under the curve from time 0 to the time of the last measurable concentration of the study drug IP-001 in the blood.', 'timeFrame': 'Prior to and +1 hour, +2 hours, +6 hours, +12 hours and + 24 hours after study treatment'}]",21,18 Years,,ALL,False,M.R. Meijerink,OTHER,2,120.0,ESTIMATED,2025-09-01T16:18:15.891425,v2_robust,True,True,False,False,True,
NCT06933524,Evaluation of Safety and Tolerability of ATB-320 in Participants With Progressive or Metastatic Solid Tumors,"An Open-Label, Multicenter, Phase 1 Clinical Trial to Evaluate the Safety and Tolerability of ATB-320 in Patients With Progressive or Metastatic Solid Tumors",ATB-320,['ATB-320'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumors,['Solid Tumors'],[],NOT_YET_RECRUITING,,2025-06-01,2028-06-01,"[{'measure': 'Dose Limiting Toxicity (DLT)', 'description': 'Occurrence of dose limiting toxicity (DLT) will be assessed for the DLT Analysis Set for each cohort until Cycle 1 Day 28 (C1D28) and will be discussed by the Data Monitoring Committee (DMC).', 'timeFrame': 'First dose to Cycle 1 Day 28 (each cycle is 28 days)'}, {'measure': 'Maximum Tolerated Dose (MTD)', 'description': 'The highest dose (cohort) at which no more than one out of three to six participants in a cohort experience a dose limiting toxicity (DLT).', 'timeFrame': 'At the end of Cycle 1 (each cycle is 28 days)'}]","[{'measure': 'Safety', 'description': 'Number of participants with AE, with abnormal physical examination findings, abnormal vital signs, abnormal ECG readings, abnormal clinical laboratory tests results', 'timeFrame': 'At the end of each cycle (each cycle is 28 days) and up to 14 days from the last dose of ATB-320'}]",3,18 Years,,ALL,False,Autotelicbio,INDUSTRY,0,24.0,ESTIMATED,2025-09-01T16:18:15.891464,v2_robust,True,True,False,False,True,
NCT02895724,Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial,Hyperbaric Oxygen Therapy to Reduce Lymphedema After Breast Cancer -an Explorative Clinical Trial,Medical Oxygen,['Medical Oxygen'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Secondary Lymphedema,['Secondary Lymphedema'],"['Hyperbaric oxygen therapy', 'secondary lymphedema']",UNKNOWN,,2016-09,2018-12,"[{'measure': 'Arm volume', 'description': 'measured by perometry and DXA scans', 'timeFrame': '8 months'}]","[{'measure': 'lymph clearance', 'description': 'upper limb lymph clearance rate measured by quantitative lymphoscintigraphy', 'timeFrame': '8 months'}, {'measure': 'Functional impairment', 'description': 'upper limb functional impairment measured by queationnaire: ""Lymph ICF""', 'timeFrame': '8 months'}, {'measure': 'psychological well-being', 'description': 'anxiety, depression and health realted quality of life measured by questionnaire', 'timeFrame': '8 months'}, {'measure': 'blood biomarkers', 'description': 'biomarkers of inflammation and levels of collagen measured by blood samples', 'timeFrame': '8 months'}]",5,18 Years,75 Years,FEMALE,False,Danish Cancer Society,OTHER,2,20.0,ACTUAL,2025-09-01T16:18:15.891562,v2_robust,True,True,False,False,False,
NCT04992624,Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee,Cannabinoid Interactions With Central and Peripheral Pain Mechanisms in Osteoarthritis of the Knee,Placebo,"['Dronabinol', 'Epidiolex', 'Cannabidiol (CBD)', 'Tetrahydrocannabinol (Marinol® or generic equivalent (e.g., dronabinol)', 'Placebo']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,"Osteoarthritis, Knee","['Osteoarthritis, Knee', 'Osteoarthritis of the Knee']","['Cannabidiol', 'Tetrahydrocannabinol']",RECRUITING,,2022-02-22,2026-10-31,"[{'measure': 'Default mode network (DMN) to insula connectivity via functional connectivity magnetic resonance imaging (fcMRI)', 'description': 'Functional connectivity difference maps of insula to DMN connectivity using Independent Component Analysis and seed based connectivity. A reduction in the Z-score as a result of treatment will serve as the primary outcome measure.', 'timeFrame': 'Day 15, and approximately day 99 of treatment'}, {'measure': 'Change in pre-post measurements of inflammatory marker IL-6.', 'description': 'Serum IL-6', 'timeFrame': 'Day 15, and approximately day 99 of treatment'}]",[],2,21 Years,75 Years,ALL,False,"Steven E Harte, PhD",OTHER,2,200.0,ESTIMATED,2025-09-01T16:18:15.891606,v2_robust,True,True,False,False,False,
NCT01223924,Single-dose Escalation Trial of M2ES in Healthy Volunteer,"Randomized ，Placebo-controlled,Single-dose Escalation Trial of M2ES in Healthy Volunteer",M2ES,"['M2ES esculating', 'M2ES']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Cancer,['Cancer'],['cancer'],COMPLETED,,2009-05,2009-09,"[{'measure': 'To determine safety, toxicity and maxinum tolerable Dosage of M2ES injection in Safety and tolerability', 'description': 'To determine safety, toxicity and maxinum tolerable Dosage of M2ES injection in Subjects With Advanced Solid Tumors', 'timeFrame': '3 weeks'}]","[{'measure': 'Pharmacokinetic (PK) behavior', 'description': 'Pharmacokinetic (PK) behavior of two different doses in healthy volunteers', 'timeFrame': '3 weeks'}]",2,19 Years,45 Years,ALL,True,Protgen Ltd,INDUSTRY,0,33.0,ACTUAL,2025-09-01T16:18:15.891675,v2_robust,True,True,True,False,True,
NCT03419624,The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients,"A 28-week, Multi-center Randomized, Double-blind, Placebo-controlled Study to Evaluate the Potential of Dapagliflozin Plus Exenatide in Combination With High-dose Intensive Insulin Therapy Compared to Placebo in Obese Insulin-resistant Patients With Type 2 Diabetes Mellitus (Proof-of-concept Study)",Dapagliflozin 10mg,"['Placebo injection', 'Dapagliflozin 10mg', 'Metformin, if taken before', 'Placebo Oral Tablet', 'Insulin', 'Exenatide 2 mg [Bydureon]']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Obesity,"['Obesity', 'Diabetes Mellitus, Type 2']","['Dapagliflozin', 'Exenatide', 'high-dose insulin therapy', 'SGLT-2 inhibitor', 'GLP-1 receptor agonist']",TERMINATED,Delay in patient enrolment,2018-02-19,2019-08-05,"[{'measure': 'Change in HbA1c from baseline (week 0) to week 28', 'description': 'To compare the absolute change from baseline in HbA1c at week 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '28 weeks'}]","[{'measure': 'Change in HbA1c from baseline (week 0) to week 14', 'description': 'To compare the absolute change in HbA1c from baseline at week 0 to week 14 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '14 weeks'}, {'measure': 'Change in total body weight from baseline (week 0) to week 14 and 28', 'description': 'To compare the change in total body weight from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '28 weeks'}, {'measure': 'Change in BMI from baseline (week 0) to week 14 and 28', 'description': 'To compare the change in BMI from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '28 weeks'}, {'measure': 'Change in FPG from baseline (week 0) to week 14 and 28', 'description': 'To compare the change in fasting plasma glucose (FPG) from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '28 weeks'}, {'measure': 'Change in TDID from baseline (week 0) to week 14 and 28', 'description': 'To compare the change in total daily insulin dose (TDID) from baseline at week 0 to week 14 and 28 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '28 weeks'}, {'measure': 'Proportion of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline', 'description': 'To compare the number of patients achieving HbA1c of ≤ 7% at week 28 compared to baseline at week 0 between Dapagliflozin plus Exenatide, Placebo or Exenatide monotherapy added to high-dose intensive insulin therapy', 'timeFrame': '28 weeks'}]",7,18 Years,75 Years,ALL,False,Universitätsklinikum Hamburg-Eppendorf,OTHER,1,13.0,ACTUAL,2025-09-01T16:18:15.891684,v2_robust,True,True,False,True,False,Delay in patient enrolment
NCT00165724,Alzheimer's Disease Long-term Follow-up Study (ALF Study),Alzheimer's Disease Long-term Follow-up Study (ALF Study),Donepezil Hydrochloride,['Donepezil Hydrochloride'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Alzheimer's Disease,"[""Alzheimer's Disease""]",[],COMPLETED,,2004-06-30,2006-12-31,[{'measure': 'ADAS-cog'}],"[{'measure': 'MMSE, CDR, GDS, NPI, ADL, SSDQ'}]",2,40 Years,90 Years,ALL,,Eisai Korea Inc.,INDUSTRY,0,114.0,ACTUAL,2025-09-01T16:18:15.891712,v2_robust,True,True,True,False,False,
NCT00677924,Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer,"A Dose-Escalation, Randomized Phase I/II Trial of Zalutumumab - a Human Monoclonal Anti-EGF Receptor Antibody - With or Without Irinotecan Chemotherapy in Cetuximab Refractory Colorectal Cancer Patients Who Have Failed Standard Chemotherapy and Progressed During or Within 3 Months of Stopping Cetuximab-Based Therapy",Zalutumumab,"['Zalutumumab', 'HuMax-EGFr']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Colorectal Cancer,['Colorectal Cancer'],"['Colorectal Neoplasms', 'Colorectal Tumors', 'Colorectal Carcinoma']",TERMINATED,Due to changes in portfolio review,2008-04,2009-04,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.', 'timeFrame': 'From first dose up to follow-up (up to approximately 1 year)'}]","[{'measure': 'Number of Participants With Best Overall Tumour Response (BOR)', 'description': 'The BOR defined as the best response recorded from the start of treatment until disease progression or recurrence per RECIST criteria. Complete response (CR) defined as the disappearance of all target lesions. Partial response (PR) defined as at least a 30% decrease in the sum of the longest diameter of target lesions, taking as reference the baseline sum longest diameter. Progressive disease (PD) defined as at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started, or the appearance of one or more new lesions since the prior scan. Stable disease (SD) defined as responses not fulfilling CR, PR or PD.', 'timeFrame': 'Up to 1 year'}]",2,18 Years,,ALL,False,Genmab,INDUSTRY,0,9.0,ACTUAL,2025-09-01T16:18:15.891719,v2_robust,True,True,False,True,True,Due to changes in portfolio review
NCT01556724,A Comparison of Postoperative Analgesic Nerve Block Ropivacaine Concentrations,A Comparison of 0.1 and 0.2% Ropivacaine in Lumbar Plexus Catheters After Primary Total Hip Arthroplasty: a Comparison of Postoperative Analgesia and Motor Function.,0.1% or 0.2% ropivacaine nerve blocks,"['Naropin (ropivacaine hcl)', '0.1% or 0.2% ropivacaine nerve blocks']",2,INTERVENTIONAL,['NA'],,,Total Hip Arthroplasty,"['Total Hip Arthroplasty', 'Postoperative Pain']","['Peripheral nerve blocks', 'Ropivacaine concentrations in lumbar plexus catheters', 'Postoperative pain', 'Total hip replacement']",COMPLETED,,2010-01,2014-12,"[{'measure': 'Opiate Consumption Postoperatively', 'description': 'Postoperative opiate consumption at 24 hours', 'timeFrame': '24 hours postoperatively'}]","[{'measure': 'Patient Satisfaction With Pain Control', 'description': ""Patient satisfaction with pain control at 24 hours (0-10 scale). Patients' satisfaction was assessed using an 11-point numeric scale (0-10, 0 = unsatisfied and 10 = very satisfied). Scores at 24 hours were not averaged with any other scores."", 'timeFrame': '24 hours postoperatively'}, {'measure': 'Numeric Rating Scale Pain Score With Movement at 24 Hours', 'description': 'Numeric rating scale (NRS) pain score with movement were assessed at 24 hours. Pain scores were followed using an 11-point NRS (0 = no pain and 10 = worst imaginable pain). Scores at 24 hours were not averaged with any other scores.', 'timeFrame': '24 hours postoperatively'}, {'measure': 'Number of Participants With Increased Infusion Rates', 'description': 'Number of patients requiring increased infusion rates to 9 mL/hour to better optimize pain control.', 'timeFrame': 'Subjects will be followed postoperatively until postoperative day 2 (i.e. the discontinuation of the lumbar plexus catheters)'}, {'measure': 'Number of Participants With Decreased Infusion Rates', 'description': 'Number of patient requiring decreased infusion rates decreased to 5 mL/hour due to increased motor blockade.', 'timeFrame': 'Subjects will be followed postoperatively until postoperative day 2 (i.e. the discontinuation of the lumbar plexus catheters)'}]",5,18 Years,75 Years,ALL,False,Sylvia Wilson,OTHER,0,41.0,ACTUAL,2025-09-01T16:18:15.891731,v2_robust,True,True,True,False,False,
NCT02683824,Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers,Detection of Integrin Alpha-v-Beta 6 in Pancreatic Cancer With [18F]-R01-MG-F2: a First in Human Study,[18F]FP-R01-MG-F2,['[18F]FP-R01-MG-F2'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Healthy Subject,"['Healthy Subject', 'Pancreatic Carcinoma']",[],COMPLETED,,2016-01-12,2022-12-01,"[{'measure': 'Biodistribution of [18F]FP-R01-MG-F2 (%ID/g)', 'description': 'From the Region-of-Interest (ROI) image analysis, the biodistribution data will be reported in percent injected dose per gram of tissue (%ID/g). ROI analysis will be performed on normal brain, thyroid, lungs, mediastinum, liver, spleen, intestines, kidneys, urinary bladder and gluteal muscle.', 'timeFrame': 'Up to 3 hours after tracer injection'}, {'measure': 'Biodistribution of [18F]FP-R01-MG-F2 (SUV)', 'description': 'From the Region-of-Interest (ROI) image analysis, the biodistribution data will be reported in Standardized Uptake Values (SUV). ROI analysis will be performed on normal brain, thyroid, lungs, mediastinum, liver, spleen, intestines, kidneys, urinary bladder and gluteal muscle.', 'timeFrame': 'Up to 3 hours after tracer injection'}, {'measure': 'Dosimetry of [18F]FP-R01-MG-F2 (rem/mCi)', 'description': ""Using the biodistribution data (uptake in %ID/g or SUV), the tracer's complete dosimetry across all organs, tissues or cells will be determined using the OLINDA software. These data will be reported in rem/mCi."", 'timeFrame': 'Up to 3 hours after tracer injection'}, {'measure': 'Dosimetry of [18F]FP-R01-MG-F2 (mSv/MBq)', 'description': ""Using the biodistribution data (uptake in %ID/g or SUV), the tracer's complete dosimetry across all organs, tissues or cells will be determined using the OLINDA software. These data will be reported in mSv/MBq."", 'timeFrame': 'Up to 3 hours after tracer injection'}]",[],4,18 Years,,ALL,True,Stanford University,OTHER,1,21.0,ACTUAL,2025-09-01T16:18:15.891767,v2_robust,True,True,True,False,False,
NCT04420624,COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction,COLchicine to Prevent Sympathetic Denervation After an Acute Myocardial Infarction,Colchicine,"['no other name', 'Colchicine']",2,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,"Myocardial Infarction, Acute","['Myocardial Infarction, Acute']","['Myocardial infarction', 'Sympathetic denervation', 'Heart failure']",TERMINATED,Inclusion period completed,2020-12-04,2022-05-24,"[{'measure': 'Percentage of myocardial denervation', 'description': 'assess by MIBG (méta-iodobenzylguanidine)-nuclear cardiac imaging', 'timeFrame': '6 month'}]","[{'measure': 'Change in the heart-to-mediastinum ratio', 'description': 'The heart-to-mediastinum (H/M) ratio, the heart count normalized for the mediastinum count, is used as a quantitative index in cardiac 123 I-MIBG imaging.', 'timeFrame': '6 month'}, {'measure': 'Left Ventricular Ejection Fraction in percent', 'description': 'By transthoracic echocardiogram (TTE)', 'timeFrame': '6 month'}, {'measure': 'Left Ventricular Ejection Fraction in percent', 'description': 'By MIBG (méta-iodobenzylguanidine)-nuclear cardiac imaging', 'timeFrame': '6 month'}, {'measure': 'Left Ventricular Ejection Fraction in percent', 'description': 'By transthoracic echocardiogram (TTE)', 'timeFrame': '1 month'}, {'measure': 'Change in Sinus variability', 'description': 'by 24 hours holter recording : SDNN (Standard Deviation of NN intervals) will be measured', 'timeFrame': '6 month'}, {'measure': 'Change in Sinus variability', 'description': 'by 24 hours holter recording : SDNN (Standard Deviation of NN intervals) will be measured', 'timeFrame': '1 month'}, {'measure': 'Basic ECG parameters (QRS duration)', 'timeFrame': '6 month'}, {'measure': 'Basic ECG parameters (QRS duration)', 'timeFrame': '1 month'}, {'measure': 'Basic ECG parameters (corrected QT)', 'timeFrame': '1 month'}, {'measure': 'Basic ECG parameters (corrected QT)', 'timeFrame': '6 month'}, {'measure': 'Number of ventricular extrasystole (2 or 3 VES) per 24 hours on the Holter', 'timeFrame': '6 month'}, {'measure': 'Number of bursts (2 or 3 VES) per 24 hours on the Holter', 'timeFrame': '1 month'}, {'measure': 'Number of bursts (2 or 3 VES) per 24 hours on the Holter', 'timeFrame': '6 month'}, {'measure': 'Number of ventricular or supraventricular tachycardia (>3 VES) episodes per 24 hours', 'timeFrame': '1 month'}, {'measure': 'Number of ventricular or supraventricular tachycardia (>3 VES) episodes per 24 hours', 'timeFrame': '6 month'}, {'measure': 'Time from randomization to death (total mortality)', 'timeFrame': '6 month'}, {'measure': 'Time from randomization to heart failure hospitalization', 'timeFrame': '6 month'}, {'measure': 'Time from randomization to all-cause hospitalization', 'timeFrame': '6 month'}, {'measure': 'Variations in the levels of neurotrophic molecular markers', 'description': 'Concentration of NGF ng/mL', 'timeFrame': 'Between hospitalization and 1 month'}, {'measure': 'Variations in the levels of neurotrophic molecular markers', 'description': 'Concentration of NGF ng/mL', 'timeFrame': 'Between 1 month and 6 months'}, {'measure': 'Variations in the levels of neurotrophic molecular markers', 'description': 'Concentration of proNGF ng/mL', 'timeFrame': 'Between hospitalization and 1 month'}, {'measure': 'Variations in the levels of neurotrophic molecular markers', 'description': 'Concentration of proNGF ng/mL', 'timeFrame': 'Between 1 month and 6 months'}, {'measure': 'Variations in the levels of neurotrophic molecular markers', 'description': 'Concentration of BDNF ng/mL', 'timeFrame': 'Between hospitalization and 1 month'}, {'measure': 'Variations in the levels of neurotrophic molecular markers', 'description': 'Concentration of BDNF ng/mL', 'timeFrame': 'Between 1 month and 6 months'}, {'measure': 'Biological evaluation of infarction size Creatine PhosphoKinase (CPK)', 'description': 'Area Under Curve (AUC) of CPK', 'timeFrame': 'During hospitalization (Day 1 to Day 5)'}, {'measure': 'Biological evaluation of infarction size (troponin)', 'description': 'Area Under Curve (AUC) of Troponin', 'timeFrame': 'During hospitalization (Day 1 to Day 5)'}, {'measure': 'Post infarction systemic inflammation evaluation', 'description': 'Concentration of biomarkers from blood : CRP (mg/L)', 'timeFrame': 'Between hospitalization and 1 month'}, {'measure': 'Post infarction systemic inflammation evaluation', 'description': 'Concentration of biomarkers from blood : CRP (mg/L)', 'timeFrame': 'Between 1 month and 6 months'}, {'measure': 'Post infarction systemic inflammation evaluation', 'description': 'Concentration of biomarkers from blood : sST2 (ng/mL)', 'timeFrame': 'Between hospitalization and 1 month'}, {'measure': 'Post infarction systemic inflammation evaluation', 'description': 'Concentration of biomarkers from blood : sST2 (ng/mL)', 'timeFrame': 'Between 1 month and 6 months'}, {'measure': 'Infarct size in percentage of left ventricular', 'timeFrame': '6 month'}, {'measure': 'Number of Adverse event', 'description': 'Comparison of adverse events between 2 arms', 'timeFrame': 'from randomization to 6 months'}]",33,18 Years,80 Years,ALL,False,"University Hospital, Montpellier",OTHER,0,54.0,ACTUAL,2025-09-01T16:18:15.891785,v2_robust,True,True,False,True,True,Inclusion period completed
NCT00000723,The Use of Chemotherapy Plus Radiotherapy Plus Azidothymidine in Patients With AIDS-Related Lymph Node Cancer,"Chemotherapy, Radiotherapy, and Azidothymidine for AIDS-Related Primary CNS Lymphoma",Methotrexate,"['Zidovudine', 'Methotrexate', 'Dexamethasone', 'Leucovorin calcium']",4,INTERVENTIONAL,['NA'],,,"Lymphoma, Non-Hodgkin","['Lymphoma, Non-Hodgkin', 'HIV Infections']","['AIDS-Related Opportunistic Infections', 'Lymphoma', 'Methotrexate', 'Leucovorin', 'Dexamethasone', 'Drug Evaluation', 'Drug Therapy, Combination', 'Combined Modality Therapy', 'Acquired Immunodeficiency Syndrome', 'Zidovudine', 'Brain Neoplasms']",TERMINATED,,,1990-03,[],[],0,18 Years,70 Years,ALL,False,National Institute of Allergy and Infectious Diseases (NIAID),NIH,0,45.0,,2025-09-01T16:18:15.891932,v2_robust,True,True,False,True,False,
NCT05489523,"Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation","An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation",Tafamidis 61 MG,['Tafamidis 61 MG'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Transthyretin Cardiac Amyloidosis,['Transthyretin Cardiac Amyloidosis'],"['heart transplantation', 'transthyretin amyloidosis', 'ATTR', 'tafamidis']",RECRUITING,,2023-05-01,2026-05-01,"[{'measure': 'Serial change from baseline in plasma TTR levels at 12 months', 'description': 'Serial change from baseline in plasma Time in Therapeutic Range (TTR) levels at 12 months is measured at 3 month intervals. TTR tetramer stability is measured using an immunoturbidimetric assay. Increase in plasma TTR levels indicate TTR tetramer stability.', 'timeFrame': 'Baseline, 3, 6, 9, and 12 months'}]","[{'measure': 'Serial change from baseline in Norfolk QoL-DN at 12 months', 'description': 'Serial change from baseline in Norfolk Quality of Life Diabetic Neuropathy (QoL-DN) at 12 months is measured at 3 month intervals. The Norfolk-QoL-DN total score differentiates between healthy subjects and individuals with ATTRv polyneuropathy as well as different stages of Transthyretin amyloidosis (ATTR) polyneuropathy. The total score has a range of -4 to 136, with a higher score indicating worse disease symptoms. There are five different domains assessed within an overall quality of life score: symptoms, large fiber, small fiber, activities of daily living and autonomic dysfunction.', 'timeFrame': 'Baseline, 3, 6, 9, and 12 months'}, {'measure': 'Serial change from baseline in Composite Autonomic Symptom Score (COMPASS-31) at12 months', 'description': 'Serial change from baseline in Composite Autonomic Symptom Score (COMPASS-31) at12 months is measured at 3 month intervals. COMPASS-31 is a 31-question participant-reported assessment that measures autonomic symptoms across 6 weighted domains on a 100-point scale: orthostatic intolerance (40 points), vasomotor (5 points), secretomotor (15 points), gastrointestinal (25 points), bladder (10 points), and pupillomotor (15 points). A higher score indicates worse autonomic dysfunction.', 'timeFrame': 'Baseline, 3, 6, 9, and 12 months'}, {'measure': 'Number of transplant-specific adverse events', 'description': 'Transplant-specific Adverse events will be determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.', 'timeFrame': '12 months'}, {'measure': 'Number of hepatic or renal transplant-specific adverse events', 'description': 'Hepatic or renal transplant-specific adverse events will be determined according to Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0.', 'timeFrame': '12 months'}, {'measure': 'Steady-state plasma concentration of tafamidis in patients undergone HT for end stage ATTR-CA', 'description': 'Steady-state plasma pharmacokinetic (PK) parameters will calculated based on plasma concentration of tafamidis in patients who have undergone HT for end stage ATTR-CA.', 'timeFrame': 'Baseline, 3, 6, 9, and 12 months'}]",6,18 Years,90 Years,ALL,False,University of Texas Southwestern Medical Center,OTHER,0,25.0,ESTIMATED,2025-09-01T16:18:15.891953,v2_robust,True,True,False,False,True,
NCT00704223,Observational Study to Evaluate the Safety and Efficacy of NovoMix® 70 in Type 2 Diabetes,Observational Study on Safety and Efficacy in Subjects Using NovoMix® 70 (Biphasic Insulin Aspart) for Treatment of Type 2 Diabetes Mellitus,biphasic insulin aspart,"['biphasic insulin aspart', 'NovoMix® 70']",2,OBSERVATIONAL,[],,,Diabetes,"['Diabetes', 'Diabetes Mellitus, Type 2']",[],COMPLETED,,2008-05,2008-11,"[{'measure': 'number of major and minor hypoglycaemic events and adverse events', 'timeFrame': '3 months'}]","[{'measure': 'HbA1c', 'timeFrame': '3 months'}, {'measure': 'PPBG', 'timeFrame': '3 months'}, {'measure': 'FBG', 'timeFrame': '3 months'}]",4,18 Years,,ALL,False,Novo Nordisk A/S,INDUSTRY,0,619.0,ACTUAL,2025-09-01T16:18:15.891985,v2_robust,False,True,True,False,True,
NCT00354523,Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,A Phase I/II Study to Evaluate the Efficacy and Toxicity of Imatinib Mesylate in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma,Capecitabine (Xeloda),"['DTIC-Dome (Dacarbazine)', 'Gleevec (Imatinib Mesylate)', 'Capecitabine (Xeloda)', 'Imatinib']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Solid Tumor,"['Solid Tumor', 'Thyroid Cancer']","['Solid Tumor', 'Thyroid Cancer', 'Medullary Thyroid Cancer', 'MTC', 'Advanced Metastatic Medullary Thyroid Carcinoma', 'Capecitabine', 'Dacarbazine', 'Imatinib', 'Gleevec', 'Imatinib Mesylate', 'DTIC-Dome', 'Xeloda']",TERMINATED,"Study closed following Phase I portion, insufficient activity to continue to Phase II.",2004-12,2013-08,"[{'measure': 'Maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine', 'description': 'The MTD is defined as the dose level below that producing dose limiting toxicity (DLT; i.e. any Grade 4 hematologic toxicity and /or non hematological toxicity \\>/= Grade 3 in 2/6 participants).', 'timeFrame': '21 day cycle'}]","[{'measure': 'Objective Response Rate', 'description': 'Objective response rate is defined to be the proportion of participants achieving Complete Response (CR) or Partial Response (PR). Response to treatment will be measured using the RECIST criteria with radiological evaluation every 9 weeks.', 'timeFrame': 'Minimally 9 weeks (overall study period 5 years)'}]",2,16 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,21.0,ACTUAL,2025-09-01T16:18:15.891993,v2_robust,True,True,False,True,False,"Study closed following Phase I portion, insufficient activity to continue to Phase II."
NCT05243823,Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy,Vaginal Estradiol Tablets (Vagifem®) and Endometrial Cancer Risk in the Treatment of Postmenopausal Vaginal Atrophy: A Register-based Cohort Study in Postmenopausal Women,Vagifem®,"['Non-Vagifem® LDVE, Estradiol', 'Vagifem®']",2,OBSERVATIONAL,[],,,Postmenopausal Vaginal Atrophy,['Postmenopausal Vaginal Atrophy'],[],COMPLETED,,2022-01-15,2022-07-31,"[{'measure': 'First time occurrence of endometrial cancer (yes/no) during time in cohort from entry (start of treatment) to exit (end of study period, occurrence of any other cancer (except non-melanoma skin cancer), date of emigration or date of death)', 'description': 'Yes/no', 'timeFrame': 'From entry (day 0) to exit (upto 19 years)'}]",[],1,50 Years,75 Years,FEMALE,,Novo Nordisk A/S,INDUSTRY,0,500000.0,ACTUAL,2025-09-01T16:18:15.892037,v2_robust,False,True,True,False,False,
NCT01651923,PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMACÊUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS,,Heparin,"['Sodium heparin (Blau Farmacêutica S/A)', 'Heparin', 'Sodium heparin (App Pharmaceuticals)']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['subjects'],UNKNOWN,,2013-02,2013-04,"[{'measure': 'Pharmacodynamic of activity of markers: Anti-Fxa and Anti-FIIA', 'description': 'Blood samples', 'timeFrame': '0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration.'}]","[{'measure': 'Pharmacodynamic of the ratio between the activity Anti-FXa/Anti-FIIa and the activity of TFPI and TTPa', 'description': 'Blood samples', 'timeFrame': 'TFPI: 0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration. TTPa: 0:20, 0:10 before administration and 1 h, 4h, 8h, 12h and 24h after drug administration'}]",2,18 Years,55 Years,MALE,True,Azidus Brasil,INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:15.892069,v2_robust,True,True,False,False,False,
NCT05572723,Comparison of the Effects of Remifentanil and Dexmedetomidine Administered Under General Anesthesia in Rhinoplasty,Comparison of the Effects of Remifentanil and Dexmedetomidine Administered Under General Anesthesia in Rhinoplasty,Remifentanil 2 MG,"['Remifentanil 2 MG', 'dexmedetomidine']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Rhinoplasty,"['Rhinoplasty', 'Dexmedetomidine', 'Remifentanil']","['Remifentanil', 'dexmedetomidine', 'pain', 'recovery', 'shivering']",COMPLETED,,2022-03-01,2022-07-31,"[{'measure': 'Mean arterial pressure', 'description': 'The investigators compare the stability of mean arterial pressure.', 'timeFrame': 'During surgery'}, {'measure': 'Postoperative pain', 'description': 'The investigators compare the effect of remifentanil and dexmedetomidine on postoperative pain. The patients pain level was assessed using the numeric pain scale (Between 0-10, 0 = no pain, 10 = worst pain).', 'timeFrame': 'Up to 30 minutes after the patient wakes up.'}, {'measure': 'Patient Recovery Time', 'description': 'The investigators compare the effect of remifentanil and dexmedetomidine on patient recovery time. The recovery time of the patient will be evaluated by calculating the time between extubated and discharged from the postoperative care unit.', 'timeFrame': 'Postoperative 1. hours'}]","[{'measure': 'Postoperative nausea and vomiting scores', 'description': 'The investigators compare the effect of remifentanil and dexmedetomidine on nausea and vomiting. The presence of PONV was assessed using the Verbal Descriptor Scale (Between 0-3, 0=no nausea, 1=mild, 2=moderate, 3=severe).', 'timeFrame': 'postoperative first 6 hours and 24 hours'}, {'measure': 'Patient satisfaction', 'description': ""The investigators will question patients' degree of postoperative satisfaction. The patient satisfaction scale was used to assess the surgical outcome (Between 1 - 5, 1 = very poor, 5 = very good)."", 'timeFrame': 'Postoperative 6. hours'}, {'measure': 'Surgeon satisfaction', 'description': ""The investigators will question surgeons' degree of satisfaction. The surgical satisfaction scale was used to assess the surgical outcome (Between 1 - 5, 1 = very poor, 5 = excellent)."", 'timeFrame': 'Postoperative 0. hours'}]",6,18 Years,65 Years,ALL,True,Baskent University,OTHER,0,50.0,ACTUAL,2025-09-01T16:18:15.892081,v2_robust,True,True,True,False,False,
NCT03154723,Effects of Early Vitamin A Supplementation on the Risk for Retinopathy of Prematurity in Extremely Preterm Infants,,Vitamin A,"['Vitamin A', 'Retinoic acid']",2,INTERVENTIONAL,['NA'],,,Retinopathy of Prematurity,['Retinopathy of Prematurity'],[],COMPLETED,,2015-08-01,2017-12-31,"[{'measure': 'The rates of Retinopathy of Prematurity', 'timeFrame': '2 years'}]",[],1,1 Hour,45 Weeks,ALL,True,Huiqing Sun,OTHER,1,262.0,ACTUAL,2025-09-01T16:18:15.892108,v2_robust,True,True,True,False,False,
NCT01883323,Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma,Phase II Study Evaluating The Infusion Of Autologous Tumor-Infiltrating Lymphocytes (TILs) And Low-Dose Interleukin-2 (IL-2) Therapy Following A Preparative Regimen Of Non-Myeloablative Lymphodepletion Using Cyclophosphamide And Fludarabine In Patients With Metastatic Melanoma,Cyclophosphamide,"['CYTOXAN, PROCYTOX', 'FLUDARA', 'Fludarabine', 'Cyclophosphamide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Metastatic, Stage III or Stage IV, Melanoma","['Metastatic, Stage III or Stage IV, Melanoma']","['Measurable', 'Unresectable', 'Stage III', 'Stage IV', 'Metastatic', 'Melanoma', 'Tumor-Infiltrating Lymphocytes', 'Low-Dose Interleukin-2', 'Cyclophosphamide', 'Fludarabine']",COMPLETED,,2013-06,2018-04,"[{'measure': 'Clinical response to treatment', 'timeFrame': '6 weeks after treatment'}]","[{'measure': 'Number occurrences and severity of side effects', 'timeFrame': 'Starting at first dose of study treatment up to 10 years'}, {'measure': 'Number of patients with an immunity and no immunity to the study treatment', 'timeFrame': 'From start of study up to 10 years'}]",3,18 Years,,ALL,False,"University Health Network, Toronto",OTHER,0,12.0,ACTUAL,2025-09-01T16:18:15.892142,v2_robust,True,True,True,False,False,
NCT03089723,Saline Lavage X Saline Lavage and Osteonil® Mini in Rizarthritis,"Comparative Study of the Intraarticular Treatment of Carpometacarpal Joint Ostearthritis of the Thumb With Lavage With Saline Solution, or Lavage and Injection of Hyaluronic Acid and Mannitol.",Lavage with physiologic saline solution,"['Lavage with physiologic saline solution and Osteonil® Mini', 'Lavage with Saline (LS)', 'Lavage with physiologic saline solution', 'Lavage with Osteonil® Mini (LO)']",4,INTERVENTIONAL,['NA'],,,Rhizarthrosis,"['Rhizarthrosis', 'Metabolic Disease']","['carpometacarpal joint ostearthritis', 'hyaluronic acid', 'Rhizarthrosis']",UNKNOWN,,2017-03-30,2019-08-30,"[{'measure': 'Improvement in grip strength at 6 months', 'description': 'Perform test and collected data in baseline, 1 month, 3 months and 6 months.', 'timeFrame': 'Baseline, 1 month, 3 months and 6 months.'}]","[{'measure': 'Assess improvement in pain', 'description': 'Answer VAS (Visual Analog Scale)', 'timeFrame': 'Baseline, 1 month, 3 months and 6 months.'}, {'measure': 'Assess improvement in range of motion', 'description': 'Measure range of motion', 'timeFrame': 'Baseline, 1 month, 3 months and 6 months.'}, {'measure': 'Assess improvement in palmar grip strength', 'description': 'Perform palmar grip strength', 'timeFrame': 'Baseline, 1 month, 3 months and 6 months.'}, {'measure': 'Assess improvement in lateral pinch strength.', 'description': 'Perform lateral pinch strength.', 'timeFrame': 'Baseline, 1 month, 3 months and 6 months.'}, {'measure': 'Assess improvement in Pulp-pulp pinch strength', 'description': 'Perform pulp-pulp pinch strength', 'timeFrame': 'Baseline, 1 month, 3 months and 6 months.'}]",6,40 Years,75 Years,ALL,False,University of Sao Paulo General Hospital,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:15.892171,v2_robust,True,True,False,False,False,
NCT00478959,Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma,Phase II Study of Lenalidomide for the Treatment of Relapsed or Refractory Hodgkin's Lymphoma,Lenalidomide (Revlimid®),"['Revlimid', 'Lenalidomide (Revlimid®)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Hodgkin Disease,['Hodgkin Disease'],"['Lenalidomide', 'Revlimid', ""Hodgkin's"", 'Hodgkin', ""Hodgkin's Lymphoma"", ""Hodgkin's Disease"", 'Lymphoma']",COMPLETED,,2006-12,2014-06,"[{'measure': ""To assess the response rate (CR + CRu + PR) of Lenalidomide given as a daily oral dose of 25 mg on days 1 - 21 followed by 7 days of no therapy of a 28 day cycle in the treatment of a population with relapsed or refractory Hodgkin's lymphoma"", 'timeFrame': 'CT scans performed every two months while on therapy'}]",[],1,18 Years,,ALL,False,"University Health Network, Toronto",OTHER,1,30.0,ACTUAL,2025-09-01T16:18:15.892330,v2_robust,True,True,True,False,False,
NCT00533559,Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl,Mechanism of Fatty Acid-induced Impairment of Glucose-stimulated Insulin Secretion - Effect of Buphenyl,sodium phenylbutyrate,"['sodium phenylbutyrate', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Diabetes,"['Diabetes', 'Insulin Resistance']","['type 2 diabetes', 'free fatty acids', 'insulin resistance', 'beta cell lipotoxic effect']",COMPLETED,,2007-09,2010-03,"[{'measure': 'we will measure insulin secretion, calculate disposition index and insulin clearance during a hyperglycemic clamp. We will also measure insulin sensitivity during a euglycemic hyperinsulinemic clamp', 'timeFrame': 'one year'}]","[{'measure': 'During the hyperglycemic clamp we will also measure Free Fatty Acid, C-peptide and triyglycerides. During the euglycemic hyperinsulinemic clamp we will determine the insulin sensitivity index and the disposition index.', 'timeFrame': '1 year'}]",2,35 Years,60 Years,MALE,True,"University Health Network, Toronto",OTHER,0,10.0,ACTUAL,2025-09-01T16:18:15.892415,v2_robust,True,True,True,False,False,
NCT01745159,Preventive Treatment of Tacrolimus Ointment in Children With Atopic Dermatitis,"Proactive Treatment With Tacrolimus Ointment in Children With Moderate/Severe Atopic Dermatitis: A Randomized, Multicenter, Open-label Study",tacrolimus,"['Protopic', 'tacrolimus']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Moderate/Severe Atopic Dermatitis,['Moderate/Severe Atopic Dermatitis'],"['tacrolimus', 'Protopic', 'pediatric', 'atopic dermatitis', 'China']",COMPLETED,,2012-09,2013-11,"[{'measure': 'Time to first DE (disease exacerbation)', 'timeFrame': '6 months of DCP(Disease Control Period) after 2 to 6 weeks of OLP(Open Label Period)'}]","[{'measure': 'Number of DEs during the DCP', 'timeFrame': '6 months of DCP (Disease Control Period)'}, {'measure': 'Eczema Area and Severity Index (EASI)', 'timeFrame': '6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)'}, {'measure': ""Investigator's Global Assessment (IGA)"", 'timeFrame': '6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)'}, {'measure': 'Duration of DE during DCP', 'timeFrame': '6 months of DCP (Disease Control Period)'}, {'measure': 'The overall efficacy during OLP', 'timeFrame': 'After 2 to 6 weeks of OLP (Open Label Period)'}, {'measure': 'Quantity of tacrolimus ointment used', 'timeFrame': '6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)'}, {'measure': 'Incidence of adverse events', 'timeFrame': '6 months of DCP (Disease Control Period) after 2 to 6 weeks of OLP (Open Label Period)'}]",8,2 Years,15 Years,ALL,False,"Astellas Pharma China, Inc.",INDUSTRY,0,125.0,ACTUAL,2025-09-01T16:18:15.892499,v2_robust,True,True,True,False,True,
NCT04668859,Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome,Midodrine as Novel Treatment of Post-Cardiopulmonary Bypass Vasoplegic Syndrome,Midodrine,"['Midodrine', 'Methylcellulose']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Use of Midodrine in Post-cardiopulmonary Bypass Vasoplegic Syndrome,['Use of Midodrine in Post-cardiopulmonary Bypass Vasoplegic Syndrome'],[],TERMINATED,PI relocated,2016-07-29,2018-08-08,"[{'measure': 'Time from procedure end until discontinuation of IV vasopressors', 'timeFrame': '12 months'}]","[{'measure': 'Rate of decline in IV vasopressor dose', 'timeFrame': '12 months'}, {'measure': 'Time until CVL removal', 'timeFrame': '12 mothns'}, {'measure': 'ICU length of stay', 'timeFrame': '12 months'}, {'measure': 'Hospital length of stay', 'timeFrame': '12 months'}, {'measure': 'Rate of major infections/complications', 'timeFrame': '12 months'}, {'measure': 'Rate of in-hospital and 30-day mortality', 'timeFrame': '12 months'}]",7,18 Years,,ALL,False,Medstar Health Research Institute,OTHER,0,10.0,ACTUAL,2025-09-01T16:18:15.892537,v2_robust,True,True,False,True,False,PI relocated
NCT03389659,XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC,"A Randomized, Multicenter, Double-blinded, Phase III Study of Vitamin D3 in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine as First-line Chemotherapy in Previously Untreated Advanced or Metastatic Colorectal Cancer",vitamin D3,"['vitamin D3', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Vitamin D3,['Vitamin D3'],"['mCRC', 'oxaliplatin plus fluoropyrimidine']",UNKNOWN,,2018-02,2022-06,"[{'measure': 'PFS(progression-free survival)', 'description': 'PFS is defined the time from the date of randomization to the date of disease progression or death due to any cause.', 'timeFrame': '5 years'}]","[{'measure': 'OS(overall survival)', 'description': 'OS is defined the time between the date of randomization and the date of death.', 'timeFrame': '5 years'}, {'measure': 'DCR', 'description': 'disease control rate', 'timeFrame': 'up to 1 year'}, {'measure': 'ORR', 'description': 'overall response rate', 'timeFrame': 'up to 1 year'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events', 'description': 'all the adverse events', 'timeFrame': 'through study completion, an average of 1 year'}]",5,18 Years,,ALL,False,Tianjin Medical University Cancer Institute and Hospital,OTHER,0,750.0,ESTIMATED,2025-09-01T16:18:15.892551,v2_robust,True,True,False,False,True,
NCT00572559,Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus,"A Randomized, Open Label, Multi-Center Clinical Trial, Comparing Microbiologic Response To Linezolid And Vancomycin In Ventilator-Associated Pneumonia (VAP) Due To Methicillin Resistant Staphylococcus Aureus (MRSA)",Vancomycin,"['Vancomycin', 'Linezolid']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Pneumonia, Ventilator-Associated","['Pneumonia, Ventilator-Associated']",[],COMPLETED,,2002-11,2005-01,"[{'measure': 'To assess early microbiologic response in patients with VAP due to MRSA based on semi-quantitative culture of bronchoscopic bronchoalveolar lavage (BAL) in patients treated with linezolid vs vancomycin.', 'timeFrame': '72-96 hours'}]","[{'measure': 'To compare duration of mechanical ventilation', 'timeFrame': '0000'}, {'measure': 'To compare post treatment tracheal colonization', 'timeFrame': 'FU: 14 days after EOT +/- 2 days'}, {'measure': 'To identify clinical correlates of infection based on microbiologic sampling as determined by original and modified CPIS (Clinical Pulmonary Infection Score)', 'timeFrame': 'EOT: Day 14; FU: 14 days after EOT +/- 2 days'}, {'measure': 'To compare the microbiological cure based on BAL specimens with the traditional criteria for microbiologic cure', 'timeFrame': '72-96 hours'}, {'measure': 'To compare mortality at End Of Treatment (EOT) and Follow up (FU); To compare clinical outcome at EOT and FU', 'timeFrame': 'EOT: Day 14; FU: 14 days after EOT +/- 2 days'}]",6,18 Years,,ALL,False,Pfizer,INDUSTRY,0,149.0,ACTUAL,2025-09-01T16:18:15.892565,v2_robust,True,True,True,False,False,
NCT02071459,Efficacy of L-threo DOPS on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With MSA,Evaluate the Long-term (3 Months) Efficacy of L-threo DOPS (DroxiDopa) on Orthostatic Hypotension Symptoms and Other Non-motor Symptoms in Patients With Multiple System Atrophy (MSA). Comparative Study Versus Placebo,L-Threo DOPS,"['L DOPS or DroxiDopa', 'placebo', 'L-Threo DOPS']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Multiple System Atrophy,['Multiple System Atrophy'],"['L-threo DOPS (DroxiDopa)', 'Orthostatic Hypotension', 'Multiple system atrophy']",COMPLETED,,2014-01-21,2019-10-28,"[{'measure': 'Evaluate the efficacy of long term efficacy of L-threo DOPS', 'description': 'Evaluate the efficacy of long term efficacy of L-threo DOPS (droxidopa) in MSA patients (probable or possible - cerebellar (C) or parkinsonian (P) type) with symptomatic NOH as measured by the relative change in mean score of Orthostatic Hypotension Symptom Assessment (OHSA) (Part I of the questionnaire on the symptoms OH (OHQ) (Kaufmann et al., 2011)) 12 weeks following randomization to therapy with droxidopa or placebo (including 8 weeks to maximum tolerated dose).', 'timeFrame': '12 weeks'}]","[{'measure': 'efficacy of L-ThreoDOPS on symptomatic OH', 'description': 'Evaluate and compare the efficacy of L-ThreoDOPS on symptomatic OH (measured by the relative change in mean score of Item 1 of the Orthostatic Hypotension Symptom Assessment (OHSA)) in MSA patients 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo', 'timeFrame': '12 weeks'}, {'measure': 'effects of L-Threo DOPS on motor symptoms', 'description': 'Evaluate the effects of L-Threo DOPS on motor symptoms (UMSARS I and II) in MSA patients after 12 weeks following randomization to continued therapy with droxidopa or placebo', 'timeFrame': '12 weeks'}, {'measure': 'effect of L-Threo DOPS on dysautonomic symptoms', 'description': 'Evaluate the effect of L-Threo DOPS on dysautonomic symptoms (COMPASS) in MSA patients after 4, 8 and 12 weeks following randomization to continued therapy with droxidopa or placebo', 'timeFrame': '12 weeks'}, {'measure': 'safety of high doses of L-ThreoDOPS', 'description': 'Determine the safety of high doses of L-ThreoDOPS in MSA patients based on the occurrence of treatment-emergent adverse events', 'timeFrame': '12 Weeks'}]",5,30 Years,80 Years,ALL,False,"University Hospital, Toulouse",OTHER,0,107.0,ACTUAL,2025-09-01T16:18:15.892581,v2_robust,True,True,True,False,True,
NCT07060859,"Topical Dexamethasone, Ascorbic Acid, and BGP for Enhancing Implant Osseointegration","The Influence of The Topical Combined Application of Dexamethasone, Ascorbic Acid, and β-Sodium Glycerophosphate on Implant Osseointegration: A Randomized Clinical Trial","Topical Application of Dexamethasone, Ascorbic Acid, and β-Sodium Glycerophosphate","['Topical Application of Dexamethasone, Ascorbic Acid, and β-Sodium Glycerophosphate']",1,INTERVENTIONAL,['NA'],,,Implant Stability and Osseointegration,['Implant Stability and Osseointegration'],"['dexamethasone', 'ascorbic acid', 'β-sodium glycerophosphate', 'osseointegration', 'implant stability quotient', 'implant stability', 'resonance frequency analysis', 'osteogenic inducer', 'Immediate dental implants']",COMPLETED,,2023-01-15,2023-09-30,"[{'measure': 'Change in Implant Stability Measured by Implant Stability Quotient (ISQ) Using Resonance Frequency Analysis (RFA)', 'description': 'Implant stability will be assessed using resonance frequency analysis (RFA), with results reported as Implant Stability Quotient (ISQ) values. The ISQ scale ranges from 1 (lowest stability) to 100 (highest stability). Higher ISQ values indicate better implant stability and osseointegration.', 'timeFrame': 'At baseline (day of surgery), 4 weeks, 8 weeks, and 16 weeks post-surgery'}]",[],1,18 Years,45 Years,ALL,False,Manar Ziad Foura-Matar,OTHER,0,18.0,ACTUAL,2025-09-01T16:18:15.892671,v2_robust,True,True,True,False,False,
NCT00887159,A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage,A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer,Cisplatin,"[""Peyrone's Chloride"", 'DDP', 'Cisplatyl', 'Metaplatin', 'Neoplatin', 'Placis', 'Platinol', 'Platinum Diamminodichloride', 'GDC-0449', 'Citoplatino', 'Lastet', 'Platinoxan', 'Platistin', 'Cis-diamminedichloridoplatinum', 'Erivedge', 'Cysplatyna', 'Cis-platinous Diamine Dichloride', 'Platinum', 'Vepesid', 'Platinex', ""Peyrone's Salt"", 'Blastolem', 'Cis-platinum II', 'Cisplatinum', 'Platinol-AQ', 'Plastistil', 'Hedgehog Antagonist GDC-0449', 'Lederplatin', 'Platiran', 'Abiplatin', 'Cis-diamminedichloro Platinum (II)', 'Cisplatin', 'Cis-diammine-dichloroplatinum', 'Platamine', 'Briplatin', 'Cis-diamminedichloroplatinum', 'VP-16', 'Platiblastin-S', 'CDDP', 'Platinol- AQ', 'Platinol-AQ VHA Plus', 'Etoposide', 'Demethyl Epipodophyllotoxin Ethylidine Glucoside', 'Platiblastin', 'Cis-platinum', 'Toposar', 'Citosin', 'VP-16-213', 'Cisplatina', 'Platosin', 'Cis-dichloroammine Platinum (II)', 'Vismodegib', 'VP 16-213', 'EPEG', 'Cismaplat', 'Cis-platinum II Diamine Dichloride']",56,INTERVENTIONAL,['PHASE2'],PHASE2,,Extensive Stage Small Cell Lung Carcinoma,"['Extensive Stage Small Cell Lung Carcinoma', 'Recurrent Small Cell Lung Carcinoma']",[],COMPLETED,,2009-07-16,2016-11-15,"[{'measure': 'Progression-free Survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the time from randomization to death or disease progression, whichever occurred first. Patients who were alive at the time of analysis are censored at the date at which they are last known to be alive and progression-free.', 'timeFrame': 'Assessed every 6 weeks while on treatment or observation; follow-up after discontinuation of treatment or observation: every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry'}]","[{'measure': 'Response Rate', 'description': 'Response rate is defined as number of patients with complete response (CR) or partial response (PR) divided by all eligible and treated patients. Responses are evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) guideline. CR is defined as disappearance of all target and non-target lesions. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameters), and persistence of one or more non-target lesion(s).', 'timeFrame': 'Assessed every 6 weeks while on treatment or observation; follow-up after discontinuation of treatment or observation: every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival is defined as the time from randomization to death or date of last known alive.', 'timeFrame': 'Assessed every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry'}, {'measure': 'PFS', 'description': 'Progression-free survival (PFS) is defined as the time from randomization to death or disease progression, whichever occurred first. Patients who were alive at the time of analysis are censored at the date at which they are last known to be alive and progression-free. This analysis is to evaluate the association between PFS and circulating tumor cells (CTCs).', 'timeFrame': 'Assessed every 6 weeks while on treatment or observation; follow-up after discontinuation of treatment or observation: every 3 months if patient is < 2 years from study entry, every 6 months if patient is 2-3 years from study entry'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,168.0,ACTUAL,2025-09-01T16:18:15.892745,v2_robust,True,True,True,False,False,
NCT03138759,Effect of Probenecid on Pexidartinib Pharmacokinetics,"An Open-label, Randomized, 2-treatment, 2-period, Crossover Study to Evaluate the Effect of Probenecid on the Pharmacokinetics of Pexidartinib in Healthy Subjects",Pexidartinib,"['Treatment B', 'Treatment A', 'Probenecid', 'Pexidartinib']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetics in Healthy Volunteers,['Pharmacokinetics in Healthy Volunteers'],[],COMPLETED,,2017-02-27,2017-03-30,"[{'measure': 'Maximum Plasma Concentration (Cmax)', 'description': 'Maximum concentration of the drug and its metabolite in plasma', 'timeFrame': 'predose to 312 hours post dose'}, {'measure': 'Time to Maximum Concentration (Tmax)', 'description': 'Time at which the maximum concentration is reached', 'timeFrame': 'within 312 hours post dose'}, {'measure': 'Area under the curve to the last quantifiable measurement (AUClast)', 'description': 'Area under the drug concentration time curve from the first measurement to the last', 'timeFrame': 'within 312 hours post dose'}]","[{'measure': 'Number of participants experiencing an adverse event', 'description': 'Total number of participants experiencing any adverse event', 'timeFrame': 'within 312 hours post dose'}]",4,18 Years,60 Years,ALL,True,Daiichi Sankyo,INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:15.892780,v2_robust,True,True,True,False,True,
NCT01164059,Clinical Effectiveness of Newer Antipsychotics in Comparison With Conventional Antipsychotics in Schizophrenia,"Clinical Effectiveness Of The Newer Antipsychotic Compounds Olanzapine, Quetiapine And Aripiprazole In Comparison With Low Dose Conventional Antipsychotics (Haloperidol And Flupentixol) In Patients With Schizophrenia",Olanzapine,"['Haloperidol', 'Olanzapine', 'Aripiprazole', 'Quetiapine', 'Flupentixol']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'atypical antipsychotic drugs', 'conventional antipsychotic drugs', 'olanzapine', 'quetiapine', 'aripiprazole', 'haloperidol', 'flupentixol']",COMPLETED,,2010-02,2014-03,"[{'measure': 'Contentment with treatment: Patient (SF-36)', 'timeFrame': '24 weeks'}, {'measure': 'Contentment with treatment: Psychiatrist (CGI)', 'timeFrame': '24 weeks'}]","[{'measure': 'Subscores of SF-36', 'timeFrame': '24 weeks'}, {'measure': 'Subjective wellbeing under neuroleptic treatment scale (SWN-K)', 'timeFrame': '24 weeks'}, {'measure': 'Positive and Negative Syndrome Scale (PANSS)', 'timeFrame': '24 weeks'}]",5,18 Years,65 Years,ALL,False,University of Bremen,OTHER,1,149.0,ACTUAL,2025-09-01T16:18:15.892796,v2_robust,True,True,True,False,False,
NCT04440059,A Study of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia,"A Multicenter, Open Clinical Trial to Evaluate the Safety and Efficacy of ICP-022 in the Treatment of Recurrent or Refractory Waldenstrom Macroglobulinemia (WM)",ICP-022,['ICP-022'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Waldenstrom's Macroglobulinemia Recurrent,"[""Waldenstrom's Macroglobulinemia Recurrent"", ""Waldenstrom's Macroglobulinemia Refractory""]",[],COMPLETED,,2019-08-10,2024-01-09,"[{'measure': 'Major response rate（MRR）', 'timeFrame': 'Up to 3 years'}]","[{'measure': 'The occurrence of adverse events and serious adverse events', 'description': 'The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 4.03 grading criteria', 'timeFrame': 'Cycle 1 (every 2 weeks), cycle 2-12 (every 4 weeks); After cycle 12 (every 12 weeks). Each cycle is 28 days.'}, {'measure': 'Duration of Major Mitigation (DOMR)', 'timeFrame': 'Evaluate during the screening period, 1-6 treatment cycle every 2 cycles (8 weeks), 6th-27th cycles every 3 cycles, evaluating every 6 cycles after the 27th cycle. Each cycle is 28 days.'}, {'measure': 'Progression Free Survival (PFS)', 'timeFrame': 'Evaluate during the screening period, 1-6 treatment cycle every 2 cycles (8 weeks), 6th-27th cycles every 3 cycles, evaluating every 6 cycles after the 27th cycle. Each cycle is 28 days.'}]",4,18 Years,,ALL,False,"Beijing InnoCare Pharma Tech Co., Ltd.",INDUSTRY,0,47.0,ACTUAL,2025-09-01T16:18:15.892854,v2_robust,True,True,True,False,True,
NCT00742859,"Phase 2 Study of the Safety, Tolerability and Pilot Efficacy of Oral Factor Xa Inhibitor Betrixaban Compared to Warfarin","A Phase 2, Randomized, Parallel Group, Dose-Finding, Multicenter, Multinational Study of the Safety, Tolerability and Pilot Efficacy of Three Blinded Doses of the Oral Factor Xa Inhibitor Betrixaban Compared With Open-Label Dose-Adjusted Warfarin in Patients With Non-Valvular Atrial Fibrillation (EXPLORE Xa)",betrixaban,"['Warfarin', 'betrixaban', 'Coumadin', 'Acenocoumarol']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Atrial Fibrillation,['Atrial Fibrillation'],"['Atrial Fibrillation', 'Betrixaban', 'Factor Xa inhibitor', 'Warfarin']",COMPLETED,,2008-10,2009-11,"[{'measure': 'Exposure-adjusted Incidence Rate of Major or Clinically Relevant Non-major Bleeding Episode', 'description': 'The primary endpoint is the time to the first occurrence of major or clinically relevant non-major bleeding. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.', 'timeFrame': 'A maximum of 1 year'}]","[{'measure': 'Exposure-adjusted Incidence Rate of Any Bleeding (Major, Clinically Relevant Non-major, or Minimal)', 'description': 'The time to the first occurrence of any bleeding event. This was presented as the exposure adjusted incidence rate which was calculated as number of subjects experiencing the event divided by total person years across all subjects, where if a patient experiencing the event, year was from first dose date to the first occurrence of the event, and to last study date if not. The confidence interval was calculated via the exact Poisson distribution.', 'timeFrame': 'A maximum of 1 year'}]",2,18 Years,,ALL,False,Portola Pharmaceuticals,INDUSTRY,0,508.0,ACTUAL,2025-09-01T16:18:15.892882,v2_robust,True,True,True,False,False,
NCT04899180,Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis,Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis: A Community Study,99mTc-PYP,['99mTc-PYP'],1,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Aortic Stenosis,"['Aortic Stenosis', 'Transthyretin Amyloidosis', 'Transthyretin Amyloid Cardiomyopathy', 'Transthyretin Cardiac Amyloidosis']",[],COMPLETED,,2023-07-14,2024-01-05,"[{'measure': 'Prevalence of TTR-CA in patients with moderate and severe aortic stenosis', 'description': 'Determine the prevalence of Transthyretin Cardiac Amyloidosis in a community based cohort of consecutive patients with moderate or severe aortic stenosis using 99mTc-Pyrophosphate (99mTc-PYP) single-photon positive emission computed tomography with computed tomography (SPECT/CT)', 'timeFrame': 'Baseline'}]",[],1,75 Years,,ALL,False,Mayo Clinic,OTHER,0,4.0,ACTUAL,2025-09-01T16:18:15.892899,v2_robust,True,True,True,False,False,
NCT03044080,Effects of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot,Effects of Repeated Use of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot in Stroke Patients: A Randomized Clinical Trial,IncobotulinumtoxinA,"['IncobotulinumtoxinA', 'OnabotulinumtoxinA']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Stroke Rehabilitation,"['Stroke Rehabilitation', 'Stroke Rehabilitation Spasticity Management']","['Walking Disorder', 'Stroke', 'Botulinum Toxin', 'Spasticity']",COMPLETED,,2015-01-01,2017-09-30,"[{'measure': 'Change in walking speed', 'description': 'Walking speed, expressed in m/s, is assessed in a 10-m corridor', 'timeFrame': 'Baseline and monthly during 18 months'}]","[{'measure': 'Change in spasticity assessed with the Modified Ashworth Scale', 'description': 'Spasticity assessed with the Modified Ashworth Scale (range 0-5)', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in walking disability assessed with the Scandinavian Stroke Scale', 'description': 'Walking disability is assessed with the Scandinavian Stroke Scale', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in functional ambulation ability assessed with the Modified Walking Categories', 'description': 'Functional ambulation ability is assessed with the Modified Walking Categories', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in step time', 'description': 'Step time (Temporal gait parameter) is expressed in seconds and assessed with instrumented gait analysis', 'timeFrame': 'Baseline and monthly during 18 months'}, {'measure': 'Change in step length', 'description': 'Step length (Spatial gait parameter) is expressed in meters and assessed with instrumented gait analysis', 'timeFrame': 'Baseline and monthly during 18 months'}]",6,18 Years,80 Years,ALL,False,Parc de Salut Mar,OTHER,0,20.0,ACTUAL,2025-09-01T16:18:15.892987,v2_robust,True,True,True,False,False,
NCT00689780,"Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940","A Phase I, Multi-Centre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability and Pharmacokinetics of AZD1940, Including an Interaction Study, After Administration of Oral Multiple Ascending Doses in Adult Subjects With Chronic Low Back Pain",AZD1940,"['Midazolam', 'AZD1940']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Low Back Pain,['Low Back Pain'],"['Pain', 'safety', 'chronic low back pain']",COMPLETED,,2008-03,2008-11,"[{'measure': 'Assessment of adverse events (AEs) occurring during the study, blood pressure (supine and standing), pulse rate, respiratory rate, body temperature, laboratory variables and ECG', 'timeFrame': 'Vital signs, laboratory variables and adverse event each day throughout the study Paper printout ECG and/or digital ECG throughout the study'}]","[{'measure': 'Assessment of psychometric rating scales ( VAMS, CDR test battery, DEQ, ARCI and Bond-Lader)', 'timeFrame': 'Psychometric tests and VAMS (Visual Analogue Mood Scale) throughout the study'}, {'measure': 'To investigate the PK profile (including dose proportionality) of AZD1940 by assessment of plasma concentrations', 'timeFrame': 'Bloodsampling Day 1,6, 10 and 15'}, {'measure': 'Plasma levels of midazolam and 4ß hydroxycholesterol and 6β hydroxycortisol:cortisol urine excretion ratio as markers', 'timeFrame': 'Bloodsampling at day -1, 14'}]",4,20 Years,65 Years,ALL,False,AstraZeneca,INDUSTRY,0,60.0,ESTIMATED,2025-09-01T16:18:15.893092,v2_robust,True,True,True,False,True,
NCT03994380,Use of DNAse in Neutrophilic Asthma,Use of DNAse in Neutrophilic Asthma,RhDNAse Inhalation Solution,['RhDNAse Inhalation Solution'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Neutrophilic Asthma,['Neutrophilic Asthma'],[],UNKNOWN,,2020-02-12,2020-12,"[{'measure': 'Lung Function', 'description': 'FEV1', 'timeFrame': '4 weeks'}, {'measure': 'Symptom Control', 'description': 'Asthma Control Test', 'timeFrame': '4 weeks'}]",[],2,18 Years,,ALL,False,National Jewish Health,OTHER,0,10.0,ESTIMATED,2025-09-01T16:18:15.893131,v2_robust,True,True,False,False,False,
NCT06080880,Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade,Ondanstron Weekly vs Every 3 Weeks for Prevention of Nausea and Vomiting Induced by Chemotherapy Combined With PD-1 Blockade：an Randomized Clinical Trial,Ondansetron every 3 weeks,"['Aprepitant', 'Dexamethasone', 'Ondansetron weekly', 'Ondansetron every 3 weeks']",4,INTERVENTIONAL,['NA'],,,Nausea With Vomiting Chemotherapy-Induced,['Nausea With Vomiting Chemotherapy-Induced'],"['Chemotherapy-induced nausea and vomiting', 'PD-1 blockade', 'Ondanstron']",RECRUITING,,2023-12-01,2027-11,"[{'measure': 'Complete response(CR) rate', 'description': 'Defined as no emesis and no rescue therapy', 'timeFrame': 'Up to 6 weeks'}]","[{'measure': 'The proportion of patients with sustained no emesis, sustained no nausea, sustained no significant nausea, and the mean time to first emetic episode.', 'description': 'The proportion of patients with sustained no emesis, sustained no nausea, sustained no significant nausea (defined as no or mild nausea), and the mean time to first emetic episode.', 'timeFrame': 'Assessed every week'}]",2,18 Years,,ALL,False,Hubei Cancer Hospital,OTHER,0,98.0,ESTIMATED,2025-09-01T16:18:15.893176,v2_robust,True,True,False,False,False,
NCT04398680,A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function,A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13),Belantamab mafodotin,['Belantamab mafodotin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Multiple Myeloma,['Multiple Myeloma'],"['DREAMM 13', 'Belantamab mafodotin monotherapy', 'Hepatic impairment', 'Normal hepatic function', 'Relapsed or refractory multiple myeloma']",RECRUITING,,2021-04-20,2025-10-13,"[{'measure': 'Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Time to Cmax (Tmax) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Concentration at the end of infusion (C-EOI)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Predose plasma concentration (Ctrough) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of Belantamab Mafodotin', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Cmax of total monoclonal antibody (mAb)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Tmax of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: C-EOI of total mAB', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Ctrough of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Tlast of total mAb', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Cmax of Cys Monomethyl Auristatin F (cys-mcMMAF)', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: Tmax of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: C-EOI of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: AUC(0-168 hours) of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}, {'measure': 'Part 1 and Part 2: tlast of cys-mcMMAF', 'timeFrame': 'Up to 48 months'}]","[{'measure': 'Part 1 and Part 2: Change from Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury [mmHg])', 'timeFrame': 'Baseline and up to 4 years'}, {'measure': 'Part 1 and Part 2: Change from Baseline in Vital Sign- Heart rate (beats per minute)', 'timeFrame': 'Baseline and up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)', 'timeFrame': 'Up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with toxicity grading for hematology parameters', 'timeFrame': 'Up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with toxicity grading for clinical chemistry parameters', 'timeFrame': 'Up to 4 years'}, {'measure': 'Part 1 and Part 2: Number of participants with toxicity grading for urine parameters', 'timeFrame': 'Up to 4 years'}]",23,18 Years,,ALL,False,GlaxoSmithKline,INDUSTRY,0,28.0,ESTIMATED,2025-09-01T16:18:15.893187,v2_robust,True,True,False,False,True,
NCT05559580,A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms,"A Phase II, Randomised, Placebo-controlled, Double-blind, Parallel Group, Efficacy and Safety Study of at Least 48 Weeks of Oral BI 685509 Treatment in Adults With Progressive Systemic Sclerosis",Avenciguat (BI 685509),"['Avenciguat (BI 685509)', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,"Scleroderma, Systemic","['Scleroderma, Systemic']",[],ACTIVE_NOT_RECRUITING,,2022-12-13,2026-02-27,"[{'measure': 'Rate of decline in forced vital capacity (FVC) (mL) over 48 weeks', 'timeFrame': '48 weeks.'}]","[{'measure': 'Absolute change from baseline in Modified Rodnan Skin Score (mRSS) at Week 48 in study participants with diffuse cutaneous systemic sclerosis (dcSSc)', 'description': 'To measure mRSS, skin thickness of the patient is rated by palpation using a scale of 0-3, with 0 = normal skin; 1= mild thickness; 2= moderate thickness and 3=severe thickness with an inability to pinch the skin into a fold (worst outcome).', 'timeFrame': 'At baseline and at week 48.'}, {'measure': 'Proportion of responders in study participants with diffuse cutaneous systemic sclerosis (dcSSc) based on the revised Composite Response Index in Systemic Sclerosis (CRISS) at Week 48', 'description': ""Revised Composite Response Index in Systemic Sclerosis (CRISS) at Week 48 (Achievement of ≥ 20% improvement from baseline to week 48 in at least 3 of the 5 core set measures, except ≥ 5% in Forced Vital Capacity (FVC) percent predicted). The CRISS is a two-step composite index which includes in Step 2 the mRSS, FVC percent predicted, HAQ-DI, patient's global assessment and clinicians's global assessment. Step 1 in the ACR-CRISS version consists of the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension. The revised version proposes that the absence of significant gastrointestinal dysmotility requiring parenteral or enteral nutrition and significant digital ischaemia requiring hospitalisation, gangrene or amputation are added to Step 1. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement."", 'timeFrame': 'At baseline and at week 48.'}, {'measure': 'Absolute change from baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) score at Week 48', 'description': 'HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area.', 'timeFrame': 'At baseline and at week 48.'}, {'measure': 'American College of Rheumatology Composite Response Index in Systemic Sclerosis (ACR-CRISS) score in study participants with diffuse cutaneous systemic sclerosis (dcSSc) at Week 48', 'description': ""The CRISS is a two-step composite index which includes in Step 2 the Modified Rodnan Skin Score (mRSS), FVC percent predicted, Health Assessment Questionnaire - Disability Index (HAQ-DI), patient's global assessment and clinicians's global assessment. Step 1 in the ACR-CRISS version consists of the absence of significant worsening of interstitial lung disease, a new scleroderma renal crisis, left ventricular failure or pulmonary arterial hypertension. The outcome is a continuous variable between 0.0 and 1.0 (0 - 100%). A higher score indicates greater improvement."", 'timeFrame': 'At week 48.'}, {'measure': 'Absolute change from baseline in forced vital capacity (FVC) (mL) at Week 48', 'timeFrame': 'At week 48.'}, {'measure': 'Absolute change from baseline in forced vital capacity (FVC) (% predicted) at Week 48', 'timeFrame': 'At baseline and at week 48.'}, {'measure': 'Absolute change from baseline in the Patient Global Assesment (PGA) Visual Analog Scale (VAS) score at Week 48', 'description': ""The PGA is a self-assessment on the patient's overall health in the prior 1 week using a 0-10 ordinal scale, with a higher score indicating a worse outcome."", 'timeFrame': 'At baseline and at week 48.'}, {'measure': 'Absolute change from baseline in the Clinician Global Assessment (CGA) Visual Analog Scale (VAS) score at Week 48', 'description': ""Clinician assessment (CGA) on the patient's overall health in the prior 1 week using a 0-10 ordinal scale, with a higher score indicating a worst outcome."", 'timeFrame': 'At baseline and at week 48.'}, {'measure': ""Composite measure of Raynaud's phenomenon (RP) activity at Week 48"", 'timeFrame': 'Week 48.'}, {'measure': 'Absolute change from baseline in Digital ulcer (DU) net burden at Week 48', 'timeFrame': 'At baseline and at week 48.'}, {'measure': 'Time to treatment failure', 'description': 'Time to treatment failure, defined as the time to one of the following events (whichever occurs first) occurring over the 48-week and extended treatment period:\n\n* death,\n* absolute decline in percent-predicted forced vital capacity (FVC) ≥10% relative to baseline,\n* ≥25% increase in Modified Rodnan Skin Score (mRSS) and an increase in mRSS of \\>5 points,\n* initiation or dose change of immunomodulating/immunosuppressive therapy for clinically significant deterioration of Diffuse cutaneous systemic sclerosis (dcSSc)', 'timeFrame': '48 weeks.'}, {'measure': 'Time to Modified Rodnan Skin Score (mRSS) progression (≥25% increase in mRSS and an increase in mRSS of >5 points) in study participants with diffuse cutaneous systemic sclerosis (dcSSc)', 'timeFrame': '48 weeks.'}, {'measure': 'Proportion of study participants with diffuse cutaneous systemic sclerosis (dcSSc) with Modified Rodnan Skin Score (mRSS) progression (25% increase in mRSS and an increase in mRSS of >5 points)', 'timeFrame': '48 weeks.'}]",14,18 Years,,ALL,False,Boehringer Ingelheim,INDUSTRY,0,214.0,ACTUAL,2025-09-01T16:18:15.893231,v2_robust,True,True,False,False,False,
NCT00024180,FR901228 in Treating Patients With Hematologic Cancer,A Phase I Study of Depsipeptide in Selected Hematologic Malignancies (NSC 630176),romidepsin,['romidepsin'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Leukemia,"['Leukemia', 'Lymphoma']","['Waldenström macroglobulinemia', 'recurrent adult acute myeloid leukemia', 'recurrent adult acute lymphoblastic leukemia', 'refractory chronic lymphocytic leukemia', 'untreated adult acute lymphoblastic leukemia', 'untreated adult acute myeloid leukemia', 'recurrent small lymphocytic lymphoma']",COMPLETED,,2002-01,2006-08,[],[],0,18 Years,,ALL,False,Ohio State University Comprehensive Cancer Center,OTHER,1,,,2025-09-01T16:18:15.893311,v2_robust,True,True,True,False,False,
NCT05169580,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Pociredir","A Phase 1 Open-Label, Multiple-Dose Study to Evaluate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of FTX-6058 in Subjects With Sickle Cell Disease (SCD)",Pociredir oral capsule(s),"['FTX-6058', 'Pociredir oral capsule(s)']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Sickle Cell Disease,"['Sickle Cell Disease', 'Sickle Cell Anemia']","['Sickle Cell Disease', 'Sickle Cell Anemia', 'Pharmacokinetics', 'Pharmacodynamics', 'Pociredir', 'Open label']",RECRUITING,,2021-12-13,2025-12,"[{'measure': 'Treatment-Emergent Adverse Events', 'description': 'To evaluate the safety and tolerability of Pociredir in adult participants with sickle cell disease based on the frequency of adverse events (AEs) and changes in clinically significant laboratory test results, vital signs and electrocardiograms (ECGs) parameters.', 'timeFrame': 'Up to approximately 16 weeks of monitoring'}, {'measure': 'Plasma Concentrations of Pociredir', 'description': 'Blood samples will be collected to measure the plasma concentration of Pociredir at specified timepoints.', 'timeFrame': 'Days 1, 14, 28, 42, 56, 70, 84 and 91'}]","[{'measure': 'Change from Baseline in percentage fetal hemoglobin (%HbF) biomarkers in peripheral blood', 'description': 'The percentage of HbF will be measured in peripheral whole blood.', 'timeFrame': 'Baseline and at Days 1, 14, 28, 42, 56, 70, 84, 91, and 112'}, {'measure': 'Change from Baseline in % Reticulocytes', 'description': 'The percentage of reticulocytes will be measured in peripheral whole blood.', 'timeFrame': 'Baseline and at Days 1, 14, 28, 42, 56, 70, 84, 91, and 112'}, {'measure': 'Change from Baseline in Absolute Reticulocyte Count', 'description': 'The absolute reticulocyte count will be measured in peripheral whole blood.', 'timeFrame': 'Baseline and at Days 1, 14, 28, 42, 56, 70, 84, 91, and 112'}, {'measure': 'Change from Baseline in Red cell distribution width', 'description': 'Blood samples will be collected for the analysis of hematology parameter: red cell distribution width', 'timeFrame': 'Baseline and at Days 1, 14, 28, 42, 56, 70, 84 and 91'}, {'measure': 'Change from Baseline in unconjugated bilirubin', 'description': 'Blood samples will be collected for the analysis of clinical chemistry parameter: unconjugated bilirubin', 'timeFrame': 'Baseline and at Days 1, 14, 28, 42, 56, 70, 84 and 91'}]",7,18 Years,65 Years,ALL,False,Fulcrum Therapeutics,INDUSTRY,0,70.0,ESTIMATED,2025-09-01T16:18:15.893318,v2_robust,True,True,False,False,True,
NCT04549480,Bioequivalence Study of Bosutinib Pediatric Capsule Relative to Commercial Tablet Under Fed Condition,"A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-PERIOD, 2-SEQUENCE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF BOSUTINIB PEDIATRIC CAPSULE AND THE COMMERCIAL TABLET FORMULATIONS IN HEALTHY PARTICIPANTS UNDER FED CONDITION",Bosutinib capsule,"['Bosutinib tablet', 'Bosutinib capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Participants,['Healthy Participants'],"['bosutinib,', 'bioequivalence,', 'Cmax,', 'AUC']",COMPLETED,,2020-09-16,2021-01-15,"[{'measure': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0-inf)]', 'description': 'Area Under the Curve From Time Zero to Extrapolated Infinite Time \\[AUC (0-inf)\\]', 'timeFrame': '6 days'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax)', 'description': 'Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': '6 days'}]","[{'measure': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'description': 'Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)', 'timeFrame': '6 days'}, {'measure': 'Time to Cmax (Tmax)', 'description': 'Time to Cmax (Tmax)', 'timeFrame': '6 days'}, {'measure': 'Apparent Oral Clearance (CL/F)', 'description': 'Clearance of a drug is a measure of the rate at which a drug is metabolized or eliminated by normal biological processes.', 'timeFrame': '6 days'}, {'measure': 'Apparent Volume of Distribution (Vz/F)', 'description': 'Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.', 'timeFrame': '6 days'}, {'measure': 'Plasma elimination half-life (t1/2)', 'description': 'Plasma elimination half-life is the time measured for the plasma concentration to decrease by one half.', 'timeFrame': '6 days'}]",7,18 Years,54 Years,ALL,True,Pfizer,INDUSTRY,0,66.0,ACTUAL,2025-09-01T16:18:15.893326,v2_robust,True,True,True,False,False,
NCT01170780,Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair,Dexamethasone Versus Placebo in Optimizing the Postoperative Period After Laparoscopic Inguinal Hernia Repair,Dexamethasone,"['Saline', 'Natriumchlorid, B. Braun 9 mg/ml', 'Dexamethasone', 'Fortecontin']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Inguinal Hernia,"['Inguinal Hernia', 'Femoral Hernia']","['Inguinal hernia', 'Transabdominal preperitoneal hernia repair', 'TAPP', 'Dexamethasone', 'Pain']",COMPLETED,,2010-08,2011-08,"[{'measure': 'pain during coughing', 'description': 'Assessed with visual analog scale (VAS 0-100 mm)', 'timeFrame': 'day 1'}]","[{'measure': 'pain during coughing', 'description': 'Assessed with VAS', 'timeFrame': '4 days'}, {'measure': 'pain at rest', 'description': 'Assessed with VAS', 'timeFrame': '4 days'}, {'measure': 'convalescence', 'description': 'Registration of number of days after operation before returning to work and recreational activities.', 'timeFrame': '1 month'}, {'measure': 'pain at rest', 'description': 'Assessed with verbal rating scale (VRS:no pain, mild pain, severe pain, worst thinkable pain)', 'timeFrame': '4 days'}, {'measure': 'nausea', 'description': 'Assessed with verbal rating scale (VRS: no nausea, mild nausea, severe nausea, worst thinkable nausea)', 'timeFrame': '2 days'}, {'measure': 'vomiting', 'description': 'yes/no question. If yes, how many times have you been vomiting?', 'timeFrame': '2 days'}, {'measure': 'discomfort', 'description': 'Assessed with visual analog scale (VAS, 0-100 mm)', 'timeFrame': '4 days'}, {'measure': 'fatigue', 'description': 'Assessed with numeric rating scale (NRS, 1-10)', 'timeFrame': '4 days'}]",9,18 Years,85 Years,MALE,False,Mette Astrup Madsen,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:15.893540,v2_robust,True,True,True,False,False,
NCT06196580,"PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval",A Clinical Study Evaluating the Pharmacokinetic Effects of SHR4640 on Repaglinide and Midazolam in Healthy Subjects and the Impact of SHR4640 on QT Interval,repaglinide; midazolam; SHR4640,"['repaglinide; midazolam; SHR4640 placebo', 'repaglinide; midazolam; SHR4640; SHR4640 placebo', 'repaglinide; midazolam; SHR4640']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Gout and Hyperuricemia,['Gout and Hyperuricemia'],[],COMPLETED,,2024-01-04,2024-02-16,"[{'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: Cmax', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: AUC0-t', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: AUC0-inf', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'QTcF corrected for baseline and placebo after oral administration of SHR4640 tablets（ ΔΔ QTcF）', 'timeFrame': 'Day 1 to Day 24'}]","[{'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: Tmax', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: t1/2', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: CL/F', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'The plasma PK parameters of repaglinide, midazolam, and SHR4640 in combination: Vz/F', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'PK parameters for oral SHR4640 tablets: Cmax', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'PK parameters for oral SHR4640 tablets: AUC0-t', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'PK parameters for oral SHR4640 tablets: Tmax', 'timeFrame': 'Day 1 to Day 24'}, {'measure': 'Safety indicators: adverse events', 'timeFrame': 'Screening period up to Day 28'}]",12,18 Years,45 Years,ALL,True,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:15.893559,v2_robust,True,True,True,False,True,
NCT01256580,Intravitreal Bevacizumab vs.Combination Therapy for CNV Due to Other Than AMD,Pilot Study of Intravitreal Bevacizumab vs. Combination Therapy for Choroidal Neovascularization Secondary to Causes Other Than Age-related Macular Degeneration,"Bevacizumab (Avastin; Genentech, Inc.)","['Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy', 'Bevacizumab (Avastin; Genentech, Inc.)']",2,INTERVENTIONAL,['NA'],,,Choroidal Neovascularization,"['Choroidal Neovascularization', 'Myopia', 'Punctate Inner Choroidopathy (PIC)', 'Multifocal Choroiditis', 'Ocular Histoplasmosis Syndrome', 'Central Serous Chorioretinopathy (CSC)', 'Angioid Streaks', 'Trauma, or Hereditary Eye Diseases']",[],WITHDRAWN,Lack of eligible subjects.,2010-08,2013-09,"[{'measure': 'Mean number of treatments per group', 'timeFrame': '12 months'}]","[{'measure': 'Mean change in visual acuity from baseline', 'description': 'Mean change in visual acuity from baseline\n\n* Proportion of subjects losing ≤8 letters (≈1.5 lines) from baseline\n* Proportion gaining ≥15 letters from baseline\n* Proportion with a Snellen equivalent of 20/200 or worse (legal blindness = 20/200 or worse in both eyes)\n* Mean change from baseline in total area of CNV and total area of leakage from CNV from baseline to month 12 by FA Mean change in central subfield macular thickness (CMT) measured by OCT from baseline to month 12 Change of in areas of hypoautofluorescence (indicating atrophy) from baseline to month 12', 'timeFrame': '12 months'}]",2,18 Years,,ALL,False,Massachusetts Eye and Ear Infirmary,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:15.893590,v2_robust,True,True,False,True,False,Lack of eligible subjects.
NCT03809780,Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone,Multicenter Phase II Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone in Elderly Unfit Patients With Newly Diagnosed Multiple Myeloma,Lenalidomide,"['Lenalidomide', 'Dexamethasone']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Myeloma,['Multiple Myeloma'],[],ACTIVE_NOT_RECRUITING,,2019-03-11,2025-12-31,"[{'measure': '2 years Progression Free Survival rates', 'description': 'To evaluate the progression free survival rates at 2 years', 'timeFrame': '2year'}]","[{'measure': '2 years Event-free survival rates', 'description': 'To evaluate the event free survival rates at 2 years', 'timeFrame': '2year'}, {'measure': '2 years Overall Survival rates', 'description': 'To evaluate the overall survival rates at 2 years', 'timeFrame': '2year'}, {'measure': 'Overall response rates', 'description': 'To evaluated the overall response rates, defined as more than partial response.', 'timeFrame': 'assessed for approximately 2 years after administration'}, {'measure': 'Incidence of Treatment-Emergent Adverse Events by CTCAE', 'description': 'To assess the incidence of lenalidomide plus dexamethasone therapy', 'timeFrame': 'assessed for approximately 2 years after administration'}, {'measure': 'Optimal dose in frail patients', 'description': 'To assess the optimal dose of lenalidomide for frail patients with newly diagnosed multiple myeloma.', 'timeFrame': 'through study completion, an average of 1 year'}]",6,70 Years,,ALL,False,Kosin University Gospel Hospital,OTHER,1,70.0,ACTUAL,2025-09-01T16:18:15.893630,v2_robust,True,True,False,False,True,
NCT05902780,Can Caudal Dexmedetomidine Provide Effective Analgesia?,Can Caudal Dexmedetomidine Provide Effective Analgesia During Pediatric Inguinoscrotal Surgery?,Caudal Bupivacaine injection,"['Caudal Dexmedetomidine Injection', 'Caudal Bupivacaine injection']",2,INTERVENTIONAL,['NA'],,,Anesthesia,"['Anesthesia', 'Local Anesthesia']","['Anesthesia', 'Caudal', 'Epidural', 'Regional', 'postoperative pain']",NOT_YET_RECRUITING,,2024-09-01,2027-10-01,"[{'measure': 'Amount of opioids needed by patients.', 'description': 'How much opioids in mcg/kg will the patient needs', 'timeFrame': 'Intraoperative (during the surgery)'}, {'measure': 'Amount of opioids needed by patients.', 'description': 'How much opioids in mcg/kg will the patient needs', 'timeFrame': 'during the first 6 hours postoperative'}, {'measure': 'Time to the first analgesic rescue', 'description': 'Measure time in minutes (min) till the patient needs opioids for the first time postoperative', 'timeFrame': 'during the first 6 hours postoperative'}]","[{'measure': 'Blood pressure', 'description': 'Measure blood pressure in mmHg of the patient every 10 min', 'timeFrame': 'Preoperative,Intraoperative and 2 hours postoperative'}, {'measure': 'Heart rate', 'description': 'Measure heart rate in beat/min every 10 min', 'timeFrame': 'Preoperative, intraoperative, and 2 hours postoperative'}, {'measure': 'Emergence agitation', 'description': 'The incidence of emergence agitation is high in children, the level of agitation will be assessed through Paediatric Anesthesia Emergence Delirium Scale (PAED SCALE) which consist of 5 criteria that are scored using 5-point scale. The scores of each criterion are added to make a total score. The maximum achieved score is 20.', 'timeFrame': 'Intraoperative with extubation'}, {'measure': 'Presence of respiratory depression', 'description': 'Measure respiratory rate in breath/ min', 'timeFrame': '2 hours Postoperative every 10 min'}]",7,1 Year,6 Years,ALL,False,Benha University,OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:15.893645,v2_robust,True,True,False,False,False,
NCT00237380,Safety and Efficacy of Ataluren (PTC124) for Cystic Fibrosis,A Phase 2 Study of PTC124 as an Oral Treatment for Nonsense-Mutation-Mediated Cystic Fibrosis,Ataluren,"['PTC124', 'Ataluren']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cystic Fibrosis,['Cystic Fibrosis'],"['Cystic fibrosis', 'Nonsense mutation', 'Premature stop codon']",COMPLETED,,2005-11-30,2006-05-31,"[{'measure': 'Change From Baseline to End of Treatment in Total Chloride Transport', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2, Day 14 and Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Number of Participants With a Chloride Transport Response', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2 and Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Number of Participants With a Chloride Transport Normalization Between Baseline and End of Treatment', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2 and Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}]","[{'measure': 'Change From Baseline in Nasal Chloride Secretion as Assessed by Transepithelial Potential Difference (TEPD)', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2, Day 14 and Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Change From Baseline in Sweat Chloride Concentration as Determined by Pilocarpine Iontophoresis', 'timeFrame': 'Baseline, Day 41'}, {'measure': 'Change From Baseline in CFTR Protein in Nasal Mucosa as Determined by Immunofluorescence', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2, Day 14 and Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Change From Baseline in Nonsense Mutation CFTR mRNA in Nasal Mucosa as Determined by Quantitative Polymerase Chain Reaction (PCR) Assay', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2, Day 14 and Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Change From Baseline in Number of Neutrophils in Blood', 'timeFrame': 'Baseline Up to Day 56'}, {'measure': 'Change From Baseline in Pulmonary Function as Measured by Spirometry', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2, Day 14 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Change From Baseline in Body Weight', 'timeFrame': 'Baseline of Cycle 1 and Cycle 2, Day 28 of Cycle 1 and Cycle 2 (1 cycle=28 days)'}, {'measure': 'Compliance with Study Treatment', 'timeFrame': 'Baseline Up to Day 56'}, {'measure': 'Pharmacokinetics (PK): Time to Maximum Concentration (Tmax) of Ataluren', 'timeFrame': '0 (predose), 1, 2, 3, and 4 hours (hrs) postdose of the midday dose; 0 (predose), 1, 2, 3, 4, and 12 hrs postdose of the evening dose on Day 1 and Day 27'}, {'measure': 'PK: Maximum Plasma Concentration (Cmax) of Ataluren', 'timeFrame': '0 (predose), 1, 2, 3, and 4 hrs postdose of the morning dose; 0 (predose), 1, 2, 3, and 4 hrs postdose of the midday dose; and 0 hrs (predose), 1, 2, 3, 4, and 12 hrs postdose of the evening dose on Days 1 and 13 of Cycles 1 and 2 (1 cycle=28 days)'}, {'measure': 'PK: Area Under the Plasma Concentration Time Curve (AUC) of Ataluren', 'timeFrame': '0 (predose), 1, 2, 3, and 4 hrs postdose of the morning dose; 0 (predose), 1, 2, 3, and 4 hrs postdose of the midday dose; and 0 hrs (predose), 1, 2, 3, 4, and 12 hrs postdose of the evening dose on Days 1 and 13 of Cycles 1 and 2 (1 cycle=28 days)'}, {'measure': 'PK: Terminal Elimination Half Life (T1/2) of Ataluren', 'timeFrame': '0 (predose), 1, 2, 3, and 4 hrs postdose of the morning dose; 0 (predose), 1, 2, 3, and 4 hrs postdose of the midday dose; and 0 hrs (predose), 1, 2, 3, 4, and 12 hrs postdose of the evening dose on Days 1 and 13 of Cycles 1 and 2 (1 cycle=28 days)'}]",15,18 Years,,ALL,False,PTC Therapeutics,INDUSTRY,0,24.0,ACTUAL,2025-09-01T16:18:15.893678,v2_robust,True,True,True,False,False,
NCT01999179,Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis,Pilot Study of Post-thrombotic Syndrome & Predictors of Recurrence in Cancer Patients With Catheter-related Thrombosis,"Heparin, Low-Molecular-Weight, or direct oral anticoagulants","['dabigatran', 'apixaban', 'rivaroxaban', 'Heparin, Low-Molecular-Weight, or direct oral anticoagulants', 'edoxaban', 'enoxaparin']",6,INTERVENTIONAL,['NA'],,,Venous Thrombosis,"['Venous Thrombosis', 'Neoplasms']","['catheter related thrombosis', 'upper extremity deep venous thrombosis', 'central venous catheters', 'cancer', 'Catheters']",COMPLETED,,2014-06,2022-04-26,"[{'measure': 'PTS Assessment Completion', 'description': 'Percentage of participants who completed post-thrombotic syndrome assessments', 'timeFrame': '1 year'}]","[{'measure': 'Biomarker Sample Collection', 'description': 'Number of participants that completed sample collection for biomarker analysis to predict recurrent venous thrombosis', 'timeFrame': '1 year'}]",2,18 Years,,ALL,False,Medical College of Wisconsin,OTHER,2,27.0,ACTUAL,2025-09-01T16:18:15.893733,v2_robust,True,True,True,False,False,
NCT02585479,Systemic Chemotherapy Versus Transcatheter Arterial Chemoembolization(TACE) for Hepatocellular Carcinoma,Systemic Chemotherapy VersusTranscatheter Arterial Chemoembolization As Palliative Chemotherapy in Patients With Advanced Hepatocellular Carcinoma(HCC),Pirarubicin,"['Lipiodol', 'Oxaliplatin', 'Pirarubicin', 'Eloxatin']",4,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Hepatocellular Carcinoma,['Hepatocellular Carcinoma'],[],WITHDRAWN,It doesn't meet the requirements of randomized trials,2015-10,2017-10,"[{'measure': 'Progression-Free-Survival', 'timeFrame': '3 months'}]","[{'measure': 'Objective response rate', 'timeFrame': '3 months'}, {'measure': 'Overall survival', 'timeFrame': '6 months and 12 months'}, {'measure': 'Time-to-Progression', 'timeFrame': '3 months'}, {'measure': 'Time-to-Progression within liver', 'timeFrame': '3 months'}, {'measure': 'Time-to-Progression outside the liver', 'timeFrame': '3 months'}]",6,18 Years,75 Years,ALL,False,Guangxi Medical University,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:15.893770,v2_robust,True,True,False,True,False,It doesn't meet the requirements of randomized trials
NCT00034879,Iressa Expanded Access Program (EAP),An Expanded Access Clinical Program With ZD1839 (IRESSA®) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC),ZD1839 (Gefitinib),"['Iressa', 'ZD1839 (Gefitinib)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Carcinoma,"['Carcinoma', 'Non-small-cell Lung', 'Metastases', 'Neoplasm']","['Locally advanced and/or metastatic non-operable', 'non-small cell lung cancer (stage III or IV)', 'patients who have failed standard therapy.']",COMPLETED,,2000-08,2003-10,[],[],0,18 Years,,ALL,False,AstraZeneca,INDUSTRY,0,,,2025-09-01T16:18:15.893783,v2_robust,True,True,True,False,False,
NCT04571879,Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children,Nebulized Lidocaine and Intranasal Midazolam for Reducing Pain/Anxiety of Nasogastric Tube Insertion in Children: A Randomized Clinical Trial,Nebulized Lidocaine,"['Intranasal Midazolam', 'Nebulized Xylocaine', 'Nebulized Lidocaine', 'IN Midazolam']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Procedural Anxiety,"['Procedural Anxiety', 'Procedural Pain']",[],UNKNOWN,,2021-08-25,2024-02-28,"[{'measure': 'Pain severity rating scale (FLACC) during insertion of NGT.', 'description': 'score from 0 to 10. Higher scores mean worse outcome', 'timeFrame': '1 year'}]","[{'measure': 'Observer/caregiver pain severity rating:', 'description': 'Score from 1 to 100. Higher scores mean worse outcome', 'timeFrame': '1 year'}, {'measure': 'The ease of procedure: difficulty of insertion on an ordinal scale from 1 to 5, where 5 is the most difficult insertion.', 'description': 'Score from 1 to 5. Higher scores mean worse outcome', 'timeFrame': '1 year'}, {'measure': 'The number of attempts required to successfully insert the NGT', 'description': 'The number of attempts of successful NGT insertion', 'timeFrame': '1 year'}, {'measure': 'Procedural complications/adverse events.', 'description': 'Records complications and adverse effects', 'timeFrame': '1 year'}, {'measure': 'FLAC score at 30 minutes, 60 minutes, 90 minutes, 120 minutes, 150 minutes and 180 minutes post insertion.', 'description': 'Scores from 0 to 10. Higher scores mean worse outcome', 'timeFrame': 'up to 180 minutes'}, {'measure': 'Length of stay in ED', 'description': 'Length of stay in minutes', 'timeFrame': 'up to 180 minutes'}, {'measure': 'Duration of NGT feed.', 'description': 'The observer records data on chart', 'timeFrame': 'up to 180 minutes'}, {'measure': 'Tolerated volume of NGT feed.', 'description': 'Amount of fluid (ml)', 'timeFrame': '1 year'}]",9,6 Months,5 Years,ALL,False,Hamad Medical Corporation,INDUSTRY,0,48.0,ESTIMATED,2025-09-01T16:18:15.893813,v2_robust,True,True,False,False,True,
NCT03652779,A Study to Evaluate the Safety and Tolerability of Tecarfarin in Healthy Chinese Volunteers,"An Open-label, Phase 1, Sequential Cohort, Single-Dose Escalation Study to Assess the Safety and Tolerability of Tecarfarin (ATI-5923) in Healthy Chinese Volunteers",Tecarfarin 10mg,"['Tecarfarin 30mg', 'Tecarfarin 10mg', 'Tecarfarin 40mg', 'Tecarfarin 20mg']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin,['Pharmacokinetic and Pharmacodynamic Profile of Tecarfarin'],[],COMPLETED,,2018-06-22,2019-10-28,"[{'measure': 'Adverse Events Frequency', 'timeFrame': '15 Days'}, {'measure': 'Adverse Events Severity', 'timeFrame': '15 Days'}]","[{'measure': 'Area under the plasma concentration versus time curve', 'timeFrame': '336 Hours'}, {'measure': 'Peak Plasma Concentration', 'timeFrame': '336 Hours'}, {'measure': 'Time which Peak Plasma Concentration is Reached', 'timeFrame': '336 Hours'}, {'measure': 'Elimination Rate Constant', 'timeFrame': '336 Hours'}, {'measure': 'Elimination Half Life', 'timeFrame': '336 Hours'}, {'measure': 'Clearance', 'timeFrame': '336 Hours'}, {'measure': 'Volume of Distribution', 'timeFrame': '336 Hours'}, {'measure': 'International Normalized Ratios', 'timeFrame': '0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15'}, {'measure': 'Prothrombin Time', 'timeFrame': '0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15'}, {'measure': 'Activated Partial Thromboplastin Time', 'timeFrame': '0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15'}, {'measure': 'Coagulation Factor II', 'description': '0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15', 'timeFrame': '8 Days'}, {'measure': 'Coagulation Factor VII', 'description': '0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15', 'timeFrame': '8 Days'}, {'measure': 'Coagulation Factor X', 'description': '0 hour, 1 hour, 4 hours, 8 hours,12 hours, day 2, day 3, day 4, day 8, day 15', 'timeFrame': '8 Days'}]",15,18 Years,55 Years,ALL,True,Lee's Pharmaceutical Limited,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:15.893881,v2_robust,True,True,True,False,True,
NCT00115479,KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients,KULeuven Intensive Insulin Therapy Study in Medical Intensive Care Patients,intensive insulin therapy to maintain normoglycemia,['intensive insulin therapy to maintain normoglycemia'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Critical Illness,['Critical Illness'],"['critical illness', 'intensive care', 'outcome', 'insulin', 'blood glucose']",COMPLETED,,2002-03,2005-06,[{'measure': 'mortality'}],"[{'measure': 'mechanical ventilatory support-dependency'}, {'measure': 'stay in Intensive Care Unit (ICU)'}, {'measure': 'stay in hospital'}, {'measure': 'organ failure'}, {'measure': 'morbidity'}, {'measure': 'a long-term follow up is planned to take place 6 and 12 months after hospital discharge'}]",7,18 Years,,ALL,False,KU Leuven,OTHER,2,1200.0,,2025-09-01T16:18:15.893897,v2_robust,True,True,True,False,False,
NCT03119779,Effect of Pulpotomy Using TheraCal Versus MTA on Survival Rate of Cariously-Exposed Vital Permanent Molars,The Effect of Pulpotomy (Partial or Complete) Using Resin-Modified Calcium Silicate Versus MTA-Anglus on Survival Rate of Cariously-Exposed Vital Young Permanent Molars:A Randomized Clinical Trial,MTA-Anglus,"['TheraCal', 'MTA-Anglus vital pulp therapy', 'TheraCal vital pulp therapy', 'MTA-Anglus']",4,INTERVENTIONAL,['NA'],,,"Caries, Dental","['Caries, Dental']","['pulpotomy', 'deep caries', 'permanent molars', 'MTA']",COMPLETED,,2015-09,2017-04-30,"[{'measure': 'Survival rate', 'description': 'absence of any complication or complementary treatment (absence of spontaneous pain or swelling)', 'timeFrame': '12 months'}]","[{'measure': 'periapical radiolucency', 'description': 'presence or absence of periapical radiolucency radiographically', 'timeFrame': '12 months'}, {'measure': 'internal/ external root resorption', 'description': 'presence or absence of internal/ external root resorption radiographically', 'timeFrame': '12 months'}, {'measure': 'Root maturation', 'description': 'Root maturation assessment radiographically', 'timeFrame': '12 months'}]",4,6 Years,9 Years,ALL,True,Cairo University,OTHER,0,22.0,ACTUAL,2025-09-01T16:18:15.893943,v2_robust,True,True,True,False,False,
NCT06692179,"An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection","An Open-Label, Pilot Clinical Trial To Test The Safety And Feasibility Of A Suspension of Freeze-dried Microbiota In Patients Undergoing Colon Resection",Orally administered preparation of fecal microbiota (MTP-101P),['Orally administered preparation of fecal microbiota (MTP-101P)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Recurrent Clostridioides Difficile Infection,"['Recurrent Clostridioides Difficile Infection', 'Colonic Surgery']",[],RECRUITING,,2025-02-18,2027-02-18,"[{'measure': 'Evaluate engraftment of donor microbiota (see 15.3 for statistics) via determination of alpha and beta diversity.', 'description': ""(via alpha and beta diversity statistics) essentially compares the study patient's microbiome composition at any time point when stool is collected to the microbiome composition of the donor fecal transplant that the study patient receives. Before receiving the fecal transplant, we do not expect the study patient's microbiome composition to mirror the donor. However, after giving the donor fecal transplant, we expect the study patient's microbiome composition to look similar to the transplant they were given."", 'timeFrame': 'Day180'}, {'measure': 'Compare baseline microbiome characteristics with changes over time after MTP-101P.', 'description': 'In addition to the microbiome compositional statistics we will calculate that are detailed above, we will assess measures of gut health and immune function before and after receiving the fecal transplant. These will be the quantity of short-chain fatty acids in the stool, gut barrier markers in the serum (CD-14, occludin, ZO-1), and overall immune function.', 'timeFrame': 'Day180'}]",[],2,18 Years,75 Years,ALL,False,University of Minnesota,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:15.893962,v2_robust,True,True,False,False,False,
NCT00000579,Acute Respiratory Distress Syndrome Clinical Network (ARDSNet),Acute Respiratory Distress Syndrome Clinical Network (ARDSNet),Lysofylline,"['Lysofylline', 'Ketoconazole', 'Methylprednisolone']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,"Respiratory Distress Syndrome, Adult","['Respiratory Distress Syndrome, Adult', 'Lung Diseases']",[],COMPLETED,,1994-09,2004-07,[{'measure': 'Vary by protocol'}],[],1,13 Years,,ALL,False,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,0,,,2025-09-01T16:18:15.894006,v2_robust,True,True,True,False,False,
NCT06534996,A Single Arm Pilot Study of the Chinese Herbal Medicine Formula (SCD-2101) for the Functional Constipation in the Elderly,A Single Arm Pilot Study of the Chinese Herbal Medicine Formula (SCD-2101) for the Functional Constipation in the Elderly,SCD-2101,['SCD-2101'],1,INTERVENTIONAL,['NA'],,,Functional Constipation,['Functional Constipation'],"['elderly, Chinese Herbal Medicine, Functional Constipation']",RECRUITING,,2024-08-01,2024-11-30,"[{'measure': 'Response rate of Complete Spontaneous Bowel Movements (CSBM)', 'description': 'A CSBM responder is defined as a patient who meets the CSBM responder criterion (i.e., a mean increase of CSBM≥1/week compared with CSBM at baseline, in at least 2 out of 4 weeks). A spontaneous bowel movement (SBM) is defined as a bowel movement without laxative use in the preceding 24 hours. A CSBM is defined as a SBM that is associated with a sense of complete evacuation. Baseline of weekly CSBM will be the average between Week -2 and Week 0.', 'timeFrame': 'from baseline to Week 2'}]","[{'measure': 'Change in the number of Complete Spontaneous Bowel Movements (CSBM) per week compared to baseline', 'description': 'A spontaneous bowel movement (SBM) is defined as a bowel movement without laxative use in the preceding 24 hours. A CSBM is defined as a SBM that is associated with a sense of complete evacuation. Baseline of weekly CSBM will be the average between Week -2 and Week 0.', 'timeFrame': 'from baseline to Week 2'}, {'measure': 'Change in the number of Spontaneous Bowel Movements (SBM) per week compared to baseline', 'description': 'weekly Spontaneous Bowel Movement (SBM)', 'timeFrame': 'from baseline to Week 2'}, {'measure': 'Types and severity of adverse reactions after taking the medication', 'description': 'Assessed by number of adverse events or side effects', 'timeFrame': 'from baseline to Week 2'}]",4,60 Years,,ALL,False,Hong Kong Baptist University,OTHER,0,14.0,ESTIMATED,2025-09-01T16:18:15.894046,v2_robust,True,True,False,False,True,
NCT06770296,The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase I Clinical Study,"Pyrotinib at Different Doses in Combination With Trastuzumab and Paclitaxel Chemotherapy for First-Line Treatment of HER2-Positive Advanced Breast Cancer: A Multicenter, Randomized, Double-Cohort Study",Pyrotinib low dose group,"['Pyrotinib normal dose group', 'Pyrotinib low dose group']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Breast Cancer,['Breast Cancer'],"['HER2 positive', 'Pyrotinib']",RECRUITING,,2024-11-01,2028-11-01,"[{'measure': 'Objective Response Rate', 'description': ""Objective Response Rate refers to the percentage of the total number of subjects in the analyzed data set who achieved the best response of CR or PR from the beginning of the study treatment to the time of the subject's disease progression group. Response Evaluation criteria in Solid Tumors (RECIST 1.1) was recommended to assess objective tumor response. Participants had to have measurable tumor lesions at baseline, and the response evaluation criteria were recommended as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to RECIST 1.1 criteria."", 'timeFrame': 'From the time of initiation of treatment in this study to the time of disease progression in the subjects,assessed up to 100 months.'}]",[],1,18 Years,75 Years,ALL,False,The First Affiliated Hospital with Nanjing Medical University,OTHER,7,200.0,ESTIMATED,2025-09-01T16:18:15.894100,v2_robust,True,True,False,False,False,
NCT02424396,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis,Biological Activity and Safety of Low Dose IL2 in Relapsing Remitting Multiple Sclerosis. Multicentric Randomized Study,IL2,"['IL2', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Relapsing Remitting Multiple Sclerosis,['Relapsing Remitting Multiple Sclerosis'],"['Interleukin 2, IL2', 'Relapsing Remitting Multiple Sclerosis', 'Autoimmune diseases', 'Regulatory T cells, Tregs']",COMPLETED,,2016-06-13,2020-06-15,"[{'measure': 'Treg response to low dose IL2 induction course period, expressed as % of total CD4 cells', 'timeFrame': 'at day5'}]","[{'measure': 'Change in Treg percentage on D15 after induction (D1-D5) compared to baseline', 'timeFrame': 'at day15'}, {'measure': 'Change in Treg percentage from D15 to M6 compared to baseline', 'timeFrame': 'Day 15 to Day 169'}, {'measure': 'The cumulative number of new lesions enhanced by Gd+ (Sum of Gd + lesions on T1 MRI on M2, M4 and M6)', 'timeFrame': 'Day 57, Day 113 and Day 169'}, {'measure': 'Frequency of patients free of Gd+ lesions at M6', 'timeFrame': 'Day 169'}, {'measure': 'The cumulative number of new T2 lesions', 'timeFrame': 'Day 169'}, {'measure': 'Annual relapse rate (number of relapses observed over a 6 month period)', 'timeFrame': 'Day 169'}, {'measure': '% of patients with flare', 'timeFrame': 'Day 169'}, {'measure': '% of disease free patient i.e % of patient with no clinical symptoms and no activity on MRI', 'timeFrame': 'Day 169'}]",9,18 Years,65 Years,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,30.0,ACTUAL,2025-09-01T16:18:15.894115,v2_robust,True,True,True,False,False,
NCT01735396,Abiraterone Acetate Trial in African American Prostate Cancer Patients,A Pilot Study of Abiraterone Acetate in African American/Black Patients With Castration Resistant Prostate Cancer,Abiraterone Acetate,"['Zytiga', 'Abiraterone Acetate']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['African American men', 'metastatic prostate cancer', 'castration resistant']",TERMINATED,poor accrual,2012-12,2016-03,"[{'measure': 'Number of Participants With ≥ 30% Change in PSA', 'description': 'The primary objective of this study is to determine a correlation between inherited genetic polymorphisms and antitumor activity (as defined by a decline in PSA of ≥ 30%) in AA patients with castration-resistant prostate cancer treated with Abiraterone. The primary endpoint is the percent change in PSA from baseline to 12 weeks. A decline of ≥ 30% will be correlated with germline SNPs.', 'timeFrame': 'baseline and 12 weeks'}]","[{'measure': 'Response Assessment', 'description': 'Post-treatment changes in measurable disease by RECIST - Response Evaluation Criteria in Solid Tumors Complete Response (CR): Disappearance of all target lesions Partial Response (PR): At least a 30% decrease in the sum of the LD of target lesions, taking as reference the baseline sum LD Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Time to Progression', 'description': 'post-treatment changes in measurable disease by time to disease progression (as per PCWG2 guidelines)', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Bone Scan', 'description': 'post-treatment changes in bone scans (as per PCWG2 guidelines) (""no new lesions"" versus ""new lesions."")', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Safety of Abiraterone', 'description': 'To determine the safety of abiraterone Adverse events as defined by CTCAE v4. Number of participants with serious adverse events grade 4 or 5', 'timeFrame': 'up to 12 weeks'}, {'measure': 'Testosterone', 'description': 'Post-treatment changes in testosterone', 'timeFrame': 'up to 12 weeks'}]",6,18 Years,,MALE,False,Icahn School of Medicine at Mount Sinai,OTHER,0,11.0,ACTUAL,2025-09-01T16:18:15.894134,v2_robust,True,True,False,True,True,poor accrual
NCT04088396,A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA),"Open-Label, Randomized Study With a Tocilizumab Reference Arm to Evaluate Safety, Efficacy and Pharmacokinetics of Baricitinib in Children From 1 to Less Than 18 Years of Age With Systemic Juvenile Idiopathic Arthritis.",Baricitinib,"['Tocilizumab', 'LY3009104', 'Baricitinib']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Systemic Juvenile Idiopathic Arthritis,['Systemic Juvenile Idiopathic Arthritis'],"['Systemic', 'Fever', 'Flare', 'sJIA', 'JIA']",RECRUITING,,2020-02-12,2026-05,"[{'measure': 'Percentage of Participants Achieving Adapted Pediatric American College of Rheumatology 30 Responder Index (PediACR30) Response Criteria at Week 12', 'description': 'Percentage of Participants Achieving Adapted PediACR30 Response Criteria', 'timeFrame': 'Week 12'}]","[{'measure': 'Percentage of Participants Achieving Adapted PediACR30 Response Criteria at Week 24', 'description': 'Percentage of Participants Achieving Adapted PediACR30 Response Criteria', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Participants with Inactive Disease', 'description': 'Percentage of Participants with Inactive Disease', 'timeFrame': 'Week 12'}, {'measure': 'Percentage of Participants with Minimal Disease Activity', 'description': 'Percentage of Participants with Minimal Disease Activity', 'timeFrame': 'Week 12'}, {'measure': 'Change from Baseline in Juvenile Arthritis Disease Activity Score (JADAS)-27', 'description': 'Change from Baseline in JADAS-27', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change from Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item', 'description': 'Change from Baseline in Arthritis-Related Pain Severity as Measured by the CHAQ Pain VAS Item', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)', 'description': 'PK: Cmax, ss of Baricitinib', 'timeFrame': 'Baseline through Week 24'}, {'measure': 'PK: Area Under the Baricitinib Concentration-Time Curve at Steady-State (AUC, ss)', 'description': 'PK: AUC, ss of Baricitinib', 'timeFrame': 'Baseline through Week 24'}]",8,1 Year,17 Years,ALL,False,Eli Lilly and Company,INDUSTRY,0,58.0,ESTIMATED,2025-09-01T16:18:15.894162,v2_robust,True,True,False,False,False,
NCT06789796,a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.,"A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.",Iparomlimab and Tuvonralimab (QL1706),"['Iparomlimab and Tuvonralimab (QL1706)', 'placebo for Iparomlimab and Tuvonralimab (QL1706)', 'placebo for QL1604', 'QL1604']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Small-cell Lung Cancer,['Small-cell Lung Cancer'],[],NOT_YET_RECRUITING,,2025-02,2030-03,"[{'measure': 'Progression-free survival (PFS)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after chemoradiotherapy (CRT) for patients with LS-SCLC as measured by Blinded Independent Review Committee (BIRC)-assessed PFS', 'timeFrame': 'up to 2 years'}, {'measure': 'Overall survival (OS)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by OS', 'timeFrame': 'up to 5 years'}]","[{'measure': 'objective response rate (ORR)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by ORR', 'timeFrame': 'up to 2 years'}, {'measure': 'disease control rate (DCR)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by DCR', 'timeFrame': 'up to 2 years'}, {'measure': 'duration of response (DoR)', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by DoR', 'timeFrame': 'up to 2 years'}, {'measure': 'PFS', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by Investigator-assessed PFS', 'timeFrame': 'up to 2 years'}, {'measure': '1-year OS rate', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by 1-year OS rate', 'timeFrame': 'up to 1 year'}, {'measure': '2-year OS rate', 'description': 'To compare and evaluate the efficacy of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by 2-year OS rate', 'timeFrame': 'up to 2 years'}, {'measure': 'adverse events', 'description': 'To compare and evaluate the safety of QL1706 versus QL1604 as consolidation therapy after CRT for patients with LS-SCLC as measured by the incidence of adverse events (Percentage of participants with treatment-related adverse events as assessed by CTCAEv5.0.) and abnormal laboratory parameters.', 'timeFrame': 'up to 2 years'}]",9,18 Years,75 Years,ALL,False,"Qilu Pharmaceutical Co., Ltd.",INDUSTRY,0,636.0,ESTIMATED,2025-09-01T16:18:15.894201,v2_robust,True,True,False,False,True,
NCT03967496,Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence and Etiologic Factors,"Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence, Implication of Type of Anesthesia and Identification of Other Etiological Factors",Preoperative Medication,"['Preoperative Medication', 'Lisinopril', 'Atorvastatin', 'Amlodipine', 'Bisoprolol', 'Hydralazine', 'Insulin', 'Metformin']",8,OBSERVATIONAL,[],,,Delirium,"['Delirium', 'Anesthesia; Adverse Effect']","['delirium', 'postoperative complications', 'anesthesia recovery period']",COMPLETED,,2019-01-01,2019-03-31,"[{'measure': 'Onset of Immediate postoperative delirium (IPD) in adult patients', 'description': 'Incidence of Immediate postoperative Delirium during Post-Anesthesia-Care-Unit (PACU) stay (at either 15 minutes or 30 minutes after end of anesthesia) as well as at the time of discharge from PACU', 'timeFrame': 'During PACU stay up to 2 hours.'}, {'measure': 'Implication of Type of Anesthesia on incidence of Immediate Postoperative Delirium', 'description': 'Includes General Anesthesia (Inhalational as well as Total intravenous anesthesia), Regional Anesthesia and Monitored anesthesia care', 'timeFrame': 'Intraoperative period'}, {'measure': 'Effect of Perioperative risk factors on incidence of Immediate Postoperative Delirium', 'description': 'Perioperative risk factors include: Electrolyte imbalance, anemia, co-morbidities like diabetes, hypertension, ischemic heart disease, chronic kidney diseases etc, preoperative medications like antihypertensives, oral hypoglycemics, insulin, antiplatelets, etc. All details of perioperative management were recorded.', 'timeFrame': 'Perioperative period prior to delirium assessment.'}]","[{'measure': 'Postoperative Length of stay', 'description': 'From Day of Surgery till Discharge', 'timeFrame': 'Postoperative period up to 8 weeks'}, {'measure': 'Postoperative Complications', 'description': 'urinary infection, Pneumonia, wound infection, Multi-organ failure or any other complications during that surgical episode.', 'timeFrame': 'Postoperative period up to 8 weeks'}, {'measure': 'Mortality rate', 'description': 'Mortality due to All causes during the specific postoperative episode up to 8 weeks', 'timeFrame': 'Postoperative episode up to 8 weeks'}, {'measure': 'Percentage of cases requiring Postoperative Delirium treatment', 'description': 'Pharmacological as well as Non-pharmacological treatment administered during the postoperative stay in the specific surgical episode up to 8 weeks.', 'timeFrame': 'Postoperative period up to 8 weeks'}]",7,18 Years,,ALL,False,Sultan Qaboos University,OTHER,0,402.0,ACTUAL,2025-09-01T16:18:15.894226,v2_robust,False,True,True,False,False,
NCT06982196,Sulodexide in Controlling the Recurrence of Psoriasis,"Multicenter, Randomized, Double-blinded，Controlled Clinical Study to Evaluate the Efficacy and Safety of Sulodexide in Controlling the Recurrence of Psoriasis",Sulodexide,"['Sulodexide', 'Vessel Due F (international brand)', 'Matching placebo for sulodexide soft capsules', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Psoriasis (PsO),"['Psoriasis (PsO)', 'Randomised Controlled Trial']",['Randomized controlled trials'],ENROLLING_BY_INVITATION,,2025-04-20,2027-12-31,"[{'measure': 'Time of appearance of the first psoriatic skin lesion', 'description': 'This outcome measures the duration (in days) from the start of the study intervention (sulodexide or placebo) until the first identifiable recurrence of a characteristic psoriatic skin lesion in participants who had previously achieved complete clearance (PASI 100) with secukinumab therapy.', 'timeFrame': '1 year'}]","[{'measure': 'Psoriasis lesion size and severity index score[PASI]', 'description': 'Psoriasis lesion size and severity index score', 'timeFrame': '1 year'}, {'measure': 'Dermatological Quality of Life Index[DLQI]', 'description': 'Dermatological Quality of Life Index', 'timeFrame': '1 year'}, {'measure': 'Self-Rating Anxiety Scale', 'description': 'The Self-Rating Anxiety Scale (SAS) is a validated 20-item questionnaire used to assess the severity of anxiety symptoms in participants. Each item is scored on a 4-point Likert scale (1 = ""None or a little of the time"" to 4 = ""Most or all of the time""), with higher total scores indicating greater anxiety levels.', 'timeFrame': '1 year'}, {'measure': 'Self-Rating Depression Scale', 'description': 'The Self-Rating Depression Scale (SDS) is a widely used psychological assessment tool designed to measure the intensity and presence of depressive symptoms in individuals.', 'timeFrame': '1 year'}, {'measure': 'Adverse Events [AEs]', 'description': 'AEs are evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events v5.0', 'timeFrame': '1 year'}]",6,18 Years,65 Years,ALL,False,Xijing Hospital,OTHER,0,160.0,ESTIMATED,2025-09-01T16:18:15.894260,v2_robust,True,True,False,False,True,
NCT01769196,Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF),"A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)",Simtuzumab,"['Simtuzumab', 'GS-6624', 'Simtuzumab placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Idiopathic Pulmonary Fibrosis,['Idiopathic Pulmonary Fibrosis'],"['Idiopathic', 'Pulmonary', 'Fibrosis', 'IPF']",TERMINATED,The Study was terminated due to lack of efficacy.,2013-01-31,2016-02-23,"[{'measure': 'Progression Free Survival', 'description': 'Progression free survival (PFS) was defined as the categorical decrease in forced vital capacity (FVC) % predicted (≥ 10% relative decrease in FVC and ≥ 5% absolute decrease in FVC from baseline) with confirmation at a consecutive visit at least 2 weeks later using the same criteria.', 'timeFrame': 'Up to 148 weeks'}, {'measure': 'PFS Among the Participants With sLOXL2 ≥ 50th Percentile', 'timeFrame': 'Up to 148 weeks'}, {'measure': 'PFS Among the Participants With sLOXL2 ≥ 75th Percentile', 'timeFrame': 'Up to 148 weeks'}]","[{'measure': 'Overall Survival (OS)', 'description': 'Overall survival was defined as the time from randomization date to death that occurred prior to the last dose date plus 30 days.', 'timeFrame': 'Up to 151 weeks'}, {'measure': 'Overall Survival Among the Participants With sLOXL2 ≥ 50th Percentile', 'timeFrame': 'Up to 151 weeks'}, {'measure': 'Overall Survival Among the Participants With sLOXL2 ≥ 75th Percentile', 'timeFrame': 'Up to 151 weeks'}, {'measure': 'Relative Change From Baseline in FVC % Predicted', 'description': '* FVC was defined as the volume of air (liters) that can forcibly be blown out after taking a full breath. FVC % predicted was defined as FVC % of the participant divided by the average FVC % in the population for any person of similar age, sex, and body composition.\n* Adjusted means were from mixed model repeated measures (MMRM) model with baseline FVC % predicted, sLOXL2 level, concomitant pirfenidone/nintedanib use (never vs. ever), treatment, visit, and treatment-by-visit interaction terms, including all data up to Week 130\n* The relative change was calculated as 100% \\* ( value at later time point minus value at baseline ) / value at baseline, with lower values indicating a decrease and higher values indicating an increase.', 'timeFrame': 'Weeks 54, 106, and 130'}, {'measure': 'Definite Acute Exacerbations of IPF Among Adjudicated Respiratory Hospitalizations', 'timeFrame': 'Up to 148 weeks'}, {'measure': 'Number of Adjudicated Respiratory Hospitalizations (ARP) Among Total Hospitalizations', 'timeFrame': 'Up to 148 weeks'}, {'measure': 'Number of Participants Experiencing Adjudicated Respiratory Deaths Among Those With Adjudicated Death', 'timeFrame': 'Up to 148 weeks'}, {'measure': 'Absolute Change From Baseline in 6 Minute Walk Distance (6MWD)', 'description': '* Adjusted means were from MMRM model with baseline 6MWD, FVC % predicted, sLOXL2 level, concomitant pirfenidone/nintedanib use (never vs. ever), treatment, visit, and treatment-by-visit interaction terms, including all data up to Week 130.\n* The absolute change was calculated as value at later time point minus value at baseline, with lower values indicating a decrease and higher values indicating an increase.', 'timeFrame': 'Weeks 58, 106, and 130'}, {'measure': ""Absolute Change From Baseline in St. George's Respiratory Questionnaire (SGRQ) Score"", 'description': '* The SGRQ is a disease-specific questionnaire designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Patients respond to questions about symptoms (frequency \\& severity) and impact components (social functioning and psychological disturbances resulting from airways disease). Scores range from 0 to 100, with higher scores indicating more limitations.\n* The absolute change was calculated as value at later time point minus value at baseline, with lower values indicating a decrease and higher values indicating an increase.', 'timeFrame': 'Week 58, 106, and 130'}]",12,45 Years,85 Years,ALL,False,Gilead Sciences,INDUSTRY,0,544.0,ACTUAL,2025-09-01T16:18:15.894338,v2_robust,True,True,False,True,False,The Study was terminated due to lack of efficacy.
NCT00779896,Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study,Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study,Tazarotene,"['Tazarotenic Acid', 'Tazarotene', 'Tazorac (trademark name)']",3,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Cutaneous T-Cell Lymphoma,['Cutaneous T-Cell Lymphoma'],"['To evaluate therapeutic potential of tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study', 'Stage I-IIA disease CTCL']",UNKNOWN,,2008-10,2012-12,"[{'measure': 'Partial response (PR) is defined as some improvement (25%-50%);significant evidence of disease remains or disease has not changed from baseline condition (<25%);no new clinically abnormal(>1.5 cm)lymph nodes,<25% progression of existence'}]",[],1,18 Years,,ALL,False,McGill University,OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:15.894551,v2_robust,True,True,False,False,False,
NCT01186796,Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women,Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women,Fulvestrant,['Fulvestrant'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Women', 'Fulvestrant Study', 'Post Menopausal Women', 'Hormones', 'Healthy Adult Women']",COMPLETED,,2009-06,2013-06,"[{'measure': 'Mean Baseline GH Concentration', 'description': 'Averaged over 90-min baseline on the saline day.', 'timeFrame': 'Withdrawal of blood samples (2.5 mL each) every 10 min for 6 hr. Sampling will begin at 0800 h and conclude at 1400 h.'}]","[{'measure': 'Mean GH Concentration (Pulsatile) in Response to Secretagogue', 'description': 'Subjects were administered 4 different secretagogues: (i) L-arginine/Saline, (ii) L-arginine/Ghrelin, (iii) L-arginine/GHRH, and (iv) L-arginine / GHRH + Ghrelin. The result was calculated by averaging values over the 6 hour collection timeframe.', 'timeFrame': 'Withdrawal of blood samples (2.5 mL each) every 10 min for 6 hr. Sampling will begin at 0800 h and conclude at 1400 h.'}, {'measure': 'Mean Mass of GH Released Per Burst in Response to Secretagogue', 'description': 'Subjects were administered 4 different secretagogues: (i) L-arginine/Saline, (ii) L-arginine/Ghrelin, (iii) L-arginine/GHRH, and (iv) L-arginine / GHRH + Ghrelin. The result was calculated on each 6-hr pool of data by utilizing a previously published deconvolution method and analyzed via two-way ANOVA.', 'timeFrame': 'Withdrawal of blood samples (2.5 mL each) every 10 min for 6 hr. Sampling will begin at 0800 h and conclude at 1400 h.'}, {'measure': 'Mean Duration of GH Bursts (Mode) in Response to Secretagogue', 'description': 'Subjects were administered 4 different secretagogues: (i) L-arginine/Saline, (ii) L-arginine/Ghrelin, (iii) L-arginine/GHRH, and (iv) L-arginine / GHRH + Ghrelin. The result was calculated on each 6-hr pool of data by utilizing a previously published deconvolution method and analyzed via two-way ANOVA.', 'timeFrame': 'Withdrawal of blood samples (2.5 mL each) every 10 min for 6 hr. Sampling will begin at 0800 h and conclude at 1400 h.'}, {'measure': 'Mean GH Half-Life in Response to Secretagogue', 'description': 'Subjects were administered 4 different secretagogues: (i) L-arginine/Saline, (ii) L-arginine/Ghrelin, (iii) L-arginine/GHRH, and (iv) L-arginine / GHRH + Ghrelin. The result was calculated on each 6-hr pool of data by utilizing a previously published deconvolution method and analyzed via two-way ANOVA.', 'timeFrame': 'Withdrawal of blood samples (2.5 mL each) every 10 min for 6 hr. Sampling will begin at 0800 h and conclude at 1400 h.'}]",5,50 Years,80 Years,FEMALE,True,Mayo Clinic,OTHER,2,30.0,ACTUAL,2025-09-01T16:18:15.894580,v2_robust,True,True,True,False,False,
NCT03146962,High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies,A Phase II Study of High Dose Vitamin C Intravenous Infusion in Patients With Resectable or Metastatic Solid Tumor Malignancies,Vitamin C,"['Ascorbic Acid', 'Vitamin C']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Colorectal Cancer,"['Colorectal Cancer', 'Pancreatic Cancer', 'Lung Cancer']",[],COMPLETED,,2017-03-29,2023-04-21,"[{'measure': 'Pathologic Response Based on Tumor Regression Grading in Cohort A Patients', 'description': 'Number of patients with partial or complete pathological response in surgically resected tumor tissue: Pathological response rate is the number of patients with partial or complete pathological response in surgically resected tumor tissue. Pathologic response was assessed by tumor regression grade. This is a pathologic assessment of the amount of residual cancer cells in the specimen and the degree of fibrosis in the sample specimen. A completer response is 0% residual cancer cells. A partial response is 10-50% residual cancer cells, and no response is \\>50% residual cancer cells within the tumor specimen.', 'timeFrame': 'cohort A - 8 weeks'}, {'measure': '3-month Disease Control Rate (DCR) Will be Evaluated Using RECIST v 1.1 in Cohort B Patients.', 'description': 'Percentage of patients with complete response, partial response, or stable disease as a result of their therapy at 3 months', 'timeFrame': 'Cohort B - 3 months'}, {'measure': 'Maximal Tolerated Dose of High Dose Vitamin C in Combination With Y90 Radioembolization', 'description': 'Maximal tolerated dose will be evaluated by assessment of dose limiting toxicities for multiple dose levels. Dose limiting toxicity will be defined as any grade 3-4 adverse event possibly, probably, or definitely attributed to vitamin C therapy in the 21 days of protocol therapy. In any group of 3 patients, if one patient experiences dose limiting toxicity, the group will be expanded by 3 additional patients (eg. 6 for that group). If, at any dose level, 2 or more patients experience a dose limiting toxicity, the maximal tolerated dose will be reached, and further dose escalation will not be pursued. The dose level may then be expanded up to 10 additional patients to confirm the safety and toxicity at that dose level.', 'timeFrame': 'Cohort C - 16 weeks'}]","[{'measure': 'Progression-free Survival (PFS)', 'description': 'PFS is defined as the time from registration to cancer progression or death due to any cause for up to 6 months. Cancer progression is defined using the Response Evaluation Criteria in Solid Tumors v1.1, as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in non-target lesions, or the appearance of new lesions.', 'timeFrame': 'cohort B - up to 6 months'}, {'measure': 'Objective Response Rate (ORR)', 'description': 'Number of patients with a partial response or complete response based on RECIST 1.1 Criteria.', 'timeFrame': 'cohort B - up to 6 months cohort C - 16 weeks'}, {'measure': 'Time to Maximum Concentration and Half-life of Vitamin C (t1/2) in Hours in Cohort B', 'description': 'The serum concentration of vitamin C was serially measured following vitamin C infusion at 1.25 g/kg at various timepoints up to 24 hours post infusion to determine the Tmax and t(1/2) in hours', 'timeFrame': 'Up to 24 hours post-infusion'}, {'measure': 'Safety of High Dose Vitamin C Administration Using CTCAE 4.03.', 'description': 'The number of participants per cohort who experienced a Grade 3 or 4 adverse event (as defined by CTCAE v4.03) that was deemed possibly, probably, or definitely related to Vitamin C.', 'timeFrame': 'Adverse events were assessed from the start of study treatment to 30 days after the last infusion of vitamin C. For Cohort A and C, this was approximately 2 months. For Cohort B this was about a 6 month duration.'}, {'measure': 'Maximum Concentration of Vitamin C in Hours in Cohort B', 'description': 'The serum concentration of vitamin C was serially measured following vitamin C infusion at 1.25 g/kg at various timepoints up to 24 hours post infusion to determine the maximum concentration (Cmax) in mM.', 'timeFrame': 'Up to 24 hours post-infusion'}]",8,18 Years,,ALL,False,Weill Medical College of Cornell University,OTHER,1,61.0,ACTUAL,2025-09-01T16:18:15.894613,v2_robust,True,True,True,False,True,
NCT01736462,"Corneal Endothelial Cell Density Changes, When Mapracorat Ophthalmic Suspension 3%, is Administered for 14 Days","An Open-Label Study to Evaluate 3 Month Corneal Endothelial Cell Density Changes in Healthy Subjects When Mapracorat Ophthalmic Suspension, 3%, is Administered 4 Times Daily for 14 Days",Mapracorat,['Mapracorat'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Corneal Endothelial Cell Changes,['Corneal Endothelial Cell Changes'],"['Cornea', 'Endothelial cell density']",COMPLETED,,2013-02,2013-07,"[{'measure': 'Endothelial Cell Density', 'description': 'The mean endothelial cell density (cells/mm2)(ECD)', 'timeFrame': '3 months (Visit 4)'}]","[{'measure': 'Area under the plasma concentration-time curve', 'description': 'Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (Ct). Blood samples will be collected for the determination of mapracorat and any potential metabolite(s). Concentrations in plasma measured within 1 hour prior to dosing on day 1 (visit 2).', 'timeFrame': 'Day 1 (Visit 2)'}, {'measure': 'Area under the plasma concentration-time curve', 'description': 'Area under the plasma concentration-time curve from time 0 to the time of the last quantifiable concentration (Ct). Blood samples will be collected for the determination of mapracorat and any potential metabolite(s). Blood samples will be collected within 1 hour prior to dosing and at 0.25, 0.5, 1, 2, and 4 hours after a single administration of mapracorat at visit 3.', 'timeFrame': 'Day 15 (Visit 3)'}]",3,18 Years,,ALL,True,Bausch & Lomb Incorporated,INDUSTRY,0,61.0,ACTUAL,2025-09-01T16:18:15.894635,v2_robust,True,True,True,False,False,
NCT02456662,Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline (SPARED) Trial,A Randomized Controlled Trial of Scheduled Prophylactic Antiemetics for Reduction of Emesis With Doxycycline,Ondansetron,"['Ondansetron', 'zofran', 'Placebo']",3,INTERVENTIONAL,['NA'],,,Drug-induced Nausea and Vomiting,['Drug-induced Nausea and Vomiting'],[],COMPLETED,,2015-10-07,2019-04-03,"[{'measure': 'Number of Participants Experiencing Symptoms', 'description': 'Number of participants experiencing symptoms (vomiting or nausea+vomiting) at the time of or after doxycycline', 'timeFrame': '24 hours'}]",[],1,18 Years,45 Years,FEMALE,True,University of Rochester,OTHER,0,319.0,ACTUAL,2025-09-01T16:18:15.894651,v2_robust,True,True,True,False,False,
NCT03833362,Efficacy and Safety of Narlaprevir Used in Combination With Ritonavir in Treatment-Naïve and Failed Prior Treatment With Pegylated Interferon/Ribavirin Patients With Chronic Hepatitis C Genotype 1 (PIONEER - Study),"International, Multicenter, Randomized, Double Blind, Active-controlled, Parallel-group Phase III Study of Narlaprevir/Ritonavir and Pegylated Interferon/Ribavirin in 2 Patient Populations - naïve and Treatment Failure Patients With Genotype 1 Chronic Hepatitis C",Narlaprevir,"['Rebetol', 'Pegasys', 'Ritonavir', 'Placebo Ritonavir', 'PegIntron', 'Pegylated interferon alfa-2a/ Pegylated interferon alfa-2b', 'Placebo Narlaprevir', 'Narlaprevir', 'Ribavirin', 'Norvir']",10,INTERVENTIONAL,['PHASE3'],PHASE3,,Hepatitis C,['Hepatitis C'],[],COMPLETED,,2014-05-07,2017-02-21,"[{'measure': 'Number of patients with Sustained Virologic Response (SVR24)', 'description': 'HCV RNA undetectable by Limit of detection (LOD)', 'timeFrame': 'Week 24 after the end of treatment'}]","[{'measure': 'Number of patients who achieve the Rapid Virological Response (RVR)', 'description': 'HCV RNA \\< LOD', 'timeFrame': 'Week 4 of treatment'}, {'measure': 'Number of patients who achieve the Early Virological Response (EVR)', 'description': 'HCV RNA \\<LOD', 'timeFrame': 'Week 12 of treatment'}, {'measure': 'Number of patients who achieve the End of Treatment Response (ETR)', 'description': 'HCV RNA \\<LOD', 'timeFrame': 'Week 24 of treatment (Arm 1), Week 48 of treatment (Arm 2)'}, {'measure': 'Number of patients who achieve the SVR12', 'description': 'HCV RNA undetectable (by LOD)', 'timeFrame': 'Week 12 after the end of treatment'}, {'measure': 'Number of patients who develop viral breakthrough', 'description': 'Greater than or equal to 1 log10 increase in HCV-RNA above nadir, or detectable HCV-RNA, while on treatment after an initial drop below detection', 'timeFrame': 'Week 24 of treatment (Arm 1), Week 48 of treatment (Arm 2)'}, {'measure': 'Number of patients who develop relapse', 'description': 'HCV RNA undetectable by LOD at end of treatment with subsequent detectable HCV RNA', 'timeFrame': 'Week 24 after the end of treatment'}, {'measure': 'Number of patients who develop anemia', 'description': 'Anemia is defined as as Hb \\<10g/dL', 'timeFrame': 'Week 24 of treatment (Arm 1), Week 48 of treatment (Arm 2)'}, {'measure': 'Number of patients who develop neutropenia', 'description': 'Neutropenia is defined as neutrophils \\<0.75x109/L', 'timeFrame': 'Week 24 of treatment (Arm 1), Week 48 of treatment (Arm 2)'}]",9,18 Years,70 Years,ALL,False,R-Pharm,INDUSTRY,0,420.0,ACTUAL,2025-09-01T16:18:15.894662,v2_robust,True,True,True,False,False,
NCT00718562,Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and Sunitinib,A Multi-center Phase II Study to Evaluate the Efficacy and Safety of AMN107 (Nilotinib) in Patients With Gastrointestinal Stromal Tumors Who Have Progressed on or Are Intolerant to Both Imatinib and Sunitinib,AMN107,['AMN107'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastrointestinal Stromal Tumors,['Gastrointestinal Stromal Tumors'],"['nilotinib', 'AMN107', 'Sunitinib', 'Sunitinib malate', 'Imatinib', 'Imatinib mesylate', 'Tyrosine']",COMPLETED,,2008-09,2013-07,"[{'measure': 'Disease Control Rate (DCR) in all patients with either sunitinib-resistant GIST or in patients with GIST who are intolerant of sunitinib', 'timeFrame': '24 weeks'}]","[{'measure': 'DCR in patients with sunitinib-resistant GIST, Progression free survival (PFS), overall survival (OS), Objective response rate (ORR)', 'timeFrame': '24 weeks'}, {'measure': 'Safety', 'timeFrame': '24 weeks'}, {'measure': 'PK profile', 'timeFrame': '24 weeks'}]",4,20 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,35.0,ACTUAL,2025-09-01T16:18:15.894692,v2_robust,True,True,True,False,True,
NCT04734262,"A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)","A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib Plus Tislelizumab or Combination With Nab-paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",Sitravatinib,"['Nanoparticle albumin-bound paclitaxel', 'BGB-A317', 'Nab-paclitaxel', 'MGCD516', 'Tislelizumab', 'Sitravatinib']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Breast Cancer,['Metastatic Breast Cancer'],['Triple Negative Breast Cancer'],ACTIVE_NOT_RECRUITING,,2021-04-01,2024-06-30,"[{'measure': 'Overall Response Rate (ORR) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'The number of people with tumor responses according to RECIST (V1.1): the proportion of participants who achieves a best overall response of complete response (CR) or partial response (PR).', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of participants experiencing ≥ Grade 3 TRAEs in Cohort B', 'description': 'TRAE are adverse events that occur during or after the first administration of the study drug until 30 days after the study drug is discontinued or the new anticancer treatment is initiated.', 'timeFrame': 'Up to 12 months'}]","[{'measure': 'Duration of Response (DOR) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'The time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Disease Control Rate (DCR) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'The proportion of participants who achieves a best overall response of CR, PR or stable disease(SD).', 'timeFrame': 'Up to 12 months'}, {'measure': 'Progression-free Survival (PFS) by Investigator in Cohort A, Cohort B and Cohort C', 'description': 'Time from the date of randomization to the date of progressive disease (PD) or death, whichever occurs first.', 'timeFrame': 'Up to 12 months'}, {'measure': 'One-year overall survival (OS) rate in Cohort A, Cohort B and Cohort C', 'description': 'OS defined as the time from the date of randomization to the date of death due to any reason. One-year survival rate (percentage of subjects alive at 1 year) was estimated from OS data.', 'timeFrame': 'Up to 12 months'}, {'measure': 'Number of participants experiencing Adverse Events (AEs), Treatment-Related Adverse Events (TRAEs) or Serious Adverse Events (SAEs) in Cohort A, Cohort B and Cohort C', 'description': 'Adverse Events (AEs) according to CTCAE v5.0', 'timeFrame': 'Up to 12 months'}, {'measure': 'Patient report outcomes (PROs) based on the EORTC QLQ-C30 (V.3) Quality of Life Questionnaire in Cohort B and Cohort C', 'description': 'Evaluating the Quality of Life of participants as assessed by EORTC QLQ-C30 Questionnaire', 'timeFrame': 'Through study completion, an average of 1 year'}, {'measure': 'Potential biomarkers associated with efficacy, drug resistance, and/or disease progression (PD) in tumor tissues in Cohort A, Cohort B and Cohort C', 'description': 'Potential biomarkers in tumor tissues associated with efficacy', 'timeFrame': 'Through study completion, an average of 1 year'}]",9,18 Years,,FEMALE,False,Fudan University,OTHER,0,98.0,ACTUAL,2025-09-01T16:18:15.894832,v2_robust,True,True,False,False,True,
NCT00348062,A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension,A Multicenter Evaluation of Methods to Reduce Hyperemia Associated With Bimatoprost Therapy for Glaucoma or Ocular Hypertension,Bimatoprost,['Bimatoprost'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Glaucoma,['Glaucoma'],[],COMPLETED,,,,[],[],0,18 Years,,ALL,,Innovative Medical,INDUSTRY,0,,,2025-09-01T16:18:15.894849,v2_robust,True,True,True,False,False,
NCT04179162,Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment,Phase I/II Trial of Bacillus Calmette-Guérin (BCG) and Intravesical Gemcitabine for Patients With BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer,Bacillus Calmette-Guérin (BCG),"['Gemcitabine', 'Bacillus Calmette-Guérin (BCG)']",2,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Non-Muscle Invasive Bladder Cancer (NMIBC),['Non-Muscle Invasive Bladder Cancer (NMIBC)'],"['Bacillus Calmette-Guérin (BCG)', 'Gemcitabine', '19-374']",ACTIVE_NOT_RECRUITING,,2019-11-22,2026-11,"[{'measure': 'evaluate the MTD (Phase I)', 'description': 'Describe the toxicities by frequency and by grade.This study will use CTCAE version 5.0 for toxicity and serious adverse event reporting.', 'timeFrame': '1 year'}, {'measure': 'proportion of patients who are disease free', 'description': 'Will be assessed by both urine cytology and cystoscopy at 6 months after initiation of therapy. Disease free (i.e., complete treatment response) is defined as no evidence of disease (negative cytology and cystoscopy).', 'timeFrame': '6 months after the start of treatment'}]",[],2,18 Years,,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,0,54.0,ACTUAL,2025-09-01T16:18:15.894855,v2_robust,True,True,False,False,True,
NCT01622946,The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach,"The Effect of Topical Application of Tranexamic Acid in Total Hip Arthroplasty Through the Direct Anterior Approach. A Prospective, Double Blind, Placebo-controlled Clinical Trial.",Tranexamic Acid,"['Tranexamic Acid', 'placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Total Hip Arthroplasty,"['Total Hip Arthroplasty', 'Postoperative Blood Loss']","['total hip arthroplasty', 'tranexamic acid', 'postoperative blood loss']",COMPLETED,,2012-04,2020-04,"[{'measure': 'postoperative blood loss in patients undergoing primary total hip arthroplasty', 'timeFrame': 'Haemoglobin levels, on which the postopererative blood loss is calculated, is measured preoperative and on day 1 and 4 postoperative'}]",[],1,18 Years,99 Years,ALL,False,Universitaire Ziekenhuizen KU Leuven,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:15.894898,v2_robust,True,True,True,False,False,
NCT03324646,Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1),Evaluation of a Novel PET Radioligand to Image Cyclooxygenase-1 (COX-1),[11C]PS13,['[11C]PS13'],1,OBSERVATIONAL,[],,,Normal Physiology,['Normal Physiology'],"['Research', 'Brain', 'Inflammation', 'Natural History']",COMPLETED,,2017-10-03,2024-01-30,"[{'measure': 'PET tracer update', 'description': 'For whole body imaging, organ uptake will be quantified as a Standardized Uptake Value (SUV), which normalizes for injected activity and body weight. Blockade by aspirin, ketoprofen, and celecoxib will be expressed as a percentage of the baseline scan in each subject and plotted relative to the plasma concentration of the drug at time of the PET scan. For dedicated brain imaging, uptake will be quantified as distribution volume (VT) calculated with compartmental modeling and serial concentrations of parent radioligand in arterial and/or venous plasma.', 'timeFrame': 'during PET scan'}]",[],1,18 Years,99 Years,ALL,False,National Institute of Mental Health (NIMH),NIH,0,52.0,ACTUAL,2025-09-01T16:18:15.894944,v2_robust,False,True,True,False,False,
NCT03299946,Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC),Cabozantinib,"['XL184', 'Cabozantinib', 'Nivolumab', 'OPDIVO, BMS 936558, MDX-1106, ONO-4538']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Locally Advanced Hepatocellular Carcinoma,['Locally Advanced Hepatocellular Carcinoma'],"['Nivolumab', 'Cabozantinib', 'Neoadjuvant', 'Immunotherapy', 'Liver Cancer', 'Borderline Resectable', 'Advance Resectable', 'Neoplasms', 'Hepatocellular Carcinoma', 'HCC', 'Resection']",COMPLETED,,2018-05-14,2021-10-01,"[{'measure': 'Number of adverse events in participants of neoadjuvant cabozantinib plus nivolumab.', 'timeFrame': '4 years'}, {'measure': 'Number of patients who complete pre-op treatment and proceed to surgery.', 'timeFrame': '4 years'}]","[{'measure': 'Percentage of participants who obtain R0 resection.', 'timeFrame': '4 years'}, {'measure': 'Percentage of participants who obtain a pathologic complete response (CR).', 'timeFrame': '4 years'}, {'measure': 'Percentage of participants who obtain a major pathologic responses (MPR)', 'timeFrame': '4 years'}, {'measure': 'Objective response rate (ORR)', 'timeFrame': '4 years'}, {'measure': 'Median Overall Survival (OS)', 'timeFrame': '5 years'}, {'measure': 'Disease free survival (DFS)', 'timeFrame': '5 years'}]",8,18 Years,,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,2,15.0,ACTUAL,2025-09-01T16:18:15.895173,v2_robust,True,True,True,False,True,
NCT00099346,MK0457 (an Aurora Kinase Inhibitor) Study in Patients With Advanced Colorectal Cancer and Other Advanced Solid Tumors (0457-001),"A Phase I/IIa Study Evaluating the Safety/Tolerability, Pharmacokinetics, and Efficacy of MK0457 Administered as a 5-Day Continuous Infusion in Patients With Advanced Colorectal Cancer and Other Solid Tumors","MK0457, VX-680 (Aurora Kinase Inhibitor)","['MK0457, VX-680 (Aurora Kinase Inhibitor)']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Colorectal Cancer,"['Colorectal Cancer', 'Advanced Solid Tumors']",[],TERMINATED,,2005-01,2007-04,[],[],0,18 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,,,2025-09-01T16:18:15.895213,v2_robust,True,True,False,True,False,
NCT03661346,Esmolol vs. Labetalol in Endoscopic Sinus Surgery,Blood Loss and Visibility With Esmolol vs. Labetalol in Endoscopic Sinus Surgery: A Randomized Trial,Labetalol,"['Esmolol', 'Labetalol']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Chronic Sinusitis,['Chronic Sinusitis'],[],COMPLETED,,2017-03-01,2018-03-30,"[{'measure': 'Intra-operative Surgical Visibility - Boezaart Scale', 'description': 'Standardized scoring systems used by surgeons to rate surgical field quality in FESS:\n\nBoezaart scale (0-5):\n\n0 = no bleeding (optimal)\n\n1. = slight bleeding with no suction required\n2. = slight bleeding with occasional suctioning required\n3. = slight bleeding with frequent suctioning required\n4. = moderate bleeding with frequent suctioning required and surgical field visibility is compromised when suctioning is removed\n5. = severe bleeding (worst) with constant suctioning required and compromised view', 'timeFrame': 'Duration of operation'}, {'measure': 'Intra-operative Surgical Visibility - Wormald Scale', 'description': 'Standardized scoring systems used by surgeons to rate surgical field quality in FESS:\n\nWormald scale (0-10):\n\n0 = No bleeding (optimal)\n\n1. = 1-2 points of blood ooze\n2. = 3-4 points of ooze\n3. = 5-6 points of ooze\n4. = 7-8 points of ooze\n5. = 9-10 points of ooze\n6. = \\>10 points of ooze, obscuring field\n7. = Mild field bleeding with slow post-nasal accumulation\n8. = Moderate field bleeding with moderate post-nasal accumulation\n9. = Moderate-severe field bleeding with rapid post-nasal accumulation\n10. = Severe bleeding (worst) with nose filling rapidly', 'timeFrame': 'Duration of operation up to 3 hours'}]","[{'measure': 'Rate of Blood Loss', 'description': 'milliliters per minute', 'timeFrame': 'Duration of operation up to 3 hours'}, {'measure': 'Average Mean Arterial Blood Pressure', 'description': 'units of mmHg, measured throughout operation', 'timeFrame': 'Duration of operation up 3 hours/completion of operation'}, {'measure': 'Average Heart Rate', 'description': 'units of beats per minute, measured throughout the operation', 'timeFrame': 'Duration of operation up to 3 hours/completion of surgery'}]",5,18 Years,,ALL,False,"The University of Texas Medical Branch, Galveston",OTHER,0,28.0,ACTUAL,2025-09-01T16:18:15.895252,v2_robust,True,True,True,False,False,
NCT06584188,The Effect of Anti-inflammatory Cryoagent on the Level of Postoperative Pain in Patients with Symptomatic Irreversible Pulpitis and Apical Periodontitis.,The Effect of Anti-inflammatory Cryoagent on the Level of Postoperative Pain in Patients with Symptomatic Irreversible Pulpitis and Apical Periodontitis.,anti-inflammatory ketorolac tromethamine,['anti-inflammatory ketorolac tromethamine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Postoperative Pain,['Postoperative Pain'],[],NOT_YET_RECRUITING,,2024-11-01,2025-09-30,"[{'measure': 'Level of Post-operative pain.', 'description': 'measure intensity of post operative pain using visual analogue scale that was represented by a 100 mm horizontal ruler with no number markings other than a 0 at one end and a 10 at the other end. The following categories of postoperative pain levels were used to assess pain: 0 indicating no pain, mild pain (1-3), moderate pain (4-7) and severe pain (8-10)', 'timeFrame': '12 hours post operative'}, {'measure': 'Level of Post-operative pain.', 'description': 'measure intensity of post operative pain using visual analogue scale that was represented by a 100 mm horizontal ruler with no number markings other than a 0 at one end and a 10 at the other end. The following categories of postoperative pain levels were used to assess pain: 0 indicating no pain, mild pain (1-3), moderate pain (4-7) and severe pain (8-10)', 'timeFrame': '24 hours post operative'}, {'measure': 'Level of Post-operative pain.', 'description': 'measure intensity of post operative pain using visual analogue scale that was represented by a 100 mm horizontal ruler with no number markings other than a 0 at one end and a 10 at the other end. The following categories of postoperative pain levels were used to assess pain: 0 indicating no pain, mild pain (1-3), moderate pain (4-7) and severe pain (8-10)', 'timeFrame': '48 hours post operative'}]","[{'measure': 'Level of substance P expression.', 'description': 'Quantification of substance P will be done using an ELISA test from peri-radicular fluid swab.', 'timeFrame': '15 minutes following access cavity preparation.'}, {'measure': 'Level of substance P expression.', 'description': 'Quantification of substance P will be done using an ELISA test from peri-radicular fluid swab.', 'timeFrame': '30 minutes following access cavity preparation.'}, {'measure': 'Level of substance P expression.', 'description': 'Quantification of substance P will be done using an ELISA test from peri-radicular fluid swab.', 'timeFrame': 'Immediately prior to obturation'}]",6,18 Years,40 Years,ALL,True,Ain Shams University,OTHER,0,60.0,ESTIMATED,2025-09-01T16:18:15.895442,v2_robust,True,True,False,False,False,
NCT03041688,"Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia",A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia,Decitabine,"['Dacogen', 'GDC-0199', 'Venclyxto', 'ABT-0199', 'Deoxyazacytidine', '(3R,5R,6S)-5-(3-Chlorophenyl)-6-(4-chlorophenyl)-3-methyl-1-((1S)-2-methyl-1-(((1-methylethyl)sulfonyl)methyl)propyl)-2-oxo-3-piperidineacetic Acid', 'Venclexta', 'KRT 232', 'AMG 232', ""5-Aza-2'-deoxycytidine"", 'ABT199', 'ABT-199', 'RG7601', 'KRT-232', 'Venetoclax', 'Navtemadlin', 'AMG-232', 'GDC0199', 'Decitabine for Injection', 'Dezocitidine', 'Decitabine', 'GDC 0199', 'KRT232', 'ABT 199', 'MDM2 Inhibitor KRT-232']",25,INTERVENTIONAL,['PHASE1'],PHASE1,,Acute Myeloid Leukemia,"['Acute Myeloid Leukemia', 'Recurrent Acute Myeloid Leukemia', 'Refractory Acute Myeloid Leukemia', 'Secondary Acute Myeloid Leukemia']",[],ACTIVE_NOT_RECRUITING,,2018-02-08,2026-06-30,"[{'measure': 'Incidence of toxicity', 'description': 'Will be evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) will be determined. Based on the toxicity observed, a derived variable, the occurrence of dose limiting toxicity, will be created. Will be correlated with MDM2 Inhibitor KRT-232 (KRT-232) (MDM2 inhibitor AMG-232 \\[AMG-232\\]) and decitabine exposure. Toxicities will be tabulated and reported according to dose level, grade, type, cycle, and attribution- and, if numbers permit, by whether the patient had newly diagnosed or previously treated acute myeloid leukemia (AML). Cumulative incidence curves will be used to estimate the proportion of patients who will discontinue therapy for reasons of toxicity or general inability to tolerate the regimen. The data from all patients treated at the RP2D, will be combined for a final summary and listing of toxicities observed.', 'timeFrame': 'Up to 4 weeks'}]","[{'measure': 'Pharmacokinetics (PK) profile', 'description': 'Will be measured using liquid chromatography/tandem mass spectrometric method. Standard descriptive methods (point estimates and confidence intervals, scatterplots) will be used to summarize the baseline levels and the changes from baseline (i.e. after treatment). The individual PK parameters from a single dose will be estimated maximum concentration (Cmax), area under the curve (AUC), half-life (T1/2), apparent clearance, and apparent volume of distribution using non-compartmental or compartmental PK methods with the software WinNonlin. Cmax and AUC will be calculated for decitabine systemic exposure.', 'timeFrame': 'Baseline, 1, 3, 5, 8 and 24 hours post dose on days 4 and 18 of course 1; baseline, 0.5 hour, prior to end of infusion, 0.25, 0.5, and 1 hour post infusion on days 1 and 4 of course 1'}, {'measure': 'P53 activation', 'description': 'Will be measured by MIC-1 levels. For serum MIC-1 levels, each individual level will be normalized to the baseline level for that patient. Will be analyzed using nonparametric statistics. Significance for comparisons will be at the p \\< 0.05 level.', 'timeFrame': 'Up to 4 weeks'}, {'measure': 'Change in p53 signaling', 'description': 'Will be correlated with KRT-232 (AMG-232) and decitabine exposure. Will be analyzed using nonparametric statistics. Significance for comparisons will be at the p \\< 0.05 level.', 'timeFrame': 'Baseline to 30 days after end of study treatment'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,58.0,ESTIMATED,2025-09-01T16:18:15.895516,v2_robust,True,True,False,False,True,
NCT00081588,"An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.","An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.",TMC114,['TMC114'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,HIV Infection,['HIV Infection'],"['TMC114-C215', 'Ritonavir', 'HIV infections', 'TMC114-C202', 'TMC114-C213']",COMPLETED,,2003-11,2008-12,"[{'measure': 'The primary parameter is the confirmed virologic response at Week 24 (a drop in viral load (copies/mL) of at least 1 log10 versus baseline.', 'timeFrame': '24 weeks'}]","[{'measure': 'Proportion of patients with a virologic response; with plasma HIV-1 RNA levels < 50 copies/mL; with plasma HIV-1 RNA levels < 400 copies/mL; Time to loss of virologic response over 144 week treatment period; Change in plasma viral load at all time points', 'timeFrame': '144 weeks'}]",2,18 Years,,ALL,False,"Tibotec Pharmaceuticals, Ireland",INDUSTRY,0,555.0,ACTUAL,2025-09-01T16:18:15.895532,v2_robust,True,True,True,False,False,
NCT06374888,Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases,"A Single-arm, Open, Multicenter Phase II Clinical Study of Nilatinib Maleate Tablets Combined With Capecitabine in the Treatment of HER2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastases",Neratinib maleate in combination with capecitabine,['Neratinib maleate in combination with capecitabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis,['Her2-positive Advanced Esophageal/Esophagogastric Junction/Gastric Adenocarcinoma With Brain Metastasis'],"['Her2-positive', 'esophageal', 'esophagogastric junction', 'gastric adenocarcinoma', 'brain metastasis']",NOT_YET_RECRUITING,,2024-04-30,2027-07-30,"[{'measure': 'Objective response rates of the central nervous system as assessed by the Independent Imaging Evaluation Committee based on RECIST1.1', 'description': 'Objective response rates: Proportion of patients whose tumor volume shrinks by 30% and is maintained for more than 4 weeks', 'timeFrame': 'Throughout the study for approximately 3.5 years'}]","[{'measure': 'Central nervous response rate', 'description': 'reference to RANO-BM evaluation criteria for neurologic tumor brain metastases', 'timeFrame': 'Throughout the study for approximately 3.5 years'}, {'measure': 'Objective response rates outside the central nervous system', 'description': 'ORR,Proportion of patients with a 30% reduction in tumor volume that lasts more than 4 weeks', 'timeFrame': 'Throughout the study for approximately 3.5 years'}, {'measure': 'Disease control rate', 'description': 'It refers to the proportion of cases with complete response, partial response, and stable disease after treatment', 'timeFrame': 'Throughout the study for approximately 3.5 years'}, {'measure': 'Duration of reaction', 'description': 'It refers to the time between the first evaluation of a tumor as CR or PR and the second evaluation as Progressive Disease (PD) or death from any cause.', 'timeFrame': 'Throughout the study for approximately 3.5 years'}, {'measure': 'Clinical benefit rate', 'description': 'Refers to the time from the first evaluation of a tumor as CR or PR to the first evaluation as PD or death from any cause.', 'timeFrame': 'Throughout the study for approximately 3.5 years'}, {'measure': 'overall survival', 'description': ""Refers to the time between the start of treatment and the patient's death or last follow-up."", 'timeFrame': 'Throughout the study for approximately 3.5 years'}]",7,18 Years,,ALL,False,"Convalife (Shanghai) Co., Ltd.",INDUSTRY,0,28.0,ESTIMATED,2025-09-01T16:18:15.895543,v2_robust,True,True,False,False,False,
NCT01476488,Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients,Conversion of Twice-a-day Tacrolimus to Once-Daily Tacrolimus Extended-Release Formulation in Stable Pediatric Kidney Transplant Recipients,tacrolimus,"['Advagraf', 'tacrolimus', 'Prograf']",3,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Kidney Transplantation,"['Kidney Transplantation', 'Pediatric Patients', 'Maintenance With Tacrolimus']",[],COMPLETED,,2011-07,,"[{'measure': 'Area Under the Curve of tacrolimus pharmacokinetics (AUC0-24)', 'description': 'The investigator will compare the changes in AUC0-24 of tacrolimus, Cmax, Tmax and correlation between C0 and Cmax'}]",[{'measure': 'Number of Participants with Adverse Event'}],2,5 Years,15 Years,ALL,False,Seoul National University Hospital,OTHER,0,,,2025-09-01T16:18:15.895608,v2_robust,True,True,True,False,True,
NCT00003288,Tirapazamine Plus Cyclophosphamide in Treating Children With Refractory Solid Tumors,A Trial of Tirapazamine and Cyclophosphamide in Children With Refractory Solid Tumors,cyclophosphamide,"['tirapazamine', 'cyclophosphamide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Childhood Solid Tumor, Protocol Specific","['Unspecified Childhood Solid Tumor, Protocol Specific']","['unspecified childhood solid tumor, protocol specific']",COMPLETED,,1998-08,,[],[],0,,21 Years,ALL,False,National Cancer Institute (NCI),NIH,0,12.0,ACTUAL,2025-09-01T16:18:15.895629,v2_robust,True,True,True,False,False,
NCT02585388,Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.,"A Randomized Phase II, Multicenter Study Evaluating the Benefit of Adding a Non Steroidal Aromatase Inhibitor to Oral Vinorelbine in Patients With Pretreated Metastatic Breast Cancer",Vinorelbine,"['Navelbine', 'ARM B', 'ARM A', 'Anastrozole', 'Vinorelbine', 'Letrozole']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],['pretreated metastatic breast cancer'],TERMINATED,Treatment toxicity,2015-10-23,2017-05-15,"[{'measure': 'Progression free survival (PFS)', 'description': 'Proportion of progression or death', 'timeFrame': 'up to 6 months'}]","[{'measure': 'Evaluation of partial and complete response rate by RECIST 1.1', 'description': 'partial and complete response rate by RECIST 1.1 in each arm', 'timeFrame': 'up to 6 months'}, {'measure': 'duration of response', 'description': 'duration of response is defined as the time from randomization and the disease progression', 'timeFrame': 'up to 6 months'}, {'measure': 'clinical benefit after 24 weeks of treatment', 'description': 'the clinical benefit is defined by the rate of complete response, by the rate of partial response and by the stability of lesions at 24 weeks according to criteria RECIST 1.1', 'timeFrame': 'up to 24 weeks'}, {'measure': 'overall survival', 'description': 'the overall survival of patients randomized is defined as the time from randomization and the date of death', 'timeFrame': 'up to 2 years'}, {'measure': 'Toxicity according to criteria NCI CTAEv4.03', 'description': 'tolerance of the treatment based on AE occurrence according to criteria NCI CTAEv4.03', 'timeFrame': 'up to 2 years'}, {'measure': 'health-related quality of life', 'description': 'health-related quality of life and symptomatic state will be evaluated by filling a questionnaire by patients', 'timeFrame': 'up to 2 years'}]",7,50 Years,95 Years,FEMALE,False,ARCAGY/ GINECO GROUP,OTHER,1,120.0,ACTUAL,2025-09-01T16:18:15.895636,v2_robust,True,True,False,True,False,Treatment toxicity
NCT02275988,Drug-Drug Interaction Study in Healthy Adult Volunteers,,K-877,"['Clarithromycin', 'K-877']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['Adult Volunteers'],COMPLETED,,2014-06,,"[{'measure': 'Maximum concentration (Cmax)', 'timeFrame': '72 hours'}]","[{'measure': 'Area under concentration curve (AUC)', 'timeFrame': '72 hours'}]",2,18 Years,45 Years,ALL,True,"Kowa Research Institute, Inc.",INDUSTRY,0,20.0,ACTUAL,2025-09-01T16:18:15.895668,v2_robust,True,True,True,False,False,
NCT00153803,Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC),"A National Web-Based Randomized Phase III Study of Erlotinib or Placebo Following Concurrent Docetaxel, Carboplatin, and Thoracic Radiotherapy in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (D0410).",Erlotinib (tarceva),"['Placebo', 'Erlotinib (tarceva)']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Carcinoma, Non-Small-Cell Lung","['Carcinoma, Non-Small-Cell Lung', 'Non-small Cell Lung Cancer', 'NSCLC']","['Erlotinib', 'Tarceva', 'Web based', 'Stage III NSCLC']",COMPLETED,,2005-05,2014-04,"[{'measure': 'Progression Free Survival', 'description': 'Progression Free Survival is defined as time from randomization until documented disease progression or death from any cause. The Response Evaluation Criteria In Solid Tumors Criteria (RECIST 1.0) was used to determine disease progression. Irradiated target lesions were considered non-measurable disease. Symptomatic radiographic changes of irradiated non-measurable disease required pathologically confirmation or positive FDG-PET scan 6 months following completion of concurrent chemoradiation to be considered locoregional disease progression. Global deterioration of health status requiring discontinuation of treatment without objective evidence of progression was considered distant disease progression.', 'timeFrame': '5 years'}]","[{'measure': 'Overall Survival', 'timeFrame': 'From date of randomization until the date of death from any cause, assessed up to 50 months'}, {'measure': 'Percent of Participants Surviving 3 Years', 'timeFrame': '36 months'}, {'measure': 'Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Concurrent Chemoradiation', 'description': 'Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.', 'timeFrame': '18 months'}, {'measure': 'Serious Adverse Event Profile Relating to Death, Disability, Life-threatening, Hospitalization, and Impairment/Damage for Erlotinib and Placebo', 'description': 'Number of participants with treatment-related serious adverse events (SAEs) observed in each SAE category for each arm relating to death, disability, life-threatening, hospitalization, and impairment/damage is reported. For participants with multiple SAEs, the SAE report having the strongest relationship to study drug is summarized.', 'timeFrame': '18 months'}]",5,18 Years,,ALL,False,Dartmouth-Hitchcock Medical Center,OTHER,2,245.0,ACTUAL,2025-09-01T16:18:15.895754,v2_robust,True,True,True,False,True,
NCT00461903,Efficacy of Perindopril to Prevent Recurrence of Atrial Fibrillation in Patients With Essential Hypertension,"A Prospective, Randomized, Double-blind Placebo-controlled Study to Determine the Efficacy of 8 mg/Day Oral Perindopril to Prevent the Recurrence of Atrial Fibrillation in Patients With Essential Hypertension",Perindopril,"['Perindopril', 'Coversyl']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Essential Hypertension,"['Essential Hypertension', 'Atrial Fibrillation']","['essential hypertension', 'symptomatic paroxysmal or persistent atrial fibrillation']",COMPLETED,,2007-12,2015-09,"[{'measure': 'The primary efficacy endpoint will be time to first sustained recurrence of AF.', 'description': '1 month treatment adjustment 3 months of endpoint follow-up - M4 6 months of endpoint follow-up - M7 12 months of endpoint follow-up - M13', 'timeFrame': '12 months follow-up'}]","[{'measure': 'Secondary efficacy endpoints will be the proportion of patients without AF throughout the 6 months of follow-up, number of documented relapses of AF, and health care resource utilization (including hospitalisations for AF and cardioversions).', 'description': 'Secondary efficacy endpoints will be the proportion of patients without AF throughout the 6 months of follow-up,number of documented relapses of AF, and health care resources utilization (including hospitalisations for AF and cardioversion)', 'timeFrame': '6 months follow-up'}]",2,18 Years,,ALL,False,Montreal Heart Institute,OTHER,1,316.0,ACTUAL,2025-09-01T16:18:15.895791,v2_robust,True,True,True,False,False,
NCT01085903,Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia,Identifying and Treating Arousal Related Deficits in Neglect and Dysphagia,Modafinil,"['Provigil', 'inert', 'Modafinil', 'Placebo']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Spatial Neglect,"['Spatial Neglect', 'Dysphagia']","['Spatial Neglect', 'Dysphagia', 'Arousal', 'Modafinil', 'Stroke']",COMPLETED,,2010-03,2015-08,"[{'measure': 'P50 Percent Habituation Score', 'description': 'This is an electrophysiological measure of arousal - a percent change in the P50 evoked response potential amplitudes with a 250 ms inter stimulus interval. The difference score is calculated as CPS - baseline and as modafinil - placebo (stroke subjects only).', 'timeFrame': 'baseline and after three days of intervention'}]","[{'measure': 'PVT Fastest 10 Percent of Reaction Times', 'description': 'This is a behavioral measure of arousal - the fastest 10 percent of all cued reaction time trials. The difference score is calculated as CPS - baseline and as modafinil - placebo (stroke subjects only).', 'timeFrame': 'baseline and after three days of intervention'}, {'measure': 'Power Function Exponent for Oral Bolus Estimation', 'description': ""This is a behavioral measure of sensation in the oral cavity. The power function exponent is equal to the slope of a regression equation relating bolus size to a person's estimate of that size. An exponent below one implies an underestimate of bolus size. The difference score is calculated as CPS - baseline and as modafinil - placebo (stroke subjects only)."", 'timeFrame': 'baseline and after three days of intervention'}, {'measure': 'Time to Swallow Puree Food', 'description': 'This is a behavioral measure of swallowing - the time it takes for pureed food to transition across a part of the throat. The difference score is calculated as CPS - placebo and as modafinil - placebo (for stroke subjects only).', 'timeFrame': 'baseline and after three days of intervention'}]",4,19 Years,85 Years,ALL,False,University of Arkansas,OTHER,1,28.0,ACTUAL,2025-09-01T16:18:15.895851,v2_robust,True,True,True,False,False,
NCT06067503,Biomarkers to Detect Endocrine Therapy Resistance,Integrating Minimally Invasive Biomarkers of Estrogen Signaling to Detect Endocrine Therapy Resistance in Metastatic Invasive Lobular Breast Cancer,18F-fluorofuranylnorprogesterone,"['18F-fluorofuranylnorprogesterone', 'FFNP']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Metastatic Cancer,"['Metastatic Cancer', 'Breast Cancer', 'Lobular Breast Carcinoma']","['Endocrine Therapy Resistance', 'circulating tumor cell', 'liquid biopsy']",RECRUITING,,2024-04-30,2026-08,"[{'measure': 'Number of Participants who have decreased FFNP uptake on PET/CT in response to endocrine therapy', 'timeFrame': 'baseline, 4 weeks'}, {'measure': 'Number of Participants who have decrease in circulating tumor cell estrogen signaling in response to endocrine therapy', 'description': 'Baseline level and on-treatment CTC ESR1 and estrogen regulated gene expression will be evaluated as well as endocrine-resistance associated mutations including ESR1 (though rare in this patient population) and PGR.', 'timeFrame': 'baseline, 4 weeks'}, {'measure': 'Number of Participants who have a decrease in concentration of Circulating Tumor DNA in response to endocrine therapy', 'timeFrame': 'baseline, 4 weeks'}]","[{'measure': 'Progression Free Survival (PFS) for 6 months', 'timeFrame': 'up to 6 months'}, {'measure': 'Correlation coefficients', 'description': 'Correlate baseline levels and dynamic on treatment changes in estrogen signaling as measured by FFNP-PET/CT and CTC liquid biopsy with clinical response to endocrine therapy and progression-free survival in patients with ER/PR+ metastatic LBC.', 'timeFrame': 'up to 6 months'}, {'measure': 'Adverse Events within 24 hours of FFNP infusion', 'timeFrame': 'a 24 hour period up to 7 days pre-treatment, a 24 hour period 4 weeks after the first infusion'}]",6,18 Years,,ALL,False,"University of Wisconsin, Madison",OTHER,0,8.0,ESTIMATED,2025-09-01T16:18:15.895886,v2_robust,True,True,False,False,True,
NCT01400503,A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease,"An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Subjects With Multicentric Castleman's Disease",Siltuximab,['Siltuximab'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Multicentric Castleman's Disease,"[""Multicentric Castleman's Disease""]","[""Multicentric Castleman's Disease"", 'Multicentric', 'Castleman', 'Siltuximab', 'Long term safety']",COMPLETED,,2011-04-01,2017-03-01,"[{'measure': 'Number of Participants With Adverse Events (AEs)', 'description': 'An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.', 'timeFrame': 'Up to 6 years'}]","[{'measure': 'Percentage of Previously Responding Participants Who Maintained Disease Control', 'description': 'Percentage of participants maintaining disease control (defined as stable or better response) was defined as the percentage of previously responding participants who had not progressed during the long-term safety extension based on investigator assessment. A worsening in any of the measures will be considered as a progression of the disease.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Percentage of Siltuximab-naive Participants Who Experienced Disease Control', 'description': ""Percentage of participants experiencing disease control was defined as the percentage of siltuximab-naïve participants who had stable or better response during the long-term safety extension based on investigator's judgment. Disease control was defined as stable or better response assessed by the investigators."", 'timeFrame': 'Up to 6 years'}, {'measure': 'Duration of Disease Control', 'description': 'Duration of disease control (DODC) was defined as the time from the first siltuximab administration in this study to disease progression as assessed by the investigator. Disease control was defined as stable or better response assessed by the investigators. Kaplan-Meier method was used to estimate the duration of disease control.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Overall Survival', 'description': 'Overall survival was defined as the time between the first study siltuximab administration and death due to any cause. Kaplan-Meier method was used to estimate the overall survival.', 'timeFrame': 'Up to 6 years'}, {'measure': 'Number of Participants Positive for Antibodies to Siltuximab', 'description': 'Serum samples were screened for antibodies binding to siltuximab and number of participants positive for antibodies to siltuximab was reported.', 'timeFrame': 'Up to 6 years'}]",6,18 Years,,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,60.0,ACTUAL,2025-09-01T16:18:15.895905,v2_robust,True,True,True,False,True,
NCT04658303,Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma,Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma,Pimonidazole,['Pimonidazole'],1,OBSERVATIONAL,[],,,Melanoma,['Melanoma'],"['immune dysfunction', 'metabolic dysfunction', 'Melanoma in-transit metastases (ITMs)', 'tumor microenvironment (TME)']",RECRUITING,,2021-02-24,2028-03-31,"[{'measure': 'Immunometabolic profiling', 'description': 'Immunometabolic profiling of individual microenvironments in ITMs (in-transit metastases) using flow cytometry via T cell subsets, markers of activation/exhaustion, and metabolic insufficiency (mitochondrial mass, glucose uptake capacity, and hypoxia by pimonidazole staining.', 'timeFrame': 'At baseline'}, {'measure': 'Tumor cell metabolism', 'description': 'Tumor cells metabolism of ITMs (in-transit metastases) will be profiled using the Seahorse flux analyzer to measure oxygen consumption rate (OCR) and extracellular acidification rate (ECAR).', 'timeFrame': 'At baseline'}, {'measure': 'Imaging of individual ITM stations', 'description': 'CODEX imaging will be conducted on sections from each station using extensive phenotyping panels.', 'timeFrame': 'At baseline'}, {'measure': 'hypoxia exposure analyses', 'description': ""Akoya Biosciences' CODEX analysis suite and custom ImageJ plugins will be used to determine proximity of cells to one another, coincidence with hypoxic areas, and accumulation of regulatory/dysfunctional populations."", 'timeFrame': 'At baseline'}]","[{'measure': 'Whole exome sequencing of tumor cells', 'description': ""Whole exome sequencing will be performed to identify mutations in tumor cells isolated from each lesion. Analysis will be in an 'intrapatient' manner as a function of distance from the primary site."", 'timeFrame': 'At baseline'}, {'measure': 'Clonal evolution analysis of individual ITMs', 'description': ""Mutations will be used to construct trees revealing clonal representation and diversity at each station. The goal is to determine how migration away from the primary site affects a tumor's heterogeneity in terms of tumor cells."", 'timeFrame': 'At baseline'}, {'measure': 'Cellular heterogeneity and transcriptomic state', 'description': 'The composition of each ITM tumor microenvironment will be analyzed using dimension reduction strategies, in collaboration with a bioinformatics core. Each biopsy sample will be sequenced simultaneously but hashed separately, allowing all ITMs to be compared in one run. Clusters will be identified using lineage-defining genes and then transcriptomic states identified within each cluster.', 'timeFrame': 'At baseline'}, {'measure': 'TCR clonotype and trajectory analysis', 'description': ""5' scRNAseq will be used for identification of TCR sequences to identify individual T cell clones. Clonotypes will be revealed in each lesion, and diffusion pseudotime analyses will be employed within each ITM and between ITMs to determine differentiation states of various T cell subsets. It is thought that distant lesions will harbor more terminally differentiated T cells."", 'timeFrame': 'At baseline'}, {'measure': 'Tumor transcriptomic states', 'description': 'Analysis of hypoxia exposure for each cell using unique pimonidazole CITE-seq strategy also allows for the a. As hypoxia promotes the terminal differentiation of T cells, it is expected that distant ITMs will harbor more hypoxic cells and that terminally differentiated T cells will experience higher levels of hypoxia.', 'timeFrame': 'At baseline'}]",9,18 Years,,ALL,False,Yana Najjar,OTHER,1,20.0,ESTIMATED,2025-09-01T16:18:15.895967,v2_robust,False,True,False,False,False,
NCT00681603,Safety and Effectiveness of Subconjunctival Injection of Bevacizumab in the Treatment of Corneal Neovasculization,The Application of Subconjunctival Injection of Bevacizumab (Avastin) in the Treatment of Corneal Neovasculization,subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg),"['subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)', 'bevacizumab ( Avastin )']",2,INTERVENTIONAL,['NA'],,,Lipid Keratopathy,"['Lipid Keratopathy', 'Penetrating Keratoplasty', 'Herpetic Keratopathy', 'Rosacea']","['corneal neovascularization', 'lipid keratopathy', 'penetrating keratopathy', 'bevacizumab', 'Avastin', 'subconjunctival injection']",COMPLETED,,2007-08,2008-02,"[{'measure': 'Resolution of corneal neovascularization, reduction of lipid infiltrate, improved visual acuity', 'timeFrame': 'prospective'}]","[{'measure': 'major side effects', 'timeFrame': 'prospective'}]",2,10 Years,70 Years,,False,National Taiwan University Hospital,OTHER,0,13.0,ACTUAL,2025-09-01T16:18:15.896052,v2_robust,True,True,True,False,False,
NCT03138603,Metoprolol to Reduce Perioperative Myocardial Injury,Metoprolol to Reduce Perioperative Myocardial Injury,Metoprolol Tartrate,"['Placebo-comparator', 'Placebo', 'Beta-blocker', 'Control', 'Sham', 'Metoprolol Tartrate']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Heart Diseases,['Heart Diseases'],"['surgery', 'heart disease', 'metoprolol', 'myocardial injury', 'coronary artery disease']",COMPLETED,,2016-12,2023-08-29,"[{'measure': 'Effectiveness of Beta-blocker Therapy Reducing Post-operative Myocardial Injury', 'description': 'Measured effectiveness of post-operative beta-blocker therapy to reduce myocardial injury by monitoring daily biomarkers (High-Sensitivity cardiac Troponin \\[HS-cTn\\]).\n\nDaily post-operative biomarker (hs-cTn) measurements to determine myocardial injury.\n\nMyocardial injury is defined as a new hscTn elevation \\>99th percentile, or a 50% increase if the baseline hscTn is already elevated \\>99th percentile', 'timeFrame': '0-3 days, following surgery'}]","[{'measure': 'Effectiveness in Reduction of Major Adverse Cardiac Events (MACE)', 'description': 'MACE are defined as myocardial ischemia (MI), cardiac death or coronary revascularization', 'timeFrame': '0-3 days, following surgery'}, {'measure': 'Monitor Post-operative Myocardial Ischemia', 'description': 'Post-operative cardiac monitoring via ECG to evaluate if myocardial ischemia is present.\n\nMyocardial Ischemia is defined as ST depression or elevation of ≥0.2 mV in one lead or ≥0.1 mV in two contiguous leads lasting ≥10 min', 'timeFrame': '0-3 days, following surgery'}, {'measure': 'Number of Stroke Related Events Following Surgery', 'description': 'Stroke will be defined as focal or global cerebral, spinal, or retinal dysfunction of sudden onset', 'timeFrame': '0-3 days, following surgery'}, {'measure': 'Number of Participants Having Vasopressor Therapy to Regulate Symptomatic Hypotension', 'description': 'Monitor participants with vasopressor requirements for blood pressure regulation due to symptomatic hypotension (rate/duration time).\n\nSymptomatic hypotension (systolic BP \\< 90 mmHg) can be determined by clinical intervention due to low blood pressure and/or patient developed clinical symptoms due to hypotension.', 'timeFrame': '0-3 days, following surgery'}, {'measure': 'Number of Participant Incidence of Clinically Relevant Bradycardia', 'description': 'Monitored participants with cumulative events of bradycardia (rate/duration time).\n\nBradycardia is defined as low heart rate (HR \\< 50/min).', 'timeFrame': '0-3 days, following surgery'}, {'measure': 'Participants Number of Days Spent Post-operative Hospitalization', 'description': 'Measurement of participants number of days spent hospitalized (0-3 days) following surgery.', 'timeFrame': '0-3 days following surgery'}, {'measure': 'Patient Recovery Progress Events at 30-days Post-operative.', 'description': 'Measured number of participant post-operative recovery events, 30-days following the surgical procedure.', 'timeFrame': '30-days from surgery'}, {'measure': 'Participant Post-operative Mortality at 1-year Following Surgery', 'description': ""Measured number of patient post-operative mortality at 1-year.\n\nMeasured by 'living', 'deceased', 'date of death'."", 'timeFrame': '1-Year from surgery'}]",9,50 Years,,ALL,False,University of Chicago,OTHER,2,72.0,ACTUAL,2025-09-01T16:18:15.896062,v2_robust,True,True,True,False,True,
NCT00358527,Mometasone Furoate on Sleep Disturbances in Subjects With Seasonal Allergic Rhinitis (Study P04608) (COMPLETED),"A Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Multicenter Study of Mometasone Furoate Nasal Spray on Sleep Disturbances and Daytime Somnolence in Subjects With Symptomatic Seasonal Allergic Rhinitis",Mometasone Furoate Nasal Spray (MFNS),"['MFNS', 'Mometasone Furoate Nasal Spray (MFNS)']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Seasonal Allergic Rhinitis,['Seasonal Allergic Rhinitis'],[],COMPLETED,,2006-05,2006-11,"[{'measure': ""Mean Change of the AM-PRIOR-reflective (Participant's Status Over the Previous 12 Hours) Total Nasal Symptoms Severity Score (TNSS) Averaged Over the Last 7 Days of Treatment From the Baseline Score."", 'description': 'The TNSS score included the sum of nasal congestion/stuffiness, rhinorrhea/nasal discharge, sneezing, and nasal itching, each scored on a scale of 0 = absent, 1 = mild, 2 = moderate, 3 = severe. The TNSS score could range from 0 to 12.\n\nNOTE: Least square means and standard errors were obtained from an ANCOVA model with the treatment effect and the variable specific Baseline as a covariate.', 'timeFrame': 'Average of the last 7 days of treatment'}, {'measure': 'Mean Change From Baseline (Day 1/Visit 3) in the Sleep Problems Index II (SLP9) Score From the Medical Outcome Study Sleep Scale (MOS-SS) at the Day 29 Visit.', 'description': 'Following Visit 2 (Screening), at Baseline, Day 15, and Day 29 visits, participants needed to complete the MOS-SS questionnaire with scores from 1 = all of the time to 6 = none of the time, according to their frequency of occurrence during the previous week. The analysis endpoint MOS-SS Sleep Problems Index II (SLP9) score was derived from MOS-SS questionnaire and scaled from 0 = none of the time to 100 = all of the time.\n\nNOTE: Least squares means and standard errors were obtained from an ANCOVA model with the treatment effect and the variable specific Baseline as a covariate.', 'timeFrame': '29 days'}]",[],2,18 Years,,ALL,False,Organon and Co,INDUSTRY,1,401.0,ACTUAL,2025-09-01T16:18:15.896120,v2_robust,True,True,True,False,False,
NCT00285727,Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression,Ropinirole Controlled Release (CR) as an Adjunctive Agent in the Treatment of Major Depression,Ropinirole CR,['Ropinirole CR'],1,INTERVENTIONAL,['NA'],,,"Depressive Disorder, Major","['Depressive Disorder, Major']",[],COMPLETED,,2006-01,2007-10,[{'measure': 'HamD'}],[{'measure': 'MADRS'}],2,18 Years,65 Years,ALL,False,Stanford University,OTHER,2,60.0,,2025-09-01T16:18:15.896144,v2_robust,True,True,True,False,False,
NCT02443727,The Role of Oxytocin in the Perception of Faces,The Role of Oxytocin in the Perception of Infant Faces,Syntocinon (synthetic oxytocin),"['Syntocinon (synthetic oxytocin)', 'OT']",2,INTERVENTIONAL,['EARLY_PHASE1'],EARLY_PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2015-04,2016-09,"[{'measure': 'Functional Magnetic Resonance Imaging (fMRI) Data', 'description': 'The effect of OT will be assessed by determining changes in brain activation between treatment and placebo groups.', 'timeFrame': '45 minutes after OT manipulation'}, {'measure': 'Eye movements data', 'description': 'The effect of OT will be assessed by determining changes in eye movements between treatment and placebo groups.', 'timeFrame': '45 minutes after OT manipulation'}]","[{'measure': 'Implicit Attitudes toward infants', 'description': 'Implicit attitudes toward infants as measured by the Implicit Association Test', 'timeFrame': '45 minutes after OT manipulation'}, {'measure': 'Theory of mind', 'description': 'Theory of mind as measured by the Reading the mind in the eyes test', 'timeFrame': '45 minutes after OT manipulation'}]",4,18 Years,25 Years,MALE,True,Rodrigo Cardenas,OTHER,1,71.0,ACTUAL,2025-09-01T16:18:15.896151,v2_robust,True,True,True,False,False,
NCT02672527,Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma,A Randomized Phase III Trial Comparing Trabectedin (Yondelis®) to the Best Supportive Care in Patients With Advanced Soft Tissue Sarcoma,Trabectedin,"['Yondelis', 'Trabectedin', 'Dexamethasone']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Soft Tissue Sarcoma,['Soft Tissue Sarcoma'],[],COMPLETED,,2015-01-22,2018-07-14,"[{'measure': 'Progression Free Survival', 'timeFrame': 'Assessed every three weeks after randomization then every six weeks until progression or death of any cause whichever came first up to 30 months'}]",[],1,18 Years,,ALL,False,"Gustave Roussy, Cancer Campus, Grand Paris",OTHER,0,103.0,ACTUAL,2025-09-01T16:18:15.896187,v2_robust,True,True,True,False,False,
NCT00324727,Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma,A Random-Assignment Study of Hepatic Arterial Infusion of Melphalan With Venous Filtration Via Peripheral Hepatic Perfusion (PHP) (Delcath System) Versus Best Alternative Care for Ocular and Cutaneous Melanoma Metastatic to the Liver,melphalan,"['regional chemotherapy', 'melphalan', 'systemic chemotherapy']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Intraocular Melanoma,"['Intraocular Melanoma', 'Melanoma (Skin)', 'Metastatic Cancer']","['liver metastases', 'extraocular extension melanoma', 'stage IV melanoma', 'recurrent melanoma', 'recurrent intraocular melanoma', 'metastatic intraocular melanoma', 'iris melanoma', 'ciliary body and choroid melanoma, medium/large size']",COMPLETED,,2006-02,2012-08,"[{'measure': 'Hepatic progression free survival', 'timeFrame': 'Treatment to time of progression'}]",[],1,18 Years,120 Years,ALL,False,Delcath Systems Inc.,INDUSTRY,1,93.0,ACTUAL,2025-09-01T16:18:15.896208,v2_robust,True,True,True,False,False,
NCT06872827,Effect of Herbal Toothpaste Versus Conventional One on Black Stains,Effect of Herbal Toothpaste Versus Conventional One on Black Stains in a Group of Egyptian Children: A Randomized Controlled Study,Herbal toothpaste,"['Herbal toothpaste', 'Dabur Red toothpaste']",2,INTERVENTIONAL,['NA'],,,Black Stains,['Black Stains'],"['black stains', 'bacteria', 'herbal', 'child']",COMPLETED,,2024-12-15,2025-03-01,"[{'measure': 'Parental satisfaction using Likert scale regarding both interventions of management of black stains (Each response was scored as follows: (5) strongly agree, (4) agree, (3) neutral, (2) disagree and (1) strongly disagree).', 'description': 'using Likert scale regarding both interventions of management of black stains (Each response was scored as follows: (5) strongly agree, (4) agree, (3) neutral, (2) disagree and (1) strongly disagree).', 'timeFrame': 'After 2 months'}]","[{'measure': 'Recurrence of black stains', 'description': 'Recurrence rate of black stains', 'timeFrame': 'After 2 months'}]",2,6 Years,12 Years,ALL,True,"National Research Centre, Egypt",OTHER,0,28.0,ACTUAL,2025-09-01T16:18:15.896254,v2_robust,True,True,True,False,False,
NCT06940427,Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis,Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis,FAPI tracer,['FAPI tracer'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Fibrosis Lung,['Fibrosis Lung'],['lung disease associated with fibrosis'],NOT_YET_RECRUITING,,2025-09,2027-06,"[{'measure': 'Change in FAPI uptake', 'description': 'FAPI uptake of fibrotic lesions as measured by Standardized Uptake Value (SUV). SUV quantifies the tracer uptake, helping to differentiate between normal and abnormal tissues and assess the extent of tumor activity.', 'timeFrame': 'Baseline to 6 months'}]",[],1,18 Years,,ALL,False,"University of Wisconsin, Madison",OTHER,0,50.0,ESTIMATED,2025-09-01T16:18:15.896296,v2_robust,True,True,False,False,False,
NCT02039427,The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery,The Effect of Prophylactic Ketorolac on Sore Throat After Thyroid Surgery,Ketorolac,"['control', 'Placebo', 'Ketorolac', 'Kerola']",4,INTERVENTIONAL,['NA'],,,Anesthesia Intubation Complication,"['Anesthesia Intubation Complication', 'Tracheal Disease']","['Sore throat', 'Hoarseness', 'Intubation', 'Thyroidectomy', 'Ketorolac', 'Dexamethasone']",COMPLETED,,2014-01,2015-10,"[{'measure': 'The Incidence of Postoperative Sore Throat(POST) Using Ketorolac and Dexamethasone in Womend After Thyroidectomy', 'description': 'The investigator asked scales to patients at 1, 6 and 24h after extubation. POST was defined as discomfort at larynx or pharynx at rest and during swallowing after surgery and was assessed using a 4-grade scale (0-3) based on verbal responses to questions: 0, none; 1, mild (less severe than with a cold); 2, moderate (similar with a cold); 3 severe (more severe than with a cold)\n\n● Incidence of sore throat : if patient rates sore throat scale more than 1, investigator will record as positive symptom.', 'timeFrame': 'at 1, 6 and 24 hours after thyroidectomy'}]","[{'measure': 'The Incidence of Postoperative Hoarseness(PH) Using Ketorolac and Dexamethasone in Womend After Thyroidectomy', 'description': 'The investigator asked scales to patients at 1, 6 and 24h after extubation. PH was assessed using a 4-grade scale (0-3): 0, none; 1, mild (noticed by the patient only); 2, severe (obvious to observer); 3 aphonia (silence of voice)\n\n● Incidence of hoarseness: If patient exhibit hoarseness scale more than 1, investigator will record as positive sign', 'timeFrame': 'at 1, 6 and 24 hours after thyroidectomy'}]",2,20 Years,60 Years,FEMALE,False,Yeungnam University College of Medicine,OTHER,0,192.0,ACTUAL,2025-09-01T16:18:15.896304,v2_robust,True,True,True,False,False,
NCT02354027,The Drug-drug Interaction of SHR3824 and Metformin,Drug Interaction Study of Henagliflozin and Metformin in Healthy Subjects,SHR3824 metformin,"['Henagliflozin metformin', 'SHR3824 metformin']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Type 2 Diabetes,['Type 2 Diabetes'],['SHR3824 metformin drug-drug interaction'],COMPLETED,,2014-09,2015-01,"[{'measure': 'The maximum plasma concentration (Cmax) of SHR3824.', 'description': ""Cmax (a measure of the body's exposure to SHR3824) will be compared before and after administration of a single dose of metformin."", 'timeFrame': 'At protocol-specified times up to Day 9.'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of SHR3824.', 'description': ""AUC (a measure of the body's exposure to SHR3824) will be compared before and after administration of a single dose of metformin."", 'timeFrame': 'At protocol-specified times up to Day 9.'}, {'measure': 'The maximum plasma concentration (Cmax) of metformin.', 'description': ""Cmax (a measure of the body's exposure to metformin) will be compared. before and after administration of multiple doses of SHR3824"", 'timeFrame': 'At protocol-specified times up to Day 9.'}, {'measure': 'The area under the plasma concentration-time curve (AUC) of metformin', 'description': ""AUC (a measure of the body's exposure to metformin) will be compared before and after administration of multiple doses of SHR3824."", 'timeFrame': 'At protocol-specified times up to Day 9.'}]","[{'measure': 'The number of volunteers with adverse events as a measure of safety and tolerability.', 'timeFrame': 'Up tp day 9.'}]",5,18 Years,45 Years,MALE,True,"Jiangsu HengRui Medicine Co., Ltd.",INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:15.896348,v2_robust,True,True,True,False,True,
NCT06026527,Intra-operative Magnesium Sulphate for Post-operative Pain in Patients Undergoing Total Abdominal Hysterectomy Under General Anesthesia,Intra-operative Magnesium Sulphate for Post-operative Pain in Patients Undergoing Total Abdominal Hysterectomy Under General Anesthesia,Magnesium sulfate,"['Magnesium sulfate', 'Normal Saline', 'NS', 'Magnesium sulphate']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Post-operative Pain,['Post-operative Pain'],"['Magnesium, Pain, NRS, Abdominal hysterectomy, MgSO4']",COMPLETED,,2024-03-03,2024-10-30,"[{'measure': 'To evaluate the efficacy of magnesium sulphate for post-operative pain', 'description': 'Post operative pain will be assessed by using Numerical rating score (NRS) of pain. The NRS is a 0-10 scale, with zero meaning ""no pain"" and 10 meaning ""the worst pain imaginable""', 'timeFrame': 'At 0, 1, 6,12 18 and 24 hours post-operatively'}]","[{'measure': 'Comparison of Numerical Rating Scale (NRS) score of pain', 'description': 'Comparison of Numerical Rating Scale score between Magnesium and control group.The NRS is a 0-10 scale, with zero meaning ""no pain"" and 10 meaning ""the worst pain imaginable""', 'timeFrame': 'at 0, 1, 6, 12, 18, 24 hours post-operatively'}, {'measure': 'Opioid as rescue analgesic use', 'description': 'To compare the timing of first rescue analgesic used', 'timeFrame': 'The time to first rescue analgesic use within 24 hours post-operatively will be noted'}, {'measure': 'Total opioid use', 'description': 'Comparison of total opioid used between two groups', 'timeFrame': 'within 24 hours post-operatively'}, {'measure': 'Side effects', 'description': 'To determine any side effects of magnesium sulphate', 'timeFrame': 'within 24 hours post-operatively'}]",5,18 Years,65 Years,FEMALE,False,"Tribhuvan University Teaching Hospital, Institute Of Medicine.",OTHER,0,42.0,ACTUAL,2025-09-01T16:18:15.896376,v2_robust,True,True,True,False,False,
NCT01946061,A Phase II Trial of Adjuvant Chemotherapy With S-1 Plus Oxaliplatin for Locally Advanced Gastric Cancer,,S-1 plus oxaliplatin,['S-1 plus oxaliplatin'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Advanced Gastric Cancer,['Advanced Gastric Cancer'],"['Oxaliplatin, S-1, Gastric cancer, Adjuvant chemotherapy']",TERMINATED,This study was stopped because of difficulties of supplying the drug.,2015-05,2016-03,"[{'measure': '3-year disease-free survival', 'description': '3-year disease-free survival will be assessed by imaging study including CT and PET.', 'timeFrame': '3 years from the surgery'}]",[],1,19 Years,75 Years,ALL,False,Yonsei University,OTHER,0,3.0,ACTUAL,2025-09-01T16:18:15.896393,v2_robust,True,True,False,True,False,This study was stopped because of difficulties of supplying the drug.
NCT02616861,Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers,"A 2-stage Phase 1 Study of Safety, Tolerability, PK, and PD of IW-1973 Tablet in Healthy Volunteers in an Open-label, Single-dose Stage, and a Randomized, Double Blind, Placebo-controlled, Multiple-ascending-dose Stage",IW-1973,"['Matching Placebo Tablet', 'IW-1973']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2015-11,2016-06,"[{'measure': 'Treatment Emergent Adverse Events', 'timeFrame': '42 Days'}, {'measure': 'Maximum observed plasma concentration (Cmax)', 'timeFrame': '42 Days'}, {'measure': 'Blood Pressure', 'timeFrame': '42 days'}, {'measure': 'Area under the plasma concentration time curve during a dosing interval (AUC)', 'timeFrame': '42 Days'}, {'measure': 'Time of maximum observed plasma concentration (Tmax)', 'timeFrame': '42 Days'}, {'measure': 'Heart rate', 'timeFrame': '42 Days'}, {'measure': 'Serum cGMP', 'timeFrame': '42 Days'}]",[],7,18 Years,55 Years,ALL,True,Cyclerion Therapeutics,INDUSTRY,0,54.0,ACTUAL,2025-09-01T16:18:15.896402,v2_robust,True,True,True,False,True,
NCT03534661,L-NMMA on GLP-2 Mediated Intestinal Lipoprotein Release,Role of a Nitric Oxide Synthase Inhibitor on GLP-2 Mediated Intestinal Lipoprotein Release,Teduglutide + Normal Saline,"['Teduglutide + L-NMMA', 'Placebo + L-NMMA', 'active treatments', 'L-NMMA control', 'Teduglutide control', 'Teduglutide + Normal Saline']",6,INTERVENTIONAL,"['PHASE2', 'PHASE3']",PHASE2,,Hyperlipidemias,['Hyperlipidemias'],[],COMPLETED,,2017-09-27,2019-03-20,"[{'measure': 'Plasma Lipid Levels', 'description': 'Lipid levels in plasma and lipoprotein fractions are measured following treatments', 'timeFrame': '10.5 hours'}]","[{'measure': 'Blood Flow', 'description': 'Mesenteric blood flow rates are measured with ultrasound following treatments', 'timeFrame': '3 hours'}]",2,18 Years,60 Years,ALL,True,"University Health Network, Toronto",OTHER,0,10.0,ACTUAL,2025-09-01T16:18:15.896422,v2_robust,True,True,True,False,False,
NCT04930861,Study of Codivir in Patients With COVID-19,Phase 1 Clinical Study of Codivir in Outpatients With COVID-19,Covidir injections,"['Experimental drug administration', 'Covidir injections']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Covid19,['Covid19'],"['Corona', 'Coronavirus', 'COVID-19', 'SARS-CoV-2']",COMPLETED,,2021-03-29,2021-08-09,"[{'measure': 'Incidence and severity of adverse events related to the investigational product.', 'timeFrame': '28 days'}]","[{'measure': 'Clinical evolution according to the score of the World Health Organization between admission and days 10 and 28.', 'timeFrame': 'up to 28 days'}, {'measure': 'Clinical evolution according to NEWS2 score between admission and days 10 and 28.', 'timeFrame': 'up to 28 days'}, {'measure': 'RT-PCR negative.', 'timeFrame': 'up to 28 days'}, {'measure': 'Evolution of IgM & IgG Anti-SARS-CoV-2.', 'timeFrame': 'up to 28 days'}]",5,18 Years,60 Years,ALL,False,Code Pharma,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:15.896591,v2_robust,True,True,True,False,True,
NCT02562742,Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection,A Prospective Observational Post-Marketing Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection,SOF,"['PSI-7977', 'Rebetol®', 'Ribavirin', 'Sovaldi®', 'GS-7977', 'SOF', 'REB']",7,OBSERVATIONAL,[],,,Hepatitis C,['Hepatitis C'],"['Hepatitis C virus', 'observational', 'post-marketing', 'sofosbuvir', 'Infection']",COMPLETED,,2015-11-12,2017-06-12,"[{'measure': 'Incidence of adverse drug reaction (ADR) under real world settings', 'timeFrame': 'Up to 16 weeks'}]","[{'measure': 'Proportion of participants with sustained virologic response (SVR) 12 and 24 weeks after discontinuation of therapy (SVR12 and SVR24)', 'description': 'SVR12 and SVR24 are defined as HCV RNA \\< the lower limit of quantification (LLOQ) 12 and 24 weeks following the last dose of study drug, respectively.', 'timeFrame': 'Posttreatment Weeks 12 and 24'}, {'measure': 'Proportion of participants with HCV NS5B resistance associated variants among patients who do not achieve SVR at 12 weeks', 'timeFrame': 'Approximately 12 weeks after treatment completion or discontinuation'}]",3,18 Years,,ALL,False,Gilead Sciences,INDUSTRY,1,554.0,ACTUAL,2025-09-01T16:18:15.896666,v2_robust,False,True,True,False,True,
NCT00182442,"Cognition, Functioning and Quality of Life","A One-Year Multi-Centre Randomized, Double Blind, Controlled Effectiveness Study of Quetiapine and Olanzapine, Comparing Their Relative Potential in Improving Neuro-Cognitive Deficits, Functional Outcomes and Quality of Life in Schizophrenia",Olanzapine & Quetiapine,['Olanzapine & Quetiapine'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Schizophrenia,['Schizophrenia'],"['Cognitive deficits', 'Psychosocial functioning', 'Quality of Life']",COMPLETED,,2003-10,2006-03,"[{'measure': 'Primary outcome measures include changes in neurocognitive test scores, changes in measures of community functioning and quality of life.'}]","[{'measure': 'Secondary outcomes include changes in treatment adherence, subjective satisfaction with antipsychotic drug therapy, clinical symptoms and side effects.'}]",2,18 Years,65 Years,ALL,False,Hamilton Health Sciences Corporation,OTHER,1,80.0,,2025-09-01T16:18:15.896673,v2_robust,True,True,True,False,False,
NCT06514742,A Study of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and Long-term Extension Treatment With Aticaprant,"A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Aticaprant 10 mg as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy and an Open Label Long-term Extension Treatment With Aticaprant",Aticaprant,"['JNJ-67953964', 'Aticaprant']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,"Depressive Disorder, Major","['Depressive Disorder, Major', 'Anhedonia']",[],TERMINATED,Sponsor decision,2024-06-26,2025-04-24,"[{'measure': 'Change From Baseline to Day 43 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score', 'description': 'Change from baseline to Day 43 in MADRS total score will be reported.', 'timeFrame': 'Baseline to Day 43'}]","[{'measure': 'Change From Baseline to Day 43 in Dimensional Anhedonia Rating Scale (DARS) Total Score', 'description': 'Change from baseline to Day 43 in DARS total score will be reported.', 'timeFrame': 'Baseline to Day 43'}, {'measure': 'Change From Baseline to Day 43 in Changes in Sexual Function Questionnaire - 14 items (CSFQ-14) Total Score', 'description': 'Change from baseline to Day 43 in CSFQ-14 total score will be reported.', 'timeFrame': 'Baseline to Day 43'}, {'measure': 'Change From Baseline Over Time in MADRS Total Score', 'description': 'Change from baseline over time in the MADRS total score will be reported.', 'timeFrame': 'For double-blind (DB) treatment phase: Baseline (Day 1), Up to Day 43; For open-label (OL) treatment phase: Baseline (Day 43), Up to Week 31'}, {'measure': 'Percentage of responders on Depressive Symptoms Scale, Defined as a Greater Than or Equal to (>=) 50 Percent (%) Improvement in MADRS Total Score From Baseline to Day 43', 'description': 'Percentage of responders on depressive symptoms scale, defined as a \\>= 50 % improvement in MADRS total score from baseline to Day 43 will be reported.', 'timeFrame': 'Baseline to Day 43'}, {'measure': 'Percentage of Participants With Remission of Depressive Symptoms, Defined as a MADRS Total Score Less Than or Equal to (<=)10 at Day 43', 'description': 'Percentage of participants with remission of depressive symptoms, defined as a MADRS total score \\<=10 at Day 43 will be reported.', 'timeFrame': 'Day 43'}, {'measure': 'Change From Baseline to Day 43 in Patient Health Questionnaire, 9-item (PHQ-9) Total Score', 'description': 'Change from baseline to Day 43 in the PHQ-9 total score will be reported.', 'timeFrame': 'Baseline to Day 43'}, {'measure': 'Change From Baseline Over Time in DARS Total score.', 'description': 'Change from baseline over time in DARS total score will be reported.', 'timeFrame': 'For DB treatment phase: Baseline (Day 1), Up to Day 43; For OL treatment phase: Baseline (Day 43), Up to Week 31'}, {'measure': 'Change From Baseline Over Time in the PHQ-9 Anhedonia-Specific Item (PHQ-9, item 1).', 'description': 'Change from baseline over time in the PHQ-9 Anhedonia-specific item (PHQ-9, Item 1) will be reported.', 'timeFrame': 'For DB treatment phase: Baseline (Day 1), Up to Day 43; For OL treatment phase: Baseline (Day 43), Up to Week 31'}, {'measure': 'Percentage of Participants With a Score Less than (<) 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43', 'description': 'Percentage of participants with a score \\< 2 in the PHQ-9 Anhedonia-specific Item (PHQ-9, Item 1) at Day 43 will be reported.', 'timeFrame': 'Day 43'}]",10,18 Years,64 Years,ALL,False,"Janssen Research & Development, LLC",INDUSTRY,0,101.0,ACTUAL,2025-09-01T16:18:15.896800,v2_robust,True,True,False,True,False,Sponsor decision
NCT01278342,Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients,"An Open-label, Two-step, Multicenter European Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients Not Adequately Controlled by Conventional Regimen",Sandostatin LAR,"['Somavert', 'Dostinex', 'octreotide acaetate', 'cabergoline', 'Sandostatin LAR', 'pegvisomant', 'octreotide acetate']",7,INTERVENTIONAL,['PHASE4'],PHASE4,,Acromegaly,['Acromegaly'],"['Sandostatin LAR', 'High Dose', 'GH-receptor antagonist', 'combination with dopamine-agonist', 'acromegalic patients', 'octreotide acetate', 'Somavert', 'Dostinex', 'pegvisomant', 'cabergoline', 'not adequately controlled', 'active acromegaly']",COMPLETED,,2006-09,2009-11,"[{'measure': 'The Percentage of Participants With Complete Response (CR) at 8 Months', 'description': 'A patient was classified as a Complete Responder (CR) if both biochemical parameters were controlled at the end of 8 months of treatment:\n\n* Mean 1 hour GH \\< 2.5µg/L (according to Central Laboratory); and\n* IGF-I within the Central Laboratory Normal Range (for age and gender).', 'timeFrame': 'From Baseline to 8 months'}]","[{'measure': 'The Percentage of Participants With Complete Response (CR) At 3 Months', 'description': 'A patient was classified as CR if both biochemical parameters were controlled at the end of 3 months of treatment:\n\n* Mean 1 hour GH \\< 2.5µg/L (according to Central Laboratory); and\n* IGF-I within the Central Laboratory Normal Range (for age and gender)', 'timeFrame': 'From Baseline to 3 months'}, {'measure': 'The Percentage of Participants With Partial Response (PR) at 8 Months', 'description': 'Patients who met one of the following criteria at the end of 8 months of treatment were defined as Partial Responders, regardless of the treatment.\n\n* Mean 1 hour GH \\> 2.5 µg/L and \\< 5 µg/L and either a decrease in IGF-I of at least 50% compared to baseline or IGF-I within normal range.\n* Mean 1 hour GH \\< 2.5 µg/L and a decrease in IGF-I of at least 50% compared to baseline and IGF-I outside normal range.', 'timeFrame': 'From Baseline to 8 months'}]",3,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,70.0,ACTUAL,2025-09-01T16:18:15.896833,v2_robust,True,True,True,False,False,
NCT01682642,The Influence of Adjuvant Medical Treatment of Peritoneal Endometriosis on the Outcome of IVF. A Prospective Randomized Analysis.,IVF Outcome in Patients With Peritoneal Endometriosis. The Impact of a Hormonal Treatment of the Endometriosis Prior to the IVF on the Pregnancy Rates.,Zoladex,['Zoladex'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Infertility,"['Infertility', 'Endometriosis']","['endometriosis', 'pregnancy', 'In Vitro Fertilization (IVF)/Intra Cytoplastic Sperm Injection (ICSI)', 'peritoneal implants', 'embryo quality']",COMPLETED,,2012-03,2014-10,"[{'measure': 'Number of Metaphase II Cells (MII)', 'description': 'number of MII cells retrieved', 'timeFrame': '3 weeks'}]","[{'measure': 'Pregnancy Rate', 'description': 'The number of ongoing pregnancies obtained which still is the most important issue for the patients.', 'timeFrame': '12 weeks'}, {'measure': 'Good Embryo Quality', 'description': 'The development of the embryo at the time of transfer on day 3. Good quality is defined by more than 7 cells and less then 20% fragmentation on day 3.', 'timeFrame': '3 days after oocyte retrieval'}, {'measure': 'Number of Pro Nuclear Cell (2PN)', 'description': 'number of 2PN', 'timeFrame': '1 day after oocyte retrieval'}, {'measure': 'Number of Cryopreserved Embryos', 'description': 'number of blastocytes that can be cryopreserved', 'timeFrame': '1 week after oocyte retrieval'}, {'measure': 'Total Follicle Stimulating Hormone (FSH) Dose', 'description': 'total dose of FSH needed at the end of stimulation', 'timeFrame': '3 weeks'}]",6,18 Years,38 Years,FEMALE,False,AZ Jan Palfijn Gent,OTHER,1,120.0,ACTUAL,2025-09-01T16:18:15.896869,v2_robust,True,True,True,False,False,
NCT03813186,Effect of Food on Blood Levels of ASTX727,A Phase 1b Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX727 (Cedazuridine and Decitabine) in Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia,ASTX727 + Day 2 Food,"['cedazuridine + decitabine + food on Day 2', 'cedazuridine + decitabine + food on Day 4', 'ASTX727 + Day 4 Food', 'ASTX727 + Day 2 Food']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Myelodysplastic Syndromes,"['Myelodysplastic Syndromes', 'Chronic Myelomonocytic Leukemia', 'Acute Myeloid Leukemia']","['MDS', 'CMML', 'ASTX727', 'decitabine', 'AML']",COMPLETED,,2018-11-08,2019-12-16,"[{'measure': 'AUC0-t (area under the concentration-time curve from time 0 to t hours).', 'description': 'Area under the concentration-time curve from time 0 to t hours.', 'timeFrame': '6 months'}, {'measure': 'AUC0-8 (area under the concentration-time curve from time 0 to 8 hours).', 'description': 'Area under the concentration-time curve from time 0 to 8 hours.', 'timeFrame': '6 months'}, {'measure': 'AUC0-24 (area under the concentration-time curve from time 0 to 24 hours).', 'description': 'Area under the concentration-time curve from time 0 to 24 hours', 'timeFrame': '6 months'}, {'measure': 'AUC0-inf (area under the concentration-time curve from time 0 to infinity).', 'description': 'Area under the concentration-time curve from time 0 to infinity.', 'timeFrame': '6 months'}, {'measure': 'Cmax (maximum plasma concentration).', 'description': 'Maximum plasma concentration.', 'timeFrame': '6 months'}]","[{'measure': 'hemoglobin level', 'description': 'Assessed in g/dL', 'timeFrame': '6 months'}, {'measure': 'platelet count', 'description': 'Assessed as 10\\^9/L', 'timeFrame': '6 months'}, {'measure': 'white blood cell count', 'description': 'Assessed as fraction of 1', 'timeFrame': '6 months'}, {'measure': 'neutrophils', 'description': 'Assessed as percent', 'timeFrame': '6 months'}, {'measure': 'Subject-reported and investigator-observed incidence and severity of adverse events.', 'timeFrame': '6 months'}]",10,18 Years,,ALL,False,"Astex Pharmaceuticals, Inc.",INDUSTRY,0,18.0,ACTUAL,2025-09-01T16:18:15.896917,v2_robust,True,True,True,False,True,
NCT00889486,Safety and Efficacy of Once-daily Oral Administrations of TZP-102 for Gastroparesis in Patients With Diabetes Mellitus,"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2 Evaluation of the Safety and Efficacy of Once-Daily Administrations of TZP 102 for the Treatment of Symptomatic Gastroparesis in Patients With Diabetes Mellitus",TZP-102,"['TZP-102', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Gastroparesis,"['Gastroparesis', 'Diabetes Mellitus']","['gastroparesis', 'diabetes mellitus', 'delayed gastric emptying']",COMPLETED,,2009-04,2010-04,"[{'measure': 'change from baseline in gastric half-emptying time', 'timeFrame': 'study days 1 and 28'}]","[{'measure': 'change from baseline in gastroparesis symptoms and health-related quality of life', 'timeFrame': 'study days 8, 15 and 28'}]",2,18 Years,80 Years,ALL,False,"Tranzyme, Inc.",INDUSTRY,0,92.0,ACTUAL,2025-09-01T16:18:15.896938,v2_robust,True,True,True,False,False,
NCT03294486,"Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients","Safety and Efficacy of the ONCOlytic VIRus Armed for Local Chemotherapy, TG6002/5-FC, in Recurrent Glioblastoma Patients","Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)","['Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)']",1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Glioblastoma,"['Glioblastoma', 'Brain Cancer']","['Glioblastoma', 'Oncolytic viruses']",UNKNOWN,,2017-10-12,2021-09,"[{'measure': 'Number of Participant with Dose Limiting Toxicities defined as Any of the following treatment-related adverse events (AEs) is evaluated and reported from Day 1 through Day 26; as assessed by NCI-CTCAE, version 4.03', 'description': 'For Phase 1\n\nAssessment of safety and tolerability :\n\nNumber of Participant with Dose Limiting Toxicities defined as Any of the following treatment-related adverse events (AEs) is evaluated and reported from Day 1 through Day 26; as assessed by NCI-CTCAE, version 4.03:\n\n* Any Grade 4 toxicity (except isolated Grade 4 lymphopenia lasting ≤ 7 days);\n* Grade 3 or 4 hypotension, disseminated intravascular coagulation (DIC), or allergic reaction/hypersensitivity;\n* Grade 3 skin lesions: ulcerative dermatitis or skin changes with pain interfering with function;\n* Number of skin lesions ≥ 10 corresponding to infection possibly or probably related to the administration of TG6002;\n* Grade 3 non-hematologic toxicity persisting for \\>7 days except increase in ASAT and/or ALAT (\\> 5x ULN), which may last \\>7 days if total bilirubin is normal or Grade 1;\n* Flu-like symptoms that do not respond to standard treatments;\n* Grade 3 hematologic toxicity persisting for \\> 7 days', 'timeFrame': 'Through day 1 to day 26'}, {'measure': 'Number of patients without documented tumor progression at 6 months from date of first TG6002 infusion according to Response Assessment Neuro-Oncology Criteria (Wen et al., 2010, JCO, PMID:20231676)', 'description': 'For Phase 2a Number of patients without documented tumor progression at 6 months from date of first TG6002 infusion according to Response Assessment Neuro-Oncology Criteria (Wen et al., 2010, JCO, PMID:20231676)', 'timeFrame': 'at 6 months according to RANO criteria'}]","[{'measure': 'TG6002 recommended dose prior to the Phase 2a part of the study (RP2D) in combination with 5-FC (Maximum Plasma Concentration [Cmax])', 'description': 'Phase 1 The Recommended Phase 2 Dose (RP2D) is the dose recommended by the DSMB for Phase 2a investigation: the DSMB performed a complete review of the available results about safety and efficacy from the first phase', 'timeFrame': 'through study completion an average of 24 months'}, {'measure': 'Overall Survival (OS)', 'description': 'After the end of the treatment patients will be followed in the neurology department according to standards of care. In case of withdrawal, patients and/or their specified contacts could be contacted for survival and information on possible subsequent anti-cancer therapy and their general safety and efficacy', 'timeFrame': 'through study completion : every 2 months the first year and then every 3 months from day 67 until the date of first documented progression or date of death from any cause wichever came first, assessed up to 51 months'}, {'measure': 'Relative quantification of circulating viral DNA', 'description': 'Relative quantification of circulating viral DNA : Quantification of the viral genome by Quantitative Polymerase Chain Reaction', 'timeFrame': 'Day1, Day2, Day 15, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-FC', 'description': 'Measurement of Cmax', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-FC', 'description': 'Measurement of Tmax', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-FC', 'description': 'Measurement of AUC', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-FC', 'description': 'Measurement of CI', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-FC', 'description': 'Measurement of MRT', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-FC', 'description': 'Measurement of Vd/F', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-Fluorouraril (5-FU)', 'description': 'Measurement of Cmax', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-Fluorouraril (5-FU)', 'description': 'Measurement of Tmax', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-Fluorouraril (5-FU)', 'description': 'Measurement of AUC', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-Fluorouraril (5-FU)', 'description': 'Measurement of CI', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-Fluorouraril (5-FU)', 'description': 'Measurement of MRT', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of 5-Fluorouraril (5-FU)', 'description': 'Measurement of Vd/F', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)', 'description': 'Measurement of Cmax', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)', 'description': 'Measurement of AUC', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)', 'description': 'Measurement of Tmax', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)', 'description': 'Measurement of CI', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)', 'description': 'Measurement of MRT', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Blood pharmacokinetics of final metabolite a-fluoro-B-alanine(FBAL)', 'description': 'Measurement of Vd/F', 'timeFrame': 'Day0, Day7, Day 14, Day 26'}, {'measure': 'Viral shedding in saliva, urine and feces', 'description': 'by Quantitative Polymerase Chain Reaction and plaque assays (if q-PCR positive)', 'timeFrame': 'Day2, Day7'}, {'measure': 'Humoral response', 'description': 'Measurement of Blood anti-vaccinia virus and anti-FCU1 antibodies in blood', 'timeFrame': 'Baseline, Day 39'}, {'measure': 'Isolation of peripheral blood mononuclear cells (PBMC);', 'description': 'Determine immunoprofile, potential predictive marker of efficacy', 'timeFrame': 'Day 0, Day 26, Day 39'}, {'measure': 'Metabolic Response', 'description': 'using PET-MRI (\\[18F\\]FDOPA -PET scans)', 'timeFrame': 'Baseline, Day 39, Day 67'}, {'measure': 'Safety and tolerability : Incidence of Treatment; evaluation of treatement-releated adverse events', 'description': 'Complete review of serious and unserious adverse events', 'timeFrame': 'through study completion an average of 51 months'}]",28,18 Years,,ALL,False,Assistance Publique - Hôpitaux de Paris,OTHER,1,78.0,ESTIMATED,2025-09-01T16:18:15.896970,v2_robust,True,True,False,False,True,
NCT06705686,Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer,Phase 1 First in Human Trial to Assess Safety and Tolerability of the Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer,(R)-9bMS,"['Mahatinib', '(R)-9bMS']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Castration-resistant Prostate Cancer (CRPC),"['Metastatic Castration-resistant Prostate Cancer (CRPC)', 'Metastatic Castration-resistant Prostate Carcinoma']","['ACK1', 'TNK2', 'Non-receptor tyrosine kinase', 'small molecule inhibitor', 'prostate cancer', 'CRPC', 'kinase inhibitor', 'Androgen receptor antagonist', 'Immune modulator']",NOT_YET_RECRUITING,,2025-03-30,2028-03-30,"[{'measure': 'Frequency of dose-limiting toxicities (Dose Escalation only)', 'description': 'Dose-limiting toxicities are defined in the protocol.', 'timeFrame': 'From day 1 of treatment through day 28 of treatment'}]","[{'measure': 'Recommended phase 2 dose (RP2D) (Dose Escalation only)', 'description': 'RP2D has traditionally been synonymous with the highest safe dose, or maximum tolerated dose (MTD) as determined based on, but can be lower than MTD based on comprehensive review of all available data from the phase I study (including dose limiting toxicity data, pharmacodynamic (PD)/pharmacokinetic (PK) study and efficacy data).', 'timeFrame': 'From day 1 of treatment through day 28 of treatment'}, {'measure': 'Change in pharmacokinetic parameters as measured by half life of drug in blood', 'description': 'The following procedures will be performed on Day 1 beginning at the time of administration of (R)-9bMS, in the clinic. Blood collection for PK measurements will be pre-dose (within 30 minutes of administration), 0.5 hour, 1, 2, 4, 8 hours, post administration of the first dose of (R)-9bMS. The second dose will be administered 12 hours after administration of the first dose. A 24-hour blood sample will be taken on Day 2. (R)-9bMS will be administered in fasting condition (of at least 1 hour prior to dosing) and patients will continue fasting at least 1 hours after dose administration.\n\nAfter the 24-hour PK sample is taken, samples will be sent to the Sample Acquisition Manager for the Cancer Pharmacology Lab at University of Wisconsin .A 25 µL aliquot of standard, QC, or sample be extracted by protein precipitation. The analyte and internal standard will be detected using a SCIEX API 5000 triple quadrupole LC-MS/MS system.', 'timeFrame': 'Pre-dose, 0.5 hours, 1 hour, 2 hours, 4 hours, 8 hours, and 24 hours post-first dose of (R)-9bMS on Day 1'}, {'measure': 'Number of patients with a prostate specific antigen (PSA) response', 'description': 'PSA response is defined by at least 50% decline in PSA level from baseline measured twice at least 3 weeks apart.', 'timeFrame': 'From baseline through end of treatment (up to 6 months)'}, {'measure': 'Overall response rate (ORR)', 'description': 'ORR is defined as proportion of patients achieving complete response (CR) and partial response (PR) by RECIST 1.1 or by PCWG3 criteria.', 'timeFrame': 'From baseline through end of treatment (up to 12 months)'}, {'measure': 'Overall survival (OS)', 'description': 'OS is defined from date of first treatment through date of death (of all cause) or last follow-up.', 'timeFrame': 'From start of treatment through the completion of follow-up (up to 24 months)'}, {'measure': 'Progression-free survival (PFS)', 'description': 'PFS is defined from date of first treatment to date of progression or death or last follow-up, whichever is earlier.', 'timeFrame': 'From start of treatment through the completion of follow-up (up to 24 months)'}, {'measure': 'Disease specific survival (DFS)', 'description': 'DFS is defined from date of first treatment to date to date of death due to disease or last follow-up.', 'timeFrame': 'From start of treatment through the completion of follow-up (up to 24 months)'}, {'measure': 'Duration of response (DoR)', 'description': 'DoR is defined from date of 1st PSA response to date of PSA progression or date of RECIST response (complete or partial response) to date of radiographic progression.', 'timeFrame': 'From date of first response through the completion of follow-up (up to 24 months)'}, {'measure': 'Number of participants with adverse events as graded by CTCAE v5.0', 'description': 'Only serious adverse events (SAEs) will be collected from day 31 through day 100.', 'timeFrame': 'From start of treatment through 100 days after completion of treatment (estimated to be 12 months and 100 days)'}]",10,18 Years,,MALE,False,"TechnoGenesys, Inc.",INDUSTRY,3,40.0,ESTIMATED,2025-09-01T16:18:15.896990,v2_robust,True,True,False,False,True,
NCT05135286,Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia,"Multicenter, Double-Masked, Randomized, Safety and Efficacy Study of BRIMOCHOL™ PF and Carbachol PF Topical Ophthalmic Solution With Emmetropic Phakic and Pseudophakic Presbyopia",BRIMOCHOL™ PF,"['Vehicle', 'carbachol monotherapy', 'carbachol/brimonidine tartrate', 'BRIMOCHOL™ PF', 'Carbachol PF']",5,INTERVENTIONAL,['PHASE3'],PHASE3,,Presbyopia,['Presbyopia'],[],COMPLETED,,2022-03-15,2025-03-13,"[{'measure': 'Change from baseline in near VA', 'description': 'Percentage of subjects with 3-line improvement in near VA without the loss of at least 1 line in distance VA', 'timeFrame': 'Baseline Day 1'}]",[],1,45 Years,80 Years,ALL,True,Visus Therapeutics,OTHER,0,629.0,ACTUAL,2025-09-01T16:18:15.897207,v2_robust,True,True,True,False,False,
NCT06589986,A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis,"A Phase III, Multicenter, Double-Blind, Placebo-Controlled, Treat-Through Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With RO7790121 in Patients With Moderately to Severely Active Ulcerative Colitis",Afimkibart,"['Afimkibart', 'PF-06480605', 'RO7790121', 'RVT-3101', 'Placebo', 'RG6631']",6,INTERVENTIONAL,['PHASE3'],PHASE3,,Moderately to Severely Active Ulcerative Colitis,['Moderately to Severely Active Ulcerative Colitis'],[],RECRUITING,,2024-09-17,2029-12-30,"[{'measure': 'Percentage of Participants with Clinical Remission at Week 12', 'description': 'Percentage of participants achieving Modified Mayo Score (mMS) \\<=2 with stool frequency subscore (SFS) = 0 or 1 (up to 1-2 stools more than normal), rectal bleeding subscore (RBS) = 0 (no blood seen) and endoscopic subscore (ES) = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Clinical Remission at Week 52', 'description': 'Percentage of participants achieving mMS \\<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.', 'timeFrame': 'At Week 52'}]","[{'measure': 'Change in Partial Modified Mayo Score (pmMS)', 'description': 'Change in pmMS from baseline to Week 2. pmMS is a composite score of ulcerative colitis signs and symptoms activity given by the sum of the SFS and RBS. SFS is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal). RBS is measured on a scale from 0 (no blood seen) to 3 (blood alone passed).', 'timeFrame': 'Baseline to Week 2'}, {'measure': 'Percentage of Participants with Endoscopic Improvement', 'description': 'Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 12.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Endoscopic Remission', 'description': 'Percentage of participants achieving endoscopic subscore of 0 (normal appearance of mucosa) at Week 12.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Clinical Response', 'description': 'Percentage of participants achieving a decrease in mMS of at least 2 points and 30% from baseline and either a decrease in RBS \\>= 1 or RBS = 0 or 1 (no blood seen or stool with streaks of blood) at Week 12. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. SFS is measured on a scale from 0 (normal number of stools) to 3 (5 or more stools than normal). RBS is measured on a scale from 0 (no blood seen) to 3 (blood alone passed). ES is measured on a scale from 0 (normal appearance of mucosa) to 3 (severe disease).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Histologic Improvement', 'description': 'Percentage of participants achieving a histologic improvement, defined as Geboes \\<=3.1 at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Histologic Remission', 'description': 'Percentage of participants achieving a histologic remission, defined as Geboes \\<2B at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Histologic-Endoscopic Mucosal Improvement', 'description': 'Percentage of participants achieving Geboes \\<= 3.1 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Histologic-Endoscopic Remission', 'description': 'Percentage of participants achieving Geboes \\< 2 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Maintenance of Remission', 'description': 'Percentage of participants with clinical remission at both Week 12 and Week 52. Clinical remission is defined as mMS \\<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease). mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.', 'timeFrame': 'Week 12 and Week 52'}, {'measure': 'Percentage of Participants with Corticosteroid-Free Remission', 'description': 'Percentage of participants in clinical remission at Week 52 with no corticosteroid use at least 8 weeks prior to Week 52. Clinical remission is defined as mMS \\<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease). mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Endoscopic Improvement', 'description': 'Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 52.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Endoscopic Remission', 'description': 'Percentage of participants achieving endoscopic subscore of 0 (normal appearance of mucosa) at Week 52.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Histologic Improvement', 'description': 'Percentage of participants achieving histologic improvement defined as Geboes \\<= 3.1 at Week 52.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Histologic Remission', 'description': 'Percentage of participants achieving histologic remission defined as Geboes \\<2B at Week 52.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Histologic-Endoscopic Mucosal Improvement', 'description': 'Percentage of participants achieving Geboes \\<= 3.1 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Histologic-Endoscopic Remission', 'description': 'Percentage of participants achieving Geboes \\< 2 and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52. Geboes is a grading system for histologic ulcerative colitis disease activity with scores ranging from 0 (no activity) to 5.4 (ulcer or granulation tissue).', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Clinical remission: Among Biomarker-Defined Subgroups of Participants', 'description': 'Percentage of participants achieving mMS \\<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 12 in biomarker-defined subgroups. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Clinical remission: Among Biomarker-Defined Subgroups of Participants', 'description': 'Percentage of participants achieving mMS \\<= 2 with SFS = 0 or 1 (up to 1-2 stools more than normal), RBS = 0 (no blood seen) and ES = 0 or 1 (normal appearance of mucosa or mild disease) at Week 52 in biomarker-defined subgroups. mMS is a composite score of ulcerative colitis disease activity, given by the sum of three subscores: SFS, RBS and ES. Each subscore is measured on a scale from 0 to 3, with higher values associated with greater severity.', 'timeFrame': 'At Week 52'}, {'measure': 'Percentage of Participants with Endoscopic Improvement: Among Biomarker-Defined Subgroups of Participants', 'description': 'Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 12 in biomarker-defined subgroups.', 'timeFrame': 'At Week 12'}, {'measure': 'Percentage of Participants with Endoscopic Improvement: Among Biomarker-Defined Subgroups of Participants', 'description': 'Percentage of participants achieving endoscopic subscore of 0 or 1 (normal appearance of mucosa or mild disease) at Week 52 in biomarker-defined subgroups.', 'timeFrame': 'At Week 52'}, {'measure': 'Change in Bowel Urgency', 'description': 'Change in bowel urgency from baseline through Week 52. Bowel urgency is measured on a scale from 0 (None) to 4 (Severe).', 'timeFrame': 'Baseline through Week 52'}, {'measure': 'Change in Abdominal Pain', 'description': 'Change in abdominal pain from baseline through Week 52. Abdominal pain is measured on a scale from 0 (None) to 4 (Severe).', 'timeFrame': 'Baseline through Week 52'}, {'measure': 'Change in Fatigue', 'description': 'Change in fatigue as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) from baseline to Week 12 and Week 52. FACIT-Fatigue is a 13-item self-reported assessment of the level and impact of fatigue. The overall FACIT-Fatigue score ranges between 0 and 52, with higher scores associated with better quality of life concerns related to fatigue.', 'timeFrame': 'Baseline to Week 12 and Week 52'}, {'measure': 'Change in Health-Related Quality of Life', 'description': 'Change in Inflammatory Bowel Disease Questionnaire (IBDQ) score from baseline to Week 12 and Week 52. IBDQ is a 32-item self-reported assessment of health-related quality of life in participants with inflammatory bowel disease. The overall IBDQ score ranges from 32 to 224, with higher scores associated with better health-related quality of life.', 'timeFrame': 'Baseline to Week 12 and Week 52'}, {'measure': 'Overall Change in UC Symptoms', 'description': 'Patient Global Impression of Change (PGIC) from baseline to Weeks 2, 12 and 52. PGIC measures overall change in ulcerative colitis symptoms from ""Much better"" to ""Much worse"".', 'timeFrame': 'Baseline to Week 2, Week 12, and Week 52'}, {'measure': 'Overall Severity in UC Symptoms', 'description': 'Patient Global Impression of Severity (PGIS) from baseline to Weeks 2, 12 and 52. PGIS measures severity of ulcerative colitis symptoms from ""None"" to ""Very severe"".', 'timeFrame': 'Baseline to Week 2, Week 12, and Week 52'}, {'measure': 'Incidence and Severity of Adverse Events (AEs)', 'description': 'Incidence and severity of AEs, including serious AEs, AEs leading to treatment discontinuation and AEs of special interest.', 'timeFrame': 'Up to 70 Weeks after Baseline'}]",29,16 Years,80 Years,ALL,False,Hoffmann-La Roche,INDUSTRY,1,400.0,ESTIMATED,2025-09-01T16:18:15.897278,v2_robust,True,True,False,False,True,
NCT05298670,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,Drug Repurposing Using Metformin for Improving the Therapeutic Outcome in Multiple Sclerosis Patients,MetFORMIN 1000 Mg Oral Tablet,"['Rebiff ® 44mcg or Avonex®', 'Cidophage ®1000 mg tablets, CID, Giza, Egypt) tablet and Rebiff ® 44mcg or Avonex®', 'Interferon beta-1a', 'MetFORMIN 1000 Mg Oral Tablet']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Multiple Sclerosis,['Multiple Sclerosis'],[],UNKNOWN,,2022-02-01,2023-03-28,"[{'measure': 'Change in IL17 in both arms as measured by ELISA.', 'description': 'Anti-inflammatory marker', 'timeFrame': 'After 6 months'}]","[{'measure': 'Percentage of Quality of Life deterioration in both arms measured by MSQOL-54.', 'description': 'Assessment of quality of life for patients, The highest and lowest values refer to the satisfaction degree of patients', 'timeFrame': 'After 6 months'}, {'measure': 'Change in IL22 in both arms as measured by ELISA.', 'description': 'Anti-inflammatory marker', 'timeFrame': 'After 6 months'}, {'measure': 'Malondialdehyde in both arms as measured by Colorimetric tests.', 'description': 'Anti-oxidant marker', 'timeFrame': 'After 6 months'}, {'measure': ""Degree of remyelination visualized by MRI, it depends on clinician's overview."", 'description': 'Determination of T2 lesions', 'timeFrame': 'After 6 months'}, {'measure': 'Degree of disability assessed by Expanded Disability Status Scale.', 'description': 'Determination disability level (0 - 6), The lowest value means that it is best outcome and the highest value is the worst outcome.', 'timeFrame': 'After 6 months'}]",6,18 Years,50 Years,ALL,False,German University in Cairo,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:15.897456,v2_robust,True,True,False,False,False,
NCT00150670,Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer,Randomized Phase III Study of TS-1 Alone Versus TS-1 Plus CDDP in Advanced Gastric Cancer,TS-1 and cisplatin,"['TS-1 and cisplatin', 'TS-1']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Gastric Cancer,['Gastric Cancer'],['Stomach cancer'],COMPLETED,,2002-03,2006-12,"[{'measure': 'Overall survival', 'timeFrame': 'every course for first three courses, then every other course'}]","[{'measure': 'Overall response rate, lesion-directed response rate, time to treatment failure (TTF), hospitalization-free survival period within the periods of TTF, and safety profile', 'timeFrame': 'every course for first three courses, then every other course'}]",2,20 Years,74 Years,ALL,False,"Taiho Pharmaceutical Co., Ltd.",INDUSTRY,0,300.0,,2025-09-01T16:18:15.897486,v2_robust,True,True,True,False,True,
NCT00679770,Study of Different Doses of a Novel Treatment for Onychomycosis,"A Randomized, Double-blind, Vehicle-controlled, Multi-center Study To Evaluate The Safety And Efficacy Of Topically Applied An2690 2.5%, 5.0%, And 7.5% Solutions Vs. Vehicle For The Treatment Of Adult Subjects With Onychomycosis Of The Great Toenail.","AN2690, 2.5%","['AN2690, 5%', 'AN2690, 2.5%', 'Vehicle', 'AN2690, 7.5%']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,"Distal, Subungual Onychomycosis","['Distal, Subungual Onychomycosis']","['Onychomycosis', 'Fungal Nail']",COMPLETED,,2006-06-30,2007-08-31,"[{'measure': 'Clinical evidence of complete great toenail clearance or at least fungal-clear great toenail growth (""complete"" = 5mm; ""partial"" = 2mm), plus a negative fungal culture from the treatment-targeted great toenail.', 'timeFrame': 'Day 180'}]","[{'measure': 'Absence of signs and symptoms of onychomycosis plus a negative fungal culture & negative KOH from the treatment-targeted toenail.', 'timeFrame': 'Day 360'}]",2,18 Years,65 Years,ALL,False,Pfizer,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:15.897520,v2_robust,True,True,True,False,False,
NCT03856970,"Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers","A Phase 1, Open-Label, Parallel, Sequential, Multi-part Study to Evaluate the Effect of IW-3718 on the Pharmacokinetics of an Oral Contraceptive, Levothyroxine, Glyburide, and Digoxin in Healthy Adult Volunteers",Microgestin®,"['Microgestin®', 'Digoxin', 'IW-3718', 'Glyburide', 'ethinyl estradiol 30 μg and norethindrone 1500 μg', 'Levothyroxine']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2019-03-11,2019-07-03,"[{'measure': 'PK of EE and NET: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time 0 to the Last Quantifiable Concentration (AUC0-t)', 'timeFrame': 'Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose'}, {'measure': 'PK of EE and NET: AUC From Time 0 Extrapolated to Infinity (AUC0-inf)', 'timeFrame': 'Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose'}, {'measure': 'PK of EE and NET: Maximum Observed Plasma Concentration (Cmax)', 'timeFrame': 'Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose'}, {'measure': 'PK of EE and NET: Time to Maximum Observed Plasma Concentration (Tmax)', 'timeFrame': 'Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose'}, {'measure': 'PK of EE and NET: Terminal Phase Half-Life (t1/2)', 'timeFrame': 'Treatment Period 1 (Days 1-6) and Treatment Period 2 (Days 14-19): predose, up to 120 hours postdose'}, {'measure': 'PK of Levothyroxine: AUC0-t', 'timeFrame': 'Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose'}, {'measure': 'PK of Levothyroxine: AUC0-inf', 'timeFrame': 'Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose'}, {'measure': 'PK of Levothyroxine: Cmax', 'timeFrame': 'Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose'}, {'measure': 'PK of Levothyroxine: Tmax', 'timeFrame': 'Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose'}, {'measure': 'PK of Levothyroxine: t1/2', 'timeFrame': 'Treatment Period 1 (Days 1-3) and Treatment Period 2 (Days 39-41): predose, up to 48 hours postdose'}, {'measure': 'PK of Glyburide: AUC0-t', 'timeFrame': 'Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose'}, {'measure': 'PK of Glyburide: AUC0-inf', 'timeFrame': 'Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose'}, {'measure': 'PK of Glyburide: Cmax', 'timeFrame': 'Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose'}, {'measure': 'PK of Glyburide: Tmax', 'timeFrame': 'Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose'}, {'measure': 'PK of Glyburide: t1/2', 'timeFrame': 'Treatment Period 1 (Days 1-4) and Treatment Period 2 (Days 11-14): predose, up to 72 hours postdose'}, {'measure': 'PK of Digoxin: AUC0-t', 'timeFrame': 'Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose'}, {'measure': 'PK of Digoxin: AUC0-inf', 'timeFrame': 'Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose'}, {'measure': 'PK of Digoxin: Cmax', 'timeFrame': 'Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose'}, {'measure': 'PK of Digoxin: Tmax', 'timeFrame': 'Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose'}, {'measure': 'PK of Digoxin: t1/2', 'timeFrame': 'Treatment Period 1 (Days 23-30) and Treatment Period 2 (Days 35-42): predose, up to 168 hours postdose'}]","[{'measure': 'Number of Participants With Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), and Discontinuations due to TEAEs', 'timeFrame': 'Part 1: up to Day 27 (±1 day); Part 2: up to Day 49 (±1 day); Part 3: Day 50 (±1 day)'}, {'measure': 'Number of Participants With ≥1 Clinically Significant Changes in Clinical Laboratory Test Results', 'timeFrame': 'Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42'}, {'measure': 'Number of Participants With ≥1 Clinically Significant Changes in Vital Sign Measurements', 'timeFrame': 'Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42'}, {'measure': 'Number of Participants With ≥1 Clinically Significant Changes in 12-lead Electrocardiogram (ECG) Results', 'timeFrame': 'Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42'}, {'measure': 'Number of Participants With ≥1 Clinically Significant Changes in Physical Examination Findings', 'timeFrame': 'Part 1: up to Day 19; Part 2: up to Day 41; Part 3: up to Day 42'}]",25,18 Years,50 Years,ALL,True,"Ironwood Pharmaceuticals, Inc.",INDUSTRY,0,87.0,ACTUAL,2025-09-01T16:18:15.897531,v2_robust,True,True,True,False,True,
NCT00086970,"Ifosfamide With or Without O(6)-Benzylguanine in Treating Patients With Unresectable, Metastatic Solid Tumors",A Phase I Study Of BG In Combination With Ifosfamide For Advanced Solid Tumors,ifosfamide,"['O6-benzylguanine', 'IFF', 'ifosfamide', 'IPP', 'Cyfos', 'BG', 'Holoxan', 'IFX']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,"Unspecified Adult Solid Tumor, Protocol Specific","['Unspecified Adult Solid Tumor, Protocol Specific']",[],TERMINATED,Administratively complete.,2004-06,,"[{'measure': 'Change in degree of myelosuppression (thrombocytopenia and neutropenia) quantified by both duration of neutropenia and severity of neutropenia', 'timeFrame': 'Baseline up to 1 year'}, {'measure': 'Maximum tolerated dose (MTD) of O6-benzylguanine defined as the dose preceding that at which 3 of 6 or 4 of 12 patients experience dose-limiting toxicity', 'description': 'DLT is defined as any \\>= grade 3 non-hematologic toxicity, grade 4 thrombocytopenia, or prolonged neutropenia.', 'timeFrame': '21 days'}]","[{'measure': 'Pharmacodynamics including apoptosis and DNA damage', 'timeFrame': 'Up to 1 year'}, {'measure': 'Pharmacokinetics of O6-benzylguanine', 'description': 'Summarized using descriptive statistics (mean, median, standard deviation, and interquartile range). Estimated via nonlinear regression.', 'timeFrame': 'Up to day 3 of course 2'}]",4,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,32.0,ACTUAL,2025-09-01T16:18:15.897567,v2_robust,True,True,False,True,False,Administratively complete.
NCT03139370,Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers,A Phase 1 Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects With Advanced Cancers,KITE-718,"['Fludarabine', 'Cyclophosphamide', 'KITE-718']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,['Solid Tumor'],[],TERMINATED,The study was terminated due to the sponsor's decision to discontinue the clinical trial.,2017-12-27,2023-06-04,"[{'measure': 'Phase 1A - Percentage of Participants Experiencing Adverse Events Defined as Dose-Limiting Toxicities', 'description': 'Dose-limiting toxicity is defined as protocol-defined KITE-718 related events with onset within the first 21 days following KITE-718 infusion.', 'timeFrame': 'Up to 21 days'}, {'measure': 'Phase 1B - Efficacy: Objective Response Rate (ORR)', 'description': 'ORR is defined as complete response + partial response for participants evaluated by RECIST v1.1 and very good partial response (VGPR) or better for multiple myeloma participants evaluated by International Myeloma Working Group (IMWG) Consensus Panel 1 Criteria.', 'timeFrame': 'Up to year 2 for solid tumor participants and up to Year 5 for multiple myeloma participants'}]","[{'measure': 'Duration of Response (DOR)', 'description': 'For participants who experience an objective response, DOR is defined as the time from the date of their first objective response to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death regardless of cause.', 'timeFrame': 'Up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from the KITE-718 infusion date to the date of disease progression per modified RECIST v1.1 or consensus panel 1 criteria or death from any cause.', 'timeFrame': 'Up to year 2 for solid tumor participants and up to year 5 for multiple myeloma participants'}, {'measure': 'Overall Survival', 'description': 'Overall survival is defined as the time from KITE-718 infusion to the date of death.', 'timeFrame': 'Up to 15 years'}, {'measure': 'Percentage of Participants Experiencing Adverse Events', 'timeFrame': 'Up to 15 years'}, {'measure': 'Percentage of Participants with Anti-KITE-718 Antibodies', 'timeFrame': 'Up to 2 years'}, {'measure': 'Percentage of Participants Experiencing Replication-competent Retrovirus (RCR)', 'timeFrame': 'Up to 2 years'}, {'measure': 'Levels of MAGE-A3/A6 TCR-transduced T Cells in Blood', 'timeFrame': 'Up to 2 years'}]",9,18 Years,,ALL,False,"Kite, A Gilead Company",INDUSTRY,0,16.0,ACTUAL,2025-09-01T16:18:15.897582,v2_robust,True,True,False,True,True,The study was terminated due to the sponsor's decision to discontinue the clinical trial.
NCT05838573,Metformin Treatment on Cognitive Impairment of Schizophrenia,The Effect of Metformin Treatment on Cognitive Impairment in Individuals With Schizophrenia: A 24-week Multicentre Randomised Controlled Trial,Metformin treatment,"['Metformin treatment', 'Placebo treatment']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Schizophrenia,['Schizophrenia'],"['Schizophrenia', 'Cognitive impairment', 'Metformin', 'Clinical trial']",RECRUITING,,2023-05-08,2027-06-30,"[{'measure': 'Changes of the score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery of interventional participants', 'description': 'At baseline and 12th week, the cognitive function of interventional participants will be assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery. Evaluator convert raw scores to scale scores, then to normalized T scores. T scores of seven domains and composite score are further calculated. The changes of scores after 12-week metformin treatment will be used for assessing the improvement of cognitive function (higher score means better function).', 'timeFrame': 'From baseline to 12th week'}, {'measure': 'Changes of brain cerebral blood flow by arterial spin labeling of interventional participants', 'description': 'At baseline and 12th week, whole brain cerebral blood flow (CBF) will be recorded by arterial spin labeling (ASL). For interventional participants, the changes in CBF (c-CBF) before and after the application of 160 units nasal insulin spray of interventional participants will be calculated. The changes of c-CBF after 12-week metformin treatment will be reported.', 'timeFrame': 'From baseline to 12th week'}, {'measure': 'Changes of resting-state functional MRI of interventional participants', 'description': 'At baseline and 12th week, the resting-state functional MRI(fMRI) will be conducted at fasting state. For interventional participants, the changes in fMRI (c-fMRI) before and after the application of 160 units nasal insulin spray will be analysed. The changes of c-fMRI after 12-week metformin treatment will be used for exploring underlying mechanism.', 'timeFrame': 'From baseline to 12th week'}, {'measure': 'The difference of cerebral blood flow between schizophrenic participants and healthy volunteers', 'description': 'At baseline, whole brain cerebral blood flow (CBF) will be recorded by arterial spin labeling (ASL) for every participants, the changes in CBF (c-CBF) before and after the application of 160 units nasal insulin spray will be calculated. The difference of c-CBF of the brain between schizophrenic participants and healthy volunteers will be reported.', 'timeFrame': 'Baseline'}, {'measure': 'The difference of resting-state functional MRI between schizophrenic participants and healthy volunteers', 'description': 'At baseline, the resting-state functional MRI(fMRI) will be conducted at fasting state. For every participants, the changes in fMRI (c-fMRI) before and after the application of 160 units nasal insulin spray will be analysed. The c-fMRI between schizophrenic participants and healthy volunteers may reflect the underlying mechanism of disease.', 'timeFrame': 'Baseline'}, {'measure': 'The difference of the score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery between schizophrenic participants and healthy volunteers', 'description': 'At baseline, the cognitive function will be assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery, including schizophrenic participants and healthy volunteers. Evaluator convert raw scores to scale scores, then to normalized T scores. T scores of seven domains and composite score are further calculated(higher score means better function). The difference of scores and their relationships with cerebral blood flow (CBF) and resting-state functional MRI(fMRI) will be used for exploring underlying mechanism.', 'timeFrame': 'Baseline'}]","[{'measure': 'Changes of the score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery of interventional participants', 'description': 'At every visit, the cognitive function of interventional participants will be assessed using the Measurement and Treatment Research to Improve Cognition in Schizophrenia Consensus Cognitive Battery. Evaluator convert raw scores to scale scores, then to normalized T scores. T scores of seven domains and composite score are further calculated. The changes of scores after 24-week metformin treatment will be used for assessing the improvement of cognitive function (higher score means better function).', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of brain cerebral blood flow by arterial spin labeling of interventional participants', 'description': 'At each visit, whole brain cerebral blood flow (CBF) will be recorded by arterial spin labeling (ASL). For interventional participants, the changes in CBF (c-CBF) before and after the application of 160 units nasal insulin spray of interventional participants will be calculated. The changes of c-CBF after 24-week metformin treatment will be reported.', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of resting-state functional MRI of interventional participants', 'description': 'At each visit, the resting-state functional MRI(fMRI) will be conducted at fasting state. For interventional participants, the changes in fMRI (c-fMRI) before and after the application of 160 units nasal insulin spray will be analysed. The changes of c-fMRI after 24-week metformin treatment will be used for exploring underlying mechanism.', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of social function by Personal and Social Performance Scale', 'description': 'The changes of Personal and Social Performance Scale of interventional participants at different follow up timepoint will be used for evaluating the improvement of personal life and social function.(higher score means better function)', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of clinical symptoms by Scale for Assessment of Negative Symptoms', 'description': 'The changes of Scale for Assessment of Negative Symptoms of interventional participants at different follow up timepoint will be used for recording the improvement of negative symptoms.(lower score means alleviation of symptoms)', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of clinical symptoms by Positive And Negative Syndrome Scale', 'description': 'The changes of Positive And Negative Syndrome Scale of interventional participants at different follow up timepoint will be used for recording the improvement of psychiatric symptoms.(lower score means alleviation of symptoms)', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of level of phosphorylated insulin receptor substrate 1 and its downstream mediators in Extracellular Vesicles of neuronal origin (NEVs) isolated from blood of interventional participants', 'description': 'Phosphorylated insulin receptor substrate 1 and its downstream mediators represent the state of neuronal insulin resistance, whose improvement means better insulin signaling. For interventional participants, blood samples will be collected and stored at -80℃ at every visit. The NEVs isolation and biomarker measurements will be processed uniformly at the end, the changes of the level of biomarkers will partly reflect the changes of central insulin resistance after metfromin treament.', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'Changes of homoeostasis model assessment-estimated insulin resistance', 'description': 'Homoeostasis model assessment-estimated insulin resistance (HOMA-IR) represents systemic insulin resistance(higher value means worse outcome). For interventional participants, the changes of HOMA-IR will partly reflect the changes of peripheral insulin resistance after metfromin treament.', 'timeFrame': 'From baseline to 24th week'}, {'measure': 'The difference of the level of phosphorylated insulin receptor substrate 1 and its downstream mediators in Extracellular Vesicles of neuronal origin isolated from blood between schizophrenic participants and healthy volunteers', 'description': 'Phosphorylated insulin receptor substrate 1 and its downstream mediators represent the state of neuronal insulin resistance, whose improvement means better insulin signaling. For schizophrenic participants and healthy volunteers, blood samples will be collected and stored at -80℃ at baseline. The NEVs isolation and biomarker measurements will be processed uniformly, and the difference of the level of phosphorylated insulin receptor substrate 1 and its downstream mediators between two groups will be used for exploring underlying mechanism of disease.', 'timeFrame': 'Baseline'}]",15,18 Years,50 Years,ALL,True,Central South University,OTHER,3,120.0,ESTIMATED,2025-09-01T16:18:15.897601,v2_robust,True,True,False,False,False,
NCT06479473,Radiotherapy to All Residual Lesions After Chemoimmunotherapy,Chemoimmunotherapy Followed by All-residual-lesions Radiotherapy for Extensive-stage Small-cell Lung Cancer: A Phase I/II Trial,Chemoimmunotherapy,['Chemoimmunotherapy'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Extensive-stage Small Cell Lung Cancer,['Extensive-stage Small Cell Lung Cancer'],"['small-cell lung cancer', 'extensive-stage', 'radiotherapy', 'residual lesion']",RECRUITING,,2024-06-01,2026-03-31,"[{'measure': 'Progression-free Survival', 'description': 'The survival time from diagnose of the disease to progression of the disease', 'timeFrame': '3 years'}]","[{'measure': 'Overall Survival', 'description': 'The survival time from diagnose of the disease to death', 'timeFrame': '3 years'}]",2,18 Years,70 Years,ALL,False,Anhui Provincial Hospital,OTHER_GOV,0,150.0,ESTIMATED,2025-09-01T16:18:15.897806,v2_robust,True,True,False,False,False,
NCT06557473,Lidocaine Versus Fentanyl for Hemodynamic Stability,Hemodynamic Stability of Fentanyl Based Versus Lidocaine Based Induction of Anesthesia in Hypertensive Adults,Lidocaine IV,"['Lidocaine IV', 'Fentanyl']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Hypertension,"['Hypertension', 'Fentanyl', 'Lidocaine']","['Hypertension', 'Postinduction hypotension', 'Lidocaine', 'Fentanyl']",COMPLETED,,2023-04-01,2024-07-01,"[{'measure': 'MAP', 'description': 'Mean Arterial blood pressure 1 minute after induction of anesthesia.', 'timeFrame': '1 minute after GA induction'}]","[{'measure': 'Number of hypotensive episodes', 'description': 'MAP less than 65 mmHg.', 'timeFrame': '20 minutes'}]",2,18 Years,60 Years,ALL,False,Theodor Bilharz Research Institute,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:15.897827,v2_robust,True,True,True,False,False,
NCT04035473,A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel,A Randomized Crossover Study to Determine the Bioequivalence of Three Consecutive Daily Doses of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel,HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules,"['HM30181 methanesulfonate monohydrate plus oral paclitaxel capsules', 'ORAXOL']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Solid Tumor,['Solid Tumor'],[],COMPLETED,,2015-08-01,2019-03-27,"[{'measure': 'Area Under the Concentration-Time Curve Zero Time Extrapolated to Infinite Time (AUC0-∞)', 'description': 'Paclitaxel plasma concentrations were normalized to 615 mg/m2 for Oraxol and 80 mg/m2 for IV paclitaxel.\n\nPharmacokinetic and statistical analyses were based on normalized plasma concentrations. Plasma concentrations for paclitaxel were analyzed to determine AUC0-∞ by noncompartmental analysis using plasma concentration-time data for oral and IV paclitaxel', 'timeFrame': 'Pharmacokinetic Sampling for IV Paclitaxel - Predose to 96 hours after infusion (Day 1-5). Pharmacokinetic Sampling for Oraxol- predose of Day1 to 144 hours after third dose of day 3 (Day 1-9)'}]","[{'measure': 'Maximum Observed Concentration (Cmax)', 'description': 'Paclitaxel plasma concentrations were normalized to 615 mg/m2 for Oraxol and 80 mg/m2 for IV paclitaxel.\n\nPharmacokinetic and statistical analyses were based on normalized plasma concentrations. Plasma concentrations for paclitaxel were analyzed to determine Cmax by noncompartmental analysis using plasma concentration-time data for oral and IV paclitaxel', 'timeFrame': 'Pharmacokinetic Sampling for IV Paclitaxel - Predose to 96 hours after infusion (Day 1-5). Pharmacokinetic Sampling for Oraxol- predose of Day1 to 144 hours after third dose of day 3 (Day 1-9)'}, {'measure': 'Area Under the Concentration-time Curve From Time 0 to Time of Last Quantifiable Concentration (AUC0-t)', 'description': 'Paclitaxel plasma concentrations were normalized to 615 mg/m2 for Oraxol and 80 mg/m2 for IV paclitaxel.\n\nPharmacokinetic and statistical analyses were based on normalized plasma concentrations. Plasma concentrations for paclitaxel were analyzed to determine AUC0-t by noncompartmental analysis using plasma concentration-time data for oral and IV paclitaxel', 'timeFrame': 'Pharmacokinetic Sampling for IV Paclitaxel - Predose to 96 hours after infusion (Day 1-5). Pharmacokinetic Sampling for Oraxol- predose of Day1 to 144 hours after third dose of day 3 (Day 1-9)'}, {'measure': 'Time at Which the Highest Drug Concentration Occurs (Tmax)', 'description': 'Paclitaxel plasma concentrations were normalized to 615 mg/m2 for Oraxol and 80 mg/m2 for IV paclitaxel.\n\nPharmacokinetic and statistical analyses were based on normalized plasma concentrations. Plasma concentrations for paclitaxel were analyzed to determine Tmax by noncompartmental analysis using plasma concentration-time data for oral and IV paclitaxel', 'timeFrame': 'Pharmacokinetic Sampling for IV Paclitaxel - Predose to 96 hours after infusion (Day 1-5). Pharmacokinetic Sampling for Oraxol- predose of Day1 to 144 hours after third dose of day 3 (Day 1-9)'}, {'measure': 'Terminal Elimination Phase Half-life (t½)', 'description': 'Paclitaxel plasma concentrations were normalized to 615 mg/m2 for Oraxol and 80 mg/m2 for IV paclitaxel.\n\nPharmacokinetic and statistical analyses were based on normalized plasma concentrations. Plasma concentrations for paclitaxel were analyzed to determine t½ by noncompartmental analysis using plasma concentration-time data for oral and IV paclitaxel', 'timeFrame': 'Pharmacokinetic Sampling for IV Paclitaxel - Predose to 96 hours after infusion (Day 1-5). Pharmacokinetic Sampling for Oraxol- predose of Day1 to 144 hours after third dose of day 3 (Day 1-9)'}, {'measure': 'Safety and Tolerability of Oraxol Compared With IV Paclitaxel', 'description': 'Safety was assessed by recording all adverse events (AEs) and serious adverse events (SAEs), including CTCAE grades (version 4.03); recording concomitant medications; clinical laboratory testing (including hematology, biochemistry, and urinalysis); measurement of vital signs (pulse rate, systolic and diastolic blood pressures, respiratory rate, and body temperature), weight, and body surface area (BSA); performance of electrocardiograms (ECGs); assessment of ECOG performance status; and performance of physical examinations', 'timeFrame': 'From screening until final visit (within 28 days after the last dose of study drug was taken, and preferably before the participant receives any additional chemotherapy)'}]",6,18 Years,,ALL,False,"Athenex, Inc.",INDUSTRY,2,42.0,ACTUAL,2025-09-01T16:18:15.897850,v2_robust,True,True,True,False,True,
NCT04116073,INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer,A Phase II Trial of INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer,INCMGA00012 (PD-1 antibody),"['MGA012', 'INCMGA00012 (PD-1 antibody)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Pancreatic Cancer Non-resectable,"['Pancreatic Cancer Non-resectable', 'Pancreatic Cancer Metastatic']","['Antibody', 'Anti-PD-1', 'Human monoclonal immunoglobulin antibody', 'Immunotherapy', 'INCMGA00012 (anti-PD-1 antibody)', 'Anti-PD-1 antibody (MGA012)', 'Metastatic adenosquamous pancreatic cancer', 'Unresectable adenosquamous pancreatic cancer', 'Adenosquamous pancreatic cancer', 'Programmed cell death protein 1 (PD-1)', 'Programmed death-ligand 1 (PD-L1)']",COMPLETED,,2020-04-09,2024-12-03,"[{'measure': 'Disease Control Rate (DCR) at 4 Months Using RECIST 1.1', 'description': 'Disease control rate (DCR) is defined as the proportion of subjects with complete response, partial response and stable disease based on RECIST 1.1 criteria. CR = disappearance of all target lesions, PR is =\\>30% decrease in sum of diameters of target lesions. SD=Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Subjects who discontinue due to toxicity prior to post-baseline tumor assessments will be evaluable and considered treatment failures.', 'timeFrame': '4 months'}]","[{'measure': 'Objective Response Rate (ORR) Using RECIST 1.1.', 'description': 'ORR is defined as the proportion subjects with partial response (PR) or complete response (CR) according to RECIST 1.1. Subjects who discontinue due to toxicity or clinical progression prior to post-baseline tumor assessments will be considered as non-responders', 'timeFrame': '4 years'}, {'measure': 'Progression-free Survival (PFS)', 'description': 'Progression-free survival (PFS) is defined as the number of months from the first dose of retifanlimab to radiographic disease progression (PD or relapse from CR as assessed using RECIST 1.1 criteria), documented clinical progression as assessed by the treating provider, or death due to any cause. PFS will be censored at the date of the last scan for subjects without documentation of disease progression at the time of analysis.', 'timeFrame': '34 months'}, {'measure': 'Grade 3 and Higher Study Drug-related Toxicities.', 'description': 'Number of participants experiencing study drug-related adverse events Grade 3 or higher as defined by CTCAE v5.0.', 'timeFrame': '26 months'}]",4,18 Years,,ALL,False,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,OTHER,2,25.0,ACTUAL,2025-09-01T16:18:15.897962,v2_robust,True,True,True,False,True,
NCT00782769,A Safety Extension Study of DR-OXY-301,"A Multicenter, Parallel-Group Extension Study to Evaluate the Safety of Two Doses of DR-3001 in Women With Overactive Bladder",Oxybutinyn Vaginal Ring 4mg,"['DR-3001', 'Oxybutinyn Vaginal Ring 4mg', 'Oxybutinyn Vaginal Ring 6mg']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Overactive Bladder,['Overactive Bladder'],[],COMPLETED,,2008-09,2010-07,"[{'measure': 'Safety, by investigating post void residual volume, physical exams, vital signs, and clinical laboratory values. The outcome of any pregnancy will be followed and reported', 'timeFrame': 'Duration of Study'}]",[],1,18 Years,,FEMALE,False,Duramed Research,INDUSTRY,0,240.0,ACTUAL,2025-09-01T16:18:15.897986,v2_robust,True,True,True,False,True,
NCT02913469,Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction,The Effects of Morphine on Loading-dose Ticagrelor in Patients With ST-segment Elevation Myocardial Infarction Before Primary Percutaneous Coronary Interven Tion,Morphine,"['morphine hydrochloride', 'Pasprtin', 'Morphine', 'Physiological Saline', 'saline', 'metoclopramide']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,ST-segment Elevation Myocardial Infarction,['ST-segment Elevation Myocardial Infarction'],['Morphine，Ticagrelor，STEMI，PCI'],UNKNOWN,,2014-12-12,2020-08-15,"[{'measure': 'Platelet Reactivity Index(PRI) Measured by VASP-P', 'description': 'Vasodilator-stimulated phosphoprotein(VASP) phosphorylation, a measure of P2Y12 receptor reactivity, was determined by flow cytometry with the use of the Platelet VASP-FCM Kit (Stago, France)and recorded as the platelet reactivity index', 'timeFrame': '2 hours after the loading dose of ticagrelor'}]","[{'measure': 'Platelet Reactivity Index (PRI) Measured by VASP-P', 'timeFrame': '0.5hour,8hours after the loading dose of ticagrelor'}, {'measure': 'the incidence of major adverse cardiovascular and cerebrovascular events', 'timeFrame': 'follow-up for 30 days after the loading dose of ticagrelor'}]",3,18 Years,80 Years,ALL,False,General Hospital of Chinese Armed Police Forces,OTHER,0,128.0,ESTIMATED,2025-09-01T16:18:15.898043,v2_robust,True,True,False,False,True,
NCT02320669,Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass,Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass,Triostat,"['Triostat', 'Placebo', 'triiodothyronine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Congenital Heart Defects,['Congenital Heart Defects'],[],COMPLETED,,2014-11,2019-10,"[{'measure': 'Time To Extubation', 'description': 'time on mechanical ventilation after aortic cross clamp removal', 'timeFrame': '30 days'}]","[{'measure': 'ICU Length of Stay', 'description': 'Length of stay in the ICU', 'timeFrame': '30 days'}]",2,,5 Months,ALL,False,Seattle Children's Hospital,OTHER,0,220.0,ACTUAL,2025-09-01T16:18:15.898187,v2_robust,True,True,True,False,False,
NCT03269669,"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma,Bendamustine Hydrochloride,"['Vincristine, sulfate', 'Doxorubin', 'CC 5013', 'Carloxan', 'Cyclophosphan', 'Adrimedac', 'TGR-1202', 'Cytoxan', 'WR- 138719', 'Adriblastine', 'Delta-Dome', '2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate', 'Doxorubicin Hydrochloride', 'Promifen', 'Cycloblastine', '1, 2-Dehydrocortisone', 'Ciclofosfamide', 'Cyclostin', 'Levact', '(-)-Cyclophosphamide', 'Cycloblastin', 'Cyclophosphamide', 'Decorton', 'RP-5264', 'Prednilonga', 'Leurocristine, sulfate', 'Meprosona-F', 'Rayos', 'Kyocristine', 'Decortisyl', 'FI-106', 'Cytophosphane', 'Ciclofosfamida', 'Prednicort', 'Vincrex', 'DOX', 'Lisacort', 'Bendeka', 'Cytostasan Hydrochloride', 'CEP-18083', 'Prednisone', 'hydroxydaunorubicin', 'Genuxal', 'Econosone', 'Umbralisib', 'Adriamycine', 'Vincosid', 'WR138719', 'Cyclophosphamidum', 'Deltacortisone', 'Cyclostine', 'Cyclophospham', 'Predicor', 'Doxorubicin.HCl', 'CP monohydrate', 'CTX', 'Orasone', 'Predicorten', 'FI 106', 'PRED', 'Bendamustine Hydrochloride', 'Leurocristine Sulfate', 'CC-5013', 'Clafen', 'Genoxal', 'Treakisym', 'Panasol-S', 'Rubex', 'Prednisone Intensol', 'Syklofosfamid', 'Ribomustin', 'Cyclophosphanum', 'Cyclophosphamid monohydrate', 'Adriamycin PFS', 'SK-Prednisone', 'Metacortandracin', 'CDC 501', 'FI106', 'B-518', 'Paracort', 'Bendamustin Hydrochloride', 'Lenalidomide', 'Delta 1-Cortisone', 'Doxolem', 'Prednitone', 'Deltison', 'Cyclophosphamide Monohydrate', 'Prednicen-M', 'Adriamycin Hydrochloride', 'Perrigo Prednisone', 'RP5264', 'Farmiblastina', 'Adasone', '.delta.1-Cortisone', 'TGR 1202', 'ADRIAMYCIN, HYDROCHLORIDE', '5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI)', 'Vincristine Sulfate', 'B 518', 'Cytophosphan', 'DOXO-CELL', 'Belrapzo', 'Deltacortene', 'Oncovin', 'Deltadehydrocortisone', 'ADM', 'CEP 18083', 'Chloridrato de Doxorrubicina', 'CC5013', 'Mitoxan', 'Fosfaseron', 'Claphene', 'Prednidib', 'Adriacin', 'CEP18083', 'Adriblastina', 'Deltasone', 'Deltra', 'Ofisolona', 'Neosar', 'Asta B 518', 'Revimmune', 'SyB L-0501', 'Treanda', 'Cicloxal', 'VIVIMUSTA', 'Ledoxina', 'WR 138719', 'Vincasar', 'Revlimid', 'Panafcort', 'WR-138719', 'Servisone', '2-((1S)-1-(4-Amino-3-(3-fluoro-4-(1-methylethoxy)phenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)ethyl)-6-fluoro-3-(3-fluorophenyl)-4H-1-benzopyran-4-one', 'Adriamycin RDF', 'DeCortin', 'Doxorubicin HCl', 'Dacortin', 'Meticorten', 'Cyclophosphane', 'TGR1202', 'Adriamycin', 'Predniment', 'Cortancyl', 'Prednisonum', 'B518', 'CYCLO-cell']",147,INTERVENTIONAL,['PHASE2'],PHASE2,,Grade 1 Follicular Lymphoma,"['Grade 1 Follicular Lymphoma', 'Grade 2 Follicular Lymphoma', 'Grade 3a Follicular Lymphoma', 'Recurrent Follicular Lymphoma', 'Refractory Follicular Lymphoma']",[],ACTIVE_NOT_RECRUITING,,2018-01-23,2025-12-31,"[{'measure': 'Complete response (CR)', 'timeFrame': 'Up to 6 cycles'}]","[{'measure': 'Sustained complete response rate (CR30)', 'description': 'Defined by centrally read positron emission tomography (PET)/computed tomography (CT).', 'timeFrame': 'Up to 30 months'}, {'measure': 'Progression-free survival (PFS)', 'description': 'Will be calculated using the method of Kaplan-Meier. 95% confidence for the survival estimates will be constructed using the method of Brookmeyer-Crowley. With 31 eligible patients in each arm, progression free survival at a particular time point, and the 30-month sustained response rate can be estimated to within at least +/- 18% with 95% confidence.', 'timeFrame': 'From date of registration to date of first observation of progressive disease, or death due to any cause, assessed up to 5 years'}, {'measure': 'Duration of response (CR, partial response [PR])', 'description': 'Will be calculated using the method of Kaplan-Meier.', 'timeFrame': 'From date of first documentation of response to treatment (CR, PR) to date of first documentation of progression, or death due to any cause, assessed up to 5 years'}, {'measure': 'Overall survival (OS)', 'description': 'Will be calculated using the method of Kaplan-Meier. 95% confidence for the survival estimates will be constructed using the method of Brookmeyer-Crowley. With 31 eligible patients in each arm, OS at a particular time point, and the 30-month sustained response rate can be estimated to within at least +/- 18% with 95% confidence.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Incidence of adverse events', 'description': 'Assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (version 5.0 will be utilized for serious adverse events reporting only). Toxicity rates can be estimated to within at least +/- 18% with 95% confidence.', 'timeFrame': 'Up to 5 years'}, {'measure': 'Non-invasive genotyping and circulating tumor deoxyribonucleic acid (DNA) assessment', 'description': 'Sensitivity, specificity, positive predictive value, negative predictive value, and kappa coefficient will be used to evaluate the concordance. Will evaluate the association of detection of active lymphoma by positron emission tomography-computed tomography and the detection of circulating tumor DNA in plasma at baseline, after 6 and 12 cycles, and at 30 months after initiation of study therapy. Chi-square test will be used to evaluate the association and odds ratio will be calculated', 'timeFrame': 'Up to 5 years'}, {'measure': 'Active lymphoma and circulating tumor DNA in plasma', 'description': 'The Cox proportional hazards model will be used to assess the association and odds ratio will be calculated.', 'timeFrame': 'From baseline up to 30 months after initiation of treatment'}, {'measure': 'm7-FLIPI model validation', 'description': 'The Cox proportional hazards model will be used to assess the association of the m7-FLIPI with to PFS.', 'timeFrame': 'Up to 5 years'}]",9,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,95.0,ESTIMATED,2025-09-01T16:18:15.898221,v2_robust,True,True,False,False,True,
NCT01416883,Oral Mucosal Absorption Study of Bicalutamide New Formulation,"Oral Mucosal Absorption Study of ICI176,334-1 (Bicalutamide New Formulation) in Japanese Healthy Male Subjects","ICI176,334-1","['ICI176,334-1']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['oral mucosal absorption', 'pharmacokinetics', 'safety', 'bicalutamide', 'Japanese', 'healthy subject']",TERMINATED,,2010-07,2010-08,"[{'measure': 'To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in saliva.', 'timeFrame': 'Blood samples are taken repeatedly for 72 hours and also taken at 168 hours after application of the investigational drug.'}, {'measure': 'To investigate the presence or absence of oral mucosal absorption of ICI176,334-1 by assessment of concentration of bicalutamide in plasma.', 'timeFrame': 'Blood samples are taken repeatedly for 72 hours and also taken at 168 hours after application of the investigational drug.'}]","[{'measure': 'To assess the safety by assessment of adverse event.', 'timeFrame': 'Subjects will be monitored for adverse events prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug.'}, {'measure': 'To assess the safety by assessment of vital signs.', 'timeFrame': 'Subjects will be monitored for vital signs prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug.'}, {'measure': 'To assess the safety by assessment of electrocardiograms (ECGs).', 'timeFrame': 'Subjects will be monitored for electrocardiograms (ECGs) prior to treatment and up to 14 to 21 days (follow-up) after application of the investigational drug.'}]",5,20 Years,45 Years,MALE,True,AstraZeneca,INDUSTRY,0,8.0,ACTUAL,2025-09-01T16:18:15.898260,v2_robust,True,True,False,True,True,
NCT00049283,"Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer","A Phase I Study of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, OSI-774, in Combination With Docetaxel and Radiation in Locally Advanced Squamous Cell Cancer of the Head and Neck",erlotinib hydrochloride,"['OSI-774', 'erlotinib', 'Taxotere', 'RP 56976', 'CP-358,774', 'erlotinib hydrochloride', 'docetaxel', 'TXT']",8,INTERVENTIONAL,['PHASE1'],PHASE1,,Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma,"['Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma', 'Stage III Squamous Cell Carcinoma of the Hypopharynx', 'Stage III Squamous Cell Carcinoma of the Larynx', 'Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage III Squamous Cell Carcinoma of the Nasopharynx', 'Stage III Squamous Cell Carcinoma of the Oropharynx', 'Stage III Verrucous Carcinoma of the Larynx', 'Stage III Verrucous Carcinoma of the Oral Cavity', 'Stage IV Squamous Cell Carcinoma of the Hypopharynx', 'Stage IV Squamous Cell Carcinoma of the Nasopharynx', 'Stage IVA Squamous Cell Carcinoma of the Larynx', 'Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage IVA Squamous Cell Carcinoma of the Oropharynx', 'Stage IVA Verrucous Carcinoma of the Larynx', 'Stage IVA Verrucous Carcinoma of the Oral Cavity', 'Stage IVB Squamous Cell Carcinoma of the Larynx', 'Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage IVB Squamous Cell Carcinoma of the Oropharynx', 'Stage IVB Verrucous Carcinoma of the Larynx', 'Stage IVB Verrucous Carcinoma of the Oral Cavity', 'Stage IVC Squamous Cell Carcinoma of the Larynx', 'Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Stage IVC Squamous Cell Carcinoma of the Oropharynx', 'Stage IVC Verrucous Carcinoma of the Larynx', 'Stage IVC Verrucous Carcinoma of the Oral Cavity', 'Tongue Cancer', 'Untreated Metastatic Squamous Neck Cancer With Occult Primary']",[],COMPLETED,,2002-09,2008-02,"[{'measure': 'MTD defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity assessed using Common Toxicity Criteria (CTC) version 3.0 (Phase I)', 'timeFrame': '9 weeks'}, {'measure': 'Pharmacokinetic profile (Phase I)', 'timeFrame': 'Pre-dose, 0.5, 1, 2, 4, 8, 12, 24 48, and 72 hours'}, {'measure': 'Time to disease progression (TTP) (Phase II)', 'timeFrame': 'Up to 5.5 years'}]","[{'measure': 'Progression-free survival (PFS) (Phase II)', 'description': 'Will be estimated by Kaplan-Meier method.', 'timeFrame': 'From the date of treatment to date of death or date of disease progression, and to date of last follow-up for those still alive and progression free, assessed up to 5.5 years'}, {'measure': 'Overall survival (OS) (Phase II)', 'description': 'Will be estimated by Kaplan-Meier method.', 'timeFrame': 'From the date of treatment to date of death, and to date of last follow-up for those still alive, assessed up to 5.5 years'}, {'measure': 'True objective response rate (Phase II)', 'description': ""Will be estimated based on the number of responses using a binomial distribution and its confidence interval will be estimated using Wilson's method."", 'timeFrame': 'Up to 5.5 years'}, {'measure': 'Changes of EGFR expression and serum markers over time (Phase II)', 'description': 'The Wilcoxon signed rank test (the non-parametric version of paired T-test) will be used.', 'timeFrame': 'Baseline and up to 5.5 years'}, {'measure': 'Patterns of gene expression data (Phase II)', 'description': 'Cluster analysis including hierarchical clustering, Gaussian clustering, k means clustering, will be used.', 'timeFrame': 'Up to 5.5 years'}]",8,18 Years,,ALL,False,National Cancer Institute (NCI),NIH,0,30.0,ACTUAL,2025-09-01T16:18:15.898286,v2_robust,True,True,True,False,False,
NCT05349383,Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities,Evaluation of Reporting of Antibody-Drug Conjugate Associated Sepsis-related Toxicities Using International Pharmacovigilance Database,Antibody-Drug Conjugate,"['Antibody-Drug Conjugate', 'Antineoplastic and immunomodulating agents other than Antibody-Drug Conjugate']",2,OBSERVATIONAL,[],,,Sepsis (SMQ),"['Sepsis (SMQ)', 'Opportunistic Infections', 'Agranulocytosis']",[],COMPLETED,,2022-04-22,2022-06-01,"[{'measure': 'Sepsis-related toxicity of antibody-drug conjugate.', 'description': 'Identification and report of the sepsis-related toxicity of ADC. The research includes the report with MedDRA terms: Sepsis(SMQ), agranulocytosis(SMQ), Opportunistic infections (SMQ). Drugs investigated are ADC: Gemtuzumab Ozogamicin, Trastuzumab Emtansine, Inotuzumab Ozogamicin, Enfortumab vedotin, Trastuzumab deruxtecan, Sacituzumab govitecan, Brentuximab Vedotin, Moxetumomab pasudotox, Polatuzumab Vedotin, Belantamab Mafodotin, loncastuximab tesirine and Tisotumab vedotin.', 'timeFrame': 'Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022'}]","[{'measure': 'Causality assessment of reported cardiovascular events according to the WHO system', 'timeFrame': 'Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022'}, {'measure': 'Description of the type of sepsis-related toxicities depending on the category of ADC', 'timeFrame': 'Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022'}, {'measure': 'Description of the drug-drug interactions associated with sepsis-related adverse events', 'timeFrame': 'Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022'}, {'measure': 'Description of the population of patients having a sepsis-related adverse events', 'timeFrame': 'Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022'}, {'measure': 'Description of the pathologies (cancer) for which the incriminated drugs have been prescribed', 'timeFrame': 'Case reported in the FDA Adverse Event Reporting System (FAERS) and other international pharmacovigilance database of individual safety case reports to 12/31/2022'}]",6,,,ALL,False,Central South University,OTHER,0,24618.0,ACTUAL,2025-09-01T16:18:15.898311,v2_robust,False,True,True,False,True,
NCT00097383,Study of Alimta and Epirubicin Administered in Patients With Locally Advanced or Metastatic Breast Cancer,A Phase 2 Study of Alimta and Epirubicin Administered Every 21 Days in Patients With Locally Advanced or Metastatic Breast Cancer,ALIMTA plus Epirubicin,['ALIMTA plus Epirubicin'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,,,[],[],0,18 Years,,FEMALE,False,Eli Lilly and Company,INDUSTRY,0,,,2025-09-01T16:18:15.898447,v2_robust,True,True,True,False,False,
NCT03219983,Pain Management After Total Shoulder Arthroplasty,Pain Management After Total Shoulder Arthroplasty: Continuous Interscalene Block Versus Local Tissue Infiltration With Liposomal Bupivacaine,Ropivacaine,"['There is not another intervention involved.', 'Ropivacaine', 'liposomal bupivacaine', 'there is not another intervention involved. Please explain to me what you are referring to.']",4,INTERVENTIONAL,['PHASE4'],PHASE4,,Glenohumeral Arthritis,"['Glenohumeral Arthritis', 'Total Shoulder Arthroplasty']","['interscalene block', 'liposomal bupivacaine']",TERMINATED,,2016-11,2017-09,"[{'measure': 'NPRS-11 Pain Scores', 'description': 'The Numeric Pain Rating Scale(NPRS) is an 11 point scale with 0 being no pain and 10 being extreme pain. Patients select a value that is most in line with the intensity of pain that they have experienced.', 'timeFrame': 'Pre-Operatively'}, {'measure': 'NPRS-11 Pain Scores', 'description': 'The Numeric Pain Rating Scale(NPRS) is an 11 point scale with 0 being no pain and 10 being extreme pain. Patients select a value that is most in line with the intensity of pain that they have experienced. Every 15 minutes while in the Post Anesthesia Recovery Unit (PACU)', 'timeFrame': 'Upon Arrival to PACU through discharge from PACU up to 4 hours.'}, {'measure': 'NPRS-11 Pain Scores', 'description': 'The Numeric Pain Rating Scale(NPRS) is an 11 point scale with 0 being no pain and 10 being extreme pain. Patients select a value that is most in line with the intensity of pain that they have experienced every 4 hours while in the Post-Operative patient Unit.', 'timeFrame': 'Upon arrival to the Patient Care Unit through Hospital Discharge up to 3 days.'}, {'measure': 'NPRS-11 Pain Scores', 'description': 'The Numeric Pain Rating Scale(NPRS) is an 11 point scale with 0 being no pain and 10 being extreme pain. Patients select a value that is most in line with the intensity of pain that they have experienced.', 'timeFrame': 'Pain scores will be recorded twice a day from hospital discharge until Post-Operative Day 7.'}]","[{'measure': 'Narcotic utilization', 'description': 'Collected in morphine sulfate equivalents', 'timeFrame': 'Daily through Day 7 post-op'}, {'measure': 'Length of Stay', 'description': 'Collected in hourly time increments', 'timeFrame': 'From Arrival to PACU through discharge form PACU up to 4 hours.'}, {'measure': 'Length of Stay', 'description': 'The amount of time the patient spent in the hospital in hourly increments.', 'timeFrame': 'From Hospital admission until hospital discharge up to 3 days.'}, {'measure': 'Discharge Status', 'description': 'Will patient be discharged home or to a Skilled Nursing Facility', 'timeFrame': 'Upon patient discharge from the hospital up to 3 days.'}, {'measure': 'Procedure Cost', 'description': 'Record the cost of the interscalene block procedure and medication versus the cost of the liposomal bupivacaine injection.', 'timeFrame': 'Through hospitalization, generally 3 days'}, {'measure': 'Range of Motion', 'description': 'This exam will include active and passive elevation, active and passive external rotation, active and passive abduction and internal rotation.', 'timeFrame': '2 weeks, 6 weeks, and 12 weeks postoperatively'}, {'measure': 'Neurovascular Status', 'description': 'This exam will evaluate motor function and sensation of the operative limb.', 'timeFrame': '2weeks, 6 weeks, and 12 weeks post-operatively'}]",11,18 Years,75 Years,ALL,False,The Christ Hospital,OTHER,0,22.0,ACTUAL,2025-09-01T16:18:15.898469,v2_robust,True,True,False,True,False,
NCT03663283,Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty,Liposomal Bupivacaine Interscalene Nerve Block in Shoulder Arthroplasty: A Single Blinded Prospective Randomized Control Trial,Liposomal Bupivacaine,"['Liposomal Bupivacaine', 'Bupivacaine Hydrochloride']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Arthropathy Shoulder,['Arthropathy Shoulder'],[],COMPLETED,,2018-10-29,2020-02-14,"[{'measure': 'Patient Pain Scores', 'description': 'Patient pain scores over the first 72 hours post-operatively as measured by the Visual Analogue Scale where Zero represents no pain and ten represents severe pain.', 'timeFrame': '72 hours post-operatively'}]","[{'measure': 'Opioid Consumption', 'description': 'Total opioid consumption as measured by morphine milligram equivalent (MME) in first 72 hours and at 3 weeks', 'timeFrame': 'Measured at 72 hours and at 3 weeks post-operatively'}, {'measure': 'Time to Cessation of Nerve Blockade', 'description': 'Measured by the number of subjects who reported cessation of nerve blockade as the first reported postoperative pain score of 3 or greater at the surgical site.', 'timeFrame': '4, 8, 12, 16, 20, 24, and 28 hours post-operatively'}, {'measure': 'Satisfaction With Pain Control Using Satisfaction Scale', 'description': 'Patient satisfaction with pain control at 72 hours post-operatively and three weeks post operatively using Patient Satisfaction with Pain Management Pain Scale where Zero represents unsatisfactory pain management and ten represents perfect pain management.', 'timeFrame': 'Measured at 72 hours and at three weeks post-operatively'}]",4,18 Years,,ALL,False,Mayo Clinic,OTHER,0,104.0,ACTUAL,2025-09-01T16:18:15.898500,v2_robust,True,True,True,False,False,
NCT02278783,"Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer","Phase 2 Trial of Regorafenib in Patients With Recurrent Ovarian, Primary Peritoneal and Fallopian Tube Cancer",regorafenib,['regorafenib'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Ovarian Cancer,"['Ovarian Cancer', 'Primary Peritoneal Cancer', 'Fallopian Tube Cancer']",[],TERMINATED,Slow Accrual,2015-03,2017-01,"[{'measure': '6 Month Progression Free Survival (PFS)', 'description': 'To evaluate the anti-tumor activity of Regorafenib as measured by progression free survival at 6 months in patients with recurrent gynecological cancers', 'timeFrame': 'Patients will be checked for PFS after 6 months on treatment'}, {'measure': 'Incidence of Adverse Events (Grade 2 or Higher), Assessed According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0', 'description': 'To determine the nature and degree of toxicity of Regorafenib in this cohort of patients. Toxicity will be summarized by attribution: regorafenib-related adverse events grade 2 or higher will be reported.', 'timeFrame': 'Patients will remain on treatment for approximately 4-6 months on average.'}]","[{'measure': 'Estimate Progression Free Survival', 'description': 'To estimate progression free survival for patients treated with this regimen', 'timeFrame': 'At 6 months patients will be checked for PFS, and compared to the expected probability of the patient being alive and progression-free for at least 6 months'}, {'measure': 'Frequency of Clinical Benefit (Stable Disease, Partial and Complete Response)', 'description': 'To determine the frequency of clinical benefit (stable disease, partial, and complete response) according to RECIST (Response Evaluation Criteria in Solid Tumors) 1.1 criteria', 'timeFrame': 'Scans will be done every 2 cycles (every 2 months) for disease assessment. Patients on average will be on treatment for 4-6 months'}]",4,18 Years,,FEMALE,False,University of Utah,OTHER,1,1.0,ACTUAL,2025-09-01T16:18:15.898558,v2_robust,True,True,False,True,True,Slow Accrual
NCT02091141,"My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors","My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents",Trastuzumab,"['Vemurafenib', 'Erlotinib', 'Perjeta', 'Zelboraf', 'Alectinib', 'Tecentriq', 'Cobimetinib', 'Atezolizumab', 'Herceptin', 'Vismodegib', 'Tarceva', 'Trastuzumab', 'Alecensa', 'Pertuzumab', 'Erivedge', 'Cotellic']",16,INTERVENTIONAL,['PHASE2'],PHASE2,,Neoplasms,"['Neoplasms', 'Solid Tumors', 'Biliary Cancer', 'Salivary Cancer', 'Bladder Cancer']",[],COMPLETED,,2014-04-14,2023-05-24,"[{'measure': 'Percentage of Participants in All Tumor-Pathway Cohorts With Overall Response, as Assessed by the Investigator', 'description': 'The Objective Response Rate (ORR) is defined as the percentage of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by investigators using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 for all arms.', 'timeFrame': 'From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)'}, {'measure': 'Percentage of Atezolizumab-Treated Participants With Tissue Tumor Mutational Burden (tTMB) ≥16 Mutations/Mb With Overall Response, as Assessed by the Independent Review Committee (IRC)', 'description': 'The Objective Response Rate (ORR) is defined as the proportion of patients whose best response on or before the first occurrence of disease progression is a complete response (CR) or partial response (PR). Tumor responses were assessed by Independent Review Committee (IRC) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.', 'timeFrame': 'From the date of first study treatment until disease progression or death from any cause, whichever occurs first (68.9 months)'}]","[{'measure': 'Percentage of Participants With Disease Control', 'description': 'Disease Control Rate (DCR) is defined as the proportion of patients whose best response is CR, PR or stable disease maintained more than 4 months (SD\\>4 months). Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.', 'timeFrame': 'From the date of first study treatment until disease progression or death from any cause, whichever occurs first (72.1 months)'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'PFS is defined as the time from the start of study treatment to the first occurrence of disease progression, or death, whichever occurs first. Tumor responses were assessed by investigators using RECIST version 1.1 for all arms.', 'timeFrame': 'From the date of first study treatment until disease progression as assessed by the investigator, or death from any cause, whichever occurs first (72.1 months)'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall Survival (OS, months) is defined as the time from the date of the first study treatment (Day 1) to the date of death from any cause.', 'timeFrame': '87.5 months'}, {'measure': 'Duration of Response (DoR)', 'description': 'Duration of Response (DoR) is defined as the time from the date of first documented response (CR or PR) to date of first occurrence of disease progression as determined by the investigator, or death from any cause, whichever occurs first.', 'timeFrame': 'From the date of first documented response (complete response [CR] or partial response [PR]) to the time of disease progression or death from any cause, whichever occurs first (70.8 months)'}, {'measure': 'Number of Participants With Adverse Events', 'description': 'Incidence, nature, and severity of Adverse Events (AE), per the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03) for participants enrolled prior to Version 6 of the protocol. The NCI CTCAE (v5.0) grading scale was used for assessing AE severity for participants enrolled under Version 6 of the protocol and subsequent versions.', 'timeFrame': 'From first study treatment administration to 30 days (45 days for vismodegib, 90 days for atezolizumab) after the last dose (up to approximately 6.3 years)'}]",7,18 Years,,ALL,False,"Genentech, Inc.",INDUSTRY,0,673.0,ACTUAL,2025-09-01T16:18:15.898617,v2_robust,True,True,True,False,True,
NCT00051441,"Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx","A Double-Blind, Randomized, Vehicle-Controlled Study Comparing the Safety and Efficacy of Benzydamine HCl 0.15% Oral Rinse Including a Separate Open-Label Standard of Care Arm in Subjects With Radiation-Induced Mucositis",Benzydamine Hydrochloride 0.15% Oral Rinse,['Benzydamine Hydrochloride 0.15% Oral Rinse'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Stomatitis,"['Stomatitis', 'Radiation Effects']","['stomatitis', 'radiation effects']",COMPLETED,,,2005-02,[{'measure': 'The primary endpoint is the cumulative proportion of patients with severe mucositis (WHO mucositis score of at least 3) at a cumulative radiation dose of 5500 cGy'}],[{'measure': 'Secondary endpoints include cumulative RT to first use of an opioid for oral mucositis; cumulative RT to first ulceration; cumulative RT to first RT suspension due to oral mucositis'}],2,18 Years,,ALL,False,"McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.",INDUSTRY,1,605.0,ACTUAL,2025-09-01T16:18:15.898738,v2_robust,True,True,True,False,False,
NCT02205541,Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU,Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo,Eculizumab,"['Eculizumab', 'Soloris®', 'Solution with 5% glucose', 'Placebo']",4,INTERVENTIONAL,['PHASE3'],PHASE3,,Hemolytic Uremic Syndrome of Childhood,['Hemolytic Uremic Syndrome of Childhood'],"['Eculizumab', 'Shiga-toxin', 'hemolytic and uremic syndrome', 'pediatric']",COMPLETED,,2015-06,2018-06,"[{'measure': 'the duration in days of extrarenal epuration', 'description': 'Extrarenal epuration means peritoneal dialysis or hemodialysis, and is assessed at each visit.', 'timeFrame': 'From the inclusion date and assessed up to 13 months'}]","[{'measure': 'Number of adverse events as a measure of Safety and tolerance of treatment injections (ECZ or placebo)', 'timeFrame': 'At each injection (treatment visits 2, 3, 4, 5, 6 at respectively day 0, 7, 14, 21, 28) and at each follow-up visit (7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Adverse reactions related to the treatment (ECZ or placebo)', 'timeFrame': 'At each injection (treatment visits 2, 3, 4, 5, 6 at respectively day 0, 7, 14, 21, 28) and at each follow-up visit (7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Duration of Acute Renal Failure (ARF)', 'description': 'Duration of ARF will be evaluated as follow : urine output measurement, creatinin clearance estimated with the Schwartz 2009 assay (based on creatinin plasma levels), ionogram, proteinuria.', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1 ), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Renal sequels', 'description': 'Renal sequels will be evaluated as follow : blood pressure, creatinin clearance, ionogram, proteinuria and microalbuminuria.', 'timeFrame': 'At 1, 6 and 12 months after last injection of ECZ (follow-up visits 7, 8, 9)'}, {'measure': 'Hematological abnormalities', 'description': '* Duration (in days) of the thrombocytopenia\n* Duration (in days) of the hemolytic anemia', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)'}, {'measure': 'Blood parameters of Complement Alternative Pathway (CAP)', 'description': 'Blood parameters of CAP will be evaluated with plasmatic dosages of the complement components C3 and CD46.', 'timeFrame': 'Inclusion visit (1 at day -3 to -1), Treatment visits (3, 4, 5, 6 at day 7, 14, 21, 28), follow-up visit (7 at month 2)'}, {'measure': 'Inhibition of the Terminal Complement Complex (TCC)', 'description': 'Inhibition of the TCC will be evaluated trough the CH50 assay and plasmatic free ECZ levels.', 'timeFrame': 'Inclusion visit (1 at day -3 to -1), Treatment visits (3, 4, 5, 6 at day 7, 14, 21, 28), follow-up visit (7 at month 2)'}, {'measure': 'Incidence of extrarenal manifestations', 'description': '* Neurological involvement (seizures, coma, focal deficit)\n* Cardiac involvement (cardiac failure, ischemic myocarditis, conduction or rhythm troubles)\n* Digestive involvement (pancreatitis, hepatitis, hemorrhagic colitis, bowel perforation, rectal prolapsus)', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28)'}, {'measure': 'Mortality', 'timeFrame': 'Inclusion Visit (1 at day -3 to -1), treatment period (visits 2, 3, 4, 5, 6 respectively at day 0, 7, 14, 21, 28), follow-up period (visits 7, 8, 9 respectively at month 2, 7, 13)'}]",10,1 Month,18 Years,ALL,False,"University Hospital, Toulouse",OTHER,0,100.0,ACTUAL,2025-09-01T16:18:15.898771,v2_robust,True,True,True,False,True,
NCT00095641,S0225 Capecitabine in Treating Patients Who Have Undergone Surgery for Locally Recurrent or Persistent Head and Neck Cancer,S0225: Phase II Study of Adjuvant Low-Dose Capecitabine After Salvage Surgery in Patients With Locally Recurrent or Persistent Squamous Cell Carcinoma of the Head and Neck,capecitabine,['capecitabine'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity,"['Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity', 'Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity', 'Recurrent Squamous Cell Carcinoma of the Hypopharynx', 'Recurrent Squamous Cell Carcinoma of the Larynx', 'Recurrent Squamous Cell Carcinoma of the Oropharynx']",[],WITHDRAWN,no longer studying this disease site,,,[],[],0,18 Years,,ALL,False,SWOG Cancer Research Network,NETWORK,1,0.0,ACTUAL,2025-09-01T16:18:15.898782,v2_robust,True,True,False,True,False,no longer studying this disease site
NCT00671541,Nasospore Stent For Use in Enodscopic Sinus Surgery,Nasospore Stent For The Use in Endoscopic Sinus Surgery,Merogel Nasal Stent and Nasopore Stent,"['Merogel Nasal Stent and Nasopore Stent', 'Merogel Stent', 'Bacatracin soaked stent', 'Nasopore Stent', 'Gentamicin soaked stent', 'Nasopore Stent and either Gentamycin or Bacitracin']",6,INTERVENTIONAL,['PHASE4'],PHASE4,,Chronic Sinusitis,['Chronic Sinusitis'],[],WITHDRAWN,Principal Investigator left the institution requested study terminated.,2006-03,2012-02,"[{'measure': 'This study will evaluate the efficacy of nasopore stent soaked in bacitracin in and one stent soaked in gentaymcin antibiotic solution', 'timeFrame': 'prospective'}]",[],1,18 Years,,ALL,False,Lahey Clinic,OTHER,0,0.0,ACTUAL,2025-09-01T16:18:15.898834,v2_robust,True,True,False,True,False,Principal Investigator left the institution requested study terminated.
NCT01953341,Single-Ascending Dose Study of AMG 333 in Healthy Subjects and Subjects With Migraines,"A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 333 in Healthy Subjects and Subjects With Migraines.",AMG 333,"['Placebo', 'AMG 333']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Migraine,['Migraine'],['Migraine'],COMPLETED,,2013-10,2014-11,"[{'measure': 'Primary', 'description': 'Treatment-emergent adverse events, including changes in vital signs, 12-lead ECGs, clinical laboratory safety tests, and physical and neurological assessments', 'timeFrame': 'Up to 29 days'}, {'measure': 'Primary', 'description': 'Headache assessment as measured by the occurrence of moderate-to-severe headache within 36 hours of treatment, as well as number of moderate-to-severe headaches within 4 days of dosing', 'timeFrame': 'Up to 29 days'}]","[{'measure': 'Secondary Outcome Measures', 'description': 'Time to maximum concentration \\[Tmax\\])', 'timeFrame': 'Up to 29 Days'}, {'measure': 'Secondary', 'description': 'Change in systolic and diastolic blood pressure in response to Cold Pressor Test (CPT)', 'timeFrame': 'Up to 29 days'}, {'measure': 'Secondary Outcome Measures', 'description': 'Area under the concentration-time curve from time 0 to the time of the last quantifiable concentration \\[AUClast\\]', 'timeFrame': 'Up to 29 Days'}, {'measure': 'Secondary Outcome Measures', 'description': 'Area under the concentration-time curve from time 0 extrapolated to infinity \\[AUCinf\\], maximum observed concentration \\[Cmax\\], and T1/2)', 'timeFrame': 'Up to 29 Days'}]",6,18 Years,55 Years,ALL,True,Amgen,INDUSTRY,0,74.0,ACTUAL,2025-09-01T16:18:15.898869,v2_robust,True,True,True,False,True,
NCT03057041,Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration,Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration: A Randomized Controlled Trial,Fentanyl,"['Fentanyl', 'placebo']",2,INTERVENTIONAL,['NA'],,,Pain Uterus,['Pain Uterus'],[],COMPLETED,,2017-03-23,2018-05-30,"[{'measure': 'Pain during uterine aspiration', 'description': 'Self reported on 100 mm VAS', 'timeFrame': 'During uterine aspiration or immediately after uterine aspiration'}]","[{'measure': 'Patient satisfaction with procedural pain control', 'description': 'Self reported on 100 mm VAS', 'timeFrame': 'approximately 15 minutes after procedure ends'}, {'measure': 'Post-procedural pain', 'description': 'Self reported on 100 mm VAS', 'timeFrame': 'approximately 15 minutes after procedure end'}]",3,14 Years,,FEMALE,True,University of Hawaii,OTHER,1,107.0,ACTUAL,2025-09-01T16:18:15.899024,v2_robust,True,True,True,False,False,
NCT02160041,BGJ398 for Patients With Tumors With FGFR Genetic Alterations,Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations,BGJ398,['BGJ398'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Solid Tumor,"['Solid Tumor', 'Hematologic Malignancies']","['Solid tumor malignancy', 'hematologic malignancy', 'mutation', 'translocations', 'amplifications,', 'fusions', 'signature', 'FGFR', 'ligand', 'BGJ398']",TERMINATED,,2014-07-24,2018-04-30,"[{'measure': 'Clinical Benefit Rate (CBR) Associated With BGJ398 Treatment', 'description': 'Tumor Response: Overall response rate (ORR) and clinical benefit rate (CBR) for solid tumor (non-lymphoma) which excludes 3 TIO and 1 Lymphoma patients (hence 80 patients and not 84)\n\nClinical benefit rate for patients with solid tumors were assessed using RECIST 1.1 and include responses of CR or PR or SD. For hematologic tumors other appropriate hematological response criteria may apply\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', 'timeFrame': '16 weeks'}]","[{'measure': 'Overall Response (OR) or Partial Response (PR) or Greater', 'description': 'The key secondary endpoint, OR, was determined by Investigator assessment for each tumor assessment and defined as responses of CR and PR per RECIST version 1.1.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR', 'timeFrame': 'baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months'}, {'measure': 'Progression-Free Survival (PFS)', 'description': 'Kaplan-Meier estimates of PFS timing, months\n\nProgression free survival (PFS) is defined as the time from the date of first dose to the date of first documented disease progression or relapse or death due to any cause', 'timeFrame': 'every 8 weeks until death, assessed up to 24 months'}, {'measure': 'Kaplan-Meier Estimates of PFS Rate, % (95% CI)', 'timeFrame': 'Months 1, 2, 3, 4, 5, 6, 12, 18, 24'}, {'measure': 'Overall Survival (OS)', 'description': 'Overall survival (OS) is defined as the time from the date of first dose to the date of death due to any cause', 'timeFrame': 'every 8 weeks until death, assessed up to 36 months'}, {'measure': 'Kaplan-Meier Estimates of Survival Rate, % (95% CI)', 'description': 'Overall survival (OS) is the time from the date of start of treatment to date of death due to any cause. If a patient was not known to have died, survival was censored at the date of last contact.', 'timeFrame': 'months 3, 6, 9, 12, 24'}, {'measure': 'Number of Participants With 99 Day Minimum Duration of Response (DOR)', 'description': 'The duration of response (PR or greater) applies only to patients whose best response was PR or greater. It is defined as the Ttime from the first documented response to the date first documented disease progression or relapse or death due to any cause', 'timeFrame': 'baseline and every 8 weeks until disease progression or end of treatment, assessed up to 24 months'}]",7,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,84.0,ACTUAL,2025-09-01T16:18:15.899073,v2_robust,True,True,False,True,False,
NCT03154541,SynRinse Irrigation Pilot (SIP) Trial,SynRinse Irrigation Pilot (SIP) Trial,Synrinse,['Synrinse'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Sinusitis, Chronic","['Sinusitis, Chronic', 'Cystic Fibrosis With Other Manifestations']","['Chronic Rhinosinusitis (CRS), Cystic Fibrosis related CRS']",COMPLETED,,2017-06-06,2018-05-30,"[{'measure': 'Sino-Nasal Outcome Test 22 (SNOT-22)', 'description': 'Test pre-treatment SNOT-22 (sinusitis-specific quality of life) and compare to post-treatment SNOT-22 scores to measure any change in disease specific quality of life.', 'timeFrame': '1 week'}]","[{'measure': 'Sinus bacteria culture', 'description': 'Obtain a pre-treatment endoscopic collected culture and a post-treatment endoscopic collected culture to see if the treatment impacts a pathogen detected in the pre-treatment culture.', 'timeFrame': '1 week'}, {'measure': 'Lund-Kennedy Endoscopy Score (LKES)', 'description': ""Measure change in pre-treatment LKES and post-treatment LKES to determine if treatment impacts any change in the appearance of the patient's sinuses on endoscopy"", 'timeFrame': '1 week'}, {'measure': 'Visual Analog Scale (VAS)', 'description': 'Determine the tolerability of SYNRINSE as measured on a 10cm VAS', 'timeFrame': '1 week'}, {'measure': 'Future use questionnaire', 'description': 'Record percentage of subjects willing to use SYNRINSE in the future', 'timeFrame': '1 week'}]",5,18 Years,,ALL,False,University of Washington,OTHER,0,30.0,ACTUAL,2025-09-01T16:18:15.899112,v2_robust,True,True,True,False,False,
NCT00020254,Vaccine Therapy Plus Sargramostim and Interleukin-2 Compared With Nilutamide Alone in Treating Patients With Prostate Cancer,A Randomized Phase II Study of Either Immunotherapy With a Regimen of Recombinant Pox Viruses That Express PSA/B7.1 Plus Adjuvant GM-CSF and IL2 or Hormone Therapy With Nilutamide in Patients With Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease,nilutamide,['nilutamide'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],"['adenocarcinoma of the prostate', 'recurrent prostate cancer']",COMPLETED,,2000-06,,[],[],0,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,,,2025-09-01T16:18:15.899193,v2_robust,True,True,True,False,False,
NCT00505154,Effect of Rosuvastatin on Left Ventricular Remodeling,A Phase III Study of the Effect of Rosuvastatin on Left Ventricular Remodeling and Inflammatory Markers in Heart Failure,Rosuvastatin,"['placebo', 'Rosuvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Dilated Cardiomyopathy,['Dilated Cardiomyopathy'],"['Heart failure', 'inflammation', 'cytokines']",COMPLETED,,2007-07,2013-07,"[{'measure': 'End points will be LV end systolic and diastolic volume (LVESV, LVEDV), and LV-ejection fraction (LV-EF).', 'timeFrame': '2009'}]","[{'measure': 'the B-type natriuretic peptide (BNP), Effect on immunological variables', 'timeFrame': '2009'}]",2,18 Years,80 Years,ALL,False,Oslo University Hospital,OTHER,0,75.0,ACTUAL,2025-09-01T16:18:15.899199,v2_robust,True,True,True,False,False,
NCT02947854,"Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant","An Open-label, Phase I/Proof of Principle, Dose Escalation Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation (PCI) of Antigen/Adjuvant in Healthy Male/Female Subjects",Fimaporfin (Photosensitizer),['Fimaporfin (Photosensitizer)'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteer,['Healthy Volunteer'],"['Vaccine', 'Photochemical Internalisation', 'Immune Response', 'Peptide vaccine', 'Anti cancer vaccine']",COMPLETED,,2016-09,2018-03-26,"[{'measure': 'Incidence of Treatment Emergent Adverse Events', 'description': 'Safety', 'timeFrame': 'Up to 1 year'}, {'measure': 'Incidence of abnormal and clinical significant measures', 'description': 'Clinical Laboratory, ECG, Vital Signs and Physical Examinations', 'timeFrame': 'Up to 1 year'}, {'measure': 'Pain as measured by Visual Analogue Scale (VAS)', 'description': 'Tolerability', 'timeFrame': 'Up to 1 year'}, {'measure': 'Incidence and grading of local skin reactions as by CTCAE v. 4.03', 'description': 'Local Tolerability (pain, erythema, oedema, induration and ulceration)', 'timeFrame': 'Up to 1 year'}]","[{'measure': 'Induction of Immune Response', 'description': 'Blood samples will be collected prior, during and after treatment for assessment of Antibody Production and T-cell Responses (change from baseline)', 'timeFrame': 'Up to 1 year'}]",5,18 Years,55 Years,ALL,True,PCI Biotech AS,INDUSTRY,0,96.0,ACTUAL,2025-09-01T16:18:15.899226,v2_robust,True,True,True,False,True,
NCT01532154,Fampridine Pregnancy Exposure Registry,Fampridine Pregnancy Exposure Registry,Fampridine,"['fampridine prolonged-release tablets', 'Fampyra', 'Ampyra', 'dalfampridine', 'Fampridine', 'BIIB041']",6,OBSERVATIONAL,[],,,Multiple Sclerosis,"['Multiple Sclerosis', 'Pregnancy']",[],TERMINATED,"Due to low enrollment, registration closed in agreement with the Regulatory Agency",2015-08,2016-02,"[{'measure': 'Spontaneous abortions', 'timeFrame': '< 22 weeks of gestation'}, {'measure': 'Elective or therapeutic terminations', 'timeFrame': 'Up to 9 months of pregnancy'}, {'measure': 'Ectopic pregnancy', 'timeFrame': 'Up to 9 months of pregnancy'}, {'measure': 'Fetal death including still births', 'timeFrame': '>22 weeks of gestation or weighing 500 grams'}, {'measure': 'Live born infants', 'timeFrame': 'During delivery time ( at expected average 9 months of pregnancy)'}, {'measure': 'Premature births', 'timeFrame': 'Delivered before 37 Weeks of gestation'}, {'measure': 'Maternal death', 'timeFrame': 'During pregnancy, labor or delivery'}, {'measure': 'Neonatal death', 'timeFrame': 'Prior to 28 days of life'}, {'measure': 'Birth Defects', 'timeFrame': 'Delivery time (expected 9 months of pregnancy)'}]",[],9,,,FEMALE,False,Biogen,INDUSTRY,0,1.0,ACTUAL,2025-09-01T16:18:15.899240,v2_robust,False,True,False,True,False,"Due to low enrollment, registration closed in agreement with the Regulatory Agency"
NCT04260854,Bupivacaine Hydrochloride for Pain Control in Cutaneous Surgery,Locally Administered Bupivacaine Hydrochloride for Post-operative Pain Control in Cutaneous Surgery: a Randomized Controlled Trial,Bupivacaine Hydrochloride,"['Saline', 'Bupivacaine Hydrochloride']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Pain, Postoperative","['Pain, Postoperative']",[],ENROLLING_BY_INVITATION,,2024-01-24,2025-06,"[{'measure': 'Reported opioid and non-opioid pain medications taken', 'description': 'Patients will report the amount of pain medications taken 3 days immediately following surgery', 'timeFrame': '3 Days Post-Surgery'}]",[],1,19 Years,,ALL,True,Northwestern University,OTHER,0,100.0,ESTIMATED,2025-09-01T16:18:15.899284,v2_robust,True,True,False,False,False,
NCT02782754,Chemotherapy Plus Reduced Radiotherapy in Intracranial Germinoma,Treatment of Intracranial Germinoma With Chemotherapy Prior to Reduced Dose and Volume of Radiotherapy,Carboplatin,"['Etoposide', 'Carboplatin', 'Bleomycin', 'Cyclophosphamide']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Intracranial Germinoma,['Intracranial Germinoma'],[],UNKNOWN,,2013-01,,"[{'measure': 'Rate of late sequelae', 'timeFrame': 'Up to 5 years'}]","[{'measure': 'Rate of event free survival', 'timeFrame': 'Up to 5 years'}]",2,3 Years,30 Years,ALL,False,Samsung Medical Center,OTHER,0,40.0,ESTIMATED,2025-09-01T16:18:15.899311,v2_robust,True,True,False,False,False,
NCT04871854,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,Comparative Study Evaluating Clinical Outcomes for Patients Treated With Tocilizumab for Sever COVID-19 Infection in Breast Cancer Patients Versus Non Cancer Patients,Tocilizumab,"['Tocilizumab', 'traditional Covid -19 therapy', 'DExa /Corticosteriods', 'Actemra']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Breast Cancer,['Breast Cancer'],[],COMPLETED,,2021-04-26,2022-08-26,"[{'measure': 'Overall survival (OS) after treatment of Tocilizumab', 'description': 'measure mortality rate', 'timeFrame': '28 days time fram'}, {'measure': 'progression free survival (PFS)', 'description': 'measure time from recovery until reinfection with Covid-19 after treatment of Tocilizumab', 'timeFrame': '3 months'}, {'measure': 'time of improvement or worsening at least one point change in ordinal scale', 'description': 'Time to improvement will be assessed by changes on the clinical improvement or worsening as it measures illness severity over time ,by using Ordinal Scale for Clinical Improvement which score zero indicate no clinical or evidence virologic infection and high score 8 indicate death', 'timeFrame': '28 days'}]","[{'measure': 'measure percentage of patients need Mechanical Ventilation Required (Including CPAP) during Follow up period, Supplemental Oxygen required', 'description': 'complications', 'timeFrame': '28 days time fram'}, {'measure': 'Duration of mechanical ventilation', 'description': 'Duration of mechanical ventilation from the start to end', 'timeFrame': '28 days'}, {'measure': 'adverse effect', 'description': 'any side effects or serious adverse effect', 'timeFrame': '28 days'}, {'measure': 'length of stay in Intensive care unit', 'description': 'admission date and discharge date documented and LOS calculated from the day of admission to day of discharge, and based on the number of nights spent in hospital. Patients admitted and discharged on the same day have a length of stay of less than one day. dividing the sum of inpatient days by the number of patients admissions.', 'timeFrame': '28 days'}]",7,18 Years,85 Years,ALL,False,Beni-Suef University,OTHER,0,100.0,ACTUAL,2025-09-01T16:18:15.899439,v2_robust,True,True,True,False,True,
NCT00440154,A Study Evaluating the Safety and Efficacy of AVE5530 (4 Weeks) in Patients With Mild to Moderate Hypercholesterolemia,"A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled,Ezetimibe-Calibrated, Multicenter Study Evaluating the Safety and Efficacy of Four Doses and Two Dose-Regimens of AVE5530 Over 4 Weeks in Patients With Mild to Moderate Primary Hypercholesterolemia",AVE5530,"['AVE5530', 'ezetimibe', 'placebo']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Hypercholesterolemia,['Hypercholesterolemia'],[],COMPLETED,,2007-02,2007-10,"[{'measure': 'Percent change in LDL-C from baseline', 'timeFrame': '4 weeks'}]","[{'measure': 'Absolute change from in LDL-C levels', 'timeFrame': '4 weeks'}, {'measure': 'Percent change in other lipids and lipoprotein fractions from baseline', 'timeFrame': '4 weeks'}]",3,18 Years,,ALL,False,Sanofi,INDUSTRY,0,206.0,ACTUAL,2025-09-01T16:18:15.899488,v2_robust,True,True,True,False,False,
NCT00410254,HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects,"An Open Label, Single-Dose Midazolam, Multiple-Dose HCV-796, Sequential 3-Period Study to Determine the Pharmacokinetics of the Potential Drug Interaction Between HCV-796 and Midazolam",HCV-796,"['HCV-796', 'midazolam']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2007-06,2007-08,[{'measure': 'Safety PK'}],[],1,18 Years,50 Years,ALL,True,Wyeth is now a wholly owned subsidiary of Pfizer,INDUSTRY,0,38.0,ESTIMATED,2025-09-01T16:18:15.899523,v2_robust,True,True,True,False,True,
NCT05169554,Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy,Beta-Lactam Containing Regimen for the Shortening of Buruli Ulcer Disease Therapy: Comparison of 8 Weeks Standard Therapy (Rifampicin Plus Clarithromycin) vs. 4 Weeks Standard Plus Amoxicillin/Clavulanate Therapy [RC8 vs. RCA4],Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.,"['Investigational [RCA4]: standard (RC) plus amoxicillin/clavulanate (A) for 4 weeks.', 'Standard [RC8]: rifampicin plus clarithromycin (RC) therapy for 8 weeks.']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Buruli Ulcer,['Buruli Ulcer'],"['Buruli ulcer', 'Neglected tropical disease', 'Treatment shortening', 'Drug combination', 'Amoxicillin/clavulanate', 'Clinical trial', 'Pharmacokinetic analysis', 'Bacterial clearance study']",RECRUITING,,2021-12-01,2026-05-31,"[{'measure': 'Cure rate, i.e. proportion of patients with complete lesion healing without recurrence and without excision surgery 12 months after treatment initiation, in the Per Protocol (PP) PCR+ population', 'description': 'The PP PCR+ population includes those randomized patients with a clinical diagnosis of Very Likely BU or Likely BU, PCR+ and with no major violations of the protocol.', 'timeFrame': '12 months after treatment initiation'}]","[{'measure': 'Derive and compare the Area Under the Curve (AUC) (pharmacokinetic parameter) for RIF, CLA and AMX for the two groups (RC8 and RCA4) at steady-state.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Derive and compare the trough concentration (Cτ) (pharmacokinetic parameter) for RIF, CLA and AMX for the two groups (RC8 and RCA4) at steady-state.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Derive and compare the maximum observed drug concentration (Cmax) (pharmacokinetic parameter) for RIF, CLA and AMX for the two groups (RC8 and RCA4) at steady-state.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Derive and compare the time to maximum observed drug concentration (tmax) (pharmacokinetic parameter) for RIF, CLA and AMX for the two groups (RC8 and RCA4) at steady-state.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Derive and compare the elimination half-life (t1/2) (pharmacokinetic parameter) for RIF, CLA and AMX for the two groups (RC8 and RCA4) at steady-state.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Characterize the POPPK in BU patients randomised on RCA4 and derive population PK arameters, such as apparent Clearance (CL/F), together with potential covariates of interest.', 'description': 'This will involve investigating inter- and intra-subject variability for RIF and AMX.\n\nThe Pharmacokinetic Population (POPPK) is defined as the participants in the Safety Population (SP) who receive at least one dose of randomised study medication and have at least one evaluable PK sample. Participants will be analysed according to the treatment actually received.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Characterize the POPPK in BU patients randomised on RCA4 and derive population PK arameters, such as apparent Volume of distribution (V/F), together with potential covariates of interest.', 'description': 'This will involve investigating inter- and intra-subject variability for RIF and AMX.\n\nThe Pharmacokinetic Population (POPPK) is defined as the participants in the Safety Population (SP) who receive at least one dose of randomised study medication and have at least one evaluable PK sample. Participants will be analysed according to the treatment actually received.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Characterize the POPPK in BU patients randomised on RCA4 and derive population PK arameters, such as Absorption Rate (Ka), together with potential covariates of interest.', 'description': 'This will involve investigating inter- and intra-subject variability for RIF and AMX.\n\nThe Pharmacokinetic Population (POPPK) is defined as the participants in the Safety Population (SP) who receive at least one dose of randomised study medication and have at least one evaluable PK sample. Participants will be analysed according to the treatment actually received.', 'timeFrame': 'Between week 1 and week 2 after treatment initiation'}, {'measure': 'Rate of complete lesion healing without recurrence and without excision surgery, 12 months after start of treatment in the Intention-to-Treat Exposed (ITT-E) PCR+, PP Clinical Diagnose (CD), and ITT-E CD populations', 'description': 'Intention To Treat Exposed (ITT-E) PCR + population:\n\nThe ITT-E PCR+ population includes those randomized patients with a clinical diagnosis of Very Likely BU or Likely BU, PCR+ that have, at least, taken one dose of the study drugs. This population might include major violators of the protocol.\n\nPer Protocol (PP) Clinical Diagnose (CD) population:\n\nThe PP CD population includes those randomized patients with a clinical diagnosis of Very Likely BU or Likely BU and with no major violations of the protocol. This population includes both PCR+ and PCR -.\n\nIntention To Treat Exposed (ITT-E) Clinical Diagnose (CD) population:\n\nThe ITT-E CD population includes those randomized patients with a clinical diagnosis of Very Likely BU or Likely BU that have, at least, taken one dose of the study drugs. This population might include both PCR+ and PCR - and major violators of the protocol.', 'timeFrame': '12 months after treatment initiation'}, {'measure': 'Rate of complete lesion healing without recurrence and without excision surgery 12 months after start of treatment by category (I, II & III) lesions analysis in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': '12 months after treatment initiation'}, {'measure': 'Recurrence rate within 12 months of treatment initiation in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation'}, {'measure': 'Treatment discontinuation rate in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Active comparator arm (RC8): 8 weeks; Experimental arm (RCA4): 4 weeks'}, {'measure': 'Treatment compliance rate in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Active comparator arm (RC8): 8 weeks; Experimental arm (RCA4): 4 weeks'}, {'measure': 'Rate of paradoxical response within 12 months of treatment initiation in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation'}, {'measure': 'Median time to healing after treatment initiation in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation until the date of healing time'}, {'measure': 'Proportion of patients with reduction in lesion surface area within 12 months of treatment initiation in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation'}, {'measure': 'Interval between healing and recurrence within 12 months of treatment initiation in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation'}, {'measure': 'Incidence of all adverse events (AEs), Serious Adverse Events (SAE), Serious unexpected suspected adverse drug reactions (SUSAR) within 12 months of treatment initiation among treatment arms in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation'}, {'measure': 'Rate of median bacterial clearance among treatment arms in the bacterial clearance sub-study population', 'timeFrame': 'Within 8 weeks or 14 weeks after treatment initiation according to the healing time'}, {'measure': 'Rate of patients with Buruli ulcer Functional Limitation Score (BUFLS) improvement within 12 months of treatment initiation among treatment arms in all ITT-E and PP populations', 'description': 'Intention-to-Treat Exposed (ITT-E): this population will consist of all randomized patients who receive at least one dose of randomized study medication. Patients will be assessed according to their randomized treatment, regardless of the treatment they receive.\n\nPer Protocol (PP): this population will consist of subjects in the ITT-E population who complete the study and are not major protocol violators.', 'timeFrame': 'Within 12 months of treatment initiation'}]",21,5 Years,70 Years,ALL,False,Fundacion Agencia Aragonesa para la Investigacion y Desarrollo (ARAID),OTHER,7,140.0,ESTIMATED,2025-09-01T16:18:15.899582,v2_robust,True,True,False,False,True,
NCT03785054,"Phase 1, Healthy Subject, Safety, Tolerability and Pharmacokinetic Study of mGlu5 NAM HTL0014242","A Phase I, Randomised, Double-blind, Placebo Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral HTL0014242 in Healthy Adults",HTL0014242,"['HTL0014242', 'Placebo oral capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],[],COMPLETED,,2018-11-14,2021-03-11,"[{'measure': 'Number of treatment related adverse event, including abnormal laboratory events', 'description': 'All AEs, including clinical laboratory, vitals signs, body temperature, respiratory rate, physical examinations and ECGs will be analyzed in all subjects receiving HTL0014242', 'timeFrame': 'Day -1 to follow up (7-14 days after discharge)'}]","[{'measure': 'Maximum observed plasma concentration (Cmax)', 'description': 'The observed peak plasma concentration determined from the plasma', 'timeFrame': 'predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose'}, {'measure': 'Area under the curve (AUC) from time 0 to 24 hours postdose (AUC0-24h)', 'description': 'Area under the plasma concentration-time curve up to 24h', 'timeFrame': 'predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose'}, {'measure': 'time to reach the maximum observed plasma concentration (tmax)', 'description': 'time to reach the maximum observed plasma concentration (tmax)', 'timeFrame': 'predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose'}, {'measure': 'Area under the curve (AUC) from time 0 to the time of the last quantifiable concentration (AUC0-tlast)', 'description': 'Area under the plasma concentration-time curve up to the last measurable timepoint', 'timeFrame': 'predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose'}, {'measure': 'Area under the curve (AUC) from time 0 extrapolated to infinity (AUC0-∞)', 'description': 'Area under the curve, calculated as AUC0-tlast + C0-tlast/λz, where C0-tlast is the last observed measurable concentration', 'timeFrame': 'predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose'}, {'measure': 't1/2 and kel', 'description': 'apparent initial elimination half-life (t1/2) and associated elimination rate onstant (kel)', 'timeFrame': 'predose and 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, and 96 hours postdose'}]",7,18 Years,55 Years,ALL,True,Nxera Pharma UK Limited,INDUSTRY,1,71.0,ACTUAL,2025-09-01T16:18:15.899616,v2_robust,True,True,True,False,True,
NCT00668005,Evaluating the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction and Hypertension,"A Randomized, Double-blind, Parallel-group, Plac-controlled Study Evaluating the Efficacy and Safety of Vardenafil Administration for 12 Weeks in a Flexible-dose Regimen Compared to Placebo in Men With Arterial Hypertension and Erectile Dysfunction","Levitra (Vardenafil, BAY38-9456)","['Levitra (Vardenafil, BAY38-9456)', 'Placebo']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Erectile Dysfunction,['Erectile Dysfunction'],"['Erectile Dysfunction', 'Arterial hypertension', 'Vardenafil']",COMPLETED,,2003-02,2003-09,"[{'measure': 'Sexual Encounter Profile (SEP), questions 2 and 3', 'timeFrame': '12 weeks'}]","[{'measure': 'International Index of Erectile Function (IIEF) - EF (Erectile Function) domain', 'timeFrame': '12 weeks'}, {'measure': 'Global Assessment Questionnaire (GAQ)', 'timeFrame': '12 weeks'}, {'measure': 'Safety and tolerability', 'timeFrame': '12 weeks'}]",4,18 Years,,MALE,False,Bayer,INDUSTRY,1,388.0,ACTUAL,2025-09-01T16:18:15.899678,v2_robust,True,True,True,False,True,
NCT00695305,An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks,"A Multicenter, Randomized, 12 Week, Double-blind, Placebo-controlled, Parallel-group, Phase IIa Study Using 18F Fluorodeoxyglucose (FDG)-PET to Measure the Effects of Rilapladib on Macrophage Activity in Subjects With Atherosclerosis",rilapladib,"['SB-659032', 'placebo', 'rilapladib']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Atherosclerosis,['Atherosclerosis'],"['rilapladib,', 'Lp-PLA2,', 'atherosclerosis', 'SB-659032,', 'FDG-PET,']",COMPLETED,,2008-11,2010-05,"[{'measure': 'Safety from AE reporting, vital signs, clinical labs, ECGs, slit lamp eye exams and electron microscopy of peripheral blood lymphocytes.', 'timeFrame': '12 weeks'}, {'measure': 'LP-PLA2 activity;', 'timeFrame': '12 weeks'}, {'measure': 'changes in mean standard values of 18 FDG uptake as assessed by PET and MRI imaging', 'timeFrame': '12 weeks'}]","[{'measure': 'Estimation of PK parameters (such as: apparent volume of distribution, apparent clearance, etc.) of rilapladib and their associated variability, appropriate to the final model', 'timeFrame': '12 weeks'}, {'measure': 'Estimation of PK/PD parameters (such as: IC50, Eo) and their associated variability, appropriate to the final model', 'timeFrame': '12 weeks'}, {'measure': '24 hour ambulatory blood pressure monitoring', 'timeFrame': '12 weeks'}, {'measure': 'PAF levels in human plasma as feasible', 'timeFrame': '12 weeks'}]",7,50 Years,80 Years,ALL,False,GlaxoSmithKline,INDUSTRY,0,83.0,ACTUAL,2025-09-01T16:18:15.899726,v2_robust,True,True,True,False,True,
NCT02657005,TK216 in Patients With Relapsed or Refractory Ewing Sarcoma,"A Phase 1 / 2, Dose Escalation Study of Intravenous TK216 in Patients With Relapsed or Refractory Ewing Sarcoma",TK216,['TK216'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Sarcoma, Ewing","['Sarcoma, Ewing']",[],TERMINATED,Sponsor Decision,2016-08,2022-06,"[{'measure': 'Overall Response Rate', 'description': 'Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions and pathologic lymph nodes; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions, no new lesions, and no progression of non-target lesions; Overall Response (OR) = CR + PR.', 'timeFrame': '36 months'}]",[],1,8 Years,,ALL,False,"Oncternal Therapeutics, Inc",INDUSTRY,0,85.0,ACTUAL,2025-09-01T16:18:15.899763,v2_robust,True,True,False,True,False,Sponsor Decision
NCT00938405,Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus,Efficacy of Colesevelam in Subjects With Type 1 Diabetes Mellitus,Colesevelam HCl,"['Colesevelam HCl', 'Placebo', 'WELCHOL (colesevelam hydrochloride)', 'Initial U.S. Approval: 2000']",4,INTERVENTIONAL,['NA'],,,"Diabetes Mellitus, Type 1","['Diabetes Mellitus, Type 1', 'Hyperlipidemias']","['type 1 diabetes mellitus', 'colesevelam', 'LDL', 'cholesterol', 'A1c', 'target range glucose values']",COMPLETED,,2009-07,2009-12,"[{'measure': 'To demonstrate a 10% LDL reduction in type 1 diabetic subjects with initial LDL > 100 after twelve weeks in the colesevelam group.', 'timeFrame': '12 weeks of treatment'}]","[{'measure': 'To evaluate colesevelam use for glucose control as measured by A1c using a 0.4% confidence interval at baseline and after one, two, and three months of therapy.', 'timeFrame': '12 weeks of treatment.'}, {'measure': 'To evaluate colesevelam use for non-inferiority of percent of target range glucose values and time spent in hyper- and hypoglycemic ranges as determined by CGM readings at baseline and after one, two, and three months of therapy.', 'timeFrame': '12 weeks of treatment.'}, {'measure': 'In addition change in insulin dose at one, two and three months from baseline will be evaluated.', 'timeFrame': '12 weeks of treatment'}]",4,18 Years,65 Years,ALL,True,"University of Colorado, Denver",OTHER,1,45.0,ACTUAL,2025-09-01T16:18:15.899811,v2_robust,True,True,True,False,False,
NCT00483405,"Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer","Phase II Study of Oxaliplatin, Capecitabine, and Cetuximab in Advanced Hepatocellular Carcinoma",capecitabine,"['Eloxatin', 'Xeloda', 'capecitabine', 'oxaliplatin']",4,INTERVENTIONAL,['PHASE2'],PHASE2,,Liver Cancer,['Liver Cancer'],"['advanced adult primary liver cancer', 'localized unresectable adult primary liver cancer', 'recurrent adult primary liver cancer', 'adult primary hepatocellular carcinoma']",COMPLETED,,2006-10,2010-12,"[{'measure': 'Disease Response Rate', 'description': 'Radiographic response will be measured every six weeks while subject is on treatment. Response will be measured using RECIST criteria.\n\nPer Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions.', 'timeFrame': '42 days (2 cycles)'}]","[{'measure': 'Number of Subjects Experiencing Adverse Events', 'description': 'Adverse events will be assessed using CTCAE criteria.', 'timeFrame': 'every 3 weeks of treatment with an average of 15 weeks on treatment'}, {'measure': 'Overall Survival', 'description': 'Overall survival will be calculated from time of enrollment to death or last contact date.', 'timeFrame': 'Median 23 month follow-up'}, {'measure': 'Time to Progression', 'description': 'Time to progression will be calculated from the time of enrollment until confirmed disease progression. Defined by RECIST (Response Evaluation Criteria in Solid Tumors), Progressive Disease (PD) - at least a 20% increase in the sum of the longest diameter of target lesions, taking as reference the smallest sum longest diameter recorded since the treatment started or the appearance of one or more new lesions.', 'timeFrame': 'Median 23 month follow-up'}]",4,18 Years,120 Years,ALL,False,UNC Lineberger Comprehensive Cancer Center,OTHER,5,33.0,ACTUAL,2025-09-01T16:18:15.899824,v2_robust,True,True,True,False,True,
NCT04935294,Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney Dysfunction,"A Phase I, Open-Label, Parallel Group Study To Evaluate ACH-0144471 Safety, Tolerability, And Pharmacokinetics In Subjects With Normal Renal Function And Subjects With Renal Dysfunction",Danicopan,"['Danicopan', 'ACH4471', 'ALXN2040', 'ACH-0144471 (formerly)', '4471', 'ACH-4471']",6,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,"['Healthy', 'Renal Dysfunction']","['Danicopan', 'ALXN2040', 'ACH-0144471', 'Renal Impairment', 'Pharmacokinetics', 'Pharmacodynamics', 'Factor D Inhibitor', 'Safety']",COMPLETED,,2018-01-24,2018-05-29,"[{'measure': 'Participants With Treatment-emergent Adverse Events', 'timeFrame': 'Day 1 through Day 10 (+/- 2 days)'}]","[{'measure': 'Area Under The Plasma Concentration-time Curve Extrapolated To Infinity (AUC0-inf) Of Danicopan', 'timeFrame': 'Up to 72 hours postdose'}, {'measure': 'Maximum Observed Plasma Concentration (Cmax) Of Danicopan', 'timeFrame': 'Up to 72 hours postdose'}, {'measure': 'Time To Reach The Maximum Observed Plasma Concentration (Tmax) Of Danicopan', 'timeFrame': 'Up to 72 hours postdose'}, {'measure': 'Alternative Pathway Activity As Measured By Wieslab Assay', 'timeFrame': 'Up to 72 hours postdose'}, {'measure': 'Change From Baseline In Plasma Bb Fragment Of Complement Factor B Concentration', 'timeFrame': 'Baseline, Up to 72 hours postdose'}, {'measure': 'Change From Baseline In Complement Factor D Concentration', 'timeFrame': 'Baseline, Up to 72 hours postdose'}]",7,18 Years,75 Years,ALL,True,"Alexion Pharmaceuticals, Inc.",INDUSTRY,1,16.0,ACTUAL,2025-09-01T16:18:15.900048,v2_robust,True,True,True,False,True,
NCT01850394,Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement,Efficacy of Low-dose Intra-articular Tranexamic Acid in Total Knee Replacement; A Prospective Triple-blinded Randomized Controlled Trial.,Tranexamic Acid,"['Physiologic saline', 'Tranexamic Acid', 'Transmin']",3,INTERVENTIONAL,['NA'],,,Primary Osteoarthritis of Knee Nos,['Primary Osteoarthritis of Knee Nos'],[],COMPLETED,,2010-01,2012-01,"[{'measure': 'Perioperative Blood Loss', 'description': '* Drainage blood loss measured by accumulating total drainage volume postoperatively\n* Calculated total blood loss measured by using specific formula and difference between hematocrit preoperatively and the fourth postoperative day', 'timeFrame': '5 days after surgery'}, {'measure': 'Total Hemoglobin Loss', 'description': 'Total hemoglobin loos measured by difference between hemoglobin preoperatively and the fourth postoperative day', 'timeFrame': '5 days after surgery'}]","[{'measure': 'Knee Function Scores', 'description': ""Knee function score was measured with 2 methods, and were evaluated preoperatively and then postoperatively at 3-month, 6-month, and 1-year period.\n\n1. Knee Society Knee Score using for rating knee function measurement and subdivided into two parts; knee score and function score 1.1. Knee score : calculated from pain, presence of deformity, total range of flexion, alignment, and stability. Total score is 100 (0-100), more score means better.\n\n   1.2. Function score : calculated from patient's ability to walk and climb stairs. The score ranges from 0-100, more score means better.\n2. Western Ontario and McMaster Universities Arthritis Index or WOMAC score : a widely used, standardized questionnaires for evaluating the condition of patients with knee osteoarthritis, including pain (score = 0-20), stiffness (0-8), and functional limitation (0-68). Total score ranges from 0-68, lower score means better."", 'timeFrame': '1 year after surgery'}, {'measure': 'Number of Patients Required Blood Transfusion', 'timeFrame': 'postoperative period (5 days after surgery)'}, {'measure': 'Number of Patients Having Postoperative Complications', 'description': 'Postoperative complications were measured as an incidence of the following complications;\n\n* wound hematoma\n* surgical site infection\n* systemic infection\n* deep vein thrombosis\n* pulmonary embolism\n* knee stiffness requiring manipulation\n* medical complication such as myocardial infarction, congestive hear failure', 'timeFrame': 'postoperative 1-year period'}]",5,50 Years,,ALL,False,Mahidol University,OTHER,0,152.0,ACTUAL,2025-09-01T16:18:15.900072,v2_robust,True,True,True,False,False,
NCT03633994,Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy,Heparin Intraoperative Instillation for Lower Urinary Tract Symptoms After Benign Hysterectomy: A Randomized Controlled Trial,Heparin,"['Heparin', 'Normal saline']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Lower Urinary Tract Symptoms,"['Lower Urinary Tract Symptoms', 'Postoperative Urinary Tract Infection']","['Randomized controlled trial', 'Heparin instillation']",UNKNOWN,,2018-08-20,2020-03-01,"[{'measure': 'Lower urinary tract symptoms', 'description': 'lower urinary tract symptoms such as urgency, frequency, dysuria, and hematuria measured by the Urinary Tract Infection Symptoms Assessment Questionnaire (UTISA)', 'timeFrame': 'Postoperative day 14'}]","[{'measure': 'Postoperative antibiotic use', 'description': 'Obtained via phone interview', 'timeFrame': 'Postoperative day 1 to 14'}, {'measure': 'Postoperative patient satisfaction', 'description': 'Surgical Satisfaction Questionnaire (SSQ-8) assessment conducted via phone interview', 'timeFrame': 'Postoperative day 14'}]",3,18 Years,85 Years,FEMALE,False,The Christ Hospital,OTHER,0,104.0,ESTIMATED,2025-09-01T16:18:15.900172,v2_robust,True,True,False,False,False,
NCT02518594,A Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix,A Randomized Trial of Pessary and Progesterone for Preterm Prevention in Twin Gestation With a Short Cervix,Vaginal progesterone,"['Vaginal progesterone', 'Prometrium', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Short Cervical Length,['Short Cervical Length'],"['women', 'cervical length of less than 30 millimeters', 'carrying twins', 'short cervix']",ACTIVE_NOT_RECRUITING,,2015-11-13,2025-06-30,"[{'measure': 'Delivery or fetal loss of either twin prior to 35 weeks gestation', 'description': 'Preterm delivery or fetal loss prior to 35 weeks gestation', 'timeFrame': 'prior to 35 weeks gestation'}]","[{'measure': 'Interval from randomization to delivery (or fetal demise)', 'description': 'Randomization may begin at 16 weeks, and most patients will be delivered by 41 weeks', 'timeFrame': 'Randomization to delivery can be up to 26 weeks'}, {'measure': 'Gestational age at delivery', 'description': 'Gestational age at the time of delivery. Randomization begins at 16 weeks gestation', 'timeFrame': 'Randomization to delivery can be up to 26 weeks'}, {'measure': 'Preterm delivery or fetal demise of either twin prior to 28 weeks gestation, 32 weeks gestation, and 37 weeks gestation', 'description': 'Preterm delivery or fetal loss of either twin prior to 28 weeks gestation; prior to 32 weeks gestation; and prior to 37 weeks gestation', 'timeFrame': 'From randomization to up to 37 weeks gestation (up to 21 weeks)'}, {'measure': 'Spontaneous preterm delivery (following preterm labor or pPROM) < 35 weeks gestation and < 32 weeks gestation', 'description': 'Spontaneous preterm delivery before 35 weeks gestation and 32 weeks gestation', 'timeFrame': 'From randomization to delivery (up to 19 weeks)'}, {'measure': 'Indicated preterm delivery < 35 weeks', 'description': 'Preterm delivery prior to 35 weeks gestation with medical indications', 'timeFrame': 'From randomization to delivery (up to 19 weeks)'}, {'measure': 'Cesarean delivery', 'description': 'Delivery by cesarean', 'timeFrame': 'Randomization to delivery can be up to 26 weeks'}, {'measure': 'Fetal or neonatal death', 'description': 'Fetal or neonatal death', 'timeFrame': 'Up to 28 days postnatal age'}, {'measure': 'Small for gestational age', 'description': 'Less than 5th percentile weight for gestational age, by sex and race of the infant based on United States birth certificate data', 'timeFrame': 'Randomization to delivery can be up to 26 weeks'}, {'measure': 'Composite neonatal outcome', 'description': 'Fetal or neonatal death, RDS, grade III or IV IVH, PVL, Stage 2 or 3 NEC, BPD, Stage III or higher ROP, or early onset sepsis', 'timeFrame': 'Birth to neonatal discharge or death, whichever is first (up to 6 weeks)'}, {'measure': 'Length of hospital stay, need for NICU or intermediate care admission and length of stay if admitted', 'description': 'Length of hospital stay in days, any Neonatal ICU or intermediate care admission, or length of hospital or intermediate care stay in days', 'timeFrame': 'Birth to neonatal discharge or death, whichever is first (up to 6 weeks)'}]",11,,,FEMALE,False,The George Washington University Biostatistics Center,OTHER,1,437.0,ACTUAL,2025-09-01T16:18:15.900206,v2_robust,True,True,False,False,False,
NCT05966194,RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer,A Randomized Placebo-Controlled Trial of Two Schedules of RRx-001 for the Attenuation of Severe Oral Mucositis in Patients Receiving Concomitant Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx,RRx-001,"['Cisplatin for injection 100 mg/m2', 'RRx-001']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Oral Mucositis,['Oral Mucositis'],"['Head and Neck Cancer', 'Neck cancer', 'Oral cancer', 'Mucositis', 'Squamous cell carcinoma (SCC)', 'HPV', 'Oropharynx', 'Oral cavity', 'IMRT']",RECRUITING,,2024-04-02,2025-10-01,"[{'measure': 'Incidence of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT)', 'description': 'The incidence of SOM defined as the proportion of patients with any WHO Grade \\>= 3 (severe to life threatening) oral mucositis during the observation period from the start of CRT through IMRT', 'timeFrame': 'Estimated up to 18 Months'}]","[{'measure': 'Duration of Severe Oral Mucositis (SOM) through Intensity-modulated radiation therapy (IMRT)', 'description': 'Duration of SOM (through the last day of radiation therapy, DoSOM). Its principal analysis employs the probability of being in response (PBIR), an intuitive concept based on the realization that the duration of response which is quantified as the area under the curve delimited by the duration of exposure (x axis) and the response probability (y axis).', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Duration of Severe Oral Mucositis (SOM) through 60 Gy', 'description': 'Duration of SOM (through 60 Gy, DoSOM) is compared between RRx-001 arms and Placebo using a two-sided log-rank test.', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Time to onset of Sever Oral Mucositis (ttSOM)', 'description': 'Time onset to SOM (ttSOM) is defined as the time interval measured from the start of the observation period to the first time SOM is observed.', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Incidence and severity of dysphagia', 'description': 'Incidence and severity of dysphagia will be analyzed similarly to the primary efficacy endpoint.', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Cumulative radiation dose to onset of SOM', 'description': 'Cumulative radiation dose to onset of SOM is compared between RRx-001 arms and placebo', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Incidence of grade 4 oral mucositis', 'description': 'Incidence of grade 4 oral mucositis through 60 Gy', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Narcotic use through resolution of SOM', 'description': 'Narcotic use through resolution of SOM will be analyzed similarly to the cumulative radiation dose', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Incidence of Severe Oral Mucositis through 60 Gy of the Radiation Treatment Plan', 'description': 'incidence of SOM defined as the proportion of patients with any WHO Grade \\>= 3 (severe to life threatening) oral mucositis during the observation period from the start of CRT through 60 Gy', 'timeFrame': 'Estimated up to 18 Months'}, {'measure': 'Progression free survival (PFS)', 'description': 'Progression free survival (PFS)', 'timeFrame': 'Estimated up to 24 Months'}, {'measure': 'Degree of Xerostomia', 'description': ""Degree of Xerostomia as analyzed by validated Xerostomia questionnaire 'XQ'"", 'timeFrame': 'Estimated up to 24 Months'}, {'measure': 'Xerostomia duration', 'description': ""Xerostomia duration as analyzed by validated Xerostomia questionnaire 'XQ'"", 'timeFrame': 'Estimated up to 24 Months'}, {'measure': 'Time to onset of dysphagia', 'description': 'Time to onset of dysphagia', 'timeFrame': 'Estimated up to 24 Months'}, {'measure': 'Duration of dysphagia', 'description': 'Duration of dysphagia', 'timeFrame': 'Estimated up to 24 Months'}]",14,18 Years,,ALL,False,"EpicentRx, Inc.",INDUSTRY,0,216.0,ESTIMATED,2025-09-01T16:18:15.900236,v2_robust,True,True,False,False,False,
NCT03315494,"Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of SKI-O-703 in Healthy Volunteers","A Phase 1, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of SKI-O-703 in Healthy Volunteers",SKI-O-703 capsule,"['Placebo capsule', 'SKI-O-703 capsule']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,"Arthritis, Rheumatoid","['Arthritis, Rheumatoid']","['rheumatoid arthritis', 'healthy volunteers', 'moderate to severe']",COMPLETED,,2016-09-22,2016-12-21,"[{'measure': 'Number of participants (Healthy Volunteers) with reported adverse events receiving multiple dose of SKI-O-703 as assessment of safety and tolerability.', 'description': 'Safety and tolerability of SKI-O-703 as measured by subject incidence of treatment-related Adverse Events.', 'timeFrame': '21 days'}]","[{'measure': 'Area under the concentration versus time curve within a dosing interval (AUC0-tau), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'AUC0-tau will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Area under the concentration versus time curve from time 0 to the last measurable concentration (AUC0-t), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'AUC0-t will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Area under the concentration versus time curve within a dosing interval (AUC0-inf), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'AUC0-inf will be reported.', 'timeFrame': 'Day 7 only'}, {'measure': 'Maximum observed concentration (Cmax), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Cmax will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Apparent oral clearance (CL/F), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'CL/F will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Terminal elimination rate constant (Kel), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Kel will be reported.', 'timeFrame': 'Day 7'}, {'measure': 'Time to reach the maximum observed concentration, to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Tmax will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Apparent terminal elimination half-life (t1/2), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 't1/2 will be reported.', 'timeFrame': 'Day 7 only'}, {'measure': 'Apparent volume of distribution (Vd/F), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Vd/F will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Metabolite ratio (Rmet), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'Rmet will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}, {'measure': 'Accumulation ratio based on AUC0-tau (RAUC), to investigate pharmacokinetic profiles of SKI-O-592 (the free base of SKI-O-703) and its metabolites (M2 and M4) in healthy volunteers.', 'description': 'RAUC will be reported.', 'timeFrame': 'Days 1-7 (dosing), post-dose (days 8-10).'}]",12,18 Years,55 Years,ALL,True,Oscotec Inc.,INDUSTRY,1,24.0,ACTUAL,2025-09-01T16:18:15.900270,v2_robust,True,True,True,False,True,
NCT02749994,A Clinical Trial to Compare the Efficacy and Safety of a Combination Therapy of Ezetimibe and Rosuvastatin Versus Monotherapy of Rosuvastatin in Hypercholesterolemia Patients (I-ROSETTE Study),,Rosuvastatin,"['Ezetimibe', 'Rosuvastatin']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Hypercholesterolemia,['Hypercholesterolemia'],[],COMPLETED,,2016-04,2017-02,"[{'measure': 'Percent change from baseline to 8 week in LDL-Cholesterol', 'timeFrame': 'baseline and 8 week'}]","[{'measure': 'Percent change from baseline to 4 and 8 week in Total Cholesterol', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in Triglyceride', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in HDL-Cholesterol', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in non-HDL-Cholesterol', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in Apolipoprotein B', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in Apolipoprotein A1', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'Percent change from baseline to 4 week in LDL-Cholesterol', 'timeFrame': 'baseline to 4 week'}, {'measure': 'Percent change from baseline to 4 and 8 week in hs-CRP(high-sensitivity C-reactive protein)', 'timeFrame': 'baseline to 4 and 8'}, {'measure': 'The change of LDL-Cholesterol/HDL-Cholesterol ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The change of Total Cholesterol/HDL-Cholesterol ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The change of non-HDL-Cholesterol/HDL-Cholesterol ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The change of Apolipoprotein B/Apolipoprotein A1 ratio', 'timeFrame': 'baseline to 4 and 8 week'}, {'measure': 'The ratio of subjects who reach the goal of LDL-Cholesterol according to NCEP(National Cholesterol Education Program Adult Treatment Panel) III Guideline', 'timeFrame': 'baseline to 4 and 8 week'}]",14,19 Years,79 Years,ALL,False,IlDong Pharmaceutical Co Ltd,INDUSTRY,0,396.0,ACTUAL,2025-09-01T16:18:15.900285,v2_robust,True,True,True,False,False,
NCT03591094,"Study Assessing PTI-428 Safety, Tolerability, Pharmacokinetics and Effect in Subjects With Cystic Fibrosis","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect of PTI-428 in Subjects With Cystic Fibrosis",PTI-428,"['PTI-428', 'Placebo']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cystic Fibrosis,['Cystic Fibrosis'],[],COMPLETED,,2018-08-21,2019-02-18,"[{'measure': 'Number of subjects with treatment-emergent adverse events (TEAEs)', 'description': 'Safety and tolerability will be assessed by adverse events (AEs), safety labs, electrocardiograms (ECGs), physical examinations and vital signs.', 'timeFrame': 'Baseline through Day 42'}]","[{'measure': 'Maximum plasma concentration (Cmax)', 'timeFrame': '28 days'}, {'measure': 'Time of Cmax (Tmax)', 'timeFrame': '28 days'}, {'measure': 'Area under the concentration time curve from time 0 to time of last measurable concentration (AUC0-t)', 'timeFrame': '28 days'}, {'measure': 'Change in FEV1 over time', 'timeFrame': 'Baseline through Day 42'}, {'measure': 'Change in sweat chloride over time', 'timeFrame': 'Baseline through Day 42'}]",6,18 Years,,ALL,False,"Proteostasis Therapeutics, Inc.",INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:15.900347,v2_robust,True,True,True,False,True,
NCT01586494,"A Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER in Children With Pain","A Single Dose Pharmacokinetic, Tolerability, and Safety Study of ULTRAM ER at Two Dose Levels in Children Seven to Eleven Years Old, Inclusive, With Pain",ULTRAM ER,['ULTRAM ER'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Pain,['Pain'],"['Pain', 'ULTRAM ER', 'Tramadol hydrochloride', 'Children']",COMPLETED,,2007-10,2009-06,"[{'measure': 'The area under the curve (AUC∞) of ULTRAM ER as the primary PK parameter', 'timeFrame': 'At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose'}]","[{'measure': 'Plasma concentration profile of ULTRAM ER', 'timeFrame': 'At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose'}, {'measure': 'Plasma concentration profiles of M1 and M5 metabolites', 'timeFrame': 'At 1, 4, 6, 8, 12, 16, 24, 36, and 48 hours post dose'}, {'measure': 'Incidence of adverse events as a measure of safety and tolerability', 'timeFrame': '48 hours post dose'}]",4,7 Years,11 Years,ALL,False,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",INDUSTRY,0,37.0,ACTUAL,2025-09-01T16:18:15.900370,v2_robust,True,True,True,False,True,
NCT01919294,Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS),Pilot Open Study of Testosterone Replacement in Non-alcoholic Steatohepatitis,testosterone undecanoate,"['Nebido', 'testosterone undecanoate']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Nonalcoholic Steatohepatitis,"['Nonalcoholic Steatohepatitis', 'Hypogonadism']","['nonalcoholic fatty liver disease', 'nonalcoholic steatohepatitis', 'hypogonadism', 'testosterone replacement therapy']",COMPLETED,,2013-07,2017-01-30,"[{'measure': 'steatosis histology', 'description': 'Proportion of patients in whom severity of steatohepatitis improves with testosterone replacement therapy, assessed by liver biopsy', 'timeFrame': 'baseline and 12 months'}]","[{'measure': 'Proportion of patients in whom liver inflammation improves', 'description': 'Proportion of patients in whom liver inflammation improves', 'timeFrame': 'baseline and 12 months'}, {'measure': 'Proportion of patients in whom liver ballooning improves', 'description': 'Proportion of patients in whom liver ballooning improves', 'timeFrame': 'baseline and 12 months'}, {'measure': 'Proportion of patients in whom liver fibrosis improves', 'description': 'Proportion of patients in whom liver fibrosis improves', 'timeFrame': 'baseline and 12 months'}, {'measure': 'Change in fat content of liver', 'description': 'Change in fat content of liver assessed by by MR spectroscopy and its correlation with steatosis on liver biopsy', 'timeFrame': 'baseline and 12 months'}, {'measure': 'Change in HOMA index', 'description': 'measure of insulin sensitivity', 'timeFrame': 'baseline and 12 months'}, {'measure': 'Change in serum liver enzymes', 'timeFrame': 'baseline and 12 months'}, {'measure': 'Adverse events', 'description': 'Adverse events recorded over 12 month period', 'timeFrame': '12 months'}]",8,18 Years,75 Years,MALE,False,Sheffield Teaching Hospitals NHS Foundation Trust,OTHER,1,3.0,ACTUAL,2025-09-01T16:18:15.900391,v2_robust,True,True,True,False,True,
NCT00928694,Fenofibrate Bioequivalence Study (0767-031),"An Open-Label, Randomized, 2-Period, Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects",fenofibrate (U.S. formulation),"['Supralip®', 'fenofibrate (U.S. formulation)', 'Tricor®', 'fenofibrate (UK formulation)']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Dyslipidemia,['Dyslipidemia'],[],COMPLETED,,2003-02,2004-04,"[{'measure': 'Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid', 'timeFrame': 'Predose and up to 168 hours postdose'}, {'measure': 'Maximum Plasma Concentration (Cmax) of Fenofibric Acid', 'timeFrame': 'Predose and up to 168 hours postdose'}]",[],2,18 Years,45 Years,ALL,True,Merck Sharp & Dohme LLC,INDUSTRY,0,14.0,ACTUAL,2025-09-01T16:18:15.900411,v2_robust,True,True,True,False,False,
NCT04812366,Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer,Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer,Apalutamide 60mg Tab,"['Prednisone 5mg Tab', 'Apalutamide 60mg Tab', 'Abiraterone Acetate 250mg', 'Niraparib 100mg Oral Capsule', 'Atezolizumab', 'Docetaxel']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],[],RECRUITING,,2021-09-21,2026-04-01,"[{'measure': 'Complete Pathologic Response (pCR)', 'description': 'Pathological Minimal Residual Disease (pMRD): pathological minimal residual disease (pMRD) is defined as residual tumour 5mm or less.', 'timeFrame': '6 years'}, {'measure': 'Pathological Minimal Residual Disease (pMRD)', 'description': 'Pathological minimal residual disease is defined as residual tumour 5 mm or less.', 'timeFrame': '6 years'}]","[{'measure': 'Pain level assessment', 'description': ""The Brief Pain Inventory-Short Form (BPI-SF) is a 9-item, self administered questionnaire which evaluates the severity of a participant's level of pain and impact on daily functioning. This questionnaire will be administered at screening, prior to receiving master protocol therapy (0 weeks), the end of receiving therapy (8 weeks), as well as the End of Treatment (EoT) visit."", 'timeFrame': '6 years'}, {'measure': 'Generic Quality of Life (QoL)', 'description': 'The EQ-5D-5L is a widely used instrument developed in Europe to evaluate the generic quality of life. The EQ-5D-5L has two components: the EQ-5D descriptive system and the EQ visual analogue scale. This questionnaire will be administered at screening, prior to receiving master protocol therapy (0 weeks), the end of receiving therapy (8 weeks) as well as at the EoT visit.', 'timeFrame': '6 years'}, {'measure': 'Quality of Life-Prostate Cancer Patients', 'description': 'This will be measured using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire. The FACT-P is a multidimensional, self-report QoL instrument specifically designed for use with patients who have prostate cancer. This questionnaire will be administered at screening, prior to receiving master protocol therapy (0 weeks), the end of receiving therapy (8 weeks) as well as at the EoT visit.', 'timeFrame': '6 years'}]",5,18 Years,,MALE,False,University of British Columbia,OTHER,2,315.0,ESTIMATED,2025-09-01T16:18:15.900676,v2_robust,True,True,False,False,False,
NCT01616966,Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Sevoflurane and Propofol,"Laryngeal Injuries After Removal of the Tracheal Tube: A Comparison Between Anesthesia With Sevoflurane and Intravenous Anesthesia With Propofol A Randomized, Prospective, Controlled Trial",Sevoflurane,"['remifentanil', 'Sevoflurane', 'propofol']",3,INTERVENTIONAL,['NA'],,,"Vocal Cord; Injury, Superficial","['Vocal Cord; Injury, Superficial']","['hoarseness', 'sore throat', 'vocal cord injuries']",COMPLETED,,2010-08,2011-10,"[{'measure': 'incidence of vocal cord injuries', 'description': 'assessed by stroboscopy', 'timeFrame': '24h after surgery'}]","[{'measure': 'incidence of hoarseness', 'timeFrame': '24h after surgery'}]",2,18 Years,80 Years,ALL,False,University of Rostock,OTHER,0,65.0,ACTUAL,2025-09-01T16:18:15.900932,v2_robust,True,True,True,False,False,
NCT00744666,IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids,IntraVitreal Triamcinolone Acetonide: Preventing Raised Eye-pressure by Tracking Elevations After Topical Steroids,Prednisolone 1% topical eye drops,['Prednisolone 1% topical eye drops'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Vitreoretinal Disease,"['Vitreoretinal Disease', 'Ocular Hypertension']","['Intravitreal triamcinolone acetonide', 'Side-effects', 'Ocular hypertension', 'Glaucoma', 'Prevention', 'Vitreoretinal diseases requiring IVTA for treatment']",UNKNOWN,,2008-09,2010-07,"[{'measure': 'To detect a 60% or greater decrease of developing ocular hypertension (>20 mmHg) in the group of patients who received a trial of prednisolone 1% gtts x 4 weeks, compared the group who did not receive a trial of topical prednisolone.', 'timeFrame': 'Monthly for 6 months'}]","[{'measure': 'Visual Acuity', 'timeFrame': 'Monthly for 6 months'}, {'measure': 'Incidence of other complications (cataract, retinal detachment, endophthalmitis)', 'timeFrame': 'Monthly for 6 months'}]",3,18 Years,,ALL,False,Hotel Dieu Hospital,OTHER,1,70.0,ESTIMATED,2025-09-01T16:18:15.900941,v2_robust,True,True,False,False,False,
NCT06794866,A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants,"A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of OnabotulinumtoxinA Purified Neurotoxin Complex for the Treatment of Moderate to Severe Forehead Lines in Japan",OnabotulinumtoxinA,"['Placebo', 'OnabotulinumtoxinA']",2,INTERVENTIONAL,['PHASE3'],PHASE3,,Forehead Lines,['Forehead Lines'],"['Forehead Lines', 'OnabotulinumtoxinA', 'FHL Japan P3']",ACTIVE_NOT_RECRUITING,,2025-01-22,2026-04,"[{'measure': ""Percentage of Participants who Achieve 'None' or 'Mild' on Facial Wrinkle Scale with Asian Photonumeric Guide (FWS-A) According to the Investigator Assessment of Forehead Lines (FHL) Severity at Maximum Contraction"", 'description': 'The investigator assesses FHL severity using the FWS-A scale ranging from none to severe.', 'timeFrame': 'Day 30'}, {'measure': 'Number of Participants with Adverse Events (AEs)', 'description': 'Description: An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.', 'timeFrame': 'Up to approximately 12 months'}]","[{'measure': ""Percentage of Participants who Achieved 'None' or 'Mild' on FWS-A According to the Participant Assessment of FHL Severity"", 'description': 'The participant assesses FHL severity using the FWS-A scale ranging from none to severe.', 'timeFrame': 'Day 30'}, {'measure': 'Percentage of Participants who Achieved at least 1-Grade Improvement from Baseline on FWS-A According to the Investigator Assessment of FHL Severity at Maximum Contraction', 'description': 'The investigator assesses FHL severity using the FWS-A scale ranging from none to severe.', 'timeFrame': 'Day 30'}, {'measure': 'Percentage of Participants who Achieved at least 1-Grade Improvement from Baseline on FWS-A According to the Investigator Assessment of FHL Severity at Rest', 'description': 'For participants rated as at least mild at baseline, the investigator assesses FHL severity using the FWS-A scale ranging from none to severe.', 'timeFrame': 'Day 30'}, {'measure': ""Time to Return to at least 'Moderate' for the Participants who Achieve Investigator FWS-A ratings of 'None' or 'Mild' on FHL Severity at Maximum Contraction"", 'description': 'The investigator assesses FHL severity using the FWS-A scale ranging from none to severe.', 'timeFrame': 'Day 30'}, {'measure': ""Percentage of Participants with Responder Status of 'Very Satisfied' or 'Mostly Satisfied' on Satisfaction with Treatment on the Facial Line Satisfaction Questionnaire (FLSQ)"", 'description': 'The FLSQ assesses treatment satisfaction and psychosocial impact. Participants assessed their satisfaction with FHL using the FLSQ scale ranging from Very dissatisfied to Very satisfied.', 'timeFrame': 'Day 60'}, {'measure': ""Percentage of Participants with Responder Status of 'Very Satisfied' or 'Mostly Satisfied' on Satisfaction with Natural Look on the FLSQ"", 'description': 'The FLSQ assesses treatment satisfaction and psychosocial impact. Participants assessed their satisfaction with FHL using the FLSQ scale ranging from Very dissatisfied to Very satisfied.', 'timeFrame': 'Day 30'}, {'measure': ""Change from Baseline in the Participant's Rasch-Transformed Score of the SKIN-Q Scale"", 'description': 'The SKIN-Q Scale is a scale that measures the appearance of skin quality response option ranging from Very dissatisfied to Very satisfied.', 'timeFrame': 'Day 30'}, {'measure': ""Change from Baseline in the Participant's Rasch-Transformed Score of the FACE-Q Social Function Scale at the Final Visit"", 'description': 'The FACE-Q Psychological Function is a scale that measures psychological function with options ranging from definitely disagree to definitely agree.', 'timeFrame': 'Day 30'}]",10,18 Years,65 Years,ALL,False,AbbVie,INDUSTRY,0,150.0,ACTUAL,2025-09-01T16:18:15.900978,v2_robust,True,True,False,False,True,
NCT00693056,Efficacy Study of RX-10100 to Treat Erectile Dysfunction (ED),"A Double-Blinded, Randomized, Placebo-Controlled, Dose-Exploring Study of RX-10100 for Eight Weeks of On-Demand Administration in Subjects With Erectile Dysfunction (ED)",Placebo,"['RX-10100 10mg', 'RX-10100 5mg', 'RX-10100 15mg', 'Placebo', 'Zoraxel']",5,INTERVENTIONAL,['PHASE2'],PHASE2,,Erectile Dysfunction (ED),['Erectile Dysfunction (ED)'],"['Erectile Dysfunctions', 'ED']",COMPLETED,,2008-06,2009-05,"[{'measure': 'Scores on IIEF-EF Questionnaires and on SEP Questions II and III', 'timeFrame': 'Weeks 4 and 8'}]","[{'measure': 'Scores on other domains of IIEF, other questions on Subject Diaries, RigiScan measurement, and ED-QoL questionnaires', 'timeFrame': 'Weeks 4 and 8'}]",2,18 Years,65 Years,MALE,False,"Rexahn Pharmaceuticals, Inc.",INDUSTRY,0,40.0,ESTIMATED,2025-09-01T16:18:15.901027,v2_robust,True,True,True,False,False,
NCT00784056,Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid) - Photo Evaluation,Dermatological Evaluation of the Photo Irritation and Photo Sensitivity Potential for Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid),Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix),['Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Hygiene,['Hygiene'],[],COMPLETED,,2008-08,2008-09,"[{'measure': 'The photo irritation test and the photosensitivity will be measured using UVA irradiation and evaluated according International Contact Dermatitis Research Group (ICDRG) scale.', 'timeFrame': 'Throughout the study'}, {'measure': 'The sensibility will be evaluated according to the skin type.', 'timeFrame': 'Throughout the study'}]",[],2,18 Years,60 Years,FEMALE,True,Sanofi,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:15.901036,v2_robust,True,True,True,False,False,
NCT04617756,Safety & Efficacy of Durvalumab+Neoadjuvant Chemotherapy for High-risk Urothelial Carcinoma of the Upper Urinary Tract,"Safety & Efficacy of Neoadjuvant Immunotherapy With Durvalumab (MEDI 4736) Combined With Neoadjuvant Chemotherapy (Gemcitabine/Cisplatin or Gemcitabine/Carboplatin) in Patients With Operable, High-risk, Localized Urothelial Carcinoma of the Upper Urinary Tract",Patients receiving neoadjuvant therapy before radical nephrectomy,['Patients receiving neoadjuvant therapy before radical nephrectomy'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Urothelial Carcinoma,"['Urothelial Carcinoma', 'Cancer']","['Durvalumab', 'Gemcitabine', 'Cisplatin', 'Chemotherapy']",RECRUITING,,2021-09-29,2026-10-01,"[{'measure': 'Pathological complete response in Cohort 1', 'description': 'For Cohort 1 (patients on treatment combining Durvalumab and Gemcitabine associated with Cisplatin) the rate of patients with pathological complete response will be calculated and presented with associated 95% confidence interval on the subpopulation of patients with ureteroscopic biopsy at diagnosis.Pathological complete response is defined as no residual signs of viable tumor cells in tissue samples removed during surgery after treatment. To find out if there is a pathologic complete response, a pathologist will perform an evaluation of the tissue samples under a microscope to see if there are still cancer cells left after the treatment.', 'timeFrame': 'Week 14 - 18'}, {'measure': 'Pathological complete response in Cohort 2', 'description': 'For Cohort 2 (patients on treatment combining Durvalumab and Gemcitabine associated with Carboplatin) the rate of patients with pathological complete response will be calculated and presented with associated 95% confidence interval on the subpopulation of patients with ureteroscopic biopsy at diagnosis.Pathological complete response is defined as no residual signs of viable tumor cells in tissue samples removed during surgery after treatment. To find out if there is a pathologic complete response, a pathologist will perform an evaluation of the tissue samples under a microscope to see if there are still cancer cells left after the treatment.', 'timeFrame': 'Week 14 - 18'}]","[{'measure': 'Partial pathological response in Cohort 1', 'description': 'Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.', 'timeFrame': 'Week 3'}, {'measure': 'Partial pathological response in Cohort 2', 'description': 'Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.', 'timeFrame': 'Week 3'}, {'measure': 'Partial pathological response in Cohort 1', 'description': 'Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.', 'timeFrame': 'Week 6'}, {'measure': 'Partial pathological response in Cohort 2', 'description': 'Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.', 'timeFrame': 'Week 6'}, {'measure': 'Partial pathological response in Cohort 1', 'description': 'Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.', 'timeFrame': 'Week 9'}, {'measure': 'Partial pathological response in Cohort 2', 'description': 'Pathological partial response is defined as downstaging to neoadjuvant pathologic stage groups ≤ ypT1N0M0 (ypT0-Ta-Tis/T1 disease).The rate of patients with partial pathological response will be calculated on the subpopulation of patients with ureteroscopic biopsy at diagnosis.', 'timeFrame': 'Week 9'}, {'measure': 'Safety and tolerability of treatment - Cohort 1', 'description': 'The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).', 'timeFrame': 'Week 3'}, {'measure': 'Safety and tolerability of treatment - Cohort 2', 'description': 'The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).', 'timeFrame': 'Week 3'}, {'measure': 'Safety and tolerability of treatment - Cohort 1', 'description': 'The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).', 'timeFrame': 'Week 6'}, {'measure': 'Safety and tolerability of treatment - Cohort 2', 'description': 'The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).', 'timeFrame': 'Week 6'}, {'measure': 'Safety and tolerability of treatment - Cohort 1', 'description': 'The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).', 'timeFrame': 'Week 9'}, {'measure': 'Safety and tolerability of treatment - Cohort 2', 'description': 'The safety and tolerability of treatment will be assessed by analysing and interpreting Common Terminology Criteria for Adverse Event (CTCAE) until surgery using the National Cancer Institute, Division of Cancer Treatment and Diagnosis (DCTD) listing of CTCAE (NCI CTCAE V5.0).', 'timeFrame': 'Week 9'}, {'measure': 'Treatment success - Overall Survival in Cohort 1', 'description': 'The overall Survival rate of Cohort 1 patients will be collected.', 'timeFrame': '2 years after surgery.'}, {'measure': 'Treatment success - bladder recurrence and dissemination in Cohort 1', 'description': 'Bladder recurrence and dissemination in Cohort 1 patients will be collected.', 'timeFrame': '2 years after surgery.'}, {'measure': 'Treatment success - Overall Survival in Cohort 2', 'description': 'The overall Survival rate of Cohort 2 patients will be collected.', 'timeFrame': '2 years after surgery.'}, {'measure': 'Treatment success - bladder recurrence and dissemination in Cohort 2', 'description': 'Bladder recurrence and dissemination will be collected.', 'timeFrame': '2 years after surgery.'}, {'measure': 'Intercycle report : Blood cells & Platelets in Cohort 1', 'description': 'The numbers of each type of blood cell and platelets will be measured per McL', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Blood cells & Platelets in Cohort 2', 'description': 'The numbers of each type of blood cell and platelets will be measured per McL', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Electrolytes in Cohort 1', 'description': 'A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Electrolytes in Cohort 2', 'description': 'A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 1 - AST', 'description': '\\- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 1 - ALT', 'description': '\\- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 1 -GGT', 'description': '\\- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 1 - LDH', 'description': '\\- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 1 - ALP', 'description': '\\- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 1 - bilirubin', 'description': '\\- Hepatic workup: Bilirubin (free/conjugated) concentration will be measured il micromoles/L', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 2 - AST', 'description': '\\- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 2 - ALT', 'description': '\\- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 2 - GGT', 'description': '\\- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 2 - LDH', 'description': '\\- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 2 - ALP', 'description': '\\- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Liver in Cohort 2 - bilirubin', 'description': '\\- Hepatic workup: bilirubin (free/conjugated) concentration will be measured in micromoles/L.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Creatinine Phosphokinase in Cohort 1', 'description': 'Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Creatinine Phosphokinase in Cohort 2', 'description': 'Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Thyroid in Cohort 1', 'description': ""A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood."", 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Thyroid in Cohort 2', 'description': ""A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood."", 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Cortisol in Cohort 1', 'description': 'Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are :\n\n5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Cortisol in Cohort 2', 'description': 'Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are :\n\n5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : C-reactive protein in Cohort 1', 'description': 'C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : C-reactive protein in Cohort 2', 'description': 'C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Urine in Cohort 1', 'description': 'Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows:\n\n(Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report : Urine in Cohort 2', 'description': 'Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows:\n\n(Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report: N-BNP, troponin in Cohort 1', 'description': 'Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report: N-BNP, troponin in Cohort 2', 'description': 'Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.', 'timeFrame': 'Week 3'}, {'measure': 'Intercycle report: Blood cells & platelets in Cohort 1', 'description': 'The numbers of each type of blood cell and platelets will be measured per McL', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report: Blood cells & Platelets in Cohort 2', 'description': 'The numbers of each type of blood cell and platelets will be measured per McL', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report: Electrolytes in Cohort 1', 'description': 'A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Electrolytes in Cohort 2', 'description': 'A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 1 - AST', 'description': 'Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured in IU/L..', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 1 - ALT', 'description': 'Hepatic workup: Aminotransferase (ALT) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 1 - GGT', 'description': 'Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentrations will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 1 - LDH', 'description': 'Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 1 - ALP', 'description': 'Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 1 - bilirubin', 'description': 'Hepatic workup: Bilirubin (free/conjugated) concentration will be measured in micromoles/L', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 2 - AST', 'description': '\\- Hepatic workup: Aspartate Aminotransferase (AST) concentration will be measured.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 2 - ALT', 'description': '\\- Hepatic workup: Alanine Aminotransferase (ALT) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 2 - GGT', 'description': '\\- Hepatic workup: Gamma-Glutamyl Transferase (GGT) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 2 - LDH', 'description': '\\- Hepatic workup: Lactate Dehydrogenase (LDH) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 2 - ALP', 'description': '\\- Hepatic workup: Alkaline Phosphatase (ALP) concentration will be measured in IU/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Liver in Cohort 2 - bilirubin', 'description': '\\- Hepatic workup: Bilirubin (free/conjugated) concentration will be measured in micromoles/L.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Creatine Phosphokinase in Cohort 1', 'description': '\\- Creatine Phosphokinase will be measured in IU/L. Normal values are usually between 60 and 400 IU/L', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Creatine Phosphokinase in Cohort 2', 'description': '\\- Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Thyroid in Cohort 1', 'description': ""A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood."", 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Thyroid in Cohort 2', 'description': ""A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood."", 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Cortisol in Cohort 1', 'description': 'Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are :\n\n5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Cortisol in Cohort 2', 'description': 'Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are :\n\n5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : C-reactive protein in Cohort 1', 'description': 'C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : C-reactive protein in Cohort 2', 'description': 'C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Urine in Cohort 1', 'description': 'Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows:\n\n(Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : Urine in Cohort 2', 'description': '\\- Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows: (Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : N-BNP, troponin in Cohort 1', 'description': 'Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report : N-BNP, troponin in Cohort 2', 'description': 'Serum N-BNP and troponin concentrations will be measured.These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.', 'timeFrame': 'Week 6'}, {'measure': 'Intercycle report: Blood cells & Platelets in Cohort 1', 'description': 'The numbers of each type of blood cell and platelets will be measured per McL', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Blood cells & Platelets in Cohort 2', 'description': 'The numbers of each type of blood cell and platelets will be measured per McL', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Electrolytes in Cohort 1', 'description': 'A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Electrolytes in Cohort 2', 'description': 'A basic metabolic panel will be run to measure Na, K, Cl and Protein levels.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Liver in Cohort 1', 'description': '\\- Hepatic workup: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP) and bilirubin (free/conjugated) concentrations will all be measured.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Liver in Cohort 2', 'description': '\\- Hepatic workup: Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), Gamma-Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Alkaline Phosphatase (ALP) and bilirubin (free/conjugated) concentrations will all be measured.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Creatine Phosphokinase in Cohort 1', 'description': 'Creatine Phosphokinase Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Creatine Phosphokinase in Cohort 2', 'description': 'Creatine Phosphokinase will be measured in IU/L. usually between 60 and 400 IU/L', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Thyroid in Cohort 1', 'description': ""A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood."", 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Thyroid in Cohort 2', 'description': ""A thyroid stimulating test (total T4 test) will be made to measure the thyroxine concentration in the patient's blood."", 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Cortisol in Cohort 1', 'description': 'Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are :\n\n5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Cortisol in Cohort 2', 'description': 'Cortisol (serum) levels will be measured at 8 a.m. only (i.e. one cycle out of two) to check whether the adrenal glands are functioning correctly. Normal levels for adults in the morning are :\n\n5-25 mcg/dL (138-690 nmol/L) or 5-23 mcg/dL (138-635 nmol/L) for elderly patients.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: C-reactive protein in Cohort 1', 'description': 'C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: C-reactive protein in Cohort 2', 'description': 'C-reactive protein will be measured in mg/L. For a standard CRP test, a normal reading is less than 10 milligram per liter (mg/L).', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report : Urine in Cohort 1', 'description': 'Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows:\n\n(Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: Urine in Cohort 2', 'description': 'Urinary balance: via a cytobacteriological examination, the protein/creatinine ratio will be calculated as follows:\n\n(Urine protein(g/L) X 1000)/Urine creatinine(mmol/L)', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: N-BNP, troponin in Cohort 1', 'description': 'Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.', 'timeFrame': 'Week 9'}, {'measure': 'Intercycle report: N-BNP, troponin in Cohort 2', 'description': 'Serum N-BNP and troponin concentrations will be measured. These are biomarkers of heart failure. N-BNP is measured in pg/mL and troponin is measured in ng/mL.', 'timeFrame': 'Week 9'}]",92,18 Years,,ALL,False,Centre Hospitalier Universitaire de Nīmes,OTHER,9,50.0,ESTIMATED,2025-09-01T16:18:15.901100,v2_robust,True,True,False,False,True,
NCT00283556,High Dose Camptothecin-11 (CPT-11) in Recurrent Unresectable Malignant Glioma,"Phase I/II Study of High Dose Irinotecan (Camptosar, CPT-11) in Patients With Recurrent Unresectable Malignant Glioma on Steroids/Anti-epileptics","Irinotecan (Camptosar, CPT-11)","['Irinotecan (Camptosar, CPT-11)']",1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Malignant Glioma,['Malignant Glioma'],"['High Dose Irinotecan', 'CPT-11', 'Camptosar', 'Malignant Glioma', 'Unresectable']",COMPLETED,,2001-08,2008-12,"[{'measure': 'The purpose of this study is to compare the response to treatment and side effects associated with high dose irinotecan in patients with recurrent brain tumors.', 'timeFrame': '2008'}]",[],1,18 Years,,ALL,False,Kentuckiana Cancer Institute,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:15.901206,v2_robust,True,True,True,False,False,
NCT00204256,Intravenous Iron in Patients With Anemia of Chronic Kidney Disease,Open Randomized Phase IV Study on Intravenous Iron in Anemic Patients With Chronic Kidney Disease,Iron sucrose,['Iron sucrose'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,"Kidney Failure, Chronic","['Kidney Failure, Chronic']","['chronic kidney disease', 'anemia', 'intravenous iron', 'recombinant human erythropoetin']",UNKNOWN,,2004-03,2005-03,[{'measure': 'Change in hemoglobin from baseline to day 43'}],[{'measure': 'Change in ferritin and transferrin saturation from baseline to day 43; incidence and severity of adverse events'}],2,18 Years,,ALL,False,University Hospital Muenster,OTHER,0,50.0,,2025-09-01T16:18:15.901290,v2_robust,True,True,False,False,True,
NCT00582556,Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy,Phase II Trial of Zometa on Bone Mineral Density on Patients With Stage D Prostate Cancer Undergoing Androgen Ablation Therapy,Zometa,"['lupron', 'zoledronic acid', 'zolodex', 'zolodronic acid', 'Zometa', 'zometa']",6,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Cancer,['Prostate Cancer'],['bone mineral density'],COMPLETED,,2003-04,2013-03,"[{'measure': 'The Number of Subjects Who Had Either an Increase or Decrease on Bone Mineral Density of the Lumbar Spine and Femoral Neck in Men Undergoing Androgen Deprivation Therapy for Prostate Adenocarcinoma.', 'description': 'Effects on bone mineral density were measured at four locations at six month intervals for 24 months.', 'timeFrame': '2 years'}]","[{'measure': 'The Number of Subjects Who Had a Significant Increase of Peripheral Blood Markers of Bone Turnover.', 'description': 'Serum bone-specific alkaline phosphatase was collected as the blood marker of bone turnover.', 'timeFrame': '2 years'}, {'measure': 'Number of Subjects Had a Significant Change in Immune Markers.', 'description': 'Immune markers were measured by isolating gamma-delta T cells one month after treatment with zoledronic acid.', 'timeFrame': '2 Years'}, {'measure': 'Number of Subjects With Decreases in Prostate Specific Antigen (PSA) After Zoledronic Acid Prior to Beginning Androgen Deprivation Therapy', 'description': 'PSA response was measured by observing the serum PSA one week after beginning zoledronic acid and prior to beginning androgen deprivation therapy.\n\nArm 2 and Arm 3 were not able to be assessed for this endpoint as all subjects were on androgen deprivation prior to receiving zoledronic acid.', 'timeFrame': '2 Years'}]",4,18 Years,,MALE,False,"University of Wisconsin, Madison",OTHER,1,44.0,ACTUAL,2025-09-01T16:18:15.901301,v2_robust,True,True,True,False,False,
NCT01861522,The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis,"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)",Bepotastine besilate,"['TALION 5mg tablets', 'Bepotastine besilate', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Perennial Allergic Rhinitis,['Perennial Allergic Rhinitis'],"['TAU-284', 'Bepotastine besilate', 'Histamine H1 receptor antagonists', 'children']",COMPLETED,,2013-04,2013-12,"[{'measure': 'Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]', 'description': 'Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 5-point scale ranging from 0 (no symptoms) to 4 (very severe).', 'timeFrame': 'Baseline and Week 2'}]","[{'measure': 'Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]', 'timeFrame': 'baseline, Week1 and Week 2'}, {'measure': 'Change From Baseline in Individual Nasal Symptom Scores (Sneezing, Rhinorrhea, Nasal Congestion, and Impairment in Daily Activities)', 'timeFrame': 'baseline, Week1 and Week 2'}, {'measure': 'Change From Baseline in Individual Scores for Local Nasal Findings (Rhinoscopic Findings)', 'timeFrame': 'baseline, Week1 and Week 2'}, {'measure': 'Change From Baseline in Severity Score for Symptoms of Allergic Rhinitis', 'timeFrame': 'Randomization, Week1 and Week 2'}, {'measure': 'Adverse Events and Adverse Drug Reactions', 'timeFrame': 'Week 2'}]",6,7 Years,15 Years,ALL,False,Mitsubishi Tanabe Pharma Corporation,INDUSTRY,0,473.0,ACTUAL,2025-09-01T16:18:15.901357,v2_robust,True,True,True,False,True,
NCT01275222,Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors,"A Phase I-II, Open-label Study of RAD001 in Combination With Glivec®/Gleevec™ (Imatinib) in Patients With Glivec/Gleevec-refractory/Resistant Gastrointestinal Stromal Tumors.",RAD001,"['Imatinib 600mg/day (Glevec is the brand name for imatinib)', 'everolimus', 'Imatinib 800mg/day (Glevec is the brand name for imatinib)', 'STI571', 'RAD001']",5,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,Gastrointestinal Stromal Tumors,['Gastrointestinal Stromal Tumors'],"['RAD001', 'everolimusGIST', 'everolimus', 'mTOR', 'Imatinib resistant', 'Imatinib-refractory/resistant', 'gastrointestinal stromal tumors', 'Gastrointestinal Stromal Tumors(GIST)', 'soft tissue sarcoma', 'stomach tumor', 'tumor of interstitial cells of Cajal (ICC)', 'digestive system cancer']",COMPLETED,,2002-11-13,2008-09-03,"[{'measure': 'Number of Participants With Adverse Events (AEs): Phase I & II', 'description': 'Assessed safety and tolerability of the combination administration of RAD001 and imatinib when given to patients with imatinib-refractory gastro-intestinal stromal tumors (GIST) by number of participants with adverse events.', 'timeFrame': '4 - 8 weeks'}, {'measure': 'Best Overall Response (BOR) as Assessed by Overall Response (Complete Response (CR) & Partial Response (PR)) - Phase I & II', 'description': 'Assessed clinical efficacy of the combination regimen in this patient population per BOR by Overall response (CR + PR). Complete response: Disappearance of all target lesions; Partial response: ≥ 30% decrease in the sum of the longest diameter of target lesions compared to baseline (and not ≥20% increase compared to smallest sum).', 'timeFrame': '6 - 8 weeks'}, {'measure': 'Trough Concentrations for RAD001 and for Imatinib - Phase II', 'description': 'Assessed the pharmacokinetics (PK) of the combination administration of RAD001 and imatinib in this patient population.', 'timeFrame': 'Part II Daily regimen: Baseline, Days 8, 15 and thereafter approximately every two months starting at month 3 whenever possible'}, {'measure': 'Overall Survival (OS) - Phase I & II', 'description': 'Assessed clinical efficacy of the combination regimen in this patient population per Overall Survival (OS). Overall survival was defined as the time from date of start of treatment to date of death due to any cause. For patients still receiving study medication at the time of the analysis, survival was censored at the date of last examination. If a patient was not known to have died but was no longer continuing with study medication, survival was censored at the date of last contact.', 'timeFrame': 'about 60 months'}, {'measure': '4-Month Progression-free Survival (PFS) Rate - Phase II', 'description': 'Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. Per protocol (PP) population includes patients with no known overall lesion response during 4 months +/- 2 weeks, or who later had response of CR/PR/stable disease (SD). PP population excludes patients with no known response during 4 months + / -2 weeks and no subsequent CR/PR/SD.', 'timeFrame': 'about 4 months'}, {'measure': 'Progression-free Survival (PFS) - Phase II', 'description': 'Assessed clinical efficacy of the combination regimen in this patient population per Progression-free survival (PFS). Progression-free survival (PFS) was the time from date of start of treatment to the date of first documented progression or death due to any cause. If a patient had not progressed or died, progression-free survival was censored at the time of last adequate tumor assessment.\n\nAccording to the study protocol no tumor assessments were performed after discontinuation of treatment with study drug. Therefore, for all patients who discontinued treatment without a documented progression but died thereafter, death was considered as PFS event only if it occurred within the regular safety follow-up of 28 days after discontinuation. Otherwise, the PFS time was censored at the last adequate tumor assessment.', 'timeFrame': 'about 60 months'}]","[{'measure': 'mTOR Pathway Activity Before Treatment, and Inhibition of mTOR Pathway Activity During Treatment as a Predictive Factor of Response, as Shown by Molecular Pathological Examination of the Tumor.', 'description': 'assess mTOR pathway activity before treatment, and inhibition of mTOR pathway activity during treatment as a predictive factor of response, as shown by molecular pathological examination of the tumor.', 'timeFrame': 'about 60 months'}, {'measure': 'Relationship Between Drug-induced Changes in the Principal Molecular Marker of Intratumoral mTOR Activity and Changes in Other Molecular Markers of Tumoral Activity (e.g. Indicators of Pathway Activity, Cell Proliferation and Apoptosis).', 'description': 'assess the relationship between drug-induced changes in the principal molecular marker of intratumoral mTOR activity and changes in other molecular markers of tumoral activity (e.g. indicators of pathway activity, cell proliferation and apoptosis).', 'timeFrame': 'about 60 months'}, {'measure': 'Relationship Between Drug-induced Changes in Tumoral Metabolism, as Shown by Functional Imaging With 18F-fluorodeoxyglucose Positron Emission Tomography (FDC-PET), With Clinical Outcome and Changes in Molecular Pathology.', 'description': 'assess the relationship between drug-induced changes in tumoral metabolism, as shown by functional imaging with 18F-fluorodeoxyglucose positron emission tomography (FDC-PET), with clinical outcome and changes in molecular pathology.', 'timeFrame': 'about 60 months'}]",9,18 Years,,ALL,False,Novartis Pharmaceuticals,INDUSTRY,0,117.0,ACTUAL,2025-09-01T16:18:15.901389,v2_robust,True,True,True,False,True,
NCT06151522,90% Effective Dose of Phenylephrine Infusions Under Intensive and Standard Treatment,90% Effective Dose of Phenylephrine Infusions for Preventing Postspinal Anesthesia Hypotension Under Intensive and Standard Treatment During Cesarean Section,Alpha-Agonist,"['norepinephrine', 'α-adrenergic receptor agonist', 'Alpha-Agonist']",3,INTERVENTIONAL,['NA'],,,Adverse Effect,['Adverse Effect'],[],NOT_YET_RECRUITING,,2025-04-01,2025-06-30,"[{'measure': 'ED50 and ED90', 'description': 'The dose of prophylactic phenylephrine that would be effective in preventing postspinal anesthesia hypotension in 50% (effective dose, ED 50) and 90% (ED90) of patients', 'timeFrame': '1-15 minutes after spinal anesthesia'}]","[{'measure': 'The incidence of post-spinal anesthesia hypotension', 'description': 'Systolic blood pressure (SBP) \\< 80% of the baseline', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'The incidence of severe post-spinal anesthesia hypotension.', 'description': 'Systolic blood pressure (SBP) \\< 60% of the baseline.', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'The incidence of bradycardia.', 'description': 'Heart rate \\< 60 beats/min.', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'The incidence of nausea and vomiting.', 'description': 'Presence of nausea and vomiting in patients after spinal anesthesia', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'The incidence of hypertension.', 'description': 'Systolic blood pressure (SBP) \\>120% of the baseline.', 'timeFrame': '1-15 minutes after spinal anesthesia.'}, {'measure': 'pH', 'description': 'From umbilical arterial blood gases.', 'timeFrame': 'Immediately after delivery'}, {'measure': 'Base excess', 'description': 'From umbilical arterial blood gases.', 'timeFrame': 'Immediately after delivery'}, {'measure': 'Partial pressure of oxygen (PO2)', 'description': 'From umbilical arterial blood gases.', 'timeFrame': 'Immediately after delivery'}, {'measure': 'APGAR score', 'description': 'A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration; 0(Worst)-10(Best)', 'timeFrame': '1 min after delivery'}, {'measure': 'APGAR score', 'description': 'A= Appearance P=Pulse G=Grimace A=Attitude R=Respiration; 0(Worst)-10(Best)', 'timeFrame': '5 min after delivery'}]",11,18 Years,45 Years,FEMALE,False,General Hospital of Ningxia Medical University,OTHER,0,80.0,ESTIMATED,2025-09-01T16:18:15.901410,v2_robust,True,True,False,False,False,
NCT01949922,Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter,Treatment of Fecal Incontinence by Injection of Autologous Muscle Fibers Into the Anal Sphincter - a Pilot Study.,Analgesia,['Analgesia'],1,INTERVENTIONAL,['NA'],,,Fecal Incontinence,"['Fecal Incontinence', 'Anal Incontinence']","['regenerative medicine', 'fecal incontinence', 'muscle fiber injection']",UNKNOWN,,2013-04,2018-01,"[{'measure': 'Efficacy of the treatment using fecal incontinence score: Wexner score.', 'timeFrame': '1 year'}]","[{'measure': 'Safety', 'description': 'Number of adverse events, pain etc.', 'timeFrame': '1 year'}]",2,18 Years,90 Years,FEMALE,False,Herlev Hospital,OTHER,0,15.0,ESTIMATED,2025-09-01T16:18:15.901435,v2_robust,True,True,False,False,True,
NCT04808622,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in Enhancing Tissue Oxygen Levels in Healthy Volunteers,"Randomized, Double-blind, Placebo-controlled, Pharmacokinetic, Pharmacodynamic Study of Trans Sodium Crocetinate Utilizing Transcutaneous Oximetry Measurement in Healthy Volunteers",Trans-Sodium Crocetinate,"['0.9% Sodium Chloride (NaCl)', 'TSC', 'Placebo', 'Trans-Sodium Crocetinate']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Subjects,['Healthy Subjects'],['Transcutaneous oximetry'],COMPLETED,,2021-03-17,2021-03-25,"[{'measure': 'Determine the Dose-Response of TSC on tcpO2 Following a Single Administration of TSC in Subjects Breathing O2.', 'description': 'Summary Statistics of tcpO2 Levels (mmHg) Overall Measurements (Median of 4 Sensors) in Healthy Subjects', 'timeFrame': '0, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 minutes post-dose'}]",[],1,18 Years,50 Years,ALL,True,Diffusion Pharmaceuticals Inc,INDUSTRY,0,30.0,ACTUAL,2025-09-01T16:18:15.901443,v2_robust,True,True,True,False,False,
NCT06236022,The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus,The Effects of Sirolimus in Patients With Dilated Cardiomyopathy Infected With Kaposi Sarcoma-associated Virus,Sirolimus,['Sirolimus'],1,INTERVENTIONAL,['PHASE4'],PHASE4,,Dilated Cardiomyopathy,"['Dilated Cardiomyopathy', ""Kaposi's Sarcoma-Associated Herpesvirus Infection""]",[],RECRUITING,,2024-01-01,2028-12-31,"[{'measure': 'Cardiac mortality', 'description': 'Death from cardiovascular disease which includes coronary artery diseases, stroke, heart failure, hypertensive heart disease, rheumatic heart disease, cardiomyopathy, heart arrhythmia, congenital heart disease, valvular heart disease and carditis', 'timeFrame': 'up to 36 months'}, {'measure': 'Rate of heart transplantation', 'description': 'The rate of heart trans plantation on patients with DCM when other medical or surgical treatments have failed', 'timeFrame': 'up to 36 months'}]","[{'measure': 'Readmission rate for cardiovascular diseases', 'description': 'The readmission rate for cardiovascular diseases', 'timeFrame': 'up to 36 months'}, {'measure': 'Recurrence rate of heart failure', 'description': 'The recurrence rate of heart failure', 'timeFrame': 'up to 36 months'}, {'measure': 'All-cause mortality', 'description': 'Death from all diseases', 'timeFrame': 'up to 36 months'}, {'measure': 'KCCQ score', 'description': 'The score of patients measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ)', 'timeFrame': 'up to 36 months'}]",6,18 Years,70 Years,ALL,False,Tongji Hospital,OTHER,3,276.0,ESTIMATED,2025-09-01T16:18:15.901470,v2_robust,True,True,False,False,False,
NCT05311722,"Comparsion of IV Dexmedetomidine, Tramdol and Ketamine for Post Spinal Anesthesia Shivering.","Comparing the Efficacy of Intravenous Dexmedetomidine, Tramadol and Ketamine for Control of Post Spinal Shivering in Obstetric Patients Undergoing Lower Segment C-section",Dexmedetomidine,"['Ketamine', 'Tramadol', 'Dexmedetomidine']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Post-Surgical Complication,['Post-Surgical Complication'],[],UNKNOWN,,2022-04-30,2023-02-20,"[{'measure': 'Assessment of post spinal shivering by observing grades of shivering', 'description': 'Control of post spinal shivering dexmedetomidine, tramadol and ketamine for control of post spinal shivering.', 'timeFrame': '10 minutes'}]",[],1,18 Years,60 Years,FEMALE,True,Sheikh Zayed Medical College,OTHER_GOV,0,71.0,ESTIMATED,2025-09-01T16:18:15.901487,v2_robust,True,True,False,False,False,
NCT06022822,"Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial",A Phase II Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy,Placebo Administration,['Placebo Administration'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Prostate Adenocarcinoma,['Prostate Adenocarcinoma'],[],RECRUITING,,2024-09-12,2027-05-01,"[{'measure': 'Percent positive change in 8-OHdG', 'description': 'The primary endpoint will be analyzed using a linear regression model. Standard descriptive statistics, including mean, standard deviation, median and interquartile range for continuous variables, and frequency and percent for categorical variables, will be used to summarize baseline variables by treatment arm. Changes will be summarized similarly. Graphical techniques, including boxplots and histograms, will be used to examine the distribution and to assess assumptions made for the primary analysis.', 'timeFrame': 'Baseline up to radical prostatectomy (RP) after 3 to 6 weeks of therapy'}]","[{'measure': 'Changes in prostate tissue and plasma concentrations of urolithin A (Uro-A), urolithin sulfate and urolithin A glucuronide', 'description': 'Measured by change from baseline to end-of-study, in comparison to changes from baseline to end-of-study in a control group receiving a placebo (except tissue levels, which will be compared between arms using end-of-tissue only). Will be analyzed using the same approach as the analysis of the primary endpoint. Changes in plasma concentrations of Uro-A, urolithin sulfate and urolithin A glucuronide, from baseline to radical prostatectomy will be estimated and summarized using standard descriptive statistics.', 'timeFrame': 'Baseline up to 2 years'}, {'measure': 'Changes in expression of cell cycle genes', 'description': 'The ribonucleic sequencing will be used to compute a single z-score (i.e. one data point per patient) which will represent the composite expression of 31 cell-cycle genes.', 'timeFrame': 'Baseline up to RP after 3 to 6 weeks of therapy'}, {'measure': 'Changes in 8-OHdG expression', 'timeFrame': 'Baseline up to RP after 3 to 6 weeks of therapy'}]",4,18 Years,,MALE,False,National Cancer Institute (NCI),NIH,0,90.0,ESTIMATED,2025-09-01T16:18:15.901495,v2_robust,True,True,False,False,False,
NCT00518622,Study the Safety and Effectiveness of MK7009 in Hepatitis C Infected Patients (MK-7009-004)(COMPLETED),"A Phase Ib Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients",Comparator: MK7009,"['Comparator: MK7009', 'Comparator: Placebo', 'MK7009']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Hepatitis C,['Hepatitis C'],[],COMPLETED,,2007-07,2008-09,"[{'measure': 'Safety and Tolerability of MK7009', 'description': 'Number of participants who reported adverse experiences while on study medication as well as for 14 days after completion of study medication', 'timeFrame': '14 days after completion of study therapy'}, {'measure': 'Antiviral Activity of MK7009', 'description': 'Change from Baseline in Log10 IU/mL hepatitis C virus (HCV) ribonucleic acid (RNA) on Day 8', 'timeFrame': 'Baseline and Day 8'}]",[],2,18 Years,55 Years,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,40.0,ACTUAL,2025-09-01T16:18:15.901546,v2_robust,True,True,True,False,True,
NCT01260922,10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.,A Relative Bioavailability Study of 10 mg Donepezil Hydrochloride Orally Disintegrating Tablets Under Fasting Conditions.,Donepezil Hydrochloride,"['Donepezil Hydrochloride (generic name)', 'Aricept®', 'Donepezil Hydrochloride']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],"['Bioequivalence', 'Healthy Subjects']",COMPLETED,,2006-04,2006-05,"[{'measure': 'Cmax of Donepezil.', 'description': 'Bioequivalence based on Donepezil Cmax (maximum observed concentration of drug substance in plasma).', 'timeFrame': 'Blood samples collected over a 72 hour period.'}, {'measure': 'AUC0-t of Donepezil.', 'description': 'Bioequivalence based on Donepezil AUC0-t (area under the concentration-time curve from time zero to time of last measurable concentration).', 'timeFrame': 'Blood samples collected over a 72 hour period.'}]",[],2,18 Years,,ALL,True,Teva Pharmaceuticals USA,INDUSTRY,0,26.0,ACTUAL,2025-09-01T16:18:15.901566,v2_robust,True,True,True,False,False,
NCT01485822,A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution,A Multicenter Study of the Pigmentation in the Trabecular Meshwork After Two Years of Treatment With TRAVATAN 0.004% Ophthalmic Solution,Travoprost 0.004% ophthalmic solution,"['Travoprost 0.004% ophthalmic solution', 'TRAVATAN', 'TRAVATAN Z']",3,OBSERVATIONAL,[],,,Open-angle Glaucoma,['Open-angle Glaucoma'],"['Glaucoma', 'Travatan', 'Trabeculectomy']",TERMINATED,Study objectives met,2004-07,2012-02,"[{'measure': 'Melanin Granule Count', 'description': 'A trabecular meshwork tissue sample was collected by the investigator. The number of pigment granules was counted for three separate microscopic fields of view. Mean melanin granule count was calculated.', 'timeFrame': 'Day 1'}]",[],1,50 Years,,ALL,False,Alcon Research,INDUSTRY,0,88.0,ACTUAL,2025-09-01T16:18:15.901577,v2_robust,False,True,False,True,False,Study objectives met
NCT05918822,A Study of Maribavir Pediatric Formulation in Healthy Adult Participants,"A Phase 1, Open-Label, Randomized, Two-Part Study in Healthy Adult Participants to Evaluate the Relative Bioavailability of Maribavir Pediatric Formulation Compared to the Commercial Formulation, as Well as, Food Effect, and Rabeprazole Gastric Acid-Reducing Effect on the Pharmacokinetics of Single-Dose Maribavir Pediatric Formulation",Maribavir Commercial Tablet Formulation,"['Maribavir Commercial Tablet Formulation', 'Rabeprazole', 'Maribavir Pediatric Powder-for-oral Suspension Formulation', 'TAK-620']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Volunteers,['Healthy Volunteers'],[],COMPLETED,,2023-07-25,2023-09-01,"[{'measure': 'Parts 1 and 2: Maximum Observed Plasma Concentration (Cmax) of Maribavir', 'description': 'Cmax was defined as maximum observed concentration of maribavir in plasma.', 'timeFrame': 'Part 1 Day 1 and Part 2 Treatment D Day 1 and Treatment E Day 5: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours post-dose'}, {'measure': 'Parts 1 and 2: Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of Maribavir', 'description': 'AUClast was defined as the area under the concentration-time curve from time 0 to the time of the last quantifiable concentration of maribavir in plasma.', 'timeFrame': 'Part 1 Day 1 and Part 2 Treatment D Day 1 and Treatment E Day 5: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours post-dose'}, {'measure': 'Parts 1 and 2: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-infinity) of Maribavir', 'description': 'AUC0-infinity was defined as the area under the plasma concentration-time curve from time 0 to infinity of maribavir in plasma.', 'timeFrame': 'Part 1 Day 1 and Part 2 Treatment D Day 1 and Treatment E Day 5: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours post-dose'}]","[{'measure': 'Parts 1 and 2: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEs', 'description': 'A TEAE was defined as an adverse event (AE) that was starting or worsening at the time of or after the first dose of maribavir administered in the study. An serious adverse event (SAE) was defined as any untoward medical occurrence that at any dose resulted in death; was life threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent or significant disability/incapacity; was a congenital anomaly/birth defect; was an important medical event that satisfies any of the following: might require intervention to prevent items 1 through 5 above and might exposed the participant to danger, even though the event is not immediately life threatening or fatal or does not result in hospitalization. Any clinically significant changes in vital signs, electrocardiogram (ECG) values and clinical laboratory parameters were considered as TEAEs.', 'timeFrame': 'Parts 1 and 2: From start of study drug administration up to follow-up (Day 16)'}, {'measure': 'Number of Participants Based on Severity of TEAEs', 'description': 'Severity of TEAEs were determined by following criteria: Mild: An AE that was usually transient and might require only minimal treatment or therapeutic intervention. The event did not generally interfere with usual activities of daily living; Moderate: An AE that was usually alleviated with additional specific therapeutic intervention. The event interfered with usual activities of daily living, causing discomfort but possessed no significant or permanent risk of harm to the research participant; Severe: An AE that interrupted usual activities of daily living, or significantly affects clinical status, or might require intensive therapeutic intervention.', 'timeFrame': 'Parts 1 and 2: From start of study drug administration up to follow-up (Day 16)'}, {'measure': 'Number of Participants Based on Causality of TEAEs', 'description': 'The causality relationship of each AE to the study drug was assessed using the following categories: Related: An AE that followed a reasonable temporal sequence from administration of a drug (including the course after withdrawal of the drug), or for which a causal relationship was at least a reasonable possibility, that was, the relationship could not be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, might also be responsible; Not Related: An AE that did not follow a reasonable temporal sequence from administration of a drug and/or that could reasonably be explained by other factors, such as underlying diseases, complications, concomitant medications and concurrent treatments. Number of participants based on causality of TEAEs as assessed by the Investigator were reported.', 'timeFrame': 'Parts 1 and 2: From start of study drug administration up to follow-up (Day 16)'}]",6,18 Years,55 Years,ALL,True,Takeda,INDUSTRY,0,32.0,ACTUAL,2025-09-01T16:18:15.901587,v2_robust,True,True,True,False,True,
NCT04677322,TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET IN PATIENTS WITH HTA,OBSERVATIONAL STUDY TO ASSESS THE EFFECTIVENESS OF THE INTERVENTION OF THE LOW-SODIUM DIET THROUGH THE MONITORING OF SODIUM IN URINE IN PATIENTS WITH HIGH BLOOD PRESSURE IN THE PRIMARY CARE SETTING,Adult patients diagnosed and treated for high blood pressure,['Adult patients diagnosed and treated for high blood pressure'],1,OBSERVATIONAL,[],,,Arterial Hypertension,"['Arterial Hypertension', 'Sodium Urine', 'Primary Care Center', 'Diet Habit']",[],TERMINATED,the principal investigator withdraws from the project for personal reasons,2020-09-01,2022-09-01,"[{'measure': 'Systolic and diastolic TA values, the upper limit being 140 (systolic) and the lower range 90 (diastolic).', 'timeFrame': 'basal'}, {'measure': 'Systolic and diastolic TA values, the upper limit being 140 (systolic) and the lower range 90 (diastolic).', 'timeFrame': '6 months'}]","[{'measure': 'Sodium and potassium levels in 24-hour urine and isolated urine sample, with sodium limits of 20 mEq/L in a random urine sample and 40 to 220 mEq per day.', 'timeFrame': 'basal'}, {'measure': 'Sodium and potassium levels in 24-hour urine and isolated urine sample, with sodium limits of 20 mEq/L in a random urine sample and 40 to 220 mEq per day, after educational intervention.', 'timeFrame': '6 months'}, {'measure': 'To analyze the use of antihypertensive drugs USING morisk-green test, after educational intervention', 'timeFrame': '6 months'}, {'measure': 'To verify compliance with the hyposodium diet and pharmacological treatment through the use of EuroQol-5D questionnaires', 'timeFrame': '6 months'}]",6,40 Years,,ALL,False,Instituto de Investigación Marqués de Valdecilla,OTHER,0,2.0,ACTUAL,2025-09-01T16:18:15.901678,v2_robust,False,True,False,True,False,the principal investigator withdraws from the project for personal reasons
NCT01831622,Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder,Influence of Stimulant Medication on Brain Processes for Decision Making in Attention Deficit Hyperactivity Disorder,Ritalin,"['Sugar pill', 'Placebo', 'Methylphenidate', 'MPH', 'Ritalin']",5,INTERVENTIONAL,['PHASE4'],PHASE4,,Attention Deficit-Hyperactivity Disorder,['Attention Deficit-Hyperactivity Disorder'],"['Decision-Making', 'functional MRI', 'pharmacological MRI', 'Reinforcement Learning', 'Methylphenidate']",COMPLETED,,2013-06,2015-06,"[{'measure': 'Effect of ADHD medication on decision making', 'description': 'The study will both use standard statistical models on reaction time and accuracy data, but also use Bayesian Statistics and mathematical modelling.\n\nThe investigators expect higher Drift Diffusion Model drift rate in the controls and patients on medication, and slower drift rate for participants off medication.', 'timeFrame': 'by may 2015 (up to 3 years)'}]",[],1,18 Years,40 Years,ALL,True,Mats Fredriksen,OTHER,3,131.0,ACTUAL,2025-09-01T16:18:15.901693,v2_robust,True,True,True,False,False,
NCT00035022,Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas,Phase I-II Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive (High Grade) T-Cell Malignancies,BCX-1777,['BCX-1777'],1,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,"Leukemia, Lymphocytic","['Leukemia, Lymphocytic', 'Lymphoma']","['Leukemia, Lymphoma, T-Cell']",COMPLETED,,2001-08,2004-03,[],[],0,0 Years,,ALL,False,BioCryst Pharmaceuticals,INDUSTRY,0,71.0,,2025-09-01T16:18:15.901704,v2_robust,True,True,True,False,False,
NCT00243022,"Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme",Phase II Randomized Evaluation of 5-Lipoxygenase Inhibition by Herbal Complementary and Alternative Medicine Approach Compared to Control as an Adjuvant Therapy in Newly Diagnosed and Recurrent High-grade Gliomas,Boswellia serrata extract,['Boswellia serrata extract'],1,INTERVENTIONAL,['PHASE2'],PHASE2,,Brain and Central Nervous System Tumors,"['Brain and Central Nervous System Tumors', 'Cerebral Edema']","['cerebral edema', 'adult glioblastoma', 'adult giant cell glioblastoma', 'adult gliosarcoma', 'adult anaplastic astrocytoma', 'adult anaplastic oligodendroglioma']",TERMINATED,Slow accrual,2004-09,2011-03,"[{'measure': 'Change From Pooled Baseline in Peritumoral Brain Edema', 'description': 'The relative change from baseline will be assessed longitudinally, however, the main comparison of interest is the relative change at the 4-month evaluation. For each patient change = edema at follow up - baseline edema', 'timeFrame': 'at 2 months'}, {'measure': 'Change From Baseline in Peritumoral Brain Edema', 'description': 'The relative change from baseline will be assessed longitudinally, however, the main comparison of interest is the relative change at the 4-month evaluation.For each patient change = edema at follow up - baseline edema.', 'timeFrame': 'at 4 months'}, {'measure': 'Change From Baseline in Peritumoral Brain Edema', 'description': 'The relative change from baseline will be assessed longitudinally, however, the main comparison of interest is the relative change at the 4-month evaluation. For each patient change = edema at follow up - baseline edema.', 'timeFrame': 'at 6 months'}]","[{'measure': 'Quality of Life at 6 Months', 'description': 'Quality of life as assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items (EORTC QLQ-C30)', 'timeFrame': 'At 2, 4, 6, 12, and 24 months'}, {'measure': 'Time-to-tumor-progression: Percentage of Patients With Tumor Progression at 6 Months', 'description': 'Percentage of participants with tumor progression (\\>25% increase in tumor volume compared to time 0) will be measured from enrollment to documented progression or death whichever comes first. The method used to calculate the time to tumor progression was Kaplan Meier test method to define the 95% confidence levels.', 'timeFrame': '6 months'}, {'measure': 'Time-to-tumor-progression: Percentage of Patients With Tumor Progression at 1 Year', 'description': 'Percentage of participants with tumor progression (\\>25% increase in tumor volume compared to time 0) will be measured from enrollment to documented progression or death whichever comes first. The method used to calculate the time to tumor progression was Kaplan Meier test method to define the 95% confidence levels.', 'timeFrame': '1 year'}, {'measure': 'Overall Survival: Percentage of Patients That Were Alive at 1 Year', 'description': 'Overall survival will be measured from the date of enrollment to date of death or last contact. Survival will be evaluated by the Kaplan Meier method to evaluate the median survival and 1 year survival rates.', 'timeFrame': '1 year.'}]",7,18 Years,,ALL,False,Ali Altunkaya,OTHER,1,12.0,ACTUAL,2025-09-01T16:18:15.901725,v2_robust,True,True,False,True,False,Slow accrual
NCT00885651,Ability of Metoprolol to Alter the Exercise Induced Elevation of Catecholamines,"A Randomised, Double Blinded, Crossover Study of the Influence of Metoprolol on Exercise Induced Elevation of Catecholamines in Healthy Subjects.",Metoprolole (Selo-Zok ®),"['Metoprolole (Selo-Zok ®)', 'Placebo']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Heart Failure,['Heart Failure'],"['SNP', 'catecholamines', 'metoprolole', 'healthy subjects', 'physiological stress']",UNKNOWN,,2008-09,2009-12,"[{'measure': 'Changes in stress-triggered response of catecholamines.', 'timeFrame': '2 weeks and 3 days'}]","[{'measure': 'Change in stress-triggered blood pressure response.', 'timeFrame': '2 weeks and 3 days'}, {'measure': 'Change in stress-triggered pulse response.', 'timeFrame': '2 weeks and 3 days'}]",3,18 Years,30 Years,MALE,True,"Rigshospitalet, Denmark",OTHER,1,30.0,ESTIMATED,2025-09-01T16:18:15.901752,v2_robust,True,True,False,False,False,
NCT00467051,Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors,"Treatment of Recurrent or Resistant Pediatric Malignant Germ Cell Tumors With Paclitaxel, Ifosfamide and Carboplatin",Carboplatin,"['Tronoxal', 'Blastocarb', 'Iphosphamide', 'Taxol Konzentrat', 'Seromida', 'Naxamide', 'Paraplatin', 'Holoxane', 'Carboplatino', 'Paraplatine', 'Iphosphamid', 'Z 4942', 'Ribocarbo', 'IFO-Cell', 'Ifolem', 'Isophosphamide', 'IFX', 'Ercar', 'Bristaxol', 'Paclitaxel', 'Novoplatinum', 'Carbotec', 'Carboplat', 'Asotax', 'Carboplatin', 'Asta Z-4942', 'Cyfos', 'Carbosol', 'Ifex', 'Carbosin', 'Holoxan', 'Z-4942', 'Taxol', 'Ifomide', 'Anzatax', 'Ifosfamidum', 'Platinwas', 'Isoendoxan', 'MJF-9325', 'Nealorin', 'Displata', 'Iso-Endoxan', 'CBDCA', 'Ifoxan', 'MJF 9325', 'Praxel', 'Ifosfamide', 'JM-8', 'Ifomida', 'Asta Z 4942', 'Paraplatin AQ', 'Carboplatin Hexal', 'Mitoxana', 'IFO']",54,INTERVENTIONAL,['PHASE2'],PHASE2,,Childhood Extracranial Germ Cell Tumor,"['Childhood Extracranial Germ Cell Tumor', 'Childhood Extragonadal Malignant Germ Cell Tumor', 'Childhood Malignant Ovarian Germ Cell Tumor', 'Childhood Malignant Testicular Germ Cell Tumor', 'Ovarian Choriocarcinoma', 'Ovarian Embryonal Carcinoma', 'Ovarian Yolk Sac Tumor', 'Recurrent Childhood Malignant Germ Cell Tumor', 'Recurrent Malignant Testicular Germ Cell Tumor', 'Recurrent Ovarian Germ Cell Tumor', 'Testicular Choriocarcinoma', 'Testicular Embryonal Carcinoma', 'Testicular Mixed Choriocarcinoma and Embryonal Carcinoma', 'Testicular Mixed Choriocarcinoma and Yolk Sac Tumor', 'Testicular Mixed Embryonal Carcinoma and Yolk Sac Tumor', 'Testicular Yolk Sac Tumor']",[],COMPLETED,,2007-11-05,2018-06-30,"[{'measure': 'Response Rate as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Criteria', 'description': 'Patients who demonstrate a PR or CR, as defined below, will be considered as responders. RECIST criteria: CR (complete response) = disappearance of all target lesions, PR (partial response) = 30% decrease in the sum of the longest diameter of target lesions, PD (progressive disease) = 20% increase in the sum of the longest diameter of target lesions and SD (stable disease) = small changes that do not meet above criteria.', 'timeFrame': 'At baseline (day 1) and after completion of protocol therapy (2 cycles or 42 days)'}]","[{'measure': 'The Number of Patients Who Experience at Least One Grade 3 or Higher CTC Version 4 Toxicity.', 'timeFrame': 'Two cycles of chemotherapy; expected to be 42 days of treatment.'}]",2,,21 Years,ALL,False,Children's Oncology Group,NETWORK,1,20.0,ACTUAL,2025-09-01T16:18:15.901862,v2_robust,True,True,True,False,False,
NCT00138151,"Isotretinoin, Interferon Alpha-2b, and Paclitaxel in Stage IV, Recurrent, or Persistent Cervical Cancer","A Phase II Trial of Chemosensitization With Paclitaxel, 13-cis Retinoic Acid and Interferon Alpha-2b in Advanced Uterine Cervical Carcinoma",isotretinoin,"['paclitaxel', 'isotretinoin']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Cervical Cancer,['Cervical Cancer'],"['recurrent cervical cancer', 'stage IVB cervical cancer']",TERMINATED,Slow accrual and lack of study drug,2001-03,2010-11,"[{'measure': 'Response Rate (Complete and Partial)', 'description': 'All patients who receive at least 3 courses of protocol therapy will be considered evaluable for response of measurable disease.', 'timeFrame': '8 years'}]","[{'measure': 'The Effect of the Regimen on Bcl-2 Family Proteins in Biopsy Specimens and Correlation With Peripheral Blood Mononuclear Cell Bcl-2 Levels.', 'timeFrame': '8 years'}, {'measure': 'The Effect of the Regimen on Raf-1 Kinase Phosphorylation in Biopsy Specimens.', 'timeFrame': '8 years'}]",3,18 Years,,FEMALE,False,University of Medicine and Dentistry of New Jersey,OTHER,1,33.0,ACTUAL,2025-09-01T16:18:15.901876,v2_robust,True,True,False,True,False,Slow accrual and lack of study drug
NCT05331651,Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting,Effect of Glycopyrronium in Combination With Tropisetron in Anti-postoperative Nausea and Vomiting,Glycopyrronium in Combination With Tropisetron,"['Glycopyrronium in Combination With Tropisetron', 'Normal Saline in Combination With Tropisetron']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,Postoperative Nausea and Vomiting,['Postoperative Nausea and Vomiting'],[],COMPLETED,,2022-04-21,2023-06-30,"[{'measure': 'incidence of postoperative nausea and vomiting', 'description': 'postoperative nausea and vomiting is recorded according to follow-up visits after surgery', 'timeFrame': 'from the ending of surgery to 24 hours after surgery'}]","[{'measure': 'intensity of postoperative nausea', 'description': 'intensity of postoperative nausea is assessed using Numeric Rating Scale (0-10, 0 represents no uncomfortable felling, 10 represents tolerableness)', 'timeFrame': 'from the ending of surgery to 24 hours after surgery'}, {'measure': 'incidence of postoperative vomiting', 'description': 'postoperative vomiting is recorded according to follow-up visits after surgery', 'timeFrame': 'from the ending of surgery to 24 hours after surgery'}, {'measure': 'incidence of intervention requirement for nausea and vomiting', 'description': 'this event is recorded according to follow-up visits after surgery', 'timeFrame': 'from the ending of surgery to 24 hours after surgery'}]",4,18 Years,70 Years,ALL,False,The Second Affiliated Hospital of Chongqing Medical University,OTHER,21,480.0,ACTUAL,2025-09-01T16:18:15.901950,v2_robust,True,True,True,False,False,
NCT01049451,Pulse ACTH vs. MP for MS,"Comparison of Monthly Pulse ACTH (Acthar Gel) Therapy With Methylprednisolone (MP, Solumedrol) for Long-Term Treatment of Multiple Sclerosis (MS) as an Add on Therapy to Beta-interferons (Avonex, Betaseron or Rebif)",ACTH,"['Solumedrol', 'ACTH', 'Acthar Gel', 'Methylprednisolone']",4,INTERVENTIONAL,['PHASE1'],PHASE1,,Multiple Sclerosis,['Multiple Sclerosis'],"['Multiple Sclerosis', 'ACTH', 'Steroids']",COMPLETED,,2009-11,2013-07,"[{'measure': 'Annualized Relapse Rate', 'timeFrame': '15 months study: 12 months treatment and 3 months follow up'}]","[{'measure': 'Multiple Sclerosis Functional Composite (MSFC), Expanded Disability Status Scale score (EDSS) and Multiple Sclerosis Quality of Life (MSQOL), peripheral blood lymphocytes measure for regulatory immune activities.', 'timeFrame': '15 months: 12 months treatmen and 3 months follow up'}]",2,18 Years,65 Years,ALL,False,University of Southern California,OTHER,0,23.0,ACTUAL,2025-09-01T16:18:15.902007,v2_robust,True,True,True,False,False,
NCT01286051,Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles,Efficacy of Single Dose Ganirelix in Gonadotropin Ovulation Induction Cycles,Follistim administration,"['Follistim plus Ganirelix', 'ganirelix', 'Follistim', 'Follistim administration']",4,INTERVENTIONAL,['NA'],,,Compare Pregnancy Rates Between FSH Stimulation and FSH and,"['Compare Pregnancy Rates Between FSH Stimulation and FSH and', 'GnRH Antagonist']","['ovulation induction, GnRH']",COMPLETED,,2011-01,2012-09,"[{'measure': 'Pregnancy rates', 'description': 'Follicle stimulating hormone (FSH) and IUI', 'timeFrame': 'One cycle of controlled ovarian stimulation (one month)'}]","[{'measure': 'Premature leuteinizing hormone (LH) surge and ovulation', 'description': 'pregnancy rate in one cycle of FSH and single injection of GnRH antagonist', 'timeFrame': 'One cycle of controlled ovarian stimulation (one month)'}]",2,18 Years,39 Years,FEMALE,True,Houston Fertility Institute,OTHER,0,80.0,ACTUAL,2025-09-01T16:18:15.902030,v2_robust,True,True,True,False,False,
NCT06996951,Sinonasal Therapies and Histologic Correlations of Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy,Sinonasal Therapies and Histologic Correlations for Patients With Cystic Fibrosis in the Era of Highly Effective Modulator Therapy,STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID,['STOP NASAL SALINE IRRIGATION WITH OR WITHOUT STEROID'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Cystic Fibrosis (CF),"['Cystic Fibrosis (CF)', 'Chronic Rhinosinusitis (CRS)']",[],NOT_YET_RECRUITING,,2025-06-16,2026-07,"[{'measure': 'SINONASAL OUTCOME TEST 22 QUESTIONNAIRE', 'description': 'THIS IS A SINONASAL QUALITY OF LIFE SURVEY, a higher score indicated worse sinus symptoms', 'timeFrame': '12 weeks'}, {'measure': 'PULMONARY FUNCTION TEST', 'description': 'PULMONARY FUNCTION TESTING WILL BE PERFORMED WITH THE FEV1/FVC , CALCULATED. A lower score means poorer lung function.', 'timeFrame': '12 weeks'}, {'measure': 'Health Care Utilization', 'description': 'Need for additional doctor visits, antibiotics, oral steroids', 'timeFrame': '12 weeks'}, {'measure': 'Nasal endoscopy', 'description': 'NASAL ENDOSCOPY WILL BE PERFORMED IN THE CLINIC TO EVALUATE THE SINONASAL CAVITIES USING THE LUND KENNEDY SCORING SYSTEM. A higher score means more sinonasal inflammatory changes seen.', 'timeFrame': '12 weeks'}]","[{'measure': 'Leukosorb test strips of nasal mucous', 'description': 'A small strip of Leukosorb paper will be placed in the nostril to collect nasal mucous and test for inflammatory markers including IL-4, IL-6, IL-8, TNF-alpha, IL-1B, Neutrophil elastase levels', 'timeFrame': '12 weeks'}]",5,18 Years,,ALL,False,Indiana University,OTHER,1,64.0,ESTIMATED,2025-09-01T16:18:15.902040,v2_robust,True,True,False,False,False,
NCT01691651,Botulinum Toxin A for the Treatment of Keratoconus,Botulinum Toxin Type A for Keratoconus,Botulinum Toxin Type A,"['Botulinum Toxin Type A', 'Botox (Allergan)']",2,INTERVENTIONAL,['NA'],,,Keratoconus,['Keratoconus'],"['Keratoconus', 'Tetanus toxin']",COMPLETED,,2012-09,2014-10,"[{'measure': 'Measurement of the palpebral fissure', 'description': 'We will evaluate the change in palpebral fissure (unit of measure=millimetre)by 18 months.These time points will be included:baseline, 3, 6, 12 and 18 months.', 'timeFrame': 'Eighteen months.'}]","[{'measure': 'Corneal topography', 'description': 'We will evaluate corneal topography \\[flattest keratometry, steepest keratometry and average keratometry(unit of measure=diopters)\\]by 18 months.These time points will be included:baseline, 3, 6,12 and 18 months.', 'timeFrame': 'Eighteen months.'}]",2,10 Years,40 Years,ALL,False,Federal University of São Paulo,OTHER,0,40.0,ACTUAL,2025-09-01T16:18:15.902056,v2_robust,True,True,True,False,False,
NCT01813929,Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes,Effect of Metformin on Vascular and Mitochondrial Function in Type 1 Diabetes,Metformin,"['glucophage', 'Placebo', 'Metformin']",3,INTERVENTIONAL,['PHASE4'],PHASE4,,Type 1 Diabetes,['Type 1 Diabetes'],"['Diabetes', 'Insulin', 'Metformin', 'Vascular', 'Vessels', 'Type 1']",COMPLETED,,2011-06,2017-03-24,"[{'measure': 'Insulin Sensitivity by Hyperinsulinemic Euglycemic Clamp', 'description': 'Determine the effect of metformin on insulin sensitivity in T1D. Reported measure is glucose infusion rate during hyperinsulinemic euglycemic clamp normalized to total body weight. For this measure, insulin was infused at 40 mU/m2 surface area. Blood sugar wass checked every 5 minutes and glucose infusion adjusted to maintain glucose level at 90 mg/dL for 2 hours. The glucose infusion rate for the final 30 minutes is reported as GIR (aka M-value or glucose disposal rate) in mg glucose/kg\\*min. A higher value corresponds to greater sensitivity to insulin. There is no strictly defined normal range.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Flow-mediated Brachial Artery Dilation', 'description': 'Measure of endothelial function by brachial ultrasound of the percent dilation after 5 minutes of occlusion.', 'timeFrame': 'End of each 6 week intervention period'}]","[{'measure': 'Arterial Stiffness by PWV', 'description': 'Pulse wave velocity by Sphygmacor as a measure of aortic stiffness in m/sec.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Arterial Stiffness by AI@75', 'description': 'Augmentation index by Sphygmacor is a measure of aortic arterial stiffness. AI@75 is the ratio of augmented pressure/pulse pressure adjusted to a heart rate of 75.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Mitochondrial Measures: Oxygen Consumption', 'description': 'Oxygen consumption rate with various substrates and max uncoupled O2 consumption.\n\nMeasure is performed on permeabilized muscle fibers from biopsy tissue from the vastus lateralis using the Oroboros OxygraphO2k high resolution respirometer. State 3 is full coupled oxygen flux using PMG or PMGS (pyruvate, malate, glutamate, +/- succinate) or OCMS (octanyl carnitine, malate, +/- succinate) as substrates. state 4 is after addition of oligomycin to inhibit the ATP synthase and thus corresponds to the maximum leak state where O2 consumption is limited by the buildup of the proton gradient and can only proceed as fast as the protons can leak back across the membrane. FCCP is added as an uncoupler, allowing free leakage of protons across the inner membrane, and thus measures maximum possible O2 flux. There are no defined normal ranges, but higher state 3 and uncoupled flux indicate better mitochondrial function, while state 4 is needed to correct state 3 to the fully coupled flux.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Mitochondrial Measures: Protein Expression Levels of Electron Transport Chain Complexes', 'description': 'Mito content by Western Blotting of electron transport chain complexes I, II, III, and V. complex 1 utilizes NADH from pyruvate/malate/glutamate while complex II utilizes FADH from succinate. complex III is the cytochrome c reductase while complex V is the ATP synthase.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Inflammatory Marker: hsCRP', 'description': 'hsCRP (mg/L) by Beckman Coulter assay', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Heart Rate Variability', 'description': 'measure of autonomic function: ratio of fastest to slowest heart rate during valsalva maneuver', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Continuous Glucose Monitor Measures of Mean Glucose', 'description': 'Mean Glucose \\& Glucose Standard Deviation (Glycemic Variability) by Dexcom CGM', 'timeFrame': 'Last Week of each 6 Week Intervention Period (over 7 days)'}, {'measure': 'Continuous Glucose Monitor Measures of Hypoglycemia', 'description': 'Percent of time less than 70 mg/dL during the final week of each phase by Dexcom CGM.', 'timeFrame': 'Last Week of each 6 Week Intervention Period (over 7 days)'}, {'measure': 'Metabolic Markers: Glucagon', 'description': 'Glucagon (pg/ml); baseline on AM of each phase final study visit.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Metabolic Markers: Glucose, Triglycerides, Cholesterol', 'description': 'Glucose (mg/dL), triglycerides (mg/dL), cholesterol (mg/dL) at baseline after each phase', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Metabolic Markers: Fatty Acids', 'description': 'fatty acids (microeq/L) at baseline after each phase in the AM of the final visit', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Metabolic Markers: Glycerol', 'description': 'glycerol (micromol/L) at baseline after each phase in the AM of the final phase visit', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Metabolic Markers: Insulin', 'description': 'insulin (microIU/ml) at baseline after each phase in the AM of the final phase visit', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Metabolic Markers: Lactate', 'description': 'lactate (mmol/L) at baseline after each phase in the AM of the final phase visit', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Metabolic Markers: Adiponection', 'description': 'adiponection (microg/ml) at baseline after each phase in the AM of the final phase visit', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Vascular Markers: Endothelin-1 (pg/ml)', 'description': 'endothelin-1 at baseline after each phase in the AM of the final phase visit by peninsula labs radioimmunoassay', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'In Vivo Mitochondrial Function: Ratio of the Amount of ATP Generated Per Unit of Oxygen Consumed', 'description': 'Measured by 31P-mass spec. This ratio measures mitochondrial efficiency. The higher the ratio, the more efficiently the individual converts metabolic substrates into ATP, with the ATP then available for energy-demanding cellular processes such as protein synthesis and biomass production', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'In Vivo Mitochondrial Function: Time Constants', 'description': 'Measured by 31P-mass spec. ADP time constant and phosphocreatine time constant. ADP time constant is a measure of the time required to convert ADP → ATP and is a measure of muscle mitochondrial health (energy metabolism). A faster recovery is a better outcome; a slower recovery is a worse outcome. Similarly for phosphocreatine.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'In Vivo Mitochondrial Function: QMax, VPCr', 'description': 'Measured by 31P-mass spec. For each measure, a higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted.\n\n* QMax is theoretical maximum activity.\n* VPCr measures the rate at which PCr is regenerated.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'In Vivo Mitochondrial Function: Oxidative Phosphorylation', 'description': 'Measured by 31P-mass spec. A higher value indicates better mitochondrial function. All re calculated from multiple measures from the MRS spectra. These are relatively new research measures and normal values are not known or generally accepted. Oxidative Phosphorylation measures the rate at which electron transport activity generates phosphorylated energy sources (ATP and PCr)', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'In Vivo Mitochondrial Function:AnGly', 'description': 'Measured by 31P-mass spec. Anaerobic glycolysis measures the amount of anaerobic ATP generation for energy. It is generally felt that a higher value here reflects impaired mitochondrial function necessitating greater reliance on anaerobic metabolism.', 'timeFrame': 'End of each 6 week intervention period'}, {'measure': 'Cardiac Function', 'description': 'Cardiac output', 'timeFrame': 'End of each 6 week intervention period'}]",24,25 Years,59 Years,ALL,False,"University of Colorado, Denver",OTHER,1,23.0,ACTUAL,2025-09-01T16:18:15.902067,v2_robust,True,True,True,False,False,
NCT01313429,"Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum","Adjuvant Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Sarcomas, Melanomas, Germ Cell Tumors, or Epithelial Malignancies Metastatic to Lungs, Pleura, or Mediastinum",Cyclophosphamide,"['Celecoxib', 'Cyclophosphamide']",2,INTERVENTIONAL,['PHASE1'],PHASE1,,Sarcoma,"['Sarcoma', 'Melanoma', 'Epithelial Malignancies', 'Pleural Malignancies']","['Metastatic Cancer', 'Cancer Vaccine', 'Immunotherapy', 'Adjuvant Therapy', 'Chest Metastases', 'Cancer', 'Melanoma', 'Lung Cancer', 'Sarcoma']",TERMINATED,"Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none developed a response, the protocol would stop accrual.",2011-03-04,2020-02-26,"[{'measure': 'Summary of adverse events', 'description': 'List of adverse event frequency', 'timeFrame': '30 days after last vaccine (up to 13 months)'}]","[{'measure': 'Number and description of immunologic responses to a panel of CT antigens in vaccinated patients', 'description': 'Number and description of immunologic responses to a panel of CT antigens in vaccinated patients', 'timeFrame': 'After last vaccine'}, {'measure': 'Paired t test analysis of difference between number and percentage of T reg cells at baseline and at treatment conclusion', 'description': 'Assessment of T regs in peripheral blood before and after initiation of CP/celecoxib treatment', 'timeFrame': 'After last vaccine'}]",3,18 Years,99 Years,ALL,False,National Cancer Institute (NCI),NIH,0,19.0,ACTUAL,2025-09-01T16:18:15.902157,v2_robust,True,True,False,True,True,"Per stopping rule if 12 patients underwent immune response analysis after 6 vaccinations and none developed a response, the protocol would stop accrual."
NCT00317629,Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis,"Double Blind, Randomized Controlled Trial, to Evaluate the Effectiveness of a Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis",controlled nitric oxide releasing patch,"['meglumine antimoniate', 'glucantime', 'controlled nitric oxide releasing patch']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Cutaneous Leishmaniasis,['Cutaneous Leishmaniasis'],"['leishmaniasis', 'nitric oxide', 'treatment', 'donor', 'controlled trial']",TERMINATED,An interim analysis showed that nitric oxide patches are not enough effective,2006-05,2009-03,"[{'measure': 'Complete reepithelization', 'timeFrame': 'three months after the beginning of the treatment'}]","[{'measure': 'Absence of reactivation and affections of the mucous membranes', 'timeFrame': 'during the first 6 months of the study'}]",2,18 Years,50 Years,ALL,False,Fundación Cardiovascular de Colombia,OTHER,5,178.0,ACTUAL,2025-09-01T16:18:15.902175,v2_robust,True,True,False,True,False,An interim analysis showed that nitric oxide patches are not enough effective
NCT04681729,Dupilumab for the Treatment of Chronic Inducible Cold Urticaria in Patients Who Remain Symptomatic Despite the Use of H1-antihistamine (LIBERTY-CINDU CUrIADS),"A Randomized, Double-blind, Placebo-controlled, Multi-center, Parallel-group Study of Dupilumab in Patients With Chronic Inducible Cold Urticaria Who Remain Symptomatic Despite the Use of H1-antihistamine Treatment",Dupilumab SAR231893,"['Non sedating H1-antihistamine', 'Dupilumab SAR231893', 'Placebo']",3,INTERVENTIONAL,['PHASE3'],PHASE3,,Cold Urticaria,['Cold Urticaria'],[],COMPLETED,,2020-12-10,2023-04-20,"[{'measure': 'Percentage of Participants With Negative Ice Cube Provocation Test at Week 24', 'description': 'The ice cube provocation test is the most frequently used provocation method for cold urticaria (ColdU). A negative ice cube provocation test was defined as the absence of confluent hives/wheal at the entire skin site of exposure after ice cube provocation test. Ice cube was applied on forearm skin for 5 minutes. Provocation test reading time was 10 minutes after removal of ice cube.', 'timeFrame': 'Week 24'}]","[{'measure': 'Change From Baseline in Urticaria Control Test (UCT) Scale Scores at Week 24', 'description': 'UCT is validated patient reported outcome (PRO) questionnaire used for assessing urticaria control. UCT has been developed and validated with participants Chronic Spontaneous Urticaria (CSU) and Chronic inducible urticaria (CIndU). It comprised of 4 items: severity of physical symptoms of urticaria (itch, hives and/or swelling); quality of life (QoL) impairment; frequency of treatment being not sufficient to control urticaria; overall urticarial control. Each item was rated on a 5-point Likert scale ranged from 0 (high disease activity) to 4 (low disease activity). The UCT total score was calculated as sum of all 4 individual item scores,ranged from 0 to 16. Higher scores indicated low disease activity, complete disease control, and vice-versa. Least square (LS) mean and standard error (SE) were analyzed using Analysis of covariance (ANCOVA) model with corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes or No) as covariates.', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Percentage of Participants With Urticaria Control Test Score >=12 at Week 24', 'description': 'The UCT is a validated PRO questionnaire used for assessing urticaria control. The questionnaire has been developed and validated with participants with CSU and CIndU. It comprised of 4 items: severity of physical symptoms of urticaria (itch, hives and/or swelling); QoL impairment; frequency of treatment being not sufficient to control urticaria; overall urticarial control. Each item was rated on a 5-point Likert scale ranging from 0 to 4, with low score indicating high disease activity and low disease control, and vice-versa. The UCT total score was calculated as sum of all 4 individual item scores, which ranged from 0 to 16. Higher scores indicated low disease activity and complete disease control, and vice-versa. A score of \\>=12 on the scale indicates well-controlled urticaria. Percentage of participants with UCT score \\>=12 (i.e., well controlled urticaria) at Week 24 are reported in this endpoint.', 'timeFrame': 'Week 24'}, {'measure': 'Percentage of Participants With an Improvement of >=3 Points From Baseline in Urticaria Control Test Score at Week 24', 'description': 'The UCT is a validated PRO questionnaire used for assessing urticaria control. The questionnaire has been developed and validated with participants with CSU and CIndU. It comprised of 4 items: severity of physical symptoms of urticaria (itch, hives and/or swelling); QoL impairment; frequency of treatment being not sufficient to control urticaria; overall urticarial control. Each item was rated on a 5-point Likert scale ranging from 0 (high disease activity) to 4 (low disease activity), with low score indicating high disease activity and low disease control, and vice-versa. The UCT total score was calculated as sum of all 4 individual item scores, which ranged from 0 to 16. Higher scores indicated low disease activity and complete disease control, and vice-versa.', 'timeFrame': 'Baseline to Week 24'}, {'measure': 'Change From Baseline in Local Wheal Intensity Likert Scale Score at Weeks 12 and 24', 'description': ""Wheal intensity Likert scale (ranging from 0 to 5) is a clinician-reported endpoint completed at the study visit, 10 minutes after removal of the ice cube from the participants' arm. The scale comprised of a single item assessing the intensity of participants' cutaneous reaction rated as follows: 0 = no wheals; 1 = numerous small, non-coalescent wheals; 2 = a large, regular, slightly edematous, coalescent wheal; 3 = a large and moderately edematous wheal; 4 = a large, regular, and significantly edematous wheal without pseudopodia; and 5 = a large, very edematous wheal with pseudopodia. Higher score indicated greater severity. LS mean and SE were analyzed using ANCOVA model with the corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes or No) as covariates."", 'timeFrame': 'Baseline, Week 12 and Week 24'}, {'measure': 'Change From Baseline in Local Itch Severity Scale Score at Weeks 12 and 24', 'description': 'Local itch (pruritus) severity was assessed using the peak pruritus numerical rating scale (NRS). Peak pruritus NRS is a PRO comprised of a single item rated on a scale ranged from 0 (""No itch"") to 10 (""Worst itch imaginable""), where higher scores indicated worse itch. Participants were asked to rate the intensity of their worst local site itch (pruritus) 10 minutes after removal of the ice cube. LS mean and SE were analyzed using ANCOVA model with the corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes or No) as covariates.', 'timeFrame': 'Baseline, Week 12 and Week 24'}, {'measure': 'Change From Baseline in Local Skin Burning Sensation Scale Score at Weeks 12 and 24', 'description': 'Local skin burning sensation was assessed using peak burning sensation NRS which is a PRO comprised of a single item rated on a scale ranged from 0 (""No burning sensation"") to 10 (""Worst imaginable burning sensation""). Higher score indicated worst burning sensation. Participants were asked to rate the intensity of the worst local site burning sensation of their skin 10 minutes after the removal of the ice cube. LS mean and SE were analyzed using ANCOVA model with the corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes or No) as covariates.', 'timeFrame': 'Baseline, Week 12 and Week 24'}, {'measure': 'Change From Baseline in Local Pain Severity Scale Score at Weeks 12 and 24', 'description': 'Local pain severity was assessed using peak pain NRS. The peak pain NRS is a PRO comprised of a single item rated on a scale ranged from 0 (""No pain"") to 10 (""Worst imaginable pain""). Higher score indicated worst pain. Participants were asked to rate the intensity of their worst local site pain 10 minutes after removal of the ice cube. LS mean and SE was analyzed using ANCOVA model with the corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes or No) as covariates.', 'timeFrame': 'Baseline, Week 12 and Week 24'}, {'measure': 'Percentage of Participants With Negative Ice Cube Provocation Test at Week 12', 'description': 'The ice cube provocation test is the most frequently used provocation method for ColdU. A negative ice cube provocation test was defined as the absence of confluent hives/wheal at the entire skin site of exposure after ice cube provocation test. Ice cube was applied on forearm skin for 5 minutes. Provocation test reading time was 10 minutes after removal of ice cube.', 'timeFrame': 'Week 12'}, {'measure': 'Change From Baseline in Cold Urticaria Signs and Symptoms Severity Scale Score at Week 24', 'description': 'Cold Urticaria Activity Score (ColdUAS) is disease-specific PRO questionnaire designed to determine cold urticaria disease activity. Intended for participants with cold urticaria aged 12 years old and above; developed and comprehensively tested with adults and adolescent participants with cold urticaria. Disease activity assessment was based on daily documentation of cold-induced skin reactions (wheals and swelling), skin sensations (itching, burning, pain or feeling hot), avoidance behavior and trigger exposure, and overall symptoms severity. Skin reaction, skin sensations, exposition to cold temperatures that usually cause ColdU symptoms and overall symptom severity were rated on a 4-point scale ranged from 0 (less severe) to 4 (more severe), where higher score indicated more signs and symptoms. LS mean and SE were analyzed using ANCOVA model with corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes/No) as covariates.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Percentage of Cold Urticaria Sign and Symptom-Free Days at Week 24', 'description': 'ColdUAS: disease-specific PRO questionnaire to determine cold urticaria disease activity in adults and adolescents with cold urticaria. For change from Baseline in percentage of cold urticaria sign and symptom-free days, responses to ColdUAS question (Q) 1 (rating severity of signs: wheals and swelling) and ColdUAS, Q2 (rating severity of symptoms: itch, burning, pain, or feeling hot) on days exposed to cold (ColdUAS Q3 responded Yes) were used. Within 14-day interval before each visit the number of sign and symptom-free days (ColdUAS Q1=0 and Q2=0) on days exposed to cold (ColdUAS Q3 greater than \\>0) was counted and divided by total number of days exposed to cold in this interval. Percentage of cold urticaria sign and symptom free days = sign and symptom free days/cold exposure days in 14 days window\\*100. LS mean and SE by ANCOVA model with the corresponding Baseline value, intervention group, region and background H1-antihistamines regular/daily use (Yes/No) as covariates.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Health-related Quality-of-life (HRQoL) as Measured by Dermatology Life Quality Index (DLQI) Scale Scores at Week 24', 'description': 'DLQI is a PRO developed to measure dermatology-specific HRQoL in adults. It comprises 10 items assessing the impact of skin disease on participant\'s HRQoL over the previous week. The items cover symptoms, leisure activities, work/school or holiday time, personal relationships including intimate, side effects of treatment, and emotional reactions to having a skin disease. It is a validated questionnaire used in clinical practice and clinical trials. For 9-items; response scale was a 4-point Likert scale ranging from 0 = ""Not at all"" to 3 = ""Very much"", where higher score=more impact of QoL, and vice-versa. The remaining 1 item about work/studying was rated on a 3-point Likert scale ranged from 0=""Not at all"" to 2=""A lot"". DLQI total score was the sum of score of all the items and ranged from 0 to 30, with a high score indicated poor HRQoL, and vice-versa. LS mean and SE from ANCOVA model.', 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Change From Baseline in Cold Urticaria Quality of Life (ColdU-QoL) Scale Score at Week 24', 'description': ""The ColdU-QoL questionnaire is a disease-specific PRO questionnaire designed to assess the impact of cold urticaria on participant's HRQoL. It has been developed and comprehensively tested with adults and adolescent participants with cold urticaria. The questionnaire contains 19 items, each rated using a 5-point Likert scale ranged from 0 (Not at all / Never) to 4 (Very much / Very often). The total raw score of the ColdU-QoL was transformed to a 0 to 100 score for analysis using the formula: ColdU-QoL total score = Sum of the score of all completed items/Maximum possible sum of the score of all completed items\\*100. Higher scores indicated higher ColdU-related QoL impairment, and vice-versa. LS mean and SE were analyzed from ANCOVA model with the corresponding Baseline value, intervention group, region and background H1-antihistamine regular/daily use (Yes or No) as covariates."", 'timeFrame': 'Baseline, Week 24'}, {'measure': 'Percentage of Participants Receiving Rescue Therapy for Primary Acquired Chronic Inducible Cold Urticaria', 'description': 'Rescue therapy included additional doses of H1-antihistamines and short course of oral corticosteroids (OCS).', 'timeFrame': 'From first investigational medicinal product (IMP) administration (Day 1) up to Week 24'}, {'measure': 'Percentage of Participants With Cold Exposure Triggered Urticaria That Required Hospitalization/Emergency Medical Care Visit or Treatment With Epinephrine', 'description': 'Percentage of participants with cold exposure triggered urticaria that required hospitalization/emergency medical care visit or treatment with epinephrine are reported in this endpoint.', 'timeFrame': 'From first IMP administration (Day 1) up to 14 weeks after last IMP administration (i.e., up to Week 36)'}, {'measure': 'Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)', 'description': 'An Adverse Event (AE) was defined as any untoward medical occurrence in a participant who received study drug and did not necessarily have to have a causal relationship with the treatment. Serious adverse events (SAEs) was defined as any untoward medical occurrence that at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was a medically important event. TEAEs were defined as AEs that developed, worsened or became serious during the treatment-emergent period (from the first IMP administration to the last IMP administration + 14 weeks).', 'timeFrame': 'From first IMP administration (Day 1) up to 14 weeks after last IMP administration (i.e., up to Week 36)'}, {'measure': 'Number of Participants With Treatment-emergent Antidrug Antibodies (ADA) Response', 'description': 'ADA response was categorized as: Treatment-emergent and Treatment-boosted. Treatment-emergent ADAs were defined as a positive response in the ADA assay post-first dose, when baseline results were negative or missing. Treatment-boosted ADAs: defined as an ADA positive response in the assay post first dose that was \\>=4-fold over baseline titer levels, when Baseline results were positive. Titer values were defined as low titer (\\< 1,000); moderate (1,000 less than or equal to \\[\\<=\\] titer \\<=10,000) and high titer (\\> 10,000).', 'timeFrame': 'From first IMP administration (Day 1) up to 14 weeks after last IMP administration (i.e., up to Week 36)'}]",17,12 Years,80 Years,ALL,False,Sanofi,INDUSTRY,1,82.0,ACTUAL,2025-09-01T16:18:15.902224,v2_robust,True,True,True,False,True,
NCT01351129,Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers,"A Phase 1, Single-Dose, Open-Label, Crossover Study To Estimate The Relative Bioavailability Of Two Controlled-Release Formulations Vs. An Immediate Release Formulation Of PF-04991532 In Healthy Adult Subjects",Formulation 1,"['Formulation 1', 'Formulation 2', 'Formulation 3']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy,['Healthy'],['formulation comparison'],COMPLETED,,2011-05,2011-06,"[{'measure': 'Area under the plasma concentration versus time profile (AUC)', 'timeFrame': 'predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,24,36,48 hrs postdose'}]","[{'measure': 'Max observed plasma concentration (Cmax)', 'timeFrame': 'predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,24,36,48 hrs postdose'}, {'measure': 'Time of Cmax (Tmax)', 'timeFrame': 'predose, 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12,24,36,48 hrs postdose'}, {'measure': 'Concentration at 24 hours postdose (C24hr)', 'timeFrame': '24 hrs postdose'}]",4,21 Years,55 Years,ALL,True,Pfizer,INDUSTRY,0,12.0,ACTUAL,2025-09-01T16:18:15.902364,v2_robust,True,True,True,False,False,
NCT01913431,Baracle Tab. ® Versus Baraclude Tab.® for Patients With HBeAg Chronic Hepatitis B,"A Multicenter, Double-blind, Active-controlled, Randomized, Parallel Group Study to Demonstrate the Comparison and Evaluation of Baracle Tab.® and Baraclude Tab.® for HBeAG Chronic Hepatitis B",Baracle Tab.®,"['Baracle Tab.®', 'Baraclude Tab.®']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,HBeAg-Positive Chronic Hepatitis B,['HBeAg-Positive Chronic Hepatitis B'],[],COMPLETED,,2013-09-12,2015-11-06,"[{'measure': 'the Difference between HBV DNA level(log10) and the base line of HBV DNA level(log10)', 'description': 'measured at 24th week of the administration', 'timeFrame': '52 weeks'}]","[{'measure': 'the percentage of participants who have less than 300 copies/ml of HBV DNA (undetectable titre)', 'description': 'measured at 24th/48th week of the administration', 'timeFrame': '52 weeks'}, {'measure': 'the proportion of participants with normalization of serum alanine aminotransferase (less than 1.0 times the upper limit of normal)', 'description': 'measured at 24th/48th week of the administration', 'timeFrame': '52 weeks'}, {'measure': 'the percentage of participants who have lost HBeAg', 'description': 'HBeAg of the participants was found positive at their screening visit. Also, the measurement performs 24th/48th week of the administration.', 'timeFrame': '52 weeks'}]",4,18 Years,65 Years,ALL,False,"Dong-A ST Co., Ltd.",INDUSTRY,0,118.0,ACTUAL,2025-09-01T16:18:15.902414,v2_robust,True,True,True,False,False,
NCT00409331,Amifostine With IMRT for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment,A Phase II Study To Assess The Efficacy of Amifostine for Submandibular and Sublingual Salivary Sparing During Head and Neck Cancer Treatment With Intensity- Modulated Radiation Therapy (IMRT) for Parotid Salivary Sparing,Amifostine,"['Ethyol', 'Amifostine']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Head and Neck Cancer,['Head and Neck Cancer'],"['Head and Neck Cancer', 'HNSCC', 'Submandibular and Sublingual Salivary Sparing', 'Amifostine', 'Ethyol', 'Radiation Therapy']",TERMINATED,Study terminated by Principal Investigator; no patients completed study.,2006-12,2009-01,"[{'measure': '12-month Clinically Relevant Salivary Flow (CRSF)', 'description': 'Primary endpoint is bilateral, 12-month Clinically Relevant Salivary Flow (CRSF) by the submandibular and sublingual salivary glands, collectively. Saliva production will be quantified using selective quantitative submandibular sialometry (total collection time of 5 minutes). A CRSF is equivalent to production of 0.05 mL of saliva post-radiation in a 5-minute collection period.', 'timeFrame': '12 months'}]",[],1,18 Years,,ALL,False,M.D. Anderson Cancer Center,OTHER,1,3.0,ACTUAL,2025-09-01T16:18:15.902444,v2_robust,True,True,False,True,False,Study terminated by Principal Investigator; no patients completed study.
NCT04825431,Mass Balance Study of [14C] TAS-205 in Healthy Volunteers,A Phase 1 Open-label Study Evaluating the Pharmacokinetics and Mass Balance of [14C] TAS-205 in Healthy Volunteers,"TAS-205, [14C]TAS-205","['TAS-205, [14C]TAS-205']",1,INTERVENTIONAL,['PHASE1'],PHASE1,,Healthy Male Subjects,['Healthy Male Subjects'],[],COMPLETED,,2021-03-22,2022-05-27,"[{'measure': 'Concentrations of total radioactivity in blood and plasma, plasma TAS-205 concentrations and the pharmacokinetics parameters of TAS-205', 'timeFrame': 'Day 1 to Day 8'}, {'measure': 'Radioactivity excretion and excretion rate，cumulative excretion, cumulative excretion rate into urine and feces.', 'timeFrame': 'Day 1 to Day 8'}, {'measure': 'Radioactivity excretion and excretion rate，cumulative excretion, cumulative excretion rate in all excreta (urine and feces).', 'timeFrame': 'Day 1 to Day 8'}, {'measure': 'Plasma, urinary, and fecal metabolite profiles of TAS-205 , and structural estimation.', 'timeFrame': 'Day 1 to Day 8'}]",[],4,20 Years,39 Years,MALE,True,"Taiho Pharmaceutical Co., Ltd.",INDUSTRY,0,6.0,ACTUAL,2025-09-01T16:18:15.902508,v2_robust,True,True,True,False,False,
NCT02312531,Prevention for Mother-to-infant Transmission of HBV,HBIG for Prevention of Mother-to-infant HBV Transmission,Hepatitis B immunoglobulin,"['HBIG', 'Hepatitis B immunoglobulin']",2,INTERVENTIONAL,['NA'],,,HBV,['HBV'],"['HBV', 'Intrauterine infection', 'hepatitis B immunoglobulin', 'immune barrier', 'virus replication', 'placenta']",COMPLETED,,2012-05,2014-08,"[{'measure': 'HBV infection of infants', 'description': 'HBV DNA and HBsAg positive at the age of 1 year old', 'timeFrame': 'one year'}, {'measure': 'Histopathological changes in placenta', 'description': 'Immunohistochemical staining of HBsAg, HBIG and CD68', 'timeFrame': 'at delivery'}]","[{'measure': 'Serum HBV markers titers、HBV DNA load and liver function changes', 'description': 'Serum HBV markers (HBsAg, HBsAb, HBeAg, and HBcAb) titers、HBV DNA load and liver function of mothers were regularly measured.', 'timeFrame': 'at weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40 of gestation'}, {'measure': 'Adverse events', 'description': 'Reports of premature and partum complications, ALT flare, delivery mode and birth defects.', 'timeFrame': 'at weeks 20, 24, 28, 32, 34, 36, 38, 39, and 40 of gestation, at delivery, at the age of 7 and 12 months of infants'}]",4,,,FEMALE,False,Xi'an Jiaotong University,OTHER,0,28.0,ACTUAL,2025-09-01T16:18:15.902609,v2_robust,True,True,True,False,True,
NCT00005631,Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma,Cytoreduction and Stem Cell Mobilization With Rituximab and ICE for Patients With Refractory or Relapsed CD20+ B-Cell IGL Eligible for ASCT: The RICE Protocol,carboplatin,"['etoposide', 'carboplatin', 'ifosfamide']",3,INTERVENTIONAL,['PHASE2'],PHASE2,,Lymphoma,['Lymphoma'],"['recurrent adult diffuse large cell lymphoma', 'recurrent adult immunoblastic large cell lymphoma', 'anaplastic large cell lymphoma']",COMPLETED,,1999-11,2002-11,[],[],0,18 Years,72 Years,ALL,False,Memorial Sloan Kettering Cancer Center,OTHER,1,,,2025-09-01T16:18:15.902631,v2_robust,True,True,True,False,False,
NCT00937131,The Use of Rituximab in Acute Thrombotic Thrombocytopenic Purpura (TTP),"A Study to Assess the Safety, Efficacy and Tolerability of Rituximab (Mabthera) in Combination With Plasma Exchange (PEX) in Patients With Acute Thrombotic Thrombocytopenic Purpura (TTP)",Rituximab,"['Rituximab', 'Rituximab (MabThera)']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Thrombotic Thrombocytopenic Purpura (TTP),['Thrombotic Thrombocytopenic Purpura (TTP)'],[],COMPLETED,,2006-03,2010-06,"[{'measure': 'The primary objective of this study is to investigate whether Rituximab and PEX decreases the time to remission of TTP patients.', 'timeFrame': 'One year'}]","[{'measure': 'Improved mortality ot TTP patients', 'timeFrame': '3 months'}, {'measure': 'Safety and toxicity of Rituximab in conjunction with standard therapy for acute TTP', 'timeFrame': '3 months'}, {'measure': 'Effect of Rituximab on B lymphocyte function', 'timeFrame': 'One year'}, {'measure': 'Effect of Rituximab on ADAMTS 13 activity and antibody production and time to relapse', 'timeFrame': 'One year'}]",5,18 Years,65 Years,ALL,False,"University College, London",OTHER,0,40.0,ACTUAL,2025-09-01T16:18:15.902637,v2_robust,True,True,True,False,True,
NCT02957331,Beta Blockade in in Traumatic Brain Injury,Beta-Adrenergic Blockade for Suppression of Catecholamine Surge Following Traumatic Brain Injury: A Randomized Trial,Propranolol,"['Propranolol', 'Inderal']",2,INTERVENTIONAL,['PHASE4'],PHASE4,,"Brain Injuries, Traumatic","['Brain Injuries, Traumatic']",[],COMPLETED,,2016-01,2018-05,"[{'measure': 'Mortality', 'description': 'Mortality will be assessed at day 30 or at hospital discharge', 'timeFrame': '30 day'}]","[{'measure': 'Urine Catecholamine Levels', 'description': 'Urine catecholamine levels will be measured in the hospital laboratory', 'timeFrame': 'Collected at baseline, Day 2, Day 5, Day 10 and Day 14.'}]",2,18 Years,,ALL,False,University of Tennessee,OTHER,0,26.0,ACTUAL,2025-09-01T16:18:15.902648,v2_robust,True,True,True,False,False,
NCT03591731,"Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)","A GCO Trial Exploring the Efficacy and Safety of Nivolumab Monotherapy or Nivolumab Plus Ipilimumab in Pre-treated Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs)",Nivolumab,"['Ipilimumab', 'Nivolumab']",2,INTERVENTIONAL,['PHASE2'],PHASE2,,Neuroendocrine Carcinoma,['Neuroendocrine Carcinoma'],"['IFCT', 'NIPINEC', 'Neuroendocrine', 'FFCD', 'GERCOR']",COMPLETED,,2019-01-02,2024-12-15,"[{'measure': 'Objective response rate', 'description': 'Number of patients with a best overall response of complete response (CR) or partial response (PR) assessed by investigators using validated criteria (i.e. RECIST 1.1) divided by the number of eligible patients.', 'timeFrame': '8 weeks after randomization'}]","[{'measure': 'Objective response rate assessed by independent central review', 'description': 'Number of patients with a best overall response of complete response (CR) or partial response (PR) assessed by independent central review using validated criteria (i.e. RECIST 1.1) divided by the number of eligible patients.', 'timeFrame': '8 weeks after randomization'}, {'measure': 'Disease control rate assessed by independent central review', 'description': 'Percentage of patients who will achieve complete response, partial response or stable disease', 'timeFrame': '8 weeks after randomization'}, {'measure': 'Response duration', 'description': 'Time between the date of the best overall response of partial or complete response until the date of progressive disease or death due to any cause.', 'timeFrame': '24 months after randomization of the last subject'}, {'measure': 'Time to symptom deterioration', 'description': 'Time between the date of treatment start and the date of event defined as the first documented symptom deterioration', 'timeFrame': '24 months after randomization of the last subject'}, {'measure': 'Progression-free survival', 'description': 'Time between the date of treatment start and the date of event defined as the first documented disease progression or death from any cause.', 'timeFrame': '24 months after randomization of the last subject'}, {'measure': 'Overall Survival', 'description': 'Time between the date of treatment start and the date of death from any cause.', 'timeFrame': '24 months after randomization of the last subject'}, {'measure': 'Frequency of adverse events', 'timeFrame': '24 months after randomization of the last subject'}]",8,18 Years,,ALL,False,Intergroupe Francophone de Cancerologie Thoracique,OTHER,2,185.0,ACTUAL,2025-09-01T16:18:15.902658,v2_robust,True,True,True,False,True,
NCT00207831,Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma,Trial UFT/RT Randomized Multicenter Phase III Randomized Trial Testing Ftorafur (UFT) Associated With Neoadjuvant Radiotherapy Versus Radiotherapy Alone in Rectal Adenocarcinoma,Tegafur and Uracil,['Tegafur and Uracil'],1,INTERVENTIONAL,['PHASE3'],PHASE3,,Rectal Cancer,"['Rectal Cancer', 'Stage II/III', 'T3 or T4 (Only Anal Extension) Rectal Cancer', 'N0-2', 'M0']","['rectal cancer', 'neoadjuvant therapy', 'UFT', 'radiochemotherapy']",TERMINATED,Terminated after interim analysis,2004-07,2008-02,[{'measure': 'Compare the rate of pathologic complete response of the primary tumor in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone'}],"[{'measure': 'Compare endoscopic ultrasonographic response in patients with operable rectal cancer receiving preoperative chemoradiotherapy versus patients receiving radiotherapy alone.'}, {'measure': 'Compare quality of life (Quality of Life Questionnaire Core 30 Items [QLQ-C 30])'}, {'measure': 'Compare the rate of sphincter conservation alone.'}, {'measure': 'Compare the safety of the chemoradiotherapy regimen to radiotherapy alone'}, {'measure': 'Compare the rate of resectability with negative resection margins in patients treated with this two regimen.'}, {'measure': 'Compare recurrence free survival and disease free survival'}, {'measure': 'Compare overall survival'}]",8,18 Years,80 Years,ALL,False,Institut Cancerologie de l'Ouest,OTHER,1,219.0,ACTUAL,2025-09-01T16:18:15.902691,v2_robust,True,True,False,True,True,Terminated after interim analysis
NCT02659631,PF-06671008 Dose Escalation Study in Advanced Solid Tumors,A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF PF-06671008 IN PATIENTS WITH ADVANCED SOLID TUMORS,PF-06671008,['PF-06671008'],1,INTERVENTIONAL,['PHASE1'],PHASE1,,Neoplasms,['Neoplasms'],"['P-cadherin', 'PF-06671008', 'solid tumors', 'lung cancer', 'breast cancer', 'colorectal cancer', 'NSCLC', 'TNBC', 'CRC', 'neoplasms', 'Triple negative breast cancer', 'Non-small cell lung cancer']",TERMINATED,,2016-04-28,2019-03-29,"[{'measure': 'Number of Participants With Dose-Limiting Toxicities (DLTs) - Part 1', 'description': 'DLT was defined as any of the following adverse events occurring in the first cycle of treatment (21 days after the first dose): a) Hematologic: Febrile neutropenia defined as an absolute neutrophil count (ANC) \\<1.0 x 10\\^9/L with a single temperature of \\>38.3°C, or 101°F, or a sustained temperature of \\>=38°C, or 100.4°F, for more than one hour; b) Non-hematologic: Delay by more than 2 weeks in receiving the next scheduled dose due to persisting treatment related toxicities; c) Any grade 3 or 4 clinically-relevant hematologic or non-hematologic toxicity.', 'timeFrame': 'Baseline through Day 21 (Cycle 1)'}, {'measure': 'Number of Participants With Objective Response (OR) - Part 2', 'description': 'Number of participants with OR based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumor (RECIST) v1.1.\n\nCR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \\<10 mm). No new lesions.\n\nPR was defined as \\>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.', 'timeFrame': 'Baseline, every 6 weeks until disease progression or unacceptable toxicity up to 24 months'}]","[{'measure': 'Maximum Serum Concentration (Cmax) of PF-06671008', 'description': 'Maximum serum concentration (Cmax) of PF-06671008 was observed directly from data.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Time to Reach Maximum Observed Serum Concentration (Tmax) of PF-06671008', 'description': 'Time for Maximum serum concentration (Tmax) of PF-06671008 was observed directly from data as time of first occurrence.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Terminal Elimination Half-life (t1/2) of PF-06671008', 'description': 'Terminal elimination half-life (t1/2) of PF-06671008 was calculated as ln(2)/kel, where kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.\n\nArithmetic mean was not calculated if fewer than 3 participants had reportable parameter values.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06671008', 'description': 'Tau refers to the dosing interval, which was 1 week. Area under the concentration-time profile from time 0 to time tau (AUCtau) was determined using linear/log trapezoidal method.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Area Under the Curve From Time 0 Extrapolated to Infinity Time (AUCinf) of PF-06671008', 'description': 'AUCinf was calculated as AUClast +(Clast\\*/kel), where AUClast is area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\\* is the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis, kel is the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve. Only those data points judged to describe the terminal log-linear decline were used in the regression.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Systemic Clearance (CL) of PF-06671008', 'description': 'Systemic Clearance (CL) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to IV arms.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Apparent Clearance (CL/F) of PF-06671008', 'description': 'Apparent Clearance (CL/F) was calculated as dose/AUCinf, where AUCinf was area under the serum concentration-time profile from time 0 extrapolated to infinite time. This outcome measure only applies to SC arm.\n\nGeometric mean was not calculated if fewer than 3 participants had reportable parameter values.', 'timeFrame': 'C1D1 0, 1, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose, C2D1 0, 2, 4, 8, 24, 48, 72 and 96 hrs post-dose'}, {'measure': 'Number of Participants With OR - Part 1', 'description': 'Number of participants with OR based on assessment of CR or PR according to RECIST v1.1.\n\nCR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \\<10 mm). No new lesions.\n\nPR was defined as \\>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.', 'timeFrame': 'Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression, unacceptable toxicity, or up to 24 months'}, {'measure': 'Number of Participants With Progression Free Survival (PFS) - Part 2', 'description': 'The period from start of study treatment to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease \\[PD\\]), or from adverse event (AE) data (where the outcome was ""Death"").', 'timeFrame': 'Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression or unacceptable toxicity, or up to 24 months'}, {'measure': 'Number of Participants With Overall Survival (OS) - Part 2', 'description': 'The period from the start of study treatment to date of death due to any cause. OS was calculated as (the death date minus the date of first dose of study medication plus 1) divided by 7. Death was determined from AE data (where outcome was death) or from follow-up contact data (where the participant current status was death).', 'timeFrame': 'Baseline and every 6 weeks for the first 6 months, then every 12 weeks until disease progression or unacceptable toxicity, or up to 24 months'}, {'measure': 'Number of Participants With Anti Drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF-06671008', 'description': 'ADA against PF-06671008 in human serum samples was determined following a tiered approach using screening, confirmation, and titer/quantification by semi-quantitative enzyme linked immunosorbent assay (ELISA). Endpoint titer \\>=1.18 was considered positive.', 'timeFrame': 'C1D1 0 hrs, D15 0 hrs, and C2D1 0 hrs, and D1 0 hrs post additional dosings, up to 24 months'}]",13,18 Years,,ALL,False,Pfizer,INDUSTRY,0,28.0,ACTUAL,2025-09-01T16:18:15.902704,v2_robust,True,True,False,True,True,
NCT01782131,A Study of the Safety and Efficacy of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis (MK-5592-069),A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole Versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069),Posaconazole,"['MK-5592', 'Noxafil®', 'SCH 056592', 'Posaconazole', 'Placebo', 'Voriconazole', 'VFEND®']",7,INTERVENTIONAL,['PHASE3'],PHASE3,,Fungal Infections,"['Fungal Infections', 'Invasive Pulmonary Aspergillosis']",[],COMPLETED,,2013-09-25,2019-09-10,"[{'measure': 'Percentage of Participants Who Died Through Day 42 in the Intention to Treat Population', 'description': 'The percentage of participants who died with posaconazole (POS) compared to voriconazole (VOR) in the first line treatment of invasive aspergillosis (IA) in the Intention to Treat (ITT) population through Day 42 was assessed.', 'timeFrame': 'Up to ~42 days'}]","[{'measure': 'Percentage of Participants Who Died Through Day 42 in the Full Analysis Set Population', 'description': 'The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the Full Analysis Set (FAS) population through Day 42 was assessed.', 'timeFrame': 'Up to ~42 days'}, {'measure': 'Percentage of Participants Who Died Through Day 84 in the ITT Population', 'description': 'The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the ITT population through Day 84 was assessed.', 'timeFrame': 'Up to ~84 days'}, {'measure': 'Percentage of Participants Who Died Through Day 84 in the FAS Population', 'description': 'The percentage of participants who died with POS compared to VOR in the first line treatment of invasive aspergillosis (IA) in the FAS population through Day 84 was assessed.', 'timeFrame': 'Up to ~ 84 days'}, {'measure': 'Percentage of Participants Achieving Global Clinical Response at Week 12 in the FAS Population', 'description': 'The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 12 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.', 'timeFrame': 'Up to 12 weeks (± 4 weeks)'}, {'measure': 'Percentage of Participants Achieving Global Clinical Response at Week 6 in the FAS Population', 'description': 'The global clinical response of POS compared to VOR in the first line treatment of invasive aspergillosis (IA) was assessed. The percentage of participants achieving adjudicated global clinical response (complete or partial) at Week 6 was reported. Complete response was classified as survival with resolution of fungal disease evidence; Partial response was survival and improvement of fungal disease.', 'timeFrame': 'Up to 6 weeks (± 2 weeks)'}, {'measure': 'Number of Participants Experiencing Mortality at Day 42, Day 84, and Day 114 in the FAS Population (Kaplan-Meier Time To Death Estimate)', 'description': ""The number of participants experiencing mortality at Day 42, Day 84 and Day 114 in participants with proven or probable IA receiving POS versus VOR were assessed. The Kaplan-Meier estimate reports the number of participants who experienced death (all causes) through Day 114 or \\~16 weeks. Participants who did not have any endpoint event until last visit or who were lost to follow-up and had no event were censored at the time of last available information (last study visit). For Day 42 and Day 84, missing or 'unable to determine' responses were considered as failures (dead)."", 'timeFrame': 'Up to ~16 weeks (± 2 weeks)'}, {'measure': 'Number of Participants Who Died Due to Invasive Aspergillosis Through Day 42 in the FAS Population', 'description': 'The number of participants who died due to IA receiving POS versus VOR through Day 42 was assessed.', 'timeFrame': 'Up to 42 days'}, {'measure': 'Number of Participants Who Died Due to Invasive Aspergillosis Through Day 84 in the FAS Population', 'description': 'The number of participants who died due to IA receiving POS versus VOR in the FAS population through Day 84 was assessed.', 'timeFrame': 'Up to 84 days'}, {'measure': 'Percentage of Participants With Tier 1 Treatment Emergent Adverse Events', 'description': 'The percentage of participants with Tier 1 treatment-emergent adverse events (TEAEs) was determined. The Tier 1 TEAEs included hepatic safety (elevated aspartate serum transaminase \\[AST\\] or alanine serum transaminase \\[ALT\\] value ≥3x upper limit of normal (ULN) and an elevated total bilirubin value ≥2x ULN and, at the same time, an alkaline phosphatase value \\<2 ULN); central nervous system (CNS) and visual disturbances (eye disorders, nervous system disorders, psychiatric disorders), dermatologic reactions, and adrenal insufficiency or temporally associated TEAEs of hypotension.', 'timeFrame': 'Up to ~16 weeks (± 2 weeks)'}, {'measure': 'Percentage of Participants With at Least One Adverse Event', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.', 'timeFrame': 'Up to ~16 weeks (± 2 weeks)'}, {'measure': 'Percentage of Participants With at Least One Drug Related Adverse Event', 'description': 'An adverse event (AE) was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.', 'timeFrame': 'Up to ~16 weeks (± 2 weeks)'}, {'measure': 'Percentage of Participants With at Least One Serious Adverse Event', 'description': 'A serious adverse event (SAE) was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.', 'timeFrame': 'Up to ~16 weeks (± 2 weeks)'}, {'measure': 'Percentage of Participants With at Least One Serious Drug Related Adverse Event', 'description': 'An SAE was an AE that resulted in death, was life threatening, required or prolonged an existing hospitalization, resulted in persistent or significant disability or incapacity, was a congenital anomaly or birth defect, or was another important medical event deemed such by medical or scientific judgment.', 'timeFrame': 'Up to ~16 weeks (± 2 weeks)'}, {'measure': 'Percentage of Participants Who Discontinued Study Treatment Due to an Adverse Event', 'description': 'An AE was defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product.', 'timeFrame': 'Up to ~12 weeks'}, {'measure': 'Steady State Average Concentration (Cavg) of Posaconazole With Food Intake', 'description': 'The characterization of the pharmacokinetics (PK) parameters of POS was determined from plasma samples taken at steady-state after receiving oral tablet of POS. Steady-state Cavg, where Cavg is defined as area under the concentration time-curve from 0 to 24 hours (AUC0-24hr) divided by the dosing interval. Data is presented in POS group column only. No evaluation of food intake on the VOR capsule was presented.', 'timeFrame': 'Baseline, and at pre-dose on Day 7, Week 2, Week 4, Week 6, and Week 12'}]",16,13 Years,,ALL,False,Merck Sharp & Dohme LLC,INDUSTRY,0,585.0,ACTUAL,2025-09-01T16:18:15.902726,v2_robust,True,True,True,False,True,
NCT03139331,PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma,Phase 1 Study of Pazopanib in Combination With Irinotecan and Temozolomide (PAZIT) for Children and Young Adults With Relapsed or Refractory Sarcoma,Pazopanib,"['Irinotecan', 'Pazopanib', 'Temozolomide']",3,INTERVENTIONAL,['PHASE1'],PHASE1,,Sarcoma,"['Sarcoma', 'Refractory Sarcoma']",[],COMPLETED,,2017-06-06,2020-09-30,"[{'measure': 'Maximum Tolerated Dose', 'description': 'Maximum tolerated dose or recommended phase 2 dose of pazopanib administered in combination with irinotecan and temozolomide', 'timeFrame': '3 weeks'}, {'measure': 'Number of Patients with Dose-Limiting Toxicities (DLTs) Using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0', 'description': 'Toxicity will be graded using the CTCAE criteria, version 4.0. DLT will be defined as any of the events as defined per the protocol that are at least possibly, probably, or definitely attributable to the combination of pazopanib, irinotecan, and temozolomide. DLTs are generally grade 3 or greater in severity.\n\nDose limiting hematological and non-hematological toxicities are defined differently, per the protocol.', 'timeFrame': '3 weeks'}, {'measure': 'Describing toxicities of PAZIT drug combination using NCI CTCAE Version 4.0', 'description': 'To describe any toxicities associated with the combination of pazopanib, irinotecan and temozolomide (PAZIT).', 'timeFrame': '3 weeks'}]","[{'measure': 'Objective Response Rate Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1', 'description': ""The best overall response is the best response recorded from the start of the treatment until disease progression/recurrence (taking as reference for progressive disease the smallest measurements recorded since the treatment started). The patient's best response assignment will depend on the achievement of both measurement and confirmation criteria. Tumor response will be assessed using RECIST version 1.1."", 'timeFrame': 'From treatment initiation until disease progression, an average of about 6 months'}, {'measure': 'Progression-Free Survival (PFS) Using RECIST Version 1.1', 'description': 'PFS is defined as the duration of time from start of treatment to time of tumor progression. Tumor response will be assessed using RECIST version 1.1.', 'timeFrame': 'From treatment initiation until disease progression, an average of about 6 months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the duration of time from start of treatment to time of death from any cause.', 'timeFrame': 'From treatment initiation until death, an average of about 1 year'}]",6,6 Years,30 Years,ALL,False,"University of California, San Francisco",OTHER,3,16.0,ACTUAL,2025-09-01T16:18:15.902804,v2_robust,True,True,True,False,True,
NCT04567602,A Study of Pulmonary Arterial Hypertension Participants Treated With Macitentan or Selexipag,Non-Interventional Study on Pulmonary Arterial Hypertension Patients Treated With Macitentan or Selexipag: Experience From an Italian Cohort (INSPECTIO),PAH medication,['PAH medication'],1,OBSERVATIONAL,[],,,Pulmonary Arterial Hypertension,['Pulmonary Arterial Hypertension'],[],COMPLETED,,2020-10-06,2024-03-05,"[{'measure': 'Change from Baseline in the Number of the Non-Invasive Low-Risk Criteria to 12 Months', 'description': 'Change from baseline in the number of the non-invasive low-risk criteria will be assessed according to the following parameters: world health organization (WHO)/functional class (FC)- I, II, 6-minute walk distance (6MWD) greater than (\\>) 440 meters (m), and brain natriuretic peptide (BNP) less than (\\<) 50 nanogram per liter (ng/l) or N-terminal-pro-hormone brain natriuretic Peptide (NT-proBNP) \\<300 ng/l.', 'timeFrame': 'Baseline and 12 Months'}]","[{'measure': 'Number of Participants with Improved, Stable or Worsened Risk profile from Baseline to 12 and 24 Months', 'description': 'Risk profile is assessed as improved, stable or worsened where improved indicates 1 or more non-invasive parameters from intermediate to low risk profile; stable indicates no change in the parameters; and worsened indicates 1 or more non-invasive parameters move from low or intermediate to intermediate or high range risk.', 'timeFrame': 'Baseline up to 12 and 24 Months'}, {'measure': 'Change in Progression in the Number of Participants with Low/High Intermediate Risk', 'description': 'Change in risk profile for the low/high intermediate risk participants according to following cut-off values for low intermediate risk/high intermediate risk, respectively: (6MWD \\[greater than or equal to \\[\\>=\\] or \\< 300m\\], Peak oxygen consumption \\[VO2\\] \\[\\>= or \\< 50% predicted\\], BNP \\[less than or equal to \\[\\<=\\] or \\> 175 ng/l\\], or NT-proBNP \\[\\<= or \\> 850 ng/l\\], right atrial area \\[RA\\] \\[\\<= or \\> 22 centimeter \\[cm\\]\\] and right atrial pressure \\[RAP\\] \\[\\<= or \\> 11 millimeter of mercury \\[mmHg\\]\\] or stroke volume index (SVI) (\\> or \\<= 38 milliliter per meter square \\[ml/m2\\])). The low intermediate risk is defined by a presence of at least three low intermediate parameters and a high intermediate risk is defined by a presence of at least three high intermediate parameters.', 'timeFrame': 'Baseline up to 24 Months'}, {'measure': 'Change from Baseline in 6MWD', 'description': 'Change from baseline in 6MWD will be reported.', 'timeFrame': 'Baseline up to 24 Months'}, {'measure': 'Change from Baseline in BNP or NT-proBNP', 'description': 'Change from baseline in BNP or NT-proBNP will be reported.', 'timeFrame': 'Baseline up to 24 Months'}, {'measure': 'Change from Baseline in Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL) 2.0 Risk Score up to 12 and 24 Months', 'description': 'The REVEAL risk calculator determines the risk status and the scores can be defined as: low risk as a score of \\<= 6, intermediate risk as a score of 7 or 8, and high risk as a score of \\>= 9 for the survival rates.', 'timeFrame': 'Baseline up to 12 and 24 Months'}, {'measure': 'Adherence to European Society of Cardiology and European Respiratory Society (ESC/ERS) guidelines and 6th World Symposium on Pulmonary Hypertension (WSPH)', 'description': 'Adherence to ESC/ERS guidelines and 6th WSPH will be reported.', 'timeFrame': 'Up to 24 Months'}, {'measure': 'Change from Baseline in Echocardiographic Parameters', 'description': 'Change in echocardiographic parameters will be reported as assessed by echocardiogram.', 'timeFrame': 'Baseline up to 24 Months'}, {'measure': 'Change from Baseline in Hemodynamic Parameters', 'description': 'Change in hemodynamic parameters will be reported.', 'timeFrame': 'Baseline up to 24 Months'}, {'measure': 'Hospitalization Rate due to Worsening of PAH', 'description': 'The hospitalization rate due to PAH worsening will be calculated based on the number of participants with at least one hospitalization. The calculation of the rate will be based on the number of events over the whole follow-up time that is exposure time.', 'timeFrame': 'Up to 24 Months'}, {'measure': 'Overall Survival (OS)', 'description': 'OS is defined as the duration/time from the start of study treatment to date of death due to any cause.', 'timeFrame': 'Up to 24 Months'}, {'measure': 'Change from Baseline in Health-Related Quality of Life (HRQoL) as Measured with Emphasis-10 Questionnaire', 'description': 'The emPHasis-10 is a short and easy questionnaire that consists of 10 items which address breathlessness, fatigue, control and confidence. Each item is scored on a semantic differential six-point scale (0-5), with contrasting adjectives at each end. A total emPHasis-10 score is derived using simple aggregation of the 10 items. emPHasis-10 scores range from 0 to 50, higher scores indicate worse quality of life.', 'timeFrame': 'Baseline up to 24 Months'}, {'measure': 'Change from Baseline in Participants with Narrative plots', 'description': 'Participants will be invited to fill in two narrative plots; one at the enrollment visit and one at the month 12 visit.', 'timeFrame': 'Baseline and 12 Months'}, {'measure': 'Change from Baseline in Caregivers with Narrative Plots', 'description': 'Caregivers will be invited to fill in two narrative plots; one at the enrollment visit and one at the month 12 visit.', 'timeFrame': 'Baseline and 12 Months'}, {'measure': 'Number of Participants with Adverse Events (AEs) and Adverse Drug Reactions (ADRs)', 'description': 'An AE is any untoward medical occurrence in a participant enrolled in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. An ADR is defined as a response to a medicinal (investigational or non-investigational) product that is noxious and unintended.', 'timeFrame': 'Up to 24 Months'}]",15,18 Years,,ALL,False,Janssen-Cilag S.p.A.,INDUSTRY,0,372.0,ACTUAL,2025-09-01T16:18:15.902839,v2_robust,False,True,True,False,True,
NCT07009002,BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma,A Phase I/II Single-center Study Evaluating the Safety and Efficacy of BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in Adults With Refractory/Relapsed Refractory/Relapsed B-cell Lymphoma,Fludarabine,"['Fludarabine Phosphate for Injection', 'Cyclophosphamide', 'Fludarabine', 'Cyclophosphamide for Injection']",4,INTERVENTIONAL,"['PHASE1', 'PHASE2']",PHASE1,,B Cell Lymphoma,['B Cell Lymphoma'],"['CAR-T cells', 'CD19']",RECRUITING,,2025-06-20,2027-05-31,"[{'measure': 'Incidence of Adverse Events (AEs)', 'description': 'AE is defined as any adverse medical event from the date of randomization to 12 months after CAR T cells infusion. Among them, cytokine release syndrome(CRS) and immune cell-associated neurotoxicity syndrome (ICANS) were graded according to American Society for Transplantation and Cellular Therapy (ASTCT) criteria. Other AEs were graded according to common terminology criteria for adverse events (CTCAE) v5.0.', 'timeFrame': '12 months'}, {'measure': 'Phase 1: Incidence of Incidence of DLT.', 'description': 'DLT is defined as any AE related to the investigational drug that occurs within 28 days after administration of the CAR19TIF cells and meets any one of the criteria listed in the DLT criteria:\n\n* Grade 3 CRS that does not resolve to grade 2 or lower within 2 weeks;\n* Grade 3 ICANS lasting for ≥ 7 days;\n* Any Grade ≥ 4 CRS or ICANS;\n* Any other Grade ≥ 4 and Grade 3 AEs related to the CAR19TIF cells that lasts for ≥ 14 days, except hematology toxicity.', 'timeFrame': 'First infusion date of CAR-T cells up to 28 days.'}, {'measure': 'RP2D', 'description': 'The recommended dose for phase 2 was determined through phase 1 study.', 'timeFrame': '12 months'}, {'measure': 'Phase 2: Complete response (CR) rate', 'description': 'CR is assessed by investigators and based on the Lugano 2014 assessment criterion. CR rate is defined as the proportion of patients who have achieved CR assessed by investigators.', 'timeFrame': '24 months'}, {'measure': 'Phase 2: Objective response rate (ORR)', 'description': 'ORR is defined as the proportion of patients who have achieved CR and partial response (PR) assessed by investigators.', 'timeFrame': '24 months'}, {'measure': 'Phase 2: Duration of Response (DOR)', 'description': 'DOR is defined as the date of their first CR or PR (which is subsequently confirmed) to PD assessed by investigators, or death regardless of cause.', 'timeFrame': '24 months'}, {'measure': 'Phase 2: Overall Survival (OS)', 'description': 'OS is defined as the time from CAR-T cells infusion to the date of death. Subjects who have not died by the analysis data cutoff date will be censored at the last contact date.', 'timeFrame': '24 months'}, {'measure': 'Phase 2: Progression Free Survival (PFS)', 'description': 'PFS is defined as the time from the CAR-T cells infusion date to the date of disease progression assessed by investigators, or death any cause. Participants not meeting the criteria for progression by the analysis data cutoff date were censored at the last evaluable disease assessment date.', 'timeFrame': '24 months'}]","[{'measure': 'Phase 1 and phase 2: Pharmacokinetics:Level of CAR-positive T cells circulating in blood over time', 'description': 'Number (cells/ul)and copy number (copies/ug DNA) of CAR-T cells were assessed by number in peripheral blood. Blood samples were collected before and one year after cell infusion (until CAR-T cells were not detected for two consecutive times) to detect the number and copy number of CAR-T cells, and to evaluate the pharmacokinetics of CAR-T.', 'timeFrame': '12 months'}, {'measure': 'Phase 1 and phase 2: Pharmacodynamics:Level of CD19+ cells in peripheral blood', 'description': 'The level of CD19+ cells (%) in peripheral blood will be detected by flow cytometry.', 'timeFrame': 'Up to 28 days after infusion.'}, {'measure': 'Phase 1 and phase 2: Peak level of cytokines in serum (phase 1 and phase 2)', 'description': 'The cytokines mainly include interleukin-2 (IL-2 ), IL-6, IL-8, IL-10, tumor necrosis factor-α (TNF-α), C reactive protein .', 'timeFrame': 'Up to 28 days after infusion'}, {'measure': 'Phase 1: 3-month ORR', 'description': 'The definition of ORR has already been mentioned above', 'timeFrame': '3 months'}, {'measure': 'Phase 1: OS', 'description': 'The definition of OS has already been mentioned above', 'timeFrame': '24 months'}, {'measure': 'Phase 1: PFS', 'description': 'The definition of PFS has already been mentioned above', 'timeFrame': '24 months'}, {'measure': 'Phase 2: Incidence of AE', 'description': 'AE is defined as any adverse medical event from the date of enrollment to 24 months after CAR-T cells infusion.', 'timeFrame': '24 months'}]",15,18 Years,70 Years,ALL,False,Chinese PLA General Hospital,OTHER,0,30.0,ESTIMATED,2025-09-01T16:18:15.902919,v2_robust,True,True,False,False,True,
